

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Tezepelumab (Tezspire®)

AstraZeneca GmbH

Modul 4 A – Anhang 4-G-2

Add-on-Erhaltungstherapie bei Erwachsenen und Jugendlichen ab 12 Jahren mit schwerem Asthma, das trotz hochdosierter inhalativer Kortikosteroide plus eines weiteren Arzneimittels zur Erhaltungstherapie unzureichend kontrolliert ist

Werte im Studienverlauf

Biomarker_{low}-Population

RCT mit dem zu bewertenden Arzneimittel

Stand: 11.11.2022

MT1FAC_IBMH0: Course of FEV1 Pre-BD - pooled NP set, DITTB _____	8
MT1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - pooled NP set, DITTB _____	10
NT1FAC_IBMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTB, DCO 1 _____	11
NT1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	13
PT3FAC_IBMH0: Course of FEV1 Pre-BD - PATHWAY, DITTB, DCO 3 _____	14
PT3FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - PATHWAY, DITTB, DCO 3 _____	16
ST1FAC_IBMH0: Course of FEV1 Pre-BD - SOURCE, DITTB _____	17
ST1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - SOURCE, DITTB _____	19
DT1FAC_BBMH0: Course of FEV1 Pre-BD - DESTINATION, DITTNB - LTE _____	20
DT1FAC_BBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - DESTINATION, DITTNB - LTE _____	22
CT1FAC_IBMH0: Course of FEV1 Pre-BD - CASCADE, DITTB _____	24
CT1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - CASCADE, DITTB _____	26
DT1FAC_HBMH0: Course of FEV1 Pre-BD - DESTINATION, DITTNB - LTE - adult _____	27
DT1FAC_HBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - DESTINATION, DITTNB - LTE - adult _____	29
NT1FAC_ABMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTB-adult, DCO 1 _____	31
NT1FAC_ABMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	33
MT1H5C_IBMH0: Course of ACQ-5 score - pooled NP set, DITTB _____	34
MT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results - pooled NP set, DITTB _____	36
NT1H5C_IBMH0: Course of ACQ-5 score - NAVIGATOR, DITTB, DCO 1 _____	38
NT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	40
PT3H5C_IBMH0: Course of ACQ-5 score - PATHWAY, DITTB, DCO 3 _____	42
PT3H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results - PATHWAY, DITTB, DCO 3 _____	46
DT1H5C_BBMH0: Course of ACQ-5 score - DESTINATION, DITTNB - LTE _____	49
DT1H5C_BBMC0: Change from baseline in ACQ-5 score - MMRM results - DESTINATION, DITTNB - LTE _____	51
CT1H5C_IBMH0: Course of ACQ-5 score - CASCADE, DITTB _____	53
CT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results - CASCADE, DITTB _____	55
MT1H6C_IBMH0: Course of ACQ-6 score - pooled NP set, DITTB _____	56
MT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results - pooled NP set, DITTB _____	58
NT1H6C_IBMH0: Course of ACQ-6 score - NAVIGATOR, DITTB, DCO 1 _____	60
NT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	62

PT3H6C_IBMH0: Course of ACQ-6 score - PATHWAY, DITTB, DCO 3	64
PT3H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results - PATHWAY, DITTB, DCO 3	68
ST1H6C_IBMH0: Course of ACQ-6 score - SOURCE, DITTB	71
ST1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results - SOURCE, DITTB	73
DT1H6C_BBMH0: Course of ACQ-6 score - DESTINATION, DITTNB - LTE	75
DT1H6C_BBMC0: Change from baseline in ACQ-6 score - MMRM results - DESTINATION, DITTNB - LTE	77
CT1H6C_IBMH0: Course of ACQ-6 score - CASCADE, DITTB	79
CT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results - CASCADE, DITTB	81
DT1H5C_HBMH0: Course of ACQ-5 score - DESTINATION, DITTNB - LTE - adult	82
DT1H5C_HBMC0: Change from baseline in ACQ-5 score - MMRM results - DESTINATION, DITTNB - LTE - adult	84
DT1H6C_HBMH0: Course of ACQ-6 score - DESTINATION, DITTNB - LTE - adult	86
DT1H6C_HBMC0: Change from baseline in ACQ-6 score - MMRM results - DESTINATION, DITTNB - LTE - adult	88
NT1H5C_ABMH0: Course of ACQ-5 score - NAVIGATOR, DITTB-adult, DCO 1	90
NT1H5C_ABMC0: Change from baseline in ACQ-5 score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1	92
NT1H6C_ABMH0: Course of ACQ-6 score - NAVIGATOR, DITTB-adult, DCO 1	94
NT1H6C_ABMC0: Change from baseline in ACQ-6 score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1	96
NT1WTC_IBMH0: Course of ASD weekly total score - NAVIGATOR, DITTB, DCO 1	98
NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results - NAVIGATOR, DITTB, DCO 1	104
ST1WTC_IBMH0: Course of ASD weekly total score - SOURCE, DITTB	110
ST1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results - SOURCE, DITTB	116
NT1WDC_IBMH0: Course of ASD weekly daytime score - NAVIGATOR, DITTB, DCO 1	121
NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results - NAVIGATOR, DITTB, DCO 1	127
ST1WDC_IBMH0: Course of ASD weekly daytime score - SOURCE, DITTB	133
ST1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results - SOURCE, DITTB	139
NT1WNC_IBMH0: Course of ASD weekly night-time score - NAVIGATOR, DITTB, DCO 1	144
NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results - NAVIGATOR, DITTB, DCO 1	150
ST1WNC_IBMH0: Course of ASD weekly night-time score - SOURCE, DITTB	156
ST1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results - SOURCE, DITTB	162
NT1WWC_IBMH0: Course of ASD weekly wheezing score - NAVIGATOR, DITTB, DCO 1	167
NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results - NAVIGATOR, DITTB, DCO 1	173

ST1WWC_IBMH0: Course of ASD weekly wheezing score - SOURCE, DITTB _____	179
ST1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results - SOURCE, DITTB _____	185
NT1WBC_IBMH0: Course of ASD weekly shortness of breath score - NAVIGATOR, DITTB, DCO 1 _____	190
NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	196
ST1WBC_IBMH0: Course of ASD weekly shortness of breath score - SOURCE, DITTB _____	202
ST1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - SOURCE, DITTB _____	208
NT1WHC_IBMH0: Course of ASD weekly cough score - NAVIGATOR, DITTB, DCO 1 _____	213
NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	219
ST1WHC_IBMH0: Course of ASD weekly cough score - SOURCE, DITTB _____	225
ST1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results - SOURCE, DITTB _____	231
NT1WEC_IBMH0: Course of ASD weekly chest tightness score - NAVIGATOR, DITTB, DCO 1 _____	236
NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	242
ST1WEC_IBMH0: Course of ASD weekly chest tightness score - SOURCE, DITTB _____	248
ST1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - SOURCE, DITTB _____	254
NT1WAC_IBMH0: Course of ASD weekly waking score - NAVIGATOR, DITTB, DCO 1 _____	259
NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	265
ST1WAC_IBMH0: Course of ASD weekly waking score - SOURCE, DITTB _____	271
ST1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results - SOURCE, DITTB _____	277
NT1WLC_IBMH0: Course of ASD weekly limiting activity score - NAVIGATOR, DITTB, DCO 1 _____	282
NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	288
ST1WLC_IBMH0: Course of ASD weekly limiting activity score - SOURCE, DITTB _____	294
ST1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - SOURCE, DITTB _____	300
NT1WTC_ABMH0: Course of ASD weekly total score - NAVIGATOR, DITTB-adult, DCO 1 _____	305
NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	311
NT1WDC_ABMH0: Course of ASD weekly daytime score - NAVIGATOR, DITTB-adult, DCO 1 _____	317
NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	323
NT1WNC_ABMH0: Course of ASD weekly night-time score - NAVIGATOR, DITTB-adult, DCO 1 _____	329
NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	335
NT1WWC_ABMH0: Course of ASD weekly wheezing score - NAVIGATOR, DITTB-adult, DCO 1 _____	341
NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	347

NT1WBC_ABMH0: Course of ASD weekly shortness of breath score - NAVIGATOR, DITTB-adult, DCO 1 _____	353
NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	359
NT1WHC_ABMH0: Course of ASD weekly cough score - NAVIGATOR, DITTB-adult, DCO 1 _____	365
NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	371
NT1WEC_ABMH0: Course of ASD weekly chest tightness score - NAVIGATOR, DITTB-adult, DCO 1 _____	377
NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	383
NT1WAC_ABMH0: Course of ASD weekly waking score - NAVIGATOR, DITTB-adult, DCO 1 _____	389
NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	395
NT1WLC_ABMH0: Course of ASD weekly limiting activity score - NAVIGATOR, DITTB-adult, DCO 1 _____	401
NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	407
MT1VSC_IBMH0: Course of EQ-5D-VAS - pooled NP set, DITTB _____	413
MT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results - pooled NP set, DITTB _____	417
NT1VSC_IBMH0: Course of EQ-5D-VAS - NAVIGATOR, DITTB, DCO 1 _____	420
NT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	424
PT3VSC_IBMH0: Course of EQ-5D-VAS - PATHWAY, DITTB, DCO 3 _____	427
PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results - PATHWAY, DITTB, DCO 3 _____	433
ST1VSC_IBMH0: Course of EQ-5D-VAS - SOURCE, DITTB _____	439
ST1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results - SOURCE, DITTB _____	443
NT1VSC_ABMH0: Course of EQ-5D-VAS - NAVIGATOR, DITTB-adult, DCO 1 _____	446
NT1VSC_ABMC0: Change from baseline in EQ-5D-VAS - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	450
MT1QTC_IBMH0: Course of AQLQ+12 total score - pooled NP set, DITTB _____	453
MT1QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results - pooled NP set, DITTB _____	455
NT1QTC_IBMH0: Course of AQLQ+12 total score - NAVIGATOR, DITTB, DCO 1 _____	456
NT1QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	458
PT3QTC_IBMH0: Course of AQLQ+12 total score - PATHWAY, DITTB, DCO 3 _____	459
PT3QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results - PATHWAY, DITTB, DCO 3 _____	461
ST1QTC_IBMH0: Course of AQLQ+12 total score - SOURCE, DITTB _____	463
ST1QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results - SOURCE, DITTB _____	465
MT1QAC_IBMH0: Course of AQLQ+12 activity limitations score - pooled NP set, DITTB _____	466
MT1QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - pooled NP set, DITTB _____	468

NT1QAC_IBMH0: Course of AQLQ+12 activity limitations score - NAVIGATOR, DITTB, DCO 1 _____	469
NT1QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	471
PT3QAC_IBMH0: Course of AQLQ+12 activity limitations score - PATHWAY, DITTB, DCO 3 _____	472
PT3QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - PATHWAY, DITTB, DCO 3 _____	474
ST1QAC_IBMH0: Course of AQLQ+12 activity limitations score - SOURCE, DITTB _____	476
ST1QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - SOURCE, DITTB _____	478
MT1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score - pooled NP set, DITTB _____	479
MT1QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - pooled NP set, DITTB _____	481
NT1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score - NAVIGATOR, DITTB, DCO 1 _____	482
NT1QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	484
PT3QEC_IBMH0: Course of AQLQ+12 environmental stimuli score - PATHWAY, DITTB, DCO 3 _____	485
PT3QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - PATHWAY, DITTB, DCO 3 _____	487
ST1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score - SOURCE, DITTB _____	489
ST1QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - SOURCE, DITTB _____	491
MT1QGC_IBMH0: Course of AQLQ+12 emotional function score - pooled NP set, DITTB _____	492
MT1QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - pooled NP set, DITTB _____	494
NT1QGC_IBMH0: Course of AQLQ+12 emotional function score - NAVIGATOR, DITTB, DCO 1 _____	495
NT1QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	497
PT3QGC_IBMH0: Course of AQLQ+12 emotional function score - PATHWAY, DITTB, DCO 3 _____	498
PT3QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - PATHWAY, DITTB, DCO 3 _____	500
ST1QGC_IBMH0: Course of AQLQ+12 emotional function score - SOURCE, DITTB _____	502
ST1QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - SOURCE, DITTB _____	504
MT1QMC_IBMH0: Course of AQLQ+12 symptom score - pooled NP set, DITTB _____	505
MT1QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - pooled NP set, DITTB _____	507
NT1QMC_IBMH0: Course of AQLQ+12 symptom score - NAVIGATOR, DITTB, DCO 1 _____	508
NT1QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	510
PT3QMC_IBMH0: Course of AQLQ+12 symptom score - PATHWAY, DITTB, DCO 3 _____	511
PT3QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - PATHWAY, DITTB, DCO 3 _____	513
ST1QMC_IBMH0: Course of AQLQ+12 symptom score - SOURCE, DITTB _____	515
ST1QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - SOURCE, DITTB _____	517

NT1QTC_ABMH0: Course of AQLQ+12 total score - NAVIGATOR, DITTB-adult, DCO 1 _____	518
NT1QTC_ABMC0: Change from baseline in AQLQ+12 total score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	520
NT1QAC_ABMH0: Course of AQLQ+12 activity limitations score - NAVIGATOR, DITTB-adult, DCO 1 _____	521
NT1QAC_ABMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	523
NT1QEC_ABMH0: Course of AQLQ+12 environmental stimuli score - NAVIGATOR, DITTB-adult, DCO 1 _____	524
NT1QEC_ABMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	526
NT1QGC_ABMH0: Course of AQLQ+12 emotional function score - NAVIGATOR, DITTB-adult, DCO 1 _____	527
NT1QGC_ABMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	529
NT1QMC_ABMH0: Course of AQLQ+12 symptom score - NAVIGATOR, DITTB-adult, DCO 1 _____	530
NT1QMC_ABMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	532
NT1GTC_IBMH0: Course of SGRQ total score - NAVIGATOR, DITTB, DCO 1 _____	533
NT1GTC_IBMC0: Change from baseline in SGRQ total score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	535
ST1GTC_IBMH0: Course of SGRQ total score - SOURCE, DITTB _____	536
ST1GTC_IBMC0: Change from baseline in SGRQ total score - MMRM results - SOURCE, DITTB _____	538
DT1GTC_BBMH0: Course of SGRQ total score - DESTINATION, DITTNB - LTE _____	539
DT1GTC_BBMC0: Change from baseline in SGRQ total score - MMRM results - DESTINATION, DITTNB - LTE _____	541
NT1GMC_IBMH0: Course of SGRQ symptom score - NAVIGATOR, DITTB, DCO 1 _____	542
NT1GMC_IBMC0: Change from baseline in SGRQ symptom score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	544
ST1GMC_IBMH0: Course of SGRQ symptom score - SOURCE, DITTB _____	545
ST1GMC_IBMC0: Change from baseline in SGRQ symptom score - MMRM results - SOURCE, DITTB _____	547
DT1GMC_BBMH0: Course of SGRQ symptom score - DESTINATION, DITTNB - LTE _____	548
DT1GMC_BBMC0: Change from baseline in SGRQ symptom score - MMRM results - DESTINATION, DITTNB - LTE _____	550
NT1GAC_IBMH0: Course of SGRQ activities score - NAVIGATOR, DITTB, DCO 1 _____	551
NT1GAC_IBMC0: Change from baseline in SGRQ activities score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	553
ST1GAC_IBMH0: Course of SGRQ activities score - SOURCE, DITTB _____	554
ST1GAC_IBMC0: Change from baseline in SGRQ activities score - MMRM results - SOURCE, DITTB _____	556
DT1GAC_BBMH0: Course of SGRQ activities score - DESTINATION, DITTNB - LTE _____	557
DT1GAC_BBMC0: Change from baseline in SGRQ activities score - MMRM results - DESTINATION, DITTNB - LTE _____	559
NT1GRC_IBMH0: Course of SGRQ impact score - NAVIGATOR, DITTB, DCO 1 _____	560
NT1GRC_IBMC0: Change from baseline in SGRQ impact score - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	562

ST1GRC_IBMH0: Course of SGRQ impact score - SOURCE, DITTB _____	563
ST1GRC_IBMC0: Change from baseline in SGRQ impact score - MMRM results - SOURCE, DITTB _____	565
DT1GRC_BBMH0: Course of SGRQ impact score - DESTINATION, DITTNB - LTE _____	566
DT1GRC_BBMC0: Change from baseline in SGRQ impact score - MMRM results - DESTINATION, DITTNB - LTE _____	568
DT1GTC_HBMH0: Course of SGRQ total score - DESTINATION, DITTNB - LTE - adult _____	569
DT1GTC_HBMC0: Change from baseline in SGRQ total score - MMRM results - DESTINATION, DITTNB - LTE - adult _____	571
DT1GMC_HBMH0: Course of SGRQ symptom score - DESTINATION, DITTNB - LTE - adult _____	572
DT1GMC_HBMC0: Change from baseline in SGRQ symptom score - MMRM results - DESTINATION, DITTNB - LTE - adult _____	574
DT1GAC_HBMH0: Course of SGRQ activities score - DESTINATION, DITTNB - LTE - adult _____	575
DT1GAC_HBMC0: Change from baseline in SGRQ activities score - MMRM results - DESTINATION, DITTNB - LTE - adult _____	577
DT1GRC_HBMH0: Course of SGRQ impact score - DESTINATION, DITTNB - LTE - adult _____	578
DT1GRC_HBMC0: Change from baseline in SGRQ impact score - MMRM results - DESTINATION, DITTNB - LTE - adult _____	580
NT1GTC_ABMH0: Course of SGRQ total score - NAVIGATOR, DITTB-adult, DCO 1 _____	581
NT1GTC_ABMC0: Change from baseline in SGRQ total score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	583
NT1GMC_ABMH0: Course of SGRQ symptom score - NAVIGATOR, DITTB-adult, DCO 1 _____	584
NT1GMC_ABMC0: Change from baseline in SGRQ symptom score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	586
NT1GAC_ABMH0: Course of SGRQ activities score - NAVIGATOR, DITTB-adult, DCO 1 _____	587
NT1GAC_ABMC0: Change from baseline in SGRQ activities score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	589
NT1GRC_ABMH0: Course of SGRQ impact score - NAVIGATOR, DITTB-adult, DCO 1 _____	590
NT1GRC_ABMC0: Change from baseline in SGRQ impact score - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	592
NT1PSC_IBMH0: Course of PGI-S - NAVIGATOR, DITTB, DCO 1 _____	593
NT1PSC_IBMC0: Change from baseline in PGI-S - MMRM results - NAVIGATOR, DITTB, DCO 1 _____	595
NT1PSC_ABMH0: Course of PGI-S - NAVIGATOR, DITTB-adult, DCO 1 _____	596
NT1PSC_ABMC0: Change from baseline in PGI-S - MMRM results - NAVIGATOR, DITTB-adult, DCO 1 _____	598

Table MT1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
FEV1 Pre-BD	Baseline	Tezepelumab	66	66 (100.0)	1.80 (0.63)	0.4	1.34	1.77	2.20	3.3	
		Placebo	48	48 (100.0)	1.76 (0.59)	0.8	1.36	1.74	2.14	3.2	
	Week 4	Tezepelumab	66	66 (100.0)	1.88 (0.67)	0.7	1.48	1.79	2.40	3.4	
		Placebo	48	47 (97.9)	1.84 (0.75)	0.7	1.32	1.73	2.32	4.8	
	Week 8	Tezepelumab	66	64 (97.0)	1.88 (0.62)	0.6	1.44	1.80	2.38	3.4	
		Placebo	48	47 (97.9)	1.85 (0.76)	0.8	1.37	1.76	2.30	4.6	
	Week 12	Tezepelumab	66	64 (97.0)	1.89 (0.68)	0.6	1.45	1.80	2.35	3.6	
		Placebo	48	47 (97.9)	1.83 (0.74)	0.8	1.31	1.66	2.25	4.6	
	Week 52	Tezepelumab	66	60 (90.9)	1.81 (0.59)	0.7	1.40	1.77	2.23	3.4	
		Placebo	48	43 (89.6)	1.78 (0.73)	0.6	1.15	1.68	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table MT1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	66	66 (100.0)	0.08 (0.34)	-0.9	-0.09	0.05	0.22	1.7	-0.04 [-0.41, 0.34]
		Placebo	48	47 (97.9)	0.09 (0.31)	-0.3	-0.05	0.07	0.16	1.6	
	Week 8	Tezepelumab	66	64 (97.0)	0.10 (0.28)	-0.8	-0.06	0.07	0.25	1.2	0.08 [-0.30, 0.46]
		Placebo	48	47 (97.9)	0.08 (0.34)	-0.8	-0.08	0.04	0.20	1.4	
	Week 12	Tezepelumab	66	64 (97.0)	0.10 (0.33)	-0.7	-0.07	0.06	0.18	1.4	0.08 [-0.29, 0.46]
		Placebo	48	47 (97.9)	0.07 (0.30)	-0.4	-0.06	0.02	0.20	1.4	
	Week 52	Tezepelumab	66	60 (90.9)	0.05 (0.33)	-1.0	-0.07	0.02	0.21	1.0	0.04 [-0.35, 0.43]
		Placebo	48	43 (89.6)	0.04 (0.34)	-1.0	-0.11	0.06	0.17	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table MT1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	66 (100.0)	0.08 (0.04)	(-0.01, 0.16)	-0.01 (0.06)	(-0.13, 0.12)	0.902
	Placebo	48	47 (97.9)	0.08 (0.05)	(-0.01, 0.18)			
Week 8	Tezepelumab	66	64 (97.0)	0.10 (0.04)	(0.03, 0.18)	0.03 (0.06)	(-0.09, 0.14)	0.657
	Placebo	48	47 (97.9)	0.08 (0.04)	(-0.01, 0.17)			
Week 12	Tezepelumab	66	64 (97.0)	0.10 (0.04)	(0.02, 0.17)	0.02 (0.06)	(-0.10, 0.14)	0.691
	Placebo	48	47 (97.9)	0.07 (0.05)	(-0.02, 0.16)			
Week 52	Tezepelumab	66	60 (90.9)	0.05 (0.04)	(-0.03, 0.14)	0.02 (0.06)	(-0.11, 0.15)	0.756
	Placebo	48	43 (89.6)	0.03 (0.05)	(-0.06, 0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline									
	Tezepelumab	55	55 (100.0)	1.80 (0.64)	0.4	1.28	1.79	2.20	3.3	
	Placebo	40	40 (100.0)	1.73 (0.53)	0.8	1.40	1.70	2.07	3.2	
	Week 2									
	Tezepelumab	55	53 (96.4)	1.86 (0.62)	0.6	1.42	1.80	2.36	3.4	
	Placebo	40	35 (87.5)	1.74 (0.66)	0.8	1.34	1.71	1.97	4.1	
	Week 4									
	Tezepelumab	55	55 (100.0)	1.85 (0.66)	0.7	1.44	1.75	2.40	3.4	
	Placebo	40	39 (97.5)	1.80 (0.72)	0.9	1.38	1.69	2.02	4.8	
	Week 8									
	Tezepelumab	55	53 (96.4)	1.85 (0.62)	0.6	1.55	1.79	2.38	3.3	
	Placebo	40	39 (97.5)	1.81 (0.70)	0.8	1.41	1.74	2.03	4.6	
	Week 12									
	Tezepelumab	55	54 (98.2)	1.86 (0.67)	0.6	1.44	1.76	2.32	3.6	
	Placebo	40	39 (97.5)	1.80 (0.71)	0.8	1.41	1.62	2.14	4.6	
	Week 16									
	Tezepelumab	55	54 (98.2)	1.91 (0.68)	0.6	1.46	1.84	2.34	3.5	
	Placebo	40	39 (97.5)	1.77 (0.71)	0.8	1.33	1.68	2.04	4.7	
	Week 24									
	Tezepelumab	55	54 (98.2)	1.84 (0.61)	0.6	1.52	1.83	2.29	3.5	
Placebo	40	36 (90.0)	1.76 (0.73)	0.8	1.38	1.63	2.09	4.8		
Week 36										
Tezepelumab	55	53 (96.4)	1.83 (0.65)	0.5	1.33	1.83	2.30	3.5		
Placebo	40	35 (87.5)	1.81 (0.68)	0.9	1.41	1.69	1.94	4.3		
Week 52										
Tezepelumab	55	51 (92.7)	1.83 (0.63)	0.7	1.43	1.79	2.26	3.4		
Placebo	40	35 (87.5)	1.76 (0.67)	0.9	1.24	1.66	2.15	4.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	55	53 (96.4)	0.05 (0.24)	-0.7	-0.01	0.05	0.15	0.8	0.14 [-0.29, 0.57]
		Placebo	40	35 (87.5)	0.01 (0.24)	-0.4	-0.09	-0.01	0.08	0.9	
	Week 4	Tezepelumab	55	55 (100.0)	0.05 (0.35)	-0.9	-0.09	0.04	0.17	1.7	-0.07 [-0.48, 0.34]
		Placebo	40	39 (97.5)	0.08 (0.31)	-0.3	-0.05	0.04	0.12	1.6	
	Week 8	Tezepelumab	55	53 (96.4)	0.08 (0.30)	-0.8	-0.07	0.04	0.19	1.2	0.06 [-0.36, 0.47]
		Placebo	40	39 (97.5)	0.07 (0.32)	-0.8	-0.07	0.04	0.18	1.4	
	Week 12	Tezepelumab	55	54 (98.2)	0.06 (0.29)	-0.7	-0.09	0.05	0.17	1.4	-0.03 [-0.44, 0.38]
		Placebo	40	39 (97.5)	0.07 (0.29)	-0.4	-0.06	0.02	0.20	1.4	
	Week 16	Tezepelumab	55	54 (98.2)	0.10 (0.33)	-0.6	-0.05	0.10	0.22	1.6	0.19 [-0.22, 0.60]
		Placebo	40	39 (97.5)	0.03 (0.33)	-0.6	-0.10	0.01	0.18	1.4	
	Week 24	Tezepelumab	55	54 (98.2)	0.07 (0.27)	-0.6	-0.11	0.00	0.22	1.0	0.14 [-0.29, 0.56]
		Placebo	40	36 (90.0)	0.02 (0.35)	-0.5	-0.11	0.03	0.09	1.6	
	Week 36	Tezepelumab	55	53 (96.4)	0.05 (0.34)	-0.8	-0.12	0.04	0.21	1.1	-0.12 [-0.55, 0.30]
		Placebo	40	35 (87.5)	0.09 (0.27)	-0.3	-0.09	0.06	0.29	1.1	
	Week 52	Tezepelumab	55	51 (92.7)	0.04 (0.35)	-1.0	-0.07	0.01	0.23	1.0	-0.03 [-0.46, 0.40]
		Placebo	40	35 (87.5)	0.05 (0.26)	-0.5	-0.08	0.06	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	55	53 (96.4)	0.05 (0.03)	(-0.01, 0.12)	0.06 (0.05)	(-0.04, 0.16)	0.260
	Placebo	40	35 (87.5)	-0.01 (0.04)	(-0.08, 0.07)			
Week 4	Tezepelumab	55	55 (100.0)	0.06 (0.05)	(-0.03, 0.15)	-0.01 (0.07)	(-0.15, 0.13)	0.857
	Placebo	40	39 (97.5)	0.07 (0.05)	(-0.04, 0.17)			
Week 8	Tezepelumab	55	53 (96.4)	0.08 (0.04)	(-0.01, 0.16)	0.01 (0.06)	(-0.12, 0.14)	0.880
	Placebo	40	39 (97.5)	0.07 (0.05)	(-0.03, 0.16)			
Week 12	Tezepelumab	55	54 (98.2)	0.06 (0.04)	(-0.01, 0.14)	-0.00 (0.06)	(-0.12, 0.12)	0.963
	Placebo	40	39 (97.5)	0.07 (0.05)	(-0.02, 0.16)			
Week 16	Tezepelumab	55	54 (98.2)	0.10 (0.04)	(0.01, 0.19)	0.07 (0.07)	(-0.06, 0.21)	0.297
	Placebo	40	39 (97.5)	0.03 (0.05)	(-0.07, 0.13)			
Week 24	Tezepelumab	55	54 (98.2)	0.07 (0.04)	(-0.01, 0.15)	0.04 (0.06)	(-0.08, 0.17)	0.516
	Placebo	40	36 (90.0)	0.03 (0.05)	(-0.07, 0.12)			
Week 36	Tezepelumab	55	53 (96.4)	0.05 (0.04)	(-0.03, 0.14)	-0.03 (0.06)	(-0.16, 0.10)	0.614
	Placebo	40	35 (87.5)	0.09 (0.05)	(-0.01, 0.19)			
Week 52	Tezepelumab	55	51 (92.7)	0.04 (0.04)	(-0.04, 0.13)	-0.00 (0.07)	(-0.13, 0.13)	0.972
	Placebo	40	35 (87.5)	0.05 (0.05)	(-0.05, 0.14)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table PT3FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline									
	Tezepelumab	12	12 (100.0)	1.90 (0.64)	1.1	1.40	1.77	2.40	3.1	
	Placebo	9	9 (100.0)	1.83 (0.83)	0.9	1.01	1.93	2.52	2.9	
Week 4	Tezepelumab	12	12 (100.0)	2.06 (0.69)	1.1	1.50	2.18	2.54	3.3	
	Placebo	9	9 (100.0)	1.96 (0.90)	0.7	1.17	1.94	2.61	3.1	
Week 8	Tezepelumab	12	12 (100.0)	2.07 (0.66)	1.4	1.42	2.05	2.47	3.4	
	Placebo	9	9 (100.0)	1.96 (0.99)	0.8	1.11	2.08	2.67	3.4	
Week 12	Tezepelumab	12	11 (91.7)	2.11 (0.76)	1.0	1.47	2.14	2.71	3.5	
	Placebo	9	9 (100.0)	1.92 (0.87)	0.9	1.20	1.93	2.50	3.3	
Week 20	Tezepelumab	12	10 (83.3)	1.86 (0.63)	1.0	1.47	1.61	2.30	2.9	
	Placebo	9	9 (100.0)	1.90 (0.96)	0.5	1.12	1.99	2.70	3.2	
Week 28	Tezepelumab	12	10 (83.3)	1.88 (0.52)	1.3	1.45	1.86	2.12	3.0	
	Placebo	9	9 (100.0)	1.84 (0.88)	0.7	1.12	1.85	2.01	3.4	
Week 40	Tezepelumab	12	10 (83.3)	1.96 (0.57)	1.2	1.45	1.95	2.33	3.0	
	Placebo	9	8 (88.9)	2.14 (0.98)	0.8	1.30	2.17	2.95	3.5	
Week 52	Tezepelumab	12	10 (83.3)	1.82 (0.54)	1.2	1.37	1.73	2.25	2.9	
	Placebo	9	9 (100.0)	1.81 (0.96)	0.6	1.08	1.86	2.00	3.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table PT3FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	12	12 (100.0)	0.16 (0.31)	-0.3	-0.05	0.09	0.34	0.8	0.10 [-0.76, 0.96]
		Placebo	9	9 (100.0)	0.13 (0.28)	-0.3	0.01	0.11	0.25	0.6	
	Week 8	Tezepelumab	12	12 (100.0)	0.17 (0.19)	-0.1	-0.03	0.27	0.32	0.4	0.15 [-0.72, 1.01]
		Placebo	9	9 (100.0)	0.13 (0.41)	-0.6	-0.09	0.15	0.29	0.9	
	Week 12	Tezepelumab	12	11 (91.7)	0.28 (0.43)	-0.1	-0.04	0.09	0.49	1.3	0.50 [-0.40, 1.40]
		Placebo	9	9 (100.0)	0.09 (0.34)	-0.4	-0.05	0.02	0.16	0.8	
	Week 20	Tezepelumab	12	10 (83.3)	0.16 (0.40)	-0.6	-0.06	0.10	0.53	0.8	0.26 [-0.65, 1.16]
		Placebo	9	9 (100.0)	0.07 (0.28)	-0.4	-0.10	0.06	0.21	0.5	
	Week 28	Tezepelumab	12	10 (83.3)	0.18 (0.25)	-0.1	0.01	0.07	0.30	0.6	0.41 [-0.50, 1.33]
		Placebo	9	9 (100.0)	0.01 (0.53)	-1.1	-0.17	0.11	0.28	0.9	
	Week 40	Tezepelumab	12	10 (83.3)	0.26 (0.36)	-0.1	0.04	0.24	0.29	1.1	0.16 [-0.78, 1.09]
		Placebo	9	8 (88.9)	0.20 (0.41)	-0.2	-0.17	0.16	0.39	1.0	
	Week 52	Tezepelumab	12	10 (83.3)	0.12 (0.23)	-0.2	-0.04	0.09	0.26	0.5	0.35 [-0.56, 1.25]
		Placebo	9	9 (100.0)	-0.02 (0.56)	-1.0	-0.26	0.06	0.17	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table PT3FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	12 (100.0)	0.14 (0.09)	(-0.06, 0.34)	0.02 (0.14)	(-0.29, 0.33)	0.897
	Placebo	9	9 (100.0)	0.12 (0.11)	(-0.11, 0.35)			
Week 8	Tezepelumab	12	12 (100.0)	0.16 (0.09)	(-0.03, 0.36)	0.03 (0.14)	(-0.26, 0.33)	0.816
	Placebo	9	9 (100.0)	0.13 (0.11)	(-0.10, 0.35)			
Week 12	Tezepelumab	12	11 (91.7)	0.24 (0.13)	(-0.03, 0.51)	0.15 (0.19)	(-0.26, 0.56)	0.440
	Placebo	9	9 (100.0)	0.08 (0.14)	(-0.22, 0.39)			
Week 20	Tezepelumab	12	10 (83.3)	0.15 (0.11)	(-0.08, 0.38)	0.08 (0.16)	(-0.26, 0.42)	0.612
	Placebo	9	9 (100.0)	0.07 (0.12)	(-0.18, 0.31)			
Week 28	Tezepelumab	12	10 (83.3)	0.13 (0.13)	(-0.15, 0.42)	0.13 (0.20)	(-0.30, 0.56)	0.528
	Placebo	9	9 (100.0)	0.00 (0.15)	(-0.31, 0.32)			
Week 40	Tezepelumab	12	10 (83.3)	0.23 (0.12)	(-0.02, 0.48)	0.01 (0.18)	(-0.36, 0.39)	0.940
	Placebo	9	8 (88.9)	0.21 (0.13)	(-0.07, 0.50)			
Week 52	Tezepelumab	12	10 (83.3)	0.10 (0.13)	(-0.18, 0.37)	0.12 (0.20)	(-0.29, 0.54)	0.537
	Placebo	9	9 (100.0)	-0.03 (0.15)	(-0.34, 0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table ST1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	12	12 (100.0)	1.38 (0.47)	0.7	0.94	1.53	1.73	2.0
		Placebo	11	11 (100.0)	1.43 (0.44)	0.9	0.93	1.45	1.75	2.3
	Week 4	Tezepelumab	12	12 (100.0)	1.50 (0.40)	1.0	1.05	1.64	1.86	2.0
		Placebo	11	11 (100.0)	1.41 (0.45)	0.9	1.00	1.26	1.82	2.2
	Week 12	Tezepelumab	12	11 (91.7)	1.44 (0.54)	0.9	0.93	1.51	2.01	2.2
		Placebo	11	11 (100.0)	1.45 (0.41)	1.0	1.06	1.40	1.62	2.3
	Week 24	Tezepelumab	12	11 (91.7)	1.42 (0.45)	0.9	0.92	1.59	1.82	2.0
		Placebo	11	11 (100.0)	1.37 (0.46)	0.8	1.03	1.27	1.66	2.5
	Week 40	Tezepelumab	12	9 (75.0)	1.63 (0.61)	0.7	1.14	1.77	2.11	2.2
		Placebo	11	11 (100.0)	1.36 (0.53)	0.7	1.01	1.25	1.67	2.5
	Week 48	Tezepelumab	12	9 (75.0)	1.60 (0.63)	0.7	0.86	1.84	2.07	2.2
		Placebo	11	10 (90.9)	1.45 (0.45)	0.8	1.10	1.38	1.67	2.3

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table ST1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	12	12 (100.0)	0.12 (0.23)	-0.2	-0.04	0.11	0.33	0.5	0.65 [-0.19, 1.49]
		Placebo	11	11 (100.0)	-0.02 (0.20)	-0.3	-0.17	-0.03	0.07	0.4	
	Week 12	Tezepelumab	12	11 (91.7)	0.09 (0.30)	-0.4	-0.15	0.19	0.30	0.6	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	0.02 (0.16)	-0.3	-0.02	0.04	0.17	0.2	
	Week 24	Tezepelumab	12	11 (91.7)	0.07 (0.21)	-0.3	-0.07	0.06	0.24	0.3	0.63 [-0.23, 1.49]
		Placebo	11	11 (100.0)	-0.05 (0.19)	-0.4	-0.13	-0.07	0.10	0.2	
	Week 40	Tezepelumab	12	9 (75.0)	0.22 (0.25)	-0.1	0.09	0.22	0.34	0.7	1.26 [0.29, 2.23]
		Placebo	11	11 (100.0)	-0.07 (0.21)	-0.4	-0.24	-0.11	0.14	0.2	
	Week 48	Tezepelumab	12	9 (75.0)	0.19 (0.18)	-0.2	0.16	0.19	0.25	0.4	1.27 [0.27, 2.27]
		Placebo	11	10 (90.9)	-0.03 (0.18)	-0.4	-0.14	0.00	0.10	0.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table ST1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	12 (100.0)	0.12 (0.06)	(-0.01, 0.25)	0.14 (0.09)	(-0.05, 0.33)	0.139
	Placebo	11	11 (100.0)	-0.02 (0.06)	(-0.15, 0.12)			
Week 12	Tezepelumab	12	11 (91.7)	0.08 (0.07)	(-0.07, 0.22)	0.05 (0.10)	(-0.16, 0.26)	0.606
	Placebo	11	11 (100.0)	0.02 (0.07)	(-0.13, 0.17)			
Week 24	Tezepelumab	12	11 (91.7)	0.06 (0.06)	(-0.06, 0.18)	0.11 (0.08)	(-0.06, 0.29)	0.191
	Placebo	11	11 (100.0)	-0.05 (0.06)	(-0.18, 0.07)			
Week 40	Tezepelumab	12	9 (75.0)	0.19 (0.08)	(0.03, 0.35)	0.26 (0.10)	(0.03, 0.48)	0.026 *
	Placebo	11	11 (100.0)	-0.06 (0.07)	(-0.21, 0.08)			
Week 48	Tezepelumab	12	9 (75.0)	0.18 (0.06)	(0.04, 0.31)	0.21 (0.08)	(0.03, 0.39)	0.025 *
	Placebo	11	10 (90.9)	-0.03 (0.06)	(-0.16, 0.09)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table DT1FAC_BBMH0: Course of FEV1 Pre-BD
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Teze+Teze	45	45 (100.0)	1.75 (0.60)	0.6	1.28	1.70	2.12	3.3	
		Pbo+Pbo	19	19 (100.0)	1.57 (0.45)	0.8	1.35	1.49	1.88	2.5	
	Week 2	Teze+Teze	45	43 (95.6)	1.83 (0.58)	0.7	1.42	1.79	2.29	2.9	
		Pbo+Pbo	19	17 (89.5)	1.46 (0.43)	0.8	1.08	1.46	1.74	2.3	
	Week 4	Teze+Teze	45	45 (100.0)	1.81 (0.65)	0.7	1.44	1.69	2.17	3.4	
		Pbo+Pbo	19	18 (94.7)	1.55 (0.47)	0.9	1.20	1.51	1.85	2.5	
	Week 8	Teze+Teze	45	44 (97.8)	1.82 (0.58)	0.7	1.49	1.72	2.38	2.9	
		Pbo+Pbo	19	18 (94.7)	1.51 (0.46)	0.8	1.27	1.51	1.76	2.4	
	Week 12	Teze+Teze	45	45 (100.0)	1.82 (0.65)	0.7	1.38	1.70	2.28	3.3	
		Pbo+Pbo	19	19 (100.0)	1.54 (0.48)	0.8	1.28	1.47	1.73	2.6	
	Week 16	Teze+Teze	45	44 (97.8)	1.85 (0.63)	0.6	1.45	1.69	2.29	3.3	
		Pbo+Pbo	19	19 (100.0)	1.52 (0.43)	0.8	1.31	1.63	1.78	2.2	
	Week 24	Teze+Teze	45	44 (97.8)	1.78 (0.60)	0.6	1.29	1.71	2.31	2.9	
		Pbo+Pbo	19	18 (94.7)	1.49 (0.42)	0.8	1.12	1.50	1.72	2.2	
	Week 36	Teze+Teze	45	43 (95.6)	1.77 (0.61)	0.5	1.25	1.71	2.14	3.1	
		Pbo+Pbo	19	17 (89.5)	1.56 (0.40)	0.9	1.41	1.57	1.74	2.4	
	Week 52	Teze+Teze	45	42 (93.3)	1.79 (0.58)	0.7	1.43	1.75	2.21	3.1	
		Pbo+Pbo	19	18 (94.7)	1.50 (0.43)	0.9	1.10	1.55	1.68	2.3	
	Week 64	Teze+Teze	45	37 (82.2)	1.79 (0.62)	0.7	1.41	1.70	2.15	3.2	
		Pbo+Pbo	19	19 (100.0)	1.55 (0.44)	0.9	1.10	1.54	1.82	2.4	
	Week 76	Teze+Teze	45	39 (86.7)	1.74 (0.65)	0.5	1.23	1.61	2.21	3.2	
		Pbo+Pbo	19	17 (89.5)	1.59 (0.49)	0.9	1.31	1.39	1.85	2.5	
	Week 88	Teze+Teze	45	35 (77.8)	1.80 (0.65)	0.6	1.40	1.70	2.12	3.3	
		Pbo+Pbo	19	19 (100.0)	1.58 (0.51)	0.9	1.09	1.55	1.89	2.5	
	Week 104	Teze+Teze	45	33 (73.3)	1.72 (0.63)	0.5	1.31	1.58	2.12	3.0	
		Pbo+Pbo	19	19 (100.0)	1.52 (0.50)	0.7	1.10	1.47	1.91	2.5	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table DT1FAC_BBMH0: Course of FEV1 Pre-BD
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Teze+Teze	45	43 (95.6)	0.06 (0.23)	-0.7	-0.01	0.05	0.12	0.8	0.48 [-0.09, 1.05]
		Pbo+Pbo	19	17 (89.5)	-0.04 (0.15)	-0.4	-0.09	-0.01	0.06	0.2	
	Week 4	Teze+Teze	45	45 (100.0)	0.05 (0.32)	-0.5	-0.09	0.01	0.15	1.7	0.17 [-0.37, 0.72]
		Pbo+Pbo	19	18 (94.7)	0.00 (0.16)	-0.3	-0.07	0.02	0.09	0.3	
	Week 8	Teze+Teze	45	44 (97.8)	0.10 (0.28)	-0.5	-0.08	0.04	0.17	1.2	0.70 [0.14, 1.26]
		Pbo+Pbo	19	18 (94.7)	-0.09 (0.24)	-0.8	-0.17	-0.04	0.05	0.2	
	Week 12	Teze+Teze	45	45 (100.0)	0.06 (0.27)	-0.3	-0.09	0.04	0.14	1.4	0.36 [-0.18, 0.90]
		Pbo+Pbo	19	19 (100.0)	-0.02 (0.17)	-0.4	-0.15	-0.02	0.06	0.4	
	Week 16	Teze+Teze	45	44 (97.8)	0.08 (0.33)	-0.6	-0.06	0.06	0.18	1.6	0.45 [-0.09, 1.00]
		Pbo+Pbo	19	19 (100.0)	-0.05 (0.20)	-0.6	-0.15	-0.03	0.06	0.3	
	Week 24	Teze+Teze	45	44 (97.8)	0.06 (0.24)	-0.4	-0.12	0.01	0.21	1.0	0.64 [0.08, 1.20]
		Pbo+Pbo	19	18 (94.7)	-0.08 (0.18)	-0.5	-0.21	-0.04	0.03	0.2	
	Week 36	Teze+Teze	45	43 (95.6)	0.04 (0.32)	-0.8	-0.13	0.01	0.16	1.1	0.01 [-0.55, 0.58]
		Pbo+Pbo	19	17 (89.5)	0.03 (0.19)	-0.3	-0.08	0.04	0.19	0.3	
	Week 52	Teze+Teze	45	42 (93.3)	0.04 (0.29)	-0.8	-0.07	0.00	0.16	1.0	0.21 [-0.34, 0.77]
		Pbo+Pbo	19	18 (94.7)	-0.02 (0.21)	-0.4	-0.22	0.02	0.13	0.4	
	Week 64	Teze+Teze	45	37 (82.2)	0.01 (0.36)	-0.9	-0.18	0.02	0.14	1.3	0.09 [-0.47, 0.64]
		Pbo+Pbo	19	19 (100.0)	-0.02 (0.17)	-0.4	-0.09	0.00	0.09	0.2	
	Week 76	Teze+Teze	45	39 (86.7)	0.02 (0.31)	-0.9	-0.17	-0.01	0.13	1.0	0.06 [-0.51, 0.63]
		Pbo+Pbo	19	17 (89.5)	-0.00 (0.16)	-0.3	-0.08	0.00	0.05	0.4	
	Week 88	Teze+Teze	45	35 (77.8)	0.06 (0.35)	-0.7	-0.09	0.03	0.20	1.3	0.13 [-0.43, 0.69]
		Pbo+Pbo	19	19 (100.0)	0.02 (0.21)	-0.5	-0.10	0.05	0.12	0.5	
	Week 104	Teze+Teze	45	33 (73.3)	0.01 (0.35)	-1.3	-0.08	0.02	0.17	1.1	0.20 [-0.37, 0.76]
		Pbo+Pbo	19	19 (100.0)	-0.05 (0.19)	-0.4	-0.17	0.02	0.11	0.2	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table DT1FAC_BBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTNB - LTE

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Teze+Teze	45	43 (95.6)	0.07 (0.03)	(0.01, 0.13)	0.13 (0.06)	(0.02, 0.24)	0.022 *
	Pbo+Pbo	19	17 (89.5)	-0.06 (0.05)	(-0.16, 0.03)			
Week 4	Teze+Teze	45	45 (100.0)	0.06 (0.04)	(-0.03, 0.14)	0.07 (0.08)	(-0.08, 0.23)	0.357
	Pbo+Pbo	19	18 (94.7)	-0.02 (0.07)	(-0.15, 0.12)			
Week 8	Teze+Teze	45	44 (97.8)	0.10 (0.04)	(0.02, 0.18)	0.19 (0.07)	(0.05, 0.34)	0.011 *
	Pbo+Pbo	19	18 (94.7)	-0.09 (0.06)	(-0.21, 0.03)			
Week 12	Teze+Teze	45	45 (100.0)	0.07 (0.04)	(-0.00, 0.14)	0.10 (0.07)	(-0.03, 0.24)	0.129
	Pbo+Pbo	19	19 (100.0)	-0.04 (0.06)	(-0.15, 0.08)			
Week 16	Teze+Teze	45	44 (97.8)	0.10 (0.04)	(0.01, 0.18)	0.16 (0.08)	(-0.00, 0.32)	0.054
	Pbo+Pbo	19	19 (100.0)	-0.06 (0.07)	(-0.19, 0.07)			
Week 24	Teze+Teze	45	44 (97.8)	0.07 (0.03)	(-0.00, 0.13)	0.16 (0.06)	(0.04, 0.29)	0.011 *
	Pbo+Pbo	19	18 (94.7)	-0.10 (0.05)	(-0.20, 0.01)			
Week 36	Teze+Teze	45	43 (95.6)	0.05 (0.04)	(-0.04, 0.13)	0.01 (0.08)	(-0.15, 0.16)	0.930
	Pbo+Pbo	19	17 (89.5)	0.04 (0.07)	(-0.09, 0.17)			
Week 52	Teze+Teze	45	42 (93.3)	0.04 (0.04)	(-0.04, 0.12)	0.07 (0.07)	(-0.07, 0.22)	0.329
	Pbo+Pbo	19	18 (94.7)	-0.03 (0.06)	(-0.15, 0.09)			
Week 64	Teze+Teze	45	37 (82.2)	0.03 (0.05)	(-0.06, 0.13)	0.06 (0.08)	(-0.10, 0.23)	0.445
	Pbo+Pbo	19	19 (100.0)	-0.03 (0.07)	(-0.17, 0.11)			
Week 76	Teze+Teze	45	39 (86.7)	0.03 (0.04)	(-0.05, 0.12)	0.05 (0.08)	(-0.11, 0.21)	0.526
	Pbo+Pbo	19	17 (89.5)	-0.02 (0.07)	(-0.15, 0.11)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table DT1FAC_BBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTNB - LTE

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 88	Teze+Teze	45	35 (77.8)	0.08 (0.05)	(-0.02, 0.18)	0.07 (0.09)	(-0.11, 0.25)	0.435
	Pbo+Pbo	19	19 (100.0)	0.01 (0.07)	(-0.14, 0.15)			
Week 104	Teze+Teze	45	33 (73.3)	0.03 (0.05)	(-0.07, 0.12)	0.09 (0.09)	(-0.09, 0.26)	0.335
	Pbo+Pbo	19	19 (100.0)	-0.06 (0.07)	(-0.20, 0.08)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table CT1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	4	4 (100.0)	1.91 (0.56)	1.4	1.46	1.79	2.35	2.6	
		Placebo	8	8 (100.0)	2.22 (0.41)	1.5	2.05	2.23	2.41	2.9	
	Week 12	Tezepelumab	4	4 (100.0)	1.86 (0.39)	1.5	1.63	1.74	2.10	2.4	
		Placebo	8	8 (100.0)	2.38 (0.53)	1.6	2.01	2.33	2.67	3.4	
	Week 28	Tezepelumab	4	4 (100.0)	1.80 (0.58)	1.1	1.36	1.81	2.23	2.5	
		Placebo	8	8 (100.0)	2.36 (0.52)	1.6	2.14	2.25	2.51	3.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table CT1FAC_IBMH0: Course of FEV1 Pre-BD
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 12	Tezepelumab	4	4 (100.0)	-0.04 (0.28)	-0.4	-0.27	-0.04	0.19	0.3	-0.79 [-2.04, 0.46]
		Placebo	8	8 (100.0)	0.15 (0.23)	-0.3	0.06	0.14	0.35	0.4	
	Week 28	Tezepelumab	4	4 (100.0)	-0.11 (0.18)	-0.3	-0.24	-0.12	0.02	0.1	-1.40 [-2.75, -0.05]
		Placebo	8	8 (100.0)	0.14 (0.18)	-0.0	0.02	0.09	0.19	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table CT1FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 12	Tezepelumab	4	4 (100.0)	-0.03 (0.13)	(-0.33, 0.28)	-0.17 (0.17)	(-0.54, 0.20)	0.333
	Placebo	8	8 (100.0)	0.14 (0.09)	(-0.07, 0.36)			
Week 28	Tezepelumab	4	4 (100.0)	-0.09 (0.09)	(-0.30, 0.12)	-0.22 (0.12)	(-0.49, 0.05)	0.094
	Placebo	8	8 (100.0)	0.13 (0.07)	(-0.02, 0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table DT1FAC_HBMH0: Course of FEV1 Pre-BD
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Teze+Teze	44	44 (100.0)	1.73 (0.59)	0.6	1.28	1.70	2.09	3.3	
		Pbo+Pbo	19	19 (100.0)	1.57 (0.45)	0.8	1.35	1.49	1.88	2.5	
	Week 2	Teze+Teze	44	42 (95.5)	1.81 (0.57)	0.7	1.42	1.76	2.17	2.9	
		Pbo+Pbo	19	17 (89.5)	1.46 (0.43)	0.8	1.08	1.46	1.74	2.3	
	Week 4	Teze+Teze	44	44 (100.0)	1.79 (0.65)	0.7	1.43	1.68	2.12	3.4	
		Pbo+Pbo	19	18 (94.7)	1.55 (0.47)	0.9	1.20	1.51	1.85	2.5	
	Week 8	Teze+Teze	44	43 (97.7)	1.80 (0.57)	0.7	1.43	1.68	2.35	2.9	
		Pbo+Pbo	19	18 (94.7)	1.51 (0.46)	0.8	1.27	1.51	1.76	2.4	
	Week 12	Teze+Teze	44	44 (100.0)	1.80 (0.64)	0.7	1.35	1.68	2.26	3.3	
		Pbo+Pbo	19	19 (100.0)	1.54 (0.48)	0.8	1.28	1.47	1.73	2.6	
	Week 16	Teze+Teze	44	43 (97.7)	1.83 (0.62)	0.6	1.43	1.67	2.27	3.3	
		Pbo+Pbo	19	19 (100.0)	1.52 (0.43)	0.8	1.31	1.63	1.78	2.2	
	Week 24	Teze+Teze	44	43 (97.7)	1.76 (0.58)	0.6	1.18	1.70	2.29	2.9	
		Pbo+Pbo	19	18 (94.7)	1.49 (0.42)	0.8	1.12	1.50	1.72	2.2	
	Week 36	Teze+Teze	44	42 (95.5)	1.74 (0.58)	0.5	1.25	1.68	2.11	2.9	
		Pbo+Pbo	19	17 (89.5)	1.56 (0.40)	0.9	1.41	1.57	1.74	2.4	
	Week 52	Teze+Teze	44	41 (93.2)	1.76 (0.55)	0.7	1.43	1.74	2.20	2.8	
		Pbo+Pbo	19	18 (94.7)	1.50 (0.43)	0.9	1.10	1.55	1.68	2.3	
	Week 64	Teze+Teze	44	36 (81.8)	1.75 (0.58)	0.7	1.35	1.70	2.14	3.0	
		Pbo+Pbo	19	19 (100.0)	1.55 (0.44)	0.9	1.10	1.54	1.82	2.4	
	Week 76	Teze+Teze	44	38 (86.4)	1.71 (0.61)	0.5	1.23	1.59	2.12	2.8	
		Pbo+Pbo	19	17 (89.5)	1.59 (0.49)	0.9	1.31	1.39	1.85	2.5	
	Week 88	Teze+Teze	44	34 (77.3)	1.76 (0.61)	0.6	1.40	1.70	2.07	3.0	
		Pbo+Pbo	19	19 (100.0)	1.58 (0.51)	0.9	1.09	1.55	1.89	2.5	
	Week 104	Teze+Teze	44	33 (75.0)	1.72 (0.63)	0.5	1.31	1.58	2.12	3.0	
		Pbo+Pbo	19	19 (100.0)	1.52 (0.50)	0.7	1.10	1.47	1.91	2.5	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table DT1FAC_HBMH0: Course of FEV1 Pre-BD
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Teze+Teze	44	42 (95.5)	0.06 (0.23)	-0.7	-0.01	0.05	0.12	0.8	0.48 [-0.09, 1.05]
		Pbo+Pbo	19	17 (89.5)	-0.04 (0.15)	-0.4	-0.09	-0.01	0.06	0.2	
	Week 4	Teze+Teze	44	44 (100.0)	0.05 (0.33)	-0.5	-0.11	0.03	0.15	1.7	0.18 [-0.37, 0.73]
		Pbo+Pbo	19	18 (94.7)	0.00 (0.16)	-0.3	-0.07	0.02	0.09	0.3	
	Week 8	Teze+Teze	44	43 (97.7)	0.10 (0.28)	-0.5	-0.08	0.04	0.18	1.2	0.70 [0.13, 1.26]
		Pbo+Pbo	19	18 (94.7)	-0.09 (0.24)	-0.8	-0.17	-0.04	0.05	0.2	
	Week 12	Teze+Teze	44	44 (100.0)	0.06 (0.27)	-0.3	-0.09	0.04	0.15	1.4	0.36 [-0.18, 0.90]
		Pbo+Pbo	19	19 (100.0)	-0.02 (0.17)	-0.4	-0.15	-0.02	0.06	0.4	
	Week 16	Teze+Teze	44	43 (97.7)	0.08 (0.33)	-0.6	-0.07	0.08	0.19	1.6	0.45 [-0.09, 1.00]
		Pbo+Pbo	19	19 (100.0)	-0.05 (0.20)	-0.6	-0.15	-0.03	0.06	0.3	
	Week 24	Teze+Teze	44	43 (97.7)	0.06 (0.24)	-0.4	-0.12	0.00	0.22	1.0	0.62 [0.06, 1.18]
		Pbo+Pbo	19	18 (94.7)	-0.08 (0.18)	-0.5	-0.21	-0.04	0.03	0.2	
	Week 36	Teze+Teze	44	42 (95.5)	0.03 (0.32)	-0.8	-0.13	-0.01	0.16	1.1	-0.01 [-0.58, 0.55]
		Pbo+Pbo	19	17 (89.5)	0.03 (0.19)	-0.3	-0.08	0.04	0.19	0.3	
	Week 52	Teze+Teze	44	41 (93.2)	0.03 (0.29)	-0.8	-0.07	0.00	0.13	1.0	0.18 [-0.37, 0.74]
		Pbo+Pbo	19	18 (94.7)	-0.02 (0.21)	-0.4	-0.22	0.02	0.13	0.4	
	Week 64	Teze+Teze	44	36 (81.8)	-0.01 (0.36)	-0.9	-0.19	0.01	0.13	1.3	0.04 [-0.51, 0.60]
		Pbo+Pbo	19	19 (100.0)	-0.02 (0.17)	-0.4	-0.09	0.00	0.09	0.2	
	Week 76	Teze+Teze	44	38 (86.4)	0.00 (0.31)	-0.9	-0.17	-0.03	0.12	1.0	0.01 [-0.56, 0.59]
		Pbo+Pbo	19	17 (89.5)	-0.00 (0.16)	-0.3	-0.08	0.00	0.05	0.4	
	Week 88	Teze+Teze	44	34 (77.3)	0.04 (0.34)	-0.7	-0.09	0.03	0.18	1.3	0.08 [-0.48, 0.64]
		Pbo+Pbo	19	19 (100.0)	0.02 (0.21)	-0.5	-0.10	0.05	0.12	0.5	
	Week 104	Teze+Teze	44	33 (75.0)	0.01 (0.35)	-1.3	-0.08	0.02	0.17	1.1	0.20 [-0.37, 0.76]
		Pbo+Pbo	19	19 (100.0)	-0.05 (0.19)	-0.4	-0.17	0.02	0.11	0.2	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table DT1FAC_HBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTNB - LTE - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Teze+Teze	44	42 (95.5)	0.07 (0.03)	(0.01, 0.13)	0.13 (0.06)	(0.02, 0.24)	0.021 *
	Pbo+Pbo	19	17 (89.5)	-0.06 (0.05)	(-0.16, 0.03)			
Week 4	Teze+Teze	44	44 (100.0)	0.06 (0.04)	(-0.03, 0.15)	0.08 (0.08)	(-0.08, 0.24)	0.337
	Pbo+Pbo	19	18 (94.7)	-0.02 (0.07)	(-0.15, 0.12)			
Week 8	Teze+Teze	44	43 (97.7)	0.10 (0.04)	(0.02, 0.18)	0.19 (0.07)	(0.05, 0.34)	0.010 *
	Pbo+Pbo	19	18 (94.7)	-0.09 (0.06)	(-0.21, 0.03)			
Week 12	Teze+Teze	44	44 (100.0)	0.07 (0.04)	(-0.01, 0.15)	0.11 (0.07)	(-0.03, 0.24)	0.131
	Pbo+Pbo	19	19 (100.0)	-0.04 (0.06)	(-0.15, 0.08)			
Week 16	Teze+Teze	44	43 (97.7)	0.10 (0.04)	(0.01, 0.19)	0.16 (0.08)	(-0.00, 0.32)	0.053
	Pbo+Pbo	19	19 (100.0)	-0.06 (0.07)	(-0.19, 0.07)			
Week 24	Teze+Teze	44	43 (97.7)	0.06 (0.03)	(-0.00, 0.13)	0.16 (0.06)	(0.04, 0.29)	0.012 *
	Pbo+Pbo	19	18 (94.7)	-0.10 (0.05)	(-0.20, 0.01)			
Week 36	Teze+Teze	44	42 (95.5)	0.04 (0.04)	(-0.04, 0.13)	-0.00 (0.08)	(-0.16, 0.15)	0.992
	Pbo+Pbo	19	17 (89.5)	0.04 (0.07)	(-0.09, 0.17)			
Week 52	Teze+Teze	44	41 (93.2)	0.04 (0.04)	(-0.04, 0.12)	0.06 (0.07)	(-0.08, 0.21)	0.374
	Pbo+Pbo	19	18 (94.7)	-0.03 (0.06)	(-0.15, 0.09)			
Week 64	Teze+Teze	44	36 (81.8)	0.02 (0.05)	(-0.07, 0.11)	0.05 (0.08)	(-0.11, 0.21)	0.549
	Pbo+Pbo	19	19 (100.0)	-0.03 (0.07)	(-0.17, 0.10)			
Week 76	Teze+Teze	44	38 (86.4)	0.02 (0.04)	(-0.07, 0.11)	0.04 (0.08)	(-0.12, 0.19)	0.620
	Pbo+Pbo	19	17 (89.5)	-0.02 (0.06)	(-0.15, 0.11)			

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table DT1FAC_HBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
 DITTNB - LTE - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 88	Teze+Teze	44	34 (77.3)	0.06 (0.05)	(-0.04, 0.16)	0.06 (0.09)	(-0.12, 0.23)	0.512
	Pbo+Pbo	19	19 (100.0)	0.01 (0.07)	(-0.14, 0.15)			
Week 104	Teze+Teze	44	33 (75.0)	0.02 (0.05)	(-0.08, 0.12)	0.08 (0.09)	(-0.10, 0.25)	0.379
	Pbo+Pbo	19	19 (100.0)	-0.06 (0.07)	(-0.20, 0.08)			

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
 Source Data: afev, created on: 28JUL2022

Table NT1FAC_ABMH0: Course of FEV1 Pre-BD
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	54	54 (100.0)	1.78 (0.63)	0.4	1.28	1.77	2.20	3.3	
		Placebo	39	39 (100.0)	1.74 (0.53)	0.8	1.39	1.70	2.10	3.2	
	Week 2	Tezepelumab	54	52 (96.3)	1.84 (0.61)	0.6	1.42	1.80	2.33	3.4	
		Placebo	39	34 (87.2)	1.75 (0.66)	0.8	1.35	1.71	1.97	4.1	
	Week 4	Tezepelumab	54	54 (100.0)	1.84 (0.66)	0.7	1.44	1.74	2.25	3.4	
		Placebo	39	38 (97.4)	1.81 (0.73)	0.9	1.38	1.71	2.02	4.8	
	Week 8	Tezepelumab	54	52 (96.3)	1.84 (0.61)	0.6	1.49	1.77	2.37	3.3	
		Placebo	39	38 (97.4)	1.82 (0.71)	0.8	1.41	1.75	2.03	4.6	
	Week 12	Tezepelumab	54	53 (98.1)	1.84 (0.66)	0.6	1.44	1.75	2.28	3.6	
		Placebo	39	38 (97.4)	1.81 (0.71)	0.8	1.41	1.64	2.14	4.6	
	Week 16	Tezepelumab	54	53 (98.1)	1.89 (0.67)	0.6	1.46	1.83	2.31	3.5	
		Placebo	39	38 (97.4)	1.77 (0.72)	0.8	1.33	1.69	2.04	4.7	
	Week 24	Tezepelumab	54	53 (98.1)	1.82 (0.59)	0.6	1.52	1.79	2.27	3.5	
		Placebo	39	35 (89.7)	1.77 (0.74)	0.8	1.36	1.63	2.11	4.8	
	Week 36	Tezepelumab	54	52 (96.3)	1.81 (0.63)	0.5	1.31	1.80	2.25	3.5	
		Placebo	39	34 (87.2)	1.82 (0.69)	0.9	1.43	1.70	1.94	4.3	
	Week 52	Tezepelumab	54	50 (92.6)	1.81 (0.61)	0.7	1.43	1.77	2.21	3.4	
		Placebo	39	34 (87.2)	1.77 (0.68)	0.9	1.24	1.67	2.15	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC_ABMH0: Course of FEV1 Pre-BD
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	54	52 (96.3)	0.05 (0.24)	-0.7	-0.02	0.05	0.15	0.8	0.13 [-0.30, 0.56]
		Placebo	39	34 (87.2)	0.01 (0.25)	-0.4	-0.09	-0.01	0.08	0.9	
	Week 4	Tezepelumab	54	54 (100.0)	0.06 (0.35)	-0.9	-0.09	0.04	0.17	1.7	-0.06 [-0.48, 0.35]
		Placebo	39	38 (97.4)	0.08 (0.32)	-0.3	-0.05	0.04	0.12	1.6	
	Week 8	Tezepelumab	54	52 (96.3)	0.08 (0.30)	-0.8	-0.08	0.05	0.20	1.2	0.07 [-0.35, 0.48]
		Placebo	39	38 (97.4)	0.06 (0.32)	-0.8	-0.07	0.04	0.18	1.4	
	Week 12	Tezepelumab	54	53 (98.1)	0.06 (0.30)	-0.7	-0.09	0.05	0.17	1.4	-0.03 [-0.45, 0.39]
		Placebo	39	38 (97.4)	0.07 (0.29)	-0.4	-0.06	0.01	0.20	1.4	
	Week 16	Tezepelumab	54	53 (98.1)	0.10 (0.33)	-0.6	-0.05	0.10	0.22	1.6	0.20 [-0.22, 0.61]
		Placebo	39	38 (97.4)	0.03 (0.33)	-0.6	-0.10	0.01	0.18	1.4	
	Week 24	Tezepelumab	54	53 (98.1)	0.06 (0.27)	-0.6	-0.11	0.00	0.22	1.0	0.13 [-0.30, 0.56]
		Placebo	39	35 (89.7)	0.02 (0.35)	-0.5	-0.11	0.03	0.10	1.6	
	Week 36	Tezepelumab	54	52 (96.3)	0.04 (0.34)	-0.8	-0.12	0.04	0.21	1.1	-0.16 [-0.59, 0.28]
		Placebo	39	34 (87.2)	0.09 (0.27)	-0.3	-0.09	0.06	0.29	1.1	
	Week 52	Tezepelumab	54	50 (92.6)	0.04 (0.35)	-1.0	-0.07	0.01	0.18	1.0	-0.05 [-0.49, 0.38]
		Placebo	39	34 (87.2)	0.05 (0.26)	-0.5	-0.08	0.05	0.15	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC_ABMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	54	52 (96.3)	0.05 (0.03)	(-0.02, 0.12)	0.06 (0.05)	(-0.05, 0.16)	0.289
	Placebo	39	34 (87.2)	-0.00 (0.04)	(-0.08, 0.07)			
Week 4	Tezepelumab	54	54 (100.0)	0.06 (0.05)	(-0.03, 0.15)	-0.01 (0.07)	(-0.15, 0.13)	0.871
	Placebo	39	38 (97.4)	0.07 (0.05)	(-0.04, 0.18)			
Week 8	Tezepelumab	54	52 (96.3)	0.08 (0.04)	(-0.01, 0.16)	0.01 (0.06)	(-0.12, 0.14)	0.852
	Placebo	39	38 (97.4)	0.07 (0.05)	(-0.03, 0.16)			
Week 12	Tezepelumab	54	53 (98.1)	0.06 (0.04)	(-0.02, 0.15)	-0.00 (0.06)	(-0.13, 0.12)	0.949
	Placebo	39	38 (97.4)	0.07 (0.05)	(-0.03, 0.16)			
Week 16	Tezepelumab	54	53 (98.1)	0.10 (0.05)	(0.01, 0.19)	0.07 (0.07)	(-0.07, 0.21)	0.296
	Placebo	39	38 (97.4)	0.03 (0.05)	(-0.08, 0.14)			
Week 24	Tezepelumab	54	53 (98.1)	0.06 (0.04)	(-0.02, 0.15)	0.04 (0.06)	(-0.09, 0.17)	0.547
	Placebo	39	35 (89.7)	0.02 (0.05)	(-0.07, 0.12)			
Week 36	Tezepelumab	54	52 (96.3)	0.05 (0.04)	(-0.04, 0.13)	-0.04 (0.07)	(-0.17, 0.09)	0.511
	Placebo	39	34 (87.2)	0.09 (0.05)	(-0.01, 0.19)			
Week 52	Tezepelumab	54	50 (92.6)	0.04 (0.04)	(-0.05, 0.12)	-0.01 (0.07)	(-0.14, 0.12)	0.903
	Placebo	39	34 (87.2)	0.04 (0.05)	(-0.06, 0.14)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table MT1H5C_IBMH0: Course of ACQ-5 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	66	66 (100.0)	2.91 (0.69)	1.8	2.40	3.00	3.20	5.2	
		Placebo	48	48 (100.0)	3.13 (0.73)	2.0	2.70	3.00	3.40	5.6	
	Week 2	Tezepelumab	66	63 (95.5)	2.28 (0.97)	0.0	1.60	2.40	2.80	4.4	
		Placebo	48	43 (89.6)	2.57 (1.06)	0.4	1.80	2.40	3.20	5.2	
	Week 4	Tezepelumab	66	64 (97.0)	2.16 (1.02)	0.0	1.60	2.40	2.80	4.4	
		Placebo	48	45 (93.8)	2.36 (0.91)	0.6	1.80	2.40	3.00	5.0	
	Week 8	Tezepelumab	66	63 (95.5)	2.07 (1.18)	0.0	1.20	2.20	2.80	5.2	
		Placebo	48	46 (95.8)	2.42 (1.03)	0.6	1.80	2.30	3.00	5.0	
	Week 12	Tezepelumab	66	63 (95.5)	1.93 (1.25)	0.0	1.00	2.00	2.80	5.6	
		Placebo	48	43 (89.6)	2.28 (1.15)	0.4	1.80	2.20	3.00	5.6	
	Week 16	Tezepelumab	66	63 (95.5)	1.85 (1.16)	0.0	1.00	2.00	2.80	4.8	
		Placebo	48	45 (93.8)	2.23 (1.07)	0.4	1.60	2.00	2.60	5.2	
	Week 20	Tezepelumab	66	64 (97.0)	1.80 (1.19)	0.0	0.80	2.00	2.60	4.8	
		Placebo	48	44 (91.7)	2.04 (1.02)	0.2	1.20	2.00	2.80	3.8	
	Week 24	Tezepelumab	66	64 (97.0)	1.77 (1.18)	0.0	0.80	1.90	2.60	4.8	
		Placebo	48	41 (85.4)	2.13 (1.11)	0.2	1.40	2.00	3.00	4.2	
	Week 28	Tezepelumab	66	63 (95.5)	1.82 (1.20)	0.0	0.80	1.80	2.80	4.8	
		Placebo	48	44 (91.7)	2.27 (1.24)	0.2	1.10	2.30	3.10	4.4	
	Week 32	Tezepelumab	66	65 (98.5)	1.84 (1.15)	0.0	1.00	1.80	2.80	4.8	
		Placebo	48	43 (89.6)	2.00 (1.04)	0.2	1.20	1.80	3.00	4.0	
	Week 36	Tezepelumab	66	66 (100.0)	1.88 (1.19)	0.0	1.00	1.80	2.60	4.8	
		Placebo	48	43 (89.6)	2.13 (1.15)	0.0	1.20	2.00	2.80	4.6	
	Week 40	Tezepelumab	66	63 (95.5)	1.90 (1.24)	0.0	1.00	2.00	3.00	4.8	
		Placebo	48	44 (91.7)	2.08 (1.17)	0.0	1.20	2.10	3.00	4.2	
	Week 44	Tezepelumab	66	65 (98.5)	1.79 (1.28)	0.0	0.80	1.80	2.80	4.8	
		Placebo	48	43 (89.6)	2.20 (1.07)	0.2	1.40	2.20	3.00	5.2	
	Week 48	Tezepelumab	66	66 (100.0)	1.96 (1.33)	0.0	1.00	2.00	2.80	5.0	
		Placebo	48	44 (91.7)	2.00 (1.23)	0.0	1.00	2.00	2.70	5.0	
	Week 52	Tezepelumab	66	61 (92.4)	1.77 (1.22)	0.0	1.00	1.80	2.80	4.8	
		Placebo	48	42 (87.5)	1.93 (1.18)	0.0	1.20	1.90	2.40	4.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H5C_IBMH0: Course of ACQ-5 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	66	63 (95.5)	-0.67 (0.92)	-3.2	-1.20	-0.60	-0.20	1.6	-0.08 [-0.47, 0.31]
	Placebo	48	43 (89.6)	-0.59 (0.94)	-2.8	-1.00	-0.40	-0.20	2.2	
Week 4	Tezepelumab	66	64 (97.0)	-0.78 (0.94)	-3.0	-1.50	-0.60	-0.10	1.0	0.01 [-0.37, 0.39]
	Placebo	48	45 (93.8)	-0.79 (0.86)	-3.0	-1.00	-0.60	-0.40	0.6	
Week 8	Tezepelumab	66	63 (95.5)	-0.88 (1.11)	-3.0	-1.60	-0.80	-0.20	2.6	-0.15 [-0.53, 0.23]
	Placebo	48	46 (95.8)	-0.72 (0.90)	-3.0	-1.00	-0.80	-0.20	2.0	
Week 12	Tezepelumab	66	63 (95.5)	-1.01 (1.12)	-3.2	-2.00	-0.80	-0.20	1.4	-0.12 [-0.50, 0.27]
	Placebo	48	43 (89.6)	-0.88 (1.07)	-3.2	-1.40	-0.80	-0.20	2.4	
Week 16	Tezepelumab	66	63 (95.5)	-1.09 (1.10)	-3.2	-2.00	-1.00	-0.40	1.2	-0.17 [-0.55, 0.21]
	Placebo	48	45 (93.8)	-0.92 (0.93)	-2.8	-1.40	-1.00	-0.40	1.0	
Week 20	Tezepelumab	66	64 (97.0)	-1.12 (1.16)	-3.2	-1.90	-1.00	-0.30	1.8	-0.01 [-0.40, 0.37]
	Placebo	48	44 (91.7)	-1.10 (0.95)	-3.2	-1.70	-1.00	-0.60	1.0	
Week 24	Tezepelumab	66	64 (97.0)	-1.16 (1.13)	-3.6	-1.80	-1.00	-0.40	0.6	-0.12 [-0.51, 0.27]
	Placebo	48	41 (85.4)	-1.03 (1.06)	-3.6	-1.80	-1.00	-0.40	1.2	
Week 28	Tezepelumab	66	63 (95.5)	-1.06 (1.13)	-3.0	-1.80	-0.80	-0.20	1.0	-0.18 [-0.56, 0.21]
	Placebo	48	44 (91.7)	-0.85 (1.20)	-3.6	-1.80	-0.70	-0.10	1.6	
Week 32	Tezepelumab	66	65 (98.5)	-1.07 (1.18)	-3.4	-1.80	-1.00	-0.20	1.6	0.06 [-0.33, 0.44]
	Placebo	48	43 (89.6)	-1.13 (1.05)	-3.6	-1.80	-1.00	-0.40	0.6	
Week 36	Tezepelumab	66	66 (100.0)	-1.02 (1.14)	-3.2	-2.00	-1.00	-0.40	1.6	-0.02 [-0.40, 0.37]
	Placebo	48	43 (89.6)	-1.00 (1.07)	-3.6	-1.60	-1.00	-0.20	0.8	
Week 40	Tezepelumab	66	63 (95.5)	-1.00 (1.20)	-3.4	-2.00	-1.00	-0.20	2.8	0.03 [-0.35, 0.42]
	Placebo	48	44 (91.7)	-1.04 (1.12)	-3.4	-1.70	-1.00	-0.40	1.4	
Week 44	Tezepelumab	66	65 (98.5)	-1.12 (1.23)	-3.4	-2.20	-1.20	-0.40	2.0	-0.17 [-0.56, 0.21]
	Placebo	48	43 (89.6)	-0.92 (0.98)	-3.4	-1.60	-0.60	-0.20	0.6	
Week 48	Tezepelumab	66	66 (100.0)	-0.95 (1.35)	-3.4	-2.00	-1.00	-0.40	2.2	0.14 [-0.24, 0.52]
	Placebo	48	44 (91.7)	-1.12 (1.13)	-3.8	-1.80	-1.00	-0.40	1.8	
Week 52	Tezepelumab	66	61 (92.4)	-1.17 (1.18)	-3.4	-2.20	-1.00	-0.40	2.0	0.03 [-0.37, 0.42]
	Placebo	48	42 (87.5)	-1.20 (1.15)	-3.8	-2.00	-1.00	-0.40	1.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	66	63 (95.5)	-0.69 (0.11)	(-0.91, -0.46)	-0.17 (0.18)	(-0.52, 0.18)	0.349
	Placebo	48	43 (89.6)	-0.52 (0.14)	(-0.79, -0.25)			
Week 4	Tezepelumab	66	64 (97.0)	-0.78 (0.11)	(-1.00, -0.56)	-0.06 (0.17)	(-0.40, 0.28)	0.731
	Placebo	48	45 (93.8)	-0.72 (0.13)	(-0.98, -0.46)			
Week 8	Tezepelumab	66	63 (95.5)	-0.89 (0.13)	(-1.14, -0.64)	-0.22 (0.20)	(-0.61, 0.18)	0.273
	Placebo	48	45 (93.8)	-0.67 (0.15)	(-0.97, -0.37)			
Week 12	Tezepelumab	66	62 (93.9)	-1.05 (0.14)	(-1.32, -0.78)	-0.20 (0.21)	(-0.63, 0.22)	0.344
	Placebo	48	42 (87.5)	-0.85 (0.16)	(-1.17, -0.52)			
Week 16	Tezepelumab	66	62 (93.9)	-1.11 (0.13)	(-1.36, -0.87)	-0.25 (0.20)	(-0.64, 0.14)	0.199
	Placebo	48	44 (91.7)	-0.86 (0.15)	(-1.16, -0.56)			
Week 20	Tezepelumab	66	62 (93.9)	-1.18 (0.13)	(-1.44, -0.92)	-0.16 (0.21)	(-0.57, 0.25)	0.442
	Placebo	48	44 (91.7)	-1.02 (0.16)	(-1.33, -0.70)			
Week 24	Tezepelumab	66	61 (92.4)	-1.21 (0.13)	(-1.47, -0.95)	-0.24 (0.21)	(-0.66, 0.17)	0.248
	Placebo	48	40 (83.3)	-0.97 (0.16)	(-1.28, -0.65)			
Week 28	Tezepelumab	66	60 (90.9)	-1.13 (0.14)	(-1.41, -0.85)	-0.37 (0.22)	(-0.80, 0.07)	0.099
	Placebo	48	43 (89.6)	-0.76 (0.17)	(-1.10, -0.43)			
Week 32	Tezepelumab	66	62 (93.9)	-1.13 (0.13)	(-1.39, -0.87)	-0.07 (0.21)	(-0.48, 0.34)	0.728
	Placebo	48	42 (87.5)	-1.06 (0.16)	(-1.38, -0.75)			
Week 36	Tezepelumab	66	63 (95.5)	-1.09 (0.13)	(-1.35, -0.83)	-0.17 (0.21)	(-0.58, 0.25)	0.424
	Placebo	48	42 (87.5)	-0.92 (0.16)	(-1.24, -0.60)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table MT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Tezepelumab	66	59 (89.4)	-1.07 (0.14)	(-1.35, -0.79)	-0.12 (0.22)	(-0.56, 0.32)	0.580
	Placebo	48	43 (89.6)	-0.95 (0.17)	(-1.28, -0.61)			
Week 44	Tezepelumab	66	60 (90.9)	-1.18 (0.14)	(-1.45, -0.91)	-0.31 (0.22)	(-0.74, 0.11)	0.148
	Placebo	48	43 (89.6)	-0.87 (0.16)	(-1.19, -0.54)			
Week 48	Tezepelumab	66	62 (93.9)	-1.01 (0.15)	(-1.31, -0.70)	0.05 (0.24)	(-0.43, 0.53)	0.827
	Placebo	48	43 (89.6)	-1.06 (0.19)	(-1.43, -0.69)			
Week 52	Tezepelumab	66	52 (78.8)	-1.15 (0.14)	(-1.43, -0.88)	-0.03 (0.22)	(-0.46, 0.40)	0.895
	Placebo	48	37 (77.1)	-1.12 (0.17)	(-1.46, -0.79)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table NT1H5C_IBMH0: Course of ACQ-5 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	55	55 (100.0)	2.92 (0.69)	1.8	2.40	3.00	3.20	5.2	
		Placebo	40	40 (100.0)	3.16 (0.76)	2.0	2.60	3.00	3.40	5.6	
	Week 2	Tezepelumab	55	54 (98.2)	2.29 (0.90)	0.0	1.80	2.40	2.80	4.4	
		Placebo	40	37 (92.5)	2.64 (1.07)	0.8	2.00	2.40	3.20	5.2	
	Week 4	Tezepelumab	55	55 (100.0)	2.16 (1.03)	0.0	1.60	2.40	2.80	4.4	
		Placebo	40	39 (97.5)	2.45 (0.88)	0.8	1.80	2.40	3.00	5.0	
	Week 8	Tezepelumab	55	54 (98.2)	2.06 (1.08)	0.0	1.40	2.20	2.80	4.4	
		Placebo	40	40 (100.0)	2.44 (1.00)	0.8	1.80	2.30	3.00	5.0	
	Week 12	Tezepelumab	55	54 (98.2)	1.93 (1.22)	0.0	1.00	2.00	2.80	5.6	
		Placebo	40	37 (92.5)	2.36 (1.17)	0.4	1.80	2.20	3.00	5.6	
	Week 16	Tezepelumab	55	54 (98.2)	1.84 (1.11)	0.0	1.00	1.90	2.60	3.8	
		Placebo	40	39 (97.5)	2.32 (1.10)	0.4	1.60	2.00	3.20	5.2	
	Week 20	Tezepelumab	55	54 (98.2)	1.79 (1.16)	0.0	0.80	2.00	2.60	4.8	
		Placebo	40	38 (95.0)	2.12 (0.94)	0.6	1.20	2.00	2.80	3.8	
	Week 24	Tezepelumab	55	54 (98.2)	1.76 (1.15)	0.0	0.80	1.90	2.60	4.8	
		Placebo	40	35 (87.5)	2.22 (1.03)	0.2	1.40	2.00	3.40	4.2	
	Week 28	Tezepelumab	55	52 (94.5)	1.79 (1.15)	0.0	0.80	1.80	2.60	4.6	
		Placebo	40	38 (95.0)	2.26 (1.20)	0.2	1.40	2.20	3.00	4.4	
	Week 32	Tezepelumab	55	54 (98.2)	1.78 (1.10)	0.0	1.00	1.80	2.60	4.0	
		Placebo	40	37 (92.5)	2.08 (1.03)	0.2	1.20	1.80	3.00	4.0	
	Week 36	Tezepelumab	55	55 (100.0)	1.85 (1.13)	0.0	1.00	1.80	2.60	4.6	
		Placebo	40	37 (92.5)	2.25 (1.03)	0.2	1.60	2.00	2.80	4.6	
	Week 40	Tezepelumab	55	52 (94.5)	1.84 (1.20)	0.0	1.00	1.90	2.90	4.6	
		Placebo	40	38 (95.0)	2.15 (1.08)	0.0	1.40	2.10	3.00	4.2	
	Week 44	Tezepelumab	55	54 (98.2)	1.71 (1.24)	0.0	0.60	1.50	2.60	4.0	
		Placebo	40	37 (92.5)	2.25 (1.03)	0.4	1.40	2.20	2.80	5.2	
	Week 48	Tezepelumab	55	55 (100.0)	1.91 (1.32)	0.0	0.80	2.00	2.80	5.0	
		Placebo	40	38 (95.0)	2.06 (1.14)	0.0	1.20	2.00	2.80	5.0	
	Week 52	Tezepelumab	55	50 (90.9)	1.71 (1.13)	0.0	1.00	1.80	2.60	4.0	
		Placebo	40	36 (90.0)	1.98 (1.15)	0.0	1.20	1.80	2.50	4.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C_IBMH0: Course of ACQ-5 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	55	54 (98.2)	-0.64 (0.88)	-3.2	-1.20	-0.60	-0.20	1.6	-0.11 [-0.53, 0.31]
	Placebo	40	37 (92.5)	-0.54 (0.94)	-2.6	-1.00	-0.40	-0.20	2.2	
Week 4	Tezepelumab	55	55 (100.0)	-0.76 (0.97)	-3.0	-1.60	-0.60	0.00	1.0	-0.05 [-0.46, 0.36]
	Placebo	40	39 (97.5)	-0.72 (0.83)	-3.0	-1.00	-0.60	-0.20	0.6	
Week 8	Tezepelumab	55	54 (98.2)	-0.87 (1.01)	-3.0	-1.60	-0.80	-0.20	2.4	-0.16 [-0.57, 0.24]
	Placebo	40	40 (100.0)	-0.72 (0.84)	-2.6	-1.00	-0.70	-0.20	2.0	
Week 12	Tezepelumab	55	54 (98.2)	-0.99 (1.12)	-3.2	-1.80	-0.80	-0.20	1.4	-0.15 [-0.57, 0.27]
	Placebo	40	37 (92.5)	-0.82 (1.08)	-3.0	-1.40	-0.80	0.00	2.4	
Week 16	Tezepelumab	55	54 (98.2)	-1.09 (1.10)	-3.2	-2.00	-1.00	-0.40	1.2	-0.24 [-0.65, 0.17]
	Placebo	40	39 (97.5)	-0.84 (0.94)	-2.6	-1.40	-0.80	-0.20	1.0	
Week 20	Tezepelumab	55	54 (98.2)	-1.13 (1.18)	-3.2	-1.80	-1.10	-0.40	1.8	-0.08 [-0.50, 0.34]
	Placebo	40	38 (95.0)	-1.04 (0.83)	-3.2	-1.40	-1.00	-0.60	0.6	
Week 24	Tezepelumab	55	54 (98.2)	-1.17 (1.15)	-3.6	-1.80	-1.00	-0.40	0.6	-0.20 [-0.63, 0.22]
	Placebo	40	35 (87.5)	-0.95 (0.94)	-3.6	-1.60	-1.00	-0.40	1.2	
Week 28	Tezepelumab	55	52 (94.5)	-1.09 (1.06)	-3.0	-1.80	-0.90	-0.30	0.8	-0.21 [-0.63, 0.21]
	Placebo	40	38 (95.0)	-0.87 (1.11)	-3.6	-1.60	-0.80	-0.20	1.2	
Week 32	Tezepelumab	55	54 (98.2)	-1.15 (1.18)	-3.4	-1.80	-1.10	-0.40	1.6	-0.08 [-0.50, 0.34]
	Placebo	40	37 (92.5)	-1.06 (1.04)	-3.6	-1.60	-1.00	-0.40	0.6	
Week 36	Tezepelumab	55	55 (100.0)	-1.07 (1.11)	-3.2	-2.00	-1.00	-0.60	1.6	-0.18 [-0.60, 0.24]
	Placebo	40	37 (92.5)	-0.88 (0.93)	-3.2	-1.40	-0.60	-0.20	0.4	
Week 40	Tezepelumab	55	52 (94.5)	-1.07 (1.18)	-3.4	-2.00	-1.00	-0.30	2.8	-0.08 [-0.50, 0.34]
	Placebo	40	38 (95.0)	-0.98 (1.00)	-3.4	-1.40	-0.90	-0.40	1.4	
Week 44	Tezepelumab	55	54 (98.2)	-1.21 (1.21)	-3.4	-2.20	-1.20	-0.40	2.0	-0.29 [-0.71, 0.13]
	Placebo	40	37 (92.5)	-0.89 (0.90)	-3.2	-1.40	-0.60	-0.40	0.6	
Week 48	Tezepelumab	55	55 (100.0)	-1.01 (1.35)	-3.4	-2.00	-1.00	-0.40	2.2	0.05 [-0.37, 0.46]
	Placebo	40	38 (95.0)	-1.06 (0.98)	-3.8	-1.60	-1.00	-0.40	0.4	
Week 52	Tezepelumab	55	50 (90.9)	-1.25 (1.09)	-3.4	-2.00	-1.10	-0.60	1.2	-0.09 [-0.51, 0.34]
	Placebo	40	36 (90.0)	-1.16 (1.01)	-3.8	-1.80	-1.00	-0.50	0.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	55	54 (98.2)	-0.69 (0.12)	(-0.92, -0.45)	-0.24 (0.18)	(-0.60, 0.13)	0.197
	Placebo	40	37 (92.5)	-0.45 (0.14)	(-0.73, -0.17)			
Week 4	Tezepelumab	55	55 (100.0)	-0.80 (0.12)	(-1.03, -0.57)	-0.15 (0.18)	(-0.51, 0.21)	0.419
	Placebo	40	39 (97.5)	-0.65 (0.14)	(-0.93, -0.38)			
Week 8	Tezepelumab	55	54 (98.2)	-0.92 (0.13)	(-1.17, -0.67)	-0.26 (0.19)	(-0.64, 0.13)	0.188
	Placebo	40	40 (100.0)	-0.66 (0.15)	(-0.95, -0.37)			
Week 12	Tezepelumab	55	54 (98.2)	-1.05 (0.15)	(-1.34, -0.75)	-0.26 (0.23)	(-0.72, 0.20)	0.262
	Placebo	40	37 (92.5)	-0.79 (0.18)	(-1.14, -0.44)			
Week 16	Tezepelumab	55	54 (98.2)	-1.12 (0.14)	(-1.39, -0.85)	-0.34 (0.21)	(-0.76, 0.07)	0.105
	Placebo	40	39 (97.5)	-0.78 (0.16)	(-1.10, -0.46)			
Week 20	Tezepelumab	55	54 (98.2)	-1.19 (0.14)	(-1.47, -0.92)	-0.25 (0.21)	(-0.67, 0.18)	0.251
	Placebo	40	38 (95.0)	-0.95 (0.16)	(-1.27, -0.62)			
Week 24	Tezepelumab	55	54 (98.2)	-1.22 (0.14)	(-1.50, -0.95)	-0.32 (0.22)	(-0.75, 0.11)	0.144
	Placebo	40	35 (87.5)	-0.90 (0.17)	(-1.23, -0.57)			
Week 28	Tezepelumab	55	52 (94.5)	-1.14 (0.15)	(-1.43, -0.85)	-0.36 (0.22)	(-0.80, 0.09)	0.117
	Placebo	40	38 (95.0)	-0.79 (0.17)	(-1.13, -0.45)			
Week 32	Tezepelumab	55	54 (98.2)	-1.18 (0.14)	(-1.47, -0.90)	-0.18 (0.22)	(-0.62, 0.26)	0.422
	Placebo	40	37 (92.5)	-1.00 (0.17)	(-1.34, -0.67)			
Week 36	Tezepelumab	55	55 (100.0)	-1.11 (0.14)	(-1.37, -0.84)	-0.28 (0.21)	(-0.70, 0.14)	0.192
	Placebo	40	37 (92.5)	-0.83 (0.16)	(-1.15, -0.50)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Tezepelumab	55	52 (94.5)	-1.11 (0.15)	(-1.41, -0.82)	-0.21 (0.23)	(-0.67, 0.25)	0.363
	Placebo	40	38 (95.0)	-0.90 (0.17)	(-1.25, -0.56)			
Week 44	Tezepelumab	55	54 (98.2)	-1.23 (0.14)	(-1.52, -0.94)	-0.40 (0.23)	(-0.85, 0.05)	0.081
	Placebo	40	37 (92.5)	-0.83 (0.17)	(-1.18, -0.49)			
Week 48	Tezepelumab	55	55 (100.0)	-1.04 (0.16)	(-1.36, -0.73)	-0.05 (0.25)	(-0.55, 0.44)	0.838
	Placebo	40	38 (95.0)	-0.99 (0.19)	(-1.37, -0.61)			
Week 52	Tezepelumab	55	50 (90.9)	-1.17 (0.15)	(-1.46, -0.87)	-0.12 (0.23)	(-0.59, 0.34)	0.593
	Placebo	40	36 (90.0)	-1.04 (0.18)	(-1.39, -0.69)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table PT3H5C_IBMH0: Course of ACQ-5 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	12	12 (100.0)	2.82 (0.68)	1.8	2.30	2.80	3.20	4.2	
		Placebo	9	9 (100.0)	2.93 (0.55)	2.0	2.80	3.00	3.40	3.6	
	Week 2	Tezepelumab	12	10 (83.3)	2.12 (1.32)	0.0	1.20	2.60	2.80	3.8	
		Placebo	9	7 (77.8)	2.17 (0.90)	0.4	1.80	2.40	2.80	3.0	
	Week 4	Tezepelumab	12	10 (83.3)	2.08 (1.05)	0.2	1.40	2.20	3.00	3.4	
		Placebo	9	7 (77.8)	1.89 (0.92)	0.6	0.80	1.80	2.60	3.0	
	Week 6	Tezepelumab	12	10 (83.3)	1.74 (1.05)	0.0	1.40	1.60	2.80	3.2	
		Placebo	9	7 (77.8)	1.94 (1.56)	0.2	1.00	1.40	2.60	5.0	
	Week 8	Tezepelumab	12	10 (83.3)	2.04 (1.66)	0.0	0.80	1.60	3.20	5.2	
		Placebo	9	7 (77.8)	2.31 (1.19)	0.6	1.00	2.40	3.20	3.8	
	Week 10	Tezepelumab	12	10 (83.3)	1.80 (1.53)	0.0	0.60	1.50	2.80	4.8	
		Placebo	9	7 (77.8)	1.89 (0.99)	0.4	1.00	1.80	3.00	3.0	
	Week 12	Tezepelumab	12	10 (83.3)	1.82 (1.47)	0.0	0.60	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.83 (0.89)	0.4	1.00	2.00	2.60	3.0	
	Week 14	Tezepelumab	12	10 (83.3)	1.66 (1.43)	0.0	0.40	1.50	2.00	4.8	
		Placebo	9	7 (77.8)	1.29 (0.62)	0.4	1.00	1.20	1.60	2.4	
	Week 16	Tezepelumab	12	10 (83.3)	1.84 (1.48)	0.0	0.80	1.90	2.80	4.8	
		Placebo	9	7 (77.8)	1.71 (0.59)	0.8	1.00	2.00	2.00	2.4	
	Week 18	Tezepelumab	12	11 (91.7)	1.85 (1.31)	0.0	1.00	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.57 (1.20)	0.0	1.00	1.20	3.20	3.2	
	Week 20	Tezepelumab	12	11 (91.7)	1.76 (1.39)	0.0	0.60	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.63 (1.34)	0.2	0.40	1.20	2.80	3.8	
	Week 22	Tezepelumab	12	11 (91.7)	1.93 (1.34)	0.0	1.00	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.40 (1.33)	0.0	0.40	1.00	1.80	4.0	
	Week 24	Tezepelumab	12	11 (91.7)	1.76 (1.34)	0.0	0.80	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.63 (1.38)	0.2	0.40	1.60	2.80	3.8	
	Week 26	Tezepelumab	12	12 (100.0)	1.88 (1.39)	0.0	0.80	1.90	2.80	4.8	
		Placebo	9	7 (77.8)	1.57 (1.32)	0.4	0.80	1.20	1.60	4.4	
	Week 28	Tezepelumab	12	12 (100.0)	1.85 (1.43)	0.0	0.70	1.70	2.90	4.8	
		Placebo	9	7 (77.8)	2.20 (1.54)	0.4	0.80	2.40	3.80	4.4	
	Week 30	Tezepelumab	12	12 (100.0)	2.02 (1.47)	0.0	0.80	2.10	2.80	4.8	
		Placebo	9	7 (77.8)	1.86 (1.24)	0.4	0.40	2.40	3.00	3.4	
	Week 32	Tezepelumab	12	12 (100.0)	2.02 (1.42)	0.0	1.00	2.20	2.90	4.8	
		Placebo	9	7 (77.8)	1.54 (0.96)	0.4	0.60	1.80	2.20	3.0	
Week 34	Tezepelumab	12	12 (100.0)	1.98 (1.52)	0.0	0.90	1.70	2.90	4.8		
	Placebo	9	7 (77.8)	1.43 (1.20)	0.0	0.00	1.80	2.20	3.2		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C_IBMH0: Course of ACQ-5 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Week 36	Tezepelumab	12	12 (100.0)	1.93 (1.48)	0.0	0.90	1.70	3.00	4.8	
		Placebo	9	7 (77.8)	1.43 (1.46)	0.0	0.00	1.60	2.60	3.6	
	Week 38	Tezepelumab	12	12 (100.0)	1.97 (1.63)	0.0	0.70	1.60	3.00	4.8	
		Placebo	9	7 (77.8)	1.51 (1.34)	0.0	0.00	1.80	3.00	3.2	
	Week 40	Tezepelumab	12	12 (100.0)	2.03 (1.47)	0.0	0.90	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.71 (1.55)	0.0	0.40	1.80	3.00	4.2	
	Week 42	Tezepelumab	12	12 (100.0)	2.08 (1.51)	0.0	0.90	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.71 (1.38)	0.0	0.40	2.00	2.80	3.8	
	Week 44	Tezepelumab	12	12 (100.0)	2.03 (1.44)	0.0	0.90	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.97 (1.22)	0.2	0.80	1.80	3.20	3.4	
	Week 46	Tezepelumab	12	12 (100.0)	2.05 (1.44)	0.0	1.00	2.00	3.00	4.8	
		Placebo	9	7 (77.8)	1.60 (1.48)	0.0	0.60	1.00	2.20	4.4	
	Week 48	Tezepelumab	12	12 (100.0)	2.07 (1.46)	0.0	1.00	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.63 (1.62)	0.0	0.20	1.80	2.40	4.6	
	Week 50	Tezepelumab	12	12 (100.0)	1.95 (1.59)	0.0	0.50	2.00	3.00	4.8	
		Placebo	9	7 (77.8)	1.69 (1.31)	0.0	0.40	2.00	2.40	3.8	
	Week 52	Tezepelumab	12	12 (100.0)	1.92 (1.57)	0.0	0.50	2.00	2.90	4.8	
		Placebo	9	7 (77.8)	1.66 (1.30)	0.0	0.40	2.00	2.40	3.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C_IBMH0: Course of ACQ-5 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	12	10 (83.3)	-0.88 (1.07)	-3.2	-1.20	-0.70	-0.20	0.4	-0.05 [-1.02, 0.92]
	Placebo	9	7 (77.8)	-0.83 (0.92)	-2.8	-1.00	-0.40	-0.20	-0.2	
Week 4	Tezepelumab	12	10 (83.3)	-0.92 (0.83)	-2.4	-1.40	-0.80	-0.20	0.2	0.22 [-0.75, 1.19]
	Placebo	9	7 (77.8)	-1.11 (0.92)	-3.0	-1.40	-1.00	-0.40	-0.2	
Week 6	Tezepelumab	12	10 (83.3)	-1.26 (0.82)	-2.8	-1.60	-1.20	-0.80	0.0	-0.18 [-1.14, 0.79]
	Placebo	9	7 (77.8)	-1.06 (1.53)	-3.4	-1.80	-1.20	-0.40	1.6	
Week 8	Tezepelumab	12	10 (83.3)	-0.96 (1.57)	-3.0	-2.00	-1.40	0.00	2.6	-0.19 [-1.16, 0.78]
	Placebo	9	7 (77.8)	-0.69 (1.26)	-3.0	-1.20	-0.80	0.20	1.0	
Week 10	Tezepelumab	12	10 (83.3)	-1.20 (1.24)	-3.0	-2.20	-1.40	0.20	0.6	-0.07 [-1.04, 0.89]
	Placebo	9	7 (77.8)	-1.11 (1.06)	-3.2	-1.40	-1.20	-0.40	0.0	
Week 12	Tezepelumab	12	10 (83.3)	-1.18 (1.11)	-2.6	-2.20	-1.20	-0.20	0.6	-0.01 [-0.97, 0.96]
	Placebo	9	7 (77.8)	-1.17 (0.94)	-3.2	-1.20	-0.80	-0.60	-0.4	
Week 14	Tezepelumab	12	10 (83.3)	-1.34 (1.05)	-2.8	-2.20	-1.40	-0.80	0.6	0.38 [-0.60, 1.35]
	Placebo	9	7 (77.8)	-1.71 (0.89)	-3.2	-2.40	-1.60	-1.20	-0.4	
Week 16	Tezepelumab	12	10 (83.3)	-1.16 (1.11)	-2.4	-2.20	-1.10	-0.40	0.6	0.13 [-0.84, 1.09]
	Placebo	9	7 (77.8)	-1.29 (0.76)	-2.8	-1.40	-1.20	-0.80	-0.4	
Week 18	Tezepelumab	12	11 (91.7)	-1.05 (1.07)	-2.8	-2.20	-1.00	0.00	0.6	0.32 [-0.64, 1.27]
	Placebo	9	7 (77.8)	-1.43 (1.36)	-3.2	-2.40	-1.40	0.20	0.4	
Week 20	Tezepelumab	12	11 (91.7)	-1.15 (1.09)	-2.6	-2.20	-1.00	-0.20	0.6	0.18 [-0.77, 1.13]
	Placebo	9	7 (77.8)	-1.37 (1.48)	-3.0	-2.80	-1.80	-0.20	1.0	
Week 22	Tezepelumab	12	11 (91.7)	-0.98 (1.03)	-2.4	-2.20	-0.80	-0.20	0.6	0.51 [-0.46, 1.47]
	Placebo	9	7 (77.8)	-1.60 (1.47)	-3.2	-2.80	-1.80	-1.00	1.2	
Week 24	Tezepelumab	12	11 (91.7)	-1.15 (1.03)	-2.4	-2.20	-1.20	-0.20	0.6	0.18 [-0.77, 1.13]
	Placebo	9	7 (77.8)	-1.37 (1.54)	-3.2	-3.00	-1.80	0.00	1.0	
Week 26	Tezepelumab	12	12 (100.0)	-0.93 (1.17)	-2.6	-2.20	-0.70	0.00	0.6	0.39 [-0.55, 1.33]
	Placebo	9	7 (77.8)	-1.43 (1.43)	-2.4	-2.40	-1.80	-1.20	1.6	
Week 28	Tezepelumab	12	12 (100.0)	-0.97 (1.41)	-2.8	-2.20	-1.10	0.50	1.0	-0.11 [-1.04, 0.82]
	Placebo	9	7 (77.8)	-0.80 (1.65)	-2.8	-2.40	-0.80	0.80	1.6	
Week 30	Tezepelumab	12	12 (100.0)	-0.80 (1.41)	-2.6	-2.20	-0.60	0.10	2.0	0.25 [-0.69, 1.18]
	Placebo	9	7 (77.8)	-1.14 (1.36)	-3.2	-2.40	-0.60	-0.20	0.6	
Week 32	Tezepelumab	12	12 (100.0)	-0.80 (1.16)	-2.4	-1.90	-0.80	0.20	1.0	0.59 [-0.37, 1.54]
	Placebo	9	7 (77.8)	-1.46 (1.05)	-3.0	-2.40	-1.20	-1.00	0.2	
Week 34	Tezepelumab	12	12 (100.0)	-0.83 (1.44)	-2.4	-2.20	-1.00	0.10	2.2	0.54 [-0.41, 1.49]
	Placebo	9	7 (77.8)	-1.57 (1.26)	-3.2	-2.80	-1.40	-0.60	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C_IBMH0: Course of ACQ-5 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 36 score	Tezepelumab	12	12 (100.0)	-0.88 (1.31)	-2.4	-2.20	-1.20	0.20	1.6	0.49 [-0.46, 1.44]
	Placebo	9	7 (77.8)	-1.57 (1.55)	-3.6	-3.20	-1.40	-0.60	0.8	
Week 38	Tezepelumab	12	12 (100.0)	-0.85 (1.55)	-2.6	-2.20	-1.30	0.20	2.6	0.43 [-0.52, 1.37]
	Placebo	9	7 (77.8)	-1.49 (1.39)	-3.2	-3.00	-1.40	0.20	0.2	
Week 40	Tezepelumab	12	12 (100.0)	-0.78 (1.30)	-2.4	-1.90	-1.00	0.20	1.8	0.35 [-0.59, 1.29]
	Placebo	9	7 (77.8)	-1.29 (1.64)	-3.2	-2.80	-1.20	0.20	1.4	
Week 42	Tezepelumab	12	12 (100.0)	-0.73 (1.37)	-2.4	-1.80	-1.00	0.20	2.2	0.40 [-0.54, 1.34]
	Placebo	9	7 (77.8)	-1.29 (1.42)	-2.8	-2.80	-1.20	-0.20	1.0	
Week 44	Tezepelumab	12	12 (100.0)	-0.78 (1.25)	-2.4	-1.80	-1.00	0.20	1.6	0.19 [-0.74, 1.12]
	Placebo	9	7 (77.8)	-1.03 (1.36)	-3.4	-1.80	-1.20	0.00	0.6	
Week 46	Tezepelumab	12	12 (100.0)	-0.77 (1.36)	-2.4	-2.20	-0.80	0.20	1.8	0.43 [-0.51, 1.38]
	Placebo	9	7 (77.8)	-1.40 (1.65)	-3.2	-2.80	-1.60	-0.60	1.6	
Week 48	Tezepelumab	12	12 (100.0)	-0.75 (1.33)	-2.4	-1.90	-0.90	0.20	2.0	0.41 [-0.53, 1.36]
	Placebo	9	7 (77.8)	-1.37 (1.77)	-3.4	-3.20	-1.60	-0.40	1.8	
Week 50	Tezepelumab	12	12 (100.0)	-0.87 (1.50)	-3.2	-2.20	-0.80	0.20	2.0	0.28 [-0.66, 1.22]
	Placebo	9	7 (77.8)	-1.31 (1.76)	-3.6	-2.80	-1.00	-0.40	1.6	
Week 52	Tezepelumab	12	12 (100.0)	-0.90 (1.48)	-3.2	-2.20	-0.80	0.10	2.0	0.28 [-0.66, 1.22]
	Placebo	9	7 (77.8)	-1.34 (1.75)	-3.6	-2.80	-1.00	-0.40	1.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 6	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 10	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 14	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 18	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 22	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 26	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 30	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 34	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 36	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 38	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	5 (55.6)					
Week 44	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 46	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 50	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table DT1H5C_BBMH0: Course of ACQ-5 score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Teze+Teze	45	45 (100.0)	2.90 (0.69)	1.8	2.40	3.00	3.20	5.2	
		Pbo+Pbo	19	19 (100.0)	3.17 (0.80)	2.2	2.60	3.00	3.40	5.6	
Week 2		Teze+Teze	45	44 (97.8)	2.18 (0.87)	0.0	1.60	2.30	2.80	4.4	
		Pbo+Pbo	19	18 (94.7)	2.26 (0.86)	0.8	1.60	2.20	2.80	3.8	
Week 4		Teze+Teze	45	45 (100.0)	2.09 (1.02)	0.0	1.60	2.40	2.80	4.4	
		Pbo+Pbo	19	19 (100.0)	2.15 (0.77)	0.8	1.60	2.20	2.80	3.4	
Week 8		Teze+Teze	45	44 (97.8)	1.92 (1.01)	0.0	1.20	2.10	2.60	4.0	
		Pbo+Pbo	19	19 (100.0)	2.26 (1.05)	1.0	1.60	2.00	3.00	5.0	
Week 12		Teze+Teze	45	44 (97.8)	1.81 (1.23)	0.0	0.90	1.90	2.70	5.6	
		Pbo+Pbo	19	19 (100.0)	1.89 (0.97)	0.4	1.00	1.80	2.40	3.8	
Week 16		Teze+Teze	45	44 (97.8)	1.74 (1.11)	0.0	1.00	1.60	2.60	3.8	
		Pbo+Pbo	19	19 (100.0)	1.89 (0.88)	0.4	1.20	1.80	2.20	3.8	
Week 20		Teze+Teze	45	44 (97.8)	1.77 (1.15)	0.0	0.80	2.00	2.70	4.8	
		Pbo+Pbo	19	19 (100.0)	1.88 (0.89)	0.6	1.00	1.60	2.80	3.6	
Week 24		Teze+Teze	45	44 (97.8)	1.72 (1.10)	0.0	0.90	1.80	2.60	3.6	
		Pbo+Pbo	19	18 (94.7)	2.01 (0.93)	0.2	1.20	1.90	3.00	3.6	
Week 28		Teze+Teze	45	43 (95.6)	1.71 (1.17)	0.0	0.80	1.60	2.60	4.6	
		Pbo+Pbo	19	19 (100.0)	1.88 (1.10)	0.2	0.80	2.20	2.80	3.8	
Week 32		Teze+Teze	45	44 (97.8)	1.76 (1.12)	0.0	0.90	1.80	2.60	4.0	
		Pbo+Pbo	19	19 (100.0)	1.74 (0.93)	0.2	1.20	1.40	2.60	3.4	
Week 36		Teze+Teze	45	45 (100.0)	1.85 (1.18)	0.0	1.00	1.80	2.60	4.6	
		Pbo+Pbo	19	19 (100.0)	2.04 (0.99)	0.2	1.20	2.00	2.60	4.4	
Week 40		Teze+Teze	45	42 (93.3)	1.79 (1.16)	0.0	0.80	1.90	2.80	3.6	
		Pbo+Pbo	19	19 (100.0)	1.94 (1.01)	0.0	1.40	2.00	2.60	3.4	
Week 44		Teze+Teze	45	44 (97.8)	1.72 (1.23)	0.0	0.70	1.50	2.70	4.0	
		Pbo+Pbo	19	19 (100.0)	2.04 (0.98)	0.4	1.20	2.20	2.80	4.0	
Week 48		Teze+Teze	45	45 (100.0)	1.76 (1.26)	0.0	0.80	1.80	2.60	5.0	
		Pbo+Pbo	19	19 (100.0)	1.81 (1.20)	0.0	1.00	1.60	2.40	4.2	
Week 52		Teze+Teze	45	43 (95.6)	1.70 (1.11)	0.0	1.00	1.80	2.60	3.6	
		Pbo+Pbo	19	19 (100.0)	1.78 (1.11)	0.0	1.00	1.60	2.20	4.6	
Week 64		Teze+Teze	45	44 (97.8)	1.65 (1.12)	0.0	1.00	1.40	2.30	4.6	
		Pbo+Pbo	19	19 (100.0)	1.97 (1.08)	0.0	1.00	2.20	2.40	4.2	
Week 76		Teze+Teze	45	43 (95.6)	1.75 (1.36)	0.0	0.40	1.60	2.80	5.4	
		Pbo+Pbo	19	19 (100.0)	1.74 (0.91)	0.2	0.80	2.00	2.60	3.0	
Week 88		Teze+Teze	45	41 (91.1)	1.51 (1.08)	0.0	0.80	1.40	2.40	3.6	
		Pbo+Pbo	19	19 (100.0)	1.96 (0.96)	0.4	1.00	2.00	3.00	3.2	
Week 104		Teze+Teze	45	40 (88.9)	1.49 (1.02)	0.0	0.80	1.40	2.20	4.2	
		Pbo+Pbo	19	19 (100.0)	1.67 (0.98)	0.0	0.80	1.80	2.60	2.8	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C_BBMH0: Course of ACQ-5 score
 DITTNB - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Teze+Teze	45	44 (97.8)	-0.73 (0.77)	-3.2	-1.10	-0.70	-0.20	0.4	0.24 [-0.31, 0.79]
	Pbo+Pbo	19	18 (94.7)	-0.92 (0.95)	-2.6	-1.80	-0.50	-0.20	0.4	
Week 4	Teze+Teze	45	45 (100.0)	-0.81 (0.91)	-3.0	-1.60	-0.60	-0.20	0.8	0.23 [-0.31, 0.77]
	Pbo+Pbo	19	19 (100.0)	-1.02 (0.93)	-3.0	-1.60	-0.60	-0.40	0.2	
Week 8	Teze+Teze	45	44 (97.8)	-1.00 (0.88)	-3.0	-1.70	-0.90	-0.40	0.4	-0.10 [-0.64, 0.44]
	Pbo+Pbo	19	19 (100.0)	-0.91 (1.02)	-2.6	-1.60	-1.00	-0.40	2.0	
Week 12	Teze+Teze	45	44 (97.8)	-1.09 (1.11)	-3.2	-2.00	-0.90	-0.20	1.2	0.17 [-0.37, 0.71]
	Pbo+Pbo	19	19 (100.0)	-1.27 (1.02)	-3.0	-2.00	-1.40	-0.40	0.4	
Week 16	Teze+Teze	45	44 (97.8)	-1.17 (1.06)	-3.2	-2.00	-1.00	-0.50	0.8	0.10 [-0.44, 0.64]
	Pbo+Pbo	19	19 (100.0)	-1.27 (0.84)	-2.6	-1.80	-1.40	-0.60	0.4	
Week 20	Teze+Teze	45	44 (97.8)	-1.13 (1.16)	-3.2	-1.80	-1.10	-0.40	1.8	0.14 [-0.40, 0.68]
	Pbo+Pbo	19	19 (100.0)	-1.28 (0.94)	-3.2	-2.00	-1.20	-0.60	0.4	
Week 24	Teze+Teze	45	44 (97.8)	-1.20 (1.12)	-3.6	-1.80	-1.00	-0.50	0.6	-0.01 [-0.56, 0.54]
	Pbo+Pbo	19	18 (94.7)	-1.19 (0.91)	-3.6	-1.60	-1.20	-0.60	0.2	
Week 28	Teze+Teze	45	43 (95.6)	-1.14 (1.06)	-3.0	-1.80	-1.00	-0.20	0.8	0.14 [-0.40, 0.68]
	Pbo+Pbo	19	19 (100.0)	-1.28 (1.03)	-3.6	-2.00	-1.20	-0.60	0.6	
Week 32	Teze+Teze	45	44 (97.8)	-1.15 (1.15)	-3.4	-1.80	-1.00	-0.40	1.0	0.24 [-0.30, 0.78]
	Pbo+Pbo	19	19 (100.0)	-1.43 (1.16)	-3.6	-2.60	-1.40	-0.60	0.4	
Week 36	Teze+Teze	45	45 (100.0)	-1.05 (1.13)	-3.2	-2.00	-1.00	-0.60	1.6	0.07 [-0.47, 0.60]
	Pbo+Pbo	19	19 (100.0)	-1.13 (1.03)	-3.2	-1.60	-1.00	-0.20	0.2	
Week 40	Teze+Teze	45	42 (93.3)	-1.10 (1.05)	-3.2	-2.00	-1.00	-0.20	0.8	0.13 [-0.42, 0.67]
	Pbo+Pbo	19	19 (100.0)	-1.23 (1.06)	-3.4	-2.00	-1.00	-0.40	0.2	
Week 44	Teze+Teze	45	44 (97.8)	-1.18 (1.14)	-3.4	-2.00	-1.10	-0.40	1.4	-0.05 [-0.58, 0.49]
	Pbo+Pbo	19	19 (100.0)	-1.13 (1.00)	-3.2	-1.80	-1.20	-0.20	0.2	
Week 48	Teze+Teze	45	45 (100.0)	-1.14 (1.27)	-3.4	-2.00	-1.20	-0.40	2.0	0.18 [-0.36, 0.72]
	Pbo+Pbo	19	19 (100.0)	-1.36 (1.10)	-3.8	-2.00	-1.20	-0.40	0.2	
Week 52	Teze+Teze	45	43 (95.6)	-1.20 (1.07)	-3.2	-2.00	-1.00	-0.40	1.2	0.17 [-0.37, 0.71]
	Pbo+Pbo	19	19 (100.0)	-1.39 (1.10)	-3.8	-2.20	-1.40	-0.60	0.0	
Week 64	Teze+Teze	45	44 (97.8)	-1.25 (1.10)	-3.0	-2.20	-1.20	-0.20	1.2	-0.05 [-0.58, 0.49]
	Pbo+Pbo	19	19 (100.0)	-1.20 (1.13)	-3.6	-2.20	-1.20	-0.20	0.8	
Week 76	Teze+Teze	45	43 (95.6)	-1.17 (1.22)	-3.2	-2.20	-1.40	-0.20	2.4	0.22 [-0.32, 0.76]
	Pbo+Pbo	19	19 (100.0)	-1.43 (1.10)	-3.6	-2.20	-1.20	-0.60	0.2	
Week 88	Teze+Teze	45	41 (91.1)	-1.40 (1.07)	-3.4	-2.20	-1.40	-0.60	0.8	-0.17 [-0.72, 0.37]
	Pbo+Pbo	19	19 (100.0)	-1.21 (1.12)	-3.4	-2.00	-1.00	-0.20	0.2	
Week 104	Teze+Teze	45	40 (88.9)	-1.45 (1.06)	-3.2	-2.20	-1.60	-0.80	1.4	0.04 [-0.50, 0.59]
	Pbo+Pbo	19	19 (100.0)	-1.49 (1.13)	-3.8	-2.60	-1.00	-0.40	-0.2	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C_BBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTNB - LTE

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 2	Teze+Teze	45	44 (97.8)	-0.76 (0.12)	(-1.00, -0.53)	0.06 (0.22)	(-0.38, 0.49)	0.798
	Pbo+Pbo	19	18 (94.7)	-0.82 (0.18)	(-1.18, -0.45)			
Week 4	Teze+Teze	45	45 (100.0)	-0.83 (0.13)	(-1.09, -0.57)	0.14 (0.24)	(-0.35, 0.62)	0.568
	Pbo+Pbo	19	19 (100.0)	-0.97 (0.20)	(-1.38, -0.57)			
Week 8	Teze+Teze	45	44 (97.8)	-1.04 (0.13)	(-1.31, -0.77)	-0.18 (0.25)	(-0.68, 0.32)	0.469
	Pbo+Pbo	19	19 (100.0)	-0.85 (0.21)	(-1.27, -0.44)			
Week 12	Teze+Teze	45	44 (97.8)	-1.14 (0.16)	(-1.46, -0.82)	0.08 (0.29)	(-0.50, 0.67)	0.774
	Pbo+Pbo	19	19 (100.0)	-1.22 (0.25)	(-1.71, -0.73)			
Week 16	Teze+Teze	45	44 (97.8)	-1.19 (0.14)	(-1.48, -0.90)	0.04 (0.27)	(-0.49, 0.57)	0.894
	Pbo+Pbo	19	19 (100.0)	-1.22 (0.22)	(-1.67, -0.78)			
Week 20	Teze+Teze	45	44 (97.8)	-1.19 (0.16)	(-1.51, -0.87)	0.04 (0.29)	(-0.54, 0.63)	0.882
	Pbo+Pbo	19	19 (100.0)	-1.23 (0.24)	(-1.72, -0.74)			
Week 24	Teze+Teze	45	44 (97.8)	-1.23 (0.15)	(-1.53, -0.93)	-0.08 (0.28)	(-0.64, 0.48)	0.774
	Pbo+Pbo	19	18 (94.7)	-1.15 (0.23)	(-1.62, -0.69)			
Week 28	Teze+Teze	45	43 (95.6)	-1.17 (0.16)	(-1.48, -0.86)	0.07 (0.29)	(-0.51, 0.64)	0.819
	Pbo+Pbo	19	19 (100.0)	-1.23 (0.24)	(-1.71, -0.75)			
Week 32	Teze+Teze	45	44 (97.8)	-1.17 (0.16)	(-1.50, -0.85)	0.21 (0.30)	(-0.39, 0.81)	0.484
	Pbo+Pbo	19	19 (100.0)	-1.38 (0.25)	(-1.88, -0.88)			
Week 36	Teze+Teze	45	45 (100.0)	-1.08 (0.16)	(-1.39, -0.76)	-0.00 (0.29)	(-0.59, 0.59)	1.000
	Pbo+Pbo	19	19 (100.0)	-1.08 (0.25)	(-1.57, -0.58)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C_BBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTNB - LTE

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Teze+Teze	45	42 (93.3)	-1.13 (0.16)	(-1.45, -0.82)	0.05 (0.29)	(-0.53, 0.62)	0.868
	Pbo+Pbo	19	19 (100.0)	-1.18 (0.24)	(-1.66, -0.70)			
Week 44	Teze+Teze	45	44 (97.8)	-1.18 (0.16)	(-1.50, -0.86)	-0.10 (0.30)	(-0.69, 0.49)	0.731
	Pbo+Pbo	19	19 (100.0)	-1.08 (0.25)	(-1.57, -0.58)			
Week 48	Teze+Teze	45	45 (100.0)	-1.16 (0.18)	(-1.52, -0.81)	0.15 (0.33)	(-0.51, 0.80)	0.655
	Pbo+Pbo	19	19 (100.0)	-1.31 (0.27)	(-1.85, -0.76)			
Week 52	Teze+Teze	45	43 (95.6)	-1.20 (0.16)	(-1.51, -0.89)	0.14 (0.29)	(-0.43, 0.71)	0.627
	Pbo+Pbo	19	19 (100.0)	-1.34 (0.24)	(-1.82, -0.86)			
Week 64	Teze+Teze	45	44 (97.8)	-1.26 (0.16)	(-1.58, -0.95)	-0.12 (0.29)	(-0.70, 0.47)	0.696
	Pbo+Pbo	19	19 (100.0)	-1.15 (0.24)	(-1.64, -0.66)			
Week 76	Teze+Teze	45	43 (95.6)	-1.16 (0.17)	(-1.50, -0.81)	0.23 (0.32)	(-0.41, 0.86)	0.483
	Pbo+Pbo	19	19 (100.0)	-1.38 (0.27)	(-1.91, -0.85)			
Week 88	Teze+Teze	45	41 (91.1)	-1.31 (0.16)	(-1.63, -0.99)	-0.15 (0.29)	(-0.74, 0.43)	0.599
	Pbo+Pbo	19	19 (100.0)	-1.16 (0.24)	(-1.64, -0.68)			
Week 104	Teze+Teze	45	40 (88.9)	-1.40 (0.16)	(-1.71, -1.08)	0.05 (0.29)	(-0.53, 0.62)	0.870
	Pbo+Pbo	19	19 (100.0)	-1.44 (0.24)	(-1.92, -0.97)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table CT1H5C_IBMH0: Course of ACQ-5 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
ACQ-5 score	Baseline	Tezepelumab	4	4 (100.0)	2.45 (0.44)	2.0	2.10	2.40	2.80	3.0	
		Placebo	8	8 (100.0)	1.78 (0.86)	0.8	1.00	1.80	2.20	3.4	
	Week 12	Tezepelumab	4	4 (100.0)	1.50 (0.84)	0.6	0.80	1.50	2.20	2.4	
		Placebo	8	8 (100.0)	1.00 (0.65)	0.0	0.40	1.30	1.40	1.8	
	Week 28	Tezepelumab	4	4 (100.0)	1.90 (1.01)	1.0	1.10	1.70	2.70	3.2	
		Placebo	8	5 (62.5)	1.04 (0.70)	0.4	0.60	0.60	1.80	1.8	
	End of treatment	Tezepelumab	4	4 (100.0)	1.90 (1.01)	1.0	1.10	1.70	2.70	3.2	
		Placebo	8	8 (100.0)	1.00 (0.59)	0.4	0.50	0.90	1.50	1.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 21FEB2022

Table CT1H5C_IBMH0: Course of ACQ-5 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 12 score	Tezepelumab	4	4 (100.0)	-0.95 (0.79)	-1.6	-1.60	-1.10	-0.30	0.0	-0.15 [-1.35, 1.05]
	Placebo	8	8 (100.0)	-0.78 (1.31)	-3.4	-1.40	-0.30	0.10	0.4	
Week 28	Tezepelumab	4	4 (100.0)	-0.55 (0.87)	-1.4	-1.30	-0.50	0.20	0.2	0.24 [-1.08, 1.56]
	Placebo	8	5 (62.5)	-0.80 (1.16)	-2.8	-0.60	-0.40	-0.40	0.2	
End of treatment	Tezepelumab	4	4 (100.0)	-0.55 (0.87)	-1.4	-1.30	-0.50	0.20	0.2	0.22 [-0.98, 1.43]
	Placebo	8	8 (100.0)	-0.78 (1.06)	-2.8	-1.30	-0.50	-0.10	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table CT1H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 12	Tezepelumab	4	4 (100.0)	-0.38 (0.39)	(-1.28, 0.51)	0.77 (0.51)	(-0.38, 1.92)	0.162
	Placebo	8	8 (100.0)	-1.16 (0.28)	(-1.79, -0.53)			
Week 28	Tezepelumab	4	4 (100.0)	0.02 (0.51)	(-1.20, 1.23)	1.09 (0.66)	(-0.45, 2.63)	0.140
	Placebo	8	5 (62.5)	-1.08 (0.39)	(-1.97, -0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C_IBMH0: Course of ACQ-6 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	66	66 (100.0)	2.72 (0.64)	1.7	2.33	2.67	3.00	4.8	
		Placebo	48	48 (100.0)	2.96 (0.73)	1.8	2.50	2.83	3.33	5.7	
	Week 2	Tezepelumab	66	63 (95.5)	2.15 (0.91)	0.0	1.50	2.33	2.83	4.0	
		Placebo	48	43 (89.6)	2.43 (1.03)	0.3	1.67	2.33	3.00	5.2	
	Week 4	Tezepelumab	66	64 (97.0)	2.02 (0.95)	0.0	1.42	2.33	2.75	4.0	
		Placebo	48	45 (93.8)	2.26 (0.91)	0.5	1.50	2.50	3.00	5.0	
	Week 8	Tezepelumab	66	63 (95.5)	1.96 (1.10)	0.0	1.33	2.17	2.67	4.8	
		Placebo	48	46 (95.8)	2.30 (1.00)	0.5	1.67	2.17	2.83	4.8	
	Week 12	Tezepelumab	66	63 (95.5)	1.81 (1.17)	0.0	1.00	2.00	2.50	5.5	
		Placebo	48	43 (89.6)	2.16 (1.15)	0.3	1.50	2.00	2.67	5.7	
	Week 16	Tezepelumab	66	63 (95.5)	1.74 (1.06)	0.0	1.00	1.83	2.50	4.3	
		Placebo	48	45 (93.8)	2.09 (1.07)	0.3	1.33	1.83	2.50	5.0	
	Week 20	Tezepelumab	66	64 (97.0)	1.69 (1.08)	0.0	1.00	1.67	2.58	4.3	
		Placebo	48	44 (91.7)	1.94 (1.01)	0.2	1.17	1.83	2.67	4.0	
	Week 24	Tezepelumab	66	64 (97.0)	1.67 (1.07)	0.0	0.83	1.67	2.50	4.3	
		Placebo	48	41 (85.4)	1.98 (1.06)	0.2	1.17	1.83	2.83	4.0	
	Week 28	Tezepelumab	66	63 (95.5)	1.71 (1.09)	0.0	0.83	1.67	2.50	4.5	
		Placebo	48	44 (91.7)	2.13 (1.19)	0.3	1.00	2.17	2.92	4.0	
	Week 32	Tezepelumab	66	65 (98.5)	1.73 (1.05)	0.0	1.00	1.83	2.50	4.3	
		Placebo	48	43 (89.6)	1.86 (0.98)	0.3	1.17	1.50	2.67	3.8	
	Week 36	Tezepelumab	66	66 (100.0)	1.78 (1.09)	0.0	1.00	1.67	2.67	4.3	
		Placebo	48	43 (89.6)	1.99 (1.08)	0.0	1.17	1.83	2.67	4.5	
	Week 40	Tezepelumab	66	63 (95.5)	1.79 (1.17)	0.0	0.83	1.83	2.67	4.3	
		Placebo	48	44 (91.7)	1.94 (1.11)	0.0	1.08	2.00	2.75	3.8	
	Week 44	Tezepelumab	66	65 (98.5)	1.66 (1.17)	0.0	0.83	1.50	2.67	4.3	
		Placebo	48	43 (89.6)	2.06 (1.02)	0.2	1.17	2.00	2.83	4.8	
	Week 48	Tezepelumab	66	66 (100.0)	1.84 (1.23)	0.0	1.00	1.75	2.67	4.5	
		Placebo	48	44 (91.7)	1.87 (1.14)	0.0	1.00	1.75	2.50	4.5	
	Week 52	Tezepelumab	66	61 (92.4)	1.65 (1.12)	0.0	1.00	1.50	2.50	4.3	
		Placebo	48	42 (87.5)	1.84 (1.11)	0.0	1.17	1.75	2.33	4.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C_IBMH0: Course of ACQ-6 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	66	63 (95.5)	-0.61 (0.85)	-3.2	-1.00	-0.50	-0.17	1.7	-0.08 [-0.47, 0.31]
	Placebo	48	43 (89.6)	-0.55 (0.86)	-2.8	-1.00	-0.33	-0.17	1.8	
Week 4	Tezepelumab	66	64 (97.0)	-0.73 (0.88)	-3.0	-1.42	-0.67	-0.17	1.0	-0.01 [-0.39, 0.37]
	Placebo	48	45 (93.8)	-0.73 (0.80)	-3.0	-1.00	-0.67	-0.33	0.8	
Week 8	Tezepelumab	66	63 (95.5)	-0.81 (1.03)	-3.0	-1.50	-0.83	-0.17	2.3	-0.14 [-0.52, 0.24]
	Placebo	48	46 (95.8)	-0.67 (0.85)	-3.0	-1.00	-0.67	-0.33	2.0	
Week 12	Tezepelumab	66	63 (95.5)	-0.94 (1.05)	-3.2	-1.83	-0.83	-0.33	1.3	-0.11 [-0.50, 0.27]
	Placebo	48	43 (89.6)	-0.82 (1.01)	-3.2	-1.33	-0.83	-0.17	2.3	
Week 16	Tezepelumab	66	63 (95.5)	-1.02 (1.00)	-3.2	-1.67	-0.83	-0.17	0.8	-0.15 [-0.54, 0.23]
	Placebo	48	45 (93.8)	-0.87 (0.89)	-2.8	-1.33	-1.00	-0.33	0.8	
Week 20	Tezepelumab	66	64 (97.0)	-1.04 (1.03)	-3.2	-1.75	-1.00	-0.33	1.3	-0.03 [-0.42, 0.35]
	Placebo	48	44 (91.7)	-1.01 (0.92)	-3.0	-1.75	-0.83	-0.50	0.8	
Week 24	Tezepelumab	66	64 (97.0)	-1.08 (1.03)	-3.3	-1.75	-1.00	-0.33	0.8	-0.09 [-0.48, 0.30]
	Placebo	48	41 (85.4)	-0.99 (1.02)	-3.2	-1.67	-1.00	-0.33	1.2	
Week 28	Tezepelumab	66	63 (95.5)	-0.98 (1.03)	-2.8	-1.67	-0.83	-0.17	1.0	-0.16 [-0.55, 0.22]
	Placebo	48	44 (91.7)	-0.81 (1.11)	-3.0	-1.67	-0.75	-0.08	1.5	
Week 32	Tezepelumab	66	65 (98.5)	-1.00 (1.06)	-3.2	-1.67	-1.00	-0.33	1.7	0.08 [-0.30, 0.47]
	Placebo	48	43 (89.6)	-1.08 (0.98)	-3.0	-1.67	-1.00	-0.50	0.7	
Week 36	Tezepelumab	66	66 (100.0)	-0.94 (1.05)	-3.2	-1.67	-0.92	-0.33	1.5	0.01 [-0.38, 0.39]
	Placebo	48	43 (89.6)	-0.95 (0.99)	-3.5	-1.50	-0.83	-0.17	0.7	
Week 40	Tezepelumab	66	63 (95.5)	-0.93 (1.11)	-3.0	-1.83	-1.00	-0.17	2.5	0.07 [-0.32, 0.45]
	Placebo	48	44 (91.7)	-1.00 (1.03)	-3.2	-1.58	-0.83	-0.42	1.2	
Week 44	Tezepelumab	66	65 (98.5)	-1.05 (1.11)	-3.0	-2.00	-1.00	-0.33	2.0	-0.16 [-0.55, 0.22]
	Placebo	48	43 (89.6)	-0.88 (0.93)	-3.3	-1.50	-0.67	-0.17	0.7	
Week 48	Tezepelumab	66	66 (100.0)	-0.88 (1.24)	-3.2	-1.83	-0.92	-0.33	2.2	0.16 [-0.22, 0.54]
	Placebo	48	44 (91.7)	-1.07 (1.07)	-3.3	-1.83	-0.83	-0.42	1.7	
Week 52	Tezepelumab	66	61 (92.4)	-1.10 (1.08)	-3.2	-1.83	-1.00	-0.50	1.8	0.01 [-0.38, 0.40]
	Placebo	48	42 (87.5)	-1.11 (1.09)	-3.5	-1.83	-1.00	-0.33	1.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	66	63 (95.5)	-0.63 (0.10)	(-0.84, -0.42)	-0.16 (0.17)	(-0.49, 0.17)	0.334
	Placebo	48	43 (89.6)	-0.47 (0.13)	(-0.72, -0.22)			
Week 4	Tezepelumab	66	64 (97.0)	-0.74 (0.10)	(-0.94, -0.53)	-0.08 (0.16)	(-0.40, 0.24)	0.622
	Placebo	48	45 (93.8)	-0.66 (0.12)	(-0.90, -0.41)			
Week 8	Tezepelumab	66	63 (95.5)	-0.82 (0.12)	(-1.05, -0.58)	-0.20 (0.19)	(-0.57, 0.17)	0.289
	Placebo	48	45 (93.8)	-0.62 (0.14)	(-0.90, -0.33)			
Week 12	Tezepelumab	66	62 (93.9)	-0.98 (0.13)	(-1.23, -0.72)	-0.19 (0.20)	(-0.60, 0.21)	0.349
	Placebo	48	42 (87.5)	-0.78 (0.16)	(-1.09, -0.47)			
Week 16	Tezepelumab	66	62 (93.9)	-1.03 (0.12)	(-1.27, -0.80)	-0.22 (0.18)	(-0.59, 0.15)	0.235
	Placebo	48	44 (91.7)	-0.81 (0.14)	(-1.09, -0.53)			
Week 20	Tezepelumab	66	62 (93.9)	-1.10 (0.12)	(-1.34, -0.86)	-0.17 (0.19)	(-0.55, 0.21)	0.374
	Placebo	48	44 (91.7)	-0.93 (0.15)	(-1.22, -0.64)			
Week 24	Tezepelumab	66	61 (92.4)	-1.12 (0.12)	(-1.37, -0.88)	-0.20 (0.19)	(-0.58, 0.19)	0.307
	Placebo	48	40 (83.3)	-0.92 (0.15)	(-1.22, -0.63)			
Week 28	Tezepelumab	66	60 (90.9)	-1.04 (0.13)	(-1.30, -0.78)	-0.32 (0.20)	(-0.73, 0.08)	0.116
	Placebo	48	43 (89.6)	-0.72 (0.16)	(-1.03, -0.41)			
Week 32	Tezepelumab	66	62 (93.9)	-1.05 (0.12)	(-1.29, -0.82)	-0.05 (0.19)	(-0.42, 0.33)	0.799
	Placebo	48	42 (87.5)	-1.01 (0.14)	(-1.29, -0.72)			
Week 36	Tezepelumab	66	63 (95.5)	-1.00 (0.12)	(-1.25, -0.76)	-0.13 (0.19)	(-0.51, 0.26)	0.509
	Placebo	48	42 (87.5)	-0.87 (0.15)	(-1.17, -0.58)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Tezepelumab	66	59 (89.4)	-0.99 (0.13)	(-1.25, -0.73)	-0.09 (0.21)	(-0.50, 0.32)	0.675
	Placebo	48	43 (89.6)	-0.90 (0.16)	(-1.22, -0.59)			
Week 44	Tezepelumab	66	60 (90.9)	-1.11 (0.13)	(-1.36, -0.85)	-0.28 (0.20)	(-0.68, 0.11)	0.156
	Placebo	48	43 (89.6)	-0.82 (0.15)	(-1.12, -0.52)			
Week 48	Tezepelumab	66	62 (93.9)	-0.93 (0.14)	(-1.21, -0.65)	0.07 (0.22)	(-0.37, 0.52)	0.747
	Placebo	48	43 (89.6)	-1.00 (0.17)	(-1.34, -0.66)			
Week 52	Tezepelumab	66	52 (78.8)	-1.07 (0.13)	(-1.33, -0.81)	-0.03 (0.20)	(-0.44, 0.37)	0.876
	Placebo	48	37 (77.1)	-1.04 (0.16)	(-1.35, -0.73)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table NT1H6C_IBMH0: Course of ACQ-6 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	55	55 (100.0)	2.73 (0.64)	1.7	2.33	2.67	3.00	4.8	
		Placebo	40	40 (100.0)	2.98 (0.77)	1.8	2.50	2.83	3.33	5.7	
	Week 2	Tezepelumab	55	54 (98.2)	2.15 (0.85)	0.0	1.67	2.25	2.83	4.0	
		Placebo	40	37 (92.5)	2.48 (1.04)	0.7	1.67	2.33	3.00	5.2	
	Week 4	Tezepelumab	55	55 (100.0)	2.00 (0.96)	0.0	1.33	2.33	2.67	4.0	
		Placebo	40	39 (97.5)	2.34 (0.88)	0.8	1.67	2.50	3.00	5.0	
	Week 8	Tezepelumab	55	54 (98.2)	1.94 (1.02)	0.0	1.33	2.17	2.50	4.2	
		Placebo	40	40 (100.0)	2.32 (0.98)	0.8	1.67	2.17	2.83	4.8	
	Week 12	Tezepelumab	55	54 (98.2)	1.81 (1.14)	0.0	1.00	1.92	2.50	5.5	
		Placebo	40	37 (92.5)	2.23 (1.17)	0.3	1.50	2.00	2.67	5.7	
	Week 16	Tezepelumab	55	54 (98.2)	1.73 (1.02)	0.0	1.00	1.75	2.50	3.7	
		Placebo	40	39 (97.5)	2.18 (1.10)	0.3	1.33	1.83	2.83	5.0	
	Week 20	Tezepelumab	55	54 (98.2)	1.67 (1.06)	0.0	0.83	1.67	2.67	4.0	
		Placebo	40	38 (95.0)	2.02 (0.94)	0.7	1.33	1.83	2.67	4.0	
	Week 24	Tezepelumab	55	54 (98.2)	1.66 (1.05)	0.0	0.83	1.67	2.67	4.3	
		Placebo	40	35 (87.5)	2.06 (0.99)	0.2	1.17	1.83	3.00	4.0	
	Week 28	Tezepelumab	55	52 (94.5)	1.69 (1.06)	0.0	0.83	1.75	2.50	4.5	
		Placebo	40	38 (95.0)	2.12 (1.15)	0.3	1.17	2.08	2.83	4.0	
	Week 32	Tezepelumab	55	54 (98.2)	1.68 (1.01)	0.0	1.00	1.75	2.50	3.7	
		Placebo	40	37 (92.5)	1.93 (0.97)	0.3	1.17	1.50	2.83	3.8	
	Week 36	Tezepelumab	55	55 (100.0)	1.75 (1.06)	0.0	0.83	1.67	2.50	4.2	
		Placebo	40	37 (92.5)	2.11 (0.99)	0.2	1.33	1.83	2.67	4.5	
	Week 40	Tezepelumab	55	52 (94.5)	1.74 (1.14)	0.0	0.83	1.75	2.75	4.3	
		Placebo	40	38 (95.0)	2.00 (1.05)	0.0	1.33	2.00	2.83	3.8	
	Week 44	Tezepelumab	55	54 (98.2)	1.59 (1.15)	0.0	0.67	1.33	2.50	3.8	
		Placebo	40	37 (92.5)	2.09 (1.00)	0.3	1.33	2.00	2.67	4.8	
	Week 48	Tezepelumab	55	55 (100.0)	1.81 (1.23)	0.0	0.83	1.67	2.67	4.5	
		Placebo	40	38 (95.0)	1.93 (1.06)	0.0	1.17	1.75	2.50	4.5	
	Week 52	Tezepelumab	55	50 (90.9)	1.60 (1.06)	0.0	1.00	1.50	2.50	3.5	
		Placebo	40	36 (90.0)	1.87 (1.08)	0.0	1.25	1.67	2.33	4.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C_IBMH0: Course of ACQ-6 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	55	54 (98.2)	-0.59 (0.83)	-3.2	-1.00	-0.50	-0.17	1.7	-0.12 [-0.54, 0.30]
	Placebo	40	37 (92.5)	-0.50 (0.83)	-2.3	-1.00	-0.33	-0.17	1.8	
Week 4	Tezepelumab	55	55 (100.0)	-0.73 (0.91)	-3.0	-1.50	-0.67	-0.17	1.0	-0.09 [-0.50, 0.32]
	Placebo	40	39 (97.5)	-0.65 (0.75)	-2.7	-1.00	-0.67	-0.33	0.8	
Week 8	Tezepelumab	55	54 (98.2)	-0.80 (0.96)	-3.0	-1.50	-0.75	-0.33	2.3	-0.16 [-0.57, 0.25]
	Placebo	40	40 (100.0)	-0.66 (0.77)	-2.2	-1.00	-0.67	-0.33	2.0	
Week 12	Tezepelumab	55	54 (98.2)	-0.92 (1.06)	-3.2	-1.67	-0.83	-0.33	1.3	-0.16 [-0.58, 0.26]
	Placebo	40	37 (92.5)	-0.75 (1.01)	-2.5	-1.33	-1.00	-0.17	2.3	
Week 16	Tezepelumab	55	54 (98.2)	-1.01 (1.01)	-3.2	-1.67	-0.83	-0.17	0.8	-0.23 [-0.65, 0.18]
	Placebo	40	39 (97.5)	-0.79 (0.88)	-2.5	-1.33	-0.83	-0.33	0.8	
Week 20	Tezepelumab	55	54 (98.2)	-1.06 (1.05)	-3.2	-1.67	-1.08	-0.33	1.3	-0.13 [-0.54, 0.29]
	Placebo	40	38 (95.0)	-0.93 (0.79)	-2.7	-1.33	-0.83	-0.50	0.8	
Week 24	Tezepelumab	55	54 (98.2)	-1.08 (1.05)	-3.3	-1.67	-1.00	-0.33	0.8	-0.17 [-0.60, 0.25]
	Placebo	40	35 (87.5)	-0.91 (0.88)	-3.2	-1.50	-0.83	-0.33	1.2	
Week 28	Tezepelumab	55	52 (94.5)	-1.00 (0.99)	-2.8	-1.67	-0.83	-0.25	1.0	-0.19 [-0.61, 0.23]
	Placebo	40	38 (95.0)	-0.81 (1.01)	-3.0	-1.67	-0.75	-0.17	1.2	
Week 32	Tezepelumab	55	54 (98.2)	-1.06 (1.07)	-3.2	-1.67	-1.08	-0.50	1.7	-0.05 [-0.47, 0.37]
	Placebo	40	37 (92.5)	-1.01 (0.96)	-3.0	-1.67	-0.83	-0.50	0.7	
Week 36	Tezepelumab	55	55 (100.0)	-0.98 (1.03)	-3.2	-1.83	-1.00	-0.50	1.5	-0.16 [-0.58, 0.26]
	Placebo	40	37 (92.5)	-0.83 (0.83)	-3.0	-1.17	-0.83	-0.17	0.7	
Week 40	Tezepelumab	55	52 (94.5)	-0.98 (1.11)	-3.0	-1.83	-1.00	-0.17	2.5	-0.05 [-0.46, 0.37]
	Placebo	40	38 (95.0)	-0.93 (0.91)	-3.0	-1.33	-0.83	-0.50	1.0	
Week 44	Tezepelumab	55	54 (98.2)	-1.13 (1.10)	-3.0	-2.00	-1.17	-0.50	2.0	-0.28 [-0.70, 0.14]
	Placebo	40	37 (92.5)	-0.85 (0.86)	-2.8	-1.50	-0.67	-0.33	0.7	
Week 48	Tezepelumab	55	55 (100.0)	-0.92 (1.25)	-3.2	-1.83	-1.00	-0.33	2.2	0.07 [-0.34, 0.49]
	Placebo	40	38 (95.0)	-1.00 (0.92)	-3.2	-1.50	-0.83	-0.33	0.5	
Week 52	Tezepelumab	55	50 (90.9)	-1.16 (1.02)	-3.2	-1.83	-1.00	-0.50	1.5	-0.08 [-0.51, 0.35]
	Placebo	40	36 (90.0)	-1.08 (0.93)	-3.3	-1.67	-1.00	-0.50	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 2	Tezepelumab	55	54 (98.2)	-0.63 (0.11)	(-0.85, -0.42)	-0.23 (0.17)	(-0.57, 0.11)	0.177																																																																																																																										
	Placebo	40	37 (92.5)	-0.40 (0.13)	(-0.66, -0.14)				Week 4	Tezepelumab	55	55 (100.0)	-0.76 (0.11)	(-0.98, -0.54)	-0.18 (0.17)	(-0.52, 0.16)	0.307	Placebo	40	39 (97.5)	-0.58 (0.13)	(-0.84, -0.33)	Week 8	Tezepelumab	55	54 (98.2)	-0.85 (0.12)	(-1.08, -0.61)	-0.24 (0.18)	(-0.61, 0.12)	0.191	Placebo	40	40 (100.0)	-0.61 (0.14)	(-0.88, -0.33)	Week 12	Tezepelumab	55	54 (98.2)	-0.97 (0.14)	(-1.25, -0.70)	-0.26 (0.22)	(-0.69, 0.18)	0.246	Placebo	40	37 (92.5)	-0.72 (0.17)	(-1.05, -0.39)	Week 16	Tezepelumab	55	54 (98.2)	-1.04 (0.13)	(-1.29, -0.79)	-0.31 (0.20)	(-0.70, 0.08)	0.116	Placebo	40	39 (97.5)	-0.73 (0.15)	(-1.02, -0.43)	Week 20	Tezepelumab	55	54 (98.2)	-1.12 (0.13)	(-1.37, -0.87)	-0.27 (0.20)	(-0.66, 0.12)	0.173	Placebo	40	38 (95.0)	-0.85 (0.15)	(-1.15, -0.55)	Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)	Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo
Week 4	Tezepelumab	55	55 (100.0)	-0.76 (0.11)	(-0.98, -0.54)	-0.18 (0.17)	(-0.52, 0.16)	0.307																																																																																																																										
	Placebo	40	39 (97.5)	-0.58 (0.13)	(-0.84, -0.33)				Week 8	Tezepelumab	55	54 (98.2)	-0.85 (0.12)	(-1.08, -0.61)	-0.24 (0.18)	(-0.61, 0.12)	0.191	Placebo	40	40 (100.0)	-0.61 (0.14)	(-0.88, -0.33)	Week 12	Tezepelumab	55	54 (98.2)	-0.97 (0.14)	(-1.25, -0.70)	-0.26 (0.22)	(-0.69, 0.18)	0.246	Placebo	40	37 (92.5)	-0.72 (0.17)	(-1.05, -0.39)	Week 16	Tezepelumab	55	54 (98.2)	-1.04 (0.13)	(-1.29, -0.79)	-0.31 (0.20)	(-0.70, 0.08)	0.116	Placebo	40	39 (97.5)	-0.73 (0.15)	(-1.02, -0.43)	Week 20	Tezepelumab	55	54 (98.2)	-1.12 (0.13)	(-1.37, -0.87)	-0.27 (0.20)	(-0.66, 0.12)	0.173	Placebo	40	38 (95.0)	-0.85 (0.15)	(-1.15, -0.55)	Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)	Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)										
Week 8	Tezepelumab	55	54 (98.2)	-0.85 (0.12)	(-1.08, -0.61)	-0.24 (0.18)	(-0.61, 0.12)	0.191																																																																																																																										
	Placebo	40	40 (100.0)	-0.61 (0.14)	(-0.88, -0.33)				Week 12	Tezepelumab	55	54 (98.2)	-0.97 (0.14)	(-1.25, -0.70)	-0.26 (0.22)	(-0.69, 0.18)	0.246	Placebo	40	37 (92.5)	-0.72 (0.17)	(-1.05, -0.39)	Week 16	Tezepelumab	55	54 (98.2)	-1.04 (0.13)	(-1.29, -0.79)	-0.31 (0.20)	(-0.70, 0.08)	0.116	Placebo	40	39 (97.5)	-0.73 (0.15)	(-1.02, -0.43)	Week 20	Tezepelumab	55	54 (98.2)	-1.12 (0.13)	(-1.37, -0.87)	-0.27 (0.20)	(-0.66, 0.12)	0.173	Placebo	40	38 (95.0)	-0.85 (0.15)	(-1.15, -0.55)	Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)	Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																								
Week 12	Tezepelumab	55	54 (98.2)	-0.97 (0.14)	(-1.25, -0.70)	-0.26 (0.22)	(-0.69, 0.18)	0.246																																																																																																																										
	Placebo	40	37 (92.5)	-0.72 (0.17)	(-1.05, -0.39)				Week 16	Tezepelumab	55	54 (98.2)	-1.04 (0.13)	(-1.29, -0.79)	-0.31 (0.20)	(-0.70, 0.08)	0.116	Placebo	40	39 (97.5)	-0.73 (0.15)	(-1.02, -0.43)	Week 20	Tezepelumab	55	54 (98.2)	-1.12 (0.13)	(-1.37, -0.87)	-0.27 (0.20)	(-0.66, 0.12)	0.173	Placebo	40	38 (95.0)	-0.85 (0.15)	(-1.15, -0.55)	Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)	Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																						
Week 16	Tezepelumab	55	54 (98.2)	-1.04 (0.13)	(-1.29, -0.79)	-0.31 (0.20)	(-0.70, 0.08)	0.116																																																																																																																										
	Placebo	40	39 (97.5)	-0.73 (0.15)	(-1.02, -0.43)				Week 20	Tezepelumab	55	54 (98.2)	-1.12 (0.13)	(-1.37, -0.87)	-0.27 (0.20)	(-0.66, 0.12)	0.173	Placebo	40	38 (95.0)	-0.85 (0.15)	(-1.15, -0.55)	Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)	Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																																				
Week 20	Tezepelumab	55	54 (98.2)	-1.12 (0.13)	(-1.37, -0.87)	-0.27 (0.20)	(-0.66, 0.12)	0.173																																																																																																																										
	Placebo	40	38 (95.0)	-0.85 (0.15)	(-1.15, -0.55)				Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)	Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																																																		
Week 24	Tezepelumab	55	54 (98.2)	-1.13 (0.13)	(-1.38, -0.88)	-0.27 (0.20)	(-0.66, 0.13)	0.187																																																																																																																										
	Placebo	40	35 (87.5)	-0.86 (0.15)	(-1.17, -0.56)				Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)	Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																																																																
Week 28	Tezepelumab	55	52 (94.5)	-1.05 (0.13)	(-1.31, -0.78)	-0.31 (0.21)	(-0.73, 0.10)	0.134																																																																																																																										
	Placebo	40	38 (95.0)	-0.73 (0.16)	(-1.04, -0.42)				Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)	Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																																																																														
Week 32	Tezepelumab	55	54 (98.2)	-1.09 (0.13)	(-1.35, -0.83)	-0.14 (0.20)	(-0.55, 0.26)	0.480																																																																																																																										
	Placebo	40	37 (92.5)	-0.95 (0.16)	(-1.25, -0.64)				Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																																																																																												
Week 36	Tezepelumab	55	55 (100.0)	-1.01 (0.13)	(-1.26, -0.76)	-0.24 (0.20)	(-0.63, 0.15)	0.226																																																																																																																										
	Placebo	40	37 (92.5)	-0.77 (0.15)	(-1.07, -0.47)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Tezepelumab	55	52 (94.5)	-1.02 (0.14)	(-1.29, -0.74)	-0.17 (0.22)	(-0.60, 0.26)	0.434
	Placebo	40	38 (95.0)	-0.85 (0.16)	(-1.18, -0.52)			
Week 44	Tezepelumab	55	54 (98.2)	-1.15 (0.13)	(-1.42, -0.89)	-0.36 (0.21)	(-0.78, 0.05)	0.086
	Placebo	40	37 (92.5)	-0.79 (0.16)	(-1.11, -0.47)			
Week 48	Tezepelumab	55	55 (100.0)	-0.95 (0.15)	(-1.25, -0.66)	-0.02 (0.23)	(-0.48, 0.44)	0.923
	Placebo	40	38 (95.0)	-0.93 (0.18)	(-1.28, -0.58)			
Week 52	Tezepelumab	55	50 (90.9)	-1.08 (0.14)	(-1.36, -0.81)	-0.11 (0.22)	(-0.54, 0.32)	0.616
	Placebo	40	36 (90.0)	-0.97 (0.16)	(-1.30, -0.65)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table PT3H6C_IBMH0: Course of ACQ-6 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	12	12 (100.0)	2.65 (0.62)	1.7	2.25	2.75	3.08	3.8	
		Placebo	9	9 (100.0)	2.80 (0.59)	1.8	2.50	2.83	3.17	3.5	
	Week 2	Tezepelumab	12	10 (83.3)	2.05 (1.24)	0.0	1.17	2.50	2.83	3.5	
		Placebo	9	7 (77.8)	2.07 (0.89)	0.3	1.67	2.17	2.67	3.0	
	Week 4	Tezepelumab	12	10 (83.3)	1.98 (0.96)	0.3	1.17	2.17	2.83	3.2	
		Placebo	9	7 (77.8)	1.74 (0.97)	0.5	0.67	1.50	2.67	3.0	
	Week 6	Tezepelumab	12	10 (83.3)	1.67 (0.94)	0.0	1.33	1.75	2.50	3.0	
		Placebo	9	7 (77.8)	1.83 (1.48)	0.2	1.00	1.17	2.67	4.7	
	Week 8	Tezepelumab	12	10 (83.3)	1.95 (1.51)	0.0	0.83	1.58	3.00	4.8	
		Placebo	9	7 (77.8)	2.17 (1.15)	0.5	1.00	2.33	3.33	3.5	
	Week 10	Tezepelumab	12	10 (83.3)	1.70 (1.39)	0.0	0.83	1.33	2.83	4.3	
		Placebo	9	7 (77.8)	1.71 (0.99)	0.3	0.83	1.67	2.67	3.2	
	Week 12	Tezepelumab	12	10 (83.3)	1.72 (1.35)	0.0	0.50	1.67	2.50	4.3	
		Placebo	9	7 (77.8)	1.69 (0.82)	0.3	0.83	1.83	2.33	2.7	
	Week 14	Tezepelumab	12	10 (83.3)	1.53 (1.28)	0.0	0.50	1.33	2.00	4.3	
		Placebo	9	7 (77.8)	1.21 (0.62)	0.3	0.83	1.00	1.83	2.2	
	Week 16	Tezepelumab	12	10 (83.3)	1.72 (1.33)	0.0	0.67	1.75	2.50	4.3	
		Placebo	9	7 (77.8)	1.55 (0.58)	0.7	0.83	1.83	2.00	2.2	
	Week 18	Tezepelumab	12	11 (91.7)	1.74 (1.17)	0.0	0.83	1.67	2.33	4.3	
		Placebo	9	7 (77.8)	1.45 (1.13)	0.0	0.83	1.17	2.83	3.2	
	Week 20	Tezepelumab	12	11 (91.7)	1.70 (1.22)	0.0	1.00	1.83	2.33	4.3	
		Placebo	9	7 (77.8)	1.48 (1.24)	0.2	0.33	1.17	2.83	3.3	
	Week 22	Tezepelumab	12	11 (91.7)	1.79 (1.20)	0.0	1.00	1.83	2.50	4.3	
		Placebo	9	7 (77.8)	1.31 (1.24)	0.0	0.33	1.00	2.00	3.7	
	Week 24	Tezepelumab	12	11 (91.7)	1.65 (1.21)	0.0	0.83	1.83	2.33	4.3	
		Placebo	9	7 (77.8)	1.52 (1.30)	0.2	0.33	1.50	2.50	3.5	
	Week 26	Tezepelumab	12	12 (100.0)	1.75 (1.24)	0.0	0.92	1.83	2.58	4.3	
		Placebo	9	7 (77.8)	1.45 (1.22)	0.3	0.67	1.00	1.83	4.0	
	Week 28	Tezepelumab	12	12 (100.0)	1.71 (1.26)	0.0	0.83	1.50	2.58	4.3	
		Placebo	9	7 (77.8)	2.02 (1.47)	0.3	0.67	2.17	3.83	4.0	
	Week 30	Tezepelumab	12	12 (100.0)	1.88 (1.31)	0.0	0.92	1.92	2.58	4.3	
		Placebo	9	7 (77.8)	1.71 (1.15)	0.3	0.33	2.00	2.83	3.0	
	Week 32	Tezepelumab	12	12 (100.0)	1.86 (1.26)	0.0	1.08	2.08	2.67	4.3	
		Placebo	9	7 (77.8)	1.43 (0.90)	0.3	0.50	1.50	2.17	2.7	
Week 34	Tezepelumab	12	12 (100.0)	1.86 (1.35)	0.0	1.00	1.67	2.67	4.3		
	Placebo	9	7 (77.8)	1.31 (1.09)	0.0	0.00	1.83	2.00	2.8		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C_IBMH0: Course of ACQ-6 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Week 36	Tezepelumab	12	12 (100.0)	1.82 (1.31)	0.0	1.08	1.50	2.67	4.3	
		Placebo	9	7 (77.8)	1.31 (1.30)	0.0	0.00	1.83	2.33	3.2	
	Week 38	Tezepelumab	12	12 (100.0)	1.85 (1.43)	0.0	0.92	1.50	2.67	4.3	
		Placebo	9	7 (77.8)	1.38 (1.27)	0.0	0.00	1.50	2.67	3.2	
	Week 40	Tezepelumab	12	12 (100.0)	1.88 (1.32)	0.0	0.92	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.55 (1.36)	0.0	0.33	2.00	2.50	3.7	
	Week 42	Tezepelumab	12	12 (100.0)	1.93 (1.33)	0.0	1.08	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.55 (1.27)	0.0	0.33	1.67	2.83	3.3	
	Week 44	Tezepelumab	12	12 (100.0)	1.89 (1.28)	0.0	1.08	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.83 (1.11)	0.2	0.67	2.00	3.00	3.0	
	Week 46	Tezepelumab	12	12 (100.0)	1.89 (1.29)	0.0	1.08	1.83	2.67	4.3	
		Placebo	9	7 (77.8)	1.45 (1.32)	0.0	0.50	1.00	2.33	3.8	
	Week 48	Tezepelumab	12	12 (100.0)	1.90 (1.30)	0.0	1.08	1.67	2.67	4.3	
		Placebo	9	7 (77.8)	1.50 (1.48)	0.0	0.17	1.67	2.17	4.2	
	Week 50	Tezepelumab	12	12 (100.0)	1.81 (1.41)	0.0	0.58	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.60 (1.26)	0.0	0.33	1.83	2.17	3.7	
	Week 52	Tezepelumab	12	12 (100.0)	1.78 (1.39)	0.0	0.58	1.75	2.58	4.3	
		Placebo	9	7 (77.8)	1.67 (1.29)	0.0	0.33	2.17	2.33	3.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C_IBMH0: Course of ACQ-6 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	12	10 (83.3)	-0.78 (0.96)	-2.8	-1.17	-0.58	-0.17	0.3	-0.02 [-0.99, 0.94]
	Placebo	9	7 (77.8)	-0.76 (0.98)	-2.8	-0.83	-0.50	-0.17	0.2	
Week 4	Tezepelumab	12	10 (83.3)	-0.85 (0.70)	-2.0	-1.17	-0.67	-0.33	0.2	0.30 [-0.67, 1.27]
	Placebo	9	7 (77.8)	-1.10 (0.97)	-3.0	-1.50	-1.00	-0.17	-0.2	
Week 6	Tezepelumab	12	10 (83.3)	-1.17 (0.69)	-2.3	-1.33	-1.08	-0.83	-0.2	-0.15 [-1.12, 0.82]
	Placebo	9	7 (77.8)	-1.00 (1.52)	-3.3	-2.00	-1.17	-0.17	1.5	
Week 8	Tezepelumab	12	10 (83.3)	-0.88 (1.35)	-2.7	-1.67	-1.08	-0.17	2.2	-0.16 [-1.13, 0.80]
	Placebo	9	7 (77.8)	-0.67 (1.29)	-3.0	-1.17	-0.83	0.50	1.0	
Week 10	Tezepelumab	12	10 (83.3)	-1.13 (1.09)	-2.7	-2.17	-1.33	0.00	0.5	-0.01 [-0.98, 0.95]
	Placebo	9	7 (77.8)	-1.12 (1.10)	-3.2	-1.50	-1.17	-0.50	0.3	
Week 12	Tezepelumab	12	10 (83.3)	-1.12 (0.99)	-2.3	-2.17	-1.08	-0.33	0.5	0.03 [-0.94, 0.99]
	Placebo	9	7 (77.8)	-1.14 (0.93)	-3.2	-1.33	-0.83	-0.67	-0.5	
Week 14	Tezepelumab	12	10 (83.3)	-1.30 (0.94)	-2.3	-2.17	-1.33	-0.83	0.5	0.35 [-0.63, 1.32]
	Placebo	9	7 (77.8)	-1.62 (0.90)	-3.2	-2.17	-1.50	-1.00	-0.3	
Week 16	Tezepelumab	12	10 (83.3)	-1.12 (0.95)	-2.3	-2.17	-1.00	-0.50	0.5	0.19 [-0.78, 1.16]
	Placebo	9	7 (77.8)	-1.29 (0.81)	-2.8	-1.67	-1.33	-0.67	-0.5	
Week 18	Tezepelumab	12	11 (91.7)	-1.00 (0.93)	-2.3	-1.83	-1.00	-0.33	0.5	0.35 [-0.61, 1.30]
	Placebo	9	7 (77.8)	-1.38 (1.33)	-3.2	-2.33	-1.33	0.33	0.3	
Week 20	Tezepelumab	12	11 (91.7)	-1.05 (0.94)	-2.3	-2.00	-0.83	-0.33	0.5	0.27 [-0.68, 1.22]
	Placebo	9	7 (77.8)	-1.36 (1.45)	-3.0	-2.83	-1.83	0.00	0.8	
Week 22	Tezepelumab	12	11 (91.7)	-0.95 (0.92)	-2.3	-1.83	-0.83	-0.17	0.5	0.49 [-0.47, 1.45]
	Placebo	9	7 (77.8)	-1.52 (1.47)	-3.2	-2.83	-1.83	-0.83	1.2	
Week 24	Tezepelumab	12	11 (91.7)	-1.09 (0.92)	-2.2	-2.00	-1.17	-0.33	0.5	0.18 [-0.77, 1.13]
	Placebo	9	7 (77.8)	-1.31 (1.55)	-3.2	-3.00	-1.67	0.00	1.0	
Week 26	Tezepelumab	12	12 (100.0)	-0.90 (1.03)	-2.3	-2.08	-0.75	0.00	0.5	0.41 [-0.54, 1.35]
	Placebo	9	7 (77.8)	-1.38 (1.40)	-2.5	-2.50	-1.83	-1.00	1.5	
Week 28	Tezepelumab	12	12 (100.0)	-0.94 (1.22)	-2.3	-2.08	-1.08	0.25	0.8	-0.10 [-1.03, 0.83]
	Placebo	9	7 (77.8)	-0.81 (1.63)	-2.8	-2.17	-1.00	1.00	1.5	
Week 30	Tezepelumab	12	12 (100.0)	-0.78 (1.26)	-2.3	-2.08	-0.67	-0.08	1.8	0.27 [-0.67, 1.20]
	Placebo	9	7 (77.8)	-1.12 (1.29)	-3.2	-2.17	-0.50	-0.33	0.5	
Week 32	Tezepelumab	12	12 (100.0)	-0.79 (1.02)	-2.3	-1.58	-0.67	-0.08	0.8	0.59 [-0.36, 1.54]
	Placebo	9	7 (77.8)	-1.40 (1.07)	-3.0	-2.33	-1.17	-0.67	0.2	
Week 34	Tezepelumab	12	12 (100.0)	-0.79 (1.27)	-2.3	-1.92	-0.83	-0.17	2.0	0.58 [-0.38, 1.53]
	Placebo	9	7 (77.8)	-1.52 (1.26)	-3.2	-2.83	-1.33	-0.67	0.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C_IBMH0: Course of ACQ-6 score
DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 36 score	Tezepelumab	12	12 (100.0)	-0.83 (1.16)	-2.3	-1.83	-1.00	-0.08	1.5	0.54 [-0.41, 1.49]
	Placebo	9	7 (77.8)	-1.52 (1.49)	-3.5	-3.17	-1.00	-0.67	0.7	
Week 38	Tezepelumab	12	12 (100.0)	-0.81 (1.35)	-2.3	-2.00	-1.00	-0.08	2.3	0.47 [-0.47, 1.42]
	Placebo	9	7 (77.8)	-1.45 (1.41)	-3.2	-3.00	-1.33	0.17	0.3	
Week 40	Tezepelumab	12	12 (100.0)	-0.78 (1.17)	-2.3	-1.58	-1.00	-0.08	1.7	0.39 [-0.56, 1.33]
	Placebo	9	7 (77.8)	-1.29 (1.56)	-3.2	-2.83	-1.17	0.00	1.2	
Week 42	Tezepelumab	12	12 (100.0)	-0.72 (1.23)	-2.3	-1.58	-0.83	-0.08	2.0	0.44 [-0.51, 1.38]
	Placebo	9	7 (77.8)	-1.29 (1.41)	-2.8	-2.83	-1.17	0.00	0.8	
Week 44	Tezepelumab	12	12 (100.0)	-0.76 (1.13)	-2.3	-1.58	-0.83	-0.08	1.5	0.20 [-0.74, 1.13]
	Placebo	9	7 (77.8)	-1.00 (1.30)	-3.3	-1.67	-0.83	0.00	0.5	
Week 46	Tezepelumab	12	12 (100.0)	-0.76 (1.22)	-2.3	-1.92	-0.83	0.00	1.7	0.46 [-0.49, 1.40]
	Placebo	9	7 (77.8)	-1.38 (1.56)	-3.2	-2.83	-1.67	-0.50	1.3	
Week 48	Tezepelumab	12	12 (100.0)	-0.75 (1.19)	-2.3	-1.75	-0.83	-0.08	1.8	0.42 [-0.53, 1.36]
	Placebo	9	7 (77.8)	-1.33 (1.72)	-3.3	-3.17	-1.50	-0.50	1.7	
Week 50	Tezepelumab	12	12 (100.0)	-0.85 (1.32)	-2.7	-2.08	-0.75	-0.08	1.8	0.27 [-0.67, 1.20]
	Placebo	9	7 (77.8)	-1.24 (1.71)	-3.5	-2.83	-0.67	-0.33	1.5	
Week 52	Tezepelumab	12	12 (100.0)	-0.87 (1.30)	-2.7	-2.08	-0.75	-0.17	1.8	0.20 [-0.74, 1.13]
	Placebo	9	7 (77.8)	-1.17 (1.75)	-3.5	-2.83	-0.67	-0.17	1.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 6	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 10	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 14	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 18	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 22	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 26	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 30	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 34	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 36	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 38	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	5 (55.6)					
Week 44	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 46	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 50	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table ST1H6C_IBMH0: Course of ACQ-6 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	12	12 (100.0)	2.36 (1.23)	0.0	1.92	2.33	3.08	4.2	
		Placebo	11	11 (100.0)	2.79 (1.18)	0.5	2.00	2.83	3.67	4.8	
	Week 4	Tezepelumab	12	11 (91.7)	2.26 (1.30)	0.3	1.33	2.00	3.17	5.0	
		Placebo	11	11 (100.0)	2.35 (0.92)	0.8	1.67	2.33	3.17	3.5	
	Week 8	Tezepelumab	12	11 (91.7)	1.82 (1.33)	0.0	0.50	1.83	3.00	3.8	
		Placebo	11	11 (100.0)	2.70 (1.08)	1.5	1.83	2.00	3.33	4.5	
	Week 12	Tezepelumab	12	11 (91.7)	2.39 (1.30)	0.2	1.33	2.50	3.67	4.3	
		Placebo	11	11 (100.0)	2.67 (1.11)	1.2	1.83	2.50	3.83	4.3	
	Week 16	Tezepelumab	12	11 (91.7)	2.14 (1.42)	0.0	1.17	1.83	3.50	4.5	
		Placebo	11	11 (100.0)	2.48 (1.10)	0.5	1.83	2.50	3.00	4.3	
	Week 20	Tezepelumab	12	11 (91.7)	1.98 (1.25)	0.3	0.83	1.83	2.83	4.7	
		Placebo	11	11 (100.0)	2.35 (1.23)	0.3	1.33	2.17	3.50	4.2	
	Week 24	Tezepelumab	12	11 (91.7)	2.08 (1.36)	0.0	0.83	2.00	3.17	4.8	
		Placebo	11	11 (100.0)	2.44 (1.08)	0.2	1.83	2.33	3.33	3.8	
	Week 28	Tezepelumab	12	9 (75.0)	1.59 (0.83)	0.5	0.83	1.67	2.17	3.0	
		Placebo	11	10 (90.9)	2.28 (1.42)	0.0	1.67	2.00	3.17	4.8	
	Week 32	Tezepelumab	12	10 (83.3)	1.98 (1.29)	0.3	1.17	1.58	2.83	4.2	
		Placebo	11	11 (100.0)	2.48 (1.20)	0.2	1.67	2.50	3.67	4.0	
	Week 36	Tezepelumab	12	10 (83.3)	1.85 (1.13)	0.0	1.17	1.92	2.00	4.0	
		Placebo	11	11 (100.0)	2.29 (1.07)	0.2	1.67	2.00	3.67	3.7	
	Week 40	Tezepelumab	12	10 (83.3)	1.73 (1.20)	0.2	0.67	1.67	2.17	3.8	
		Placebo	11	11 (100.0)	2.38 (1.17)	0.2	1.83	2.17	3.33	4.2	
	Week 44	Tezepelumab	12	9 (75.0)	1.78 (1.10)	0.3	1.50	1.67	1.83	4.2	
		Placebo	11	10 (90.9)	2.10 (1.36)	0.0	1.67	1.83	2.50	4.5	
	Week 48	Tezepelumab	12	9 (75.0)	1.61 (1.14)	0.3	0.67	1.33	2.17	3.8	
		Placebo	11	10 (90.9)	1.97 (1.26)	0.2	1.17	1.67	3.17	4.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table ST1H6C_IBMH0: Course of ACQ-6 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 4 score	Tezepelumab	12	11 (91.7)	-0.26 (1.45)	-2.0	-1.00	-0.67	0.17	3.5	0.16 [-0.67, 1.00]
	Placebo	11	11 (100.0)	-0.44 (0.63)	-1.5	-1.00	-0.33	0.00	0.5	
Week 8	Tezepelumab	12	11 (91.7)	-0.70 (1.02)	-2.3	-1.33	-0.33	0.17	0.5	-0.70 [-1.56, 0.17]
	Placebo	11	11 (100.0)	-0.09 (0.69)	-0.8	-0.50	-0.33	0.33	1.3	
Week 12	Tezepelumab	12	11 (91.7)	-0.12 (1.76)	-2.2	-1.50	-0.33	0.67	4.3	-0.00 [-0.84, 0.84]
	Placebo	11	11 (100.0)	-0.12 (0.76)	-1.3	-0.67	-0.33	0.50	1.3	
Week 16	Tezepelumab	12	11 (91.7)	-0.38 (1.27)	-2.3	-1.33	-0.50	0.83	1.3	-0.07 [-0.90, 0.77]
	Placebo	11	11 (100.0)	-0.30 (0.95)	-1.5	-1.17	-0.50	0.67	1.3	
Week 20	Tezepelumab	12	11 (91.7)	-0.53 (1.27)	-2.3	-1.83	-0.50	0.50	1.8	-0.09 [-0.92, 0.75]
	Placebo	11	11 (100.0)	-0.44 (0.80)	-1.7	-1.33	-0.33	0.17	0.8	
Week 24	Tezepelumab	12	11 (91.7)	-0.44 (1.64)	-2.5	-1.50	-0.67	0.67	3.3	-0.07 [-0.90, 0.77]
	Placebo	11	11 (100.0)	-0.35 (1.00)	-1.8	-1.17	-0.50	0.17	1.8	
Week 28	Tezepelumab	12	9 (75.0)	-0.81 (1.39)	-2.5	-1.50	-1.17	-0.33	2.3	-0.34 [-1.24, 0.57]
	Placebo	11	10 (90.9)	-0.42 (0.96)	-2.0	-1.00	-0.42	0.33	1.2	
Week 32	Tezepelumab	12	10 (83.3)	-0.37 (1.60)	-3.0	-1.33	-0.42	0.50	2.3	-0.05 [-0.91, 0.80]
	Placebo	11	11 (100.0)	-0.30 (0.63)	-1.8	-0.50	-0.17	0.00	0.7	
Week 36	Tezepelumab	12	10 (83.3)	-0.50 (1.43)	-2.3	-1.50	-0.75	0.67	2.0	-0.00 [-0.86, 0.86]
	Placebo	11	11 (100.0)	-0.50 (0.90)	-1.8	-1.17	-0.33	0.00	1.2	
Week 40	Tezepelumab	12	10 (83.3)	-0.62 (1.63)	-2.8	-1.67	-1.00	0.50	2.2	-0.15 [-1.01, 0.71]
	Placebo	11	11 (100.0)	-0.41 (1.12)	-2.7	-0.67	-0.17	0.17	1.7	
Week 44	Tezepelumab	12	9 (75.0)	-0.46 (1.73)	-2.3	-1.33	-1.00	-0.50	2.5	0.09 [-0.81, 0.99]
	Placebo	11	10 (90.9)	-0.60 (1.24)	-2.8	-1.00	-0.58	0.17	1.3	
Week 48	Tezepelumab	12	9 (75.0)	-0.63 (1.50)	-2.3	-1.83	-0.83	0.00	2.0	0.15 [-0.75, 1.05]
	Placebo	11	10 (90.9)	-0.82 (0.96)	-2.5	-1.33	-0.75	0.00	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table ST1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	11 (91.7)	-0.27 (0.32)	(-0.94, 0.40)	0.14 (0.45)	(-0.81, 1.10)	0.757
	Placebo	11	11 (100.0)	-0.41 (0.32)	(-1.09, 0.26)			
Week 8	Tezepelumab	12	11 (91.7)	-0.71 (0.25)	(-1.24, -0.18)	-0.65 (0.36)	(-1.41, 0.11)	0.092
	Placebo	11	11 (100.0)	-0.06 (0.26)	(-0.60, 0.47)			
Week 12	Tezepelumab	12	11 (91.7)	-0.13 (0.38)	(-0.95, 0.68)	-0.04 (0.55)	(-1.19, 1.12)	0.943
	Placebo	11	11 (100.0)	-0.09 (0.39)	(-0.91, 0.72)			
Week 16	Tezepelumab	12	11 (91.7)	-0.39 (0.32)	(-1.07, 0.29)	-0.12 (0.46)	(-1.08, 0.85)	0.805
	Placebo	11	11 (100.0)	-0.28 (0.33)	(-0.96, 0.41)			
Week 20	Tezepelumab	12	11 (91.7)	-0.54 (0.31)	(-1.19, 0.10)	-0.13 (0.44)	(-1.05, 0.79)	0.768
	Placebo	11	11 (100.0)	-0.41 (0.31)	(-1.06, 0.24)			
Week 24	Tezepelumab	12	11 (91.7)	-0.45 (0.39)	(-1.27, 0.36)	-0.13 (0.55)	(-1.29, 1.03)	0.815
	Placebo	11	11 (100.0)	-0.32 (0.39)	(-1.14, 0.50)			
Week 28	Tezepelumab	12	9 (75.0)	-0.49 (0.37)	(-1.28, 0.30)	0.02 (0.53)	(-1.09, 1.13)	0.968
	Placebo	11	10 (90.9)	-0.51 (0.37)	(-1.29, 0.27)			
Week 32	Tezepelumab	12	10 (83.3)	-0.32 (0.35)	(-1.05, 0.42)	-0.04 (0.49)	(-1.08, 1.00)	0.935
	Placebo	11	11 (100.0)	-0.28 (0.34)	(-1.00, 0.45)			
Week 36	Tezepelumab	12	10 (83.3)	-0.43 (0.34)	(-1.14, 0.29)	0.04 (0.48)	(-0.97, 1.06)	0.927
	Placebo	11	11 (100.0)	-0.47 (0.34)	(-1.19, 0.24)			
Week 40	Tezepelumab	12	10 (83.3)	-0.56 (0.40)	(-1.40, 0.28)	-0.18 (0.56)	(-1.36, 1.00)	0.751
	Placebo	11	11 (100.0)	-0.38 (0.39)	(-1.21, 0.45)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table ST1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	9 (75.0)	-0.30 (0.42)	(-1.17, 0.58)	0.29 (0.59)	(-0.94, 1.52)	0.622
	Placebo	11	10 (90.9)	-0.59 (0.41)	(-1.45, 0.27)			
Week 48	Tezepelumab	12	9 (75.0)	-0.38 (0.37)	(-1.17, 0.41)	0.48 (0.53)	(-0.62, 1.59)	0.372
	Placebo	11	10 (90.9)	-0.86 (0.37)	(-1.63, -0.09)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table DT1H6C_BBMH0: Course of ACQ-6 score
 DITTNB - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Teze+Teze	45	45 (100.0)	2.73 (0.67)	1.7	2.17	2.67	3.00	4.8
		Pbo+Pbo	19	19 (100.0)	2.96 (0.85)	1.8	2.50	2.83	3.33	5.7
Week 2	Teze+Teze	45	44 (97.8)	2.04 (0.82)	0.0	1.50	2.17	2.58	4.0	
	Pbo+Pbo	19	18 (94.7)	2.13 (0.85)	0.7	1.67	2.08	2.67	3.7	
Week 4	Teze+Teze	45	45 (100.0)	1.94 (0.95)	0.0	1.33	2.17	2.50	4.0	
	Pbo+Pbo	19	19 (100.0)	2.03 (0.74)	0.8	1.50	2.00	2.67	3.2	
Week 8	Teze+Teze	45	44 (97.8)	1.80 (0.96)	0.0	1.00	2.00	2.50	3.7	
	Pbo+Pbo	19	19 (100.0)	2.13 (1.05)	0.8	1.50	1.83	2.67	4.8	
Week 12	Teze+Teze	45	44 (97.8)	1.70 (1.16)	0.0	0.92	1.75	2.42	5.5	
	Pbo+Pbo	19	19 (100.0)	1.79 (0.96)	0.3	1.00	1.67	2.17	4.2	
Week 16	Teze+Teze	45	44 (97.8)	1.63 (1.02)	0.0	0.92	1.67	2.42	3.7	
	Pbo+Pbo	19	19 (100.0)	1.77 (0.91)	0.3	1.17	1.50	2.17	4.2	
Week 20	Teze+Teze	45	44 (97.8)	1.65 (1.06)	0.0	0.83	1.67	2.67	4.0	
	Pbo+Pbo	19	19 (100.0)	1.78 (0.86)	0.7	1.00	1.50	2.50	3.3	
Week 24	Teze+Teze	45	44 (97.8)	1.62 (1.01)	0.0	0.83	1.67	2.58	3.2	
	Pbo+Pbo	19	18 (94.7)	1.87 (0.94)	0.2	1.00	1.83	2.67	3.8	
Week 28	Teze+Teze	45	43 (95.6)	1.61 (1.07)	0.0	0.67	1.83	2.50	4.5	
	Pbo+Pbo	19	19 (100.0)	1.75 (1.10)	0.3	0.67	1.83	2.50	4.0	
Week 32	Teze+Teze	45	44 (97.8)	1.66 (1.02)	0.0	0.92	1.75	2.42	3.7	
	Pbo+Pbo	19	19 (100.0)	1.61 (0.90)	0.3	1.00	1.17	2.33	3.3	
Week 36	Teze+Teze	45	45 (100.0)	1.74 (1.09)	0.0	1.00	1.67	2.33	4.2	
	Pbo+Pbo	19	19 (100.0)	1.90 (0.97)	0.2	1.17	1.83	2.50	4.5	
Week 40	Teze+Teze	45	42 (93.3)	1.70 (1.11)	0.0	0.83	1.75	2.67	3.5	
	Pbo+Pbo	19	19 (100.0)	1.79 (1.00)	0.0	1.33	1.83	2.50	3.8	
Week 44	Teze+Teze	45	44 (97.8)	1.60 (1.12)	0.0	0.67	1.42	2.50	3.8	
	Pbo+Pbo	19	19 (100.0)	1.89 (0.97)	0.3	1.17	2.00	2.50	4.2	
Week 48	Teze+Teze	45	45 (100.0)	1.67 (1.17)	0.0	0.67	1.67	2.50	4.5	
	Pbo+Pbo	19	19 (100.0)	1.69 (1.15)	0.0	1.00	1.50	2.33	4.3	
Week 52	Teze+Teze	45	43 (95.6)	1.60 (1.06)	0.0	1.00	1.50	2.50	3.5	
	Pbo+Pbo	19	19 (100.0)	1.67 (1.09)	0.0	1.00	1.50	2.17	4.8	
Week 64	Teze+Teze	45	44 (97.8)	1.52 (1.02)	0.0	0.83	1.42	2.33	4.0	
	Pbo+Pbo	19	19 (100.0)	1.88 (1.07)	0.2	1.00	1.83	2.33	4.5	
Week 76	Teze+Teze	45	43 (95.6)	1.64 (1.23)	0.0	0.50	1.50	2.67	4.8	
	Pbo+Pbo	19	19 (100.0)	1.65 (0.86)	0.2	0.83	2.00	2.50	3.0	
Week 88	Teze+Teze	45	41 (91.1)	1.45 (1.01)	0.0	0.67	1.50	2.33	3.5	
	Pbo+Pbo	19	19 (100.0)	1.83 (0.89)	0.5	0.83	1.83	2.67	3.2	
Week 104	Teze+Teze	45	40 (88.9)	1.44 (1.00)	0.0	0.67	1.25	2.25	4.5	
	Pbo+Pbo	19	19 (100.0)	1.61 (0.92)	0.0	0.67	1.67	2.33	3.0	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C_BBMH0: Course of ACQ-6 score
 DITTNB - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Teze+Teze	45	44 (97.8)	-0.69 (0.72)	-3.2	-1.00	-0.50	-0.25	0.3	0.19 [-0.36, 0.74]
	Pbo+Pbo	19	18 (94.7)	-0.83 (0.81)	-2.3	-1.67	-0.42	-0.17	0.2	
Week 4	Teze+Teze	45	45 (100.0)	-0.78 (0.85)	-3.0	-1.50	-0.67	-0.17	0.7	0.18 [-0.36, 0.72]
	Pbo+Pbo	19	19 (100.0)	-0.93 (0.77)	-2.7	-1.50	-0.67	-0.50	0.2	
Week 8	Teze+Teze	45	44 (97.8)	-0.94 (0.84)	-3.0	-1.50	-0.92	-0.33	0.8	-0.14 [-0.68, 0.40]
	Pbo+Pbo	19	19 (100.0)	-0.82 (0.93)	-2.2	-1.33	-0.83	-0.33	2.0	
Week 12	Teze+Teze	45	44 (97.8)	-1.02 (1.04)	-3.2	-1.92	-0.92	-0.33	1.3	0.14 [-0.40, 0.68]
	Pbo+Pbo	19	19 (100.0)	-1.17 (0.91)	-2.5	-1.83	-1.33	-0.17	0.3	
Week 16	Teze+Teze	45	44 (97.8)	-1.11 (0.98)	-3.2	-1.75	-0.92	-0.42	0.7	0.08 [-0.46, 0.62]
	Pbo+Pbo	19	19 (100.0)	-1.18 (0.77)	-2.5	-1.67	-1.33	-0.50	0.3	
Week 20	Teze+Teze	45	44 (97.8)	-1.07 (1.05)	-3.2	-1.67	-1.08	-0.33	1.3	0.11 [-0.43, 0.65]
	Pbo+Pbo	19	19 (100.0)	-1.18 (0.86)	-2.7	-1.83	-1.00	-0.67	0.3	
Week 24	Teze+Teze	45	44 (97.8)	-1.12 (1.03)	-3.3	-1.58	-1.00	-0.42	0.7	-0.00 [-0.55, 0.55]
	Pbo+Pbo	19	18 (94.7)	-1.12 (0.83)	-3.2	-1.67	-1.08	-0.50	0.2	
Week 28	Teze+Teze	45	43 (95.6)	-1.06 (0.99)	-2.8	-1.67	-0.83	-0.33	0.8	0.14 [-0.40, 0.68]
	Pbo+Pbo	19	19 (100.0)	-1.20 (0.93)	-3.0	-1.83	-1.17	-0.67	0.7	
Week 32	Teze+Teze	45	44 (97.8)	-1.07 (1.05)	-3.2	-1.67	-1.00	-0.42	1.0	0.27 [-0.27, 0.81]
	Pbo+Pbo	19	19 (100.0)	-1.35 (1.05)	-3.0	-2.33	-1.33	-0.67	0.2	
Week 36	Teze+Teze	45	45 (100.0)	-0.98 (1.06)	-3.2	-1.83	-0.83	-0.50	1.5	0.07 [-0.47, 0.61]
	Pbo+Pbo	19	19 (100.0)	-1.05 (0.90)	-3.0	-1.50	-1.00	-0.17	0.2	
Week 40	Teze+Teze	45	42 (93.3)	-1.01 (1.01)	-3.0	-1.83	-0.92	-0.17	1.3	0.16 [-0.39, 0.70]
	Pbo+Pbo	19	19 (100.0)	-1.17 (0.96)	-3.0	-1.83	-1.00	-0.50	0.2	
Week 44	Teze+Teze	45	44 (97.8)	-1.12 (1.03)	-3.0	-1.92	-1.08	-0.42	1.3	-0.06 [-0.59, 0.48]
	Pbo+Pbo	19	19 (100.0)	-1.06 (0.92)	-2.8	-1.83	-1.00	-0.17	0.2	
Week 48	Teze+Teze	45	45 (100.0)	-1.06 (1.16)	-3.2	-1.83	-1.00	-0.50	1.8	0.18 [-0.36, 0.72]
	Pbo+Pbo	19	19 (100.0)	-1.26 (1.01)	-3.2	-2.00	-1.17	-0.33	0.2	
Week 52	Teze+Teze	45	43 (95.6)	-1.13 (1.04)	-3.2	-1.83	-1.00	-0.50	1.5	0.16 [-0.38, 0.70]
	Pbo+Pbo	19	19 (100.0)	-1.29 (0.99)	-3.3	-2.17	-1.33	-0.50	0.0	
Week 64	Teze+Teze	45	44 (97.8)	-1.20 (0.99)	-2.8	-2.00	-1.33	-0.33	1.0	-0.12 [-0.66, 0.42]
	Pbo+Pbo	19	19 (100.0)	-1.08 (1.01)	-3.0	-2.00	-1.17	-0.17	0.8	
Week 76	Teze+Teze	45	43 (95.6)	-1.10 (1.10)	-3.2	-2.00	-1.17	-0.17	1.8	0.20 [-0.35, 0.74]
	Pbo+Pbo	19	19 (100.0)	-1.31 (1.00)	-3.2	-2.00	-1.33	-0.50	0.2	
Week 88	Teze+Teze	45	41 (91.1)	-1.28 (0.98)	-3.0	-2.17	-1.33	-0.33	0.8	-0.16 [-0.70, 0.39]
	Pbo+Pbo	19	19 (100.0)	-1.12 (1.04)	-3.5	-1.83	-1.00	-0.33	0.2	
Week 104	Teze+Teze	45	40 (88.9)	-1.32 (1.02)	-3.2	-2.08	-1.33	-0.67	1.8	0.03 [-0.51, 0.58]
	Pbo+Pbo	19	19 (100.0)	-1.35 (1.03)	-3.3	-2.50	-0.67	-0.50	-0.2	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C_BBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTNB - LTE

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Teze+Teze	45	44 (97.8)	-0.72 (0.11)	(-0.93, -0.51)	0.03 (0.20)	(-0.37, 0.42)	0.896
	Pbo+Pbo	19	18 (94.7)	-0.74 (0.16)	(-1.07, -0.41)			
Week 4	Teze+Teze	45	45 (100.0)	-0.80 (0.12)	(-1.04, -0.56)	0.09 (0.22)	(-0.35, 0.52)	0.684
	Pbo+Pbo	19	19 (100.0)	-0.89 (0.18)	(-1.25, -0.52)			
Week 8	Teze+Teze	45	44 (97.8)	-0.98 (0.13)	(-1.23, -0.72)	-0.19 (0.23)	(-0.66, 0.28)	0.415
	Pbo+Pbo	19	19 (100.0)	-0.78 (0.20)	(-1.17, -0.39)			
Week 12	Teze+Teze	45	44 (97.8)	-1.07 (0.15)	(-1.37, -0.78)	0.05 (0.27)	(-0.49, 0.60)	0.847
	Pbo+Pbo	19	19 (100.0)	-1.13 (0.23)	(-1.58, -0.67)			
Week 16	Teze+Teze	45	44 (97.8)	-1.12 (0.13)	(-1.38, -0.86)	0.02 (0.24)	(-0.46, 0.51)	0.926
	Pbo+Pbo	19	19 (100.0)	-1.14 (0.20)	(-1.55, -0.74)			
Week 20	Teze+Teze	45	44 (97.8)	-1.12 (0.14)	(-1.40, -0.83)	0.02 (0.26)	(-0.51, 0.54)	0.951
	Pbo+Pbo	19	19 (100.0)	-1.13 (0.22)	(-1.58, -0.69)			
Week 24	Teze+Teze	45	44 (97.8)	-1.15 (0.14)	(-1.43, -0.88)	-0.06 (0.26)	(-0.57, 0.45)	0.816
	Pbo+Pbo	19	18 (94.7)	-1.09 (0.21)	(-1.52, -0.66)			
Week 28	Teze+Teze	45	43 (95.6)	-1.08 (0.14)	(-1.36, -0.79)	0.09 (0.26)	(-0.44, 0.61)	0.747
	Pbo+Pbo	19	19 (100.0)	-1.16 (0.22)	(-1.60, -0.72)			
Week 32	Teze+Teze	45	44 (97.8)	-1.08 (0.15)	(-1.38, -0.79)	0.23 (0.27)	(-0.31, 0.77)	0.407
	Pbo+Pbo	19	19 (100.0)	-1.31 (0.23)	(-1.76, -0.86)			
Week 36	Teze+Teze	45	45 (100.0)	-1.00 (0.15)	(-1.29, -0.71)	0.01 (0.27)	(-0.53, 0.55)	0.965
	Pbo+Pbo	19	19 (100.0)	-1.01 (0.23)	(-1.46, -0.56)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C_BBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTNB - LTE

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Teze+Teze	45	42 (93.3)	-1.04 (0.15)	(-1.34, -0.74)	0.08 (0.27)	(-0.46, 0.63)	0.761
	Pbo+Pbo	19	19 (100.0)	-1.13 (0.23)	(-1.58, -0.67)			
Week 44	Teze+Teze	45	44 (97.8)	-1.12 (0.15)	(-1.41, -0.83)	-0.10 (0.27)	(-0.63, 0.44)	0.719
	Pbo+Pbo	19	19 (100.0)	-1.02 (0.22)	(-1.47, -0.57)			
Week 48	Teze+Teze	45	45 (100.0)	-1.08 (0.16)	(-1.40, -0.75)	0.14 (0.30)	(-0.45, 0.74)	0.631
	Pbo+Pbo	19	19 (100.0)	-1.22 (0.25)	(-1.72, -0.72)			
Week 52	Teze+Teze	45	43 (95.6)	-1.12 (0.15)	(-1.41, -0.82)	0.13 (0.27)	(-0.41, 0.67)	0.628
	Pbo+Pbo	19	19 (100.0)	-1.25 (0.23)	(-1.70, -0.80)			
Week 64	Teze+Teze	45	44 (97.8)	-1.21 (0.14)	(-1.49, -0.92)	-0.17 (0.26)	(-0.69, 0.36)	0.525
	Pbo+Pbo	19	19 (100.0)	-1.04 (0.22)	(-1.48, -0.60)			
Week 76	Teze+Teze	45	43 (95.6)	-1.07 (0.16)	(-1.39, -0.75)	0.20 (0.29)	(-0.38, 0.78)	0.499
	Pbo+Pbo	19	19 (100.0)	-1.27 (0.24)	(-1.75, -0.78)			
Week 88	Teze+Teze	45	41 (91.1)	-1.21 (0.15)	(-1.50, -0.91)	-0.12 (0.27)	(-0.66, 0.41)	0.644
	Pbo+Pbo	19	19 (100.0)	-1.08 (0.22)	(-1.53, -0.64)			
Week 104	Teze+Teze	45	40 (88.9)	-1.24 (0.15)	(-1.55, -0.94)	0.07 (0.28)	(-0.49, 0.62)	0.810
	Pbo+Pbo	19	19 (100.0)	-1.31 (0.23)	(-1.77, -0.85)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table CT1H6C_IBMH0: Course of ACQ-6 score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	4	4 (100.0)	2.25 (0.52)	1.8	1.92	2.08	2.58	3.0	
		Placebo	8	8 (100.0)	1.71 (0.81)	0.8	1.08	1.67	2.00	3.3	
	Week 12	Tezepelumab	4	4 (100.0)	1.50 (0.98)	0.5	0.67	1.50	2.33	2.5	
		Placebo	8	8 (100.0)	0.92 (0.60)	0.0	0.33	1.25	1.33	1.5	
	Week 28	Tezepelumab	4	4 (100.0)	1.83 (1.11)	0.8	0.92	1.67	2.75	3.2	
		Placebo	8	5 (62.5)	0.97 (0.72)	0.3	0.50	0.50	1.67	1.8	
	End of treatment	Tezepelumab	4	4 (100.0)	1.83 (1.11)	0.8	0.92	1.67	2.75	3.2	
		Placebo	8	8 (100.0)	0.94 (0.61)	0.3	0.42	0.75	1.50	1.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 21FEB2022

Table CT1H6C_IBMH0: Course of ACQ-6 score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 12 score	Tezepelumab	4	4 (100.0)	-0.75 (0.73)	-1.3	-1.33	-0.92	-0.17	0.2	0.04 [-1.16, 1.24]
	Placebo	8	8 (100.0)	-0.79 (1.23)	-3.3	-1.33	-0.33	-0.08	0.5	
Week 28	Tezepelumab	4	4 (100.0)	-0.42 (0.78)	-1.2	-1.08	-0.42	0.25	0.3	0.30 [-1.02, 1.63]
	Placebo	8	5 (62.5)	-0.73 (1.22)	-2.8	-0.50	-0.33	-0.33	0.3	
End of treatment	Tezepelumab	4	4 (100.0)	-0.42 (0.78)	-1.2	-1.08	-0.42	0.25	0.3	0.37 [-0.84, 1.58]
	Placebo	8	8 (100.0)	-0.77 (1.02)	-2.8	-1.25	-0.42	-0.17	0.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 21FEB2022

Table CT1H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 12	Tezepelumab	4	4 (100.0)	-0.34 (0.41)	(-1.26, 0.58)	0.70 (0.51)	(-0.46, 1.87)	0.205
	Placebo	8	8 (100.0)	-1.04 (0.28)	(-1.68, -0.40)			
Week 28	Tezepelumab	4	4 (100.0)	-0.00 (0.50)	(-1.17, 1.16)	0.93 (0.64)	(-0.54, 2.41)	0.183
	Placebo	8	5 (62.5)	-0.94 (0.38)	(-1.80, -0.07)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table DT1H5C_HBMH0: Course of ACQ-5 score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Teze+Teze	44	44 (100.0)	2.91 (0.70)	1.8	2.30	3.00	3.20	5.2	
		Pbo+Pbo	19	19 (100.0)	3.17 (0.80)	2.2	2.60	3.00	3.40	5.6	
Week 2		Teze+Teze	44	43 (97.7)	2.20 (0.87)	0.0	1.60	2.40	2.80	4.4	
		Pbo+Pbo	19	18 (94.7)	2.26 (0.86)	0.8	1.60	2.20	2.80	3.8	
Week 4		Teze+Teze	44	44 (100.0)	2.12 (1.02)	0.0	1.60	2.40	2.80	4.4	
		Pbo+Pbo	19	19 (100.0)	2.15 (0.77)	0.8	1.60	2.20	2.80	3.4	
Week 8		Teze+Teze	44	43 (97.7)	1.93 (1.01)	0.0	1.20	2.20	2.60	4.0	
		Pbo+Pbo	19	19 (100.0)	2.26 (1.05)	1.0	1.60	2.00	3.00	5.0	
Week 12		Teze+Teze	44	43 (97.7)	1.83 (1.24)	0.0	0.80	2.00	2.80	5.6	
		Pbo+Pbo	19	19 (100.0)	1.89 (0.97)	0.4	1.00	1.80	2.40	3.8	
Week 16		Teze+Teze	44	43 (97.7)	1.75 (1.12)	0.0	1.00	1.60	2.60	3.8	
		Pbo+Pbo	19	19 (100.0)	1.89 (0.88)	0.4	1.20	1.80	2.20	3.8	
Week 20		Teze+Teze	44	43 (97.7)	1.79 (1.16)	0.0	0.80	2.00	2.80	4.8	
		Pbo+Pbo	19	19 (100.0)	1.88 (0.89)	0.6	1.00	1.60	2.80	3.6	
Week 24		Teze+Teze	44	43 (97.7)	1.73 (1.11)	0.0	0.80	1.80	2.60	3.6	
		Pbo+Pbo	19	18 (94.7)	2.01 (0.93)	0.2	1.20	1.90	3.00	3.6	
Week 28		Teze+Teze	44	42 (95.5)	1.73 (1.18)	0.0	0.80	1.80	2.60	4.6	
		Pbo+Pbo	19	19 (100.0)	1.88 (1.10)	0.2	0.80	2.20	2.80	3.8	
Week 32		Teze+Teze	44	43 (97.7)	1.79 (1.11)	0.0	1.00	1.80	2.60	4.0	
		Pbo+Pbo	19	19 (100.0)	1.74 (0.93)	0.2	1.20	1.40	2.60	3.4	
Week 36		Teze+Teze	44	44 (100.0)	1.88 (1.18)	0.0	1.10	1.90	2.60	4.6	
		Pbo+Pbo	19	19 (100.0)	2.04 (0.99)	0.2	1.20	2.00	2.60	4.4	
Week 40		Teze+Teze	44	41 (93.2)	1.82 (1.16)	0.0	1.00	2.00	2.80	3.6	
		Pbo+Pbo	19	19 (100.0)	1.94 (1.01)	0.0	1.40	2.00	2.60	3.4	
Week 44		Teze+Teze	44	43 (97.7)	1.75 (1.24)	0.0	0.80	1.60	2.80	4.0	
		Pbo+Pbo	19	19 (100.0)	2.04 (0.98)	0.4	1.20	2.20	2.80	4.0	
Week 48		Teze+Teze	44	44 (100.0)	1.79 (1.26)	0.0	0.70	1.80	2.60	5.0	
		Pbo+Pbo	19	19 (100.0)	1.81 (1.20)	0.0	1.00	1.60	2.40	4.2	
Week 52		Teze+Teze	44	42 (95.5)	1.73 (1.11)	0.0	1.20	1.90	2.60	3.6	
		Pbo+Pbo	19	19 (100.0)	1.78 (1.11)	0.0	1.00	1.60	2.20	4.6	
Week 64		Teze+Teze	44	43 (97.7)	1.68 (1.12)	0.0	1.00	1.40	2.40	4.6	
		Pbo+Pbo	19	19 (100.0)	1.97 (1.08)	0.0	1.00	2.20	2.40	4.2	
Week 76		Teze+Teze	44	42 (95.5)	1.79 (1.36)	0.0	0.60	1.70	2.80	5.4	
		Pbo+Pbo	19	19 (100.0)	1.74 (0.91)	0.2	0.80	2.00	2.60	3.0	
Week 88		Teze+Teze	44	40 (90.9)	1.53 (1.09)	0.0	0.80	1.50	2.50	3.6	
		Pbo+Pbo	19	19 (100.0)	1.96 (0.96)	0.4	1.00	2.00	3.00	3.2	
Week 104		Teze+Teze	44	39 (88.6)	1.51 (1.03)	0.0	0.80	1.40	2.20	4.2	
		Pbo+Pbo	19	19 (100.0)	1.67 (0.98)	0.0	0.80	1.80	2.60	2.8	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C_HBMH0: Course of ACQ-5 score
 DITTNB - LTE - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Teze+Teze	44	43 (97.7)	-0.72 (0.77)	-3.2	-1.00	-0.60	-0.20	0.4	0.25 [-0.30, 0.80]
	Pbo+Pbo	19	18 (94.7)	-0.92 (0.95)	-2.6	-1.80	-0.50	-0.20	0.4	
Week 4	Teze+Teze	44	44 (100.0)	-0.79 (0.92)	-3.0	-1.50	-0.60	-0.20	0.8	0.25 [-0.29, 0.79]
	Pbo+Pbo	19	19 (100.0)	-1.02 (0.93)	-3.0	-1.60	-0.60	-0.40	0.2	
Week 8	Teze+Teze	44	43 (97.7)	-0.99 (0.89)	-3.0	-1.80	-0.80	-0.40	0.4	-0.09 [-0.63, 0.45]
	Pbo+Pbo	19	19 (100.0)	-0.91 (1.02)	-2.6	-1.60	-1.00	-0.40	2.0	
Week 12	Teze+Teze	44	43 (97.7)	-1.07 (1.12)	-3.2	-2.00	-0.80	-0.20	1.2	0.18 [-0.36, 0.72]
	Pbo+Pbo	19	19 (100.0)	-1.27 (1.02)	-3.0	-2.00	-1.40	-0.40	0.4	
Week 16	Teze+Teze	44	43 (97.7)	-1.16 (1.07)	-3.2	-2.00	-1.00	-0.40	0.8	0.11 [-0.43, 0.65]
	Pbo+Pbo	19	19 (100.0)	-1.27 (0.84)	-2.6	-1.80	-1.40	-0.60	0.4	
Week 20	Teze+Teze	44	43 (97.7)	-1.12 (1.17)	-3.2	-1.80	-1.00	-0.40	1.8	0.15 [-0.39, 0.69]
	Pbo+Pbo	19	19 (100.0)	-1.28 (0.94)	-3.2	-2.00	-1.20	-0.60	0.4	
Week 24	Teze+Teze	44	43 (97.7)	-1.19 (1.13)	-3.6	-1.80	-1.00	-0.40	0.6	-0.00 [-0.55, 0.55]
	Pbo+Pbo	19	18 (94.7)	-1.19 (0.91)	-3.6	-1.60	-1.20	-0.60	0.2	
Week 28	Teze+Teze	44	42 (95.5)	-1.12 (1.07)	-3.0	-1.80	-0.90	-0.20	0.8	0.15 [-0.39, 0.69]
	Pbo+Pbo	19	19 (100.0)	-1.28 (1.03)	-3.6	-2.00	-1.20	-0.60	0.6	
Week 32	Teze+Teze	44	43 (97.7)	-1.13 (1.15)	-3.4	-1.80	-1.00	-0.40	1.0	0.26 [-0.28, 0.81]
	Pbo+Pbo	19	19 (100.0)	-1.43 (1.16)	-3.6	-2.60	-1.40	-0.60	0.4	
Week 36	Teze+Teze	44	44 (100.0)	-1.03 (1.14)	-3.2	-1.90	-0.90	-0.50	1.6	0.09 [-0.45, 0.62]
	Pbo+Pbo	19	19 (100.0)	-1.13 (1.03)	-3.2	-1.60	-1.00	-0.20	0.2	
Week 40	Teze+Teze	44	41 (93.2)	-1.08 (1.05)	-3.2	-1.80	-1.00	-0.20	0.8	0.15 [-0.40, 0.69]
	Pbo+Pbo	19	19 (100.0)	-1.23 (1.06)	-3.4	-2.00	-1.00	-0.40	0.2	
Week 44	Teze+Teze	44	43 (97.7)	-1.16 (1.14)	-3.4	-2.00	-1.00	-0.40	1.4	-0.03 [-0.57, 0.51]
	Pbo+Pbo	19	19 (100.0)	-1.13 (1.00)	-3.2	-1.80	-1.20	-0.20	0.2	
Week 48	Teze+Teze	44	44 (100.0)	-1.12 (1.28)	-3.4	-2.10	-1.10	-0.40	2.0	0.19 [-0.35, 0.73]
	Pbo+Pbo	19	19 (100.0)	-1.36 (1.10)	-3.8	-2.00	-1.20	-0.40	0.2	
Week 52	Teze+Teze	44	42 (95.5)	-1.19 (1.08)	-3.2	-2.00	-1.00	-0.40	1.2	0.19 [-0.35, 0.73]
	Pbo+Pbo	19	19 (100.0)	-1.39 (1.10)	-3.8	-2.20	-1.40	-0.60	0.0	
Week 64	Teze+Teze	44	43 (97.7)	-1.23 (1.11)	-3.0	-2.20	-1.20	-0.20	1.2	-0.03 [-0.57, 0.51]
	Pbo+Pbo	19	19 (100.0)	-1.20 (1.13)	-3.6	-2.20	-1.20	-0.20	0.8	
Week 76	Teze+Teze	44	42 (95.5)	-1.14 (1.22)	-3.2	-2.20	-1.30	-0.20	2.4	0.24 [-0.30, 0.79]
	Pbo+Pbo	19	19 (100.0)	-1.43 (1.10)	-3.6	-2.20	-1.20	-0.60	0.2	
Week 88	Teze+Teze	44	40 (90.9)	-1.39 (1.08)	-3.4	-2.30	-1.30	-0.50	0.8	-0.16 [-0.71, 0.39]
	Pbo+Pbo	19	19 (100.0)	-1.21 (1.12)	-3.4	-2.00	-1.00	-0.20	0.2	
Week 104	Teze+Teze	44	39 (88.6)	-1.44 (1.07)	-3.2	-2.20	-1.60	-0.80	1.4	0.05 [-0.50, 0.60]
	Pbo+Pbo	19	19 (100.0)	-1.49 (1.13)	-3.8	-2.60	-1.00	-0.40	-0.2	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C_HBMC0: Change from baseline in ACQ-5 score - MMRM results
DITTNB - LTE - adult

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 2	Teze+Teze	44	43 (97.7)	-0.75 (0.12)	(-0.99, -0.51)	0.06 (0.22)	(-0.37, 0.50)	0.770
	Pbo+Pbo	19	18 (94.7)	-0.82 (0.18)	(-1.18, -0.45)			
Week 4	Teze+Teze	44	44 (100.0)	-0.81 (0.13)	(-1.08, -0.55)	0.15 (0.24)	(-0.33, 0.64)	0.527
	Pbo+Pbo	19	19 (100.0)	-0.97 (0.20)	(-1.37, -0.57)			
Week 8	Teze+Teze	44	43 (97.7)	-1.03 (0.14)	(-1.30, -0.75)	-0.18 (0.25)	(-0.68, 0.33)	0.487
	Pbo+Pbo	19	19 (100.0)	-0.85 (0.21)	(-1.27, -0.44)			
Week 12	Teze+Teze	44	43 (97.7)	-1.13 (0.16)	(-1.45, -0.81)	0.09 (0.30)	(-0.50, 0.68)	0.756
	Pbo+Pbo	19	19 (100.0)	-1.22 (0.25)	(-1.71, -0.73)			
Week 16	Teze+Teze	44	43 (97.7)	-1.18 (0.15)	(-1.47, -0.89)	0.04 (0.27)	(-0.49, 0.58)	0.873
	Pbo+Pbo	19	19 (100.0)	-1.22 (0.22)	(-1.67, -0.78)			
Week 20	Teze+Teze	44	43 (97.7)	-1.18 (0.16)	(-1.50, -0.86)	0.06 (0.29)	(-0.53, 0.64)	0.852
	Pbo+Pbo	19	19 (100.0)	-1.23 (0.25)	(-1.72, -0.74)			
Week 24	Teze+Teze	44	43 (97.7)	-1.23 (0.15)	(-1.53, -0.92)	-0.07 (0.28)	(-0.63, 0.49)	0.793
	Pbo+Pbo	19	18 (94.7)	-1.15 (0.23)	(-1.62, -0.68)			
Week 28	Teze+Teze	44	42 (95.5)	-1.15 (0.16)	(-1.47, -0.84)	0.08 (0.29)	(-0.50, 0.66)	0.787
	Pbo+Pbo	19	19 (100.0)	-1.23 (0.24)	(-1.71, -0.75)			
Week 32	Teze+Teze	44	43 (97.7)	-1.15 (0.16)	(-1.47, -0.82)	0.23 (0.30)	(-0.36, 0.83)	0.439
	Pbo+Pbo	19	19 (100.0)	-1.38 (0.25)	(-1.88, -0.88)			
Week 36	Teze+Teze	44	44 (100.0)	-1.06 (0.16)	(-1.38, -0.73)	0.02 (0.29)	(-0.57, 0.61)	0.949
	Pbo+Pbo	19	19 (100.0)	-1.07 (0.25)	(-1.57, -0.58)			

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 20JUL2022

Table DT1H5C_HBMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTNB - LTE - adult

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Teze+Teze	44	41 (93.2)	-1.11 (0.16)	(-1.43, -0.80)	0.07 (0.29)	(-0.51, 0.64)	0.819
	Pbo+Pbo	19	19 (100.0)	-1.18 (0.24)	(-1.66, -0.70)			
Week 44	Teze+Teze	44	43 (97.7)	-1.16 (0.16)	(-1.49, -0.83)	-0.09 (0.30)	(-0.68, 0.51)	0.774
	Pbo+Pbo	19	19 (100.0)	-1.07 (0.25)	(-1.57, -0.58)			
Week 48	Teze+Teze	44	44 (100.0)	-1.15 (0.18)	(-1.51, -0.79)	0.16 (0.33)	(-0.50, 0.82)	0.630
	Pbo+Pbo	19	19 (100.0)	-1.31 (0.27)	(-1.86, -0.76)			
Week 52	Teze+Teze	44	42 (95.5)	-1.18 (0.16)	(-1.50, -0.87)	0.16 (0.29)	(-0.42, 0.73)	0.588
	Pbo+Pbo	19	19 (100.0)	-1.34 (0.24)	(-1.81, -0.86)			
Week 64	Teze+Teze	44	43 (97.7)	-1.24 (0.16)	(-1.57, -0.92)	-0.10 (0.29)	(-0.68, 0.49)	0.746
	Pbo+Pbo	19	19 (100.0)	-1.15 (0.24)	(-1.64, -0.66)			
Week 76	Teze+Teze	44	42 (95.5)	-1.13 (0.18)	(-1.48, -0.78)	0.25 (0.32)	(-0.39, 0.89)	0.443
	Pbo+Pbo	19	19 (100.0)	-1.38 (0.27)	(-1.91, -0.85)			
Week 88	Teze+Teze	44	40 (90.9)	-1.30 (0.16)	(-1.63, -0.98)	-0.14 (0.29)	(-0.73, 0.44)	0.623
	Pbo+Pbo	19	19 (100.0)	-1.16 (0.24)	(-1.65, -0.67)			
Week 104	Teze+Teze	44	39 (88.6)	-1.39 (0.16)	(-1.71, -1.07)	0.05 (0.29)	(-0.52, 0.63)	0.851
	Pbo+Pbo	19	19 (100.0)	-1.44 (0.24)	(-1.92, -0.97)			

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C_HBMH0: Course of ACQ-6 score
DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Teze+Teze	44	44 (100.0)	2.73 (0.67)	1.7	2.17	2.67	3.00	4.8	
		Pbo+Pbo	19	19 (100.0)	2.96 (0.85)	1.8	2.50	2.83	3.33	5.7	
Week 2		Teze+Teze	44	43 (97.7)	2.06 (0.82)	0.0	1.50	2.17	2.67	4.0	
		Pbo+Pbo	19	18 (94.7)	2.13 (0.85)	0.7	1.67	2.08	2.67	3.7	
Week 4		Teze+Teze	44	44 (100.0)	1.97 (0.95)	0.0	1.42	2.25	2.50	4.0	
		Pbo+Pbo	19	19 (100.0)	2.03 (0.74)	0.8	1.50	2.00	2.67	3.2	
Week 8		Teze+Teze	44	43 (97.7)	1.81 (0.96)	0.0	1.00	2.00	2.50	3.7	
		Pbo+Pbo	19	19 (100.0)	2.13 (1.05)	0.8	1.50	1.83	2.67	4.8	
Week 12		Teze+Teze	44	43 (97.7)	1.72 (1.17)	0.0	1.00	1.83	2.50	5.5	
		Pbo+Pbo	19	19 (100.0)	1.79 (0.96)	0.3	1.00	1.67	2.17	4.2	
Week 16		Teze+Teze	44	43 (97.7)	1.64 (1.02)	0.0	1.00	1.67	2.50	3.7	
		Pbo+Pbo	19	19 (100.0)	1.77 (0.91)	0.3	1.17	1.50	2.17	4.2	
Week 20		Teze+Teze	44	43 (97.7)	1.67 (1.06)	0.0	0.83	1.67	2.67	4.0	
		Pbo+Pbo	19	19 (100.0)	1.78 (0.86)	0.7	1.00	1.50	2.50	3.3	
Week 24		Teze+Teze	44	43 (97.7)	1.64 (1.02)	0.0	0.83	1.67	2.67	3.2	
		Pbo+Pbo	19	18 (94.7)	1.87 (0.94)	0.2	1.00	1.83	2.67	3.8	
Week 28		Teze+Teze	44	42 (95.5)	1.63 (1.08)	0.0	0.67	1.83	2.50	4.5	
		Pbo+Pbo	19	19 (100.0)	1.75 (1.10)	0.3	0.67	1.83	2.50	4.0	
Week 32		Teze+Teze	44	43 (97.7)	1.69 (1.01)	0.0	1.00	1.83	2.50	3.7	
		Pbo+Pbo	19	19 (100.0)	1.61 (0.90)	0.3	1.00	1.17	2.33	3.3	
Week 36		Teze+Teze	44	44 (100.0)	1.77 (1.08)	0.0	1.00	1.75	2.42	4.2	
		Pbo+Pbo	19	19 (100.0)	1.90 (0.97)	0.2	1.17	1.83	2.50	4.5	
Week 40		Teze+Teze	44	41 (93.2)	1.73 (1.11)	0.0	1.00	1.83	2.67	3.5	
		Pbo+Pbo	19	19 (100.0)	1.79 (1.00)	0.0	1.33	1.83	2.50	3.8	
Week 44		Teze+Teze	44	43 (97.7)	1.63 (1.12)	0.0	0.83	1.50	2.50	3.8	
		Pbo+Pbo	19	19 (100.0)	1.89 (0.97)	0.3	1.17	2.00	2.50	4.2	
Week 48		Teze+Teze	44	44 (100.0)	1.69 (1.17)	0.0	0.75	1.67	2.50	4.5	
		Pbo+Pbo	19	19 (100.0)	1.69 (1.15)	0.0	1.00	1.50	2.33	4.3	
Week 52		Teze+Teze	44	42 (95.5)	1.63 (1.06)	0.0	1.00	1.58	2.50	3.5	
		Pbo+Pbo	19	19 (100.0)	1.67 (1.09)	0.0	1.00	1.50	2.17	4.8	
Week 64		Teze+Teze	44	43 (97.7)	1.55 (1.01)	0.0	0.83	1.50	2.33	4.0	
		Pbo+Pbo	19	19 (100.0)	1.88 (1.07)	0.2	1.00	1.83	2.33	4.5	
Week 76		Teze+Teze	44	42 (95.5)	1.67 (1.23)	0.0	0.67	1.67	2.67	4.8	
		Pbo+Pbo	19	19 (100.0)	1.65 (0.86)	0.2	0.83	2.00	2.50	3.0	
Week 88		Teze+Teze	44	40 (90.9)	1.47 (1.01)	0.0	0.75	1.50	2.42	3.5	
		Pbo+Pbo	19	19 (100.0)	1.83 (0.89)	0.5	0.83	1.83	2.67	3.2	
Week 104		Teze+Teze	44	39 (88.6)	1.46 (1.00)	0.0	0.67	1.33	2.33	4.5	
		Pbo+Pbo	19	19 (100.0)	1.61 (0.92)	0.0	0.67	1.67	2.33	3.0	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Source Data: aacq, created on: 20JUL2022

Table DT1H6C_HBMH0: Course of ACQ-6 score
 DITTNB - LTE - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Teze+Teze	44	43 (97.7)	-0.68 (0.72)	-3.2	-1.00	-0.50	-0.17	0.3	0.20 [-0.35, 0.75]
	Pbo+Pbo	19	18 (94.7)	-0.83 (0.81)	-2.3	-1.67	-0.42	-0.17	0.2	
Week 4	Teze+Teze	44	44 (100.0)	-0.77 (0.85)	-3.0	-1.50	-0.58	-0.17	0.7	0.20 [-0.34, 0.74]
	Pbo+Pbo	19	19 (100.0)	-0.93 (0.77)	-2.7	-1.50	-0.67	-0.50	0.2	
Week 8	Teze+Teze	44	43 (97.7)	-0.93 (0.85)	-3.0	-1.50	-0.83	-0.33	0.8	-0.13 [-0.67, 0.42]
	Pbo+Pbo	19	19 (100.0)	-0.82 (0.93)	-2.2	-1.33	-0.83	-0.33	2.0	
Week 12	Teze+Teze	44	43 (97.7)	-1.01 (1.05)	-3.2	-2.00	-0.83	-0.33	1.3	0.15 [-0.39, 0.69]
	Pbo+Pbo	19	19 (100.0)	-1.17 (0.91)	-2.5	-1.83	-1.33	-0.17	0.3	
Week 16	Teze+Teze	44	43 (97.7)	-1.10 (0.99)	-3.2	-1.83	-0.83	-0.33	0.7	0.09 [-0.45, 0.63]
	Pbo+Pbo	19	19 (100.0)	-1.18 (0.77)	-2.5	-1.67	-1.33	-0.50	0.3	
Week 20	Teze+Teze	44	43 (97.7)	-1.05 (1.05)	-3.2	-1.67	-1.00	-0.33	1.3	0.12 [-0.42, 0.66]
	Pbo+Pbo	19	19 (100.0)	-1.18 (0.86)	-2.7	-1.83	-1.00	-0.67	0.3	
Week 24	Teze+Teze	44	43 (97.7)	-1.11 (1.04)	-3.3	-1.67	-1.00	-0.33	0.7	0.01 [-0.54, 0.56]
	Pbo+Pbo	19	18 (94.7)	-1.12 (0.83)	-3.2	-1.67	-1.08	-0.50	0.2	
Week 28	Teze+Teze	44	42 (95.5)	-1.05 (0.99)	-2.8	-1.67	-0.83	-0.33	0.8	0.16 [-0.38, 0.70]
	Pbo+Pbo	19	19 (100.0)	-1.20 (0.93)	-3.0	-1.83	-1.17	-0.67	0.7	
Week 32	Teze+Teze	44	43 (97.7)	-1.05 (1.05)	-3.2	-1.67	-1.00	-0.33	1.0	0.29 [-0.26, 0.83]
	Pbo+Pbo	19	19 (100.0)	-1.35 (1.05)	-3.0	-2.33	-1.33	-0.67	0.2	
Week 36	Teze+Teze	44	44 (100.0)	-0.96 (1.06)	-3.2	-1.75	-0.83	-0.42	1.5	0.09 [-0.45, 0.63]
	Pbo+Pbo	19	19 (100.0)	-1.05 (0.90)	-3.0	-1.50	-1.00	-0.17	0.2	
Week 40	Teze+Teze	44	41 (93.2)	-0.99 (1.02)	-3.0	-1.67	-0.83	-0.17	1.3	0.17 [-0.37, 0.72]
	Pbo+Pbo	19	19 (100.0)	-1.17 (0.96)	-3.0	-1.83	-1.00	-0.50	0.2	
Week 44	Teze+Teze	44	43 (97.7)	-1.10 (1.03)	-3.0	-2.00	-1.00	-0.33	1.3	-0.04 [-0.58, 0.50]
	Pbo+Pbo	19	19 (100.0)	-1.06 (0.92)	-2.8	-1.83	-1.00	-0.17	0.2	
Week 48	Teze+Teze	44	44 (100.0)	-1.05 (1.17)	-3.2	-1.83	-1.00	-0.50	1.8	0.19 [-0.35, 0.73]
	Pbo+Pbo	19	19 (100.0)	-1.26 (1.01)	-3.2	-2.00	-1.17	-0.33	0.2	
Week 52	Teze+Teze	44	42 (95.5)	-1.11 (1.04)	-3.2	-1.83	-1.00	-0.50	1.5	0.17 [-0.37, 0.72]
	Pbo+Pbo	19	19 (100.0)	-1.29 (0.99)	-3.3	-2.17	-1.33	-0.50	0.0	
Week 64	Teze+Teze	44	43 (97.7)	-1.18 (0.99)	-2.8	-2.00	-1.33	-0.33	1.0	-0.10 [-0.64, 0.44]
	Pbo+Pbo	19	19 (100.0)	-1.08 (1.01)	-3.0	-2.00	-1.17	-0.17	0.8	
Week 76	Teze+Teze	44	42 (95.5)	-1.08 (1.11)	-3.2	-2.00	-1.17	-0.17	1.8	0.22 [-0.33, 0.76]
	Pbo+Pbo	19	19 (100.0)	-1.31 (1.00)	-3.2	-2.00	-1.33	-0.50	0.2	
Week 88	Teze+Teze	44	40 (90.9)	-1.27 (0.99)	-3.0	-2.17	-1.25	-0.33	0.8	-0.15 [-0.69, 0.40]
	Pbo+Pbo	19	19 (100.0)	-1.12 (1.04)	-3.5	-1.83	-1.00	-0.33	0.2	
Week 104	Teze+Teze	44	39 (88.6)	-1.31 (1.03)	-3.2	-2.17	-1.33	-0.67	1.8	0.04 [-0.51, 0.59]
	Pbo+Pbo	19	19 (100.0)	-1.35 (1.03)	-3.3	-2.50	-0.67	-0.50	-0.2	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C_HBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTNB - LTE - adult

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Teze+Teze	44	43 (97.7)	-0.71 (0.11)	(-0.92, -0.49)	0.03 (0.20)	(-0.36, 0.43)	0.864	
	Pbo+Pbo	19	18 (94.7)	-0.74 (0.16)	(-1.07, -0.41)				
Week 4	Teze+Teze	44	44 (100.0)	-0.78 (0.12)	(-1.02, -0.55)	0.10 (0.22)	(-0.33, 0.54)	0.638	
	Pbo+Pbo	19	19 (100.0)	-0.89 (0.18)	(-1.25, -0.52)				
Week 8	Teze+Teze	44	43 (97.7)	-0.97 (0.13)	(-1.23, -0.71)	-0.19 (0.24)	(-0.66, 0.29)	0.433	
	Pbo+Pbo	19	19 (100.0)	-0.78 (0.20)	(-1.17, -0.39)				
Week 12	Teze+Teze	44	43 (97.7)	-1.06 (0.15)	(-1.37, -0.76)	0.06 (0.28)	(-0.49, 0.61)	0.828	
	Pbo+Pbo	19	19 (100.0)	-1.12 (0.23)	(-1.58, -0.66)				
Week 16	Teze+Teze	44	43 (97.7)	-1.11 (0.13)	(-1.38, -0.84)	0.03 (0.24)	(-0.46, 0.52)	0.905	
	Pbo+Pbo	19	19 (100.0)	-1.14 (0.20)	(-1.55, -0.73)				
Week 20	Teze+Teze	44	43 (97.7)	-1.11 (0.14)	(-1.40, -0.82)	0.03 (0.26)	(-0.50, 0.56)	0.921	
	Pbo+Pbo	19	19 (100.0)	-1.13 (0.22)	(-1.57, -0.69)				
Week 24	Teze+Teze	44	43 (97.7)	-1.14 (0.14)	(-1.43, -0.86)	-0.05 (0.26)	(-0.57, 0.46)	0.835	
	Pbo+Pbo	19	18 (94.7)	-1.09 (0.21)	(-1.52, -0.66)				
Week 28	Teze+Teze	44	42 (95.5)	-1.06 (0.15)	(-1.35, -0.77)	0.10 (0.26)	(-0.43, 0.63)	0.716	
	Pbo+Pbo	19	19 (100.0)	-1.16 (0.22)	(-1.60, -0.72)				
Week 32	Teze+Teze	44	43 (97.7)	-1.06 (0.15)	(-1.36, -0.77)	0.24 (0.27)	(-0.29, 0.78)	0.366	
	Pbo+Pbo	19	19 (100.0)	-1.31 (0.22)	(-1.76, -0.86)				
Week 36	Teze+Teze	44	44 (100.0)	-0.98 (0.15)	(-1.28, -0.69)	0.03 (0.27)	(-0.51, 0.57)	0.915	
	Pbo+Pbo	19	19 (100.0)	-1.01 (0.22)	(-1.46, -0.56)				

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C_HBMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTNB - LTE - adult

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Teze+Teze	44	41 (93.2)	-1.02 (0.15)	(-1.33, -0.72)	0.10 (0.27)	(-0.45, 0.65)	0.716
	Pbo+Pbo	19	19 (100.0)	-1.12 (0.23)	(-1.58, -0.67)			
Week 44	Teze+Teze	44	43 (97.7)	-1.10 (0.15)	(-1.40, -0.81)	-0.08 (0.27)	(-0.62, 0.45)	0.759
	Pbo+Pbo	19	19 (100.0)	-1.02 (0.22)	(-1.47, -0.57)			
Week 48	Teze+Teze	44	44 (100.0)	-1.06 (0.17)	(-1.40, -0.73)	0.16 (0.30)	(-0.45, 0.76)	0.607
	Pbo+Pbo	19	19 (100.0)	-1.22 (0.25)	(-1.72, -0.72)			
Week 52	Teze+Teze	44	42 (95.5)	-1.10 (0.15)	(-1.40, -0.80)	0.15 (0.27)	(-0.40, 0.69)	0.590
	Pbo+Pbo	19	19 (100.0)	-1.25 (0.23)	(-1.70, -0.80)			
Week 64	Teze+Teze	44	43 (97.7)	-1.19 (0.14)	(-1.48, -0.90)	-0.15 (0.26)	(-0.68, 0.37)	0.566
	Pbo+Pbo	19	19 (100.0)	-1.04 (0.22)	(-1.48, -0.60)			
Week 76	Teze+Teze	44	42 (95.5)	-1.05 (0.16)	(-1.37, -0.73)	0.22 (0.29)	(-0.36, 0.80)	0.459
	Pbo+Pbo	19	19 (100.0)	-1.26 (0.24)	(-1.75, -0.78)			
Week 88	Teze+Teze	44	40 (90.9)	-1.20 (0.15)	(-1.49, -0.90)	-0.12 (0.27)	(-0.65, 0.42)	0.667
	Pbo+Pbo	19	19 (100.0)	-1.08 (0.22)	(-1.53, -0.64)			
Week 104	Teze+Teze	44	39 (88.6)	-1.23 (0.15)	(-1.54, -0.92)	0.07 (0.28)	(-0.48, 0.63)	0.791
	Pbo+Pbo	19	19 (100.0)	-1.31 (0.23)	(-1.77, -0.85)			

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20JUL2022

Table NT1H5C_ABMH0: Course of ACQ-5 score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	54	54 (100.0)	2.93 (0.70)	1.8	2.40	3.00	3.20	5.2	
		Placebo	39	39 (100.0)	3.17 (0.76)	2.0	2.60	3.00	3.40	5.6	
	Week 2	Tezepelumab	54	53 (98.1)	2.31 (0.90)	0.0	1.80	2.40	2.80	4.4	
		Placebo	39	36 (92.3)	2.64 (1.09)	0.8	1.90	2.40	3.20	5.2	
	Week 4	Tezepelumab	54	54 (100.0)	2.18 (1.02)	0.0	1.60	2.40	2.80	4.4	
		Placebo	39	38 (97.4)	2.45 (0.89)	0.8	1.80	2.40	3.00	5.0	
	Week 8	Tezepelumab	54	53 (98.1)	2.08 (1.08)	0.0	1.40	2.20	2.80	4.4	
		Placebo	39	39 (100.0)	2.44 (1.01)	0.8	1.80	2.20	3.00	5.0	
	Week 12	Tezepelumab	54	53 (98.1)	1.95 (1.22)	0.0	1.20	2.00	2.80	5.6	
		Placebo	39	36 (92.3)	2.37 (1.18)	0.4	1.80	2.20	3.00	5.6	
	Week 16	Tezepelumab	54	53 (98.1)	1.85 (1.11)	0.0	1.00	2.00	2.60	3.8	
		Placebo	39	38 (97.4)	2.33 (1.12)	0.4	1.60	2.10	3.20	5.2	
	Week 20	Tezepelumab	54	53 (98.1)	1.81 (1.16)	0.0	0.80	2.00	2.60	4.8	
		Placebo	39	37 (94.9)	2.12 (0.95)	0.6	1.20	2.00	2.80	3.8	
	Week 24	Tezepelumab	54	53 (98.1)	1.77 (1.15)	0.0	0.80	2.00	2.60	4.8	
		Placebo	39	34 (87.2)	2.23 (1.04)	0.2	1.40	2.10	3.40	4.2	
	Week 28	Tezepelumab	54	51 (94.4)	1.81 (1.15)	0.0	0.80	2.00	2.60	4.6	
		Placebo	39	37 (94.9)	2.28 (1.21)	0.2	1.60	2.20	3.00	4.4	
	Week 32	Tezepelumab	54	53 (98.1)	1.80 (1.09)	0.0	1.00	1.80	2.60	4.0	
		Placebo	39	36 (92.3)	2.08 (1.05)	0.2	1.20	1.90	3.10	4.0	
	Week 36	Tezepelumab	54	54 (100.0)	1.87 (1.13)	0.0	1.00	1.80	2.60	4.6	
		Placebo	39	36 (92.3)	2.26 (1.05)	0.2	1.50	2.20	2.80	4.6	
	Week 40	Tezepelumab	54	51 (94.4)	1.87 (1.20)	0.0	1.00	2.00	3.00	4.6	
		Placebo	39	37 (94.9)	2.15 (1.10)	0.0	1.40	2.20	3.00	4.2	
	Week 44	Tezepelumab	54	53 (98.1)	1.73 (1.24)	0.0	0.80	1.60	2.60	4.0	
		Placebo	39	36 (92.3)	2.25 (1.05)	0.4	1.40	2.30	2.90	5.2	
	Week 48	Tezepelumab	54	54 (100.0)	1.93 (1.32)	0.0	1.00	2.00	2.80	5.0	
		Placebo	39	37 (94.9)	2.06 (1.16)	0.0	1.20	2.00	2.80	5.0	
	Week 52	Tezepelumab	54	49 (90.7)	1.73 (1.13)	0.0	1.00	1.80	2.60	4.0	
		Placebo	39	35 (89.7)	1.99 (1.17)	0.0	1.20	1.80	2.60	4.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C_ABMH0: Course of ACQ-5 score
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	54	53 (98.1)	-0.63 (0.89)	-3.2	-1.00	-0.60	-0.20	1.6	-0.09 [-0.51, 0.33]
	Placebo	39	36 (92.3)	-0.54 (0.95)	-2.6	-1.00	-0.40	-0.20	2.2	
Week 4	Tezepelumab	54	54 (100.0)	-0.75 (0.97)	-3.0	-1.60	-0.60	0.00	1.0	-0.02 [-0.44, 0.39]
	Placebo	39	38 (97.4)	-0.73 (0.84)	-3.0	-1.00	-0.60	-0.20	0.6	
Week 8	Tezepelumab	54	53 (98.1)	-0.86 (1.02)	-3.0	-1.60	-0.80	-0.20	2.4	-0.14 [-0.55, 0.27]
	Placebo	39	39 (100.0)	-0.73 (0.85)	-2.6	-1.00	-0.80	-0.20	2.0	
Week 12	Tezepelumab	54	53 (98.1)	-0.97 (1.13)	-3.2	-1.80	-0.80	-0.20	1.4	-0.14 [-0.56, 0.29]
	Placebo	39	36 (92.3)	-0.82 (1.10)	-3.0	-1.50	-0.90	0.00	2.4	
Week 16	Tezepelumab	54	53 (98.1)	-1.08 (1.11)	-3.2	-2.00	-1.00	-0.40	1.2	-0.22 [-0.64, 0.20]
	Placebo	39	38 (97.4)	-0.85 (0.95)	-2.6	-1.40	-0.90	-0.20	1.0	
Week 20	Tezepelumab	54	53 (98.1)	-1.11 (1.18)	-3.2	-1.80	-1.00	-0.40	1.8	-0.06 [-0.48, 0.36]
	Placebo	39	37 (94.9)	-1.05 (0.83)	-3.2	-1.40	-1.00	-0.60	0.6	
Week 24	Tezepelumab	54	53 (98.1)	-1.17 (1.16)	-3.6	-1.80	-1.00	-0.40	0.6	-0.19 [-0.62, 0.24]
	Placebo	39	34 (87.2)	-0.96 (0.96)	-3.6	-1.60	-1.00	-0.40	1.2	
Week 28	Tezepelumab	54	51 (94.4)	-1.08 (1.07)	-3.0	-1.80	-0.80	-0.20	0.8	-0.20 [-0.62, 0.22]
	Placebo	39	37 (94.9)	-0.86 (1.13)	-3.6	-1.60	-0.60	-0.20	1.2	
Week 32	Tezepelumab	54	53 (98.1)	-1.13 (1.18)	-3.4	-1.80	-1.00	-0.40	1.6	-0.05 [-0.48, 0.37]
	Placebo	39	36 (92.3)	-1.07 (1.05)	-3.6	-1.60	-1.00	-0.30	0.6	
Week 36	Tezepelumab	54	54 (100.0)	-1.05 (1.11)	-3.2	-1.80	-1.00	-0.60	1.6	-0.16 [-0.58, 0.27]
	Placebo	39	36 (92.3)	-0.89 (0.94)	-3.2	-1.40	-0.80	-0.20	0.4	
Week 40	Tezepelumab	54	51 (94.4)	-1.05 (1.19)	-3.4	-2.00	-1.00	-0.20	2.8	-0.06 [-0.48, 0.37]
	Placebo	39	37 (94.9)	-0.99 (1.01)	-3.4	-1.40	-1.00	-0.40	1.4	
Week 44	Tezepelumab	54	53 (98.1)	-1.19 (1.22)	-3.4	-2.20	-1.20	-0.40	2.0	-0.26 [-0.69, 0.16]
	Placebo	39	36 (92.3)	-0.90 (0.91)	-3.2	-1.50	-0.60	-0.30	0.6	
Week 48	Tezepelumab	54	54 (100.0)	-0.99 (1.36)	-3.4	-2.00	-1.00	-0.40	2.2	0.07 [-0.35, 0.49]
	Placebo	39	37 (94.9)	-1.08 (0.99)	-3.8	-1.60	-1.00	-0.40	0.4	
Week 52	Tezepelumab	54	49 (90.7)	-1.24 (1.10)	-3.4	-2.00	-1.00	-0.60	1.2	-0.06 [-0.50, 0.37]
	Placebo	39	35 (89.7)	-1.17 (1.02)	-3.8	-1.80	-1.00	-0.40	0.6	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20FEB2022

Table NT1H5C_ABMC0: Change from baseline in ACQ-5 score - MMRM results
DITTB - adult

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	54	53 (98.1)	-0.68 (0.12)	(-0.91, -0.44)	-0.23 (0.19)	(-0.60, 0.15)	0.231
	Placebo	39	36 (92.3)	-0.45 (0.14)	(-0.74, -0.17)			
Week 4	Tezepelumab	54	54 (100.0)	-0.79 (0.12)	(-1.02, -0.55)	-0.13 (0.19)	(-0.50, 0.24)	0.483
	Placebo	39	38 (97.4)	-0.66 (0.14)	(-0.94, -0.38)			
Week 8	Tezepelumab	54	53 (98.1)	-0.91 (0.13)	(-1.17, -0.66)	-0.24 (0.20)	(-0.63, 0.15)	0.228
	Placebo	39	39 (100.0)	-0.67 (0.15)	(-0.97, -0.37)			
Week 12	Tezepelumab	54	53 (98.1)	-1.04 (0.15)	(-1.34, -0.74)	-0.25 (0.24)	(-0.72, 0.22)	0.294
	Placebo	39	36 (92.3)	-0.79 (0.18)	(-1.15, -0.43)			
Week 16	Tezepelumab	54	53 (98.1)	-1.12 (0.14)	(-1.39, -0.84)	-0.33 (0.22)	(-0.76, 0.09)	0.123
	Placebo	39	38 (97.4)	-0.78 (0.16)	(-1.11, -0.46)			
Week 20	Tezepelumab	54	53 (98.1)	-1.18 (0.14)	(-1.46, -0.91)	-0.23 (0.22)	(-0.66, 0.20)	0.293
	Placebo	39	37 (94.9)	-0.95 (0.17)	(-1.28, -0.62)			
Week 24	Tezepelumab	54	53 (98.1)	-1.22 (0.14)	(-1.50, -0.94)	-0.32 (0.22)	(-0.76, 0.13)	0.160
	Placebo	39	34 (87.2)	-0.90 (0.17)	(-1.24, -0.56)			
Week 28	Tezepelumab	54	51 (94.4)	-1.13 (0.15)	(-1.42, -0.84)	-0.36 (0.23)	(-0.81, 0.10)	0.121
	Placebo	39	37 (94.9)	-0.77 (0.17)	(-1.12, -0.43)			
Week 32	Tezepelumab	54	53 (98.1)	-1.17 (0.14)	(-1.45, -0.88)	-0.16 (0.23)	(-0.61, 0.29)	0.487
	Placebo	39	36 (92.3)	-1.01 (0.17)	(-1.35, -0.67)			
Week 36	Tezepelumab	54	54 (100.0)	-1.09 (0.14)	(-1.36, -0.82)	-0.26 (0.22)	(-0.69, 0.17)	0.233
	Placebo	39	36 (92.3)	-0.83 (0.17)	(-1.16, -0.50)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C_ABMC0: Change from baseline in ACQ-5 score - MMRM results
 DITTB - adult

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 40	Tezepelumab	54	51 (94.4)	-1.10 (0.15)	(-1.40, -0.80)	-0.19 (0.23)	(-0.65, 0.28)	0.422
	Placebo	39	37 (94.9)	-0.91 (0.18)	(-1.26, -0.56)			
Week 44	Tezepelumab	54	53 (98.1)	-1.22 (0.15)	(-1.51, -0.93)	-0.38 (0.23)	(-0.83, 0.08)	0.106
	Placebo	39	36 (92.3)	-0.84 (0.18)	(-1.19, -0.49)			
Week 48	Tezepelumab	54	54 (100.0)	-1.03 (0.16)	(-1.35, -0.71)	-0.03 (0.25)	(-0.53, 0.47)	0.907
	Placebo	39	37 (94.9)	-1.00 (0.19)	(-1.39, -0.62)			
Week 52	Tezepelumab	54	49 (90.7)	-1.15 (0.15)	(-1.45, -0.85)	-0.11 (0.24)	(-0.58, 0.36)	0.657
	Placebo	39	35 (89.7)	-1.05 (0.18)	(-1.41, -0.69)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C_ABMH0: Course of ACQ-6 score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	54	54 (100.0)	2.74 (0.65)	1.7	2.33	2.67	3.00	4.8	
		Placebo	39	39 (100.0)	3.00 (0.77)	1.8	2.50	2.83	3.33	5.7	
	Week 2	Tezepelumab	54	53 (98.1)	2.16 (0.85)	0.0	1.67	2.33	2.83	4.0	
		Placebo	39	36 (92.3)	2.50 (1.05)	0.7	1.67	2.33	3.17	5.2	
	Week 4	Tezepelumab	54	54 (100.0)	2.02 (0.96)	0.0	1.50	2.33	2.67	4.0	
		Placebo	39	38 (97.4)	2.35 (0.89)	0.8	1.67	2.50	3.00	5.0	
	Week 8	Tezepelumab	54	53 (98.1)	1.96 (1.02)	0.0	1.33	2.17	2.50	4.2	
		Placebo	39	39 (100.0)	2.33 (0.99)	0.8	1.67	2.17	2.83	4.8	
	Week 12	Tezepelumab	54	53 (98.1)	1.83 (1.15)	0.0	1.00	2.00	2.50	5.5	
		Placebo	39	36 (92.3)	2.25 (1.19)	0.3	1.50	2.08	2.75	5.7	
	Week 16	Tezepelumab	54	53 (98.1)	1.75 (1.02)	0.0	1.00	1.83	2.50	3.7	
		Placebo	39	38 (97.4)	2.19 (1.11)	0.3	1.33	1.92	2.83	5.0	
	Week 20	Tezepelumab	54	53 (98.1)	1.69 (1.06)	0.0	1.00	1.67	2.67	4.0	
		Placebo	39	37 (94.9)	2.03 (0.95)	0.7	1.33	1.83	2.67	4.0	
	Week 24	Tezepelumab	54	53 (98.1)	1.67 (1.06)	0.0	0.83	1.67	2.67	4.3	
		Placebo	39	34 (87.2)	2.07 (1.00)	0.2	1.17	1.92	3.00	4.0	
	Week 28	Tezepelumab	54	51 (94.4)	1.71 (1.06)	0.0	0.83	1.83	2.50	4.5	
		Placebo	39	37 (94.9)	2.15 (1.15)	0.3	1.33	2.17	2.83	4.0	
	Week 32	Tezepelumab	54	53 (98.1)	1.70 (1.00)	0.0	1.00	1.83	2.50	3.7	
		Placebo	39	36 (92.3)	1.94 (0.98)	0.3	1.17	1.67	2.83	3.8	
	Week 36	Tezepelumab	54	54 (100.0)	1.77 (1.05)	0.0	1.00	1.67	2.50	4.2	
		Placebo	39	36 (92.3)	2.13 (1.00)	0.2	1.33	1.92	2.67	4.5	
	Week 40	Tezepelumab	54	51 (94.4)	1.77 (1.14)	0.0	0.83	1.83	2.83	4.3	
		Placebo	39	37 (94.9)	2.01 (1.06)	0.0	1.33	2.00	2.83	3.8	
	Week 44	Tezepelumab	54	53 (98.1)	1.61 (1.15)	0.0	0.83	1.33	2.50	3.8	
		Placebo	39	36 (92.3)	2.10 (1.01)	0.3	1.25	2.08	2.75	4.8	
	Week 48	Tezepelumab	54	54 (100.0)	1.83 (1.23)	0.0	1.00	1.75	2.67	4.5	
		Placebo	39	37 (94.9)	1.94 (1.07)	0.0	1.17	1.83	2.50	4.5	
	Week 52	Tezepelumab	54	49 (90.7)	1.62 (1.06)	0.0	1.00	1.50	2.50	3.5	
		Placebo	39	35 (89.7)	1.88 (1.09)	0.0	1.17	1.67	2.33	4.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C_ABMH0: Course of ACQ-6 score
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	54	53 (98.1)	-0.58 (0.84)	-3.2	-1.00	-0.50	-0.17	1.7	-0.09 [-0.52, 0.33]
	Placebo	39	36 (92.3)	-0.50 (0.84)	-2.3	-1.00	-0.33	-0.17	1.8	
Week 4	Tezepelumab	54	54 (100.0)	-0.71 (0.91)	-3.0	-1.50	-0.58	-0.17	1.0	-0.06 [-0.48, 0.35]
	Placebo	39	38 (97.4)	-0.66 (0.76)	-2.7	-1.00	-0.67	-0.33	0.8	
Week 8	Tezepelumab	54	53 (98.1)	-0.79 (0.97)	-3.0	-1.50	-0.67	-0.33	2.3	-0.14 [-0.55, 0.28]
	Placebo	39	39 (100.0)	-0.67 (0.78)	-2.2	-1.00	-0.67	-0.33	2.0	
Week 12	Tezepelumab	54	53 (98.1)	-0.91 (1.07)	-3.2	-1.67	-0.83	-0.33	1.3	-0.14 [-0.56, 0.28]
	Placebo	39	36 (92.3)	-0.76 (1.03)	-2.5	-1.33	-1.00	-0.08	2.3	
Week 16	Tezepelumab	54	53 (98.1)	-1.00 (1.02)	-3.2	-1.67	-0.83	-0.17	0.8	-0.21 [-0.63, 0.21]
	Placebo	39	38 (97.4)	-0.79 (0.89)	-2.5	-1.33	-0.92	-0.33	0.8	
Week 20	Tezepelumab	54	53 (98.1)	-1.04 (1.06)	-3.2	-1.67	-1.00	-0.33	1.3	-0.10 [-0.52, 0.32]
	Placebo	39	37 (94.9)	-0.95 (0.80)	-2.7	-1.33	-0.83	-0.50	0.8	
Week 24	Tezepelumab	54	53 (98.1)	-1.08 (1.06)	-3.3	-1.67	-1.00	-0.33	0.8	-0.15 [-0.59, 0.28]
	Placebo	39	34 (87.2)	-0.92 (0.89)	-3.2	-1.50	-0.92	-0.33	1.2	
Week 28	Tezepelumab	54	51 (94.4)	-0.99 (0.99)	-2.8	-1.67	-0.83	-0.17	1.0	-0.18 [-0.61, 0.24]
	Placebo	39	37 (94.9)	-0.81 (1.02)	-3.0	-1.67	-0.67	-0.17	1.2	
Week 32	Tezepelumab	54	53 (98.1)	-1.04 (1.07)	-3.2	-1.67	-1.00	-0.50	1.7	-0.02 [-0.45, 0.40]
	Placebo	39	36 (92.3)	-1.02 (0.97)	-3.0	-1.67	-0.92	-0.42	0.7	
Week 36	Tezepelumab	54	54 (100.0)	-0.97 (1.04)	-3.2	-1.67	-0.92	-0.50	1.5	-0.13 [-0.55, 0.29]
	Placebo	39	36 (92.3)	-0.84 (0.84)	-3.0	-1.33	-0.83	-0.17	0.7	
Week 40	Tezepelumab	54	51 (94.4)	-0.96 (1.11)	-3.0	-1.83	-1.00	-0.17	2.5	-0.02 [-0.44, 0.40]
	Placebo	39	37 (94.9)	-0.94 (0.92)	-3.0	-1.33	-0.83	-0.50	1.0	
Week 44	Tezepelumab	54	53 (98.1)	-1.12 (1.10)	-3.0	-2.00	-1.17	-0.50	2.0	-0.25 [-0.68, 0.17]
	Placebo	39	36 (92.3)	-0.86 (0.87)	-2.8	-1.50	-0.67	-0.25	0.7	
Week 48	Tezepelumab	54	54 (100.0)	-0.91 (1.25)	-3.2	-1.83	-1.00	-0.33	2.2	0.10 [-0.32, 0.52]
	Placebo	39	37 (94.9)	-1.02 (0.92)	-3.2	-1.50	-0.83	-0.33	0.5	
Week 52	Tezepelumab	54	49 (90.7)	-1.15 (1.03)	-3.2	-1.83	-1.00	-0.50	1.5	-0.05 [-0.49, 0.38]
	Placebo	39	35 (89.7)	-1.10 (0.95)	-3.3	-1.67	-1.00	-0.50	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
 Source Data: aacq, created on: 20FEB2022

Table NT1H6C_ABMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB - adult

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 2	Tezepelumab	54	53 (98.1)	-0.63 (0.11)	(-0.85, -0.41)	-0.22 (0.17)	(-0.57, 0.12)	0.206
	Placebo	39	36 (92.3)	-0.40 (0.13)	(-0.67, -0.14)			
Week 4	Tezepelumab	54	54 (100.0)	-0.75 (0.11)	(-0.97, -0.53)	-0.16 (0.17)	(-0.51, 0.18)	0.355
	Placebo	39	38 (97.4)	-0.59 (0.13)	(-0.85, -0.32)			
Week 8	Tezepelumab	54	53 (98.1)	-0.84 (0.12)	(-1.08, -0.60)	-0.23 (0.19)	(-0.60, 0.14)	0.227
	Placebo	39	39 (100.0)	-0.61 (0.14)	(-0.90, -0.33)			
Week 12	Tezepelumab	54	53 (98.1)	-0.97 (0.14)	(-1.25, -0.68)	-0.25 (0.22)	(-0.69, 0.20)	0.274
	Placebo	39	36 (92.3)	-0.72 (0.17)	(-1.06, -0.38)			
Week 16	Tezepelumab	54	53 (98.1)	-1.03 (0.13)	(-1.29, -0.78)	-0.30 (0.20)	(-0.70, 0.10)	0.134
	Placebo	39	38 (97.4)	-0.73 (0.15)	(-1.03, -0.43)			
Week 20	Tezepelumab	54	53 (98.1)	-1.11 (0.13)	(-1.37, -0.86)	-0.26 (0.20)	(-0.66, 0.14)	0.203
	Placebo	39	37 (94.9)	-0.85 (0.15)	(-1.16, -0.55)			
Week 24	Tezepelumab	54	53 (98.1)	-1.13 (0.13)	(-1.38, -0.87)	-0.26 (0.20)	(-0.67, 0.15)	0.206
	Placebo	39	34 (87.2)	-0.87 (0.16)	(-1.18, -0.55)			
Week 28	Tezepelumab	54	51 (94.4)	-1.04 (0.14)	(-1.31, -0.77)	-0.32 (0.21)	(-0.74, 0.10)	0.139
	Placebo	39	37 (94.9)	-0.72 (0.16)	(-1.04, -0.40)			
Week 32	Tezepelumab	54	53 (98.1)	-1.08 (0.13)	(-1.34, -0.81)	-0.12 (0.21)	(-0.54, 0.29)	0.547
	Placebo	39	36 (92.3)	-0.95 (0.16)	(-1.26, -0.64)			
Week 36	Tezepelumab	54	54 (100.0)	-1.00 (0.13)	(-1.26, -0.75)	-0.22 (0.20)	(-0.62, 0.18)	0.269
	Placebo	39	36 (92.3)	-0.78 (0.15)	(-1.08, -0.47)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C_ABMC0: Change from baseline in ACQ-6 score - MMRM results
 DITTB - adult

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Tezepelumab	54	51 (94.4)	-1.01 (0.14)	(-1.29, -0.73)	-0.15 (0.22)	(-0.59, 0.29)	0.495
	Placebo	39	37 (94.9)	-0.86 (0.17)	(-1.19, -0.52)			
Week 44	Tezepelumab	54	53 (98.1)	-1.14 (0.14)	(-1.41, -0.87)	-0.34 (0.21)	(-0.77, 0.08)	0.111
	Placebo	39	36 (92.3)	-0.80 (0.16)	(-1.12, -0.48)			
Week 48	Tezepelumab	54	54 (100.0)	-0.94 (0.15)	(-1.24, -0.64)	-0.00 (0.24)	(-0.47, 0.46)	0.989
	Placebo	39	37 (94.9)	-0.94 (0.18)	(-1.30, -0.58)			
Week 52	Tezepelumab	54	49 (90.7)	-1.07 (0.14)	(-1.35, -0.79)	-0.09 (0.22)	(-0.53, 0.35)	0.678
	Placebo	39	35 (89.7)	-0.98 (0.17)	(-1.31, -0.64)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	55	55 (100.0)	1.35 (0.58)	0.1	1.00	1.33	1.76	2.6	
		Placebo	40	40 (100.0)	1.53 (0.54)	0.6	1.08	1.50	1.91	2.8	
	Week 1	Tezepelumab	55	54 (98.2)	1.21 (0.54)	0.1	0.91	1.12	1.49	2.5	
		Placebo	40	40 (100.0)	1.41 (0.52)	0.6	1.01	1.37	1.71	2.8	
	Week 2	Tezepelumab	55	54 (98.2)	1.12 (0.59)	0.0	0.83	1.07	1.57	2.3	
		Placebo	40	39 (97.5)	1.35 (0.54)	0.4	0.96	1.32	1.74	2.6	
	Week 3	Tezepelumab	55	55 (100.0)	1.11 (0.55)	0.0	0.86	1.11	1.44	2.6	
		Placebo	40	38 (95.0)	1.30 (0.61)	0.0	0.89	1.22	1.73	2.4	
	Week 4	Tezepelumab	55	54 (98.2)	1.05 (0.58)	0.0	0.63	1.02	1.48	2.6	
		Placebo	40	39 (97.5)	1.29 (0.55)	0.2	0.87	1.23	1.70	2.6	
	Week 5	Tezepelumab	55	53 (96.4)	1.02 (0.58)	0.0	0.61	0.96	1.43	2.5	
		Placebo	40	38 (95.0)	1.16 (0.53)	0.0	0.84	1.13	1.56	2.1	
	Week 6	Tezepelumab	55	52 (94.5)	1.06 (0.63)	0.0	0.67	0.97	1.47	2.7	
		Placebo	40	40 (100.0)	1.28 (0.57)	0.1	0.86	1.23	1.68	3.1	
	Week 7	Tezepelumab	55	51 (92.7)	1.04 (0.63)	0.0	0.71	1.01	1.39	2.8	
		Placebo	40	40 (100.0)	1.22 (0.57)	0.1	0.82	1.21	1.69	2.7	
	Week 8	Tezepelumab	55	51 (92.7)	1.00 (0.62)	0.0	0.62	0.94	1.40	2.6	
		Placebo	40	39 (97.5)	1.23 (0.52)	0.1	0.86	1.09	1.58	2.5	
	Week 9	Tezepelumab	55	53 (96.4)	0.96 (0.60)	0.0	0.51	0.89	1.39	2.5	
		Placebo	40	40 (100.0)	1.22 (0.56)	0.1	0.84	1.11	1.54	2.7	
	Week 10	Tezepelumab	55	53 (96.4)	0.96 (0.66)	0.0	0.44	0.87	1.39	2.7	
		Placebo	40	40 (100.0)	1.20 (0.51)	0.1	0.89	1.09	1.66	2.4	
	Week 11	Tezepelumab	55	51 (92.7)	0.99 (0.64)	0.0	0.46	0.98	1.41	2.7	
		Placebo	40	40 (100.0)	1.13 (0.53)	0.1	0.82	1.07	1.53	2.6	
	Week 12	Tezepelumab	55	52 (94.5)	0.94 (0.65)	0.0	0.49	0.84	1.40	2.8	
		Placebo	40	38 (95.0)	1.12 (0.55)	0.0	0.77	1.04	1.59	2.1	
	Week 13	Tezepelumab	55	49 (89.1)	0.94 (0.65)	0.0	0.50	0.78	1.42	2.7	
		Placebo	40	38 (95.0)	1.07 (0.51)	0.1	0.71	1.07	1.50	2.2	
	Week 14	Tezepelumab	55	52 (94.5)	0.98 (0.69)	0.0	0.53	0.95	1.43	2.6	
		Placebo	40	37 (92.5)	1.08 (0.50)	0.1	0.69	1.00	1.50	2.2	
	Week 15	Tezepelumab	55	51 (92.7)	0.91 (0.62)	0.0	0.50	0.91	1.40	2.4	
		Placebo	40	39 (97.5)	1.05 (0.54)	0.0	0.72	0.90	1.47	2.2	
	Week 16	Tezepelumab	55	51 (92.7)	0.89 (0.63)	0.0	0.42	0.81	1.40	2.2	
		Placebo	40	38 (95.0)	1.06 (0.51)	0.0	0.73	0.97	1.50	2.1	
Week 17	Tezepelumab	55	52 (94.5)	0.90 (0.64)	0.0	0.44	0.80	1.33	2.5		
	Placebo	40	38 (95.0)	1.11 (0.53)	0.1	0.76	1.10	1.51	2.3		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	55	52 (94.5)	0.94 (0.68)	0.0	0.45	0.89	1.41	2.7	
		Placebo	40	38 (95.0)	1.10 (0.51)	0.2	0.73	1.05	1.50	2.1	
	Week 19	Tezepelumab	55	49 (89.1)	0.89 (0.69)	0.0	0.22	0.83	1.27	2.2	
		Placebo	40	39 (97.5)	1.11 (0.50)	0.0	0.78	1.10	1.50	2.2	
	Week 20	Tezepelumab	55	51 (92.7)	0.88 (0.67)	0.0	0.37	0.86	1.43	2.4	
		Placebo	40	37 (92.5)	1.09 (0.52)	0.0	0.77	1.01	1.48	2.3	
	Week 21	Tezepelumab	55	46 (83.6)	0.90 (0.66)	0.0	0.45	0.82	1.40	2.2	
		Placebo	40	38 (95.0)	1.06 (0.56)	0.0	0.77	0.94	1.51	2.3	
	Week 22	Tezepelumab	55	47 (85.5)	0.95 (0.61)	0.0	0.53	0.93	1.40	2.4	
		Placebo	40	38 (95.0)	1.08 (0.54)	0.1	0.79	1.08	1.49	2.4	
	Week 23	Tezepelumab	55	49 (89.1)	0.91 (0.68)	0.0	0.36	0.88	1.38	2.6	
		Placebo	40	36 (90.0)	1.06 (0.51)	0.0	0.81	1.07	1.42	2.3	
	Week 24	Tezepelumab	55	51 (92.7)	0.88 (0.70)	0.0	0.33	0.81	1.16	2.7	
		Placebo	40	36 (90.0)	0.98 (0.49)	0.0	0.66	0.90	1.39	1.9	
	Week 25	Tezepelumab	55	49 (89.1)	0.90 (0.65)	0.0	0.45	0.90	1.20	2.4	
		Placebo	40	36 (90.0)	1.04 (0.56)	0.0	0.54	0.89	1.54	2.3	
	Week 26	Tezepelumab	55	50 (90.9)	0.87 (0.67)	0.0	0.34	0.74	1.40	2.6	
		Placebo	40	37 (92.5)	1.05 (0.60)	0.0	0.54	1.07	1.51	2.3	
	Week 27	Tezepelumab	55	46 (83.6)	0.97 (0.70)	0.0	0.51	1.01	1.40	3.1	
		Placebo	40	36 (90.0)	1.10 (0.66)	0.0	0.56	1.08	1.51	2.8	
	Week 28	Tezepelumab	55	49 (89.1)	0.96 (0.69)	0.0	0.44	1.00	1.40	2.8	
		Placebo	40	36 (90.0)	1.07 (0.63)	0.0	0.68	0.96	1.51	2.4	
	Week 29	Tezepelumab	55	48 (87.3)	0.88 (0.65)	0.0	0.31	0.88	1.26	2.3	
		Placebo	40	37 (92.5)	1.05 (0.63)	0.0	0.60	0.99	1.54	2.6	
	Week 30	Tezepelumab	55	48 (87.3)	0.98 (0.64)	0.0	0.52	1.00	1.48	2.3	
		Placebo	40	36 (90.0)	1.01 (0.58)	0.0	0.56	0.95	1.46	2.8	
	Week 31	Tezepelumab	55	48 (87.3)	0.87 (0.61)	0.0	0.41	0.91	1.30	2.5	
		Placebo	40	37 (92.5)	0.99 (0.61)	0.0	0.54	0.90	1.33	2.8	
	Week 32	Tezepelumab	55	49 (89.1)	0.89 (0.62)	0.0	0.34	0.90	1.29	2.0	
		Placebo	40	37 (92.5)	1.00 (0.62)	0.0	0.53	0.90	1.43	2.8	
	Week 33	Tezepelumab	55	48 (87.3)	0.90 (0.63)	0.0	0.42	0.92	1.34	2.3	
		Placebo	40	37 (92.5)	1.06 (0.62)	0.0	0.63	0.91	1.43	2.8	
	Week 34	Tezepelumab	55	50 (90.9)	0.89 (0.64)	0.0	0.43	0.96	1.29	2.4	
		Placebo	40	38 (95.0)	1.05 (0.62)	0.0	0.50	0.90	1.47	2.8	
	Week 35	Tezepelumab	55	48 (87.3)	0.90 (0.65)	0.0	0.46	0.79	1.33	2.5	
		Placebo	40	36 (90.0)	1.04 (0.61)	0.0	0.62	0.99	1.41	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	55	48 (87.3)	0.92 (0.67)	0.0	0.38	0.88	1.41	2.4	
		Placebo	40	38 (95.0)	1.10 (0.57)	0.1	0.66	0.97	1.52	2.8	
	Week 37	Tezepelumab	55	47 (85.5)	0.92 (0.65)	0.0	0.37	0.90	1.40	2.6	
		Placebo	40	37 (92.5)	1.09 (0.53)	0.1	0.80	1.03	1.46	2.7	
	Week 38	Tezepelumab	55	47 (85.5)	0.96 (0.69)	0.0	0.43	0.85	1.40	2.6	
		Placebo	40	37 (92.5)	1.04 (0.56)	0.0	0.61	0.96	1.44	2.8	
	Week 39	Tezepelumab	55	49 (89.1)	0.93 (0.67)	0.0	0.30	0.92	1.28	2.6	
		Placebo	40	37 (92.5)	1.04 (0.61)	0.0	0.61	0.93	1.50	2.8	
	Week 40	Tezepelumab	55	49 (89.1)	0.94 (0.65)	0.0	0.51	0.90	1.35	2.6	
		Placebo	40	38 (95.0)	1.09 (0.69)	0.0	0.54	1.00	1.50	2.8	
	Week 41	Tezepelumab	55	50 (90.9)	0.92 (0.66)	0.0	0.40	0.80	1.38	2.5	
		Placebo	40	36 (90.0)	1.10 (0.67)	0.0	0.64	0.96	1.56	2.8	
	Week 42	Tezepelumab	55	47 (85.5)	0.93 (0.69)	0.0	0.27	0.86	1.40	2.7	
		Placebo	40	36 (90.0)	1.12 (0.65)	0.0	0.74	1.04	1.56	2.8	
	Week 43	Tezepelumab	55	49 (89.1)	0.91 (0.71)	0.0	0.28	0.90	1.40	3.0	
		Placebo	40	37 (92.5)	1.06 (0.62)	0.0	0.70	0.96	1.51	2.8	
	Week 44	Tezepelumab	55	48 (87.3)	0.85 (0.64)	0.0	0.21	0.90	1.22	2.5	
		Placebo	40	35 (87.5)	1.09 (0.59)	0.1	0.67	1.02	1.59	2.8	
	Week 45	Tezepelumab	55	48 (87.3)	0.90 (0.69)	0.0	0.35	0.89	1.36	2.8	
		Placebo	40	36 (90.0)	0.99 (0.63)	0.0	0.46	0.96	1.41	2.8	
	Week 46	Tezepelumab	55	47 (85.5)	0.89 (0.66)	0.0	0.29	0.94	1.42	2.6	
		Placebo	40	37 (92.5)	1.00 (0.66)	0.0	0.43	0.97	1.47	2.8	
	Week 47	Tezepelumab	55	46 (83.6)	0.89 (0.69)	0.0	0.36	0.87	1.44	2.8	
		Placebo	40	37 (92.5)	1.01 (0.64)	0.0	0.45	0.90	1.50	2.8	
	Week 48	Tezepelumab	55	49 (89.1)	0.94 (0.73)	0.0	0.40	0.93	1.27	2.6	
		Placebo	40	36 (90.0)	0.98 (0.65)	0.0	0.40	0.95	1.53	2.8	
	Week 49	Tezepelumab	55	47 (85.5)	1.00 (0.71)	0.0	0.57	0.94	1.64	2.5	
		Placebo	40	36 (90.0)	0.99 (0.65)	0.0	0.48	0.90	1.52	2.8	
	Week 50	Tezepelumab	55	44 (80.0)	0.94 (0.68)	0.0	0.46	0.89	1.52	2.4	
		Placebo	40	35 (87.5)	0.96 (0.65)	0.0	0.40	0.90	1.50	2.8	
	Week 51	Tezepelumab	55	45 (81.8)	0.99 (0.66)	0.0	0.56	1.00	1.64	2.5	
		Placebo	40	33 (82.5)	0.99 (0.65)	0.0	0.50	0.90	1.60	2.8	
	Week 52	Tezepelumab	55	39 (70.9)	0.95 (0.66)	0.0	0.53	0.90	1.58	2.4	
		Placebo	40	32 (80.0)	1.02 (0.67)	0.0	0.46	0.89	1.61	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	55	54 (98.2)	-0.15 (0.46)	-2.2	-0.23	-0.02	0.07	0.5	-0.09 [-0.50, 0.32]
		Placebo	40	40 (100.0)	-0.12 (0.30)	-0.9	-0.20	-0.12	0.00	0.8	
	Week 2	Tezepelumab	55	54 (98.2)	-0.23 (0.49)	-2.6	-0.30	-0.10	0.01	0.3	-0.11 [-0.52, 0.30]
		Placebo	40	39 (97.5)	-0.18 (0.51)	-1.9	-0.35	-0.10	0.03	1.1	
	Week 3	Tezepelumab	55	55 (100.0)	-0.24 (0.51)	-2.6	-0.41	-0.12	0.01	0.6	-0.03 [-0.44, 0.38]
		Placebo	40	38 (95.0)	-0.22 (0.64)	-2.4	-0.37	-0.07	0.01	1.0	
	Week 4	Tezepelumab	55	54 (98.2)	-0.29 (0.51)	-2.6	-0.44	-0.13	0.00	0.5	-0.11 [-0.53, 0.30]
		Placebo	40	39 (97.5)	-0.23 (0.56)	-2.4	-0.43	-0.04	0.06	0.5	
	Week 5	Tezepelumab	55	53 (96.4)	-0.33 (0.52)	-2.6	-0.44	-0.14	-0.03	0.3	0.03 [-0.38, 0.45]
		Placebo	40	38 (95.0)	-0.34 (0.63)	-2.6	-0.68	-0.18	0.04	1.1	
	Week 6	Tezepelumab	55	52 (94.5)	-0.28 (0.51)	-2.6	-0.43	-0.16	0.02	0.5	-0.08 [-0.49, 0.34]
		Placebo	40	40 (100.0)	-0.24 (0.58)	-2.5	-0.46	-0.10	0.11	0.5	
	Week 7	Tezepelumab	55	51 (92.7)	-0.28 (0.54)	-2.6	-0.48	-0.17	0.04	0.8	0.03 [-0.38, 0.45]
		Placebo	40	40 (100.0)	-0.30 (0.55)	-2.5	-0.61	-0.18	0.02	0.7	
	Week 8	Tezepelumab	55	51 (92.7)	-0.34 (0.54)	-2.6	-0.60	-0.17	-0.01	0.5	-0.12 [-0.53, 0.30]
		Placebo	40	39 (97.5)	-0.27 (0.60)	-2.5	-0.49	-0.18	0.05	1.4	
	Week 9	Tezepelumab	55	53 (96.4)	-0.38 (0.56)	-2.6	-0.71	-0.17	-0.03	0.7	-0.12 [-0.53, 0.29]
		Placebo	40	40 (100.0)	-0.31 (0.65)	-2.5	-0.69	-0.24	0.09	1.6	
	Week 10	Tezepelumab	55	53 (96.4)	-0.38 (0.58)	-2.6	-0.67	-0.25	-0.03	0.7	-0.09 [-0.50, 0.32]
		Placebo	40	40 (100.0)	-0.33 (0.58)	-2.5	-0.64	-0.11	-0.01	0.8	
	Week 11	Tezepelumab	55	51 (92.7)	-0.37 (0.55)	-2.6	-0.71	-0.19	0.00	0.6	0.05 [-0.37, 0.46]
		Placebo	40	40 (100.0)	-0.40 (0.59)	-2.4	-0.71	-0.28	0.01	0.6	
	Week 12	Tezepelumab	55	52 (94.5)	-0.40 (0.59)	-2.6	-0.75	-0.28	0.00	0.6	0.01 [-0.41, 0.43]
		Placebo	40	38 (95.0)	-0.41 (0.65)	-2.4	-0.72	-0.32	-0.03	1.4	
	Week 13	Tezepelumab	55	49 (89.1)	-0.37 (0.60)	-2.6	-0.66	-0.16	-0.01	0.6	0.14 [-0.29, 0.56]
		Placebo	40	38 (95.0)	-0.45 (0.62)	-2.4	-0.86	-0.28	-0.09	1.4	
	Week 14	Tezepelumab	55	52 (94.5)	-0.39 (0.60)	-2.6	-0.76	-0.23	-0.04	0.8	0.07 [-0.36, 0.49]
		Placebo	40	37 (92.5)	-0.43 (0.64)	-2.4	-0.91	-0.33	-0.10	0.8	
	Week 15	Tezepelumab	55	51 (92.7)	-0.40 (0.58)	-2.6	-0.63	-0.19	-0.07	0.6	0.09 [-0.33, 0.50]
		Placebo	40	39 (97.5)	-0.45 (0.68)	-2.4	-0.95	-0.32	-0.04	1.4	
	Week 16	Tezepelumab	55	51 (92.7)	-0.44 (0.58)	-2.6	-0.84	-0.26	-0.03	0.4	0.03 [-0.39, 0.45]
		Placebo	40	38 (95.0)	-0.45 (0.61)	-2.4	-0.81	-0.28	-0.04	0.9	
	Week 17	Tezepelumab	55	52 (94.5)	-0.46 (0.60)	-2.6	-0.76	-0.36	-0.04	0.6	-0.09 [-0.51, 0.32]
		Placebo	40	38 (95.0)	-0.40 (0.60)	-2.5	-0.73	-0.20	-0.04	0.7	
	Week 18	Tezepelumab	55	52 (94.5)	-0.42 (0.63)	-2.6	-0.79	-0.26	-0.03	0.8	-0.06 [-0.48, 0.36]
		Placebo	40	38 (95.0)	-0.39 (0.58)	-2.4	-0.68	-0.19	0.01	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	55	49 (89.1)	-0.43 (0.63)	-2.6	-0.76	-0.24	-0.03	0.4	-0.04 [-0.46, 0.38]
		Placebo	40	39 (97.5)	-0.40 (0.60)	-2.6	-0.76	-0.25	-0.04	0.7	
	Week 20	Tezepelumab	55	51 (92.7)	-0.46 (0.62)	-2.6	-0.81	-0.27	-0.04	0.5	-0.04 [-0.46, 0.39]
		Placebo	40	37 (92.5)	-0.43 (0.59)	-2.3	-0.77	-0.29	-0.05	0.7	
	Week 21	Tezepelumab	55	46 (83.6)	-0.45 (0.61)	-2.6	-0.77	-0.27	-0.07	0.4	0.01 [-0.42, 0.44]
		Placebo	40	38 (95.0)	-0.46 (0.65)	-2.4	-0.79	-0.39	0.03	1.2	
	Week 22	Tezepelumab	55	47 (85.5)	-0.40 (0.59)	-2.6	-0.76	-0.19	0.03	0.3	0.06 [-0.37, 0.49]
		Placebo	40	38 (95.0)	-0.44 (0.63)	-2.5	-0.85	-0.30	-0.01	1.2	
	Week 23	Tezepelumab	55	49 (89.1)	-0.45 (0.64)	-2.6	-0.87	-0.27	-0.01	0.5	0.05 [-0.38, 0.48]
		Placebo	40	36 (90.0)	-0.48 (0.58)	-2.2	-0.84	-0.26	-0.07	0.3	
	Week 24	Tezepelumab	55	51 (92.7)	-0.47 (0.63)	-2.6	-0.84	-0.34	-0.06	0.6	0.11 [-0.32, 0.54]
		Placebo	40	36 (90.0)	-0.53 (0.59)	-2.4	-0.82	-0.34	-0.08	0.1	
	Week 25	Tezepelumab	55	49 (89.1)	-0.47 (0.56)	-2.6	-0.79	-0.29	-0.03	0.3	0.05 [-0.38, 0.48]
		Placebo	40	36 (90.0)	-0.50 (0.65)	-2.6	-0.96	-0.36	-0.05	0.5	
	Week 26	Tezepelumab	55	50 (90.9)	-0.42 (0.62)	-2.6	-0.80	-0.29	0.02	0.5	0.09 [-0.33, 0.52]
		Placebo	40	37 (92.5)	-0.48 (0.73)	-2.6	-0.91	-0.36	-0.07	1.2	
	Week 27	Tezepelumab	55	46 (83.6)	-0.37 (0.64)	-2.6	-0.73	-0.22	0.04	0.8	0.12 [-0.31, 0.56]
		Placebo	40	36 (90.0)	-0.45 (0.79)	-2.6	-1.02	-0.35	-0.06	2.0	
	Week 28	Tezepelumab	55	49 (89.1)	-0.36 (0.62)	-2.5	-0.66	-0.19	0.00	0.9	0.13 [-0.30, 0.56]
		Placebo	40	36 (90.0)	-0.45 (0.71)	-2.6	-0.90	-0.29	0.05	0.7	
	Week 29	Tezepelumab	55	48 (87.3)	-0.48 (0.59)	-2.6	-0.80	-0.29	-0.09	0.3	-0.03 [-0.46, 0.40]
		Placebo	40	37 (92.5)	-0.46 (0.74)	-2.6	-0.89	-0.36	0.09	0.8	
	Week 30	Tezepelumab	55	48 (87.3)	-0.44 (0.57)	-2.6	-0.78	-0.26	-0.04	0.4	0.15 [-0.28, 0.59]
		Placebo	40	36 (90.0)	-0.53 (0.68)	-2.6	-1.06	-0.51	-0.09	0.9	
	Week 31	Tezepelumab	55	48 (87.3)	-0.47 (0.64)	-2.6	-0.78	-0.34	-0.06	0.6	0.07 [-0.36, 0.50]
		Placebo	40	37 (92.5)	-0.52 (0.69)	-2.6	-1.08	-0.39	-0.11	1.2	
	Week 32	Tezepelumab	55	49 (89.1)	-0.46 (0.60)	-2.6	-0.79	-0.33	-0.07	0.5	0.07 [-0.36, 0.50]
		Placebo	40	37 (92.5)	-0.51 (0.70)	-2.6	-0.91	-0.46	-0.10	1.1	
	Week 33	Tezepelumab	55	48 (87.3)	-0.48 (0.65)	-2.6	-0.87	-0.31	0.00	0.5	-0.05 [-0.47, 0.38]
		Placebo	40	37 (92.5)	-0.45 (0.67)	-2.6	-0.72	-0.36	-0.10	1.0	
	Week 34	Tezepelumab	55	50 (90.9)	-0.51 (0.62)	-2.6	-0.86	-0.37	-0.01	0.5	-0.05 [-0.48, 0.37]
		Placebo	40	38 (95.0)	-0.47 (0.67)	-2.6	-0.82	-0.40	-0.07	0.9	
	Week 35	Tezepelumab	55	48 (87.3)	-0.45 (0.61)	-2.6	-0.80	-0.30	-0.04	0.6	0.08 [-0.36, 0.51]
		Placebo	40	36 (90.0)	-0.50 (0.66)	-2.6	-0.85	-0.45	-0.10	1.0	
	Week 36	Tezepelumab	55	48 (87.3)	-0.46 (0.61)	-2.6	-0.81	-0.31	-0.05	0.5	-0.05 [-0.47, 0.38]
		Placebo	40	38 (95.0)	-0.43 (0.62)	-2.5	-0.77	-0.35	-0.07	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	55	47 (85.5)	-0.43 (0.60)	-2.6	-0.83	-0.31	0.00	0.4	-0.02 [-0.45, 0.41]
		Placebo	40	37 (92.5)	-0.42 (0.58)	-2.2	-0.72	-0.30	-0.09	0.8	
	Week 38	Tezepelumab	55	47 (85.5)	-0.39 (0.65)	-2.6	-0.76	-0.24	0.03	0.8	0.14 [-0.29, 0.57]
		Placebo	40	37 (92.5)	-0.48 (0.56)	-2.0	-0.85	-0.31	-0.10	0.7	
	Week 39	Tezepelumab	55	49 (89.1)	-0.42 (0.61)	-2.6	-0.74	-0.30	0.00	0.6	0.09 [-0.34, 0.51]
		Placebo	40	37 (92.5)	-0.47 (0.58)	-2.3	-0.77	-0.38	-0.07	0.5	
	Week 40	Tezepelumab	55	49 (89.1)	-0.45 (0.63)	-2.6	-0.84	-0.26	-0.01	0.6	-0.02 [-0.45, 0.40]
		Placebo	40	38 (95.0)	-0.44 (0.67)	-2.4	-0.91	-0.42	-0.09	1.2	
	Week 41	Tezepelumab	55	50 (90.9)	-0.47 (0.63)	-2.6	-0.84	-0.35	-0.01	0.7	-0.09 [-0.52, 0.34]
		Placebo	40	36 (90.0)	-0.41 (0.74)	-2.4	-0.80	-0.36	-0.08	1.5	
	Week 42	Tezepelumab	55	47 (85.5)	-0.44 (0.63)	-2.6	-0.84	-0.24	-0.03	0.3	-0.07 [-0.50, 0.36]
		Placebo	40	36 (90.0)	-0.40 (0.59)	-1.8	-0.74	-0.38	-0.06	0.5	
	Week 43	Tezepelumab	55	49 (89.1)	-0.46 (0.61)	-2.6	-0.84	-0.33	-0.06	0.6	-0.02 [-0.45, 0.41]
		Placebo	40	37 (92.5)	-0.45 (0.54)	-1.8	-0.74	-0.40	-0.09	0.5	
	Week 44	Tezepelumab	55	48 (87.3)	-0.53 (0.59)	-2.6	-0.90	-0.38	-0.05	0.3	-0.13 [-0.57, 0.30]
		Placebo	40	35 (87.5)	-0.45 (0.57)	-1.9	-0.77	-0.31	-0.09	0.7	
	Week 45	Tezepelumab	55	48 (87.3)	-0.47 (0.63)	-2.6	-0.84	-0.32	-0.01	0.5	0.10 [-0.33, 0.54]
		Placebo	40	36 (90.0)	-0.54 (0.61)	-2.4	-0.95	-0.42	-0.10	0.6	
	Week 46	Tezepelumab	55	47 (85.5)	-0.43 (0.66)	-2.6	-0.86	-0.31	0.01	0.8	0.12 [-0.31, 0.55]
		Placebo	40	37 (92.5)	-0.51 (0.65)	-2.6	-0.91	-0.45	-0.07	0.5	
	Week 47	Tezepelumab	55	46 (83.6)	-0.45 (0.67)	-2.6	-0.87	-0.26	0.00	0.8	0.08 [-0.35, 0.52]
		Placebo	40	37 (92.5)	-0.50 (0.62)	-2.6	-0.77	-0.38	-0.07	0.5	
	Week 48	Tezepelumab	55	49 (89.1)	-0.37 (0.69)	-2.6	-0.79	-0.17	0.07	0.9	0.25 [-0.18, 0.68]
		Placebo	40	36 (90.0)	-0.54 (0.62)	-2.6	-0.95	-0.45	-0.09	0.5	
	Week 49	Tezepelumab	55	47 (85.5)	-0.37 (0.67)	-2.6	-0.73	-0.18	0.06	0.9	0.23 [-0.20, 0.67]
		Placebo	40	36 (90.0)	-0.52 (0.61)	-2.6	-0.83	-0.38	-0.09	0.5	
	Week 50	Tezepelumab	55	44 (80.0)	-0.43 (0.61)	-2.6	-0.81	-0.21	-0.07	0.7	0.18 [-0.26, 0.63]
		Placebo	40	35 (87.5)	-0.54 (0.59)	-2.6	-0.86	-0.39	-0.10	0.5	
	Week 51	Tezepelumab	55	45 (81.8)	-0.37 (0.62)	-2.6	-0.70	-0.16	0.04	0.7	0.30 [-0.15, 0.75]
		Placebo	40	33 (82.5)	-0.55 (0.61)	-2.6	-0.78	-0.47	-0.17	0.5	
	Week 52	Tezepelumab	55	39 (70.9)	-0.38 (0.61)	-2.6	-0.77	-0.17	0.00	0.6	0.32 [-0.15, 0.79]
		Placebo	40	32 (80.0)	-0.57 (0.60)	-2.6	-0.82	-0.51	-0.26	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	55	54 (98.2)	-0.18 (0.07)	(-0.32, -0.04)	-0.11 (0.11)	(-0.33, 0.11)	0.340
	Placebo	40	40 (100.0)	-0.07 (0.09)	(-0.24, 0.10)			
Week 2	Tezepelumab	55	54 (98.2)	-0.26 (0.07)	(-0.41, -0.12)	-0.14 (0.11)	(-0.36, 0.08)	0.216
	Placebo	40	39 (97.5)	-0.12 (0.09)	(-0.29, 0.05)			
Week 3	Tezepelumab	55	55 (100.0)	-0.27 (0.07)	(-0.41, -0.13)	-0.11 (0.11)	(-0.34, 0.11)	0.310
	Placebo	40	38 (95.0)	-0.16 (0.09)	(-0.33, 0.01)			
Week 4	Tezepelumab	55	54 (98.2)	-0.33 (0.07)	(-0.48, -0.19)	-0.16 (0.11)	(-0.38, 0.06)	0.164
	Placebo	40	39 (97.5)	-0.18 (0.09)	(-0.34, -0.01)			
Week 5	Tezepelumab	55	53 (96.4)	-0.36 (0.07)	(-0.50, -0.21)	-0.07 (0.11)	(-0.29, 0.15)	0.520
	Placebo	40	38 (95.0)	-0.28 (0.09)	(-0.45, -0.11)			
Week 6	Tezepelumab	55	52 (94.5)	-0.31 (0.07)	(-0.45, -0.16)	-0.11 (0.11)	(-0.33, 0.11)	0.331
	Placebo	40	40 (100.0)	-0.20 (0.09)	(-0.37, -0.03)			
Week 7	Tezepelumab	55	51 (92.7)	-0.31 (0.07)	(-0.46, -0.17)	-0.06 (0.11)	(-0.28, 0.16)	0.614
	Placebo	40	40 (100.0)	-0.26 (0.09)	(-0.42, -0.09)			
Week 8	Tezepelumab	55	51 (92.7)	-0.35 (0.07)	(-0.50, -0.21)	-0.14 (0.11)	(-0.36, 0.09)	0.227
	Placebo	40	39 (97.5)	-0.22 (0.09)	(-0.39, -0.05)			
Week 9	Tezepelumab	55	53 (96.4)	-0.41 (0.07)	(-0.55, -0.26)	-0.15 (0.11)	(-0.37, 0.07)	0.192
	Placebo	40	40 (100.0)	-0.26 (0.09)	(-0.43, -0.09)			
Week 10	Tezepelumab	55	53 (96.4)	-0.41 (0.07)	(-0.56, -0.27)	-0.13 (0.11)	(-0.35, 0.09)	0.253
	Placebo	40	40 (100.0)	-0.29 (0.09)	(-0.45, -0.12)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	55	51 (92.7)	-0.41 (0.07)	(-0.56, -0.27)	-0.06 (0.11)	(-0.28, 0.16)	0.604
	Placebo	40	40 (100.0)	-0.35 (0.09)	(-0.52, -0.18)			
Week 12	Tezepelumab	55	52 (94.5)	-0.43 (0.07)	(-0.57, -0.28)	-0.08 (0.11)	(-0.30, 0.14)	0.466
	Placebo	40	38 (95.0)	-0.35 (0.09)	(-0.51, -0.18)			
Week 13	Tezepelumab	55	49 (89.1)	-0.42 (0.07)	(-0.56, -0.27)	-0.03 (0.11)	(-0.26, 0.19)	0.768
	Placebo	40	38 (95.0)	-0.38 (0.09)	(-0.55, -0.21)			
Week 14	Tezepelumab	55	52 (94.5)	-0.39 (0.07)	(-0.53, -0.24)	-0.03 (0.11)	(-0.26, 0.19)	0.770
	Placebo	40	37 (92.5)	-0.35 (0.09)	(-0.52, -0.18)			
Week 15	Tezepelumab	55	51 (92.7)	-0.42 (0.07)	(-0.57, -0.28)	-0.02 (0.11)	(-0.24, 0.21)	0.882
	Placebo	40	39 (97.5)	-0.40 (0.09)	(-0.57, -0.24)			
Week 16	Tezepelumab	55	51 (92.7)	-0.46 (0.07)	(-0.60, -0.31)	-0.06 (0.11)	(-0.28, 0.16)	0.596
	Placebo	40	38 (95.0)	-0.40 (0.09)	(-0.57, -0.23)			
Week 17	Tezepelumab	55	52 (94.5)	-0.46 (0.07)	(-0.60, -0.31)	-0.11 (0.11)	(-0.34, 0.11)	0.319
	Placebo	40	38 (95.0)	-0.34 (0.09)	(-0.51, -0.18)			
Week 18	Tezepelumab	55	52 (94.5)	-0.44 (0.07)	(-0.58, -0.29)	-0.10 (0.11)	(-0.32, 0.12)	0.366
	Placebo	40	38 (95.0)	-0.33 (0.09)	(-0.50, -0.16)			
Week 19	Tezepelumab	55	49 (89.1)	-0.46 (0.07)	(-0.60, -0.31)	-0.10 (0.11)	(-0.33, 0.12)	0.361
	Placebo	40	39 (97.5)	-0.35 (0.09)	(-0.52, -0.18)			
Week 20	Tezepelumab	55	51 (92.7)	-0.48 (0.07)	(-0.62, -0.33)	-0.08 (0.11)	(-0.30, 0.14)	0.477
	Placebo	40	37 (92.5)	-0.40 (0.09)	(-0.56, -0.23)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	55	46 (83.6)	-0.49 (0.07)	(-0.64, -0.35)	-0.09 (0.11)	(-0.31, 0.13)	0.428
	Placebo	40	38 (95.0)	-0.40 (0.09)	(-0.57, -0.23)			
Week 22	Tezepelumab	55	47 (85.5)	-0.46 (0.07)	(-0.60, -0.31)	-0.07 (0.11)	(-0.30, 0.15)	0.527
	Placebo	40	38 (95.0)	-0.38 (0.09)	(-0.55, -0.21)			
Week 23	Tezepelumab	55	49 (89.1)	-0.46 (0.07)	(-0.61, -0.32)	-0.10 (0.11)	(-0.32, 0.13)	0.398
	Placebo	40	36 (90.0)	-0.37 (0.09)	(-0.54, -0.20)			
Week 24	Tezepelumab	55	51 (92.7)	-0.48 (0.07)	(-0.62, -0.33)	-0.05 (0.11)	(-0.27, 0.18)	0.676
	Placebo	40	36 (90.0)	-0.43 (0.09)	(-0.60, -0.26)			
Week 25	Tezepelumab	55	49 (89.1)	-0.50 (0.07)	(-0.64, -0.35)	-0.10 (0.11)	(-0.32, 0.13)	0.400
	Placebo	40	36 (90.0)	-0.40 (0.09)	(-0.57, -0.23)			
Week 26	Tezepelumab	55	50 (90.9)	-0.48 (0.07)	(-0.63, -0.34)	-0.09 (0.11)	(-0.31, 0.14)	0.445
	Placebo	40	37 (92.5)	-0.39 (0.09)	(-0.57, -0.22)			
Week 27	Tezepelumab	55	46 (83.6)	-0.43 (0.07)	(-0.57, -0.28)	-0.05 (0.11)	(-0.28, 0.17)	0.638
	Placebo	40	36 (90.0)	-0.37 (0.09)	(-0.54, -0.20)			
Week 28	Tezepelumab	55	49 (89.1)	-0.44 (0.07)	(-0.58, -0.29)	-0.10 (0.11)	(-0.32, 0.13)	0.395
	Placebo	40	36 (90.0)	-0.34 (0.09)	(-0.51, -0.17)			
Week 29	Tezepelumab	55	48 (87.3)	-0.50 (0.07)	(-0.65, -0.36)	-0.11 (0.11)	(-0.34, 0.11)	0.326
	Placebo	40	37 (92.5)	-0.39 (0.09)	(-0.56, -0.22)			
Week 30	Tezepelumab	55	48 (87.3)	-0.48 (0.07)	(-0.62, -0.33)	-0.03 (0.11)	(-0.25, 0.20)	0.817
	Placebo	40	36 (90.0)	-0.45 (0.09)	(-0.62, -0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	55	48 (87.3)	-0.49 (0.07)	(-0.63, -0.34)	-0.04 (0.11)	(-0.26, 0.19)	0.748
	Placebo	40	37 (92.5)	-0.45 (0.09)	(-0.62, -0.28)			
Week 32	Tezepelumab	55	49 (89.1)	-0.51 (0.07)	(-0.65, -0.36)	-0.07 (0.11)	(-0.29, 0.16)	0.561
	Placebo	40	37 (92.5)	-0.44 (0.09)	(-0.61, -0.27)			
Week 33	Tezepelumab	55	48 (87.3)	-0.51 (0.07)	(-0.65, -0.36)	-0.10 (0.11)	(-0.33, 0.12)	0.367
	Placebo	40	37 (92.5)	-0.40 (0.09)	(-0.58, -0.23)			
Week 34	Tezepelumab	55	50 (90.9)	-0.53 (0.07)	(-0.68, -0.39)	-0.12 (0.11)	(-0.34, 0.11)	0.307
	Placebo	40	38 (95.0)	-0.42 (0.09)	(-0.59, -0.25)			
Week 35	Tezepelumab	55	48 (87.3)	-0.49 (0.07)	(-0.64, -0.34)	-0.06 (0.12)	(-0.29, 0.17)	0.604
	Placebo	40	36 (90.0)	-0.43 (0.09)	(-0.60, -0.26)			
Week 36	Tezepelumab	55	48 (87.3)	-0.46 (0.07)	(-0.61, -0.32)	-0.09 (0.12)	(-0.32, 0.13)	0.416
	Placebo	40	38 (95.0)	-0.37 (0.09)	(-0.54, -0.20)			
Week 37	Tezepelumab	55	47 (85.5)	-0.49 (0.08)	(-0.64, -0.34)	-0.13 (0.12)	(-0.36, 0.09)	0.247
	Placebo	40	37 (92.5)	-0.36 (0.09)	(-0.53, -0.18)			
Week 38	Tezepelumab	55	47 (85.5)	-0.46 (0.08)	(-0.61, -0.31)	-0.04 (0.12)	(-0.27, 0.18)	0.701
	Placebo	40	37 (92.5)	-0.42 (0.09)	(-0.59, -0.24)			
Week 39	Tezepelumab	55	49 (89.1)	-0.49 (0.07)	(-0.64, -0.34)	-0.08 (0.12)	(-0.30, 0.15)	0.510
	Placebo	40	37 (92.5)	-0.41 (0.09)	(-0.59, -0.24)			
Week 40	Tezepelumab	55	49 (89.1)	-0.48 (0.07)	(-0.63, -0.34)	-0.10 (0.12)	(-0.33, 0.13)	0.387
	Placebo	40	38 (95.0)	-0.38 (0.09)	(-0.55, -0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	55	50 (90.9)	-0.48 (0.07)	(-0.63, -0.34)	-0.13 (0.12)	(-0.35, 0.10)	0.272
	Placebo	40	36 (90.0)	-0.36 (0.09)	(-0.53, -0.18)			
Week 42	Tezepelumab	55	47 (85.5)	-0.47 (0.08)	(-0.62, -0.32)	-0.12 (0.12)	(-0.35, 0.11)	0.312
	Placebo	40	36 (90.0)	-0.35 (0.09)	(-0.52, -0.18)			
Week 43	Tezepelumab	55	49 (89.1)	-0.50 (0.08)	(-0.64, -0.35)	-0.10 (0.12)	(-0.33, 0.12)	0.372
	Placebo	40	37 (92.5)	-0.39 (0.09)	(-0.57, -0.22)			
Week 44	Tezepelumab	55	48 (87.3)	-0.55 (0.08)	(-0.69, -0.40)	-0.15 (0.12)	(-0.38, 0.08)	0.203
	Placebo	40	35 (87.5)	-0.40 (0.09)	(-0.57, -0.22)			
Week 45	Tezepelumab	55	48 (87.3)	-0.52 (0.07)	(-0.67, -0.37)	-0.04 (0.12)	(-0.27, 0.18)	0.700
	Placebo	40	36 (90.0)	-0.47 (0.09)	(-0.65, -0.30)			
Week 46	Tezepelumab	55	47 (85.5)	-0.51 (0.07)	(-0.66, -0.36)	-0.06 (0.12)	(-0.28, 0.17)	0.635
	Placebo	40	37 (92.5)	-0.46 (0.09)	(-0.63, -0.28)			
Week 47	Tezepelumab	55	46 (83.6)	-0.49 (0.08)	(-0.64, -0.35)	-0.04 (0.12)	(-0.27, 0.19)	0.728
	Placebo	40	37 (92.5)	-0.45 (0.09)	(-0.63, -0.28)			
Week 48	Tezepelumab	55	49 (89.1)	-0.43 (0.07)	(-0.57, -0.28)	0.05 (0.12)	(-0.18, 0.28)	0.648
	Placebo	40	36 (90.0)	-0.48 (0.09)	(-0.66, -0.31)			
Week 49	Tezepelumab	55	47 (85.5)	-0.43 (0.08)	(-0.58, -0.29)	0.04 (0.12)	(-0.19, 0.27)	0.754
	Placebo	40	36 (90.0)	-0.47 (0.09)	(-0.64, -0.30)			
Week 50	Tezepelumab	55	44 (80.0)	-0.48 (0.08)	(-0.63, -0.33)	0.01 (0.12)	(-0.22, 0.24)	0.924
	Placebo	40	35 (87.5)	-0.49 (0.09)	(-0.67, -0.32)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	55	45 (81.8)	-0.45 (0.08)	(-0.60, -0.30)	0.03 (0.12)	(-0.20, 0.26)	0.788
	Placebo	40	33 (82.5)	-0.48 (0.09)	(-0.66, -0.31)			
Week 52	Tezepelumab	55	39 (70.9)	-0.45 (0.08)	(-0.61, -0.30)	0.02 (0.12)	(-0.21, 0.26)	0.864
	Placebo	40	32 (80.0)	-0.47 (0.09)	(-0.65, -0.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	12	12 (100.0)	1.32 (0.76)	0.0	0.86	1.34	1.67	2.6	
		Placebo	11	11 (100.0)	1.86 (0.96)	0.2	1.50	1.81	2.40	3.7	
	Week 1	Tezepelumab	12	12 (100.0)	1.23 (0.63)	0.5	0.80	1.02	1.56	2.5	
		Placebo	11	11 (100.0)	1.62 (0.66)	0.5	0.99	1.78	2.03	2.7	
	Week 2	Tezepelumab	12	12 (100.0)	1.18 (0.64)	0.4	0.83	0.99	1.42	2.5	
		Placebo	11	10 (90.9)	1.55 (0.62)	0.4	1.00	1.78	1.90	2.4	
	Week 3	Tezepelumab	12	12 (100.0)	1.17 (0.61)	0.5	0.89	0.95	1.21	2.5	
		Placebo	11	10 (90.9)	1.46 (0.60)	0.6	1.04	1.36	1.90	2.5	
	Week 4	Tezepelumab	12	11 (91.7)	1.26 (0.67)	0.4	0.87	1.04	1.63	2.6	
		Placebo	11	11 (100.0)	1.55 (0.55)	0.6	1.10	1.66	1.90	2.4	
	Week 5	Tezepelumab	12	11 (91.7)	1.14 (0.72)	0.0	0.90	1.11	1.47	2.3	
		Placebo	11	11 (100.0)	1.47 (0.49)	0.9	0.90	1.69	1.90	2.1	
	Week 6	Tezepelumab	12	11 (91.7)	1.11 (0.73)	0.0	0.90	1.01	1.44	2.3	
		Placebo	11	11 (100.0)	1.44 (0.58)	0.7	0.87	1.66	1.90	2.3	
	Week 7	Tezepelumab	12	11 (91.7)	1.15 (0.67)	0.0	0.70	1.16	1.46	2.3	
		Placebo	11	11 (100.0)	1.46 (0.54)	0.6	0.89	1.33	1.90	2.3	
	Week 8	Tezepelumab	12	10 (83.3)	1.20 (0.64)	0.1	1.00	1.18	1.41	2.3	
		Placebo	11	11 (100.0)	1.61 (0.54)	0.8	1.03	1.82	2.02	2.3	
	Week 9	Tezepelumab	12	12 (100.0)	1.12 (0.68)	0.0	0.71	1.16	1.46	2.3	
		Placebo	11	11 (100.0)	1.65 (0.64)	0.6	1.04	1.66	2.26	2.6	
	Week 10	Tezepelumab	12	12 (100.0)	1.17 (0.65)	0.0	0.94	1.09	1.51	2.3	
		Placebo	11	10 (90.9)	1.51 (0.54)	0.5	1.14	1.64	1.90	2.3	
	Week 11	Tezepelumab	12	12 (100.0)	1.16 (0.70)	0.1	0.77	1.04	1.50	2.5	
		Placebo	11	10 (90.9)	1.38 (0.51)	0.5	0.94	1.51	1.73	2.1	
	Week 12	Tezepelumab	12	11 (91.7)	1.24 (0.68)	0.2	0.69	1.25	1.93	2.3	
		Placebo	11	11 (100.0)	1.54 (0.63)	0.5	1.01	1.64	1.71	2.7	
	Week 13	Tezepelumab	12	11 (91.7)	1.34 (0.65)	0.4	0.90	1.37	1.81	2.4	
		Placebo	11	11 (100.0)	1.57 (0.59)	0.4	1.24	1.59	1.90	2.6	
	Week 14	Tezepelumab	12	11 (91.7)	1.26 (0.66)	0.3	0.80	1.26	1.67	2.3	
		Placebo	11	11 (100.0)	1.61 (0.64)	0.5	1.23	1.63	2.19	2.5	
	Week 15	Tezepelumab	12	11 (91.7)	1.11 (0.68)	0.0	0.79	1.00	1.48	2.4	
		Placebo	11	11 (100.0)	1.51 (0.74)	0.4	0.84	1.47	2.19	2.7	
	Week 16	Tezepelumab	12	11 (91.7)	1.15 (0.69)	0.1	0.80	1.01	1.63	2.4	
		Placebo	11	11 (100.0)	1.42 (0.60)	0.5	0.79	1.49	1.76	2.4	
Week 17	Tezepelumab	12	11 (91.7)	1.17 (0.70)	0.2	0.59	1.00	1.73	2.2		
	Placebo	11	11 (100.0)	1.36 (0.63)	0.5	0.73	1.43	1.69	2.5		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	12	11 (91.7)	1.18 (0.82)	0.1	0.60	1.08	1.54	2.8	
		Placebo	11	11 (100.0)	1.33 (0.62)	0.5	0.80	1.47	1.61	2.5	
	Week 19	Tezepelumab	12	11 (91.7)	1.18 (0.87)	0.0	0.79	1.00	1.47	3.1	
		Placebo	11	11 (100.0)	1.39 (0.60)	0.5	0.96	1.47	1.78	2.6	
	Week 20	Tezepelumab	12	11 (91.7)	1.18 (0.80)	0.0	0.74	1.00	1.59	2.8	
		Placebo	11	11 (100.0)	1.42 (0.66)	0.4	1.00	1.43	1.83	2.5	
	Week 21	Tezepelumab	12	11 (91.7)	1.26 (0.80)	0.1	0.83	1.20	1.50	3.0	
		Placebo	11	11 (100.0)	1.42 (0.69)	0.1	0.94	1.50	1.83	2.7	
	Week 22	Tezepelumab	12	11 (91.7)	1.15 (0.68)	0.0	0.68	1.00	1.51	2.3	
		Placebo	11	11 (100.0)	1.40 (0.76)	0.0	0.80	1.58	1.89	2.6	
	Week 23	Tezepelumab	12	11 (91.7)	1.18 (0.77)	0.0	0.67	1.00	1.57	2.8	
		Placebo	11	11 (100.0)	1.39 (0.78)	0.0	0.70	1.80	1.91	2.6	
	Week 24	Tezepelumab	12	11 (91.7)	1.20 (0.70)	0.0	0.64	1.27	1.52	2.5	
		Placebo	11	11 (100.0)	1.46 (0.75)	0.0	0.78	1.78	2.07	2.5	
	Week 25	Tezepelumab	12	11 (91.7)	1.36 (0.88)	0.0	0.72	1.33	2.20	2.7	
		Placebo	11	11 (100.0)	1.33 (0.73)	0.0	0.92	1.20	1.84	2.6	
	Week 26	Tezepelumab	12	11 (91.7)	1.36 (0.78)	0.0	0.87	1.38	1.90	2.8	
		Placebo	11	11 (100.0)	1.30 (0.72)	0.0	0.87	1.33	2.01	2.5	
	Week 27	Tezepelumab	12	10 (83.3)	1.38 (0.89)	0.0	0.89	1.34	1.53	3.1	
		Placebo	11	11 (100.0)	1.43 (0.81)	0.0	0.97	1.35	2.16	2.6	
	Week 28	Tezepelumab	12	9 (75.0)	1.48 (0.74)	0.6	1.10	1.30	1.53	2.9	
		Placebo	11	11 (100.0)	1.47 (0.84)	0.0	0.90	1.38	2.19	2.8	
	Week 29	Tezepelumab	12	8 (66.7)	1.25 (0.88)	0.2	0.88	1.05	1.37	3.2	
		Placebo	11	11 (100.0)	1.49 (0.89)	0.0	0.81	1.60	2.47	2.7	
	Week 30	Tezepelumab	12	10 (83.3)	1.27 (0.94)	0.1	0.70	1.08	1.54	3.2	
		Placebo	11	11 (100.0)	1.39 (0.84)	0.0	0.81	1.43	2.09	2.6	
	Week 31	Tezepelumab	12	9 (75.0)	1.37 (0.98)	0.1	0.97	1.06	1.43	3.4	
		Placebo	11	11 (100.0)	1.39 (0.79)	0.0	0.93	1.44	1.97	2.6	
	Week 32	Tezepelumab	12	10 (83.3)	1.33 (0.92)	0.3	0.80	1.01	1.68	3.5	
		Placebo	11	11 (100.0)	1.45 (0.79)	0.0	1.00	1.39	2.13	2.6	
	Week 33	Tezepelumab	12	10 (83.3)	1.35 (0.80)	0.7	0.77	1.09	1.70	3.4	
		Placebo	11	11 (100.0)	1.39 (0.73)	0.0	1.00	1.40	1.88	2.6	
	Week 34	Tezepelumab	12	10 (83.3)	1.25 (0.83)	0.5	0.70	0.99	1.52	3.3	
		Placebo	11	11 (100.0)	1.46 (0.83)	0.0	0.86	1.37	2.02	2.7	
	Week 35	Tezepelumab	12	10 (83.3)	1.20 (0.83)	0.2	0.71	1.03	1.40	3.2	
		Placebo	11	11 (100.0)	1.39 (0.87)	0.0	0.84	1.10	2.03	2.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	12	10 (83.3)	1.16 (0.87)	0.1	0.86	0.99	1.42	3.1	
		Placebo	11	11 (100.0)	1.38 (0.85)	0.0	0.79	1.16	2.00	2.8	
	Week 37	Tezepelumab	12	9 (75.0)	1.32 (0.82)	0.2	0.90	1.10	1.71	3.0	
		Placebo	11	11 (100.0)	1.31 (0.79)	0.0	0.81	1.20	1.88	2.9	
	Week 38	Tezepelumab	12	9 (75.0)	1.32 (0.90)	0.3	0.80	1.03	1.76	3.3	
		Placebo	11	11 (100.0)	1.39 (0.77)	0.0	0.83	1.50	1.89	2.8	
	Week 39	Tezepelumab	12	9 (75.0)	1.37 (0.89)	0.3	0.87	1.00	1.63	3.2	
		Placebo	11	10 (90.9)	1.28 (0.79)	0.0	0.90	1.17	1.78	2.8	
	Week 40	Tezepelumab	12	9 (75.0)	1.39 (0.89)	0.4	0.83	1.00	1.73	3.2	
		Placebo	11	11 (100.0)	1.41 (0.86)	0.0	0.71	1.40	2.10	2.9	
	Week 41	Tezepelumab	12	8 (66.7)	1.39 (0.94)	0.3	0.84	1.02	1.95	3.2	
		Placebo	11	10 (90.9)	1.30 (0.79)	0.0	0.93	1.22	1.46	2.9	
	Week 42	Tezepelumab	12	8 (66.7)	1.28 (0.85)	0.3	0.72	1.02	1.78	2.9	
		Placebo	11	11 (100.0)	1.30 (0.82)	0.0	0.59	1.20	1.87	2.8	
	Week 43	Tezepelumab	12	8 (66.7)	1.36 (0.90)	0.2	0.90	1.13	1.83	3.0	
		Placebo	11	11 (100.0)	1.35 (0.84)	0.0	0.77	1.22	1.92	2.9	
	Week 44	Tezepelumab	12	8 (66.7)	1.28 (0.92)	0.3	0.76	1.00	1.74	3.0	
		Placebo	11	11 (100.0)	1.33 (0.91)	0.0	0.50	1.22	2.00	2.9	
	Week 45	Tezepelumab	12	8 (66.7)	1.26 (0.88)	0.2	0.78	1.00	1.80	2.8	
		Placebo	11	10 (90.9)	1.16 (0.81)	0.0	0.60	1.03	1.27	2.6	
	Week 46	Tezepelumab	12	7 (58.3)	1.27 (0.94)	0.1	0.68	1.00	2.40	2.7	
		Placebo	11	11 (100.0)	1.26 (0.77)	0.0	0.51	1.20	2.08	2.5	
	Week 47	Tezepelumab	12	8 (66.7)	1.25 (0.92)	0.1	0.56	1.00	2.05	2.7	
		Placebo	11	11 (100.0)	1.21 (0.80)	0.0	0.50	1.23	1.90	2.5	
	Week 48	Tezepelumab	12	7 (58.3)	1.41 (0.83)	0.6	0.79	1.03	2.30	2.8	
		Placebo	11	11 (100.0)	1.21 (0.79)	0.0	0.50	1.20	1.92	2.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	12	12 (100.0)	-0.09 (0.43)	-0.9	-0.35	-0.06	0.11	0.8	0.29 [-0.53, 1.11]
		Placebo	11	11 (100.0)	-0.24 (0.56)	-1.7	-0.51	-0.03	0.12	0.3	
	Week 2	Tezepelumab	12	12 (100.0)	-0.14 (0.35)	-0.8	-0.40	-0.04	0.06	0.4	-0.07 [-0.91, 0.77]
		Placebo	11	10 (90.9)	-0.12 (0.33)	-0.5	-0.46	-0.04	0.10	0.5	
	Week 3	Tezepelumab	12	12 (100.0)	-0.15 (0.51)	-1.1	-0.46	-0.07	0.09	0.7	0.15 [-0.69, 0.99]
		Placebo	11	10 (90.9)	-0.22 (0.41)	-0.7	-0.57	-0.28	0.00	0.5	
	Week 4	Tezepelumab	12	11 (91.7)	-0.18 (0.58)	-1.2	-0.61	-0.20	0.11	0.9	0.19 [-0.64, 1.03]
		Placebo	11	11 (100.0)	-0.31 (0.70)	-2.0	-0.56	-0.23	0.13	0.7	
	Week 5	Tezepelumab	12	11 (91.7)	-0.21 (0.58)	-1.6	-0.43	-0.11	0.20	0.6	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.39 (0.88)	-2.6	-0.69	-0.13	0.01	0.7	
	Week 6	Tezepelumab	12	11 (91.7)	-0.23 (0.59)	-1.6	-0.61	-0.14	0.04	0.6	0.24 [-0.60, 1.08]
		Placebo	11	11 (100.0)	-0.41 (0.88)	-2.6	-0.74	-0.10	0.05	0.6	
	Week 7	Tezepelumab	12	11 (91.7)	-0.19 (0.64)	-1.6	-0.61	0.02	0.19	0.7	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.40 (0.87)	-2.4	-0.65	-0.39	0.07	0.8	
	Week 8	Tezepelumab	12	10 (83.3)	-0.28 (0.61)	-1.6	-0.61	-0.21	0.13	0.7	-0.05 [-0.91, 0.81]
		Placebo	11	11 (100.0)	-0.25 (0.76)	-1.8	-0.78	-0.07	0.44	0.8	
	Week 9	Tezepelumab	12	12 (100.0)	-0.20 (0.72)	-1.5	-0.71	-0.22	0.42	0.8	0.01 [-0.81, 0.83]
		Placebo	11	11 (100.0)	-0.21 (0.90)	-2.2	-0.70	-0.06	0.44	0.9	
	Week 10	Tezepelumab	12	12 (100.0)	-0.15 (0.72)	-1.4	-0.71	-0.08	0.40	1.0	0.22 [-0.62, 1.06]
		Placebo	11	10 (90.9)	-0.31 (0.82)	-1.7	-0.70	-0.33	-0.09	0.9	
	Week 11	Tezepelumab	12	12 (100.0)	-0.16 (0.60)	-1.4	-0.49	-0.03	0.17	0.7	0.41 [-0.44, 1.26]
		Placebo	11	10 (90.9)	-0.44 (0.80)	-1.9	-0.71	-0.61	-0.01	0.8	
	Week 12	Tezepelumab	12	11 (91.7)	-0.20 (0.78)	-1.4	-0.61	-0.29	0.16	1.5	0.16 [-0.68, 1.00]
		Placebo	11	11 (100.0)	-0.32 (0.80)	-2.0	-0.76	-0.23	0.56	0.7	
	Week 13	Tezepelumab	12	11 (91.7)	-0.10 (0.75)	-1.2	-0.61	-0.19	0.54	1.3	0.24 [-0.60, 1.08]
		Placebo	11	11 (100.0)	-0.29 (0.89)	-1.9	-0.73	-0.23	0.46	1.2	
	Week 14	Tezepelumab	12	11 (91.7)	-0.18 (0.70)	-1.4	-0.66	-0.24	0.27	0.9	0.09 [-0.74, 0.93]
		Placebo	11	11 (100.0)	-0.25 (0.79)	-1.2	-0.70	-0.46	0.32	1.4	
	Week 15	Tezepelumab	12	11 (91.7)	-0.32 (0.66)	-1.4	-0.93	-0.20	0.21	0.7	0.04 [-0.79, 0.88]
		Placebo	11	11 (100.0)	-0.35 (0.67)	-1.5	-0.66	-0.44	0.11	0.7	
	Week 16	Tezepelumab	12	11 (91.7)	-0.29 (0.64)	-1.4	-0.86	-0.21	0.22	0.6	0.20 [-0.63, 1.04]
		Placebo	11	11 (100.0)	-0.44 (0.84)	-2.1	-0.77	-0.51	0.22	1.2	
	Week 17	Tezepelumab	12	11 (91.7)	-0.27 (0.60)	-1.4	-0.70	-0.22	0.27	0.5	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.49 (0.89)	-2.3	-0.90	-0.71	0.26	1.1	
	Week 18	Tezepelumab	12	11 (91.7)	-0.26 (0.86)	-1.4	-0.94	-0.27	0.19	1.6	0.34 [-0.51, 1.18]
		Placebo	11	11 (100.0)	-0.53 (0.76)	-2.1	-0.90	-0.70	0.30	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	12	11 (91.7)	-0.26 (0.97)	-1.5	-1.01	-0.50	0.44	1.8	0.24 [-0.60, 1.08]
		Placebo	11	11 (100.0)	-0.47 (0.74)	-1.9	-1.02	-0.43	0.39	0.5	
	Week 20	Tezepelumab	12	11 (91.7)	-0.26 (0.88)	-1.3	-0.98	-0.38	0.33	1.5	0.23 [-0.61, 1.07]
		Placebo	11	11 (100.0)	-0.44 (0.67)	-1.5	-0.97	-0.43	0.31	0.5	
	Week 21	Tezepelumab	12	11 (91.7)	-0.18 (0.94)	-1.4	-0.96	-0.45	0.60	1.7	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.44 (0.85)	-1.9	-0.91	-0.57	0.52	0.7	
	Week 22	Tezepelumab	12	11 (91.7)	-0.29 (0.78)	-1.2	-1.03	-0.44	0.47	1.0	0.23 [-0.61, 1.06]
		Placebo	11	11 (100.0)	-0.46 (0.74)	-1.6	-0.91	-0.60	0.30	0.6	
	Week 23	Tezepelumab	12	11 (91.7)	-0.26 (0.87)	-1.2	-1.04	-0.40	0.33	1.5	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.47 (0.79)	-1.7	-0.90	-0.60	0.14	0.7	
	Week 24	Tezepelumab	12	11 (91.7)	-0.24 (0.88)	-1.2	-1.00	-0.40	0.76	1.2	0.18 [-0.66, 1.02]
		Placebo	11	11 (100.0)	-0.39 (0.82)	-1.6	-0.90	-0.62	0.36	0.8	
	Week 25	Tezepelumab	12	11 (91.7)	-0.08 (1.14)	-1.2	-1.01	-0.27	0.88	2.2	0.43 [-0.42, 1.27]
		Placebo	11	11 (100.0)	-0.53 (0.97)	-2.6	-0.90	-0.56	0.34	0.7	
	Week 26	Tezepelumab	12	11 (91.7)	-0.08 (1.01)	-1.2	-1.00	-0.27	0.93	1.5	0.50 [-0.35, 1.35]
		Placebo	11	11 (100.0)	-0.55 (0.86)	-2.3	-0.90	-0.49	0.26	0.5	
	Week 27	Tezepelumab	12	10 (83.3)	0.04 (1.18)	-1.3	-1.01	-0.18	1.11	1.8	0.47 [-0.40, 1.34]
		Placebo	11	11 (100.0)	-0.43 (0.79)	-1.8	-0.90	-0.46	0.36	0.5	
	Week 28	Tezepelumab	12	9 (75.0)	0.10 (1.14)	-1.3	-0.83	-0.16	1.11	1.7	0.52 [-0.37, 1.42]
		Placebo	11	11 (100.0)	-0.39 (0.76)	-1.7	-0.89	-0.43	0.34	0.6	
	Week 29	Tezepelumab	12	8 (66.7)	-0.20 (1.11)	-1.4	-1.10	-0.27	0.32	1.9	0.17 [-0.74, 1.08]
		Placebo	11	11 (100.0)	-0.37 (0.90)	-2.0	-0.90	-0.33	0.46	0.8	
	Week 30	Tezepelumab	12	10 (83.3)	-0.07 (1.20)	-1.5	-1.01	-0.24	0.44	2.0	0.40 [-0.47, 1.26]
		Placebo	11	11 (100.0)	-0.46 (0.75)	-1.7	-0.90	-0.58	0.37	0.5	
	Week 31	Tezepelumab	12	9 (75.0)	-0.01 (1.29)	-1.5	-1.01	0.01	0.56	2.2	0.45 [-0.44, 1.35]
		Placebo	11	11 (100.0)	-0.47 (0.75)	-1.7	-0.90	-0.54	0.21	0.5	
	Week 32	Tezepelumab	12	10 (83.3)	-0.00 (1.18)	-1.4	-1.01	-0.02	0.39	2.2	0.41 [-0.45, 1.28]
		Placebo	11	11 (100.0)	-0.41 (0.75)	-1.7	-0.90	-0.50	0.13	0.8	
	Week 33	Tezepelumab	12	10 (83.3)	0.01 (1.06)	-1.4	-0.86	0.00	0.51	2.1	0.49 [-0.38, 1.36]
		Placebo	11	11 (100.0)	-0.47 (0.90)	-2.3	-0.90	-0.41	0.21	0.8	
	Week 34	Tezepelumab	12	10 (83.3)	-0.08 (1.07)	-1.5	-1.01	-0.16	0.57	2.1	0.34 [-0.52, 1.20]
		Placebo	11	11 (100.0)	-0.39 (0.74)	-1.7	-0.90	-0.55	0.37	0.7	
	Week 35	Tezepelumab	12	10 (83.3)	-0.13 (1.08)	-1.5	-1.00	-0.23	0.64	1.9	0.37 [-0.50, 1.23]
		Placebo	11	11 (100.0)	-0.46 (0.70)	-1.7	-0.90	-0.66	0.19	0.6	
	Week 36	Tezepelumab	12	10 (83.3)	-0.18 (1.08)	-1.6	-0.89	-0.29	0.53	1.9	0.32 [-0.54, 1.18]
		Placebo	11	11 (100.0)	-0.48 (0.73)	-1.6	-0.90	-0.71	0.40	0.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMH0: Course of ASD weekly total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	12	9 (75.0)	-0.05 (1.10)	-1.5	-0.81	0.26	0.51	1.8	0.52 [-0.38, 1.42]
		Placebo	11	11 (100.0)	-0.55 (0.81)	-1.8	-0.87	-0.69	0.26	0.7	
	Week 38	Tezepelumab	12	9 (75.0)	-0.05 (1.18)	-1.5	-0.91	0.07	0.34	2.0	0.40 [-0.49, 1.29]
		Placebo	11	11 (100.0)	-0.47 (0.88)	-2.0	-0.81	-0.60	0.41	0.7	
	Week 39	Tezepelumab	12	9 (75.0)	-0.01 (1.21)	-1.6	-0.84	0.11	0.46	2.0	0.39 [-0.52, 1.30]
		Placebo	11	10 (90.9)	-0.39 (0.77)	-1.7	-0.81	-0.58	0.34	0.8	
	Week 40	Tezepelumab	12	9 (75.0)	0.01 (1.21)	-1.6	-0.89	0.27	0.37	2.0	0.46 [-0.43, 1.35]
		Placebo	11	11 (100.0)	-0.45 (0.82)	-1.7	-1.15	-0.63	0.47	0.9	
	Week 41	Tezepelumab	12	8 (66.7)	0.02 (1.31)	-1.5	-1.13	-0.06	1.09	1.9	0.45 [-0.49, 1.39]
		Placebo	11	10 (90.9)	-0.50 (1.02)	-2.2	-1.00	-0.53	0.69	0.9	
	Week 42	Tezepelumab	12	8 (66.7)	-0.09 (1.20)	-1.5	-1.18	-0.16	0.91	1.7	0.46 [-0.46, 1.38]
		Placebo	11	11 (100.0)	-0.56 (0.86)	-1.8	-1.16	-0.61	0.34	0.8	
	Week 43	Tezepelumab	12	8 (66.7)	-0.01 (1.33)	-1.6	-1.18	-0.12	1.19	1.8	0.45 [-0.47, 1.37]
		Placebo	11	11 (100.0)	-0.51 (0.94)	-1.9	-1.21	-0.60	0.53	1.1	
	Week 44	Tezepelumab	12	8 (66.7)	-0.09 (1.25)	-1.6	-1.09	-0.26	0.94	1.7	0.42 [-0.50, 1.34]
		Placebo	11	11 (100.0)	-0.53 (0.89)	-1.9	-1.21	-0.60	0.21	0.9	
	Week 45	Tezepelumab	12	8 (66.7)	-0.11 (1.23)	-1.6	-1.14	-0.22	0.86	1.7	0.48 [-0.46, 1.42]
		Placebo	11	10 (90.9)	-0.65 (1.03)	-2.6	-1.21	-0.59	0.36	0.7	
	Week 46	Tezepelumab	12	7 (58.3)	0.08 (1.17)	-1.5	-0.83	0.14	1.46	1.6	0.70 [-0.28, 1.68]
		Placebo	11	11 (100.0)	-0.60 (0.82)	-2.0	-1.21	-0.54	0.27	0.7	
	Week 47	Tezepelumab	12	8 (66.7)	-0.12 (1.25)	-1.6	-1.22	-0.35	1.10	1.6	0.54 [-0.39, 1.47]
		Placebo	11	11 (100.0)	-0.65 (0.77)	-1.8	-1.21	-0.60	-0.06	0.7	
	Week 48	Tezepelumab	12	7 (58.3)	0.08 (1.19)	-1.5	-0.93	0.20	1.54	1.5	0.77 [-0.22, 1.75]
		Placebo	11	11 (100.0)	-0.65 (0.76)	-1.7	-1.21	-0.61	-0.01	0.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 1	Tezepelumab	12	12 (100.0)	-0.26 (0.20)	(-0.66, 0.14)	-0.16 (0.29)	(-0.74, 0.42)	0.585																																																																																																																										
	Placebo	11	11 (100.0)	-0.10 (0.21)	(-0.52, 0.31)				Week 2	Tezepelumab	12	12 (100.0)	-0.31 (0.20)	(-0.71, 0.08)	-0.18 (0.29)	(-0.76, 0.41)	0.549	Placebo	11	10 (90.9)	-0.14 (0.21)	(-0.55, 0.28)	Week 3	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.07 (0.29)	(-0.65, 0.51)	0.805	Placebo	11	10 (90.9)	-0.24 (0.21)	(-0.66, 0.17)	Week 4	Tezepelumab	12	11 (91.7)	-0.30 (0.20)	(-0.70, 0.10)	-0.13 (0.29)	(-0.71, 0.46)	0.666	Placebo	11	11 (100.0)	-0.17 (0.21)	(-0.59, 0.24)	Week 5	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.01)	-0.15 (0.29)	(-0.74, 0.43)	0.599	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 6	Tezepelumab	12	11 (91.7)	-0.45 (0.20)	(-0.85, -0.05)	-0.17 (0.29)	(-0.75, 0.41)	0.566	Placebo	11	11 (100.0)	-0.28 (0.21)	(-0.69, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)	Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo
Week 2	Tezepelumab	12	12 (100.0)	-0.31 (0.20)	(-0.71, 0.08)	-0.18 (0.29)	(-0.76, 0.41)	0.549																																																																																																																										
	Placebo	11	10 (90.9)	-0.14 (0.21)	(-0.55, 0.28)				Week 3	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.07 (0.29)	(-0.65, 0.51)	0.805	Placebo	11	10 (90.9)	-0.24 (0.21)	(-0.66, 0.17)	Week 4	Tezepelumab	12	11 (91.7)	-0.30 (0.20)	(-0.70, 0.10)	-0.13 (0.29)	(-0.71, 0.46)	0.666	Placebo	11	11 (100.0)	-0.17 (0.21)	(-0.59, 0.24)	Week 5	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.01)	-0.15 (0.29)	(-0.74, 0.43)	0.599	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 6	Tezepelumab	12	11 (91.7)	-0.45 (0.20)	(-0.85, -0.05)	-0.17 (0.29)	(-0.75, 0.41)	0.566	Placebo	11	11 (100.0)	-0.28 (0.21)	(-0.69, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)	Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)										
Week 3	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.07 (0.29)	(-0.65, 0.51)	0.805																																																																																																																										
	Placebo	11	10 (90.9)	-0.24 (0.21)	(-0.66, 0.17)				Week 4	Tezepelumab	12	11 (91.7)	-0.30 (0.20)	(-0.70, 0.10)	-0.13 (0.29)	(-0.71, 0.46)	0.666	Placebo	11	11 (100.0)	-0.17 (0.21)	(-0.59, 0.24)	Week 5	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.01)	-0.15 (0.29)	(-0.74, 0.43)	0.599	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 6	Tezepelumab	12	11 (91.7)	-0.45 (0.20)	(-0.85, -0.05)	-0.17 (0.29)	(-0.75, 0.41)	0.566	Placebo	11	11 (100.0)	-0.28 (0.21)	(-0.69, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)	Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																								
Week 4	Tezepelumab	12	11 (91.7)	-0.30 (0.20)	(-0.70, 0.10)	-0.13 (0.29)	(-0.71, 0.46)	0.666																																																																																																																										
	Placebo	11	11 (100.0)	-0.17 (0.21)	(-0.59, 0.24)				Week 5	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.01)	-0.15 (0.29)	(-0.74, 0.43)	0.599	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 6	Tezepelumab	12	11 (91.7)	-0.45 (0.20)	(-0.85, -0.05)	-0.17 (0.29)	(-0.75, 0.41)	0.566	Placebo	11	11 (100.0)	-0.28 (0.21)	(-0.69, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)	Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																						
Week 5	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.01)	-0.15 (0.29)	(-0.74, 0.43)	0.599																																																																																																																										
	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)				Week 6	Tezepelumab	12	11 (91.7)	-0.45 (0.20)	(-0.85, -0.05)	-0.17 (0.29)	(-0.75, 0.41)	0.566	Placebo	11	11 (100.0)	-0.28 (0.21)	(-0.69, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)	Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																																				
Week 6	Tezepelumab	12	11 (91.7)	-0.45 (0.20)	(-0.85, -0.05)	-0.17 (0.29)	(-0.75, 0.41)	0.566																																																																																																																										
	Placebo	11	11 (100.0)	-0.28 (0.21)	(-0.69, 0.13)				Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)	Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																																																		
Week 7	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.02)	-0.15 (0.29)	(-0.74, 0.43)	0.600																																																																																																																										
	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.68, 0.15)				Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)	Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																																																																
Week 8	Tezepelumab	12	10 (83.3)	-0.44 (0.20)	(-0.84, -0.04)	-0.33 (0.29)	(-0.91, 0.26)	0.268																																																																																																																										
	Placebo	11	11 (100.0)	-0.11 (0.21)	(-0.53, 0.30)				Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																																																																														
Week 9	Tezepelumab	12	12 (100.0)	-0.37 (0.20)	(-0.77, 0.03)	-0.29 (0.29)	(-0.88, 0.29)	0.316																																																																																																																										
	Placebo	11	11 (100.0)	-0.08 (0.21)	(-0.49, 0.34)				Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																																																																																												
Week 10	Tezepelumab	12	12 (100.0)	-0.32 (0.20)	(-0.71, 0.08)	-0.20 (0.29)	(-0.78, 0.38)	0.498																																																																																																																										
	Placebo	11	10 (90.9)	-0.12 (0.21)	(-0.53, 0.30)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 11	Tezepelumab	12	12 (100.0)	-0.33 (0.20)	(-0.73, 0.07)	-0.09 (0.29)	(-0.67, 0.49)	0.751																																																																																																																										
	Placebo	11	10 (90.9)	-0.24 (0.21)	(-0.65, 0.18)				Week 12	Tezepelumab	12	11 (91.7)	-0.34 (0.20)	(-0.74, 0.06)	-0.15 (0.29)	(-0.73, 0.43)	0.602	Placebo	11	11 (100.0)	-0.19 (0.21)	(-0.60, 0.22)	Week 13	Tezepelumab	12	11 (91.7)	-0.24 (0.20)	(-0.64, 0.16)	-0.08 (0.29)	(-0.66, 0.50)	0.781	Placebo	11	11 (100.0)	-0.16 (0.21)	(-0.57, 0.25)	Week 14	Tezepelumab	12	11 (91.7)	-0.32 (0.20)	(-0.73, 0.08)	-0.20 (0.29)	(-0.79, 0.38)	0.486	Placebo	11	11 (100.0)	-0.12 (0.21)	(-0.53, 0.29)	Week 15	Tezepelumab	12	11 (91.7)	-0.46 (0.20)	(-0.87, -0.06)	-0.24 (0.29)	(-0.83, 0.34)	0.406	Placebo	11	11 (100.0)	-0.22 (0.21)	(-0.63, 0.19)	Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.20)	(-0.83, -0.02)	-0.12 (0.29)	(-0.70, 0.47)	0.690	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)	Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)	Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo
Week 12	Tezepelumab	12	11 (91.7)	-0.34 (0.20)	(-0.74, 0.06)	-0.15 (0.29)	(-0.73, 0.43)	0.602																																																																																																																										
	Placebo	11	11 (100.0)	-0.19 (0.21)	(-0.60, 0.22)				Week 13	Tezepelumab	12	11 (91.7)	-0.24 (0.20)	(-0.64, 0.16)	-0.08 (0.29)	(-0.66, 0.50)	0.781	Placebo	11	11 (100.0)	-0.16 (0.21)	(-0.57, 0.25)	Week 14	Tezepelumab	12	11 (91.7)	-0.32 (0.20)	(-0.73, 0.08)	-0.20 (0.29)	(-0.79, 0.38)	0.486	Placebo	11	11 (100.0)	-0.12 (0.21)	(-0.53, 0.29)	Week 15	Tezepelumab	12	11 (91.7)	-0.46 (0.20)	(-0.87, -0.06)	-0.24 (0.29)	(-0.83, 0.34)	0.406	Placebo	11	11 (100.0)	-0.22 (0.21)	(-0.63, 0.19)	Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.20)	(-0.83, -0.02)	-0.12 (0.29)	(-0.70, 0.47)	0.690	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)	Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)	Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)										
Week 13	Tezepelumab	12	11 (91.7)	-0.24 (0.20)	(-0.64, 0.16)	-0.08 (0.29)	(-0.66, 0.50)	0.781																																																																																																																										
	Placebo	11	11 (100.0)	-0.16 (0.21)	(-0.57, 0.25)				Week 14	Tezepelumab	12	11 (91.7)	-0.32 (0.20)	(-0.73, 0.08)	-0.20 (0.29)	(-0.79, 0.38)	0.486	Placebo	11	11 (100.0)	-0.12 (0.21)	(-0.53, 0.29)	Week 15	Tezepelumab	12	11 (91.7)	-0.46 (0.20)	(-0.87, -0.06)	-0.24 (0.29)	(-0.83, 0.34)	0.406	Placebo	11	11 (100.0)	-0.22 (0.21)	(-0.63, 0.19)	Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.20)	(-0.83, -0.02)	-0.12 (0.29)	(-0.70, 0.47)	0.690	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)	Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)	Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																								
Week 14	Tezepelumab	12	11 (91.7)	-0.32 (0.20)	(-0.73, 0.08)	-0.20 (0.29)	(-0.79, 0.38)	0.486																																																																																																																										
	Placebo	11	11 (100.0)	-0.12 (0.21)	(-0.53, 0.29)				Week 15	Tezepelumab	12	11 (91.7)	-0.46 (0.20)	(-0.87, -0.06)	-0.24 (0.29)	(-0.83, 0.34)	0.406	Placebo	11	11 (100.0)	-0.22 (0.21)	(-0.63, 0.19)	Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.20)	(-0.83, -0.02)	-0.12 (0.29)	(-0.70, 0.47)	0.690	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)	Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)	Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																						
Week 15	Tezepelumab	12	11 (91.7)	-0.46 (0.20)	(-0.87, -0.06)	-0.24 (0.29)	(-0.83, 0.34)	0.406																																																																																																																										
	Placebo	11	11 (100.0)	-0.22 (0.21)	(-0.63, 0.19)				Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.20)	(-0.83, -0.02)	-0.12 (0.29)	(-0.70, 0.47)	0.690	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)	Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)	Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																																				
Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.20)	(-0.83, -0.02)	-0.12 (0.29)	(-0.70, 0.47)	0.690																																																																																																																										
	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)				Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)	Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																																																		
Week 17	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.81, -0.00)	-0.05 (0.29)	(-0.63, 0.54)	0.873																																																																																																																										
	Placebo	11	11 (100.0)	-0.36 (0.21)	(-0.77, 0.05)				Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																																																																
Week 18	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.79, 0.02)	0.01 (0.29)	(-0.58, 0.59)	0.982																																																																																																																										
	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)				Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																																																																														
Week 19	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.01)	-0.06 (0.29)	(-0.65, 0.53)	0.840																																																																																																																										
	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)				Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																																																																																												
Week 20	Tezepelumab	12	11 (91.7)	-0.39 (0.20)	(-0.80, 0.02)	-0.08 (0.29)	(-0.67, 0.50)	0.774																																																																																																																										
	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.11)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 21	Tezepelumab	12	11 (91.7)	-0.31 (0.20)	(-0.72, 0.10)	-0.00 (0.29)	(-0.59, 0.58)	0.996																																																																																																																										
	Placebo	11	11 (100.0)	-0.31 (0.21)	(-0.72, 0.10)				Week 22	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.01)	-0.09 (0.29)	(-0.67, 0.50)	0.765	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.09)	Week 23	Tezepelumab	12	11 (91.7)	-0.38 (0.21)	(-0.79, 0.03)	-0.05 (0.29)	(-0.64, 0.54)	0.868	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 24	Tezepelumab	12	11 (91.7)	-0.37 (0.21)	(-0.77, 0.04)	-0.10 (0.29)	(-0.69, 0.48)	0.725	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 25	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.19 (0.29)	(-0.39, 0.78)	0.512	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.22 (0.29)	(-0.37, 0.80)	0.466	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.83, -0.01)	Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)	Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo
Week 22	Tezepelumab	12	11 (91.7)	-0.42 (0.20)	(-0.82, -0.01)	-0.09 (0.29)	(-0.67, 0.50)	0.765																																																																																																																										
	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.09)				Week 23	Tezepelumab	12	11 (91.7)	-0.38 (0.21)	(-0.79, 0.03)	-0.05 (0.29)	(-0.64, 0.54)	0.868	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)	Week 24	Tezepelumab	12	11 (91.7)	-0.37 (0.21)	(-0.77, 0.04)	-0.10 (0.29)	(-0.69, 0.48)	0.725	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 25	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.19 (0.29)	(-0.39, 0.78)	0.512	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.22 (0.29)	(-0.37, 0.80)	0.466	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.83, -0.01)	Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)	Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)										
Week 23	Tezepelumab	12	11 (91.7)	-0.38 (0.21)	(-0.79, 0.03)	-0.05 (0.29)	(-0.64, 0.54)	0.868																																																																																																																										
	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)				Week 24	Tezepelumab	12	11 (91.7)	-0.37 (0.21)	(-0.77, 0.04)	-0.10 (0.29)	(-0.69, 0.48)	0.725	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 25	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.19 (0.29)	(-0.39, 0.78)	0.512	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.22 (0.29)	(-0.37, 0.80)	0.466	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.83, -0.01)	Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)	Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																								
Week 24	Tezepelumab	12	11 (91.7)	-0.37 (0.21)	(-0.77, 0.04)	-0.10 (0.29)	(-0.69, 0.48)	0.725																																																																																																																										
	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)				Week 25	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.19 (0.29)	(-0.39, 0.78)	0.512	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)	Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.22 (0.29)	(-0.37, 0.80)	0.466	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.83, -0.01)	Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)	Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																						
Week 25	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.19 (0.29)	(-0.39, 0.78)	0.512																																																																																																																										
	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)				Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.22 (0.29)	(-0.37, 0.80)	0.466	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.83, -0.01)	Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)	Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																																				
Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.21)	(-0.61, 0.21)	0.22 (0.29)	(-0.37, 0.80)	0.466																																																																																																																										
	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.83, -0.01)				Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)	Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																																																		
Week 27	Tezepelumab	12	10 (83.3)	-0.10 (0.21)	(-0.51, 0.31)	0.20 (0.30)	(-0.39, 0.78)	0.511																																																																																																																										
	Placebo	11	11 (100.0)	-0.30 (0.21)	(-0.71, 0.12)				Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)	Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																																																																
Week 28	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.28)	0.12 (0.30)	(-0.47, 0.71)	0.681																																																																																																																										
	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)				Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)	Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																																																																														
Week 29	Tezepelumab	12	8 (66.7)	-0.22 (0.21)	(-0.64, 0.20)	0.02 (0.30)	(-0.57, 0.61)	0.946																																																																																																																										
	Placebo	11	11 (100.0)	-0.24 (0.21)	(-0.65, 0.18)				Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																																																																																												
Week 30	Tezepelumab	12	10 (83.3)	-0.22 (0.21)	(-0.63, 0.20)	0.11 (0.30)	(-0.48, 0.71)	0.701																																																																																																																										
	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	12	9 (75.0)	-0.18 (0.21)	(-0.60, 0.24)	0.16 (0.30)	(-0.44, 0.75)	0.603
	Placebo	11	11 (100.0)	-0.34 (0.21)	(-0.75, 0.08)			
Week 32	Tezepelumab	12	10 (83.3)	-0.15 (0.21)	(-0.57, 0.27)	0.12 (0.30)	(-0.47, 0.72)	0.679
	Placebo	11	11 (100.0)	-0.27 (0.21)	(-0.69, 0.14)			
Week 33	Tezepelumab	12	10 (83.3)	-0.14 (0.21)	(-0.56, 0.29)	0.20 (0.30)	(-0.40, 0.80)	0.508
	Placebo	11	11 (100.0)	-0.34 (0.21)	(-0.75, 0.08)			
Week 34	Tezepelumab	12	10 (83.3)	-0.23 (0.21)	(-0.65, 0.19)	0.03 (0.30)	(-0.57, 0.63)	0.921
	Placebo	11	11 (100.0)	-0.26 (0.21)	(-0.67, 0.15)			
Week 35	Tezepelumab	12	10 (83.3)	-0.28 (0.21)	(-0.71, 0.14)	0.05 (0.30)	(-0.55, 0.65)	0.867
	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.74, 0.08)			
Week 36	Tezepelumab	12	10 (83.3)	-0.33 (0.21)	(-0.76, 0.10)	0.01 (0.30)	(-0.59, 0.61)	0.968
	Placebo	11	11 (100.0)	-0.34 (0.21)	(-0.76, 0.07)			
Week 37	Tezepelumab	12	9 (75.0)	-0.27 (0.22)	(-0.70, 0.16)	0.14 (0.30)	(-0.46, 0.74)	0.641
	Placebo	11	11 (100.0)	-0.41 (0.21)	(-0.83, -0.00)			
Week 38	Tezepelumab	12	9 (75.0)	-0.27 (0.22)	(-0.70, 0.16)	0.06 (0.30)	(-0.54, 0.66)	0.842
	Placebo	11	11 (100.0)	-0.33 (0.21)	(-0.75, 0.08)			
Week 39	Tezepelumab	12	9 (75.0)	-0.22 (0.22)	(-0.66, 0.21)	0.15 (0.30)	(-0.45, 0.76)	0.616
	Placebo	11	10 (90.9)	-0.37 (0.21)	(-0.79, 0.04)			
Week 40	Tezepelumab	12	9 (75.0)	-0.20 (0.22)	(-0.63, 0.24)	0.12 (0.30)	(-0.49, 0.73)	0.696
	Placebo	11	11 (100.0)	-0.32 (0.21)	(-0.73, 0.10)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC_IBMC0: Change from baseline in ASD weekly total score - MMRM results
DITTB

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	12	8 (66.7)	-0.15 (0.22)	(-0.59, 0.29)	0.23 (0.31)	(-0.38, 0.84)	0.456
	Placebo	11	10 (90.9)	-0.38 (0.21)	(-0.80, 0.03)			
Week 42	Tezepelumab	12	8 (66.7)	-0.26 (0.22)	(-0.71, 0.19)	0.16 (0.31)	(-0.45, 0.78)	0.597
	Placebo	11	11 (100.0)	-0.42 (0.21)	(-0.84, -0.01)			
Week 43	Tezepelumab	12	8 (66.7)	-0.17 (0.23)	(-0.62, 0.28)	0.20 (0.31)	(-0.41, 0.82)	0.515
	Placebo	11	11 (100.0)	-0.38 (0.21)	(-0.79, 0.04)			
Week 44	Tezepelumab	12	8 (66.7)	-0.25 (0.23)	(-0.71, 0.20)	0.14 (0.31)	(-0.48, 0.76)	0.651
	Placebo	11	11 (100.0)	-0.40 (0.21)	(-0.81, 0.02)			
Week 45	Tezepelumab	12	8 (66.7)	-0.27 (0.23)	(-0.73, 0.18)	0.22 (0.31)	(-0.40, 0.84)	0.485
	Placebo	11	10 (90.9)	-0.49 (0.21)	(-0.91, -0.08)			
Week 46	Tezepelumab	12	7 (58.3)	-0.29 (0.23)	(-0.75, 0.17)	0.18 (0.31)	(-0.45, 0.80)	0.578
	Placebo	11	11 (100.0)	-0.47 (0.21)	(-0.88, -0.05)			
Week 47	Tezepelumab	12	8 (66.7)	-0.28 (0.23)	(-0.74, 0.18)	0.24 (0.31)	(-0.39, 0.86)	0.449
	Placebo	11	11 (100.0)	-0.52 (0.21)	(-0.93, -0.10)			
Week 48	Tezepelumab	12	7 (58.3)	-0.27 (0.24)	(-0.74, 0.20)	0.24 (0.32)	(-0.39, 0.87)	0.446
	Placebo	11	11 (100.0)	-0.51 (0.21)	(-0.93, -0.10)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	55	55 (100.0)	1.44 (0.59)	0.0	0.97	1.51	1.97	2.6	
		Placebo	40	40 (100.0)	1.67 (0.57)	0.7	1.29	1.59	2.06	2.9	
	Week 1	Tezepelumab	55	54 (98.2)	1.32 (0.54)	0.2	1.03	1.26	1.71	2.5	
		Placebo	40	40 (100.0)	1.51 (0.55)	0.5	1.14	1.47	1.87	2.8	
	Week 2	Tezepelumab	55	54 (98.2)	1.22 (0.61)	0.0	0.91	1.19	1.74	2.3	
		Placebo	40	39 (97.5)	1.45 (0.60)	0.4	1.06	1.32	1.89	2.9	
	Week 3	Tezepelumab	55	55 (100.0)	1.22 (0.58)	0.0	0.89	1.20	1.57	2.7	
		Placebo	40	38 (95.0)	1.43 (0.68)	0.0	0.94	1.29	1.86	2.7	
	Week 4	Tezepelumab	55	55 (100.0)	1.14 (0.60)	0.0	0.71	1.14	1.53	2.7	
		Placebo	40	39 (97.5)	1.42 (0.61)	0.2	0.94	1.40	1.80	2.8	
	Week 5	Tezepelumab	55	54 (98.2)	1.14 (0.62)	0.0	0.80	1.00	1.60	2.6	
		Placebo	40	39 (97.5)	1.28 (0.60)	0.0	0.83	1.31	1.80	2.5	
	Week 6	Tezepelumab	55	53 (96.4)	1.18 (0.67)	0.0	0.77	1.08	1.57	2.8	
		Placebo	40	40 (100.0)	1.38 (0.61)	0.1	0.97	1.34	1.73	3.1	
	Week 7	Tezepelumab	55	52 (94.5)	1.17 (0.68)	0.0	0.76	1.15	1.54	3.1	
		Placebo	40	40 (100.0)	1.34 (0.60)	0.1	0.90	1.34	1.77	3.1	
	Week 8	Tezepelumab	55	54 (98.2)	1.15 (0.65)	0.0	0.74	1.10	1.60	2.7	
		Placebo	40	40 (100.0)	1.36 (0.56)	0.1	0.96	1.29	1.71	2.4	
	Week 9	Tezepelumab	55	55 (100.0)	1.09 (0.65)	0.0	0.60	1.00	1.66	2.7	
		Placebo	40	40 (100.0)	1.33 (0.57)	0.1	0.99	1.24	1.66	2.9	
	Week 10	Tezepelumab	55	54 (98.2)	1.08 (0.69)	0.0	0.57	1.03	1.67	2.8	
		Placebo	40	40 (100.0)	1.30 (0.53)	0.0	1.00	1.23	1.76	2.5	
	Week 11	Tezepelumab	55	54 (98.2)	1.09 (0.69)	0.0	0.54	1.05	1.60	2.9	
		Placebo	40	40 (100.0)	1.23 (0.56)	0.1	0.83	1.23	1.64	2.6	
	Week 12	Tezepelumab	55	54 (98.2)	1.06 (0.67)	0.0	0.63	0.99	1.63	2.9	
		Placebo	40	38 (95.0)	1.22 (0.60)	0.0	0.87	1.13	1.74	2.2	
	Week 13	Tezepelumab	55	52 (94.5)	1.03 (0.69)	0.0	0.53	0.94	1.60	2.9	
		Placebo	40	39 (97.5)	1.20 (0.57)	0.0	0.77	1.26	1.60	2.3	
	Week 14	Tezepelumab	55	53 (96.4)	1.08 (0.71)	0.0	0.60	1.00	1.54	2.8	
		Placebo	40	38 (95.0)	1.21 (0.55)	0.1	0.77	1.20	1.63	2.2	
	Week 15	Tezepelumab	55	53 (96.4)	1.03 (0.66)	0.0	0.60	0.95	1.53	2.6	
		Placebo	40	40 (100.0)	1.16 (0.57)	0.0	0.78	1.21	1.61	2.2	
	Week 16	Tezepelumab	55	54 (98.2)	1.02 (0.67)	0.0	0.49	0.97	1.60	2.3	
		Placebo	40	39 (97.5)	1.19 (0.57)	0.0	0.77	1.23	1.69	2.1	
	Week 17	Tezepelumab	55	54 (98.2)	0.99 (0.69)	0.0	0.40	0.97	1.52	2.5	
		Placebo	40	39 (97.5)	1.23 (0.57)	0.1	0.77	1.23	1.60	2.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	55	53 (96.4)	1.01 (0.71)	0.0	0.43	1.00	1.60	2.8	
		Placebo	40	39 (97.5)	1.22 (0.55)	0.2	0.80	1.20	1.69	2.2	
	Week 19	Tezepelumab	55	51 (92.7)	1.00 (0.75)	0.0	0.27	0.92	1.60	2.3	
		Placebo	40	39 (97.5)	1.23 (0.57)	0.0	0.80	1.30	1.67	2.3	
	Week 20	Tezepelumab	55	51 (92.7)	0.97 (0.72)	0.0	0.40	0.90	1.60	2.3	
		Placebo	40	39 (97.5)	1.20 (0.58)	0.0	0.80	1.17	1.66	2.4	
	Week 21	Tezepelumab	55	50 (90.9)	0.99 (0.72)	0.0	0.43	1.01	1.60	2.2	
		Placebo	40	38 (95.0)	1.17 (0.62)	0.1	0.80	1.11	1.60	2.6	
	Week 22	Tezepelumab	55	49 (89.1)	1.02 (0.64)	0.0	0.66	1.00	1.40	2.3	
		Placebo	40	39 (97.5)	1.22 (0.62)	0.0	0.77	1.30	1.66	2.8	
	Week 23	Tezepelumab	55	52 (94.5)	0.99 (0.70)	0.0	0.45	0.99	1.51	2.6	
		Placebo	40	37 (92.5)	1.19 (0.58)	0.1	0.86	1.17	1.60	2.6	
	Week 24	Tezepelumab	55	53 (96.4)	0.96 (0.73)	0.0	0.34	0.97	1.27	2.7	
		Placebo	40	38 (95.0)	1.15 (0.60)	0.0	0.80	1.10	1.60	2.7	
	Week 25	Tezepelumab	55	52 (94.5)	0.96 (0.69)	0.0	0.37	1.00	1.36	2.4	
		Placebo	40	37 (92.5)	1.16 (0.60)	0.0	0.80	1.00	1.63	2.5	
	Week 26	Tezepelumab	55	53 (96.4)	0.94 (0.70)	0.0	0.46	0.95	1.44	2.5	
		Placebo	40	38 (95.0)	1.20 (0.66)	0.0	0.66	1.27	1.73	2.4	
	Week 27	Tezepelumab	55	50 (90.9)	1.01 (0.71)	0.0	0.51	1.00	1.40	3.0	
		Placebo	40	36 (90.0)	1.21 (0.74)	0.0	0.69	1.17	1.67	3.2	
	Week 28	Tezepelumab	55	52 (94.5)	1.00 (0.74)	0.0	0.34	1.00	1.47	2.8	
		Placebo	40	38 (95.0)	1.23 (0.71)	0.0	0.80	1.10	1.74	2.6	
	Week 29	Tezepelumab	55	51 (92.7)	0.95 (0.67)	0.0	0.50	1.00	1.40	2.3	
		Placebo	40	37 (92.5)	1.17 (0.69)	0.0	0.80	1.00	1.69	2.7	
	Week 30	Tezepelumab	55	49 (89.1)	1.05 (0.66)	0.0	0.63	1.00	1.57	2.3	
		Placebo	40	37 (92.5)	1.11 (0.65)	0.0	0.57	1.00	1.60	2.8	
	Week 31	Tezepelumab	55	53 (96.4)	0.99 (0.68)	0.0	0.49	1.00	1.46	2.6	
		Placebo	40	37 (92.5)	1.08 (0.66)	0.0	0.63	1.00	1.54	2.8	
	Week 32	Tezepelumab	55	52 (94.5)	0.96 (0.67)	0.0	0.40	1.00	1.45	2.1	
		Placebo	40	37 (92.5)	1.10 (0.68)	0.0	0.51	1.00	1.60	2.8	
	Week 33	Tezepelumab	55	52 (94.5)	0.96 (0.66)	0.0	0.46	0.93	1.44	2.2	
		Placebo	40	38 (95.0)	1.16 (0.66)	0.0	0.69	1.00	1.60	2.8	
	Week 34	Tezepelumab	55	52 (94.5)	0.94 (0.68)	0.0	0.37	1.00	1.44	2.5	
		Placebo	40	38 (95.0)	1.14 (0.67)	0.0	0.60	1.00	1.60	2.8	
	Week 35	Tezepelumab	55	50 (90.9)	0.99 (0.68)	0.0	0.47	0.99	1.34	2.5	
		Placebo	40	37 (92.5)	1.14 (0.67)	0.0	0.66	1.03	1.63	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	55	51 (92.7)	0.99 (0.71)	0.0	0.40	1.00	1.50	2.5	
		Placebo	40	38 (95.0)	1.20 (0.62)	0.1	0.77	1.03	1.69	2.8	
	Week 37	Tezepelumab	55	50 (90.9)	1.02 (0.67)	0.0	0.54	1.00	1.60	2.6	
		Placebo	40	38 (95.0)	1.21 (0.58)	0.1	0.80	1.16	1.54	2.8	
	Week 38	Tezepelumab	55	51 (92.7)	1.02 (0.73)	0.0	0.47	0.97	1.53	2.6	
		Placebo	40	38 (95.0)	1.17 (0.64)	0.0	0.71	1.10	1.57	2.8	
	Week 39	Tezepelumab	55	52 (94.5)	0.97 (0.71)	0.0	0.36	1.00	1.53	2.3	
		Placebo	40	38 (95.0)	1.16 (0.67)	0.0	0.63	1.12	1.60	2.8	
	Week 40	Tezepelumab	55	52 (94.5)	1.00 (0.68)	0.0	0.47	1.00	1.45	2.5	
		Placebo	40	38 (95.0)	1.18 (0.74)	0.0	0.60	1.13	1.60	3.1	
	Week 41	Tezepelumab	55	53 (96.4)	1.01 (0.69)	0.0	0.60	1.00	1.40	2.4	
		Placebo	40	37 (92.5)	1.21 (0.74)	0.0	0.66	1.14	1.74	2.8	
	Week 42	Tezepelumab	55	51 (92.7)	1.01 (0.73)	0.0	0.34	1.00	1.49	2.7	
		Placebo	40	38 (95.0)	1.21 (0.69)	0.0	0.74	1.25	1.77	2.8	
	Week 43	Tezepelumab	55	51 (92.7)	0.98 (0.74)	0.0	0.28	1.00	1.43	2.9	
		Placebo	40	38 (95.0)	1.18 (0.68)	0.0	0.74	1.12	1.77	2.8	
	Week 44	Tezepelumab	55	50 (90.9)	0.93 (0.66)	0.0	0.30	1.00	1.30	2.4	
		Placebo	40	36 (90.0)	1.21 (0.65)	0.0	0.74	1.18	1.79	2.8	
	Week 45	Tezepelumab	55	51 (92.7)	0.97 (0.72)	0.0	0.33	1.00	1.46	2.9	
		Placebo	40	38 (95.0)	1.10 (0.68)	0.0	0.60	1.02	1.60	2.8	
	Week 46	Tezepelumab	55	52 (94.5)	0.98 (0.71)	0.0	0.25	1.00	1.49	2.5	
		Placebo	40	37 (92.5)	1.09 (0.71)	0.0	0.67	1.00	1.49	2.8	
	Week 47	Tezepelumab	55	46 (83.6)	0.97 (0.72)	0.0	0.37	0.99	1.66	2.8	
		Placebo	40	38 (95.0)	1.10 (0.69)	0.0	0.63	1.00	1.60	2.8	
	Week 48	Tezepelumab	55	51 (92.7)	1.04 (0.77)	0.0	0.49	1.00	1.54	2.8	
		Placebo	40	36 (90.0)	1.05 (0.70)	0.0	0.51	1.00	1.71	2.9	
	Week 49	Tezepelumab	55	49 (89.1)	1.08 (0.76)	0.0	0.57	1.00	1.63	2.7	
		Placebo	40	37 (92.5)	1.10 (0.71)	0.0	0.57	1.03	1.66	2.8	
	Week 50	Tezepelumab	55	49 (89.1)	1.03 (0.72)	0.0	0.60	1.00	1.57	2.7	
		Placebo	40	36 (90.0)	1.05 (0.68)	0.0	0.47	1.00	1.58	2.8	
	Week 51	Tezepelumab	55	47 (85.5)	1.07 (0.72)	0.0	0.63	1.00	1.80	2.6	
		Placebo	40	33 (82.5)	1.06 (0.70)	0.0	0.60	1.00	1.66	2.8	
	Week 52	Tezepelumab	55	43 (78.2)	1.07 (0.71)	0.0	0.63	1.00	1.63	2.5	
		Placebo	40	33 (82.5)	1.10 (0.71)	0.0	0.51	1.00	1.63	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	55	54 (98.2)	-0.13 (0.45)	-1.7	-0.20	0.00	0.14	0.6	0.08 [-0.33, 0.49]
		Placebo	40	40 (100.0)	-0.16 (0.31)	-0.9	-0.41	-0.16	0.00	0.7	
	Week 2	Tezepelumab	55	54 (98.2)	-0.23 (0.49)	-2.2	-0.31	-0.04	0.00	0.4	0.00 [-0.41, 0.41]
		Placebo	40	39 (97.5)	-0.23 (0.55)	-2.0	-0.36	-0.17	0.05	1.3	
	Week 3	Tezepelumab	55	55 (100.0)	-0.22 (0.52)	-2.2	-0.37	-0.11	0.03	0.7	0.05 [-0.36, 0.47]
		Placebo	40	38 (95.0)	-0.26 (0.70)	-2.6	-0.37	-0.13	0.03	1.2	
	Week 4	Tezepelumab	55	55 (100.0)	-0.30 (0.53)	-2.2	-0.46	-0.11	0.03	0.7	-0.07 [-0.48, 0.34]
		Placebo	40	39 (97.5)	-0.26 (0.60)	-2.6	-0.42	-0.11	0.03	0.6	
	Week 5	Tezepelumab	55	54 (98.2)	-0.31 (0.53)	-2.2	-0.57	-0.11	0.00	0.4	0.14 [-0.27, 0.55]
		Placebo	40	39 (97.5)	-0.39 (0.66)	-2.8	-0.73	-0.30	0.00	1.1	
	Week 6	Tezepelumab	55	53 (96.4)	-0.26 (0.52)	-2.2	-0.43	-0.17	0.03	0.5	0.04 [-0.37, 0.45]
		Placebo	40	40 (100.0)	-0.29 (0.60)	-2.7	-0.53	-0.12	0.07	0.6	
	Week 7	Tezepelumab	55	52 (94.5)	-0.25 (0.56)	-2.2	-0.44	-0.10	0.04	0.9	0.14 [-0.27, 0.55]
		Placebo	40	40 (100.0)	-0.34 (0.57)	-2.6	-0.57	-0.21	-0.01	0.6	
	Week 8	Tezepelumab	55	54 (98.2)	-0.28 (0.56)	-2.2	-0.60	-0.10	0.03	1.1	0.05 [-0.36, 0.46]
		Placebo	40	40 (100.0)	-0.31 (0.60)	-2.6	-0.57	-0.21	0.01	0.8	
	Week 9	Tezepelumab	55	55 (100.0)	-0.35 (0.60)	-2.2	-0.60	-0.20	0.09	0.8	-0.01 [-0.42, 0.40]
		Placebo	40	40 (100.0)	-0.35 (0.65)	-2.7	-0.76	-0.22	0.00	1.4	
	Week 10	Tezepelumab	55	54 (98.2)	-0.35 (0.59)	-2.2	-0.71	-0.20	0.00	0.8	0.03 [-0.38, 0.44]
		Placebo	40	40 (100.0)	-0.37 (0.61)	-2.7	-0.72	-0.23	0.00	0.6	
	Week 11	Tezepelumab	55	54 (98.2)	-0.34 (0.59)	-2.2	-0.80	-0.11	0.06	0.7	0.16 [-0.25, 0.57]
		Placebo	40	40 (100.0)	-0.44 (0.63)	-2.6	-0.89	-0.25	-0.02	0.6	
	Week 12	Tezepelumab	55	54 (98.2)	-0.39 (0.63)	-2.2	-0.94	-0.17	0.00	0.8	0.11 [-0.30, 0.53]
		Placebo	40	38 (95.0)	-0.46 (0.69)	-2.7	-0.91	-0.35	-0.02	1.3	
	Week 13	Tezepelumab	55	52 (94.5)	-0.40 (0.66)	-2.2	-0.94	-0.21	0.04	0.7	0.12 [-0.30, 0.54]
		Placebo	40	39 (97.5)	-0.48 (0.67)	-2.7	-0.87	-0.34	-0.09	1.4	
	Week 14	Tezepelumab	55	53 (96.4)	-0.36 (0.65)	-2.2	-0.60	-0.16	0.06	0.8	0.17 [-0.25, 0.59]
		Placebo	40	38 (95.0)	-0.47 (0.66)	-2.6	-0.84	-0.35	-0.11	0.8	
	Week 15	Tezepelumab	55	53 (96.4)	-0.40 (0.62)	-2.2	-0.86	-0.17	0.00	0.6	0.17 [-0.24, 0.58]
		Placebo	40	40 (100.0)	-0.51 (0.71)	-2.6	-0.97	-0.39	-0.07	1.3	
	Week 16	Tezepelumab	55	54 (98.2)	-0.43 (0.60)	-2.2	-0.91	-0.20	0.00	0.3	0.10 [-0.32, 0.51]
		Placebo	40	39 (97.5)	-0.49 (0.64)	-2.5	-0.80	-0.31	-0.06	0.9	
Week 17	Tezepelumab	55	54 (98.2)	-0.46 (0.63)	-2.2	-0.83	-0.25	0.03	0.5	-0.01 [-0.42, 0.40]	
	Placebo	40	39 (97.5)	-0.45 (0.62)	-2.6	-0.80	-0.31	-0.03	0.7		
Week 18	Tezepelumab	55	53 (96.4)	-0.44 (0.67)	-2.2	-0.77	-0.26	0.00	0.8	-0.00 [-0.41, 0.41]	
	Placebo	40	39 (97.5)	-0.44 (0.60)	-2.5	-0.74	-0.29	-0.06	0.8		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	55	51 (92.7)	-0.43 (0.67)	-2.2	-0.94	-0.17	0.00	0.5	-0.01 [-0.42, 0.41]
		Placebo	40	39 (97.5)	-0.43 (0.66)	-2.8	-0.74	-0.23	-0.06	0.8	
	Week 20	Tezepelumab	55	51 (92.7)	-0.47 (0.66)	-2.2	-0.90	-0.26	0.03	0.5	0.01 [-0.41, 0.43]
		Placebo	40	39 (97.5)	-0.47 (0.61)	-2.4	-0.76	-0.31	-0.11	0.7	
	Week 21	Tezepelumab	55	50 (90.9)	-0.47 (0.67)	-2.2	-0.94	-0.21	0.00	0.4	0.05 [-0.38, 0.47]
		Placebo	40	38 (95.0)	-0.50 (0.70)	-2.6	-0.86	-0.35	-0.06	1.3	
	Week 22	Tezepelumab	55	49 (89.1)	-0.44 (0.65)	-2.2	-0.77	-0.24	0.03	0.5	0.04 [-0.38, 0.46]
		Placebo	40	39 (97.5)	-0.46 (0.69)	-2.7	-0.87	-0.34	-0.03	1.3	
	Week 23	Tezepelumab	55	52 (94.5)	-0.46 (0.68)	-2.2	-0.97	-0.29	0.10	0.7	0.08 [-0.35, 0.50]
		Placebo	40	37 (92.5)	-0.51 (0.63)	-2.4	-0.80	-0.34	-0.06	0.4	
	Week 24	Tezepelumab	55	53 (96.4)	-0.48 (0.69)	-2.2	-0.94	-0.34	0.00	0.7	0.10 [-0.32, 0.52]
		Placebo	40	38 (95.0)	-0.55 (0.62)	-2.4	-0.86	-0.34	-0.08	0.3	
	Week 25	Tezepelumab	55	52 (94.5)	-0.50 (0.64)	-2.2	-0.90	-0.32	0.00	0.5	0.06 [-0.36, 0.48]
		Placebo	40	37 (92.5)	-0.53 (0.67)	-2.8	-1.00	-0.37	-0.06	0.5	
	Week 26	Tezepelumab	55	53 (96.4)	-0.48 (0.66)	-2.2	-1.00	-0.34	0.00	0.6	0.03 [-0.38, 0.45]
		Placebo	40	38 (95.0)	-0.50 (0.76)	-2.8	-1.07	-0.35	-0.06	1.1	
	Week 27	Tezepelumab	55	50 (90.9)	-0.41 (0.67)	-2.2	-0.81	-0.30	0.03	0.8	0.12 [-0.31, 0.55]
		Placebo	40	36 (90.0)	-0.50 (0.86)	-2.8	-1.02	-0.41	-0.05	2.2	
	Week 28	Tezepelumab	55	52 (94.5)	-0.41 (0.70)	-2.2	-0.77	-0.27	0.02	1.1	0.07 [-0.34, 0.49]
		Placebo	40	38 (95.0)	-0.47 (0.75)	-2.8	-0.98	-0.31	0.00	0.7	
	Week 29	Tezepelumab	55	51 (92.7)	-0.48 (0.64)	-2.2	-0.94	-0.26	0.03	0.2	0.04 [-0.38, 0.46]
		Placebo	40	37 (92.5)	-0.51 (0.79)	-2.8	-1.04	-0.37	0.00	0.9	
	Week 30	Tezepelumab	55	49 (89.1)	-0.46 (0.61)	-2.2	-0.86	-0.23	0.00	0.3	0.21 [-0.22, 0.63]
		Placebo	40	37 (92.5)	-0.60 (0.74)	-2.8	-1.17	-0.46	-0.06	0.9	
	Week 31	Tezepelumab	55	53 (96.4)	-0.47 (0.68)	-2.2	-0.82	-0.26	0.03	1.0	0.17 [-0.25, 0.59]
		Placebo	40	37 (92.5)	-0.59 (0.77)	-2.8	-1.05	-0.43	-0.10	1.3	
	Week 32	Tezepelumab	55	52 (94.5)	-0.51 (0.65)	-2.2	-0.86	-0.31	0.00	0.7	0.09 [-0.34, 0.51]
		Placebo	40	37 (92.5)	-0.57 (0.76)	-2.8	-1.03	-0.49	-0.07	1.3	
	Week 33	Tezepelumab	55	52 (94.5)	-0.48 (0.68)	-2.2	-0.94	-0.26	0.01	0.5	0.06 [-0.36, 0.48]
		Placebo	40	38 (95.0)	-0.53 (0.73)	-2.7	-0.89	-0.37	-0.11	1.1	
	Week 34	Tezepelumab	55	52 (94.5)	-0.53 (0.63)	-2.2	-0.95	-0.35	0.00	0.4	0.02 [-0.40, 0.44]
		Placebo	40	38 (95.0)	-0.54 (0.73)	-2.8	-1.04	-0.41	-0.06	1.1	
	Week 35	Tezepelumab	55	50 (90.9)	-0.46 (0.64)	-2.2	-0.73	-0.29	0.00	0.5	0.16 [-0.26, 0.59]
		Placebo	40	37 (92.5)	-0.57 (0.72)	-2.8	-1.01	-0.45	-0.14	1.1	
	Week 36	Tezepelumab	55	51 (92.7)	-0.47 (0.64)	-2.2	-0.80	-0.31	0.00	0.5	0.01 [-0.41, 0.43]
		Placebo	40	38 (95.0)	-0.48 (0.66)	-2.6	-0.90	-0.39	-0.09	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	55	50 (90.9)	-0.42 (0.63)	-2.2	-0.80	-0.21	0.00	0.8	0.08 [-0.34, 0.50]
		Placebo	40	38 (95.0)	-0.47 (0.63)	-2.4	-0.82	-0.35	-0.07	1.0	
	Week 38	Tezepelumab	55	51 (92.7)	-0.43 (0.68)	-2.2	-0.80	-0.29	0.00	1.0	0.12 [-0.30, 0.54]
		Placebo	40	38 (95.0)	-0.51 (0.62)	-2.1	-0.94	-0.33	-0.15	1.1	
	Week 39	Tezepelumab	55	52 (94.5)	-0.46 (0.67)	-2.2	-0.85	-0.27	0.00	0.6	0.09 [-0.33, 0.51]
		Placebo	40	38 (95.0)	-0.52 (0.63)	-2.5	-0.90	-0.39	-0.03	0.6	
	Week 40	Tezepelumab	55	52 (94.5)	-0.46 (0.65)	-2.2	-0.86	-0.25	0.01	0.6	0.05 [-0.37, 0.47]
		Placebo	40	38 (95.0)	-0.50 (0.71)	-2.5	-1.04	-0.40	-0.03	0.8	
	Week 41	Tezepelumab	55	53 (96.4)	-0.46 (0.65)	-2.2	-0.88	-0.28	0.00	0.7	0.00 [-0.42, 0.42]
		Placebo	40	37 (92.5)	-0.46 (0.80)	-2.6	-0.87	-0.37	-0.03	1.6	
	Week 42	Tezepelumab	55	51 (92.7)	-0.46 (0.66)	-2.2	-0.86	-0.17	0.00	0.5	0.02 [-0.40, 0.44]
		Placebo	40	38 (95.0)	-0.47 (0.64)	-1.9	-0.97	-0.39	-0.03	0.7	
	Week 43	Tezepelumab	55	51 (92.7)	-0.46 (0.65)	-2.2	-0.92	-0.31	0.00	0.7	0.06 [-0.36, 0.48]
		Placebo	40	38 (95.0)	-0.50 (0.61)	-2.0	-0.97	-0.37	-0.03	0.6	
	Week 44	Tezepelumab	55	50 (90.9)	-0.53 (0.62)	-2.2	-0.94	-0.36	0.00	0.3	-0.05 [-0.48, 0.38]
		Placebo	40	36 (90.0)	-0.50 (0.62)	-2.1	-0.86	-0.37	-0.06	0.9	
	Week 45	Tezepelumab	55	51 (92.7)	-0.48 (0.66)	-2.2	-0.97	-0.31	0.00	0.7	0.15 [-0.27, 0.57]
		Placebo	40	38 (95.0)	-0.58 (0.67)	-2.5	-1.09	-0.40	-0.06	0.7	
	Week 46	Tezepelumab	55	52 (94.5)	-0.48 (0.69)	-2.2	-1.00	-0.33	0.06	0.9	0.15 [-0.27, 0.57]
		Placebo	40	37 (92.5)	-0.58 (0.70)	-2.8	-1.12	-0.38	-0.06	0.6	
	Week 47	Tezepelumab	55	46 (83.6)	-0.45 (0.71)	-2.2	-1.00	-0.19	0.00	1.0	0.18 [-0.25, 0.61]
		Placebo	40	38 (95.0)	-0.58 (0.66)	-2.8	-1.04	-0.37	-0.06	0.6	
	Week 48	Tezepelumab	55	51 (92.7)	-0.38 (0.73)	-2.2	-0.82	-0.17	0.09	1.1	0.35 [-0.08, 0.78]
		Placebo	40	36 (90.0)	-0.63 (0.68)	-2.8	-1.16	-0.45	-0.10	0.5	
	Week 49	Tezepelumab	55	49 (89.1)	-0.39 (0.74)	-2.2	-0.94	-0.14	0.06	1.1	0.27 [-0.16, 0.69]
		Placebo	40	37 (92.5)	-0.58 (0.65)	-2.8	-1.06	-0.37	-0.06	0.2	
	Week 50	Tezepelumab	55	49 (89.1)	-0.43 (0.68)	-2.2	-0.80	-0.17	0.00	0.9	0.30 [-0.13, 0.74]
		Placebo	40	36 (90.0)	-0.63 (0.63)	-2.8	-1.07	-0.43	-0.19	0.1	
	Week 51	Tezepelumab	55	47 (85.5)	-0.41 (0.69)	-2.2	-0.94	-0.19	0.03	0.8	0.33 [-0.12, 0.77]
		Placebo	40	33 (82.5)	-0.63 (0.65)	-2.8	-0.97	-0.49	-0.20	0.3	
	Week 52	Tezepelumab	55	43 (78.2)	-0.40 (0.67)	-2.2	-0.94	-0.22	0.06	0.6	0.35 [-0.11, 0.81]
		Placebo	40	33 (82.5)	-0.63 (0.64)	-2.8	-0.88	-0.50	-0.29	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	55	54 (98.2)	-0.17 (0.08)	(-0.32, -0.01)	-0.06 (0.12)	(-0.30, 0.17)	0.594
	Placebo	40	40 (100.0)	-0.10 (0.09)	(-0.29, 0.08)			
Week 2	Tezepelumab	55	54 (98.2)	-0.27 (0.08)	(-0.43, -0.12)	-0.11 (0.12)	(-0.35, 0.13)	0.367
	Placebo	40	39 (97.5)	-0.16 (0.09)	(-0.34, 0.02)			
Week 3	Tezepelumab	55	55 (100.0)	-0.27 (0.08)	(-0.43, -0.12)	-0.10 (0.12)	(-0.34, 0.14)	0.422
	Placebo	40	38 (95.0)	-0.17 (0.09)	(-0.36, 0.01)			
Week 4	Tezepelumab	55	55 (100.0)	-0.34 (0.08)	(-0.50, -0.19)	-0.15 (0.12)	(-0.39, 0.09)	0.213
	Placebo	40	39 (97.5)	-0.19 (0.09)	(-0.37, -0.01)			
Week 5	Tezepelumab	55	54 (98.2)	-0.35 (0.08)	(-0.50, -0.19)	-0.02 (0.12)	(-0.26, 0.22)	0.872
	Placebo	40	39 (97.5)	-0.33 (0.09)	(-0.51, -0.14)			
Week 6	Tezepelumab	55	53 (96.4)	-0.29 (0.08)	(-0.44, -0.13)	-0.05 (0.12)	(-0.29, 0.18)	0.654
	Placebo	40	40 (100.0)	-0.23 (0.09)	(-0.41, -0.05)			
Week 7	Tezepelumab	55	52 (94.5)	-0.29 (0.08)	(-0.44, -0.13)	-0.01 (0.12)	(-0.25, 0.23)	0.953
	Placebo	40	40 (100.0)	-0.28 (0.09)	(-0.46, -0.10)			
Week 8	Tezepelumab	55	54 (98.2)	-0.32 (0.08)	(-0.48, -0.17)	-0.07 (0.12)	(-0.31, 0.17)	0.579
	Placebo	40	40 (100.0)	-0.26 (0.09)	(-0.44, -0.08)			
Week 9	Tezepelumab	55	55 (100.0)	-0.40 (0.08)	(-0.55, -0.24)	-0.11 (0.12)	(-0.34, 0.13)	0.381
	Placebo	40	40 (100.0)	-0.29 (0.09)	(-0.47, -0.11)			
Week 10	Tezepelumab	55	54 (98.2)	-0.41 (0.08)	(-0.56, -0.25)	-0.09 (0.12)	(-0.33, 0.15)	0.444
	Placebo	40	40 (100.0)	-0.32 (0.09)	(-0.50, -0.14)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	55	54 (98.2)	-0.40 (0.08)	(-0.55, -0.25)	-0.01 (0.12)	(-0.25, 0.23)	0.912
	Placebo	40	40 (100.0)	-0.39 (0.09)	(-0.57, -0.21)			
Week 12	Tezepelumab	55	54 (98.2)	-0.41 (0.08)	(-0.57, -0.26)	-0.03 (0.12)	(-0.27, 0.21)	0.793
	Placebo	40	38 (95.0)	-0.38 (0.09)	(-0.56, -0.20)			
Week 13	Tezepelumab	55	52 (94.5)	-0.43 (0.08)	(-0.59, -0.28)	-0.01 (0.12)	(-0.25, 0.22)	0.903
	Placebo	40	39 (97.5)	-0.42 (0.09)	(-0.60, -0.23)			
Week 14	Tezepelumab	55	53 (96.4)	-0.39 (0.08)	(-0.54, -0.23)	0.01 (0.12)	(-0.23, 0.25)	0.957
	Placebo	40	38 (95.0)	-0.39 (0.09)	(-0.57, -0.21)			
Week 15	Tezepelumab	55	53 (96.4)	-0.42 (0.08)	(-0.58, -0.27)	0.03 (0.12)	(-0.21, 0.27)	0.783
	Placebo	40	40 (100.0)	-0.46 (0.09)	(-0.64, -0.28)			
Week 16	Tezepelumab	55	54 (98.2)	-0.46 (0.08)	(-0.61, -0.30)	-0.03 (0.12)	(-0.27, 0.21)	0.785
	Placebo	40	39 (97.5)	-0.43 (0.09)	(-0.61, -0.24)			
Week 17	Tezepelumab	55	54 (98.2)	-0.49 (0.08)	(-0.64, -0.33)	-0.10 (0.12)	(-0.34, 0.14)	0.418
	Placebo	40	39 (97.5)	-0.39 (0.09)	(-0.57, -0.21)			
Week 18	Tezepelumab	55	53 (96.4)	-0.46 (0.08)	(-0.62, -0.31)	-0.09 (0.12)	(-0.33, 0.15)	0.459
	Placebo	40	39 (97.5)	-0.37 (0.09)	(-0.55, -0.19)			
Week 19	Tezepelumab	55	51 (92.7)	-0.47 (0.08)	(-0.62, -0.31)	-0.11 (0.12)	(-0.35, 0.13)	0.382
	Placebo	40	39 (97.5)	-0.36 (0.09)	(-0.54, -0.18)			
Week 20	Tezepelumab	55	51 (92.7)	-0.50 (0.08)	(-0.65, -0.34)	-0.06 (0.12)	(-0.30, 0.18)	0.625
	Placebo	40	39 (97.5)	-0.44 (0.09)	(-0.62, -0.26)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	55	50 (90.9)	-0.52 (0.08)	(-0.67, -0.36)	-0.09 (0.12)	(-0.33, 0.15)	0.477
	Placebo	40	38 (95.0)	-0.43 (0.09)	(-0.61, -0.25)			
Week 22	Tezepelumab	55	49 (89.1)	-0.48 (0.08)	(-0.64, -0.32)	-0.08 (0.12)	(-0.32, 0.16)	0.533
	Placebo	40	39 (97.5)	-0.40 (0.09)	(-0.59, -0.22)			
Week 23	Tezepelumab	55	52 (94.5)	-0.49 (0.08)	(-0.64, -0.33)	-0.09 (0.12)	(-0.33, 0.15)	0.447
	Placebo	40	37 (92.5)	-0.40 (0.09)	(-0.58, -0.21)			
Week 24	Tezepelumab	55	53 (96.4)	-0.50 (0.08)	(-0.66, -0.35)	-0.06 (0.12)	(-0.30, 0.18)	0.648
	Placebo	40	38 (95.0)	-0.45 (0.09)	(-0.63, -0.26)			
Week 25	Tezepelumab	55	52 (94.5)	-0.52 (0.08)	(-0.67, -0.36)	-0.09 (0.12)	(-0.33, 0.15)	0.444
	Placebo	40	37 (92.5)	-0.42 (0.09)	(-0.61, -0.24)			
Week 26	Tezepelumab	55	53 (96.4)	-0.52 (0.08)	(-0.67, -0.36)	-0.11 (0.12)	(-0.36, 0.13)	0.351
	Placebo	40	38 (95.0)	-0.40 (0.09)	(-0.59, -0.22)			
Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.08)	(-0.62, -0.31)	-0.08 (0.12)	(-0.32, 0.16)	0.520
	Placebo	40	36 (90.0)	-0.39 (0.09)	(-0.57, -0.20)			
Week 28	Tezepelumab	55	52 (94.5)	-0.47 (0.08)	(-0.63, -0.32)	-0.10 (0.12)	(-0.34, 0.14)	0.433
	Placebo	40	38 (95.0)	-0.37 (0.09)	(-0.56, -0.19)			
Week 29	Tezepelumab	55	51 (92.7)	-0.52 (0.08)	(-0.68, -0.37)	-0.11 (0.12)	(-0.35, 0.13)	0.370
	Placebo	40	37 (92.5)	-0.41 (0.09)	(-0.60, -0.23)			
Week 30	Tezepelumab	55	49 (89.1)	-0.50 (0.08)	(-0.65, -0.34)	0.01 (0.12)	(-0.23, 0.25)	0.941
	Placebo	40	37 (92.5)	-0.51 (0.09)	(-0.69, -0.32)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	55	53 (96.4)	-0.50 (0.08)	(-0.65, -0.34)	0.00 (0.12)	(-0.24, 0.24)	0.991
	Placebo	40	37 (92.5)	-0.50 (0.09)	(-0.68, -0.32)			
Week 32	Tezepelumab	55	52 (94.5)	-0.53 (0.08)	(-0.68, -0.37)	-0.05 (0.12)	(-0.29, 0.19)	0.683
	Placebo	40	37 (92.5)	-0.48 (0.09)	(-0.66, -0.29)			
Week 33	Tezepelumab	55	52 (94.5)	-0.53 (0.08)	(-0.69, -0.38)	-0.08 (0.12)	(-0.32, 0.16)	0.521
	Placebo	40	38 (95.0)	-0.45 (0.09)	(-0.64, -0.27)			
Week 34	Tezepelumab	55	52 (94.5)	-0.57 (0.08)	(-0.72, -0.41)	-0.10 (0.12)	(-0.34, 0.15)	0.435
	Placebo	40	38 (95.0)	-0.47 (0.09)	(-0.65, -0.28)			
Week 35	Tezepelumab	55	50 (90.9)	-0.51 (0.08)	(-0.66, -0.35)	-0.02 (0.12)	(-0.26, 0.23)	0.899
	Placebo	40	37 (92.5)	-0.49 (0.09)	(-0.67, -0.30)			
Week 36	Tezepelumab	55	51 (92.7)	-0.47 (0.08)	(-0.63, -0.32)	-0.07 (0.12)	(-0.31, 0.18)	0.597
	Placebo	40	38 (95.0)	-0.41 (0.09)	(-0.59, -0.22)			
Week 37	Tezepelumab	55	50 (90.9)	-0.49 (0.08)	(-0.65, -0.34)	-0.10 (0.12)	(-0.34, 0.15)	0.440
	Placebo	40	38 (95.0)	-0.40 (0.09)	(-0.58, -0.21)			
Week 38	Tezepelumab	55	51 (92.7)	-0.46 (0.08)	(-0.62, -0.31)	-0.02 (0.12)	(-0.27, 0.22)	0.840
	Placebo	40	38 (95.0)	-0.44 (0.09)	(-0.62, -0.25)			
Week 39	Tezepelumab	55	52 (94.5)	-0.51 (0.08)	(-0.66, -0.35)	-0.06 (0.12)	(-0.30, 0.19)	0.647
	Placebo	40	38 (95.0)	-0.45 (0.09)	(-0.64, -0.27)			
Week 40	Tezepelumab	55	52 (94.5)	-0.50 (0.08)	(-0.66, -0.34)	-0.07 (0.12)	(-0.31, 0.18)	0.589
	Placebo	40	38 (95.0)	-0.43 (0.09)	(-0.62, -0.25)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 41	Tezepelumab	55	53 (96.4)	-0.49 (0.08)	(-0.65, -0.33)	-0.08 (0.12)	(-0.32, 0.16)	0.528
	Placebo	40	37 (92.5)	-0.41 (0.09)	(-0.60, -0.23)			
Week 42	Tezepelumab	55	51 (92.7)	-0.49 (0.08)	(-0.64, -0.33)	-0.08 (0.12)	(-0.32, 0.16)	0.522
	Placebo	40	38 (95.0)	-0.41 (0.09)	(-0.59, -0.22)			
Week 43	Tezepelumab	55	51 (92.7)	-0.50 (0.08)	(-0.66, -0.35)	-0.07 (0.12)	(-0.31, 0.18)	0.583
	Placebo	40	38 (95.0)	-0.43 (0.09)	(-0.62, -0.25)			
Week 44	Tezepelumab	55	50 (90.9)	-0.56 (0.08)	(-0.71, -0.40)	-0.11 (0.12)	(-0.36, 0.13)	0.361
	Placebo	40	36 (90.0)	-0.44 (0.09)	(-0.63, -0.26)			
Week 45	Tezepelumab	55	51 (92.7)	-0.54 (0.08)	(-0.70, -0.39)	-0.03 (0.12)	(-0.27, 0.22)	0.831
	Placebo	40	38 (95.0)	-0.52 (0.09)	(-0.70, -0.33)			
Week 46	Tezepelumab	55	52 (94.5)	-0.52 (0.08)	(-0.67, -0.36)	-0.01 (0.12)	(-0.26, 0.23)	0.919
	Placebo	40	37 (92.5)	-0.50 (0.09)	(-0.69, -0.32)			
Week 47	Tezepelumab	55	46 (83.6)	-0.52 (0.08)	(-0.67, -0.36)	0.00 (0.12)	(-0.24, 0.25)	0.993
	Placebo	40	38 (95.0)	-0.52 (0.09)	(-0.70, -0.33)			
Week 48	Tezepelumab	55	51 (92.7)	-0.44 (0.08)	(-0.60, -0.29)	0.10 (0.12)	(-0.14, 0.34)	0.423
	Placebo	40	36 (90.0)	-0.54 (0.09)	(-0.73, -0.36)			
Week 49	Tezepelumab	55	49 (89.1)	-0.45 (0.08)	(-0.60, -0.29)	0.07 (0.12)	(-0.17, 0.32)	0.563
	Placebo	40	37 (92.5)	-0.52 (0.09)	(-0.70, -0.33)			
Week 50	Tezepelumab	55	49 (89.1)	-0.49 (0.08)	(-0.65, -0.33)	0.04 (0.12)	(-0.20, 0.29)	0.739
	Placebo	40	36 (90.0)	-0.53 (0.09)	(-0.72, -0.34)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	55	47 (85.5)	-0.46 (0.08)	(-0.62, -0.30)	0.07 (0.13)	(-0.18, 0.32)	0.566
	Placebo	40	33 (82.5)	-0.53 (0.10)	(-0.72, -0.35)			
Week 52	Tezepelumab	55	43 (78.2)	-0.46 (0.08)	(-0.62, -0.30)	0.06 (0.13)	(-0.19, 0.31)	0.624
	Placebo	40	33 (82.5)	-0.52 (0.10)	(-0.71, -0.33)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	12	12 (100.0)	1.46 (0.81)	0.0	0.94	1.46	2.01	2.7	
		Placebo	11	11 (100.0)	2.01 (0.94)	0.3	1.77	2.00	2.60	3.6	
	Week 1	Tezepelumab	12	12 (100.0)	1.33 (0.64)	0.6	0.93	1.16	1.71	2.6	
		Placebo	11	11 (100.0)	1.78 (0.70)	0.5	1.20	1.93	2.27	2.9	
	Week 2	Tezepelumab	12	12 (100.0)	1.27 (0.68)	0.3	0.89	1.00	1.60	2.6	
		Placebo	11	11 (100.0)	1.90 (0.82)	0.5	1.20	2.00	2.31	3.7	
	Week 3	Tezepelumab	12	12 (100.0)	1.25 (0.67)	0.3	0.97	1.04	1.35	2.6	
		Placebo	11	11 (100.0)	1.64 (0.61)	0.7	1.06	1.72	2.14	2.4	
	Week 4	Tezepelumab	12	12 (100.0)	1.25 (0.72)	0.3	0.84	1.04	1.44	2.8	
		Placebo	11	11 (100.0)	1.69 (0.56)	0.6	1.34	1.80	2.11	2.4	
	Week 5	Tezepelumab	12	12 (100.0)	1.15 (0.78)	0.0	0.56	1.22	1.51	2.4	
		Placebo	11	11 (100.0)	1.64 (0.50)	0.9	1.26	1.83	2.11	2.3	
	Week 6	Tezepelumab	12	11 (91.7)	1.24 (0.74)	0.1	1.00	1.09	1.77	2.5	
		Placebo	11	11 (100.0)	1.61 (0.60)	0.6	1.17	1.74	2.11	2.4	
	Week 7	Tezepelumab	12	11 (91.7)	1.30 (0.70)	0.1	0.83	1.34	1.77	2.4	
		Placebo	11	11 (100.0)	1.64 (0.58)	0.6	1.26	1.51	2.23	2.5	
	Week 8	Tezepelumab	12	11 (91.7)	1.26 (0.66)	0.1	0.71	1.23	1.66	2.4	
		Placebo	11	11 (100.0)	1.78 (0.58)	0.7	1.51	1.93	2.11	2.5	
	Week 9	Tezepelumab	12	12 (100.0)	1.20 (0.76)	0.0	0.61	1.33	1.75	2.4	
		Placebo	11	11 (100.0)	1.78 (0.61)	0.5	1.34	1.74	2.40	2.6	
	Week 10	Tezepelumab	12	12 (100.0)	1.27 (0.71)	0.0	1.00	1.17	1.72	2.5	
		Placebo	11	10 (90.9)	1.67 (0.59)	0.5	1.26	1.76	2.11	2.4	
	Week 11	Tezepelumab	12	12 (100.0)	1.24 (0.76)	0.1	0.80	1.03	1.71	2.6	
		Placebo	11	10 (90.9)	1.54 (0.55)	0.4	1.26	1.63	1.94	2.1	
	Week 12	Tezepelumab	12	11 (91.7)	1.36 (0.71)	0.2	0.74	1.54	2.03	2.4	
		Placebo	11	11 (100.0)	1.71 (0.67)	0.4	1.43	1.74	2.17	3.0	
	Week 13	Tezepelumab	12	11 (91.7)	1.45 (0.69)	0.4	1.00	1.69	1.94	2.5	
		Placebo	11	11 (100.0)	1.72 (0.62)	0.3	1.46	1.80	2.03	2.9	
	Week 14	Tezepelumab	12	11 (91.7)	1.38 (0.74)	0.3	0.97	1.49	1.86	2.4	
		Placebo	11	11 (100.0)	1.76 (0.68)	0.4	1.37	1.89	2.06	2.8	
	Week 15	Tezepelumab	12	11 (91.7)	1.20 (0.73)	0.0	0.83	1.11	1.60	2.4	
		Placebo	11	11 (100.0)	1.67 (0.82)	0.4	1.11	1.53	2.09	3.0	
	Week 16	Tezepelumab	12	11 (91.7)	1.24 (0.73)	0.2	0.91	1.17	1.90	2.5	
		Placebo	11	11 (100.0)	1.54 (0.62)	0.4	1.17	1.57	1.91	2.7	
	Week 17	Tezepelumab	12	11 (91.7)	1.28 (0.75)	0.3	0.71	1.00	2.11	2.4	
		Placebo	11	11 (100.0)	1.47 (0.65)	0.4	1.00	1.57	1.83	2.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	12	11 (91.7)	1.28 (0.84)	0.0	0.71	1.29	1.66	2.9	
		Placebo	11	11 (100.0)	1.46 (0.65)	0.4	1.00	1.57	1.91	2.7	
	Week 19	Tezepelumab	12	11 (91.7)	1.28 (0.93)	0.0	0.89	1.00	1.60	3.3	
		Placebo	11	11 (100.0)	1.52 (0.66)	0.4	1.00	1.60	1.91	2.9	
	Week 20	Tezepelumab	12	11 (91.7)	1.30 (0.88)	0.1	0.80	1.00	1.80	3.1	
		Placebo	11	11 (100.0)	1.57 (0.70)	0.4	1.00	1.60	2.00	2.7	
	Week 21	Tezepelumab	12	11 (91.7)	1.38 (0.84)	0.1	0.97	1.37	1.67	3.2	
		Placebo	11	11 (100.0)	1.57 (0.72)	0.1	1.23	1.60	2.00	2.9	
	Week 22	Tezepelumab	12	11 (91.7)	1.25 (0.73)	0.0	0.86	1.00	1.74	2.5	
		Placebo	11	11 (100.0)	1.54 (0.83)	0.0	1.00	1.69	2.09	2.7	
	Week 23	Tezepelumab	12	11 (91.7)	1.29 (0.81)	0.0	0.83	1.00	1.80	2.9	
		Placebo	11	11 (100.0)	1.53 (0.85)	0.0	1.00	1.91	2.00	2.8	
	Week 24	Tezepelumab	12	11 (91.7)	1.28 (0.74)	0.0	0.71	1.43	1.73	2.5	
		Placebo	11	11 (100.0)	1.63 (0.77)	0.0	1.06	2.00	2.06	2.7	
	Week 25	Tezepelumab	12	11 (91.7)	1.47 (0.95)	0.0	0.83	1.49	2.31	3.0	
		Placebo	11	11 (100.0)	1.46 (0.76)	0.0	1.00	1.40	2.00	2.8	
	Week 26	Tezepelumab	12	11 (91.7)	1.51 (0.86)	0.0	1.00	1.49	2.14	3.1	
		Placebo	11	11 (100.0)	1.44 (0.74)	0.0	1.00	1.43	2.00	2.6	
	Week 27	Tezepelumab	12	10 (83.3)	1.51 (0.94)	0.0	1.00	1.40	1.80	3.2	
		Placebo	11	11 (100.0)	1.57 (0.81)	0.0	1.00	1.57	2.20	2.7	
	Week 28	Tezepelumab	12	9 (75.0)	1.61 (0.75)	0.8	1.00	1.43	1.71	3.0	
		Placebo	11	11 (100.0)	1.62 (0.87)	0.0	1.03	1.49	2.40	2.9	
	Week 29	Tezepelumab	12	8 (66.7)	1.37 (0.92)	0.2	1.03	1.10	1.55	3.4	
		Placebo	11	11 (100.0)	1.63 (0.89)	0.0	1.00	1.83	2.37	2.9	
	Week 30	Tezepelumab	12	10 (83.3)	1.35 (1.01)	0.2	0.80	1.05	1.77	3.4	
		Placebo	11	11 (100.0)	1.57 (0.90)	0.0	1.00	1.74	2.23	2.8	
	Week 31	Tezepelumab	12	9 (75.0)	1.48 (1.01)	0.2	0.97	1.23	1.77	3.5	
		Placebo	11	11 (100.0)	1.57 (0.85)	0.0	1.00	1.60	2.06	2.9	
	Week 32	Tezepelumab	12	10 (83.3)	1.42 (0.99)	0.3	0.86	1.01	2.00	3.6	
		Placebo	11	11 (100.0)	1.62 (0.88)	0.0	1.00	1.69	2.06	2.9	
	Week 33	Tezepelumab	12	10 (83.3)	1.44 (0.88)	0.7	0.83	1.11	1.91	3.5	
		Placebo	11	11 (100.0)	1.53 (0.78)	0.0	1.00	1.71	2.00	2.9	
	Week 34	Tezepelumab	12	10 (83.3)	1.34 (0.85)	0.5	0.80	1.03	1.70	3.4	
		Placebo	11	11 (100.0)	1.63 (0.87)	0.0	1.00	1.54	2.23	2.9	
	Week 35	Tezepelumab	12	10 (83.3)	1.30 (0.91)	0.3	0.80	1.09	1.60	3.4	
		Placebo	11	11 (100.0)	1.59 (0.92)	0.0	1.00	1.31	2.23	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	12	10 (83.3)	1.21 (0.92)	0.1	0.83	0.99	1.63	3.2	
		Placebo	11	11 (100.0)	1.54 (0.86)	0.0	1.00	1.34	2.03	3.0	
	Week 37	Tezepelumab	12	10 (83.3)	1.34 (0.92)	0.2	0.91	1.08	1.89	3.3	
		Placebo	11	11 (100.0)	1.44 (0.84)	0.0	1.00	1.40	2.08	3.0	
	Week 38	Tezepelumab	12	9 (75.0)	1.43 (1.01)	0.3	0.91	1.00	2.00	3.6	
		Placebo	11	11 (100.0)	1.56 (0.78)	0.0	1.00	1.54	2.03	3.0	
	Week 39	Tezepelumab	12	9 (75.0)	1.48 (0.92)	0.5	1.00	1.00	1.80	3.4	
		Placebo	11	11 (100.0)	1.55 (0.84)	0.0	1.00	1.54	2.06	3.0	
	Week 40	Tezepelumab	12	9 (75.0)	1.52 (0.92)	0.6	0.94	1.00	2.06	3.3	
		Placebo	11	11 (100.0)	1.61 (0.89)	0.0	1.00	1.60	2.09	3.0	
	Week 41	Tezepelumab	12	8 (66.7)	1.46 (0.94)	0.4	0.97	1.05	2.04	3.2	
		Placebo	11	11 (100.0)	1.52 (0.75)	0.0	1.09	1.57	1.92	3.0	
	Week 42	Tezepelumab	12	8 (66.7)	1.40 (0.88)	0.3	0.90	1.02	1.99	3.1	
		Placebo	11	11 (100.0)	1.51 (0.84)	0.0	0.97	1.50	2.26	3.0	
	Week 43	Tezepelumab	12	8 (66.7)	1.39 (0.96)	0.2	0.98	1.00	1.90	3.2	
		Placebo	11	11 (100.0)	1.55 (0.85)	0.0	1.00	1.40	2.27	3.0	
	Week 44	Tezepelumab	12	8 (66.7)	1.35 (0.95)	0.4	0.86	1.00	1.80	3.1	
		Placebo	11	11 (100.0)	1.49 (0.88)	0.0	1.00	1.40	2.24	3.0	
	Week 45	Tezepelumab	12	8 (66.7)	1.34 (0.92)	0.3	0.84	1.01	1.92	2.9	
		Placebo	11	11 (100.0)	1.42 (0.80)	0.0	1.00	1.26	2.10	2.9	
	Week 46	Tezepelumab	12	8 (66.7)	1.35 (0.89)	0.2	0.94	1.02	1.90	2.8	
		Placebo	11	11 (100.0)	1.45 (0.77)	0.0	1.00	1.40	2.23	2.6	
	Week 47	Tezepelumab	12	8 (66.7)	1.35 (1.00)	0.2	0.59	1.02	2.25	2.8	
		Placebo	11	11 (100.0)	1.39 (0.86)	0.0	1.00	1.40	2.10	2.7	
	Week 48	Tezepelumab	12	7 (58.3)	1.56 (0.86)	0.9	0.91	1.06	2.60	2.9	
		Placebo	11	11 (100.0)	1.38 (0.83)	0.0	1.00	1.40	2.07	2.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	12	12 (100.0)	-0.13 (0.43)	-0.9	-0.29	-0.04	0.06	0.6	0.23 [-0.59, 1.05]
		Placebo	11	11 (100.0)	-0.23 (0.51)	-1.4	-0.57	0.00	0.09	0.3	
	Week 2	Tezepelumab	12	12 (100.0)	-0.19 (0.37)	-0.9	-0.43	-0.06	0.01	0.3	-0.20 [-1.02, 0.62]
		Placebo	11	11 (100.0)	-0.11 (0.36)	-0.7	-0.37	-0.05	0.23	0.5	
	Week 3	Tezepelumab	12	12 (100.0)	-0.21 (0.51)	-1.3	-0.40	-0.11	0.06	0.5	0.28 [-0.54, 1.10]
		Placebo	11	11 (100.0)	-0.38 (0.67)	-1.9	-0.71	-0.36	0.06	0.6	
	Week 4	Tezepelumab	12	12 (100.0)	-0.21 (0.60)	-1.5	-0.50	-0.07	0.17	0.7	0.18 [-0.64, 1.00]
		Placebo	11	11 (100.0)	-0.32 (0.63)	-1.6	-0.73	-0.34	0.03	0.8	
	Week 5	Tezepelumab	12	12 (100.0)	-0.31 (0.69)	-2.0	-0.61	-0.26	0.25	0.5	0.09 [-0.73, 0.91]
		Placebo	11	11 (100.0)	-0.38 (0.83)	-2.3	-0.77	-0.20	0.06	0.8	
	Week 6	Tezepelumab	12	11 (91.7)	-0.26 (0.70)	-2.0	-0.63	-0.11	0.29	0.4	0.18 [-0.66, 1.02]
		Placebo	11	11 (100.0)	-0.41 (0.87)	-2.4	-0.86	-0.23	0.14	0.7	
	Week 7	Tezepelumab	12	11 (91.7)	-0.20 (0.79)	-2.0	-0.63	-0.06	0.34	0.8	0.21 [-0.63, 1.04]
		Placebo	11	11 (100.0)	-0.37 (0.86)	-2.2	-0.77	-0.49	0.12	0.9	
	Week 8	Tezepelumab	12	11 (91.7)	-0.24 (0.77)	-2.0	-0.63	-0.17	0.23	0.8	-0.02 [-0.85, 0.82]
		Placebo	11	11 (100.0)	-0.23 (0.74)	-1.5	-0.83	0.00	0.18	0.9	
	Week 9	Tezepelumab	12	12 (100.0)	-0.25 (0.78)	-1.9	-0.77	-0.16	0.30	0.8	-0.03 [-0.85, 0.79]
		Placebo	11	11 (100.0)	-0.23 (0.87)	-1.9	-0.71	-0.03	0.23	1.0	
	Week 10	Tezepelumab	12	12 (100.0)	-0.19 (0.82)	-1.8	-0.79	-0.08	0.41	1.0	0.14 [-0.70, 0.98]
		Placebo	11	10 (90.9)	-0.30 (0.77)	-1.3	-0.57	-0.45	-0.11	1.0	
	Week 11	Tezepelumab	12	12 (100.0)	-0.21 (0.71)	-1.9	-0.51	-0.04	0.27	0.8	0.31 [-0.54, 1.15]
		Placebo	11	10 (90.9)	-0.44 (0.77)	-1.5	-0.75	-0.59	0.00	0.8	
	Week 12	Tezepelumab	12	11 (91.7)	-0.23 (0.87)	-1.9	-0.63	-0.35	0.26	1.4	0.09 [-0.75, 0.93]
		Placebo	11	11 (100.0)	-0.31 (0.76)	-1.5	-0.72	-0.34	0.60	0.7	
	Week 13	Tezepelumab	12	11 (91.7)	-0.14 (0.84)	-1.7	-0.63	-0.26	0.57	1.3	0.18 [-0.66, 1.01]
		Placebo	11	11 (100.0)	-0.29 (0.91)	-1.6	-0.77	-0.47	0.49	1.4	
	Week 14	Tezepelumab	12	11 (91.7)	-0.21 (0.81)	-1.8	-0.75	-0.14	0.37	1.0	0.05 [-0.79, 0.88]
		Placebo	11	11 (100.0)	-0.25 (0.88)	-1.4	-0.87	-0.51	0.35	1.7	
	Week 15	Tezepelumab	12	11 (91.7)	-0.38 (0.75)	-1.9	-0.97	-0.29	0.28	0.7	-0.06 [-0.89, 0.78]
		Placebo	11	11 (100.0)	-0.34 (0.68)	-1.4	-0.81	-0.65	0.23	0.8	
	Week 16	Tezepelumab	12	11 (91.7)	-0.35 (0.72)	-1.9	-0.80	-0.23	0.16	0.6	0.16 [-0.68, 0.99]
		Placebo	11	11 (100.0)	-0.47 (0.84)	-1.8	-1.06	-0.60	0.29	1.1	
	Week 17	Tezepelumab	12	11 (91.7)	-0.31 (0.69)	-1.8	-0.63	-0.20	0.31	0.6	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	-0.54 (0.91)	-2.2	-1.00	-0.77	0.29	1.1	
	Week 18	Tezepelumab	12	11 (91.7)	-0.31 (0.93)	-1.8	-1.03	-0.28	0.09	1.6	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.55 (0.77)	-1.9	-1.00	-0.69	0.32	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	12	11 (91.7)	-0.31 (1.08)	-1.9	-1.06	-0.44	0.34	2.1	0.19 [-0.64, 1.03]
		Placebo	11	11 (100.0)	-0.49 (0.80)	-1.7	-1.03	-0.63	0.43	0.7	
	Week 20	Tezepelumab	12	11 (91.7)	-0.29 (1.00)	-1.7	-1.09	-0.34	0.26	1.8	0.18 [-0.66, 1.02]
		Placebo	11	11 (100.0)	-0.45 (0.73)	-1.4	-1.03	-0.60	0.32	0.5	
	Week 21	Tezepelumab	12	11 (91.7)	-0.21 (1.04)	-1.8	-0.97	-0.43	0.63	1.9	0.24 [-0.60, 1.08]
		Placebo	11	11 (100.0)	-0.44 (0.89)	-1.7	-1.00	-0.60	0.52	0.9	
	Week 22	Tezepelumab	12	11 (91.7)	-0.34 (0.86)	-1.6	-1.06	-0.43	0.31	1.2	0.17 [-0.67, 1.00]
		Placebo	11	11 (100.0)	-0.48 (0.76)	-1.8	-1.00	-0.57	0.26	0.6	
	Week 23	Tezepelumab	12	11 (91.7)	-0.30 (0.97)	-1.6	-1.11	-0.31	0.29	1.6	0.21 [-0.63, 1.05]
		Placebo	11	11 (100.0)	-0.48 (0.79)	-1.8	-1.00	-0.60	0.23	0.7	
	Week 24	Tezepelumab	12	11 (91.7)	-0.31 (0.93)	-1.6	-1.00	-0.34	0.85	1.2	0.09 [-0.75, 0.93]
		Placebo	11	11 (100.0)	-0.39 (0.85)	-1.8	-1.00	-0.60	0.32	0.9	
	Week 25	Tezepelumab	12	11 (91.7)	-0.12 (1.24)	-1.7	-1.11	-0.26	0.91	2.2	0.39 [-0.45, 1.23]
		Placebo	11	11 (100.0)	-0.55 (1.00)	-2.5	-1.00	-0.51	0.43	0.7	
	Week 26	Tezepelumab	12	11 (91.7)	-0.08 (1.12)	-1.5	-0.97	-0.20	1.05	1.8	0.49 [-0.36, 1.34]
		Placebo	11	11 (100.0)	-0.58 (0.88)	-2.1	-1.03	-0.54	0.23	0.6	
	Week 27	Tezepelumab	12	10 (83.3)	0.02 (1.29)	-1.5	-1.00	-0.14	1.11	1.9	0.44 [-0.43, 1.31]
		Placebo	11	11 (100.0)	-0.44 (0.79)	-1.8	-1.00	-0.42	0.38	0.5	
	Week 28	Tezepelumab	12	9 (75.0)	0.07 (1.24)	-1.4	-0.94	-0.11	1.09	1.8	0.46 [-0.44, 1.35]
		Placebo	11	11 (100.0)	-0.39 (0.78)	-1.8	-0.97	-0.53	0.46	0.7	
	Week 29	Tezepelumab	12	8 (66.7)	-0.26 (1.22)	-1.9	-1.15	-0.24	0.24	2.1	0.12 [-0.79, 1.03]
		Placebo	11	11 (100.0)	-0.39 (0.90)	-1.8	-1.00	-0.50	0.51	0.9	
	Week 30	Tezepelumab	12	10 (83.3)	-0.14 (1.31)	-1.9	-1.14	-0.26	0.23	2.1	0.29 [-0.57, 1.15]
		Placebo	11	11 (100.0)	-0.44 (0.73)	-1.8	-1.00	-0.60	0.43	0.5	
	Week 31	Tezepelumab	12	9 (75.0)	-0.06 (1.39)	-1.9	-1.14	0.03	0.34	2.2	0.35 [-0.53, 1.24]
		Placebo	11	11 (100.0)	-0.45 (0.74)	-1.8	-0.98	-0.60	0.37	0.5	
	Week 32	Tezepelumab	12	10 (83.3)	-0.07 (1.31)	-1.8	-1.14	-0.01	0.26	2.3	0.30 [-0.57, 1.16]
		Placebo	11	11 (100.0)	-0.39 (0.77)	-1.8	-0.99	-0.54	0.23	0.9	
	Week 33	Tezepelumab	12	10 (83.3)	-0.05 (1.17)	-1.5	-1.14	-0.08	0.34	2.2	0.41 [-0.45, 1.28]
		Placebo	11	11 (100.0)	-0.48 (0.88)	-1.9	-1.00	-0.54	0.29	0.9	
	Week 34	Tezepelumab	12	10 (83.3)	-0.15 (1.15)	-1.6	-1.14	-0.13	0.43	2.1	0.23 [-0.63, 1.09]
		Placebo	11	11 (100.0)	-0.38 (0.76)	-1.8	-0.87	-0.54	0.55	0.7	
	Week 35	Tezepelumab	12	10 (83.3)	-0.19 (1.21)	-1.8	-1.14	-0.22	0.51	2.1	0.24 [-0.62, 1.10]
		Placebo	11	11 (100.0)	-0.43 (0.71)	-1.8	-0.77	-0.60	0.34	0.6	
	Week 36	Tezepelumab	12	10 (83.3)	-0.29 (1.16)	-1.9	-0.97	-0.36	0.43	1.9	0.19 [-0.67, 1.05]
		Placebo	11	11 (100.0)	-0.47 (0.77)	-1.7	-0.87	-0.71	0.60	0.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMH0: Course of ASD weekly daytime score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	12	10 (83.3)	-0.15 (1.20)	-1.9	-0.94	-0.17	0.49	2.0	0.42 [-0.44, 1.29]
		Placebo	11	11 (100.0)	-0.57 (0.79)	-1.8	-1.00	-0.66	0.14	0.7	
	Week 38	Tezepelumab	12	9 (75.0)	-0.12 (1.34)	-1.8	-1.03	-0.09	0.26	2.3	0.30 [-0.58, 1.19]
		Placebo	11	11 (100.0)	-0.45 (0.85)	-1.8	-0.77	-0.57	0.60	0.7	
	Week 39	Tezepelumab	12	9 (75.0)	-0.07 (1.31)	-1.7	-0.94	0.06	0.29	2.1	0.37 [-0.52, 1.26]
		Placebo	11	11 (100.0)	-0.46 (0.82)	-1.8	-1.00	-0.66	0.57	0.9	
	Week 40	Tezepelumab	12	9 (75.0)	-0.03 (1.30)	-1.7	-1.00	0.23	0.31	2.0	0.35 [-0.54, 1.24]
		Placebo	11	11 (100.0)	-0.40 (0.81)	-1.8	-0.77	-0.69	0.63	0.9	
	Week 41	Tezepelumab	12	8 (66.7)	-0.06 (1.40)	-1.7	-1.33	-0.11	1.10	1.9	0.37 [-0.55, 1.29]
		Placebo	11	11 (100.0)	-0.50 (1.00)	-2.1	-1.00	-0.68	0.63	1.0	
	Week 42	Tezepelumab	12	8 (66.7)	-0.12 (1.36)	-1.8	-1.38	-0.16	1.04	1.8	0.35 [-0.56, 1.27]
		Placebo	11	11 (100.0)	-0.51 (0.84)	-1.8	-1.00	-0.60	0.46	0.9	
	Week 43	Tezepelumab	12	8 (66.7)	-0.13 (1.44)	-1.9	-1.35	-0.31	1.15	1.9	0.29 [-0.63, 1.20]
		Placebo	11	11 (100.0)	-0.46 (0.91)	-1.8	-1.06	-0.60	0.63	1.1	
	Week 44	Tezepelumab	12	8 (66.7)	-0.17 (1.37)	-1.7	-1.33	-0.31	0.91	1.8	0.32 [-0.60, 1.24]
		Placebo	11	11 (100.0)	-0.52 (0.88)	-1.8	-1.06	-0.68	0.29	0.9	
	Week 45	Tezepelumab	12	8 (66.7)	-0.18 (1.35)	-1.8	-1.31	-0.29	0.90	1.7	0.36 [-0.56, 1.28]
		Placebo	11	11 (100.0)	-0.59 (0.99)	-2.4	-1.06	-0.51	0.49	0.8	
	Week 46	Tezepelumab	12	8 (66.7)	-0.17 (1.34)	-1.9	-1.31	-0.20	0.90	1.7	0.37 [-0.55, 1.29]
		Placebo	11	11 (100.0)	-0.56 (0.80)	-1.8	-1.00	-0.57	0.26	0.7	
	Week 47	Tezepelumab	12	8 (66.7)	-0.18 (1.41)	-1.9	-1.37	-0.49	1.21	1.7	0.42 [-0.50, 1.34]
		Placebo	11	11 (100.0)	-0.62 (0.73)	-1.8	-1.06	-0.77	-0.11	0.7	
	Week 48	Tezepelumab	12	7 (58.3)	0.12 (1.30)	-1.7	-1.03	0.23	1.66	1.7	0.77 [-0.22, 1.75]
		Placebo	11	11 (100.0)	-0.63 (0.73)	-1.8	-1.06	-0.77	-0.06	0.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	12	12 (100.0)	-0.31 (0.21)	(-0.74, 0.11)	-0.21 (0.31)	(-0.83, 0.41)	0.493
	Placebo	11	11 (100.0)	-0.10 (0.22)	(-0.54, 0.34)			
Week 2	Tezepelumab	12	12 (100.0)	-0.37 (0.21)	(-0.80, 0.05)	-0.40 (0.31)	(-1.02, 0.22)	0.207
	Placebo	11	11 (100.0)	0.02 (0.22)	(-0.42, 0.46)			
Week 3	Tezepelumab	12	12 (100.0)	-0.40 (0.21)	(-0.82, 0.03)	-0.16 (0.31)	(-0.78, 0.46)	0.617
	Placebo	11	11 (100.0)	-0.24 (0.22)	(-0.68, 0.20)			
Week 4	Tezepelumab	12	12 (100.0)	-0.39 (0.21)	(-0.82, 0.03)	-0.21 (0.31)	(-0.83, 0.41)	0.506
	Placebo	11	11 (100.0)	-0.19 (0.22)	(-0.63, 0.26)			
Week 5	Tezepelumab	12	12 (100.0)	-0.49 (0.21)	(-0.92, -0.07)	-0.25 (0.31)	(-0.87, 0.37)	0.420
	Placebo	11	11 (100.0)	-0.24 (0.22)	(-0.68, 0.20)			
Week 6	Tezepelumab	12	11 (91.7)	-0.50 (0.21)	(-0.93, -0.08)	-0.23 (0.31)	(-0.85, 0.39)	0.458
	Placebo	11	11 (100.0)	-0.27 (0.22)	(-0.71, 0.17)			
Week 7	Tezepelumab	12	11 (91.7)	-0.44 (0.22)	(-0.87, -0.02)	-0.21 (0.31)	(-0.83, 0.41)	0.503
	Placebo	11	11 (100.0)	-0.23 (0.22)	(-0.67, 0.21)			
Week 8	Tezepelumab	12	11 (91.7)	-0.49 (0.21)	(-0.92, -0.06)	-0.40 (0.31)	(-1.02, 0.22)	0.208
	Placebo	11	11 (100.0)	-0.09 (0.22)	(-0.54, 0.35)			
Week 9	Tezepelumab	12	12 (100.0)	-0.44 (0.21)	(-0.87, -0.01)	-0.35 (0.31)	(-0.97, 0.27)	0.268
	Placebo	11	11 (100.0)	-0.09 (0.22)	(-0.53, 0.35)			
Week 10	Tezepelumab	12	12 (100.0)	-0.38 (0.21)	(-0.80, 0.05)	-0.27 (0.31)	(-0.89, 0.35)	0.390
	Placebo	11	10 (90.9)	-0.11 (0.22)	(-0.55, 0.34)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	12	12 (100.0)	-0.40 (0.21)	(-0.82, 0.03)	-0.17 (0.31)	(-0.79, 0.45)	0.586
	Placebo	11	10 (90.9)	-0.23 (0.22)	(-0.67, 0.21)			
Week 12	Tezepelumab	12	11 (91.7)	-0.38 (0.21)	(-0.81, 0.04)	-0.21 (0.31)	(-0.83, 0.41)	0.498
	Placebo	11	11 (100.0)	-0.17 (0.22)	(-0.61, 0.27)			
Week 13	Tezepelumab	12	11 (91.7)	-0.28 (0.22)	(-0.71, 0.15)	-0.13 (0.31)	(-0.75, 0.49)	0.680
	Placebo	11	11 (100.0)	-0.15 (0.22)	(-0.59, 0.29)			
Week 14	Tezepelumab	12	11 (91.7)	-0.36 (0.22)	(-0.79, 0.07)	-0.24 (0.31)	(-0.86, 0.38)	0.446
	Placebo	11	11 (100.0)	-0.12 (0.22)	(-0.56, 0.32)			
Week 15	Tezepelumab	12	11 (91.7)	-0.53 (0.22)	(-0.96, -0.10)	-0.32 (0.31)	(-0.94, 0.31)	0.313
	Placebo	11	11 (100.0)	-0.21 (0.22)	(-0.65, 0.23)			
Week 16	Tezepelumab	12	11 (91.7)	-0.49 (0.22)	(-0.92, -0.06)	-0.15 (0.31)	(-0.78, 0.47)	0.624
	Placebo	11	11 (100.0)	-0.33 (0.22)	(-0.78, 0.11)			
Week 17	Tezepelumab	12	11 (91.7)	-0.45 (0.22)	(-0.89, -0.02)	-0.05 (0.31)	(-0.67, 0.58)	0.884
	Placebo	11	11 (100.0)	-0.41 (0.22)	(-0.85, 0.03)			
Week 18	Tezepelumab	12	11 (91.7)	-0.44 (0.22)	(-0.88, -0.01)	-0.02 (0.31)	(-0.65, 0.60)	0.941
	Placebo	11	11 (100.0)	-0.42 (0.22)	(-0.86, 0.02)			
Week 19	Tezepelumab	12	11 (91.7)	-0.44 (0.22)	(-0.88, -0.01)	-0.09 (0.31)	(-0.71, 0.54)	0.788
	Placebo	11	11 (100.0)	-0.36 (0.22)	(-0.80, 0.08)			
Week 20	Tezepelumab	12	11 (91.7)	-0.43 (0.22)	(-0.86, 0.01)	-0.11 (0.31)	(-0.74, 0.51)	0.721
	Placebo	11	11 (100.0)	-0.31 (0.22)	(-0.75, 0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	12	11 (91.7)	-0.34 (0.22)	(-0.78, 0.09)	-0.04 (0.31)	(-0.66, 0.59)	0.907
	Placebo	11	11 (100.0)	-0.31 (0.22)	(-0.75, 0.13)			
Week 22	Tezepelumab	12	11 (91.7)	-0.47 (0.22)	(-0.91, -0.04)	-0.13 (0.31)	(-0.76, 0.50)	0.679
	Placebo	11	11 (100.0)	-0.34 (0.22)	(-0.78, 0.10)			
Week 23	Tezepelumab	12	11 (91.7)	-0.43 (0.22)	(-0.86, 0.01)	-0.08 (0.31)	(-0.70, 0.55)	0.806
	Placebo	11	11 (100.0)	-0.35 (0.22)	(-0.79, 0.09)			
Week 24	Tezepelumab	12	11 (91.7)	-0.44 (0.22)	(-0.87, 0.00)	-0.18 (0.31)	(-0.81, 0.44)	0.560
	Placebo	11	11 (100.0)	-0.25 (0.22)	(-0.69, 0.19)			
Week 25	Tezepelumab	12	11 (91.7)	-0.24 (0.22)	(-0.68, 0.20)	0.18 (0.32)	(-0.45, 0.80)	0.578
	Placebo	11	11 (100.0)	-0.42 (0.22)	(-0.86, 0.02)			
Week 26	Tezepelumab	12	11 (91.7)	-0.21 (0.22)	(-0.65, 0.23)	0.23 (0.32)	(-0.40, 0.86)	0.467
	Placebo	11	11 (100.0)	-0.44 (0.22)	(-0.88, 0.00)			
Week 27	Tezepelumab	12	10 (83.3)	-0.12 (0.22)	(-0.56, 0.32)	0.19 (0.32)	(-0.44, 0.82)	0.548
	Placebo	11	11 (100.0)	-0.31 (0.22)	(-0.75, 0.13)			
Week 28	Tezepelumab	12	9 (75.0)	-0.16 (0.22)	(-0.61, 0.28)	0.10 (0.32)	(-0.54, 0.73)	0.765
	Placebo	11	11 (100.0)	-0.26 (0.22)	(-0.70, 0.18)			
Week 29	Tezepelumab	12	8 (66.7)	-0.25 (0.23)	(-0.70, 0.20)	0.00 (0.32)	(-0.63, 0.64)	0.994
	Placebo	11	11 (100.0)	-0.25 (0.22)	(-0.69, 0.19)			
Week 30	Tezepelumab	12	10 (83.3)	-0.28 (0.23)	(-0.73, 0.17)	0.02 (0.32)	(-0.61, 0.66)	0.945
	Placebo	11	11 (100.0)	-0.30 (0.22)	(-0.74, 0.14)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	12	9 (75.0)	-0.23 (0.23)	(-0.68, 0.23)	0.08 (0.32)	(-0.55, 0.72)	0.792
	Placebo	11	11 (100.0)	-0.31 (0.22)	(-0.75, 0.13)			
Week 32	Tezepelumab	12	10 (83.3)	-0.22 (0.23)	(-0.67, 0.23)	0.03 (0.32)	(-0.60, 0.67)	0.920
	Placebo	11	11 (100.0)	-0.25 (0.22)	(-0.69, 0.19)			
Week 33	Tezepelumab	12	10 (83.3)	-0.20 (0.23)	(-0.66, 0.25)	0.14 (0.32)	(-0.50, 0.78)	0.659
	Placebo	11	11 (100.0)	-0.34 (0.22)	(-0.79, 0.10)			
Week 34	Tezepelumab	12	10 (83.3)	-0.30 (0.23)	(-0.76, 0.15)	-0.06 (0.32)	(-0.70, 0.58)	0.856
	Placebo	11	11 (100.0)	-0.24 (0.22)	(-0.68, 0.20)			
Week 35	Tezepelumab	12	10 (83.3)	-0.34 (0.23)	(-0.80, 0.12)	-0.05 (0.32)	(-0.69, 0.59)	0.877
	Placebo	11	11 (100.0)	-0.29 (0.22)	(-0.73, 0.15)			
Week 36	Tezepelumab	12	10 (83.3)	-0.44 (0.23)	(-0.89, 0.02)	-0.10 (0.32)	(-0.74, 0.54)	0.751
	Placebo	11	11 (100.0)	-0.33 (0.22)	(-0.78, 0.11)			
Week 37	Tezepelumab	12	10 (83.3)	-0.30 (0.23)	(-0.76, 0.16)	0.14 (0.32)	(-0.50, 0.78)	0.672
	Placebo	11	11 (100.0)	-0.44 (0.22)	(-0.88, 0.00)			
Week 38	Tezepelumab	12	9 (75.0)	-0.32 (0.23)	(-0.78, 0.14)	-0.01 (0.32)	(-0.65, 0.64)	0.985
	Placebo	11	11 (100.0)	-0.31 (0.22)	(-0.75, 0.13)			
Week 39	Tezepelumab	12	9 (75.0)	-0.26 (0.23)	(-0.73, 0.20)	0.06 (0.32)	(-0.59, 0.70)	0.858
	Placebo	11	11 (100.0)	-0.32 (0.22)	(-0.76, 0.12)			
Week 40	Tezepelumab	12	9 (75.0)	-0.22 (0.24)	(-0.69, 0.24)	0.04 (0.33)	(-0.61, 0.69)	0.903
	Placebo	11	11 (100.0)	-0.26 (0.22)	(-0.71, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC_IBMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	12	8 (66.7)	-0.21 (0.24)	(-0.69, 0.26)	0.15 (0.33)	(-0.50, 0.80)	0.650
	Placebo	11	11 (100.0)	-0.36 (0.22)	(-0.80, 0.08)			
Week 42	Tezepelumab	12	8 (66.7)	-0.27 (0.24)	(-0.75, 0.20)	0.10 (0.33)	(-0.56, 0.75)	0.768
	Placebo	11	11 (100.0)	-0.37 (0.22)	(-0.81, 0.07)			
Week 43	Tezepelumab	12	8 (66.7)	-0.28 (0.24)	(-0.76, 0.21)	0.04 (0.33)	(-0.62, 0.70)	0.893
	Placebo	11	11 (100.0)	-0.32 (0.22)	(-0.76, 0.12)			
Week 44	Tezepelumab	12	8 (66.7)	-0.32 (0.25)	(-0.81, 0.17)	0.07 (0.33)	(-0.60, 0.73)	0.843
	Placebo	11	11 (100.0)	-0.39 (0.22)	(-0.83, 0.05)			
Week 45	Tezepelumab	12	8 (66.7)	-0.33 (0.25)	(-0.82, 0.16)	0.13 (0.33)	(-0.54, 0.80)	0.698
	Placebo	11	11 (100.0)	-0.46 (0.22)	(-0.90, -0.02)			
Week 46	Tezepelumab	12	8 (66.7)	-0.32 (0.25)	(-0.82, 0.17)	0.10 (0.34)	(-0.56, 0.77)	0.756
	Placebo	11	11 (100.0)	-0.43 (0.22)	(-0.87, 0.01)			
Week 47	Tezepelumab	12	8 (66.7)	-0.33 (0.25)	(-0.82, 0.17)	0.16 (0.34)	(-0.51, 0.83)	0.640
	Placebo	11	11 (100.0)	-0.48 (0.22)	(-0.93, -0.04)			
Week 48	Tezepelumab	12	7 (58.3)	-0.25 (0.25)	(-0.76, 0.25)	0.24 (0.34)	(-0.44, 0.92)	0.482
	Placebo	11	11 (100.0)	-0.50 (0.22)	(-0.94, -0.05)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	55	55 (100.0)	1.27 (0.63)	0.1	0.91	1.17	1.63	2.8	
		Placebo	40	40 (100.0)	1.37 (0.54)	0.6	0.90	1.40	1.71	2.6	
	Week 1	Tezepelumab	55	54 (98.2)	1.10 (0.59)	0.1	0.71	1.00	1.50	2.9	
		Placebo	40	40 (100.0)	1.30 (0.52)	0.5	0.88	1.29	1.57	2.8	
	Week 2	Tezepelumab	55	54 (98.2)	1.02 (0.61)	0.0	0.66	1.03	1.40	2.6	
		Placebo	40	39 (97.5)	1.26 (0.51)	0.2	0.86	1.20	1.63	2.2	
	Week 3	Tezepelumab	55	55 (100.0)	1.01 (0.58)	0.0	0.69	1.00	1.31	2.5	
		Placebo	40	38 (95.0)	1.18 (0.56)	0.0	0.83	1.11	1.57	2.2	
	Week 4	Tezepelumab	55	55 (100.0)	0.96 (0.60)	0.0	0.54	0.94	1.34	2.5	
		Placebo	40	39 (97.5)	1.17 (0.51)	0.1	0.80	1.06	1.57	2.4	
	Week 5	Tezepelumab	55	54 (98.2)	0.88 (0.58)	0.0	0.51	0.84	1.31	2.3	
		Placebo	40	39 (97.5)	1.10 (0.53)	0.1	0.73	1.00	1.54	2.3	
	Week 6	Tezepelumab	55	53 (96.4)	0.96 (0.64)	0.0	0.51	0.86	1.40	2.6	
		Placebo	40	40 (100.0)	1.19 (0.55)	0.1	0.78	1.07	1.54	3.0	
	Week 7	Tezepelumab	55	53 (96.4)	0.95 (0.61)	0.0	0.66	0.89	1.29	2.6	
		Placebo	40	40 (100.0)	1.11 (0.57)	0.0	0.76	1.00	1.51	2.4	
	Week 8	Tezepelumab	55	53 (96.4)	0.89 (0.62)	0.0	0.54	0.80	1.23	2.5	
		Placebo	40	39 (97.5)	1.13 (0.52)	0.1	0.77	1.00	1.51	2.6	
	Week 9	Tezepelumab	55	55 (100.0)	0.87 (0.59)	0.0	0.43	0.80	1.32	2.3	
		Placebo	40	40 (100.0)	1.12 (0.56)	0.1	0.74	1.00	1.44	2.5	
	Week 10	Tezepelumab	55	54 (98.2)	0.85 (0.65)	0.0	0.30	0.79	1.20	2.6	
		Placebo	40	40 (100.0)	1.09 (0.51)	0.1	0.80	0.97	1.53	2.4	
	Week 11	Tezepelumab	55	54 (98.2)	0.87 (0.63)	0.0	0.37	0.85	1.30	2.4	
		Placebo	40	40 (100.0)	1.03 (0.52)	0.0	0.76	0.93	1.39	2.5	
	Week 12	Tezepelumab	55	53 (96.4)	0.83 (0.63)	0.0	0.29	0.86	1.20	2.8	
		Placebo	40	38 (95.0)	1.03 (0.53)	0.1	0.66	0.99	1.40	2.3	
	Week 13	Tezepelumab	55	51 (92.7)	0.85 (0.62)	0.0	0.43	0.74	1.20	2.6	
		Placebo	40	39 (97.5)	0.98 (0.50)	0.1	0.60	0.87	1.40	2.1	
	Week 14	Tezepelumab	55	52 (94.5)	0.87 (0.66)	0.0	0.43	0.88	1.23	2.5	
		Placebo	40	38 (95.0)	1.00 (0.50)	0.1	0.67	0.94	1.37	2.1	
	Week 15	Tezepelumab	55	52 (94.5)	0.82 (0.58)	0.0	0.43	0.80	1.20	2.2	
		Placebo	40	39 (97.5)	0.97 (0.55)	0.0	0.63	0.80	1.34	2.1	
	Week 16	Tezepelumab	55	53 (96.4)	0.81 (0.59)	0.0	0.31	0.83	1.17	2.1	
		Placebo	40	38 (95.0)	0.95 (0.49)	0.0	0.67	0.94	1.32	2.2	
	Week 17	Tezepelumab	55	53 (96.4)	0.82 (0.61)	0.0	0.31	0.72	1.20	2.3	
		Placebo	40	38 (95.0)	1.01 (0.53)	0.0	0.69	0.90	1.40	2.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	55	53 (96.4)	0.85 (0.64)	0.0	0.37	0.80	1.26	2.5	
		Placebo	40	40 (100.0)	1.06 (0.53)	0.1	0.71	0.96	1.43	2.1	
	Week 19	Tezepelumab	55	53 (96.4)	0.81 (0.63)	0.0	0.29	0.74	1.14	2.3	
		Placebo	40	40 (100.0)	1.01 (0.49)	0.0	0.67	1.01	1.28	2.1	
	Week 20	Tezepelumab	55	52 (94.5)	0.79 (0.63)	0.0	0.32	0.73	1.21	2.4	
		Placebo	40	39 (97.5)	1.03 (0.52)	0.0	0.74	0.94	1.40	2.1	
	Week 21	Tezepelumab	55	50 (90.9)	0.79 (0.62)	0.0	0.40	0.69	1.20	2.2	
		Placebo	40	39 (97.5)	0.98 (0.55)	0.0	0.57	0.86	1.40	2.1	
	Week 22	Tezepelumab	55	52 (94.5)	0.83 (0.60)	0.0	0.40	0.80	1.17	2.4	
		Placebo	40	39 (97.5)	1.00 (0.52)	0.1	0.69	0.97	1.43	2.2	
	Week 23	Tezepelumab	55	52 (94.5)	0.81 (0.64)	0.0	0.30	0.77	1.20	2.6	
		Placebo	40	37 (92.5)	0.99 (0.49)	0.0	0.80	0.91	1.40	2.1	
	Week 24	Tezepelumab	55	53 (96.4)	0.80 (0.64)	0.0	0.31	0.74	1.11	2.7	
		Placebo	40	37 (92.5)	0.91 (0.49)	0.0	0.53	0.83	1.23	2.0	
	Week 25	Tezepelumab	55	50 (90.9)	0.80 (0.61)	0.0	0.29	0.81	1.09	2.5	
		Placebo	40	38 (95.0)	0.95 (0.55)	0.0	0.46	0.86	1.28	2.2	
	Week 26	Tezepelumab	55	53 (96.4)	0.80 (0.66)	0.0	0.37	0.71	1.20	2.7	
		Placebo	40	37 (92.5)	0.93 (0.57)	0.0	0.54	0.86	1.37	2.1	
	Week 27	Tezepelumab	55	53 (96.4)	0.83 (0.69)	0.0	0.33	0.77	1.20	3.2	
		Placebo	40	36 (90.0)	0.99 (0.59)	0.0	0.47	0.94	1.34	2.4	
	Week 28	Tezepelumab	55	53 (96.4)	0.87 (0.65)	0.0	0.30	0.93	1.26	2.7	
		Placebo	40	37 (92.5)	0.97 (0.58)	0.0	0.60	0.91	1.31	2.3	
	Week 29	Tezepelumab	55	52 (94.5)	0.78 (0.61)	0.0	0.21	0.83	1.09	2.4	
		Placebo	40	37 (92.5)	0.94 (0.59)	0.0	0.49	0.89	1.40	2.5	
	Week 30	Tezepelumab	55	52 (94.5)	0.83 (0.64)	0.0	0.30	0.81	1.24	2.4	
		Placebo	40	37 (92.5)	0.91 (0.54)	0.0	0.53	0.83	1.31	2.8	
	Week 31	Tezepelumab	55	54 (98.2)	0.78 (0.57)	0.0	0.29	0.80	1.09	2.3	
		Placebo	40	38 (95.0)	0.93 (0.59)	0.0	0.54	0.80	1.29	2.8	
	Week 32	Tezepelumab	55	53 (96.4)	0.78 (0.58)	0.0	0.23	0.80	1.14	2.0	
		Placebo	40	38 (95.0)	0.93 (0.59)	0.0	0.47	0.80	1.28	2.8	
	Week 33	Tezepelumab	55	53 (96.4)	0.81 (0.60)	0.0	0.37	0.80	1.20	2.4	
		Placebo	40	38 (95.0)	0.97 (0.59)	0.0	0.49	0.85	1.40	2.8	
	Week 34	Tezepelumab	55	54 (98.2)	0.78 (0.60)	0.0	0.26	0.80	1.11	2.4	
		Placebo	40	38 (95.0)	0.97 (0.60)	0.0	0.49	0.86	1.40	2.8	
	Week 35	Tezepelumab	55	53 (96.4)	0.80 (0.62)	0.0	0.29	0.74	1.17	2.6	
		Placebo	40	36 (90.0)	0.95 (0.58)	0.0	0.61	0.90	1.29	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	55	52 (94.5)	0.84 (0.63)	0.0	0.34	0.80	1.25	2.3	
		Placebo	40	38 (95.0)	0.99 (0.56)	0.1	0.60	0.84	1.43	2.8	
	Week 37	Tezepelumab	55	52 (94.5)	0.80 (0.62)	0.0	0.23	0.79	1.11	2.5	
		Placebo	40	38 (95.0)	1.02 (0.53)	0.0	0.77	0.97	1.37	2.7	
	Week 38	Tezepelumab	55	50 (90.9)	0.86 (0.66)	0.0	0.37	0.80	1.20	2.5	
		Placebo	40	38 (95.0)	0.95 (0.54)	0.0	0.60	0.84	1.29	2.8	
	Week 39	Tezepelumab	55	52 (94.5)	0.83 (0.66)	0.0	0.23	0.81	1.19	2.8	
		Placebo	40	38 (95.0)	0.96 (0.60)	0.0	0.54	0.83	1.32	2.8	
	Week 40	Tezepelumab	55	53 (96.4)	0.83 (0.63)	0.0	0.34	0.86	1.20	2.7	
		Placebo	40	38 (95.0)	1.01 (0.67)	0.0	0.57	0.93	1.40	2.7	
	Week 41	Tezepelumab	55	53 (96.4)	0.81 (0.63)	0.0	0.34	0.80	1.20	2.7	
		Placebo	40	37 (92.5)	1.04 (0.63)	0.0	0.63	1.00	1.43	2.8	
	Week 42	Tezepelumab	55	50 (90.9)	0.82 (0.70)	0.0	0.23	0.73	1.20	2.8	
		Placebo	40	38 (95.0)	1.04 (0.64)	0.0	0.60	0.99	1.46	2.8	
	Week 43	Tezepelumab	55	51 (92.7)	0.80 (0.68)	0.0	0.25	0.80	1.20	3.1	
		Placebo	40	37 (92.5)	0.97 (0.59)	0.0	0.60	0.86	1.40	2.8	
	Week 44	Tezepelumab	55	51 (92.7)	0.77 (0.63)	0.0	0.20	0.77	1.14	2.6	
		Placebo	40	36 (90.0)	0.99 (0.55)	0.1	0.64	0.91	1.37	2.8	
	Week 45	Tezepelumab	55	51 (92.7)	0.79 (0.65)	0.0	0.20	0.72	1.23	2.7	
		Placebo	40	37 (92.5)	0.90 (0.60)	0.0	0.40	0.80	1.10	2.8	
	Week 46	Tezepelumab	55	52 (94.5)	0.80 (0.65)	0.0	0.23	0.80	1.15	2.7	
		Placebo	40	37 (92.5)	0.91 (0.63)	0.0	0.40	0.80	1.29	2.8	
	Week 47	Tezepelumab	55	50 (90.9)	0.78 (0.65)	0.0	0.20	0.75	1.17	2.8	
		Placebo	40	37 (92.5)	0.94 (0.62)	0.0	0.40	0.80	1.43	2.8	
	Week 48	Tezepelumab	55	52 (94.5)	0.85 (0.67)	0.0	0.36	0.80	1.24	2.5	
		Placebo	40	38 (95.0)	0.95 (0.62)	0.0	0.46	0.86	1.43	2.8	
	Week 49	Tezepelumab	55	52 (94.5)	0.85 (0.66)	0.0	0.34	0.80	1.19	2.6	
		Placebo	40	38 (95.0)	0.94 (0.63)	0.0	0.40	0.80	1.43	2.8	
	Week 50	Tezepelumab	55	51 (92.7)	0.82 (0.64)	0.0	0.26	0.83	1.31	2.3	
		Placebo	40	36 (90.0)	0.87 (0.61)	0.0	0.41	0.80	1.21	2.8	
	Week 51	Tezepelumab	55	47 (85.5)	0.85 (0.66)	0.0	0.31	0.86	1.49	2.4	
		Placebo	40	35 (87.5)	0.91 (0.60)	0.0	0.49	0.80	1.30	2.8	
	Week 52	Tezepelumab	55	43 (78.2)	0.81 (0.63)	0.0	0.33	0.80	1.26	2.4	
		Placebo	40	33 (82.5)	0.94 (0.64)	0.0	0.51	0.86	1.46	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	55	54 (98.2)	-0.17 (0.49)	-2.5	-0.23	-0.01	0.06	0.5	-0.25 [-0.66, 0.17]
		Placebo	40	40 (100.0)	-0.07 (0.32)	-0.8	-0.16	-0.06	0.03	1.1	
	Week 2	Tezepelumab	55	54 (98.2)	-0.25 (0.51)	-2.8	-0.43	-0.11	0.03	0.3	-0.27 [-0.68, 0.14]
		Placebo	40	39 (97.5)	-0.11 (0.49)	-1.7	-0.20	-0.05	0.14	1.0	
	Week 3	Tezepelumab	55	55 (100.0)	-0.26 (0.53)	-2.8	-0.49	-0.11	0.03	0.5	-0.14 [-0.55, 0.27]
		Placebo	40	38 (95.0)	-0.18 (0.58)	-2.3	-0.37	-0.07	0.11	0.8	
	Week 4	Tezepelumab	55	55 (100.0)	-0.31 (0.55)	-2.8	-0.63	-0.17	0.00	0.4	-0.21 [-0.62, 0.20]
		Placebo	40	39 (97.5)	-0.19 (0.52)	-2.3	-0.40	-0.06	0.11	0.5	
	Week 5	Tezepelumab	55	54 (98.2)	-0.39 (0.57)	-2.8	-0.69	-0.19	-0.03	0.5	-0.21 [-0.62, 0.20]
		Placebo	40	39 (97.5)	-0.27 (0.60)	-2.4	-0.57	-0.14	0.09	1.2	
	Week 6	Tezepelumab	55	53 (96.4)	-0.31 (0.52)	-2.8	-0.51	-0.17	0.00	0.5	-0.22 [-0.64, 0.19]
		Placebo	40	40 (100.0)	-0.19 (0.57)	-2.3	-0.40	-0.09	0.11	0.8	
	Week 7	Tezepelumab	55	53 (96.4)	-0.30 (0.54)	-2.8	-0.46	-0.17	0.00	0.8	-0.08 [-0.49, 0.34]
		Placebo	40	40 (100.0)	-0.26 (0.54)	-2.5	-0.51	-0.19	0.09	0.8	
	Week 8	Tezepelumab	55	53 (96.4)	-0.38 (0.56)	-2.8	-0.67	-0.26	-0.03	0.9	-0.27 [-0.68, 0.15]
		Placebo	40	39 (97.5)	-0.22 (0.62)	-2.4	-0.43	-0.14	0.09	1.9	
	Week 9	Tezepelumab	55	55 (100.0)	-0.40 (0.57)	-2.8	-0.77	-0.26	-0.03	0.6	-0.24 [-0.64, 0.17]
		Placebo	40	40 (100.0)	-0.25 (0.66)	-2.3	-0.60	-0.25	0.09	1.8	
	Week 10	Tezepelumab	55	54 (98.2)	-0.41 (0.59)	-2.8	-0.74	-0.23	-0.03	0.6	-0.22 [-0.63, 0.19]
		Placebo	40	40 (100.0)	-0.29 (0.57)	-2.4	-0.51	-0.19	0.04	0.9	
	Week 11	Tezepelumab	55	54 (98.2)	-0.41 (0.54)	-2.8	-0.74	-0.29	-0.08	0.5	-0.12 [-0.53, 0.29]
		Placebo	40	40 (100.0)	-0.34 (0.57)	-2.2	-0.64	-0.23	0.06	0.7	
	Week 12	Tezepelumab	55	53 (96.4)	-0.43 (0.60)	-2.8	-0.74	-0.29	-0.06	0.6	-0.17 [-0.58, 0.25]
		Placebo	40	38 (95.0)	-0.33 (0.63)	-2.2	-0.60	-0.29	0.00	1.7	
	Week 13	Tezepelumab	55	51 (92.7)	-0.39 (0.60)	-2.8	-0.66	-0.26	0.00	0.6	-0.00 [-0.42, 0.42]
		Placebo	40	39 (97.5)	-0.39 (0.56)	-2.2	-0.74	-0.28	-0.06	1.3	
	Week 14	Tezepelumab	55	52 (94.5)	-0.41 (0.60)	-2.8	-0.67	-0.24	-0.10	0.8	-0.08 [-0.50, 0.34]
		Placebo	40	38 (95.0)	-0.36 (0.62)	-2.3	-0.77	-0.24	0.01	0.9	
	Week 15	Tezepelumab	55	52 (94.5)	-0.41 (0.58)	-2.8	-0.69	-0.26	-0.05	0.7	-0.04 [-0.45, 0.38]
		Placebo	40	39 (97.5)	-0.39 (0.64)	-2.3	-0.80	-0.20	0.00	1.5	
	Week 16	Tezepelumab	55	53 (96.4)	-0.44 (0.58)	-2.8	-0.69	-0.26	-0.08	0.5	-0.05 [-0.47, 0.36]
		Placebo	40	38 (95.0)	-0.41 (0.59)	-2.2	-0.80	-0.23	0.00	0.9	
	Week 17	Tezepelumab	55	53 (96.4)	-0.44 (0.60)	-2.8	-0.71	-0.31	-0.03	0.5	-0.15 [-0.56, 0.27]
		Placebo	40	38 (95.0)	-0.35 (0.58)	-2.3	-0.69	-0.18	0.03	0.8	
	Week 18	Tezepelumab	55	53 (96.4)	-0.42 (0.62)	-2.8	-0.71	-0.29	-0.06	0.9	-0.18 [-0.59, 0.23]
		Placebo	40	40 (100.0)	-0.31 (0.57)	-2.3	-0.64	-0.17	0.03	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	55	53 (96.4)	-0.46 (0.60)	-2.8	-0.74	-0.31	-0.03	0.6	-0.17 [-0.58, 0.25]
		Placebo	40	40 (100.0)	-0.36 (0.56)	-2.5	-0.69	-0.20	0.03	0.7	
	Week 20	Tezepelumab	55	52 (94.5)	-0.47 (0.63)	-2.8	-0.72	-0.31	-0.09	0.9	-0.20 [-0.62, 0.21]
		Placebo	40	39 (97.5)	-0.34 (0.57)	-2.1	-0.69	-0.23	0.03	0.9	
	Week 21	Tezepelumab	55	50 (90.9)	-0.44 (0.61)	-2.8	-0.74	-0.30	-0.03	0.7	-0.09 [-0.51, 0.33]
		Placebo	40	39 (97.5)	-0.39 (0.60)	-2.3	-0.71	-0.29	-0.03	1.2	
	Week 22	Tezepelumab	55	52 (94.5)	-0.42 (0.58)	-2.8	-0.73	-0.29	-0.01	0.8	-0.09 [-0.51, 0.32]
		Placebo	40	39 (97.5)	-0.37 (0.58)	-2.3	-0.69	-0.20	0.03	1.1	
	Week 23	Tezepelumab	55	52 (94.5)	-0.43 (0.63)	-2.8	-0.74	-0.27	-0.07	1.0	-0.06 [-0.49, 0.36]
		Placebo	40	37 (92.5)	-0.40 (0.54)	-2.1	-0.69	-0.23	-0.02	0.3	
	Week 24	Tezepelumab	55	53 (96.4)	-0.45 (0.61)	-2.8	-0.69	-0.29	-0.06	1.1	0.02 [-0.40, 0.44]
		Placebo	40	37 (92.5)	-0.46 (0.54)	-2.3	-0.69	-0.27	-0.06	0.2	
	Week 25	Tezepelumab	55	50 (90.9)	-0.47 (0.58)	-2.8	-0.82	-0.31	-0.09	0.7	-0.05 [-0.48, 0.37]
		Placebo	40	38 (95.0)	-0.44 (0.62)	-2.5	-0.80	-0.28	-0.06	0.5	
	Week 26	Tezepelumab	55	53 (96.4)	-0.43 (0.61)	-2.8	-0.71	-0.29	0.03	0.4	0.01 [-0.41, 0.43]
		Placebo	40	37 (92.5)	-0.44 (0.69)	-2.5	-0.86	-0.31	-0.03	1.2	
	Week 27	Tezepelumab	55	53 (96.4)	-0.41 (0.63)	-2.8	-0.74	-0.26	0.00	0.8	-0.01 [-0.44, 0.41]
		Placebo	40	36 (90.0)	-0.40 (0.73)	-2.5	-0.82	-0.29	-0.04	1.8	
	Week 28	Tezepelumab	55	53 (96.4)	-0.37 (0.59)	-2.7	-0.60	-0.31	0.00	1.0	-0.01 [-0.43, 0.41]
		Placebo	40	37 (92.5)	-0.36 (0.67)	-2.5	-0.70	-0.20	0.09	0.6	
	Week 29	Tezepelumab	55	52 (94.5)	-0.46 (0.57)	-2.8	-0.77	-0.29	-0.07	0.7	-0.10 [-0.52, 0.33]
		Placebo	40	37 (92.5)	-0.40 (0.68)	-2.5	-0.87	-0.34	0.07	0.7	
	Week 30	Tezepelumab	55	52 (94.5)	-0.45 (0.58)	-2.8	-0.73	-0.29	-0.06	0.8	-0.02 [-0.44, 0.40]
		Placebo	40	37 (92.5)	-0.43 (0.63)	-2.5	-0.71	-0.40	-0.06	0.9	
	Week 31	Tezepelumab	55	54 (98.2)	-0.50 (0.64)	-2.8	-0.74	-0.36	-0.11	0.7	-0.11 [-0.52, 0.31]
		Placebo	40	38 (95.0)	-0.43 (0.64)	-2.5	-0.80	-0.33	-0.14	1.1	
	Week 32	Tezepelumab	55	53 (96.4)	-0.46 (0.62)	-2.8	-0.74	-0.29	-0.03	0.7	-0.03 [-0.45, 0.38]
		Placebo	40	38 (95.0)	-0.44 (0.65)	-2.5	-0.80	-0.41	-0.14	1.1	
	Week 33	Tezepelumab	55	53 (96.4)	-0.47 (0.63)	-2.8	-0.77	-0.34	-0.03	0.6	-0.12 [-0.54, 0.30]
		Placebo	40	38 (95.0)	-0.40 (0.63)	-2.5	-0.57	-0.34	-0.11	1.1	
	Week 34	Tezepelumab	55	54 (98.2)	-0.48 (0.63)	-2.8	-0.89	-0.37	-0.06	0.9	-0.15 [-0.56, 0.27]
		Placebo	40	38 (95.0)	-0.39 (0.64)	-2.4	-0.80	-0.36	-0.10	0.9	
	Week 35	Tezepelumab	55	53 (96.4)	-0.46 (0.60)	-2.8	-0.74	-0.31	-0.11	1.0	-0.09 [-0.51, 0.34]
		Placebo	40	36 (90.0)	-0.41 (0.62)	-2.5	-0.69	-0.37	-0.09	0.8	
	Week 36	Tezepelumab	55	52 (94.5)	-0.43 (0.62)	-2.8	-0.71	-0.34	-0.07	0.7	-0.11 [-0.53, 0.31]
		Placebo	40	38 (95.0)	-0.37 (0.60)	-2.4	-0.74	-0.25	-0.09	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	55	52 (94.5)	-0.47 (0.61)	-2.8	-0.76	-0.30	-0.09	0.8	-0.22 [-0.64, 0.20]
		Placebo	40	38 (95.0)	-0.34 (0.54)	-2.1	-0.66	-0.30	-0.06	0.7	
	Week 38	Tezepelumab	55	50 (90.9)	-0.42 (0.66)	-2.8	-0.74	-0.29	-0.09	0.9	-0.01 [-0.44, 0.41]
		Placebo	40	38 (95.0)	-0.41 (0.52)	-1.9	-0.70	-0.35	-0.10	0.8	
	Week 39	Tezepelumab	55	52 (94.5)	-0.46 (0.64)	-2.8	-0.73	-0.31	-0.01	0.6	-0.10 [-0.52, 0.32]
		Placebo	40	38 (95.0)	-0.40 (0.54)	-2.0	-0.77	-0.35	-0.09	0.8	
	Week 40	Tezepelumab	55	53 (96.4)	-0.45 (0.63)	-2.8	-0.78	-0.29	-0.03	0.8	-0.15 [-0.57, 0.27]
		Placebo	40	38 (95.0)	-0.35 (0.65)	-2.3	-0.69	-0.39	-0.06	1.7	
	Week 41	Tezepelumab	55	53 (96.4)	-0.46 (0.63)	-2.8	-0.80	-0.33	-0.03	0.6	-0.22 [-0.64, 0.21]
		Placebo	40	37 (92.5)	-0.32 (0.68)	-2.3	-0.69	-0.31	-0.06	1.4	
	Week 42	Tezepelumab	55	50 (90.9)	-0.42 (0.62)	-2.8	-0.74	-0.29	-0.03	0.7	-0.17 [-0.59, 0.26]
		Placebo	40	38 (95.0)	-0.32 (0.54)	-1.7	-0.66	-0.35	0.00	0.8	
	Week 43	Tezepelumab	55	51 (92.7)	-0.46 (0.60)	-2.8	-0.77	-0.31	-0.03	0.6	-0.15 [-0.58, 0.27]
		Placebo	40	37 (92.5)	-0.37 (0.51)	-1.6	-0.69	-0.40	-0.03	0.8	
	Week 44	Tezepelumab	55	51 (92.7)	-0.52 (0.61)	-2.8	-0.94	-0.31	-0.06	0.6	-0.26 [-0.69, 0.17]
		Placebo	40	36 (90.0)	-0.36 (0.54)	-1.8	-0.69	-0.27	-0.03	0.8	
	Week 45	Tezepelumab	55	51 (92.7)	-0.49 (0.64)	-2.8	-0.94	-0.34	0.01	0.5	-0.08 [-0.50, 0.34]
		Placebo	40	37 (92.5)	-0.44 (0.57)	-2.3	-0.80	-0.37	-0.06	0.8	
	Week 46	Tezepelumab	55	52 (94.5)	-0.47 (0.67)	-2.8	-0.75	-0.41	0.00	0.8	-0.07 [-0.49, 0.35]
		Placebo	40	37 (92.5)	-0.43 (0.61)	-2.5	-0.69	-0.40	0.00	0.8	
	Week 47	Tezepelumab	55	50 (90.9)	-0.48 (0.66)	-2.8	-0.80	-0.34	-0.03	0.8	-0.13 [-0.55, 0.30]
		Placebo	40	37 (92.5)	-0.40 (0.60)	-2.5	-0.57	-0.34	-0.09	0.8	
	Week 48	Tezepelumab	55	52 (94.5)	-0.41 (0.69)	-2.8	-0.80	-0.27	0.03	0.7	0.02 [-0.40, 0.44]
		Placebo	40	38 (95.0)	-0.42 (0.57)	-2.5	-0.69	-0.39	-0.09	0.9	
	Week 49	Tezepelumab	55	52 (94.5)	-0.40 (0.65)	-2.8	-0.74	-0.29	0.00	0.8	0.03 [-0.39, 0.45]
		Placebo	40	38 (95.0)	-0.42 (0.58)	-2.5	-0.69	-0.39	-0.11	0.8	
	Week 50	Tezepelumab	55	51 (92.7)	-0.45 (0.63)	-2.8	-0.74	-0.31	-0.03	0.8	0.03 [-0.39, 0.46]
		Placebo	40	36 (90.0)	-0.47 (0.57)	-2.5	-0.71	-0.39	-0.16	0.8	
	Week 51	Tezepelumab	55	47 (85.5)	-0.36 (0.60)	-2.8	-0.66	-0.26	0.03	0.6	0.15 [-0.29, 0.59]
		Placebo	40	35 (87.5)	-0.45 (0.59)	-2.5	-0.74	-0.38	-0.03	0.8	
	Week 52	Tezepelumab	55	43 (78.2)	-0.41 (0.61)	-2.8	-0.74	-0.29	-0.03	0.8	0.10 [-0.36, 0.55]
		Placebo	40	33 (82.5)	-0.47 (0.59)	-2.5	-0.69	-0.42	-0.17	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	55	54 (98.2)	-0.18 (0.07)	(-0.32, -0.05)	-0.15 (0.11)	(-0.36, 0.06)	0.166
	Placebo	40	40 (100.0)	-0.03 (0.08)	(-0.20, 0.13)			
Week 2	Tezepelumab	55	54 (98.2)	-0.26 (0.07)	(-0.40, -0.12)	-0.19 (0.11)	(-0.40, 0.02)	0.082
	Placebo	40	39 (97.5)	-0.07 (0.08)	(-0.23, 0.09)			
Week 3	Tezepelumab	55	55 (100.0)	-0.27 (0.07)	(-0.41, -0.14)	-0.14 (0.11)	(-0.35, 0.07)	0.190
	Placebo	40	38 (95.0)	-0.13 (0.08)	(-0.29, 0.03)			
Week 4	Tezepelumab	55	55 (100.0)	-0.32 (0.07)	(-0.46, -0.19)	-0.17 (0.11)	(-0.38, 0.05)	0.124
	Placebo	40	39 (97.5)	-0.16 (0.08)	(-0.32, 0.00)			
Week 5	Tezepelumab	55	54 (98.2)	-0.40 (0.07)	(-0.53, -0.26)	-0.17 (0.11)	(-0.38, 0.04)	0.116
	Placebo	40	39 (97.5)	-0.23 (0.08)	(-0.39, -0.07)			
Week 6	Tezepelumab	55	53 (96.4)	-0.31 (0.07)	(-0.45, -0.17)	-0.16 (0.11)	(-0.37, 0.05)	0.144
	Placebo	40	40 (100.0)	-0.15 (0.08)	(-0.31, 0.01)			
Week 7	Tezepelumab	55	53 (96.4)	-0.31 (0.07)	(-0.45, -0.17)	-0.08 (0.11)	(-0.29, 0.13)	0.472
	Placebo	40	40 (100.0)	-0.23 (0.08)	(-0.39, -0.07)			
Week 8	Tezepelumab	55	53 (96.4)	-0.37 (0.07)	(-0.51, -0.23)	-0.20 (0.11)	(-0.41, 0.02)	0.069
	Placebo	40	39 (97.5)	-0.17 (0.08)	(-0.33, -0.01)			
Week 9	Tezepelumab	55	55 (100.0)	-0.41 (0.07)	(-0.55, -0.28)	-0.19 (0.11)	(-0.40, 0.02)	0.075
	Placebo	40	40 (100.0)	-0.22 (0.08)	(-0.38, -0.06)			
Week 10	Tezepelumab	55	54 (98.2)	-0.42 (0.07)	(-0.56, -0.28)	-0.17 (0.11)	(-0.38, 0.04)	0.121
	Placebo	40	40 (100.0)	-0.25 (0.08)	(-0.41, -0.09)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	55	54 (98.2)	-0.41 (0.07)	(-0.54, -0.27)	-0.10 (0.11)	(-0.31, 0.11)	0.365
	Placebo	40	40 (100.0)	-0.31 (0.08)	(-0.47, -0.15)			
Week 12	Tezepelumab	55	53 (96.4)	-0.44 (0.07)	(-0.58, -0.30)	-0.15 (0.11)	(-0.36, 0.06)	0.166
	Placebo	40	38 (95.0)	-0.29 (0.08)	(-0.45, -0.13)			
Week 13	Tezepelumab	55	51 (92.7)	-0.41 (0.07)	(-0.55, -0.28)	-0.06 (0.11)	(-0.28, 0.15)	0.553
	Placebo	40	39 (97.5)	-0.35 (0.08)	(-0.51, -0.19)			
Week 14	Tezepelumab	55	52 (94.5)	-0.39 (0.07)	(-0.53, -0.25)	-0.08 (0.11)	(-0.29, 0.13)	0.468
	Placebo	40	38 (95.0)	-0.31 (0.08)	(-0.48, -0.15)			
Week 15	Tezepelumab	55	52 (94.5)	-0.42 (0.07)	(-0.56, -0.28)	-0.07 (0.11)	(-0.28, 0.14)	0.501
	Placebo	40	39 (97.5)	-0.35 (0.08)	(-0.51, -0.19)			
Week 16	Tezepelumab	55	53 (96.4)	-0.45 (0.07)	(-0.58, -0.31)	-0.09 (0.11)	(-0.30, 0.13)	0.423
	Placebo	40	38 (95.0)	-0.36 (0.08)	(-0.52, -0.20)			
Week 17	Tezepelumab	55	53 (96.4)	-0.44 (0.07)	(-0.58, -0.30)	-0.14 (0.11)	(-0.35, 0.07)	0.195
	Placebo	40	38 (95.0)	-0.30 (0.08)	(-0.46, -0.14)			
Week 18	Tezepelumab	55	53 (96.4)	-0.42 (0.07)	(-0.56, -0.28)	-0.14 (0.11)	(-0.35, 0.07)	0.200
	Placebo	40	40 (100.0)	-0.28 (0.08)	(-0.44, -0.12)			
Week 19	Tezepelumab	55	53 (96.4)	-0.46 (0.07)	(-0.60, -0.32)	-0.13 (0.11)	(-0.34, 0.08)	0.235
	Placebo	40	40 (100.0)	-0.33 (0.08)	(-0.49, -0.17)			
Week 20	Tezepelumab	55	52 (94.5)	-0.47 (0.07)	(-0.61, -0.33)	-0.14 (0.11)	(-0.35, 0.07)	0.194
	Placebo	40	39 (97.5)	-0.33 (0.08)	(-0.49, -0.17)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	55	50 (90.9)	-0.48 (0.07)	(-0.62, -0.34)	-0.12 (0.11)	(-0.33, 0.09)	0.266
	Placebo	40	39 (97.5)	-0.36 (0.08)	(-0.52, -0.20)			
Week 22	Tezepelumab	55	52 (94.5)	-0.45 (0.07)	(-0.58, -0.31)	-0.11 (0.11)	(-0.32, 0.10)	0.315
	Placebo	40	39 (97.5)	-0.34 (0.08)	(-0.50, -0.18)			
Week 23	Tezepelumab	55	52 (94.5)	-0.45 (0.07)	(-0.59, -0.31)	-0.13 (0.11)	(-0.35, 0.08)	0.222
	Placebo	40	37 (92.5)	-0.32 (0.08)	(-0.48, -0.16)			
Week 24	Tezepelumab	55	53 (96.4)	-0.45 (0.07)	(-0.59, -0.32)	-0.06 (0.11)	(-0.28, 0.15)	0.567
	Placebo	40	37 (92.5)	-0.39 (0.08)	(-0.55, -0.23)			
Week 25	Tezepelumab	55	50 (90.9)	-0.48 (0.07)	(-0.62, -0.34)	-0.10 (0.11)	(-0.31, 0.11)	0.355
	Placebo	40	38 (95.0)	-0.38 (0.08)	(-0.54, -0.22)			
Week 26	Tezepelumab	55	53 (96.4)	-0.46 (0.07)	(-0.60, -0.32)	-0.08 (0.11)	(-0.30, 0.13)	0.437
	Placebo	40	37 (92.5)	-0.37 (0.08)	(-0.54, -0.21)			
Week 27	Tezepelumab	55	53 (96.4)	-0.43 (0.07)	(-0.57, -0.29)	-0.08 (0.11)	(-0.30, 0.13)	0.452
	Placebo	40	36 (90.0)	-0.35 (0.08)	(-0.51, -0.18)			
Week 28	Tezepelumab	55	53 (96.4)	-0.41 (0.07)	(-0.55, -0.27)	-0.10 (0.11)	(-0.32, 0.11)	0.337
	Placebo	40	37 (92.5)	-0.31 (0.08)	(-0.47, -0.14)			
Week 29	Tezepelumab	55	52 (94.5)	-0.49 (0.07)	(-0.63, -0.35)	-0.13 (0.11)	(-0.35, 0.08)	0.218
	Placebo	40	37 (92.5)	-0.36 (0.08)	(-0.52, -0.19)			
Week 30	Tezepelumab	55	52 (94.5)	-0.46 (0.07)	(-0.60, -0.32)	-0.08 (0.11)	(-0.29, 0.14)	0.483
	Placebo	40	37 (92.5)	-0.39 (0.08)	(-0.55, -0.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	55	54 (98.2)	-0.50 (0.07)	(-0.64, -0.37)	-0.11 (0.11)	(-0.33, 0.10)	0.290
	Placebo	40	38 (95.0)	-0.39 (0.08)	(-0.55, -0.23)			
Week 32	Tezepelumab	55	53 (96.4)	-0.49 (0.07)	(-0.63, -0.35)	-0.09 (0.11)	(-0.31, 0.12)	0.397
	Placebo	40	38 (95.0)	-0.40 (0.08)	(-0.56, -0.24)			
Week 33	Tezepelumab	55	53 (96.4)	-0.48 (0.07)	(-0.62, -0.35)	-0.12 (0.11)	(-0.34, 0.09)	0.264
	Placebo	40	38 (95.0)	-0.36 (0.08)	(-0.52, -0.20)			
Week 34	Tezepelumab	55	54 (98.2)	-0.50 (0.07)	(-0.64, -0.37)	-0.15 (0.11)	(-0.37, 0.06)	0.162
	Placebo	40	38 (95.0)	-0.35 (0.08)	(-0.52, -0.19)			
Week 35	Tezepelumab	55	53 (96.4)	-0.49 (0.07)	(-0.62, -0.35)	-0.12 (0.11)	(-0.34, 0.09)	0.265
	Placebo	40	36 (90.0)	-0.37 (0.08)	(-0.53, -0.20)			
Week 36	Tezepelumab	55	52 (94.5)	-0.45 (0.07)	(-0.59, -0.32)	-0.12 (0.11)	(-0.34, 0.09)	0.266
	Placebo	40	38 (95.0)	-0.33 (0.08)	(-0.50, -0.17)			
Week 37	Tezepelumab	55	52 (94.5)	-0.48 (0.07)	(-0.62, -0.35)	-0.18 (0.11)	(-0.39, 0.04)	0.108
	Placebo	40	38 (95.0)	-0.31 (0.08)	(-0.47, -0.14)			
Week 38	Tezepelumab	55	50 (90.9)	-0.46 (0.07)	(-0.60, -0.32)	-0.08 (0.11)	(-0.29, 0.14)	0.473
	Placebo	40	38 (95.0)	-0.38 (0.08)	(-0.54, -0.22)			
Week 39	Tezepelumab	55	52 (94.5)	-0.48 (0.07)	(-0.62, -0.34)	-0.11 (0.11)	(-0.32, 0.10)	0.316
	Placebo	40	38 (95.0)	-0.37 (0.08)	(-0.53, -0.21)			
Week 40	Tezepelumab	55	53 (96.4)	-0.47 (0.07)	(-0.61, -0.33)	-0.15 (0.11)	(-0.36, 0.07)	0.174
	Placebo	40	38 (95.0)	-0.32 (0.08)	(-0.49, -0.16)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	55	53 (96.4)	-0.48 (0.07)	(-0.62, -0.35)	-0.19 (0.11)	(-0.40, 0.03)	0.086
	Placebo	40	37 (92.5)	-0.30 (0.08)	(-0.46, -0.13)			
Week 42	Tezepelumab	55	50 (90.9)	-0.46 (0.07)	(-0.59, -0.32)	-0.17 (0.11)	(-0.38, 0.05)	0.132
	Placebo	40	38 (95.0)	-0.29 (0.08)	(-0.46, -0.13)			
Week 43	Tezepelumab	55	51 (92.7)	-0.49 (0.07)	(-0.63, -0.35)	-0.15 (0.11)	(-0.36, 0.07)	0.174
	Placebo	40	37 (92.5)	-0.34 (0.08)	(-0.50, -0.17)			
Week 44	Tezepelumab	55	51 (92.7)	-0.53 (0.07)	(-0.67, -0.39)	-0.19 (0.11)	(-0.40, 0.03)	0.090
	Placebo	40	36 (90.0)	-0.34 (0.08)	(-0.51, -0.18)			
Week 45	Tezepelumab	55	51 (92.7)	-0.51 (0.07)	(-0.64, -0.37)	-0.09 (0.11)	(-0.31, 0.12)	0.389
	Placebo	40	37 (92.5)	-0.41 (0.08)	(-0.58, -0.25)			
Week 46	Tezepelumab	55	52 (94.5)	-0.49 (0.07)	(-0.63, -0.35)	-0.09 (0.11)	(-0.31, 0.12)	0.387
	Placebo	40	37 (92.5)	-0.39 (0.08)	(-0.56, -0.23)			
Week 47	Tezepelumab	55	50 (90.9)	-0.48 (0.07)	(-0.62, -0.34)	-0.11 (0.11)	(-0.33, 0.10)	0.297
	Placebo	40	37 (92.5)	-0.37 (0.08)	(-0.53, -0.20)			
Week 48	Tezepelumab	55	52 (94.5)	-0.44 (0.07)	(-0.58, -0.30)	-0.05 (0.11)	(-0.27, 0.16)	0.632
	Placebo	40	38 (95.0)	-0.39 (0.08)	(-0.55, -0.22)			
Week 49	Tezepelumab	55	52 (94.5)	-0.44 (0.07)	(-0.58, -0.30)	-0.05 (0.11)	(-0.26, 0.17)	0.652
	Placebo	40	38 (95.0)	-0.39 (0.08)	(-0.56, -0.23)			
Week 50	Tezepelumab	55	51 (92.7)	-0.48 (0.07)	(-0.62, -0.34)	-0.06 (0.11)	(-0.27, 0.16)	0.600
	Placebo	40	36 (90.0)	-0.42 (0.08)	(-0.59, -0.26)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	55	47 (85.5)	-0.44 (0.07)	(-0.58, -0.30)	-0.03 (0.11)	(-0.25, 0.18)	0.761
	Placebo	40	35 (87.5)	-0.41 (0.08)	(-0.57, -0.24)			
Week 52	Tezepelumab	55	43 (78.2)	-0.46 (0.07)	(-0.60, -0.32)	-0.07 (0.11)	(-0.29, 0.15)	0.547
	Placebo	40	33 (82.5)	-0.39 (0.09)	(-0.56, -0.23)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	12	12 (100.0)	1.18 (0.74)	0.0	0.79	1.13	1.54	2.4	
		Placebo	11	11 (100.0)	1.70 (1.01)	0.2	1.17	1.66	2.20	3.7	
	Week 1	Tezepelumab	12	12 (100.0)	1.11 (0.64)	0.3	0.71	0.92	1.40	2.5	
		Placebo	11	11 (100.0)	1.46 (0.64)	0.5	0.69	1.57	1.83	2.5	
	Week 2	Tezepelumab	12	12 (100.0)	1.07 (0.63)	0.3	0.67	0.91	1.24	2.4	
		Placebo	11	11 (100.0)	1.57 (0.89)	0.3	0.83	1.63	2.03	3.4	
	Week 3	Tezepelumab	12	12 (100.0)	1.12 (0.61)	0.3	0.83	0.93	1.25	2.4	
		Placebo	11	11 (100.0)	1.29 (0.58)	0.5	0.83	1.23	1.80	2.4	
	Week 4	Tezepelumab	12	11 (91.7)	1.18 (0.67)	0.3	0.74	1.00	1.74	2.4	
		Placebo	11	11 (100.0)	1.41 (0.60)	0.5	1.09	1.37	1.80	2.5	
	Week 5	Tezepelumab	12	12 (100.0)	0.97 (0.70)	0.0	0.50	0.91	1.28	2.2	
		Placebo	11	11 (100.0)	1.29 (0.55)	0.5	0.83	1.11	1.80	2.1	
	Week 6	Tezepelumab	12	11 (91.7)	1.02 (0.69)	0.0	0.80	0.94	1.11	2.2	
		Placebo	11	11 (100.0)	1.29 (0.62)	0.5	0.80	1.20	1.80	2.4	
	Week 7	Tezepelumab	12	11 (91.7)	1.00 (0.66)	0.0	0.40	1.00	1.14	2.2	
		Placebo	11	11 (100.0)	1.27 (0.56)	0.5	0.69	1.17	1.80	2.0	
	Week 8	Tezepelumab	12	11 (91.7)	1.03 (0.61)	0.1	0.65	0.97	1.20	2.3	
		Placebo	11	11 (100.0)	1.44 (0.56)	0.5	0.80	1.63	1.97	2.1	
	Week 9	Tezepelumab	12	12 (100.0)	1.01 (0.62)	0.0	0.70	1.06	1.21	2.2	
		Placebo	11	11 (100.0)	1.51 (0.71)	0.5	0.80	1.51	2.00	2.8	
	Week 10	Tezepelumab	12	12 (100.0)	1.08 (0.60)	0.1	0.80	1.09	1.32	2.2	
		Placebo	11	10 (90.9)	1.34 (0.57)	0.4	1.03	1.34	1.74	2.3	
	Week 11	Tezepelumab	12	12 (100.0)	1.08 (0.65)	0.0	0.74	1.06	1.29	2.3	
		Placebo	11	11 (100.0)	1.34 (0.64)	0.5	0.66	1.31	1.63	2.6	
	Week 12	Tezepelumab	12	11 (91.7)	1.14 (0.65)	0.2	0.63	1.00	1.83	2.3	
		Placebo	11	11 (100.0)	1.36 (0.63)	0.6	0.74	1.40	1.69	2.5	
	Week 13	Tezepelumab	12	11 (91.7)	1.23 (0.62)	0.4	0.80	1.06	1.77	2.3	
		Placebo	11	11 (100.0)	1.41 (0.60)	0.4	1.03	1.46	1.80	2.4	
	Week 14	Tezepelumab	12	11 (91.7)	1.14 (0.61)	0.3	0.63	1.03	1.47	2.2	
		Placebo	11	11 (100.0)	1.45 (0.64)	0.4	1.03	1.40	2.14	2.3	
	Week 15	Tezepelumab	12	11 (91.7)	1.02 (0.65)	0.0	0.69	1.00	1.37	2.3	
		Placebo	11	11 (100.0)	1.34 (0.71)	0.2	0.60	1.40	1.80	2.5	
	Week 16	Tezepelumab	12	11 (91.7)	1.06 (0.66)	0.1	0.69	1.00	1.34	2.2	
		Placebo	11	11 (100.0)	1.29 (0.61)	0.3	0.60	1.40	1.63	2.1	
Week 17	Tezepelumab	12	11 (91.7)	1.05 (0.68)	0.2	0.46	1.00	1.77	2.1		
	Placebo	11	11 (100.0)	1.26 (0.64)	0.3	0.60	1.31	1.54	2.4		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	12	11 (91.7)	1.10 (0.81)	0.1	0.49	1.00	1.43	2.8	
		Placebo	11	11 (100.0)	1.21 (0.62)	0.4	0.60	1.31	1.51	2.3	
	Week 19	Tezepelumab	12	11 (91.7)	1.08 (0.81)	0.0	0.69	1.00	1.37	2.9	
		Placebo	11	11 (100.0)	1.26 (0.57)	0.5	0.77	1.33	1.74	2.3	
	Week 20	Tezepelumab	12	11 (91.7)	1.05 (0.72)	0.0	0.60	1.00	1.37	2.4	
		Placebo	11	11 (100.0)	1.27 (0.66)	0.4	0.60	1.27	1.89	2.3	
	Week 21	Tezepelumab	12	11 (91.7)	1.14 (0.76)	0.0	0.69	1.09	1.40	2.8	
		Placebo	11	11 (100.0)	1.27 (0.68)	0.1	0.66	1.40	1.66	2.5	
	Week 22	Tezepelumab	12	11 (91.7)	1.06 (0.65)	0.0	0.50	1.06	1.49	2.2	
		Placebo	11	11 (100.0)	1.26 (0.72)	0.1	0.57	1.47	1.91	2.4	
	Week 23	Tezepelumab	12	11 (91.7)	1.06 (0.71)	0.0	0.51	1.00	1.43	2.5	
		Placebo	11	11 (100.0)	1.25 (0.73)	0.1	0.43	1.60	1.74	2.4	
	Week 24	Tezepelumab	12	11 (91.7)	1.12 (0.68)	0.0	0.57	1.06	1.54	2.4	
		Placebo	11	11 (100.0)	1.31 (0.74)	0.0	0.50	1.57	1.86	2.4	
	Week 25	Tezepelumab	12	11 (91.7)	1.26 (0.81)	0.0	0.63	1.17	2.09	2.5	
		Placebo	11	11 (100.0)	1.19 (0.71)	0.0	0.57	1.03	1.63	2.4	
	Week 26	Tezepelumab	12	11 (91.7)	1.21 (0.70)	0.0	0.74	1.17	1.66	2.5	
		Placebo	11	11 (100.0)	1.18 (0.73)	0.0	0.51	1.23	1.80	2.3	
	Week 27	Tezepelumab	12	10 (83.3)	1.24 (0.84)	0.0	0.77	1.24	1.31	3.0	
		Placebo	11	11 (100.0)	1.28 (0.83)	0.0	0.60	1.13	2.29	2.5	
	Week 28	Tezepelumab	12	9 (75.0)	1.33 (0.74)	0.4	0.91	1.17	1.34	2.8	
		Placebo	11	11 (100.0)	1.32 (0.83)	0.0	0.57	1.28	2.00	2.7	
	Week 29	Tezepelumab	12	9 (75.0)	1.25 (0.86)	0.2	0.86	1.00	1.23	3.1	
		Placebo	11	11 (100.0)	1.34 (0.89)	0.0	0.46	1.37	2.34	2.6	
	Week 30	Tezepelumab	12	10 (83.3)	1.18 (0.88)	0.1	0.60	1.06	1.31	3.0	
		Placebo	11	11 (100.0)	1.23 (0.82)	0.0	0.46	1.17	1.94	2.4	
	Week 31	Tezepelumab	12	9 (75.0)	1.25 (0.97)	0.1	0.83	1.00	1.12	3.4	
		Placebo	11	11 (100.0)	1.21 (0.79)	0.0	0.60	1.29	1.60	2.5	
	Week 32	Tezepelumab	12	10 (83.3)	1.25 (0.86)	0.4	0.74	1.00	1.34	3.3	
		Placebo	11	11 (100.0)	1.28 (0.75)	0.0	0.94	1.17	1.72	2.5	
	Week 33	Tezepelumab	12	10 (83.3)	1.25 (0.74)	0.6	0.83	1.06	1.49	3.2	
		Placebo	11	11 (100.0)	1.25 (0.70)	0.0	1.00	1.17	1.71	2.4	
	Week 34	Tezepelumab	12	10 (83.3)	1.16 (0.81)	0.5	0.60	1.01	1.30	3.3	
		Placebo	11	11 (100.0)	1.30 (0.82)	0.0	0.51	1.20	2.03	2.5	
	Week 35	Tezepelumab	12	10 (83.3)	1.10 (0.76)	0.2	0.63	0.99	1.20	3.0	
		Placebo	11	11 (100.0)	1.20 (0.84)	0.0	0.46	1.00	2.03	2.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	12	10 (83.3)	1.10 (0.84)	0.1	0.80	0.97	1.20	3.1	
		Placebo	11	11 (100.0)	1.22 (0.85)	0.0	0.40	1.00	2.00	2.7	
	Week 37	Tezepelumab	12	10 (83.3)	1.08 (0.77)	0.2	0.63	1.00	1.54	2.8	
		Placebo	11	11 (100.0)	1.19 (0.76)	0.0	0.57	1.06	1.60	2.7	
	Week 38	Tezepelumab	12	9 (75.0)	1.21 (0.80)	0.2	0.69	1.00	1.51	3.0	
		Placebo	11	11 (100.0)	1.23 (0.78)	0.0	0.46	1.40	1.69	2.6	
	Week 39	Tezepelumab	12	9 (75.0)	1.26 (0.86)	0.2	0.86	0.97	1.46	3.1	
		Placebo	11	10 (90.9)	1.10 (0.80)	0.0	0.57	0.99	1.60	2.7	
	Week 40	Tezepelumab	12	9 (75.0)	1.26 (0.89)	0.2	0.71	1.00	1.46	3.1	
		Placebo	11	11 (100.0)	1.21 (0.87)	0.0	0.51	1.14	2.09	2.8	
	Week 41	Tezepelumab	12	8 (66.7)	1.31 (0.94)	0.2	0.72	1.00	1.86	3.1	
		Placebo	11	11 (100.0)	1.17 (0.80)	0.0	0.60	1.03	1.60	2.7	
	Week 42	Tezepelumab	12	8 (66.7)	1.16 (0.83)	0.2	0.54	1.01	1.57	2.8	
		Placebo	11	11 (100.0)	1.10 (0.82)	0.0	0.43	1.00	1.60	2.7	
	Week 43	Tezepelumab	12	8 (66.7)	1.34 (0.88)	0.1	0.81	1.07	1.96	2.9	
		Placebo	11	11 (100.0)	1.15 (0.88)	0.0	0.54	1.03	1.68	2.7	
	Week 44	Tezepelumab	12	8 (66.7)	1.21 (0.89)	0.2	0.66	1.00	1.67	2.8	
		Placebo	11	11 (100.0)	1.17 (0.96)	0.0	0.34	1.03	1.80	2.8	
	Week 45	Tezepelumab	12	8 (66.7)	1.17 (0.84)	0.0	0.71	0.98	1.67	2.6	
		Placebo	11	11 (100.0)	1.04 (0.83)	0.0	0.37	1.00	1.84	2.4	
	Week 46	Tezepelumab	12	8 (66.7)	1.15 (0.87)	0.0	0.63	0.98	1.66	2.6	
		Placebo	11	11 (100.0)	1.07 (0.80)	0.0	0.34	1.00	1.97	2.3	
	Week 47	Tezepelumab	12	8 (66.7)	1.16 (0.85)	0.0	0.53	0.99	1.86	2.5	
		Placebo	11	11 (100.0)	1.02 (0.77)	0.0	0.17	1.03	1.71	2.3	
	Week 48	Tezepelumab	12	7 (58.3)	1.26 (0.81)	0.4	0.66	1.00	2.00	2.7	
		Placebo	11	11 (100.0)	1.04 (0.79)	0.0	0.23	1.00	1.77	2.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	12	12 (100.0)	-0.07 (0.43)	-0.8	-0.34	-0.05	0.19	0.8	0.33 [-0.49, 1.15]
		Placebo	11	11 (100.0)	-0.25 (0.63)	-1.9	-0.46	-0.09	0.20	0.3	
	Week 2	Tezepelumab	12	12 (100.0)	-0.11 (0.33)	-0.6	-0.34	-0.06	0.09	0.5	0.07 [-0.75, 0.89]
		Placebo	11	11 (100.0)	-0.13 (0.31)	-0.7	-0.37	-0.03	0.06	0.4	
	Week 3	Tezepelumab	12	12 (100.0)	-0.07 (0.58)	-0.9	-0.49	-0.10	0.16	1.3	0.52 [-0.31, 1.35]
		Placebo	11	11 (100.0)	-0.42 (0.76)	-2.4	-0.66	-0.31	0.00	0.4	
	Week 4	Tezepelumab	12	11 (91.7)	-0.11 (0.58)	-0.9	-0.60	-0.06	0.11	1.1	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.30 (0.80)	-2.4	-0.63	-0.20	0.23	0.7	
	Week 5	Tezepelumab	12	12 (100.0)	-0.22 (0.51)	-1.1	-0.63	-0.11	0.11	0.7	0.27 [-0.56, 1.09]
		Placebo	11	11 (100.0)	-0.41 (0.94)	-2.9	-0.65	-0.06	0.00	0.5	
	Week 6	Tezepelumab	12	11 (91.7)	-0.18 (0.51)	-1.2	-0.60	-0.17	0.03	0.7	0.32 [-0.52, 1.16]
		Placebo	11	11 (100.0)	-0.42 (0.91)	-2.9	-0.69	-0.14	0.03	0.5	
	Week 7	Tezepelumab	12	11 (91.7)	-0.20 (0.50)	-1.2	-0.60	-0.17	0.11	0.5	0.32 [-0.53, 1.16]
		Placebo	11	11 (100.0)	-0.43 (0.90)	-2.7	-0.74	-0.29	0.03	0.7	
	Week 8	Tezepelumab	12	11 (91.7)	-0.16 (0.52)	-1.1	-0.57	-0.14	0.17	0.7	0.15 [-0.69, 0.98]
		Placebo	11	11 (100.0)	-0.27 (0.83)	-2.1	-0.71	-0.14	0.51	0.8	
	Week 9	Tezepelumab	12	12 (100.0)	-0.17 (0.66)	-1.1	-0.64	-0.31	0.43	0.9	0.02 [-0.79, 0.84]
		Placebo	11	11 (100.0)	-0.19 (0.97)	-2.5	-0.71	0.00	0.60	0.9	
	Week 10	Tezepelumab	12	12 (100.0)	-0.10 (0.63)	-1.0	-0.64	-0.07	0.40	0.9	0.29 [-0.55, 1.13]
		Placebo	11	10 (90.9)	-0.33 (0.95)	-2.4	-0.89	-0.24	0.17	0.9	
	Week 11	Tezepelumab	12	12 (100.0)	-0.11 (0.52)	-1.0	-0.47	-0.08	0.11	0.9	0.35 [-0.48, 1.17]
		Placebo	11	11 (100.0)	-0.36 (0.91)	-2.4	-0.79	-0.60	0.46	0.7	
	Week 12	Tezepelumab	12	11 (91.7)	-0.15 (0.73)	-0.9	-0.66	-0.31	0.06	1.6	0.23 [-0.60, 1.07]
		Placebo	11	11 (100.0)	-0.34 (0.90)	-2.5	-0.80	-0.11	0.51	0.6	
	Week 13	Tezepelumab	12	11 (91.7)	-0.06 (0.68)	-0.8	-0.63	-0.11	0.51	1.3	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.29 (0.92)	-2.3	-0.83	-0.14	0.43	1.1	
	Week 14	Tezepelumab	12	11 (91.7)	-0.16 (0.60)	-0.9	-0.60	-0.23	0.17	0.8	0.14 [-0.70, 0.98]
		Placebo	11	11 (100.0)	-0.25 (0.77)	-1.6	-0.83	-0.26	0.29	1.1	
	Week 15	Tezepelumab	12	11 (91.7)	-0.27 (0.58)	-1.0	-0.80	-0.13	0.11	0.7	0.14 [-0.70, 0.97]
		Placebo	11	11 (100.0)	-0.36 (0.77)	-2.1	-0.69	-0.26	0.06	0.7	
	Week 16	Tezepelumab	12	11 (91.7)	-0.23 (0.57)	-1.0	-0.71	-0.26	0.26	0.7	0.24 [-0.59, 1.08]
		Placebo	11	11 (100.0)	-0.42 (0.89)	-2.3	-0.86	-0.40	0.14	1.2	
	Week 17	Tezepelumab	12	11 (91.7)	-0.24 (0.52)	-1.0	-0.80	-0.25	0.26	0.5	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	-0.45 (0.90)	-2.4	-0.83	-0.66	0.11	1.0	
	Week 18	Tezepelumab	12	11 (91.7)	-0.19 (0.80)	-1.0	-0.89	-0.28	0.29	1.6	0.38 [-0.47, 1.22]
		Placebo	11	11 (100.0)	-0.50 (0.81)	-2.3	-0.89	-0.71	0.23	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	12	11 (91.7)	-0.22 (0.87)	-1.1	-1.03	-0.54	0.54	1.6	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	-0.44 (0.73)	-2.0	-0.93	-0.49	0.29	0.4	
	Week 20	Tezepelumab	12	11 (91.7)	-0.24 (0.75)	-1.1	-0.97	-0.42	0.40	1.2	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.43 (0.67)	-1.7	-0.88	-0.63	0.20	0.4	
	Week 21	Tezepelumab	12	11 (91.7)	-0.15 (0.87)	-1.0	-0.97	-0.48	0.57	1.5	0.33 [-0.52, 1.17]
		Placebo	11	11 (100.0)	-0.44 (0.87)	-2.2	-0.85	-0.63	0.46	0.5	
	Week 22	Tezepelumab	12	11 (91.7)	-0.23 (0.72)	-1.0	-0.94	-0.45	0.63	0.9	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	-0.44 (0.79)	-1.8	-0.85	-0.69	0.37	0.5	
	Week 23	Tezepelumab	12	11 (91.7)	-0.23 (0.76)	-1.0	-0.97	-0.48	0.37	1.2	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.45 (0.84)	-2.0	-0.85	-0.60	0.37	0.7	
	Week 24	Tezepelumab	12	11 (91.7)	-0.17 (0.85)	-1.1	-0.74	-0.45	0.66	1.3	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.40 (0.85)	-1.9	-0.80	-0.63	0.40	0.8	
	Week 25	Tezepelumab	12	11 (91.7)	-0.03 (1.06)	-1.1	-0.85	-0.28	0.89	2.2	0.47 [-0.37, 1.32]
		Placebo	11	11 (100.0)	-0.51 (0.98)	-2.7	-0.80	-0.60	0.26	0.6	
	Week 26	Tezepelumab	12	11 (91.7)	-0.08 (0.90)	-1.1	-0.74	-0.33	0.77	1.5	0.50 [-0.35, 1.35]
		Placebo	11	11 (100.0)	-0.53 (0.88)	-2.5	-0.80	-0.40	0.14	0.5	
	Week 27	Tezepelumab	12	10 (83.3)	0.06 (1.08)	-1.1	-0.77	-0.24	1.11	1.7	0.50 [-0.37, 1.37]
		Placebo	11	11 (100.0)	-0.42 (0.84)	-2.2	-0.80	-0.12	0.20	0.5	
	Week 28	Tezepelumab	12	9 (75.0)	0.13 (1.04)	-1.1	-0.71	-0.17	1.14	1.6	0.56 [-0.34, 1.46]
		Placebo	11	11 (100.0)	-0.38 (0.82)	-1.9	-0.80	-0.20	0.23	0.7	
	Week 29	Tezepelumab	12	9 (75.0)	0.05 (1.10)	-1.2	-0.89	-0.09	0.77	1.8	0.41 [-0.48, 1.30]
		Placebo	11	11 (100.0)	-0.37 (0.93)	-2.3	-0.83	-0.20	0.40	0.7	
	Week 30	Tezepelumab	12	10 (83.3)	-0.00 (1.10)	-1.3	-0.89	-0.20	0.66	1.8	0.50 [-0.37, 1.37]
		Placebo	11	11 (100.0)	-0.47 (0.80)	-2.1	-0.80	-0.54	0.29	0.4	
	Week 31	Tezepelumab	12	9 (75.0)	0.05 (1.20)	-1.3	-0.89	-0.11	0.77	2.1	0.53 [-0.37, 1.43]
		Placebo	11	11 (100.0)	-0.49 (0.88)	-2.5	-0.80	-0.31	0.11	0.5	
	Week 32	Tezepelumab	12	10 (83.3)	0.06 (1.06)	-1.3	-0.80	-0.03	0.54	2.1	0.52 [-0.35, 1.39]
		Placebo	11	11 (100.0)	-0.43 (0.82)	-2.1	-0.80	-0.31	0.03	0.8	
	Week 33	Tezepelumab	12	10 (83.3)	0.07 (0.96)	-1.3	-0.60	0.00	0.74	1.9	0.54 [-0.33, 1.42]
		Placebo	11	11 (100.0)	-0.45 (0.96)	-2.6	-0.80	-0.49	0.30	0.8	
	Week 34	Tezepelumab	12	10 (83.3)	-0.02 (1.00)	-1.4	-0.71	-0.20	0.67	2.0	0.44 [-0.43, 1.31]
		Placebo	11	11 (100.0)	-0.41 (0.77)	-1.5	-0.80	-0.50	0.49	0.6	
	Week 35	Tezepelumab	12	10 (83.3)	-0.08 (0.97)	-1.4	-0.86	-0.23	0.57	1.7	0.50 [-0.37, 1.37]
		Placebo	11	11 (100.0)	-0.50 (0.73)	-1.5	-0.82	-0.74	0.14	0.6	
	Week 36	Tezepelumab	12	10 (83.3)	-0.08 (1.02)	-1.5	-0.91	-0.23	0.63	1.8	0.46 [-0.41, 1.33]
		Placebo	11	11 (100.0)	-0.49 (0.74)	-1.5	-0.86	-0.77	0.20	0.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMH0: Course of ASD weekly night-time score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	12	10 (83.3)	-0.10 (0.95)	-1.4	-0.88	-0.24	0.54	1.5	0.45 [-0.42, 1.32]
		Placebo	11	11 (100.0)	-0.51 (0.88)	-2.1	-0.80	-0.74	0.37	0.7	
	Week 38	Tezepelumab	12	9 (75.0)	0.01 (1.03)	-1.4	-0.80	0.23	0.46	1.7	0.50 [-0.40, 1.39]
		Placebo	11	11 (100.0)	-0.48 (0.94)	-2.3	-0.86	-0.60	0.51	0.7	
	Week 39	Tezepelumab	12	9 (75.0)	0.06 (1.11)	-1.4	-0.74	-0.06	0.66	1.9	0.49 [-0.43, 1.40]
		Placebo	11	10 (90.9)	-0.40 (0.73)	-1.5	-0.82	-0.64	0.11	0.7	
	Week 40	Tezepelumab	12	9 (75.0)	0.06 (1.11)	-1.4	-0.77	0.26	0.51	1.9	0.56 [-0.34, 1.46]
		Placebo	11	11 (100.0)	-0.49 (0.88)	-1.7	-1.52	-0.63	0.31	0.8	
	Week 41	Tezepelumab	12	8 (66.7)	0.10 (1.21)	-1.4	-0.90	-0.01	1.07	1.9	0.59 [-0.35, 1.52]
		Placebo	11	11 (100.0)	-0.54 (0.98)	-2.4	-1.32	-0.54	0.40	0.8	
	Week 42	Tezepelumab	12	8 (66.7)	-0.06 (1.05)	-1.4	-0.93	-0.16	0.79	1.5	0.55 [-0.38, 1.48]
		Placebo	11	11 (100.0)	-0.60 (0.94)	-2.3	-1.51	-0.68	0.23	0.8	
	Week 43	Tezepelumab	12	8 (66.7)	0.13 (1.25)	-1.5	-0.90	0.06	1.29	1.6	0.60 [-0.33, 1.53]
		Placebo	11	11 (100.0)	-0.56 (1.05)	-2.4	-1.54	-0.52	0.37	1.0	
	Week 44	Tezepelumab	12	8 (66.7)	-0.01 (1.14)	-1.4	-0.84	-0.21	0.94	1.6	0.50 [-0.42, 1.43]
		Placebo	11	11 (100.0)	-0.53 (0.97)	-2.2	-1.54	-0.40	0.14	0.8	
	Week 45	Tezepelumab	12	8 (66.7)	-0.04 (1.12)	-1.4	-0.91	-0.22	0.90	1.6	0.58 [-0.35, 1.52]
		Placebo	11	11 (100.0)	-0.66 (1.02)	-2.8	-1.54	-0.48	0.17	0.7	
	Week 46	Tezepelumab	12	8 (66.7)	-0.07 (1.09)	-1.3	-0.94	-0.29	0.83	1.6	0.57 [-0.36, 1.50]
		Placebo	11	11 (100.0)	-0.64 (0.92)	-2.4	-1.54	-0.63	0.14	0.6	
	Week 47	Tezepelumab	12	8 (66.7)	-0.05 (1.11)	-1.4	-0.99	-0.21	1.00	1.4	0.64 [-0.29, 1.58]
		Placebo	11	11 (100.0)	-0.68 (0.89)	-2.3	-1.54	-0.63	-0.03	0.6	
	Week 48	Tezepelumab	12	7 (58.3)	0.03 (1.09)	-1.4	-0.83	0.14	1.37	1.4	0.73 [-0.25, 1.71]
		Placebo	11	11 (100.0)	-0.66 (0.87)	-2.1	-1.54	-0.66	0.03	0.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 1	Tezepelumab	12	12 (100.0)	-0.23 (0.19)	(-0.62, 0.15)	-0.12 (0.28)	(-0.68, 0.44)	0.669																																																																																																																										
	Placebo	11	11 (100.0)	-0.11 (0.20)	(-0.51, 0.29)				Week 2	Tezepelumab	12	12 (100.0)	-0.28 (0.19)	(-0.66, 0.11)	-0.27 (0.28)	(-0.83, 0.29)	0.332	Placebo	11	11 (100.0)	-0.00 (0.20)	(-0.40, 0.40)	Week 3	Tezepelumab	12	12 (100.0)	-0.23 (0.19)	(-0.62, 0.15)	0.05 (0.28)	(-0.51, 0.61)	0.852	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.68, 0.11)	Week 4	Tezepelumab	12	11 (91.7)	-0.20 (0.19)	(-0.59, 0.18)	-0.04 (0.28)	(-0.60, 0.52)	0.897	Placebo	11	11 (100.0)	-0.17 (0.20)	(-0.57, 0.23)	Week 5	Tezepelumab	12	12 (100.0)	-0.38 (0.19)	(-0.77, 0.00)	-0.10 (0.28)	(-0.66, 0.46)	0.726	Placebo	11	11 (100.0)	-0.28 (0.20)	(-0.68, 0.12)	Week 6	Tezepelumab	12	11 (91.7)	-0.41 (0.19)	(-0.79, -0.02)	-0.12 (0.28)	(-0.68, 0.44)	0.669	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)	Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)	Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo
Week 2	Tezepelumab	12	12 (100.0)	-0.28 (0.19)	(-0.66, 0.11)	-0.27 (0.28)	(-0.83, 0.29)	0.332																																																																																																																										
	Placebo	11	11 (100.0)	-0.00 (0.20)	(-0.40, 0.40)				Week 3	Tezepelumab	12	12 (100.0)	-0.23 (0.19)	(-0.62, 0.15)	0.05 (0.28)	(-0.51, 0.61)	0.852	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.68, 0.11)	Week 4	Tezepelumab	12	11 (91.7)	-0.20 (0.19)	(-0.59, 0.18)	-0.04 (0.28)	(-0.60, 0.52)	0.897	Placebo	11	11 (100.0)	-0.17 (0.20)	(-0.57, 0.23)	Week 5	Tezepelumab	12	12 (100.0)	-0.38 (0.19)	(-0.77, 0.00)	-0.10 (0.28)	(-0.66, 0.46)	0.726	Placebo	11	11 (100.0)	-0.28 (0.20)	(-0.68, 0.12)	Week 6	Tezepelumab	12	11 (91.7)	-0.41 (0.19)	(-0.79, -0.02)	-0.12 (0.28)	(-0.68, 0.44)	0.669	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)	Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)	Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)										
Week 3	Tezepelumab	12	12 (100.0)	-0.23 (0.19)	(-0.62, 0.15)	0.05 (0.28)	(-0.51, 0.61)	0.852																																																																																																																										
	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.68, 0.11)				Week 4	Tezepelumab	12	11 (91.7)	-0.20 (0.19)	(-0.59, 0.18)	-0.04 (0.28)	(-0.60, 0.52)	0.897	Placebo	11	11 (100.0)	-0.17 (0.20)	(-0.57, 0.23)	Week 5	Tezepelumab	12	12 (100.0)	-0.38 (0.19)	(-0.77, 0.00)	-0.10 (0.28)	(-0.66, 0.46)	0.726	Placebo	11	11 (100.0)	-0.28 (0.20)	(-0.68, 0.12)	Week 6	Tezepelumab	12	11 (91.7)	-0.41 (0.19)	(-0.79, -0.02)	-0.12 (0.28)	(-0.68, 0.44)	0.669	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)	Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)	Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																								
Week 4	Tezepelumab	12	11 (91.7)	-0.20 (0.19)	(-0.59, 0.18)	-0.04 (0.28)	(-0.60, 0.52)	0.897																																																																																																																										
	Placebo	11	11 (100.0)	-0.17 (0.20)	(-0.57, 0.23)				Week 5	Tezepelumab	12	12 (100.0)	-0.38 (0.19)	(-0.77, 0.00)	-0.10 (0.28)	(-0.66, 0.46)	0.726	Placebo	11	11 (100.0)	-0.28 (0.20)	(-0.68, 0.12)	Week 6	Tezepelumab	12	11 (91.7)	-0.41 (0.19)	(-0.79, -0.02)	-0.12 (0.28)	(-0.68, 0.44)	0.669	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)	Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)	Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																						
Week 5	Tezepelumab	12	12 (100.0)	-0.38 (0.19)	(-0.77, 0.00)	-0.10 (0.28)	(-0.66, 0.46)	0.726																																																																																																																										
	Placebo	11	11 (100.0)	-0.28 (0.20)	(-0.68, 0.12)				Week 6	Tezepelumab	12	11 (91.7)	-0.41 (0.19)	(-0.79, -0.02)	-0.12 (0.28)	(-0.68, 0.44)	0.669	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)	Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)	Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																																				
Week 6	Tezepelumab	12	11 (91.7)	-0.41 (0.19)	(-0.79, -0.02)	-0.12 (0.28)	(-0.68, 0.44)	0.669																																																																																																																										
	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)				Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)	Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																																																		
Week 7	Tezepelumab	12	11 (91.7)	-0.43 (0.19)	(-0.82, -0.04)	-0.13 (0.28)	(-0.69, 0.43)	0.643																																																																																																																										
	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)				Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)	Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																																																																
Week 8	Tezepelumab	12	11 (91.7)	-0.40 (0.19)	(-0.79, -0.01)	-0.26 (0.28)	(-0.83, 0.30)	0.351																																																																																																																										
	Placebo	11	11 (100.0)	-0.13 (0.20)	(-0.53, 0.27)				Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)	Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																																																																														
Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.19)	(-0.72, 0.05)	-0.28 (0.28)	(-0.84, 0.28)	0.327																																																																																																																										
	Placebo	11	11 (100.0)	-0.06 (0.20)	(-0.46, 0.34)				Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																																																																																												
Week 10	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.65, 0.12)	-0.14 (0.28)	(-0.70, 0.42)	0.620																																																																																																																										
	Placebo	11	10 (90.9)	-0.13 (0.20)	(-0.53, 0.27)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	12	12 (100.0)	-0.27 (0.19)	(-0.66, 0.11)	-0.04 (0.28)	(-0.60, 0.52)	0.883	
	Placebo	11	11 (100.0)	-0.23 (0.20)	(-0.63, 0.17)				
Week 12	Tezepelumab	12	11 (91.7)	-0.30 (0.19)	(-0.69, 0.09)	-0.09 (0.28)	(-0.65, 0.47)	0.744	
	Placebo	11	11 (100.0)	-0.21 (0.20)	(-0.61, 0.19)				
Week 13	Tezepelumab	12	11 (91.7)	-0.21 (0.20)	(-0.60, 0.18)	-0.05 (0.28)	(-0.61, 0.51)	0.867	
	Placebo	11	11 (100.0)	-0.16 (0.20)	(-0.56, 0.24)				
Week 14	Tezepelumab	12	11 (91.7)	-0.30 (0.20)	(-0.69, 0.09)	-0.18 (0.28)	(-0.75, 0.38)	0.522	
	Placebo	11	11 (100.0)	-0.12 (0.20)	(-0.52, 0.28)				
Week 15	Tezepelumab	12	11 (91.7)	-0.41 (0.20)	(-0.80, -0.02)	-0.18 (0.28)	(-0.75, 0.38)	0.521	
	Placebo	11	11 (100.0)	-0.23 (0.20)	(-0.63, 0.17)				
Week 16	Tezepelumab	12	11 (91.7)	-0.37 (0.20)	(-0.77, 0.02)	-0.09 (0.28)	(-0.65, 0.47)	0.751	
	Placebo	11	11 (100.0)	-0.28 (0.20)	(-0.68, 0.12)				
Week 17	Tezepelumab	12	11 (91.7)	-0.38 (0.20)	(-0.77, 0.01)	-0.06 (0.28)	(-0.63, 0.50)	0.822	
	Placebo	11	11 (100.0)	-0.31 (0.20)	(-0.71, 0.09)				
Week 18	Tezepelumab	12	11 (91.7)	-0.33 (0.20)	(-0.72, 0.06)	0.04 (0.28)	(-0.53, 0.60)	0.902	
	Placebo	11	11 (100.0)	-0.37 (0.20)	(-0.77, 0.03)				
Week 19	Tezepelumab	12	11 (91.7)	-0.35 (0.20)	(-0.74, 0.04)	-0.04 (0.28)	(-0.61, 0.53)	0.889	
	Placebo	11	11 (100.0)	-0.31 (0.20)	(-0.71, 0.09)				
Week 20	Tezepelumab	12	11 (91.7)	-0.37 (0.20)	(-0.77, 0.02)	-0.07 (0.28)	(-0.63, 0.50)	0.811	
	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	12	11 (91.7)	-0.28 (0.20)	(-0.68, 0.11)	0.02 (0.28)	(-0.55, 0.59)	0.941
	Placebo	11	11 (100.0)	-0.30 (0.20)	(-0.70, 0.10)			
Week 22	Tezepelumab	12	11 (91.7)	-0.36 (0.20)	(-0.76, 0.03)	-0.05 (0.28)	(-0.62, 0.52)	0.856
	Placebo	11	11 (100.0)	-0.31 (0.20)	(-0.71, 0.09)			
Week 23	Tezepelumab	12	11 (91.7)	-0.36 (0.20)	(-0.75, 0.04)	-0.04 (0.28)	(-0.61, 0.53)	0.893
	Placebo	11	11 (100.0)	-0.32 (0.20)	(-0.72, 0.08)			
Week 24	Tezepelumab	12	11 (91.7)	-0.30 (0.20)	(-0.69, 0.10)	-0.03 (0.29)	(-0.60, 0.54)	0.914
	Placebo	11	11 (100.0)	-0.27 (0.20)	(-0.67, 0.13)			
Week 25	Tezepelumab	12	11 (91.7)	-0.15 (0.20)	(-0.55, 0.24)	0.23 (0.29)	(-0.34, 0.80)	0.426
	Placebo	11	11 (100.0)	-0.38 (0.20)	(-0.78, 0.02)			
Week 26	Tezepelumab	12	11 (91.7)	-0.20 (0.20)	(-0.60, 0.19)	0.19 (0.29)	(-0.38, 0.76)	0.502
	Placebo	11	11 (100.0)	-0.39 (0.20)	(-0.79, 0.00)			
Week 27	Tezepelumab	12	10 (83.3)	-0.09 (0.20)	(-0.49, 0.31)	0.20 (0.29)	(-0.37, 0.77)	0.488
	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)			
Week 28	Tezepelumab	12	9 (75.0)	-0.12 (0.20)	(-0.52, 0.29)	0.13 (0.29)	(-0.44, 0.70)	0.648
	Placebo	11	11 (100.0)	-0.25 (0.20)	(-0.65, 0.15)			
Week 29	Tezepelumab	12	9 (75.0)	-0.19 (0.20)	(-0.59, 0.22)	0.05 (0.29)	(-0.53, 0.62)	0.873
	Placebo	11	11 (100.0)	-0.23 (0.20)	(-0.63, 0.17)			
Week 30	Tezepelumab	12	10 (83.3)	-0.15 (0.20)	(-0.56, 0.25)	0.19 (0.29)	(-0.38, 0.77)	0.511
	Placebo	11	11 (100.0)	-0.34 (0.20)	(-0.74, 0.06)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	12	9 (75.0)	-0.14 (0.21)	(-0.55, 0.27)	0.22 (0.29)	(-0.35, 0.80)	0.440
	Placebo	11	11 (100.0)	-0.36 (0.20)	(-0.76, 0.04)			
Week 32	Tezepelumab	12	10 (83.3)	-0.09 (0.21)	(-0.50, 0.32)	0.20 (0.29)	(-0.37, 0.78)	0.483
	Placebo	11	11 (100.0)	-0.29 (0.20)	(-0.69, 0.11)			
Week 33	Tezepelumab	12	10 (83.3)	-0.08 (0.21)	(-0.49, 0.33)	0.23 (0.29)	(-0.34, 0.81)	0.422
	Placebo	11	11 (100.0)	-0.32 (0.20)	(-0.72, 0.08)			
Week 34	Tezepelumab	12	10 (83.3)	-0.17 (0.21)	(-0.59, 0.24)	0.10 (0.29)	(-0.48, 0.68)	0.731
	Placebo	11	11 (100.0)	-0.27 (0.20)	(-0.67, 0.13)			
Week 35	Tezepelumab	12	10 (83.3)	-0.23 (0.21)	(-0.65, 0.18)	0.13 (0.29)	(-0.45, 0.71)	0.647
	Placebo	11	11 (100.0)	-0.37 (0.20)	(-0.77, 0.03)			
Week 36	Tezepelumab	12	10 (83.3)	-0.24 (0.21)	(-0.65, 0.18)	0.12 (0.29)	(-0.46, 0.70)	0.684
	Placebo	11	11 (100.0)	-0.36 (0.20)	(-0.75, 0.04)			
Week 37	Tezepelumab	12	10 (83.3)	-0.26 (0.21)	(-0.67, 0.16)	0.12 (0.29)	(-0.46, 0.70)	0.673
	Placebo	11	11 (100.0)	-0.38 (0.20)	(-0.78, 0.02)			
Week 38	Tezepelumab	12	9 (75.0)	-0.22 (0.21)	(-0.64, 0.19)	0.12 (0.29)	(-0.46, 0.70)	0.683
	Placebo	11	11 (100.0)	-0.34 (0.20)	(-0.74, 0.05)			
Week 39	Tezepelumab	12	9 (75.0)	-0.17 (0.21)	(-0.60, 0.25)	0.24 (0.29)	(-0.34, 0.83)	0.415
	Placebo	11	10 (90.9)	-0.42 (0.20)	(-0.82, -0.02)			
Week 40	Tezepelumab	12	9 (75.0)	-0.17 (0.21)	(-0.59, 0.25)	0.19 (0.30)	(-0.39, 0.78)	0.516
	Placebo	11	11 (100.0)	-0.36 (0.20)	(-0.76, 0.04)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC_IBMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	12	8 (66.7)	-0.09 (0.22)	(-0.52, 0.33)	0.31 (0.30)	(-0.28, 0.90)	0.302
	Placebo	11	11 (100.0)	-0.40 (0.20)	(-0.80, -0.00)			
Week 42	Tezepelumab	12	8 (66.7)	-0.25 (0.22)	(-0.68, 0.19)	0.22 (0.30)	(-0.37, 0.82)	0.461
	Placebo	11	11 (100.0)	-0.47 (0.20)	(-0.87, -0.07)			
Week 43	Tezepelumab	12	8 (66.7)	-0.06 (0.22)	(-0.50, 0.38)	0.36 (0.30)	(-0.23, 0.96)	0.230
	Placebo	11	11 (100.0)	-0.42 (0.20)	(-0.82, -0.02)			
Week 44	Tezepelumab	12	8 (66.7)	-0.19 (0.22)	(-0.63, 0.25)	0.21 (0.30)	(-0.39, 0.81)	0.492
	Placebo	11	11 (100.0)	-0.40 (0.20)	(-0.80, 0.00)			
Week 45	Tezepelumab	12	8 (66.7)	-0.22 (0.22)	(-0.67, 0.22)	0.31 (0.30)	(-0.30, 0.91)	0.313
	Placebo	11	11 (100.0)	-0.53 (0.20)	(-0.93, -0.13)			
Week 46	Tezepelumab	12	8 (66.7)	-0.25 (0.23)	(-0.70, 0.20)	0.26 (0.30)	(-0.35, 0.86)	0.402
	Placebo	11	11 (100.0)	-0.50 (0.20)	(-0.90, -0.10)			
Week 47	Tezepelumab	12	8 (66.7)	-0.23 (0.23)	(-0.68, 0.22)	0.32 (0.31)	(-0.28, 0.93)	0.294
	Placebo	11	11 (100.0)	-0.55 (0.20)	(-0.95, -0.15)			
Week 48	Tezepelumab	12	7 (58.3)	-0.29 (0.23)	(-0.74, 0.17)	0.25 (0.31)	(-0.37, 0.86)	0.426
	Placebo	11	11 (100.0)	-0.53 (0.20)	(-0.93, -0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	55	55 (100.0)	1.23 (0.75)	0.0	0.64	1.36	1.93	2.7	
		Placebo	40	40 (100.0)	1.55 (0.70)	0.2	1.00	1.68	2.00	3.0	
	Week 1	Tezepelumab	55	54 (98.2)	1.11 (0.71)	0.0	0.50	1.07	1.71	2.5	
		Placebo	40	40 (100.0)	1.45 (0.70)	0.0	1.00	1.58	2.00	3.0	
	Week 2	Tezepelumab	55	54 (98.2)	1.02 (0.73)	0.0	0.36	1.00	1.79	2.3	
		Placebo	40	39 (97.5)	1.41 (0.72)	0.0	1.00	1.50	1.92	3.0	
	Week 3	Tezepelumab	55	55 (100.0)	1.04 (0.71)	0.0	0.50	1.00	1.50	2.9	
		Placebo	40	38 (95.0)	1.37 (0.77)	0.0	1.00	1.14	2.00	3.4	
	Week 4	Tezepelumab	55	54 (98.2)	0.96 (0.74)	0.0	0.29	1.00	1.58	2.9	
		Placebo	40	39 (97.5)	1.33 (0.74)	0.0	1.00	1.21	1.93	4.0	
	Week 5	Tezepelumab	55	53 (96.4)	0.93 (0.74)	0.0	0.14	0.93	1.57	2.6	
		Placebo	40	38 (95.0)	1.18 (0.75)	0.0	0.79	1.00	1.79	3.2	
	Week 6	Tezepelumab	55	52 (94.5)	0.97 (0.76)	0.0	0.23	1.00	1.39	3.0	
		Placebo	40	40 (100.0)	1.31 (0.72)	0.0	1.00	1.09	1.86	3.1	
	Week 7	Tezepelumab	55	51 (92.7)	0.96 (0.78)	0.0	0.20	0.93	1.50	3.1	
		Placebo	40	40 (100.0)	1.28 (0.73)	0.0	1.00	1.19	1.93	3.0	
	Week 8	Tezepelumab	55	51 (92.7)	0.92 (0.76)	0.0	0.20	0.92	1.50	2.6	
		Placebo	40	39 (97.5)	1.33 (0.65)	0.0	1.00	1.21	2.00	3.0	
	Week 9	Tezepelumab	55	53 (96.4)	0.91 (0.74)	0.0	0.25	0.93	1.29	2.6	
		Placebo	40	40 (100.0)	1.30 (0.67)	0.0	0.96	1.14	1.86	3.0	
	Week 10	Tezepelumab	55	53 (96.4)	0.91 (0.81)	0.0	0.07	0.86	1.40	2.9	
		Placebo	40	40 (100.0)	1.25 (0.67)	0.0	1.00	1.21	1.75	3.0	
	Week 11	Tezepelumab	55	51 (92.7)	0.94 (0.79)	0.0	0.08	1.00	1.43	3.1	
		Placebo	40	40 (100.0)	1.16 (0.67)	0.0	0.86	1.04	1.63	3.0	
	Week 12	Tezepelumab	55	52 (94.5)	0.88 (0.79)	0.0	0.05	0.79	1.39	2.9	
		Placebo	40	38 (95.0)	1.14 (0.69)	0.0	0.93	1.00	1.64	3.0	
	Week 13	Tezepelumab	55	49 (89.1)	0.90 (0.77)	0.0	0.00	0.93	1.29	2.9	
		Placebo	40	38 (95.0)	1.05 (0.66)	0.0	0.58	1.00	1.33	3.0	
	Week 14	Tezepelumab	55	52 (94.5)	0.95 (0.82)	0.0	0.06	0.96	1.38	3.0	
		Placebo	40	37 (92.5)	1.05 (0.69)	0.0	0.57	1.00	1.36	3.0	
	Week 15	Tezepelumab	55	51 (92.7)	0.89 (0.80)	0.0	0.07	1.00	1.33	3.0	
		Placebo	40	39 (97.5)	0.99 (0.72)	0.0	0.33	1.00	1.50	3.0	
	Week 16	Tezepelumab	55	51 (92.7)	0.82 (0.77)	0.0	0.00	0.75	1.17	2.1	
		Placebo	40	38 (95.0)	1.04 (0.71)	0.0	0.36	1.00	1.50	3.0	
Week 17	Tezepelumab	55	52 (94.5)	0.84 (0.79)	0.0	0.00	0.79	1.50	2.5		
	Placebo	40	38 (95.0)	1.12 (0.73)	0.0	0.75	1.00	1.64	3.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	55	52 (94.5)	0.94 (0.81)	0.0	0.18	0.86	1.75	3.0	
		Placebo	40	38 (95.0)	1.09 (0.71)	0.0	0.71	1.00	1.50	3.0	
	Week 19	Tezepelumab	55	49 (89.1)	0.87 (0.83)	0.0	0.00	0.86	1.21	2.4	
		Placebo	40	39 (97.5)	1.09 (0.75)	0.0	0.50	1.00	1.71	3.0	
	Week 20	Tezepelumab	55	51 (92.7)	0.86 (0.79)	0.0	0.00	0.75	1.70	2.3	
		Placebo	40	37 (92.5)	1.10 (0.75)	0.0	0.67	1.10	1.57	3.0	
	Week 21	Tezepelumab	55	46 (83.6)	0.84 (0.81)	0.0	0.00	0.61	1.67	2.3	
		Placebo	40	38 (95.0)	1.09 (0.78)	0.0	0.29	1.07	1.75	3.0	
	Week 22	Tezepelumab	55	47 (85.5)	0.90 (0.76)	0.0	0.10	1.00	1.75	2.2	
		Placebo	40	38 (95.0)	1.07 (0.74)	0.0	0.20	1.13	1.50	3.0	
	Week 23	Tezepelumab	55	49 (89.1)	0.88 (0.81)	0.0	0.00	0.93	1.38	2.5	
		Placebo	40	36 (90.0)	1.08 (0.76)	0.0	0.32	1.09	1.65	3.0	
	Week 24	Tezepelumab	55	51 (92.7)	0.86 (0.83)	0.0	0.00	1.00	1.14	2.8	
		Placebo	40	36 (90.0)	0.97 (0.76)	0.0	0.04	1.00	1.57	2.9	
	Week 25	Tezepelumab	55	49 (89.1)	0.88 (0.79)	0.0	0.00	1.00	1.20	2.5	
		Placebo	40	36 (90.0)	1.05 (0.79)	0.0	0.24	1.00	1.71	3.0	
	Week 26	Tezepelumab	55	50 (90.9)	0.84 (0.76)	0.0	0.00	1.00	1.13	2.4	
		Placebo	40	37 (92.5)	1.07 (0.85)	0.0	0.14	1.08	1.58	3.0	
	Week 27	Tezepelumab	55	46 (83.6)	0.92 (0.80)	0.0	0.10	1.00	1.50	3.0	
		Placebo	40	36 (90.0)	1.10 (0.87)	0.0	0.32	1.00	1.61	3.1	
	Week 28	Tezepelumab	55	49 (89.1)	0.91 (0.83)	0.0	0.00	1.00	1.36	2.9	
		Placebo	40	36 (90.0)	1.02 (0.84)	0.0	0.21	1.00	1.53	3.4	
	Week 29	Tezepelumab	55	48 (87.3)	0.85 (0.79)	0.0	0.00	0.96	1.41	2.7	
		Placebo	40	37 (92.5)	1.00 (0.81)	0.0	0.08	1.00	1.50	3.0	
	Week 30	Tezepelumab	55	48 (87.3)	0.95 (0.75)	0.0	0.10	1.00	1.65	2.3	
		Placebo	40	36 (90.0)	1.02 (0.78)	0.0	0.38	1.00	1.49	3.0	
	Week 31	Tezepelumab	55	48 (87.3)	0.84 (0.73)	0.0	0.00	1.00	1.37	2.5	
		Placebo	40	37 (92.5)	1.00 (0.81)	0.0	0.33	1.00	1.29	3.1	
	Week 32	Tezepelumab	55	49 (89.1)	0.88 (0.74)	0.0	0.00	1.00	1.43	2.1	
		Placebo	40	37 (92.5)	1.01 (0.80)	0.0	0.29	1.00	1.42	3.0	
	Week 33	Tezepelumab	55	48 (87.3)	0.84 (0.74)	0.0	0.00	0.96	1.23	2.3	
		Placebo	40	37 (92.5)	1.04 (0.78)	0.0	0.36	1.00	1.67	3.0	
	Week 34	Tezepelumab	55	50 (90.9)	0.81 (0.73)	0.0	0.00	1.00	1.29	2.1	
		Placebo	40	38 (95.0)	1.02 (0.78)	0.0	0.08	1.00	1.71	3.0	
	Week 35	Tezepelumab	55	48 (87.3)	0.83 (0.74)	0.0	0.00	0.89	1.19	2.3	
		Placebo	40	36 (90.0)	1.02 (0.76)	0.0	0.35	1.00	1.33	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMH0: Course of ASD weekly wheezing score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	55	48 (87.3)	0.85 (0.75)	0.0	0.00	1.00	1.25	2.6	
		Placebo	40	38 (95.0)	1.08 (0.75)	0.0	0.50	1.00	1.43	3.0	
	Week 37	Tezepelumab	55	47 (85.5)	0.87 (0.75)	0.0	0.00	1.00	1.21	2.6	
		Placebo	40	37 (92.5)	1.11 (0.71)	0.0	0.86	1.00	1.64	3.0	
	Week 38	Tezepelumab	55	47 (85.5)	0.88 (0.81)	0.0	0.00	1.00	1.42	2.9	
		Placebo	40	37 (92.5)	1.04 (0.73)	0.0	0.58	1.00	1.42	3.0	
	Week 39	Tezepelumab	55	49 (89.1)	0.85 (0.78)	0.0	0.00	1.00	1.07	2.5	
		Placebo	40	37 (92.5)	1.04 (0.77)	0.0	0.21	1.00	1.50	3.0	
	Week 40	Tezepelumab	55	49 (89.1)	0.88 (0.77)	0.0	0.00	1.00	1.10	2.6	
		Placebo	40	38 (95.0)	1.11 (0.85)	0.0	0.14	1.00	1.75	3.0	
	Week 41	Tezepelumab	55	50 (90.9)	0.84 (0.77)	0.0	0.00	1.00	1.29	2.4	
		Placebo	40	36 (90.0)	1.10 (0.81)	0.0	0.29	1.00	1.86	3.0	
	Week 42	Tezepelumab	55	47 (85.5)	0.82 (0.77)	0.0	0.00	1.00	1.17	2.5	
		Placebo	40	36 (90.0)	1.08 (0.80)	0.0	0.09	1.07	1.76	3.0	
	Week 43	Tezepelumab	55	49 (89.1)	0.84 (0.79)	0.0	0.00	1.00	1.14	2.8	
		Placebo	40	37 (92.5)	1.09 (0.78)	0.0	0.42	1.00	1.79	3.0	
	Week 44	Tezepelumab	55	48 (87.3)	0.80 (0.74)	0.0	0.00	1.00	1.04	2.2	
		Placebo	40	35 (87.5)	1.09 (0.72)	0.0	0.58	1.00	1.71	3.0	
	Week 45	Tezepelumab	55	48 (87.3)	0.85 (0.78)	0.0	0.00	1.00	1.36	2.4	
		Placebo	40	36 (90.0)	1.00 (0.78)	0.0	0.37	1.00	1.21	3.0	
	Week 46	Tezepelumab	55	47 (85.5)	0.80 (0.79)	0.0	0.00	0.88	1.42	2.2	
		Placebo	40	37 (92.5)	1.05 (0.85)	0.0	0.21	1.00	1.64	3.2	
	Week 47	Tezepelumab	55	46 (83.6)	0.81 (0.81)	0.0	0.00	1.00	1.21	2.7	
		Placebo	40	37 (92.5)	1.06 (0.82)	0.0	0.21	1.00	1.92	3.0	
	Week 48	Tezepelumab	55	49 (89.1)	0.85 (0.85)	0.0	0.00	1.00	1.57	2.9	
		Placebo	40	36 (90.0)	1.00 (0.84)	0.0	0.11	1.00	1.61	3.0	
	Week 49	Tezepelumab	55	47 (85.5)	0.92 (0.83)	0.0	0.00	1.00	1.75	2.6	
		Placebo	40	36 (90.0)	1.03 (0.81)	0.0	0.25	1.00	1.54	3.0	
	Week 50	Tezepelumab	55	44 (80.0)	0.86 (0.79)	0.0	0.00	1.00	1.54	2.5	
		Placebo	40	35 (87.5)	0.94 (0.79)	0.0	0.10	1.00	1.43	3.0	
	Week 51	Tezepelumab	55	45 (81.8)	0.91 (0.81)	0.0	0.00	1.00	1.75	2.2	
		Placebo	40	33 (82.5)	1.01 (0.84)	0.0	0.00	1.00	1.50	3.0	
	Week 52	Tezepelumab	55	39 (70.9)	0.90 (0.81)	0.0	0.00	1.00	1.83	2.4	
		Placebo	40	32 (80.0)	1.00 (0.85)	0.0	0.08	1.00	1.46	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	55	54 (98.2)	-0.13 (0.50)	-2.1	-0.17	0.00	0.14	0.8	-0.07 [-0.48, 0.34]
		Placebo	40	40 (100.0)	-0.10 (0.31)	-0.7	-0.29	-0.13	0.00	0.8	
	Week 2	Tezepelumab	55	54 (98.2)	-0.21 (0.54)	-2.6	-0.29	-0.02	0.07	0.6	-0.13 [-0.54, 0.29]
		Placebo	40	39 (97.5)	-0.14 (0.51)	-1.9	-0.29	-0.02	0.02	1.2	
	Week 3	Tezepelumab	55	55 (100.0)	-0.19 (0.53)	-2.6	-0.36	0.00	0.07	0.9	-0.02 [-0.43, 0.40]
		Placebo	40	38 (95.0)	-0.19 (0.63)	-2.4	-0.44	0.00	0.07	1.3	
	Week 4	Tezepelumab	55	54 (98.2)	-0.26 (0.56)	-2.6	-0.40	-0.07	0.00	0.7	-0.08 [-0.49, 0.34]
		Placebo	40	39 (97.5)	-0.22 (0.58)	-2.4	-0.36	-0.07	0.08	1.0	
	Week 5	Tezepelumab	55	53 (96.4)	-0.29 (0.58)	-2.5	-0.50	-0.07	0.06	0.6	0.10 [-0.32, 0.52]
		Placebo	40	38 (95.0)	-0.35 (0.64)	-2.6	-0.71	-0.21	0.07	1.2	
	Week 6	Tezepelumab	55	52 (94.5)	-0.24 (0.55)	-2.6	-0.43	-0.14	0.04	1.1	-0.00 [-0.41, 0.41]
		Placebo	40	40 (100.0)	-0.24 (0.62)	-2.4	-0.56	-0.08	0.11	0.9	
	Week 7	Tezepelumab	55	51 (92.7)	-0.22 (0.62)	-2.6	-0.43	-0.07	0.07	1.0	0.07 [-0.34, 0.49]
		Placebo	40	40 (100.0)	-0.27 (0.60)	-2.5	-0.67	-0.08	0.07	0.8	
	Week 8	Tezepelumab	55	51 (92.7)	-0.29 (0.61)	-2.6	-0.50	-0.08	0.00	1.0	-0.14 [-0.56, 0.28]
		Placebo	40	39 (97.5)	-0.20 (0.64)	-2.5	-0.64	0.00	0.17	1.2	
	Week 9	Tezepelumab	55	53 (96.4)	-0.30 (0.65)	-2.6	-0.64	-0.07	0.07	1.0	-0.08 [-0.49, 0.33]
		Placebo	40	40 (100.0)	-0.25 (0.69)	-2.4	-0.73	-0.19	0.07	1.6	
	Week 10	Tezepelumab	55	53 (96.4)	-0.31 (0.66)	-2.6	-0.54	-0.07	0.00	1.0	-0.01 [-0.42, 0.40]
		Placebo	40	40 (100.0)	-0.30 (0.63)	-2.5	-0.71	-0.14	0.06	0.8	
	Week 11	Tezepelumab	55	51 (92.7)	-0.28 (0.64)	-2.6	-0.68	0.00	0.14	1.0	0.16 [-0.26, 0.57]
		Placebo	40	40 (100.0)	-0.38 (0.68)	-2.4	-0.84	-0.29	0.00	1.0	
	Week 12	Tezepelumab	55	52 (94.5)	-0.33 (0.72)	-2.6	-0.64	-0.14	0.12	1.4	0.12 [-0.30, 0.54]
		Placebo	40	38 (95.0)	-0.41 (0.70)	-2.4	-0.92	-0.33	0.07	1.3	
	Week 13	Tezepelumab	55	49 (89.1)	-0.27 (0.68)	-2.6	-0.50	-0.14	0.07	1.0	0.33 [-0.10, 0.75]
		Placebo	40	38 (95.0)	-0.50 (0.74)	-2.4	-0.92	-0.36	0.00	1.2	
	Week 14	Tezepelumab	55	52 (94.5)	-0.28 (0.65)	-2.6	-0.62	-0.11	0.07	1.0	0.31 [-0.12, 0.73]
		Placebo	40	37 (92.5)	-0.49 (0.76)	-2.4	-0.97	-0.36	0.07	1.2	
	Week 15	Tezepelumab	55	51 (92.7)	-0.28 (0.66)	-2.6	-0.64	-0.07	0.07	1.0	0.36 [-0.06, 0.78]
		Placebo	40	39 (97.5)	-0.54 (0.78)	-2.7	-1.00	-0.36	0.07	1.1	
	Week 16	Tezepelumab	55	51 (92.7)	-0.37 (0.65)	-2.6	-0.76	-0.14	0.00	1.0	0.20 [-0.22, 0.62]
		Placebo	40	38 (95.0)	-0.50 (0.69)	-2.4	-1.00	-0.29	0.00	0.9	
	Week 17	Tezepelumab	55	52 (94.5)	-0.38 (0.66)	-2.6	-0.71	-0.14	0.00	1.0	0.06 [-0.36, 0.48]
		Placebo	40	38 (95.0)	-0.42 (0.70)	-2.5	-1.00	-0.21	0.00	0.8	
	Week 18	Tezepelumab	55	52 (94.5)	-0.29 (0.69)	-2.6	-0.68	-0.15	0.07	1.0	0.19 [-0.22, 0.61]
		Placebo	40	38 (95.0)	-0.43 (0.71)	-2.4	-0.93	-0.21	0.00	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	55	49 (89.1)	-0.32 (0.70)	-2.6	-0.64	-0.08	0.07	1.0	0.17 [-0.25, 0.59]
		Placebo	40	39 (97.5)	-0.44 (0.73)	-2.7	-0.92	-0.21	0.00	1.0	
	Week 20	Tezepelumab	55	51 (92.7)	-0.35 (0.68)	-2.6	-0.64	-0.14	0.00	1.0	0.16 [-0.26, 0.59]
		Placebo	40	37 (92.5)	-0.46 (0.73)	-2.7	-1.00	-0.33	0.00	0.9	
	Week 21	Tezepelumab	55	46 (83.6)	-0.35 (0.70)	-2.6	-0.86	-0.11	0.01	1.0	0.14 [-0.29, 0.57]
		Placebo	40	38 (95.0)	-0.45 (0.79)	-2.7	-1.00	-0.31	0.07	1.5	
	Week 22	Tezepelumab	55	47 (85.5)	-0.32 (0.67)	-2.6	-0.64	-0.07	0.00	1.0	0.23 [-0.20, 0.66]
		Placebo	40	38 (95.0)	-0.48 (0.75)	-2.7	-0.92	-0.35	0.00	1.1	
	Week 23	Tezepelumab	55	49 (89.1)	-0.34 (0.72)	-2.6	-0.67	-0.07	0.00	1.0	0.21 [-0.22, 0.64]
		Placebo	40	36 (90.0)	-0.50 (0.78)	-2.7	-0.93	-0.35	0.04	0.9	
	Week 24	Tezepelumab	55	51 (92.7)	-0.35 (0.69)	-2.6	-0.64	-0.14	0.00	1.0	0.35 [-0.08, 0.78]
		Placebo	40	36 (90.0)	-0.60 (0.76)	-2.7	-1.00	-0.43	-0.04	0.5	
	Week 25	Tezepelumab	55	49 (89.1)	-0.33 (0.63)	-2.6	-0.64	-0.10	0.00	1.0	0.27 [-0.16, 0.71]
		Placebo	40	36 (90.0)	-0.52 (0.80)	-2.7	-1.00	-0.36	0.00	0.7	
	Week 26	Tezepelumab	55	50 (90.9)	-0.31 (0.68)	-2.6	-0.64	-0.04	0.07	1.0	0.26 [-0.16, 0.69]
		Placebo	40	37 (92.5)	-0.52 (0.90)	-2.8	-0.93	-0.36	0.00	1.6	
	Week 27	Tezepelumab	55	46 (83.6)	-0.29 (0.70)	-2.6	-0.57	-0.07	0.08	1.0	0.27 [-0.17, 0.70]
		Placebo	40	36 (90.0)	-0.50 (0.92)	-2.7	-0.96	-0.35	0.04	1.8	
	Week 28	Tezepelumab	55	49 (89.1)	-0.27 (0.66)	-2.6	-0.57	0.00	0.08	1.0	0.36 [-0.07, 0.79]
		Placebo	40	36 (90.0)	-0.54 (0.86)	-2.7	-1.00	-0.60	0.07	1.1	
	Week 29	Tezepelumab	55	48 (87.3)	-0.36 (0.66)	-2.6	-0.64	-0.11	0.00	1.0	0.23 [-0.20, 0.66]
		Placebo	40	37 (92.5)	-0.54 (0.92)	-2.7	-1.00	-0.55	0.00	1.5	
	Week 30	Tezepelumab	55	48 (87.3)	-0.34 (0.65)	-2.6	-0.71	-0.14	0.04	1.0	0.26 [-0.18, 0.69]
		Placebo	40	36 (90.0)	-0.54 (0.89)	-2.7	-1.07	-0.47	0.00	1.8	
	Week 31	Tezepelumab	55	48 (87.3)	-0.35 (0.71)	-2.6	-0.64	-0.18	0.07	1.0	0.24 [-0.19, 0.67]
		Placebo	40	37 (92.5)	-0.54 (0.87)	-2.7	-1.00	-0.45	0.00	2.0	
	Week 32	Tezepelumab	55	49 (89.1)	-0.31 (0.66)	-2.6	-0.59	-0.14	0.00	1.0	0.28 [-0.15, 0.71]
		Placebo	40	37 (92.5)	-0.53 (0.86)	-2.7	-1.00	-0.50	0.00	1.8	
	Week 33	Tezepelumab	55	48 (87.3)	-0.39 (0.73)	-2.6	-0.88	-0.15	0.09	1.0	0.14 [-0.29, 0.57]
		Placebo	40	37 (92.5)	-0.49 (0.79)	-2.6	-0.93	-0.21	0.00	1.5	
	Week 34	Tezepelumab	55	50 (90.9)	-0.44 (0.68)	-2.6	-0.93	-0.15	0.00	1.0	0.14 [-0.28, 0.56]
		Placebo	40	38 (95.0)	-0.54 (0.78)	-2.7	-1.00	-0.50	0.00	0.9	
	Week 35	Tezepelumab	55	48 (87.3)	-0.38 (0.64)	-2.6	-0.71	-0.15	0.04	1.0	0.22 [-0.21, 0.66]
		Placebo	40	36 (90.0)	-0.53 (0.76)	-2.7	-0.96	-0.63	0.01	1.1	
	Week 36	Tezepelumab	55	48 (87.3)	-0.36 (0.68)	-2.6	-0.65	-0.18	0.07	1.0	0.17 [-0.26, 0.60]
		Placebo	40	38 (95.0)	-0.48 (0.73)	-2.7	-1.00	-0.40	0.00	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	55	47 (85.5)	-0.33 (0.66)	-2.6	-0.64	-0.14	0.07	1.0	0.16 [-0.28, 0.59]
		Placebo	40	37 (92.5)	-0.43 (0.73)	-2.7	-1.00	-0.43	0.00	1.2	
	Week 38	Tezepelumab	55	47 (85.5)	-0.31 (0.68)	-2.6	-0.64	-0.14	0.07	1.0	0.28 [-0.15, 0.71]
		Placebo	40	37 (92.5)	-0.51 (0.70)	-2.7	-1.00	-0.44	0.00	1.0	
	Week 39	Tezepelumab	55	49 (89.1)	-0.36 (0.65)	-2.6	-0.71	-0.14	0.07	1.0	0.22 [-0.21, 0.65]
		Placebo	40	37 (92.5)	-0.51 (0.70)	-2.7	-1.00	-0.36	0.00	0.8	
	Week 40	Tezepelumab	55	49 (89.1)	-0.36 (0.68)	-2.6	-0.71	-0.14	0.00	1.0	0.11 [-0.31, 0.54]
		Placebo	40	38 (95.0)	-0.44 (0.80)	-2.7	-1.00	-0.36	0.00	1.7	
	Week 41	Tezepelumab	55	50 (90.9)	-0.41 (0.66)	-2.6	-0.93	-0.14	0.00	0.5	0.04 [-0.39, 0.47]
		Placebo	40	36 (90.0)	-0.43 (0.82)	-2.5	-0.96	-0.44	0.04	1.8	
	Week 42	Tezepelumab	55	47 (85.5)	-0.39 (0.68)	-2.6	-1.00	-0.14	0.00	0.8	0.12 [-0.31, 0.56]
		Placebo	40	36 (90.0)	-0.47 (0.67)	-2.0	-0.96	-0.57	0.04	0.9	
	Week 43	Tezepelumab	55	49 (89.1)	-0.39 (0.68)	-2.6	-0.93	-0.27	0.00	0.9	0.09 [-0.33, 0.52]
		Placebo	40	37 (92.5)	-0.45 (0.63)	-2.0	-1.00	-0.37	0.00	1.0	
	Week 44	Tezepelumab	55	48 (87.3)	-0.42 (0.70)	-2.6	-0.91	-0.32	0.00	1.0	0.09 [-0.35, 0.52]
		Placebo	40	35 (87.5)	-0.48 (0.63)	-2.0	-1.00	-0.36	0.00	0.9	
	Week 45	Tezepelumab	55	48 (87.3)	-0.38 (0.71)	-2.6	-0.72	-0.15	0.11	1.1	0.25 [-0.19, 0.68]
		Placebo	40	36 (90.0)	-0.55 (0.72)	-2.2	-1.00	-0.61	0.03	0.9	
	Week 46	Tezepelumab	55	47 (85.5)	-0.36 (0.76)	-2.6	-0.93	-0.14	0.10	1.6	0.17 [-0.27, 0.60]
		Placebo	40	37 (92.5)	-0.49 (0.79)	-2.7	-0.93	-0.50	0.00	1.4	
	Week 47	Tezepelumab	55	46 (83.6)	-0.37 (0.73)	-2.6	-0.93	-0.11	0.00	1.0	0.15 [-0.28, 0.58]
		Placebo	40	37 (92.5)	-0.48 (0.72)	-2.7	-0.90	-0.36	0.00	0.8	
	Week 48	Tezepelumab	55	49 (89.1)	-0.30 (0.73)	-2.6	-0.65	-0.12	0.07	1.0	0.32 [-0.11, 0.75]
		Placebo	40	36 (90.0)	-0.53 (0.71)	-2.7	-0.96	-0.45	-0.01	0.8	
	Week 49	Tezepelumab	55	47 (85.5)	-0.30 (0.74)	-2.6	-0.66	-0.07	0.14	1.1	0.28 [-0.15, 0.72]
		Placebo	40	36 (90.0)	-0.50 (0.72)	-2.7	-0.96	-0.37	0.00	1.0	
	Week 50	Tezepelumab	55	44 (80.0)	-0.35 (0.69)	-2.6	-0.66	-0.15	0.07	1.0	0.32 [-0.12, 0.77]
		Placebo	40	35 (87.5)	-0.57 (0.68)	-2.7	-0.93	-0.50	0.00	0.5	
	Week 51	Tezepelumab	55	45 (81.8)	-0.30 (0.68)	-2.6	-0.64	-0.07	0.08	1.0	0.33 [-0.12, 0.78]
		Placebo	40	33 (82.5)	-0.54 (0.76)	-2.7	-1.00	-0.41	-0.07	1.2	
	Week 52	Tezepelumab	55	39 (70.9)	-0.28 (0.69)	-2.6	-0.64	0.00	0.14	1.1	0.50 [0.03, 0.98]
		Placebo	40	32 (80.0)	-0.63 (0.69)	-2.7	-1.00	-0.62	-0.18	1.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	55	54 (98.2)	-0.17 (0.08)	(-0.33, -0.00)	-0.14 (0.13)	(-0.40, 0.11)	0.267
	Placebo	40	40 (100.0)	-0.03 (0.10)	(-0.22, 0.17)			
Week 2	Tezepelumab	55	54 (98.2)	-0.25 (0.08)	(-0.42, -0.09)	-0.19 (0.13)	(-0.45, 0.06)	0.138
	Placebo	40	39 (97.5)	-0.06 (0.10)	(-0.25, 0.13)			
Week 3	Tezepelumab	55	55 (100.0)	-0.24 (0.08)	(-0.40, -0.08)	-0.15 (0.13)	(-0.40, 0.11)	0.253
	Placebo	40	38 (95.0)	-0.09 (0.10)	(-0.29, 0.10)			
Week 4	Tezepelumab	55	54 (98.2)	-0.32 (0.08)	(-0.48, -0.15)	-0.18 (0.13)	(-0.43, 0.08)	0.174
	Placebo	40	39 (97.5)	-0.14 (0.10)	(-0.33, 0.05)			
Week 5	Tezepelumab	55	53 (96.4)	-0.33 (0.08)	(-0.50, -0.17)	-0.07 (0.13)	(-0.32, 0.19)	0.609
	Placebo	40	38 (95.0)	-0.27 (0.10)	(-0.46, -0.08)			
Week 6	Tezepelumab	55	52 (94.5)	-0.27 (0.08)	(-0.44, -0.11)	-0.10 (0.13)	(-0.35, 0.15)	0.438
	Placebo	40	40 (100.0)	-0.17 (0.10)	(-0.36, 0.02)			
Week 7	Tezepelumab	55	51 (92.7)	-0.27 (0.08)	(-0.43, -0.10)	-0.07 (0.13)	(-0.32, 0.19)	0.595
	Placebo	40	40 (100.0)	-0.20 (0.10)	(-0.39, -0.01)			
Week 8	Tezepelumab	55	51 (92.7)	-0.32 (0.08)	(-0.48, -0.15)	-0.19 (0.13)	(-0.44, 0.07)	0.144
	Placebo	40	39 (97.5)	-0.13 (0.10)	(-0.32, 0.06)			
Week 9	Tezepelumab	55	53 (96.4)	-0.34 (0.08)	(-0.51, -0.18)	-0.16 (0.13)	(-0.42, 0.09)	0.207
	Placebo	40	40 (100.0)	-0.18 (0.10)	(-0.37, 0.01)			
Week 10	Tezepelumab	55	53 (96.4)	-0.35 (0.08)	(-0.51, -0.18)	-0.12 (0.13)	(-0.37, 0.14)	0.358
	Placebo	40	40 (100.0)	-0.23 (0.10)	(-0.42, -0.04)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	55	51 (92.7)	-0.33 (0.08)	(-0.50, -0.17)	-0.02 (0.13)	(-0.27, 0.23)	0.876
	Placebo	40	40 (100.0)	-0.31 (0.10)	(-0.51, -0.12)			
Week 12	Tezepelumab	55	52 (94.5)	-0.37 (0.08)	(-0.53, -0.20)	-0.03 (0.13)	(-0.29, 0.22)	0.790
	Placebo	40	38 (95.0)	-0.33 (0.10)	(-0.52, -0.14)			
Week 13	Tezepelumab	55	49 (89.1)	-0.33 (0.08)	(-0.49, -0.16)	0.08 (0.13)	(-0.18, 0.33)	0.552
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.60, -0.21)			
Week 14	Tezepelumab	55	52 (94.5)	-0.29 (0.08)	(-0.45, -0.12)	0.09 (0.13)	(-0.16, 0.34)	0.488
	Placebo	40	37 (92.5)	-0.38 (0.10)	(-0.57, -0.18)			
Week 15	Tezepelumab	55	51 (92.7)	-0.33 (0.08)	(-0.49, -0.16)	0.14 (0.13)	(-0.12, 0.39)	0.282
	Placebo	40	39 (97.5)	-0.47 (0.10)	(-0.66, -0.27)			
Week 16	Tezepelumab	55	51 (92.7)	-0.40 (0.08)	(-0.57, -0.24)	0.01 (0.13)	(-0.25, 0.26)	0.959
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.60, -0.22)			
Week 17	Tezepelumab	55	52 (94.5)	-0.40 (0.08)	(-0.57, -0.24)	-0.07 (0.13)	(-0.33, 0.18)	0.576
	Placebo	40	38 (95.0)	-0.33 (0.10)	(-0.52, -0.14)			
Week 18	Tezepelumab	55	52 (94.5)	-0.32 (0.08)	(-0.48, -0.15)	0.02 (0.13)	(-0.23, 0.28)	0.871
	Placebo	40	38 (95.0)	-0.34 (0.10)	(-0.53, -0.15)			
Week 19	Tezepelumab	55	49 (89.1)	-0.36 (0.08)	(-0.53, -0.19)	0.00 (0.13)	(-0.25, 0.26)	0.976
	Placebo	40	39 (97.5)	-0.36 (0.10)	(-0.56, -0.17)			
Week 20	Tezepelumab	55	51 (92.7)	-0.38 (0.08)	(-0.55, -0.22)	0.01 (0.13)	(-0.25, 0.26)	0.965
	Placebo	40	37 (92.5)	-0.39 (0.10)	(-0.58, -0.20)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	55	46 (83.6)	-0.42 (0.08)	(-0.59, -0.25)	-0.05 (0.13)	(-0.31, 0.21)	0.699
	Placebo	40	38 (95.0)	-0.37 (0.10)	(-0.56, -0.17)			
Week 22	Tezepelumab	55	47 (85.5)	-0.39 (0.08)	(-0.56, -0.22)	0.00 (0.13)	(-0.25, 0.26)	0.971
	Placebo	40	38 (95.0)	-0.39 (0.10)	(-0.59, -0.20)			
Week 23	Tezepelumab	55	49 (89.1)	-0.38 (0.08)	(-0.54, -0.21)	-0.02 (0.13)	(-0.28, 0.23)	0.864
	Placebo	40	36 (90.0)	-0.36 (0.10)	(-0.55, -0.16)			
Week 24	Tezepelumab	55	51 (92.7)	-0.39 (0.08)	(-0.55, -0.22)	0.08 (0.13)	(-0.18, 0.34)	0.544
	Placebo	40	36 (90.0)	-0.47 (0.10)	(-0.66, -0.27)			
Week 25	Tezepelumab	55	49 (89.1)	-0.40 (0.08)	(-0.56, -0.23)	0.00 (0.13)	(-0.26, 0.26)	0.985
	Placebo	40	36 (90.0)	-0.40 (0.10)	(-0.60, -0.20)			
Week 26	Tezepelumab	55	50 (90.9)	-0.38 (0.08)	(-0.54, -0.21)	0.01 (0.13)	(-0.24, 0.27)	0.917
	Placebo	40	37 (92.5)	-0.39 (0.10)	(-0.59, -0.20)			
Week 27	Tezepelumab	55	46 (83.6)	-0.35 (0.08)	(-0.52, -0.19)	0.03 (0.13)	(-0.23, 0.29)	0.826
	Placebo	40	36 (90.0)	-0.38 (0.10)	(-0.58, -0.19)			
Week 28	Tezepelumab	55	49 (89.1)	-0.36 (0.08)	(-0.53, -0.20)	0.04 (0.13)	(-0.22, 0.30)	0.747
	Placebo	40	36 (90.0)	-0.41 (0.10)	(-0.60, -0.21)			
Week 29	Tezepelumab	55	48 (87.3)	-0.40 (0.08)	(-0.56, -0.23)	0.04 (0.13)	(-0.22, 0.30)	0.772
	Placebo	40	37 (92.5)	-0.44 (0.10)	(-0.63, -0.24)			
Week 30	Tezepelumab	55	48 (87.3)	-0.41 (0.08)	(-0.58, -0.25)	0.03 (0.13)	(-0.22, 0.29)	0.791
	Placebo	40	36 (90.0)	-0.45 (0.10)	(-0.64, -0.25)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	55	48 (87.3)	-0.39 (0.08)	(-0.55, -0.22)	0.05 (0.13)	(-0.21, 0.31)	0.706
	Placebo	40	37 (92.5)	-0.44 (0.10)	(-0.63, -0.24)			
Week 32	Tezepelumab	55	49 (89.1)	-0.40 (0.08)	(-0.56, -0.23)	0.03 (0.13)	(-0.23, 0.29)	0.829
	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.62, -0.23)			
Week 33	Tezepelumab	55	48 (87.3)	-0.44 (0.08)	(-0.61, -0.28)	-0.02 (0.13)	(-0.28, 0.24)	0.867
	Placebo	40	37 (92.5)	-0.42 (0.10)	(-0.62, -0.23)			
Week 34	Tezepelumab	55	50 (90.9)	-0.49 (0.08)	(-0.66, -0.32)	-0.04 (0.13)	(-0.30, 0.22)	0.757
	Placebo	40	38 (95.0)	-0.45 (0.10)	(-0.65, -0.25)			
Week 35	Tezepelumab	55	48 (87.3)	-0.44 (0.09)	(-0.60, -0.27)	0.01 (0.13)	(-0.25, 0.27)	0.935
	Placebo	40	36 (90.0)	-0.45 (0.10)	(-0.64, -0.25)			
Week 36	Tezepelumab	55	48 (87.3)	-0.40 (0.09)	(-0.57, -0.23)	-0.01 (0.13)	(-0.27, 0.25)	0.941
	Placebo	40	38 (95.0)	-0.39 (0.10)	(-0.59, -0.19)			
Week 37	Tezepelumab	55	47 (85.5)	-0.41 (0.09)	(-0.58, -0.24)	-0.07 (0.13)	(-0.33, 0.19)	0.578
	Placebo	40	37 (92.5)	-0.34 (0.10)	(-0.53, -0.14)			
Week 38	Tezepelumab	55	47 (85.5)	-0.41 (0.09)	(-0.58, -0.24)	0.00 (0.13)	(-0.26, 0.26)	0.984
	Placebo	40	37 (92.5)	-0.41 (0.10)	(-0.61, -0.21)			
Week 39	Tezepelumab	55	49 (89.1)	-0.45 (0.09)	(-0.61, -0.28)	-0.03 (0.13)	(-0.30, 0.23)	0.792
	Placebo	40	37 (92.5)	-0.41 (0.10)	(-0.61, -0.21)			
Week 40	Tezepelumab	55	49 (89.1)	-0.42 (0.09)	(-0.59, -0.25)	-0.06 (0.13)	(-0.32, 0.20)	0.674
	Placebo	40	38 (95.0)	-0.36 (0.10)	(-0.56, -0.17)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 41	Tezepelumab	55	50 (90.9)	-0.44 (0.09)	(-0.61, -0.28)	-0.09 (0.13)	(-0.35, 0.17)	0.501
	Placebo	40	36 (90.0)	-0.35 (0.10)	(-0.55, -0.16)			
Week 42	Tezepelumab	55	47 (85.5)	-0.44 (0.09)	(-0.61, -0.28)	-0.08 (0.13)	(-0.34, 0.18)	0.551
	Placebo	40	36 (90.0)	-0.37 (0.10)	(-0.56, -0.17)			
Week 43	Tezepelumab	55	49 (89.1)	-0.44 (0.09)	(-0.61, -0.27)	-0.08 (0.13)	(-0.34, 0.18)	0.532
	Placebo	40	37 (92.5)	-0.36 (0.10)	(-0.56, -0.16)			
Week 44	Tezepelumab	55	48 (87.3)	-0.48 (0.09)	(-0.65, -0.31)	-0.08 (0.13)	(-0.34, 0.18)	0.533
	Placebo	40	35 (87.5)	-0.39 (0.10)	(-0.59, -0.19)			
Week 45	Tezepelumab	55	48 (87.3)	-0.45 (0.09)	(-0.62, -0.28)	0.01 (0.13)	(-0.25, 0.27)	0.952
	Placebo	40	36 (90.0)	-0.46 (0.10)	(-0.66, -0.26)			
Week 46	Tezepelumab	55	47 (85.5)	-0.47 (0.09)	(-0.64, -0.30)	-0.06 (0.13)	(-0.33, 0.20)	0.626
	Placebo	40	37 (92.5)	-0.40 (0.10)	(-0.60, -0.21)			
Week 47	Tezepelumab	55	46 (83.6)	-0.44 (0.09)	(-0.61, -0.27)	-0.04 (0.13)	(-0.30, 0.22)	0.777
	Placebo	40	37 (92.5)	-0.40 (0.10)	(-0.60, -0.20)			
Week 48	Tezepelumab	55	49 (89.1)	-0.39 (0.09)	(-0.55, -0.22)	0.08 (0.13)	(-0.18, 0.34)	0.558
	Placebo	40	36 (90.0)	-0.46 (0.10)	(-0.66, -0.27)			
Week 49	Tezepelumab	55	47 (85.5)	-0.39 (0.09)	(-0.56, -0.22)	0.04 (0.13)	(-0.22, 0.31)	0.738
	Placebo	40	36 (90.0)	-0.43 (0.10)	(-0.63, -0.23)			
Week 50	Tezepelumab	55	44 (80.0)	-0.44 (0.09)	(-0.61, -0.27)	0.05 (0.13)	(-0.21, 0.32)	0.696
	Placebo	40	35 (87.5)	-0.50 (0.10)	(-0.70, -0.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	55	45 (81.8)	-0.41 (0.09)	(-0.58, -0.24)	0.03 (0.14)	(-0.23, 0.30)	0.814
	Placebo	40	33 (82.5)	-0.44 (0.10)	(-0.65, -0.24)			
Week 52	Tezepelumab	55	39 (70.9)	-0.39 (0.09)	(-0.57, -0.21)	0.08 (0.14)	(-0.19, 0.35)	0.539
	Placebo	40	32 (80.0)	-0.47 (0.10)	(-0.68, -0.27)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	12	12 (100.0)	1.39 (0.90)	0.0	0.86	1.43	2.00	3.0	
		Placebo	11	11 (100.0)	2.07 (0.95)	0.5	1.29	2.00	3.00	3.8	
	Week 1	Tezepelumab	12	12 (100.0)	1.24 (0.78)	0.2	0.88	1.07	1.32	3.0	
		Placebo	11	11 (100.0)	1.80 (0.72)	0.8	1.00	2.00	2.43	2.9	
	Week 2	Tezepelumab	12	12 (100.0)	1.23 (0.82)	0.2	0.75	1.00	1.50	3.0	
		Placebo	11	10 (90.9)	1.63 (0.83)	0.3	1.14	1.61	2.36	2.6	
	Week 3	Tezepelumab	12	12 (100.0)	1.20 (0.70)	0.3	0.89	1.00	1.18	3.0	
		Placebo	11	10 (90.9)	1.49 (0.79)	0.3	1.00	1.14	2.14	2.7	
	Week 4	Tezepelumab	12	11 (91.7)	1.28 (0.79)	0.0	0.93	1.14	1.86	3.0	
		Placebo	11	11 (100.0)	1.61 (0.62)	0.7	1.00	1.75	2.14	2.6	
	Week 5	Tezepelumab	12	11 (91.7)	1.17 (0.83)	0.0	1.00	1.07	1.43	3.0	
		Placebo	11	11 (100.0)	1.48 (0.70)	0.4	0.92	1.36	2.08	2.4	
	Week 6	Tezepelumab	12	11 (91.7)	1.09 (0.85)	0.0	0.86	1.00	1.07	3.0	
		Placebo	11	11 (100.0)	1.49 (0.88)	0.2	0.50	1.36	2.14	2.9	
	Week 7	Tezepelumab	12	11 (91.7)	1.11 (0.84)	0.0	0.64	1.00	1.21	3.0	
		Placebo	11	11 (100.0)	1.48 (0.88)	0.1	0.57	1.79	2.10	2.8	
	Week 8	Tezepelumab	12	10 (83.3)	1.06 (0.84)	0.0	0.50	1.00	1.36	2.9	
		Placebo	11	11 (100.0)	1.67 (0.75)	0.3	0.71	2.00	2.08	2.8	
	Week 9	Tezepelumab	12	12 (100.0)	1.01 (0.89)	0.0	0.25	1.00	1.32	3.0	
		Placebo	11	11 (100.0)	1.73 (0.82)	0.1	0.86	2.00	2.14	2.8	
	Week 10	Tezepelumab	12	12 (100.0)	1.06 (0.88)	0.0	0.47	1.00	1.26	3.0	
		Placebo	11	10 (90.9)	1.50 (0.81)	0.1	0.86	1.89	2.00	2.4	
	Week 11	Tezepelumab	12	12 (100.0)	1.07 (0.84)	0.0	0.50	1.04	1.21	3.0	
		Placebo	11	10 (90.9)	1.46 (0.74)	0.1	0.80	1.78	2.00	2.2	
	Week 12	Tezepelumab	12	11 (91.7)	1.14 (0.86)	0.0	0.50	1.00	1.75	3.0	
		Placebo	11	11 (100.0)	1.58 (0.81)	0.0	1.14	1.64	2.00	3.0	
	Week 13	Tezepelumab	12	11 (91.7)	1.23 (0.85)	0.0	0.57	1.21	1.86	3.0	
		Placebo	11	11 (100.0)	1.59 (0.84)	0.0	1.07	1.86	2.00	3.0	
	Week 14	Tezepelumab	12	11 (91.7)	1.26 (0.78)	0.0	0.79	1.21	1.36	3.0	
		Placebo	11	11 (100.0)	1.69 (0.91)	0.0	1.00	2.00	2.50	2.9	
	Week 15	Tezepelumab	12	11 (91.7)	1.03 (0.85)	0.0	0.21	1.00	1.14	3.0	
		Placebo	11	11 (100.0)	1.54 (1.02)	0.0	0.21	2.00	2.20	3.0	
	Week 16	Tezepelumab	12	11 (91.7)	1.12 (0.91)	0.0	0.29	1.00	1.14	3.0	
		Placebo	11	11 (100.0)	1.47 (1.03)	0.0	0.21	1.86	2.00	3.0	
Week 17	Tezepelumab	12	11 (91.7)	1.13 (0.93)	0.0	0.33	1.00	1.75	3.0		
	Placebo	11	11 (100.0)	1.46 (0.97)	0.0	0.36	1.79	2.00	3.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMH0: Course of ASD weekly wheezing score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	12	11 (91.7)	1.06 (0.87)	0.0	0.36	1.00	1.29	3.0	
		Placebo	11	11 (100.0)	1.51 (0.93)	0.0	0.50	1.93	2.07	3.0	
	Week 19	Tezepelumab	12	11 (91.7)	1.12 (1.04)	0.0	0.58	1.00	1.14	3.8	
		Placebo	11	11 (100.0)	1.53 (0.88)	0.0	0.64	1.92	2.00	3.0	
	Week 20	Tezepelumab	12	11 (91.7)	1.16 (0.97)	0.0	0.71	1.00	1.07	3.4	
		Placebo	11	11 (100.0)	1.57 (0.90)	0.0	0.64	2.00	2.08	3.0	
	Week 21	Tezepelumab	12	11 (91.7)	1.20 (0.94)	0.0	1.00	1.00	1.64	3.4	
		Placebo	11	11 (100.0)	1.58 (0.87)	0.0	1.00	2.00	2.00	2.9	
	Week 22	Tezepelumab	12	11 (91.7)	1.12 (0.81)	0.0	0.93	1.00	1.36	2.9	
		Placebo	11	11 (100.0)	1.59 (0.98)	0.0	0.57	2.00	2.36	2.9	
	Week 23	Tezepelumab	12	11 (91.7)	1.17 (0.89)	0.0	0.93	1.00	1.43	3.3	
		Placebo	11	11 (100.0)	1.50 (1.02)	0.0	0.21	2.00	2.00	2.9	
	Week 24	Tezepelumab	12	11 (91.7)	1.21 (0.79)	0.0	1.00	1.00	1.57	2.9	
		Placebo	11	11 (100.0)	1.55 (0.94)	0.0	0.50	2.00	2.14	2.9	
	Week 25	Tezepelumab	12	11 (91.7)	1.41 (1.07)	0.0	1.00	1.08	2.08	3.6	
		Placebo	11	11 (100.0)	1.47 (0.94)	0.0	0.42	2.00	2.00	3.0	
	Week 26	Tezepelumab	12	11 (91.7)	1.41 (0.96)	0.1	0.92	1.42	2.10	3.3	
		Placebo	11	11 (100.0)	1.40 (0.97)	0.0	0.21	1.58	2.07	3.0	
	Week 27	Tezepelumab	12	10 (83.3)	1.47 (1.13)	0.0	1.00	1.40	2.07	3.8	
		Placebo	11	11 (100.0)	1.57 (1.01)	0.0	0.50	1.92	2.25	3.0	
	Week 28	Tezepelumab	12	9 (75.0)	1.64 (1.00)	0.2	1.00	1.64	2.08	3.6	
		Placebo	11	11 (100.0)	1.52 (0.98)	0.0	0.42	1.93	2.13	3.0	
	Week 29	Tezepelumab	12	8 (66.7)	1.45 (1.18)	0.0	1.00	1.08	1.75	3.9	
		Placebo	11	11 (100.0)	1.64 (1.05)	0.0	0.43	2.00	2.29	3.0	
	Week 30	Tezepelumab	12	10 (83.3)	1.48 (1.17)	0.0	1.00	1.00	2.20	3.9	
		Placebo	11	11 (100.0)	1.49 (1.05)	0.0	0.07	2.00	2.30	3.0	
	Week 31	Tezepelumab	12	9 (75.0)	1.49 (1.15)	0.0	1.00	1.00	2.00	4.0	
		Placebo	11	11 (100.0)	1.51 (0.98)	0.0	0.43	1.93	2.14	3.0	
	Week 32	Tezepelumab	12	10 (83.3)	1.46 (1.13)	0.0	0.92	1.00	2.00	3.9	
		Placebo	11	11 (100.0)	1.53 (0.98)	0.0	0.79	1.86	2.10	3.0	
	Week 33	Tezepelumab	12	10 (83.3)	1.64 (0.96)	0.8	1.00	1.25	2.00	3.9	
		Placebo	11	11 (100.0)	1.50 (0.88)	0.0	1.00	1.57	2.00	3.1	
	Week 34	Tezepelumab	12	10 (83.3)	1.49 (1.03)	0.7	1.00	1.00	1.21	3.9	
		Placebo	11	11 (100.0)	1.52 (1.03)	0.0	0.43	1.58	2.08	3.0	
	Week 35	Tezepelumab	12	10 (83.3)	1.37 (1.15)	0.1	1.00	1.00	1.29	3.9	
		Placebo	11	11 (100.0)	1.46 (1.08)	0.0	0.14	1.71	2.07	3.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMH0: Course of ASD weekly wheezing score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	12	10 (83.3)	1.32 (1.21)	0.0	1.00	1.00	1.21	4.0	
		Placebo	11	11 (100.0)	1.45 (1.04)	0.0	0.36	1.40	2.00	3.0	
	Week 37	Tezepelumab	12	9 (75.0)	1.46 (1.14)	0.0	1.00	1.00	1.50	3.9	
		Placebo	11	11 (100.0)	1.37 (1.01)	0.0	0.21	1.25	2.10	3.0	
	Week 38	Tezepelumab	12	9 (75.0)	1.53 (1.11)	0.0	1.00	1.00	2.00	3.8	
		Placebo	11	11 (100.0)	1.41 (0.96)	0.0	0.29	1.86	2.00	3.0	
	Week 39	Tezepelumab	12	9 (75.0)	1.51 (1.12)	0.0	1.00	1.14	1.83	4.0	
		Placebo	11	10 (90.9)	1.33 (0.91)	0.0	0.57	1.17	2.00	3.0	
	Week 40	Tezepelumab	12	9 (75.0)	1.54 (1.15)	0.0	1.00	1.00	2.00	4.0	
		Placebo	11	11 (100.0)	1.49 (1.05)	0.0	0.58	1.36	2.07	3.1	
	Week 41	Tezepelumab	12	8 (66.7)	1.46 (1.18)	0.0	1.00	1.00	1.82	4.0	
		Placebo	11	10 (90.9)	1.31 (0.88)	0.0	0.75	1.25	2.00	3.0	
	Week 42	Tezepelumab	12	8 (66.7)	1.44 (1.18)	0.0	0.96	1.04	1.75	4.0	
		Placebo	11	11 (100.0)	1.30 (1.02)	0.0	0.14	1.20	2.07	3.0	
	Week 43	Tezepelumab	12	8 (66.7)	1.44 (1.14)	0.0	1.00	1.14	1.67	3.9	
		Placebo	11	11 (100.0)	1.25 (1.02)	0.0	0.14	1.00	2.00	3.0	
	Week 44	Tezepelumab	12	8 (66.7)	1.37 (1.16)	0.0	0.89	1.00	1.64	3.9	
		Placebo	11	11 (100.0)	1.30 (1.06)	0.0	0.21	1.00	2.10	3.0	
	Week 45	Tezepelumab	12	8 (66.7)	1.34 (1.03)	0.0	0.96	1.00	1.64	3.5	
		Placebo	11	10 (90.9)	1.13 (1.01)	0.0	0.33	1.04	2.00	3.0	
	Week 46	Tezepelumab	12	7 (58.3)	1.44 (1.17)	0.0	1.00	1.00	2.00	3.7	
		Placebo	11	11 (100.0)	1.29 (1.00)	0.0	0.29	1.14	2.08	3.0	
	Week 47	Tezepelumab	12	8 (66.7)	1.44 (1.21)	0.0	0.86	1.00	1.89	4.0	
		Placebo	11	11 (100.0)	1.25 (1.04)	0.0	0.14	1.00	2.08	3.0	
	Week 48	Tezepelumab	12	7 (58.3)	1.60 (1.13)	0.8	1.00	1.00	2.00	4.0	
		Placebo	11	11 (100.0)	1.26 (1.01)	0.0	0.29	1.00	2.00	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	12	12 (100.0)	-0.15 (0.48)	-1.0	-0.56	0.00	0.14	0.8	0.23 [-0.59, 1.05]
		Placebo	11	11 (100.0)	-0.27 (0.56)	-1.6	-0.42	-0.07	0.05	0.4	
	Week 2	Tezepelumab	12	12 (100.0)	-0.16 (0.48)	-1.0	-0.61	0.00	0.18	0.4	0.23 [-0.61, 1.07]
		Placebo	11	10 (90.9)	-0.27 (0.43)	-1.1	-0.42	-0.14	0.07	0.2	
	Week 3	Tezepelumab	12	12 (100.0)	-0.20 (0.68)	-1.4	-0.68	-0.07	0.07	0.9	0.32 [-0.52, 1.17]
		Placebo	11	10 (90.9)	-0.40 (0.61)	-1.4	-0.93	-0.26	0.07	0.4	
	Week 4	Tezepelumab	12	11 (91.7)	-0.24 (0.81)	-1.7	-0.71	-0.30	0.21	1.1	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	-0.45 (0.76)	-2.1	-1.00	-0.14	0.29	0.4	
	Week 5	Tezepelumab	12	11 (91.7)	-0.26 (0.74)	-1.7	-0.93	0.00	0.21	0.9	0.37 [-0.47, 1.22]
		Placebo	11	11 (100.0)	-0.59 (1.00)	-2.9	-1.32	-0.07	0.18	0.4	
	Week 6	Tezepelumab	12	11 (91.7)	-0.34 (0.73)	-1.7	-1.00	-0.21	0.07	0.9	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.58 (1.01)	-2.7	-1.25	-0.07	0.00	0.6	
	Week 7	Tezepelumab	12	11 (91.7)	-0.32 (0.77)	-1.7	-1.07	-0.07	0.26	0.7	0.28 [-0.56, 1.13]
		Placebo	11	11 (100.0)	-0.59 (1.09)	-2.7	-1.54	-0.36	0.07	0.9	
	Week 8	Tezepelumab	12	10 (83.3)	-0.51 (0.85)	-2.0	-1.00	-0.39	0.29	0.4	-0.12 [-0.98, 0.73]
		Placebo	11	11 (100.0)	-0.40 (1.00)	-2.1	-1.04	-0.21	0.54	1.0	
	Week 9	Tezepelumab	12	12 (100.0)	-0.39 (0.92)	-2.0	-1.00	-0.32	0.39	0.9	-0.05 [-0.87, 0.77]
		Placebo	11	11 (100.0)	-0.34 (1.02)	-2.1	-0.96	-0.21	0.55	1.0	
	Week 10	Tezepelumab	12	12 (100.0)	-0.33 (0.93)	-1.9	-1.00	-0.08	0.32	1.0	0.23 [-0.61, 1.07]
		Placebo	11	10 (90.9)	-0.55 (0.95)	-1.9	-1.42	-0.43	0.07	1.0	
	Week 11	Tezepelumab	12	12 (100.0)	-0.33 (0.85)	-1.8	-0.82	-0.14	0.15	1.1	0.30 [-0.55, 1.14]
		Placebo	11	10 (90.9)	-0.59 (0.95)	-1.9	-0.95	-0.83	0.21	1.0	
	Week 12	Tezepelumab	12	11 (91.7)	-0.38 (1.03)	-1.9	-1.00	-0.50	0.00	1.9	0.11 [-0.73, 0.94]
		Placebo	11	11 (100.0)	-0.49 (1.00)	-2.2	-1.00	-0.36	0.14	1.0	
	Week 13	Tezepelumab	12	11 (91.7)	-0.29 (1.01)	-1.7	-1.00	-0.29	0.29	1.8	0.18 [-0.66, 1.02]
		Placebo	11	11 (100.0)	-0.47 (1.07)	-2.1	-1.25	-0.29	0.71	1.0	
	Week 14	Tezepelumab	12	11 (91.7)	-0.26 (0.86)	-1.7	-1.00	-0.21	0.29	1.3	0.12 [-0.71, 0.96]
		Placebo	11	11 (100.0)	-0.37 (0.97)	-2.0	-1.30	-0.29	0.61	1.0	
	Week 15	Tezepelumab	12	11 (91.7)	-0.49 (0.84)	-1.8	-1.00	-0.50	0.14	0.9	0.03 [-0.80, 0.87]
		Placebo	11	11 (100.0)	-0.52 (0.95)	-2.0	-1.54	-0.43	0.00	1.0	
	Week 16	Tezepelumab	12	11 (91.7)	-0.40 (0.87)	-1.7	-1.00	-0.21	0.14	1.1	0.21 [-0.63, 1.05]
		Placebo	11	11 (100.0)	-0.60 (1.00)	-2.0	-1.75	-0.43	-0.20	1.0	
	Week 17	Tezepelumab	12	11 (91.7)	-0.39 (0.82)	-1.7	-1.00	0.00	0.29	0.5	0.23 [-0.61, 1.07]
		Placebo	11	11 (100.0)	-0.61 (1.09)	-2.2	-1.68	-0.79	0.50	1.0	
Week 18	Tezepelumab	12	11 (91.7)	-0.46 (1.12)	-1.8	-1.64	-0.56	0.29	1.8	0.09 [-0.74, 0.93]	
	Placebo	11	11 (100.0)	-0.56 (1.08)	-2.1	-1.46	-0.86	0.64	1.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMH0: Course of ASD weekly wheezing score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	12	11 (91.7)	-0.40 (1.32)	-2.1	-1.42	-0.64	0.29	2.6	0.11 [-0.73, 0.94]
		Placebo	11	11 (100.0)	-0.53 (1.07)	-2.0	-1.25	-0.86	0.71	1.0	
	Week 20	Tezepelumab	12	11 (91.7)	-0.36 (1.18)	-2.0	-1.00	-0.64	0.29	2.2	0.12 [-0.71, 0.96]
		Placebo	11	11 (100.0)	-0.50 (1.01)	-2.0	-1.11	-0.90	0.63	1.0	
	Week 21	Tezepelumab	12	11 (91.7)	-0.32 (1.26)	-2.0	-1.00	-0.64	0.64	2.2	0.15 [-0.69, 0.98]
		Placebo	11	11 (100.0)	-0.49 (1.06)	-2.0	-1.42	-1.00	0.61	1.0	
	Week 22	Tezepelumab	12	11 (91.7)	-0.40 (1.10)	-1.9	-1.00	-0.64	0.36	1.6	0.07 [-0.77, 0.90]
		Placebo	11	11 (100.0)	-0.47 (1.01)	-2.0	-1.37	-0.64	0.61	1.0	
	Week 23	Tezepelumab	12	11 (91.7)	-0.35 (1.19)	-2.0	-1.00	-0.64	0.43	2.0	0.19 [-0.65, 1.03]
		Placebo	11	11 (100.0)	-0.57 (1.03)	-2.0	-1.37	-1.00	0.68	1.0	
	Week 24	Tezepelumab	12	11 (91.7)	-0.31 (1.15)	-2.0	-1.00	-0.50	0.45	1.6	0.19 [-0.65, 1.03]
		Placebo	11	11 (100.0)	-0.51 (1.01)	-2.0	-1.50	-0.86	0.61	1.0	
	Week 25	Tezepelumab	12	11 (91.7)	-0.11 (1.45)	-2.0	-1.00	-0.27	0.45	2.4	0.38 [-0.46, 1.22]
		Placebo	11	11 (100.0)	-0.60 (1.12)	-2.4	-1.33	-0.93	0.71	1.0	
	Week 26	Tezepelumab	12	11 (91.7)	-0.11 (1.32)	-2.1	-1.00	-0.02	0.70	2.1	0.46 [-0.38, 1.31]
		Placebo	11	11 (100.0)	-0.66 (1.04)	-2.2	-1.61	-0.79	0.00	1.0	
	Week 27	Tezepelumab	12	10 (83.3)	0.00 (1.52)	-2.0	-1.00	-0.25	1.36	2.6	0.39 [-0.47, 1.26]
		Placebo	11	11 (100.0)	-0.50 (0.98)	-2.0	-1.54	-0.33	0.30	1.0	
	Week 28	Tezepelumab	12	9 (75.0)	0.12 (1.55)	-2.0	-1.00	-0.27	1.57	2.4	0.54 [-0.36, 1.43]
		Placebo	11	11 (100.0)	-0.55 (0.93)	-2.0	-1.33	-0.88	0.21	1.0	
	Week 29	Tezepelumab	12	8 (66.7)	-0.18 (1.53)	-2.0	-1.36	-0.32	0.61	2.7	0.20 [-0.72, 1.11]
		Placebo	11	11 (100.0)	-0.43 (1.09)	-2.0	-1.54	-0.71	0.71	1.0	
	Week 30	Tezepelumab	12	10 (83.3)	0.01 (1.47)	-2.0	-1.00	-0.05	0.93	2.7	0.47 [-0.40, 1.34]
		Placebo	11	11 (100.0)	-0.58 (1.00)	-2.0	-1.50	-0.86	0.21	1.0	
	Week 31	Tezepelumab	12	9 (75.0)	-0.04 (1.58)	-2.3	-1.00	-0.14	0.93	2.8	0.41 [-0.48, 1.30]
		Placebo	11	11 (100.0)	-0.56 (0.96)	-2.0	-1.32	-0.86	0.43	1.0	
	Week 32	Tezepelumab	12	10 (83.3)	-0.01 (1.44)	-2.1	-1.00	0.01	0.93	2.7	0.44 [-0.42, 1.31]
		Placebo	11	11 (100.0)	-0.53 (0.87)	-2.0	-1.00	-0.90	-0.04	1.0	
	Week 33	Tezepelumab	12	10 (83.3)	0.17 (1.29)	-1.9	-0.64	0.02	0.93	2.7	0.62 [-0.26, 1.50]
		Placebo	11	11 (100.0)	-0.57 (1.06)	-2.2	-1.00	-0.71	0.63	1.0	
	Week 34	Tezepelumab	12	10 (83.3)	0.02 (1.27)	-2.0	-0.71	-0.04	0.57	2.6	0.51 [-0.36, 1.38]
		Placebo	11	11 (100.0)	-0.54 (0.94)	-2.0	-1.00	-0.87	0.30	1.0	
	Week 35	Tezepelumab	12	10 (83.3)	-0.11 (1.39)	-2.0	-1.00	-0.16	0.48	2.7	0.43 [-0.44, 1.29]
		Placebo	11	11 (100.0)	-0.61 (0.98)	-2.0	-1.06	-0.94	0.43	1.0	
	Week 36	Tezepelumab	12	10 (83.3)	-0.15 (1.41)	-2.0	-1.00	-0.21	0.50	2.8	0.40 [-0.47, 1.26]
		Placebo	11	11 (100.0)	-0.62 (0.94)	-2.0	-1.07	-1.00	0.11	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMH0: Course of ASD weekly wheezing score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	12	9 (75.0)	-0.06 (1.46)	-2.0	-1.00	0.21	0.50	2.7	0.53 [-0.37, 1.42]
		Placebo	11	11 (100.0)	-0.70 (0.96)	-2.0	-1.38	-1.00	-0.04	1.0	
	Week 38	Tezepelumab	12	9 (75.0)	0.01 (1.50)	-2.0	-1.00	0.14	0.93	2.6	0.52 [-0.38, 1.42]
		Placebo	11	11 (100.0)	-0.66 (1.07)	-2.0	-1.68	-1.00	0.57	1.0	
	Week 39	Tezepelumab	12	9 (75.0)	-0.01 (1.53)	-2.0	-1.00	-0.07	1.07	2.8	0.44 [-0.48, 1.35]
		Placebo	11	10 (90.9)	-0.56 (0.95)	-2.0	-1.14	-1.00	0.05	1.0	
	Week 40	Tezepelumab	12	9 (75.0)	0.02 (1.53)	-2.0	-1.00	0.00	0.86	2.8	0.48 [-0.41, 1.38]
		Placebo	11	11 (100.0)	-0.58 (0.91)	-2.0	-1.00	-0.83	0.07	1.0	
	Week 41	Tezepelumab	12	8 (66.7)	0.04 (1.65)	-2.0	-1.36	0.00	1.11	2.8	0.51 [-0.44, 1.46]
		Placebo	11	10 (90.9)	-0.67 (1.11)	-2.2	-1.39	-1.00	0.21	1.0	
	Week 42	Tezepelumab	12	8 (66.7)	0.02 (1.61)	-1.9	-1.36	0.07	0.93	2.8	0.61 [-0.32, 1.55]
		Placebo	11	11 (100.0)	-0.77 (0.99)	-2.0	-1.61	-1.00	-0.09	1.0	
	Week 43	Tezepelumab	12	8 (66.7)	0.02 (1.63)	-2.0	-1.36	-0.07	1.17	2.7	0.65 [-0.29, 1.59]
		Placebo	11	11 (100.0)	-0.82 (0.99)	-2.0	-1.64	-1.00	-0.29	1.0	
	Week 44	Tezepelumab	12	8 (66.7)	-0.05 (1.59)	-2.0	-1.36	-0.18	1.00	2.7	0.56 [-0.37, 1.49]
		Placebo	11	11 (100.0)	-0.76 (0.98)	-2.0	-1.64	-0.90	-0.29	1.0	
	Week 45	Tezepelumab	12	8 (66.7)	-0.08 (1.51)	-2.0	-1.36	-0.18	1.07	2.3	0.58 [-0.38, 1.53]
		Placebo	11	10 (90.9)	-0.85 (1.17)	-2.7	-1.64	-0.86	-0.21	1.0	
	Week 46	Tezepelumab	12	7 (58.3)	0.24 (1.46)	-1.7	-1.00	0.36	1.29	2.5	0.86 [-0.14, 1.85]
		Placebo	11	11 (100.0)	-0.78 (1.00)	-2.0	-1.64	-0.92	-0.14	1.0	
	Week 47	Tezepelumab	12	8 (66.7)	0.02 (1.64)	-2.0	-1.36	0.00	1.04	2.8	0.64 [-0.29, 1.58]
		Placebo	11	11 (100.0)	-0.81 (0.98)	-2.0	-1.64	-1.00	-0.37	1.0	
	Week 48	Tezepelumab	12	7 (58.3)	0.22 (1.59)	-2.0	-1.00	0.43	1.29	2.8	0.83 [-0.16, 1.82]
		Placebo	11	11 (100.0)	-0.81 (0.98)	-2.0	-1.64	-1.00	-0.29	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 1	Tezepelumab	12	12 (100.0)	-0.37 (0.26)	(-0.90, 0.16)	-0.27 (0.38)	(-1.04, 0.50)	0.483																																																																																																																										
	Placebo	11	11 (100.0)	-0.10 (0.27)	(-0.64, 0.44)				Week 2	Tezepelumab	12	12 (100.0)	-0.38 (0.26)	(-0.91, 0.14)	-0.14 (0.39)	(-0.91, 0.63)	0.709	Placebo	11	10 (90.9)	-0.24 (0.27)	(-0.78, 0.31)	Week 3	Tezepelumab	12	12 (100.0)	-0.42 (0.26)	(-0.94, 0.11)	-0.03 (0.39)	(-0.80, 0.74)	0.934	Placebo	11	10 (90.9)	-0.38 (0.27)	(-0.93, 0.16)	Week 4	Tezepelumab	12	11 (91.7)	-0.40 (0.26)	(-0.93, 0.13)	-0.12 (0.38)	(-0.89, 0.65)	0.762	Placebo	11	11 (100.0)	-0.28 (0.27)	(-0.83, 0.26)	Week 5	Tezepelumab	12	11 (91.7)	-0.50 (0.26)	(-1.02, 0.03)	-0.08 (0.39)	(-0.85, 0.69)	0.832	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.13)	Week 6	Tezepelumab	12	11 (91.7)	-0.59 (0.26)	(-1.11, -0.06)	-0.18 (0.39)	(-0.95, 0.59)	0.645	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)	Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo
Week 2	Tezepelumab	12	12 (100.0)	-0.38 (0.26)	(-0.91, 0.14)	-0.14 (0.39)	(-0.91, 0.63)	0.709																																																																																																																										
	Placebo	11	10 (90.9)	-0.24 (0.27)	(-0.78, 0.31)				Week 3	Tezepelumab	12	12 (100.0)	-0.42 (0.26)	(-0.94, 0.11)	-0.03 (0.39)	(-0.80, 0.74)	0.934	Placebo	11	10 (90.9)	-0.38 (0.27)	(-0.93, 0.16)	Week 4	Tezepelumab	12	11 (91.7)	-0.40 (0.26)	(-0.93, 0.13)	-0.12 (0.38)	(-0.89, 0.65)	0.762	Placebo	11	11 (100.0)	-0.28 (0.27)	(-0.83, 0.26)	Week 5	Tezepelumab	12	11 (91.7)	-0.50 (0.26)	(-1.02, 0.03)	-0.08 (0.39)	(-0.85, 0.69)	0.832	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.13)	Week 6	Tezepelumab	12	11 (91.7)	-0.59 (0.26)	(-1.11, -0.06)	-0.18 (0.39)	(-0.95, 0.59)	0.645	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)	Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)										
Week 3	Tezepelumab	12	12 (100.0)	-0.42 (0.26)	(-0.94, 0.11)	-0.03 (0.39)	(-0.80, 0.74)	0.934																																																																																																																										
	Placebo	11	10 (90.9)	-0.38 (0.27)	(-0.93, 0.16)				Week 4	Tezepelumab	12	11 (91.7)	-0.40 (0.26)	(-0.93, 0.13)	-0.12 (0.38)	(-0.89, 0.65)	0.762	Placebo	11	11 (100.0)	-0.28 (0.27)	(-0.83, 0.26)	Week 5	Tezepelumab	12	11 (91.7)	-0.50 (0.26)	(-1.02, 0.03)	-0.08 (0.39)	(-0.85, 0.69)	0.832	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.13)	Week 6	Tezepelumab	12	11 (91.7)	-0.59 (0.26)	(-1.11, -0.06)	-0.18 (0.39)	(-0.95, 0.59)	0.645	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)	Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																								
Week 4	Tezepelumab	12	11 (91.7)	-0.40 (0.26)	(-0.93, 0.13)	-0.12 (0.38)	(-0.89, 0.65)	0.762																																																																																																																										
	Placebo	11	11 (100.0)	-0.28 (0.27)	(-0.83, 0.26)				Week 5	Tezepelumab	12	11 (91.7)	-0.50 (0.26)	(-1.02, 0.03)	-0.08 (0.39)	(-0.85, 0.69)	0.832	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.13)	Week 6	Tezepelumab	12	11 (91.7)	-0.59 (0.26)	(-1.11, -0.06)	-0.18 (0.39)	(-0.95, 0.59)	0.645	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)	Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																						
Week 5	Tezepelumab	12	11 (91.7)	-0.50 (0.26)	(-1.02, 0.03)	-0.08 (0.39)	(-0.85, 0.69)	0.832																																																																																																																										
	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.13)				Week 6	Tezepelumab	12	11 (91.7)	-0.59 (0.26)	(-1.11, -0.06)	-0.18 (0.39)	(-0.95, 0.59)	0.645	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)	Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)	Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																																				
Week 6	Tezepelumab	12	11 (91.7)	-0.59 (0.26)	(-1.11, -0.06)	-0.18 (0.39)	(-0.95, 0.59)	0.645																																																																																																																										
	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)				Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)	Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																																																		
Week 7	Tezepelumab	12	11 (91.7)	-0.58 (0.26)	(-1.11, -0.05)	-0.16 (0.39)	(-0.93, 0.61)	0.681																																																																																																																										
	Placebo	11	11 (100.0)	-0.42 (0.27)	(-0.96, 0.12)				Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)	Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																																																																
Week 8	Tezepelumab	12	10 (83.3)	-0.69 (0.26)	(-1.21, -0.16)	-0.46 (0.39)	(-1.23, 0.31)	0.239																																																																																																																										
	Placebo	11	11 (100.0)	-0.23 (0.27)	(-0.77, 0.32)				Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)	Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																																																																														
Week 9	Tezepelumab	12	12 (100.0)	-0.61 (0.26)	(-1.13, -0.08)	-0.44 (0.38)	(-1.21, 0.33)	0.260																																																																																																																										
	Placebo	11	11 (100.0)	-0.17 (0.27)	(-0.71, 0.37)				Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																																																																																												
Week 10	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.08, -0.03)	-0.27 (0.39)	(-1.04, 0.50)	0.482																																																																																																																										
	Placebo	11	10 (90.9)	-0.28 (0.27)	(-0.83, 0.26)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	12	12 (100.0)	-0.55 (0.26)	(-1.07, -0.02)	-0.24 (0.39)	(-1.01, 0.53)	0.542
	Placebo	11	10 (90.9)	-0.31 (0.27)	(-0.86, 0.23)			
Week 12	Tezepelumab	12	11 (91.7)	-0.56 (0.26)	(-1.09, -0.03)	-0.24 (0.38)	(-1.01, 0.53)	0.530
	Placebo	11	11 (100.0)	-0.32 (0.27)	(-0.86, 0.22)			
Week 13	Tezepelumab	12	11 (91.7)	-0.47 (0.26)	(-0.99, 0.06)	-0.16 (0.39)	(-0.93, 0.61)	0.675
	Placebo	11	11 (100.0)	-0.30 (0.27)	(-0.85, 0.24)			
Week 14	Tezepelumab	12	11 (91.7)	-0.44 (0.27)	(-0.97, 0.09)	-0.24 (0.39)	(-1.01, 0.54)	0.544
	Placebo	11	11 (100.0)	-0.20 (0.27)	(-0.74, 0.34)			
Week 15	Tezepelumab	12	11 (91.7)	-0.67 (0.27)	(-1.20, -0.14)	-0.32 (0.39)	(-1.09, 0.45)	0.413
	Placebo	11	11 (100.0)	-0.35 (0.27)	(-0.90, 0.19)			
Week 16	Tezepelumab	12	11 (91.7)	-0.57 (0.27)	(-1.11, -0.04)	-0.15 (0.39)	(-0.92, 0.63)	0.705
	Placebo	11	11 (100.0)	-0.43 (0.27)	(-0.97, 0.11)			
Week 17	Tezepelumab	12	11 (91.7)	-0.56 (0.27)	(-1.09, -0.03)	-0.13 (0.39)	(-0.90, 0.65)	0.747
	Placebo	11	11 (100.0)	-0.44 (0.27)	(-0.98, 0.11)			
Week 18	Tezepelumab	12	11 (91.7)	-0.63 (0.27)	(-1.17, -0.10)	-0.24 (0.39)	(-1.01, 0.53)	0.535
	Placebo	11	11 (100.0)	-0.39 (0.27)	(-0.93, 0.15)			
Week 19	Tezepelumab	12	11 (91.7)	-0.57 (0.27)	(-1.11, -0.04)	-0.21 (0.39)	(-0.99, 0.56)	0.585
	Placebo	11	11 (100.0)	-0.36 (0.27)	(-0.90, 0.18)			
Week 20	Tezepelumab	12	11 (91.7)	-0.53 (0.27)	(-1.07, 0.00)	-0.21 (0.39)	(-0.98, 0.57)	0.598
	Placebo	11	11 (100.0)	-0.33 (0.27)	(-0.87, 0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	12	11 (91.7)	-0.49 (0.27)	(-1.02, 0.05)	-0.17 (0.39)	(-0.94, 0.61)	0.668
	Placebo	11	11 (100.0)	-0.32 (0.27)	(-0.86, 0.22)			
Week 22	Tezepelumab	12	11 (91.7)	-0.57 (0.27)	(-1.11, -0.03)	-0.27 (0.39)	(-1.04, 0.51)	0.492
	Placebo	11	11 (100.0)	-0.30 (0.27)	(-0.85, 0.24)			
Week 23	Tezepelumab	12	11 (91.7)	-0.52 (0.27)	(-1.06, 0.02)	-0.12 (0.39)	(-0.90, 0.65)	0.748
	Placebo	11	11 (100.0)	-0.40 (0.27)	(-0.94, 0.15)			
Week 24	Tezepelumab	12	11 (91.7)	-0.48 (0.27)	(-1.01, 0.06)	-0.13 (0.39)	(-0.91, 0.64)	0.737
	Placebo	11	11 (100.0)	-0.35 (0.27)	(-0.89, 0.20)			
Week 25	Tezepelumab	12	11 (91.7)	-0.28 (0.27)	(-0.81, 0.26)	0.16 (0.39)	(-0.62, 0.93)	0.690
	Placebo	11	11 (100.0)	-0.43 (0.27)	(-0.97, 0.11)			
Week 26	Tezepelumab	12	11 (91.7)	-0.28 (0.27)	(-0.82, 0.26)	0.22 (0.39)	(-0.56, 0.99)	0.580
	Placebo	11	11 (100.0)	-0.49 (0.27)	(-1.04, 0.05)			
Week 27	Tezepelumab	12	10 (83.3)	-0.15 (0.27)	(-0.69, 0.40)	0.18 (0.39)	(-0.60, 0.96)	0.643
	Placebo	11	11 (100.0)	-0.33 (0.27)	(-0.87, 0.22)			
Week 28	Tezepelumab	12	9 (75.0)	-0.12 (0.27)	(-0.67, 0.42)	0.26 (0.39)	(-0.52, 1.04)	0.512
	Placebo	11	11 (100.0)	-0.38 (0.27)	(-0.92, 0.16)			
Week 29	Tezepelumab	12	8 (66.7)	-0.21 (0.28)	(-0.76, 0.34)	0.05 (0.39)	(-0.73, 0.83)	0.900
	Placebo	11	11 (100.0)	-0.26 (0.27)	(-0.80, 0.28)			
Week 30	Tezepelumab	12	10 (83.3)	-0.14 (0.27)	(-0.69, 0.41)	0.27 (0.39)	(-0.51, 1.05)	0.493
	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	12	9 (75.0)	-0.22 (0.28)	(-0.78, 0.33)	0.17 (0.39)	(-0.62, 0.95)	0.675
	Placebo	11	11 (100.0)	-0.39 (0.27)	(-0.93, 0.15)			
Week 32	Tezepelumab	12	10 (83.3)	-0.16 (0.28)	(-0.72, 0.39)	0.20 (0.39)	(-0.58, 0.99)	0.610
	Placebo	11	11 (100.0)	-0.36 (0.27)	(-0.91, 0.18)			
Week 33	Tezepelumab	12	10 (83.3)	0.01 (0.28)	(-0.54, 0.57)	0.41 (0.39)	(-0.38, 1.20)	0.301
	Placebo	11	11 (100.0)	-0.40 (0.27)	(-0.94, 0.15)			
Week 34	Tezepelumab	12	10 (83.3)	-0.13 (0.28)	(-0.69, 0.42)	0.24 (0.39)	(-0.55, 1.03)	0.542
	Placebo	11	11 (100.0)	-0.37 (0.27)	(-0.92, 0.17)			
Week 35	Tezepelumab	12	10 (83.3)	-0.26 (0.28)	(-0.82, 0.30)	0.18 (0.39)	(-0.61, 0.97)	0.648
	Placebo	11	11 (100.0)	-0.44 (0.27)	(-0.98, 0.10)			
Week 36	Tezepelumab	12	10 (83.3)	-0.31 (0.28)	(-0.86, 0.25)	0.15 (0.39)	(-0.64, 0.93)	0.714
	Placebo	11	11 (100.0)	-0.45 (0.27)	(-0.99, 0.09)			
Week 37	Tezepelumab	12	9 (75.0)	-0.29 (0.28)	(-0.85, 0.27)	0.23 (0.40)	(-0.56, 1.03)	0.556
	Placebo	11	11 (100.0)	-0.53 (0.27)	(-1.07, 0.01)			
Week 38	Tezepelumab	12	9 (75.0)	-0.22 (0.28)	(-0.79, 0.34)	0.27 (0.40)	(-0.53, 1.06)	0.507
	Placebo	11	11 (100.0)	-0.49 (0.27)	(-1.03, 0.06)			
Week 39	Tezepelumab	12	9 (75.0)	-0.23 (0.28)	(-0.80, 0.34)	0.22 (0.40)	(-0.57, 1.02)	0.575
	Placebo	11	10 (90.9)	-0.46 (0.27)	(-1.00, 0.09)			
Week 40	Tezepelumab	12	9 (75.0)	-0.20 (0.29)	(-0.77, 0.37)	0.21 (0.40)	(-0.59, 1.00)	0.606
	Placebo	11	11 (100.0)	-0.41 (0.27)	(-0.95, 0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC_IBMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	12	8 (66.7)	-0.18 (0.29)	(-0.76, 0.39)	0.34 (0.40)	(-0.46, 1.15)	0.395
	Placebo	11	10 (90.9)	-0.53 (0.27)	(-1.07, 0.02)			
Week 42	Tezepelumab	12	8 (66.7)	-0.20 (0.29)	(-0.78, 0.38)	0.40 (0.40)	(-0.41, 1.21)	0.326
	Placebo	11	11 (100.0)	-0.60 (0.27)	(-1.14, -0.06)			
Week 43	Tezepelumab	12	8 (66.7)	-0.19 (0.30)	(-0.78, 0.39)	0.46 (0.41)	(-0.35, 1.26)	0.266
	Placebo	11	11 (100.0)	-0.65 (0.27)	(-1.19, -0.11)			
Week 44	Tezepelumab	12	8 (66.7)	-0.27 (0.30)	(-0.86, 0.33)	0.33 (0.41)	(-0.48, 1.14)	0.422
	Placebo	11	11 (100.0)	-0.60 (0.27)	(-1.14, -0.05)			
Week 45	Tezepelumab	12	8 (66.7)	-0.30 (0.30)	(-0.89, 0.30)	0.39 (0.41)	(-0.43, 1.20)	0.347
	Placebo	11	10 (90.9)	-0.69 (0.27)	(-1.23, -0.14)			
Week 46	Tezepelumab	12	7 (58.3)	-0.25 (0.30)	(-0.85, 0.35)	0.36 (0.41)	(-0.46, 1.18)	0.388
	Placebo	11	11 (100.0)	-0.61 (0.27)	(-1.15, -0.07)			
Week 47	Tezepelumab	12	8 (66.7)	-0.20 (0.30)	(-0.80, 0.40)	0.45 (0.41)	(-0.38, 1.27)	0.284
	Placebo	11	11 (100.0)	-0.64 (0.27)	(-1.19, -0.10)			
Week 48	Tezepelumab	12	7 (58.3)	-0.23 (0.31)	(-0.84, 0.38)	0.41 (0.41)	(-0.42, 1.24)	0.328
	Placebo	11	11 (100.0)	-0.64 (0.27)	(-1.18, -0.09)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	55	55 (100.0)	1.53 (0.63)	0.0	1.14	1.57	2.00	2.8	
		Placebo	40	40 (100.0)	1.77 (0.64)	0.4	1.25	1.90	2.14	3.0	
	Week 1	Tezepelumab	55	54 (98.2)	1.38 (0.62)	0.0	1.00	1.43	1.93	2.5	
		Placebo	40	40 (100.0)	1.63 (0.65)	0.3	1.15	1.58	2.00	3.3	
	Week 2	Tezepelumab	55	54 (98.2)	1.30 (0.68)	0.0	0.93	1.36	2.00	2.3	
		Placebo	40	39 (97.5)	1.56 (0.59)	0.4	1.07	1.58	1.93	3.1	
	Week 3	Tezepelumab	55	55 (100.0)	1.28 (0.61)	0.0	1.00	1.36	1.83	2.4	
		Placebo	40	38 (95.0)	1.52 (0.72)	0.0	1.07	1.46	2.00	3.1	
	Week 4	Tezepelumab	55	54 (98.2)	1.21 (0.67)	0.0	0.71	1.18	1.71	2.7	
		Placebo	40	39 (97.5)	1.51 (0.66)	0.1	1.07	1.36	2.00	3.0	
	Week 5	Tezepelumab	55	53 (96.4)	1.17 (0.72)	0.0	0.79	1.00	1.93	2.4	
		Placebo	40	38 (95.0)	1.36 (0.68)	0.1	0.92	1.21	2.00	3.0	
	Week 6	Tezepelumab	55	52 (94.5)	1.23 (0.74)	0.0	0.64	1.25	1.96	3.0	
		Placebo	40	40 (100.0)	1.47 (0.71)	0.0	1.00	1.39	1.96	3.3	
	Week 7	Tezepelumab	55	51 (92.7)	1.17 (0.71)	0.0	0.79	1.10	1.79	3.1	
		Placebo	40	40 (100.0)	1.42 (0.72)	0.0	1.00	1.35	2.00	3.0	
	Week 8	Tezepelumab	55	51 (92.7)	1.15 (0.72)	0.0	0.57	1.08	2.00	2.7	
		Placebo	40	39 (97.5)	1.43 (0.67)	0.0	1.00	1.42	2.00	2.9	
	Week 9	Tezepelumab	55	53 (96.4)	1.12 (0.71)	0.0	0.64	1.00	1.92	2.6	
		Placebo	40	40 (100.0)	1.45 (0.71)	0.0	1.00	1.37	2.00	2.7	
	Week 10	Tezepelumab	55	53 (96.4)	1.11 (0.77)	0.0	0.42	1.00	1.93	2.9	
		Placebo	40	40 (100.0)	1.41 (0.68)	0.0	1.00	1.35	1.96	2.9	
	Week 11	Tezepelumab	55	51 (92.7)	1.15 (0.74)	0.0	0.63	1.07	1.92	3.0	
		Placebo	40	40 (100.0)	1.33 (0.70)	0.0	1.00	1.20	1.89	2.9	
	Week 12	Tezepelumab	55	52 (94.5)	1.08 (0.78)	0.0	0.41	1.04	1.89	2.9	
		Placebo	40	38 (95.0)	1.37 (0.76)	0.0	1.00	1.25	2.00	3.0	
	Week 13	Tezepelumab	55	49 (89.1)	1.10 (0.76)	0.0	0.50	1.00	1.79	2.9	
		Placebo	40	38 (95.0)	1.35 (0.76)	0.0	1.00	1.25	2.00	3.2	
	Week 14	Tezepelumab	55	52 (94.5)	1.13 (0.80)	0.0	0.50	1.07	1.85	2.9	
		Placebo	40	37 (92.5)	1.35 (0.71)	0.0	1.00	1.20	2.00	3.0	
	Week 15	Tezepelumab	55	51 (92.7)	1.05 (0.71)	0.0	0.29	1.00	1.63	2.2	
		Placebo	40	39 (97.5)	1.34 (0.74)	0.0	1.00	1.14	2.00	3.0	
	Week 16	Tezepelumab	55	51 (92.7)	1.04 (0.74)	0.0	0.25	1.07	1.86	2.3	
		Placebo	40	38 (95.0)	1.35 (0.71)	0.0	1.00	1.28	1.93	2.9	
Week 17	Tezepelumab	55	52 (94.5)	1.04 (0.75)	0.0	0.37	1.00	1.73	2.8		
	Placebo	40	38 (95.0)	1.37 (0.73)	0.0	1.00	1.32	1.90	3.2		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	55	52 (94.5)	1.05 (0.79)	0.0	0.32	1.00	1.85	3.0	
		Placebo	40	38 (95.0)	1.39 (0.73)	0.0	1.00	1.36	2.00	2.9	
	Week 19	Tezepelumab	55	49 (89.1)	1.03 (0.82)	0.0	0.10	1.00	2.00	2.4	
		Placebo	40	39 (97.5)	1.39 (0.71)	0.0	1.00	1.42	2.00	3.0	
	Week 20	Tezepelumab	55	51 (92.7)	1.03 (0.79)	0.0	0.14	1.00	1.86	2.4	
		Placebo	40	37 (92.5)	1.35 (0.74)	0.0	1.00	1.21	2.00	3.0	
	Week 21	Tezepelumab	55	46 (83.6)	1.05 (0.77)	0.0	0.21	1.00	1.93	2.4	
		Placebo	40	38 (95.0)	1.30 (0.72)	0.0	0.93	1.26	2.00	2.6	
	Week 22	Tezepelumab	55	47 (85.5)	1.10 (0.71)	0.0	0.63	1.00	1.92	2.2	
		Placebo	40	38 (95.0)	1.31 (0.68)	0.0	1.00	1.29	1.93	2.5	
	Week 23	Tezepelumab	55	49 (89.1)	1.05 (0.80)	0.0	0.21	1.00	1.83	2.6	
		Placebo	40	36 (90.0)	1.28 (0.70)	0.0	0.96	1.21	1.96	2.6	
	Week 24	Tezepelumab	55	51 (92.7)	1.02 (0.83)	0.0	0.00	1.00	2.00	2.6	
		Placebo	40	36 (90.0)	1.21 (0.70)	0.0	0.91	1.04	1.89	2.5	
	Week 25	Tezepelumab	55	49 (89.1)	1.05 (0.77)	0.0	0.43	1.00	1.83	2.7	
		Placebo	40	36 (90.0)	1.34 (0.74)	0.0	1.00	1.08	2.00	2.7	
	Week 26	Tezepelumab	55	50 (90.9)	1.02 (0.81)	0.0	0.21	1.04	1.86	2.9	
		Placebo	40	37 (92.5)	1.36 (0.81)	0.0	1.00	1.33	2.00	3.0	
	Week 27	Tezepelumab	55	46 (83.6)	1.13 (0.83)	0.0	0.29	1.00	1.86	3.1	
		Placebo	40	36 (90.0)	1.36 (0.80)	0.0	1.00	1.39	2.00	2.9	
	Week 28	Tezepelumab	55	49 (89.1)	1.10 (0.81)	0.0	0.36	1.00	2.00	3.0	
		Placebo	40	36 (90.0)	1.32 (0.82)	0.0	0.93	1.15	2.00	2.9	
	Week 29	Tezepelumab	55	48 (87.3)	1.03 (0.76)	0.0	0.31	1.00	1.66	2.6	
		Placebo	40	37 (92.5)	1.31 (0.82)	0.0	1.00	1.07	2.00	2.9	
	Week 30	Tezepelumab	55	48 (87.3)	1.16 (0.72)	0.0	0.71	1.00	1.93	2.4	
		Placebo	40	36 (90.0)	1.28 (0.77)	0.0	0.79	1.04	2.00	3.0	
	Week 31	Tezepelumab	55	48 (87.3)	1.00 (0.72)	0.0	0.15	1.00	1.43	2.4	
		Placebo	40	37 (92.5)	1.24 (0.74)	0.0	0.86	1.00	2.00	3.0	
	Week 32	Tezepelumab	55	49 (89.1)	1.01 (0.74)	0.0	0.29	1.00	1.88	2.2	
		Placebo	40	37 (92.5)	1.28 (0.74)	0.0	0.92	1.00	2.00	3.0	
	Week 33	Tezepelumab	55	48 (87.3)	1.05 (0.74)	0.0	0.39	1.04	1.73	2.4	
		Placebo	40	37 (92.5)	1.33 (0.80)	0.0	0.86	1.07	2.00	3.0	
	Week 34	Tezepelumab	55	50 (90.9)	1.03 (0.73)	0.0	0.50	1.00	1.67	2.4	
		Placebo	40	38 (95.0)	1.33 (0.80)	0.0	0.93	1.04	2.00	3.1	
	Week 35	Tezepelumab	55	48 (87.3)	1.00 (0.73)	0.0	0.42	1.00	1.43	2.6	
		Placebo	40	36 (90.0)	1.34 (0.77)	0.0	1.00	1.11	2.00	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	55	48 (87.3)	1.04 (0.76)	0.0	0.39	1.00	1.57	2.6	
		Placebo	40	38 (95.0)	1.39 (0.77)	0.0	1.00	1.18	2.00	3.6	
	Week 37	Tezepelumab	55	47 (85.5)	1.04 (0.75)	0.0	0.21	1.00	1.71	2.6	
		Placebo	40	37 (92.5)	1.36 (0.73)	0.0	1.00	1.00	2.00	3.0	
	Week 38	Tezepelumab	55	47 (85.5)	1.08 (0.78)	0.0	0.50	1.07	1.67	2.7	
		Placebo	40	37 (92.5)	1.28 (0.79)	0.0	0.93	1.00	2.00	3.1	
	Week 39	Tezepelumab	55	49 (89.1)	1.04 (0.80)	0.0	0.13	1.00	1.71	2.6	
		Placebo	40	37 (92.5)	1.28 (0.82)	0.0	1.00	1.21	2.00	3.4	
	Week 40	Tezepelumab	55	49 (89.1)	1.08 (0.73)	0.0	0.60	1.00	1.71	2.6	
		Placebo	40	38 (95.0)	1.30 (0.85)	0.0	1.00	1.15	2.00	3.4	
	Week 41	Tezepelumab	55	50 (90.9)	1.05 (0.77)	0.0	0.25	1.00	1.64	2.6	
		Placebo	40	36 (90.0)	1.32 (0.82)	0.0	0.96	1.27	2.00	3.0	
	Week 42	Tezepelumab	55	47 (85.5)	1.06 (0.80)	0.0	0.07	1.00	1.79	3.1	
		Placebo	40	36 (90.0)	1.32 (0.82)	0.0	0.81	1.25	2.00	3.0	
	Week 43	Tezepelumab	55	49 (89.1)	1.04 (0.82)	0.0	0.17	1.00	1.64	3.3	
		Placebo	40	37 (92.5)	1.28 (0.79)	0.0	1.00	1.13	1.93	3.0	
	Week 44	Tezepelumab	55	48 (87.3)	0.99 (0.76)	0.0	0.11	1.00	1.54	2.9	
		Placebo	40	35 (87.5)	1.35 (0.79)	0.0	1.00	1.25	2.00	3.0	
	Week 45	Tezepelumab	55	48 (87.3)	1.02 (0.80)	0.0	0.07	1.00	1.66	3.2	
		Placebo	40	36 (90.0)	1.25 (0.85)	0.0	0.92	1.00	1.96	3.2	
	Week 46	Tezepelumab	55	47 (85.5)	1.02 (0.80)	0.0	0.08	1.00	1.86	3.1	
		Placebo	40	37 (92.5)	1.26 (0.88)	0.0	0.92	1.07	1.93	3.3	
	Week 47	Tezepelumab	55	46 (83.6)	1.02 (0.80)	0.0	0.13	1.00	1.71	3.2	
		Placebo	40	37 (92.5)	1.29 (0.84)	0.0	1.00	1.07	1.93	3.1	
	Week 48	Tezepelumab	55	49 (89.1)	1.08 (0.83)	0.0	0.29	1.00	1.75	3.2	
		Placebo	40	36 (90.0)	1.28 (0.84)	0.0	0.93	1.00	2.00	3.0	
	Week 49	Tezepelumab	55	47 (85.5)	1.15 (0.81)	0.0	0.58	1.00	1.75	2.9	
		Placebo	40	36 (90.0)	1.27 (0.85)	0.0	0.73	1.00	2.00	3.1	
	Week 50	Tezepelumab	55	44 (80.0)	1.12 (0.79)	0.0	0.61	1.04	1.83	2.9	
		Placebo	40	35 (87.5)	1.22 (0.82)	0.0	0.70	1.00	2.00	3.0	
	Week 51	Tezepelumab	55	45 (81.8)	1.17 (0.78)	0.0	0.79	1.00	2.00	3.1	
		Placebo	40	33 (82.5)	1.32 (0.91)	0.0	1.00	1.08	2.00	3.5	
	Week 52	Tezepelumab	55	39 (70.9)	1.12 (0.77)	0.0	0.50	1.07	1.93	2.9	
		Placebo	40	32 (80.0)	1.34 (0.89)	0.0	0.86	1.04	1.96	3.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	55	54 (98.2)	-0.16 (0.50)	-2.1	-0.36	-0.07	0.14	0.6	-0.05 [-0.45, 0.36]
		Placebo	40	40 (100.0)	-0.14 (0.30)	-0.8	-0.36	-0.13	0.02	0.4	
	Week 2	Tezepelumab	55	54 (98.2)	-0.24 (0.55)	-2.6	-0.44	-0.10	0.00	0.5	-0.04 [-0.45, 0.37]
		Placebo	40	39 (97.5)	-0.22 (0.51)	-1.9	-0.43	-0.16	0.07	1.3	
	Week 3	Tezepelumab	55	55 (100.0)	-0.25 (0.53)	-2.6	-0.43	-0.14	0.06	0.6	0.04 [-0.38, 0.45]
		Placebo	40	38 (95.0)	-0.27 (0.67)	-2.7	-0.57	-0.15	0.00	1.5	
	Week 4	Tezepelumab	55	54 (98.2)	-0.32 (0.52)	-2.6	-0.59	-0.14	0.00	0.4	-0.10 [-0.51, 0.31]
		Placebo	40	39 (97.5)	-0.26 (0.63)	-2.7	-0.57	-0.14	0.07	0.8	
	Week 5	Tezepelumab	55	53 (96.4)	-0.36 (0.57)	-2.6	-0.64	-0.14	0.00	0.6	0.05 [-0.37, 0.46]
		Placebo	40	38 (95.0)	-0.39 (0.70)	-2.7	-0.71	-0.21	0.00	1.8	
	Week 6	Tezepelumab	55	52 (94.5)	-0.30 (0.56)	-2.6	-0.54	-0.14	0.01	0.5	-0.01 [-0.42, 0.40]
		Placebo	40	40 (100.0)	-0.29 (0.65)	-2.8	-0.64	-0.11	0.08	1.0	
	Week 7	Tezepelumab	55	51 (92.7)	-0.35 (0.57)	-2.6	-0.64	-0.20	0.00	0.8	0.01 [-0.41, 0.42]
		Placebo	40	40 (100.0)	-0.35 (0.64)	-2.8	-0.79	-0.21	0.04	0.6	
	Week 8	Tezepelumab	55	51 (92.7)	-0.38 (0.57)	-2.6	-0.79	-0.17	0.00	0.4	-0.10 [-0.52, 0.31]
		Placebo	40	39 (97.5)	-0.32 (0.70)	-2.7	-0.72	-0.14	0.07	1.1	
	Week 9	Tezepelumab	55	53 (96.4)	-0.39 (0.61)	-2.6	-0.79	-0.15	0.00	1.0	-0.10 [-0.51, 0.31]
		Placebo	40	40 (100.0)	-0.32 (0.75)	-2.8	-0.81	-0.15	0.07	1.7	
	Week 10	Tezepelumab	55	53 (96.4)	-0.40 (0.64)	-2.6	-0.79	-0.14	0.00	1.0	-0.07 [-0.48, 0.34]
		Placebo	40	40 (100.0)	-0.35 (0.72)	-2.8	-0.74	-0.17	0.05	0.9	
	Week 11	Tezepelumab	55	51 (92.7)	-0.40 (0.60)	-2.6	-0.86	-0.14	0.00	0.5	0.05 [-0.37, 0.46]
		Placebo	40	40 (100.0)	-0.43 (0.74)	-2.8	-0.92	-0.25	0.07	0.7	
	Week 12	Tezepelumab	55	52 (94.5)	-0.44 (0.68)	-2.6	-0.86	-0.14	0.00	0.6	-0.03 [-0.45, 0.38]
		Placebo	40	38 (95.0)	-0.42 (0.80)	-2.8	-0.92	-0.18	0.00	1.6	
	Week 13	Tezepelumab	55	49 (89.1)	-0.39 (0.64)	-2.6	-0.86	-0.14	0.00	0.6	0.04 [-0.38, 0.46]
		Placebo	40	38 (95.0)	-0.42 (0.79)	-2.8	-0.82	-0.23	0.00	1.9	
	Week 14	Tezepelumab	55	52 (94.5)	-0.43 (0.67)	-2.6	-0.86	-0.21	0.00	0.8	-0.00 [-0.43, 0.42]
		Placebo	40	37 (92.5)	-0.43 (0.75)	-2.8	-0.92	-0.21	0.07	0.8	
	Week 15	Tezepelumab	55	51 (92.7)	-0.45 (0.62)	-2.6	-0.79	-0.21	0.00	0.4	-0.05 [-0.47, 0.36]
		Placebo	40	39 (97.5)	-0.41 (0.77)	-2.8	-0.94	-0.21	0.00	1.8	
	Week 16	Tezepelumab	55	51 (92.7)	-0.47 (0.64)	-2.6	-0.86	-0.21	0.00	0.4	-0.09 [-0.51, 0.33]
		Placebo	40	38 (95.0)	-0.41 (0.72)	-2.6	-1.00	-0.18	0.04	1.0	
	Week 17	Tezepelumab	55	52 (94.5)	-0.51 (0.65)	-2.6	-0.95	-0.29	-0.04	0.8	-0.18 [-0.60, 0.24]
		Placebo	40	38 (95.0)	-0.39 (0.72)	-2.7	-0.92	-0.21	0.00	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	55	52 (94.5)	-0.49 (0.70)	-2.6	-0.96	-0.31	-0.07	1.0	-0.21 [-0.62, 0.21]
		Placebo	40	38 (95.0)	-0.35 (0.67)	-2.7	-0.77	-0.21	0.07	0.8	
	Week 19	Tezepelumab	55	49 (89.1)	-0.47 (0.68)	-2.6	-0.86	-0.21	0.00	0.4	-0.15 [-0.57, 0.27]
		Placebo	40	39 (97.5)	-0.37 (0.69)	-2.8	-0.83	-0.17	0.07	0.9	
	Week 20	Tezepelumab	55	51 (92.7)	-0.49 (0.69)	-2.6	-1.00	-0.25	0.00	0.4	-0.12 [-0.54, 0.30]
		Placebo	40	37 (92.5)	-0.41 (0.71)	-2.7	-0.92	-0.21	0.00	0.9	
	Week 21	Tezepelumab	55	46 (83.6)	-0.50 (0.67)	-2.6	-0.86	-0.27	0.00	0.4	-0.03 [-0.46, 0.40]
		Placebo	40	38 (95.0)	-0.47 (0.79)	-2.8	-0.93	-0.29	0.00	1.3	
	Week 22	Tezepelumab	55	47 (85.5)	-0.43 (0.65)	-2.6	-0.86	-0.19	0.00	0.5	0.06 [-0.37, 0.49]
		Placebo	40	38 (95.0)	-0.47 (0.75)	-2.8	-0.86	-0.42	0.00	1.2	
	Week 23	Tezepelumab	55	49 (89.1)	-0.50 (0.73)	-2.6	-1.00	-0.14	0.00	0.4	0.01 [-0.42, 0.44]
		Placebo	40	36 (90.0)	-0.51 (0.70)	-2.6	-0.92	-0.34	-0.04	0.6	
	Week 24	Tezepelumab	55	51 (92.7)	-0.52 (0.69)	-2.6	-1.00	-0.21	0.00	0.4	0.05 [-0.37, 0.48]
		Placebo	40	36 (90.0)	-0.56 (0.73)	-2.8	-0.96	-0.39	0.00	0.7	
	Week 25	Tezepelumab	55	49 (89.1)	-0.51 (0.64)	-2.6	-0.86	-0.29	-0.07	0.4	-0.09 [-0.52, 0.34]
		Placebo	40	36 (90.0)	-0.44 (0.79)	-2.8	-1.04	-0.25	0.07	1.3	
	Week 26	Tezepelumab	55	50 (90.9)	-0.44 (0.71)	-2.6	-0.86	-0.24	0.00	0.9	-0.01 [-0.44, 0.41]
		Placebo	40	37 (92.5)	-0.43 (0.89)	-2.8	-0.92	-0.25	0.07	1.6	
	Week 27	Tezepelumab	55	46 (83.6)	-0.39 (0.75)	-2.6	-0.86	-0.18	0.08	0.9	0.06 [-0.37, 0.50]
		Placebo	40	36 (90.0)	-0.44 (0.93)	-2.8	-0.96	-0.38	0.04	2.4	
	Week 28	Tezepelumab	55	49 (89.1)	-0.40 (0.70)	-2.5	-0.86	-0.14	0.00	0.9	0.07 [-0.37, 0.50]
		Placebo	40	36 (90.0)	-0.45 (0.88)	-2.8	-0.96	-0.18	0.07	1.0	
	Week 29	Tezepelumab	55	48 (87.3)	-0.51 (0.68)	-2.6	-0.89	-0.21	0.00	0.5	-0.05 [-0.48, 0.38]
		Placebo	40	37 (92.5)	-0.47 (0.88)	-2.8	-0.92	-0.21	0.07	1.0	
	Week 30	Tezepelumab	55	48 (87.3)	-0.46 (0.65)	-2.6	-0.96	-0.23	0.00	0.5	0.09 [-0.34, 0.52]
		Placebo	40	36 (90.0)	-0.52 (0.82)	-2.8	-0.96	-0.49	0.04	1.0	
	Week 31	Tezepelumab	55	48 (87.3)	-0.54 (0.73)	-2.6	-0.93	-0.35	-0.07	1.0	-0.00 [-0.43, 0.43]
		Placebo	40	37 (92.5)	-0.53 (0.77)	-2.8	-1.01	-0.43	-0.14	0.9	
	Week 32	Tezepelumab	55	49 (89.1)	-0.54 (0.66)	-2.6	-0.93	-0.29	0.00	0.4	-0.06 [-0.49, 0.37]
		Placebo	40	37 (92.5)	-0.49 (0.78)	-2.8	-0.92	-0.43	-0.14	1.3	
	Week 33	Tezepelumab	55	48 (87.3)	-0.52 (0.72)	-2.6	-0.96	-0.25	0.00	0.7	-0.10 [-0.53, 0.33]
		Placebo	40	37 (92.5)	-0.44 (0.76)	-2.8	-0.90	-0.36	0.00	0.9	
	Week 34	Tezepelumab	55	50 (90.9)	-0.56 (0.71)	-2.6	-1.00	-0.46	-0.07	0.6	-0.14 [-0.56, 0.28]
		Placebo	40	38 (95.0)	-0.46 (0.77)	-2.8	-0.96	-0.36	0.07	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	55	48 (87.3)	-0.52 (0.67)	-2.6	-0.88	-0.28	0.00	0.4	-0.08 [-0.52, 0.35]
		Placebo	40	36 (90.0)	-0.46 (0.73)	-2.8	-0.89	-0.36	0.00	0.9	
	Week 36	Tezepelumab	55	48 (87.3)	-0.51 (0.68)	-2.6	-0.85	-0.36	-0.07	0.6	-0.17 [-0.60, 0.26]
		Placebo	40	38 (95.0)	-0.39 (0.73)	-2.8	-0.86	-0.34	0.07	0.9	
	Week 37	Tezepelumab	55	47 (85.5)	-0.50 (0.68)	-2.6	-0.92	-0.21	0.00	0.4	-0.12 [-0.55, 0.31]
		Placebo	40	37 (92.5)	-0.42 (0.72)	-2.8	-0.87	-0.30	0.01	0.8	
	Week 38	Tezepelumab	55	47 (85.5)	-0.46 (0.71)	-2.6	-0.93	-0.21	0.01	0.7	0.05 [-0.38, 0.49]
		Placebo	40	37 (92.5)	-0.50 (0.74)	-2.8	-0.92	-0.43	0.07	0.7	
	Week 39	Tezepelumab	55	49 (89.1)	-0.50 (0.72)	-2.6	-1.00	-0.14	0.00	0.8	0.00 [-0.42, 0.43]
		Placebo	40	37 (92.5)	-0.50 (0.73)	-2.8	-1.00	-0.43	0.07	0.7	
	Week 40	Tezepelumab	55	49 (89.1)	-0.50 (0.70)	-2.6	-1.00	-0.29	0.00	0.4	-0.02 [-0.44, 0.41]
		Placebo	40	38 (95.0)	-0.49 (0.78)	-2.8	-1.00	-0.49	0.07	1.1	
	Week 41	Tezepelumab	55	50 (90.9)	-0.52 (0.69)	-2.6	-1.00	-0.32	0.00	0.4	-0.09 [-0.52, 0.34]
		Placebo	40	36 (90.0)	-0.45 (0.86)	-2.8	-1.00	-0.46	0.04	1.9	
	Week 42	Tezepelumab	55	47 (85.5)	-0.50 (0.72)	-2.6	-0.93	-0.21	0.00	0.6	-0.06 [-0.50, 0.37]
		Placebo	40	36 (90.0)	-0.46 (0.74)	-2.8	-0.96	-0.36	0.04	0.8	
	Week 43	Tezepelumab	55	49 (89.1)	-0.52 (0.71)	-2.6	-1.00	-0.29	-0.07	0.8	-0.03 [-0.46, 0.39]
		Placebo	40	37 (92.5)	-0.50 (0.71)	-2.8	-0.91	-0.50	0.05	0.6	
	Week 44	Tezepelumab	55	48 (87.3)	-0.59 (0.70)	-2.6	-1.00	-0.36	-0.07	0.5	-0.15 [-0.59, 0.28]
		Placebo	40	35 (87.5)	-0.48 (0.75)	-2.8	-0.92	-0.36	0.05	0.6	
	Week 45	Tezepelumab	55	48 (87.3)	-0.53 (0.72)	-2.6	-1.00	-0.29	0.00	0.7	0.02 [-0.41, 0.46]
		Placebo	40	36 (90.0)	-0.55 (0.76)	-2.8	-0.96	-0.66	0.04	0.7	
	Week 46	Tezepelumab	55	47 (85.5)	-0.51 (0.75)	-2.6	-1.00	-0.21	0.00	0.6	0.01 [-0.42, 0.44]
		Placebo	40	37 (92.5)	-0.52 (0.79)	-2.8	-1.00	-0.43	0.07	0.8	
	Week 47	Tezepelumab	55	46 (83.6)	-0.51 (0.73)	-2.6	-1.00	-0.18	0.00	0.7	-0.04 [-0.47, 0.40]
		Placebo	40	37 (92.5)	-0.48 (0.73)	-2.8	-0.92	-0.43	0.07	0.6	
	Week 48	Tezepelumab	55	49 (89.1)	-0.41 (0.75)	-2.6	-0.86	-0.14	0.00	1.0	0.11 [-0.32, 0.54]
		Placebo	40	36 (90.0)	-0.49 (0.74)	-2.8	-0.96	-0.33	0.04	0.6	
	Week 49	Tezepelumab	55	47 (85.5)	-0.41 (0.76)	-2.6	-0.86	-0.21	0.00	1.2	0.12 [-0.31, 0.56]
		Placebo	40	36 (90.0)	-0.51 (0.75)	-2.8	-0.96	-0.57	0.04	0.7	
	Week 50	Tezepelumab	55	44 (80.0)	-0.44 (0.69)	-2.6	-0.82	-0.15	-0.04	0.8	0.14 [-0.30, 0.59]
		Placebo	40	35 (87.5)	-0.54 (0.73)	-2.8	-1.00	-0.62	-0.08	0.7	
	Week 51	Tezepelumab	55	45 (81.8)	-0.39 (0.70)	-2.6	-0.86	-0.14	0.00	0.8	0.14 [-0.31, 0.59]
		Placebo	40	33 (82.5)	-0.50 (0.81)	-2.8	-0.92	-0.57	-0.05	1.2	
	Week 52	Tezepelumab	55	39 (70.9)	-0.43 (0.70)	-2.6	-0.86	-0.14	0.00	0.5	0.14 [-0.33, 0.61]
		Placebo	40	32 (80.0)	-0.54 (0.80)	-2.8	-1.00	-0.64	-0.04	1.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	55	54 (98.2)	-0.20 (0.09)	(-0.37, -0.03)	-0.10 (0.13)	(-0.36, 0.16)	0.453
	Placebo	40	40 (100.0)	-0.10 (0.10)	(-0.30, 0.10)			
Week 2	Tezepelumab	55	54 (98.2)	-0.28 (0.09)	(-0.45, -0.11)	-0.12 (0.13)	(-0.38, 0.14)	0.376
	Placebo	40	39 (97.5)	-0.16 (0.10)	(-0.36, 0.04)			
Week 3	Tezepelumab	55	55 (100.0)	-0.29 (0.09)	(-0.46, -0.12)	-0.09 (0.13)	(-0.36, 0.17)	0.492
	Placebo	40	38 (95.0)	-0.20 (0.10)	(-0.40, 0.00)			
Week 4	Tezepelumab	55	54 (98.2)	-0.36 (0.09)	(-0.53, -0.19)	-0.16 (0.13)	(-0.42, 0.10)	0.235
	Placebo	40	39 (97.5)	-0.20 (0.10)	(-0.40, -0.00)			
Week 5	Tezepelumab	55	53 (96.4)	-0.40 (0.09)	(-0.57, -0.23)	-0.07 (0.13)	(-0.33, 0.19)	0.601
	Placebo	40	38 (95.0)	-0.33 (0.10)	(-0.53, -0.13)			
Week 6	Tezepelumab	55	52 (94.5)	-0.32 (0.09)	(-0.49, -0.15)	-0.07 (0.13)	(-0.33, 0.19)	0.608
	Placebo	40	40 (100.0)	-0.25 (0.10)	(-0.45, -0.05)			
Week 7	Tezepelumab	55	51 (92.7)	-0.38 (0.09)	(-0.55, -0.21)	-0.07 (0.13)	(-0.34, 0.19)	0.597
	Placebo	40	40 (100.0)	-0.31 (0.10)	(-0.51, -0.11)			
Week 8	Tezepelumab	55	51 (92.7)	-0.40 (0.09)	(-0.57, -0.23)	-0.14 (0.13)	(-0.40, 0.13)	0.307
	Placebo	40	39 (97.5)	-0.26 (0.10)	(-0.46, -0.06)			
Week 9	Tezepelumab	55	53 (96.4)	-0.43 (0.09)	(-0.60, -0.26)	-0.16 (0.13)	(-0.42, 0.11)	0.242
	Placebo	40	40 (100.0)	-0.28 (0.10)	(-0.48, -0.08)			
Week 10	Tezepelumab	55	53 (96.4)	-0.44 (0.09)	(-0.61, -0.27)	-0.14 (0.13)	(-0.40, 0.13)	0.310
	Placebo	40	40 (100.0)	-0.31 (0.10)	(-0.51, -0.11)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	55	51 (92.7)	-0.44 (0.09)	(-0.61, -0.27)	-0.06 (0.13)	(-0.32, 0.21)	0.679
	Placebo	40	40 (100.0)	-0.39 (0.10)	(-0.59, -0.19)			
Week 12	Tezepelumab	55	52 (94.5)	-0.47 (0.09)	(-0.64, -0.30)	-0.13 (0.13)	(-0.39, 0.14)	0.349
	Placebo	40	38 (95.0)	-0.35 (0.10)	(-0.55, -0.15)			
Week 13	Tezepelumab	55	49 (89.1)	-0.45 (0.09)	(-0.62, -0.28)	-0.10 (0.13)	(-0.36, 0.17)	0.461
	Placebo	40	38 (95.0)	-0.35 (0.10)	(-0.55, -0.15)			
Week 14	Tezepelumab	55	52 (94.5)	-0.43 (0.09)	(-0.60, -0.26)	-0.08 (0.13)	(-0.35, 0.18)	0.539
	Placebo	40	37 (92.5)	-0.35 (0.10)	(-0.55, -0.15)			
Week 15	Tezepelumab	55	51 (92.7)	-0.47 (0.09)	(-0.64, -0.30)	-0.10 (0.13)	(-0.37, 0.16)	0.452
	Placebo	40	39 (97.5)	-0.37 (0.10)	(-0.57, -0.17)			
Week 16	Tezepelumab	55	51 (92.7)	-0.50 (0.09)	(-0.67, -0.33)	-0.14 (0.13)	(-0.40, 0.13)	0.304
	Placebo	40	38 (95.0)	-0.36 (0.10)	(-0.56, -0.16)			
Week 17	Tezepelumab	55	52 (94.5)	-0.52 (0.09)	(-0.69, -0.34)	-0.18 (0.13)	(-0.44, 0.09)	0.185
	Placebo	40	38 (95.0)	-0.34 (0.10)	(-0.54, -0.14)			
Week 18	Tezepelumab	55	52 (94.5)	-0.51 (0.09)	(-0.69, -0.34)	-0.21 (0.13)	(-0.48, 0.05)	0.112
	Placebo	40	38 (95.0)	-0.30 (0.10)	(-0.50, -0.10)			
Week 19	Tezepelumab	55	49 (89.1)	-0.50 (0.09)	(-0.67, -0.33)	-0.19 (0.13)	(-0.45, 0.08)	0.171
	Placebo	40	39 (97.5)	-0.32 (0.10)	(-0.52, -0.12)			
Week 20	Tezepelumab	55	51 (92.7)	-0.52 (0.09)	(-0.69, -0.34)	-0.14 (0.14)	(-0.41, 0.12)	0.298
	Placebo	40	37 (92.5)	-0.38 (0.10)	(-0.58, -0.17)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	55	46 (83.6)	-0.54 (0.09)	(-0.71, -0.37)	-0.13 (0.14)	(-0.40, 0.14)	0.341
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.61, -0.21)			
Week 22	Tezepelumab	55	47 (85.5)	-0.50 (0.09)	(-0.68, -0.33)	-0.09 (0.14)	(-0.36, 0.17)	0.490
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.61, -0.21)			
Week 23	Tezepelumab	55	49 (89.1)	-0.53 (0.09)	(-0.70, -0.36)	-0.14 (0.14)	(-0.41, 0.13)	0.308
	Placebo	40	36 (90.0)	-0.39 (0.10)	(-0.59, -0.19)			
Week 24	Tezepelumab	55	51 (92.7)	-0.54 (0.09)	(-0.71, -0.36)	-0.09 (0.14)	(-0.36, 0.18)	0.519
	Placebo	40	36 (90.0)	-0.45 (0.10)	(-0.65, -0.25)			
Week 25	Tezepelumab	55	49 (89.1)	-0.55 (0.09)	(-0.72, -0.38)	-0.21 (0.14)	(-0.47, 0.06)	0.132
	Placebo	40	36 (90.0)	-0.34 (0.10)	(-0.55, -0.14)			
Week 26	Tezepelumab	55	50 (90.9)	-0.51 (0.09)	(-0.68, -0.34)	-0.18 (0.14)	(-0.45, 0.09)	0.186
	Placebo	40	37 (92.5)	-0.33 (0.10)	(-0.54, -0.13)			
Week 27	Tezepelumab	55	46 (83.6)	-0.46 (0.09)	(-0.63, -0.29)	-0.11 (0.14)	(-0.38, 0.16)	0.433
	Placebo	40	36 (90.0)	-0.36 (0.10)	(-0.56, -0.15)			
Week 28	Tezepelumab	55	49 (89.1)	-0.48 (0.09)	(-0.65, -0.31)	-0.14 (0.14)	(-0.41, 0.13)	0.311
	Placebo	40	36 (90.0)	-0.34 (0.10)	(-0.55, -0.14)			
Week 29	Tezepelumab	55	48 (87.3)	-0.54 (0.09)	(-0.71, -0.36)	-0.14 (0.14)	(-0.41, 0.12)	0.291
	Placebo	40	37 (92.5)	-0.39 (0.10)	(-0.59, -0.19)			
Week 30	Tezepelumab	55	48 (87.3)	-0.51 (0.09)	(-0.68, -0.34)	-0.08 (0.14)	(-0.35, 0.18)	0.542
	Placebo	40	36 (90.0)	-0.43 (0.10)	(-0.63, -0.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	55	48 (87.3)	-0.56 (0.09)	(-0.73, -0.39)	-0.11 (0.14)	(-0.37, 0.16)	0.437
	Placebo	40	37 (92.5)	-0.45 (0.10)	(-0.66, -0.25)			
Week 32	Tezepelumab	55	49 (89.1)	-0.58 (0.09)	(-0.76, -0.41)	-0.17 (0.14)	(-0.44, 0.10)	0.217
	Placebo	40	37 (92.5)	-0.42 (0.10)	(-0.62, -0.21)			
Week 33	Tezepelumab	55	48 (87.3)	-0.56 (0.09)	(-0.74, -0.39)	-0.18 (0.14)	(-0.45, 0.09)	0.193
	Placebo	40	37 (92.5)	-0.38 (0.10)	(-0.59, -0.18)			
Week 34	Tezepelumab	55	50 (90.9)	-0.59 (0.09)	(-0.76, -0.41)	-0.20 (0.14)	(-0.46, 0.07)	0.151
	Placebo	40	38 (95.0)	-0.39 (0.10)	(-0.60, -0.19)			
Week 35	Tezepelumab	55	48 (87.3)	-0.58 (0.09)	(-0.75, -0.40)	-0.18 (0.14)	(-0.45, 0.09)	0.187
	Placebo	40	36 (90.0)	-0.39 (0.10)	(-0.60, -0.19)			
Week 36	Tezepelumab	55	48 (87.3)	-0.54 (0.09)	(-0.72, -0.37)	-0.22 (0.14)	(-0.49, 0.05)	0.114
	Placebo	40	38 (95.0)	-0.33 (0.10)	(-0.53, -0.12)			
Week 37	Tezepelumab	55	47 (85.5)	-0.58 (0.09)	(-0.75, -0.40)	-0.23 (0.14)	(-0.50, 0.04)	0.099
	Placebo	40	37 (92.5)	-0.35 (0.10)	(-0.55, -0.14)			
Week 38	Tezepelumab	55	47 (85.5)	-0.54 (0.09)	(-0.71, -0.36)	-0.11 (0.14)	(-0.38, 0.16)	0.423
	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.63, -0.22)			
Week 39	Tezepelumab	55	49 (89.1)	-0.58 (0.09)	(-0.75, -0.40)	-0.15 (0.14)	(-0.42, 0.12)	0.281
	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.64, -0.23)			
Week 40	Tezepelumab	55	49 (89.1)	-0.55 (0.09)	(-0.72, -0.37)	-0.12 (0.14)	(-0.39, 0.15)	0.382
	Placebo	40	38 (95.0)	-0.43 (0.10)	(-0.63, -0.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 41	Tezepelumab	55	50 (90.9)	-0.55 (0.09)	(-0.73, -0.38)	-0.16 (0.14)	(-0.43, 0.11)	0.246																																																																																																																										
	Placebo	40	36 (90.0)	-0.39 (0.10)	(-0.60, -0.19)				Week 42	Tezepelumab	55	47 (85.5)	-0.54 (0.09)	(-0.71, -0.36)	-0.14 (0.14)	(-0.41, 0.13)	0.315	Placebo	40	36 (90.0)	-0.40 (0.10)	(-0.60, -0.19)	Week 43	Tezepelumab	55	49 (89.1)	-0.57 (0.09)	(-0.74, -0.39)	-0.14 (0.14)	(-0.41, 0.13)	0.322	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.64, -0.23)	Week 44	Tezepelumab	55	48 (87.3)	-0.61 (0.09)	(-0.79, -0.44)	-0.20 (0.14)	(-0.48, 0.07)	0.141	Placebo	40	35 (87.5)	-0.41 (0.11)	(-0.62, -0.20)	Week 45	Tezepelumab	55	48 (87.3)	-0.59 (0.09)	(-0.76, -0.41)	-0.12 (0.14)	(-0.39, 0.15)	0.398	Placebo	40	36 (90.0)	-0.47 (0.11)	(-0.68, -0.27)	Week 46	Tezepelumab	55	47 (85.5)	-0.59 (0.09)	(-0.76, -0.41)	-0.13 (0.14)	(-0.40, 0.14)	0.339	Placebo	40	37 (92.5)	-0.45 (0.11)	(-0.66, -0.25)	Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)	Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo
Week 42	Tezepelumab	55	47 (85.5)	-0.54 (0.09)	(-0.71, -0.36)	-0.14 (0.14)	(-0.41, 0.13)	0.315																																																																																																																										
	Placebo	40	36 (90.0)	-0.40 (0.10)	(-0.60, -0.19)				Week 43	Tezepelumab	55	49 (89.1)	-0.57 (0.09)	(-0.74, -0.39)	-0.14 (0.14)	(-0.41, 0.13)	0.322	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.64, -0.23)	Week 44	Tezepelumab	55	48 (87.3)	-0.61 (0.09)	(-0.79, -0.44)	-0.20 (0.14)	(-0.48, 0.07)	0.141	Placebo	40	35 (87.5)	-0.41 (0.11)	(-0.62, -0.20)	Week 45	Tezepelumab	55	48 (87.3)	-0.59 (0.09)	(-0.76, -0.41)	-0.12 (0.14)	(-0.39, 0.15)	0.398	Placebo	40	36 (90.0)	-0.47 (0.11)	(-0.68, -0.27)	Week 46	Tezepelumab	55	47 (85.5)	-0.59 (0.09)	(-0.76, -0.41)	-0.13 (0.14)	(-0.40, 0.14)	0.339	Placebo	40	37 (92.5)	-0.45 (0.11)	(-0.66, -0.25)	Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)	Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)										
Week 43	Tezepelumab	55	49 (89.1)	-0.57 (0.09)	(-0.74, -0.39)	-0.14 (0.14)	(-0.41, 0.13)	0.322																																																																																																																										
	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.64, -0.23)				Week 44	Tezepelumab	55	48 (87.3)	-0.61 (0.09)	(-0.79, -0.44)	-0.20 (0.14)	(-0.48, 0.07)	0.141	Placebo	40	35 (87.5)	-0.41 (0.11)	(-0.62, -0.20)	Week 45	Tezepelumab	55	48 (87.3)	-0.59 (0.09)	(-0.76, -0.41)	-0.12 (0.14)	(-0.39, 0.15)	0.398	Placebo	40	36 (90.0)	-0.47 (0.11)	(-0.68, -0.27)	Week 46	Tezepelumab	55	47 (85.5)	-0.59 (0.09)	(-0.76, -0.41)	-0.13 (0.14)	(-0.40, 0.14)	0.339	Placebo	40	37 (92.5)	-0.45 (0.11)	(-0.66, -0.25)	Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)	Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																								
Week 44	Tezepelumab	55	48 (87.3)	-0.61 (0.09)	(-0.79, -0.44)	-0.20 (0.14)	(-0.48, 0.07)	0.141																																																																																																																										
	Placebo	40	35 (87.5)	-0.41 (0.11)	(-0.62, -0.20)				Week 45	Tezepelumab	55	48 (87.3)	-0.59 (0.09)	(-0.76, -0.41)	-0.12 (0.14)	(-0.39, 0.15)	0.398	Placebo	40	36 (90.0)	-0.47 (0.11)	(-0.68, -0.27)	Week 46	Tezepelumab	55	47 (85.5)	-0.59 (0.09)	(-0.76, -0.41)	-0.13 (0.14)	(-0.40, 0.14)	0.339	Placebo	40	37 (92.5)	-0.45 (0.11)	(-0.66, -0.25)	Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)	Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																						
Week 45	Tezepelumab	55	48 (87.3)	-0.59 (0.09)	(-0.76, -0.41)	-0.12 (0.14)	(-0.39, 0.15)	0.398																																																																																																																										
	Placebo	40	36 (90.0)	-0.47 (0.11)	(-0.68, -0.27)				Week 46	Tezepelumab	55	47 (85.5)	-0.59 (0.09)	(-0.76, -0.41)	-0.13 (0.14)	(-0.40, 0.14)	0.339	Placebo	40	37 (92.5)	-0.45 (0.11)	(-0.66, -0.25)	Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)	Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																																				
Week 46	Tezepelumab	55	47 (85.5)	-0.59 (0.09)	(-0.76, -0.41)	-0.13 (0.14)	(-0.40, 0.14)	0.339																																																																																																																										
	Placebo	40	37 (92.5)	-0.45 (0.11)	(-0.66, -0.25)				Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)	Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																																																		
Week 47	Tezepelumab	55	46 (83.6)	-0.56 (0.09)	(-0.73, -0.38)	-0.14 (0.14)	(-0.41, 0.14)	0.327																																																																																																																										
	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.63, -0.22)				Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)	Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																																																																
Week 48	Tezepelumab	55	49 (89.1)	-0.47 (0.09)	(-0.65, -0.30)	-0.03 (0.14)	(-0.31, 0.24)	0.810																																																																																																																										
	Placebo	40	36 (90.0)	-0.44 (0.11)	(-0.65, -0.23)				Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)	Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																																																																														
Week 49	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.30)	-0.02 (0.14)	(-0.30, 0.25)	0.858																																																																																																																										
	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)				Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																																																																																												
Week 50	Tezepelumab	55	44 (80.0)	-0.52 (0.09)	(-0.70, -0.35)	-0.04 (0.14)	(-0.31, 0.23)	0.779																																																																																																																										
	Placebo	40	35 (87.5)	-0.49 (0.11)	(-0.69, -0.28)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	55	45 (81.8)	-0.49 (0.09)	(-0.67, -0.31)	-0.07 (0.14)	(-0.34, 0.21)	0.625
	Placebo	40	33 (82.5)	-0.42 (0.11)	(-0.63, -0.21)			
Week 52	Tezepelumab	55	39 (70.9)	-0.51 (0.09)	(-0.70, -0.33)	-0.07 (0.14)	(-0.35, 0.21)	0.622
	Placebo	40	32 (80.0)	-0.44 (0.11)	(-0.65, -0.23)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	12	12 (100.0)	1.51 (0.91)	0.0	1.00	1.43	2.00	3.1	
		Placebo	11	11 (100.0)	2.10 (0.97)	0.4	1.64	2.00	3.00	3.9	
	Week 1	Tezepelumab	12	12 (100.0)	1.42 (0.83)	0.4	0.96	1.08	1.75	3.0	
		Placebo	11	11 (100.0)	1.94 (0.62)	0.7	1.50	2.00	2.42	2.9	
	Week 2	Tezepelumab	12	12 (100.0)	1.33 (0.85)	0.4	1.00	1.00	1.50	3.0	
		Placebo	11	10 (90.9)	1.94 (0.65)	0.5	1.50	2.04	2.50	2.8	
	Week 3	Tezepelumab	12	12 (100.0)	1.34 (0.81)	0.7	0.93	1.00	1.34	3.0	
		Placebo	11	10 (90.9)	1.87 (0.58)	0.7	1.50	2.00	2.14	2.6	
	Week 4	Tezepelumab	12	11 (91.7)	1.47 (0.81)	0.7	1.00	1.07	1.79	3.0	
		Placebo	11	11 (100.0)	1.98 (0.46)	1.0	1.71	2.00	2.43	2.5	
	Week 5	Tezepelumab	12	11 (91.7)	1.32 (0.96)	0.0	1.00	1.17	1.57	3.0	
		Placebo	11	11 (100.0)	1.87 (0.38)	1.3	1.43	2.00	2.17	2.5	
	Week 6	Tezepelumab	12	11 (91.7)	1.34 (1.13)	0.0	1.00	1.07	1.50	3.9	
		Placebo	11	11 (100.0)	1.79 (0.47)	1.0	1.43	1.93	2.07	2.5	
	Week 7	Tezepelumab	12	11 (91.7)	1.47 (1.14)	0.2	0.70	1.21	1.79	4.0	
		Placebo	11	11 (100.0)	1.81 (0.48)	1.0	1.57	2.00	2.10	2.5	
	Week 8	Tezepelumab	12	10 (83.3)	1.60 (1.17)	0.1	1.00	1.32	1.93	4.0	
		Placebo	11	11 (100.0)	1.91 (0.52)	1.0	1.50	2.00	2.36	2.5	
	Week 9	Tezepelumab	12	12 (100.0)	1.39 (1.17)	0.0	0.68	1.04	1.96	4.0	
		Placebo	11	11 (100.0)	1.95 (0.58)	0.9	1.36	2.00	2.57	2.7	
	Week 10	Tezepelumab	12	12 (100.0)	1.46 (1.11)	0.0	0.89	1.07	1.96	4.0	
		Placebo	11	10 (90.9)	1.91 (0.53)	0.9	1.50	1.93	2.36	2.7	
	Week 11	Tezepelumab	12	12 (100.0)	1.43 (1.16)	0.0	0.79	1.00	1.93	4.0	
		Placebo	11	10 (90.9)	1.69 (0.58)	0.8	1.00	2.00	2.13	2.4	
	Week 12	Tezepelumab	12	11 (91.7)	1.58 (1.14)	0.0	1.00	1.50	2.00	4.0	
		Placebo	11	11 (100.0)	1.90 (0.58)	1.0	1.43	2.00	2.43	2.9	
	Week 13	Tezepelumab	12	11 (91.7)	1.64 (1.13)	0.0	1.00	1.64	2.14	4.0	
		Placebo	11	11 (100.0)	1.90 (0.53)	0.7	1.71	2.00	2.07	2.9	
	Week 14	Tezepelumab	12	11 (91.7)	1.56 (1.14)	0.0	0.93	1.21	2.17	4.0	
		Placebo	11	11 (100.0)	2.03 (0.66)	0.9	1.57	2.00	2.14	3.4	
	Week 15	Tezepelumab	12	11 (91.7)	1.46 (1.20)	0.0	0.86	1.00	1.93	4.0	
		Placebo	11	11 (100.0)	1.91 (0.72)	0.6	1.43	2.00	2.21	3.0	
	Week 16	Tezepelumab	12	11 (91.7)	1.45 (1.18)	0.0	0.93	1.07	1.92	4.0	
		Placebo	11	11 (100.0)	1.76 (0.44)	1.0	1.43	2.00	2.07	2.4	
Week 17	Tezepelumab	12	11 (91.7)	1.46 (1.16)	0.1	0.50	1.00	1.75	4.0		
	Placebo	11	11 (100.0)	1.71 (0.59)	0.7	1.00	2.00	2.07	2.6		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	12	11 (91.7)	1.49 (1.22)	0.1	0.50	1.14	2.00	4.0	
		Placebo	11	11 (100.0)	1.67 (0.56)	0.7	1.00	2.00	2.07	2.3	
	Week 19	Tezepelumab	12	11 (91.7)	1.50 (1.19)	0.0	0.79	1.07	1.86	4.0	
		Placebo	11	11 (100.0)	1.78 (0.58)	1.0	1.00	1.92	2.21	2.6	
	Week 20	Tezepelumab	12	11 (91.7)	1.49 (1.20)	0.0	0.64	1.07	2.00	4.0	
		Placebo	11	11 (100.0)	1.73 (0.65)	0.7	1.00	2.00	2.10	2.8	
	Week 21	Tezepelumab	12	11 (91.7)	1.54 (1.22)	0.0	1.00	1.21	1.86	4.0	
		Placebo	11	11 (100.0)	1.73 (0.79)	0.0	1.21	2.00	2.08	2.9	
	Week 22	Tezepelumab	12	11 (91.7)	1.51 (1.09)	0.0	0.71	1.07	2.00	4.0	
		Placebo	11	11 (100.0)	1.75 (0.91)	0.0	1.00	2.00	2.25	3.1	
	Week 23	Tezepelumab	12	11 (91.7)	1.48 (1.26)	0.0	0.50	1.14	2.07	4.0	
		Placebo	11	11 (100.0)	1.80 (0.99)	0.0	1.00	2.00	2.93	3.0	
	Week 24	Tezepelumab	12	11 (91.7)	1.42 (1.10)	0.0	0.71	1.50	2.00	3.9	
		Placebo	11	11 (100.0)	1.82 (0.91)	0.0	1.14	2.00	2.79	3.0	
	Week 25	Tezepelumab	12	11 (91.7)	1.66 (1.21)	0.0	1.00	1.67	2.71	4.0	
		Placebo	11	11 (100.0)	1.65 (0.81)	0.0	1.07	2.00	2.07	3.0	
	Week 26	Tezepelumab	12	11 (91.7)	1.62 (1.18)	0.0	1.00	1.58	2.00	4.0	
		Placebo	11	11 (100.0)	1.59 (0.69)	0.0	1.00	1.93	2.07	2.2	
	Week 27	Tezepelumab	12	10 (83.3)	1.47 (0.98)	0.0	1.00	1.46	1.71	3.1	
		Placebo	11	11 (100.0)	1.76 (0.84)	0.0	1.00	2.00	2.33	2.8	
	Week 28	Tezepelumab	12	9 (75.0)	1.62 (0.86)	0.4	1.13	1.50	1.70	3.1	
		Placebo	11	11 (100.0)	1.79 (0.91)	0.0	1.00	2.00	2.38	3.0	
	Week 29	Tezepelumab	12	8 (66.7)	1.37 (0.93)	0.0	1.04	1.15	1.67	3.3	
		Placebo	11	11 (100.0)	1.78 (0.94)	0.0	1.00	2.00	2.64	2.9	
	Week 30	Tezepelumab	12	10 (83.3)	1.40 (1.02)	0.0	1.00	1.19	1.64	3.2	
		Placebo	11	11 (100.0)	1.74 (0.94)	0.0	1.00	2.08	2.29	2.9	
	Week 31	Tezepelumab	12	9 (75.0)	1.57 (1.11)	0.0	1.00	1.43	1.57	3.7	
		Placebo	11	11 (100.0)	1.73 (0.86)	0.0	1.00	2.00	2.36	3.0	
	Week 32	Tezepelumab	12	10 (83.3)	1.49 (1.12)	0.0	1.00	1.04	2.08	3.9	
		Placebo	11	11 (100.0)	1.73 (0.91)	0.0	1.00	2.00	2.21	2.9	
	Week 33	Tezepelumab	12	10 (83.3)	1.47 (1.05)	0.0	1.00	1.11	2.00	3.9	
		Placebo	11	11 (100.0)	1.65 (0.87)	0.0	1.00	1.83	2.17	3.0	
	Week 34	Tezepelumab	12	10 (83.3)	1.36 (0.97)	0.0	0.93	1.04	2.00	3.5	
		Placebo	11	11 (100.0)	1.73 (0.87)	0.0	1.00	2.00	2.50	3.0	
	Week 35	Tezepelumab	12	10 (83.3)	1.34 (0.92)	0.0	1.00	1.04	2.00	3.3	
		Placebo	11	11 (100.0)	1.69 (0.94)	0.0	1.00	2.00	2.36	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	12	10 (83.3)	1.27 (0.97)	0.0	0.93	1.00	2.00	3.3	
		Placebo	11	11 (100.0)	1.63 (0.87)	0.0	1.00	2.00	2.20	3.0	
	Week 37	Tezepelumab	12	9 (75.0)	1.43 (0.94)	0.1	1.00	1.10	2.14	3.1	
		Placebo	11	11 (100.0)	1.56 (0.82)	0.0	1.00	1.92	2.00	3.0	
	Week 38	Tezepelumab	12	9 (75.0)	1.44 (1.09)	0.2	1.00	1.00	2.14	3.8	
		Placebo	11	11 (100.0)	1.69 (0.80)	0.0	1.14	2.00	2.21	3.0	
	Week 39	Tezepelumab	12	9 (75.0)	1.50 (1.03)	0.2	1.00	1.00	2.00	3.5	
		Placebo	11	10 (90.9)	1.54 (0.84)	0.0	1.00	1.74	2.00	3.0	
	Week 40	Tezepelumab	12	9 (75.0)	1.53 (1.03)	0.4	1.00	1.00	2.21	3.3	
		Placebo	11	11 (100.0)	1.68 (0.95)	0.0	1.00	2.00	2.29	3.0	
	Week 41	Tezepelumab	12	8 (66.7)	1.57 (1.15)	0.4	0.89	1.00	2.43	3.6	
		Placebo	11	10 (90.9)	1.53 (0.86)	0.0	1.07	1.43	2.10	3.0	
	Week 42	Tezepelumab	12	8 (66.7)	1.38 (0.99)	0.1	0.75	1.00	2.14	3.1	
		Placebo	11	11 (100.0)	1.59 (0.86)	0.0	1.00	1.90	2.14	3.0	
	Week 43	Tezepelumab	12	8 (66.7)	1.45 (1.04)	0.0	1.00	1.11	2.13	3.1	
		Placebo	11	11 (100.0)	1.55 (0.88)	0.0	0.93	1.75	2.21	3.0	
	Week 44	Tezepelumab	12	8 (66.7)	1.39 (1.08)	0.3	0.71	1.00	2.14	3.1	
		Placebo	11	11 (100.0)	1.55 (0.94)	0.0	0.64	1.93	2.10	3.0	
	Week 45	Tezepelumab	12	8 (66.7)	1.35 (1.08)	0.2	0.64	1.00	2.14	3.0	
		Placebo	11	10 (90.9)	1.42 (0.88)	0.0	0.86	1.29	2.00	2.7	
	Week 46	Tezepelumab	12	7 (58.3)	1.42 (1.10)	0.2	0.60	1.00	2.93	3.0	
		Placebo	11	11 (100.0)	1.49 (0.81)	0.0	0.64	2.00	2.10	2.3	
	Week 47	Tezepelumab	12	8 (66.7)	1.38 (1.14)	0.0	0.61	1.00	2.39	3.0	
		Placebo	11	11 (100.0)	1.48 (0.92)	0.0	0.50	2.00	2.17	2.6	
	Week 48	Tezepelumab	12	7 (58.3)	1.56 (1.05)	0.4	1.00	1.00	3.00	3.1	
		Placebo	11	11 (100.0)	1.46 (0.87)	0.0	0.50	2.00	2.17	2.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	12	12 (100.0)	-0.10 (0.51)	-0.9	-0.35	0.00	0.11	0.8	0.12 [-0.70, 0.94]
		Placebo	11	11 (100.0)	-0.17 (0.64)	-1.8	-0.42	0.00	0.20	0.6	
	Week 2	Tezepelumab	12	12 (100.0)	-0.18 (0.41)	-0.9	-0.43	0.00	0.00	0.4	-0.47 [-1.33, 0.38]
		Placebo	11	10 (90.9)	0.02 (0.42)	-0.5	-0.25	-0.01	0.14	1.0	
	Week 3	Tezepelumab	12	12 (100.0)	-0.17 (0.57)	-1.4	-0.46	0.00	0.07	0.8	-0.21 [-1.05, 0.63]
		Placebo	11	10 (90.9)	-0.05 (0.57)	-0.9	-0.42	0.03	0.29	1.0	
	Week 4	Tezepelumab	12	11 (91.7)	-0.18 (0.64)	-1.3	-0.64	-0.07	0.07	1.2	-0.09 [-0.92, 0.75]
		Placebo	11	11 (100.0)	-0.12 (0.69)	-1.4	-0.57	0.00	0.29	1.0	
	Week 5	Tezepelumab	12	11 (91.7)	-0.24 (0.72)	-2.1	-0.48	0.00	0.10	0.6	-0.01 [-0.85, 0.82]
		Placebo	11	11 (100.0)	-0.23 (0.91)	-2.2	-0.79	-0.15	0.29	1.1	
	Week 6	Tezepelumab	12	11 (91.7)	-0.21 (0.76)	-2.0	-0.64	-0.07	0.14	0.9	0.11 [-0.72, 0.95]
		Placebo	11	11 (100.0)	-0.31 (0.87)	-2.3	-0.71	-0.08	0.29	0.9	
	Week 7	Tezepelumab	12	11 (91.7)	-0.09 (0.82)	-1.9	-0.64	0.21	0.50	1.0	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.29 (0.82)	-2.0	-0.83	-0.35	0.29	1.0	
	Week 8	Tezepelumab	12	10 (83.3)	-0.12 (0.91)	-2.1	-0.64	0.00	0.46	1.0	0.09 [-0.77, 0.94]
		Placebo	11	11 (100.0)	-0.19 (0.73)	-1.4	-0.83	-0.07	0.29	1.0	
	Week 9	Tezepelumab	12	12 (100.0)	-0.12 (0.89)	-2.0	-0.79	0.11	0.43	1.0	0.03 [-0.78, 0.85]
		Placebo	11	11 (100.0)	-0.15 (0.88)	-1.9	-0.73	-0.07	0.62	1.0	
	Week 10	Tezepelumab	12	12 (100.0)	-0.06 (0.94)	-2.0	-0.75	0.18	0.77	1.0	0.16 [-0.68, 1.00]
		Placebo	11	10 (90.9)	-0.19 (0.76)	-1.2	-0.64	-0.38	0.07	1.1	
	Week 11	Tezepelumab	12	12 (100.0)	-0.08 (0.86)	-2.1	-0.46	0.04	0.32	1.0	0.42 [-0.43, 1.26]
		Placebo	11	10 (90.9)	-0.42 (0.74)	-1.5	-0.88	-0.58	0.00	1.0	
	Week 12	Tezepelumab	12	11 (91.7)	-0.07 (0.98)	-2.1	-0.64	-0.07	1.00	1.2	0.15 [-0.69, 0.99]
		Placebo	11	11 (100.0)	-0.20 (0.78)	-1.5	-0.64	-0.29	0.71	1.0	
	Week 13	Tezepelumab	12	11 (91.7)	-0.01 (1.00)	-2.1	-0.64	0.07	1.00	1.1	0.20 [-0.63, 1.04]
		Placebo	11	11 (100.0)	-0.20 (0.94)	-1.7	-0.93	-0.21	0.77	1.4	
	Week 14	Tezepelumab	12	11 (91.7)	-0.09 (0.95)	-2.1	-0.64	0.00	0.64	1.2	-0.02 [-0.86, 0.81]
		Placebo	11	11 (100.0)	-0.07 (0.87)	-0.9	-0.79	-0.43	0.70	1.8	
	Week 15	Tezepelumab	12	11 (91.7)	-0.19 (0.92)	-2.1	-0.86	0.00	0.38	1.0	0.00 [-0.83, 0.84]
		Placebo	11	11 (100.0)	-0.19 (0.69)	-1.0	-0.79	-0.33	0.29	1.0	
	Week 16	Tezepelumab	12	11 (91.7)	-0.19 (0.91)	-2.1	-0.86	-0.07	0.36	1.0	0.18 [-0.66, 1.02]
		Placebo	11	11 (100.0)	-0.34 (0.74)	-1.5	-0.93	-0.49	-0.01	1.0	
	Week 17	Tezepelumab	12	11 (91.7)	-0.19 (0.81)	-2.0	-0.64	0.00	0.46	1.0	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.39 (0.81)	-1.8	-1.00	-0.56	0.36	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	12	11 (91.7)	-0.16 (1.10)	-1.9	-0.93	-0.24	0.86	1.9	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.43 (0.78)	-1.8	-0.93	-0.64	0.20	1.0	
	Week 19	Tezepelumab	12	11 (91.7)	-0.15 (1.10)	-1.9	-1.00	0.00	0.86	1.9	0.19 [-0.65, 1.03]
		Placebo	11	11 (100.0)	-0.33 (0.80)	-1.5	-1.00	-0.42	0.56	1.0	
	Week 20	Tezepelumab	12	11 (91.7)	-0.16 (1.09)	-1.9	-1.00	0.07	1.00	1.7	0.23 [-0.61, 1.07]
		Placebo	11	11 (100.0)	-0.37 (0.70)	-1.2	-1.00	-0.63	0.20	1.0	
	Week 21	Tezepelumab	12	11 (91.7)	-0.11 (1.18)	-2.0	-1.00	0.03	0.86	2.1	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.38 (0.96)	-1.6	-1.00	-0.58	0.85	1.0	
	Week 22	Tezepelumab	12	11 (91.7)	-0.14 (0.98)	-1.4	-1.00	0.07	1.00	1.3	0.22 [-0.62, 1.06]
		Placebo	11	11 (100.0)	-0.35 (0.88)	-1.6	-1.00	-0.67	0.50	1.0	
	Week 23	Tezepelumab	12	11 (91.7)	-0.17 (1.20)	-2.1	-1.00	-0.07	1.00	2.0	0.12 [-0.72, 0.96]
		Placebo	11	11 (100.0)	-0.30 (0.92)	-1.6	-1.00	-0.75	0.79	1.0	
	Week 24	Tezepelumab	12	11 (91.7)	-0.23 (1.10)	-2.1	-1.00	-0.29	0.93	1.1	0.05 [-0.79, 0.88]
		Placebo	11	11 (100.0)	-0.28 (0.95)	-1.6	-1.00	-0.75	0.79	1.0	
	Week 25	Tezepelumab	12	11 (91.7)	0.01 (1.33)	-2.1	-1.00	0.14	1.08	2.1	0.37 [-0.47, 1.21]
		Placebo	11	11 (100.0)	-0.45 (1.15)	-2.7	-1.00	-0.42	0.71	1.0	
	Week 26	Tezepelumab	12	11 (91.7)	-0.03 (1.22)	-2.1	-1.00	0.01	1.00	1.7	0.44 [-0.41, 1.29]
		Placebo	11	11 (100.0)	-0.51 (0.94)	-2.2	-1.00	-0.49	0.13	1.0	
	Week 27	Tezepelumab	12	10 (83.3)	-0.05 (1.36)	-1.9	-1.00	-0.27	1.14	1.9	0.26 [-0.60, 1.12]
		Placebo	11	11 (100.0)	-0.34 (0.86)	-1.6	-1.00	-0.27	0.50	1.0	
	Week 28	Tezepelumab	12	9 (75.0)	0.05 (1.32)	-1.8	-0.86	-0.07	1.07	1.8	0.34 [-0.55, 1.23]
		Placebo	11	11 (100.0)	-0.32 (0.84)	-1.6	-1.00	-0.58	0.50	1.0	
	Week 29	Tezepelumab	12	8 (66.7)	-0.27 (1.27)	-2.1	-1.11	-0.24	0.36	2.0	0.05 [-0.86, 0.96]
		Placebo	11	11 (100.0)	-0.32 (1.03)	-2.1	-1.00	-0.36	0.77	1.0	
	Week 30	Tezepelumab	12	10 (83.3)	-0.11 (1.37)	-2.1	-0.86	-0.26	0.43	2.0	0.22 [-0.64, 1.08]
		Placebo	11	11 (100.0)	-0.36 (0.86)	-1.6	-1.00	-0.63	0.29	1.0	
	Week 31	Tezepelumab	12	9 (75.0)	0.00 (1.51)	-2.1	-0.86	0.00	0.43	2.4	0.31 [-0.58, 1.19]
		Placebo	11	11 (100.0)	-0.37 (0.89)	-1.6	-1.00	-0.49	0.43	1.0	
	Week 32	Tezepelumab	12	10 (83.3)	-0.02 (1.49)	-2.1	-0.86	0.14	0.51	2.6	0.29 [-0.57, 1.16]
		Placebo	11	11 (100.0)	-0.37 (0.82)	-1.6	-1.00	-0.21	0.07	1.0	
	Week 33	Tezepelumab	12	10 (83.3)	-0.04 (1.42)	-2.1	-0.86	0.17	0.43	2.6	0.33 [-0.53, 1.19]
		Placebo	11	11 (100.0)	-0.45 (1.04)	-2.3	-1.00	-0.57	0.29	1.0	
	Week 34	Tezepelumab	12	10 (83.3)	-0.15 (1.34)	-2.1	-0.86	-0.04	0.64	2.2	0.19 [-0.66, 1.05]
		Placebo	11	11 (100.0)	-0.37 (0.94)	-1.6	-1.00	-0.56	0.57	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMH0: Course of ASD weekly shortness of breath score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	12	10 (83.3)	-0.17 (1.32)	-2.1	-0.86	-0.06	0.60	2.0	0.22 [-0.64, 1.08]
		Placebo	11	11 (100.0)	-0.41 (0.87)	-1.6	-1.00	-0.80	0.21	1.0	
	Week 36	Tezepelumab	12	10 (83.3)	-0.24 (1.32)	-2.1	-0.86	-0.18	0.50	2.0	0.21 [-0.65, 1.06]
		Placebo	11	11 (100.0)	-0.47 (0.92)	-1.6	-1.00	-0.93	0.50	1.0	
	Week 37	Tezepelumab	12	9 (75.0)	-0.14 (1.36)	-2.1	-0.86	0.14	0.57	1.9	0.35 [-0.54, 1.24]
		Placebo	11	11 (100.0)	-0.54 (0.95)	-1.9	-1.00	-0.86	0.29	1.0	
	Week 38	Tezepelumab	12	9 (75.0)	-0.14 (1.45)	-2.1	-0.86	-0.07	0.57	2.5	0.23 [-0.66, 1.11]
		Placebo	11	11 (100.0)	-0.41 (0.97)	-1.7	-1.00	-0.56	0.79	1.0	
	Week 39	Tezepelumab	12	9 (75.0)	-0.07 (1.46)	-2.1	-0.86	0.21	0.43	2.2	0.26 [-0.65, 1.16]
		Placebo	11	10 (90.9)	-0.38 (0.91)	-1.6	-1.00	-0.64	0.50	1.0	
	Week 40	Tezepelumab	12	9 (75.0)	-0.04 (1.43)	-2.1	-0.86	-0.14	0.64	2.0	0.33 [-0.56, 1.21]
		Placebo	11	11 (100.0)	-0.42 (0.94)	-1.6	-1.00	-0.90	0.64	1.0	
	Week 41	Tezepelumab	12	8 (66.7)	0.00 (1.63)	-2.1	-1.32	-0.21	1.43	2.3	0.34 [-0.59, 1.28]
		Placebo	11	10 (90.9)	-0.48 (1.21)	-2.6	-1.33	-0.52	0.92	1.0	
	Week 42	Tezepelumab	12	8 (66.7)	-0.20 (1.47)	-2.1	-1.43	-0.36	1.14	1.8	0.26 [-0.66, 1.17]
		Placebo	11	11 (100.0)	-0.51 (1.00)	-1.8	-1.43	-0.71	0.64	1.0	
	Week 43	Tezepelumab	12	8 (66.7)	-0.12 (1.57)	-2.1	-1.46	-0.11	1.24	1.9	0.33 [-0.58, 1.25]
		Placebo	11	11 (100.0)	-0.55 (1.04)	-2.2	-1.50	-0.70	0.57	1.0	
	Week 44	Tezepelumab	12	8 (66.7)	-0.18 (1.51)	-2.1	-1.36	-0.39	1.05	2.0	0.30 [-0.62, 1.22]
		Placebo	11	11 (100.0)	-0.55 (0.99)	-2.0	-1.50	-0.70	0.29	1.0	
	Week 45	Tezepelumab	12	8 (66.7)	-0.22 (1.51)	-2.1	-1.39	-0.46	1.00	2.0	0.28 [-0.65, 1.22]
		Placebo	11	10 (90.9)	-0.60 (1.14)	-2.7	-1.50	-0.54	0.50	1.0	
	Week 46	Tezepelumab	12	7 (58.3)	0.07 (1.39)	-1.9	-0.86	0.03	1.64	2.0	0.61 [-0.36, 1.58]
		Placebo	11	11 (100.0)	-0.61 (0.88)	-1.8	-1.50	-0.75	-0.01	1.0	
	Week 47	Tezepelumab	12	8 (66.7)	-0.20 (1.55)	-2.1	-1.39	-0.61	1.25	2.0	0.36 [-0.56, 1.28]
		Placebo	11	11 (100.0)	-0.62 (0.84)	-1.6	-1.47	-0.83	-0.19	1.0	
	Week 48	Tezepelumab	12	7 (58.3)	0.07 (1.46)	-2.1	-0.86	-0.14	1.80	2.0	0.65 [-0.32, 1.63]
		Placebo	11	11 (100.0)	-0.64 (0.81)	-1.6	-1.47	-0.83	-0.07	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	12	12 (100.0)	-0.27 (0.25)	(-0.77, 0.23)	-0.24 (0.36)	(-0.97, 0.49)	0.510	
	Placebo	11	11 (100.0)	-0.03 (0.26)	(-0.55, 0.49)				
Week 2	Tezepelumab	12	12 (100.0)	-0.36 (0.25)	(-0.85, 0.14)	-0.36 (0.36)	(-1.08, 0.37)	0.332	
	Placebo	11	10 (90.9)	0.00 (0.26)	(-0.52, 0.52)				
Week 3	Tezepelumab	12	12 (100.0)	-0.35 (0.25)	(-0.85, 0.15)	-0.29 (0.36)	(-1.02, 0.44)	0.429	
	Placebo	11	10 (90.9)	-0.06 (0.26)	(-0.58, 0.46)				
Week 4	Tezepelumab	12	11 (91.7)	-0.30 (0.25)	(-0.80, 0.20)	-0.32 (0.36)	(-1.04, 0.41)	0.390	
	Placebo	11	11 (100.0)	0.02 (0.26)	(-0.50, 0.53)				
Week 5	Tezepelumab	12	11 (91.7)	-0.44 (0.25)	(-0.94, 0.06)	-0.35 (0.36)	(-1.08, 0.38)	0.339	
	Placebo	11	11 (100.0)	-0.09 (0.26)	(-0.61, 0.43)				
Week 6	Tezepelumab	12	11 (91.7)	-0.43 (0.25)	(-0.93, 0.07)	-0.26 (0.37)	(-0.99, 0.47)	0.477	
	Placebo	11	11 (100.0)	-0.17 (0.26)	(-0.69, 0.35)				
Week 7	Tezepelumab	12	11 (91.7)	-0.32 (0.25)	(-0.82, 0.18)	-0.16 (0.37)	(-0.89, 0.56)	0.655	
	Placebo	11	11 (100.0)	-0.15 (0.26)	(-0.67, 0.36)				
Week 8	Tezepelumab	12	10 (83.3)	-0.29 (0.25)	(-0.80, 0.21)	-0.24 (0.37)	(-0.97, 0.49)	0.511	
	Placebo	11	11 (100.0)	-0.05 (0.26)	(-0.57, 0.46)				
Week 9	Tezepelumab	12	12 (100.0)	-0.29 (0.25)	(-0.79, 0.20)	-0.28 (0.36)	(-1.01, 0.44)	0.441	
	Placebo	11	11 (100.0)	-0.01 (0.26)	(-0.53, 0.50)				
Week 10	Tezepelumab	12	12 (100.0)	-0.23 (0.25)	(-0.73, 0.27)	-0.26 (0.36)	(-0.99, 0.46)	0.473	
	Placebo	11	10 (90.9)	0.03 (0.26)	(-0.49, 0.55)				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	12	12 (100.0)	-0.26 (0.25)	(-0.76, 0.24)	-0.07 (0.36)	(-0.80, 0.65)	0.841
	Placebo	11	10 (90.9)	-0.18 (0.26)	(-0.70, 0.33)			
Week 12	Tezepelumab	12	11 (91.7)	-0.22 (0.25)	(-0.72, 0.28)	-0.16 (0.36)	(-0.89, 0.57)	0.660
	Placebo	11	11 (100.0)	-0.06 (0.26)	(-0.58, 0.45)			
Week 13	Tezepelumab	12	11 (91.7)	-0.16 (0.25)	(-0.66, 0.34)	-0.09 (0.37)	(-0.82, 0.63)	0.797
	Placebo	11	11 (100.0)	-0.07 (0.26)	(-0.58, 0.45)			
Week 14	Tezepelumab	12	11 (91.7)	-0.24 (0.25)	(-0.74, 0.26)	-0.31 (0.37)	(-1.04, 0.42)	0.403
	Placebo	11	11 (100.0)	0.07 (0.26)	(-0.45, 0.58)			
Week 15	Tezepelumab	12	11 (91.7)	-0.33 (0.25)	(-0.84, 0.17)	-0.28 (0.37)	(-1.01, 0.45)	0.445
	Placebo	11	11 (100.0)	-0.05 (0.26)	(-0.57, 0.46)			
Week 16	Tezepelumab	12	11 (91.7)	-0.34 (0.25)	(-0.85, 0.17)	-0.14 (0.37)	(-0.87, 0.60)	0.712
	Placebo	11	11 (100.0)	-0.21 (0.26)	(-0.72, 0.31)			
Week 17	Tezepelumab	12	11 (91.7)	-0.34 (0.25)	(-0.84, 0.17)	-0.08 (0.37)	(-0.81, 0.65)	0.829
	Placebo	11	11 (100.0)	-0.26 (0.26)	(-0.77, 0.26)			
Week 18	Tezepelumab	12	11 (91.7)	-0.30 (0.26)	(-0.81, 0.21)	-0.00 (0.37)	(-0.74, 0.73)	0.989
	Placebo	11	11 (100.0)	-0.29 (0.26)	(-0.81, 0.22)			
Week 19	Tezepelumab	12	11 (91.7)	-0.28 (0.26)	(-0.79, 0.22)	-0.10 (0.37)	(-0.83, 0.64)	0.796
	Placebo	11	11 (100.0)	-0.19 (0.26)	(-0.71, 0.33)			
Week 20	Tezepelumab	12	11 (91.7)	-0.29 (0.26)	(-0.80, 0.22)	-0.06 (0.37)	(-0.79, 0.67)	0.870
	Placebo	11	11 (100.0)	-0.23 (0.26)	(-0.75, 0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	12	11 (91.7)	-0.24 (0.26)	(-0.75, 0.27)	-0.00 (0.37)	(-0.74, 0.73)	0.990
	Placebo	11	11 (100.0)	-0.24 (0.26)	(-0.76, 0.28)			
Week 22	Tezepelumab	12	11 (91.7)	-0.28 (0.26)	(-0.79, 0.23)	-0.06 (0.37)	(-0.80, 0.67)	0.861
	Placebo	11	11 (100.0)	-0.21 (0.26)	(-0.73, 0.31)			
Week 23	Tezepelumab	12	11 (91.7)	-0.30 (0.26)	(-0.82, 0.21)	-0.14 (0.37)	(-0.87, 0.59)	0.705
	Placebo	11	11 (100.0)	-0.16 (0.26)	(-0.68, 0.35)			
Week 24	Tezepelumab	12	11 (91.7)	-0.36 (0.26)	(-0.87, 0.15)	-0.22 (0.37)	(-0.95, 0.52)	0.557
	Placebo	11	11 (100.0)	-0.14 (0.26)	(-0.66, 0.37)			
Week 25	Tezepelumab	12	11 (91.7)	-0.12 (0.26)	(-0.63, 0.39)	0.20 (0.37)	(-0.54, 0.93)	0.597
	Placebo	11	11 (100.0)	-0.32 (0.26)	(-0.83, 0.20)			
Week 26	Tezepelumab	12	11 (91.7)	-0.16 (0.26)	(-0.67, 0.35)	0.22 (0.37)	(-0.52, 0.95)	0.555
	Placebo	11	11 (100.0)	-0.38 (0.26)	(-0.89, 0.14)			
Week 27	Tezepelumab	12	10 (83.3)	-0.08 (0.26)	(-0.60, 0.43)	0.12 (0.37)	(-0.62, 0.86)	0.747
	Placebo	11	11 (100.0)	-0.20 (0.26)	(-0.72, 0.32)			
Week 28	Tezepelumab	12	9 (75.0)	-0.08 (0.26)	(-0.60, 0.44)	0.10 (0.37)	(-0.64, 0.84)	0.787
	Placebo	11	11 (100.0)	-0.18 (0.26)	(-0.70, 0.34)			
Week 29	Tezepelumab	12	8 (66.7)	-0.15 (0.26)	(-0.67, 0.38)	0.04 (0.37)	(-0.70, 0.79)	0.912
	Placebo	11	11 (100.0)	-0.19 (0.26)	(-0.70, 0.33)			
Week 30	Tezepelumab	12	10 (83.3)	-0.16 (0.26)	(-0.69, 0.36)	0.06 (0.37)	(-0.69, 0.80)	0.879
	Placebo	11	11 (100.0)	-0.22 (0.26)	(-0.74, 0.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	12	9 (75.0)	-0.08 (0.27)	(-0.61, 0.44)	0.15 (0.37)	(-0.60, 0.89)	0.696
	Placebo	11	11 (100.0)	-0.23 (0.26)	(-0.75, 0.29)			
Week 32	Tezepelumab	12	10 (83.3)	-0.09 (0.27)	(-0.62, 0.44)	0.14 (0.37)	(-0.60, 0.89)	0.702
	Placebo	11	11 (100.0)	-0.23 (0.26)	(-0.75, 0.28)			
Week 33	Tezepelumab	12	10 (83.3)	-0.12 (0.27)	(-0.65, 0.41)	0.20 (0.37)	(-0.55, 0.94)	0.599
	Placebo	11	11 (100.0)	-0.32 (0.26)	(-0.83, 0.20)			
Week 34	Tezepelumab	12	10 (83.3)	-0.23 (0.27)	(-0.76, 0.30)	0.01 (0.38)	(-0.74, 0.75)	0.989
	Placebo	11	11 (100.0)	-0.24 (0.26)	(-0.75, 0.28)			
Week 35	Tezepelumab	12	10 (83.3)	-0.26 (0.27)	(-0.79, 0.27)	0.02 (0.38)	(-0.73, 0.77)	0.962
	Placebo	11	11 (100.0)	-0.28 (0.26)	(-0.79, 0.24)			
Week 36	Tezepelumab	12	10 (83.3)	-0.33 (0.27)	(-0.87, 0.20)	0.00 (0.38)	(-0.75, 0.75)	0.991
	Placebo	11	11 (100.0)	-0.34 (0.26)	(-0.85, 0.18)			
Week 37	Tezepelumab	12	9 (75.0)	-0.30 (0.27)	(-0.84, 0.24)	0.11 (0.38)	(-0.64, 0.86)	0.772
	Placebo	11	11 (100.0)	-0.41 (0.26)	(-0.92, 0.11)			
Week 38	Tezepelumab	12	9 (75.0)	-0.29 (0.27)	(-0.83, 0.25)	-0.02 (0.38)	(-0.78, 0.74)	0.958
	Placebo	11	11 (100.0)	-0.27 (0.26)	(-0.79, 0.24)			
Week 39	Tezepelumab	12	9 (75.0)	-0.23 (0.27)	(-0.77, 0.32)	0.10 (0.38)	(-0.65, 0.86)	0.786
	Placebo	11	10 (90.9)	-0.33 (0.26)	(-0.85, 0.19)			
Week 40	Tezepelumab	12	9 (75.0)	-0.19 (0.28)	(-0.74, 0.35)	0.09 (0.38)	(-0.67, 0.85)	0.809
	Placebo	11	11 (100.0)	-0.29 (0.26)	(-0.80, 0.23)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC_IBMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	12	8 (66.7)	-0.07 (0.28)	(-0.63, 0.48)	0.33 (0.38)	(-0.44, 1.09)	0.397
	Placebo	11	10 (90.9)	-0.40 (0.26)	(-0.92, 0.12)			
Week 42	Tezepelumab	12	8 (66.7)	-0.28 (0.28)	(-0.83, 0.28)	0.09 (0.39)	(-0.67, 0.86)	0.806
	Placebo	11	11 (100.0)	-0.37 (0.26)	(-0.89, 0.15)			
Week 43	Tezepelumab	12	8 (66.7)	-0.20 (0.28)	(-0.77, 0.36)	0.21 (0.39)	(-0.56, 0.98)	0.587
	Placebo	11	11 (100.0)	-0.41 (0.26)	(-0.93, 0.10)			
Week 44	Tezepelumab	12	8 (66.7)	-0.27 (0.29)	(-0.84, 0.30)	0.15 (0.39)	(-0.63, 0.92)	0.707
	Placebo	11	11 (100.0)	-0.42 (0.26)	(-0.93, 0.10)			
Week 45	Tezepelumab	12	8 (66.7)	-0.31 (0.29)	(-0.89, 0.26)	0.17 (0.39)	(-0.61, 0.95)	0.663
	Placebo	11	10 (90.9)	-0.48 (0.26)	(-1.00, 0.03)			
Week 46	Tezepelumab	12	7 (58.3)	-0.29 (0.29)	(-0.87, 0.29)	0.18 (0.39)	(-0.60, 0.96)	0.652
	Placebo	11	11 (100.0)	-0.47 (0.26)	(-0.99, 0.05)			
Week 47	Tezepelumab	12	8 (66.7)	-0.29 (0.29)	(-0.87, 0.29)	0.19 (0.39)	(-0.59, 0.98)	0.622
	Placebo	11	11 (100.0)	-0.49 (0.26)	(-1.00, 0.03)			
Week 48	Tezepelumab	12	7 (58.3)	-0.26 (0.30)	(-0.85, 0.33)	0.25 (0.40)	(-0.54, 1.04)	0.535
	Placebo	11	11 (100.0)	-0.51 (0.26)	(-1.02, 0.01)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	55	55 (100.0)	1.36 (0.73)	0.0	1.00	1.36	2.00	2.6	
		Placebo	40	40 (100.0)	1.39 (0.74)	0.0	1.11	1.33	2.00	2.6	
	Week 1	Tezepelumab	55	54 (98.2)	1.24 (0.70)	0.0	0.71	1.29	1.71	2.6	
		Placebo	40	40 (100.0)	1.29 (0.74)	0.0	1.07	1.21	1.81	3.1	
	Week 2	Tezepelumab	55	54 (98.2)	1.12 (0.75)	0.0	0.57	1.14	1.71	2.8	
		Placebo	40	39 (97.5)	1.28 (0.75)	0.0	0.86	1.14	1.92	3.0	
	Week 3	Tezepelumab	55	55 (100.0)	1.10 (0.73)	0.0	0.43	1.07	1.71	2.6	
		Placebo	40	38 (95.0)	1.23 (0.80)	0.0	0.86	1.11	1.93	2.5	
	Week 4	Tezepelumab	55	54 (98.2)	1.05 (0.72)	0.0	0.38	1.00	1.64	2.3	
		Placebo	40	39 (97.5)	1.18 (0.77)	0.0	0.57	1.14	1.92	2.4	
	Week 5	Tezepelumab	55	53 (96.4)	1.02 (0.73)	0.0	0.43	1.00	1.64	2.5	
		Placebo	40	38 (95.0)	1.06 (0.68)	0.0	0.57	1.11	1.64	2.2	
	Week 6	Tezepelumab	55	52 (94.5)	1.08 (0.78)	0.0	0.39	1.00	1.69	2.9	
		Placebo	40	40 (100.0)	1.17 (0.76)	0.0	0.64	1.09	1.93	2.7	
	Week 7	Tezepelumab	55	51 (92.7)	1.09 (0.79)	0.0	0.29	1.00	1.86	2.4	
		Placebo	40	40 (100.0)	1.04 (0.77)	0.0	0.20	1.00	1.80	2.4	
	Week 8	Tezepelumab	55	51 (92.7)	1.04 (0.80)	0.0	0.21	1.00	1.71	2.7	
		Placebo	40	39 (97.5)	1.06 (0.84)	0.0	0.21	1.00	1.64	3.1	
	Week 9	Tezepelumab	55	53 (96.4)	1.00 (0.80)	0.0	0.14	1.00	1.64	2.6	
		Placebo	40	40 (100.0)	1.05 (0.90)	0.0	0.07	1.00	1.43	3.4	
	Week 10	Tezepelumab	55	53 (96.4)	0.99 (0.82)	0.0	0.10	0.93	1.67	2.5	
		Placebo	40	40 (100.0)	1.05 (0.77)	0.0	0.27	1.00	1.88	2.4	
	Week 11	Tezepelumab	55	51 (92.7)	1.00 (0.80)	0.0	0.10	1.00	1.70	2.6	
		Placebo	40	40 (100.0)	1.01 (0.78)	0.0	0.31	1.00	1.50	3.0	
	Week 12	Tezepelumab	55	52 (94.5)	0.94 (0.79)	0.0	0.19	1.00	1.61	2.9	
		Placebo	40	38 (95.0)	1.00 (0.76)	0.0	0.29	1.00	1.50	2.8	
	Week 13	Tezepelumab	55	49 (89.1)	0.96 (0.83)	0.0	0.14	1.00	1.43	3.0	
		Placebo	40	38 (95.0)	0.95 (0.75)	0.0	0.29	1.00	1.57	2.3	
	Week 14	Tezepelumab	55	52 (94.5)	0.99 (0.85)	0.0	0.17	1.00	1.69	3.0	
		Placebo	40	37 (92.5)	1.01 (0.75)	0.0	0.30	1.00	1.67	2.6	
	Week 15	Tezepelumab	55	51 (92.7)	0.94 (0.79)	0.0	0.07	1.00	1.42	3.0	
		Placebo	40	39 (97.5)	0.94 (0.80)	0.0	0.14	1.00	1.67	2.8	
	Week 16	Tezepelumab	55	51 (92.7)	0.92 (0.81)	0.0	0.10	1.00	1.43	3.0	
		Placebo	40	38 (95.0)	0.94 (0.72)	0.0	0.25	1.00	1.25	2.1	
Week 17	Tezepelumab	55	52 (94.5)	0.95 (0.80)	0.0	0.07	0.93	1.52	2.6		
	Placebo	40	38 (95.0)	0.99 (0.79)	0.0	0.14	1.00	1.64	2.4		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	55	52 (94.5)	0.98 (0.81)	0.0	0.17	1.00	1.64	3.0	
		Placebo	40	38 (95.0)	1.01 (0.76)	0.0	0.50	1.00	1.64	3.0	
	Week 19	Tezepelumab	55	49 (89.1)	0.92 (0.79)	0.0	0.08	1.00	1.30	2.5	
		Placebo	40	39 (97.5)	1.01 (0.79)	0.0	0.10	1.00	1.75	3.0	
	Week 20	Tezepelumab	55	51 (92.7)	0.89 (0.76)	0.0	0.08	1.00	1.29	2.7	
		Placebo	40	37 (92.5)	1.02 (0.79)	0.0	0.21	1.00	1.71	2.9	
	Week 21	Tezepelumab	55	46 (83.6)	0.89 (0.72)	0.0	0.17	1.00	1.21	2.4	
		Placebo	40	38 (95.0)	0.97 (0.70)	0.0	0.43	1.00	1.29	2.4	
	Week 22	Tezepelumab	55	47 (85.5)	0.98 (0.72)	0.0	0.29	1.00	1.36	2.4	
		Placebo	40	38 (95.0)	1.04 (0.71)	0.0	0.57	1.00	1.58	2.5	
	Week 23	Tezepelumab	55	49 (89.1)	0.96 (0.79)	0.0	0.00	1.00	1.50	2.6	
		Placebo	40	36 (90.0)	1.02 (0.71)	0.0	0.29	1.00	1.59	2.4	
	Week 24	Tezepelumab	55	51 (92.7)	0.90 (0.78)	0.0	0.00	0.93	1.21	2.9	
		Placebo	40	36 (90.0)	0.95 (0.71)	0.0	0.20	1.00	1.45	2.5	
	Week 25	Tezepelumab	55	49 (89.1)	0.89 (0.74)	0.0	0.14	1.00	1.29	2.6	
		Placebo	40	36 (90.0)	0.93 (0.74)	0.0	0.19	1.00	1.29	2.4	
	Week 26	Tezepelumab	55	50 (90.9)	0.90 (0.80)	0.0	0.00	1.00	1.43	2.7	
		Placebo	40	37 (92.5)	0.94 (0.78)	0.0	0.10	1.00	1.42	2.3	
	Week 27	Tezepelumab	55	46 (83.6)	0.99 (0.83)	0.0	0.07	1.00	1.29	3.1	
		Placebo	40	36 (90.0)	1.06 (0.79)	0.0	0.54	1.00	1.61	3.1	
	Week 28	Tezepelumab	55	49 (89.1)	1.04 (0.81)	0.0	0.30	1.00	1.64	3.0	
		Placebo	40	36 (90.0)	1.08 (0.73)	0.0	0.50	1.00	1.70	2.7	
	Week 29	Tezepelumab	55	48 (87.3)	0.93 (0.75)	0.0	0.12	1.00	1.39	2.6	
		Placebo	40	37 (92.5)	0.98 (0.77)	0.0	0.42	1.00	1.36	2.9	
	Week 30	Tezepelumab	55	48 (87.3)	1.02 (0.78)	0.0	0.39	1.00	1.68	2.5	
		Placebo	40	36 (90.0)	0.89 (0.71)	0.0	0.32	1.00	1.14	3.0	
	Week 31	Tezepelumab	55	48 (87.3)	0.92 (0.74)	0.0	0.09	1.00	1.36	2.6	
		Placebo	40	37 (92.5)	0.94 (0.76)	0.0	0.29	1.00	1.40	3.0	
	Week 32	Tezepelumab	55	49 (89.1)	0.94 (0.75)	0.0	0.21	1.00	1.50	2.6	
		Placebo	40	37 (92.5)	0.88 (0.79)	0.0	0.07	1.00	1.36	3.0	
	Week 33	Tezepelumab	55	48 (87.3)	0.93 (0.77)	0.0	0.04	1.00	1.39	3.0	
		Placebo	40	37 (92.5)	0.99 (0.82)	0.0	0.14	1.00	1.38	3.0	
	Week 34	Tezepelumab	55	50 (90.9)	0.96 (0.79)	0.0	0.07	1.00	1.42	3.0	
		Placebo	40	38 (95.0)	0.97 (0.80)	0.0	0.07	1.00	1.30	3.0	
	Week 35	Tezepelumab	55	48 (87.3)	0.96 (0.81)	0.0	0.14	1.00	1.46	3.0	
		Placebo	40	36 (90.0)	0.97 (0.82)	0.0	0.07	1.00	1.50	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMH0: Course of ASD weekly cough score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	55	48 (87.3)	0.97 (0.83)	0.0	0.21	1.00	1.50	3.0	
		Placebo	40	38 (95.0)	1.01 (0.71)	0.0	0.42	1.00	1.50	3.1	
	Week 37	Tezepelumab	55	47 (85.5)	0.96 (0.77)	0.0	0.20	1.00	1.50	3.0	
		Placebo	40	37 (92.5)	1.03 (0.75)	0.0	0.21	1.00	1.57	2.9	
	Week 38	Tezepelumab	55	47 (85.5)	1.00 (0.83)	0.0	0.21	1.00	1.50	3.0	
		Placebo	40	37 (92.5)	0.96 (0.69)	0.0	0.29	1.00	1.29	3.0	
	Week 39	Tezepelumab	55	49 (89.1)	1.02 (0.78)	0.0	0.36	1.00	1.29	3.0	
		Placebo	40	37 (92.5)	0.96 (0.76)	0.0	0.43	1.00	1.17	3.0	
	Week 40	Tezepelumab	55	49 (89.1)	1.00 (0.77)	0.0	0.20	1.00	1.60	2.6	
		Placebo	40	38 (95.0)	1.06 (0.75)	0.0	0.50	1.00	1.50	2.9	
	Week 41	Tezepelumab	55	50 (90.9)	0.99 (0.80)	0.0	0.10	1.00	1.50	2.9	
		Placebo	40	36 (90.0)	1.06 (0.75)	0.0	0.43	1.00	1.50	3.0	
	Week 42	Tezepelumab	55	47 (85.5)	0.99 (0.90)	0.0	0.00	1.00	1.71	3.0	
		Placebo	40	36 (90.0)	1.16 (0.71)	0.0	0.93	1.00	1.52	3.0	
	Week 43	Tezepelumab	55	49 (89.1)	0.96 (0.90)	0.0	0.07	1.00	1.33	3.2	
		Placebo	40	37 (92.5)	0.98 (0.74)	0.0	0.21	1.00	1.40	3.0	
	Week 44	Tezepelumab	55	48 (87.3)	0.89 (0.83)	0.0	0.00	0.91	1.26	3.0	
		Placebo	40	35 (87.5)	1.03 (0.74)	0.0	0.29	1.00	1.50	3.0	
	Week 45	Tezepelumab	55	48 (87.3)	0.96 (0.85)	0.0	0.14	1.00	1.32	3.3	
		Placebo	40	36 (90.0)	0.90 (0.76)	0.0	0.08	1.00	1.26	3.0	
	Week 46	Tezepelumab	55	47 (85.5)	0.94 (0.80)	0.0	0.17	1.00	1.36	2.9	
		Placebo	40	37 (92.5)	0.89 (0.82)	0.0	0.08	1.00	1.14	3.0	
	Week 47	Tezepelumab	55	46 (83.6)	0.98 (0.77)	0.0	0.29	1.00	1.50	3.0	
		Placebo	40	37 (92.5)	0.89 (0.77)	0.0	0.17	1.00	1.29	3.0	
	Week 48	Tezepelumab	55	49 (89.1)	1.01 (0.85)	0.0	0.21	1.00	1.57	3.0	
		Placebo	40	36 (90.0)	0.87 (0.78)	0.0	0.04	1.00	1.27	3.0	
	Week 49	Tezepelumab	55	47 (85.5)	1.06 (0.81)	0.0	0.40	1.00	1.64	3.0	
		Placebo	40	36 (90.0)	0.86 (0.78)	0.0	0.11	1.00	1.12	3.0	
	Week 50	Tezepelumab	55	44 (80.0)	0.95 (0.77)	0.0	0.15	1.00	1.54	2.8	
		Placebo	40	35 (87.5)	0.87 (0.80)	0.0	0.00	1.00	1.42	3.0	
	Week 51	Tezepelumab	55	45 (81.8)	0.99 (0.75)	0.0	0.21	1.00	1.75	2.2	
		Placebo	40	33 (82.5)	0.86 (0.75)	0.0	0.00	1.00	1.20	3.0	
	Week 52	Tezepelumab	55	39 (70.9)	0.95 (0.77)	0.0	0.17	1.00	1.64	2.5	
		Placebo	40	32 (80.0)	0.92 (0.74)	0.0	0.21	1.00	1.19	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	55	54 (98.2)	-0.13 (0.51)	-2.3	-0.21	0.00	0.07	0.7	-0.08 [-0.49, 0.33]
		Placebo	40	40 (100.0)	-0.10 (0.39)	-1.1	-0.21	-0.01	0.00	1.5	
	Week 2	Tezepelumab	55	54 (98.2)	-0.25 (0.52)	-2.6	-0.36	-0.11	0.05	0.4	-0.26 [-0.67, 0.16]
		Placebo	40	39 (97.5)	-0.11 (0.62)	-1.9	-0.17	-0.07	0.08	1.4	
	Week 3	Tezepelumab	55	55 (100.0)	-0.26 (0.56)	-2.6	-0.57	-0.07	0.00	0.6	-0.15 [-0.56, 0.26]
		Placebo	40	38 (95.0)	-0.16 (0.81)	-2.6	-0.37	0.00	0.14	1.9	
	Week 4	Tezepelumab	55	54 (98.2)	-0.30 (0.61)	-2.6	-0.71	-0.14	0.07	0.7	-0.16 [-0.58, 0.25]
		Placebo	40	39 (97.5)	-0.20 (0.66)	-2.6	-0.36	0.00	0.14	0.7	
	Week 5	Tezepelumab	55	53 (96.4)	-0.33 (0.61)	-2.6	-0.63	-0.18	0.00	0.7	-0.06 [-0.48, 0.35]
		Placebo	40	38 (95.0)	-0.29 (0.67)	-2.6	-0.44	-0.14	0.00	0.7	
	Week 6	Tezepelumab	55	52 (94.5)	-0.27 (0.57)	-2.6	-0.54	-0.11	0.05	0.9	-0.09 [-0.50, 0.33]
		Placebo	40	40 (100.0)	-0.22 (0.66)	-2.6	-0.44	-0.04	0.12	0.7	
	Week 7	Tezepelumab	55	51 (92.7)	-0.24 (0.65)	-2.6	-0.50	-0.14	0.14	1.0	0.16 [-0.25, 0.58]
		Placebo	40	40 (100.0)	-0.35 (0.66)	-2.6	-0.50	-0.14	0.00	0.7	
	Week 8	Tezepelumab	55	51 (92.7)	-0.29 (0.67)	-2.6	-0.64	-0.14	0.11	1.1	0.01 [-0.40, 0.43]
		Placebo	40	39 (97.5)	-0.30 (0.78)	-2.6	-0.71	-0.08	0.21	1.7	
	Week 9	Tezepelumab	55	53 (96.4)	-0.35 (0.67)	-2.6	-0.79	-0.14	0.00	1.0	-0.01 [-0.42, 0.40]
		Placebo	40	40 (100.0)	-0.34 (0.88)	-2.6	-0.95	-0.19	0.00	2.0	
	Week 10	Tezepelumab	55	53 (96.4)	-0.37 (0.68)	-2.6	-0.79	-0.21	0.00	1.1	-0.03 [-0.44, 0.38]
		Placebo	40	40 (100.0)	-0.34 (0.79)	-2.6	-0.96	-0.15	0.21	1.4	
	Week 11	Tezepelumab	55	51 (92.7)	-0.37 (0.63)	-2.6	-0.71	-0.14	0.00	0.9	0.01 [-0.40, 0.43]
		Placebo	40	40 (100.0)	-0.38 (0.70)	-2.5	-0.85	-0.14	0.00	1.1	
	Week 12	Tezepelumab	55	52 (94.5)	-0.40 (0.69)	-2.6	-0.79	-0.37	0.00	0.9	-0.03 [-0.45, 0.39]
		Placebo	40	38 (95.0)	-0.38 (0.72)	-2.6	-0.93	-0.14	0.08	0.8	
	Week 13	Tezepelumab	55	49 (89.1)	-0.35 (0.71)	-2.6	-0.79	-0.18	0.14	1.0	0.10 [-0.32, 0.53]
		Placebo	40	38 (95.0)	-0.42 (0.66)	-2.4	-0.83	-0.17	0.00	0.8	
	Week 14	Tezepelumab	55	52 (94.5)	-0.38 (0.70)	-2.6	-0.79	-0.18	0.04	1.0	-0.03 [-0.45, 0.39]
		Placebo	40	37 (92.5)	-0.36 (0.73)	-2.4	-0.77	-0.20	0.00	1.1	
	Week 15	Tezepelumab	55	51 (92.7)	-0.39 (0.70)	-2.6	-0.71	-0.14	0.00	1.0	0.05 [-0.37, 0.47]
		Placebo	40	39 (97.5)	-0.42 (0.78)	-2.1	-1.00	-0.23	0.08	0.8	
	Week 16	Tezepelumab	55	51 (92.7)	-0.42 (0.69)	-2.6	-0.93	-0.14	0.07	1.0	0.00 [-0.42, 0.42]
		Placebo	40	38 (95.0)	-0.42 (0.73)	-2.1	-1.00	-0.24	0.00	0.9	
	Week 17	Tezepelumab	55	52 (94.5)	-0.41 (0.77)	-2.6	-0.88	-0.27	0.07	0.9	-0.06 [-0.48, 0.36]
		Placebo	40	38 (95.0)	-0.37 (0.76)	-2.5	-1.00	-0.11	0.07	0.9	
	Week 18	Tezepelumab	55	52 (94.5)	-0.38 (0.75)	-2.6	-0.79	-0.29	0.04	1.0	-0.06 [-0.48, 0.36]
		Placebo	40	38 (95.0)	-0.33 (0.74)	-2.1	-1.00	-0.14	0.00	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	55	49 (89.1)	-0.40 (0.73)	-2.6	-0.79	-0.21	0.07	0.8	-0.04 [-0.47, 0.38]
		Placebo	40	39 (97.5)	-0.36 (0.84)	-2.6	-0.92	-0.14	0.07	1.4	
	Week 20	Tezepelumab	55	51 (92.7)	-0.44 (0.76)	-2.6	-0.95	-0.29	0.00	0.9	-0.10 [-0.52, 0.32]
		Placebo	40	37 (92.5)	-0.37 (0.73)	-1.8	-0.86	-0.15	0.11	0.7	
	Week 21	Tezepelumab	55	46 (83.6)	-0.46 (0.76)	-2.6	-0.93	-0.36	0.02	0.9	-0.07 [-0.50, 0.36]
		Placebo	40	38 (95.0)	-0.40 (0.72)	-2.1	-1.00	-0.14	0.00	1.0	
	Week 22	Tezepelumab	55	47 (85.5)	-0.40 (0.77)	-2.6	-0.86	-0.17	0.07	1.1	-0.08 [-0.50, 0.35]
		Placebo	40	38 (95.0)	-0.34 (0.76)	-2.3	-1.00	-0.14	0.07	1.1	
	Week 23	Tezepelumab	55	49 (89.1)	-0.41 (0.75)	-2.6	-0.86	-0.21	0.00	1.0	-0.03 [-0.46, 0.40]
		Placebo	40	36 (90.0)	-0.39 (0.73)	-1.9	-1.00	-0.15	0.00	1.0	
	Week 24	Tezepelumab	55	51 (92.7)	-0.45 (0.77)	-2.6	-1.00	-0.43	0.00	1.4	-0.02 [-0.45, 0.40]
		Placebo	40	36 (90.0)	-0.43 (0.69)	-2.1	-0.96	-0.11	0.00	0.6	
	Week 25	Tezepelumab	55	49 (89.1)	-0.48 (0.66)	-2.6	-0.93	-0.36	0.00	0.6	0.01 [-0.42, 0.44]
		Placebo	40	36 (90.0)	-0.48 (0.74)	-2.6	-0.92	-0.29	0.00	0.8	
	Week 26	Tezepelumab	55	50 (90.9)	-0.41 (0.73)	-2.6	-0.86	-0.21	0.09	0.9	0.08 [-0.34, 0.51]
		Placebo	40	37 (92.5)	-0.47 (0.78)	-2.6	-1.07	-0.17	0.00	0.9	
	Week 27	Tezepelumab	55	46 (83.6)	-0.36 (0.76)	-2.6	-0.67	-0.10	0.00	1.1	0.02 [-0.42, 0.45]
		Placebo	40	36 (90.0)	-0.37 (0.83)	-2.6	-1.00	-0.29	0.05	1.9	
	Week 28	Tezepelumab	55	49 (89.1)	-0.30 (0.75)	-2.5	-0.71	-0.14	0.07	1.4	0.01 [-0.42, 0.44]
		Placebo	40	36 (90.0)	-0.31 (0.70)	-2.6	-0.71	-0.19	0.00	1.1	
	Week 29	Tezepelumab	55	48 (87.3)	-0.46 (0.70)	-2.6	-0.82	-0.21	0.00	0.7	-0.11 [-0.54, 0.32]
		Placebo	40	37 (92.5)	-0.38 (0.71)	-2.6	-0.86	-0.29	0.00	0.7	
	Week 30	Tezepelumab	55	48 (87.3)	-0.38 (0.71)	-2.6	-0.82	-0.21	0.07	1.1	0.20 [-0.24, 0.63]
		Placebo	40	36 (90.0)	-0.52 (0.64)	-2.6	-0.99	-0.46	0.00	0.5	
	Week 31	Tezepelumab	55	48 (87.3)	-0.44 (0.73)	-2.6	-0.75	-0.25	0.03	0.8	-0.01 [-0.44, 0.42]
		Placebo	40	37 (92.5)	-0.43 (0.78)	-2.6	-0.71	-0.24	-0.10	2.2	
	Week 32	Tezepelumab	55	49 (89.1)	-0.42 (0.73)	-2.6	-0.90	-0.36	0.00	1.5	0.08 [-0.35, 0.51]
		Placebo	40	37 (92.5)	-0.49 (0.86)	-2.6	-1.00	-0.24	-0.08	2.4	
	Week 33	Tezepelumab	55	48 (87.3)	-0.45 (0.76)	-2.6	-0.89	-0.32	0.00	1.2	-0.09 [-0.51, 0.34]
		Placebo	40	37 (92.5)	-0.38 (0.88)	-2.6	-0.72	-0.21	0.00	2.5	
	Week 34	Tezepelumab	55	50 (90.9)	-0.44 (0.78)	-2.6	-1.00	-0.33	0.00	1.2	-0.03 [-0.45, 0.39]
		Placebo	40	38 (95.0)	-0.42 (0.85)	-2.6	-1.00	-0.26	0.00	2.2	
	Week 35	Tezepelumab	55	48 (87.3)	-0.42 (0.73)	-2.6	-0.83	-0.22	0.00	1.2	0.02 [-0.41, 0.45]
		Placebo	40	36 (90.0)	-0.44 (0.85)	-2.6	-1.00	-0.25	0.00	2.1	
	Week 36	Tezepelumab	55	48 (87.3)	-0.44 (0.75)	-2.6	-0.89	-0.33	0.00	1.2	-0.09 [-0.52, 0.33]
		Placebo	40	38 (95.0)	-0.37 (0.73)	-2.2	-0.86	-0.19	0.07	1.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	55	47 (85.5)	-0.41 (0.73)	-2.6	-0.83	-0.26	0.00	1.2	-0.10 [-0.53, 0.34]
		Placebo	40	37 (92.5)	-0.34 (0.67)	-1.9	-0.80	-0.20	0.00	1.3	
	Week 38	Tezepelumab	55	47 (85.5)	-0.35 (0.80)	-2.6	-0.71	-0.21	0.07	1.2	0.08 [-0.35, 0.51]
		Placebo	40	37 (92.5)	-0.41 (0.59)	-1.6	-0.90	-0.28	-0.07	1.0	
	Week 39	Tezepelumab	55	49 (89.1)	-0.34 (0.75)	-2.6	-0.71	-0.21	0.07	1.6	0.10 [-0.33, 0.53]
		Placebo	40	37 (92.5)	-0.41 (0.59)	-1.8	-0.83	-0.29	0.00	0.8	
	Week 40	Tezepelumab	55	49 (89.1)	-0.40 (0.80)	-2.6	-0.99	-0.21	0.08	1.9	-0.10 [-0.53, 0.32]
		Placebo	40	38 (95.0)	-0.32 (0.73)	-2.1	-0.80	-0.25	0.00	1.9	
	Week 41	Tezepelumab	55	50 (90.9)	-0.40 (0.80)	-2.6	-1.00	-0.23	0.07	1.7	-0.13 [-0.55, 0.30]
		Placebo	40	36 (90.0)	-0.31 (0.79)	-2.0	-0.94	-0.15	0.11	1.6	
	Week 42	Tezepelumab	55	47 (85.5)	-0.40 (0.72)	-2.6	-0.79	-0.21	0.00	1.2	-0.22 [-0.66, 0.21]
		Placebo	40	36 (90.0)	-0.24 (0.66)	-1.4	-0.74	-0.15	0.02	1.0	
	Week 43	Tezepelumab	55	49 (89.1)	-0.42 (0.75)	-2.6	-0.82	-0.32	0.07	1.2	-0.04 [-0.46, 0.39]
		Placebo	40	37 (92.5)	-0.39 (0.66)	-1.6	-0.93	-0.20	0.00	0.9	
	Week 44	Tezepelumab	55	48 (87.3)	-0.50 (0.70)	-2.6	-0.89	-0.35	0.00	1.2	-0.22 [-0.66, 0.22]
		Placebo	40	35 (87.5)	-0.35 (0.65)	-2.1	-1.00	-0.29	0.00	0.9	
	Week 45	Tezepelumab	55	48 (87.3)	-0.45 (0.76)	-2.6	-0.89	-0.39	-0.03	1.5	0.03 [-0.41, 0.46]
		Placebo	40	36 (90.0)	-0.47 (0.65)	-2.2	-1.00	-0.41	0.00	0.9	
	Week 46	Tezepelumab	55	47 (85.5)	-0.40 (0.73)	-2.6	-0.79	-0.29	0.07	1.1	0.10 [-0.33, 0.53]
		Placebo	40	37 (92.5)	-0.47 (0.70)	-2.6	-0.80	-0.44	0.00	1.1	
	Week 47	Tezepelumab	55	46 (83.6)	-0.39 (0.77)	-2.6	-0.79	-0.29	0.07	1.8	0.11 [-0.32, 0.54]
		Placebo	40	37 (92.5)	-0.47 (0.70)	-2.6	-0.93	-0.40	0.00	0.9	
	Week 48	Tezepelumab	55	49 (89.1)	-0.31 (0.82)	-2.6	-0.79	-0.14	0.07	1.6	0.25 [-0.18, 0.68]
		Placebo	40	36 (90.0)	-0.51 (0.73)	-2.6	-1.00	-0.35	0.00	0.9	
	Week 49	Tezepelumab	55	47 (85.5)	-0.33 (0.81)	-2.6	-0.79	-0.14	0.10	1.3	0.23 [-0.21, 0.67]
		Placebo	40	36 (90.0)	-0.51 (0.71)	-2.6	-1.00	-0.23	-0.03	0.6	
	Week 50	Tezepelumab	55	44 (80.0)	-0.43 (0.71)	-2.6	-0.75	-0.30	0.00	1.4	0.13 [-0.32, 0.57]
		Placebo	40	35 (87.5)	-0.52 (0.71)	-2.6	-1.00	-0.29	0.00	0.5	
	Week 51	Tezepelumab	55	45 (81.8)	-0.34 (0.78)	-2.6	-0.71	-0.14	0.13	1.8	0.28 [-0.17, 0.74]
		Placebo	40	33 (82.5)	-0.55 (0.68)	-2.6	-1.00	-0.44	-0.08	0.9	
	Week 52	Tezepelumab	55	39 (70.9)	-0.37 (0.77)	-2.6	-0.79	-0.15	0.07	1.5	0.22 [-0.25, 0.69]
		Placebo	40	32 (80.0)	-0.53 (0.66)	-2.6	-1.00	-0.46	-0.14	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	55	54 (98.2)	-0.13 (0.09)	(-0.30, 0.04)	-0.04 (0.13)	(-0.31, 0.22)	0.744
	Placebo	40	40 (100.0)	-0.09 (0.10)	(-0.29, 0.11)			
Week 2	Tezepelumab	55	54 (98.2)	-0.25 (0.09)	(-0.42, -0.08)	-0.16 (0.13)	(-0.42, 0.11)	0.245
	Placebo	40	39 (97.5)	-0.09 (0.10)	(-0.29, 0.11)			
Week 3	Tezepelumab	55	55 (100.0)	-0.26 (0.09)	(-0.43, -0.09)	-0.13 (0.13)	(-0.39, 0.13)	0.342
	Placebo	40	38 (95.0)	-0.13 (0.10)	(-0.33, 0.07)			
Week 4	Tezepelumab	55	54 (98.2)	-0.31 (0.09)	(-0.48, -0.15)	-0.13 (0.13)	(-0.39, 0.13)	0.330
	Placebo	40	39 (97.5)	-0.18 (0.10)	(-0.38, 0.01)			
Week 5	Tezepelumab	55	53 (96.4)	-0.33 (0.09)	(-0.50, -0.16)	-0.05 (0.13)	(-0.32, 0.21)	0.686
	Placebo	40	38 (95.0)	-0.28 (0.10)	(-0.48, -0.08)			
Week 6	Tezepelumab	55	52 (94.5)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.13)	(-0.34, 0.18)	0.535
	Placebo	40	40 (100.0)	-0.21 (0.10)	(-0.41, -0.01)			
Week 7	Tezepelumab	55	51 (92.7)	-0.24 (0.09)	(-0.41, -0.07)	0.10 (0.13)	(-0.16, 0.37)	0.439
	Placebo	40	40 (100.0)	-0.34 (0.10)	(-0.54, -0.14)			
Week 8	Tezepelumab	55	51 (92.7)	-0.27 (0.09)	(-0.44, -0.09)	0.03 (0.13)	(-0.23, 0.29)	0.837
	Placebo	40	39 (97.5)	-0.29 (0.10)	(-0.49, -0.09)			
Week 9	Tezepelumab	55	53 (96.4)	-0.36 (0.09)	(-0.53, -0.19)	-0.02 (0.13)	(-0.29, 0.24)	0.852
	Placebo	40	40 (100.0)	-0.33 (0.10)	(-0.53, -0.13)			
Week 10	Tezepelumab	55	53 (96.4)	-0.38 (0.09)	(-0.55, -0.21)	-0.04 (0.13)	(-0.30, 0.22)	0.744
	Placebo	40	40 (100.0)	-0.33 (0.10)	(-0.53, -0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	55	51 (92.7)	-0.38 (0.09)	(-0.55, -0.21)	-0.00 (0.13)	(-0.26, 0.26)	0.982
	Placebo	40	40 (100.0)	-0.37 (0.10)	(-0.57, -0.18)			
Week 12	Tezepelumab	55	52 (94.5)	-0.39 (0.09)	(-0.56, -0.22)	-0.01 (0.13)	(-0.27, 0.25)	0.954
	Placebo	40	38 (95.0)	-0.39 (0.10)	(-0.58, -0.19)			
Week 13	Tezepelumab	55	49 (89.1)	-0.38 (0.09)	(-0.56, -0.21)	0.03 (0.13)	(-0.23, 0.29)	0.822
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.61, -0.21)			
Week 14	Tezepelumab	55	52 (94.5)	-0.34 (0.09)	(-0.51, -0.17)	-0.01 (0.13)	(-0.27, 0.26)	0.959
	Placebo	40	37 (92.5)	-0.34 (0.10)	(-0.54, -0.14)			
Week 15	Tezepelumab	55	51 (92.7)	-0.39 (0.09)	(-0.56, -0.22)	0.03 (0.13)	(-0.23, 0.30)	0.807
	Placebo	40	39 (97.5)	-0.42 (0.10)	(-0.62, -0.22)			
Week 16	Tezepelumab	55	51 (92.7)	-0.42 (0.09)	(-0.59, -0.24)	0.01 (0.13)	(-0.25, 0.27)	0.940
	Placebo	40	38 (95.0)	-0.43 (0.10)	(-0.63, -0.23)			
Week 17	Tezepelumab	55	52 (94.5)	-0.38 (0.09)	(-0.55, -0.21)	-0.01 (0.13)	(-0.28, 0.25)	0.922
	Placebo	40	38 (95.0)	-0.37 (0.10)	(-0.57, -0.17)			
Week 18	Tezepelumab	55	52 (94.5)	-0.37 (0.09)	(-0.54, -0.20)	-0.05 (0.13)	(-0.31, 0.21)	0.708
	Placebo	40	38 (95.0)	-0.32 (0.10)	(-0.52, -0.12)			
Week 19	Tezepelumab	55	49 (89.1)	-0.41 (0.09)	(-0.59, -0.24)	-0.07 (0.13)	(-0.33, 0.20)	0.625
	Placebo	40	39 (97.5)	-0.35 (0.10)	(-0.55, -0.15)			
Week 20	Tezepelumab	55	51 (92.7)	-0.45 (0.09)	(-0.62, -0.27)	-0.08 (0.13)	(-0.35, 0.18)	0.537
	Placebo	40	37 (92.5)	-0.36 (0.10)	(-0.56, -0.16)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	55	46 (83.6)	-0.49 (0.09)	(-0.66, -0.31)	-0.08 (0.14)	(-0.35, 0.18)	0.533
	Placebo	40	38 (95.0)	-0.40 (0.10)	(-0.60, -0.20)			
Week 22	Tezepelumab	55	47 (85.5)	-0.43 (0.09)	(-0.60, -0.25)	-0.09 (0.14)	(-0.36, 0.18)	0.503
	Placebo	40	38 (95.0)	-0.34 (0.10)	(-0.54, -0.14)			
Week 23	Tezepelumab	55	49 (89.1)	-0.41 (0.09)	(-0.58, -0.24)	-0.07 (0.14)	(-0.34, 0.19)	0.590
	Placebo	40	36 (90.0)	-0.34 (0.10)	(-0.54, -0.13)			
Week 24	Tezepelumab	55	51 (92.7)	-0.43 (0.09)	(-0.60, -0.26)	-0.04 (0.14)	(-0.31, 0.22)	0.754
	Placebo	40	36 (90.0)	-0.39 (0.10)	(-0.59, -0.19)			
Week 25	Tezepelumab	55	49 (89.1)	-0.48 (0.09)	(-0.65, -0.31)	-0.04 (0.14)	(-0.31, 0.22)	0.753
	Placebo	40	36 (90.0)	-0.44 (0.10)	(-0.64, -0.24)			
Week 26	Tezepelumab	55	50 (90.9)	-0.46 (0.09)	(-0.63, -0.29)	-0.03 (0.14)	(-0.29, 0.24)	0.843
	Placebo	40	37 (92.5)	-0.44 (0.10)	(-0.64, -0.23)			
Week 27	Tezepelumab	55	46 (83.6)	-0.41 (0.09)	(-0.58, -0.23)	-0.07 (0.14)	(-0.34, 0.20)	0.609
	Placebo	40	36 (90.0)	-0.34 (0.10)	(-0.54, -0.13)			
Week 28	Tezepelumab	55	49 (89.1)	-0.35 (0.09)	(-0.53, -0.18)	-0.10 (0.14)	(-0.37, 0.17)	0.469
	Placebo	40	36 (90.0)	-0.26 (0.10)	(-0.46, -0.05)			
Week 29	Tezepelumab	55	48 (87.3)	-0.45 (0.09)	(-0.63, -0.28)	-0.09 (0.14)	(-0.36, 0.17)	0.484
	Placebo	40	37 (92.5)	-0.36 (0.10)	(-0.56, -0.16)			
Week 30	Tezepelumab	55	48 (87.3)	-0.39 (0.09)	(-0.57, -0.22)	0.09 (0.14)	(-0.18, 0.35)	0.518
	Placebo	40	36 (90.0)	-0.48 (0.10)	(-0.69, -0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	55	48 (87.3)	-0.42 (0.09)	(-0.59, -0.24)	-0.01 (0.14)	(-0.28, 0.26)	0.942
	Placebo	40	37 (92.5)	-0.41 (0.10)	(-0.61, -0.20)			
Week 32	Tezepelumab	55	49 (89.1)	-0.44 (0.09)	(-0.61, -0.27)	0.02 (0.14)	(-0.24, 0.29)	0.874
	Placebo	40	37 (92.5)	-0.46 (0.10)	(-0.67, -0.26)			
Week 33	Tezepelumab	55	48 (87.3)	-0.44 (0.09)	(-0.61, -0.27)	-0.05 (0.14)	(-0.32, 0.21)	0.687
	Placebo	40	37 (92.5)	-0.38 (0.10)	(-0.59, -0.18)			
Week 34	Tezepelumab	55	50 (90.9)	-0.44 (0.09)	(-0.61, -0.26)	-0.03 (0.14)	(-0.30, 0.23)	0.813
	Placebo	40	38 (95.0)	-0.40 (0.10)	(-0.61, -0.20)			
Week 35	Tezepelumab	55	48 (87.3)	-0.39 (0.09)	(-0.57, -0.22)	0.01 (0.14)	(-0.26, 0.28)	0.927
	Placebo	40	36 (90.0)	-0.40 (0.10)	(-0.61, -0.20)			
Week 36	Tezepelumab	55	48 (87.3)	-0.40 (0.09)	(-0.57, -0.22)	-0.03 (0.14)	(-0.30, 0.24)	0.811
	Placebo	40	38 (95.0)	-0.36 (0.10)	(-0.57, -0.16)			
Week 37	Tezepelumab	55	47 (85.5)	-0.42 (0.09)	(-0.59, -0.24)	-0.10 (0.14)	(-0.37, 0.17)	0.485
	Placebo	40	37 (92.5)	-0.32 (0.10)	(-0.53, -0.12)			
Week 38	Tezepelumab	55	47 (85.5)	-0.39 (0.09)	(-0.56, -0.21)	0.00 (0.14)	(-0.27, 0.27)	0.980
	Placebo	40	37 (92.5)	-0.39 (0.10)	(-0.59, -0.19)			
Week 39	Tezepelumab	55	49 (89.1)	-0.37 (0.09)	(-0.55, -0.19)	0.02 (0.14)	(-0.25, 0.29)	0.891
	Placebo	40	37 (92.5)	-0.39 (0.10)	(-0.59, -0.18)			
Week 40	Tezepelumab	55	49 (89.1)	-0.40 (0.09)	(-0.57, -0.22)	-0.08 (0.14)	(-0.35, 0.18)	0.540
	Placebo	40	38 (95.0)	-0.31 (0.10)	(-0.52, -0.11)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	55	50 (90.9)	-0.39 (0.09)	(-0.56, -0.21)	-0.09 (0.14)	(-0.36, 0.18)	0.502
	Placebo	40	36 (90.0)	-0.29 (0.10)	(-0.50, -0.09)			
Week 42	Tezepelumab	55	47 (85.5)	-0.41 (0.09)	(-0.58, -0.23)	-0.19 (0.14)	(-0.46, 0.08)	0.174
	Placebo	40	36 (90.0)	-0.22 (0.10)	(-0.42, -0.01)			
Week 43	Tezepelumab	55	49 (89.1)	-0.42 (0.09)	(-0.60, -0.24)	-0.04 (0.14)	(-0.31, 0.23)	0.760
	Placebo	40	37 (92.5)	-0.38 (0.10)	(-0.58, -0.17)			
Week 44	Tezepelumab	55	48 (87.3)	-0.50 (0.09)	(-0.67, -0.32)	-0.14 (0.14)	(-0.41, 0.13)	0.299
	Placebo	40	35 (87.5)	-0.36 (0.11)	(-0.56, -0.15)			
Week 45	Tezepelumab	55	48 (87.3)	-0.46 (0.09)	(-0.64, -0.29)	-0.01 (0.14)	(-0.28, 0.26)	0.959
	Placebo	40	36 (90.0)	-0.45 (0.11)	(-0.66, -0.25)			
Week 46	Tezepelumab	55	47 (85.5)	-0.46 (0.09)	(-0.63, -0.28)	0.01 (0.14)	(-0.26, 0.28)	0.951
	Placebo	40	37 (92.5)	-0.47 (0.10)	(-0.67, -0.26)			
Week 47	Tezepelumab	55	46 (83.6)	-0.41 (0.09)	(-0.59, -0.24)	0.05 (0.14)	(-0.22, 0.32)	0.701
	Placebo	40	37 (92.5)	-0.47 (0.10)	(-0.67, -0.26)			
Week 48	Tezepelumab	55	49 (89.1)	-0.35 (0.09)	(-0.52, -0.17)	0.15 (0.14)	(-0.12, 0.42)	0.288
	Placebo	40	36 (90.0)	-0.49 (0.11)	(-0.70, -0.29)			
Week 49	Tezepelumab	55	47 (85.5)	-0.35 (0.09)	(-0.53, -0.18)	0.14 (0.14)	(-0.13, 0.41)	0.313
	Placebo	40	36 (90.0)	-0.49 (0.11)	(-0.70, -0.29)			
Week 50	Tezepelumab	55	44 (80.0)	-0.41 (0.09)	(-0.59, -0.23)	0.10 (0.14)	(-0.18, 0.37)	0.481
	Placebo	40	35 (87.5)	-0.51 (0.11)	(-0.71, -0.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	55	45 (81.8)	-0.38 (0.09)	(-0.56, -0.20)	0.14 (0.14)	(-0.13, 0.42)	0.311
	Placebo	40	33 (82.5)	-0.52 (0.11)	(-0.73, -0.31)			
Week 52	Tezepelumab	55	39 (70.9)	-0.39 (0.09)	(-0.58, -0.21)	0.10 (0.14)	(-0.18, 0.38)	0.482
	Placebo	40	32 (80.0)	-0.49 (0.11)	(-0.71, -0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	12	12 (100.0)	1.30 (0.57)	0.0	1.00	1.29	1.71	2.1	
		Placebo	11	11 (100.0)	1.52 (1.10)	0.0	0.75	1.21	2.58	3.2	
	Week 1	Tezepelumab	12	12 (100.0)	1.30 (0.49)	0.8	0.93	1.15	1.64	2.1	
		Placebo	11	11 (100.0)	1.17 (1.08)	0.0	0.07	1.07	2.29	2.7	
	Week 2	Tezepelumab	12	12 (100.0)	1.18 (0.44)	0.4	1.00	1.04	1.29	2.0	
		Placebo	11	10 (90.9)	1.05 (0.89)	0.0	0.17	0.89	2.00	2.4	
	Week 3	Tezepelumab	12	12 (100.0)	1.16 (0.46)	0.6	0.88	1.04	1.40	2.1	
		Placebo	11	10 (90.9)	0.96 (0.92)	0.1	0.17	0.68	2.00	2.4	
	Week 4	Tezepelumab	12	11 (91.7)	1.26 (0.53)	0.6	1.00	1.07	1.64	2.3	
		Placebo	11	11 (100.0)	1.12 (1.00)	0.0	0.07	1.14	2.00	2.6	
	Week 5	Tezepelumab	12	11 (91.7)	1.03 (0.57)	0.0	0.86	1.00	1.36	1.9	
		Placebo	11	11 (100.0)	0.98 (0.80)	0.0	0.29	0.75	2.00	2.1	
	Week 6	Tezepelumab	12	11 (91.7)	1.05 (0.58)	0.0	1.00	1.07	1.50	1.9	
		Placebo	11	11 (100.0)	0.96 (0.85)	0.0	0.29	0.80	2.00	2.3	
	Week 7	Tezepelumab	12	11 (91.7)	1.01 (0.49)	0.0	0.70	1.00	1.58	1.6	
		Placebo	11	11 (100.0)	1.07 (0.80)	0.0	0.50	0.93	2.00	2.4	
	Week 8	Tezepelumab	12	10 (83.3)	1.10 (0.59)	0.1	1.00	1.11	1.43	2.0	
		Placebo	11	11 (100.0)	1.30 (0.63)	0.5	0.67	1.25	2.00	2.2	
	Week 9	Tezepelumab	12	12 (100.0)	1.03 (0.66)	0.0	0.57	1.14	1.39	2.0	
		Placebo	11	11 (100.0)	1.32 (0.86)	0.0	0.50	1.21	2.00	2.8	
	Week 10	Tezepelumab	12	12 (100.0)	1.19 (0.63)	0.0	1.00	1.21	1.50	2.3	
		Placebo	11	10 (90.9)	1.10 (0.70)	0.0	0.57	1.07	1.50	2.4	
	Week 11	Tezepelumab	12	12 (100.0)	1.22 (0.70)	0.1	0.79	1.00	1.89	2.4	
		Placebo	11	10 (90.9)	0.97 (0.63)	0.0	0.38	1.07	1.29	2.1	
	Week 12	Tezepelumab	12	11 (91.7)	1.16 (0.75)	0.0	0.42	1.07	2.00	2.2	
		Placebo	11	11 (100.0)	1.14 (0.92)	0.0	0.20	1.00	1.79	3.0	
	Week 13	Tezepelumab	12	11 (91.7)	1.36 (0.74)	0.0	0.93	1.43	1.93	2.6	
		Placebo	11	11 (100.0)	1.18 (0.95)	0.0	0.14	1.00	2.00	3.0	
	Week 14	Tezepelumab	12	11 (91.7)	1.24 (0.63)	0.3	0.86	1.14	1.57	2.4	
		Placebo	11	11 (100.0)	1.20 (0.96)	0.0	0.14	1.00	2.00	2.9	
	Week 15	Tezepelumab	12	11 (91.7)	1.08 (0.79)	0.0	0.43	1.00	1.43	2.7	
		Placebo	11	11 (100.0)	1.15 (1.00)	0.0	0.07	1.00	2.00	2.9	
	Week 16	Tezepelumab	12	11 (91.7)	1.10 (0.69)	0.1	0.43	1.00	1.67	2.3	
		Placebo	11	11 (100.0)	1.06 (0.97)	0.0	0.07	1.00	1.93	2.9	
Week 17	Tezepelumab	12	11 (91.7)	1.17 (0.62)	0.3	0.86	1.00	1.58	2.4		
	Placebo	11	11 (100.0)	0.99 (0.95)	0.0	0.00	1.00	1.64	2.9		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	12	11 (91.7)	1.19 (0.89)	0.1	0.57	1.00	1.83	3.4	
		Placebo	11	11 (100.0)	0.87 (0.93)	0.0	0.00	1.00	1.10	2.9	
	Week 19	Tezepelumab	12	11 (91.7)	1.12 (0.99)	0.0	0.42	1.00	1.93	3.4	
		Placebo	11	11 (100.0)	1.03 (0.90)	0.0	0.29	1.00	1.67	3.1	
	Week 20	Tezepelumab	12	11 (91.7)	1.18 (0.94)	0.1	0.29	1.00	1.86	3.3	
		Placebo	11	11 (100.0)	1.11 (0.91)	0.0	0.21	1.00	1.75	3.0	
	Week 21	Tezepelumab	12	11 (91.7)	1.30 (0.86)	0.0	0.93	1.07	1.86	3.2	
		Placebo	11	11 (100.0)	1.03 (0.91)	0.0	0.29	1.00	1.64	3.0	
	Week 22	Tezepelumab	12	11 (91.7)	1.12 (0.79)	0.0	0.50	1.00	1.64	2.6	
		Placebo	11	11 (100.0)	0.95 (0.99)	0.0	0.00	0.93	1.79	3.0	
	Week 23	Tezepelumab	12	11 (91.7)	1.20 (0.91)	0.0	0.43	1.00	1.93	3.1	
		Placebo	11	11 (100.0)	0.95 (1.00)	0.0	0.00	1.00	1.64	3.0	
	Week 24	Tezepelumab	12	11 (91.7)	1.22 (0.96)	0.0	0.14	1.33	2.00	2.9	
		Placebo	11	11 (100.0)	1.09 (1.00)	0.0	0.00	1.00	1.86	3.0	
	Week 25	Tezepelumab	12	11 (91.7)	1.29 (1.04)	0.0	0.08	1.42	2.00	3.1	
		Placebo	11	11 (100.0)	0.99 (0.95)	0.0	0.00	1.00	1.57	3.0	
	Week 26	Tezepelumab	12	11 (91.7)	1.38 (1.00)	0.0	0.86	1.14	2.00	3.3	
		Placebo	11	11 (100.0)	0.92 (0.96)	0.0	0.00	1.00	1.36	3.0	
	Week 27	Tezepelumab	12	10 (83.3)	1.70 (0.93)	0.0	1.17	1.61	2.00	3.2	
		Placebo	11	11 (100.0)	1.00 (1.05)	0.0	0.00	1.00	1.67	3.0	
	Week 28	Tezepelumab	12	9 (75.0)	1.76 (0.83)	0.9	1.13	1.58	1.93	3.4	
		Placebo	11	11 (100.0)	1.06 (1.03)	0.0	0.00	1.07	1.79	3.0	
	Week 29	Tezepelumab	12	8 (66.7)	1.37 (0.91)	0.6	0.82	1.14	1.50	3.4	
		Placebo	11	11 (100.0)	1.00 (1.11)	0.0	0.00	1.00	1.83	3.0	
	Week 30	Tezepelumab	12	10 (83.3)	1.39 (1.18)	0.0	0.57	1.00	2.00	3.7	
		Placebo	11	11 (100.0)	1.01 (1.10)	0.0	0.00	1.00	2.00	3.0	
	Week 31	Tezepelumab	12	9 (75.0)	1.47 (1.25)	0.0	0.71	1.00	1.86	3.9	
		Placebo	11	11 (100.0)	0.95 (1.03)	0.0	0.00	1.00	1.64	3.0	
	Week 32	Tezepelumab	12	10 (83.3)	1.51 (1.12)	0.0	1.00	1.30	1.83	3.9	
		Placebo	11	11 (100.0)	1.20 (0.97)	0.0	0.00	1.07	1.93	3.0	
	Week 33	Tezepelumab	12	10 (83.3)	1.58 (1.04)	0.1	1.00	1.36	2.07	3.8	
		Placebo	11	11 (100.0)	1.06 (0.91)	0.0	0.08	1.00	1.29	3.0	
	Week 34	Tezepelumab	12	10 (83.3)	1.33 (0.97)	0.0	0.64	1.14	1.93	3.5	
		Placebo	11	11 (100.0)	1.20 (1.00)	0.0	0.14	1.00	2.00	3.0	
	Week 35	Tezepelumab	12	10 (83.3)	1.32 (0.94)	0.1	0.64	1.04	2.00	3.1	
Placebo		11	11 (100.0)	1.16 (1.04)	0.0	0.14	1.00	2.00	3.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	12	10 (83.3)	1.38 (1.03)	0.1	0.93	1.00	2.00	3.4	
		Placebo	11	11 (100.0)	1.03 (1.07)	0.0	0.07	1.00	2.00	3.0	
	Week 37	Tezepelumab	12	9 (75.0)	1.51 (0.79)	0.9	1.00	1.00	2.21	3.0	
		Placebo	11	11 (100.0)	0.97 (0.94)	0.0	0.07	1.00	1.67	3.0	
	Week 38	Tezepelumab	12	9 (75.0)	1.43 (0.95)	0.5	0.93	1.00	2.00	3.3	
		Placebo	11	11 (100.0)	1.23 (0.94)	0.0	0.21	1.00	2.00	3.0	
	Week 39	Tezepelumab	12	9 (75.0)	1.57 (1.01)	0.7	1.00	1.07	2.00	3.5	
		Placebo	11	10 (90.9)	0.97 (0.95)	0.0	0.00	1.00	1.00	3.0	
	Week 40	Tezepelumab	12	9 (75.0)	1.64 (1.03)	0.6	1.00	1.14	2.14	3.6	
		Placebo	11	11 (100.0)	1.00 (0.98)	0.0	0.07	1.00	2.00	3.0	
	Week 41	Tezepelumab	12	8 (66.7)	1.56 (1.10)	0.4	1.00	1.00	2.29	3.5	
		Placebo	11	10 (90.9)	1.02 (1.03)	0.0	0.00	0.83	1.71	3.0	
	Week 42	Tezepelumab	12	8 (66.7)	1.45 (0.93)	0.2	1.00	1.00	2.14	3.1	
		Placebo	11	11 (100.0)	1.00 (0.98)	0.0	0.14	1.00	1.79	3.0	
	Week 43	Tezepelumab	12	8 (66.7)	1.50 (0.93)	0.7	0.88	1.13	2.10	3.1	
		Placebo	11	11 (100.0)	1.16 (1.04)	0.0	0.00	1.00	2.00	3.0	
	Week 44	Tezepelumab	12	8 (66.7)	1.48 (0.97)	0.8	0.93	1.00	2.04	3.1	
		Placebo	11	11 (100.0)	1.04 (1.07)	0.0	0.00	1.00	1.57	3.0	
	Week 45	Tezepelumab	12	8 (66.7)	1.45 (0.95)	0.4	1.00	1.00	2.07	3.0	
		Placebo	11	10 (90.9)	0.95 (1.00)	0.0	0.08	0.75	1.08	2.9	
	Week 46	Tezepelumab	12	7 (58.3)	1.41 (1.06)	0.1	0.93	1.00	2.79	3.0	
		Placebo	11	11 (100.0)	1.01 (0.97)	0.0	0.00	1.00	1.42	3.0	
	Week 47	Tezepelumab	12	8 (66.7)	1.32 (0.99)	0.2	0.54	1.00	2.12	3.0	
		Placebo	11	11 (100.0)	0.92 (0.96)	0.0	0.00	1.00	1.50	3.0	
	Week 48	Tezepelumab	12	7 (58.3)	1.46 (0.85)	0.5	1.00	1.08	2.17	3.0	
		Placebo	11	11 (100.0)	0.92 (0.97)	0.0	0.00	1.00	1.50	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	12	12 (100.0)	0.00 (0.51)	-0.9	-0.38	-0.02	0.36	0.8	0.75 [-0.10, 1.60]
		Placebo	11	11 (100.0)	-0.35 (0.42)	-1.0	-0.68	-0.35	0.00	0.1	
	Week 2	Tezepelumab	12	12 (100.0)	-0.12 (0.37)	-0.7	-0.38	-0.11	0.07	0.4	0.45 [-0.40, 1.30]
		Placebo	11	10 (90.9)	-0.31 (0.48)	-1.0	-0.64	-0.36	0.07	0.5	
	Week 3	Tezepelumab	12	12 (100.0)	-0.14 (0.44)	-0.8	-0.54	-0.10	0.18	0.8	0.55 [-0.31, 1.41]
		Placebo	11	10 (90.9)	-0.39 (0.46)	-1.0	-0.79	-0.48	0.00	0.4	
	Week 4	Tezepelumab	12	11 (91.7)	-0.16 (0.49)	-0.8	-0.64	-0.21	0.14	0.9	0.39 [-0.46, 1.23]
		Placebo	11	11 (100.0)	-0.41 (0.75)	-1.7	-0.93	-0.35	0.00	1.1	
	Week 5	Tezepelumab	12	11 (91.7)	-0.29 (0.54)	-1.1	-0.79	-0.21	0.17	0.6	0.36 [-0.48, 1.21]
		Placebo	11	11 (100.0)	-0.54 (0.83)	-2.5	-0.83	-0.71	0.00	0.7	
	Week 6	Tezepelumab	12	11 (91.7)	-0.27 (0.59)	-1.1	-0.79	-0.14	0.29	0.6	0.42 [-0.43, 1.27]
		Placebo	11	11 (100.0)	-0.56 (0.78)	-2.4	-0.93	-0.70	0.00	0.4	
	Week 7	Tezepelumab	12	11 (91.7)	-0.32 (0.74)	-1.3	-1.14	-0.21	0.29	0.7	0.17 [-0.67, 1.00]
		Placebo	11	11 (100.0)	-0.45 (0.86)	-2.3	-0.83	-0.71	0.00	0.9	
	Week 8	Tezepelumab	12	10 (83.3)	-0.36 (0.76)	-1.8	-0.71	-0.29	0.06	1.1	-0.19 [-1.05, 0.67]
		Placebo	11	11 (100.0)	-0.22 (0.66)	-1.6	-0.68	-0.25	0.21	0.8	
	Week 9	Tezepelumab	12	12 (100.0)	-0.27 (0.85)	-1.8	-0.81	-0.36	0.39	1.1	-0.08 [-0.90, 0.74]
		Placebo	11	11 (100.0)	-0.21 (0.82)	-1.9	-0.75	-0.08	0.36	1.2	
	Week 10	Tezepelumab	12	12 (100.0)	-0.12 (0.85)	-1.6	-0.71	-0.07	0.68	1.0	0.24 [-0.60, 1.08]
		Placebo	11	10 (90.9)	-0.32 (0.85)	-1.7	-0.79	-0.49	0.02	1.1	
	Week 11	Tezepelumab	12	12 (100.0)	-0.09 (0.69)	-1.3	-0.54	-0.07	0.18	1.1	0.48 [-0.38, 1.33]
		Placebo	11	10 (90.9)	-0.45 (0.84)	-1.6	-0.93	-0.73	0.07	1.1	
	Week 12	Tezepelumab	12	11 (91.7)	-0.26 (0.91)	-1.8	-0.79	-0.57	0.86	1.1	0.14 [-0.69, 0.98]
		Placebo	11	11 (100.0)	-0.39 (0.89)	-1.9	-0.93	-0.70	0.42	1.0	
	Week 13	Tezepelumab	12	11 (91.7)	-0.06 (0.94)	-1.8	-0.71	0.07	0.71	1.2	0.31 [-0.53, 1.16]
		Placebo	11	11 (100.0)	-0.35 (0.90)	-1.6	-0.93	-0.75	0.42	1.1	
	Week 14	Tezepelumab	12	11 (91.7)	-0.18 (0.78)	-1.3	-0.81	-0.07	0.14	1.2	0.17 [-0.67, 1.01]
		Placebo	11	11 (100.0)	-0.32 (0.81)	-1.3	-0.93	-0.63	0.27	1.0	
	Week 15	Tezepelumab	12	11 (91.7)	-0.34 (0.89)	-1.8	-0.81	-0.43	-0.14	1.3	0.05 [-0.79, 0.88]
		Placebo	11	11 (100.0)	-0.37 (0.71)	-1.5	-0.93	-0.42	0.07	1.0	
	Week 16	Tezepelumab	12	11 (91.7)	-0.32 (0.72)	-1.4	-0.79	-0.64	0.48	0.8	0.15 [-0.69, 0.99]
		Placebo	11	11 (100.0)	-0.46 (1.05)	-2.2	-0.93	-0.75	0.07	1.9	
	Week 17	Tezepelumab	12	11 (91.7)	-0.25 (0.67)	-1.0	-0.79	-0.36	0.64	0.9	0.33 [-0.51, 1.17]
		Placebo	11	11 (100.0)	-0.53 (1.00)	-2.2	-1.00	-0.83	0.00	1.6	
	Week 18	Tezepelumab	12	11 (91.7)	-0.23 (0.98)	-1.3	-1.00	-0.50	0.26	2.0	0.48 [-0.37, 1.33]
		Placebo	11	11 (100.0)	-0.65 (0.74)	-2.1	-1.00	-0.79	0.00	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	12	11 (91.7)	-0.30 (1.05)	-1.4	-1.06	-0.64	0.36	2.1	0.22 [-0.62, 1.06]
		Placebo	11	11 (100.0)	-0.49 (0.68)	-1.4	-1.21	-0.21	0.02	0.5	
	Week 20	Tezepelumab	12	11 (91.7)	-0.24 (1.03)	-1.5	-0.99	-0.57	0.50	2.0	0.19 [-0.64, 1.03]
		Placebo	11	11 (100.0)	-0.41 (0.69)	-1.2	-1.17	0.00	0.21	0.4	
	Week 21	Tezepelumab	12	11 (91.7)	-0.12 (0.96)	-1.5	-0.86	-0.14	0.33	1.9	0.41 [-0.43, 1.26]
		Placebo	11	11 (100.0)	-0.50 (0.86)	-1.7	-1.21	-0.25	0.42	0.6	
	Week 22	Tezepelumab	12	11 (91.7)	-0.30 (0.88)	-1.5	-1.07	-0.29	-0.07	1.3	0.32 [-0.52, 1.16]
		Placebo	11	11 (100.0)	-0.57 (0.80)	-1.9	-1.21	-0.58	0.21	0.4	
	Week 23	Tezepelumab	12	11 (91.7)	-0.22 (1.02)	-1.5	-1.07	-0.43	0.71	1.7	0.37 [-0.48, 1.21]
		Placebo	11	11 (100.0)	-0.57 (0.88)	-1.9	-1.21	-0.75	0.36	0.5	
	Week 24	Tezepelumab	12	11 (91.7)	-0.20 (1.07)	-1.8	-1.00	-0.64	1.00	1.6	0.23 [-0.61, 1.07]
		Placebo	11	11 (100.0)	-0.43 (0.99)	-1.9	-1.21	-0.75	0.42	1.4	
	Week 25	Tezepelumab	12	11 (91.7)	-0.13 (1.20)	-1.8	-1.07	-0.15	1.07	1.7	0.36 [-0.49, 1.20]
		Placebo	11	11 (100.0)	-0.53 (1.06)	-2.3	-1.21	-0.75	0.42	1.0	
	Week 26	Tezepelumab	12	11 (91.7)	-0.04 (1.19)	-1.8	-1.07	0.01	1.07	1.9	0.52 [-0.33, 1.37]
		Placebo	11	11 (100.0)	-0.60 (0.93)	-2.1	-1.21	-0.75	0.36	0.4	
	Week 27	Tezepelumab	12	10 (83.3)	0.32 (1.07)	-1.1	-0.64	0.46	0.79	2.0	0.87 [-0.03, 1.77]
		Placebo	11	11 (100.0)	-0.52 (0.85)	-1.9	-1.21	-0.61	0.11	0.7	
	Week 28	Tezepelumab	12	9 (75.0)	0.35 (1.09)	-1.0	-0.52	0.43	0.71	2.0	0.85 [-0.07, 1.77]
		Placebo	11	11 (100.0)	-0.46 (0.83)	-1.9	-1.21	-0.49	0.25	0.6	
	Week 29	Tezepelumab	12	8 (66.7)	-0.11 (1.00)	-1.2	-0.75	-0.21	0.11	2.1	0.45 [-0.47, 1.37]
		Placebo	11	11 (100.0)	-0.52 (0.86)	-1.9	-1.21	-0.35	0.08	0.7	
	Week 30	Tezepelumab	12	10 (83.3)	0.01 (1.31)	-1.8	-0.65	-0.46	0.43	2.4	0.48 [-0.39, 1.35]
		Placebo	11	11 (100.0)	-0.51 (0.81)	-1.9	-1.20	-0.70	0.07	0.7	
	Week 31	Tezepelumab	12	9 (75.0)	0.06 (1.41)	-1.8	-0.64	-0.21	0.29	2.6	0.56 [-0.34, 1.46]
		Placebo	11	11 (100.0)	-0.57 (0.79)	-1.9	-1.21	-0.68	0.14	0.4	
	Week 32	Tezepelumab	12	10 (83.3)	0.13 (1.24)	-1.8	-0.64	-0.09	0.43	2.6	0.39 [-0.47, 1.26]
		Placebo	11	11 (100.0)	-0.32 (1.07)	-1.9	-1.21	-0.07	0.32	1.9	
	Week 33	Tezepelumab	12	10 (83.3)	0.20 (1.17)	-1.7	-0.64	0.07	1.07	2.4	0.61 [-0.26, 1.49]
		Placebo	11	11 (100.0)	-0.46 (0.99)	-1.9	-1.13	-0.14	0.08	1.3	
	Week 34	Tezepelumab	12	10 (83.3)	-0.05 (1.08)	-1.8	-0.64	-0.18	0.36	2.1	0.28 [-0.58, 1.14]
		Placebo	11	11 (100.0)	-0.32 (0.82)	-1.9	-0.92	-0.14	0.29	1.0	
	Week 35	Tezepelumab	12	10 (83.3)	-0.06 (1.05)	-1.7	-0.64	-0.21	0.93	1.8	0.34 [-0.52, 1.20]
		Placebo	11	11 (100.0)	-0.37 (0.73)	-1.9	-0.92	-0.14	0.14	0.5	
	Week 36	Tezepelumab	12	10 (83.3)	-0.00 (1.08)	-1.1	-0.86	-0.25	1.07	2.0	0.55 [-0.32, 1.43]
		Placebo	11	11 (100.0)	-0.49 (0.65)	-1.9	-0.92	-0.56	0.00	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMH0: Course of ASD weekly cough score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	12	9 (75.0)	0.10 (0.93)	-0.9	-0.64	-0.21	0.79	1.6	0.76 [-0.15, 1.68]
		Placebo	11	11 (100.0)	-0.55 (0.80)	-1.9	-0.99	-0.75	0.10	0.5	
	Week 38	Tezepelumab	12	9 (75.0)	0.02 (1.10)	-1.3	-0.64	-0.29	0.43	2.0	0.31 [-0.58, 1.19]
		Placebo	11	11 (100.0)	-0.29 (0.91)	-1.9	-0.85	-0.14	0.42	0.9	
	Week 39	Tezepelumab	12	9 (75.0)	0.16 (1.18)	-1.1	-0.64	-0.14	0.43	2.1	0.54 [-0.38, 1.46]
		Placebo	11	10 (90.9)	-0.39 (0.82)	-1.9	-0.92	-0.35	0.00	1.0	
	Week 40	Tezepelumab	12	9 (75.0)	0.23 (1.24)	-1.1	-0.64	-0.07	0.57	2.2	0.72 [-0.19, 1.63]
		Placebo	11	11 (100.0)	-0.52 (0.86)	-1.9	-1.14	-0.75	0.29	1.0	
	Week 41	Tezepelumab	12	8 (66.7)	0.17 (1.36)	-1.4	-0.89	-0.21	1.39	2.1	0.63 [-0.32, 1.59]
		Placebo	11	10 (90.9)	-0.56 (0.94)	-1.9	-1.21	-0.69	0.42	1.0	
	Week 42	Tezepelumab	12	8 (66.7)	0.05 (1.22)	-1.6	-0.89	-0.21	1.25	1.7	0.56 [-0.37, 1.49]
		Placebo	11	11 (100.0)	-0.52 (0.88)	-1.9	-1.21	-0.61	0.21	1.1	
	Week 43	Tezepelumab	12	8 (66.7)	0.10 (1.18)	-1.1	-0.84	-0.18	1.05	1.9	0.40 [-0.52, 1.32]
		Placebo	11	11 (100.0)	-0.37 (1.16)	-1.9	-1.21	-0.64	0.42	2.0	
	Week 44	Tezepelumab	12	8 (66.7)	0.08 (1.19)	-1.1	-0.75	-0.21	0.79	2.2	0.54 [-0.39, 1.47]
		Placebo	11	11 (100.0)	-0.48 (0.94)	-1.9	-1.21	-0.64	0.30	1.1	
	Week 45	Tezepelumab	12	8 (66.7)	0.05 (1.18)	-1.1	-0.79	-0.43	0.96	2.1	0.62 [-0.33, 1.58]
		Placebo	11	10 (90.9)	-0.62 (1.01)	-2.1	-1.21	-0.65	0.27	1.0	
	Week 46	Tezepelumab	12	7 (58.3)	0.12 (1.20)	-1.1	-0.86	-0.21	1.43	2.1	0.59 [-0.38, 1.56]
		Placebo	11	11 (100.0)	-0.51 (1.00)	-1.9	-1.21	-0.64	0.42	1.0	
	Week 47	Tezepelumab	12	8 (66.7)	-0.08 (1.28)	-1.4	-1.07	-0.57	1.01	2.1	0.49 [-0.43, 1.42]
		Placebo	11	11 (100.0)	-0.60 (0.90)	-1.9	-1.21	-0.75	0.08	1.0	
	Week 48	Tezepelumab	12	7 (58.3)	0.05 (1.20)	-1.3	-1.06	-0.21	0.81	2.1	0.64 [-0.33, 1.61]
		Placebo	11	11 (100.0)	-0.60 (0.90)	-1.9	-1.21	-0.75	0.08	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	12	12 (100.0)	-0.07 (0.23)	(-0.53, 0.39)	0.25 (0.34)	(-0.42, 0.92)	0.458
	Placebo	11	11 (100.0)	-0.32 (0.24)	(-0.80, 0.16)			
Week 2	Tezepelumab	12	12 (100.0)	-0.19 (0.23)	(-0.65, 0.27)	0.17 (0.34)	(-0.50, 0.84)	0.619
	Placebo	11	10 (90.9)	-0.35 (0.24)	(-0.84, 0.13)			
Week 3	Tezepelumab	12	12 (100.0)	-0.21 (0.23)	(-0.67, 0.25)	0.25 (0.34)	(-0.42, 0.92)	0.457
	Placebo	11	10 (90.9)	-0.46 (0.24)	(-0.95, 0.02)			
Week 4	Tezepelumab	12	11 (91.7)	-0.17 (0.23)	(-0.64, 0.29)	0.20 (0.34)	(-0.47, 0.87)	0.558
	Placebo	11	11 (100.0)	-0.37 (0.24)	(-0.85, 0.11)			
Week 5	Tezepelumab	12	11 (91.7)	-0.39 (0.23)	(-0.85, 0.07)	0.12 (0.34)	(-0.55, 0.79)	0.725
	Placebo	11	11 (100.0)	-0.51 (0.24)	(-0.99, -0.03)			
Week 6	Tezepelumab	12	11 (91.7)	-0.38 (0.23)	(-0.85, 0.08)	0.14 (0.34)	(-0.53, 0.81)	0.669
	Placebo	11	11 (100.0)	-0.53 (0.24)	(-1.01, -0.05)			
Week 7	Tezepelumab	12	11 (91.7)	-0.44 (0.23)	(-0.90, 0.03)	-0.02 (0.34)	(-0.69, 0.65)	0.951
	Placebo	11	11 (100.0)	-0.42 (0.24)	(-0.90, 0.06)			
Week 8	Tezepelumab	12	10 (83.3)	-0.40 (0.23)	(-0.87, 0.06)	-0.21 (0.34)	(-0.88, 0.46)	0.533
	Placebo	11	11 (100.0)	-0.19 (0.24)	(-0.67, 0.29)			
Week 9	Tezepelumab	12	12 (100.0)	-0.34 (0.23)	(-0.80, 0.12)	-0.17 (0.34)	(-0.83, 0.50)	0.623
	Placebo	11	11 (100.0)	-0.17 (0.24)	(-0.65, 0.31)			
Week 10	Tezepelumab	12	12 (100.0)	-0.18 (0.23)	(-0.65, 0.28)	0.07 (0.34)	(-0.60, 0.74)	0.840
	Placebo	11	10 (90.9)	-0.25 (0.24)	(-0.74, 0.23)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	12	12 (100.0)	-0.15 (0.23)	(-0.62, 0.31)	0.20 (0.34)	(-0.47, 0.87)	0.548
	Placebo	11	10 (90.9)	-0.36 (0.24)	(-0.84, 0.13)			
Week 12	Tezepelumab	12	11 (91.7)	-0.31 (0.23)	(-0.77, 0.16)	0.05 (0.34)	(-0.62, 0.72)	0.890
	Placebo	11	11 (100.0)	-0.35 (0.24)	(-0.83, 0.13)			
Week 13	Tezepelumab	12	11 (91.7)	-0.10 (0.24)	(-0.57, 0.36)	0.21 (0.34)	(-0.46, 0.88)	0.539
	Placebo	11	11 (100.0)	-0.31 (0.24)	(-0.79, 0.17)			
Week 14	Tezepelumab	12	11 (91.7)	-0.23 (0.24)	(-0.70, 0.24)	0.06 (0.34)	(-0.61, 0.73)	0.863
	Placebo	11	11 (100.0)	-0.29 (0.24)	(-0.77, 0.19)			
Week 15	Tezepelumab	12	11 (91.7)	-0.38 (0.24)	(-0.85, 0.09)	-0.04 (0.34)	(-0.71, 0.64)	0.910
	Placebo	11	11 (100.0)	-0.34 (0.24)	(-0.82, 0.14)			
Week 16	Tezepelumab	12	11 (91.7)	-0.36 (0.24)	(-0.84, 0.11)	0.06 (0.34)	(-0.61, 0.73)	0.860
	Placebo	11	11 (100.0)	-0.42 (0.24)	(-0.90, 0.06)			
Week 17	Tezepelumab	12	11 (91.7)	-0.28 (0.24)	(-0.76, 0.19)	0.21 (0.34)	(-0.47, 0.89)	0.538
	Placebo	11	11 (100.0)	-0.49 (0.24)	(-0.97, -0.01)			
Week 18	Tezepelumab	12	11 (91.7)	-0.27 (0.24)	(-0.74, 0.21)	0.35 (0.34)	(-0.33, 1.02)	0.311
	Placebo	11	11 (100.0)	-0.62 (0.24)	(-1.10, -0.13)			
Week 19	Tezepelumab	12	11 (91.7)	-0.33 (0.24)	(-0.81, 0.14)	0.13 (0.34)	(-0.55, 0.80)	0.712
	Placebo	11	11 (100.0)	-0.46 (0.24)	(-0.94, 0.02)			
Week 20	Tezepelumab	12	11 (91.7)	-0.27 (0.24)	(-0.75, 0.20)	0.10 (0.34)	(-0.57, 0.78)	0.761
	Placebo	11	11 (100.0)	-0.38 (0.24)	(-0.86, 0.10)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	12	11 (91.7)	-0.15 (0.24)	(-0.63, 0.33)	0.31 (0.34)	(-0.36, 0.99)	0.360
	Placebo	11	11 (100.0)	-0.46 (0.24)	(-0.94, 0.02)			
Week 22	Tezepelumab	12	11 (91.7)	-0.33 (0.24)	(-0.81, 0.14)	0.21 (0.34)	(-0.47, 0.88)	0.549
	Placebo	11	11 (100.0)	-0.54 (0.24)	(-1.02, -0.06)			
Week 23	Tezepelumab	12	11 (91.7)	-0.25 (0.24)	(-0.72, 0.23)	0.29 (0.34)	(-0.39, 0.97)	0.402
	Placebo	11	11 (100.0)	-0.53 (0.24)	(-1.01, -0.05)			
Week 24	Tezepelumab	12	11 (91.7)	-0.22 (0.24)	(-0.70, 0.26)	0.18 (0.34)	(-0.50, 0.86)	0.606
	Placebo	11	11 (100.0)	-0.40 (0.24)	(-0.88, 0.08)			
Week 25	Tezepelumab	12	11 (91.7)	-0.15 (0.24)	(-0.63, 0.33)	0.34 (0.34)	(-0.34, 1.02)	0.318
	Placebo	11	11 (100.0)	-0.50 (0.24)	(-0.98, -0.02)			
Week 26	Tezepelumab	12	11 (91.7)	-0.07 (0.24)	(-0.55, 0.41)	0.50 (0.34)	(-0.18, 1.18)	0.150
	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.08)			
Week 27	Tezepelumab	12	10 (83.3)	0.13 (0.24)	(-0.36, 0.61)	0.61 (0.34)	(-0.07, 1.30)	0.077
	Placebo	11	11 (100.0)	-0.49 (0.24)	(-0.97, -0.01)			
Week 28	Tezepelumab	12	9 (75.0)	0.04 (0.25)	(-0.45, 0.53)	0.48 (0.35)	(-0.21, 1.16)	0.173
	Placebo	11	11 (100.0)	-0.43 (0.24)	(-0.91, 0.05)			
Week 29	Tezepelumab	12	8 (66.7)	-0.15 (0.25)	(-0.65, 0.34)	0.34 (0.35)	(-0.35, 1.03)	0.337
	Placebo	11	11 (100.0)	-0.49 (0.24)	(-0.97, -0.01)			
Week 30	Tezepelumab	12	10 (83.3)	-0.15 (0.25)	(-0.64, 0.34)	0.33 (0.35)	(-0.36, 1.02)	0.346
	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.01)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	12	9 (75.0)	-0.13 (0.25)	(-0.62, 0.37)	0.40 (0.35)	(-0.29, 1.10)	0.248
	Placebo	11	11 (100.0)	-0.53 (0.24)	(-1.01, -0.05)			
Week 32	Tezepelumab	12	10 (83.3)	-0.01 (0.25)	(-0.51, 0.48)	0.28 (0.35)	(-0.41, 0.97)	0.421
	Placebo	11	11 (100.0)	-0.29 (0.24)	(-0.77, 0.19)			
Week 33	Tezepelumab	12	10 (83.3)	0.07 (0.25)	(-0.43, 0.56)	0.50 (0.35)	(-0.19, 1.19)	0.155
	Placebo	11	11 (100.0)	-0.43 (0.24)	(-0.91, 0.05)			
Week 34	Tezepelumab	12	10 (83.3)	-0.17 (0.25)	(-0.67, 0.33)	0.12 (0.35)	(-0.58, 0.81)	0.742
	Placebo	11	11 (100.0)	-0.29 (0.24)	(-0.77, 0.19)			
Week 35	Tezepelumab	12	10 (83.3)	-0.18 (0.25)	(-0.68, 0.32)	0.16 (0.35)	(-0.54, 0.85)	0.656
	Placebo	11	11 (100.0)	-0.33 (0.24)	(-0.81, 0.15)			
Week 36	Tezepelumab	12	10 (83.3)	-0.11 (0.25)	(-0.61, 0.39)	0.34 (0.35)	(-0.35, 1.04)	0.327
	Placebo	11	11 (100.0)	-0.46 (0.24)	(-0.94, 0.02)			
Week 37	Tezepelumab	12	9 (75.0)	-0.10 (0.25)	(-0.61, 0.40)	0.42 (0.35)	(-0.28, 1.11)	0.239
	Placebo	11	11 (100.0)	-0.52 (0.24)	(-1.00, -0.04)			
Week 38	Tezepelumab	12	9 (75.0)	-0.17 (0.26)	(-0.68, 0.34)	0.08 (0.35)	(-0.62, 0.79)	0.810
	Placebo	11	11 (100.0)	-0.25 (0.24)	(-0.74, 0.23)			
Week 39	Tezepelumab	12	9 (75.0)	-0.02 (0.26)	(-0.53, 0.49)	0.44 (0.35)	(-0.26, 1.14)	0.218
	Placebo	11	10 (90.9)	-0.46 (0.24)	(-0.94, 0.02)			
Week 40	Tezepelumab	12	9 (75.0)	0.07 (0.26)	(-0.45, 0.58)	0.56 (0.36)	(-0.15, 1.26)	0.121
	Placebo	11	11 (100.0)	-0.49 (0.24)	(-0.97, -0.01)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC_IBMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB

Change from baseline in ASD weekly cough score				Repeated measures analysis																																																																																																		
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																														
Week 41	Tezepelumab	12	8 (66.7)	0.05 (0.26)	(-0.47, 0.58)	0.52 (0.36)	(-0.19, 1.24)	0.147																																																																																														
	Placebo	11	10 (90.9)	-0.47 (0.24)	(-0.95, 0.01)				Week 42	Tezepelumab	12	8 (66.7)	-0.05 (0.27)	(-0.58, 0.48)	0.44 (0.36)	(-0.28, 1.15)	0.230	Placebo	11	11 (100.0)	-0.49 (0.24)	(-0.97, -0.01)	Week 43	Tezepelumab	12	8 (66.7)	0.00 (0.27)	(-0.53, 0.54)	0.34 (0.36)	(-0.38, 1.06)	0.355	Placebo	11	11 (100.0)	-0.33 (0.24)	(-0.81, 0.15)	Week 44	Tezepelumab	12	8 (66.7)	-0.01 (0.27)	(-0.55, 0.53)	0.44 (0.36)	(-0.28, 1.16)	0.232	Placebo	11	11 (100.0)	-0.45 (0.24)	(-0.93, 0.03)	Week 45	Tezepelumab	12	8 (66.7)	-0.04 (0.27)	(-0.58, 0.51)	0.47 (0.37)	(-0.26, 1.19)	0.205	Placebo	11	10 (90.9)	-0.50 (0.24)	(-0.99, -0.02)	Week 46	Tezepelumab	12	7 (58.3)	-0.12 (0.28)	(-0.67, 0.43)	0.35 (0.37)	(-0.38, 1.08)	0.338	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.00)	Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)	Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo
Week 42	Tezepelumab	12	8 (66.7)	-0.05 (0.27)	(-0.58, 0.48)	0.44 (0.36)	(-0.28, 1.15)	0.230																																																																																														
	Placebo	11	11 (100.0)	-0.49 (0.24)	(-0.97, -0.01)				Week 43	Tezepelumab	12	8 (66.7)	0.00 (0.27)	(-0.53, 0.54)	0.34 (0.36)	(-0.38, 1.06)	0.355	Placebo	11	11 (100.0)	-0.33 (0.24)	(-0.81, 0.15)	Week 44	Tezepelumab	12	8 (66.7)	-0.01 (0.27)	(-0.55, 0.53)	0.44 (0.36)	(-0.28, 1.16)	0.232	Placebo	11	11 (100.0)	-0.45 (0.24)	(-0.93, 0.03)	Week 45	Tezepelumab	12	8 (66.7)	-0.04 (0.27)	(-0.58, 0.51)	0.47 (0.37)	(-0.26, 1.19)	0.205	Placebo	11	10 (90.9)	-0.50 (0.24)	(-0.99, -0.02)	Week 46	Tezepelumab	12	7 (58.3)	-0.12 (0.28)	(-0.67, 0.43)	0.35 (0.37)	(-0.38, 1.08)	0.338	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.00)	Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)	Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)										
Week 43	Tezepelumab	12	8 (66.7)	0.00 (0.27)	(-0.53, 0.54)	0.34 (0.36)	(-0.38, 1.06)	0.355																																																																																														
	Placebo	11	11 (100.0)	-0.33 (0.24)	(-0.81, 0.15)				Week 44	Tezepelumab	12	8 (66.7)	-0.01 (0.27)	(-0.55, 0.53)	0.44 (0.36)	(-0.28, 1.16)	0.232	Placebo	11	11 (100.0)	-0.45 (0.24)	(-0.93, 0.03)	Week 45	Tezepelumab	12	8 (66.7)	-0.04 (0.27)	(-0.58, 0.51)	0.47 (0.37)	(-0.26, 1.19)	0.205	Placebo	11	10 (90.9)	-0.50 (0.24)	(-0.99, -0.02)	Week 46	Tezepelumab	12	7 (58.3)	-0.12 (0.28)	(-0.67, 0.43)	0.35 (0.37)	(-0.38, 1.08)	0.338	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.00)	Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)	Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)																								
Week 44	Tezepelumab	12	8 (66.7)	-0.01 (0.27)	(-0.55, 0.53)	0.44 (0.36)	(-0.28, 1.16)	0.232																																																																																														
	Placebo	11	11 (100.0)	-0.45 (0.24)	(-0.93, 0.03)				Week 45	Tezepelumab	12	8 (66.7)	-0.04 (0.27)	(-0.58, 0.51)	0.47 (0.37)	(-0.26, 1.19)	0.205	Placebo	11	10 (90.9)	-0.50 (0.24)	(-0.99, -0.02)	Week 46	Tezepelumab	12	7 (58.3)	-0.12 (0.28)	(-0.67, 0.43)	0.35 (0.37)	(-0.38, 1.08)	0.338	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.00)	Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)	Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)																																						
Week 45	Tezepelumab	12	8 (66.7)	-0.04 (0.27)	(-0.58, 0.51)	0.47 (0.37)	(-0.26, 1.19)	0.205																																																																																														
	Placebo	11	10 (90.9)	-0.50 (0.24)	(-0.99, -0.02)				Week 46	Tezepelumab	12	7 (58.3)	-0.12 (0.28)	(-0.67, 0.43)	0.35 (0.37)	(-0.38, 1.08)	0.338	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.00)	Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)	Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)																																																				
Week 46	Tezepelumab	12	7 (58.3)	-0.12 (0.28)	(-0.67, 0.43)	0.35 (0.37)	(-0.38, 1.08)	0.338																																																																																														
	Placebo	11	11 (100.0)	-0.48 (0.24)	(-0.96, 0.00)				Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)	Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)																																																																		
Week 47	Tezepelumab	12	8 (66.7)	-0.16 (0.28)	(-0.70, 0.39)	0.42 (0.37)	(-0.31, 1.15)	0.262																																																																																														
	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)				Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)																																																																																
Week 48	Tezepelumab	12	7 (58.3)	-0.15 (0.28)	(-0.71, 0.41)	0.42 (0.37)	(-0.31, 1.16)	0.259																																																																																														
	Placebo	11	11 (100.0)	-0.57 (0.24)	(-1.05, -0.09)																																																																																																	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	55	55 (100.0)	1.37 (0.70)	0.0	1.00	1.36	2.00	2.6	
		Placebo	40	40 (100.0)	1.58 (0.77)	0.0	1.08	1.79	2.00	3.0	
	Week 1	Tezepelumab	55	54 (98.2)	1.23 (0.70)	0.0	0.57	1.11	1.86	2.5	
		Placebo	40	40 (100.0)	1.48 (0.73)	0.0	1.00	1.58	2.00	2.8	
	Week 2	Tezepelumab	55	54 (98.2)	1.16 (0.72)	0.0	0.58	1.14	1.90	2.3	
		Placebo	40	39 (97.5)	1.40 (0.71)	0.0	1.00	1.43	1.93	2.7	
	Week 3	Tezepelumab	55	55 (100.0)	1.15 (0.70)	0.0	0.64	1.21	1.79	3.0	
		Placebo	40	38 (95.0)	1.31 (0.73)	0.0	0.79	1.43	1.79	2.6	
	Week 4	Tezepelumab	55	54 (98.2)	1.11 (0.76)	0.0	0.36	1.11	1.75	2.9	
		Placebo	40	39 (97.5)	1.37 (0.70)	0.0	1.00	1.36	2.00	2.8	
	Week 5	Tezepelumab	55	53 (96.4)	1.07 (0.76)	0.0	0.30	1.10	1.64	2.9	
		Placebo	40	38 (95.0)	1.21 (0.69)	0.0	0.71	1.21	1.93	2.3	
	Week 6	Tezepelumab	55	52 (94.5)	1.04 (0.81)	0.0	0.25	1.15	1.64	2.8	
		Placebo	40	40 (100.0)	1.38 (0.74)	0.0	0.92	1.43	1.89	3.3	
	Week 7	Tezepelumab	55	51 (92.7)	1.05 (0.78)	0.0	0.36	1.00	1.64	3.1	
		Placebo	40	40 (100.0)	1.33 (0.75)	0.0	1.00	1.36	2.00	3.1	
	Week 8	Tezepelumab	55	51 (92.7)	1.01 (0.77)	0.0	0.25	1.00	1.50	2.8	
		Placebo	40	39 (97.5)	1.27 (0.64)	0.0	0.93	1.33	1.75	2.6	
	Week 9	Tezepelumab	55	53 (96.4)	0.97 (0.75)	0.0	0.36	1.00	1.57	2.9	
		Placebo	40	40 (100.0)	1.26 (0.72)	0.0	1.00	1.29	1.82	3.0	
	Week 10	Tezepelumab	55	53 (96.4)	0.95 (0.79)	0.0	0.25	1.00	1.50	3.0	
		Placebo	40	40 (100.0)	1.23 (0.73)	0.0	1.00	1.23	1.86	2.9	
	Week 11	Tezepelumab	55	51 (92.7)	1.00 (0.81)	0.0	0.17	1.00	1.79	2.9	
		Placebo	40	40 (100.0)	1.18 (0.74)	0.0	0.96	1.14	1.81	3.0	
	Week 12	Tezepelumab	55	52 (94.5)	0.95 (0.80)	0.0	0.20	1.00	1.71	2.9	
		Placebo	40	38 (95.0)	1.16 (0.74)	0.0	0.92	1.05	1.93	2.8	
	Week 13	Tezepelumab	55	49 (89.1)	0.92 (0.80)	0.0	0.21	0.80	1.50	2.9	
		Placebo	40	38 (95.0)	1.09 (0.78)	0.0	0.50	1.04	1.60	3.2	
	Week 14	Tezepelumab	55	52 (94.5)	0.97 (0.79)	0.0	0.29	1.00	1.63	3.0	
		Placebo	40	37 (92.5)	1.06 (0.76)	0.0	0.50	1.00	1.83	2.2	
	Week 15	Tezepelumab	55	51 (92.7)	0.91 (0.74)	0.0	0.14	1.00	1.58	2.2	
		Placebo	40	39 (97.5)	1.07 (0.79)	0.0	0.36	1.00	1.80	3.1	
	Week 16	Tezepelumab	55	51 (92.7)	0.88 (0.76)	0.0	0.14	1.00	1.29	2.5	
		Placebo	40	38 (95.0)	1.03 (0.74)	0.0	0.21	1.00	1.79	2.3	
Week 17	Tezepelumab	55	52 (94.5)	0.90 (0.77)	0.0	0.10	1.00	1.43	2.8		
	Placebo	40	38 (95.0)	1.11 (0.72)	0.0	0.71	1.00	1.71	2.1		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	55	52 (94.5)	0.90 (0.78)	0.0	0.07	0.96	1.71	2.3	
		Placebo	40	38 (95.0)	1.10 (0.73)	0.0	0.50	1.00	1.71	2.3	
	Week 19	Tezepelumab	55	49 (89.1)	0.88 (0.82)	0.0	0.07	1.00	1.50	2.6	
		Placebo	40	39 (97.5)	1.11 (0.73)	0.0	0.70	1.00	1.79	2.0	
	Week 20	Tezepelumab	55	51 (92.7)	0.87 (0.76)	0.0	0.00	0.92	1.43	2.2	
		Placebo	40	37 (92.5)	1.08 (0.69)	0.0	0.75	1.07	1.58	2.3	
	Week 21	Tezepelumab	55	46 (83.6)	0.93 (0.80)	0.0	0.07	1.00	1.86	2.1	
		Placebo	40	38 (95.0)	1.08 (0.77)	0.0	0.36	1.00	1.79	2.5	
	Week 22	Tezepelumab	55	47 (85.5)	0.97 (0.78)	0.0	0.07	1.00	1.80	2.2	
		Placebo	40	38 (95.0)	1.09 (0.74)	0.0	0.57	1.07	1.71	2.5	
	Week 23	Tezepelumab	55	49 (89.1)	0.92 (0.77)	0.0	0.10	1.00	1.75	2.1	
		Placebo	40	36 (90.0)	1.04 (0.72)	0.0	0.36	1.00	1.62	2.5	
	Week 24	Tezepelumab	55	51 (92.7)	0.88 (0.81)	0.0	0.00	1.00	1.43	2.7	
		Placebo	40	36 (90.0)	0.92 (0.68)	0.0	0.18	1.00	1.36	2.0	
	Week 25	Tezepelumab	55	49 (89.1)	0.90 (0.76)	0.0	0.07	1.00	1.36	2.5	
		Placebo	40	36 (90.0)	0.99 (0.76)	0.0	0.14	1.00	1.61	2.5	
	Week 26	Tezepelumab	55	50 (90.9)	0.79 (0.76)	0.0	0.00	0.63	1.25	2.6	
		Placebo	40	37 (92.5)	0.98 (0.80)	0.0	0.14	1.00	1.75	2.4	
	Week 27	Tezepelumab	55	46 (83.6)	0.95 (0.78)	0.0	0.10	1.00	1.50	3.1	
		Placebo	40	36 (90.0)	1.06 (0.87)	0.0	0.04	1.00	1.92	2.7	
	Week 28	Tezepelumab	55	49 (89.1)	0.91 (0.80)	0.0	0.07	1.00	1.50	2.8	
		Placebo	40	36 (90.0)	1.04 (0.81)	0.0	0.11	1.04	2.00	2.1	
	Week 29	Tezepelumab	55	48 (87.3)	0.88 (0.76)	0.0	0.07	1.00	1.25	2.6	
		Placebo	40	37 (92.5)	1.08 (0.82)	0.0	0.17	1.00	1.90	2.9	
	Week 30	Tezepelumab	55	48 (87.3)	0.94 (0.76)	0.0	0.21	1.00	1.50	2.4	
		Placebo	40	36 (90.0)	0.96 (0.78)	0.0	0.25	1.00	1.34	3.0	
	Week 31	Tezepelumab	55	48 (87.3)	0.82 (0.71)	0.0	0.04	1.00	1.23	2.0	
		Placebo	40	37 (92.5)	0.92 (0.76)	0.0	0.07	1.00	1.20	3.0	
	Week 32	Tezepelumab	55	49 (89.1)	0.87 (0.76)	0.0	0.07	1.00	1.40	2.3	
		Placebo	40	37 (92.5)	1.00 (0.82)	0.0	0.29	1.00	1.57	3.0	
	Week 33	Tezepelumab	55	48 (87.3)	0.88 (0.75)	0.0	0.07	1.00	1.57	2.1	
		Placebo	40	37 (92.5)	1.04 (0.79)	0.0	0.17	1.00	1.58	3.0	
	Week 34	Tezepelumab	55	50 (90.9)	0.88 (0.72)	0.0	0.00	1.00	1.43	2.0	
		Placebo	40	38 (95.0)	1.07 (0.80)	0.0	0.14	1.00	1.75	3.0	
	Week 35	Tezepelumab	55	48 (87.3)	0.92 (0.76)	0.0	0.13	1.00	1.50	2.5	
		Placebo	40	36 (90.0)	1.03 (0.78)	0.0	0.39	1.00	1.50	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	55	48 (87.3)	0.94 (0.78)	0.0	0.00	1.00	1.62	2.7	
		Placebo	40	38 (95.0)	1.10 (0.75)	0.0	0.75	1.00	1.60	3.0	
	Week 37	Tezepelumab	55	47 (85.5)	0.91 (0.76)	0.0	0.07	1.00	1.50	2.6	
		Placebo	40	37 (92.5)	1.08 (0.76)	0.0	0.57	1.00	1.33	3.0	
	Week 38	Tezepelumab	55	47 (85.5)	0.97 (0.78)	0.0	0.08	1.00	1.58	2.5	
		Placebo	40	37 (92.5)	1.04 (0.78)	0.0	0.43	1.00	1.30	3.0	
	Week 39	Tezepelumab	55	49 (89.1)	0.93 (0.80)	0.0	0.08	1.00	1.58	2.9	
		Placebo	40	37 (92.5)	1.07 (0.82)	0.0	0.36	1.00	1.42	3.0	
	Week 40	Tezepelumab	55	49 (89.1)	0.93 (0.76)	0.0	0.08	1.00	1.64	2.1	
		Placebo	40	38 (95.0)	1.11 (0.87)	0.0	0.43	1.00	1.93	3.0	
	Week 41	Tezepelumab	55	50 (90.9)	0.91 (0.77)	0.0	0.10	1.00	1.50	2.6	
		Placebo	40	36 (90.0)	1.09 (0.89)	0.0	0.26	1.00	1.93	3.0	
	Week 42	Tezepelumab	55	47 (85.5)	0.91 (0.77)	0.0	0.00	1.00	1.50	2.5	
		Placebo	40	36 (90.0)	1.11 (0.86)	0.0	0.30	1.00	1.82	3.0	
	Week 43	Tezepelumab	55	49 (89.1)	0.90 (0.81)	0.0	0.00	1.00	1.57	2.8	
		Placebo	40	37 (92.5)	1.09 (0.80)	0.0	0.58	1.00	1.83	3.0	
	Week 44	Tezepelumab	55	48 (87.3)	0.85 (0.74)	0.0	0.00	1.00	1.21	2.2	
		Placebo	40	35 (87.5)	1.10 (0.84)	0.0	0.29	1.07	1.83	3.0	
	Week 45	Tezepelumab	55	48 (87.3)	0.91 (0.78)	0.0	0.00	1.00	1.59	2.2	
		Placebo	40	36 (90.0)	0.99 (0.84)	0.0	0.21	1.00	1.41	3.0	
	Week 46	Tezepelumab	55	47 (85.5)	0.91 (0.74)	0.0	0.00	1.00	1.43	2.1	
		Placebo	40	37 (92.5)	1.01 (0.83)	0.0	0.17	1.00	1.50	3.0	
	Week 47	Tezepelumab	55	46 (83.6)	0.88 (0.74)	0.0	0.07	1.00	1.50	2.0	
		Placebo	40	37 (92.5)	0.98 (0.83)	0.0	0.14	1.00	1.60	3.0	
	Week 48	Tezepelumab	55	49 (89.1)	0.94 (0.80)	0.0	0.08	1.00	1.64	2.6	
		Placebo	40	36 (90.0)	0.96 (0.84)	0.0	0.04	1.00	1.54	3.0	
	Week 49	Tezepelumab	55	47 (85.5)	1.00 (0.80)	0.0	0.08	1.00	1.75	2.7	
		Placebo	40	36 (90.0)	1.01 (0.84)	0.0	0.14	1.00	1.80	3.0	
	Week 50	Tezepelumab	55	44 (80.0)	0.99 (0.79)	0.0	0.07	1.00	1.79	2.5	
		Placebo	40	35 (87.5)	1.01 (0.79)	0.0	0.21	1.00	1.50	3.0	
	Week 51	Tezepelumab	55	45 (81.8)	1.03 (0.77)	0.0	0.10	1.00	1.79	2.1	
		Placebo	40	33 (82.5)	0.99 (0.78)	0.0	0.50	1.00	1.30	3.0	
	Week 52	Tezepelumab	55	39 (70.9)	0.98 (0.76)	0.0	0.07	1.00	1.83	2.0	
		Placebo	40	32 (80.0)	1.04 (0.80)	0.0	0.39	1.00	1.76	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	55	54 (98.2)	-0.15 (0.50)	-2.2	-0.22	0.00	0.07	0.5	-0.11 [-0.52, 0.30]
		Placebo	40	40 (100.0)	-0.10 (0.32)	-1.0	-0.26	-0.07	0.08	0.6	
	Week 2	Tezepelumab	55	54 (98.2)	-0.22 (0.51)	-2.6	-0.29	-0.12	0.00	0.5	-0.05 [-0.46, 0.36]
		Placebo	40	39 (97.5)	-0.19 (0.65)	-2.1	-0.48	0.00	0.08	1.6	
	Week 3	Tezepelumab	55	55 (100.0)	-0.22 (0.58)	-2.6	-0.43	-0.10	0.07	0.7	0.08 [-0.33, 0.50]
		Placebo	40	38 (95.0)	-0.27 (0.71)	-2.6	-0.57	-0.04	0.07	1.4	
	Week 4	Tezepelumab	55	54 (98.2)	-0.25 (0.56)	-2.6	-0.43	-0.07	0.07	0.5	-0.06 [-0.47, 0.35]
		Placebo	40	39 (97.5)	-0.22 (0.65)	-2.5	-0.54	0.00	0.21	1.0	
	Week 5	Tezepelumab	55	53 (96.4)	-0.30 (0.61)	-2.6	-0.43	-0.11	0.00	0.9	0.07 [-0.35, 0.48]
		Placebo	40	38 (95.0)	-0.34 (0.81)	-2.9	-0.79	-0.17	0.08	2.1	
	Week 6	Tezepelumab	55	52 (94.5)	-0.32 (0.61)	-2.6	-0.58	-0.14	0.00	0.7	-0.17 [-0.58, 0.25]
		Placebo	40	40 (100.0)	-0.21 (0.71)	-2.6	-0.61	-0.04	0.21	1.4	
	Week 7	Tezepelumab	55	51 (92.7)	-0.29 (0.56)	-2.6	-0.50	-0.14	0.00	0.6	-0.07 [-0.48, 0.35]
		Placebo	40	40 (100.0)	-0.25 (0.65)	-2.7	-0.67	-0.04	0.08	1.0	
	Week 8	Tezepelumab	55	51 (92.7)	-0.35 (0.59)	-2.6	-0.79	-0.20	0.00	0.6	-0.09 [-0.50, 0.33]
		Placebo	40	39 (97.5)	-0.29 (0.74)	-2.6	-0.79	-0.14	0.07	1.5	
	Week 9	Tezepelumab	55	53 (96.4)	-0.38 (0.61)	-2.6	-0.86	-0.21	0.00	0.9	-0.09 [-0.50, 0.32]
		Placebo	40	40 (100.0)	-0.32 (0.75)	-2.6	-0.66	-0.07	0.01	1.6	
	Week 10	Tezepelumab	55	53 (96.4)	-0.40 (0.64)	-2.6	-0.86	-0.20	0.00	0.8	-0.08 [-0.49, 0.33]
		Placebo	40	40 (100.0)	-0.35 (0.72)	-2.6	-0.71	-0.18	0.05	0.9	
	Week 11	Tezepelumab	55	51 (92.7)	-0.37 (0.63)	-2.6	-0.86	-0.14	0.07	0.8	0.06 [-0.35, 0.48]
		Placebo	40	40 (100.0)	-0.41 (0.72)	-2.4	-0.79	-0.28	0.00	0.9	
	Week 12	Tezepelumab	55	52 (94.5)	-0.40 (0.63)	-2.6	-0.79	-0.21	0.00	0.5	0.03 [-0.38, 0.45]
		Placebo	40	38 (95.0)	-0.43 (0.77)	-2.5	-0.80	-0.21	0.00	1.5	
	Week 13	Tezepelumab	55	49 (89.1)	-0.39 (0.67)	-2.6	-0.86	-0.14	0.00	0.9	0.14 [-0.29, 0.56]
		Placebo	40	38 (95.0)	-0.49 (0.75)	-2.6	-0.85	-0.50	0.00	1.8	
	Week 14	Tezepelumab	55	52 (94.5)	-0.43 (0.69)	-2.6	-0.93	-0.21	0.00	0.6	0.12 [-0.30, 0.54]
		Placebo	40	37 (92.5)	-0.52 (0.80)	-2.7	-0.97	-0.29	0.00	0.8	
	Week 15	Tezepelumab	55	51 (92.7)	-0.42 (0.64)	-2.6	-0.86	-0.21	0.00	0.6	0.10 [-0.32, 0.51]
		Placebo	40	39 (97.5)	-0.49 (0.83)	-2.4	-1.00	-0.42	0.00	1.8	
	Week 16	Tezepelumab	55	51 (92.7)	-0.46 (0.65)	-2.6	-0.86	-0.21	0.00	0.7	0.10 [-0.32, 0.52]
		Placebo	40	38 (95.0)	-0.53 (0.76)	-2.6	-1.00	-0.29	0.00	1.0	
	Week 17	Tezepelumab	55	52 (94.5)	-0.49 (0.65)	-2.6	-0.93	-0.27	0.00	0.4	-0.05 [-0.46, 0.37]
		Placebo	40	38 (95.0)	-0.45 (0.72)	-2.6	-0.70	-0.29	0.00	0.9	
	Week 18	Tezepelumab	55	52 (94.5)	-0.48 (0.65)	-2.6	-0.95	-0.29	-0.03	0.5	-0.04 [-0.46, 0.37]
		Placebo	40	38 (95.0)	-0.45 (0.73)	-2.5	-0.79	-0.23	0.00	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	55	49 (89.1)	-0.47 (0.67)	-2.6	-0.93	-0.25	0.00	0.4	-0.00 [-0.42, 0.42]
		Placebo	40	39 (97.5)	-0.46 (0.75)	-2.9	-0.91	-0.21	0.00	0.9	
	Week 20	Tezepelumab	55	51 (92.7)	-0.49 (0.65)	-2.6	-0.88	-0.29	0.00	0.6	0.01 [-0.41, 0.43]
		Placebo	40	37 (92.5)	-0.50 (0.70)	-2.1	-0.84	-0.21	0.00	0.9	
	Week 21	Tezepelumab	55	46 (83.6)	-0.44 (0.64)	-2.6	-0.93	-0.23	0.00	0.5	0.08 [-0.35, 0.51]
		Placebo	40	38 (95.0)	-0.50 (0.80)	-2.5	-1.00	-0.32	0.00	1.4	
	Week 22	Tezepelumab	55	47 (85.5)	-0.40 (0.63)	-2.6	-0.79	-0.21	0.00	0.4	0.13 [-0.30, 0.56]
		Placebo	40	38 (95.0)	-0.48 (0.75)	-2.5	-0.91	-0.27	0.00	1.1	
	Week 23	Tezepelumab	55	49 (89.1)	-0.48 (0.67)	-2.6	-0.97	-0.29	0.00	0.6	0.08 [-0.35, 0.52]
		Placebo	40	36 (90.0)	-0.54 (0.72)	-2.4	-0.93	-0.29	0.00	0.9	
	Week 24	Tezepelumab	55	51 (92.7)	-0.50 (0.66)	-2.6	-1.00	-0.29	0.00	0.6	0.20 [-0.23, 0.63]
		Placebo	40	36 (90.0)	-0.64 (0.75)	-2.9	-1.02	-0.45	-0.04	0.9	
	Week 25	Tezepelumab	55	49 (89.1)	-0.48 (0.61)	-2.6	-0.86	-0.43	0.00	0.4	0.16 [-0.27, 0.59]
		Placebo	40	36 (90.0)	-0.59 (0.79)	-2.9	-1.04	-0.39	0.00	0.9	
	Week 26	Tezepelumab	55	50 (90.9)	-0.51 (0.64)	-2.6	-0.86	-0.29	0.00	0.5	0.11 [-0.31, 0.54]
		Placebo	40	37 (92.5)	-0.60 (0.88)	-2.9	-1.08	-0.47	0.00	1.7	
	Week 27	Tezepelumab	55	46 (83.6)	-0.39 (0.67)	-2.6	-0.79	-0.18	0.00	0.7	0.17 [-0.27, 0.61]
		Placebo	40	36 (90.0)	-0.53 (0.96)	-2.9	-1.00	-0.36	0.00	2.6	
	Week 28	Tezepelumab	55	49 (89.1)	-0.42 (0.64)	-2.5	-0.86	-0.25	0.00	0.6	0.14 [-0.29, 0.57]
		Placebo	40	36 (90.0)	-0.52 (0.84)	-2.9	-0.86	-0.26	0.00	1.4	
	Week 29	Tezepelumab	55	48 (87.3)	-0.50 (0.66)	-2.6	-1.00	-0.25	0.00	0.6	-0.01 [-0.44, 0.42]
		Placebo	40	37 (92.5)	-0.50 (0.87)	-2.9	-0.86	-0.29	0.00	1.3	
	Week 30	Tezepelumab	55	48 (87.3)	-0.50 (0.66)	-2.6	-0.97	-0.28	0.00	0.5	0.18 [-0.25, 0.62]
		Placebo	40	36 (90.0)	-0.63 (0.82)	-2.9	-1.03	-0.57	-0.04	1.1	
	Week 31	Tezepelumab	55	48 (87.3)	-0.54 (0.70)	-2.6	-0.99	-0.42	0.00	0.8	0.16 [-0.27, 0.58]
		Placebo	40	37 (92.5)	-0.65 (0.79)	-2.9	-1.08	-0.79	-0.07	0.9	
	Week 32	Tezepelumab	55	49 (89.1)	-0.51 (0.67)	-2.6	-0.99	-0.29	0.00	0.6	0.09 [-0.34, 0.52]
		Placebo	40	37 (92.5)	-0.57 (0.82)	-2.9	-1.00	-0.64	0.00	1.2	
	Week 33	Tezepelumab	55	48 (87.3)	-0.51 (0.71)	-2.6	-1.00	-0.33	0.00	0.9	0.02 [-0.40, 0.45]
		Placebo	40	37 (92.5)	-0.53 (0.80)	-2.9	-0.86	-0.36	0.00	0.9	
	Week 34	Tezepelumab	55	50 (90.9)	-0.54 (0.69)	-2.6	-1.00	-0.43	0.00	0.9	-0.03 [-0.45, 0.40]
		Placebo	40	38 (95.0)	-0.52 (0.79)	-2.9	-0.86	-0.39	0.00	0.9	
	Week 35	Tezepelumab	55	48 (87.3)	-0.44 (0.71)	-2.6	-0.95	-0.32	0.00	1.2	0.17 [-0.27, 0.60]
		Placebo	40	36 (90.0)	-0.56 (0.73)	-2.9	-0.89	-0.42	0.00	0.5	
	Week 36	Tezepelumab	55	48 (87.3)	-0.48 (0.71)	-2.6	-1.00	-0.30	0.00	0.9	0.01 [-0.41, 0.44]
		Placebo	40	38 (95.0)	-0.49 (0.78)	-2.9	-0.92	-0.25	0.03	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	55	47 (85.5)	-0.45 (0.68)	-2.6	-1.00	-0.29	0.00	0.8	0.06 [-0.37, 0.49]
		Placebo	40	37 (92.5)	-0.50 (0.72)	-2.3	-0.86	-0.29	0.00	0.9	
	Week 38	Tezepelumab	55	47 (85.5)	-0.39 (0.74)	-2.6	-1.00	-0.29	0.07	1.0	0.20 [-0.24, 0.63]
		Placebo	40	37 (92.5)	-0.53 (0.72)	-2.0	-1.06	-0.29	0.00	0.9	
	Week 39	Tezepelumab	55	49 (89.1)	-0.44 (0.74)	-2.6	-1.00	-0.29	0.00	1.3	0.10 [-0.33, 0.52]
		Placebo	40	37 (92.5)	-0.51 (0.75)	-2.0	-1.00	-0.29	0.00	1.1	
	Week 40	Tezepelumab	55	49 (89.1)	-0.48 (0.72)	-2.6	-1.00	-0.29	0.00	1.3	0.00 [-0.42, 0.42]
		Placebo	40	38 (95.0)	-0.48 (0.83)	-2.4	-1.00	-0.36	0.00	1.5	
	Week 41	Tezepelumab	55	50 (90.9)	-0.49 (0.74)	-2.5	-1.07	-0.29	0.00	1.5	-0.01 [-0.44, 0.42]
		Placebo	40	36 (90.0)	-0.48 (0.92)	-2.6	-1.04	-0.32	0.00	2.2	
	Week 42	Tezepelumab	55	47 (85.5)	-0.48 (0.74)	-2.6	-1.00	-0.29	0.00	0.7	-0.04 [-0.47, 0.39]
		Placebo	40	36 (90.0)	-0.45 (0.73)	-2.0	-0.89	-0.29	0.00	1.1	
	Week 43	Tezepelumab	55	49 (89.1)	-0.49 (0.72)	-2.6	-1.07	-0.29	0.00	0.6	-0.01 [-0.43, 0.42]
		Placebo	40	37 (92.5)	-0.48 (0.69)	-2.0	-0.84	-0.29	-0.02	0.9	
	Week 44	Tezepelumab	55	48 (87.3)	-0.55 (0.70)	-2.6	-1.00	-0.39	-0.07	0.6	-0.07 [-0.50, 0.37]
		Placebo	40	35 (87.5)	-0.50 (0.72)	-2.0	-0.81	-0.44	0.00	0.9	
	Week 45	Tezepelumab	55	48 (87.3)	-0.48 (0.75)	-2.6	-1.00	-0.29	0.00	1.1	0.16 [-0.27, 0.60]
		Placebo	40	36 (90.0)	-0.60 (0.79)	-2.6	-0.96	-0.57	-0.04	0.9	
	Week 46	Tezepelumab	55	47 (85.5)	-0.44 (0.76)	-2.6	-1.00	-0.36	0.00	0.9	0.17 [-0.26, 0.60]
		Placebo	40	37 (92.5)	-0.57 (0.80)	-2.9	-1.00	-0.50	0.00	0.9	
	Week 47	Tezepelumab	55	46 (83.6)	-0.47 (0.78)	-2.6	-1.00	-0.32	0.00	1.3	0.15 [-0.28, 0.58]
		Placebo	40	37 (92.5)	-0.59 (0.79)	-2.9	-1.00	-0.29	0.00	0.9	
	Week 48	Tezepelumab	55	49 (89.1)	-0.39 (0.77)	-2.6	-0.90	-0.14	0.07	1.1	0.31 [-0.12, 0.75]
		Placebo	40	36 (90.0)	-0.63 (0.76)	-2.9	-1.01	-0.46	-0.07	0.9	
	Week 49	Tezepelumab	55	47 (85.5)	-0.39 (0.73)	-2.6	-0.86	-0.17	0.00	1.1	0.22 [-0.22, 0.66]
		Placebo	40	36 (90.0)	-0.56 (0.77)	-2.9	-0.97	-0.53	0.00	0.9	
	Week 50	Tezepelumab	55	44 (80.0)	-0.43 (0.68)	-2.6	-0.93	-0.25	0.00	0.6	0.16 [-0.29, 0.60]
		Placebo	40	35 (87.5)	-0.54 (0.74)	-2.9	-1.00	-0.30	0.00	0.9	
	Week 51	Tezepelumab	55	45 (81.8)	-0.35 (0.73)	-2.6	-0.79	-0.14	0.00	1.6	0.35 [-0.11, 0.80]
		Placebo	40	33 (82.5)	-0.61 (0.77)	-2.9	-1.07	-0.50	0.00	0.9	
	Week 52	Tezepelumab	55	39 (70.9)	-0.38 (0.72)	-2.6	-1.00	-0.14	0.00	1.4	0.32 [-0.15, 0.79]
		Placebo	40	32 (80.0)	-0.62 (0.77)	-2.9	-0.93	-0.52	-0.07	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	55	54 (98.2)	-0.18 (0.09)	(-0.35, -0.01)	-0.13 (0.13)	(-0.38, 0.13)	0.334
	Placebo	40	40 (100.0)	-0.05 (0.10)	(-0.25, 0.14)			
Week 2	Tezepelumab	55	54 (98.2)	-0.25 (0.08)	(-0.42, -0.09)	-0.12 (0.13)	(-0.38, 0.14)	0.362
	Placebo	40	39 (97.5)	-0.13 (0.10)	(-0.33, 0.06)			
Week 3	Tezepelumab	55	55 (100.0)	-0.26 (0.08)	(-0.42, -0.09)	-0.05 (0.13)	(-0.31, 0.21)	0.707
	Placebo	40	38 (95.0)	-0.21 (0.10)	(-0.40, -0.01)			
Week 4	Tezepelumab	55	54 (98.2)	-0.31 (0.08)	(-0.48, -0.14)	-0.15 (0.13)	(-0.41, 0.11)	0.252
	Placebo	40	39 (97.5)	-0.16 (0.10)	(-0.36, 0.04)			
Week 5	Tezepelumab	55	53 (96.4)	-0.33 (0.09)	(-0.50, -0.17)	-0.06 (0.13)	(-0.32, 0.20)	0.649
	Placebo	40	38 (95.0)	-0.27 (0.10)	(-0.47, -0.08)			
Week 6	Tezepelumab	55	52 (94.5)	-0.34 (0.09)	(-0.51, -0.17)	-0.18 (0.13)	(-0.44, 0.08)	0.171
	Placebo	40	40 (100.0)	-0.16 (0.10)	(-0.35, 0.04)			
Week 7	Tezepelumab	55	51 (92.7)	-0.35 (0.09)	(-0.51, -0.18)	-0.14 (0.13)	(-0.40, 0.12)	0.281
	Placebo	40	40 (100.0)	-0.20 (0.10)	(-0.40, -0.01)			
Week 8	Tezepelumab	55	51 (92.7)	-0.38 (0.09)	(-0.55, -0.21)	-0.16 (0.13)	(-0.42, 0.10)	0.230
	Placebo	40	39 (97.5)	-0.22 (0.10)	(-0.42, -0.03)			
Week 9	Tezepelumab	55	53 (96.4)	-0.42 (0.09)	(-0.58, -0.25)	-0.14 (0.13)	(-0.40, 0.11)	0.272
	Placebo	40	40 (100.0)	-0.27 (0.10)	(-0.47, -0.08)			
Week 10	Tezepelumab	55	53 (96.4)	-0.44 (0.09)	(-0.60, -0.27)	-0.14 (0.13)	(-0.39, 0.12)	0.302
	Placebo	40	40 (100.0)	-0.30 (0.10)	(-0.50, -0.11)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	55	51 (92.7)	-0.43 (0.09)	(-0.59, -0.26)	-0.07 (0.13)	(-0.32, 0.19)	0.615
	Placebo	40	40 (100.0)	-0.36 (0.10)	(-0.56, -0.16)			
Week 12	Tezepelumab	55	52 (94.5)	-0.45 (0.09)	(-0.61, -0.28)	-0.10 (0.13)	(-0.36, 0.16)	0.454
	Placebo	40	38 (95.0)	-0.35 (0.10)	(-0.54, -0.15)			
Week 13	Tezepelumab	55	49 (89.1)	-0.46 (0.09)	(-0.63, -0.29)	-0.05 (0.13)	(-0.31, 0.21)	0.712
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.61, -0.21)			
Week 14	Tezepelumab	55	52 (94.5)	-0.43 (0.09)	(-0.60, -0.26)	-0.01 (0.13)	(-0.27, 0.25)	0.938
	Placebo	40	37 (92.5)	-0.42 (0.10)	(-0.62, -0.23)			
Week 15	Tezepelumab	55	51 (92.7)	-0.45 (0.09)	(-0.62, -0.28)	-0.01 (0.13)	(-0.27, 0.25)	0.942
	Placebo	40	39 (97.5)	-0.44 (0.10)	(-0.64, -0.24)			
Week 16	Tezepelumab	55	51 (92.7)	-0.49 (0.09)	(-0.66, -0.32)	-0.03 (0.13)	(-0.29, 0.23)	0.841
	Placebo	40	38 (95.0)	-0.47 (0.10)	(-0.66, -0.27)			
Week 17	Tezepelumab	55	52 (94.5)	-0.50 (0.09)	(-0.66, -0.33)	-0.10 (0.13)	(-0.36, 0.15)	0.429
	Placebo	40	38 (95.0)	-0.39 (0.10)	(-0.59, -0.20)			
Week 18	Tezepelumab	55	52 (94.5)	-0.50 (0.09)	(-0.67, -0.33)	-0.11 (0.13)	(-0.36, 0.15)	0.425
	Placebo	40	38 (95.0)	-0.39 (0.10)	(-0.59, -0.20)			
Week 19	Tezepelumab	55	49 (89.1)	-0.50 (0.09)	(-0.67, -0.34)	-0.10 (0.13)	(-0.36, 0.16)	0.450
	Placebo	40	39 (97.5)	-0.40 (0.10)	(-0.60, -0.21)			
Week 20	Tezepelumab	55	51 (92.7)	-0.52 (0.09)	(-0.68, -0.35)	-0.06 (0.13)	(-0.32, 0.20)	0.664
	Placebo	40	37 (92.5)	-0.46 (0.10)	(-0.66, -0.26)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	55	46 (83.6)	-0.50 (0.09)	(-0.67, -0.33)	-0.07 (0.13)	(-0.33, 0.19)	0.613
	Placebo	40	38 (95.0)	-0.43 (0.10)	(-0.63, -0.23)			
Week 22	Tezepelumab	55	47 (85.5)	-0.46 (0.09)	(-0.63, -0.29)	-0.04 (0.13)	(-0.30, 0.22)	0.747
	Placebo	40	38 (95.0)	-0.41 (0.10)	(-0.61, -0.22)			
Week 23	Tezepelumab	55	49 (89.1)	-0.50 (0.09)	(-0.67, -0.33)	-0.08 (0.13)	(-0.34, 0.18)	0.544
	Placebo	40	36 (90.0)	-0.42 (0.10)	(-0.62, -0.22)			
Week 24	Tezepelumab	55	51 (92.7)	-0.51 (0.09)	(-0.68, -0.34)	0.01 (0.13)	(-0.25, 0.27)	0.957
	Placebo	40	36 (90.0)	-0.52 (0.10)	(-0.72, -0.32)			
Week 25	Tezepelumab	55	49 (89.1)	-0.53 (0.09)	(-0.70, -0.36)	-0.04 (0.13)	(-0.30, 0.22)	0.764
	Placebo	40	36 (90.0)	-0.49 (0.10)	(-0.69, -0.29)			
Week 26	Tezepelumab	55	50 (90.9)	-0.57 (0.09)	(-0.74, -0.40)	-0.07 (0.13)	(-0.33, 0.19)	0.612
	Placebo	40	37 (92.5)	-0.50 (0.10)	(-0.70, -0.30)			
Week 27	Tezepelumab	55	46 (83.6)	-0.46 (0.09)	(-0.63, -0.29)	-0.02 (0.13)	(-0.28, 0.24)	0.884
	Placebo	40	36 (90.0)	-0.44 (0.10)	(-0.64, -0.24)			
Week 28	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.69, -0.35)	-0.11 (0.13)	(-0.38, 0.15)	0.394
	Placebo	40	36 (90.0)	-0.41 (0.10)	(-0.61, -0.21)			
Week 29	Tezepelumab	55	48 (87.3)	-0.55 (0.09)	(-0.72, -0.38)	-0.14 (0.13)	(-0.40, 0.12)	0.286
	Placebo	40	37 (92.5)	-0.41 (0.10)	(-0.61, -0.21)			
Week 30	Tezepelumab	55	48 (87.3)	-0.55 (0.09)	(-0.72, -0.38)	-0.02 (0.13)	(-0.28, 0.24)	0.892
	Placebo	40	36 (90.0)	-0.53 (0.10)	(-0.73, -0.33)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	55	48 (87.3)	-0.56 (0.09)	(-0.73, -0.39)	0.00 (0.13)	(-0.26, 0.27)	0.972
	Placebo	40	37 (92.5)	-0.57 (0.10)	(-0.77, -0.37)			
Week 32	Tezepelumab	55	49 (89.1)	-0.56 (0.09)	(-0.73, -0.39)	-0.07 (0.13)	(-0.33, 0.19)	0.608
	Placebo	40	37 (92.5)	-0.49 (0.10)	(-0.69, -0.29)			
Week 33	Tezepelumab	55	48 (87.3)	-0.56 (0.09)	(-0.73, -0.40)	-0.09 (0.13)	(-0.36, 0.17)	0.480
	Placebo	40	37 (92.5)	-0.47 (0.10)	(-0.67, -0.27)			
Week 34	Tezepelumab	55	50 (90.9)	-0.58 (0.09)	(-0.75, -0.41)	-0.12 (0.13)	(-0.39, 0.14)	0.349
	Placebo	40	38 (95.0)	-0.45 (0.10)	(-0.65, -0.25)			
Week 35	Tezepelumab	55	48 (87.3)	-0.51 (0.09)	(-0.68, -0.34)	-0.04 (0.13)	(-0.30, 0.23)	0.780
	Placebo	40	36 (90.0)	-0.47 (0.10)	(-0.67, -0.27)			
Week 36	Tezepelumab	55	48 (87.3)	-0.48 (0.09)	(-0.65, -0.31)	-0.06 (0.13)	(-0.32, 0.21)	0.673
	Placebo	40	38 (95.0)	-0.43 (0.10)	(-0.63, -0.23)			
Week 37	Tezepelumab	55	47 (85.5)	-0.54 (0.09)	(-0.71, -0.37)	-0.11 (0.13)	(-0.37, 0.15)	0.414
	Placebo	40	37 (92.5)	-0.43 (0.10)	(-0.63, -0.23)			
Week 38	Tezepelumab	55	47 (85.5)	-0.48 (0.09)	(-0.65, -0.31)	-0.02 (0.13)	(-0.28, 0.25)	0.891
	Placebo	40	37 (92.5)	-0.46 (0.10)	(-0.66, -0.26)			
Week 39	Tezepelumab	55	49 (89.1)	-0.51 (0.09)	(-0.68, -0.34)	-0.07 (0.13)	(-0.34, 0.19)	0.586
	Placebo	40	37 (92.5)	-0.44 (0.10)	(-0.64, -0.24)			
Week 40	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.69, -0.35)	-0.10 (0.13)	(-0.36, 0.17)	0.471
	Placebo	40	38 (95.0)	-0.42 (0.10)	(-0.62, -0.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	55	50 (90.9)	-0.51 (0.09)	(-0.68, -0.34)	-0.09 (0.13)	(-0.36, 0.17)	0.498
	Placebo	40	36 (90.0)	-0.42 (0.10)	(-0.62, -0.22)			
Week 42	Tezepelumab	55	47 (85.5)	-0.50 (0.09)	(-0.67, -0.33)	-0.07 (0.13)	(-0.34, 0.19)	0.595
	Placebo	40	36 (90.0)	-0.43 (0.10)	(-0.63, -0.23)			
Week 43	Tezepelumab	55	49 (89.1)	-0.53 (0.09)	(-0.70, -0.36)	-0.11 (0.13)	(-0.37, 0.16)	0.417
	Placebo	40	37 (92.5)	-0.42 (0.10)	(-0.62, -0.22)			
Week 44	Tezepelumab	55	48 (87.3)	-0.57 (0.09)	(-0.74, -0.40)	-0.13 (0.14)	(-0.39, 0.14)	0.353
	Placebo	40	35 (87.5)	-0.44 (0.10)	(-0.65, -0.24)			
Week 45	Tezepelumab	55	48 (87.3)	-0.54 (0.09)	(-0.71, -0.36)	-0.01 (0.14)	(-0.27, 0.26)	0.948
	Placebo	40	36 (90.0)	-0.53 (0.10)	(-0.73, -0.32)			
Week 46	Tezepelumab	55	47 (85.5)	-0.52 (0.09)	(-0.69, -0.35)	-0.01 (0.14)	(-0.27, 0.26)	0.955
	Placebo	40	37 (92.5)	-0.51 (0.10)	(-0.71, -0.31)			
Week 47	Tezepelumab	55	46 (83.6)	-0.52 (0.09)	(-0.69, -0.34)	0.02 (0.14)	(-0.25, 0.28)	0.905
	Placebo	40	37 (92.5)	-0.53 (0.10)	(-0.73, -0.33)			
Week 48	Tezepelumab	55	49 (89.1)	-0.44 (0.09)	(-0.62, -0.27)	0.11 (0.14)	(-0.16, 0.37)	0.419
	Placebo	40	36 (90.0)	-0.55 (0.10)	(-0.76, -0.35)			
Week 49	Tezepelumab	55	47 (85.5)	-0.47 (0.09)	(-0.64, -0.30)	0.03 (0.14)	(-0.24, 0.29)	0.850
	Placebo	40	36 (90.0)	-0.50 (0.10)	(-0.70, -0.30)			
Week 50	Tezepelumab	55	44 (80.0)	-0.49 (0.09)	(-0.66, -0.31)	0.00 (0.14)	(-0.27, 0.27)	0.997
	Placebo	40	35 (87.5)	-0.49 (0.10)	(-0.69, -0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	55	45 (81.8)	-0.45 (0.09)	(-0.62, -0.27)	0.07 (0.14)	(-0.20, 0.34)	0.587
	Placebo	40	33 (82.5)	-0.52 (0.10)	(-0.72, -0.31)			
Week 52	Tezepelumab	55	39 (70.9)	-0.46 (0.09)	(-0.64, -0.28)	0.04 (0.14)	(-0.23, 0.31)	0.778
	Placebo	40	32 (80.0)	-0.50 (0.11)	(-0.71, -0.29)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	12	12 (100.0)	1.27 (1.06)	0.0	0.29	1.14	1.82	3.1	
		Placebo	11	11 (100.0)	1.98 (1.06)	0.0	1.50	2.00	2.92	3.5	
	Week 1	Tezepelumab	12	12 (100.0)	1.17 (0.96)	0.0	0.59	1.00	1.37	3.0	
		Placebo	11	11 (100.0)	1.74 (0.73)	0.6	0.93	2.00	2.25	2.8	
	Week 2	Tezepelumab	12	12 (100.0)	1.17 (0.95)	0.0	0.46	1.00	1.39	3.0	
		Placebo	11	10 (90.9)	1.72 (0.77)	0.5	0.93	2.00	2.43	2.5	
	Week 3	Tezepelumab	12	12 (100.0)	1.16 (0.90)	0.0	0.77	1.00	1.07	3.0	
		Placebo	11	10 (90.9)	1.66 (0.69)	0.8	0.93	1.83	2.21	2.6	
	Week 4	Tezepelumab	12	11 (91.7)	1.22 (0.99)	0.0	0.50	1.00	1.57	3.0	
		Placebo	11	11 (100.0)	1.59 (0.72)	0.7	0.79	1.71	2.00	2.7	
	Week 5	Tezepelumab	12	11 (91.7)	1.18 (1.04)	0.0	0.00	1.14	1.36	3.0	
		Placebo	11	11 (100.0)	1.56 (0.76)	0.4	0.67	1.93	2.17	2.5	
	Week 6	Tezepelumab	12	11 (91.7)	1.14 (1.00)	0.0	0.07	1.07	1.21	3.0	
		Placebo	11	11 (100.0)	1.54 (0.75)	0.3	0.93	1.86	2.00	2.5	
	Week 7	Tezepelumab	12	11 (91.7)	1.15 (1.02)	0.0	0.42	1.00	1.33	3.0	
		Placebo	11	11 (100.0)	1.52 (0.75)	0.1	1.00	1.64	2.17	2.4	
	Week 8	Tezepelumab	12	10 (83.3)	1.20 (1.05)	0.0	0.36	1.00	1.67	3.1	
		Placebo	11	11 (100.0)	1.68 (0.67)	0.4	1.36	1.71	2.00	2.9	
	Week 9	Tezepelumab	12	12 (100.0)	1.13 (1.04)	0.0	0.25	1.07	1.29	3.1	
		Placebo	11	11 (100.0)	1.73 (0.84)	0.0	1.07	1.93	2.30	2.9	
	Week 10	Tezepelumab	12	12 (100.0)	1.15 (1.06)	0.0	0.50	1.00	1.15	3.3	
		Placebo	11	10 (90.9)	1.67 (0.73)	0.2	1.42	1.73	2.21	2.7	
	Week 11	Tezepelumab	12	12 (100.0)	1.12 (1.05)	0.0	0.36	1.00	1.14	3.5	
		Placebo	11	10 (90.9)	1.52 (0.87)	0.1	0.92	1.50	2.13	3.0	
	Week 12	Tezepelumab	12	11 (91.7)	1.30 (1.18)	0.0	0.33	1.00	2.14	3.6	
		Placebo	11	11 (100.0)	1.65 (0.97)	0.0	1.21	1.93	2.36	3.0	
	Week 13	Tezepelumab	12	11 (91.7)	1.37 (1.15)	0.0	0.36	1.00	2.00	3.6	
		Placebo	11	11 (100.0)	1.68 (0.89)	0.0	1.33	1.93	2.21	3.0	
	Week 14	Tezepelumab	12	11 (91.7)	1.16 (1.02)	0.0	0.25	1.00	1.50	3.1	
		Placebo	11	11 (100.0)	1.61 (0.81)	0.0	1.36	2.00	2.21	2.3	
	Week 15	Tezepelumab	12	11 (91.7)	1.04 (1.00)	0.0	0.00	1.00	1.21	3.1	
		Placebo	11	11 (100.0)	1.53 (0.84)	0.0	0.79	1.86	2.00	2.8	
Week 16	Tezepelumab	12	11 (91.7)	1.13 (1.03)	0.0	0.17	1.00	1.36	3.1		
	Placebo	11	11 (100.0)	1.45 (0.63)	0.0	1.07	1.50	2.00	2.1		
Week 17	Tezepelumab	12	11 (91.7)	1.12 (1.08)	0.0	0.25	1.00	1.92	3.6		
	Placebo	11	11 (100.0)	1.35 (0.69)	0.0	1.00	1.29	2.00	2.1		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	12	11 (91.7)	1.16 (1.16)	0.0	0.07	1.00	2.07	3.6	
		Placebo	11	11 (100.0)	1.37 (0.82)	0.0	1.00	1.57	2.00	2.2	
	Week 19	Tezepelumab	12	11 (91.7)	1.10 (1.01)	0.0	0.00	1.00	2.00	3.1	
		Placebo	11	11 (100.0)	1.35 (0.76)	0.0	1.00	1.50	2.00	2.1	
	Week 20	Tezepelumab	12	11 (91.7)	1.06 (1.00)	0.0	0.00	0.93	1.93	2.8	
		Placebo	11	11 (100.0)	1.36 (0.78)	0.0	1.00	1.50	2.00	2.2	
	Week 21	Tezepelumab	12	11 (91.7)	1.12 (0.96)	0.0	0.00	1.00	1.86	2.9	
		Placebo	11	11 (100.0)	1.41 (0.76)	0.0	1.00	1.50	2.00	2.6	
	Week 22	Tezepelumab	12	11 (91.7)	0.98 (0.80)	0.0	0.07	1.00	1.79	2.4	
		Placebo	11	11 (100.0)	1.38 (0.71)	0.0	0.79	1.50	2.00	2.0	
	Week 23	Tezepelumab	12	11 (91.7)	1.04 (0.91)	0.0	0.00	1.00	1.79	2.5	
		Placebo	11	11 (100.0)	1.38 (0.70)	0.0	0.93	1.33	2.00	2.1	
	Week 24	Tezepelumab	12	11 (91.7)	1.12 (0.87)	0.0	0.00	1.00	1.79	2.4	
		Placebo	11	11 (100.0)	1.45 (0.73)	0.0	1.00	1.50	2.00	2.3	
	Week 25	Tezepelumab	12	11 (91.7)	1.26 (1.06)	0.0	0.00	1.08	2.43	2.9	
		Placebo	11	11 (100.0)	1.28 (0.83)	0.0	0.33	1.67	2.00	2.0	
	Week 26	Tezepelumab	12	11 (91.7)	1.19 (0.93)	0.0	0.00	1.00	2.00	2.6	
		Placebo	11	11 (100.0)	1.34 (0.83)	0.0	0.83	1.79	2.00	2.3	
	Week 27	Tezepelumab	12	10 (83.3)	1.14 (0.98)	0.0	0.00	1.15	1.57	3.0	
		Placebo	11	11 (100.0)	1.48 (0.92)	0.0	1.00	1.86	2.07	3.0	
	Week 28	Tezepelumab	12	9 (75.0)	1.25 (0.88)	0.0	1.00	1.13	1.71	2.6	
		Placebo	11	11 (100.0)	1.59 (0.97)	0.0	1.00	1.58	2.50	3.0	
	Week 29	Tezepelumab	12	8 (66.7)	1.11 (0.99)	0.0	0.46	1.01	1.41	3.1	
		Placebo	11	11 (100.0)	1.62 (1.04)	0.0	1.00	1.57	2.79	2.8	
	Week 30	Tezepelumab	12	10 (83.3)	1.10 (0.96)	0.0	0.33	1.04	1.20	3.1	
		Placebo	11	11 (100.0)	1.38 (0.86)	0.0	0.71	1.71	2.00	2.3	
	Week 31	Tezepelumab	12	9 (75.0)	1.14 (0.93)	0.0	0.93	1.00	1.25	3.0	
		Placebo	11	11 (100.0)	1.42 (0.84)	0.0	1.00	1.64	2.00	2.5	
	Week 32	Tezepelumab	12	10 (83.3)	1.12 (0.90)	0.0	0.93	1.00	1.10	3.1	
		Placebo	11	11 (100.0)	1.46 (0.83)	0.0	1.00	1.86	2.10	2.2	
	Week 33	Tezepelumab	12	10 (83.3)	1.09 (0.92)	0.0	0.83	1.00	1.14	3.3	
		Placebo	11	11 (100.0)	1.41 (0.75)	0.0	0.93	1.36	2.14	2.3	
	Week 34	Tezepelumab	12	10 (83.3)	1.10 (0.95)	0.0	0.71	1.07	1.21	3.4	
		Placebo	11	11 (100.0)	1.47 (0.85)	0.0	1.00	1.79	2.00	2.6	
	Week 35	Tezepelumab	12	10 (83.3)	1.01 (0.89)	0.0	0.50	1.00	1.14	3.2	
		Placebo	11	11 (100.0)	1.39 (0.85)	0.0	1.00	1.57	2.07	2.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	12	10 (83.3)	0.95 (0.90)	0.0	0.07	1.00	1.10	3.1	
		Placebo	11	11 (100.0)	1.55 (0.82)	0.0	1.00	1.57	2.17	2.9	
	Week 37	Tezepelumab	12	9 (75.0)	1.17 (0.87)	0.0	0.79	1.00	1.36	3.0	
		Placebo	11	11 (100.0)	1.43 (0.81)	0.0	1.07	1.33	2.00	3.0	
	Week 38	Tezepelumab	12	9 (75.0)	1.15 (0.95)	0.0	0.86	1.00	1.21	3.3	
		Placebo	11	11 (100.0)	1.44 (0.81)	0.0	1.00	1.64	2.00	2.8	
	Week 39	Tezepelumab	12	9 (75.0)	1.14 (1.01)	0.0	0.86	1.00	1.14	3.3	
		Placebo	11	10 (90.9)	1.43 (0.84)	0.0	1.00	1.39	2.00	3.0	
	Week 40	Tezepelumab	12	9 (75.0)	1.14 (1.02)	0.0	0.57	1.00	1.43	3.3	
		Placebo	11	11 (100.0)	1.53 (0.85)	0.0	1.00	1.57	2.00	3.0	
	Week 41	Tezepelumab	12	8 (66.7)	1.36 (0.87)	0.0	1.00	1.16	1.79	3.0	
		Placebo	11	10 (90.9)	1.43 (0.87)	0.0	1.00	1.18	2.00	3.0	
	Week 42	Tezepelumab	12	8 (66.7)	1.16 (0.81)	0.0	0.75	1.04	1.46	2.8	
		Placebo	11	11 (100.0)	1.41 (0.86)	0.0	0.71	1.21	2.00	3.0	
	Week 43	Tezepelumab	12	8 (66.7)	1.33 (0.88)	0.0	0.96	1.21	1.63	3.1	
		Placebo	11	11 (100.0)	1.51 (0.89)	0.0	1.00	1.43	2.10	3.0	
	Week 44	Tezepelumab	12	8 (66.7)	1.21 (0.92)	0.0	0.75	1.00	1.57	3.0	
		Placebo	11	11 (100.0)	1.51 (0.98)	0.0	1.00	1.07	2.60	3.0	
	Week 45	Tezepelumab	12	8 (66.7)	1.22 (0.88)	0.0	0.82	1.00	1.62	2.9	
		Placebo	11	10 (90.9)	1.22 (0.93)	0.0	0.42	1.07	2.00	2.6	
	Week 46	Tezepelumab	12	7 (58.3)	1.15 (0.81)	0.0	0.50	1.00	2.00	2.4	
		Placebo	11	11 (100.0)	1.31 (0.92)	0.0	0.50	1.10	2.07	2.6	
	Week 47	Tezepelumab	12	8 (66.7)	1.17 (0.84)	0.0	0.57	1.08	1.82	2.4	
		Placebo	11	11 (100.0)	1.24 (0.83)	0.0	0.50	1.14	2.00	2.3	
	Week 48	Tezepelumab	12	7 (58.3)	1.35 (0.71)	0.5	0.93	1.08	2.00	2.6	
		Placebo	11	11 (100.0)	1.26 (0.84)	0.0	0.50	1.36	2.00	2.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	12	12 (100.0)	-0.11 (0.45)	-0.9	-0.35	0.00	0.04	0.8	0.23 [-0.59, 1.05]
		Placebo	11	11 (100.0)	-0.24 (0.66)	-1.9	-0.57	0.00	0.07	0.6	
	Week 2	Tezepelumab	12	12 (100.0)	-0.10 (0.40)	-0.8	-0.36	0.00	0.14	0.4	0.03 [-0.81, 0.87]
		Placebo	11	10 (90.9)	-0.11 (0.37)	-0.6	-0.42	-0.01	0.00	0.6	
	Week 3	Tezepelumab	12	12 (100.0)	-0.11 (0.66)	-1.4	-0.55	0.00	0.18	1.0	0.10 [-0.74, 0.94]
		Placebo	11	10 (90.9)	-0.17 (0.54)	-0.9	-0.57	-0.20	0.00	0.8	
	Week 4	Tezepelumab	12	11 (91.7)	-0.17 (0.78)	-1.6	-0.71	0.00	0.00	1.5	0.26 [-0.58, 1.10]
		Placebo	11	11 (100.0)	-0.39 (0.94)	-2.8	-0.80	-0.20	0.00	0.9	
	Week 5	Tezepelumab	12	11 (91.7)	-0.12 (0.74)	-1.9	-0.54	0.00	0.21	1.1	0.34 [-0.50, 1.18]
		Placebo	11	11 (100.0)	-0.42 (0.99)	-2.8	-0.83	-0.08	0.07	0.9	
	Week 6	Tezepelumab	12	11 (91.7)	-0.16 (0.75)	-1.8	-0.71	0.00	0.07	1.1	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.44 (1.11)	-3.2	-1.00	-0.14	0.07	0.9	
	Week 7	Tezepelumab	12	11 (91.7)	-0.15 (0.75)	-1.9	-0.71	0.00	0.35	0.8	0.34 [-0.50, 1.19]
		Placebo	11	11 (100.0)	-0.46 (1.05)	-2.9	-0.83	-0.36	0.00	1.0	
	Week 8	Tezepelumab	12	10 (83.3)	-0.23 (0.73)	-1.9	-0.71	0.00	0.29	0.6	0.10 [-0.76, 0.95]
		Placebo	11	11 (100.0)	-0.30 (0.85)	-1.9	-0.92	-0.29	0.43	1.0	
	Week 9	Tezepelumab	12	12 (100.0)	-0.14 (0.84)	-1.9	-0.75	0.00	0.32	1.2	0.11 [-0.70, 0.93]
		Placebo	11	11 (100.0)	-0.25 (1.14)	-2.7	-1.00	-0.07	0.43	1.4	
	Week 10	Tezepelumab	12	12 (100.0)	-0.12 (0.86)	-1.9	-0.75	-0.04	0.49	1.1	0.19 [-0.65, 1.03]
		Placebo	11	10 (90.9)	-0.30 (1.01)	-2.1	-0.79	-0.40	0.29	1.4	
	Week 11	Tezepelumab	12	12 (100.0)	-0.16 (0.76)	-1.9	-0.54	-0.07	0.29	1.1	0.32 [-0.52, 1.17]
		Placebo	11	10 (90.9)	-0.45 (1.07)	-2.6	-0.88	-0.54	0.50	1.1	
	Week 12	Tezepelumab	12	11 (91.7)	-0.09 (1.03)	-1.9	-0.71	-0.07	0.64	2.1	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.33 (0.94)	-2.1	-1.00	-0.07	0.57	0.9	
	Week 13	Tezepelumab	12	11 (91.7)	-0.02 (1.01)	-1.9	-0.71	0.00	0.57	1.9	0.28 [-0.56, 1.12]
		Placebo	11	11 (100.0)	-0.30 (0.99)	-1.9	-1.00	-0.14	0.27	1.6	
	Week 14	Tezepelumab	12	11 (91.7)	-0.23 (0.93)	-1.9	-0.79	-0.07	0.14	1.4	0.15 [-0.69, 0.99]
		Placebo	11	11 (100.0)	-0.37 (0.96)	-1.6	-1.00	-0.43	0.00	1.9	
	Week 15	Tezepelumab	12	11 (91.7)	-0.35 (0.86)	-1.9	-1.00	-0.29	0.07	1.1	0.12 [-0.72, 0.96]
		Placebo	11	11 (100.0)	-0.45 (0.77)	-1.6	-1.00	-0.43	0.29	0.7	
	Week 16	Tezepelumab	12	11 (91.7)	-0.26 (0.86)	-1.9	-0.83	-0.20	0.07	1.3	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.53 (0.99)	-2.4	-1.00	-0.50	-0.01	1.3	
	Week 17	Tezepelumab	12	11 (91.7)	-0.27 (0.86)	-1.9	-0.86	0.00	0.57	0.7	0.37 [-0.47, 1.22]
		Placebo	11	11 (100.0)	-0.63 (1.05)	-2.9	-1.00	-0.71	-0.01	1.0	
	Week 18	Tezepelumab	12	11 (91.7)	-0.23 (0.99)	-1.9	-1.00	0.00	0.64	1.4	0.40 [-0.44, 1.25]
		Placebo	11	11 (100.0)	-0.61 (0.89)	-2.5	-1.00	-0.43	0.00	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	12	11 (91.7)	-0.29 (1.08)	-1.9	-1.07	-0.67	0.71	1.8	0.34 [-0.50, 1.18]
		Placebo	11	11 (100.0)	-0.63 (0.88)	-2.3	-1.08	-0.50	0.00	1.0	
	Week 20	Tezepelumab	12	11 (91.7)	-0.33 (1.02)	-1.9	-1.14	-0.43	0.64	1.5	0.32 [-0.52, 1.16]
		Placebo	11	11 (100.0)	-0.62 (0.78)	-2.0	-1.17	-0.50	0.00	0.6	
	Week 21	Tezepelumab	12	11 (91.7)	-0.27 (1.12)	-1.9	-1.00	-0.79	0.57	1.6	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.57 (0.97)	-2.4	-1.27	-0.50	0.36	0.9	
	Week 22	Tezepelumab	12	11 (91.7)	-0.41 (0.92)	-1.8	-1.29	-0.64	0.57	0.9	0.23 [-0.61, 1.06]
		Placebo	11	11 (100.0)	-0.60 (0.78)	-2.0	-1.00	-0.58	-0.07	0.5	
	Week 23	Tezepelumab	12	11 (91.7)	-0.35 (1.01)	-1.9	-1.29	-0.50	0.86	1.0	0.26 [-0.58, 1.09]
		Placebo	11	11 (100.0)	-0.60 (0.95)	-2.5	-1.00	-0.67	0.06	0.8	
	Week 24	Tezepelumab	12	11 (91.7)	-0.27 (1.09)	-1.9	-1.00	-0.64	0.92	1.7	0.26 [-0.58, 1.10]
		Placebo	11	11 (100.0)	-0.53 (0.91)	-2.1	-1.00	-0.50	-0.01	1.1	
	Week 25	Tezepelumab	12	11 (91.7)	-0.13 (1.40)	-1.9	-1.00	-0.57	1.25	2.8	0.46 [-0.38, 1.31]
		Placebo	11	11 (100.0)	-0.70 (1.04)	-3.2	-1.00	-0.43	0.00	0.8	
	Week 26	Tezepelumab	12	11 (91.7)	-0.20 (1.15)	-1.9	-1.00	-0.71	1.08	1.9	0.43 [-0.41, 1.28]
		Placebo	11	11 (100.0)	-0.64 (0.88)	-2.7	-1.00	-0.50	-0.07	0.6	
	Week 27	Tezepelumab	12	10 (83.3)	-0.09 (1.33)	-1.9	-1.00	-0.31	1.50	1.7	0.38 [-0.49, 1.24]
		Placebo	11	11 (100.0)	-0.51 (0.84)	-2.3	-1.00	-0.14	0.00	0.7	
	Week 28	Tezepelumab	12	9 (75.0)	-0.01 (1.30)	-1.9	-0.71	0.00	1.36	1.6	0.36 [-0.53, 1.25]
		Placebo	11	11 (100.0)	-0.40 (0.89)	-2.1	-1.00	-0.42	0.14	0.9	
	Week 29	Tezepelumab	12	8 (66.7)	-0.24 (1.26)	-1.9	-1.13	-0.39	0.57	1.9	0.11 [-0.80, 1.02]
		Placebo	11	11 (100.0)	-0.36 (0.99)	-2.3	-1.00	-0.35	0.70	0.9	
	Week 30	Tezepelumab	12	10 (83.3)	-0.13 (1.32)	-1.9	-0.79	-0.33	1.00	1.9	0.43 [-0.43, 1.30]
		Placebo	11	11 (100.0)	-0.60 (0.80)	-2.3	-1.00	-0.43	0.00	0.4	
	Week 31	Tezepelumab	12	9 (75.0)	-0.12 (1.32)	-1.9	-0.79	-0.07	1.00	1.7	0.42 [-0.47, 1.31]
		Placebo	11	11 (100.0)	-0.56 (0.80)	-2.1	-1.00	-0.42	0.00	0.7	
	Week 32	Tezepelumab	12	10 (83.3)	-0.11 (1.28)	-2.0	-0.79	0.00	0.86	1.8	0.41 [-0.46, 1.27]
		Placebo	11	11 (100.0)	-0.52 (0.71)	-1.7	-1.00	-0.43	0.00	0.6	
	Week 33	Tezepelumab	12	10 (83.3)	-0.14 (1.26)	-1.9	-0.79	-0.08	0.93	2.0	0.39 [-0.48, 1.25]
		Placebo	11	11 (100.0)	-0.57 (0.95)	-2.6	-1.00	-0.64	0.06	0.8	
	Week 34	Tezepelumab	12	10 (83.3)	-0.12 (1.27)	-1.9	-0.79	-0.14	0.90	2.1	0.38 [-0.49, 1.24]
		Placebo	11	11 (100.0)	-0.51 (0.76)	-1.5	-1.00	-0.50	0.00	0.9	
	Week 35	Tezepelumab	12	10 (83.3)	-0.22 (1.22)	-2.0	-0.79	-0.25	0.50	1.9	0.37 [-0.49, 1.24]
		Placebo	11	11 (100.0)	-0.59 (0.71)	-1.5	-1.00	-0.85	0.00	0.6	
	Week 36	Tezepelumab	12	10 (83.3)	-0.28 (1.20)	-2.0	-0.93	-0.36	0.58	1.8	0.15 [-0.71, 1.00]
		Placebo	11	11 (100.0)	-0.43 (0.90)	-1.5	-1.00	-0.83	0.79	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMH0: Course of ASD weekly chest tightness score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	12	9 (75.0)	-0.08 (1.30)	-1.9	-0.79	0.36	0.71	1.7	0.41 [-0.48, 1.31]
		Placebo	11	11 (100.0)	-0.55 (0.96)	-2.2	-1.00	-0.86	0.50	0.9	
	Week 38	Tezepelumab	12	9 (75.0)	-0.10 (1.38)	-2.1	-0.79	0.21	0.79	2.0	0.37 [-0.51, 1.26]
		Placebo	11	11 (100.0)	-0.54 (0.96)	-2.4	-1.00	-0.43	0.36	0.9	
	Week 39	Tezepelumab	12	9 (75.0)	-0.11 (1.40)	-2.1	-0.79	0.00	0.79	2.0	0.25 [-0.66, 1.15]
		Placebo	11	10 (90.9)	-0.40 (0.88)	-1.5	-1.00	-0.76	0.71	0.9	
	Week 40	Tezepelumab	12	9 (75.0)	-0.12 (1.38)	-2.1	-0.79	0.00	0.50	2.0	0.28 [-0.61, 1.16]
		Placebo	11	11 (100.0)	-0.45 (1.06)	-1.9	-1.42	-0.63	0.92	1.0	
	Week 41	Tezepelumab	12	8 (66.7)	-0.05 (1.43)	-1.9	-1.30	-0.07	1.25	1.7	0.31 [-0.63, 1.24]
		Placebo	11	10 (90.9)	-0.45 (1.17)	-2.5	-1.25	-0.49	0.92	1.0	
	Week 42	Tezepelumab	12	8 (66.7)	-0.25 (1.30)	-2.0	-1.32	-0.14	0.71	1.5	0.28 [-0.63, 1.20]
		Placebo	11	11 (100.0)	-0.57 (1.03)	-2.3	-1.43	-0.63	0.71	0.9	
	Week 43	Tezepelumab	12	8 (66.7)	-0.08 (1.51)	-2.1	-1.33	-0.18	1.35	1.8	0.30 [-0.61, 1.22]
		Placebo	11	11 (100.0)	-0.47 (1.11)	-2.3	-1.50	-0.43	0.92	1.1	
	Week 44	Tezepelumab	12	8 (66.7)	-0.21 (1.41)	-2.1	-1.32	-0.29	0.96	1.7	0.22 [-0.70, 1.13]
		Placebo	11	11 (100.0)	-0.47 (1.08)	-2.4	-1.50	-0.40	0.64	1.0	
	Week 45	Tezepelumab	12	8 (66.7)	-0.19 (1.41)	-2.1	-1.32	-0.29	1.07	1.6	0.36 [-0.58, 1.30]
		Placebo	11	10 (90.9)	-0.65 (1.15)	-3.1	-1.50	-0.39	0.36	0.8	
	Week 46	Tezepelumab	12	7 (58.3)	-0.02 (1.17)	-1.9	-0.79	0.21	1.07	1.5	0.66 [-0.31, 1.64]
		Placebo	11	11 (100.0)	-0.67 (0.85)	-2.4	-1.50	-0.42	-0.08	0.6	
	Week 47	Tezepelumab	12	8 (66.7)	-0.24 (1.29)	-1.9	-1.32	-0.32	0.88	1.5	0.48 [-0.44, 1.41]
		Placebo	11	11 (100.0)	-0.74 (0.82)	-2.4	-1.50	-0.75	-0.07	0.3	
	Week 48	Tezepelumab	12	7 (58.3)	0.00 (1.25)	-2.0	-0.79	0.36	1.30	1.5	0.74 [-0.24, 1.72]
		Placebo	11	11 (100.0)	-0.72 (0.77)	-2.1	-1.50	-0.58	-0.08	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	12	12 (100.0)	-0.31 (0.23)	(-0.76, 0.14)	-0.25 (0.33)	(-0.90, 0.41)	0.454
	Placebo	11	11 (100.0)	-0.07 (0.23)	(-0.53, 0.40)			
Week 2	Tezepelumab	12	12 (100.0)	-0.31 (0.23)	(-0.76, 0.14)	-0.18 (0.33)	(-0.84, 0.48)	0.587
	Placebo	11	10 (90.9)	-0.13 (0.24)	(-0.60, 0.34)			
Week 3	Tezepelumab	12	12 (100.0)	-0.32 (0.23)	(-0.77, 0.13)	-0.11 (0.33)	(-0.76, 0.55)	0.751
	Placebo	11	10 (90.9)	-0.21 (0.24)	(-0.68, 0.26)			
Week 4	Tezepelumab	12	11 (91.7)	-0.33 (0.23)	(-0.78, 0.12)	-0.11 (0.33)	(-0.76, 0.55)	0.751
	Placebo	11	11 (100.0)	-0.22 (0.23)	(-0.69, 0.24)			
Week 5	Tezepelumab	12	11 (91.7)	-0.37 (0.23)	(-0.82, 0.08)	-0.12 (0.33)	(-0.78, 0.54)	0.713
	Placebo	11	11 (100.0)	-0.25 (0.23)	(-0.71, 0.22)			
Week 6	Tezepelumab	12	11 (91.7)	-0.42 (0.23)	(-0.87, 0.03)	-0.15 (0.33)	(-0.81, 0.50)	0.642
	Placebo	11	11 (100.0)	-0.26 (0.23)	(-0.73, 0.20)			
Week 7	Tezepelumab	12	11 (91.7)	-0.41 (0.23)	(-0.86, 0.04)	-0.12 (0.33)	(-0.78, 0.54)	0.711
	Placebo	11	11 (100.0)	-0.29 (0.23)	(-0.76, 0.18)			
Week 8	Tezepelumab	12	10 (83.3)	-0.43 (0.23)	(-0.88, 0.02)	-0.30 (0.33)	(-0.96, 0.36)	0.371
	Placebo	11	11 (100.0)	-0.13 (0.23)	(-0.60, 0.33)			
Week 9	Tezepelumab	12	12 (100.0)	-0.35 (0.23)	(-0.79, 0.10)	-0.26 (0.33)	(-0.92, 0.39)	0.428
	Placebo	11	11 (100.0)	-0.08 (0.23)	(-0.55, 0.38)			
Week 10	Tezepelumab	12	12 (100.0)	-0.33 (0.23)	(-0.78, 0.12)	-0.26 (0.33)	(-0.92, 0.39)	0.429
	Placebo	11	10 (90.9)	-0.07 (0.24)	(-0.54, 0.40)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	12	12 (100.0)	-0.36 (0.23)	(-0.81, 0.09)	-0.17 (0.33)	(-0.82, 0.49)	0.616
	Placebo	11	10 (90.9)	-0.20 (0.24)	(-0.66, 0.27)			
Week 12	Tezepelumab	12	11 (91.7)	-0.27 (0.23)	(-0.72, 0.19)	-0.11 (0.33)	(-0.76, 0.55)	0.747
	Placebo	11	11 (100.0)	-0.16 (0.23)	(-0.63, 0.31)			
Week 13	Tezepelumab	12	11 (91.7)	-0.20 (0.23)	(-0.65, 0.26)	-0.07 (0.33)	(-0.73, 0.59)	0.833
	Placebo	11	11 (100.0)	-0.13 (0.23)	(-0.59, 0.34)			
Week 14	Tezepelumab	12	11 (91.7)	-0.40 (0.23)	(-0.86, 0.05)	-0.21 (0.33)	(-0.87, 0.45)	0.535
	Placebo	11	11 (100.0)	-0.20 (0.23)	(-0.66, 0.27)			
Week 15	Tezepelumab	12	11 (91.7)	-0.52 (0.23)	(-0.98, -0.07)	-0.25 (0.33)	(-0.91, 0.41)	0.457
	Placebo	11	11 (100.0)	-0.28 (0.23)	(-0.74, 0.19)			
Week 16	Tezepelumab	12	11 (91.7)	-0.43 (0.23)	(-0.89, 0.03)	-0.08 (0.33)	(-0.74, 0.58)	0.815
	Placebo	11	11 (100.0)	-0.35 (0.23)	(-0.82, 0.11)			
Week 17	Tezepelumab	12	11 (91.7)	-0.44 (0.23)	(-0.90, 0.02)	0.02 (0.33)	(-0.64, 0.68)	0.960
	Placebo	11	11 (100.0)	-0.46 (0.23)	(-0.92, 0.01)			
Week 18	Tezepelumab	12	11 (91.7)	-0.40 (0.23)	(-0.86, 0.06)	0.04 (0.33)	(-0.63, 0.70)	0.912
	Placebo	11	11 (100.0)	-0.44 (0.23)	(-0.91, 0.03)			
Week 19	Tezepelumab	12	11 (91.7)	-0.46 (0.23)	(-0.92, -0.00)	-0.01 (0.33)	(-0.67, 0.66)	0.986
	Placebo	11	11 (100.0)	-0.46 (0.23)	(-0.92, 0.01)			
Week 20	Tezepelumab	12	11 (91.7)	-0.49 (0.23)	(-0.95, -0.03)	-0.05 (0.33)	(-0.71, 0.62)	0.888
	Placebo	11	11 (100.0)	-0.45 (0.23)	(-0.91, 0.02)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	12	11 (91.7)	-0.43 (0.23)	(-0.89, 0.03)	-0.03 (0.33)	(-0.69, 0.63)	0.926
	Placebo	11	11 (100.0)	-0.40 (0.23)	(-0.87, 0.07)			
Week 22	Tezepelumab	12	11 (91.7)	-0.58 (0.23)	(-1.04, -0.11)	-0.14 (0.33)	(-0.81, 0.52)	0.668
	Placebo	11	11 (100.0)	-0.43 (0.23)	(-0.90, 0.03)			
Week 23	Tezepelumab	12	11 (91.7)	-0.51 (0.23)	(-0.98, -0.05)	-0.08 (0.33)	(-0.75, 0.58)	0.804
	Placebo	11	11 (100.0)	-0.43 (0.23)	(-0.90, 0.04)			
Week 24	Tezepelumab	12	11 (91.7)	-0.43 (0.23)	(-0.89, 0.04)	-0.07 (0.33)	(-0.73, 0.60)	0.838
	Placebo	11	11 (100.0)	-0.36 (0.23)	(-0.82, 0.11)			
Week 25	Tezepelumab	12	11 (91.7)	-0.29 (0.23)	(-0.75, 0.17)	0.24 (0.33)	(-0.42, 0.90)	0.476
	Placebo	11	11 (100.0)	-0.53 (0.23)	(-1.00, -0.06)			
Week 26	Tezepelumab	12	11 (91.7)	-0.35 (0.23)	(-0.82, 0.11)	0.11 (0.33)	(-0.55, 0.78)	0.736
	Placebo	11	11 (100.0)	-0.47 (0.23)	(-0.93, -0.00)			
Week 27	Tezepelumab	12	10 (83.3)	-0.31 (0.23)	(-0.78, 0.16)	0.02 (0.34)	(-0.64, 0.69)	0.948
	Placebo	11	11 (100.0)	-0.33 (0.23)	(-0.80, 0.13)			
Week 28	Tezepelumab	12	9 (75.0)	-0.31 (0.24)	(-0.78, 0.16)	-0.09 (0.34)	(-0.76, 0.58)	0.792
	Placebo	11	11 (100.0)	-0.22 (0.23)	(-0.69, 0.24)			
Week 29	Tezepelumab	12	8 (66.7)	-0.33 (0.24)	(-0.80, 0.15)	-0.14 (0.34)	(-0.81, 0.54)	0.685
	Placebo	11	11 (100.0)	-0.19 (0.23)	(-0.66, 0.28)			
Week 30	Tezepelumab	12	10 (83.3)	-0.35 (0.24)	(-0.83, 0.12)	0.07 (0.34)	(-0.60, 0.75)	0.827
	Placebo	11	11 (100.0)	-0.43 (0.23)	(-0.89, 0.04)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	12	9 (75.0)	-0.36 (0.24)	(-0.83, 0.12)	0.03 (0.34)	(-0.64, 0.71)	0.926
	Placebo	11	11 (100.0)	-0.39 (0.23)	(-0.85, 0.08)			
Week 32	Tezepelumab	12	10 (83.3)	-0.33 (0.24)	(-0.81, 0.15)	0.02 (0.34)	(-0.66, 0.70)	0.953
	Placebo	11	11 (100.0)	-0.35 (0.23)	(-0.82, 0.12)			
Week 33	Tezepelumab	12	10 (83.3)	-0.36 (0.24)	(-0.84, 0.12)	0.04 (0.34)	(-0.64, 0.71)	0.918
	Placebo	11	11 (100.0)	-0.40 (0.23)	(-0.86, 0.07)			
Week 34	Tezepelumab	12	10 (83.3)	-0.35 (0.24)	(-0.83, 0.13)	-0.01 (0.34)	(-0.69, 0.67)	0.983
	Placebo	11	11 (100.0)	-0.34 (0.23)	(-0.81, 0.13)			
Week 35	Tezepelumab	12	10 (83.3)	-0.45 (0.24)	(-0.93, 0.04)	-0.03 (0.34)	(-0.71, 0.65)	0.931
	Placebo	11	11 (100.0)	-0.42 (0.23)	(-0.88, 0.05)			
Week 36	Tezepelumab	12	10 (83.3)	-0.50 (0.24)	(-0.99, -0.02)	-0.24 (0.34)	(-0.92, 0.44)	0.481
	Placebo	11	11 (100.0)	-0.26 (0.23)	(-0.73, 0.21)			
Week 37	Tezepelumab	12	9 (75.0)	-0.37 (0.25)	(-0.86, 0.12)	0.00 (0.34)	(-0.68, 0.69)	0.992
	Placebo	11	11 (100.0)	-0.38 (0.23)	(-0.84, 0.09)			
Week 38	Tezepelumab	12	9 (75.0)	-0.39 (0.25)	(-0.88, 0.11)	-0.02 (0.34)	(-0.71, 0.66)	0.951
	Placebo	11	11 (100.0)	-0.36 (0.23)	(-0.83, 0.10)			
Week 39	Tezepelumab	12	9 (75.0)	-0.39 (0.25)	(-0.89, 0.10)	-0.00 (0.35)	(-0.69, 0.69)	0.993
	Placebo	11	10 (90.9)	-0.39 (0.24)	(-0.86, 0.08)			
Week 40	Tezepelumab	12	9 (75.0)	-0.39 (0.25)	(-0.89, 0.10)	-0.11 (0.35)	(-0.80, 0.58)	0.749
	Placebo	11	11 (100.0)	-0.28 (0.23)	(-0.75, 0.19)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC_IBMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	12	8 (66.7)	-0.30 (0.25)	(-0.81, 0.20)	0.02 (0.35)	(-0.67, 0.72)	0.952
	Placebo	11	10 (90.9)	-0.33 (0.24)	(-0.79, 0.14)			
Week 42	Tezepelumab	12	8 (66.7)	-0.50 (0.26)	(-1.00, 0.01)	-0.09 (0.35)	(-0.79, 0.60)	0.789
	Placebo	11	11 (100.0)	-0.40 (0.23)	(-0.87, 0.06)			
Week 43	Tezepelumab	12	8 (66.7)	-0.32 (0.26)	(-0.83, 0.19)	-0.02 (0.35)	(-0.72, 0.68)	0.951
	Placebo	11	11 (100.0)	-0.30 (0.23)	(-0.76, 0.17)			
Week 44	Tezepelumab	12	8 (66.7)	-0.44 (0.26)	(-0.96, 0.08)	-0.14 (0.35)	(-0.84, 0.56)	0.694
	Placebo	11	11 (100.0)	-0.30 (0.23)	(-0.77, 0.17)			
Week 45	Tezepelumab	12	8 (66.7)	-0.42 (0.26)	(-0.94, 0.10)	0.05 (0.36)	(-0.66, 0.75)	0.897
	Placebo	11	10 (90.9)	-0.47 (0.24)	(-0.93, 0.00)			
Week 46	Tezepelumab	12	7 (58.3)	-0.49 (0.27)	(-1.02, 0.03)	0.01 (0.36)	(-0.70, 0.72)	0.984
	Placebo	11	11 (100.0)	-0.50 (0.23)	(-0.97, -0.04)			
Week 47	Tezepelumab	12	8 (66.7)	-0.46 (0.27)	(-0.98, 0.07)	0.11 (0.36)	(-0.60, 0.82)	0.755
	Placebo	11	11 (100.0)	-0.57 (0.23)	(-1.04, -0.10)			
Week 48	Tezepelumab	12	7 (58.3)	-0.43 (0.27)	(-0.96, 0.11)	0.12 (0.36)	(-0.59, 0.84)	0.731
	Placebo	11	11 (100.0)	-0.55 (0.23)	(-1.02, -0.08)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	55	55 (100.0)	0.94 (0.75)	0.0	0.43	0.86	1.00	3.3	
		Placebo	40	40 (100.0)	0.87 (0.63)	0.0	0.43	1.00	1.21	3.0	
	Week 1	Tezepelumab	55	54 (98.2)	0.69 (0.73)	0.0	0.14	0.57	1.00	3.3	
		Placebo	40	40 (100.0)	0.80 (0.68)	0.0	0.29	0.79	1.07	3.0	
	Week 2	Tezepelumab	55	54 (98.2)	0.67 (0.70)	0.0	0.00	0.57	1.00	3.0	
		Placebo	40	39 (97.5)	0.72 (0.62)	0.0	0.14	0.86	1.00	3.0	
	Week 3	Tezepelumab	55	55 (100.0)	0.63 (0.64)	0.0	0.00	0.57	1.00	2.9	
		Placebo	40	38 (95.0)	0.69 (0.63)	0.0	0.14	0.86	1.00	3.0	
	Week 4	Tezepelumab	55	55 (100.0)	0.60 (0.63)	0.0	0.00	0.71	1.00	3.0	
		Placebo	40	39 (97.5)	0.68 (0.66)	0.0	0.14	0.71	1.00	2.7	
	Week 5	Tezepelumab	55	54 (98.2)	0.50 (0.60)	0.0	0.00	0.29	0.86	3.0	
		Placebo	40	39 (97.5)	0.63 (0.66)	0.0	0.00	0.57	1.00	2.7	
	Week 6	Tezepelumab	55	53 (96.4)	0.59 (0.68)	0.0	0.00	0.43	1.00	2.9	
		Placebo	40	40 (100.0)	0.73 (0.71)	0.0	0.00	0.64	1.00	2.7	
	Week 7	Tezepelumab	55	53 (96.4)	0.55 (0.68)	0.0	0.00	0.29	1.00	3.4	
		Placebo	40	40 (100.0)	0.68 (0.76)	0.0	0.00	0.44	1.00	2.7	
	Week 8	Tezepelumab	55	53 (96.4)	0.49 (0.65)	0.0	0.00	0.29	0.86	3.3	
		Placebo	40	39 (97.5)	0.68 (0.72)	0.0	0.00	0.71	1.00	2.6	
	Week 9	Tezepelumab	55	55 (100.0)	0.41 (0.54)	0.0	0.00	0.14	0.86	2.0	
		Placebo	40	40 (100.0)	0.70 (0.73)	0.0	0.00	0.61	1.00	2.7	
	Week 10	Tezepelumab	55	54 (98.2)	0.45 (0.62)	0.0	0.00	0.14	0.71	3.1	
		Placebo	40	40 (100.0)	0.62 (0.67)	0.0	0.00	0.50	1.00	2.6	
	Week 11	Tezepelumab	55	54 (98.2)	0.44 (0.65)	0.0	0.00	0.14	0.71	3.3	
		Placebo	40	40 (100.0)	0.59 (0.67)	0.0	0.00	0.29	1.00	2.4	
	Week 12	Tezepelumab	55	53 (96.4)	0.44 (0.57)	0.0	0.00	0.14	0.71	2.3	
		Placebo	40	38 (95.0)	0.56 (0.71)	0.0	0.00	0.14	1.00	3.0	
	Week 13	Tezepelumab	55	51 (92.7)	0.46 (0.56)	0.0	0.00	0.29	1.00	2.6	
		Placebo	40	39 (97.5)	0.53 (0.67)	0.0	0.00	0.29	1.00	2.3	
	Week 14	Tezepelumab	55	52 (94.5)	0.47 (0.60)	0.0	0.00	0.14	0.93	2.9	
		Placebo	40	38 (95.0)	0.54 (0.66)	0.0	0.00	0.14	1.00	2.1	
	Week 15	Tezepelumab	55	52 (94.5)	0.39 (0.50)	0.0	0.00	0.15	0.79	2.2	
		Placebo	40	39 (97.5)	0.58 (0.80)	0.0	0.00	0.17	1.00	3.2	
	Week 16	Tezepelumab	55	53 (96.4)	0.43 (0.54)	0.0	0.00	0.14	0.86	2.4	
		Placebo	40	38 (95.0)	0.51 (0.65)	0.0	0.00	0.15	1.00	2.6	
Week 17	Tezepelumab	55	53 (96.4)	0.43 (0.57)	0.0	0.00	0.20	0.71	2.9		
	Placebo	40	38 (95.0)	0.55 (0.66)	0.0	0.00	0.21	1.00	2.2		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMH0: Course of ASD weekly waking score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	55	53 (96.4)	0.48 (0.66)	0.0	0.00	0.14	0.86	3.0	
		Placebo	40	40 (100.0)	0.59 (0.73)	0.0	0.00	0.29	1.00	2.5	
	Week 19	Tezepelumab	55	53 (96.4)	0.43 (0.64)	0.0	0.00	0.14	0.86	3.3	
		Placebo	40	40 (100.0)	0.56 (0.64)	0.0	0.00	0.29	1.00	2.0	
	Week 20	Tezepelumab	55	52 (94.5)	0.41 (0.63)	0.0	0.00	0.00	0.79	3.1	
		Placebo	40	39 (97.5)	0.55 (0.64)	0.0	0.00	0.17	1.00	2.0	
	Week 21	Tezepelumab	55	50 (90.9)	0.42 (0.63)	0.0	0.00	0.00	0.86	3.0	
		Placebo	40	39 (97.5)	0.51 (0.64)	0.0	0.00	0.14	1.00	2.3	
	Week 22	Tezepelumab	55	52 (94.5)	0.42 (0.63)	0.0	0.00	0.14	0.86	3.3	
		Placebo	40	39 (97.5)	0.55 (0.69)	0.0	0.00	0.14	1.00	2.3	
	Week 23	Tezepelumab	55	52 (94.5)	0.45 (0.69)	0.0	0.00	0.00	0.79	3.3	
		Placebo	40	37 (92.5)	0.50 (0.67)	0.0	0.00	0.14	1.00	2.5	
	Week 24	Tezepelumab	55	53 (96.4)	0.40 (0.63)	0.0	0.00	0.14	0.57	3.3	
		Placebo	40	37 (92.5)	0.49 (0.55)	0.0	0.00	0.29	1.00	2.0	
	Week 25	Tezepelumab	55	50 (90.9)	0.37 (0.54)	0.0	0.00	0.00	0.71	2.6	
		Placebo	40	38 (95.0)	0.49 (0.64)	0.0	0.00	0.00	1.00	2.3	
	Week 26	Tezepelumab	55	53 (96.4)	0.48 (0.70)	0.0	0.00	0.14	0.86	3.1	
		Placebo	40	37 (92.5)	0.47 (0.55)	0.0	0.00	0.29	1.00	2.1	
	Week 27	Tezepelumab	55	53 (96.4)	0.47 (0.70)	0.0	0.00	0.14	0.83	3.4	
		Placebo	40	36 (90.0)	0.47 (0.55)	0.0	0.00	0.21	0.93	2.0	
	Week 28	Tezepelumab	55	53 (96.4)	0.49 (0.64)	0.0	0.00	0.00	1.00	3.0	
		Placebo	40	37 (92.5)	0.48 (0.54)	0.0	0.00	0.29	1.00	1.8	
	Week 29	Tezepelumab	55	52 (94.5)	0.37 (0.60)	0.0	0.00	0.00	0.64	2.9	
		Placebo	40	37 (92.5)	0.47 (0.57)	0.0	0.00	0.14	1.00	2.3	
	Week 30	Tezepelumab	55	52 (94.5)	0.41 (0.62)	0.0	0.00	0.00	0.86	2.7	
		Placebo	40	37 (92.5)	0.52 (0.66)	0.0	0.00	0.14	1.00	2.7	
	Week 31	Tezepelumab	55	54 (98.2)	0.37 (0.52)	0.0	0.00	0.14	0.71	2.6	
		Placebo	40	38 (95.0)	0.56 (0.73)	0.0	0.00	0.00	1.00	3.0	
	Week 32	Tezepelumab	55	53 (96.4)	0.40 (0.58)	0.0	0.00	0.00	0.71	2.1	
		Placebo	40	38 (95.0)	0.52 (0.68)	0.0	0.00	0.14	1.00	3.0	
	Week 33	Tezepelumab	55	53 (96.4)	0.47 (0.60)	0.0	0.00	0.17	0.83	2.7	
		Placebo	40	38 (95.0)	0.55 (0.71)	0.0	0.00	0.17	1.00	3.0	
	Week 34	Tezepelumab	55	54 (98.2)	0.42 (0.61)	0.0	0.00	0.00	0.86	3.0	
		Placebo	40	38 (95.0)	0.56 (0.71)	0.0	0.00	0.18	1.00	3.0	
	Week 35	Tezepelumab	55	53 (96.4)	0.42 (0.64)	0.0	0.00	0.00	0.86	3.1	
		Placebo	40	36 (90.0)	0.48 (0.66)	0.0	0.00	0.00	1.00	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	55	52 (94.5)	0.43 (0.63)	0.0	0.00	0.07	0.92	3.0	
		Placebo	40	38 (95.0)	0.57 (0.68)	0.0	0.00	0.31	1.00	2.9	
	Week 37	Tezepelumab	55	52 (94.5)	0.44 (0.61)	0.0	0.00	0.14	0.83	2.6	
		Placebo	40	38 (95.0)	0.54 (0.71)	0.0	0.00	0.18	1.00	3.0	
	Week 38	Tezepelumab	55	50 (90.9)	0.46 (0.62)	0.0	0.00	0.15	0.86	2.9	
		Placebo	40	38 (95.0)	0.51 (0.69)	0.0	0.00	0.14	1.00	3.0	
	Week 39	Tezepelumab	55	52 (94.5)	0.43 (0.65)	0.0	0.00	0.00	0.86	3.1	
		Placebo	40	38 (95.0)	0.53 (0.70)	0.0	0.00	0.14	1.00	3.0	
	Week 40	Tezepelumab	55	53 (96.4)	0.44 (0.63)	0.0	0.00	0.00	0.86	3.0	
		Placebo	40	38 (95.0)	0.56 (0.78)	0.0	0.00	0.15	1.00	3.0	
	Week 41	Tezepelumab	55	53 (96.4)	0.44 (0.62)	0.0	0.00	0.14	1.00	2.6	
		Placebo	40	37 (92.5)	0.57 (0.77)	0.0	0.00	0.29	1.00	3.0	
	Week 42	Tezepelumab	55	50 (90.9)	0.49 (0.75)	0.0	0.00	0.00	1.00	3.0	
		Placebo	40	38 (95.0)	0.54 (0.72)	0.0	0.00	0.14	1.00	3.0	
	Week 43	Tezepelumab	55	51 (92.7)	0.44 (0.66)	0.0	0.00	0.00	1.00	3.3	
		Placebo	40	37 (92.5)	0.49 (0.67)	0.0	0.00	0.29	1.00	3.0	
	Week 44	Tezepelumab	55	51 (92.7)	0.40 (0.60)	0.0	0.00	0.00	1.00	2.9	
		Placebo	40	36 (90.0)	0.51 (0.67)	0.0	0.00	0.23	1.00	3.0	
	Week 45	Tezepelumab	55	51 (92.7)	0.39 (0.61)	0.0	0.00	0.00	0.86	2.9	
		Placebo	40	37 (92.5)	0.46 (0.66)	0.0	0.00	0.00	1.00	3.0	
	Week 46	Tezepelumab	55	52 (94.5)	0.43 (0.62)	0.0	0.00	0.07	0.93	3.0	
		Placebo	40	37 (92.5)	0.44 (0.64)	0.0	0.00	0.14	1.00	3.0	
	Week 47	Tezepelumab	55	50 (90.9)	0.40 (0.62)	0.0	0.00	0.00	0.83	2.9	
		Placebo	40	37 (92.5)	0.50 (0.66)	0.0	0.00	0.29	1.00	3.0	
	Week 48	Tezepelumab	55	52 (94.5)	0.43 (0.62)	0.0	0.00	0.07	0.85	3.0	
		Placebo	40	38 (95.0)	0.52 (0.71)	0.0	0.00	0.14	1.00	3.0	
	Week 49	Tezepelumab	55	52 (94.5)	0.45 (0.63)	0.0	0.00	0.00	1.00	3.0	
		Placebo	40	38 (95.0)	0.48 (0.72)	0.0	0.00	0.00	1.00	3.0	
	Week 50	Tezepelumab	55	51 (92.7)	0.40 (0.57)	0.0	0.00	0.00	1.00	2.3	
		Placebo	40	36 (90.0)	0.42 (0.69)	0.0	0.00	0.00	1.00	3.0	
	Week 51	Tezepelumab	55	47 (85.5)	0.42 (0.61)	0.0	0.00	0.00	0.80	2.7	
		Placebo	40	35 (87.5)	0.41 (0.66)	0.0	0.00	0.00	1.00	3.0	
	Week 52	Tezepelumab	55	43 (78.2)	0.36 (0.55)	0.0	0.00	0.00	0.83	2.4	
		Placebo	40	33 (82.5)	0.40 (0.66)	0.0	0.00	0.00	0.71	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMH0: Course of ASD weekly waking score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	55	54 (98.2)	-0.25 (0.53)	-2.6	-0.43	-0.14	0.00	0.6	-0.38 [-0.79, 0.03]
		Placebo	40	40 (100.0)	-0.07 (0.43)	-1.0	-0.22	0.00	0.00	1.5	
	Week 2	Tezepelumab	55	54 (98.2)	-0.27 (0.54)	-2.6	-0.57	-0.14	0.00	0.7	-0.29 [-0.70, 0.12]
		Placebo	40	39 (97.5)	-0.13 (0.38)	-1.3	-0.14	0.00	0.00	0.6	
	Week 3	Tezepelumab	55	55 (100.0)	-0.31 (0.52)	-2.6	-0.57	-0.14	0.00	0.6	-0.35 [-0.76, 0.07]
		Placebo	40	38 (95.0)	-0.14 (0.43)	-1.3	-0.14	0.00	0.00	0.9	
	Week 4	Tezepelumab	55	55 (100.0)	-0.34 (0.55)	-2.6	-0.71	-0.17	0.00	0.8	-0.34 [-0.75, 0.07]
		Placebo	40	39 (97.5)	-0.17 (0.44)	-1.4	-0.43	0.00	0.02	0.8	
	Week 5	Tezepelumab	55	54 (98.2)	-0.44 (0.57)	-2.6	-0.86	-0.29	0.00	0.5	-0.44 [-0.85, -0.02]
		Placebo	40	39 (97.5)	-0.21 (0.46)	-1.4	-0.43	-0.14	0.00	0.6	
	Week 6	Tezepelumab	55	53 (96.4)	-0.35 (0.52)	-2.6	-0.57	-0.17	0.00	0.4	-0.40 [-0.81, 0.02]
		Placebo	40	40 (100.0)	-0.14 (0.52)	-1.4	-0.43	0.00	0.14	0.9	
	Week 7	Tezepelumab	55	53 (96.4)	-0.36 (0.57)	-2.6	-0.69	-0.29	0.00	1.5	-0.33 [-0.74, 0.08]
		Placebo	40	40 (100.0)	-0.19 (0.49)	-1.4	-0.46	-0.14	0.00	1.3	
	Week 8	Tezepelumab	55	53 (96.4)	-0.46 (0.54)	-2.6	-0.71	-0.43	-0.09	0.9	-0.51 [-0.93, -0.09]
		Placebo	40	39 (97.5)	-0.18 (0.60)	-1.4	-0.50	-0.14	0.00	2.0	
	Week 9	Tezepelumab	55	55 (100.0)	-0.53 (0.54)	-2.6	-0.86	-0.43	-0.14	0.7	-0.62 [-1.03, -0.20]
		Placebo	40	40 (100.0)	-0.17 (0.62)	-1.4	-0.43	-0.14	0.00	1.7	
	Week 10	Tezepelumab	55	54 (98.2)	-0.51 (0.54)	-2.6	-0.86	-0.44	-0.14	0.6	-0.52 [-0.93, -0.10]
		Placebo	40	40 (100.0)	-0.24 (0.47)	-1.4	-0.50	-0.20	0.00	1.1	
	Week 11	Tezepelumab	55	54 (98.2)	-0.50 (0.57)	-2.6	-0.86	-0.43	0.00	0.6	-0.42 [-0.83, -0.00]
		Placebo	40	40 (100.0)	-0.28 (0.48)	-1.3	-0.57	-0.21	0.00	1.0	
	Week 12	Tezepelumab	55	53 (96.4)	-0.50 (0.58)	-2.6	-0.86	-0.43	-0.05	0.9	-0.40 [-0.83, 0.02]
		Placebo	40	38 (95.0)	-0.27 (0.56)	-1.3	-0.57	-0.15	0.00	2.0	
	Week 13	Tezepelumab	55	51 (92.7)	-0.47 (0.63)	-2.6	-1.00	-0.29	0.00	0.9	-0.26 [-0.68, 0.16]
		Placebo	40	39 (97.5)	-0.32 (0.49)	-1.3	-0.57	-0.29	0.00	1.3	
	Week 14	Tezepelumab	55	52 (94.5)	-0.50 (0.58)	-2.6	-0.98	-0.43	0.00	1.0	-0.37 [-0.79, 0.05]
		Placebo	40	38 (95.0)	-0.29 (0.55)	-1.4	-0.57	-0.21	0.00	1.1	
	Week 15	Tezepelumab	55	52 (94.5)	-0.50 (0.61)	-2.6	-0.93	-0.43	0.00	0.9	-0.36 [-0.78, 0.06]
		Placebo	40	39 (97.5)	-0.27 (0.62)	-1.4	-0.57	-0.29	0.00	2.2	
	Week 16	Tezepelumab	55	53 (96.4)	-0.48 (0.65)	-2.6	-1.00	-0.42	0.00	0.9	-0.26 [-0.68, 0.16]
		Placebo	40	38 (95.0)	-0.33 (0.49)	-1.4	-0.57	-0.29	0.00	1.1	
	Week 17	Tezepelumab	55	53 (96.4)	-0.48 (0.64)	-2.6	-0.86	-0.43	0.00	0.9	-0.33 [-0.75, 0.09]
		Placebo	40	38 (95.0)	-0.29 (0.51)	-1.4	-0.57	-0.14	0.00	1.0	
	Week 18	Tezepelumab	55	53 (96.4)	-0.46 (0.64)	-2.6	-0.86	-0.43	0.00	1.1	-0.30 [-0.71, 0.12]
		Placebo	40	40 (100.0)	-0.28 (0.54)	-1.4	-0.54	-0.14	0.00	1.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	55	53 (96.4)	-0.51 (0.60)	-2.6	-0.86	-0.43	0.00	0.7	-0.34 [-0.76, 0.07]
		Placebo	40	40 (100.0)	-0.31 (0.50)	-1.4	-0.57	-0.29	0.00	0.7	
	Week 20	Tezepelumab	55	52 (94.5)	-0.50 (0.61)	-2.6	-1.00	-0.43	-0.02	1.0	-0.28 [-0.70, 0.14]
		Placebo	40	39 (97.5)	-0.34 (0.54)	-1.6	-0.57	-0.14	0.00	0.7	
	Week 21	Tezepelumab	55	50 (90.9)	-0.50 (0.58)	-2.6	-0.86	-0.43	0.00	0.7	-0.28 [-0.70, 0.14]
		Placebo	40	39 (97.5)	-0.34 (0.49)	-1.4	-0.57	-0.26	0.00	0.7	
	Week 22	Tezepelumab	55	52 (94.5)	-0.49 (0.60)	-2.6	-0.93	-0.43	0.00	0.9	-0.32 [-0.74, 0.09]
		Placebo	40	39 (97.5)	-0.31 (0.52)	-1.6	-0.57	-0.14	0.00	1.2	
	Week 23	Tezepelumab	55	52 (94.5)	-0.47 (0.60)	-2.6	-0.86	-0.43	0.00	1.4	-0.27 [-0.69, 0.15]
		Placebo	40	37 (92.5)	-0.32 (0.50)	-1.6	-0.50	-0.14	0.00	0.7	
	Week 24	Tezepelumab	55	53 (96.4)	-0.51 (0.62)	-2.6	-0.86	-0.43	0.00	1.4	-0.37 [-0.79, 0.06]
		Placebo	40	37 (92.5)	-0.30 (0.50)	-1.6	-0.50	-0.14	0.00	0.6	
	Week 25	Tezepelumab	55	50 (90.9)	-0.57 (0.60)	-2.6	-1.00	-0.54	-0.14	0.7	-0.37 [-0.79, 0.06]
		Placebo	40	38 (95.0)	-0.36 (0.50)	-1.6	-0.57	-0.36	0.00	0.6	
	Week 26	Tezepelumab	55	53 (96.4)	-0.44 (0.66)	-2.6	-0.86	-0.29	0.00	1.2	-0.19 [-0.61, 0.23]
		Placebo	40	37 (92.5)	-0.32 (0.52)	-1.6	-0.57	-0.19	0.00	0.7	
	Week 27	Tezepelumab	55	53 (96.4)	-0.45 (0.66)	-2.6	-0.86	-0.43	0.00	1.0	-0.19 [-0.62, 0.23]
		Placebo	40	36 (90.0)	-0.33 (0.51)	-1.6	-0.57	-0.15	0.00	0.6	
	Week 28	Tezepelumab	55	53 (96.4)	-0.43 (0.63)	-2.6	-0.86	-0.43	0.00	1.3	-0.22 [-0.64, 0.20]
		Placebo	40	37 (92.5)	-0.29 (0.55)	-1.6	-0.57	-0.14	0.00	0.8	
	Week 29	Tezepelumab	55	52 (94.5)	-0.55 (0.56)	-2.6	-0.93	-0.44	-0.14	0.4	-0.45 [-0.87, -0.02]
		Placebo	40	37 (92.5)	-0.30 (0.56)	-1.4	-0.57	-0.14	0.00	0.9	
	Week 30	Tezepelumab	55	52 (94.5)	-0.55 (0.56)	-2.6	-0.98	-0.57	-0.14	0.6	-0.52 [-0.95, -0.09]
		Placebo	40	37 (92.5)	-0.25 (0.59)	-1.6	-0.50	-0.14	0.00	1.2	
	Week 31	Tezepelumab	55	54 (98.2)	-0.57 (0.62)	-2.6	-1.00	-0.43	-0.14	0.9	-0.47 [-0.89, -0.05]
		Placebo	40	38 (95.0)	-0.27 (0.63)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 32	Tezepelumab	55	53 (96.4)	-0.53 (0.60)	-2.6	-1.00	-0.57	0.00	0.4	-0.35 [-0.77, 0.07]
		Placebo	40	38 (95.0)	-0.31 (0.61)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 33	Tezepelumab	55	53 (96.4)	-0.50 (0.61)	-2.6	-1.00	-0.43	0.00	0.9	-0.35 [-0.77, 0.07]
		Placebo	40	38 (95.0)	-0.28 (0.59)	-1.4	-0.57	-0.27	0.00	1.6	
	Week 34	Tezepelumab	55	54 (98.2)	-0.52 (0.59)	-2.6	-0.86	-0.50	-0.14	1.0	-0.43 [-0.84, -0.01]
		Placebo	40	38 (95.0)	-0.27 (0.60)	-1.6	-0.57	-0.18	0.00	1.6	
	Week 35	Tezepelumab	55	53 (96.4)	-0.51 (0.62)	-2.6	-1.00	-0.43	-0.14	1.3	-0.32 [-0.74, 0.11]
		Placebo	40	36 (90.0)	-0.31 (0.61)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 36	Tezepelumab	55	52 (94.5)	-0.49 (0.58)	-2.6	-0.86	-0.43	-0.07	0.9	-0.41 [-0.83, 0.01]
		Placebo	40	38 (95.0)	-0.26 (0.56)	-1.4	-0.57	-0.14	0.00	1.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	55	52 (94.5)	-0.49 (0.59)	-2.6	-0.86	-0.43	0.00	0.9	-0.35 [-0.77, 0.07]
		Placebo	40	38 (95.0)	-0.29 (0.57)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 38	Tezepelumab	55	50 (90.9)	-0.48 (0.63)	-2.6	-0.86	-0.43	-0.14	1.3	-0.27 [-0.69, 0.16]
		Placebo	40	38 (95.0)	-0.32 (0.57)	-1.6	-0.57	-0.16	0.00	1.6	
	Week 39	Tezepelumab	55	52 (94.5)	-0.54 (0.58)	-2.6	-1.00	-0.46	-0.14	0.7	-0.41 [-0.83, 0.01]
		Placebo	40	38 (95.0)	-0.30 (0.60)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 40	Tezepelumab	55	53 (96.4)	-0.52 (0.61)	-2.6	-1.00	-0.47	-0.07	0.7	-0.40 [-0.82, 0.02]
		Placebo	40	38 (95.0)	-0.27 (0.64)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 41	Tezepelumab	55	53 (96.4)	-0.52 (0.59)	-2.6	-0.86	-0.57	0.00	0.7	-0.43 [-0.85, -0.00]
		Placebo	40	37 (92.5)	-0.26 (0.64)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 42	Tezepelumab	55	50 (90.9)	-0.42 (0.59)	-2.6	-0.86	-0.30	0.00	1.1	-0.22 [-0.65, 0.20]
		Placebo	40	38 (95.0)	-0.29 (0.57)	-1.5	-0.57	-0.14	0.00	1.6	
	Week 43	Tezepelumab	55	51 (92.7)	-0.50 (0.56)	-2.6	-0.88	-0.43	0.00	0.9	-0.40 [-0.83, 0.03]
		Placebo	40	37 (92.5)	-0.28 (0.54)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 44	Tezepelumab	55	51 (92.7)	-0.54 (0.60)	-2.6	-1.00	-0.57	-0.14	1.0	-0.45 [-0.88, -0.02]
		Placebo	40	36 (90.0)	-0.27 (0.57)	-1.4	-0.56	-0.14	0.00	1.6	
	Week 45	Tezepelumab	55	51 (92.7)	-0.55 (0.57)	-2.6	-1.00	-0.52	-0.14	0.9	-0.43 [-0.86, -0.00]
		Placebo	40	37 (92.5)	-0.31 (0.58)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 46	Tezepelumab	55	52 (94.5)	-0.50 (0.62)	-2.6	-0.93	-0.48	-0.14	0.9	-0.29 [-0.71, 0.14]
		Placebo	40	37 (92.5)	-0.33 (0.57)	-1.6	-0.57	-0.17	0.00	1.6	
	Week 47	Tezepelumab	55	50 (90.9)	-0.53 (0.60)	-2.6	-1.00	-0.57	-0.14	1.0	-0.44 [-0.87, -0.01]
		Placebo	40	37 (92.5)	-0.27 (0.57)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 48	Tezepelumab	55	52 (94.5)	-0.51 (0.63)	-2.6	-1.00	-0.43	0.00	0.7	-0.32 [-0.74, 0.10]
		Placebo	40	38 (95.0)	-0.31 (0.57)	-1.6	-0.57	-0.20	0.00	1.6	
	Week 49	Tezepelumab	55	52 (94.5)	-0.49 (0.61)	-2.6	-1.00	-0.45	0.00	0.9	-0.23 [-0.65, 0.19]
		Placebo	40	38 (95.0)	-0.35 (0.58)	-1.6	-0.69	-0.21	0.00	1.6	
	Week 50	Tezepelumab	55	51 (92.7)	-0.55 (0.60)	-2.6	-1.00	-0.43	-0.14	0.9	-0.34 [-0.77, 0.09]
		Placebo	40	36 (90.0)	-0.34 (0.59)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 51	Tezepelumab	55	47 (85.5)	-0.50 (0.58)	-2.6	-1.00	-0.43	-0.03	0.7	-0.22 [-0.66, 0.22]
		Placebo	40	35 (87.5)	-0.37 (0.58)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 52	Tezepelumab	55	43 (78.2)	-0.52 (0.58)	-2.6	-1.00	-0.57	0.00	0.6	-0.25 [-0.71, 0.20]
		Placebo	40	33 (82.5)	-0.37 (0.59)	-1.6	-0.57	-0.40	0.00	1.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	55	54 (98.2)	-0.23 (0.07)	(-0.36, -0.09)	-0.15 (0.10)	(-0.36, 0.05)	0.143
	Placebo	40	40 (100.0)	-0.07 (0.08)	(-0.23, 0.08)			
Week 2	Tezepelumab	55	54 (98.2)	-0.25 (0.07)	(-0.38, -0.11)	-0.12 (0.10)	(-0.33, 0.08)	0.245
	Placebo	40	39 (97.5)	-0.13 (0.08)	(-0.28, 0.03)			
Week 3	Tezepelumab	55	55 (100.0)	-0.29 (0.07)	(-0.42, -0.16)	-0.16 (0.10)	(-0.37, 0.04)	0.121
	Placebo	40	38 (95.0)	-0.13 (0.08)	(-0.29, 0.03)			
Week 4	Tezepelumab	55	55 (100.0)	-0.32 (0.07)	(-0.45, -0.19)	-0.15 (0.10)	(-0.35, 0.06)	0.154
	Placebo	40	39 (97.5)	-0.17 (0.08)	(-0.33, -0.02)			
Week 5	Tezepelumab	55	54 (98.2)	-0.41 (0.07)	(-0.55, -0.28)	-0.20 (0.10)	(-0.40, 0.01)	0.059
	Placebo	40	39 (97.5)	-0.22 (0.08)	(-0.37, -0.06)			
Week 6	Tezepelumab	55	53 (96.4)	-0.33 (0.07)	(-0.46, -0.20)	-0.18 (0.10)	(-0.39, 0.03)	0.086
	Placebo	40	40 (100.0)	-0.15 (0.08)	(-0.31, 0.01)			
Week 7	Tezepelumab	55	53 (96.4)	-0.34 (0.07)	(-0.47, -0.20)	-0.14 (0.10)	(-0.35, 0.06)	0.171
	Placebo	40	40 (100.0)	-0.19 (0.08)	(-0.35, -0.04)			
Week 8	Tezepelumab	55	53 (96.4)	-0.43 (0.07)	(-0.56, -0.29)	-0.27 (0.10)	(-0.48, -0.07)	0.009 *
	Placebo	40	39 (97.5)	-0.15 (0.08)	(-0.31, 0.00)			
Week 9	Tezepelumab	55	55 (100.0)	-0.51 (0.07)	(-0.64, -0.37)	-0.32 (0.10)	(-0.53, -0.12)	0.002 *
	Placebo	40	40 (100.0)	-0.18 (0.08)	(-0.34, -0.03)			
Week 10	Tezepelumab	55	54 (98.2)	-0.48 (0.07)	(-0.62, -0.35)	-0.23 (0.10)	(-0.44, -0.03)	0.027 *
	Placebo	40	40 (100.0)	-0.25 (0.08)	(-0.41, -0.10)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	55	54 (98.2)	-0.48 (0.07)	(-0.61, -0.35)	-0.19 (0.10)	(-0.40, 0.01)	0.068
	Placebo	40	40 (100.0)	-0.29 (0.08)	(-0.44, -0.13)			
Week 12	Tezepelumab	55	53 (96.4)	-0.48 (0.07)	(-0.62, -0.35)	-0.22 (0.10)	(-0.43, -0.01)	0.036 *
	Placebo	40	38 (95.0)	-0.26 (0.08)	(-0.42, -0.11)			
Week 13	Tezepelumab	55	51 (92.7)	-0.45 (0.07)	(-0.59, -0.32)	-0.14 (0.11)	(-0.35, 0.06)	0.178
	Placebo	40	39 (97.5)	-0.31 (0.08)	(-0.47, -0.15)			
Week 14	Tezepelumab	55	52 (94.5)	-0.46 (0.07)	(-0.59, -0.33)	-0.19 (0.11)	(-0.39, 0.02)	0.079
	Placebo	40	38 (95.0)	-0.28 (0.08)	(-0.43, -0.12)			
Week 15	Tezepelumab	55	52 (94.5)	-0.49 (0.07)	(-0.62, -0.35)	-0.23 (0.11)	(-0.43, -0.02)	0.031 *
	Placebo	40	39 (97.5)	-0.26 (0.08)	(-0.42, -0.10)			
Week 16	Tezepelumab	55	53 (96.4)	-0.46 (0.07)	(-0.59, -0.32)	-0.16 (0.11)	(-0.36, 0.05)	0.133
	Placebo	40	38 (95.0)	-0.30 (0.08)	(-0.45, -0.14)			
Week 17	Tezepelumab	55	53 (96.4)	-0.45 (0.07)	(-0.58, -0.31)	-0.19 (0.11)	(-0.40, 0.01)	0.068
	Placebo	40	38 (95.0)	-0.25 (0.08)	(-0.41, -0.10)			
Week 18	Tezepelumab	55	53 (96.4)	-0.44 (0.07)	(-0.58, -0.31)	-0.15 (0.10)	(-0.36, 0.05)	0.142
	Placebo	40	40 (100.0)	-0.29 (0.08)	(-0.44, -0.13)			
Week 19	Tezepelumab	55	53 (96.4)	-0.49 (0.07)	(-0.62, -0.35)	-0.17 (0.10)	(-0.37, 0.04)	0.113
	Placebo	40	40 (100.0)	-0.32 (0.08)	(-0.48, -0.16)			
Week 20	Tezepelumab	55	52 (94.5)	-0.48 (0.07)	(-0.61, -0.34)	-0.14 (0.11)	(-0.35, 0.07)	0.181
	Placebo	40	39 (97.5)	-0.34 (0.08)	(-0.49, -0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	55	50 (90.9)	-0.48 (0.07)	(-0.61, -0.34)	-0.13 (0.11)	(-0.34, 0.07)	0.209
	Placebo	40	39 (97.5)	-0.35 (0.08)	(-0.50, -0.19)			
Week 22	Tezepelumab	55	52 (94.5)	-0.47 (0.07)	(-0.60, -0.33)	-0.16 (0.11)	(-0.36, 0.05)	0.136
	Placebo	40	39 (97.5)	-0.31 (0.08)	(-0.47, -0.15)			
Week 23	Tezepelumab	55	52 (94.5)	-0.44 (0.07)	(-0.57, -0.30)	-0.14 (0.11)	(-0.35, 0.07)	0.181
	Placebo	40	37 (92.5)	-0.29 (0.08)	(-0.45, -0.14)			
Week 24	Tezepelumab	55	53 (96.4)	-0.47 (0.07)	(-0.60, -0.34)	-0.19 (0.11)	(-0.39, 0.02)	0.078
	Placebo	40	37 (92.5)	-0.28 (0.08)	(-0.44, -0.12)			
Week 25	Tezepelumab	55	50 (90.9)	-0.51 (0.07)	(-0.65, -0.38)	-0.18 (0.11)	(-0.38, 0.03)	0.099
	Placebo	40	38 (95.0)	-0.34 (0.08)	(-0.50, -0.18)			
Week 26	Tezepelumab	55	53 (96.4)	-0.43 (0.07)	(-0.56, -0.29)	-0.12 (0.11)	(-0.32, 0.09)	0.269
	Placebo	40	37 (92.5)	-0.31 (0.08)	(-0.47, -0.15)			
Week 27	Tezepelumab	55	53 (96.4)	-0.42 (0.07)	(-0.56, -0.29)	-0.09 (0.11)	(-0.30, 0.12)	0.384
	Placebo	40	36 (90.0)	-0.33 (0.08)	(-0.49, -0.17)			
Week 28	Tezepelumab	55	53 (96.4)	-0.42 (0.07)	(-0.55, -0.28)	-0.13 (0.11)	(-0.33, 0.08)	0.231
	Placebo	40	37 (92.5)	-0.29 (0.08)	(-0.45, -0.13)			
Week 29	Tezepelumab	55	52 (94.5)	-0.52 (0.07)	(-0.65, -0.39)	-0.19 (0.11)	(-0.40, 0.02)	0.076
	Placebo	40	37 (92.5)	-0.33 (0.08)	(-0.49, -0.17)			
Week 30	Tezepelumab	55	52 (94.5)	-0.51 (0.07)	(-0.64, -0.38)	-0.22 (0.11)	(-0.43, -0.02)	0.035 *
	Placebo	40	37 (92.5)	-0.29 (0.08)	(-0.45, -0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	55	54 (98.2)	-0.54 (0.07)	(-0.67, -0.41)	-0.24 (0.11)	(-0.45, -0.04)	0.021 *
	Placebo	40	38 (95.0)	-0.30 (0.08)	(-0.46, -0.14)			
Week 32	Tezepelumab	55	53 (96.4)	-0.51 (0.07)	(-0.65, -0.38)	-0.18 (0.11)	(-0.39, 0.03)	0.093
	Placebo	40	38 (95.0)	-0.34 (0.08)	(-0.49, -0.18)			
Week 33	Tezepelumab	55	53 (96.4)	-0.47 (0.07)	(-0.60, -0.33)	-0.16 (0.11)	(-0.37, 0.05)	0.128
	Placebo	40	38 (95.0)	-0.30 (0.08)	(-0.46, -0.15)			
Week 34	Tezepelumab	55	54 (98.2)	-0.51 (0.07)	(-0.64, -0.37)	-0.21 (0.11)	(-0.42, -0.00)	0.045 *
	Placebo	40	38 (95.0)	-0.29 (0.08)	(-0.45, -0.13)			
Week 35	Tezepelumab	55	53 (96.4)	-0.49 (0.07)	(-0.63, -0.36)	-0.16 (0.11)	(-0.37, 0.05)	0.141
	Placebo	40	36 (90.0)	-0.34 (0.08)	(-0.50, -0.18)			
Week 36	Tezepelumab	55	52 (94.5)	-0.47 (0.07)	(-0.61, -0.34)	-0.19 (0.11)	(-0.40, 0.02)	0.069
	Placebo	40	38 (95.0)	-0.28 (0.08)	(-0.44, -0.12)			
Week 37	Tezepelumab	55	52 (94.5)	-0.46 (0.07)	(-0.60, -0.33)	-0.15 (0.11)	(-0.36, 0.05)	0.147
	Placebo	40	38 (95.0)	-0.31 (0.08)	(-0.47, -0.15)			
Week 38	Tezepelumab	55	50 (90.9)	-0.46 (0.07)	(-0.60, -0.33)	-0.12 (0.11)	(-0.33, 0.09)	0.258
	Placebo	40	38 (95.0)	-0.34 (0.08)	(-0.50, -0.18)			
Week 39	Tezepelumab	55	52 (94.5)	-0.51 (0.07)	(-0.64, -0.38)	-0.19 (0.11)	(-0.40, 0.02)	0.079
	Placebo	40	38 (95.0)	-0.32 (0.08)	(-0.48, -0.16)			
Week 40	Tezepelumab	55	53 (96.4)	-0.49 (0.07)	(-0.63, -0.36)	-0.20 (0.11)	(-0.41, 0.01)	0.062
	Placebo	40	38 (95.0)	-0.29 (0.08)	(-0.45, -0.13)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	55	53 (96.4)	-0.49 (0.07)	(-0.63, -0.36)	-0.22 (0.11)	(-0.43, -0.01)	0.040 *
	Placebo	40	37 (92.5)	-0.27 (0.08)	(-0.43, -0.11)			
Week 42	Tezepelumab	55	50 (90.9)	-0.41 (0.07)	(-0.54, -0.27)	-0.10 (0.11)	(-0.31, 0.11)	0.352
	Placebo	40	38 (95.0)	-0.31 (0.08)	(-0.47, -0.15)			
Week 43	Tezepelumab	55	51 (92.7)	-0.48 (0.07)	(-0.61, -0.34)	-0.15 (0.11)	(-0.36, 0.06)	0.171
	Placebo	40	37 (92.5)	-0.33 (0.08)	(-0.49, -0.17)			
Week 44	Tezepelumab	55	51 (92.7)	-0.51 (0.07)	(-0.65, -0.38)	-0.19 (0.11)	(-0.40, 0.03)	0.085
	Placebo	40	36 (90.0)	-0.33 (0.08)	(-0.49, -0.17)			
Week 45	Tezepelumab	55	51 (92.7)	-0.53 (0.07)	(-0.66, -0.39)	-0.17 (0.11)	(-0.38, 0.04)	0.110
	Placebo	40	37 (92.5)	-0.35 (0.08)	(-0.52, -0.19)			
Week 46	Tezepelumab	55	52 (94.5)	-0.48 (0.07)	(-0.61, -0.34)	-0.10 (0.11)	(-0.31, 0.11)	0.329
	Placebo	40	37 (92.5)	-0.37 (0.08)	(-0.54, -0.21)			
Week 47	Tezepelumab	55	50 (90.9)	-0.51 (0.07)	(-0.64, -0.37)	-0.19 (0.11)	(-0.40, 0.02)	0.073
	Placebo	40	37 (92.5)	-0.32 (0.08)	(-0.48, -0.16)			
Week 48	Tezepelumab	55	52 (94.5)	-0.50 (0.07)	(-0.63, -0.36)	-0.16 (0.11)	(-0.37, 0.05)	0.131
	Placebo	40	38 (95.0)	-0.34 (0.08)	(-0.50, -0.18)			
Week 49	Tezepelumab	55	52 (94.5)	-0.48 (0.07)	(-0.62, -0.35)	-0.11 (0.11)	(-0.32, 0.10)	0.291
	Placebo	40	38 (95.0)	-0.37 (0.08)	(-0.53, -0.21)			
Week 50	Tezepelumab	55	51 (92.7)	-0.54 (0.07)	(-0.67, -0.40)	-0.16 (0.11)	(-0.37, 0.05)	0.142
	Placebo	40	36 (90.0)	-0.38 (0.08)	(-0.54, -0.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	55	47 (85.5)	-0.51 (0.07)	(-0.65, -0.38)	-0.12 (0.11)	(-0.33, 0.10)	0.283
	Placebo	40	35 (87.5)	-0.40 (0.08)	(-0.56, -0.23)			
Week 52	Tezepelumab	55	43 (78.2)	-0.51 (0.07)	(-0.65, -0.37)	-0.14 (0.11)	(-0.35, 0.08)	0.221
	Placebo	40	33 (82.5)	-0.38 (0.08)	(-0.54, -0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	12	12 (100.0)	0.70 (0.62)	0.0	0.07	0.79	1.07	2.0	
		Placebo	11	11 (100.0)	1.08 (1.14)	0.0	0.00	1.00	1.00	4.0	
	Week 1	Tezepelumab	12	12 (100.0)	0.62 (0.60)	0.0	0.07	0.69	0.93	2.0	
		Placebo	11	11 (100.0)	0.91 (0.62)	0.0	0.43	1.00	1.29	2.1	
	Week 2	Tezepelumab	12	12 (100.0)	0.57 (0.58)	0.0	0.14	0.45	0.86	2.0	
		Placebo	11	11 (100.0)	1.10 (1.00)	0.0	0.14	1.00	1.29	3.5	
	Week 3	Tezepelumab	12	12 (100.0)	0.65 (0.60)	0.0	0.14	0.63	1.00	2.0	
		Placebo	11	11 (100.0)	0.75 (0.61)	0.0	0.00	1.00	1.00	2.0	
	Week 4	Tezepelumab	12	11 (91.7)	0.73 (0.65)	0.0	0.00	1.00	1.00	2.0	
		Placebo	11	11 (100.0)	0.87 (0.60)	0.0	0.14	1.00	1.14	2.0	
	Week 5	Tezepelumab	12	12 (100.0)	0.58 (0.62)	0.0	0.00	0.63	0.93	2.0	
		Placebo	11	11 (100.0)	0.81 (0.52)	0.0	0.14	1.00	1.14	1.6	
	Week 6	Tezepelumab	12	11 (91.7)	0.58 (0.61)	0.0	0.00	0.57	1.00	2.0	
		Placebo	11	11 (100.0)	0.86 (0.60)	0.0	0.14	1.00	1.14	2.0	
	Week 7	Tezepelumab	12	11 (91.7)	0.62 (0.60)	0.0	0.00	0.57	1.00	2.0	
		Placebo	11	11 (100.0)	0.83 (0.65)	0.0	0.00	1.00	1.14	2.2	
	Week 8	Tezepelumab	12	11 (91.7)	0.62 (0.61)	0.0	0.14	0.50	1.00	2.0	
		Placebo	11	11 (100.0)	0.92 (0.69)	0.0	0.00	1.00	1.29	2.0	
	Week 9	Tezepelumab	12	12 (100.0)	0.63 (0.65)	0.0	0.00	0.73	1.00	2.0	
		Placebo	11	11 (100.0)	0.94 (0.65)	0.0	0.29	1.00	1.20	2.1	
	Week 10	Tezepelumab	12	12 (100.0)	0.66 (0.59)	0.0	0.17	0.62	1.00	2.0	
		Placebo	11	10 (90.9)	0.87 (0.60)	0.0	0.29	1.00	1.17	2.0	
	Week 11	Tezepelumab	12	12 (100.0)	0.68 (0.61)	0.0	0.00	0.86	1.00	2.0	
		Placebo	11	11 (100.0)	0.85 (0.60)	0.0	0.14	1.00	1.14	2.0	
	Week 12	Tezepelumab	12	11 (91.7)	0.63 (0.62)	0.0	0.14	0.43	1.00	2.0	
		Placebo	11	11 (100.0)	0.84 (0.60)	0.0	0.14	1.00	1.00	2.0	
	Week 13	Tezepelumab	12	11 (91.7)	0.68 (0.60)	0.0	0.00	0.71	1.00	2.0	
		Placebo	11	11 (100.0)	0.90 (0.58)	0.0	0.71	1.00	1.00	2.1	
	Week 14	Tezepelumab	12	11 (91.7)	0.68 (0.60)	0.0	0.00	0.86	1.00	2.0	
		Placebo	11	11 (100.0)	0.95 (0.65)	0.0	0.57	1.00	1.14	2.0	
	Week 15	Tezepelumab	12	11 (91.7)	0.64 (0.59)	0.0	0.14	0.43	1.00	2.0	
		Placebo	11	11 (100.0)	0.87 (0.66)	0.0	0.00	1.00	1.00	2.1	
	Week 16	Tezepelumab	12	11 (91.7)	0.60 (0.65)	0.0	0.00	0.29	1.00	2.0	
		Placebo	11	11 (100.0)	0.91 (0.57)	0.0	0.71	1.00	1.00	2.0	
Week 17	Tezepelumab	12	11 (91.7)	0.54 (0.62)	0.0	0.00	0.33	1.00	2.0		
	Placebo	11	11 (100.0)	0.87 (0.53)	0.0	0.71	1.00	1.00	1.9		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	12	11 (91.7)	0.68 (0.67)	0.0	0.00	0.57	1.00	2.0	
		Placebo	11	11 (100.0)	0.79 (0.65)	0.0	0.00	1.00	1.00	2.0	
	Week 19	Tezepelumab	12	11 (91.7)	0.62 (0.63)	0.0	0.00	0.43	1.00	2.0	
		Placebo	11	11 (100.0)	0.80 (0.57)	0.0	0.29	0.83	1.00	1.8	
	Week 20	Tezepelumab	12	11 (91.7)	0.56 (0.67)	0.0	0.00	0.29	1.00	2.0	
		Placebo	11	11 (100.0)	0.77 (0.66)	0.0	0.14	0.57	1.14	1.9	
	Week 21	Tezepelumab	12	11 (91.7)	0.66 (0.63)	0.0	0.00	0.71	1.00	2.0	
		Placebo	11	11 (100.0)	0.83 (0.58)	0.0	0.29	0.86	1.29	1.9	
	Week 22	Tezepelumab	12	11 (91.7)	0.64 (0.62)	0.0	0.00	0.71	1.00	2.0	
		Placebo	11	11 (100.0)	0.81 (0.67)	0.0	0.14	1.00	1.14	1.9	
	Week 23	Tezepelumab	12	11 (91.7)	0.60 (0.63)	0.0	0.00	0.57	1.00	2.0	
		Placebo	11	11 (100.0)	0.78 (0.57)	0.0	0.14	1.00	1.00	1.6	
	Week 24	Tezepelumab	12	11 (91.7)	0.66 (0.66)	0.0	0.00	0.71	1.00	2.0	
		Placebo	11	11 (100.0)	0.83 (0.68)	0.0	0.14	1.00	1.00	2.0	
	Week 25	Tezepelumab	12	11 (91.7)	0.75 (0.77)	0.0	0.00	0.57	1.00	2.1	
		Placebo	11	11 (100.0)	0.70 (0.62)	0.0	0.00	0.86	1.00	1.9	
	Week 26	Tezepelumab	12	11 (91.7)	0.74 (0.67)	0.0	0.00	0.86	1.00	2.0	
		Placebo	11	11 (100.0)	0.74 (0.66)	0.0	0.00	1.00	1.14	2.0	
	Week 27	Tezepelumab	12	10 (83.3)	0.73 (0.55)	0.0	0.00	0.93	1.00	1.6	
		Placebo	11	11 (100.0)	0.75 (0.70)	0.0	0.00	0.83	1.33	2.0	
	Week 28	Tezepelumab	12	9 (75.0)	0.59 (0.41)	0.0	0.29	0.57	1.00	1.0	
		Placebo	11	11 (100.0)	0.87 (0.77)	0.0	0.00	0.86	1.57	2.0	
	Week 29	Tezepelumab	12	9 (75.0)	0.66 (0.54)	0.0	0.29	0.83	1.00	1.6	
		Placebo	11	11 (100.0)	0.87 (0.72)	0.0	0.00	1.00	1.57	2.0	
	Week 30	Tezepelumab	12	10 (83.3)	0.58 (0.44)	0.0	0.29	0.54	1.00	1.3	
		Placebo	11	11 (100.0)	0.77 (0.74)	0.0	0.00	1.00	1.14	2.1	
	Week 31	Tezepelumab	12	9 (75.0)	0.78 (0.66)	0.0	0.29	0.86	1.00	2.1	
		Placebo	11	11 (100.0)	0.77 (0.68)	0.0	0.00	1.00	1.14	2.1	
	Week 32	Tezepelumab	12	10 (83.3)	0.73 (0.64)	0.0	0.14	0.86	1.00	2.0	
		Placebo	11	11 (100.0)	0.82 (0.73)	0.0	0.14	1.00	1.14	2.1	
	Week 33	Tezepelumab	12	10 (83.3)	0.57 (0.51)	0.0	0.00	0.64	1.00	1.4	
		Placebo	11	11 (100.0)	0.77 (0.62)	0.0	0.14	1.00	1.00	2.0	
	Week 34	Tezepelumab	12	10 (83.3)	0.57 (0.58)	0.0	0.00	0.50	0.86	1.9	
		Placebo	11	11 (100.0)	0.86 (0.79)	0.0	0.00	1.00	1.14	2.2	
	Week 35	Tezepelumab	12	10 (83.3)	0.57 (0.53)	0.0	0.00	0.49	1.00	1.6	
		Placebo	11	11 (100.0)	0.70 (0.79)	0.0	0.00	0.17	1.29	2.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	12	10 (83.3)	0.50 (0.45)	0.0	0.00	0.50	0.86	1.3	
		Placebo	11	11 (100.0)	0.68 (0.79)	0.0	0.00	0.29	1.29	2.0	
	Week 37	Tezepelumab	12	10 (83.3)	0.50 (0.51)	0.0	0.00	0.43	1.00	1.3	
		Placebo	11	11 (100.0)	0.73 (0.72)	0.0	0.00	0.43	1.50	2.0	
	Week 38	Tezepelumab	12	9 (75.0)	0.58 (0.42)	0.0	0.29	0.71	1.00	1.0	
		Placebo	11	11 (100.0)	0.60 (0.67)	0.0	0.00	0.43	1.00	1.9	
	Week 39	Tezepelumab	12	9 (75.0)	0.61 (0.43)	0.0	0.29	0.83	0.86	1.1	
		Placebo	11	10 (90.9)	0.57 (0.66)	0.0	0.00	0.29	1.00	1.7	
	Week 40	Tezepelumab	12	9 (75.0)	0.61 (0.51)	0.0	0.17	0.71	1.00	1.4	
		Placebo	11	11 (100.0)	0.80 (0.91)	0.0	0.00	0.57	1.86	2.3	
	Week 41	Tezepelumab	12	8 (66.7)	0.64 (0.60)	0.0	0.00	0.71	1.07	1.6	
		Placebo	11	11 (100.0)	0.74 (0.68)	0.0	0.20	0.57	1.29	2.0	
	Week 42	Tezepelumab	12	8 (66.7)	0.55 (0.53)	0.0	0.00	0.64	1.00	1.1	
		Placebo	11	11 (100.0)	0.65 (0.74)	0.0	0.00	0.17	1.43	2.0	
	Week 43	Tezepelumab	12	8 (66.7)	0.82 (0.62)	0.0	0.29	0.85	1.31	1.7	
		Placebo	11	11 (100.0)	0.71 (0.83)	0.0	0.00	0.14	1.71	2.1	
	Week 44	Tezepelumab	12	8 (66.7)	0.59 (0.46)	0.0	0.14	0.71	1.00	1.0	
		Placebo	11	11 (100.0)	0.72 (0.88)	0.0	0.00	0.17	1.71	2.3	
	Week 45	Tezepelumab	12	8 (66.7)	0.60 (0.43)	0.0	0.21	0.70	1.00	1.0	
		Placebo	11	11 (100.0)	0.57 (0.69)	0.0	0.00	0.14	1.00	2.0	
	Week 46	Tezepelumab	12	8 (66.7)	0.56 (0.48)	0.0	0.10	0.56	1.00	1.1	
		Placebo	11	11 (100.0)	0.63 (0.70)	0.0	0.00	0.29	1.50	1.6	
	Week 47	Tezepelumab	12	8 (66.7)	0.54 (0.47)	0.0	0.08	0.57	0.93	1.1	
		Placebo	11	11 (100.0)	0.59 (0.63)	0.0	0.00	0.50	1.00	1.7	
Week 48	Tezepelumab	12	7 (58.3)	0.56 (0.63)	0.0	0.00	0.29	1.00	1.7		
	Placebo	11	11 (100.0)	0.58 (0.73)	0.0	0.00	0.00	1.00	1.9		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	12	12 (100.0)	-0.08 (0.37)	-0.8	-0.29	0.00	0.08	0.7	0.14 [-0.68, 0.96]
		Placebo	11	11 (100.0)	-0.17 (0.81)	-2.6	0.00	0.00	0.14	0.4	
	Week 2	Tezepelumab	12	12 (100.0)	-0.13 (0.32)	-0.8	-0.29	-0.07	0.07	0.3	-0.58 [-1.41, 0.26]
		Placebo	11	11 (100.0)	0.02 (0.20)	-0.5	0.00	0.00	0.14	0.3	
	Week 3	Tezepelumab	12	12 (100.0)	-0.05 (0.57)	-1.0	-0.29	0.00	0.20	1.2	0.37 [-0.45, 1.20]
		Placebo	11	11 (100.0)	-0.32 (0.90)	-3.0	-0.14	0.00	0.00	0.0	
	Week 4	Tezepelumab	12	11 (91.7)	-0.04 (0.52)	-1.0	-0.14	-0.14	0.00	1.1	0.24 [-0.60, 1.08]
		Placebo	11	11 (100.0)	-0.21 (0.83)	-2.7	0.00	0.00	0.14	0.1	
	Week 5	Tezepelumab	12	12 (100.0)	-0.12 (0.36)	-1.0	-0.21	-0.07	0.00	0.4	0.22 [-0.60, 1.04]
		Placebo	11	11 (100.0)	-0.27 (0.92)	-3.0	0.00	0.00	0.14	0.1	
	Week 6	Tezepelumab	12	11 (91.7)	-0.09 (0.27)	-0.6	-0.29	0.00	0.00	0.4	0.20 [-0.64, 1.04]
		Placebo	11	11 (100.0)	-0.22 (0.88)	-2.9	0.00	0.00	0.14	0.1	
	Week 7	Tezepelumab	12	11 (91.7)	-0.06 (0.29)	-0.6	-0.14	0.00	0.14	0.5	0.29 [-0.55, 1.13]
		Placebo	11	11 (100.0)	-0.24 (0.87)	-2.9	0.00	0.00	0.00	0.2	
	Week 8	Tezepelumab	12	11 (91.7)	-0.05 (0.36)	-0.8	-0.29	0.00	0.14	0.5	0.15 [-0.69, 0.99]
		Placebo	11	11 (100.0)	-0.16 (0.92)	-2.7	0.00	0.00	0.00	1.1	
	Week 9	Tezepelumab	12	12 (100.0)	-0.07 (0.60)	-1.1	-0.29	0.00	0.29	0.9	0.09 [-0.73, 0.91]
		Placebo	11	11 (100.0)	-0.14 (0.93)	-2.9	0.00	0.00	0.20	0.7	
	Week 10	Tezepelumab	12	12 (100.0)	-0.04 (0.47)	-0.8	-0.29	-0.07	0.29	0.7	0.25 [-0.60, 1.09]
		Placebo	11	10 (90.9)	-0.21 (0.88)	-2.7	0.00	0.00	0.14	0.3	
	Week 11	Tezepelumab	12	12 (100.0)	-0.02 (0.39)	-0.6	-0.14	-0.07	0.00	1.0	0.30 [-0.52, 1.12]
		Placebo	11	11 (100.0)	-0.22 (0.88)	-2.9	0.00	0.00	0.14	0.3	
	Week 12	Tezepelumab	12	11 (91.7)	-0.14 (0.55)	-0.7	-0.67	-0.14	0.00	1.3	0.14 [-0.70, 0.97]
		Placebo	11	11 (100.0)	-0.23 (0.82)	-2.7	0.00	0.00	0.00	0.1	
	Week 13	Tezepelumab	12	11 (91.7)	-0.09 (0.44)	-0.7	-0.43	-0.14	0.00	1.0	0.13 [-0.71, 0.96]
		Placebo	11	11 (100.0)	-0.18 (0.91)	-2.9	0.00	0.00	0.00	0.7	
	Week 14	Tezepelumab	12	11 (91.7)	-0.09 (0.47)	-1.0	-0.43	0.00	0.19	0.9	0.07 [-0.76, 0.91]
		Placebo	11	11 (100.0)	-0.13 (0.69)	-2.0	0.00	0.00	0.00	0.9	
	Week 15	Tezepelumab	12	11 (91.7)	-0.13 (0.38)	-0.9	-0.43	0.00	0.14	0.4	0.13 [-0.71, 0.96]
		Placebo	11	11 (100.0)	-0.21 (0.79)	-2.6	0.00	0.00	0.00	0.1	
	Week 16	Tezepelumab	12	11 (91.7)	-0.17 (0.45)	-1.0	-0.29	-0.14	0.00	0.6	0.00 [-0.83, 0.84]
		Placebo	11	11 (100.0)	-0.17 (0.82)	-2.6	0.00	0.00	0.00	0.7	
	Week 17	Tezepelumab	12	11 (91.7)	-0.23 (0.38)	-0.8	-0.67	-0.14	0.00	0.3	-0.03 [-0.87, 0.81]
		Placebo	11	11 (100.0)	-0.21 (0.86)	-2.7	-0.14	0.00	0.00	0.7	
	Week 18	Tezepelumab	12	11 (91.7)	-0.09 (0.37)	-0.9	-0.43	0.00	0.29	0.4	0.34 [-0.51, 1.18]
		Placebo	11	11 (100.0)	-0.29 (0.76)	-2.5	0.00	0.00	0.00	0.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	12	11 (91.7)	-0.14 (0.43)	-1.0	-0.43	0.00	0.00	0.4	0.21 [-0.63, 1.05]
		Placebo	11	11 (100.0)	-0.27 (0.77)	-2.4	-0.19	0.00	0.00	0.5	
	Week 20	Tezepelumab	12	11 (91.7)	-0.21 (0.51)	-1.0	-0.71	-0.14	0.00	0.7	0.17 [-0.67, 1.01]
		Placebo	11	11 (100.0)	-0.31 (0.66)	-2.2	-0.43	0.00	0.00	0.1	
	Week 21	Tezepelumab	12	11 (91.7)	-0.10 (0.45)	-1.0	-0.43	-0.14	0.00	0.7	0.22 [-0.62, 1.06]
		Placebo	11	11 (100.0)	-0.25 (0.80)	-2.6	-0.14	0.00	0.00	0.3	
	Week 22	Tezepelumab	12	11 (91.7)	-0.13 (0.44)	-1.0	-0.43	-0.14	0.00	0.7	0.25 [-0.59, 1.09]
		Placebo	11	11 (100.0)	-0.27 (0.67)	-2.1	-0.57	0.00	0.14	0.1	
	Week 23	Tezepelumab	12	11 (91.7)	-0.17 (0.35)	-1.0	-0.43	0.00	0.00	0.3	0.22 [-0.61, 1.06]
		Placebo	11	11 (100.0)	-0.30 (0.74)	-2.4	-0.43	0.00	0.00	0.1	
	Week 24	Tezepelumab	12	11 (91.7)	-0.10 (0.51)	-0.9	-0.43	0.00	0.14	1.0	0.23 [-0.60, 1.07]
		Placebo	11	11 (100.0)	-0.25 (0.69)	-2.1	-0.14	0.00	0.00	0.3	
	Week 25	Tezepelumab	12	11 (91.7)	-0.02 (0.83)	-1.0	-0.43	-0.14	0.26	2.1	0.43 [-0.42, 1.27]
		Placebo	11	11 (100.0)	-0.38 (0.87)	-2.9	-0.14	0.00	0.00	0.0	
	Week 26	Tezepelumab	12	11 (91.7)	-0.03 (0.61)	-1.0	-0.29	0.00	0.00	1.6	0.40 [-0.44, 1.25]
		Placebo	11	11 (100.0)	-0.34 (0.89)	-2.9	0.00	0.00	0.00	0.1	
	Week 27	Tezepelumab	12	10 (83.3)	0.09 (0.58)	-1.0	-0.14	0.00	0.43	1.0	0.58 [-0.30, 1.46]
		Placebo	11	11 (100.0)	-0.33 (0.82)	-2.6	-0.36	0.00	0.00	0.3	
	Week 28	Tezepelumab	12	9 (75.0)	-0.02 (0.45)	-0.4	-0.29	-0.14	0.00	0.9	0.32 [-0.57, 1.21]
		Placebo	11	11 (100.0)	-0.21 (0.70)	-2.0	-0.14	0.00	0.14	0.6	
	Week 29	Tezepelumab	12	9 (75.0)	0.06 (0.49)	-0.7	-0.31	0.00	0.43	0.9	0.38 [-0.51, 1.27]
		Placebo	11	11 (100.0)	-0.21 (0.84)	-2.4	0.00	0.00	0.14	0.7	
	Week 30	Tezepelumab	12	10 (83.3)	-0.07 (0.45)	-0.7	-0.43	0.00	0.14	0.9	0.39 [-0.47, 1.26]
		Placebo	11	11 (100.0)	-0.31 (0.73)	-2.3	-0.36	0.00	0.00	0.1	
	Week 31	Tezepelumab	12	9 (75.0)	0.17 (0.61)	-0.7	-0.14	0.00	0.86	1.0	0.64 [-0.26, 1.55]
		Placebo	11	11 (100.0)	-0.31 (0.86)	-2.7	-0.14	0.00	0.14	0.1	
	Week 32	Tezepelumab	12	10 (83.3)	0.09 (0.49)	-0.7	-0.14	0.07	0.20	0.9	0.57 [-0.31, 1.44]
		Placebo	11	11 (100.0)	-0.26 (0.71)	-2.1	-0.26	0.00	0.14	0.1	
	Week 33	Tezepelumab	12	10 (83.3)	-0.07 (0.46)	-0.9	-0.43	-0.07	0.29	0.7	0.33 [-0.53, 1.19]
		Placebo	11	11 (100.0)	-0.31 (0.89)	-2.9	0.00	0.00	0.00	0.2	
	Week 34	Tezepelumab	12	10 (83.3)	-0.07 (0.48)	-0.7	-0.43	-0.07	0.00	0.7	0.26 [-0.60, 1.12]
		Placebo	11	11 (100.0)	-0.22 (0.64)	-1.9	-0.14	0.00	0.14	0.2	
	Week 35	Tezepelumab	12	10 (83.3)	-0.07 (0.45)	-0.7	-0.43	-0.07	0.43	0.6	0.51 [-0.36, 1.38]
		Placebo	11	11 (100.0)	-0.37 (0.69)	-2.0	-0.83	0.00	0.00	0.3	
	Week 36	Tezepelumab	12	10 (83.3)	-0.14 (0.42)	-0.7	-0.57	-0.07	0.14	0.6	0.44 [-0.43, 1.30]
		Placebo	11	11 (100.0)	-0.40 (0.72)	-2.1	-0.86	0.00	0.00	0.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMH0: Course of ASD weekly waking score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	12	10 (83.3)	-0.14 (0.48)	-1.0	-0.43	-0.07	0.14	0.6	0.30 [-0.56, 1.16]
		Placebo	11	11 (100.0)	-0.35 (0.86)	-2.5	-0.86	0.00	0.00	0.6	
	Week 38	Tezepelumab	12	9 (75.0)	-0.02 (0.41)	-0.6	-0.34	0.00	0.14	0.7	0.60 [-0.30, 1.51]
		Placebo	11	11 (100.0)	-0.48 (0.94)	-3.0	-1.00	0.00	0.00	0.3	
	Week 39	Tezepelumab	12	9 (75.0)	0.01 (0.45)	-0.7	-0.17	0.00	0.29	0.7	0.49 [-0.43, 1.40]
		Placebo	11	10 (90.9)	-0.21 (0.47)	-1.0	-0.43	0.00	0.00	0.4	
	Week 40	Tezepelumab	12	9 (75.0)	0.00 (0.29)	-0.4	-0.14	0.00	0.29	0.4	0.50 [-0.40, 1.39]
		Placebo	11	11 (100.0)	-0.27 (0.71)	-1.7	-1.00	0.00	0.14	0.9	
	Week 41	Tezepelumab	12	8 (66.7)	0.04 (0.34)	-0.4	-0.21	0.00	0.29	0.6	0.49 [-0.43, 1.42]
		Placebo	11	11 (100.0)	-0.34 (0.95)	-2.7	-0.67	0.00	0.29	0.7	
	Week 42	Tezepelumab	12	8 (66.7)	-0.05 (0.22)	-0.4	-0.14	-0.07	0.07	0.3	0.57 [-0.36, 1.50]
		Placebo	11	11 (100.0)	-0.43 (0.84)	-2.6	-0.86	0.00	0.00	0.4	
	Week 43	Tezepelumab	12	8 (66.7)	0.22 (0.71)	-0.6	-0.30	0.07	0.60	1.6	0.75 [-0.20, 1.69]
		Placebo	11	11 (100.0)	-0.36 (0.83)	-2.3	-1.00	0.00	0.14	0.7	
	Week 44	Tezepelumab	12	8 (66.7)	-0.02 (0.44)	-0.6	-0.29	-0.07	0.14	0.9	0.49 [-0.44, 1.41]
		Placebo	11	11 (100.0)	-0.36 (0.84)	-2.3	-1.00	0.00	0.00	0.9	
	Week 45	Tezepelumab	12	8 (66.7)	-0.00 (0.48)	-0.6	-0.30	-0.14	0.29	0.9	0.65 [-0.29, 1.58]
		Placebo	11	11 (100.0)	-0.51 (0.93)	-3.0	-1.00	0.00	0.00	0.1	
	Week 46	Tezepelumab	12	8 (66.7)	-0.05 (0.46)	-0.7	-0.30	-0.07	0.10	0.9	0.58 [-0.35, 1.51]
		Placebo	11	11 (100.0)	-0.45 (0.81)	-2.4	-1.00	0.00	0.00	0.6	
	Week 47	Tezepelumab	12	8 (66.7)	-0.07 (0.22)	-0.4	-0.21	0.00	0.01	0.3	0.70 [-0.24, 1.64]
		Placebo	11	11 (100.0)	-0.49 (0.76)	-2.3	-1.00	0.00	0.00	0.3	
	Week 48	Tezepelumab	12	7 (58.3)	-0.13 (0.39)	-0.7	-0.43	-0.14	0.14	0.5	0.55 [-0.42, 1.52]
		Placebo	11	11 (100.0)	-0.50 (0.78)	-2.1	-1.00	-0.17	0.00	0.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 1	Tezepelumab	12	12 (100.0)	-0.18 (0.14)	(-0.45, 0.09)	-0.11 (0.20)	(-0.50, 0.28)	0.591
	Placebo	11	11 (100.0)	-0.07 (0.14)	(-0.35, 0.21)			
Week 2	Tezepelumab	12	12 (100.0)	-0.23 (0.14)	(-0.50, 0.04)	-0.35 (0.20)	(-0.74, 0.04)	0.082
	Placebo	11	11 (100.0)	0.12 (0.14)	(-0.17, 0.40)			
Week 3	Tezepelumab	12	12 (100.0)	-0.14 (0.14)	(-0.41, 0.13)	0.09 (0.20)	(-0.30, 0.48)	0.667
	Placebo	11	11 (100.0)	-0.23 (0.14)	(-0.51, 0.05)			
Week 4	Tezepelumab	12	11 (91.7)	-0.07 (0.14)	(-0.35, 0.20)	0.04 (0.20)	(-0.35, 0.43)	0.852
	Placebo	11	11 (100.0)	-0.11 (0.14)	(-0.39, 0.17)			
Week 5	Tezepelumab	12	12 (100.0)	-0.22 (0.14)	(-0.49, 0.05)	-0.04 (0.20)	(-0.43, 0.35)	0.839
	Placebo	11	11 (100.0)	-0.18 (0.14)	(-0.46, 0.10)			
Week 6	Tezepelumab	12	11 (91.7)	-0.26 (0.14)	(-0.54, 0.01)	-0.14 (0.20)	(-0.53, 0.25)	0.484
	Placebo	11	11 (100.0)	-0.12 (0.14)	(-0.41, 0.16)			
Week 7	Tezepelumab	12	11 (91.7)	-0.23 (0.14)	(-0.50, 0.04)	-0.08 (0.20)	(-0.48, 0.31)	0.676
	Placebo	11	11 (100.0)	-0.15 (0.14)	(-0.43, 0.13)			
Week 8	Tezepelumab	12	11 (91.7)	-0.23 (0.14)	(-0.50, 0.04)	-0.17 (0.20)	(-0.56, 0.22)	0.400
	Placebo	11	11 (100.0)	-0.06 (0.14)	(-0.34, 0.22)			
Week 9	Tezepelumab	12	12 (100.0)	-0.16 (0.14)	(-0.43, 0.10)	-0.12 (0.20)	(-0.51, 0.27)	0.534
	Placebo	11	11 (100.0)	-0.04 (0.14)	(-0.32, 0.24)			
Week 10	Tezepelumab	12	12 (100.0)	-0.14 (0.14)	(-0.41, 0.13)	-0.06 (0.20)	(-0.45, 0.33)	0.757
	Placebo	11	10 (90.9)	-0.08 (0.14)	(-0.36, 0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	12	12 (100.0)	-0.12 (0.14)	(-0.39, 0.15)	0.01 (0.20)	(-0.38, 0.40)	0.966
	Placebo	11	11 (100.0)	-0.13 (0.14)	(-0.41, 0.15)			
Week 12	Tezepelumab	12	11 (91.7)	-0.23 (0.14)	(-0.50, 0.05)	-0.09 (0.20)	(-0.48, 0.30)	0.654
	Placebo	11	11 (100.0)	-0.14 (0.14)	(-0.42, 0.14)			
Week 13	Tezepelumab	12	11 (91.7)	-0.17 (0.14)	(-0.45, 0.10)	-0.09 (0.20)	(-0.48, 0.31)	0.656
	Placebo	11	11 (100.0)	-0.09 (0.14)	(-0.37, 0.20)			
Week 14	Tezepelumab	12	11 (91.7)	-0.17 (0.14)	(-0.44, 0.11)	-0.13 (0.20)	(-0.53, 0.26)	0.507
	Placebo	11	11 (100.0)	-0.03 (0.14)	(-0.31, 0.25)			
Week 15	Tezepelumab	12	11 (91.7)	-0.21 (0.14)	(-0.49, 0.07)	-0.10 (0.20)	(-0.49, 0.30)	0.635
	Placebo	11	11 (100.0)	-0.11 (0.14)	(-0.39, 0.17)			
Week 16	Tezepelumab	12	11 (91.7)	-0.24 (0.14)	(-0.52, 0.04)	-0.17 (0.20)	(-0.57, 0.23)	0.402
	Placebo	11	11 (100.0)	-0.07 (0.14)	(-0.36, 0.21)			
Week 17	Tezepelumab	12	11 (91.7)	-0.30 (0.14)	(-0.58, -0.02)	-0.19 (0.20)	(-0.59, 0.21)	0.350
	Placebo	11	11 (100.0)	-0.11 (0.14)	(-0.39, 0.17)			
Week 18	Tezepelumab	12	11 (91.7)	-0.16 (0.14)	(-0.44, 0.12)	0.03 (0.20)	(-0.36, 0.43)	0.866
	Placebo	11	11 (100.0)	-0.20 (0.14)	(-0.48, 0.09)			
Week 19	Tezepelumab	12	11 (91.7)	-0.21 (0.14)	(-0.49, 0.07)	-0.03 (0.20)	(-0.43, 0.36)	0.867
	Placebo	11	11 (100.0)	-0.18 (0.14)	(-0.46, 0.10)			
Week 20	Tezepelumab	12	11 (91.7)	-0.28 (0.14)	(-0.56, 0.00)	-0.07 (0.20)	(-0.46, 0.33)	0.747
	Placebo	11	11 (100.0)	-0.21 (0.14)	(-0.49, 0.07)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	12	11 (91.7)	-0.17 (0.14)	(-0.45, 0.11)	-0.02 (0.20)	(-0.42, 0.38)	0.917
	Placebo	11	11 (100.0)	-0.15 (0.14)	(-0.43, 0.13)			
Week 22	Tezepelumab	12	11 (91.7)	-0.20 (0.14)	(-0.48, 0.08)	-0.02 (0.20)	(-0.42, 0.38)	0.920
	Placebo	11	11 (100.0)	-0.18 (0.14)	(-0.46, 0.10)			
Week 23	Tezepelumab	12	11 (91.7)	-0.23 (0.14)	(-0.52, 0.05)	-0.03 (0.20)	(-0.43, 0.37)	0.872
	Placebo	11	11 (100.0)	-0.20 (0.14)	(-0.48, 0.08)			
Week 24	Tezepelumab	12	11 (91.7)	-0.17 (0.14)	(-0.45, 0.11)	-0.02 (0.20)	(-0.42, 0.38)	0.925
	Placebo	11	11 (100.0)	-0.15 (0.14)	(-0.43, 0.13)			
Week 25	Tezepelumab	12	11 (91.7)	-0.08 (0.14)	(-0.36, 0.20)	0.20 (0.20)	(-0.20, 0.60)	0.317
	Placebo	11	11 (100.0)	-0.28 (0.14)	(-0.56, -0.00)			
Week 26	Tezepelumab	12	11 (91.7)	-0.09 (0.14)	(-0.38, 0.19)	0.15 (0.20)	(-0.25, 0.54)	0.469
	Placebo	11	11 (100.0)	-0.24 (0.14)	(-0.52, 0.04)			
Week 27	Tezepelumab	12	10 (83.3)	0.01 (0.14)	(-0.27, 0.30)	0.25 (0.20)	(-0.16, 0.65)	0.229
	Placebo	11	11 (100.0)	-0.23 (0.14)	(-0.51, 0.05)			
Week 28	Tezepelumab	12	9 (75.0)	-0.20 (0.15)	(-0.49, 0.09)	-0.09 (0.21)	(-0.49, 0.32)	0.675
	Placebo	11	11 (100.0)	-0.11 (0.14)	(-0.39, 0.17)			
Week 29	Tezepelumab	12	9 (75.0)	-0.11 (0.15)	(-0.41, 0.18)	0.00 (0.21)	(-0.41, 0.41)	0.998
	Placebo	11	11 (100.0)	-0.11 (0.14)	(-0.39, 0.17)			
Week 30	Tezepelumab	12	10 (83.3)	-0.16 (0.15)	(-0.45, 0.13)	0.05 (0.21)	(-0.36, 0.45)	0.817
	Placebo	11	11 (100.0)	-0.21 (0.14)	(-0.49, 0.07)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	12	9 (75.0)	0.05 (0.15)	(-0.25, 0.34)	0.26 (0.21)	(-0.15, 0.67)	0.209
	Placebo	11	11 (100.0)	-0.22 (0.14)	(-0.50, 0.07)			
Week 32	Tezepelumab	12	10 (83.3)	-0.01 (0.15)	(-0.31, 0.28)	0.15 (0.21)	(-0.26, 0.55)	0.478
	Placebo	11	11 (100.0)	-0.16 (0.14)	(-0.44, 0.12)			
Week 33	Tezepelumab	12	10 (83.3)	-0.18 (0.15)	(-0.47, 0.11)	0.03 (0.21)	(-0.37, 0.44)	0.874
	Placebo	11	11 (100.0)	-0.21 (0.14)	(-0.49, 0.07)			
Week 34	Tezepelumab	12	10 (83.3)	-0.18 (0.15)	(-0.48, 0.11)	-0.06 (0.21)	(-0.47, 0.35)	0.769
	Placebo	11	11 (100.0)	-0.12 (0.14)	(-0.40, 0.16)			
Week 35	Tezepelumab	12	10 (83.3)	-0.19 (0.15)	(-0.48, 0.11)	0.09 (0.21)	(-0.32, 0.50)	0.666
	Placebo	11	11 (100.0)	-0.28 (0.14)	(-0.56, 0.00)			
Week 36	Tezepelumab	12	10 (83.3)	-0.26 (0.15)	(-0.55, 0.04)	0.05 (0.21)	(-0.36, 0.46)	0.820
	Placebo	11	11 (100.0)	-0.31 (0.14)	(-0.59, -0.02)			
Week 37	Tezepelumab	12	10 (83.3)	-0.26 (0.15)	(-0.56, 0.03)	-0.00 (0.21)	(-0.41, 0.40)	0.983
	Placebo	11	11 (100.0)	-0.26 (0.14)	(-0.54, 0.02)			
Week 38	Tezepelumab	12	9 (75.0)	-0.22 (0.15)	(-0.52, 0.08)	0.16 (0.21)	(-0.26, 0.57)	0.456
	Placebo	11	11 (100.0)	-0.38 (0.14)	(-0.66, -0.10)			
Week 39	Tezepelumab	12	9 (75.0)	-0.18 (0.15)	(-0.48, 0.12)	0.13 (0.21)	(-0.28, 0.55)	0.527
	Placebo	11	10 (90.9)	-0.32 (0.14)	(-0.60, -0.03)			
Week 40	Tezepelumab	12	9 (75.0)	-0.18 (0.16)	(-0.49, 0.12)	-0.00 (0.21)	(-0.42, 0.41)	0.989
	Placebo	11	11 (100.0)	-0.18 (0.14)	(-0.46, 0.10)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC_IBMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	12	8 (66.7)	-0.10 (0.16)	(-0.41, 0.22)	0.14 (0.21)	(-0.28, 0.57)	0.502
	Placebo	11	11 (100.0)	-0.24 (0.14)	(-0.52, 0.04)			
Week 42	Tezepelumab	12	8 (66.7)	-0.19 (0.16)	(-0.51, 0.13)	0.14 (0.22)	(-0.28, 0.57)	0.514
	Placebo	11	11 (100.0)	-0.33 (0.14)	(-0.61, -0.05)			
Week 43	Tezepelumab	12	8 (66.7)	0.08 (0.16)	(-0.24, 0.40)	0.35 (0.22)	(-0.08, 0.78)	0.111
	Placebo	11	11 (100.0)	-0.27 (0.14)	(-0.55, 0.01)			
Week 44	Tezepelumab	12	8 (66.7)	-0.16 (0.16)	(-0.48, 0.17)	0.11 (0.22)	(-0.32, 0.54)	0.617
	Placebo	11	11 (100.0)	-0.26 (0.14)	(-0.55, 0.02)			
Week 45	Tezepelumab	12	8 (66.7)	-0.14 (0.17)	(-0.47, 0.18)	0.27 (0.22)	(-0.16, 0.70)	0.223
	Placebo	11	11 (100.0)	-0.41 (0.14)	(-0.69, -0.13)			
Week 46	Tezepelumab	12	8 (66.7)	-0.19 (0.17)	(-0.52, 0.14)	0.16 (0.22)	(-0.27, 0.59)	0.468
	Placebo	11	11 (100.0)	-0.35 (0.14)	(-0.63, -0.07)			
Week 47	Tezepelumab	12	8 (66.7)	-0.21 (0.17)	(-0.54, 0.12)	0.18 (0.22)	(-0.25, 0.62)	0.410
	Placebo	11	11 (100.0)	-0.39 (0.14)	(-0.67, -0.11)			
Week 48	Tezepelumab	12	7 (58.3)	-0.25 (0.17)	(-0.59, 0.08)	0.14 (0.22)	(-0.29, 0.58)	0.517
	Placebo	11	11 (100.0)	-0.40 (0.14)	(-0.68, -0.12)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	55	55 (100.0)	1.59 (0.70)	0.0	1.00	1.57	2.00	3.4	
		Placebo	40	40 (100.0)	1.79 (0.73)	0.1	1.23	1.86	2.18	3.9	
	Week 1	Tezepelumab	55	54 (98.2)	1.48 (0.67)	0.0	1.00	1.36	2.00	3.0	
		Placebo	40	40 (100.0)	1.57 (0.60)	0.0	1.15	1.62	2.00	2.9	
	Week 2	Tezepelumab	55	54 (98.2)	1.38 (0.74)	0.0	1.00	1.29	2.00	3.0	
		Placebo	40	39 (97.5)	1.50 (0.68)	0.0	1.00	1.29	2.00	3.3	
	Week 3	Tezepelumab	55	55 (100.0)	1.35 (0.75)	0.0	1.00	1.17	1.86	3.0	
		Placebo	40	38 (95.0)	1.51 (0.81)	0.0	1.00	1.23	2.00	3.0	
	Week 4	Tezepelumab	55	55 (100.0)	1.28 (0.74)	0.0	1.00	1.14	1.71	3.0	
		Placebo	40	39 (97.5)	1.49 (0.66)	0.0	1.00	1.29	2.00	2.8	
	Week 5	Tezepelumab	55	54 (98.2)	1.30 (0.74)	0.0	1.00	1.07	1.86	3.0	
		Placebo	40	39 (97.5)	1.38 (0.73)	0.0	1.00	1.17	2.00	3.0	
	Week 6	Tezepelumab	55	53 (96.4)	1.37 (0.80)	0.0	1.00	1.29	1.86	3.0	
		Placebo	40	40 (100.0)	1.46 (0.69)	0.0	1.00	1.36	2.00	3.3	
	Week 7	Tezepelumab	55	52 (94.5)	1.35 (0.87)	0.0	1.00	1.15	1.93	3.4	
		Placebo	40	40 (100.0)	1.42 (0.73)	0.0	1.00	1.36	2.00	4.0	
	Week 8	Tezepelumab	55	54 (98.2)	1.29 (0.79)	0.0	1.00	1.10	2.00	3.0	
		Placebo	40	40 (100.0)	1.49 (0.73)	0.0	1.00	1.31	2.00	3.9	
	Week 9	Tezepelumab	55	55 (100.0)	1.21 (0.73)	0.0	0.83	1.00	2.00	3.0	
		Placebo	40	40 (100.0)	1.40 (0.69)	0.0	1.00	1.33	2.00	2.9	
	Week 10	Tezepelumab	55	54 (98.2)	1.23 (0.77)	0.0	0.71	1.00	2.00	3.0	
		Placebo	40	40 (100.0)	1.43 (0.63)	0.0	1.00	1.43	1.86	2.6	
	Week 11	Tezepelumab	55	54 (98.2)	1.22 (0.81)	0.0	0.83	1.00	1.86	3.0	
		Placebo	40	40 (100.0)	1.33 (0.66)	0.0	1.00	1.29	1.93	2.9	
	Week 12	Tezepelumab	55	54 (98.2)	1.22 (0.80)	0.0	0.71	1.00	2.00	2.9	
		Placebo	40	38 (95.0)	1.34 (0.78)	0.0	1.00	1.07	2.00	3.5	
	Week 13	Tezepelumab	55	52 (94.5)	1.16 (0.83)	0.0	0.57	1.00	1.86	3.1	
		Placebo	40	39 (97.5)	1.33 (0.74)	0.0	1.00	1.29	1.86	3.6	
	Week 14	Tezepelumab	55	53 (96.4)	1.22 (0.82)	0.0	0.83	1.14	1.71	3.0	
		Placebo	40	38 (95.0)	1.39 (0.73)	0.0	1.00	1.17	2.00	2.9	
	Week 15	Tezepelumab	55	53 (96.4)	1.18 (0.76)	0.0	0.86	1.00	1.83	3.0	
		Placebo	40	40 (100.0)	1.30 (0.77)	0.0	0.93	1.14	2.00	3.5	
	Week 16	Tezepelumab	55	54 (98.2)	1.15 (0.79)	0.0	0.57	1.00	2.00	3.0	
		Placebo	40	39 (97.5)	1.35 (0.81)	0.0	1.00	1.14	2.00	3.1	
Week 17	Tezepelumab	55	54 (98.2)	1.12 (0.79)	0.0	0.43	1.00	1.75	3.0		
	Placebo	40	39 (97.5)	1.37 (0.75)	0.0	1.00	1.17	2.00	3.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	55	53 (96.4)	1.13 (0.80)	0.0	0.29	1.00	1.86	3.0	
		Placebo	40	39 (97.5)	1.35 (0.78)	0.0	1.00	1.14	2.00	3.7	
	Week 19	Tezepelumab	55	51 (92.7)	1.13 (0.83)	0.0	0.17	1.00	2.00	2.6	
		Placebo	40	39 (97.5)	1.35 (0.72)	0.0	1.00	1.20	2.00	2.9	
	Week 20	Tezepelumab	55	51 (92.7)	1.08 (0.82)	0.0	0.14	1.00	2.00	3.0	
		Placebo	40	39 (97.5)	1.29 (0.73)	0.0	1.00	1.14	2.00	2.6	
	Week 21	Tezepelumab	55	50 (90.9)	1.10 (0.81)	0.0	0.29	1.00	2.00	3.0	
		Placebo	40	38 (95.0)	1.25 (0.81)	0.0	0.86	1.00	2.00	3.0	
	Week 22	Tezepelumab	55	49 (89.1)	1.15 (0.73)	0.0	1.00	1.00	1.83	3.0	
		Placebo	40	39 (97.5)	1.32 (0.80)	0.0	1.00	1.14	2.00	3.0	
	Week 23	Tezepelumab	55	52 (94.5)	1.08 (0.77)	0.0	0.59	1.00	1.69	3.1	
		Placebo	40	37 (92.5)	1.29 (0.72)	0.0	1.00	1.20	2.00	2.9	
	Week 24	Tezepelumab	55	53 (96.4)	1.09 (0.81)	0.0	0.57	1.00	1.86	3.4	
		Placebo	40	38 (95.0)	1.32 (0.76)	0.0	0.83	1.14	2.00	2.9	
	Week 25	Tezepelumab	55	52 (94.5)	1.11 (0.78)	0.0	0.63	1.00	1.86	2.7	
		Placebo	40	37 (92.5)	1.31 (0.78)	0.0	1.00	1.00	2.00	3.0	
	Week 26	Tezepelumab	55	53 (96.4)	1.08 (0.78)	0.0	0.40	1.00	1.57	2.7	
		Placebo	40	38 (95.0)	1.37 (0.89)	0.0	1.00	1.31	2.00	3.4	
	Week 27	Tezepelumab	55	50 (90.9)	1.15 (0.80)	0.0	0.75	1.00	1.86	3.0	
		Placebo	40	36 (90.0)	1.33 (0.92)	0.0	0.92	1.14	2.00	4.0	
	Week 28	Tezepelumab	55	52 (94.5)	1.15 (0.87)	0.0	0.43	1.00	2.00	3.3	
		Placebo	40	38 (95.0)	1.38 (0.87)	0.0	1.00	1.00	2.00	3.1	
	Week 29	Tezepelumab	55	51 (92.7)	1.03 (0.73)	0.0	0.43	1.00	1.57	2.8	
		Placebo	40	37 (92.5)	1.32 (0.91)	0.0	0.86	1.00	2.00	3.3	
	Week 30	Tezepelumab	55	49 (89.1)	1.17 (0.77)	0.0	0.71	1.14	1.57	3.0	
		Placebo	40	37 (92.5)	1.26 (0.89)	0.0	0.57	1.00	2.00	3.0	
	Week 31	Tezepelumab	55	53 (96.4)	1.13 (0.78)	0.0	0.86	1.00	1.60	3.0	
		Placebo	40	37 (92.5)	1.19 (0.88)	0.0	0.57	1.00	2.00	3.3	
	Week 32	Tezepelumab	55	52 (94.5)	1.08 (0.75)	0.0	0.61	1.00	1.46	2.7	
		Placebo	40	37 (92.5)	1.20 (0.86)	0.0	0.57	1.00	1.86	3.0	
	Week 33	Tezepelumab	55	52 (94.5)	1.09 (0.77)	0.0	0.50	1.00	1.66	3.0	
		Placebo	40	38 (95.0)	1.27 (0.84)	0.0	0.57	1.00	2.00	3.0	
	Week 34	Tezepelumab	55	52 (94.5)	1.03 (0.79)	0.0	0.14	1.00	1.50	3.0	
		Placebo	40	38 (95.0)	1.22 (0.81)	0.0	0.71	1.00	1.86	3.0	
	Week 35	Tezepelumab	55	50 (90.9)	1.11 (0.79)	0.0	0.57	1.00	1.57	3.0	
		Placebo	40	37 (92.5)	1.18 (0.81)	0.0	0.71	1.00	2.00	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	55	51 (92.7)	1.12 (0.80)	0.0	0.57	1.00	1.71	3.0	
		Placebo	40	38 (95.0)	1.27 (0.75)	0.0	0.83	1.00	1.83	3.0	
	Week 37	Tezepelumab	55	50 (90.9)	1.19 (0.80)	0.0	0.86	1.00	2.00	3.0	
		Placebo	40	38 (95.0)	1.31 (0.78)	0.0	1.00	1.00	1.86	3.0	
	Week 38	Tezepelumab	55	51 (92.7)	1.16 (0.86)	0.0	0.50	1.00	2.00	3.0	
		Placebo	40	38 (95.0)	1.26 (0.86)	0.0	0.71	1.00	2.00	3.0	
	Week 39	Tezepelumab	55	52 (94.5)	1.10 (0.84)	0.0	0.31	1.00	1.92	3.0	
		Placebo	40	38 (95.0)	1.22 (0.89)	0.0	0.43	1.00	2.00	3.0	
	Week 40	Tezepelumab	55	52 (94.5)	1.11 (0.79)	0.0	0.59	1.00	1.69	3.0	
		Placebo	40	38 (95.0)	1.23 (0.90)	0.0	0.57	1.00	2.00	3.0	
	Week 41	Tezepelumab	55	53 (96.4)	1.13 (0.83)	0.0	0.83	1.00	1.71	3.0	
		Placebo	40	37 (92.5)	1.33 (0.95)	0.0	1.00	1.00	2.00	3.4	
	Week 42	Tezepelumab	55	51 (92.7)	1.19 (0.84)	0.0	0.40	1.00	2.00	3.0	
		Placebo	40	38 (95.0)	1.29 (0.90)	0.0	0.71	1.14	2.00	3.1	
	Week 43	Tezepelumab	55	51 (92.7)	1.11 (0.85)	0.0	0.20	1.00	2.00	3.1	
		Placebo	40	38 (95.0)	1.27 (0.89)	0.0	0.86	1.15	2.00	3.0	
	Week 44	Tezepelumab	55	50 (90.9)	1.05 (0.76)	0.0	0.14	1.00	1.71	2.7	
		Placebo	40	36 (90.0)	1.29 (0.83)	0.0	0.93	1.07	2.00	3.0	
	Week 45	Tezepelumab	55	51 (92.7)	1.10 (0.83)	0.0	0.43	1.00	2.00	3.3	
		Placebo	40	38 (95.0)	1.14 (0.83)	0.0	1.00	1.00	1.71	3.0	
	Week 46	Tezepelumab	55	52 (94.5)	1.10 (0.78)	0.0	0.41	1.00	1.93	2.9	
		Placebo	40	37 (92.5)	1.16 (0.88)	0.0	0.43	1.00	2.00	3.0	
	Week 47	Tezepelumab	55	46 (83.6)	1.11 (0.79)	0.0	0.57	1.00	1.86	3.0	
		Placebo	40	38 (95.0)	1.14 (0.86)	0.0	0.33	1.00	2.00	3.0	
	Week 48	Tezepelumab	55	51 (92.7)	1.16 (0.81)	0.0	0.83	1.00	2.00	3.0	
		Placebo	40	36 (90.0)	1.13 (0.88)	0.0	0.43	1.00	1.71	3.0	
	Week 49	Tezepelumab	55	49 (89.1)	1.25 (0.87)	0.0	1.00	1.00	2.00	2.9	
		Placebo	40	37 (92.5)	1.14 (0.87)	0.0	0.33	1.00	1.86	3.0	
	Week 50	Tezepelumab	55	49 (89.1)	1.15 (0.77)	0.0	1.00	1.00	1.86	3.0	
		Placebo	40	36 (90.0)	1.08 (0.81)	0.0	0.17	1.00	1.69	3.0	
	Week 51	Tezepelumab	55	47 (85.5)	1.18 (0.79)	0.0	1.00	1.00	2.00	3.0	
		Placebo	40	33 (82.5)	1.08 (0.86)	0.0	0.00	1.00	1.50	3.0	
	Week 52	Tezepelumab	55	43 (78.2)	1.21 (0.80)	0.0	1.00	1.14	2.00	2.9	
		Placebo	40	33 (82.5)	1.16 (0.89)	0.0	0.57	1.00	1.67	3.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	55	54 (98.2)	-0.13 (0.51)	-1.8	-0.29	0.00	0.14	0.9	0.19 [-0.22, 0.60]
		Placebo	40	40 (100.0)	-0.22 (0.46)	-1.7	-0.52	-0.14	0.00	0.5	
	Week 2	Tezepelumab	55	54 (98.2)	-0.23 (0.54)	-2.2	-0.43	-0.13	0.00	0.6	0.14 [-0.28, 0.55]
		Placebo	40	39 (97.5)	-0.31 (0.69)	-2.1	-0.71	-0.14	0.00	1.3	
	Week 3	Tezepelumab	55	55 (100.0)	-0.25 (0.66)	-2.2	-0.43	-0.14	0.00	1.0	0.08 [-0.33, 0.49]
		Placebo	40	38 (95.0)	-0.30 (0.82)	-2.9	-0.43	-0.14	0.00	1.0	
	Week 4	Tezepelumab	55	55 (100.0)	-0.31 (0.59)	-2.2	-0.57	-0.14	0.00	1.1	0.00 [-0.41, 0.41]
		Placebo	40	39 (97.5)	-0.31 (0.69)	-2.5	-0.40	-0.12	0.00	0.9	
	Week 5	Tezepelumab	55	54 (98.2)	-0.30 (0.55)	-2.2	-0.57	-0.14	0.00	0.9	0.18 [-0.23, 0.60]
		Placebo	40	39 (97.5)	-0.42 (0.78)	-2.7	-0.86	-0.14	0.00	1.0	
	Week 6	Tezepelumab	55	53 (96.4)	-0.24 (0.57)	-2.2	-0.43	-0.14	0.11	0.9	0.17 [-0.24, 0.58]
		Placebo	40	40 (100.0)	-0.34 (0.67)	-2.7	-0.56	-0.15	0.01	0.9	
	Week 7	Tezepelumab	55	52 (94.5)	-0.23 (0.68)	-2.2	-0.64	0.00	0.14	1.4	0.20 [-0.22, 0.61]
		Placebo	40	40 (100.0)	-0.37 (0.70)	-2.5	-0.84	-0.14	0.00	0.9	
	Week 8	Tezepelumab	55	54 (98.2)	-0.30 (0.67)	-2.2	-0.67	-0.14	0.00	1.2	0.01 [-0.40, 0.42]
		Placebo	40	40 (100.0)	-0.31 (0.72)	-2.7	-0.62	0.00	0.07	0.9	
	Week 9	Tezepelumab	55	55 (100.0)	-0.38 (0.73)	-2.4	-0.86	-0.17	0.00	1.0	0.02 [-0.39, 0.43]
		Placebo	40	40 (100.0)	-0.40 (0.72)	-2.7	-0.79	-0.15	0.00	0.9	
	Week 10	Tezepelumab	55	54 (98.2)	-0.36 (0.69)	-2.2	-0.86	-0.14	0.00	1.0	0.01 [-0.40, 0.42]
		Placebo	40	40 (100.0)	-0.36 (0.72)	-2.7	-0.81	-0.13	0.11	0.7	
	Week 11	Tezepelumab	55	54 (98.2)	-0.37 (0.69)	-2.2	-0.86	-0.15	0.00	1.0	0.14 [-0.27, 0.55]
		Placebo	40	40 (100.0)	-0.46 (0.77)	-2.7	-0.99	-0.21	0.14	0.9	
	Week 12	Tezepelumab	55	54 (98.2)	-0.38 (0.72)	-2.2	-0.86	-0.08	0.00	1.0	0.11 [-0.30, 0.53]
		Placebo	40	38 (95.0)	-0.48 (0.92)	-2.7	-1.00	-0.14	0.00	2.3	
	Week 13	Tezepelumab	55	52 (94.5)	-0.43 (0.78)	-2.2	-0.86	-0.29	0.00	1.3	0.06 [-0.36, 0.47]
		Placebo	40	39 (97.5)	-0.48 (0.87)	-2.7	-1.00	-0.29	0.00	2.4	
	Week 14	Tezepelumab	55	53 (96.4)	-0.38 (0.73)	-2.2	-0.71	-0.14	0.00	1.1	0.05 [-0.36, 0.47]
		Placebo	40	38 (95.0)	-0.43 (0.91)	-2.6	-1.06	-0.21	0.00	1.7	
	Week 15	Tezepelumab	55	53 (96.4)	-0.40 (0.70)	-2.2	-0.86	-0.17	0.00	0.8	0.11 [-0.30, 0.52]
		Placebo	40	40 (100.0)	-0.49 (0.93)	-2.7	-1.07	-0.29	0.00	2.3	
	Week 16	Tezepelumab	55	54 (98.2)	-0.46 (0.68)	-2.2	-0.79	-0.29	0.00	0.6	-0.00 [-0.42, 0.41]
		Placebo	40	39 (97.5)	-0.46 (0.90)	-2.7	-1.00	-0.29	0.00	2.0	
	Week 17	Tezepelumab	55	54 (98.2)	-0.49 (0.72)	-2.4	-0.86	-0.36	0.00	0.6	-0.07 [-0.48, 0.34]
		Placebo	40	39 (97.5)	-0.43 (0.83)	-2.7	-1.00	-0.29	0.00	1.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	55	53 (96.4)	-0.49 (0.78)	-2.4	-1.00	-0.29	0.00	1.0	-0.06 [-0.47, 0.35]
		Placebo	40	39 (97.5)	-0.44 (0.82)	-2.7	-0.86	-0.29	0.00	1.7	
	Week 19	Tezepelumab	55	51 (92.7)	-0.47 (0.79)	-2.4	-0.86	-0.29	0.00	0.9	-0.04 [-0.46, 0.37]
		Placebo	40	39 (97.5)	-0.44 (0.84)	-2.7	-1.00	-0.29	0.00	1.5	
	Week 20	Tezepelumab	55	51 (92.7)	-0.52 (0.75)	-2.4	-1.00	-0.29	0.00	0.6	-0.04 [-0.45, 0.38]
		Placebo	40	39 (97.5)	-0.49 (0.84)	-2.7	-1.00	-0.17	0.00	1.2	
	Week 21	Tezepelumab	55	50 (90.9)	-0.53 (0.79)	-2.4	-1.04	-0.29	0.00	0.9	0.03 [-0.39, 0.45]
		Placebo	40	38 (95.0)	-0.55 (0.90)	-2.7	-1.00	-0.36	0.00	1.8	
	Week 22	Tezepelumab	55	49 (89.1)	-0.47 (0.75)	-2.4	-0.86	-0.29	0.00	0.9	0.02 [-0.40, 0.44]
		Placebo	40	39 (97.5)	-0.49 (0.91)	-2.7	-1.00	-0.14	0.00	1.8	
	Week 23	Tezepelumab	55	52 (94.5)	-0.53 (0.76)	-2.4	-1.02	-0.29	0.00	0.7	0.01 [-0.41, 0.43]
		Placebo	40	37 (92.5)	-0.54 (0.81)	-2.7	-1.00	-0.29	0.00	0.9	
	Week 24	Tezepelumab	55	53 (96.4)	-0.51 (0.79)	-2.4	-1.00	-0.29	0.00	0.9	-0.01 [-0.42, 0.41]
		Placebo	40	38 (95.0)	-0.50 (0.84)	-2.7	-1.00	-0.20	0.00	0.9	
	Week 25	Tezepelumab	55	52 (94.5)	-0.51 (0.74)	-2.4	-1.00	-0.29	0.00	0.9	-0.00 [-0.42, 0.42]
		Placebo	40	37 (92.5)	-0.51 (0.88)	-2.7	-1.00	-0.23	0.00	1.4	
	Week 26	Tezepelumab	55	53 (96.4)	-0.50 (0.74)	-2.2	-1.00	-0.29	0.00	0.9	-0.05 [-0.47, 0.37]
		Placebo	40	38 (95.0)	-0.46 (0.99)	-2.7	-1.11	-0.19	0.14	1.6	
	Week 27	Tezepelumab	55	50 (90.9)	-0.43 (0.75)	-2.4	-0.86	-0.15	0.00	0.7	0.09 [-0.34, 0.52]
		Placebo	40	36 (90.0)	-0.51 (1.00)	-2.7	-1.17	-0.21	0.00	2.0	
	Week 28	Tezepelumab	55	52 (94.5)	-0.42 (0.81)	-2.4	-0.93	-0.29	0.00	1.1	0.03 [-0.39, 0.44]
		Placebo	40	38 (95.0)	-0.45 (0.93)	-2.7	-1.11	-0.21	0.00	1.6	
	Week 29	Tezepelumab	55	51 (92.7)	-0.54 (0.75)	-2.4	-0.86	-0.29	0.00	0.9	-0.05 [-0.48, 0.37]
		Placebo	40	37 (92.5)	-0.49 (1.03)	-2.7	-1.20	-0.29	0.02	1.9	
	Week 30	Tezepelumab	55	49 (89.1)	-0.50 (0.67)	-2.4	-0.86	-0.29	0.00	0.4	0.12 [-0.31, 0.55]
		Placebo	40	37 (92.5)	-0.60 (0.96)	-2.7	-1.29	-0.43	0.00	1.6	
	Week 31	Tezepelumab	55	53 (96.4)	-0.48 (0.76)	-2.4	-1.00	-0.40	0.00	1.0	0.15 [-0.27, 0.57]
		Placebo	40	37 (92.5)	-0.62 (1.01)	-2.7	-1.40	-0.29	0.00	1.9	
	Week 32	Tezepelumab	55	52 (94.5)	-0.56 (0.75)	-2.4	-0.93	-0.43	0.00	1.1	0.07 [-0.35, 0.49]
		Placebo	40	37 (92.5)	-0.61 (0.99)	-2.7	-1.20	-0.57	0.00	1.6	
	Week 33	Tezepelumab	55	52 (94.5)	-0.52 (0.77)	-2.4	-1.00	-0.29	0.00	0.9	0.03 [-0.39, 0.45]
		Placebo	40	38 (95.0)	-0.55 (0.96)	-2.7	-1.12	-0.41	0.00	1.6	
	Week 34	Tezepelumab	55	52 (94.5)	-0.59 (0.69)	-2.4	-1.00	-0.48	0.00	0.4	-0.00 [-0.42, 0.41]
		Placebo	40	38 (95.0)	-0.59 (0.95)	-2.7	-1.14	-0.49	0.00	1.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	55	50 (90.9)	-0.51 (0.76)	-2.4	-0.98	-0.29	0.00	0.9	0.20 [-0.23, 0.63]
		Placebo	40	37 (92.5)	-0.68 (0.96)	-2.7	-1.43	-0.43	0.00	1.3	
	Week 36	Tezepelumab	55	51 (92.7)	-0.49 (0.71)	-2.3	-0.86	-0.29	0.00	0.9	0.08 [-0.35, 0.50]
		Placebo	40	38 (95.0)	-0.55 (0.86)	-2.7	-1.17	-0.30	0.00	1.1	
	Week 37	Tezepelumab	55	50 (90.9)	-0.42 (0.74)	-2.4	-0.86	-0.21	0.00	1.1	0.09 [-0.33, 0.52]
		Placebo	40	38 (95.0)	-0.50 (0.89)	-2.7	-1.00	-0.35	0.00	1.6	
	Week 38	Tezepelumab	55	51 (92.7)	-0.45 (0.82)	-2.6	-0.86	-0.29	0.00	1.4	0.12 [-0.30, 0.54]
		Placebo	40	38 (95.0)	-0.55 (0.87)	-2.6	-1.00	-0.21	0.00	1.3	
	Week 39	Tezepelumab	55	52 (94.5)	-0.49 (0.77)	-2.3	-1.00	-0.29	0.00	0.9	0.12 [-0.30, 0.53]
		Placebo	40	38 (95.0)	-0.59 (0.88)	-2.7	-1.11	-0.21	0.00	0.9	
	Week 40	Tezepelumab	55	52 (94.5)	-0.51 (0.74)	-2.4	-0.93	-0.29	0.00	0.9	0.09 [-0.33, 0.51]
		Placebo	40	38 (95.0)	-0.58 (0.91)	-2.7	-1.20	-0.23	0.00	1.1	
	Week 41	Tezepelumab	55	53 (96.4)	-0.50 (0.74)	-2.4	-0.86	-0.29	0.00	0.9	-0.03 [-0.45, 0.39]
		Placebo	40	37 (92.5)	-0.47 (1.01)	-2.7	-1.11	-0.14	0.00	2.1	
	Week 42	Tezepelumab	55	51 (92.7)	-0.45 (0.74)	-2.4	-0.86	-0.14	0.00	0.9	0.09 [-0.33, 0.51]
		Placebo	40	38 (95.0)	-0.52 (0.88)	-2.5	-1.11	-0.14	0.10	1.1	
	Week 43	Tezepelumab	55	51 (92.7)	-0.49 (0.74)	-2.4	-0.86	-0.29	0.00	0.9	0.06 [-0.36, 0.48]
		Placebo	40	38 (95.0)	-0.54 (0.88)	-2.7	-1.00	-0.23	0.00	1.2	
	Week 44	Tezepelumab	55	50 (90.9)	-0.57 (0.71)	-2.4	-1.00	-0.43	0.00	0.9	-0.03 [-0.46, 0.40]
		Placebo	40	36 (90.0)	-0.54 (0.89)	-2.7	-1.07	-0.21	0.00	1.4	
	Week 45	Tezepelumab	55	51 (92.7)	-0.51 (0.74)	-2.2	-1.00	-0.29	0.00	0.9	0.19 [-0.23, 0.61]
		Placebo	40	38 (95.0)	-0.67 (0.91)	-2.7	-1.20	-0.57	0.00	1.6	
	Week 46	Tezepelumab	55	52 (94.5)	-0.51 (0.77)	-2.4	-1.00	-0.29	0.00	0.9	0.17 [-0.25, 0.59]
		Placebo	40	37 (92.5)	-0.65 (0.95)	-2.7	-1.40	-0.60	0.00	1.3	
	Week 47	Tezepelumab	55	46 (83.6)	-0.49 (0.86)	-2.4	-1.00	-0.29	0.00	1.9	0.21 [-0.22, 0.64]
		Placebo	40	38 (95.0)	-0.67 (0.90)	-2.7	-1.29	-0.32	0.00	1.1	
	Week 48	Tezepelumab	55	51 (92.7)	-0.42 (0.85)	-2.4	-1.00	-0.14	0.00	1.4	0.32 [-0.11, 0.75]
		Placebo	40	36 (90.0)	-0.70 (0.91)	-2.7	-1.24	-0.59	-0.01	1.1	
	Week 49	Tezepelumab	55	49 (89.1)	-0.39 (0.82)	-2.4	-1.00	0.00	0.00	1.0	0.33 [-0.10, 0.76]
		Placebo	40	37 (92.5)	-0.66 (0.85)	-2.7	-1.14	-0.29	0.00	0.7	
	Week 50	Tezepelumab	55	49 (89.1)	-0.45 (0.77)	-2.4	-0.86	-0.25	0.00	1.4	0.34 [-0.10, 0.77]
		Placebo	40	36 (90.0)	-0.72 (0.85)	-2.7	-1.29	-0.43	0.00	0.3	
	Week 51	Tezepelumab	55	47 (85.5)	-0.45 (0.76)	-2.4	-0.94	-0.29	0.00	1.0	0.37 [-0.08, 0.82]
		Placebo	40	33 (82.5)	-0.75 (0.88)	-2.7	-1.14	-0.57	0.00	0.4	
	Week 52	Tezepelumab	55	43 (78.2)	-0.41 (0.78)	-2.4	-0.86	-0.14	0.00	0.9	0.36 [-0.10, 0.82]
		Placebo	40	33 (82.5)	-0.70 (0.86)	-2.7	-1.14	-0.57	-0.14	0.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	55	54 (98.2)	-0.17 (0.09)	(-0.35, 0.02)	0.00 (0.15)	(-0.28, 0.29)	0.976
	Placebo	40	40 (100.0)	-0.17 (0.11)	(-0.39, 0.04)			
Week 2	Tezepelumab	55	54 (98.2)	-0.27 (0.09)	(-0.45, -0.09)	-0.02 (0.15)	(-0.31, 0.26)	0.874
	Placebo	40	39 (97.5)	-0.25 (0.11)	(-0.46, -0.03)			
Week 3	Tezepelumab	55	55 (100.0)	-0.29 (0.09)	(-0.48, -0.11)	-0.07 (0.15)	(-0.35, 0.22)	0.653
	Placebo	40	38 (95.0)	-0.23 (0.11)	(-0.44, -0.01)			
Week 4	Tezepelumab	55	55 (100.0)	-0.36 (0.09)	(-0.54, -0.17)	-0.11 (0.15)	(-0.39, 0.18)	0.464
	Placebo	40	39 (97.5)	-0.25 (0.11)	(-0.47, -0.04)			
Week 5	Tezepelumab	55	54 (98.2)	-0.34 (0.09)	(-0.52, -0.16)	0.03 (0.15)	(-0.26, 0.31)	0.861
	Placebo	40	39 (97.5)	-0.37 (0.11)	(-0.58, -0.15)			
Week 6	Tezepelumab	55	53 (96.4)	-0.25 (0.09)	(-0.44, -0.07)	0.04 (0.15)	(-0.25, 0.32)	0.792
	Placebo	40	40 (100.0)	-0.29 (0.11)	(-0.51, -0.07)			
Week 7	Tezepelumab	55	52 (94.5)	-0.27 (0.09)	(-0.46, -0.09)	0.05 (0.15)	(-0.23, 0.34)	0.727
	Placebo	40	40 (100.0)	-0.32 (0.11)	(-0.54, -0.11)			
Week 8	Tezepelumab	55	54 (98.2)	-0.34 (0.09)	(-0.53, -0.16)	-0.08 (0.14)	(-0.37, 0.20)	0.571
	Placebo	40	40 (100.0)	-0.26 (0.11)	(-0.48, -0.04)			
Week 9	Tezepelumab	55	55 (100.0)	-0.43 (0.09)	(-0.61, -0.25)	-0.08 (0.14)	(-0.37, 0.20)	0.575
	Placebo	40	40 (100.0)	-0.35 (0.11)	(-0.56, -0.13)			
Week 10	Tezepelumab	55	54 (98.2)	-0.41 (0.09)	(-0.60, -0.23)	-0.10 (0.14)	(-0.38, 0.19)	0.500
	Placebo	40	40 (100.0)	-0.31 (0.11)	(-0.53, -0.10)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	55	54 (98.2)	-0.43 (0.09)	(-0.61, -0.24)	-0.01 (0.14)	(-0.30, 0.27)	0.941
	Placebo	40	40 (100.0)	-0.42 (0.11)	(-0.63, -0.20)			
Week 12	Tezepelumab	55	54 (98.2)	-0.41 (0.09)	(-0.59, -0.22)	-0.01 (0.15)	(-0.29, 0.28)	0.958
	Placebo	40	38 (95.0)	-0.40 (0.11)	(-0.62, -0.18)			
Week 13	Tezepelumab	55	52 (94.5)	-0.45 (0.09)	(-0.64, -0.27)	-0.04 (0.15)	(-0.32, 0.25)	0.807
	Placebo	40	39 (97.5)	-0.42 (0.11)	(-0.64, -0.20)			
Week 14	Tezepelumab	55	53 (96.4)	-0.40 (0.09)	(-0.59, -0.22)	-0.05 (0.15)	(-0.34, 0.24)	0.733
	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.14)			
Week 15	Tezepelumab	55	53 (96.4)	-0.43 (0.09)	(-0.61, -0.24)	0.02 (0.15)	(-0.27, 0.30)	0.905
	Placebo	40	40 (100.0)	-0.44 (0.11)	(-0.66, -0.23)			
Week 16	Tezepelumab	55	54 (98.2)	-0.49 (0.09)	(-0.67, -0.30)	-0.09 (0.15)	(-0.37, 0.20)	0.557
	Placebo	40	39 (97.5)	-0.40 (0.11)	(-0.62, -0.19)			
Week 17	Tezepelumab	55	54 (98.2)	-0.52 (0.09)	(-0.70, -0.33)	-0.14 (0.15)	(-0.42, 0.15)	0.352
	Placebo	40	39 (97.5)	-0.38 (0.11)	(-0.60, -0.16)			
Week 18	Tezepelumab	55	53 (96.4)	-0.51 (0.09)	(-0.69, -0.32)	-0.13 (0.15)	(-0.41, 0.16)	0.376
	Placebo	40	39 (97.5)	-0.38 (0.11)	(-0.59, -0.16)			
Week 19	Tezepelumab	55	51 (92.7)	-0.50 (0.09)	(-0.69, -0.31)	-0.13 (0.15)	(-0.42, 0.16)	0.375
	Placebo	40	39 (97.5)	-0.37 (0.11)	(-0.59, -0.15)			
Week 20	Tezepelumab	55	51 (92.7)	-0.54 (0.09)	(-0.73, -0.35)	-0.07 (0.15)	(-0.35, 0.22)	0.648
	Placebo	40	39 (97.5)	-0.47 (0.11)	(-0.69, -0.26)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 21	Tezepelumab	55	50 (90.9)	-0.56 (0.10)	(-0.75, -0.37)	-0.08 (0.15)	(-0.36, 0.21)	0.593																																																																																																																										
	Placebo	40	38 (95.0)	-0.48 (0.11)	(-0.70, -0.27)				Week 22	Tezepelumab	55	49 (89.1)	-0.52 (0.10)	(-0.70, -0.33)	-0.08 (0.15)	(-0.37, 0.20)	0.576	Placebo	40	39 (97.5)	-0.44 (0.11)	(-0.65, -0.22)	Week 23	Tezepelumab	55	52 (94.5)	-0.56 (0.09)	(-0.75, -0.38)	-0.15 (0.15)	(-0.44, 0.14)	0.305	Placebo	40	37 (92.5)	-0.41 (0.11)	(-0.63, -0.20)	Week 24	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.42, 0.15)	0.349	Placebo	40	38 (95.0)	-0.40 (0.11)	(-0.61, -0.18)	Week 25	Tezepelumab	55	52 (94.5)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.43, 0.15)	0.342	Placebo	40	37 (92.5)	-0.39 (0.11)	(-0.61, -0.17)	Week 26	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.225	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)	Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo
Week 22	Tezepelumab	55	49 (89.1)	-0.52 (0.10)	(-0.70, -0.33)	-0.08 (0.15)	(-0.37, 0.20)	0.576																																																																																																																										
	Placebo	40	39 (97.5)	-0.44 (0.11)	(-0.65, -0.22)				Week 23	Tezepelumab	55	52 (94.5)	-0.56 (0.09)	(-0.75, -0.38)	-0.15 (0.15)	(-0.44, 0.14)	0.305	Placebo	40	37 (92.5)	-0.41 (0.11)	(-0.63, -0.20)	Week 24	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.42, 0.15)	0.349	Placebo	40	38 (95.0)	-0.40 (0.11)	(-0.61, -0.18)	Week 25	Tezepelumab	55	52 (94.5)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.43, 0.15)	0.342	Placebo	40	37 (92.5)	-0.39 (0.11)	(-0.61, -0.17)	Week 26	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.225	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)	Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)										
Week 23	Tezepelumab	55	52 (94.5)	-0.56 (0.09)	(-0.75, -0.38)	-0.15 (0.15)	(-0.44, 0.14)	0.305																																																																																																																										
	Placebo	40	37 (92.5)	-0.41 (0.11)	(-0.63, -0.20)				Week 24	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.42, 0.15)	0.349	Placebo	40	38 (95.0)	-0.40 (0.11)	(-0.61, -0.18)	Week 25	Tezepelumab	55	52 (94.5)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.43, 0.15)	0.342	Placebo	40	37 (92.5)	-0.39 (0.11)	(-0.61, -0.17)	Week 26	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.225	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)	Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																								
Week 24	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.42, 0.15)	0.349																																																																																																																										
	Placebo	40	38 (95.0)	-0.40 (0.11)	(-0.61, -0.18)				Week 25	Tezepelumab	55	52 (94.5)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.43, 0.15)	0.342	Placebo	40	37 (92.5)	-0.39 (0.11)	(-0.61, -0.17)	Week 26	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.225	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)	Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																						
Week 25	Tezepelumab	55	52 (94.5)	-0.53 (0.09)	(-0.72, -0.35)	-0.14 (0.15)	(-0.43, 0.15)	0.342																																																																																																																										
	Placebo	40	37 (92.5)	-0.39 (0.11)	(-0.61, -0.17)				Week 26	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.225	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)	Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																																				
Week 26	Tezepelumab	55	53 (96.4)	-0.53 (0.09)	(-0.72, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.225																																																																																																																										
	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)				Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)	Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																																																		
Week 27	Tezepelumab	55	50 (90.9)	-0.47 (0.09)	(-0.66, -0.29)	-0.08 (0.15)	(-0.37, 0.21)	0.590																																																																																																																										
	Placebo	40	36 (90.0)	-0.39 (0.11)	(-0.61, -0.17)				Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)	Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																																																																
Week 28	Tezepelumab	55	52 (94.5)	-0.48 (0.09)	(-0.67, -0.30)	-0.13 (0.15)	(-0.42, 0.15)	0.359																																																																																																																										
	Placebo	40	38 (95.0)	-0.35 (0.11)	(-0.57, -0.13)				Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)	Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																																																																														
Week 29	Tezepelumab	55	51 (92.7)	-0.60 (0.09)	(-0.78, -0.41)	-0.18 (0.15)	(-0.47, 0.11)	0.222																																																																																																																										
	Placebo	40	37 (92.5)	-0.42 (0.11)	(-0.64, -0.20)				Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																																																																																												
Week 30	Tezepelumab	55	49 (89.1)	-0.52 (0.09)	(-0.71, -0.34)	-0.02 (0.15)	(-0.31, 0.26)	0.870																																																																																																																										
	Placebo	40	37 (92.5)	-0.50 (0.11)	(-0.72, -0.28)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	55	53 (96.4)	-0.51 (0.09)	(-0.69, -0.32)	0.03 (0.15)	(-0.26, 0.32)	0.837
	Placebo	40	37 (92.5)	-0.54 (0.11)	(-0.76, -0.32)			
Week 32	Tezepelumab	55	52 (94.5)	-0.58 (0.09)	(-0.76, -0.39)	-0.04 (0.15)	(-0.33, 0.25)	0.789
	Placebo	40	37 (92.5)	-0.54 (0.11)	(-0.76, -0.32)			
Week 33	Tezepelumab	55	52 (94.5)	-0.57 (0.09)	(-0.76, -0.39)	-0.09 (0.15)	(-0.38, 0.20)	0.546
	Placebo	40	38 (95.0)	-0.48 (0.11)	(-0.71, -0.26)			
Week 34	Tezepelumab	55	52 (94.5)	-0.61 (0.09)	(-0.80, -0.43)	-0.08 (0.15)	(-0.37, 0.21)	0.572
	Placebo	40	38 (95.0)	-0.53 (0.11)	(-0.75, -0.31)			
Week 35	Tezepelumab	55	50 (90.9)	-0.55 (0.09)	(-0.74, -0.37)	0.03 (0.15)	(-0.25, 0.32)	0.813
	Placebo	40	37 (92.5)	-0.59 (0.11)	(-0.81, -0.37)			
Week 36	Tezepelumab	55	51 (92.7)	-0.50 (0.09)	(-0.68, -0.31)	-0.01 (0.15)	(-0.30, 0.28)	0.948
	Placebo	40	38 (95.0)	-0.49 (0.11)	(-0.71, -0.27)			
Week 37	Tezepelumab	55	50 (90.9)	-0.50 (0.09)	(-0.69, -0.32)	-0.06 (0.15)	(-0.35, 0.23)	0.672
	Placebo	40	38 (95.0)	-0.44 (0.11)	(-0.66, -0.22)			
Week 38	Tezepelumab	55	51 (92.7)	-0.47 (0.09)	(-0.66, -0.29)	0.02 (0.15)	(-0.27, 0.31)	0.902
	Placebo	40	38 (95.0)	-0.49 (0.11)	(-0.71, -0.27)			
Week 39	Tezepelumab	55	52 (94.5)	-0.53 (0.09)	(-0.72, -0.34)	-0.00 (0.15)	(-0.29, 0.29)	0.995
	Placebo	40	38 (95.0)	-0.53 (0.11)	(-0.75, -0.31)			
Week 40	Tezepelumab	55	52 (94.5)	-0.54 (0.09)	(-0.73, -0.36)	-0.02 (0.15)	(-0.31, 0.27)	0.898
	Placebo	40	38 (95.0)	-0.52 (0.11)	(-0.75, -0.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Time	Treatment	N	n (%)	Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	55	53 (96.4)	-0.52 (0.09)	(-0.71, -0.34)	-0.09 (0.15)	(-0.38, 0.20)	0.529
	Placebo	40	37 (92.5)	-0.43 (0.11)	(-0.65, -0.21)			
Week 42	Tezepelumab	55	51 (92.7)	-0.47 (0.09)	(-0.66, -0.29)	-0.01 (0.15)	(-0.30, 0.28)	0.951
	Placebo	40	38 (95.0)	-0.46 (0.11)	(-0.69, -0.24)			
Week 43	Tezepelumab	55	51 (92.7)	-0.52 (0.10)	(-0.71, -0.34)	-0.04 (0.15)	(-0.33, 0.25)	0.775
	Placebo	40	38 (95.0)	-0.48 (0.11)	(-0.70, -0.26)			
Week 44	Tezepelumab	55	50 (90.9)	-0.59 (0.10)	(-0.77, -0.40)	-0.09 (0.15)	(-0.38, 0.21)	0.566
	Placebo	40	36 (90.0)	-0.50 (0.11)	(-0.72, -0.28)			
Week 45	Tezepelumab	55	51 (92.7)	-0.56 (0.10)	(-0.75, -0.37)	0.05 (0.15)	(-0.24, 0.34)	0.741
	Placebo	40	38 (95.0)	-0.61 (0.11)	(-0.83, -0.39)			
Week 46	Tezepelumab	55	52 (94.5)	-0.54 (0.10)	(-0.73, -0.35)	0.04 (0.15)	(-0.25, 0.33)	0.801
	Placebo	40	37 (92.5)	-0.58 (0.11)	(-0.80, -0.35)			
Week 47	Tezepelumab	55	46 (83.6)	-0.55 (0.10)	(-0.74, -0.36)	0.06 (0.15)	(-0.23, 0.35)	0.688
	Placebo	40	38 (95.0)	-0.61 (0.11)	(-0.83, -0.39)			
Week 48	Tezepelumab	55	51 (92.7)	-0.48 (0.10)	(-0.67, -0.29)	0.13 (0.15)	(-0.17, 0.42)	0.399
	Placebo	40	36 (90.0)	-0.61 (0.11)	(-0.83, -0.38)			
Week 49	Tezepelumab	55	49 (89.1)	-0.44 (0.10)	(-0.63, -0.25)	0.17 (0.15)	(-0.12, 0.46)	0.257
	Placebo	40	37 (92.5)	-0.61 (0.11)	(-0.83, -0.38)			
Week 50	Tezepelumab	55	49 (89.1)	-0.51 (0.10)	(-0.70, -0.32)	0.12 (0.15)	(-0.17, 0.42)	0.407
	Placebo	40	36 (90.0)	-0.63 (0.11)	(-0.85, -0.41)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	55	47 (85.5)	-0.50 (0.10)	(-0.69, -0.30)	0.15 (0.15)	(-0.14, 0.45)	0.309
	Placebo	40	33 (82.5)	-0.65 (0.11)	(-0.87, -0.42)			
Week 52	Tezepelumab	55	43 (78.2)	-0.47 (0.10)	(-0.66, -0.27)	0.12 (0.15)	(-0.18, 0.42)	0.449
	Placebo	40	33 (82.5)	-0.58 (0.12)	(-0.81, -0.36)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	12	12 (100.0)	1.54 (0.91)	0.0	1.00	1.50	2.21	3.0	
		Placebo	11	11 (100.0)	2.16 (1.07)	0.0	1.43	2.17	3.00	4.0	
	Week 1	Tezepelumab	12	12 (100.0)	1.39 (0.78)	0.3	1.00	1.17	1.80	3.0	
		Placebo	11	11 (100.0)	1.98 (0.85)	0.3	1.71	2.00	2.71	3.0	
	Week 2	Tezepelumab	12	12 (100.0)	1.33 (0.81)	0.3	0.93	1.00	2.00	3.0	
		Placebo	11	11 (100.0)	2.22 (0.95)	0.6	1.86	2.00	3.00	4.0	
	Week 3	Tezepelumab	12	12 (100.0)	1.38 (0.72)	0.3	1.00	1.14	1.74	3.0	
		Placebo	11	11 (100.0)	1.95 (0.93)	0.4	1.00	2.00	3.00	3.0	
	Week 4	Tezepelumab	12	12 (100.0)	1.29 (0.82)	0.3	1.00	1.00	1.29	3.0	
		Placebo	11	11 (100.0)	2.04 (0.91)	0.4	1.43	2.00	3.00	3.0	
	Week 5	Tezepelumab	12	12 (100.0)	1.25 (0.93)	0.0	0.50	1.29	1.87	3.0	
		Placebo	11	11 (100.0)	2.05 (0.73)	0.9	1.86	2.00	3.00	3.0	
	Week 6	Tezepelumab	12	11 (91.7)	1.32 (0.91)	0.0	0.86	1.00	2.00	3.0	
		Placebo	11	11 (100.0)	1.98 (0.75)	0.5	1.60	2.00	2.71	3.0	
	Week 7	Tezepelumab	12	11 (91.7)	1.44 (0.94)	0.0	0.83	1.57	2.00	3.0	
		Placebo	11	11 (100.0)	2.00 (0.81)	0.6	1.29	2.00	3.00	3.0	
	Week 8	Tezepelumab	12	11 (91.7)	1.38 (0.94)	0.0	0.60	1.14	2.00	3.0	
		Placebo	11	11 (100.0)	2.08 (0.81)	0.3	1.86	2.00	3.00	3.0	
	Week 9	Tezepelumab	12	12 (100.0)	1.39 (0.99)	0.0	0.58	1.43	2.00	3.0	
		Placebo	11	11 (100.0)	2.09 (0.73)	0.7	1.57	2.00	3.00	3.0	
	Week 10	Tezepelumab	12	12 (100.0)	1.37 (0.92)	0.0	1.00	1.14	1.93	3.0	
		Placebo	11	10 (90.9)	1.91 (0.92)	0.0	1.43	2.00	2.83	3.0	
	Week 11	Tezepelumab	12	12 (100.0)	1.27 (0.92)	0.0	0.57	1.07	2.00	3.0	
		Placebo	11	10 (90.9)	1.75 (0.89)	0.0	1.29	1.93	2.43	3.0	
	Week 12	Tezepelumab	12	11 (91.7)	1.43 (0.89)	0.0	0.86	1.29	2.00	3.0	
		Placebo	11	11 (100.0)	1.98 (0.88)	0.2	1.57	2.00	2.71	3.0	
	Week 13	Tezepelumab	12	11 (91.7)	1.53 (0.97)	0.0	1.00	1.57	2.00	3.4	
		Placebo	11	11 (100.0)	2.07 (0.83)	0.0	1.86	2.00	2.86	3.0	
	Week 14	Tezepelumab	12	11 (91.7)	1.45 (0.99)	0.0	1.00	1.29	2.14	3.3	
		Placebo	11	11 (100.0)	2.04 (0.93)	0.0	1.71	2.00	3.00	3.3	
	Week 15	Tezepelumab	12	11 (91.7)	1.29 (0.93)	0.0	0.71	1.00	2.00	3.0	
		Placebo	11	11 (100.0)	1.91 (1.01)	0.0	1.33	2.00	3.00	3.1	
Week 16	Tezepelumab	12	11 (91.7)	1.33 (0.91)	0.0	0.86	1.00	2.00	3.0		
	Placebo	11	11 (100.0)	1.75 (0.91)	0.0	1.00	2.00	2.14	3.0		
Week 17	Tezepelumab	12	11 (91.7)	1.37 (1.08)	0.0	0.33	1.00	2.17	3.0		
	Placebo	11	11 (100.0)	1.74 (0.89)	0.0	1.00	1.86	2.17	3.0		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	12	11 (91.7)	1.39 (1.03)	0.0	0.14	1.43	2.00	3.0	
		Placebo	11	11 (100.0)	1.68 (0.90)	0.0	1.00	1.86	2.17	3.0	
	Week 19	Tezepelumab	12	11 (91.7)	1.48 (1.08)	0.0	0.86	1.14	2.00	3.3	
		Placebo	11	11 (100.0)	1.71 (0.88)	0.0	1.00	1.86	2.00	3.0	
	Week 20	Tezepelumab	12	11 (91.7)	1.44 (1.01)	0.0	0.43	1.00	2.43	3.0	
		Placebo	11	11 (100.0)	1.84 (0.96)	0.0	1.00	2.00	2.86	3.0	
	Week 21	Tezepelumab	12	11 (91.7)	1.56 (0.97)	0.1	0.86	1.71	2.33	3.0	
		Placebo	11	11 (100.0)	1.86 (0.89)	0.0	1.00	2.00	2.43	3.0	
	Week 22	Tezepelumab	12	11 (91.7)	1.44 (0.96)	0.0	0.57	1.00	2.43	3.0	
		Placebo	11	11 (100.0)	1.82 (0.99)	0.0	1.00	2.00	2.71	3.0	
	Week 23	Tezepelumab	12	11 (91.7)	1.47 (0.95)	0.2	0.57	1.29	2.14	3.0	
		Placebo	11	11 (100.0)	1.87 (1.07)	0.0	1.00	2.00	2.86	3.0	
	Week 24	Tezepelumab	12	11 (91.7)	1.38 (1.00)	0.0	0.86	1.14	2.00	3.3	
		Placebo	11	11 (100.0)	1.99 (0.99)	0.0	1.00	2.00	3.00	3.0	
	Week 25	Tezepelumab	12	11 (91.7)	1.62 (1.12)	0.0	1.00	1.86	3.00	3.0	
		Placebo	11	11 (100.0)	1.79 (0.93)	0.0	1.00	2.00	2.29	3.0	
	Week 26	Tezepelumab	12	11 (91.7)	1.65 (1.08)	0.0	1.00	1.43	2.67	3.5	
		Placebo	11	11 (100.0)	1.79 (0.90)	0.0	1.00	2.00	2.00	3.0	
	Week 27	Tezepelumab	12	10 (83.3)	1.50 (1.08)	0.0	1.00	1.21	2.33	3.3	
		Placebo	11	11 (100.0)	1.90 (0.92)	0.0	1.14	2.00	2.50	3.3	
	Week 28	Tezepelumab	12	9 (75.0)	1.64 (0.79)	0.7	1.00	1.43	2.00	3.0	
		Placebo	11	11 (100.0)	1.92 (0.96)	0.0	1.00	2.00	3.00	3.2	
	Week 29	Tezepelumab	12	8 (66.7)	1.29 (0.95)	0.0	0.79	1.07	1.79	3.0	
		Placebo	11	11 (100.0)	1.94 (0.95)	0.0	1.00	2.14	2.83	3.0	
	Week 30	Tezepelumab	12	10 (83.3)	1.34 (1.05)	0.0	0.43	1.17	2.00	3.0	
		Placebo	11	11 (100.0)	1.93 (1.02)	0.0	1.00	2.14	2.80	3.0	
	Week 31	Tezepelumab	12	9 (75.0)	1.55 (1.03)	0.0	1.00	1.43	2.29	3.0	
		Placebo	11	11 (100.0)	1.88 (0.96)	0.0	1.00	2.00	2.86	3.0	
	Week 32	Tezepelumab	12	10 (83.3)	1.44 (1.10)	0.0	1.00	1.07	2.83	3.0	
		Placebo	11	11 (100.0)	1.86 (1.03)	0.0	1.00	2.00	3.00	3.1	
	Week 33	Tezepelumab	12	10 (83.3)	1.38 (0.95)	0.1	0.67	1.00	2.50	2.8	
		Placebo	11	11 (100.0)	1.88 (1.00)	0.0	1.00	2.00	2.71	3.0	
	Week 34	Tezepelumab	12	10 (83.3)	1.39 (0.93)	0.1	0.86	1.00	2.00	3.0	
		Placebo	11	11 (100.0)	1.92 (1.06)	0.0	1.00	2.00	3.00	3.0	
	Week 35	Tezepelumab	12	10 (83.3)	1.41 (1.01)	0.1	1.00	1.07	2.00	3.1	
		Placebo	11	11 (100.0)	1.84 (1.10)	0.0	1.00	2.00	3.00	3.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	12	10 (83.3)	1.22 (1.05)	0.0	0.29	1.00	2.00	3.1	
		Placebo	11	11 (100.0)	1.83 (0.99)	0.0	1.00	2.00	3.00	3.0	
	Week 37	Tezepelumab	12	10 (83.3)	1.37 (1.12)	0.0	0.40	1.00	2.14	3.3	
		Placebo	11	11 (100.0)	1.73 (0.99)	0.0	1.00	2.00	2.50	3.0	
	Week 38	Tezepelumab	12	9 (75.0)	1.49 (1.16)	0.2	1.00	1.00	2.43	3.5	
		Placebo	11	11 (100.0)	1.75 (0.91)	0.0	1.00	2.00	2.29	3.0	
	Week 39	Tezepelumab	12	9 (75.0)	1.59 (0.99)	0.4	1.00	1.00	2.71	3.0	
		Placebo	11	11 (100.0)	1.79 (0.96)	0.0	1.00	2.00	2.83	3.0	
	Week 40	Tezepelumab	12	9 (75.0)	1.55 (0.94)	0.6	1.00	1.00	2.67	2.9	
		Placebo	11	11 (100.0)	1.91 (1.03)	0.0	1.00	2.00	2.83	3.4	
	Week 41	Tezepelumab	12	8 (66.7)	1.32 (0.85)	0.3	0.86	1.00	1.79	3.0	
		Placebo	11	11 (100.0)	1.78 (0.84)	0.0	1.14	2.00	2.43	3.0	
	Week 42	Tezepelumab	12	8 (66.7)	1.37 (0.82)	0.3	0.93	1.00	2.14	2.6	
		Placebo	11	11 (100.0)	1.78 (0.95)	0.0	1.00	2.00	2.57	3.0	
	Week 43	Tezepelumab	12	8 (66.7)	1.39 (0.92)	0.1	1.00	1.07	2.00	2.8	
		Placebo	11	11 (100.0)	1.84 (0.97)	0.0	1.00	2.00	3.00	3.0	
	Week 44	Tezepelumab	12	8 (66.7)	1.33 (0.96)	0.4	0.71	1.00	1.87	3.0	
		Placebo	11	11 (100.0)	1.78 (0.95)	0.0	1.00	2.00	2.57	3.0	
	Week 45	Tezepelumab	12	8 (66.7)	1.29 (0.89)	0.3	0.71	1.07	1.71	3.0	
		Placebo	11	11 (100.0)	1.73 (0.91)	0.0	1.00	2.00	2.14	3.0	
	Week 46	Tezepelumab	12	8 (66.7)	1.32 (0.91)	0.4	0.71	1.00	1.93	2.9	
		Placebo	11	11 (100.0)	1.74 (0.95)	0.0	1.00	2.00	2.29	3.0	
	Week 47	Tezepelumab	12	8 (66.7)	1.38 (1.05)	0.0	0.71	1.00	2.30	3.0	
		Placebo	11	11 (100.0)	1.70 (1.07)	0.0	1.00	2.00	2.71	3.0	
	Week 48	Tezepelumab	12	7 (58.3)	1.55 (0.94)	0.6	1.00	1.00	2.71	3.0	
		Placebo	11	11 (100.0)	1.74 (1.05)	0.0	1.00	2.00	2.86	3.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	12	12 (100.0)	-0.15 (0.46)	-1.0	-0.26	0.00	0.07	0.6	0.05 [-0.77, 0.87]
		Placebo	11	11 (100.0)	-0.18 (0.57)	-1.6	-0.50	0.00	0.29	0.4	
	Week 2	Tezepelumab	12	12 (100.0)	-0.20 (0.37)	-1.0	-0.36	-0.07	0.00	0.3	-0.76 [-1.61, 0.09]
		Placebo	11	11 (100.0)	0.06 (0.32)	-0.4	-0.17	0.00	0.29	0.6	
	Week 3	Tezepelumab	12	12 (100.0)	-0.16 (0.62)	-1.4	-0.56	0.00	0.10	1.0	0.08 [-0.74, 0.90]
		Placebo	11	11 (100.0)	-0.21 (0.65)	-1.6	-0.57	0.00	0.17	0.6	
	Week 4	Tezepelumab	12	12 (100.0)	-0.25 (0.73)	-1.4	-0.86	-0.14	0.13	0.9	-0.20 [-1.03, 0.62]
		Placebo	11	11 (100.0)	-0.12 (0.54)	-1.3	-0.17	0.00	0.17	0.6	
	Week 5	Tezepelumab	12	12 (100.0)	-0.28 (0.83)	-2.3	-0.71	0.00	0.30	0.6	-0.22 [-1.04, 0.60]
		Placebo	11	11 (100.0)	-0.10 (0.80)	-2.1	-0.29	0.00	0.29	1.0	
	Week 6	Tezepelumab	12	11 (91.7)	-0.26 (0.87)	-2.4	-0.71	0.00	0.29	0.6	-0.10 [-0.93, 0.74]
		Placebo	11	11 (100.0)	-0.17 (0.92)	-2.4	-0.31	0.00	0.43	1.1	
	Week 7	Tezepelumab	12	11 (91.7)	-0.15 (0.96)	-2.4	-0.71	0.00	0.69	0.9	0.01 [-0.83, 0.85]
		Placebo	11	11 (100.0)	-0.15 (0.80)	-1.9	-0.57	0.00	0.17	1.3	
	Week 8	Tezepelumab	12	11 (91.7)	-0.21 (0.92)	-2.4	-0.71	0.00	0.57	0.9	-0.15 [-0.99, 0.69]
		Placebo	11	11 (100.0)	-0.08 (0.78)	-1.6	-0.31	0.00	0.43	1.3	
	Week 9	Tezepelumab	12	12 (100.0)	-0.14 (0.96)	-2.3	-0.86	0.07	0.50	1.1	-0.08 [-0.90, 0.74]
		Placebo	11	11 (100.0)	-0.07 (0.83)	-2.0	-0.17	0.00	0.17	1.4	
	Week 10	Tezepelumab	12	12 (100.0)	-0.17 (0.98)	-2.4	-0.86	0.05	0.50	1.0	0.01 [-0.83, 0.85]
		Placebo	11	10 (90.9)	-0.18 (0.81)	-1.4	-0.50	-0.14	0.00	1.4	
	Week 11	Tezepelumab	12	12 (100.0)	-0.26 (0.85)	-2.4	-0.64	0.00	0.21	0.9	0.10 [-0.74, 0.93]
		Placebo	11	10 (90.9)	-0.34 (0.73)	-1.5	-0.71	-0.23	0.14	0.7	
	Week 12	Tezepelumab	12	11 (91.7)	-0.24 (1.02)	-2.4	-0.71	-0.14	0.00	1.6	-0.07 [-0.91, 0.76]
		Placebo	11	11 (100.0)	-0.18 (0.69)	-1.4	-0.43	-0.14	0.17	0.9	
	Week 13	Tezepelumab	12	11 (91.7)	-0.14 (1.05)	-2.4	-0.71	0.00	0.71	1.3	-0.06 [-0.89, 0.78]
		Placebo	11	11 (100.0)	-0.09 (0.93)	-1.7	-0.29	0.00	0.17	1.9	
	Week 14	Tezepelumab	12	11 (91.7)	-0.22 (1.01)	-2.4	-1.00	0.00	0.29	1.0	-0.11 [-0.95, 0.72]
		Placebo	11	11 (100.0)	-0.12 (0.84)	-1.4	-0.71	-0.14	0.17	1.9	
	Week 15	Tezepelumab	12	11 (91.7)	-0.39 (0.88)	-2.4	-1.00	-0.14	0.05	0.9	-0.19 [-1.03, 0.65]
		Placebo	11	11 (100.0)	-0.24 (0.60)	-1.4	-0.86	-0.17	0.17	0.6	
	Week 16	Tezepelumab	12	11 (91.7)	-0.35 (0.87)	-2.4	-0.71	-0.07	0.14	0.7	0.07 [-0.77, 0.90]
		Placebo	11	11 (100.0)	-0.40 (0.80)	-1.9	-1.00	-0.29	0.17	0.7	
	Week 17	Tezepelumab	12	11 (91.7)	-0.31 (0.94)	-2.4	-0.71	-0.29	0.43	0.9	0.12 [-0.72, 0.95]
		Placebo	11	11 (100.0)	-0.41 (0.89)	-2.1	-1.00	-0.14	0.17	0.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	12	11 (91.7)	-0.29 (0.98)	-2.3	-1.00	-0.29	0.43	1.3	0.22 [-0.62, 1.06]
		Placebo	11	11 (100.0)	-0.48 (0.77)	-1.8	-1.00	-0.31	0.00	0.9	
	Week 19	Tezepelumab	12	11 (91.7)	-0.19 (1.16)	-2.4	-1.00	0.00	0.57	2.0	0.24 [-0.59, 1.08]
		Placebo	11	11 (100.0)	-0.44 (0.83)	-2.0	-1.00	-0.17	0.14	0.9	
	Week 20	Tezepelumab	12	11 (91.7)	-0.24 (0.93)	-2.0	-1.00	-0.14	0.14	1.4	0.09 [-0.74, 0.93]
		Placebo	11	11 (100.0)	-0.32 (0.76)	-1.4	-1.00	-0.17	0.43	0.7	
	Week 21	Tezepelumab	12	11 (91.7)	-0.12 (1.08)	-2.3	-0.71	-0.24	0.71	1.7	0.19 [-0.65, 1.03]
		Placebo	11	11 (100.0)	-0.30 (0.85)	-1.6	-1.00	-0.17	0.43	1.0	
	Week 22	Tezepelumab	12	11 (91.7)	-0.23 (0.89)	-1.9	-1.00	-0.14	0.29	1.1	0.13 [-0.71, 0.97]
		Placebo	11	11 (100.0)	-0.34 (0.72)	-1.4	-1.00	-0.17	0.43	0.6	
	Week 23	Tezepelumab	12	11 (91.7)	-0.21 (0.98)	-2.0	-0.83	-0.29	0.29	1.5	0.10 [-0.74, 0.93]
		Placebo	11	11 (100.0)	-0.29 (0.66)	-1.4	-1.00	-0.17	0.17	0.6	
	Week 24	Tezepelumab	12	11 (91.7)	-0.29 (1.05)	-2.4	-1.00	-0.50	0.86	1.1	-0.14 [-0.97, 0.70]
		Placebo	11	11 (100.0)	-0.17 (0.75)	-1.4	-1.00	0.00	0.43	1.0	
	Week 25	Tezepelumab	12	11 (91.7)	-0.05 (1.41)	-2.4	-1.00	-0.14	0.86	2.7	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-0.37 (0.88)	-2.2	-1.00	-0.17	0.43	0.6	
	Week 26	Tezepelumab	12	11 (91.7)	-0.02 (1.27)	-2.1	-1.00	-0.43	1.43	1.9	0.31 [-0.53, 1.15]
		Placebo	11	11 (100.0)	-0.36 (0.88)	-2.0	-1.00	-0.17	0.43	0.7	
	Week 27	Tezepelumab	12	10 (83.3)	-0.04 (1.36)	-2.1	-1.00	-0.33	0.86	2.1	0.19 [-0.67, 1.05]
		Placebo	11	11 (100.0)	-0.25 (0.87)	-1.5	-1.00	-0.17	0.43	1.1	
	Week 28	Tezepelumab	12	9 (75.0)	0.04 (1.24)	-1.7	-0.71	-0.57	1.14	1.9	0.27 [-0.62, 1.15]
		Placebo	11	11 (100.0)	-0.23 (0.78)	-1.4	-1.00	-0.17	0.43	1.0	
	Week 29	Tezepelumab	12	8 (66.7)	-0.38 (1.21)	-2.4	-1.00	-0.43	0.29	1.7	-0.15 [-1.06, 0.77]
		Placebo	11	11 (100.0)	-0.22 (0.96)	-1.9	-1.00	-0.14	0.57	1.3	
	Week 30	Tezepelumab	12	10 (83.3)	-0.20 (1.27)	-2.4	-0.71	-0.57	0.33	1.9	0.02 [-0.84, 0.88]
		Placebo	11	11 (100.0)	-0.23 (0.72)	-1.4	-1.00	-0.14	0.43	0.7	
	Week 31	Tezepelumab	12	9 (75.0)	-0.06 (1.34)	-2.4	-0.71	-0.29	0.43	1.9	0.21 [-0.68, 1.09]
		Placebo	11	11 (100.0)	-0.27 (0.74)	-1.4	-1.00	-0.17	0.43	0.7	
	Week 32	Tezepelumab	12	10 (83.3)	-0.10 (1.27)	-2.4	-0.86	0.00	0.26	1.9	0.20 [-0.66, 1.05]
		Placebo	11	11 (100.0)	-0.30 (0.69)	-1.4	-1.00	-0.17	0.43	0.6	
	Week 33	Tezepelumab	12	10 (83.3)	-0.16 (1.16)	-2.3	-1.00	-0.10	0.43	1.5	0.12 [-0.74, 0.97]
		Placebo	11	11 (100.0)	-0.27 (0.75)	-1.6	-1.00	0.00	0.26	0.6	
	Week 34	Tezepelumab	12	10 (83.3)	-0.16 (1.10)	-2.3	-0.86	-0.07	0.57	1.6	0.09 [-0.77, 0.94]
		Placebo	11	11 (100.0)	-0.23 (0.65)	-1.4	-1.00	0.00	0.17	0.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMH0: Course of ASD weekly limiting activity score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	12	10 (83.3)	-0.13 (1.21)	-2.3	-1.00	-0.16	0.86	1.9	0.19 [-0.67, 1.05]
		Placebo	11	11 (100.0)	-0.31 (0.61)	-1.4	-0.86	-0.29	0.17	0.6	
	Week 36	Tezepelumab	12	10 (83.3)	-0.33 (1.10)	-2.4	-1.00	-0.36	0.57	1.3	-0.00 [-0.86, 0.86]
		Placebo	11	11 (100.0)	-0.32 (0.74)	-1.4	-1.00	-0.29	0.17	1.0	
	Week 37	Tezepelumab	12	10 (83.3)	-0.17 (1.21)	-2.4	-1.00	-0.30	0.71	1.7	0.25 [-0.61, 1.11]
		Placebo	11	11 (100.0)	-0.42 (0.71)	-1.5	-1.00	-0.43	0.17	0.6	
	Week 38	Tezepelumab	12	9 (75.0)	-0.12 (1.33)	-2.3	-1.00	0.00	0.29	2.2	0.26 [-0.62, 1.15]
		Placebo	11	11 (100.0)	-0.40 (0.83)	-1.9	-0.86	-0.45	0.17	1.0	
	Week 39	Tezepelumab	12	9 (75.0)	-0.02 (1.16)	-1.6	-1.00	0.14	0.43	1.9	0.37 [-0.52, 1.26]
		Placebo	11	11 (100.0)	-0.36 (0.72)	-1.4	-1.00	-0.29	0.17	0.9	
	Week 40	Tezepelumab	12	9 (75.0)	-0.06 (1.11)	-1.6	-1.00	0.14	0.29	1.7	0.21 [-0.67, 1.10]
		Placebo	11	11 (100.0)	-0.25 (0.71)	-1.4	-0.57	-0.29	0.17	1.1	
	Week 41	Tezepelumab	12	8 (66.7)	-0.16 (1.27)	-2.1	-1.00	-0.14	0.64	1.9	0.20 [-0.71, 1.11]
		Placebo	11	11 (100.0)	-0.38 (0.91)	-1.9	-1.00	-0.40	0.17	1.4	
	Week 42	Tezepelumab	12	8 (66.7)	-0.11 (1.28)	-2.1	-1.00	-0.07	1.00	1.4	0.27 [-0.65, 1.18]
		Placebo	11	11 (100.0)	-0.38 (0.77)	-1.4	-1.00	-0.17	0.17	0.9	
	Week 43	Tezepelumab	12	8 (66.7)	-0.09 (1.39)	-2.3	-1.00	-0.29	1.21	1.7	0.20 [-0.71, 1.12]
		Placebo	11	11 (100.0)	-0.31 (0.78)	-1.4	-1.00	-0.17	0.17	1.1	
	Week 44	Tezepelumab	12	8 (66.7)	-0.16 (1.28)	-2.0	-1.00	-0.29	0.73	1.9	0.22 [-0.70, 1.13]
		Placebo	11	11 (100.0)	-0.38 (0.77)	-1.4	-1.00	-0.17	0.17	0.9	
	Week 45	Tezepelumab	12	8 (66.7)	-0.20 (1.21)	-2.0	-0.93	-0.36	0.57	1.9	0.22 [-0.69, 1.14]
		Placebo	11	11 (100.0)	-0.43 (0.92)	-2.2	-1.00	-0.17	0.17	1.0	
	Week 46	Tezepelumab	12	8 (66.7)	-0.16 (1.25)	-2.0	-1.00	-0.29	0.79	1.7	0.25 [-0.66, 1.17]
		Placebo	11	11 (100.0)	-0.42 (0.78)	-1.7	-1.00	-0.29	0.17	0.7	
	Week 47	Tezepelumab	12	8 (66.7)	-0.10 (1.35)	-2.0	-1.00	-0.50	1.16	1.9	0.35 [-0.57, 1.27]
		Placebo	11	11 (100.0)	-0.45 (0.65)	-1.4	-1.00	-0.29	0.00	0.6	
	Week 48	Tezepelumab	12	7 (58.3)	0.20 (1.16)	-1.0	-1.00	0.29	1.43	1.9	0.70 [-0.28, 1.68]
		Placebo	11	11 (100.0)	-0.42 (0.66)	-1.4	-1.00	-0.29	0.17	0.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	12	12 (100.0)	-0.29 (0.23)	(-0.75, 0.17)	-0.22 (0.34)	(-0.90, 0.45)	0.508
	Placebo	11	11 (100.0)	-0.06 (0.24)	(-0.54, 0.42)			
Week 2	Tezepelumab	12	12 (100.0)	-0.34 (0.23)	(-0.80, 0.12)	-0.51 (0.34)	(-1.19, 0.16)	0.132
	Placebo	11	11 (100.0)	0.17 (0.24)	(-0.31, 0.65)			
Week 3	Tezepelumab	12	12 (100.0)	-0.30 (0.23)	(-0.76, 0.16)	-0.20 (0.34)	(-0.87, 0.47)	0.553
	Placebo	11	11 (100.0)	-0.10 (0.24)	(-0.58, 0.38)			
Week 4	Tezepelumab	12	12 (100.0)	-0.39 (0.23)	(-0.85, 0.07)	-0.38 (0.34)	(-1.06, 0.29)	0.260
	Placebo	11	11 (100.0)	-0.01 (0.24)	(-0.49, 0.47)			
Week 5	Tezepelumab	12	12 (100.0)	-0.42 (0.23)	(-0.88, 0.04)	-0.43 (0.34)	(-1.10, 0.24)	0.206
	Placebo	11	11 (100.0)	0.01 (0.24)	(-0.47, 0.49)			
Week 6	Tezepelumab	12	11 (91.7)	-0.47 (0.23)	(-0.93, -0.00)	-0.41 (0.34)	(-1.08, 0.27)	0.235
	Placebo	11	11 (100.0)	-0.06 (0.24)	(-0.54, 0.42)			
Week 7	Tezepelumab	12	11 (91.7)	-0.36 (0.23)	(-0.82, 0.11)	-0.31 (0.34)	(-0.99, 0.36)	0.358
	Placebo	11	11 (100.0)	-0.04 (0.24)	(-0.52, 0.44)			
Week 8	Tezepelumab	12	11 (91.7)	-0.42 (0.23)	(-0.88, 0.05)	-0.45 (0.34)	(-1.13, 0.22)	0.185
	Placebo	11	11 (100.0)	0.03 (0.24)	(-0.45, 0.51)			
Week 9	Tezepelumab	12	12 (100.0)	-0.28 (0.23)	(-0.74, 0.18)	-0.32 (0.34)	(-1.00, 0.35)	0.342
	Placebo	11	11 (100.0)	0.04 (0.24)	(-0.44, 0.52)			
Week 10	Tezepelumab	12	12 (100.0)	-0.31 (0.23)	(-0.77, 0.15)	-0.27 (0.34)	(-0.94, 0.41)	0.432
	Placebo	11	10 (90.9)	-0.04 (0.24)	(-0.52, 0.44)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	12	12 (100.0)	-0.40 (0.23)	(-0.86, 0.06)	-0.21 (0.34)	(-0.88, 0.47)	0.546
	Placebo	11	10 (90.9)	-0.20 (0.24)	(-0.68, 0.29)			
Week 12	Tezepelumab	12	11 (91.7)	-0.34 (0.23)	(-0.81, 0.12)	-0.28 (0.34)	(-0.95, 0.40)	0.418
	Placebo	11	11 (100.0)	-0.07 (0.24)	(-0.55, 0.41)			
Week 13	Tezepelumab	12	11 (91.7)	-0.24 (0.23)	(-0.71, 0.22)	-0.27 (0.34)	(-0.94, 0.41)	0.433
	Placebo	11	11 (100.0)	0.03 (0.24)	(-0.45, 0.50)			
Week 14	Tezepelumab	12	11 (91.7)	-0.32 (0.24)	(-0.79, 0.15)	-0.31 (0.34)	(-0.99, 0.36)	0.358
	Placebo	11	11 (100.0)	-0.01 (0.24)	(-0.48, 0.47)			
Week 15	Tezepelumab	12	11 (91.7)	-0.48 (0.24)	(-0.95, -0.01)	-0.35 (0.34)	(-1.03, 0.33)	0.305
	Placebo	11	11 (100.0)	-0.13 (0.24)	(-0.61, 0.35)			
Week 16	Tezepelumab	12	11 (91.7)	-0.44 (0.24)	(-0.91, 0.03)	-0.15 (0.34)	(-0.83, 0.53)	0.658
	Placebo	11	11 (100.0)	-0.29 (0.24)	(-0.77, 0.19)			
Week 17	Tezepelumab	12	11 (91.7)	-0.40 (0.24)	(-0.87, 0.07)	-0.10 (0.34)	(-0.78, 0.58)	0.773
	Placebo	11	11 (100.0)	-0.30 (0.24)	(-0.78, 0.18)			
Week 18	Tezepelumab	12	11 (91.7)	-0.38 (0.24)	(-0.85, 0.09)	-0.01 (0.34)	(-0.69, 0.67)	0.969
	Placebo	11	11 (100.0)	-0.37 (0.24)	(-0.85, 0.11)			
Week 19	Tezepelumab	12	11 (91.7)	-0.29 (0.24)	(-0.76, 0.19)	0.04 (0.34)	(-0.64, 0.72)	0.904
	Placebo	11	11 (100.0)	-0.33 (0.24)	(-0.81, 0.15)			
Week 20	Tezepelumab	12	11 (91.7)	-0.33 (0.24)	(-0.81, 0.14)	-0.13 (0.34)	(-0.81, 0.55)	0.713
	Placebo	11	11 (100.0)	-0.20 (0.24)	(-0.68, 0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	12	11 (91.7)	-0.21 (0.24)	(-0.68, 0.27)	-0.02 (0.34)	(-0.70, 0.66)	0.953
	Placebo	11	11 (100.0)	-0.19 (0.24)	(-0.67, 0.29)			
Week 22	Tezepelumab	12	11 (91.7)	-0.33 (0.24)	(-0.80, 0.15)	-0.10 (0.34)	(-0.78, 0.58)	0.773
	Placebo	11	11 (100.0)	-0.23 (0.24)	(-0.71, 0.25)			
Week 23	Tezepelumab	12	11 (91.7)	-0.30 (0.24)	(-0.77, 0.18)	-0.12 (0.34)	(-0.80, 0.56)	0.727
	Placebo	11	11 (100.0)	-0.18 (0.24)	(-0.66, 0.30)			
Week 24	Tezepelumab	12	11 (91.7)	-0.38 (0.24)	(-0.86, 0.09)	-0.33 (0.34)	(-1.01, 0.36)	0.345
	Placebo	11	11 (100.0)	-0.06 (0.24)	(-0.54, 0.42)			
Week 25	Tezepelumab	12	11 (91.7)	-0.14 (0.24)	(-0.62, 0.34)	0.11 (0.34)	(-0.57, 0.79)	0.743
	Placebo	11	11 (100.0)	-0.25 (0.24)	(-0.73, 0.23)			
Week 26	Tezepelumab	12	11 (91.7)	-0.11 (0.24)	(-0.59, 0.36)	0.14 (0.34)	(-0.54, 0.82)	0.686
	Placebo	11	11 (100.0)	-0.25 (0.24)	(-0.73, 0.23)			
Week 27	Tezepelumab	12	10 (83.3)	-0.08 (0.24)	(-0.56, 0.40)	0.06 (0.34)	(-0.62, 0.74)	0.864
	Placebo	11	11 (100.0)	-0.14 (0.24)	(-0.62, 0.34)			
Week 28	Tezepelumab	12	9 (75.0)	-0.10 (0.25)	(-0.59, 0.39)	0.02 (0.35)	(-0.67, 0.71)	0.951
	Placebo	11	11 (100.0)	-0.12 (0.24)	(-0.60, 0.36)			
Week 29	Tezepelumab	12	8 (66.7)	-0.26 (0.25)	(-0.75, 0.24)	-0.15 (0.35)	(-0.84, 0.54)	0.671
	Placebo	11	11 (100.0)	-0.11 (0.24)	(-0.59, 0.37)			
Week 30	Tezepelumab	12	10 (83.3)	-0.27 (0.25)	(-0.76, 0.22)	-0.15 (0.35)	(-0.84, 0.54)	0.658
	Placebo	11	11 (100.0)	-0.11 (0.24)	(-0.59, 0.37)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	12	9 (75.0)	-0.14 (0.25)	(-0.63, 0.35)	0.02 (0.35)	(-0.67, 0.71)	0.951
	Placebo	11	11 (100.0)	-0.16 (0.24)	(-0.64, 0.32)			
Week 32	Tezepelumab	12	10 (83.3)	-0.18 (0.25)	(-0.67, 0.32)	0.01 (0.35)	(-0.68, 0.70)	0.977
	Placebo	11	11 (100.0)	-0.19 (0.24)	(-0.67, 0.29)			
Week 33	Tezepelumab	12	10 (83.3)	-0.24 (0.25)	(-0.73, 0.25)	-0.08 (0.35)	(-0.77, 0.62)	0.823
	Placebo	11	11 (100.0)	-0.16 (0.24)	(-0.64, 0.32)			
Week 34	Tezepelumab	12	10 (83.3)	-0.24 (0.25)	(-0.74, 0.26)	-0.12 (0.35)	(-0.81, 0.58)	0.736
	Placebo	11	11 (100.0)	-0.12 (0.24)	(-0.60, 0.36)			
Week 35	Tezepelumab	12	10 (83.3)	-0.22 (0.25)	(-0.72, 0.28)	-0.02 (0.35)	(-0.72, 0.68)	0.957
	Placebo	11	11 (100.0)	-0.20 (0.24)	(-0.68, 0.28)			
Week 36	Tezepelumab	12	10 (83.3)	-0.42 (0.25)	(-0.91, 0.08)	-0.20 (0.35)	(-0.90, 0.49)	0.562
	Placebo	11	11 (100.0)	-0.21 (0.24)	(-0.69, 0.27)			
Week 37	Tezepelumab	12	10 (83.3)	-0.27 (0.25)	(-0.77, 0.23)	0.04 (0.35)	(-0.66, 0.74)	0.906
	Placebo	11	11 (100.0)	-0.31 (0.24)	(-0.79, 0.17)			
Week 38	Tezepelumab	12	9 (75.0)	-0.26 (0.25)	(-0.76, 0.25)	0.03 (0.35)	(-0.67, 0.74)	0.922
	Placebo	11	11 (100.0)	-0.29 (0.24)	(-0.77, 0.19)			
Week 39	Tezepelumab	12	9 (75.0)	-0.15 (0.26)	(-0.66, 0.35)	0.10 (0.35)	(-0.61, 0.80)	0.782
	Placebo	11	11 (100.0)	-0.25 (0.24)	(-0.73, 0.23)			
Week 40	Tezepelumab	12	9 (75.0)	-0.19 (0.26)	(-0.70, 0.32)	-0.05 (0.36)	(-0.76, 0.65)	0.879
	Placebo	11	11 (100.0)	-0.14 (0.24)	(-0.62, 0.34)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC_IBMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	12	8 (66.7)	-0.26 (0.26)	(-0.78, 0.26)	0.01 (0.36)	(-0.71, 0.72)	0.988
	Placebo	11	11 (100.0)	-0.26 (0.24)	(-0.74, 0.21)			
Week 42	Tezepelumab	12	8 (66.7)	-0.21 (0.26)	(-0.74, 0.31)	0.05 (0.36)	(-0.66, 0.77)	0.880
	Placebo	11	11 (100.0)	-0.26 (0.24)	(-0.74, 0.21)			
Week 43	Tezepelumab	12	8 (66.7)	-0.20 (0.27)	(-0.73, 0.33)	0.00 (0.36)	(-0.72, 0.72)	0.999
	Placebo	11	11 (100.0)	-0.20 (0.24)	(-0.68, 0.28)			
Week 44	Tezepelumab	12	8 (66.7)	-0.27 (0.27)	(-0.80, 0.27)	-0.00 (0.37)	(-0.73, 0.72)	0.992
	Placebo	11	11 (100.0)	-0.26 (0.24)	(-0.74, 0.21)			
Week 45	Tezepelumab	12	8 (66.7)	-0.31 (0.27)	(-0.85, 0.23)	0.01 (0.37)	(-0.72, 0.74)	0.984
	Placebo	11	11 (100.0)	-0.32 (0.24)	(-0.80, 0.16)			
Week 46	Tezepelumab	12	8 (66.7)	-0.28 (0.27)	(-0.82, 0.26)	0.02 (0.37)	(-0.71, 0.75)	0.947
	Placebo	11	11 (100.0)	-0.30 (0.24)	(-0.78, 0.18)			
Week 47	Tezepelumab	12	8 (66.7)	-0.23 (0.28)	(-0.77, 0.32)	0.12 (0.37)	(-0.62, 0.85)	0.752
	Placebo	11	11 (100.0)	-0.34 (0.24)	(-0.82, 0.14)			
Week 48	Tezepelumab	12	7 (58.3)	-0.18 (0.28)	(-0.73, 0.38)	0.13 (0.37)	(-0.61, 0.87)	0.731
	Placebo	11	11 (100.0)	-0.30 (0.24)	(-0.78, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMH0: Course of ASD weekly total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	54	54 (100.0)	1.36 (0.58)	0.1	1.00	1.34	1.76	2.6	
		Placebo	39	39 (100.0)	1.53 (0.55)	0.6	1.07	1.54	1.94	2.8	
	Week 1	Tezepelumab	54	53 (98.1)	1.21 (0.55)	0.1	0.93	1.13	1.49	2.5	
		Placebo	39	39 (100.0)	1.41 (0.53)	0.6	0.93	1.44	1.73	2.8	
	Week 2	Tezepelumab	54	53 (98.1)	1.13 (0.59)	0.0	0.84	1.07	1.57	2.3	
		Placebo	39	38 (97.4)	1.36 (0.54)	0.4	0.97	1.34	1.74	2.6	
	Week 3	Tezepelumab	54	54 (100.0)	1.12 (0.55)	0.0	0.89	1.12	1.44	2.6	
		Placebo	39	37 (94.9)	1.32 (0.62)	0.0	0.89	1.28	1.73	2.4	
	Week 4	Tezepelumab	54	53 (98.1)	1.06 (0.59)	0.0	0.63	1.03	1.48	2.6	
		Placebo	39	38 (97.4)	1.31 (0.55)	0.2	0.87	1.26	1.70	2.6	
	Week 5	Tezepelumab	54	52 (96.3)	1.02 (0.59)	0.0	0.59	0.99	1.44	2.5	
		Placebo	39	37 (94.9)	1.16 (0.53)	0.0	0.84	1.16	1.56	2.1	
	Week 6	Tezepelumab	54	51 (94.4)	1.06 (0.63)	0.0	0.65	0.99	1.49	2.7	
		Placebo	39	39 (100.0)	1.29 (0.57)	0.1	0.86	1.24	1.70	3.1	
	Week 7	Tezepelumab	54	50 (92.6)	1.05 (0.63)	0.0	0.71	1.02	1.39	2.8	
		Placebo	39	39 (100.0)	1.23 (0.58)	0.1	0.80	1.24	1.70	2.7	
	Week 8	Tezepelumab	54	50 (92.6)	1.01 (0.62)	0.0	0.62	0.94	1.40	2.6	
		Placebo	39	38 (97.4)	1.24 (0.52)	0.1	0.86	1.12	1.58	2.5	
	Week 9	Tezepelumab	54	52 (96.3)	0.97 (0.61)	0.0	0.51	0.89	1.41	2.5	
		Placebo	39	39 (100.0)	1.23 (0.56)	0.1	0.83	1.14	1.55	2.7	
	Week 10	Tezepelumab	54	52 (96.3)	0.96 (0.67)	0.0	0.41	0.89	1.48	2.7	
		Placebo	39	39 (100.0)	1.20 (0.51)	0.1	0.87	1.10	1.67	2.4	
	Week 11	Tezepelumab	54	50 (92.6)	0.99 (0.65)	0.0	0.46	0.98	1.41	2.7	
		Placebo	39	39 (100.0)	1.13 (0.53)	0.1	0.80	1.09	1.56	2.6	
	Week 12	Tezepelumab	54	51 (94.4)	0.94 (0.65)	0.0	0.47	0.87	1.41	2.8	
		Placebo	39	37 (94.9)	1.13 (0.56)	0.0	0.77	1.07	1.59	2.1	
	Week 13	Tezepelumab	54	48 (88.9)	0.95 (0.66)	0.0	0.49	0.86	1.44	2.7	
		Placebo	39	37 (94.9)	1.07 (0.52)	0.1	0.71	1.08	1.50	2.2	
	Week 14	Tezepelumab	54	51 (94.4)	0.98 (0.69)	0.0	0.53	0.96	1.43	2.6	
		Placebo	39	36 (92.3)	1.09 (0.51)	0.1	0.68	1.03	1.52	2.2	
	Week 15	Tezepelumab	54	50 (92.6)	0.91 (0.63)	0.0	0.50	0.92	1.40	2.4	
		Placebo	39	38 (97.4)	1.06 (0.55)	0.0	0.72	0.91	1.47	2.2	
	Week 16	Tezepelumab	54	50 (92.6)	0.89 (0.63)	0.0	0.42	0.83	1.40	2.2	
		Placebo	39	37 (94.9)	1.06 (0.52)	0.0	0.73	1.04	1.50	2.1	
Week 17	Tezepelumab	54	51 (94.4)	0.90 (0.65)	0.0	0.39	0.81	1.37	2.5		
	Placebo	39	37 (94.9)	1.12 (0.53)	0.1	0.76	1.11	1.51	2.3		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMH0: Course of ASD weekly total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	54	51 (94.4)	0.94 (0.68)	0.0	0.44	0.92	1.43	2.7	
		Placebo	39	37 (94.9)	1.11 (0.51)	0.2	0.73	1.10	1.50	2.1	
	Week 19	Tezepelumab	54	48 (88.9)	0.89 (0.70)	0.0	0.18	0.85	1.34	2.2	
		Placebo	39	38 (97.4)	1.11 (0.51)	0.0	0.78	1.10	1.50	2.2	
	Week 20	Tezepelumab	54	50 (92.6)	0.88 (0.68)	0.0	0.37	0.87	1.43	2.4	
		Placebo	39	36 (92.3)	1.09 (0.53)	0.0	0.76	1.06	1.48	2.3	
	Week 21	Tezepelumab	54	45 (83.3)	0.90 (0.67)	0.0	0.45	0.81	1.40	2.2	
		Placebo	39	37 (94.9)	1.06 (0.57)	0.0	0.77	0.96	1.51	2.3	
	Week 22	Tezepelumab	54	46 (85.2)	0.95 (0.62)	0.0	0.53	0.94	1.40	2.4	
		Placebo	39	37 (94.9)	1.08 (0.54)	0.1	0.79	1.08	1.49	2.4	
	Week 23	Tezepelumab	54	48 (88.9)	0.92 (0.69)	0.0	0.34	0.89	1.39	2.6	
		Placebo	39	35 (89.7)	1.06 (0.51)	0.0	0.80	1.09	1.48	2.3	
	Week 24	Tezepelumab	54	50 (92.6)	0.88 (0.70)	0.0	0.33	0.81	1.16	2.7	
		Placebo	39	35 (89.7)	0.98 (0.50)	0.0	0.59	0.90	1.44	1.9	
	Week 25	Tezepelumab	54	48 (88.9)	0.90 (0.65)	0.0	0.43	0.92	1.21	2.4	
		Placebo	39	35 (89.7)	1.04 (0.57)	0.0	0.53	0.90	1.54	2.3	
	Week 26	Tezepelumab	54	49 (90.7)	0.87 (0.67)	0.0	0.34	0.74	1.40	2.6	
		Placebo	39	36 (92.3)	1.06 (0.61)	0.0	0.50	1.08	1.52	2.3	
	Week 27	Tezepelumab	54	45 (83.3)	0.98 (0.70)	0.0	0.60	1.03	1.40	3.1	
		Placebo	39	35 (89.7)	1.10 (0.67)	0.0	0.54	1.10	1.53	2.8	
	Week 28	Tezepelumab	54	48 (88.9)	0.97 (0.70)	0.0	0.40	1.01	1.41	2.8	
		Placebo	39	35 (89.7)	1.07 (0.64)	0.0	0.66	1.03	1.52	2.4	
	Week 29	Tezepelumab	54	47 (87.0)	0.89 (0.66)	0.0	0.23	0.94	1.28	2.3	
		Placebo	39	36 (92.3)	1.06 (0.64)	0.0	0.59	0.99	1.59	2.6	
	Week 30	Tezepelumab	54	47 (87.0)	0.99 (0.65)	0.0	0.50	1.00	1.55	2.3	
		Placebo	39	35 (89.7)	1.01 (0.59)	0.0	0.55	1.00	1.50	2.8	
	Week 31	Tezepelumab	54	47 (87.0)	0.87 (0.61)	0.0	0.38	0.91	1.33	2.5	
		Placebo	39	36 (92.3)	0.99 (0.61)	0.0	0.54	0.91	1.36	2.8	
	Week 32	Tezepelumab	54	48 (88.9)	0.90 (0.62)	0.0	0.34	0.90	1.32	2.0	
		Placebo	39	36 (92.3)	1.01 (0.63)	0.0	0.49	0.90	1.44	2.8	
	Week 33	Tezepelumab	54	47 (87.0)	0.90 (0.64)	0.0	0.37	0.94	1.40	2.3	
		Placebo	39	36 (92.3)	1.07 (0.63)	0.0	0.62	0.96	1.47	2.8	
	Week 34	Tezepelumab	54	49 (90.7)	0.89 (0.64)	0.0	0.43	0.97	1.29	2.4	
		Placebo	39	37 (94.9)	1.06 (0.63)	0.0	0.50	0.90	1.47	2.8	
	Week 35	Tezepelumab	54	47 (87.0)	0.90 (0.66)	0.0	0.45	0.80	1.39	2.5	
		Placebo	39	35 (89.7)	1.04 (0.62)	0.0	0.61	1.01	1.41	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMH0: Course of ASD weekly total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	54	47 (87.0)	0.93 (0.68)	0.0	0.32	0.90	1.43	2.4	
		Placebo	39	37 (94.9)	1.11 (0.57)	0.1	0.66	0.98	1.52	2.8	
	Week 37	Tezepelumab	54	46 (85.2)	0.93 (0.66)	0.0	0.37	0.91	1.40	2.6	
		Placebo	39	36 (92.3)	1.10 (0.54)	0.1	0.80	1.05	1.46	2.7	
	Week 38	Tezepelumab	54	46 (85.2)	0.96 (0.70)	0.0	0.43	0.88	1.40	2.6	
		Placebo	39	36 (92.3)	1.04 (0.57)	0.0	0.60	1.02	1.45	2.8	
	Week 39	Tezepelumab	54	48 (88.9)	0.93 (0.68)	0.0	0.29	0.92	1.36	2.6	
		Placebo	39	36 (92.3)	1.04 (0.62)	0.0	0.59	0.95	1.50	2.8	
	Week 40	Tezepelumab	54	48 (88.9)	0.94 (0.65)	0.0	0.48	0.95	1.38	2.6	
		Placebo	39	37 (94.9)	1.10 (0.70)	0.0	0.54	1.00	1.50	2.8	
	Week 41	Tezepelumab	54	49 (90.7)	0.92 (0.67)	0.0	0.40	0.80	1.38	2.5	
		Placebo	39	35 (89.7)	1.10 (0.67)	0.0	0.63	0.98	1.60	2.8	
	Week 42	Tezepelumab	54	46 (85.2)	0.93 (0.70)	0.0	0.27	0.89	1.40	2.7	
		Placebo	39	35 (89.7)	1.12 (0.66)	0.0	0.67	1.08	1.57	2.8	
	Week 43	Tezepelumab	54	48 (88.9)	0.91 (0.71)	0.0	0.27	0.91	1.43	3.0	
		Placebo	39	36 (92.3)	1.07 (0.62)	0.0	0.59	0.98	1.55	2.8	
	Week 44	Tezepelumab	54	47 (87.0)	0.85 (0.65)	0.0	0.19	0.90	1.30	2.5	
		Placebo	39	34 (87.2)	1.10 (0.59)	0.1	0.67	1.06	1.59	2.8	
	Week 45	Tezepelumab	54	47 (87.0)	0.90 (0.69)	0.0	0.34	0.89	1.43	2.8	
		Placebo	39	35 (89.7)	0.99 (0.64)	0.0	0.42	0.99	1.49	2.8	
	Week 46	Tezepelumab	54	46 (85.2)	0.90 (0.67)	0.0	0.29	0.95	1.42	2.6	
		Placebo	39	36 (92.3)	1.01 (0.67)	0.0	0.42	0.97	1.51	2.8	
	Week 47	Tezepelumab	54	45 (83.3)	0.90 (0.69)	0.0	0.36	0.89	1.44	2.8	
		Placebo	39	36 (92.3)	1.01 (0.65)	0.0	0.40	0.90	1.53	2.8	
	Week 48	Tezepelumab	54	48 (88.9)	0.94 (0.73)	0.0	0.37	0.96	1.42	2.6	
		Placebo	39	36 (92.3)	0.98 (0.65)	0.0	0.40	0.95	1.53	2.8	
	Week 49	Tezepelumab	54	46 (85.2)	1.01 (0.72)	0.0	0.57	0.97	1.64	2.5	
		Placebo	39	35 (89.7)	0.99 (0.66)	0.0	0.42	0.90	1.54	2.8	
	Week 50	Tezepelumab	54	43 (79.6)	0.95 (0.69)	0.0	0.44	0.91	1.57	2.4	
		Placebo	39	34 (87.2)	0.96 (0.65)	0.0	0.40	0.92	1.50	2.8	
	Week 51	Tezepelumab	54	44 (81.5)	1.00 (0.67)	0.0	0.58	1.00	1.66	2.5	
		Placebo	39	32 (82.1)	0.99 (0.66)	0.0	0.44	0.91	1.60	2.8	
	Week 52	Tezepelumab	54	38 (70.4)	0.96 (0.67)	0.0	0.53	0.95	1.58	2.4	
		Placebo	39	31 (79.5)	1.02 (0.68)	0.0	0.45	0.89	1.63	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMH0: Course of ASD weekly total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	54	53 (98.1)	-0.16 (0.47)	-2.2	-0.23	-0.03	0.07	0.5	-0.09 [-0.50, 0.32]
		Placebo	39	39 (100.0)	-0.12 (0.30)	-0.9	-0.21	-0.13	0.00	0.8	
	Week 2	Tezepelumab	54	53 (98.1)	-0.24 (0.50)	-2.6	-0.30	-0.10	0.01	0.3	-0.13 [-0.54, 0.29]
		Placebo	39	38 (97.4)	-0.18 (0.51)	-1.9	-0.21	-0.10	0.03	1.1	
	Week 3	Tezepelumab	54	54 (100.0)	-0.24 (0.51)	-2.6	-0.41	-0.12	0.01	0.6	-0.04 [-0.46, 0.38]
		Placebo	39	37 (94.9)	-0.22 (0.64)	-2.4	-0.34	-0.07	0.01	1.0	
	Week 4	Tezepelumab	54	53 (98.1)	-0.29 (0.51)	-2.6	-0.44	-0.13	0.00	0.5	-0.13 [-0.55, 0.29]
		Placebo	39	38 (97.4)	-0.22 (0.56)	-2.4	-0.43	-0.04	0.06	0.5	
	Week 5	Tezepelumab	54	52 (96.3)	-0.33 (0.52)	-2.6	-0.48	-0.14	-0.02	0.3	0.02 [-0.40, 0.44]
		Placebo	39	37 (94.9)	-0.34 (0.64)	-2.6	-0.68	-0.18	0.04	1.1	
	Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.52)	-2.6	-0.44	-0.17	0.04	0.5	-0.09 [-0.51, 0.33]
		Placebo	39	39 (100.0)	-0.24 (0.58)	-2.5	-0.49	-0.09	0.11	0.5	
	Week 7	Tezepelumab	54	50 (92.6)	-0.29 (0.55)	-2.6	-0.48	-0.18	0.04	0.8	0.02 [-0.40, 0.44]
		Placebo	39	39 (100.0)	-0.30 (0.55)	-2.5	-0.61	-0.17	0.02	0.7	
	Week 8	Tezepelumab	54	50 (92.6)	-0.34 (0.54)	-2.6	-0.60	-0.18	-0.01	0.5	-0.13 [-0.55, 0.29]
		Placebo	39	38 (97.4)	-0.27 (0.61)	-2.5	-0.49	-0.18	0.05	1.4	
	Week 9	Tezepelumab	54	52 (96.3)	-0.38 (0.57)	-2.6	-0.74	-0.18	-0.02	0.7	-0.13 [-0.54, 0.29]
		Placebo	39	39 (100.0)	-0.30 (0.66)	-2.5	-0.70	-0.23	0.14	1.6	
	Week 10	Tezepelumab	54	52 (96.3)	-0.39 (0.58)	-2.6	-0.69	-0.26	-0.02	0.7	-0.10 [-0.52, 0.32]
		Placebo	39	39 (100.0)	-0.33 (0.59)	-2.5	-0.66	-0.10	-0.01	0.8	
	Week 11	Tezepelumab	54	50 (92.6)	-0.38 (0.56)	-2.6	-0.71	-0.20	0.00	0.6	0.04 [-0.38, 0.46]
		Placebo	39	39 (100.0)	-0.40 (0.60)	-2.4	-0.71	-0.26	0.01	0.6	
	Week 12	Tezepelumab	54	51 (94.4)	-0.41 (0.60)	-2.6	-0.79	-0.28	0.01	0.6	0.00 [-0.42, 0.43]
		Placebo	39	37 (94.9)	-0.41 (0.66)	-2.4	-0.72	-0.30	-0.03	1.4	
	Week 13	Tezepelumab	54	48 (88.9)	-0.37 (0.61)	-2.6	-0.72	-0.16	0.00	0.6	0.13 [-0.30, 0.56]
		Placebo	39	37 (94.9)	-0.45 (0.62)	-2.4	-0.86	-0.27	-0.09	1.4	
	Week 14	Tezepelumab	54	51 (94.4)	-0.40 (0.61)	-2.6	-0.79	-0.24	-0.03	0.8	0.06 [-0.37, 0.48]
		Placebo	39	36 (92.3)	-0.43 (0.65)	-2.4	-0.92	-0.32	-0.07	0.8	
	Week 15	Tezepelumab	54	50 (92.6)	-0.40 (0.59)	-2.6	-0.63	-0.21	-0.07	0.6	0.08 [-0.34, 0.50]
		Placebo	39	38 (97.4)	-0.45 (0.69)	-2.4	-0.95	-0.30	-0.04	1.4	
	Week 16	Tezepelumab	54	50 (92.6)	-0.45 (0.59)	-2.6	-0.84	-0.28	-0.03	0.4	0.02 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.46 (0.62)	-2.4	-0.81	-0.27	-0.04	0.9	
	Week 17	Tezepelumab	54	51 (94.4)	-0.46 (0.61)	-2.6	-0.79	-0.40	-0.04	0.6	-0.10 [-0.53, 0.32]
		Placebo	39	37 (94.9)	-0.40 (0.61)	-2.5	-0.73	-0.19	-0.04	0.7	
	Week 18	Tezepelumab	54	51 (94.4)	-0.43 (0.63)	-2.6	-0.84	-0.27	-0.02	0.8	-0.07 [-0.49, 0.35]
		Placebo	39	37 (94.9)	-0.39 (0.59)	-2.4	-0.68	-0.17	0.01	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMH0: Course of ASD weekly total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	54	48 (88.9)	-0.44 (0.63)	-2.6	-0.77	-0.25	-0.02	0.4	-0.05 [-0.48, 0.37]
		Placebo	39	38 (97.4)	-0.40 (0.61)	-2.6	-0.76	-0.23	-0.04	0.7	
	Week 20	Tezepelumab	54	50 (92.6)	-0.46 (0.62)	-2.6	-0.81	-0.30	-0.04	0.5	-0.05 [-0.48, 0.38]
		Placebo	39	36 (92.3)	-0.43 (0.60)	-2.3	-0.83	-0.29	-0.03	0.7	
	Week 21	Tezepelumab	54	45 (83.3)	-0.46 (0.61)	-2.6	-0.77	-0.30	-0.09	0.4	-0.00 [-0.44, 0.43]
		Placebo	39	37 (94.9)	-0.46 (0.66)	-2.4	-0.79	-0.39	0.03	1.2	
	Week 22	Tezepelumab	54	46 (85.2)	-0.41 (0.60)	-2.6	-0.76	-0.24	0.03	0.3	0.05 [-0.39, 0.48]
		Placebo	39	37 (94.9)	-0.44 (0.64)	-2.5	-0.85	-0.27	-0.01	1.2	
	Week 23	Tezepelumab	54	48 (88.9)	-0.46 (0.64)	-2.6	-0.88	-0.27	-0.04	0.5	0.04 [-0.40, 0.47]
		Placebo	39	35 (89.7)	-0.48 (0.59)	-2.2	-0.85	-0.25	-0.07	0.3	
	Week 24	Tezepelumab	54	50 (92.6)	-0.48 (0.63)	-2.6	-0.84	-0.34	-0.07	0.6	0.10 [-0.33, 0.53]
		Placebo	39	35 (89.7)	-0.54 (0.59)	-2.4	-0.87	-0.30	-0.06	0.1	
	Week 25	Tezepelumab	54	48 (88.9)	-0.47 (0.56)	-2.6	-0.81	-0.31	-0.03	0.3	0.05 [-0.39, 0.48]
		Placebo	39	35 (89.7)	-0.50 (0.66)	-2.6	-1.06	-0.33	-0.04	0.5	
	Week 26	Tezepelumab	54	49 (90.7)	-0.42 (0.63)	-2.6	-0.80	-0.29	0.02	0.5	0.10 [-0.34, 0.53]
		Placebo	39	36 (92.3)	-0.49 (0.74)	-2.6	-0.99	-0.32	-0.06	1.2	
	Week 27	Tezepelumab	54	45 (83.3)	-0.37 (0.65)	-2.6	-0.73	-0.21	0.04	0.8	0.12 [-0.32, 0.57]
		Placebo	39	35 (89.7)	-0.46 (0.80)	-2.6	-1.02	-0.35	-0.05	2.0	
	Week 28	Tezepelumab	54	48 (88.9)	-0.36 (0.63)	-2.5	-0.67	-0.17	0.01	0.9	0.13 [-0.31, 0.56]
		Placebo	39	35 (89.7)	-0.45 (0.72)	-2.6	-1.03	-0.27	0.06	0.7	
	Week 29	Tezepelumab	54	47 (87.0)	-0.48 (0.60)	-2.6	-0.83	-0.28	-0.09	0.3	-0.03 [-0.47, 0.40]
		Placebo	39	36 (92.3)	-0.46 (0.75)	-2.6	-1.01	-0.36	0.09	0.8	
	Week 30	Tezepelumab	54	47 (87.0)	-0.44 (0.57)	-2.6	-0.82	-0.24	0.00	0.4	0.15 [-0.28, 0.59]
		Placebo	39	35 (89.7)	-0.54 (0.69)	-2.6	-1.08	-0.51	-0.07	0.9	
	Week 31	Tezepelumab	54	47 (87.0)	-0.48 (0.64)	-2.6	-0.81	-0.34	-0.03	0.6	0.07 [-0.36, 0.51]
		Placebo	39	36 (92.3)	-0.52 (0.70)	-2.6	-1.10	-0.42	-0.11	1.2	
	Week 32	Tezepelumab	54	48 (88.9)	-0.47 (0.60)	-2.6	-0.81	-0.33	-0.04	0.5	0.07 [-0.36, 0.50]
		Placebo	39	36 (92.3)	-0.51 (0.71)	-2.6	-0.97	-0.48	-0.07	1.1	
	Week 33	Tezepelumab	54	47 (87.0)	-0.48 (0.65)	-2.6	-0.89	-0.31	0.00	0.5	-0.05 [-0.48, 0.38]
		Placebo	39	36 (92.3)	-0.45 (0.68)	-2.6	-0.75	-0.32	-0.10	1.0	
	Week 34	Tezepelumab	54	49 (90.7)	-0.51 (0.62)	-2.6	-0.86	-0.39	-0.01	0.5	-0.06 [-0.48, 0.37]
		Placebo	39	37 (94.9)	-0.48 (0.68)	-2.6	-0.82	-0.42	-0.07	0.9	
	Week 35	Tezepelumab	54	47 (87.0)	-0.46 (0.61)	-2.6	-0.81	-0.31	-0.03	0.6	0.07 [-0.36, 0.51]
		Placebo	39	35 (89.7)	-0.50 (0.67)	-2.6	-0.96	-0.49	-0.09	1.0	
	Week 36	Tezepelumab	54	47 (87.0)	-0.46 (0.62)	-2.6	-0.83	-0.31	-0.04	0.5	-0.05 [-0.48, 0.38]
		Placebo	39	37 (94.9)	-0.43 (0.63)	-2.5	-0.77	-0.35	-0.07	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMH0: Course of ASD weekly total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	54	46 (85.2)	-0.43 (0.60)	-2.6	-0.83	-0.31	0.00	0.4	-0.02 [-0.46, 0.41]
		Placebo	39	36 (92.3)	-0.42 (0.59)	-2.2	-0.75	-0.29	-0.07	0.8	
	Week 38	Tezepelumab	54	46 (85.2)	-0.39 (0.65)	-2.6	-0.76	-0.25	0.03	0.8	0.14 [-0.30, 0.58]
		Placebo	39	36 (92.3)	-0.48 (0.57)	-2.0	-0.92	-0.31	-0.10	0.7	
	Week 39	Tezepelumab	54	48 (88.9)	-0.43 (0.62)	-2.6	-0.75	-0.26	0.00	0.6	0.09 [-0.35, 0.52]
		Placebo	39	36 (92.3)	-0.48 (0.58)	-2.3	-0.83	-0.39	-0.05	0.5	
	Week 40	Tezepelumab	54	48 (88.9)	-0.46 (0.63)	-2.6	-0.87	-0.29	0.00	0.6	-0.03 [-0.46, 0.40]
		Placebo	39	37 (94.9)	-0.44 (0.68)	-2.4	-0.91	-0.42	-0.09	1.2	
	Week 41	Tezepelumab	54	49 (90.7)	-0.48 (0.63)	-2.6	-0.84	-0.37	-0.01	0.7	-0.10 [-0.53, 0.34]
		Placebo	39	35 (89.7)	-0.41 (0.75)	-2.4	-0.84	-0.34	-0.06	1.5	
	Week 42	Tezepelumab	54	46 (85.2)	-0.45 (0.63)	-2.6	-0.84	-0.25	-0.03	0.3	-0.08 [-0.52, 0.36]
		Placebo	39	35 (89.7)	-0.40 (0.59)	-1.8	-0.76	-0.38	-0.06	0.5	
	Week 43	Tezepelumab	54	48 (88.9)	-0.47 (0.62)	-2.6	-0.84	-0.34	-0.05	0.6	-0.03 [-0.46, 0.40]
		Placebo	39	36 (92.3)	-0.45 (0.55)	-1.8	-0.77	-0.43	-0.07	0.5	
	Week 44	Tezepelumab	54	47 (87.0)	-0.53 (0.60)	-2.6	-0.90	-0.41	-0.04	0.3	-0.14 [-0.58, 0.30]
		Placebo	39	34 (87.2)	-0.45 (0.58)	-1.9	-0.77	-0.30	-0.09	0.7	
	Week 45	Tezepelumab	54	47 (87.0)	-0.48 (0.64)	-2.6	-0.84	-0.33	0.00	0.5	0.10 [-0.33, 0.54]
		Placebo	39	35 (89.7)	-0.54 (0.62)	-2.4	-1.04	-0.43	-0.09	0.6	
	Week 46	Tezepelumab	54	46 (85.2)	-0.44 (0.66)	-2.6	-0.86	-0.31	0.01	0.8	0.12 [-0.32, 0.55]
		Placebo	39	36 (92.3)	-0.51 (0.65)	-2.6	-0.92	-0.50	-0.06	0.5	
	Week 47	Tezepelumab	54	45 (83.3)	-0.45 (0.68)	-2.6	-0.87	-0.21	0.00	0.8	0.08 [-0.36, 0.52]
		Placebo	39	36 (92.3)	-0.51 (0.63)	-2.6	-0.80	-0.37	-0.06	0.5	
	Week 48	Tezepelumab	54	48 (88.9)	-0.37 (0.70)	-2.6	-0.81	-0.16	0.07	0.9	0.25 [-0.18, 0.68]
		Placebo	39	36 (92.3)	-0.54 (0.62)	-2.6	-0.95	-0.45	-0.09	0.5	
	Week 49	Tezepelumab	54	46 (85.2)	-0.37 (0.68)	-2.6	-0.73	-0.18	0.06	0.9	0.23 [-0.21, 0.67]
		Placebo	39	35 (89.7)	-0.52 (0.61)	-2.6	-0.90	-0.37	-0.07	0.5	
	Week 50	Tezepelumab	54	43 (79.6)	-0.43 (0.62)	-2.6	-0.84	-0.19	-0.07	0.7	0.18 [-0.27, 0.63]
		Placebo	39	34 (87.2)	-0.54 (0.60)	-2.6	-0.86	-0.39	-0.10	0.5	
	Week 51	Tezepelumab	54	44 (81.5)	-0.37 (0.63)	-2.6	-0.75	-0.15	0.04	0.7	0.31 [-0.15, 0.76]
		Placebo	39	32 (82.1)	-0.56 (0.62)	-2.6	-0.88	-0.48	-0.15	0.5	
	Week 52	Tezepelumab	54	38 (70.4)	-0.38 (0.62)	-2.6	-0.77	-0.15	0.00	0.6	0.32 [-0.16, 0.80]
		Placebo	39	31 (79.5)	-0.58 (0.61)	-2.6	-0.85	-0.52	-0.23	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 1	Tezepelumab	54	53 (98.1)	-0.18 (0.07)	(-0.33, -0.04)	-0.11 (0.12)	(-0.33, 0.12)	0.350
	Placebo	39	39 (100.0)	-0.07 (0.09)	(-0.25, 0.10)			
Week 2	Tezepelumab	54	53 (98.1)	-0.27 (0.07)	(-0.41, -0.12)	-0.15 (0.12)	(-0.37, 0.08)	0.203
	Placebo	39	38 (97.4)	-0.12 (0.09)	(-0.29, 0.05)			
Week 3	Tezepelumab	54	54 (100.0)	-0.27 (0.07)	(-0.42, -0.13)	-0.12 (0.12)	(-0.35, 0.11)	0.295
	Placebo	39	37 (94.9)	-0.15 (0.09)	(-0.33, 0.02)			
Week 4	Tezepelumab	54	53 (98.1)	-0.34 (0.07)	(-0.48, -0.19)	-0.16 (0.12)	(-0.39, 0.06)	0.154
	Placebo	39	38 (97.4)	-0.17 (0.09)	(-0.34, 0.00)			
Week 5	Tezepelumab	54	52 (96.3)	-0.36 (0.07)	(-0.51, -0.21)	-0.08 (0.12)	(-0.30, 0.15)	0.499
	Placebo	39	37 (94.9)	-0.28 (0.09)	(-0.45, -0.11)			
Week 6	Tezepelumab	54	51 (94.4)	-0.31 (0.07)	(-0.46, -0.16)	-0.12 (0.12)	(-0.34, 0.11)	0.312
	Placebo	39	39 (100.0)	-0.19 (0.09)	(-0.37, -0.02)			
Week 7	Tezepelumab	54	50 (92.6)	-0.32 (0.07)	(-0.46, -0.17)	-0.06 (0.12)	(-0.29, 0.17)	0.596
	Placebo	39	39 (100.0)	-0.25 (0.09)	(-0.43, -0.08)			
Week 8	Tezepelumab	54	50 (92.6)	-0.36 (0.07)	(-0.50, -0.21)	-0.14 (0.12)	(-0.37, 0.08)	0.217
	Placebo	39	38 (97.4)	-0.21 (0.09)	(-0.39, -0.04)			
Week 9	Tezepelumab	54	52 (96.3)	-0.41 (0.07)	(-0.56, -0.26)	-0.15 (0.12)	(-0.38, 0.07)	0.188
	Placebo	39	39 (100.0)	-0.26 (0.09)	(-0.43, -0.09)			
Week 10	Tezepelumab	54	52 (96.3)	-0.42 (0.07)	(-0.57, -0.27)	-0.13 (0.12)	(-0.36, 0.09)	0.246
	Placebo	39	39 (100.0)	-0.28 (0.09)	(-0.46, -0.11)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	54	50 (92.6)	-0.42 (0.07)	(-0.56, -0.27)	-0.06 (0.12)	(-0.29, 0.16)	0.590
	Placebo	39	39 (100.0)	-0.35 (0.09)	(-0.53, -0.18)			
Week 12	Tezepelumab	54	51 (94.4)	-0.43 (0.07)	(-0.58, -0.29)	-0.09 (0.12)	(-0.31, 0.14)	0.453
	Placebo	39	37 (94.9)	-0.35 (0.09)	(-0.52, -0.17)			
Week 13	Tezepelumab	54	48 (88.9)	-0.42 (0.08)	(-0.57, -0.27)	-0.04 (0.12)	(-0.26, 0.19)	0.759
	Placebo	39	37 (94.9)	-0.38 (0.09)	(-0.56, -0.21)			
Week 14	Tezepelumab	54	51 (94.4)	-0.39 (0.07)	(-0.54, -0.24)	-0.04 (0.12)	(-0.26, 0.19)	0.749
	Placebo	39	36 (92.3)	-0.35 (0.09)	(-0.53, -0.18)			
Week 15	Tezepelumab	54	50 (92.6)	-0.43 (0.08)	(-0.57, -0.28)	-0.02 (0.12)	(-0.25, 0.21)	0.858
	Placebo	39	38 (97.4)	-0.41 (0.09)	(-0.58, -0.23)			
Week 16	Tezepelumab	54	50 (92.6)	-0.46 (0.08)	(-0.61, -0.32)	-0.06 (0.12)	(-0.29, 0.16)	0.587
	Placebo	39	37 (94.9)	-0.40 (0.09)	(-0.57, -0.23)			
Week 17	Tezepelumab	54	51 (94.4)	-0.46 (0.07)	(-0.61, -0.32)	-0.12 (0.12)	(-0.35, 0.11)	0.308
	Placebo	39	37 (94.9)	-0.35 (0.09)	(-0.52, -0.17)			
Week 18	Tezepelumab	54	51 (94.4)	-0.44 (0.07)	(-0.59, -0.29)	-0.11 (0.12)	(-0.33, 0.12)	0.354
	Placebo	39	37 (94.9)	-0.33 (0.09)	(-0.51, -0.16)			
Week 19	Tezepelumab	54	48 (88.9)	-0.46 (0.08)	(-0.61, -0.31)	-0.11 (0.12)	(-0.34, 0.12)	0.345
	Placebo	39	38 (97.4)	-0.35 (0.09)	(-0.53, -0.18)			
Week 20	Tezepelumab	54	50 (92.6)	-0.48 (0.08)	(-0.63, -0.33)	-0.08 (0.12)	(-0.31, 0.14)	0.465
	Placebo	39	36 (92.3)	-0.40 (0.09)	(-0.57, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	54	45 (83.3)	-0.50 (0.08)	(-0.65, -0.35)	-0.10 (0.12)	(-0.33, 0.13)	0.407
	Placebo	39	37 (94.9)	-0.40 (0.09)	(-0.58, -0.23)			
Week 22	Tezepelumab	54	46 (85.2)	-0.46 (0.08)	(-0.61, -0.31)	-0.08 (0.12)	(-0.31, 0.15)	0.503
	Placebo	39	37 (94.9)	-0.38 (0.09)	(-0.56, -0.21)			
Week 23	Tezepelumab	54	48 (88.9)	-0.47 (0.08)	(-0.62, -0.32)	-0.10 (0.12)	(-0.33, 0.13)	0.381
	Placebo	39	35 (89.7)	-0.37 (0.09)	(-0.55, -0.20)			
Week 24	Tezepelumab	54	50 (92.6)	-0.48 (0.08)	(-0.63, -0.34)	-0.05 (0.12)	(-0.28, 0.18)	0.652
	Placebo	39	35 (89.7)	-0.43 (0.09)	(-0.61, -0.26)			
Week 25	Tezepelumab	54	48 (88.9)	-0.50 (0.08)	(-0.65, -0.36)	-0.10 (0.12)	(-0.33, 0.13)	0.394
	Placebo	39	35 (89.7)	-0.40 (0.09)	(-0.58, -0.23)			
Week 26	Tezepelumab	54	49 (90.7)	-0.48 (0.08)	(-0.63, -0.34)	-0.09 (0.12)	(-0.32, 0.14)	0.458
	Placebo	39	36 (92.3)	-0.40 (0.09)	(-0.57, -0.22)			
Week 27	Tezepelumab	54	45 (83.3)	-0.43 (0.08)	(-0.57, -0.28)	-0.05 (0.12)	(-0.28, 0.18)	0.655
	Placebo	39	35 (89.7)	-0.37 (0.09)	(-0.55, -0.20)			
Week 28	Tezepelumab	54	48 (88.9)	-0.44 (0.08)	(-0.59, -0.29)	-0.10 (0.12)	(-0.33, 0.13)	0.399
	Placebo	39	35 (89.7)	-0.34 (0.09)	(-0.52, -0.17)			
Week 29	Tezepelumab	54	47 (87.0)	-0.50 (0.08)	(-0.65, -0.36)	-0.11 (0.12)	(-0.34, 0.12)	0.337
	Placebo	39	36 (92.3)	-0.39 (0.09)	(-0.57, -0.22)			
Week 30	Tezepelumab	54	47 (87.0)	-0.48 (0.08)	(-0.63, -0.33)	-0.03 (0.12)	(-0.26, 0.20)	0.830
	Placebo	39	35 (89.7)	-0.45 (0.09)	(-0.63, -0.28)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	54	47 (87.0)	-0.49 (0.08)	(-0.64, -0.34)	-0.03 (0.12)	(-0.26, 0.20)	0.772
	Placebo	39	36 (92.3)	-0.46 (0.09)	(-0.63, -0.28)			
Week 32	Tezepelumab	54	48 (88.9)	-0.51 (0.08)	(-0.66, -0.36)	-0.07 (0.12)	(-0.30, 0.16)	0.572
	Placebo	39	36 (92.3)	-0.44 (0.09)	(-0.62, -0.27)			
Week 33	Tezepelumab	54	47 (87.0)	-0.51 (0.08)	(-0.66, -0.36)	-0.10 (0.12)	(-0.34, 0.13)	0.371
	Placebo	39	36 (92.3)	-0.41 (0.09)	(-0.58, -0.23)			
Week 34	Tezepelumab	54	49 (90.7)	-0.54 (0.08)	(-0.69, -0.39)	-0.12 (0.12)	(-0.35, 0.11)	0.315
	Placebo	39	37 (94.9)	-0.42 (0.09)	(-0.60, -0.24)			
Week 35	Tezepelumab	54	47 (87.0)	-0.49 (0.08)	(-0.64, -0.34)	-0.06 (0.12)	(-0.29, 0.17)	0.614
	Placebo	39	35 (89.7)	-0.43 (0.09)	(-0.61, -0.26)			
Week 36	Tezepelumab	54	47 (87.0)	-0.47 (0.08)	(-0.62, -0.32)	-0.09 (0.12)	(-0.33, 0.14)	0.425
	Placebo	39	37 (94.9)	-0.37 (0.09)	(-0.55, -0.20)			
Week 37	Tezepelumab	54	46 (85.2)	-0.49 (0.08)	(-0.64, -0.34)	-0.14 (0.12)	(-0.37, 0.10)	0.250
	Placebo	39	36 (92.3)	-0.36 (0.09)	(-0.53, -0.18)			
Week 38	Tezepelumab	54	46 (85.2)	-0.46 (0.08)	(-0.61, -0.31)	-0.04 (0.12)	(-0.28, 0.19)	0.705
	Placebo	39	36 (92.3)	-0.42 (0.09)	(-0.60, -0.24)			
Week 39	Tezepelumab	54	48 (88.9)	-0.49 (0.08)	(-0.64, -0.34)	-0.08 (0.12)	(-0.31, 0.16)	0.521
	Placebo	39	36 (92.3)	-0.42 (0.09)	(-0.59, -0.24)			
Week 40	Tezepelumab	54	48 (88.9)	-0.49 (0.08)	(-0.64, -0.34)	-0.10 (0.12)	(-0.34, 0.13)	0.383
	Placebo	39	37 (94.9)	-0.38 (0.09)	(-0.56, -0.21)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	54	49 (90.7)	-0.49 (0.08)	(-0.64, -0.34)	-0.13 (0.12)	(-0.36, 0.10)	0.264
	Placebo	39	35 (89.7)	-0.36 (0.09)	(-0.54, -0.18)			
Week 42	Tezepelumab	54	46 (85.2)	-0.47 (0.08)	(-0.62, -0.32)	-0.12 (0.12)	(-0.35, 0.11)	0.310
	Placebo	39	35 (89.7)	-0.35 (0.09)	(-0.53, -0.17)			
Week 43	Tezepelumab	54	48 (88.9)	-0.50 (0.08)	(-0.65, -0.35)	-0.11 (0.12)	(-0.34, 0.13)	0.368
	Placebo	39	36 (92.3)	-0.40 (0.09)	(-0.57, -0.22)			
Week 44	Tezepelumab	54	47 (87.0)	-0.55 (0.08)	(-0.70, -0.40)	-0.15 (0.12)	(-0.38, 0.08)	0.206
	Placebo	39	34 (87.2)	-0.40 (0.09)	(-0.58, -0.22)			
Week 45	Tezepelumab	54	47 (87.0)	-0.52 (0.08)	(-0.67, -0.37)	-0.04 (0.12)	(-0.28, 0.19)	0.715
	Placebo	39	35 (89.7)	-0.48 (0.09)	(-0.66, -0.30)			
Week 46	Tezepelumab	54	46 (85.2)	-0.52 (0.08)	(-0.67, -0.36)	-0.05 (0.12)	(-0.29, 0.18)	0.649
	Placebo	39	36 (92.3)	-0.46 (0.09)	(-0.64, -0.28)			
Week 47	Tezepelumab	54	45 (83.3)	-0.50 (0.08)	(-0.65, -0.35)	-0.04 (0.12)	(-0.27, 0.19)	0.742
	Placebo	39	36 (92.3)	-0.46 (0.09)	(-0.63, -0.28)			
Week 48	Tezepelumab	54	48 (88.9)	-0.43 (0.08)	(-0.58, -0.28)	0.06 (0.12)	(-0.18, 0.29)	0.637
	Placebo	39	36 (92.3)	-0.49 (0.09)	(-0.66, -0.31)			
Week 49	Tezepelumab	54	46 (85.2)	-0.43 (0.08)	(-0.59, -0.28)	0.04 (0.12)	(-0.20, 0.27)	0.744
	Placebo	39	35 (89.7)	-0.47 (0.09)	(-0.65, -0.30)			
Week 50	Tezepelumab	54	43 (79.6)	-0.48 (0.08)	(-0.63, -0.33)	0.01 (0.12)	(-0.22, 0.25)	0.908
	Placebo	39	34 (87.2)	-0.50 (0.09)	(-0.68, -0.32)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC_ABMC0: Change from baseline in ASD weekly total score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	54	44 (81.5)	-0.45 (0.08)	(-0.60, -0.30)	0.04 (0.12)	(-0.20, 0.27)	0.767
	Placebo	39	32 (82.1)	-0.49 (0.09)	(-0.67, -0.31)			
Week 52	Tezepelumab	54	38 (70.4)	-0.46 (0.08)	(-0.61, -0.30)	0.02 (0.12)	(-0.22, 0.26)	0.855
	Placebo	39	31 (79.5)	-0.48 (0.09)	(-0.66, -0.30)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMH0: Course of ASD weekly daytime score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	54	54 (100.0)	1.45 (0.59)	0.0	1.00	1.51	1.97	2.6	
		Placebo	39	39 (100.0)	1.68 (0.57)	0.7	1.26	1.60	2.06	2.9	
	Week 1	Tezepelumab	54	53 (98.1)	1.33 (0.55)	0.2	1.03	1.26	1.71	2.5	
		Placebo	39	39 (100.0)	1.52 (0.56)	0.5	1.13	1.49	1.89	2.8	
	Week 2	Tezepelumab	54	53 (98.1)	1.23 (0.62)	0.0	0.91	1.20	1.74	2.3	
		Placebo	39	38 (97.4)	1.46 (0.60)	0.4	1.10	1.33	1.89	2.9	
	Week 3	Tezepelumab	54	54 (100.0)	1.22 (0.58)	0.0	0.94	1.21	1.57	2.7	
		Placebo	39	37 (94.9)	1.44 (0.69)	0.0	0.94	1.40	1.86	2.7	
	Week 4	Tezepelumab	54	54 (100.0)	1.15 (0.61)	0.0	0.71	1.14	1.53	2.7	
		Placebo	39	38 (97.4)	1.43 (0.61)	0.2	0.94	1.43	1.80	2.8	
	Week 5	Tezepelumab	54	53 (98.1)	1.14 (0.63)	0.0	0.80	1.00	1.60	2.6	
		Placebo	39	38 (97.4)	1.29 (0.60)	0.0	0.83	1.33	1.80	2.5	
	Week 6	Tezepelumab	54	52 (96.3)	1.19 (0.68)	0.0	0.74	1.13	1.63	2.8	
		Placebo	39	39 (100.0)	1.39 (0.61)	0.1	0.97	1.37	1.80	3.1	
	Week 7	Tezepelumab	54	51 (94.4)	1.18 (0.69)	0.0	0.74	1.16	1.54	3.1	
		Placebo	39	39 (100.0)	1.34 (0.60)	0.1	0.86	1.37	1.80	3.1	
	Week 8	Tezepelumab	54	53 (98.1)	1.15 (0.66)	0.0	0.74	1.11	1.60	2.7	
		Placebo	39	39 (100.0)	1.37 (0.56)	0.1	0.91	1.31	1.77	2.4	
	Week 9	Tezepelumab	54	54 (100.0)	1.10 (0.65)	0.0	0.60	1.00	1.66	2.7	
		Placebo	39	39 (100.0)	1.33 (0.58)	0.1	0.97	1.26	1.70	2.9	
	Week 10	Tezepelumab	54	53 (98.1)	1.09 (0.69)	0.0	0.57	1.06	1.67	2.8	
		Placebo	39	39 (100.0)	1.31 (0.54)	0.0	1.00	1.23	1.77	2.5	
	Week 11	Tezepelumab	54	53 (98.1)	1.09 (0.70)	0.0	0.54	1.07	1.60	2.9	
		Placebo	39	39 (100.0)	1.24 (0.56)	0.1	0.80	1.26	1.66	2.6	
	Week 12	Tezepelumab	54	53 (98.1)	1.07 (0.67)	0.0	0.63	1.00	1.63	2.9	
		Placebo	39	37 (94.9)	1.23 (0.61)	0.0	0.87	1.14	1.74	2.2	
	Week 13	Tezepelumab	54	51 (94.4)	1.03 (0.70)	0.0	0.49	0.97	1.60	2.9	
		Placebo	39	38 (97.4)	1.20 (0.58)	0.0	0.77	1.29	1.60	2.3	
	Week 14	Tezepelumab	54	52 (96.3)	1.08 (0.72)	0.0	0.60	1.00	1.57	2.8	
		Placebo	39	37 (94.9)	1.21 (0.56)	0.1	0.77	1.20	1.63	2.2	
	Week 15	Tezepelumab	54	52 (96.3)	1.03 (0.67)	0.0	0.54	0.96	1.57	2.6	
		Placebo	39	39 (100.0)	1.16 (0.57)	0.0	0.77	1.23	1.63	2.2	
	Week 16	Tezepelumab	54	53 (98.1)	1.02 (0.68)	0.0	0.49	1.00	1.60	2.3	
		Placebo	39	38 (97.4)	1.20 (0.58)	0.0	0.77	1.26	1.69	2.1	
Week 17	Tezepelumab	54	53 (98.1)	1.00 (0.69)	0.0	0.40	1.00	1.52	2.5		
	Placebo	39	38 (97.4)	1.24 (0.57)	0.1	0.77	1.28	1.60	2.5		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMH0: Course of ASD weekly daytime score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	54	52 (96.3)	1.02 (0.72)	0.0	0.41	1.00	1.60	2.8	
		Placebo	39	38 (97.4)	1.23 (0.56)	0.2	0.80	1.23	1.69	2.2	
	Week 19	Tezepelumab	54	50 (92.6)	1.00 (0.75)	0.0	0.27	0.95	1.60	2.3	
		Placebo	39	38 (97.4)	1.24 (0.58)	0.0	0.80	1.31	1.67	2.3	
	Week 20	Tezepelumab	54	50 (92.6)	0.97 (0.73)	0.0	0.40	0.95	1.60	2.3	
		Placebo	39	38 (97.4)	1.20 (0.58)	0.0	0.80	1.20	1.66	2.4	
	Week 21	Tezepelumab	54	49 (90.7)	0.99 (0.72)	0.0	0.43	1.03	1.60	2.2	
		Placebo	39	37 (94.9)	1.17 (0.63)	0.1	0.80	1.14	1.60	2.6	
	Week 22	Tezepelumab	54	48 (88.9)	1.02 (0.65)	0.0	0.63	1.01	1.50	2.3	
		Placebo	39	38 (97.4)	1.22 (0.63)	0.0	0.77	1.33	1.66	2.8	
	Week 23	Tezepelumab	54	51 (94.4)	0.99 (0.71)	0.0	0.43	1.00	1.53	2.6	
		Placebo	39	36 (92.3)	1.19 (0.59)	0.1	0.86	1.19	1.63	2.6	
	Week 24	Tezepelumab	54	52 (96.3)	0.96 (0.74)	0.0	0.34	0.93	1.35	2.7	
		Placebo	39	37 (94.9)	1.16 (0.61)	0.0	0.80	1.11	1.60	2.7	
	Week 25	Tezepelumab	54	51 (94.4)	0.97 (0.69)	0.0	0.34	1.00	1.37	2.4	
		Placebo	39	36 (92.3)	1.16 (0.60)	0.0	0.77	1.00	1.70	2.5	
	Week 26	Tezepelumab	54	52 (96.3)	0.95 (0.70)	0.0	0.41	0.96	1.46	2.5	
		Placebo	39	37 (94.9)	1.20 (0.67)	0.0	0.66	1.29	1.73	2.4	
	Week 27	Tezepelumab	54	49 (90.7)	1.02 (0.72)	0.0	0.51	1.00	1.40	3.0	
		Placebo	39	35 (89.7)	1.22 (0.75)	0.0	0.66	1.20	1.71	3.2	
	Week 28	Tezepelumab	54	51 (94.4)	1.00 (0.75)	0.0	0.34	1.00	1.54	2.8	
		Placebo	39	37 (94.9)	1.24 (0.72)	0.0	0.80	1.14	1.74	2.6	
	Week 29	Tezepelumab	54	50 (92.6)	0.96 (0.68)	0.0	0.50	1.00	1.40	2.3	
		Placebo	39	36 (92.3)	1.17 (0.70)	0.0	0.80	1.04	1.74	2.7	
	Week 30	Tezepelumab	54	48 (88.9)	1.06 (0.66)	0.0	0.60	1.00	1.59	2.3	
		Placebo	39	36 (92.3)	1.11 (0.65)	0.0	0.57	1.00	1.60	2.8	
	Week 31	Tezepelumab	54	52 (96.3)	1.00 (0.68)	0.0	0.46	1.00	1.49	2.6	
		Placebo	39	36 (92.3)	1.08 (0.67)	0.0	0.59	1.00	1.57	2.8	
	Week 32	Tezepelumab	54	51 (94.4)	0.97 (0.67)	0.0	0.37	1.00	1.47	2.1	
		Placebo	39	36 (92.3)	1.11 (0.69)	0.0	0.51	1.02	1.63	2.8	
	Week 33	Tezepelumab	54	51 (94.4)	0.97 (0.67)	0.0	0.31	1.00	1.50	2.2	
		Placebo	39	37 (94.9)	1.16 (0.67)	0.0	0.69	1.00	1.60	2.8	
	Week 34	Tezepelumab	54	51 (94.4)	0.95 (0.69)	0.0	0.31	1.00	1.49	2.5	
		Placebo	39	37 (94.9)	1.14 (0.68)	0.0	0.60	1.00	1.60	2.8	
	Week 35	Tezepelumab	54	49 (90.7)	1.00 (0.68)	0.0	0.47	1.00	1.34	2.5	
		Placebo	39	36 (92.3)	1.15 (0.67)	0.0	0.63	1.07	1.65	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMH0: Course of ASD weekly daytime score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	54	50 (92.6)	1.00 (0.71)	0.0	0.40	1.00	1.50	2.5	
		Placebo	39	37 (94.9)	1.21 (0.62)	0.1	0.77	1.06	1.69	2.8	
	Week 37	Tezepelumab	54	49 (90.7)	1.03 (0.67)	0.0	0.54	1.00	1.60	2.6	
		Placebo	39	37 (94.9)	1.22 (0.59)	0.1	0.80	1.23	1.54	2.8	
	Week 38	Tezepelumab	54	50 (92.6)	1.02 (0.73)	0.0	0.47	0.99	1.53	2.6	
		Placebo	39	37 (94.9)	1.18 (0.65)	0.0	0.71	1.20	1.57	2.8	
	Week 39	Tezepelumab	54	51 (94.4)	0.98 (0.72)	0.0	0.35	1.00	1.57	2.3	
		Placebo	39	37 (94.9)	1.17 (0.68)	0.0	0.63	1.13	1.60	2.8	
	Week 40	Tezepelumab	54	51 (94.4)	1.01 (0.68)	0.0	0.46	1.00	1.50	2.5	
		Placebo	39	37 (94.9)	1.19 (0.75)	0.0	0.60	1.27	1.60	3.1	
	Week 41	Tezepelumab	54	52 (96.3)	1.02 (0.70)	0.0	0.54	1.00	1.42	2.4	
		Placebo	39	36 (92.3)	1.21 (0.75)	0.0	0.64	1.17	1.74	2.8	
	Week 42	Tezepelumab	54	50 (92.6)	1.02 (0.74)	0.0	0.34	1.00	1.49	2.7	
		Placebo	39	37 (94.9)	1.21 (0.70)	0.0	0.74	1.26	1.77	2.8	
	Week 43	Tezepelumab	54	50 (92.6)	0.99 (0.74)	0.0	0.28	1.00	1.43	2.9	
		Placebo	39	37 (94.9)	1.19 (0.69)	0.0	0.74	1.20	1.77	2.8	
	Week 44	Tezepelumab	54	49 (90.7)	0.93 (0.67)	0.0	0.30	1.00	1.30	2.4	
		Placebo	39	35 (89.7)	1.22 (0.66)	0.0	0.71	1.20	1.80	2.8	
	Week 45	Tezepelumab	54	50 (92.6)	0.97 (0.73)	0.0	0.33	1.00	1.46	2.9	
		Placebo	39	37 (94.9)	1.10 (0.69)	0.0	0.60	1.04	1.60	2.8	
	Week 46	Tezepelumab	54	51 (94.4)	0.98 (0.71)	0.0	0.24	1.00	1.51	2.5	
		Placebo	39	36 (92.3)	1.09 (0.72)	0.0	0.56	1.03	1.53	2.8	
	Week 47	Tezepelumab	54	45 (83.3)	0.98 (0.73)	0.0	0.37	1.00	1.66	2.8	
		Placebo	39	37 (94.9)	1.10 (0.70)	0.0	0.63	1.00	1.60	2.8	
	Week 48	Tezepelumab	54	50 (92.6)	1.05 (0.77)	0.0	0.49	1.00	1.54	2.8	
		Placebo	39	36 (92.3)	1.05 (0.70)	0.0	0.51	1.00	1.71	2.9	
	Week 49	Tezepelumab	54	48 (88.9)	1.09 (0.76)	0.0	0.57	1.00	1.74	2.7	
		Placebo	39	36 (92.3)	1.10 (0.72)	0.0	0.50	1.03	1.67	2.8	
	Week 50	Tezepelumab	54	48 (88.9)	1.03 (0.72)	0.0	0.58	1.00	1.64	2.7	
		Placebo	39	35 (89.7)	1.05 (0.69)	0.0	0.46	1.00	1.60	2.8	
	Week 51	Tezepelumab	54	46 (85.2)	1.07 (0.72)	0.0	0.63	1.01	1.80	2.6	
		Placebo	39	32 (82.1)	1.07 (0.71)	0.0	0.55	1.00	1.69	2.8	
	Week 52	Tezepelumab	54	42 (77.8)	1.08 (0.71)	0.0	0.63	1.03	1.63	2.5	
		Placebo	39	32 (82.1)	1.10 (0.72)	0.0	0.51	1.03	1.69	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMH0: Course of ASD weekly daytime score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	54	53 (98.1)	-0.13 (0.45)	-1.7	-0.20	0.00	0.14	0.6	0.08 [-0.34, 0.49]
		Placebo	39	39 (100.0)	-0.16 (0.31)	-0.9	-0.45	-0.17	0.00	0.7	
	Week 2	Tezepelumab	54	53 (98.1)	-0.23 (0.49)	-2.2	-0.31	-0.06	0.00	0.4	-0.01 [-0.43, 0.41]
		Placebo	39	38 (97.4)	-0.23 (0.56)	-2.0	-0.36	-0.16	0.05	1.3	
	Week 3	Tezepelumab	54	54 (100.0)	-0.23 (0.53)	-2.2	-0.37	-0.13	0.03	0.7	0.04 [-0.38, 0.46]
		Placebo	39	37 (94.9)	-0.25 (0.71)	-2.6	-0.34	-0.12	0.03	1.2	
	Week 4	Tezepelumab	54	54 (100.0)	-0.30 (0.53)	-2.2	-0.46	-0.11	0.03	0.7	-0.09 [-0.50, 0.33]
		Placebo	39	38 (97.4)	-0.25 (0.60)	-2.6	-0.42	-0.09	0.03	0.6	
	Week 5	Tezepelumab	54	53 (98.1)	-0.31 (0.53)	-2.2	-0.57	-0.11	0.00	0.4	0.13 [-0.29, 0.54]
		Placebo	39	38 (97.4)	-0.39 (0.67)	-2.8	-0.73	-0.28	0.00	1.1	
	Week 6	Tezepelumab	54	52 (96.3)	-0.27 (0.53)	-2.2	-0.43	-0.17	0.03	0.5	0.03 [-0.38, 0.45]
		Placebo	39	39 (100.0)	-0.29 (0.61)	-2.7	-0.54	-0.11	0.09	0.6	
	Week 7	Tezepelumab	54	51 (94.4)	-0.26 (0.57)	-2.2	-0.46	-0.09	0.06	0.9	0.14 [-0.28, 0.55]
		Placebo	39	39 (100.0)	-0.33 (0.58)	-2.6	-0.63	-0.20	0.00	0.6	
	Week 8	Tezepelumab	54	53 (98.1)	-0.29 (0.57)	-2.2	-0.60	-0.09	0.03	1.1	0.04 [-0.37, 0.45]
		Placebo	39	39 (100.0)	-0.31 (0.61)	-2.6	-0.58	-0.14	0.03	0.8	
	Week 9	Tezepelumab	54	54 (100.0)	-0.35 (0.60)	-2.2	-0.60	-0.20	0.09	0.8	-0.01 [-0.43, 0.40]
		Placebo	39	39 (100.0)	-0.34 (0.66)	-2.7	-0.79	-0.20	0.00	1.4	
	Week 10	Tezepelumab	54	53 (98.1)	-0.36 (0.59)	-2.2	-0.71	-0.20	0.00	0.8	0.02 [-0.39, 0.44]
		Placebo	39	39 (100.0)	-0.37 (0.62)	-2.7	-0.84	-0.20	0.00	0.6	
	Week 11	Tezepelumab	54	53 (98.1)	-0.35 (0.60)	-2.2	-0.80	-0.11	0.06	0.7	0.16 [-0.26, 0.57]
		Placebo	39	39 (100.0)	-0.44 (0.64)	-2.6	-0.91	-0.22	0.00	0.6	
	Week 12	Tezepelumab	54	53 (98.1)	-0.39 (0.63)	-2.2	-0.94	-0.17	0.00	0.8	0.10 [-0.32, 0.52]
		Placebo	39	37 (94.9)	-0.46 (0.70)	-2.7	-0.91	-0.34	-0.02	1.3	
	Week 13	Tezepelumab	54	51 (94.4)	-0.41 (0.67)	-2.2	-0.94	-0.23	0.04	0.7	0.12 [-0.31, 0.54]
		Placebo	39	38 (97.4)	-0.48 (0.68)	-2.7	-0.87	-0.33	-0.09	1.4	
	Week 14	Tezepelumab	54	52 (96.3)	-0.37 (0.66)	-2.2	-0.62	-0.16	0.07	0.8	0.16 [-0.26, 0.58]
		Placebo	39	37 (94.9)	-0.48 (0.67)	-2.6	-0.84	-0.34	-0.11	0.8	
	Week 15	Tezepelumab	54	52 (96.3)	-0.41 (0.62)	-2.2	-0.89	-0.18	0.01	0.6	0.17 [-0.25, 0.58]
		Placebo	39	39 (100.0)	-0.52 (0.72)	-2.6	-1.12	-0.41	-0.06	1.3	
	Week 16	Tezepelumab	54	53 (98.1)	-0.43 (0.60)	-2.2	-0.91	-0.20	0.00	0.3	0.09 [-0.33, 0.51]
		Placebo	39	38 (97.4)	-0.49 (0.65)	-2.5	-0.80	-0.30	-0.06	0.9	
	Week 17	Tezepelumab	54	53 (98.1)	-0.46 (0.64)	-2.2	-0.83	-0.26	0.03	0.5	-0.02 [-0.43, 0.40]
		Placebo	39	38 (97.4)	-0.45 (0.63)	-2.6	-0.80	-0.29	-0.03	0.7	
	Week 18	Tezepelumab	54	52 (96.3)	-0.45 (0.67)	-2.2	-0.79	-0.26	0.01	0.8	-0.01 [-0.43, 0.41]
		Placebo	39	38 (97.4)	-0.44 (0.60)	-2.5	-0.74	-0.26	-0.06	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMH0: Course of ASD weekly daytime score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	54	50 (92.6)	-0.44 (0.68)	-2.2	-0.94	-0.20	0.00	0.5	-0.02 [-0.44, 0.41]
		Placebo	39	38 (97.4)	-0.43 (0.67)	-2.8	-0.74	-0.23	-0.06	0.8	
	Week 20	Tezepelumab	54	50 (92.6)	-0.47 (0.66)	-2.2	-0.90	-0.29	0.03	0.5	0.00 [-0.42, 0.42]
		Placebo	39	38 (97.4)	-0.47 (0.62)	-2.4	-0.76	-0.28	-0.11	0.7	
	Week 21	Tezepelumab	54	49 (90.7)	-0.48 (0.67)	-2.2	-0.94	-0.23	0.00	0.4	0.04 [-0.39, 0.46]
		Placebo	39	37 (94.9)	-0.51 (0.71)	-2.6	-0.86	-0.34	-0.06	1.3	
	Week 22	Tezepelumab	54	48 (88.9)	-0.45 (0.66)	-2.2	-0.86	-0.25	0.03	0.5	0.03 [-0.39, 0.46]
		Placebo	39	38 (97.4)	-0.47 (0.70)	-2.7	-0.87	-0.34	-0.03	1.3	
	Week 23	Tezepelumab	54	51 (94.4)	-0.47 (0.69)	-2.2	-0.97	-0.29	0.11	0.7	0.07 [-0.36, 0.50]
		Placebo	39	36 (92.3)	-0.52 (0.64)	-2.4	-0.83	-0.34	-0.05	0.4	
	Week 24	Tezepelumab	54	52 (96.3)	-0.49 (0.69)	-2.2	-0.99	-0.35	0.00	0.7	0.09 [-0.33, 0.52]
		Placebo	39	37 (94.9)	-0.55 (0.63)	-2.4	-0.86	-0.34	-0.08	0.3	
	Week 25	Tezepelumab	54	51 (94.4)	-0.50 (0.64)	-2.2	-0.94	-0.32	0.00	0.5	0.05 [-0.37, 0.48]
		Placebo	39	36 (92.3)	-0.54 (0.68)	-2.8	-1.02	-0.36	-0.06	0.5	
	Week 26	Tezepelumab	54	52 (96.3)	-0.48 (0.67)	-2.2	-1.00	-0.35	0.01	0.6	0.04 [-0.39, 0.46]
		Placebo	39	37 (94.9)	-0.50 (0.77)	-2.8	-1.07	-0.34	-0.06	1.1	
	Week 27	Tezepelumab	54	49 (90.7)	-0.41 (0.68)	-2.2	-0.81	-0.29	0.03	0.8	0.12 [-0.31, 0.56]
		Placebo	39	35 (89.7)	-0.50 (0.87)	-2.8	-1.05	-0.43	-0.04	2.2	
	Week 28	Tezepelumab	54	51 (94.4)	-0.42 (0.71)	-2.2	-0.80	-0.29	0.03	1.1	0.07 [-0.35, 0.50]
		Placebo	39	37 (94.9)	-0.47 (0.76)	-2.8	-0.98	-0.29	0.00	0.7	
	Week 29	Tezepelumab	54	50 (92.6)	-0.48 (0.65)	-2.2	-0.94	-0.21	0.03	0.2	0.04 [-0.39, 0.47]
		Placebo	39	36 (92.3)	-0.51 (0.80)	-2.8	-1.12	-0.39	0.00	0.9	
	Week 30	Tezepelumab	54	48 (88.9)	-0.46 (0.61)	-2.2	-0.90	-0.20	0.00	0.3	0.21 [-0.23, 0.64]
		Placebo	39	36 (92.3)	-0.60 (0.75)	-2.8	-1.19	-0.46	-0.06	0.9	
	Week 31	Tezepelumab	54	52 (96.3)	-0.47 (0.69)	-2.2	-0.88	-0.26	0.03	1.0	0.17 [-0.26, 0.60]
		Placebo	39	36 (92.3)	-0.60 (0.78)	-2.8	-1.09	-0.44	-0.08	1.3	
	Week 32	Tezepelumab	54	51 (94.4)	-0.51 (0.66)	-2.2	-0.89	-0.31	0.00	0.7	0.09 [-0.34, 0.51]
		Placebo	39	36 (92.3)	-0.57 (0.77)	-2.8	-1.04	-0.49	-0.06	1.3	
	Week 33	Tezepelumab	54	51 (94.4)	-0.49 (0.69)	-2.2	-0.94	-0.26	0.03	0.5	0.06 [-0.36, 0.48]
		Placebo	39	37 (94.9)	-0.53 (0.74)	-2.7	-0.89	-0.37	-0.11	1.1	
	Week 34	Tezepelumab	54	51 (94.4)	-0.53 (0.64)	-2.2	-0.96	-0.37	0.00	0.4	0.02 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.55 (0.74)	-2.8	-1.04	-0.46	-0.06	1.1	
	Week 35	Tezepelumab	54	49 (90.7)	-0.46 (0.64)	-2.2	-0.73	-0.31	0.00	0.5	0.16 [-0.27, 0.59]
		Placebo	39	36 (92.3)	-0.57 (0.73)	-2.8	-1.03	-0.45	-0.11	1.1	
	Week 36	Tezepelumab	54	50 (92.6)	-0.48 (0.64)	-2.2	-0.80	-0.31	0.00	0.5	0.01 [-0.42, 0.43]
		Placebo	39	37 (94.9)	-0.48 (0.67)	-2.6	-0.90	-0.38	-0.09	1.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMH0: Course of ASD weekly daytime score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	54	49 (90.7)	-0.42 (0.64)	-2.2	-0.80	-0.20	0.00	0.8	0.08 [-0.35, 0.51]
		Placebo	39	37 (94.9)	-0.47 (0.64)	-2.4	-0.82	-0.34	-0.07	1.0	
	Week 38	Tezepelumab	54	50 (92.6)	-0.43 (0.69)	-2.2	-0.80	-0.29	0.00	1.0	0.12 [-0.31, 0.54]
		Placebo	39	37 (94.9)	-0.51 (0.63)	-2.1	-0.94	-0.31	-0.15	1.1	
	Week 39	Tezepelumab	54	51 (94.4)	-0.46 (0.67)	-2.2	-0.87	-0.26	0.00	0.6	0.09 [-0.34, 0.51]
		Placebo	39	37 (94.9)	-0.52 (0.63)	-2.5	-0.90	-0.40	-0.03	0.6	
	Week 40	Tezepelumab	54	51 (94.4)	-0.47 (0.66)	-2.2	-0.89	-0.25	0.01	0.6	0.05 [-0.37, 0.47]
		Placebo	39	37 (94.9)	-0.50 (0.72)	-2.5	-1.04	-0.42	-0.03	0.8	
	Week 41	Tezepelumab	54	52 (96.3)	-0.47 (0.65)	-2.2	-0.91	-0.28	0.01	0.7	-0.00 [-0.43, 0.42]
		Placebo	39	36 (92.3)	-0.47 (0.81)	-2.6	-1.00	-0.37	-0.02	1.6	
	Week 42	Tezepelumab	54	50 (92.6)	-0.47 (0.67)	-2.2	-0.86	-0.19	0.00	0.5	0.02 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.48 (0.65)	-1.9	-0.97	-0.41	-0.03	0.7	
	Week 43	Tezepelumab	54	50 (92.6)	-0.47 (0.65)	-2.2	-0.92	-0.34	0.00	0.7	0.06 [-0.37, 0.48]
		Placebo	39	37 (94.9)	-0.50 (0.62)	-2.0	-0.97	-0.37	-0.03	0.6	
	Week 44	Tezepelumab	54	49 (90.7)	-0.53 (0.63)	-2.2	-0.94	-0.37	0.00	0.3	-0.05 [-0.49, 0.38]
		Placebo	39	35 (89.7)	-0.50 (0.62)	-2.1	-0.87	-0.37	-0.06	0.9	
	Week 45	Tezepelumab	54	50 (92.6)	-0.49 (0.67)	-2.2	-0.97	-0.33	0.00	0.7	0.15 [-0.28, 0.57]
		Placebo	39	37 (94.9)	-0.59 (0.67)	-2.5	-1.09	-0.43	-0.06	0.7	
	Week 46	Tezepelumab	54	51 (94.4)	-0.48 (0.69)	-2.2	-1.00	-0.31	0.09	0.9	0.15 [-0.27, 0.58]
		Placebo	39	36 (92.3)	-0.59 (0.71)	-2.8	-1.13	-0.43	-0.05	0.6	
	Week 47	Tezepelumab	54	45 (83.3)	-0.46 (0.72)	-2.2	-1.00	-0.17	0.00	1.0	0.18 [-0.25, 0.62]
		Placebo	39	37 (94.9)	-0.59 (0.67)	-2.8	-1.04	-0.37	-0.06	0.6	
	Week 48	Tezepelumab	54	50 (92.6)	-0.38 (0.73)	-2.2	-0.82	-0.15	0.09	1.1	0.35 [-0.09, 0.78]
		Placebo	39	36 (92.3)	-0.63 (0.68)	-2.8	-1.16	-0.45	-0.10	0.5	
	Week 49	Tezepelumab	54	48 (88.9)	-0.39 (0.74)	-2.2	-0.94	-0.13	0.09	1.1	0.27 [-0.17, 0.70]
		Placebo	39	36 (92.3)	-0.58 (0.65)	-2.8	-1.06	-0.37	-0.05	0.2	
	Week 50	Tezepelumab	54	48 (88.9)	-0.43 (0.68)	-2.2	-0.87	-0.15	0.00	0.9	0.31 [-0.13, 0.75]
		Placebo	39	35 (89.7)	-0.63 (0.64)	-2.8	-1.11	-0.45	-0.18	0.1	
	Week 51	Tezepelumab	54	46 (85.2)	-0.41 (0.70)	-2.2	-0.94	-0.18	0.03	0.8	0.33 [-0.12, 0.79]
		Placebo	39	32 (82.1)	-0.64 (0.66)	-2.8	-0.98	-0.52	-0.16	0.3	
	Week 52	Tezepelumab	54	42 (77.8)	-0.40 (0.68)	-2.2	-0.94	-0.20	0.06	0.6	0.35 [-0.11, 0.82]
		Placebo	39	32 (82.1)	-0.64 (0.65)	-2.8	-0.97	-0.51	-0.23	0.4	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	54	53 (98.1)	-0.17 (0.08)	(-0.33, -0.01)	-0.07 (0.12)	(-0.31, 0.18)	0.599
	Placebo	39	39 (100.0)	-0.11 (0.09)	(-0.29, 0.08)			
Week 2	Tezepelumab	54	53 (98.1)	-0.27 (0.08)	(-0.43, -0.12)	-0.12 (0.12)	(-0.36, 0.13)	0.347
	Placebo	39	38 (97.4)	-0.16 (0.09)	(-0.34, 0.03)			
Week 3	Tezepelumab	54	54 (100.0)	-0.27 (0.08)	(-0.43, -0.12)	-0.10 (0.12)	(-0.35, 0.14)	0.405
	Placebo	39	37 (94.9)	-0.17 (0.09)	(-0.36, 0.02)			
Week 4	Tezepelumab	54	54 (100.0)	-0.35 (0.08)	(-0.51, -0.19)	-0.16 (0.12)	(-0.40, 0.08)	0.200
	Placebo	39	38 (97.4)	-0.19 (0.09)	(-0.38, -0.00)			
Week 5	Tezepelumab	54	53 (98.1)	-0.35 (0.08)	(-0.51, -0.19)	-0.02 (0.12)	(-0.27, 0.22)	0.843
	Placebo	39	38 (97.4)	-0.33 (0.09)	(-0.51, -0.14)			
Week 6	Tezepelumab	54	52 (96.3)	-0.29 (0.08)	(-0.45, -0.13)	-0.06 (0.12)	(-0.30, 0.18)	0.630
	Placebo	39	39 (100.0)	-0.23 (0.09)	(-0.42, -0.05)			
Week 7	Tezepelumab	54	51 (94.4)	-0.29 (0.08)	(-0.45, -0.13)	-0.01 (0.12)	(-0.25, 0.23)	0.939
	Placebo	39	39 (100.0)	-0.28 (0.09)	(-0.47, -0.09)			
Week 8	Tezepelumab	54	53 (98.1)	-0.33 (0.08)	(-0.48, -0.17)	-0.07 (0.12)	(-0.31, 0.17)	0.568
	Placebo	39	39 (100.0)	-0.25 (0.09)	(-0.44, -0.07)			
Week 9	Tezepelumab	54	54 (100.0)	-0.40 (0.08)	(-0.56, -0.24)	-0.11 (0.12)	(-0.35, 0.13)	0.376
	Placebo	39	39 (100.0)	-0.29 (0.09)	(-0.48, -0.11)			
Week 10	Tezepelumab	54	53 (98.1)	-0.41 (0.08)	(-0.57, -0.26)	-0.10 (0.12)	(-0.34, 0.15)	0.436
	Placebo	39	39 (100.0)	-0.32 (0.09)	(-0.50, -0.13)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	54	53 (98.1)	-0.40 (0.08)	(-0.56, -0.25)	-0.02 (0.12)	(-0.26, 0.23)	0.900
	Placebo	39	39 (100.0)	-0.39 (0.09)	(-0.57, -0.20)			
Week 12	Tezepelumab	54	53 (98.1)	-0.42 (0.08)	(-0.58, -0.26)	-0.04 (0.12)	(-0.28, 0.21)	0.776
	Placebo	39	37 (94.9)	-0.38 (0.09)	(-0.57, -0.20)			
Week 13	Tezepelumab	54	51 (94.4)	-0.44 (0.08)	(-0.59, -0.28)	-0.02 (0.12)	(-0.26, 0.23)	0.892
	Placebo	39	38 (97.4)	-0.42 (0.09)	(-0.60, -0.23)			
Week 14	Tezepelumab	54	52 (96.3)	-0.39 (0.08)	(-0.55, -0.23)	0.00 (0.12)	(-0.24, 0.25)	0.973
	Placebo	39	37 (94.9)	-0.39 (0.09)	(-0.58, -0.21)			
Week 15	Tezepelumab	54	52 (96.3)	-0.43 (0.08)	(-0.59, -0.27)	0.03 (0.12)	(-0.21, 0.28)	0.803
	Placebo	39	39 (100.0)	-0.46 (0.09)	(-0.65, -0.28)			
Week 16	Tezepelumab	54	53 (98.1)	-0.46 (0.08)	(-0.62, -0.31)	-0.04 (0.12)	(-0.28, 0.21)	0.775
	Placebo	39	38 (97.4)	-0.43 (0.09)	(-0.61, -0.24)			
Week 17	Tezepelumab	54	53 (98.1)	-0.49 (0.08)	(-0.65, -0.33)	-0.10 (0.12)	(-0.35, 0.14)	0.410
	Placebo	39	38 (97.4)	-0.39 (0.09)	(-0.58, -0.20)			
Week 18	Tezepelumab	54	52 (96.3)	-0.47 (0.08)	(-0.63, -0.31)	-0.09 (0.12)	(-0.34, 0.15)	0.451
	Placebo	39	38 (97.4)	-0.37 (0.09)	(-0.56, -0.19)			
Week 19	Tezepelumab	54	50 (92.6)	-0.48 (0.08)	(-0.63, -0.32)	-0.11 (0.12)	(-0.36, 0.13)	0.369
	Placebo	39	38 (97.4)	-0.36 (0.09)	(-0.55, -0.18)			
Week 20	Tezepelumab	54	50 (92.6)	-0.50 (0.08)	(-0.66, -0.35)	-0.06 (0.12)	(-0.31, 0.18)	0.621
	Placebo	39	38 (97.4)	-0.44 (0.09)	(-0.63, -0.26)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	54	49 (90.7)	-0.53 (0.08)	(-0.69, -0.37)	-0.09 (0.12)	(-0.34, 0.15)	0.462
	Placebo	39	37 (94.9)	-0.43 (0.09)	(-0.62, -0.25)			
Week 22	Tezepelumab	54	48 (88.9)	-0.49 (0.08)	(-0.65, -0.33)	-0.08 (0.12)	(-0.33, 0.16)	0.510
	Placebo	39	38 (97.4)	-0.41 (0.09)	(-0.59, -0.22)			
Week 23	Tezepelumab	54	51 (94.4)	-0.50 (0.08)	(-0.66, -0.34)	-0.10 (0.13)	(-0.34, 0.15)	0.433
	Placebo	39	36 (92.3)	-0.40 (0.10)	(-0.59, -0.21)			
Week 24	Tezepelumab	54	52 (96.3)	-0.51 (0.08)	(-0.67, -0.35)	-0.06 (0.13)	(-0.31, 0.19)	0.627
	Placebo	39	37 (94.9)	-0.45 (0.10)	(-0.64, -0.26)			
Week 25	Tezepelumab	54	51 (94.4)	-0.52 (0.08)	(-0.68, -0.36)	-0.10 (0.13)	(-0.34, 0.15)	0.436
	Placebo	39	36 (92.3)	-0.42 (0.10)	(-0.61, -0.24)			
Week 26	Tezepelumab	54	52 (96.3)	-0.52 (0.08)	(-0.68, -0.36)	-0.11 (0.13)	(-0.36, 0.13)	0.363
	Placebo	39	37 (94.9)	-0.41 (0.10)	(-0.59, -0.22)			
Week 27	Tezepelumab	54	49 (90.7)	-0.47 (0.08)	(-0.63, -0.31)	-0.08 (0.13)	(-0.32, 0.17)	0.537
	Placebo	39	35 (89.7)	-0.39 (0.10)	(-0.58, -0.20)			
Week 28	Tezepelumab	54	51 (94.4)	-0.47 (0.08)	(-0.63, -0.32)	-0.10 (0.13)	(-0.34, 0.15)	0.437
	Placebo	39	37 (94.9)	-0.38 (0.10)	(-0.56, -0.19)			
Week 29	Tezepelumab	54	50 (92.6)	-0.53 (0.08)	(-0.69, -0.37)	-0.11 (0.13)	(-0.36, 0.14)	0.380
	Placebo	39	36 (92.3)	-0.42 (0.10)	(-0.61, -0.23)			
Week 30	Tezepelumab	54	48 (88.9)	-0.50 (0.08)	(-0.66, -0.34)	0.01 (0.13)	(-0.23, 0.26)	0.924
	Placebo	39	36 (92.3)	-0.51 (0.10)	(-0.70, -0.32)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	54	52 (96.3)	-0.50 (0.08)	(-0.66, -0.34)	0.01 (0.13)	(-0.24, 0.25)	0.967
	Placebo	39	36 (92.3)	-0.51 (0.10)	(-0.69, -0.32)			
Week 32	Tezepelumab	54	51 (94.4)	-0.53 (0.08)	(-0.69, -0.37)	-0.05 (0.13)	(-0.30, 0.20)	0.699
	Placebo	39	36 (92.3)	-0.48 (0.10)	(-0.67, -0.29)			
Week 33	Tezepelumab	54	51 (94.4)	-0.54 (0.08)	(-0.69, -0.38)	-0.08 (0.13)	(-0.33, 0.17)	0.528
	Placebo	39	37 (94.9)	-0.46 (0.10)	(-0.65, -0.27)			
Week 34	Tezepelumab	54	51 (94.4)	-0.57 (0.08)	(-0.73, -0.41)	-0.10 (0.13)	(-0.34, 0.15)	0.448
	Placebo	39	37 (94.9)	-0.47 (0.10)	(-0.66, -0.28)			
Week 35	Tezepelumab	54	49 (90.7)	-0.51 (0.08)	(-0.67, -0.35)	-0.01 (0.13)	(-0.26, 0.23)	0.909
	Placebo	39	36 (92.3)	-0.49 (0.10)	(-0.68, -0.31)			
Week 36	Tezepelumab	54	50 (92.6)	-0.48 (0.08)	(-0.63, -0.32)	-0.07 (0.13)	(-0.31, 0.18)	0.605
	Placebo	39	37 (94.9)	-0.41 (0.10)	(-0.60, -0.22)			
Week 37	Tezepelumab	54	49 (90.7)	-0.50 (0.08)	(-0.66, -0.34)	-0.10 (0.13)	(-0.34, 0.15)	0.442
	Placebo	39	37 (94.9)	-0.40 (0.10)	(-0.59, -0.21)			
Week 38	Tezepelumab	54	50 (92.6)	-0.47 (0.08)	(-0.63, -0.31)	-0.02 (0.13)	(-0.27, 0.22)	0.844
	Placebo	39	37 (94.9)	-0.44 (0.10)	(-0.63, -0.25)			
Week 39	Tezepelumab	54	51 (94.4)	-0.51 (0.08)	(-0.67, -0.35)	-0.06 (0.13)	(-0.30, 0.19)	0.662
	Placebo	39	37 (94.9)	-0.45 (0.10)	(-0.64, -0.26)			
Week 40	Tezepelumab	54	51 (94.4)	-0.50 (0.08)	(-0.66, -0.35)	-0.07 (0.13)	(-0.32, 0.18)	0.590
	Placebo	39	37 (94.9)	-0.44 (0.10)	(-0.63, -0.25)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 41	Tezepelumab	54	52 (96.3)	-0.50 (0.08)	(-0.65, -0.34)	-0.08 (0.13)	(-0.33, 0.17)	0.520
	Placebo	39	36 (92.3)	-0.41 (0.10)	(-0.60, -0.22)			
Week 42	Tezepelumab	54	50 (92.6)	-0.49 (0.08)	(-0.65, -0.33)	-0.08 (0.13)	(-0.33, 0.17)	0.519
	Placebo	39	37 (94.9)	-0.41 (0.10)	(-0.60, -0.22)			
Week 43	Tezepelumab	54	50 (92.6)	-0.51 (0.08)	(-0.67, -0.35)	-0.07 (0.13)	(-0.32, 0.18)	0.581
	Placebo	39	37 (94.9)	-0.44 (0.10)	(-0.63, -0.25)			
Week 44	Tezepelumab	54	49 (90.7)	-0.56 (0.08)	(-0.72, -0.40)	-0.12 (0.13)	(-0.37, 0.13)	0.362
	Placebo	39	35 (89.7)	-0.45 (0.10)	(-0.64, -0.26)			
Week 45	Tezepelumab	54	50 (92.6)	-0.55 (0.08)	(-0.71, -0.39)	-0.02 (0.13)	(-0.27, 0.22)	0.845
	Placebo	39	37 (94.9)	-0.52 (0.10)	(-0.71, -0.33)			
Week 46	Tezepelumab	54	51 (94.4)	-0.52 (0.08)	(-0.68, -0.36)	-0.01 (0.13)	(-0.26, 0.24)	0.940
	Placebo	39	36 (92.3)	-0.51 (0.10)	(-0.70, -0.32)			
Week 47	Tezepelumab	54	45 (83.3)	-0.52 (0.08)	(-0.68, -0.36)	0.00 (0.13)	(-0.25, 0.25)	0.975
	Placebo	39	37 (94.9)	-0.52 (0.10)	(-0.71, -0.33)			
Week 48	Tezepelumab	54	50 (92.6)	-0.45 (0.08)	(-0.61, -0.29)	0.10 (0.13)	(-0.15, 0.35)	0.416
	Placebo	39	36 (92.3)	-0.55 (0.10)	(-0.74, -0.36)			
Week 49	Tezepelumab	54	48 (88.9)	-0.45 (0.08)	(-0.61, -0.29)	0.08 (0.13)	(-0.17, 0.33)	0.549
	Placebo	39	36 (92.3)	-0.52 (0.10)	(-0.71, -0.33)			
Week 50	Tezepelumab	54	48 (88.9)	-0.49 (0.08)	(-0.65, -0.33)	0.05 (0.13)	(-0.21, 0.30)	0.723
	Placebo	39	35 (89.7)	-0.54 (0.10)	(-0.73, -0.35)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC_ABMC0: Change from baseline in ASD weekly daytime score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	46 (85.2)	-0.46 (0.08)	(-0.63, -0.30)	0.08 (0.13)	(-0.18, 0.33)	0.548
	Placebo	39	32 (82.1)	-0.54 (0.10)	(-0.73, -0.35)			
Week 52	Tezepelumab	54	42 (77.8)	-0.46 (0.08)	(-0.63, -0.30)	0.07 (0.13)	(-0.19, 0.32)	0.613
	Placebo	39	32 (82.1)	-0.53 (0.10)	(-0.72, -0.34)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMH0: Course of ASD weekly night-time score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	54	54 (100.0)	1.28 (0.63)	0.1	0.91	1.23	1.63	2.8	
		Placebo	39	39 (100.0)	1.38 (0.55)	0.6	0.87	1.46	1.71	2.6	
	Week 1	Tezepelumab	54	53 (98.1)	1.11 (0.59)	0.1	0.74	1.00	1.50	2.9	
		Placebo	39	39 (100.0)	1.31 (0.53)	0.5	0.83	1.31	1.63	2.8	
	Week 2	Tezepelumab	54	53 (98.1)	1.03 (0.61)	0.0	0.66	1.03	1.40	2.6	
		Placebo	39	38 (97.4)	1.27 (0.51)	0.2	0.86	1.23	1.63	2.2	
	Week 3	Tezepelumab	54	54 (100.0)	1.02 (0.58)	0.0	0.69	1.01	1.31	2.5	
		Placebo	39	37 (94.9)	1.19 (0.56)	0.0	0.83	1.11	1.57	2.2	
	Week 4	Tezepelumab	54	54 (100.0)	0.97 (0.60)	0.0	0.54	0.97	1.34	2.5	
		Placebo	39	38 (97.4)	1.18 (0.51)	0.1	0.80	1.06	1.57	2.4	
	Week 5	Tezepelumab	54	53 (98.1)	0.89 (0.58)	0.0	0.51	0.86	1.31	2.3	
		Placebo	39	38 (97.4)	1.10 (0.54)	0.1	0.73	1.00	1.54	2.3	
	Week 6	Tezepelumab	54	52 (96.3)	0.97 (0.64)	0.0	0.51	0.87	1.40	2.6	
		Placebo	39	39 (100.0)	1.20 (0.55)	0.1	0.80	1.08	1.54	3.0	
	Week 7	Tezepelumab	54	52 (96.3)	0.95 (0.62)	0.0	0.63	0.89	1.30	2.6	
		Placebo	39	39 (100.0)	1.12 (0.58)	0.0	0.74	1.03	1.51	2.4	
	Week 8	Tezepelumab	54	52 (96.3)	0.89 (0.62)	0.0	0.50	0.80	1.26	2.5	
		Placebo	39	38 (97.4)	1.14 (0.52)	0.1	0.80	1.01	1.51	2.6	
	Week 9	Tezepelumab	54	54 (100.0)	0.87 (0.59)	0.0	0.43	0.81	1.32	2.3	
		Placebo	39	39 (100.0)	1.12 (0.57)	0.1	0.74	1.03	1.46	2.5	
	Week 10	Tezepelumab	54	53 (98.1)	0.85 (0.66)	0.0	0.30	0.80	1.20	2.6	
		Placebo	39	39 (100.0)	1.09 (0.51)	0.1	0.80	0.97	1.54	2.4	
	Week 11	Tezepelumab	54	53 (98.1)	0.87 (0.63)	0.0	0.37	0.86	1.30	2.4	
		Placebo	39	39 (100.0)	1.04 (0.52)	0.0	0.74	0.97	1.40	2.5	
	Week 12	Tezepelumab	54	52 (96.3)	0.84 (0.64)	0.0	0.27	0.87	1.22	2.8	
		Placebo	39	37 (94.9)	1.04 (0.54)	0.1	0.66	1.00	1.40	2.3	
	Week 13	Tezepelumab	54	50 (92.6)	0.85 (0.62)	0.0	0.43	0.77	1.20	2.6	
		Placebo	39	38 (97.4)	0.99 (0.50)	0.1	0.60	0.90	1.40	2.1	
	Week 14	Tezepelumab	54	51 (94.4)	0.88 (0.67)	0.0	0.43	0.89	1.26	2.5	
		Placebo	39	37 (94.9)	1.00 (0.51)	0.1	0.67	0.97	1.37	2.1	
	Week 15	Tezepelumab	54	51 (94.4)	0.82 (0.59)	0.0	0.40	0.80	1.20	2.2	
		Placebo	39	38 (97.4)	0.97 (0.55)	0.0	0.63	0.80	1.34	2.1	
	Week 16	Tezepelumab	54	52 (96.3)	0.82 (0.59)	0.0	0.31	0.83	1.19	2.1	
		Placebo	39	37 (94.9)	0.95 (0.50)	0.0	0.67	0.97	1.32	2.2	
Week 17	Tezepelumab	54	52 (96.3)	0.82 (0.61)	0.0	0.31	0.78	1.20	2.3		
	Placebo	39	37 (94.9)	1.01 (0.53)	0.0	0.69	0.91	1.40	2.0		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMH0: Course of ASD weekly night-time score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	54	52 (96.3)	0.85 (0.65)	0.0	0.34	0.80	1.26	2.5	
		Placebo	39	39 (100.0)	1.06 (0.54)	0.1	0.71	0.97	1.46	2.1	
	Week 19	Tezepelumab	54	52 (96.3)	0.82 (0.64)	0.0	0.24	0.77	1.17	2.3	
		Placebo	39	39 (100.0)	1.01 (0.50)	0.0	0.63	1.03	1.30	2.1	
	Week 20	Tezepelumab	54	51 (94.4)	0.79 (0.63)	0.0	0.31	0.77	1.23	2.4	
		Placebo	39	38 (97.4)	1.03 (0.52)	0.0	0.74	0.97	1.40	2.1	
	Week 21	Tezepelumab	54	49 (90.7)	0.79 (0.63)	0.0	0.40	0.63	1.20	2.2	
		Placebo	39	38 (97.4)	0.99 (0.56)	0.0	0.57	0.89	1.40	2.1	
	Week 22	Tezepelumab	54	51 (94.4)	0.83 (0.61)	0.0	0.40	0.80	1.20	2.4	
		Placebo	39	38 (97.4)	1.01 (0.52)	0.1	0.69	0.97	1.43	2.2	
	Week 23	Tezepelumab	54	51 (94.4)	0.81 (0.65)	0.0	0.23	0.80	1.20	2.6	
		Placebo	39	36 (92.3)	0.99 (0.50)	0.0	0.80	0.93	1.40	2.1	
	Week 24	Tezepelumab	54	52 (96.3)	0.80 (0.65)	0.0	0.30	0.74	1.14	2.7	
		Placebo	39	36 (92.3)	0.91 (0.49)	0.0	0.50	0.83	1.24	2.0	
	Week 25	Tezepelumab	54	49 (90.7)	0.81 (0.62)	0.0	0.29	0.83	1.09	2.5	
		Placebo	39	37 (94.9)	0.95 (0.56)	0.0	0.46	0.89	1.28	2.2	
	Week 26	Tezepelumab	54	52 (96.3)	0.81 (0.66)	0.0	0.31	0.76	1.23	2.7	
		Placebo	39	36 (92.3)	0.93 (0.58)	0.0	0.51	0.91	1.38	2.1	
	Week 27	Tezepelumab	54	52 (96.3)	0.84 (0.70)	0.0	0.28	0.77	1.23	3.2	
		Placebo	39	35 (89.7)	0.99 (0.60)	0.0	0.43	0.94	1.37	2.4	
	Week 28	Tezepelumab	54	52 (96.3)	0.88 (0.66)	0.0	0.29	0.97	1.26	2.7	
		Placebo	39	36 (92.3)	0.97 (0.58)	0.0	0.60	0.96	1.36	2.3	
	Week 29	Tezepelumab	54	51 (94.4)	0.79 (0.61)	0.0	0.20	0.84	1.14	2.4	
		Placebo	39	36 (92.3)	0.94 (0.60)	0.0	0.47	0.89	1.41	2.5	
	Week 30	Tezepelumab	54	51 (94.4)	0.84 (0.64)	0.0	0.29	0.83	1.26	2.4	
		Placebo	39	36 (92.3)	0.91 (0.55)	0.0	0.50	0.84	1.31	2.8	
	Week 31	Tezepelumab	54	53 (98.1)	0.78 (0.57)	0.0	0.29	0.80	1.09	2.3	
		Placebo	39	37 (94.9)	0.94 (0.60)	0.0	0.54	0.80	1.29	2.8	
	Week 32	Tezepelumab	54	52 (96.3)	0.79 (0.59)	0.0	0.21	0.80	1.16	2.0	
		Placebo	39	37 (94.9)	0.93 (0.60)	0.0	0.47	0.80	1.28	2.8	
	Week 33	Tezepelumab	54	52 (96.3)	0.81 (0.61)	0.0	0.31	0.80	1.21	2.4	
		Placebo	39	37 (94.9)	0.97 (0.60)	0.0	0.49	0.88	1.40	2.8	
	Week 34	Tezepelumab	54	53 (98.1)	0.78 (0.60)	0.0	0.26	0.80	1.11	2.4	
		Placebo	39	37 (94.9)	0.98 (0.61)	0.0	0.49	0.87	1.40	2.8	
	Week 35	Tezepelumab	54	52 (96.3)	0.81 (0.62)	0.0	0.26	0.77	1.19	2.6	
	Placebo	39	35 (89.7)	0.96 (0.59)	0.0	0.57	0.91	1.31	2.8		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMH0: Course of ASD weekly night-time score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	54	51 (94.4)	0.84 (0.64)	0.0	0.34	0.80	1.30	2.3	
		Placebo	39	37 (94.9)	1.00 (0.56)	0.1	0.60	0.86	1.43	2.8	
	Week 37	Tezepelumab	54	51 (94.4)	0.81 (0.63)	0.0	0.23	0.80	1.14	2.5	
		Placebo	39	37 (94.9)	1.03 (0.54)	0.0	0.77	1.00	1.37	2.7	
	Week 38	Tezepelumab	54	49 (90.7)	0.86 (0.66)	0.0	0.37	0.80	1.20	2.5	
		Placebo	39	37 (94.9)	0.95 (0.55)	0.0	0.60	0.89	1.29	2.8	
	Week 39	Tezepelumab	54	51 (94.4)	0.84 (0.66)	0.0	0.23	0.83	1.20	2.8	
		Placebo	39	37 (94.9)	0.96 (0.60)	0.0	0.54	0.83	1.32	2.8	
	Week 40	Tezepelumab	54	52 (96.3)	0.83 (0.63)	0.0	0.30	0.87	1.20	2.7	
		Placebo	39	37 (94.9)	1.01 (0.68)	0.0	0.57	0.97	1.40	2.7	
	Week 41	Tezepelumab	54	52 (96.3)	0.82 (0.64)	0.0	0.30	0.80	1.24	2.7	
		Placebo	39	36 (92.3)	1.04 (0.64)	0.0	0.63	1.01	1.44	2.8	
	Week 42	Tezepelumab	54	49 (90.7)	0.82 (0.70)	0.0	0.23	0.77	1.20	2.8	
		Placebo	39	37 (94.9)	1.05 (0.64)	0.0	0.60	1.00	1.46	2.8	
	Week 43	Tezepelumab	54	50 (92.6)	0.81 (0.69)	0.0	0.25	0.81	1.20	3.1	
		Placebo	39	36 (92.3)	0.97 (0.60)	0.0	0.53	0.91	1.41	2.8	
	Week 44	Tezepelumab	54	50 (92.6)	0.78 (0.64)	0.0	0.20	0.79	1.14	2.6	
		Placebo	39	35 (89.7)	1.00 (0.56)	0.1	0.63	0.91	1.40	2.8	
	Week 45	Tezepelumab	54	50 (92.6)	0.80 (0.65)	0.0	0.20	0.76	1.23	2.7	
		Placebo	39	36 (92.3)	0.90 (0.60)	0.0	0.40	0.81	1.25	2.8	
	Week 46	Tezepelumab	54	51 (94.4)	0.80 (0.66)	0.0	0.23	0.80	1.17	2.7	
		Placebo	39	36 (92.3)	0.92 (0.64)	0.0	0.40	0.86	1.31	2.8	
	Week 47	Tezepelumab	54	49 (90.7)	0.78 (0.66)	0.0	0.20	0.75	1.17	2.8	
		Placebo	39	36 (92.3)	0.94 (0.63)	0.0	0.40	0.81	1.43	2.8	
	Week 48	Tezepelumab	54	51 (94.4)	0.86 (0.68)	0.0	0.34	0.80	1.34	2.5	
		Placebo	39	37 (94.9)	0.95 (0.63)	0.0	0.46	0.91	1.43	2.8	
	Week 49	Tezepelumab	54	51 (94.4)	0.86 (0.67)	0.0	0.26	0.80	1.31	2.6	
		Placebo	39	37 (94.9)	0.94 (0.63)	0.0	0.40	0.80	1.43	2.8	
	Week 50	Tezepelumab	54	50 (92.6)	0.82 (0.64)	0.0	0.26	0.87	1.31	2.3	
		Placebo	39	35 (89.7)	0.87 (0.62)	0.0	0.40	0.80	1.31	2.8	
	Week 51	Tezepelumab	54	46 (85.2)	0.86 (0.66)	0.0	0.31	0.90	1.49	2.4	
		Placebo	39	34 (87.2)	0.91 (0.61)	0.0	0.49	0.85	1.30	2.8	
	Week 52	Tezepelumab	54	42 (77.8)	0.82 (0.63)	0.0	0.33	0.82	1.26	2.4	
		Placebo	39	32 (82.1)	0.94 (0.65)	0.0	0.44	0.87	1.47	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMH0: Course of ASD weekly night-time score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	54	53 (98.1)	-0.17 (0.50)	-2.5	-0.23	0.00	0.06	0.5	-0.25 [-0.66, 0.17]
		Placebo	39	39 (100.0)	-0.07 (0.33)	-0.8	-0.17	-0.06	0.03	1.1	
	Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.52)	-2.8	-0.43	-0.11	0.03	0.3	-0.29 [-0.71, 0.13]
		Placebo	39	38 (97.4)	-0.11 (0.49)	-1.7	-0.18	-0.04	0.14	1.0	
	Week 3	Tezepelumab	54	54 (100.0)	-0.26 (0.53)	-2.8	-0.49	-0.11	0.03	0.5	-0.15 [-0.57, 0.27]
		Placebo	39	37 (94.9)	-0.17 (0.59)	-2.3	-0.26	-0.06	0.11	0.8	
	Week 4	Tezepelumab	54	54 (100.0)	-0.31 (0.56)	-2.8	-0.63	-0.18	0.00	0.4	-0.22 [-0.64, 0.19]
		Placebo	39	38 (97.4)	-0.19 (0.53)	-2.3	-0.37	-0.06	0.11	0.5	
	Week 5	Tezepelumab	54	53 (98.1)	-0.39 (0.58)	-2.8	-0.69	-0.20	-0.03	0.5	-0.22 [-0.64, 0.19]
		Placebo	39	38 (97.4)	-0.26 (0.61)	-2.4	-0.57	-0.14	0.09	1.2	
	Week 6	Tezepelumab	54	52 (96.3)	-0.31 (0.52)	-2.8	-0.51	-0.19	0.01	0.5	-0.24 [-0.66, 0.18]
		Placebo	39	39 (100.0)	-0.18 (0.58)	-2.3	-0.40	-0.03	0.11	0.8	
	Week 7	Tezepelumab	54	52 (96.3)	-0.31 (0.54)	-2.8	-0.46	-0.20	0.02	0.8	-0.09 [-0.50, 0.33]
		Placebo	39	39 (100.0)	-0.26 (0.54)	-2.5	-0.51	-0.17	0.09	0.8	
	Week 8	Tezepelumab	54	52 (96.3)	-0.38 (0.56)	-2.8	-0.69	-0.26	-0.03	0.9	-0.28 [-0.70, 0.14]
		Placebo	39	38 (97.4)	-0.22 (0.63)	-2.4	-0.43	-0.14	0.09	1.9	
	Week 9	Tezepelumab	54	54 (100.0)	-0.40 (0.57)	-2.8	-0.77	-0.26	-0.03	0.6	-0.25 [-0.66, 0.17]
		Placebo	39	39 (100.0)	-0.25 (0.67)	-2.3	-0.63	-0.24	0.09	1.8	
	Week 10	Tezepelumab	54	53 (98.1)	-0.42 (0.59)	-2.8	-0.74	-0.23	-0.03	0.6	-0.24 [-0.65, 0.18]
		Placebo	39	39 (100.0)	-0.28 (0.57)	-2.4	-0.54	-0.18	0.06	0.9	
	Week 11	Tezepelumab	54	53 (98.1)	-0.41 (0.54)	-2.8	-0.74	-0.29	-0.08	0.5	-0.13 [-0.55, 0.28]
		Placebo	39	39 (100.0)	-0.34 (0.58)	-2.2	-0.66	-0.20	0.07	0.7	
	Week 12	Tezepelumab	54	52 (96.3)	-0.43 (0.60)	-2.8	-0.77	-0.29	-0.03	0.6	-0.18 [-0.60, 0.25]
		Placebo	39	37 (94.9)	-0.33 (0.64)	-2.2	-0.60	-0.26	0.00	1.7	
	Week 13	Tezepelumab	54	50 (92.6)	-0.39 (0.60)	-2.8	-0.66	-0.27	0.00	0.6	-0.01 [-0.43, 0.41]
		Placebo	39	38 (97.4)	-0.39 (0.57)	-2.2	-0.74	-0.27	-0.06	1.3	
	Week 14	Tezepelumab	54	51 (94.4)	-0.42 (0.60)	-2.8	-0.74	-0.26	-0.11	0.8	-0.09 [-0.51, 0.33]
		Placebo	39	37 (94.9)	-0.36 (0.63)	-2.3	-0.77	-0.23	0.01	0.9	
	Week 15	Tezepelumab	54	51 (94.4)	-0.42 (0.59)	-2.8	-0.74	-0.26	-0.06	0.7	-0.05 [-0.47, 0.37]
		Placebo	39	38 (97.4)	-0.39 (0.65)	-2.3	-0.80	-0.20	0.00	1.5	
	Week 16	Tezepelumab	54	52 (96.3)	-0.45 (0.59)	-2.8	-0.70	-0.27	-0.05	0.5	-0.06 [-0.48, 0.36]
		Placebo	39	37 (94.9)	-0.41 (0.60)	-2.2	-0.80	-0.23	0.00	0.9	
	Week 17	Tezepelumab	54	52 (96.3)	-0.44 (0.61)	-2.8	-0.73	-0.31	-0.01	0.5	-0.16 [-0.58, 0.26]
		Placebo	39	37 (94.9)	-0.35 (0.59)	-2.3	-0.69	-0.16	0.03	0.8	
	Week 18	Tezepelumab	54	52 (96.3)	-0.43 (0.62)	-2.8	-0.73	-0.30	-0.04	0.9	-0.19 [-0.61, 0.22]
		Placebo	39	39 (100.0)	-0.31 (0.58)	-2.3	-0.66	-0.14	0.03	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMH0: Course of ASD weekly night-time score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	54	52 (96.3)	-0.47 (0.61)	-2.8	-0.75	-0.33	-0.04	0.6	-0.18 [-0.60, 0.24]
		Placebo	39	39 (100.0)	-0.36 (0.57)	-2.5	-0.69	-0.20	0.03	0.7	
	Week 20	Tezepelumab	54	51 (94.4)	-0.47 (0.63)	-2.8	-0.74	-0.31	-0.09	0.9	-0.22 [-0.64, 0.20]
		Placebo	39	38 (97.4)	-0.34 (0.58)	-2.1	-0.69	-0.21	0.03	0.9	
	Week 21	Tezepelumab	54	49 (90.7)	-0.45 (0.61)	-2.8	-0.74	-0.31	-0.03	0.7	-0.11 [-0.53, 0.32]
		Placebo	39	38 (97.4)	-0.39 (0.60)	-2.3	-0.71	-0.24	-0.03	1.2	
	Week 22	Tezepelumab	54	51 (94.4)	-0.43 (0.59)	-2.8	-0.74	-0.29	0.00	0.8	-0.10 [-0.52, 0.32]
		Placebo	39	38 (97.4)	-0.37 (0.58)	-2.3	-0.69	-0.20	0.03	1.1	
	Week 23	Tezepelumab	54	51 (94.4)	-0.44 (0.63)	-2.8	-0.74	-0.29	-0.09	1.0	-0.08 [-0.50, 0.35]
		Placebo	39	36 (92.3)	-0.40 (0.55)	-2.1	-0.76	-0.21	-0.01	0.3	
	Week 24	Tezepelumab	54	52 (96.3)	-0.46 (0.62)	-2.8	-0.71	-0.30	-0.07	1.1	0.01 [-0.41, 0.44]
		Placebo	39	36 (92.3)	-0.46 (0.55)	-2.3	-0.71	-0.25	-0.04	0.2	
	Week 25	Tezepelumab	54	49 (90.7)	-0.48 (0.58)	-2.8	-0.82	-0.34	-0.09	0.7	-0.06 [-0.49, 0.37]
		Placebo	39	37 (94.9)	-0.44 (0.63)	-2.5	-0.80	-0.26	-0.06	0.5	
	Week 26	Tezepelumab	54	52 (96.3)	-0.43 (0.62)	-2.8	-0.73	-0.27	0.03	0.4	0.01 [-0.41, 0.44]
		Placebo	39	36 (92.3)	-0.44 (0.70)	-2.5	-0.90	-0.31	0.03	1.2	
	Week 27	Tezepelumab	54	52 (96.3)	-0.41 (0.64)	-2.8	-0.74	-0.26	0.00	0.8	-0.02 [-0.44, 0.41]
		Placebo	39	35 (89.7)	-0.40 (0.74)	-2.5	-0.91	-0.29	-0.03	1.8	
	Week 28	Tezepelumab	54	52 (96.3)	-0.37 (0.60)	-2.7	-0.61	-0.31	0.01	1.0	-0.01 [-0.43, 0.42]
		Placebo	39	36 (92.3)	-0.36 (0.68)	-2.5	-0.78	-0.20	0.09	0.6	
	Week 29	Tezepelumab	54	51 (94.4)	-0.46 (0.58)	-2.8	-0.80	-0.29	-0.06	0.7	-0.10 [-0.53, 0.33]
		Placebo	39	36 (92.3)	-0.40 (0.69)	-2.5	-0.88	-0.29	0.08	0.7	
	Week 30	Tezepelumab	54	51 (94.4)	-0.45 (0.58)	-2.8	-0.74	-0.29	-0.03	0.8	-0.03 [-0.45, 0.40]
		Placebo	39	36 (92.3)	-0.43 (0.64)	-2.5	-0.81	-0.36	-0.06	0.9	
	Week 31	Tezepelumab	54	53 (98.1)	-0.50 (0.65)	-2.8	-0.74	-0.34	-0.11	0.7	-0.11 [-0.53, 0.31]
		Placebo	39	37 (94.9)	-0.43 (0.65)	-2.5	-0.80	-0.32	-0.14	1.1	
	Week 32	Tezepelumab	54	52 (96.3)	-0.46 (0.62)	-2.8	-0.74	-0.30	-0.03	0.7	-0.04 [-0.46, 0.38]
		Placebo	39	37 (94.9)	-0.44 (0.66)	-2.5	-0.80	-0.42	-0.14	1.1	
	Week 33	Tezepelumab	54	52 (96.3)	-0.48 (0.63)	-2.8	-0.83	-0.36	-0.01	0.6	-0.13 [-0.55, 0.30]
		Placebo	39	37 (94.9)	-0.40 (0.64)	-2.5	-0.57	-0.34	-0.11	1.1	
	Week 34	Tezepelumab	54	53 (98.1)	-0.49 (0.63)	-2.8	-0.89	-0.39	-0.06	0.9	-0.15 [-0.57, 0.27]
		Placebo	39	37 (94.9)	-0.39 (0.64)	-2.4	-0.80	-0.34	-0.10	0.9	
	Week 35	Tezepelumab	54	52 (96.3)	-0.47 (0.60)	-2.8	-0.81	-0.33	-0.11	1.0	-0.09 [-0.52, 0.34]
		Placebo	39	35 (89.7)	-0.41 (0.62)	-2.5	-0.69	-0.34	-0.06	0.8	
	Week 36	Tezepelumab	54	51 (94.4)	-0.43 (0.62)	-2.8	-0.74	-0.34	-0.03	0.7	-0.11 [-0.53, 0.31]
		Placebo	39	37 (94.9)	-0.37 (0.60)	-2.4	-0.74	-0.23	-0.09	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMH0: Course of ASD weekly night-time score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	54	51 (94.4)	-0.47 (0.62)	-2.8	-0.77	-0.31	-0.09	0.8	-0.22 [-0.65, 0.20]
		Placebo	39	37 (94.9)	-0.34 (0.55)	-2.1	-0.66	-0.29	-0.06	0.7	
	Week 38	Tezepelumab	54	49 (90.7)	-0.42 (0.66)	-2.8	-0.74	-0.29	-0.09	0.9	-0.02 [-0.45, 0.41]
		Placebo	39	37 (94.9)	-0.41 (0.53)	-1.9	-0.70	-0.34	-0.10	0.8	
	Week 39	Tezepelumab	54	51 (94.4)	-0.47 (0.65)	-2.8	-0.74	-0.31	0.00	0.6	-0.11 [-0.53, 0.32]
		Placebo	39	37 (94.9)	-0.40 (0.54)	-2.0	-0.77	-0.32	-0.09	0.8	
	Week 40	Tezepelumab	54	52 (96.3)	-0.46 (0.63)	-2.8	-0.80	-0.31	-0.03	0.8	-0.16 [-0.58, 0.26]
		Placebo	39	37 (94.9)	-0.35 (0.66)	-2.3	-0.69	-0.37	-0.06	1.7	
	Week 41	Tezepelumab	54	52 (96.3)	-0.47 (0.63)	-2.8	-0.81	-0.33	0.00	0.6	-0.23 [-0.65, 0.20]
		Placebo	39	36 (92.3)	-0.32 (0.69)	-2.3	-0.73	-0.30	-0.04	1.4	
	Week 42	Tezepelumab	54	49 (90.7)	-0.42 (0.62)	-2.8	-0.74	-0.29	-0.03	0.7	-0.17 [-0.60, 0.25]
		Placebo	39	37 (94.9)	-0.32 (0.55)	-1.7	-0.66	-0.35	0.00	0.8	
	Week 43	Tezepelumab	54	50 (92.6)	-0.46 (0.61)	-2.8	-0.77	-0.31	-0.03	0.6	-0.16 [-0.59, 0.27]
		Placebo	39	36 (92.3)	-0.37 (0.52)	-1.6	-0.73	-0.39	-0.03	0.8	
	Week 44	Tezepelumab	54	50 (92.6)	-0.52 (0.61)	-2.8	-0.94	-0.31	-0.06	0.6	-0.27 [-0.70, 0.17]
		Placebo	39	35 (89.7)	-0.36 (0.55)	-1.8	-0.69	-0.20	-0.03	0.8	
	Week 45	Tezepelumab	54	50 (92.6)	-0.49 (0.65)	-2.8	-0.94	-0.31	0.01	0.5	-0.08 [-0.51, 0.35]
		Placebo	39	36 (92.3)	-0.44 (0.58)	-2.3	-0.80	-0.37	-0.06	0.8	
	Week 46	Tezepelumab	54	51 (94.4)	-0.47 (0.67)	-2.8	-0.77	-0.46	0.00	0.8	-0.07 [-0.50, 0.36]
		Placebo	39	36 (92.3)	-0.43 (0.62)	-2.5	-0.74	-0.39	0.01	0.8	
	Week 47	Tezepelumab	54	49 (90.7)	-0.48 (0.67)	-2.8	-0.80	-0.34	-0.03	0.8	-0.13 [-0.56, 0.30]
		Placebo	39	36 (92.3)	-0.40 (0.61)	-2.5	-0.63	-0.29	-0.04	0.8	
	Week 48	Tezepelumab	54	51 (94.4)	-0.41 (0.69)	-2.8	-0.80	-0.26	0.03	0.7	0.02 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.42 (0.58)	-2.5	-0.69	-0.37	-0.09	0.9	
	Week 49	Tezepelumab	54	51 (94.4)	-0.41 (0.66)	-2.8	-0.74	-0.29	0.00	0.8	0.03 [-0.40, 0.45]
		Placebo	39	37 (94.9)	-0.42 (0.58)	-2.5	-0.69	-0.37	-0.11	0.8	
	Week 50	Tezepelumab	54	50 (92.6)	-0.45 (0.63)	-2.8	-0.74	-0.31	-0.03	0.8	0.03 [-0.40, 0.47]
		Placebo	39	35 (89.7)	-0.47 (0.58)	-2.5	-0.74	-0.37	-0.15	0.8	
	Week 51	Tezepelumab	54	46 (85.2)	-0.36 (0.61)	-2.8	-0.66	-0.23	0.03	0.6	0.15 [-0.29, 0.60]
		Placebo	39	34 (87.2)	-0.45 (0.60)	-2.5	-0.74	-0.36	-0.03	0.8	
	Week 52	Tezepelumab	54	42 (77.8)	-0.41 (0.61)	-2.8	-0.74	-0.24	-0.03	0.8	0.10 [-0.37, 0.56]
		Placebo	39	32 (82.1)	-0.47 (0.60)	-2.5	-0.73	-0.43	-0.16	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	54	53 (98.1)	-0.18 (0.07)	(-0.32, -0.05)	-0.15 (0.11)	(-0.36, 0.07)	0.177
	Placebo	39	39 (100.0)	-0.04 (0.08)	(-0.20, 0.13)			
Week 2	Tezepelumab	54	53 (98.1)	-0.26 (0.07)	(-0.40, -0.12)	-0.20 (0.11)	(-0.41, 0.02)	0.076
	Placebo	39	38 (97.4)	-0.07 (0.08)	(-0.23, 0.10)			
Week 3	Tezepelumab	54	54 (100.0)	-0.27 (0.07)	(-0.41, -0.14)	-0.15 (0.11)	(-0.36, 0.07)	0.179
	Placebo	39	37 (94.9)	-0.13 (0.08)	(-0.29, 0.04)			
Week 4	Tezepelumab	54	54 (100.0)	-0.33 (0.07)	(-0.47, -0.19)	-0.17 (0.11)	(-0.39, 0.04)	0.116
	Placebo	39	38 (97.4)	-0.15 (0.08)	(-0.32, 0.01)			
Week 5	Tezepelumab	54	53 (98.1)	-0.40 (0.07)	(-0.54, -0.26)	-0.18 (0.11)	(-0.39, 0.04)	0.111
	Placebo	39	38 (97.4)	-0.23 (0.08)	(-0.39, -0.06)			
Week 6	Tezepelumab	54	52 (96.3)	-0.31 (0.07)	(-0.45, -0.17)	-0.17 (0.11)	(-0.38, 0.05)	0.133
	Placebo	39	39 (100.0)	-0.15 (0.08)	(-0.31, 0.02)			
Week 7	Tezepelumab	54	52 (96.3)	-0.31 (0.07)	(-0.45, -0.17)	-0.08 (0.11)	(-0.30, 0.13)	0.451
	Placebo	39	39 (100.0)	-0.23 (0.08)	(-0.39, -0.06)			
Week 8	Tezepelumab	54	52 (96.3)	-0.37 (0.07)	(-0.51, -0.23)	-0.20 (0.11)	(-0.42, 0.01)	0.064
	Placebo	39	38 (97.4)	-0.17 (0.08)	(-0.33, -0.00)			
Week 9	Tezepelumab	54	54 (100.0)	-0.42 (0.07)	(-0.56, -0.28)	-0.20 (0.11)	(-0.41, 0.02)	0.073
	Placebo	39	39 (100.0)	-0.22 (0.08)	(-0.38, -0.06)			
Week 10	Tezepelumab	54	53 (98.1)	-0.43 (0.07)	(-0.57, -0.29)	-0.17 (0.11)	(-0.39, 0.04)	0.116
	Placebo	39	39 (100.0)	-0.25 (0.08)	(-0.42, -0.09)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results
DITTB - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	54	53 (98.1)	-0.41 (0.07)	(-0.55, -0.27)	-0.10 (0.11)	(-0.32, 0.11)	0.354
	Placebo	39	39 (100.0)	-0.31 (0.08)	(-0.47, -0.14)			
Week 12	Tezepelumab	54	52 (96.3)	-0.44 (0.07)	(-0.59, -0.30)	-0.16 (0.11)	(-0.37, 0.06)	0.160
	Placebo	39	37 (94.9)	-0.29 (0.08)	(-0.45, -0.13)			
Week 13	Tezepelumab	54	50 (92.6)	-0.42 (0.07)	(-0.56, -0.28)	-0.07 (0.11)	(-0.28, 0.15)	0.547
	Placebo	39	38 (97.4)	-0.35 (0.08)	(-0.51, -0.19)			
Week 14	Tezepelumab	54	51 (94.4)	-0.40 (0.07)	(-0.54, -0.26)	-0.08 (0.11)	(-0.30, 0.13)	0.449
	Placebo	39	37 (94.9)	-0.31 (0.08)	(-0.48, -0.15)			
Week 15	Tezepelumab	54	51 (94.4)	-0.42 (0.07)	(-0.57, -0.28)	-0.08 (0.11)	(-0.29, 0.14)	0.479
	Placebo	39	38 (97.4)	-0.35 (0.08)	(-0.51, -0.18)			
Week 16	Tezepelumab	54	52 (96.3)	-0.45 (0.07)	(-0.59, -0.31)	-0.09 (0.11)	(-0.31, 0.13)	0.416
	Placebo	39	37 (94.9)	-0.36 (0.08)	(-0.52, -0.19)			
Week 17	Tezepelumab	54	52 (96.3)	-0.44 (0.07)	(-0.59, -0.30)	-0.15 (0.11)	(-0.36, 0.07)	0.186
	Placebo	39	37 (94.9)	-0.30 (0.08)	(-0.46, -0.13)			
Week 18	Tezepelumab	54	52 (96.3)	-0.43 (0.07)	(-0.57, -0.29)	-0.14 (0.11)	(-0.36, 0.07)	0.189
	Placebo	39	39 (100.0)	-0.28 (0.08)	(-0.45, -0.12)			
Week 19	Tezepelumab	54	52 (96.3)	-0.47 (0.07)	(-0.61, -0.33)	-0.13 (0.11)	(-0.35, 0.08)	0.222
	Placebo	39	39 (100.0)	-0.33 (0.08)	(-0.50, -0.17)			
Week 20	Tezepelumab	54	51 (94.4)	-0.48 (0.07)	(-0.62, -0.33)	-0.15 (0.11)	(-0.36, 0.07)	0.183
	Placebo	39	38 (97.4)	-0.33 (0.08)	(-0.49, -0.16)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	54	49 (90.7)	-0.49 (0.07)	(-0.63, -0.35)	-0.13 (0.11)	(-0.34, 0.09)	0.248
	Placebo	39	38 (97.4)	-0.36 (0.08)	(-0.52, -0.19)			
Week 22	Tezepelumab	54	51 (94.4)	-0.45 (0.07)	(-0.59, -0.31)	-0.11 (0.11)	(-0.33, 0.10)	0.299
	Placebo	39	38 (97.4)	-0.34 (0.08)	(-0.50, -0.17)			
Week 23	Tezepelumab	54	51 (94.4)	-0.46 (0.07)	(-0.60, -0.32)	-0.14 (0.11)	(-0.36, 0.08)	0.209
	Placebo	39	36 (92.3)	-0.32 (0.08)	(-0.48, -0.15)			
Week 24	Tezepelumab	54	52 (96.3)	-0.46 (0.07)	(-0.60, -0.32)	-0.07 (0.11)	(-0.29, 0.15)	0.542
	Placebo	39	36 (92.3)	-0.39 (0.08)	(-0.56, -0.23)			
Week 25	Tezepelumab	54	49 (90.7)	-0.49 (0.07)	(-0.63, -0.35)	-0.10 (0.11)	(-0.32, 0.11)	0.354
	Placebo	39	37 (94.9)	-0.38 (0.08)	(-0.55, -0.22)			
Week 26	Tezepelumab	54	52 (96.3)	-0.46 (0.07)	(-0.60, -0.32)	-0.08 (0.11)	(-0.30, 0.13)	0.450
	Placebo	39	36 (92.3)	-0.38 (0.08)	(-0.54, -0.21)			
Week 27	Tezepelumab	54	52 (96.3)	-0.43 (0.07)	(-0.57, -0.29)	-0.08 (0.11)	(-0.30, 0.14)	0.463
	Placebo	39	35 (89.7)	-0.35 (0.09)	(-0.51, -0.18)			
Week 28	Tezepelumab	54	52 (96.3)	-0.41 (0.07)	(-0.55, -0.27)	-0.11 (0.11)	(-0.32, 0.11)	0.343
	Placebo	39	36 (92.3)	-0.31 (0.08)	(-0.47, -0.14)			
Week 29	Tezepelumab	54	51 (94.4)	-0.49 (0.07)	(-0.63, -0.35)	-0.13 (0.11)	(-0.35, 0.08)	0.228
	Placebo	39	36 (92.3)	-0.36 (0.09)	(-0.52, -0.19)			
Week 30	Tezepelumab	54	51 (94.4)	-0.46 (0.07)	(-0.60, -0.32)	-0.08 (0.11)	(-0.29, 0.14)	0.490
	Placebo	39	36 (92.3)	-0.39 (0.09)	(-0.55, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	54	53 (98.1)	-0.51 (0.07)	(-0.65, -0.37)	-0.11 (0.11)	(-0.33, 0.10)	0.303
	Placebo	39	37 (94.9)	-0.39 (0.09)	(-0.56, -0.22)			
Week 32	Tezepelumab	54	52 (96.3)	-0.49 (0.07)	(-0.63, -0.35)	-0.09 (0.11)	(-0.31, 0.13)	0.405
	Placebo	39	37 (94.9)	-0.40 (0.09)	(-0.57, -0.23)			
Week 33	Tezepelumab	54	52 (96.3)	-0.48 (0.07)	(-0.62, -0.34)	-0.12 (0.11)	(-0.34, 0.09)	0.265
	Placebo	39	37 (94.9)	-0.36 (0.09)	(-0.53, -0.19)			
Week 34	Tezepelumab	54	53 (98.1)	-0.51 (0.07)	(-0.65, -0.37)	-0.15 (0.11)	(-0.37, 0.06)	0.166
	Placebo	39	37 (94.9)	-0.35 (0.09)	(-0.52, -0.19)			
Week 35	Tezepelumab	54	52 (96.3)	-0.49 (0.07)	(-0.63, -0.35)	-0.12 (0.11)	(-0.34, 0.10)	0.272
	Placebo	39	35 (89.7)	-0.37 (0.09)	(-0.53, -0.20)			
Week 36	Tezepelumab	54	51 (94.4)	-0.46 (0.07)	(-0.60, -0.32)	-0.12 (0.11)	(-0.34, 0.10)	0.275
	Placebo	39	37 (94.9)	-0.33 (0.09)	(-0.50, -0.17)			
Week 37	Tezepelumab	54	51 (94.4)	-0.49 (0.07)	(-0.63, -0.35)	-0.18 (0.11)	(-0.40, 0.04)	0.110
	Placebo	39	37 (94.9)	-0.31 (0.09)	(-0.48, -0.14)			
Week 38	Tezepelumab	54	49 (90.7)	-0.46 (0.07)	(-0.60, -0.32)	-0.08 (0.11)	(-0.30, 0.14)	0.477
	Placebo	39	37 (94.9)	-0.38 (0.09)	(-0.55, -0.21)			
Week 39	Tezepelumab	54	51 (94.4)	-0.48 (0.07)	(-0.62, -0.34)	-0.11 (0.11)	(-0.33, 0.11)	0.321
	Placebo	39	37 (94.9)	-0.37 (0.09)	(-0.54, -0.20)			
Week 40	Tezepelumab	54	52 (96.3)	-0.48 (0.07)	(-0.62, -0.34)	-0.15 (0.11)	(-0.37, 0.07)	0.170
	Placebo	39	37 (94.9)	-0.32 (0.09)	(-0.49, -0.15)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	54	52 (96.3)	-0.49 (0.07)	(-0.63, -0.35)	-0.19 (0.11)	(-0.41, 0.02)	0.082
	Placebo	39	36 (92.3)	-0.30 (0.09)	(-0.46, -0.13)			
Week 42	Tezepelumab	54	49 (90.7)	-0.46 (0.07)	(-0.60, -0.32)	-0.17 (0.11)	(-0.39, 0.05)	0.132
	Placebo	39	37 (94.9)	-0.29 (0.09)	(-0.46, -0.12)			
Week 43	Tezepelumab	54	50 (92.6)	-0.49 (0.07)	(-0.64, -0.35)	-0.15 (0.11)	(-0.37, 0.07)	0.171
	Placebo	39	36 (92.3)	-0.34 (0.09)	(-0.51, -0.17)			
Week 44	Tezepelumab	54	50 (92.6)	-0.53 (0.07)	(-0.67, -0.39)	-0.19 (0.11)	(-0.41, 0.03)	0.093
	Placebo	39	35 (89.7)	-0.34 (0.09)	(-0.51, -0.17)			
Week 45	Tezepelumab	54	50 (92.6)	-0.51 (0.07)	(-0.65, -0.37)	-0.09 (0.11)	(-0.31, 0.13)	0.403
	Placebo	39	36 (92.3)	-0.41 (0.09)	(-0.58, -0.24)			
Week 46	Tezepelumab	54	51 (94.4)	-0.49 (0.07)	(-0.63, -0.35)	-0.10 (0.11)	(-0.32, 0.12)	0.394
	Placebo	39	36 (92.3)	-0.39 (0.09)	(-0.56, -0.23)			
Week 47	Tezepelumab	54	49 (90.7)	-0.48 (0.07)	(-0.62, -0.34)	-0.12 (0.11)	(-0.34, 0.11)	0.304
	Placebo	39	36 (92.3)	-0.37 (0.09)	(-0.54, -0.20)			
Week 48	Tezepelumab	54	51 (94.4)	-0.44 (0.07)	(-0.58, -0.30)	-0.05 (0.11)	(-0.27, 0.17)	0.647
	Placebo	39	37 (94.9)	-0.39 (0.09)	(-0.56, -0.22)			
Week 49	Tezepelumab	54	51 (94.4)	-0.44 (0.07)	(-0.59, -0.30)	-0.05 (0.11)	(-0.27, 0.17)	0.657
	Placebo	39	37 (94.9)	-0.39 (0.09)	(-0.56, -0.23)			
Week 50	Tezepelumab	54	50 (92.6)	-0.48 (0.07)	(-0.62, -0.34)	-0.06 (0.11)	(-0.28, 0.16)	0.617
	Placebo	39	35 (89.7)	-0.42 (0.09)	(-0.59, -0.25)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC_ABMC0: Change from baseline in ASD weekly night-time score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	46 (85.2)	-0.44 (0.07)	(-0.58, -0.30)	-0.03 (0.11)	(-0.25, 0.19)	0.782
	Placebo	39	34 (87.2)	-0.41 (0.09)	(-0.58, -0.24)			
Week 52	Tezepelumab	54	42 (77.8)	-0.46 (0.07)	(-0.61, -0.32)	-0.07 (0.12)	(-0.29, 0.16)	0.555
	Placebo	39	32 (82.1)	-0.40 (0.09)	(-0.57, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMH0: Course of ASD weekly wheezing score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	54	54 (100.0)	1.25 (0.74)	0.0	0.79	1.36	1.93	2.7	
		Placebo	39	39 (100.0)	1.53 (0.70)	0.2	1.00	1.64	2.00	3.0	
	Week 1	Tezepelumab	54	53 (98.1)	1.13 (0.70)	0.0	0.71	1.07	1.71	2.5	
		Placebo	39	39 (100.0)	1.45 (0.71)	0.0	1.00	1.57	2.00	3.0	
	Week 2	Tezepelumab	54	53 (98.1)	1.04 (0.72)	0.0	0.50	1.00	1.79	2.3	
		Placebo	39	38 (97.4)	1.42 (0.72)	0.0	1.00	1.54	1.92	3.0	
	Week 3	Tezepelumab	54	54 (100.0)	1.05 (0.70)	0.0	0.50	1.00	1.50	2.9	
		Placebo	39	37 (94.9)	1.38 (0.78)	0.0	1.00	1.14	2.00	3.4	
	Week 4	Tezepelumab	54	53 (98.1)	0.97 (0.74)	0.0	0.36	1.00	1.58	2.9	
		Placebo	39	38 (97.4)	1.34 (0.75)	0.0	1.00	1.29	1.93	4.0	
	Week 5	Tezepelumab	54	52 (96.3)	0.94 (0.74)	0.0	0.21	0.93	1.57	2.6	
		Placebo	39	37 (94.9)	1.18 (0.76)	0.0	0.79	1.00	1.79	3.2	
	Week 6	Tezepelumab	54	51 (94.4)	0.99 (0.75)	0.0	0.29	1.00	1.43	3.0	
		Placebo	39	39 (100.0)	1.32 (0.73)	0.0	1.00	1.10	1.93	3.1	
	Week 7	Tezepelumab	54	50 (92.6)	0.98 (0.78)	0.0	0.21	0.93	1.50	3.1	
		Placebo	39	39 (100.0)	1.29 (0.73)	0.0	1.00	1.21	2.00	3.0	
	Week 8	Tezepelumab	54	50 (92.6)	0.94 (0.76)	0.0	0.20	0.92	1.50	2.6	
		Placebo	39	38 (97.4)	1.34 (0.66)	0.0	1.00	1.25	2.00	3.0	
	Week 9	Tezepelumab	54	52 (96.3)	0.93 (0.73)	0.0	0.27	0.96	1.39	2.6	
		Placebo	39	39 (100.0)	1.30 (0.67)	0.0	0.93	1.14	1.93	3.0	
	Week 10	Tezepelumab	54	52 (96.3)	0.92 (0.81)	0.0	0.14	0.93	1.49	2.9	
		Placebo	39	39 (100.0)	1.25 (0.67)	0.0	1.00	1.21	1.79	3.0	
	Week 11	Tezepelumab	54	50 (92.6)	0.96 (0.79)	0.0	0.17	1.00	1.43	3.1	
		Placebo	39	39 (100.0)	1.17 (0.68)	0.0	0.79	1.07	1.67	3.0	
	Week 12	Tezepelumab	54	51 (94.4)	0.90 (0.79)	0.0	0.10	0.79	1.57	2.9	
		Placebo	39	37 (94.9)	1.14 (0.70)	0.0	0.93	1.00	1.64	3.0	
	Week 13	Tezepelumab	54	48 (88.9)	0.92 (0.77)	0.0	0.06	0.96	1.39	2.9	
		Placebo	39	37 (94.9)	1.05 (0.67)	0.0	0.58	1.00	1.33	3.0	
	Week 14	Tezepelumab	54	51 (94.4)	0.97 (0.82)	0.0	0.13	1.00	1.63	3.0	
		Placebo	39	36 (92.3)	1.05 (0.69)	0.0	0.49	1.00	1.36	3.0	
	Week 15	Tezepelumab	54	50 (92.6)	0.90 (0.79)	0.0	0.07	1.00	1.33	3.0	
		Placebo	39	38 (97.4)	0.99 (0.73)	0.0	0.33	1.00	1.50	3.0	
	Week 16	Tezepelumab	54	50 (92.6)	0.84 (0.77)	0.0	0.07	0.79	1.17	2.1	
		Placebo	39	37 (94.9)	1.04 (0.72)	0.0	0.36	1.00	1.50	3.0	
Week 17	Tezepelumab	54	51 (94.4)	0.86 (0.78)	0.0	0.00	0.79	1.79	2.5		
	Placebo	39	37 (94.9)	1.13 (0.74)	0.0	0.75	1.00	1.64	3.0		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMH0: Course of ASD weekly wheezing score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	54	51 (94.4)	0.96 (0.81)	0.0	0.21	0.86	2.00	3.0	
		Placebo	39	37 (94.9)	1.09 (0.72)	0.0	0.71	1.00	1.50	3.0	
	Week 19	Tezepelumab	54	48 (88.9)	0.88 (0.83)	0.0	0.00	0.88	1.61	2.4	
		Placebo	39	38 (97.4)	1.09 (0.76)	0.0	0.50	1.00	1.71	3.0	
	Week 20	Tezepelumab	54	50 (92.6)	0.88 (0.78)	0.0	0.00	0.80	1.70	2.3	
		Placebo	39	36 (92.3)	1.10 (0.76)	0.0	0.50	1.12	1.64	3.0	
	Week 21	Tezepelumab	54	45 (83.3)	0.86 (0.80)	0.0	0.00	0.64	1.67	2.3	
		Placebo	39	37 (94.9)	1.09 (0.79)	0.0	0.29	1.07	1.75	3.0	
	Week 22	Tezepelumab	54	46 (85.2)	0.92 (0.75)	0.0	0.10	1.00	1.75	2.2	
		Placebo	39	37 (94.9)	1.07 (0.75)	0.0	0.20	1.17	1.50	3.0	
	Week 23	Tezepelumab	54	48 (88.9)	0.90 (0.80)	0.0	0.04	0.96	1.56	2.5	
		Placebo	39	35 (89.7)	1.08 (0.77)	0.0	0.29	1.10	1.67	3.0	
	Week 24	Tezepelumab	54	50 (92.6)	0.88 (0.83)	0.0	0.00	1.00	1.14	2.8	
		Placebo	39	35 (89.7)	0.97 (0.78)	0.0	0.00	1.00	1.57	2.9	
	Week 25	Tezepelumab	54	48 (88.9)	0.90 (0.79)	0.0	0.00	1.00	1.35	2.5	
		Placebo	39	35 (89.7)	1.05 (0.81)	0.0	0.07	1.00	1.79	3.0	
	Week 26	Tezepelumab	54	49 (90.7)	0.85 (0.76)	0.0	0.00	1.00	1.13	2.4	
		Placebo	39	36 (92.3)	1.07 (0.86)	0.0	0.14	1.11	1.65	3.0	
	Week 27	Tezepelumab	54	45 (83.3)	0.94 (0.79)	0.0	0.21	1.00	1.50	3.0	
		Placebo	39	35 (89.7)	1.11 (0.88)	0.0	0.21	1.00	1.64	3.1	
	Week 28	Tezepelumab	54	48 (88.9)	0.93 (0.83)	0.0	0.04	1.00	1.54	2.9	
		Placebo	39	35 (89.7)	1.03 (0.85)	0.0	0.07	1.00	1.64	3.4	
	Week 29	Tezepelumab	54	47 (87.0)	0.87 (0.79)	0.0	0.00	1.00	1.43	2.7	
		Placebo	39	36 (92.3)	1.00 (0.82)	0.0	0.04	1.00	1.61	3.0	
	Week 30	Tezepelumab	54	47 (87.0)	0.97 (0.75)	0.0	0.13	1.00	1.67	2.3	
		Placebo	39	35 (89.7)	1.02 (0.80)	0.0	0.33	1.00	1.57	3.0	
	Week 31	Tezepelumab	54	47 (87.0)	0.86 (0.73)	0.0	0.00	1.00	1.40	2.5	
		Placebo	39	36 (92.3)	1.00 (0.82)	0.0	0.25	1.00	1.32	3.1	
	Week 32	Tezepelumab	54	48 (88.9)	0.90 (0.74)	0.0	0.00	1.00	1.46	2.1	
		Placebo	39	36 (92.3)	1.02 (0.81)	0.0	0.25	1.00	1.42	3.0	
	Week 33	Tezepelumab	54	47 (87.0)	0.85 (0.74)	0.0	0.00	1.00	1.25	2.3	
		Placebo	39	36 (92.3)	1.04 (0.79)	0.0	0.35	1.00	1.71	3.0	
	Week 34	Tezepelumab	54	49 (90.7)	0.83 (0.73)	0.0	0.00	1.00	1.29	2.1	
		Placebo	39	37 (94.9)	1.02 (0.79)	0.0	0.08	1.00	1.71	3.0	
	Week 35	Tezepelumab	54	47 (87.0)	0.85 (0.74)	0.0	0.00	0.93	1.21	2.3	
		Placebo	39	35 (89.7)	1.03 (0.77)	0.0	0.33	1.00	1.33	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMH0: Course of ASD weekly wheezing score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	54	47 (87.0)	0.87 (0.75)	0.0	0.00	1.00	1.36	2.6	
		Placebo	39	37 (94.9)	1.08 (0.76)	0.0	0.50	1.00	1.43	3.0	
	Week 37	Tezepelumab	54	46 (85.2)	0.89 (0.75)	0.0	0.07	1.00	1.21	2.6	
		Placebo	39	36 (92.3)	1.11 (0.72)	0.0	0.82	1.00	1.71	3.0	
	Week 38	Tezepelumab	54	46 (85.2)	0.90 (0.81)	0.0	0.00	1.00	1.42	2.9	
		Placebo	39	36 (92.3)	1.04 (0.74)	0.0	0.51	1.00	1.53	3.0	
	Week 39	Tezepelumab	54	48 (88.9)	0.86 (0.78)	0.0	0.00	1.00	1.16	2.5	
		Placebo	39	36 (92.3)	1.04 (0.78)	0.0	0.18	1.00	1.50	3.0	
	Week 40	Tezepelumab	54	48 (88.9)	0.90 (0.77)	0.0	0.04	1.00	1.18	2.6	
		Placebo	39	37 (94.9)	1.11 (0.86)	0.0	0.14	1.00	1.75	3.0	
	Week 41	Tezepelumab	54	49 (90.7)	0.85 (0.76)	0.0	0.00	1.00	1.29	2.4	
		Placebo	39	35 (89.7)	1.10 (0.82)	0.0	0.21	1.00	1.86	3.0	
	Week 42	Tezepelumab	54	46 (85.2)	0.84 (0.77)	0.0	0.00	1.00	1.17	2.5	
		Placebo	39	35 (89.7)	1.09 (0.82)	0.0	0.07	1.07	1.88	3.0	
	Week 43	Tezepelumab	54	48 (88.9)	0.85 (0.79)	0.0	0.00	1.00	1.14	2.8	
		Placebo	39	36 (92.3)	1.10 (0.79)	0.0	0.39	1.04	1.85	3.0	
	Week 44	Tezepelumab	54	47 (87.0)	0.81 (0.74)	0.0	0.00	1.00	1.07	2.2	
		Placebo	39	34 (87.2)	1.10 (0.74)	0.0	0.58	1.00	1.71	3.0	
	Week 45	Tezepelumab	54	47 (87.0)	0.86 (0.77)	0.0	0.00	1.00	1.43	2.4	
		Placebo	39	35 (89.7)	1.00 (0.79)	0.0	0.33	1.00	1.21	3.0	
	Week 46	Tezepelumab	54	46 (85.2)	0.82 (0.79)	0.0	0.00	0.90	1.42	2.2	
		Placebo	39	36 (92.3)	1.06 (0.86)	0.0	0.14	1.00	1.79	3.2	
	Week 47	Tezepelumab	54	45 (83.3)	0.83 (0.81)	0.0	0.00	1.00	1.21	2.7	
		Placebo	39	36 (92.3)	1.06 (0.83)	0.0	0.18	1.00	1.92	3.0	
	Week 48	Tezepelumab	54	48 (88.9)	0.87 (0.85)	0.0	0.00	1.00	1.61	2.9	
		Placebo	39	36 (92.3)	1.00 (0.84)	0.0	0.11	1.00	1.61	3.0	
	Week 49	Tezepelumab	54	46 (85.2)	0.94 (0.83)	0.0	0.00	1.00	1.75	2.6	
		Placebo	39	35 (89.7)	1.03 (0.83)	0.0	0.07	1.00	1.64	3.0	
	Week 50	Tezepelumab	54	43 (79.6)	0.88 (0.79)	0.0	0.00	1.00	1.57	2.5	
		Placebo	39	34 (87.2)	0.94 (0.80)	0.0	0.10	1.00	1.43	3.0	
	Week 51	Tezepelumab	54	44 (81.5)	0.93 (0.81)	0.0	0.00	1.00	1.80	2.2	
		Placebo	39	32 (82.1)	1.02 (0.85)	0.0	0.00	1.00	1.54	3.0	
	Week 52	Tezepelumab	54	38 (70.4)	0.92 (0.81)	0.0	0.00	1.00	1.83	2.4	
		Placebo	39	31 (79.5)	1.00 (0.86)	0.0	0.00	1.00	1.64	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMH0: Course of ASD weekly wheezing score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	54	53 (98.1)	-0.13 (0.51)	-2.1	-0.17	0.00	0.14	0.8	-0.09 [-0.51, 0.32]
		Placebo	39	39 (100.0)	-0.09 (0.31)	-0.7	-0.25	-0.11	0.00	0.8	
	Week 2	Tezepelumab	54	53 (98.1)	-0.21 (0.55)	-2.6	-0.29	-0.04	0.07	0.6	-0.18 [-0.60, 0.24]
		Placebo	39	38 (97.4)	-0.12 (0.49)	-1.9	-0.26	-0.02	0.02	1.2	
	Week 3	Tezepelumab	54	54 (100.0)	-0.20 (0.54)	-2.6	-0.36	-0.04	0.07	0.9	-0.06 [-0.48, 0.36]
		Placebo	39	37 (94.9)	-0.16 (0.63)	-2.4	-0.19	0.00	0.07	1.3	
	Week 4	Tezepelumab	54	53 (98.1)	-0.27 (0.57)	-2.6	-0.40	-0.07	0.00	0.7	-0.12 [-0.54, 0.30]
		Placebo	39	38 (97.4)	-0.20 (0.58)	-2.4	-0.36	-0.04	0.08	1.0	
	Week 5	Tezepelumab	54	52 (96.3)	-0.30 (0.58)	-2.5	-0.50	-0.11	0.06	0.6	0.06 [-0.36, 0.48]
		Placebo	39	37 (94.9)	-0.33 (0.64)	-2.6	-0.71	-0.21	0.07	1.2	
	Week 6	Tezepelumab	54	51 (94.4)	-0.25 (0.55)	-2.6	-0.43	-0.14	0.07	1.1	-0.05 [-0.47, 0.37]
		Placebo	39	39 (100.0)	-0.22 (0.62)	-2.4	-0.56	-0.07	0.14	0.9	
	Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.62)	-2.6	-0.43	-0.08	0.07	1.0	0.03 [-0.39, 0.45]
		Placebo	39	39 (100.0)	-0.25 (0.59)	-2.5	-0.63	-0.07	0.07	0.8	
	Week 8	Tezepelumab	54	50 (92.6)	-0.30 (0.62)	-2.6	-0.50	-0.08	0.00	1.0	-0.18 [-0.60, 0.24]
		Placebo	39	38 (97.4)	-0.18 (0.63)	-2.5	-0.62	0.00	0.17	1.2	
	Week 9	Tezepelumab	54	52 (96.3)	-0.31 (0.66)	-2.6	-0.68	-0.08	0.07	1.0	-0.12 [-0.53, 0.30]
		Placebo	39	39 (100.0)	-0.23 (0.69)	-2.4	-0.61	-0.17	0.07	1.6	
	Week 10	Tezepelumab	54	52 (96.3)	-0.31 (0.67)	-2.6	-0.57	-0.08	0.04	1.0	-0.05 [-0.47, 0.36]
		Placebo	39	39 (100.0)	-0.28 (0.63)	-2.5	-0.71	-0.14	0.07	0.8	
	Week 11	Tezepelumab	54	50 (92.6)	-0.29 (0.64)	-2.6	-0.68	-0.04	0.14	1.0	0.12 [-0.30, 0.54]
		Placebo	39	39 (100.0)	-0.37 (0.68)	-2.4	-0.79	-0.27	0.00	1.0	
	Week 12	Tezepelumab	54	51 (94.4)	-0.33 (0.72)	-2.6	-0.64	-0.14	0.14	1.4	0.09 [-0.33, 0.52]
		Placebo	39	37 (94.9)	-0.40 (0.70)	-2.4	-0.90	-0.30	0.07	1.3	
	Week 13	Tezepelumab	54	48 (88.9)	-0.27 (0.69)	-2.6	-0.57	-0.14	0.07	1.0	0.30 [-0.13, 0.73]
		Placebo	39	37 (94.9)	-0.48 (0.74)	-2.4	-0.86	-0.36	0.00	1.2	
	Week 14	Tezepelumab	54	51 (94.4)	-0.28 (0.66)	-2.6	-0.64	-0.14	0.07	1.0	0.28 [-0.15, 0.70]
		Placebo	39	36 (92.3)	-0.48 (0.76)	-2.4	-0.95	-0.36	0.07	1.2	
	Week 15	Tezepelumab	54	50 (92.6)	-0.29 (0.67)	-2.6	-0.64	-0.08	0.07	1.0	0.34 [-0.09, 0.76]
		Placebo	39	38 (97.4)	-0.53 (0.78)	-2.7	-1.00	-0.36	0.07	1.1	
	Week 16	Tezepelumab	54	50 (92.6)	-0.38 (0.65)	-2.6	-0.76	-0.14	0.00	1.0	0.16 [-0.26, 0.59]
		Placebo	39	37 (94.9)	-0.49 (0.69)	-2.4	-0.93	-0.29	0.00	0.9	
	Week 17	Tezepelumab	54	51 (94.4)	-0.39 (0.67)	-2.6	-0.71	-0.14	0.00	1.0	0.02 [-0.40, 0.45]
		Placebo	39	37 (94.9)	-0.40 (0.70)	-2.5	-0.93	-0.21	0.00	0.8	
Week 18	Tezepelumab	54	51 (94.4)	-0.30 (0.70)	-2.6	-0.71	-0.17	0.07	1.0	0.16 [-0.26, 0.59]	
	Placebo	39	37 (94.9)	-0.41 (0.72)	-2.4	-0.85	-0.21	0.00	1.0		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMH0: Course of ASD weekly wheezing score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	54	48 (88.9)	-0.33 (0.71)	-2.6	-0.64	-0.11	0.09	1.0	0.14 [-0.28, 0.57]
		Placebo	39	38 (97.4)	-0.43 (0.73)	-2.7	-0.90	-0.21	0.00	1.0	
	Week 20	Tezepelumab	54	50 (92.6)	-0.35 (0.68)	-2.6	-0.64	-0.15	0.00	1.0	0.13 [-0.30, 0.56]
		Placebo	39	36 (92.3)	-0.44 (0.74)	-2.7	-0.96	-0.31	0.01	0.9	
	Week 21	Tezepelumab	54	45 (83.3)	-0.36 (0.70)	-2.6	-0.86	-0.14	0.01	1.0	0.11 [-0.33, 0.54]
		Placebo	39	37 (94.9)	-0.44 (0.80)	-2.7	-0.93	-0.29	0.07	1.5	
	Week 22	Tezepelumab	54	46 (85.2)	-0.32 (0.67)	-2.6	-0.64	-0.07	0.00	1.0	0.20 [-0.23, 0.63]
		Placebo	39	37 (94.9)	-0.46 (0.76)	-2.7	-0.86	-0.33	0.00	1.1	
	Week 23	Tezepelumab	54	48 (88.9)	-0.35 (0.73)	-2.6	-0.69	-0.08	0.04	1.0	0.18 [-0.26, 0.61]
		Placebo	39	35 (89.7)	-0.49 (0.79)	-2.7	-0.93	-0.33	0.07	0.9	
	Week 24	Tezepelumab	54	50 (92.6)	-0.35 (0.69)	-2.6	-0.64	-0.14	0.00	1.0	0.33 [-0.11, 0.76]
		Placebo	39	35 (89.7)	-0.59 (0.76)	-2.7	-1.00	-0.43	0.00	0.5	
	Week 25	Tezepelumab	54	48 (88.9)	-0.34 (0.63)	-2.6	-0.64	-0.12	0.00	1.0	0.24 [-0.19, 0.68]
		Placebo	39	35 (89.7)	-0.51 (0.81)	-2.7	-1.00	-0.36	0.00	0.7	
	Week 26	Tezepelumab	54	49 (90.7)	-0.32 (0.68)	-2.6	-0.64	-0.07	0.07	1.0	0.24 [-0.20, 0.67]
		Placebo	39	36 (92.3)	-0.50 (0.91)	-2.8	-0.93	-0.33	0.04	1.6	
	Week 27	Tezepelumab	54	45 (83.3)	-0.30 (0.70)	-2.6	-0.57	-0.07	0.08	1.0	0.24 [-0.21, 0.68]
		Placebo	39	35 (89.7)	-0.49 (0.93)	-2.7	-0.93	-0.33	0.07	1.8	
	Week 28	Tezepelumab	54	48 (88.9)	-0.28 (0.67)	-2.6	-0.57	0.00	0.11	1.0	0.33 [-0.11, 0.77]
		Placebo	39	35 (89.7)	-0.53 (0.87)	-2.7	-1.00	-0.56	0.07	1.1	
	Week 29	Tezepelumab	54	47 (87.0)	-0.37 (0.67)	-2.6	-0.64	-0.14	0.00	1.0	0.21 [-0.23, 0.64]
		Placebo	39	36 (92.3)	-0.53 (0.93)	-2.7	-1.04	-0.52	0.00	1.5	
	Week 30	Tezepelumab	54	47 (87.0)	-0.35 (0.66)	-2.6	-0.79	-0.21	0.07	1.0	0.23 [-0.21, 0.67]
		Placebo	39	35 (89.7)	-0.52 (0.90)	-2.7	-1.14	-0.45	0.00	1.8	
	Week 31	Tezepelumab	54	47 (87.0)	-0.36 (0.72)	-2.6	-0.64	-0.21	0.07	1.0	0.21 [-0.22, 0.65]
		Placebo	39	36 (92.3)	-0.53 (0.88)	-2.7	-1.00	-0.44	0.04	2.0	
	Week 32	Tezepelumab	54	48 (88.9)	-0.32 (0.66)	-2.6	-0.62	-0.18	0.04	1.0	0.25 [-0.18, 0.69]
		Placebo	39	36 (92.3)	-0.51 (0.87)	-2.7	-1.00	-0.50	0.00	1.8	
	Week 33	Tezepelumab	54	47 (87.0)	-0.40 (0.73)	-2.6	-0.90	-0.17	0.10	1.0	0.11 [-0.32, 0.54]
		Placebo	39	36 (92.3)	-0.48 (0.79)	-2.6	-0.91	-0.21	0.00	1.5	
	Week 34	Tezepelumab	54	49 (90.7)	-0.45 (0.69)	-2.6	-0.93	-0.15	0.00	1.0	0.11 [-0.32, 0.54]
		Placebo	39	37 (94.9)	-0.53 (0.79)	-2.7	-1.00	-0.43	0.00	0.9	
	Week 35	Tezepelumab	54	47 (87.0)	-0.38 (0.65)	-2.6	-0.71	-0.17	0.07	1.0	0.19 [-0.25, 0.63]
		Placebo	39	35 (89.7)	-0.52 (0.77)	-2.7	-0.93	-0.55	0.02	1.1	
	Week 36	Tezepelumab	54	47 (87.0)	-0.36 (0.69)	-2.6	-0.66	-0.20	0.14	1.0	0.14 [-0.29, 0.57]
		Placebo	39	37 (94.9)	-0.46 (0.73)	-2.7	-0.93	-0.38	0.00	0.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMH0: Course of ASD weekly wheezing score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	54	46 (85.2)	-0.33 (0.66)	-2.6	-0.64	-0.15	0.07	1.0	0.12 [-0.31, 0.56]
		Placebo	39	36 (92.3)	-0.42 (0.73)	-2.7	-0.96	-0.39	0.04	1.2	
	Week 38	Tezepelumab	54	46 (85.2)	-0.32 (0.68)	-2.6	-0.64	-0.14	0.07	1.0	0.25 [-0.19, 0.69]
		Placebo	39	36 (92.3)	-0.49 (0.70)	-2.7	-1.00	-0.40	0.00	1.0	
	Week 39	Tezepelumab	54	48 (88.9)	-0.36 (0.66)	-2.6	-0.75	-0.14	0.07	1.0	0.19 [-0.24, 0.62]
		Placebo	39	36 (92.3)	-0.49 (0.71)	-2.7	-0.96	-0.33	0.00	0.8	
	Week 40	Tezepelumab	54	48 (88.9)	-0.37 (0.69)	-2.6	-0.80	-0.21	0.00	1.0	0.08 [-0.35, 0.51]
		Placebo	39	37 (94.9)	-0.43 (0.81)	-2.7	-0.93	-0.36	0.00	1.7	
	Week 41	Tezepelumab	54	49 (90.7)	-0.41 (0.67)	-2.6	-0.93	-0.14	0.00	0.5	0.00 [-0.43, 0.44]
		Placebo	39	35 (89.7)	-0.42 (0.83)	-2.5	-0.93	-0.38	0.07	1.8	
	Week 42	Tezepelumab	54	46 (85.2)	-0.40 (0.68)	-2.6	-1.00	-0.17	0.00	0.8	0.09 [-0.35, 0.53]
		Placebo	39	35 (89.7)	-0.46 (0.67)	-2.0	-0.93	-0.43	0.07	0.9	
	Week 43	Tezepelumab	54	48 (88.9)	-0.39 (0.68)	-2.6	-0.93	-0.28	0.00	0.9	0.06 [-0.37, 0.49]
		Placebo	39	36 (92.3)	-0.43 (0.63)	-2.0	-0.96	-0.36	0.01	1.0	
	Week 44	Tezepelumab	54	47 (87.0)	-0.43 (0.70)	-2.6	-1.00	-0.36	0.00	1.0	0.05 [-0.39, 0.49]
		Placebo	39	34 (87.2)	-0.47 (0.63)	-2.0	-0.99	-0.32	0.00	0.9	
	Week 45	Tezepelumab	54	47 (87.0)	-0.39 (0.72)	-2.6	-0.80	-0.17	0.14	1.1	0.22 [-0.22, 0.66]
		Placebo	39	35 (89.7)	-0.54 (0.73)	-2.2	-1.00	-0.57	0.07	0.9	
	Week 46	Tezepelumab	54	46 (85.2)	-0.37 (0.77)	-2.6	-0.93	-0.15	0.10	1.6	0.14 [-0.30, 0.57]
		Placebo	39	36 (92.3)	-0.47 (0.80)	-2.7	-0.93	-0.43	0.00	1.4	
	Week 47	Tezepelumab	54	45 (83.3)	-0.38 (0.74)	-2.6	-0.93	-0.14	0.00	1.0	0.12 [-0.32, 0.56]
		Placebo	39	36 (92.3)	-0.47 (0.72)	-2.7	-0.88	-0.36	0.00	0.8	
	Week 48	Tezepelumab	54	48 (88.9)	-0.31 (0.74)	-2.6	-0.68	-0.13	0.09	1.0	0.31 [-0.12, 0.75]
		Placebo	39	36 (92.3)	-0.53 (0.71)	-2.7	-0.96	-0.45	-0.01	0.8	
	Week 49	Tezepelumab	54	46 (85.2)	-0.30 (0.75)	-2.6	-0.66	-0.08	0.14	1.1	0.25 [-0.19, 0.70]
		Placebo	39	35 (89.7)	-0.49 (0.73)	-2.7	-0.93	-0.36	0.00	1.0	
	Week 50	Tezepelumab	54	43 (79.6)	-0.36 (0.70)	-2.6	-0.69	-0.17	0.07	1.0	0.29 [-0.16, 0.74]
		Placebo	39	34 (87.2)	-0.56 (0.68)	-2.7	-0.93	-0.46	0.00	0.5	
	Week 51	Tezepelumab	54	44 (81.5)	-0.31 (0.68)	-2.6	-0.71	-0.07	0.10	1.0	0.30 [-0.16, 0.76]
		Placebo	39	32 (82.1)	-0.52 (0.77)	-2.7	-0.96	-0.39	-0.07	1.2	
	Week 52	Tezepelumab	54	38 (70.4)	-0.29 (0.69)	-2.6	-0.64	0.00	0.14	1.1	0.47 [-0.01, 0.95]
		Placebo	39	31 (79.5)	-0.61 (0.70)	-2.7	-1.00	-0.62	-0.14	1.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results
DITTB - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	54	53 (98.1)	-0.17 (0.09)	(-0.33, 0.00)	-0.14 (0.13)	(-0.40, 0.12)	0.288
	Placebo	39	39 (100.0)	-0.03 (0.10)	(-0.22, 0.17)			
Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.08)	(-0.42, -0.08)	-0.21 (0.13)	(-0.47, 0.05)	0.115
	Placebo	39	38 (97.4)	-0.04 (0.10)	(-0.24, 0.15)			
Week 3	Tezepelumab	54	54 (100.0)	-0.24 (0.08)	(-0.41, -0.07)	-0.16 (0.13)	(-0.42, 0.10)	0.223
	Placebo	39	37 (94.9)	-0.08 (0.10)	(-0.27, 0.12)			
Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.08)	(-0.48, -0.15)	-0.19 (0.13)	(-0.45, 0.07)	0.153
	Placebo	39	38 (97.4)	-0.13 (0.10)	(-0.32, 0.07)			
Week 5	Tezepelumab	54	52 (96.3)	-0.33 (0.09)	(-0.50, -0.17)	-0.08 (0.13)	(-0.33, 0.18)	0.565
	Placebo	39	37 (94.9)	-0.26 (0.10)	(-0.46, -0.06)			
Week 6	Tezepelumab	54	51 (94.4)	-0.27 (0.09)	(-0.44, -0.10)	-0.11 (0.13)	(-0.37, 0.15)	0.389
	Placebo	39	39 (100.0)	-0.16 (0.10)	(-0.35, 0.04)			
Week 7	Tezepelumab	54	50 (92.6)	-0.27 (0.09)	(-0.43, -0.10)	-0.08 (0.13)	(-0.34, 0.18)	0.548
	Placebo	39	39 (100.0)	-0.19 (0.10)	(-0.38, 0.01)			
Week 8	Tezepelumab	54	50 (92.6)	-0.32 (0.09)	(-0.49, -0.15)	-0.20 (0.13)	(-0.46, 0.06)	0.125
	Placebo	39	38 (97.4)	-0.11 (0.10)	(-0.31, 0.08)			
Week 9	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.18)	-0.18 (0.13)	(-0.43, 0.08)	0.183
	Placebo	39	39 (100.0)	-0.17 (0.10)	(-0.36, 0.03)			
Week 10	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.13 (0.13)	(-0.39, 0.13)	0.324
	Placebo	39	39 (100.0)	-0.22 (0.10)	(-0.41, -0.02)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results
DITTB - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	54	50 (92.6)	-0.33 (0.09)	(-0.50, -0.17)	-0.03 (0.13)	(-0.29, 0.23)	0.826
	Placebo	39	39 (100.0)	-0.30 (0.10)	(-0.50, -0.11)			
Week 12	Tezepelumab	54	51 (94.4)	-0.37 (0.09)	(-0.53, -0.20)	-0.04 (0.13)	(-0.30, 0.22)	0.742
	Placebo	39	37 (94.9)	-0.32 (0.10)	(-0.52, -0.13)			
Week 13	Tezepelumab	54	48 (88.9)	-0.33 (0.09)	(-0.50, -0.16)	0.07 (0.13)	(-0.19, 0.33)	0.591
	Placebo	39	37 (94.9)	-0.40 (0.10)	(-0.60, -0.20)			
Week 14	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.45, -0.12)	0.08 (0.13)	(-0.18, 0.34)	0.526
	Placebo	39	36 (92.3)	-0.37 (0.10)	(-0.57, -0.17)			
Week 15	Tezepelumab	54	50 (92.6)	-0.33 (0.09)	(-0.49, -0.16)	0.14 (0.13)	(-0.12, 0.39)	0.307
	Placebo	39	38 (97.4)	-0.46 (0.10)	(-0.66, -0.26)			
Week 16	Tezepelumab	54	50 (92.6)	-0.41 (0.09)	(-0.57, -0.24)	-0.00 (0.13)	(-0.26, 0.26)	0.994
	Placebo	39	37 (94.9)	-0.41 (0.10)	(-0.60, -0.21)			
Week 17	Tezepelumab	54	51 (94.4)	-0.40 (0.09)	(-0.57, -0.24)	-0.08 (0.13)	(-0.34, 0.18)	0.534
	Placebo	39	37 (94.9)	-0.32 (0.10)	(-0.52, -0.12)			
Week 18	Tezepelumab	54	51 (94.4)	-0.32 (0.09)	(-0.49, -0.15)	0.01 (0.13)	(-0.25, 0.27)	0.927
	Placebo	39	37 (94.9)	-0.33 (0.10)	(-0.53, -0.14)			
Week 19	Tezepelumab	54	48 (88.9)	-0.36 (0.09)	(-0.53, -0.19)	-0.00 (0.13)	(-0.26, 0.26)	0.976
	Placebo	39	38 (97.4)	-0.36 (0.10)	(-0.55, -0.16)			
Week 20	Tezepelumab	54	50 (92.6)	-0.39 (0.09)	(-0.55, -0.22)	-0.00 (0.13)	(-0.26, 0.26)	0.989
	Placebo	39	36 (92.3)	-0.38 (0.10)	(-0.58, -0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	54	45 (83.3)	-0.42 (0.09)	(-0.59, -0.25)	-0.06 (0.13)	(-0.32, 0.20)	0.654
	Placebo	39	37 (94.9)	-0.36 (0.10)	(-0.56, -0.16)			
Week 22	Tezepelumab	54	46 (85.2)	-0.39 (0.09)	(-0.56, -0.22)	-0.00 (0.13)	(-0.26, 0.26)	0.982
	Placebo	39	37 (94.9)	-0.39 (0.10)	(-0.59, -0.19)			
Week 23	Tezepelumab	54	48 (88.9)	-0.38 (0.09)	(-0.55, -0.21)	-0.03 (0.13)	(-0.29, 0.23)	0.816
	Placebo	39	35 (89.7)	-0.35 (0.10)	(-0.55, -0.15)			
Week 24	Tezepelumab	54	50 (92.6)	-0.39 (0.09)	(-0.56, -0.22)	0.07 (0.13)	(-0.19, 0.34)	0.580
	Placebo	39	35 (89.7)	-0.46 (0.10)	(-0.66, -0.26)			
Week 25	Tezepelumab	54	48 (88.9)	-0.40 (0.09)	(-0.57, -0.23)	-0.01 (0.13)	(-0.27, 0.26)	0.968
	Placebo	39	35 (89.7)	-0.39 (0.10)	(-0.59, -0.19)			
Week 26	Tezepelumab	54	49 (90.7)	-0.38 (0.09)	(-0.55, -0.21)	0.01 (0.13)	(-0.26, 0.27)	0.964
	Placebo	39	36 (92.3)	-0.39 (0.10)	(-0.59, -0.19)			
Week 27	Tezepelumab	54	45 (83.3)	-0.36 (0.09)	(-0.52, -0.19)	0.02 (0.13)	(-0.24, 0.28)	0.872
	Placebo	39	35 (89.7)	-0.38 (0.10)	(-0.58, -0.18)			
Week 28	Tezepelumab	54	48 (88.9)	-0.37 (0.09)	(-0.53, -0.20)	0.04 (0.13)	(-0.23, 0.30)	0.791
	Placebo	39	35 (89.7)	-0.40 (0.10)	(-0.60, -0.20)			
Week 29	Tezepelumab	54	47 (87.0)	-0.40 (0.09)	(-0.57, -0.23)	0.03 (0.13)	(-0.23, 0.29)	0.816
	Placebo	39	36 (92.3)	-0.43 (0.10)	(-0.63, -0.23)			
Week 30	Tezepelumab	54	47 (87.0)	-0.41 (0.09)	(-0.58, -0.24)	0.03 (0.13)	(-0.23, 0.29)	0.834
	Placebo	39	35 (89.7)	-0.44 (0.10)	(-0.64, -0.24)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	54	47 (87.0)	-0.39 (0.09)	(-0.56, -0.22)	0.04 (0.13)	(-0.22, 0.31)	0.749
	Placebo	39	36 (92.3)	-0.43 (0.10)	(-0.63, -0.23)			
Week 32	Tezepelumab	54	48 (88.9)	-0.40 (0.09)	(-0.57, -0.23)	0.02 (0.13)	(-0.24, 0.28)	0.874
	Placebo	39	36 (92.3)	-0.42 (0.10)	(-0.62, -0.22)			
Week 33	Tezepelumab	54	47 (87.0)	-0.45 (0.09)	(-0.62, -0.28)	-0.03 (0.13)	(-0.29, 0.23)	0.821
	Placebo	39	36 (92.3)	-0.42 (0.10)	(-0.62, -0.22)			
Week 34	Tezepelumab	54	49 (90.7)	-0.49 (0.09)	(-0.66, -0.33)	-0.05 (0.13)	(-0.31, 0.21)	0.714
	Placebo	39	37 (94.9)	-0.45 (0.10)	(-0.65, -0.24)			
Week 35	Tezepelumab	54	47 (87.0)	-0.44 (0.09)	(-0.61, -0.27)	0.00 (0.13)	(-0.26, 0.27)	0.980
	Placebo	39	35 (89.7)	-0.44 (0.10)	(-0.64, -0.24)			
Week 36	Tezepelumab	54	47 (87.0)	-0.40 (0.09)	(-0.57, -0.23)	-0.02 (0.13)	(-0.28, 0.25)	0.894
	Placebo	39	37 (94.9)	-0.38 (0.10)	(-0.58, -0.18)			
Week 37	Tezepelumab	54	46 (85.2)	-0.41 (0.09)	(-0.58, -0.24)	-0.08 (0.14)	(-0.35, 0.18)	0.536
	Placebo	39	36 (92.3)	-0.33 (0.10)	(-0.53, -0.13)			
Week 38	Tezepelumab	54	46 (85.2)	-0.41 (0.09)	(-0.58, -0.24)	-0.01 (0.14)	(-0.27, 0.26)	0.970
	Placebo	39	36 (92.3)	-0.40 (0.10)	(-0.61, -0.20)			
Week 39	Tezepelumab	54	48 (88.9)	-0.45 (0.09)	(-0.62, -0.28)	-0.04 (0.14)	(-0.31, 0.22)	0.748
	Placebo	39	36 (92.3)	-0.40 (0.10)	(-0.61, -0.20)			
Week 40	Tezepelumab	54	48 (88.9)	-0.42 (0.09)	(-0.59, -0.25)	-0.07 (0.13)	(-0.33, 0.20)	0.630
	Placebo	39	37 (94.9)	-0.36 (0.10)	(-0.56, -0.15)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	54	49 (90.7)	-0.45 (0.09)	(-0.62, -0.27)	-0.10 (0.14)	(-0.37, 0.17)	0.462
	Placebo	39	35 (89.7)	-0.35 (0.10)	(-0.55, -0.14)			
Week 42	Tezepelumab	54	46 (85.2)	-0.45 (0.09)	(-0.62, -0.27)	-0.09 (0.14)	(-0.36, 0.18)	0.511
	Placebo	39	35 (89.7)	-0.36 (0.10)	(-0.56, -0.16)			
Week 43	Tezepelumab	54	48 (88.9)	-0.45 (0.09)	(-0.62, -0.27)	-0.09 (0.14)	(-0.36, 0.17)	0.492
	Placebo	39	36 (92.3)	-0.35 (0.10)	(-0.55, -0.15)			
Week 44	Tezepelumab	54	47 (87.0)	-0.48 (0.09)	(-0.65, -0.31)	-0.09 (0.14)	(-0.36, 0.17)	0.495
	Placebo	39	34 (87.2)	-0.39 (0.10)	(-0.59, -0.18)			
Week 45	Tezepelumab	54	47 (87.0)	-0.45 (0.09)	(-0.62, -0.28)	0.00 (0.14)	(-0.27, 0.27)	0.997
	Placebo	39	35 (89.7)	-0.45 (0.10)	(-0.65, -0.25)			
Week 46	Tezepelumab	54	46 (85.2)	-0.47 (0.09)	(-0.64, -0.30)	-0.07 (0.14)	(-0.34, 0.19)	0.584
	Placebo	39	36 (92.3)	-0.40 (0.10)	(-0.60, -0.19)			
Week 47	Tezepelumab	54	45 (83.3)	-0.44 (0.09)	(-0.61, -0.27)	-0.05 (0.14)	(-0.31, 0.22)	0.732
	Placebo	39	36 (92.3)	-0.39 (0.10)	(-0.60, -0.19)			
Week 48	Tezepelumab	54	48 (88.9)	-0.39 (0.09)	(-0.56, -0.22)	0.07 (0.14)	(-0.20, 0.34)	0.602
	Placebo	39	36 (92.3)	-0.46 (0.10)	(-0.66, -0.26)			
Week 49	Tezepelumab	54	46 (85.2)	-0.39 (0.09)	(-0.56, -0.22)	0.04 (0.14)	(-0.23, 0.31)	0.782
	Placebo	39	35 (89.7)	-0.43 (0.10)	(-0.63, -0.22)			
Week 50	Tezepelumab	54	43 (79.6)	-0.45 (0.09)	(-0.62, -0.27)	0.05 (0.14)	(-0.22, 0.32)	0.737
	Placebo	39	34 (87.2)	-0.49 (0.10)	(-0.70, -0.29)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC_ABMC0: Change from baseline in ASD weekly wheezing score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	44 (81.5)	-0.41 (0.09)	(-0.59, -0.24)	0.02 (0.14)	(-0.25, 0.30)	0.859
	Placebo	39	32 (82.1)	-0.44 (0.10)	(-0.64, -0.23)			
Week 52	Tezepelumab	54	38 (70.4)	-0.39 (0.09)	(-0.57, -0.21)	0.08 (0.14)	(-0.20, 0.35)	0.575
	Placebo	39	31 (79.5)	-0.47 (0.11)	(-0.68, -0.26)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMH0: Course of ASD weekly shortness of breath score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	54	54 (100.0)	1.54 (0.63)	0.0	1.14	1.57	2.00	2.8	
		Placebo	39	39 (100.0)	1.76 (0.65)	0.4	1.25	1.90	2.14	3.0	
	Week 1	Tezepelumab	54	53 (98.1)	1.39 (0.63)	0.0	1.00	1.43	1.93	2.5	
		Placebo	39	39 (100.0)	1.62 (0.65)	0.3	1.13	1.58	2.00	3.3	
	Week 2	Tezepelumab	54	53 (98.1)	1.30 (0.69)	0.0	0.93	1.36	2.00	2.3	
		Placebo	39	38 (97.4)	1.57 (0.59)	0.4	1.07	1.61	1.93	3.1	
	Week 3	Tezepelumab	54	54 (100.0)	1.29 (0.62)	0.0	1.00	1.36	1.83	2.4	
		Placebo	39	37 (94.9)	1.53 (0.73)	0.0	1.07	1.50	2.00	3.1	
	Week 4	Tezepelumab	54	53 (98.1)	1.21 (0.67)	0.0	0.71	1.21	1.71	2.7	
		Placebo	39	38 (97.4)	1.53 (0.66)	0.1	1.07	1.39	2.00	3.0	
	Week 5	Tezepelumab	54	52 (96.3)	1.17 (0.73)	0.0	0.71	1.04	1.96	2.4	
		Placebo	39	37 (94.9)	1.37 (0.69)	0.1	0.92	1.21	2.00	3.0	
	Week 6	Tezepelumab	54	51 (94.4)	1.23 (0.74)	0.0	0.57	1.29	2.00	3.0	
		Placebo	39	39 (100.0)	1.49 (0.71)	0.0	1.00	1.43	2.00	3.3	
	Week 7	Tezepelumab	54	50 (92.6)	1.17 (0.72)	0.0	0.79	1.12	1.79	3.1	
		Placebo	39	39 (100.0)	1.43 (0.73)	0.0	1.00	1.36	2.00	3.0	
	Week 8	Tezepelumab	54	50 (92.6)	1.15 (0.73)	0.0	0.57	1.11	2.00	2.7	
		Placebo	39	38 (97.4)	1.45 (0.67)	0.0	1.00	1.46	2.00	2.9	
	Week 9	Tezepelumab	54	52 (96.3)	1.13 (0.72)	0.0	0.57	1.00	1.92	2.6	
		Placebo	39	39 (100.0)	1.46 (0.71)	0.0	1.00	1.38	2.00	2.7	
	Week 10	Tezepelumab	54	52 (96.3)	1.12 (0.77)	0.0	0.39	1.04	1.93	2.9	
		Placebo	39	39 (100.0)	1.43 (0.69)	0.0	1.00	1.36	2.00	2.9	
	Week 11	Tezepelumab	54	50 (92.6)	1.15 (0.74)	0.0	0.63	1.07	1.92	3.0	
		Placebo	39	39 (100.0)	1.34 (0.71)	0.0	1.00	1.25	1.93	2.9	
	Week 12	Tezepelumab	54	51 (94.4)	1.08 (0.78)	0.0	0.40	1.07	1.93	2.9	
		Placebo	39	37 (94.9)	1.38 (0.77)	0.0	1.00	1.29	2.00	3.0	
	Week 13	Tezepelumab	54	48 (88.9)	1.10 (0.77)	0.0	0.50	1.00	1.81	2.9	
		Placebo	39	37 (94.9)	1.36 (0.77)	0.0	1.00	1.29	2.00	3.2	
	Week 14	Tezepelumab	54	51 (94.4)	1.13 (0.80)	0.0	0.50	1.07	1.86	2.9	
		Placebo	39	36 (92.3)	1.36 (0.71)	0.0	1.00	1.24	2.00	3.0	
	Week 15	Tezepelumab	54	50 (92.6)	1.05 (0.72)	0.0	0.29	1.00	1.63	2.2	
		Placebo	39	38 (97.4)	1.34 (0.75)	0.0	1.00	1.17	2.00	3.0	
	Week 16	Tezepelumab	54	50 (92.6)	1.04 (0.75)	0.0	0.25	1.07	1.86	2.3	
		Placebo	39	37 (94.9)	1.36 (0.72)	0.0	1.00	1.40	1.93	2.9	
Week 17	Tezepelumab	54	51 (94.4)	1.04 (0.76)	0.0	0.36	1.00	1.75	2.8		
	Placebo	39	37 (94.9)	1.38 (0.74)	0.0	1.00	1.36	1.90	3.2		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMH0: Course of ASD weekly shortness of breath score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	54	51 (94.4)	1.05 (0.79)	0.0	0.21	1.00	1.86	3.0	
		Placebo	39	37 (94.9)	1.41 (0.74)	0.0	1.00	1.36	2.00	2.9	
	Week 19	Tezepelumab	54	48 (88.9)	1.04 (0.83)	0.0	0.10	1.00	2.00	2.4	
		Placebo	39	38 (97.4)	1.40 (0.72)	0.0	1.00	1.46	2.00	3.0	
	Week 20	Tezepelumab	54	50 (92.6)	1.03 (0.80)	0.0	0.14	1.00	1.86	2.4	
		Placebo	39	36 (92.3)	1.36 (0.74)	0.0	1.00	1.39	2.00	3.0	
	Week 21	Tezepelumab	54	45 (83.3)	1.06 (0.77)	0.0	0.21	1.00	1.93	2.4	
		Placebo	39	37 (94.9)	1.31 (0.73)	0.0	0.93	1.36	2.00	2.6	
	Week 22	Tezepelumab	54	46 (85.2)	1.11 (0.72)	0.0	0.63	1.04	1.92	2.2	
		Placebo	39	37 (94.9)	1.31 (0.69)	0.0	1.00	1.33	1.93	2.5	
	Week 23	Tezepelumab	54	48 (88.9)	1.05 (0.81)	0.0	0.17	1.00	1.88	2.6	
		Placebo	39	35 (89.7)	1.29 (0.71)	0.0	0.93	1.21	2.00	2.6	
	Week 24	Tezepelumab	54	50 (92.6)	1.02 (0.83)	0.0	0.00	1.00	2.00	2.6	
		Placebo	39	35 (89.7)	1.22 (0.71)	0.0	0.90	1.07	1.93	2.5	
	Week 25	Tezepelumab	54	48 (88.9)	1.05 (0.78)	0.0	0.40	1.00	1.85	2.7	
		Placebo	39	35 (89.7)	1.35 (0.75)	0.0	1.00	1.08	2.00	2.7	
	Week 26	Tezepelumab	54	49 (90.7)	1.02 (0.82)	0.0	0.21	1.07	1.86	2.9	
		Placebo	39	36 (92.3)	1.37 (0.82)	0.0	0.86	1.42	2.00	3.0	
	Week 27	Tezepelumab	54	45 (83.3)	1.13 (0.84)	0.0	0.29	1.00	1.86	3.1	
		Placebo	39	35 (89.7)	1.37 (0.81)	0.0	1.00	1.43	2.00	2.9	
	Week 28	Tezepelumab	54	48 (88.9)	1.11 (0.82)	0.0	0.29	1.04	2.00	3.0	
		Placebo	39	35 (89.7)	1.33 (0.83)	0.0	0.93	1.17	2.00	2.9	
	Week 29	Tezepelumab	54	47 (87.0)	1.03 (0.77)	0.0	0.20	1.00	1.70	2.6	
		Placebo	39	36 (92.3)	1.31 (0.83)	0.0	0.86	1.14	2.00	2.9	
	Week 30	Tezepelumab	54	47 (87.0)	1.17 (0.73)	0.0	0.71	1.00	2.00	2.4	
		Placebo	39	35 (89.7)	1.29 (0.78)	0.0	0.64	1.07	2.00	3.0	
	Week 31	Tezepelumab	54	47 (87.0)	1.00 (0.73)	0.0	0.10	1.00	1.43	2.4	
		Placebo	39	36 (92.3)	1.25 (0.75)	0.0	0.83	1.00	2.00	3.0	
	Week 32	Tezepelumab	54	48 (88.9)	1.01 (0.75)	0.0	0.25	1.00	1.89	2.2	
		Placebo	39	36 (92.3)	1.29 (0.75)	0.0	0.78	1.04	2.00	3.0	
	Week 33	Tezepelumab	54	47 (87.0)	1.05 (0.74)	0.0	0.29	1.07	1.75	2.4	
		Placebo	39	36 (92.3)	1.34 (0.81)	0.0	0.79	1.12	2.00	3.0	
	Week 34	Tezepelumab	54	49 (90.7)	1.04 (0.74)	0.0	0.50	1.00	1.67	2.4	
		Placebo	39	37 (94.9)	1.34 (0.81)	0.0	0.93	1.07	2.00	3.1	
	Week 35	Tezepelumab	54	47 (87.0)	1.00 (0.74)	0.0	0.33	1.00	1.50	2.6	
		Placebo	39	35 (89.7)	1.35 (0.78)	0.0	1.00	1.14	2.00	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMH0: Course of ASD weekly shortness of breath score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	54	47 (87.0)	1.04 (0.77)	0.0	0.29	1.00	1.71	2.6	
		Placebo	39	37 (94.9)	1.41 (0.78)	0.0	1.00	1.29	2.00	3.6	
	Week 37	Tezepelumab	54	46 (85.2)	1.05 (0.76)	0.0	0.21	1.00	1.71	2.6	
		Placebo	39	36 (92.3)	1.37 (0.74)	0.0	1.00	1.06	2.00	3.0	
	Week 38	Tezepelumab	54	46 (85.2)	1.09 (0.79)	0.0	0.50	1.07	1.67	2.7	
		Placebo	39	36 (92.3)	1.29 (0.80)	0.0	0.89	1.04	2.00	3.1	
	Week 39	Tezepelumab	54	48 (88.9)	1.04 (0.81)	0.0	0.10	1.00	1.73	2.6	
		Placebo	39	36 (92.3)	1.29 (0.83)	0.0	0.88	1.21	2.00	3.4	
	Week 40	Tezepelumab	54	48 (88.9)	1.08 (0.74)	0.0	0.59	1.00	1.73	2.6	
		Placebo	39	37 (94.9)	1.31 (0.86)	0.0	1.00	1.20	2.00	3.4	
	Week 41	Tezepelumab	54	49 (90.7)	1.05 (0.78)	0.0	0.25	1.00	1.64	2.6	
		Placebo	39	35 (89.7)	1.33 (0.83)	0.0	0.93	1.29	2.00	3.0	
	Week 42	Tezepelumab	54	46 (85.2)	1.06 (0.80)	0.0	0.07	1.00	1.79	3.1	
		Placebo	39	35 (89.7)	1.33 (0.83)	0.0	0.71	1.29	2.00	3.0	
	Week 43	Tezepelumab	54	48 (88.9)	1.04 (0.83)	0.0	0.15	1.00	1.79	3.3	
		Placebo	39	36 (92.3)	1.29 (0.80)	0.0	0.83	1.21	1.96	3.0	
	Week 44	Tezepelumab	54	47 (87.0)	0.99 (0.77)	0.0	0.07	1.00	1.71	2.9	
		Placebo	39	34 (87.2)	1.36 (0.80)	0.0	1.00	1.27	2.00	3.0	
	Week 45	Tezepelumab	54	47 (87.0)	1.02 (0.81)	0.0	0.07	1.00	1.71	3.2	
		Placebo	39	35 (89.7)	1.26 (0.86)	0.0	0.83	1.00	2.00	3.2	
	Week 46	Tezepelumab	54	46 (85.2)	1.02 (0.81)	0.0	0.08	1.00	1.86	3.1	
		Placebo	39	36 (92.3)	1.27 (0.89)	0.0	0.78	1.11	1.93	3.3	
	Week 47	Tezepelumab	54	45 (83.3)	1.02 (0.81)	0.0	0.13	1.00	1.71	3.2	
		Placebo	39	36 (92.3)	1.30 (0.85)	0.0	0.96	1.08	1.96	3.1	
	Week 48	Tezepelumab	54	48 (88.9)	1.08 (0.84)	0.0	0.27	1.00	1.88	3.2	
		Placebo	39	36 (92.3)	1.28 (0.84)	0.0	0.93	1.00	2.00	3.0	
	Week 49	Tezepelumab	54	46 (85.2)	1.15 (0.82)	0.0	0.58	1.04	1.75	2.9	
		Placebo	39	35 (89.7)	1.28 (0.86)	0.0	0.71	1.00	2.00	3.1	
	Week 50	Tezepelumab	54	43 (79.6)	1.12 (0.79)	0.0	0.50	1.07	1.86	2.9	
		Placebo	39	34 (87.2)	1.23 (0.83)	0.0	0.70	1.04	2.00	3.0	
	Week 51	Tezepelumab	54	44 (81.5)	1.17 (0.79)	0.0	0.74	1.00	2.00	3.1	
		Placebo	39	32 (82.1)	1.33 (0.92)	0.0	0.89	1.13	2.00	3.5	
	Week 52	Tezepelumab	54	38 (70.4)	1.13 (0.78)	0.0	0.50	1.07	1.93	2.9	
		Placebo	39	31 (79.5)	1.35 (0.91)	0.0	0.80	1.07	2.00	3.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMH0: Course of ASD weekly shortness of breath score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	54	53 (98.1)	-0.16 (0.50)	-2.1	-0.36	-0.07	0.14	0.6	-0.05 [-0.46, 0.37]
		Placebo	39	39 (100.0)	-0.14 (0.30)	-0.8	-0.36	-0.13	0.03	0.4	
	Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.56)	-2.6	-0.44	-0.11	0.00	0.5	-0.07 [-0.49, 0.35]
		Placebo	39	38 (97.4)	-0.21 (0.51)	-1.9	-0.43	-0.15	0.07	1.3	
	Week 3	Tezepelumab	54	54 (100.0)	-0.25 (0.53)	-2.6	-0.43	-0.14	0.06	0.6	0.01 [-0.41, 0.42]
		Placebo	39	37 (94.9)	-0.25 (0.68)	-2.7	-0.51	-0.13	0.00	1.5	
	Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.53)	-2.6	-0.59	-0.14	0.00	0.4	-0.14 [-0.55, 0.28]
		Placebo	39	38 (97.4)	-0.24 (0.63)	-2.7	-0.57	-0.14	0.07	0.8	
	Week 5	Tezepelumab	54	52 (96.3)	-0.36 (0.58)	-2.6	-0.68	-0.15	0.00	0.6	0.02 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.38 (0.71)	-2.7	-0.71	-0.21	0.00	1.8	
	Week 6	Tezepelumab	54	51 (94.4)	-0.30 (0.56)	-2.6	-0.57	-0.14	0.02	0.5	-0.04 [-0.46, 0.38]
		Placebo	39	39 (100.0)	-0.28 (0.65)	-2.8	-0.57	-0.08	0.08	1.0	
	Week 7	Tezepelumab	54	50 (92.6)	-0.35 (0.58)	-2.6	-0.64	-0.21	0.00	0.8	-0.03 [-0.44, 0.39]
		Placebo	39	39 (100.0)	-0.33 (0.64)	-2.8	-0.79	-0.21	0.07	0.6	
	Week 8	Tezepelumab	54	50 (92.6)	-0.38 (0.58)	-2.6	-0.79	-0.19	0.00	0.4	-0.13 [-0.56, 0.29]
		Placebo	39	38 (97.4)	-0.30 (0.70)	-2.7	-0.50	-0.14	0.07	1.1	
	Week 9	Tezepelumab	54	52 (96.3)	-0.40 (0.62)	-2.6	-0.82	-0.15	0.00	1.0	-0.13 [-0.55, 0.28]
		Placebo	39	39 (100.0)	-0.31 (0.76)	-2.8	-0.73	-0.14	0.07	1.7	
	Week 10	Tezepelumab	54	52 (96.3)	-0.41 (0.65)	-2.6	-0.79	-0.18	0.00	1.0	-0.10 [-0.51, 0.32]
		Placebo	39	39 (100.0)	-0.34 (0.73)	-2.8	-0.71	-0.14	0.07	0.9	
	Week 11	Tezepelumab	54	50 (92.6)	-0.41 (0.60)	-2.6	-0.86	-0.14	0.00	0.5	0.02 [-0.40, 0.44]
		Placebo	39	39 (100.0)	-0.42 (0.75)	-2.8	-0.93	-0.21	0.07	0.7	
	Week 12	Tezepelumab	54	51 (94.4)	-0.45 (0.69)	-2.6	-0.86	-0.14	0.00	0.6	-0.06 [-0.48, 0.36]
		Placebo	39	37 (94.9)	-0.41 (0.81)	-2.8	-0.92	-0.14	0.00	1.6	
	Week 13	Tezepelumab	54	48 (88.9)	-0.40 (0.65)	-2.6	-0.86	-0.15	0.00	0.6	0.01 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.41 (0.79)	-2.8	-0.79	-0.21	0.00	1.9	
	Week 14	Tezepelumab	54	51 (94.4)	-0.44 (0.67)	-2.6	-0.86	-0.21	0.00	0.8	-0.03 [-0.46, 0.40]
		Placebo	39	36 (92.3)	-0.42 (0.76)	-2.8	-0.89	-0.18	0.08	0.8	
	Week 15	Tezepelumab	54	50 (92.6)	-0.46 (0.62)	-2.6	-0.79	-0.21	0.00	0.4	-0.08 [-0.50, 0.34]
		Placebo	39	38 (97.4)	-0.40 (0.78)	-2.8	-0.94	-0.21	0.00	1.8	
	Week 16	Tezepelumab	54	50 (92.6)	-0.48 (0.65)	-2.6	-0.86	-0.24	0.00	0.4	-0.12 [-0.54, 0.31]
		Placebo	39	37 (94.9)	-0.40 (0.73)	-2.6	-1.00	-0.14	0.04	1.0	
	Week 17	Tezepelumab	54	51 (94.4)	-0.52 (0.66)	-2.6	-0.98	-0.29	0.00	0.8	-0.21 [-0.63, 0.22]
		Placebo	39	37 (94.9)	-0.38 (0.72)	-2.7	-0.86	-0.21	0.00	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMH0: Course of ASD weekly shortness of breath score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	54	51 (94.4)	-0.50 (0.70)	-2.6	-1.00	-0.33	-0.07	1.0	-0.24 [-0.66, 0.19]
		Placebo	39	37 (94.9)	-0.33 (0.68)	-2.7	-0.64	-0.21	0.07	0.8	
	Week 19	Tezepelumab	54	48 (88.9)	-0.48 (0.69)	-2.6	-0.86	-0.25	0.01	0.4	-0.18 [-0.61, 0.25]
		Placebo	39	38 (97.4)	-0.35 (0.70)	-2.8	-0.79	-0.16	0.07	0.9	
	Week 20	Tezepelumab	54	50 (92.6)	-0.50 (0.69)	-2.6	-1.00	-0.26	0.00	0.4	-0.15 [-0.58, 0.28]
		Placebo	39	36 (92.3)	-0.40 (0.72)	-2.7	-0.82	-0.21	0.04	0.9	
	Week 21	Tezepelumab	54	45 (83.3)	-0.50 (0.68)	-2.6	-0.86	-0.29	0.00	0.4	-0.06 [-0.50, 0.37]
		Placebo	39	37 (94.9)	-0.46 (0.80)	-2.8	-0.93	-0.29	0.00	1.3	
	Week 22	Tezepelumab	54	46 (85.2)	-0.44 (0.65)	-2.6	-0.86	-0.20	0.00	0.5	0.03 [-0.40, 0.47]
		Placebo	39	37 (94.9)	-0.46 (0.75)	-2.8	-0.81	-0.42	0.00	1.2	
	Week 23	Tezepelumab	54	48 (88.9)	-0.51 (0.73)	-2.6	-1.00	-0.16	0.00	0.4	-0.01 [-0.45, 0.42]
		Placebo	39	35 (89.7)	-0.50 (0.70)	-2.6	-0.93	-0.30	0.00	0.6	
	Week 24	Tezepelumab	54	50 (92.6)	-0.53 (0.70)	-2.6	-1.00	-0.25	0.00	0.4	0.03 [-0.41, 0.46]
		Placebo	39	35 (89.7)	-0.55 (0.74)	-2.8	-1.00	-0.36	0.00	0.7	
	Week 25	Tezepelumab	54	48 (88.9)	-0.52 (0.65)	-2.6	-0.89	-0.29	-0.07	0.4	-0.12 [-0.56, 0.31]
		Placebo	39	35 (89.7)	-0.43 (0.80)	-2.8	-1.07	-0.21	0.07	1.3	
	Week 26	Tezepelumab	54	49 (90.7)	-0.45 (0.72)	-2.6	-0.86	-0.26	0.00	0.9	-0.04 [-0.47, 0.40]
		Placebo	39	36 (92.3)	-0.42 (0.90)	-2.8	-0.93	-0.20	0.07	1.6	
	Week 27	Tezepelumab	54	45 (83.3)	-0.39 (0.75)	-2.6	-0.86	-0.21	0.08	0.9	0.04 [-0.40, 0.48]
		Placebo	39	35 (89.7)	-0.43 (0.94)	-2.8	-1.00	-0.36	0.07	2.4	
	Week 28	Tezepelumab	54	48 (88.9)	-0.40 (0.71)	-2.5	-0.86	-0.16	0.00	0.9	0.04 [-0.39, 0.48]
		Placebo	39	35 (89.7)	-0.44 (0.88)	-2.8	-1.00	-0.14	0.07	1.0	
	Week 29	Tezepelumab	54	47 (87.0)	-0.52 (0.68)	-2.6	-0.93	-0.21	0.00	0.5	-0.08 [-0.51, 0.36]
		Placebo	39	36 (92.3)	-0.46 (0.89)	-2.8	-0.95	-0.21	0.08	1.0	
	Week 30	Tezepelumab	54	47 (87.0)	-0.46 (0.65)	-2.6	-1.00	-0.25	0.00	0.5	0.07 [-0.37, 0.50]
		Placebo	39	35 (89.7)	-0.51 (0.83)	-2.8	-1.00	-0.43	0.07	1.0	
	Week 31	Tezepelumab	54	47 (87.0)	-0.54 (0.74)	-2.6	-1.00	-0.36	-0.07	1.0	-0.03 [-0.46, 0.41]
		Placebo	39	36 (92.3)	-0.52 (0.78)	-2.8	-1.04	-0.43	-0.07	0.9	
	Week 32	Tezepelumab	54	48 (88.9)	-0.54 (0.67)	-2.6	-0.96	-0.32	0.00	0.4	-0.09 [-0.52, 0.35]
		Placebo	39	36 (92.3)	-0.48 (0.79)	-2.8	-0.95	-0.39	-0.07	1.3	
	Week 33	Tezepelumab	54	47 (87.0)	-0.52 (0.73)	-2.6	-1.00	-0.29	0.00	0.7	-0.13 [-0.56, 0.31]
		Placebo	39	36 (92.3)	-0.43 (0.77)	-2.8	-0.84	-0.29	0.00	0.9	
	Week 34	Tezepelumab	54	49 (90.7)	-0.57 (0.71)	-2.6	-1.00	-0.57	-0.07	0.6	-0.17 [-0.59, 0.26]
		Placebo	39	37 (94.9)	-0.44 (0.77)	-2.8	-0.96	-0.36	0.07	0.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMH0: Course of ASD weekly shortness of breath score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	54	47 (87.0)	-0.53 (0.67)	-2.6	-0.89	-0.29	0.00	0.4	-0.11 [-0.55, 0.33]
		Placebo	39	35 (89.7)	-0.45 (0.73)	-2.8	-0.86	-0.29	0.00	0.9	
	Week 36	Tezepelumab	54	47 (87.0)	-0.52 (0.68)	-2.6	-0.86	-0.36	-0.07	0.6	-0.20 [-0.63, 0.23]
		Placebo	39	37 (94.9)	-0.38 (0.73)	-2.8	-0.79	-0.30	0.07	0.9	
	Week 37	Tezepelumab	54	46 (85.2)	-0.51 (0.69)	-2.6	-0.92	-0.24	0.00	0.4	-0.15 [-0.58, 0.29]
		Placebo	39	36 (92.3)	-0.40 (0.72)	-2.8	-0.86	-0.26	0.04	0.8	
	Week 38	Tezepelumab	54	46 (85.2)	-0.46 (0.72)	-2.6	-0.93	-0.25	0.01	0.7	0.03 [-0.41, 0.46]
		Placebo	39	36 (92.3)	-0.48 (0.75)	-2.8	-0.94	-0.39	0.07	0.7	
	Week 39	Tezepelumab	54	48 (88.9)	-0.50 (0.73)	-2.6	-1.00	-0.17	0.00	0.8	-0.02 [-0.45, 0.41]
		Placebo	39	36 (92.3)	-0.49 (0.74)	-2.8	-1.00	-0.42	0.07	0.7	
	Week 40	Tezepelumab	54	48 (88.9)	-0.51 (0.71)	-2.6	-1.00	-0.32	0.00	0.4	-0.04 [-0.47, 0.39]
		Placebo	39	37 (94.9)	-0.47 (0.79)	-2.8	-1.00	-0.43	0.07	1.1	
	Week 41	Tezepelumab	54	49 (90.7)	-0.53 (0.70)	-2.6	-1.00	-0.36	0.00	0.4	-0.12 [-0.55, 0.31]
		Placebo	39	35 (89.7)	-0.44 (0.87)	-2.8	-1.00	-0.43	0.07	1.9	
	Week 42	Tezepelumab	54	46 (85.2)	-0.51 (0.73)	-2.6	-0.93	-0.21	0.00	0.6	-0.09 [-0.53, 0.35]
		Placebo	39	35 (89.7)	-0.45 (0.75)	-2.8	-1.00	-0.29	0.07	0.8	
	Week 43	Tezepelumab	54	48 (88.9)	-0.53 (0.72)	-2.6	-1.00	-0.32	-0.04	0.8	-0.06 [-0.49, 0.37]
		Placebo	39	36 (92.3)	-0.49 (0.72)	-2.8	-0.91	-0.46	0.06	0.6	
	Week 44	Tezepelumab	54	47 (87.0)	-0.60 (0.70)	-2.6	-1.00	-0.37	-0.07	0.5	-0.18 [-0.63, 0.26]
		Placebo	39	34 (87.2)	-0.46 (0.76)	-2.8	-0.80	-0.36	0.05	0.6	
	Week 45	Tezepelumab	54	47 (87.0)	-0.54 (0.72)	-2.6	-1.00	-0.29	0.00	0.7	-0.00 [-0.44, 0.44]
		Placebo	39	35 (89.7)	-0.54 (0.77)	-2.8	-1.00	-0.61	0.07	0.7	
	Week 46	Tezepelumab	54	46 (85.2)	-0.52 (0.76)	-2.6	-1.00	-0.25	0.00	0.6	-0.01 [-0.45, 0.42]
		Placebo	39	36 (92.3)	-0.51 (0.80)	-2.8	-1.00	-0.37	0.07	0.8	
	Week 47	Tezepelumab	54	45 (83.3)	-0.52 (0.74)	-2.6	-1.00	-0.21	0.00	0.7	-0.06 [-0.50, 0.38]
		Placebo	39	36 (92.3)	-0.47 (0.73)	-2.8	-0.91	-0.38	0.07	0.6	
	Week 48	Tezepelumab	54	48 (88.9)	-0.41 (0.76)	-2.6	-0.86	-0.14	0.04	1.0	0.10 [-0.33, 0.53]
		Placebo	39	36 (92.3)	-0.49 (0.74)	-2.8	-0.96	-0.33	0.04	0.6	
	Week 49	Tezepelumab	54	46 (85.2)	-0.42 (0.76)	-2.6	-0.86	-0.25	0.00	1.2	0.10 [-0.34, 0.54]
		Placebo	39	35 (89.7)	-0.49 (0.76)	-2.8	-1.00	-0.50	0.07	0.7	
	Week 50	Tezepelumab	54	43 (79.6)	-0.45 (0.70)	-2.6	-0.86	-0.16	0.00	0.8	0.12 [-0.33, 0.57]
		Placebo	39	34 (87.2)	-0.53 (0.74)	-2.8	-1.00	-0.52	-0.08	0.7	
	Week 51	Tezepelumab	54	44 (81.5)	-0.40 (0.71)	-2.6	-0.86	-0.14	0.00	0.8	0.11 [-0.34, 0.57]
		Placebo	39	32 (82.1)	-0.48 (0.82)	-2.8	-0.96	-0.50	-0.03	1.2	
	Week 52	Tezepelumab	54	38 (70.4)	-0.44 (0.71)	-2.6	-0.86	-0.18	0.00	0.5	0.11 [-0.36, 0.59]
		Placebo	39	31 (79.5)	-0.53 (0.81)	-2.8	-1.00	-0.64	0.00	1.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	54	53 (98.1)	-0.20 (0.09)	(-0.37, -0.02)	-0.10 (0.14)	(-0.37, 0.17)	0.477
	Placebo	39	39 (100.0)	-0.10 (0.10)	(-0.30, 0.11)			
Week 2	Tezepelumab	54	53 (98.1)	-0.28 (0.09)	(-0.45, -0.11)	-0.13 (0.14)	(-0.40, 0.14)	0.342
	Placebo	39	38 (97.4)	-0.15 (0.10)	(-0.36, 0.05)			
Week 3	Tezepelumab	54	54 (100.0)	-0.29 (0.09)	(-0.46, -0.11)	-0.11 (0.14)	(-0.37, 0.16)	0.443
	Placebo	39	37 (94.9)	-0.18 (0.10)	(-0.39, 0.02)			
Week 4	Tezepelumab	54	53 (98.1)	-0.37 (0.09)	(-0.54, -0.19)	-0.18 (0.14)	(-0.44, 0.09)	0.200
	Placebo	39	38 (97.4)	-0.19 (0.10)	(-0.39, 0.01)			
Week 5	Tezepelumab	54	52 (96.3)	-0.40 (0.09)	(-0.57, -0.23)	-0.08 (0.14)	(-0.35, 0.19)	0.543
	Placebo	39	37 (94.9)	-0.32 (0.10)	(-0.52, -0.11)			
Week 6	Tezepelumab	54	51 (94.4)	-0.32 (0.09)	(-0.49, -0.14)	-0.08 (0.14)	(-0.35, 0.19)	0.546
	Placebo	39	39 (100.0)	-0.23 (0.10)	(-0.44, -0.03)			
Week 7	Tezepelumab	54	50 (92.6)	-0.38 (0.09)	(-0.55, -0.20)	-0.09 (0.14)	(-0.36, 0.18)	0.527
	Placebo	39	39 (100.0)	-0.29 (0.10)	(-0.50, -0.09)			
Week 8	Tezepelumab	54	50 (92.6)	-0.40 (0.09)	(-0.57, -0.22)	-0.15 (0.14)	(-0.42, 0.12)	0.267
	Placebo	39	38 (97.4)	-0.25 (0.10)	(-0.45, -0.04)			
Week 9	Tezepelumab	54	52 (96.3)	-0.44 (0.09)	(-0.61, -0.26)	-0.17 (0.14)	(-0.44, 0.10)	0.208
	Placebo	39	39 (100.0)	-0.26 (0.10)	(-0.47, -0.06)			
Week 10	Tezepelumab	54	52 (96.3)	-0.45 (0.09)	(-0.62, -0.27)	-0.15 (0.14)	(-0.42, 0.12)	0.270
	Placebo	39	39 (100.0)	-0.30 (0.10)	(-0.50, -0.09)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
DITTB - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 11	Tezepelumab	54	50 (92.6)	-0.45 (0.09)	(-0.62, -0.27)	-0.07 (0.14)	(-0.34, 0.20)	0.619	
	Placebo	39	39 (100.0)	-0.38 (0.10)	(-0.58, -0.17)				
Week 12	Tezepelumab	54	51 (94.4)	-0.47 (0.09)	(-0.65, -0.30)	-0.14 (0.14)	(-0.41, 0.13)	0.307	
	Placebo	39	37 (94.9)	-0.33 (0.10)	(-0.54, -0.13)				
Week 13	Tezepelumab	54	48 (88.9)	-0.45 (0.09)	(-0.63, -0.28)	-0.11 (0.14)	(-0.38, 0.16)	0.411	
	Placebo	39	37 (94.9)	-0.34 (0.10)	(-0.54, -0.13)				
Week 14	Tezepelumab	54	51 (94.4)	-0.43 (0.09)	(-0.61, -0.26)	-0.10 (0.14)	(-0.37, 0.17)	0.484	
	Placebo	39	36 (92.3)	-0.34 (0.10)	(-0.54, -0.13)				
Week 15	Tezepelumab	54	50 (92.6)	-0.47 (0.09)	(-0.65, -0.30)	-0.11 (0.14)	(-0.38, 0.15)	0.403	
	Placebo	39	38 (97.4)	-0.36 (0.10)	(-0.56, -0.16)				
Week 16	Tezepelumab	54	50 (92.6)	-0.50 (0.09)	(-0.68, -0.33)	-0.15 (0.14)	(-0.42, 0.12)	0.266	
	Placebo	39	37 (94.9)	-0.35 (0.10)	(-0.55, -0.14)				
Week 17	Tezepelumab	54	51 (94.4)	-0.52 (0.09)	(-0.69, -0.35)	-0.19 (0.14)	(-0.46, 0.08)	0.158	
	Placebo	39	37 (94.9)	-0.33 (0.10)	(-0.53, -0.12)				
Week 18	Tezepelumab	54	51 (94.4)	-0.52 (0.09)	(-0.69, -0.34)	-0.23 (0.14)	(-0.50, 0.04)	0.093	
	Placebo	39	37 (94.9)	-0.29 (0.10)	(-0.49, -0.08)				
Week 19	Tezepelumab	54	48 (88.9)	-0.51 (0.09)	(-0.68, -0.33)	-0.20 (0.14)	(-0.47, 0.07)	0.145	
	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.51, -0.10)				
Week 20	Tezepelumab	54	50 (92.6)	-0.52 (0.09)	(-0.70, -0.35)	-0.16 (0.14)	(-0.43, 0.12)	0.261	
	Placebo	39	36 (92.3)	-0.37 (0.10)	(-0.57, -0.16)				

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	54	45 (83.3)	-0.55 (0.09)	(-0.72, -0.37)	-0.14 (0.14)	(-0.41, 0.13)	0.301
	Placebo	39	37 (94.9)	-0.40 (0.10)	(-0.61, -0.20)			
Week 22	Tezepelumab	54	46 (85.2)	-0.51 (0.09)	(-0.68, -0.33)	-0.11 (0.14)	(-0.38, 0.17)	0.441
	Placebo	39	37 (94.9)	-0.40 (0.10)	(-0.61, -0.19)			
Week 23	Tezepelumab	54	48 (88.9)	-0.54 (0.09)	(-0.71, -0.36)	-0.15 (0.14)	(-0.43, 0.12)	0.271
	Placebo	39	35 (89.7)	-0.38 (0.11)	(-0.59, -0.17)			
Week 24	Tezepelumab	54	50 (92.6)	-0.54 (0.09)	(-0.72, -0.37)	-0.10 (0.14)	(-0.37, 0.17)	0.469
	Placebo	39	35 (89.7)	-0.44 (0.11)	(-0.65, -0.23)			
Week 25	Tezepelumab	54	48 (88.9)	-0.55 (0.09)	(-0.73, -0.38)	-0.22 (0.14)	(-0.49, 0.05)	0.111
	Placebo	39	35 (89.7)	-0.33 (0.11)	(-0.54, -0.13)			
Week 26	Tezepelumab	54	49 (90.7)	-0.52 (0.09)	(-0.69, -0.34)	-0.20 (0.14)	(-0.47, 0.08)	0.159
	Placebo	39	36 (92.3)	-0.32 (0.11)	(-0.53, -0.11)			
Week 27	Tezepelumab	54	45 (83.3)	-0.47 (0.09)	(-0.64, -0.29)	-0.12 (0.14)	(-0.39, 0.15)	0.385
	Placebo	39	35 (89.7)	-0.34 (0.11)	(-0.55, -0.14)			
Week 28	Tezepelumab	54	48 (88.9)	-0.48 (0.09)	(-0.66, -0.31)	-0.15 (0.14)	(-0.43, 0.12)	0.272
	Placebo	39	35 (89.7)	-0.33 (0.11)	(-0.54, -0.12)			
Week 29	Tezepelumab	54	47 (87.0)	-0.54 (0.09)	(-0.71, -0.36)	-0.16 (0.14)	(-0.43, 0.11)	0.255
	Placebo	39	36 (92.3)	-0.38 (0.11)	(-0.59, -0.17)			
Week 30	Tezepelumab	54	47 (87.0)	-0.52 (0.09)	(-0.69, -0.34)	-0.10 (0.14)	(-0.37, 0.18)	0.490
	Placebo	39	35 (89.7)	-0.42 (0.11)	(-0.63, -0.21)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	54	47 (87.0)	-0.57 (0.09)	(-0.74, -0.39)	-0.12 (0.14)	(-0.39, 0.15)	0.392
	Placebo	39	36 (92.3)	-0.45 (0.11)	(-0.65, -0.24)			
Week 32	Tezepelumab	54	48 (88.9)	-0.59 (0.09)	(-0.76, -0.41)	-0.18 (0.14)	(-0.46, 0.09)	0.188
	Placebo	39	36 (92.3)	-0.41 (0.11)	(-0.61, -0.20)			
Week 33	Tezepelumab	54	47 (87.0)	-0.57 (0.09)	(-0.74, -0.39)	-0.19 (0.14)	(-0.47, 0.08)	0.166
	Placebo	39	36 (92.3)	-0.37 (0.11)	(-0.58, -0.17)			
Week 34	Tezepelumab	54	49 (90.7)	-0.59 (0.09)	(-0.77, -0.42)	-0.21 (0.14)	(-0.48, 0.06)	0.129
	Placebo	39	37 (94.9)	-0.38 (0.11)	(-0.59, -0.17)			
Week 35	Tezepelumab	54	47 (87.0)	-0.58 (0.09)	(-0.76, -0.40)	-0.20 (0.14)	(-0.47, 0.08)	0.161
	Placebo	39	35 (89.7)	-0.38 (0.11)	(-0.59, -0.18)			
Week 36	Tezepelumab	54	47 (87.0)	-0.55 (0.09)	(-0.73, -0.37)	-0.23 (0.14)	(-0.51, 0.04)	0.095
	Placebo	39	37 (94.9)	-0.32 (0.11)	(-0.52, -0.11)			
Week 37	Tezepelumab	54	46 (85.2)	-0.58 (0.09)	(-0.76, -0.40)	-0.24 (0.14)	(-0.52, 0.03)	0.083
	Placebo	39	36 (92.3)	-0.34 (0.11)	(-0.55, -0.13)			
Week 38	Tezepelumab	54	46 (85.2)	-0.54 (0.09)	(-0.72, -0.36)	-0.12 (0.14)	(-0.40, 0.15)	0.378
	Placebo	39	36 (92.3)	-0.42 (0.11)	(-0.63, -0.21)			
Week 39	Tezepelumab	54	48 (88.9)	-0.58 (0.09)	(-0.76, -0.41)	-0.16 (0.14)	(-0.44, 0.11)	0.246
	Placebo	39	36 (92.3)	-0.42 (0.11)	(-0.63, -0.21)			
Week 40	Tezepelumab	54	48 (88.9)	-0.55 (0.09)	(-0.73, -0.37)	-0.13 (0.14)	(-0.41, 0.14)	0.339
	Placebo	39	37 (94.9)	-0.42 (0.11)	(-0.63, -0.21)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
DITTB - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	54	49 (90.7)	-0.56 (0.09)	(-0.74, -0.38)	-0.17 (0.14)	(-0.45, 0.10)	0.214
	Placebo	39	35 (89.7)	-0.38 (0.11)	(-0.59, -0.17)			
Week 42	Tezepelumab	54	46 (85.2)	-0.54 (0.09)	(-0.72, -0.36)	-0.15 (0.14)	(-0.43, 0.12)	0.276
	Placebo	39	35 (89.7)	-0.39 (0.11)	(-0.60, -0.18)			
Week 43	Tezepelumab	54	48 (88.9)	-0.58 (0.09)	(-0.75, -0.40)	-0.15 (0.14)	(-0.43, 0.13)	0.284
	Placebo	39	36 (92.3)	-0.42 (0.11)	(-0.63, -0.21)			
Week 44	Tezepelumab	54	47 (87.0)	-0.62 (0.09)	(-0.80, -0.44)	-0.22 (0.14)	(-0.50, 0.06)	0.119
	Placebo	39	34 (87.2)	-0.40 (0.11)	(-0.61, -0.19)			
Week 45	Tezepelumab	54	47 (87.0)	-0.60 (0.09)	(-0.77, -0.42)	-0.13 (0.14)	(-0.41, 0.15)	0.355
	Placebo	39	35 (89.7)	-0.46 (0.11)	(-0.68, -0.25)			
Week 46	Tezepelumab	54	46 (85.2)	-0.59 (0.09)	(-0.77, -0.41)	-0.15 (0.14)	(-0.42, 0.13)	0.299
	Placebo	39	36 (92.3)	-0.45 (0.11)	(-0.66, -0.23)			
Week 47	Tezepelumab	54	45 (83.3)	-0.56 (0.09)	(-0.74, -0.39)	-0.15 (0.14)	(-0.43, 0.13)	0.288
	Placebo	39	36 (92.3)	-0.41 (0.11)	(-0.62, -0.20)			
Week 48	Tezepelumab	54	48 (88.9)	-0.48 (0.09)	(-0.66, -0.30)	-0.05 (0.14)	(-0.32, 0.23)	0.747
	Placebo	39	36 (92.3)	-0.43 (0.11)	(-0.64, -0.22)			
Week 49	Tezepelumab	54	46 (85.2)	-0.48 (0.09)	(-0.66, -0.30)	-0.04 (0.14)	(-0.31, 0.24)	0.794
	Placebo	39	35 (89.7)	-0.44 (0.11)	(-0.66, -0.23)			
Week 50	Tezepelumab	54	43 (79.6)	-0.53 (0.09)	(-0.71, -0.35)	-0.05 (0.14)	(-0.33, 0.23)	0.718
	Placebo	39	34 (87.2)	-0.48 (0.11)	(-0.69, -0.27)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC_ABMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	44 (81.5)	-0.49 (0.09)	(-0.67, -0.31)	-0.08 (0.14)	(-0.36, 0.20)	0.566
	Placebo	39	32 (82.1)	-0.41 (0.11)	(-0.62, -0.20)			
Week 52	Tezepelumab	54	38 (70.4)	-0.52 (0.09)	(-0.70, -0.33)	-0.08 (0.15)	(-0.37, 0.20)	0.564
	Placebo	39	31 (79.5)	-0.43 (0.11)	(-0.65, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMH0: Course of ASD weekly cough score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	54	54 (100.0)	1.38 (0.73)	0.0	1.00	1.38	2.00	2.6	
		Placebo	39	39 (100.0)	1.40 (0.75)	0.0	1.14	1.33	2.00	2.6	
	Week 1	Tezepelumab	54	53 (98.1)	1.25 (0.71)	0.0	0.93	1.29	1.71	2.6	
		Placebo	39	39 (100.0)	1.30 (0.75)	0.0	1.07	1.21	1.88	3.1	
	Week 2	Tezepelumab	54	53 (98.1)	1.13 (0.75)	0.0	0.57	1.14	1.71	2.8	
		Placebo	39	38 (97.4)	1.29 (0.75)	0.0	0.86	1.18	1.92	3.0	
	Week 3	Tezepelumab	54	54 (100.0)	1.12 (0.73)	0.0	0.43	1.07	1.71	2.6	
		Placebo	39	37 (94.9)	1.23 (0.81)	0.0	0.86	1.14	1.93	2.5	
	Week 4	Tezepelumab	54	53 (98.1)	1.06 (0.72)	0.0	0.38	1.00	1.64	2.3	
		Placebo	39	38 (97.4)	1.19 (0.78)	0.0	0.57	1.14	1.92	2.4	
	Week 5	Tezepelumab	54	52 (96.3)	1.03 (0.74)	0.0	0.40	1.00	1.64	2.5	
		Placebo	39	37 (94.9)	1.06 (0.69)	0.0	0.57	1.14	1.64	2.2	
	Week 6	Tezepelumab	54	51 (94.4)	1.10 (0.78)	0.0	0.43	1.00	1.71	2.9	
		Placebo	39	39 (100.0)	1.18 (0.77)	0.0	0.64	1.10	1.93	2.7	
	Week 7	Tezepelumab	54	50 (92.6)	1.11 (0.79)	0.0	0.43	1.00	1.86	2.4	
		Placebo	39	39 (100.0)	1.04 (0.78)	0.0	0.14	1.00	1.86	2.4	
	Week 8	Tezepelumab	54	50 (92.6)	1.06 (0.80)	0.0	0.36	1.00	1.71	2.7	
		Placebo	39	38 (97.4)	1.06 (0.85)	0.0	0.21	1.04	1.64	3.1	
	Week 9	Tezepelumab	54	52 (96.3)	1.02 (0.80)	0.0	0.18	1.00	1.68	2.6	
		Placebo	39	39 (100.0)	1.05 (0.92)	0.0	0.00	1.00	1.43	3.4	
	Week 10	Tezepelumab	54	52 (96.3)	1.00 (0.82)	0.0	0.09	0.96	1.76	2.5	
		Placebo	39	39 (100.0)	1.05 (0.78)	0.0	0.25	1.00	1.90	2.4	
	Week 11	Tezepelumab	54	50 (92.6)	1.01 (0.80)	0.0	0.10	1.00	1.70	2.6	
		Placebo	39	39 (100.0)	1.01 (0.79)	0.0	0.29	1.00	1.50	3.0	
	Week 12	Tezepelumab	54	51 (94.4)	0.95 (0.79)	0.0	0.17	1.00	1.64	2.9	
		Placebo	39	37 (94.9)	1.00 (0.77)	0.0	0.29	1.00	1.50	2.8	
	Week 13	Tezepelumab	54	48 (88.9)	0.98 (0.83)	0.0	0.11	1.00	1.50	3.0	
		Placebo	39	37 (94.9)	0.95 (0.76)	0.0	0.29	1.00	1.57	2.3	
	Week 14	Tezepelumab	54	51 (94.4)	1.00 (0.85)	0.0	0.17	1.00	1.71	3.0	
		Placebo	39	36 (92.3)	1.01 (0.76)	0.0	0.29	1.00	1.69	2.6	
	Week 15	Tezepelumab	54	50 (92.6)	0.94 (0.80)	0.0	0.07	1.00	1.42	3.0	
		Placebo	39	38 (97.4)	0.93 (0.81)	0.0	0.14	1.00	1.67	2.8	
	Week 16	Tezepelumab	54	50 (92.6)	0.93 (0.81)	0.0	0.10	1.00	1.43	3.0	
		Placebo	39	37 (94.9)	0.94 (0.73)	0.0	0.25	1.00	1.25	2.1	
Week 17	Tezepelumab	54	51 (94.4)	0.96 (0.81)	0.0	0.00	0.93	1.75	2.6		
	Placebo	39	37 (94.9)	0.99 (0.80)	0.0	0.14	1.00	1.64	2.4		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMH0: Course of ASD weekly cough score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	54	51 (94.4)	0.99 (0.81)	0.0	0.14	1.00	1.64	3.0	
		Placebo	39	37 (94.9)	1.01 (0.77)	0.0	0.50	1.00	1.64	3.0	
	Week 19	Tezepelumab	54	48 (88.9)	0.93 (0.79)	0.0	0.08	1.00	1.36	2.5	
		Placebo	39	38 (97.4)	1.01 (0.80)	0.0	0.10	1.00	1.75	3.0	
	Week 20	Tezepelumab	54	50 (92.6)	0.91 (0.76)	0.0	0.08	1.00	1.29	2.7	
		Placebo	39	36 (92.3)	1.02 (0.81)	0.0	0.21	1.00	1.73	2.9	
	Week 21	Tezepelumab	54	45 (83.3)	0.89 (0.72)	0.0	0.17	1.00	1.21	2.4	
		Placebo	39	37 (94.9)	0.97 (0.71)	0.0	0.43	1.00	1.29	2.4	
	Week 22	Tezepelumab	54	46 (85.2)	0.98 (0.73)	0.0	0.29	1.00	1.36	2.4	
		Placebo	39	37 (94.9)	1.04 (0.72)	0.0	0.57	1.00	1.58	2.5	
	Week 23	Tezepelumab	54	48 (88.9)	0.96 (0.80)	0.0	0.00	1.00	1.57	2.6	
		Placebo	39	35 (89.7)	1.02 (0.72)	0.0	0.29	1.00	1.60	2.4	
	Week 24	Tezepelumab	54	50 (92.6)	0.90 (0.79)	0.0	0.00	0.96	1.21	2.9	
		Placebo	39	35 (89.7)	0.95 (0.72)	0.0	0.14	1.00	1.57	2.5	
	Week 25	Tezepelumab	54	48 (88.9)	0.90 (0.75)	0.0	0.11	1.00	1.31	2.6	
		Placebo	39	35 (89.7)	0.93 (0.75)	0.0	0.17	1.00	1.36	2.4	
	Week 26	Tezepelumab	54	49 (90.7)	0.92 (0.79)	0.0	0.07	1.00	1.43	2.7	
		Placebo	39	36 (92.3)	0.94 (0.79)	0.0	0.09	1.00	1.66	2.3	
	Week 27	Tezepelumab	54	45 (83.3)	1.01 (0.83)	0.0	0.07	1.00	1.29	3.1	
		Placebo	39	35 (89.7)	1.07 (0.80)	0.0	0.50	1.00	1.86	3.1	
	Week 28	Tezepelumab	54	48 (88.9)	1.05 (0.81)	0.0	0.26	1.00	1.64	3.0	
		Placebo	39	35 (89.7)	1.08 (0.74)	0.0	0.50	1.00	1.83	2.7	
	Week 29	Tezepelumab	54	47 (87.0)	0.95 (0.74)	0.0	0.10	1.00	1.40	2.6	
		Placebo	39	36 (92.3)	0.98 (0.78)	0.0	0.35	1.00	1.50	2.9	
	Week 30	Tezepelumab	54	47 (87.0)	1.03 (0.78)	0.0	0.42	1.00	1.71	2.5	
		Placebo	39	35 (89.7)	0.89 (0.72)	0.0	0.29	1.00	1.14	3.0	
	Week 31	Tezepelumab	54	47 (87.0)	0.94 (0.74)	0.0	0.10	1.00	1.42	2.6	
		Placebo	39	36 (92.3)	0.94 (0.77)	0.0	0.27	1.00	1.45	3.0	
	Week 32	Tezepelumab	54	48 (88.9)	0.95 (0.75)	0.0	0.19	1.00	1.58	2.6	
		Placebo	39	36 (92.3)	0.88 (0.80)	0.0	0.04	1.00	1.39	3.0	
	Week 33	Tezepelumab	54	47 (87.0)	0.94 (0.78)	0.0	0.00	1.00	1.57	3.0	
		Placebo	39	36 (92.3)	0.99 (0.83)	0.0	0.11	1.00	1.44	3.0	
	Week 34	Tezepelumab	54	49 (90.7)	0.97 (0.80)	0.0	0.07	1.00	1.42	3.0	
		Placebo	39	37 (94.9)	0.97 (0.81)	0.0	0.07	1.00	1.30	3.0	
	Week 35	Tezepelumab	54	47 (87.0)	0.98 (0.82)	0.0	0.14	1.00	1.50	3.0	
		Placebo	39	35 (89.7)	0.96 (0.83)	0.0	0.07	1.00	1.58	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMH0: Course of ASD weekly cough score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	54	47 (87.0)	0.98 (0.83)	0.0	0.21	1.00	1.57	3.0	
		Placebo	39	37 (94.9)	1.01 (0.72)	0.0	0.42	1.00	1.50	3.1	
	Week 37	Tezepelumab	54	46 (85.2)	0.97 (0.78)	0.0	0.20	1.00	1.50	3.0	
		Placebo	39	36 (92.3)	1.03 (0.76)	0.0	0.21	1.00	1.58	2.9	
	Week 38	Tezepelumab	54	46 (85.2)	1.01 (0.84)	0.0	0.21	1.00	1.50	3.0	
		Placebo	39	36 (92.3)	0.96 (0.70)	0.0	0.29	1.00	1.31	3.0	
	Week 39	Tezepelumab	54	48 (88.9)	1.03 (0.79)	0.0	0.33	1.00	1.39	3.0	
		Placebo	39	36 (92.3)	0.96 (0.77)	0.0	0.30	1.00	1.25	3.0	
	Week 40	Tezepelumab	54	48 (88.9)	1.00 (0.78)	0.0	0.17	1.00	1.61	2.6	
		Placebo	39	37 (94.9)	1.07 (0.76)	0.0	0.50	1.00	1.50	2.9	
	Week 41	Tezepelumab	54	49 (90.7)	0.98 (0.81)	0.0	0.10	1.00	1.50	2.9	
		Placebo	39	35 (89.7)	1.06 (0.77)	0.0	0.25	1.00	1.64	3.0	
	Week 42	Tezepelumab	54	46 (85.2)	1.00 (0.91)	0.0	0.00	1.00	1.71	3.0	
		Placebo	39	35 (89.7)	1.17 (0.72)	0.0	0.86	1.00	1.64	3.0	
	Week 43	Tezepelumab	54	48 (88.9)	0.96 (0.91)	0.0	0.04	1.00	1.45	3.2	
		Placebo	39	36 (92.3)	0.98 (0.76)	0.0	0.18	1.00	1.45	3.0	
	Week 44	Tezepelumab	54	47 (87.0)	0.90 (0.84)	0.0	0.00	0.92	1.43	3.0	
		Placebo	39	34 (87.2)	1.03 (0.75)	0.0	0.29	1.00	1.50	3.0	
	Week 45	Tezepelumab	54	47 (87.0)	0.97 (0.86)	0.0	0.08	1.00	1.43	3.3	
		Placebo	39	35 (89.7)	0.90 (0.77)	0.0	0.07	1.00	1.30	3.0	
	Week 46	Tezepelumab	54	46 (85.2)	0.95 (0.80)	0.0	0.17	1.00	1.36	2.9	
		Placebo	39	36 (92.3)	0.89 (0.83)	0.0	0.08	1.00	1.17	3.0	
	Week 47	Tezepelumab	54	45 (83.3)	0.99 (0.77)	0.0	0.29	1.00	1.50	3.0	
		Placebo	39	36 (92.3)	0.89 (0.78)	0.0	0.15	1.00	1.31	3.0	
	Week 48	Tezepelumab	54	48 (88.9)	1.02 (0.85)	0.0	0.17	1.00	1.64	3.0	
		Placebo	39	36 (92.3)	0.87 (0.78)	0.0	0.04	1.00	1.27	3.0	
	Week 49	Tezepelumab	54	46 (85.2)	1.08 (0.81)	0.0	0.40	1.00	1.64	3.0	
		Placebo	39	35 (89.7)	0.86 (0.79)	0.0	0.07	1.00	1.17	3.0	
	Week 50	Tezepelumab	54	43 (79.6)	0.96 (0.77)	0.0	0.14	1.00	1.57	2.8	
		Placebo	39	34 (87.2)	0.87 (0.81)	0.0	0.00	1.00	1.42	3.0	
	Week 51	Tezepelumab	54	44 (81.5)	1.01 (0.75)	0.0	0.32	1.00	1.77	2.2	
		Placebo	39	32 (82.1)	0.86 (0.77)	0.0	0.00	1.00	1.24	3.0	
	Week 52	Tezepelumab	54	38 (70.4)	0.96 (0.78)	0.0	0.17	1.00	1.64	2.5	
		Placebo	39	31 (79.5)	0.92 (0.75)	0.0	0.14	1.00	1.25	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMH0: Course of ASD weekly cough score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	54	53 (98.1)	-0.14 (0.52)	-2.3	-0.21	0.00	0.07	0.7	-0.08 [-0.49, 0.33]
		Placebo	39	39 (100.0)	-0.10 (0.40)	-1.1	-0.21	0.00	0.00	1.5	
	Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.53)	-2.6	-0.36	-0.07	0.05	0.4	-0.25 [-0.67, 0.16]
		Placebo	39	38 (97.4)	-0.11 (0.63)	-1.9	-0.17	-0.04	0.08	1.4	
	Week 3	Tezepelumab	54	54 (100.0)	-0.26 (0.56)	-2.6	-0.57	-0.07	0.00	0.6	-0.15 [-0.57, 0.27]
		Placebo	39	37 (94.9)	-0.16 (0.82)	-2.6	-0.37	0.00	0.14	1.9	
	Week 4	Tezepelumab	54	53 (98.1)	-0.31 (0.61)	-2.6	-0.71	-0.14	0.07	0.7	-0.16 [-0.58, 0.25]
		Placebo	39	38 (97.4)	-0.20 (0.67)	-2.6	-0.36	0.00	0.14	0.7	
	Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.62)	-2.6	-0.67	-0.16	0.00	0.7	-0.06 [-0.48, 0.36]
		Placebo	39	37 (94.9)	-0.30 (0.68)	-2.6	-0.44	-0.14	0.00	0.7	
	Week 6	Tezepelumab	54	51 (94.4)	-0.27 (0.58)	-2.6	-0.57	-0.07	0.07	0.9	-0.08 [-0.49, 0.34]
		Placebo	39	39 (100.0)	-0.22 (0.67)	-2.6	-0.44	0.00	0.14	0.7	
	Week 7	Tezepelumab	54	50 (92.6)	-0.24 (0.66)	-2.6	-0.43	-0.11	0.14	1.0	0.18 [-0.24, 0.60]
		Placebo	39	39 (100.0)	-0.35 (0.67)	-2.6	-0.50	-0.14	0.00	0.7	
	Week 8	Tezepelumab	54	50 (92.6)	-0.28 (0.67)	-2.6	-0.64	-0.14	0.11	1.1	0.03 [-0.40, 0.45]
		Placebo	39	38 (97.4)	-0.30 (0.79)	-2.6	-0.71	-0.12	0.21	1.7	
	Week 9	Tezepelumab	54	52 (96.3)	-0.34 (0.68)	-2.6	-0.79	-0.14	0.00	1.0	0.01 [-0.41, 0.42]
		Placebo	39	39 (100.0)	-0.35 (0.90)	-2.6	-1.00	-0.21	0.00	2.0	
	Week 10	Tezepelumab	54	52 (96.3)	-0.36 (0.69)	-2.6	-0.79	-0.21	0.00	1.1	-0.02 [-0.44, 0.39]
		Placebo	39	39 (100.0)	-0.35 (0.80)	-2.6	-0.96	-0.17	0.21	1.4	
	Week 11	Tezepelumab	54	50 (92.6)	-0.37 (0.64)	-2.6	-0.71	-0.14	0.00	0.9	0.03 [-0.39, 0.45]
		Placebo	39	39 (100.0)	-0.39 (0.71)	-2.5	-0.90	-0.14	0.00	1.1	
	Week 12	Tezepelumab	54	51 (94.4)	-0.40 (0.70)	-2.6	-0.79	-0.36	0.00	0.9	-0.02 [-0.44, 0.41]
		Placebo	39	37 (94.9)	-0.39 (0.73)	-2.6	-0.93	-0.14	0.08	0.8	
	Week 13	Tezepelumab	54	48 (88.9)	-0.35 (0.72)	-2.6	-0.79	-0.16	0.14	1.0	0.12 [-0.31, 0.55]
		Placebo	39	37 (94.9)	-0.43 (0.66)	-2.4	-0.83	-0.17	0.00	0.8	
	Week 14	Tezepelumab	54	51 (94.4)	-0.38 (0.71)	-2.6	-0.79	-0.14	0.07	1.0	-0.02 [-0.45, 0.41]
		Placebo	39	36 (92.3)	-0.37 (0.74)	-2.4	-0.80	-0.21	0.00	1.1	
	Week 15	Tezepelumab	54	50 (92.6)	-0.40 (0.71)	-2.6	-0.71	-0.14	0.00	1.0	0.05 [-0.37, 0.47]
		Placebo	39	38 (97.4)	-0.43 (0.79)	-2.1	-1.00	-0.26	0.08	0.8	
	Week 16	Tezepelumab	54	50 (92.6)	-0.42 (0.70)	-2.6	-0.93	-0.14	0.07	1.0	0.02 [-0.41, 0.44]
		Placebo	39	37 (94.9)	-0.43 (0.73)	-2.1	-1.00	-0.29	0.00	0.9	
	Week 17	Tezepelumab	54	51 (94.4)	-0.41 (0.78)	-2.6	-0.90	-0.25	0.07	0.9	-0.05 [-0.47, 0.37]
		Placebo	39	37 (94.9)	-0.37 (0.77)	-2.5	-1.00	-0.14	0.07	0.9	
Week 18	Tezepelumab	54	51 (94.4)	-0.38 (0.75)	-2.6	-0.79	-0.29	0.07	1.0	-0.05 [-0.48, 0.37]	
	Placebo	39	37 (94.9)	-0.34 (0.75)	-2.1	-1.00	-0.14	0.00	0.9		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMH0: Course of ASD weekly cough score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	54	48 (88.9)	-0.41 (0.74)	-2.6	-0.89	-0.21	0.08	0.8	-0.04 [-0.47, 0.38]
		Placebo	39	38 (97.4)	-0.37 (0.85)	-2.6	-0.92	-0.14	0.07	1.4	
	Week 20	Tezepelumab	54	50 (92.6)	-0.44 (0.77)	-2.6	-0.95	-0.27	0.00	0.9	-0.09 [-0.52, 0.34]
		Placebo	39	36 (92.3)	-0.38 (0.74)	-1.8	-0.93	-0.18	0.14	0.7	
	Week 21	Tezepelumab	54	45 (83.3)	-0.47 (0.76)	-2.6	-0.93	-0.36	0.00	0.9	-0.08 [-0.51, 0.36]
		Placebo	39	37 (94.9)	-0.41 (0.73)	-2.1	-1.00	-0.14	0.00	1.0	
	Week 22	Tezepelumab	54	46 (85.2)	-0.41 (0.78)	-2.6	-0.86	-0.19	0.00	1.1	-0.08 [-0.52, 0.35]
		Placebo	39	37 (94.9)	-0.34 (0.77)	-2.3	-1.00	-0.14	0.07	1.1	
	Week 23	Tezepelumab	54	48 (88.9)	-0.42 (0.76)	-2.6	-0.92	-0.25	0.00	1.0	-0.03 [-0.47, 0.40]
		Placebo	39	35 (89.7)	-0.40 (0.74)	-1.9	-1.00	-0.17	0.00	1.0	
	Week 24	Tezepelumab	54	50 (92.6)	-0.46 (0.77)	-2.6	-1.00	-0.46	0.00	1.4	-0.03 [-0.46, 0.40]
		Placebo	39	35 (89.7)	-0.44 (0.70)	-2.1	-1.00	-0.14	0.00	0.6	
	Week 25	Tezepelumab	54	48 (88.9)	-0.48 (0.66)	-2.6	-0.95	-0.37	0.00	0.6	0.02 [-0.42, 0.46]
		Placebo	39	35 (89.7)	-0.50 (0.74)	-2.6	-0.93	-0.29	0.00	0.8	
	Week 26	Tezepelumab	54	49 (90.7)	-0.40 (0.74)	-2.6	-0.86	-0.14	0.09	0.9	0.11 [-0.33, 0.54]
		Placebo	39	36 (92.3)	-0.48 (0.79)	-2.6	-1.11	-0.21	0.02	0.9	
	Week 27	Tezepelumab	54	45 (83.3)	-0.35 (0.77)	-2.6	-0.67	-0.07	0.00	1.1	0.03 [-0.41, 0.48]
		Placebo	39	35 (89.7)	-0.38 (0.84)	-2.6	-1.00	-0.29	0.10	1.9	
	Week 28	Tezepelumab	54	48 (88.9)	-0.30 (0.76)	-2.5	-0.71	-0.14	0.07	1.4	0.02 [-0.42, 0.45]
		Placebo	39	35 (89.7)	-0.31 (0.71)	-2.6	-0.71	-0.21	0.00	1.1	
	Week 29	Tezepelumab	54	47 (87.0)	-0.46 (0.71)	-2.6	-0.86	-0.14	0.00	0.7	-0.10 [-0.53, 0.34]
		Placebo	39	36 (92.3)	-0.39 (0.72)	-2.6	-0.88	-0.29	0.04	0.7	
	Week 30	Tezepelumab	54	47 (87.0)	-0.38 (0.72)	-2.6	-0.86	-0.21	0.07	1.1	0.21 [-0.23, 0.65]
		Placebo	39	35 (89.7)	-0.53 (0.64)	-2.6	-1.00	-0.49	0.00	0.5	
	Week 31	Tezepelumab	54	47 (87.0)	-0.43 (0.73)	-2.6	-0.79	-0.21	0.06	0.8	0.01 [-0.43, 0.44]
		Placebo	39	36 (92.3)	-0.44 (0.79)	-2.6	-0.77	-0.26	-0.12	2.2	
	Week 32	Tezepelumab	54	48 (88.9)	-0.43 (0.74)	-2.6	-0.90	-0.32	0.00	1.5	0.09 [-0.34, 0.52]
		Placebo	39	36 (92.3)	-0.50 (0.87)	-2.6	-1.00	-0.26	-0.11	2.4	
	Week 33	Tezepelumab	54	47 (87.0)	-0.45 (0.77)	-2.6	-1.00	-0.36	0.00	1.2	-0.08 [-0.51, 0.36]
		Placebo	39	36 (92.3)	-0.39 (0.89)	-2.6	-0.82	-0.21	0.04	2.5	
	Week 34	Tezepelumab	54	49 (90.7)	-0.44 (0.78)	-2.6	-1.00	-0.29	0.00	1.2	-0.02 [-0.44, 0.41]
		Placebo	39	37 (94.9)	-0.43 (0.86)	-2.6	-1.00	-0.30	0.00	2.2	
	Week 35	Tezepelumab	54	47 (87.0)	-0.43 (0.73)	-2.6	-0.87	-0.21	0.00	1.2	0.03 [-0.41, 0.47]
		Placebo	39	35 (89.7)	-0.45 (0.86)	-2.6	-1.00	-0.29	0.00	2.1	
	Week 36	Tezepelumab	54	47 (87.0)	-0.44 (0.76)	-2.6	-1.00	-0.31	0.00	1.2	-0.08 [-0.51, 0.35]
		Placebo	39	37 (94.9)	-0.38 (0.74)	-2.2	-0.86	-0.21	0.07	1.4	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMH0: Course of ASD weekly cough score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	54	46 (85.2)	-0.41 (0.73)	-2.6	-0.83	-0.27	0.00	1.2	-0.09 [-0.53, 0.34]
		Placebo	39	36 (92.3)	-0.35 (0.68)	-1.9	-0.83	-0.21	0.01	1.3	
	Week 38	Tezepelumab	54	46 (85.2)	-0.36 (0.81)	-2.6	-0.71	-0.21	0.07	1.2	0.08 [-0.36, 0.52]
		Placebo	39	36 (92.3)	-0.42 (0.59)	-1.6	-0.91	-0.28	-0.04	1.0	
	Week 39	Tezepelumab	54	48 (88.9)	-0.34 (0.76)	-2.6	-0.75	-0.18	0.07	1.6	0.11 [-0.32, 0.54]
		Placebo	39	36 (92.3)	-0.42 (0.60)	-1.8	-0.85	-0.34	0.00	0.8	
	Week 40	Tezepelumab	54	48 (88.9)	-0.41 (0.80)	-2.6	-0.99	-0.23	0.08	1.9	-0.11 [-0.54, 0.32]
		Placebo	39	37 (94.9)	-0.33 (0.74)	-2.1	-0.80	-0.27	0.00	1.9	
	Week 41	Tezepelumab	54	49 (90.7)	-0.42 (0.80)	-2.6	-1.00	-0.24	0.00	1.7	-0.14 [-0.58, 0.29]
		Placebo	39	35 (89.7)	-0.31 (0.80)	-2.0	-1.00	-0.17	0.14	1.6	
	Week 42	Tezepelumab	54	46 (85.2)	-0.41 (0.73)	-2.6	-0.79	-0.23	0.00	1.2	-0.23 [-0.67, 0.21]
		Placebo	39	35 (89.7)	-0.25 (0.67)	-1.4	-0.74	-0.17	0.04	1.0	
	Week 43	Tezepelumab	54	48 (88.9)	-0.43 (0.75)	-2.6	-0.86	-0.33	0.04	1.2	-0.05 [-0.48, 0.39]
		Placebo	39	36 (92.3)	-0.40 (0.66)	-1.6	-0.96	-0.24	0.00	0.9	
	Week 44	Tezepelumab	54	47 (87.0)	-0.51 (0.71)	-2.6	-1.00	-0.36	0.00	1.2	-0.22 [-0.66, 0.22]
		Placebo	39	34 (87.2)	-0.36 (0.66)	-2.1	-1.00	-0.32	0.00	0.9	
	Week 45	Tezepelumab	54	47 (87.0)	-0.45 (0.77)	-2.6	-1.00	-0.36	0.00	1.5	0.04 [-0.40, 0.48]
		Placebo	39	35 (89.7)	-0.48 (0.65)	-2.2	-1.00	-0.43	0.00	0.9	
	Week 46	Tezepelumab	54	46 (85.2)	-0.40 (0.73)	-2.6	-0.79	-0.29	0.07	1.1	0.12 [-0.32, 0.55]
		Placebo	39	36 (92.3)	-0.48 (0.71)	-2.6	-0.90	-0.47	0.00	1.1	
	Week 47	Tezepelumab	54	45 (83.3)	-0.39 (0.78)	-2.6	-0.79	-0.29	0.07	1.8	0.13 [-0.31, 0.56]
		Placebo	39	36 (92.3)	-0.48 (0.70)	-2.6	-0.96	-0.45	0.00	0.9	
	Week 48	Tezepelumab	54	48 (88.9)	-0.31 (0.83)	-2.6	-0.80	-0.14	0.10	1.6	0.25 [-0.18, 0.69]
		Placebo	39	36 (92.3)	-0.51 (0.73)	-2.6	-1.00	-0.35	0.00	0.9	
	Week 49	Tezepelumab	54	46 (85.2)	-0.33 (0.82)	-2.6	-0.79	-0.11	0.10	1.3	0.24 [-0.20, 0.68]
		Placebo	39	35 (89.7)	-0.52 (0.72)	-2.6	-1.00	-0.29	-0.01	0.6	
	Week 50	Tezepelumab	54	43 (79.6)	-0.43 (0.72)	-2.6	-0.79	-0.29	0.00	1.4	0.14 [-0.31, 0.59]
		Placebo	39	34 (87.2)	-0.53 (0.71)	-2.6	-1.00	-0.29	0.00	0.5	
	Week 51	Tezepelumab	54	44 (81.5)	-0.33 (0.79)	-2.6	-0.75	-0.14	0.13	1.8	0.31 [-0.15, 0.77]
		Placebo	39	32 (82.1)	-0.57 (0.69)	-2.6	-1.00	-0.48	-0.11	0.9	
	Week 52	Tezepelumab	54	38 (70.4)	-0.37 (0.78)	-2.6	-0.79	-0.15	0.07	1.5	0.24 [-0.24, 0.71]
		Placebo	39	31 (79.5)	-0.55 (0.67)	-2.6	-1.00	-0.50	-0.14	1.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 1	Tezepelumab	54	53 (98.1)	-0.13 (0.09)	(-0.31, 0.04)	-0.04 (0.14)	(-0.31, 0.22)	0.757																																																																																																																										
	Placebo	39	39 (100.0)	-0.09 (0.10)	(-0.30, 0.11)				Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.09)	(-0.42, -0.08)	-0.15 (0.14)	(-0.42, 0.11)	0.256	Placebo	39	38 (97.4)	-0.09 (0.10)	(-0.30, 0.11)	Week 3	Tezepelumab	54	54 (100.0)	-0.26 (0.09)	(-0.43, -0.09)	-0.12 (0.14)	(-0.39, 0.14)	0.361	Placebo	39	37 (94.9)	-0.14 (0.10)	(-0.34, 0.07)	Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.09)	(-0.49, -0.14)	-0.13 (0.14)	(-0.40, 0.14)	0.345	Placebo	39	38 (97.4)	-0.19 (0.10)	(-0.39, 0.01)	Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.16)	-0.05 (0.14)	(-0.32, 0.22)	0.718	Placebo	39	37 (94.9)	-0.29 (0.10)	(-0.49, -0.08)	Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.14)	(-0.34, 0.19)	0.575	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.42, -0.01)	Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)	Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo
Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.09)	(-0.42, -0.08)	-0.15 (0.14)	(-0.42, 0.11)	0.256																																																																																																																										
	Placebo	39	38 (97.4)	-0.09 (0.10)	(-0.30, 0.11)				Week 3	Tezepelumab	54	54 (100.0)	-0.26 (0.09)	(-0.43, -0.09)	-0.12 (0.14)	(-0.39, 0.14)	0.361	Placebo	39	37 (94.9)	-0.14 (0.10)	(-0.34, 0.07)	Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.09)	(-0.49, -0.14)	-0.13 (0.14)	(-0.40, 0.14)	0.345	Placebo	39	38 (97.4)	-0.19 (0.10)	(-0.39, 0.01)	Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.16)	-0.05 (0.14)	(-0.32, 0.22)	0.718	Placebo	39	37 (94.9)	-0.29 (0.10)	(-0.49, -0.08)	Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.14)	(-0.34, 0.19)	0.575	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.42, -0.01)	Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)	Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)										
Week 3	Tezepelumab	54	54 (100.0)	-0.26 (0.09)	(-0.43, -0.09)	-0.12 (0.14)	(-0.39, 0.14)	0.361																																																																																																																										
	Placebo	39	37 (94.9)	-0.14 (0.10)	(-0.34, 0.07)				Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.09)	(-0.49, -0.14)	-0.13 (0.14)	(-0.40, 0.14)	0.345	Placebo	39	38 (97.4)	-0.19 (0.10)	(-0.39, 0.01)	Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.16)	-0.05 (0.14)	(-0.32, 0.22)	0.718	Placebo	39	37 (94.9)	-0.29 (0.10)	(-0.49, -0.08)	Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.14)	(-0.34, 0.19)	0.575	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.42, -0.01)	Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)	Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																								
Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.09)	(-0.49, -0.14)	-0.13 (0.14)	(-0.40, 0.14)	0.345																																																																																																																										
	Placebo	39	38 (97.4)	-0.19 (0.10)	(-0.39, 0.01)				Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.16)	-0.05 (0.14)	(-0.32, 0.22)	0.718	Placebo	39	37 (94.9)	-0.29 (0.10)	(-0.49, -0.08)	Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.14)	(-0.34, 0.19)	0.575	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.42, -0.01)	Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)	Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																						
Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.16)	-0.05 (0.14)	(-0.32, 0.22)	0.718																																																																																																																										
	Placebo	39	37 (94.9)	-0.29 (0.10)	(-0.49, -0.08)				Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.14)	(-0.34, 0.19)	0.575	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.42, -0.01)	Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)	Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																																				
Week 6	Tezepelumab	54	51 (94.4)	-0.29 (0.09)	(-0.46, -0.12)	-0.08 (0.14)	(-0.34, 0.19)	0.575																																																																																																																										
	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.42, -0.01)				Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)	Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																																																		
Week 7	Tezepelumab	54	50 (92.6)	-0.23 (0.09)	(-0.40, -0.06)	0.12 (0.14)	(-0.15, 0.38)	0.391																																																																																																																										
	Placebo	39	39 (100.0)	-0.35 (0.10)	(-0.55, -0.14)				Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)	Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																																																																
Week 8	Tezepelumab	54	50 (92.6)	-0.26 (0.09)	(-0.43, -0.09)	0.04 (0.14)	(-0.23, 0.31)	0.775																																																																																																																										
	Placebo	39	38 (97.4)	-0.30 (0.10)	(-0.50, -0.10)				Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)	Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																																																																														
Week 9	Tezepelumab	54	52 (96.3)	-0.35 (0.09)	(-0.52, -0.18)	-0.01 (0.14)	(-0.28, 0.26)	0.943																																																																																																																										
	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)				Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																																																																																												
Week 10	Tezepelumab	54	52 (96.3)	-0.37 (0.09)	(-0.55, -0.20)	-0.03 (0.14)	(-0.30, 0.23)	0.809																																																																																																																										
	Placebo	39	39 (100.0)	-0.34 (0.10)	(-0.54, -0.14)																																																																																																																													

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	54	50 (92.6)	-0.37 (0.09)	(-0.55, -0.20)	0.01 (0.14)	(-0.26, 0.28)	0.948
	Placebo	39	39 (100.0)	-0.38 (0.10)	(-0.59, -0.18)			
Week 12	Tezepelumab	54	51 (94.4)	-0.39 (0.09)	(-0.57, -0.22)	0.00 (0.14)	(-0.27, 0.27)	0.991
	Placebo	39	37 (94.9)	-0.39 (0.10)	(-0.60, -0.19)			
Week 13	Tezepelumab	54	48 (88.9)	-0.38 (0.09)	(-0.55, -0.20)	0.04 (0.14)	(-0.22, 0.31)	0.745
	Placebo	39	37 (94.9)	-0.42 (0.10)	(-0.63, -0.22)			
Week 14	Tezepelumab	54	51 (94.4)	-0.34 (0.09)	(-0.52, -0.17)	-0.00 (0.14)	(-0.27, 0.27)	0.995
	Placebo	39	36 (92.3)	-0.34 (0.10)	(-0.55, -0.14)			
Week 15	Tezepelumab	54	50 (92.6)	-0.40 (0.09)	(-0.57, -0.22)	0.04 (0.14)	(-0.23, 0.30)	0.794
	Placebo	39	38 (97.4)	-0.43 (0.10)	(-0.63, -0.23)			
Week 16	Tezepelumab	54	50 (92.6)	-0.41 (0.09)	(-0.59, -0.24)	0.02 (0.14)	(-0.25, 0.29)	0.868
	Placebo	39	37 (94.9)	-0.44 (0.10)	(-0.64, -0.23)			
Week 17	Tezepelumab	54	51 (94.4)	-0.38 (0.09)	(-0.56, -0.21)	-0.01 (0.14)	(-0.27, 0.26)	0.969
	Placebo	39	37 (94.9)	-0.38 (0.10)	(-0.58, -0.17)			
Week 18	Tezepelumab	54	51 (94.4)	-0.37 (0.09)	(-0.54, -0.19)	-0.04 (0.14)	(-0.31, 0.23)	0.757
	Placebo	39	37 (94.9)	-0.32 (0.10)	(-0.53, -0.12)			
Week 19	Tezepelumab	54	48 (88.9)	-0.42 (0.09)	(-0.60, -0.24)	-0.06 (0.14)	(-0.33, 0.21)	0.642
	Placebo	39	38 (97.4)	-0.36 (0.10)	(-0.56, -0.15)			
Week 20	Tezepelumab	54	50 (92.6)	-0.45 (0.09)	(-0.62, -0.27)	-0.07 (0.14)	(-0.34, 0.20)	0.589
	Placebo	39	36 (92.3)	-0.37 (0.10)	(-0.58, -0.17)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	54	45 (83.3)	-0.50 (0.09)	(-0.68, -0.32)	-0.09 (0.14)	(-0.36, 0.18)	0.527
	Placebo	39	37 (94.9)	-0.41 (0.10)	(-0.62, -0.21)			
Week 22	Tezepelumab	54	46 (85.2)	-0.44 (0.09)	(-0.62, -0.26)	-0.09 (0.14)	(-0.37, 0.18)	0.499
	Placebo	39	37 (94.9)	-0.35 (0.10)	(-0.55, -0.14)			
Week 23	Tezepelumab	54	48 (88.9)	-0.42 (0.09)	(-0.60, -0.24)	-0.07 (0.14)	(-0.35, 0.20)	0.594
	Placebo	39	35 (89.7)	-0.35 (0.11)	(-0.55, -0.14)			
Week 24	Tezepelumab	54	50 (92.6)	-0.44 (0.09)	(-0.62, -0.27)	-0.05 (0.14)	(-0.32, 0.23)	0.744
	Placebo	39	35 (89.7)	-0.40 (0.11)	(-0.61, -0.19)			
Week 25	Tezepelumab	54	48 (88.9)	-0.49 (0.09)	(-0.66, -0.31)	-0.04 (0.14)	(-0.31, 0.24)	0.800
	Placebo	39	35 (89.7)	-0.45 (0.11)	(-0.66, -0.24)			
Week 26	Tezepelumab	54	49 (90.7)	-0.46 (0.09)	(-0.63, -0.28)	-0.01 (0.14)	(-0.28, 0.26)	0.940
	Placebo	39	36 (92.3)	-0.45 (0.11)	(-0.66, -0.24)			
Week 27	Tezepelumab	54	45 (83.3)	-0.40 (0.09)	(-0.58, -0.23)	-0.06 (0.14)	(-0.33, 0.22)	0.686
	Placebo	39	35 (89.7)	-0.35 (0.11)	(-0.55, -0.14)			
Week 28	Tezepelumab	54	48 (88.9)	-0.36 (0.09)	(-0.53, -0.18)	-0.09 (0.14)	(-0.37, 0.18)	0.498
	Placebo	39	35 (89.7)	-0.26 (0.11)	(-0.47, -0.05)			
Week 29	Tezepelumab	54	47 (87.0)	-0.45 (0.09)	(-0.63, -0.28)	-0.08 (0.14)	(-0.36, 0.19)	0.549
	Placebo	39	36 (92.3)	-0.37 (0.11)	(-0.58, -0.16)			
Week 30	Tezepelumab	54	47 (87.0)	-0.39 (0.09)	(-0.57, -0.22)	0.10 (0.14)	(-0.17, 0.37)	0.473
	Placebo	39	35 (89.7)	-0.49 (0.11)	(-0.70, -0.29)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	54	47 (87.0)	-0.41 (0.09)	(-0.58, -0.23)	0.01 (0.14)	(-0.27, 0.28)	0.959
	Placebo	39	36 (92.3)	-0.42 (0.11)	(-0.62, -0.21)			
Week 32	Tezepelumab	54	48 (88.9)	-0.44 (0.09)	(-0.62, -0.27)	0.03 (0.14)	(-0.24, 0.30)	0.819
	Placebo	39	36 (92.3)	-0.47 (0.11)	(-0.68, -0.27)			
Week 33	Tezepelumab	54	47 (87.0)	-0.44 (0.09)	(-0.62, -0.26)	-0.05 (0.14)	(-0.32, 0.22)	0.730
	Placebo	39	36 (92.3)	-0.39 (0.11)	(-0.60, -0.18)			
Week 34	Tezepelumab	54	49 (90.7)	-0.44 (0.09)	(-0.61, -0.26)	-0.02 (0.14)	(-0.30, 0.25)	0.870
	Placebo	39	37 (94.9)	-0.41 (0.11)	(-0.62, -0.21)			
Week 35	Tezepelumab	54	47 (87.0)	-0.39 (0.09)	(-0.57, -0.22)	0.02 (0.14)	(-0.25, 0.29)	0.881
	Placebo	39	35 (89.7)	-0.41 (0.11)	(-0.62, -0.21)			
Week 36	Tezepelumab	54	47 (87.0)	-0.39 (0.09)	(-0.57, -0.21)	-0.02 (0.14)	(-0.29, 0.25)	0.882
	Placebo	39	37 (94.9)	-0.37 (0.11)	(-0.58, -0.16)			
Week 37	Tezepelumab	54	46 (85.2)	-0.42 (0.09)	(-0.60, -0.24)	-0.09 (0.14)	(-0.37, 0.18)	0.506
	Placebo	39	36 (92.3)	-0.33 (0.11)	(-0.54, -0.12)			
Week 38	Tezepelumab	54	46 (85.2)	-0.39 (0.09)	(-0.57, -0.21)	0.01 (0.14)	(-0.27, 0.28)	0.958
	Placebo	39	36 (92.3)	-0.40 (0.11)	(-0.61, -0.19)			
Week 39	Tezepelumab	54	48 (88.9)	-0.37 (0.09)	(-0.55, -0.19)	0.03 (0.14)	(-0.25, 0.30)	0.835
	Placebo	39	36 (92.3)	-0.40 (0.11)	(-0.61, -0.19)			
Week 40	Tezepelumab	54	48 (88.9)	-0.41 (0.09)	(-0.59, -0.23)	-0.09 (0.14)	(-0.36, 0.19)	0.530
	Placebo	39	37 (94.9)	-0.32 (0.11)	(-0.53, -0.11)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	54	49 (90.7)	-0.40 (0.09)	(-0.58, -0.23)	-0.10 (0.14)	(-0.38, 0.17)	0.459
	Placebo	39	35 (89.7)	-0.30 (0.11)	(-0.51, -0.09)			
Week 42	Tezepelumab	54	46 (85.2)	-0.42 (0.09)	(-0.59, -0.24)	-0.19 (0.14)	(-0.47, 0.08)	0.171
	Placebo	39	35 (89.7)	-0.22 (0.11)	(-0.43, -0.01)			
Week 43	Tezepelumab	54	48 (88.9)	-0.43 (0.09)	(-0.61, -0.25)	-0.05 (0.14)	(-0.32, 0.23)	0.742
	Placebo	39	36 (92.3)	-0.39 (0.11)	(-0.60, -0.18)			
Week 44	Tezepelumab	54	47 (87.0)	-0.51 (0.09)	(-0.68, -0.33)	-0.14 (0.14)	(-0.42, 0.14)	0.317
	Placebo	39	34 (87.2)	-0.36 (0.11)	(-0.58, -0.15)			
Week 45	Tezepelumab	54	47 (87.0)	-0.46 (0.09)	(-0.64, -0.28)	0.00 (0.14)	(-0.27, 0.28)	0.973
	Placebo	39	35 (89.7)	-0.47 (0.11)	(-0.68, -0.25)			
Week 46	Tezepelumab	54	46 (85.2)	-0.46 (0.09)	(-0.64, -0.28)	0.02 (0.14)	(-0.26, 0.30)	0.885
	Placebo	39	36 (92.3)	-0.48 (0.11)	(-0.69, -0.27)			
Week 47	Tezepelumab	54	45 (83.3)	-0.41 (0.09)	(-0.59, -0.23)	0.07 (0.14)	(-0.21, 0.34)	0.641
	Placebo	39	36 (92.3)	-0.48 (0.11)	(-0.69, -0.27)			
Week 48	Tezepelumab	54	48 (88.9)	-0.34 (0.09)	(-0.52, -0.17)	0.16 (0.14)	(-0.11, 0.44)	0.252
	Placebo	39	36 (92.3)	-0.51 (0.11)	(-0.72, -0.29)			
Week 49	Tezepelumab	54	46 (85.2)	-0.35 (0.09)	(-0.53, -0.17)	0.15 (0.14)	(-0.13, 0.43)	0.285
	Placebo	39	35 (89.7)	-0.51 (0.11)	(-0.72, -0.29)			
Week 50	Tezepelumab	54	43 (79.6)	-0.41 (0.09)	(-0.59, -0.23)	0.11 (0.14)	(-0.17, 0.39)	0.427
	Placebo	39	34 (87.2)	-0.52 (0.11)	(-0.73, -0.31)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC_ABMC0: Change from baseline in ASD weekly cough score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	44 (81.5)	-0.37 (0.09)	(-0.56, -0.19)	0.16 (0.14)	(-0.12, 0.44)	0.258
	Placebo	39	32 (82.1)	-0.54 (0.11)	(-0.75, -0.32)			
Week 52	Tezepelumab	54	38 (70.4)	-0.40 (0.10)	(-0.58, -0.21)	0.11 (0.15)	(-0.18, 0.40)	0.448
	Placebo	39	31 (79.5)	-0.51 (0.11)	(-0.72, -0.29)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMH0: Course of ASD weekly chest tightness score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	54	54 (100.0)	1.36 (0.70)	0.0	1.00	1.36	2.00	2.6	
		Placebo	39	39 (100.0)	1.60 (0.77)	0.0	1.08	1.79	2.00	3.0	
	Week 1	Tezepelumab	54	53 (98.1)	1.21 (0.69)	0.0	0.57	1.08	1.86	2.5	
		Placebo	39	39 (100.0)	1.49 (0.73)	0.0	1.00	1.58	2.00	2.8	
	Week 2	Tezepelumab	54	53 (98.1)	1.14 (0.72)	0.0	0.58	1.14	1.79	2.3	
		Placebo	39	38 (97.4)	1.41 (0.71)	0.0	1.00	1.50	1.93	2.7	
	Week 3	Tezepelumab	54	54 (100.0)	1.14 (0.69)	0.0	0.64	1.18	1.64	3.0	
		Placebo	39	37 (94.9)	1.32 (0.73)	0.0	0.79	1.43	1.79	2.6	
	Week 4	Tezepelumab	54	53 (98.1)	1.09 (0.75)	0.0	0.36	1.08	1.64	2.9	
		Placebo	39	38 (97.4)	1.38 (0.70)	0.0	1.07	1.36	2.00	2.8	
	Week 5	Tezepelumab	54	52 (96.3)	1.05 (0.76)	0.0	0.28	1.09	1.64	2.9	
		Placebo	39	37 (94.9)	1.22 (0.70)	0.0	0.71	1.21	1.93	2.3	
	Week 6	Tezepelumab	54	51 (94.4)	1.02 (0.80)	0.0	0.21	1.08	1.64	2.8	
		Placebo	39	39 (100.0)	1.39 (0.74)	0.0	0.93	1.43	1.92	3.3	
	Week 7	Tezepelumab	54	50 (92.6)	1.03 (0.78)	0.0	0.36	1.00	1.60	3.1	
		Placebo	39	39 (100.0)	1.34 (0.76)	0.0	1.00	1.36	2.00	3.1	
	Week 8	Tezepelumab	54	50 (92.6)	0.99 (0.76)	0.0	0.25	1.00	1.50	2.8	
		Placebo	39	38 (97.4)	1.28 (0.65)	0.0	1.00	1.33	1.75	2.6	
	Week 9	Tezepelumab	54	52 (96.3)	0.95 (0.75)	0.0	0.26	1.00	1.50	2.9	
		Placebo	39	39 (100.0)	1.27 (0.73)	0.0	1.00	1.29	1.93	3.0	
	Week 10	Tezepelumab	54	52 (96.3)	0.93 (0.78)	0.0	0.21	0.96	1.46	3.0	
		Placebo	39	39 (100.0)	1.24 (0.74)	0.0	1.00	1.25	1.86	2.9	
	Week 11	Tezepelumab	54	50 (92.6)	0.98 (0.81)	0.0	0.17	1.00	1.70	2.9	
		Placebo	39	39 (100.0)	1.18 (0.74)	0.0	0.92	1.14	1.83	3.0	
	Week 12	Tezepelumab	54	51 (94.4)	0.93 (0.79)	0.0	0.14	1.00	1.71	2.9	
		Placebo	39	37 (94.9)	1.16 (0.75)	0.0	0.92	1.10	1.93	2.8	
	Week 13	Tezepelumab	54	48 (88.9)	0.90 (0.80)	0.0	0.21	0.79	1.39	2.9	
		Placebo	39	37 (94.9)	1.09 (0.79)	0.0	0.50	1.08	1.60	3.2	
	Week 14	Tezepelumab	54	51 (94.4)	0.95 (0.79)	0.0	0.29	1.00	1.63	3.0	
		Placebo	39	36 (92.3)	1.06 (0.77)	0.0	0.32	1.00	1.88	2.2	
	Week 15	Tezepelumab	54	50 (92.6)	0.89 (0.73)	0.0	0.14	0.96	1.50	2.2	
		Placebo	39	38 (97.4)	1.07 (0.80)	0.0	0.36	1.00	1.80	3.1	
Week 16	Tezepelumab	54	50 (92.6)	0.86 (0.75)	0.0	0.14	0.93	1.29	2.5		
	Placebo	39	37 (94.9)	1.03 (0.75)	0.0	0.21	1.00	1.79	2.3		
Week 17	Tezepelumab	54	51 (94.4)	0.88 (0.77)	0.0	0.10	1.00	1.36	2.8		
	Placebo	39	37 (94.9)	1.11 (0.72)	0.0	0.71	1.00	1.71	2.1		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMH0: Course of ASD weekly chest tightness score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	54	51 (94.4)	0.87 (0.78)	0.0	0.07	0.93	1.64	2.3	
		Placebo	39	37 (94.9)	1.10 (0.74)	0.0	0.50	1.00	1.71	2.3	
	Week 19	Tezepelumab	54	48 (88.9)	0.85 (0.81)	0.0	0.04	0.96	1.46	2.6	
		Placebo	39	38 (97.4)	1.11 (0.74)	0.0	0.70	1.07	1.79	2.0	
	Week 20	Tezepelumab	54	50 (92.6)	0.85 (0.75)	0.0	0.00	0.85	1.43	2.2	
		Placebo	39	36 (92.3)	1.08 (0.70)	0.0	0.73	1.11	1.65	2.3	
	Week 21	Tezepelumab	54	45 (83.3)	0.91 (0.79)	0.0	0.07	1.00	1.83	2.1	
		Placebo	39	37 (94.9)	1.08 (0.78)	0.0	0.36	1.00	1.79	2.5	
	Week 22	Tezepelumab	54	46 (85.2)	0.94 (0.78)	0.0	0.07	1.00	1.71	2.2	
		Placebo	39	37 (94.9)	1.10 (0.75)	0.0	0.57	1.14	1.71	2.5	
	Week 23	Tezepelumab	54	48 (88.9)	0.89 (0.76)	0.0	0.05	0.96	1.71	2.1	
		Placebo	39	35 (89.7)	1.04 (0.73)	0.0	0.21	1.00	1.67	2.5	
	Week 24	Tezepelumab	54	50 (92.6)	0.86 (0.81)	0.0	0.00	0.96	1.40	2.7	
		Placebo	39	35 (89.7)	0.92 (0.69)	0.0	0.14	1.00	1.36	2.0	
	Week 25	Tezepelumab	54	48 (88.9)	0.89 (0.76)	0.0	0.04	1.00	1.36	2.5	
		Placebo	39	35 (89.7)	0.99 (0.77)	0.0	0.14	1.00	1.64	2.5	
	Week 26	Tezepelumab	54	49 (90.7)	0.78 (0.76)	0.0	0.00	0.63	1.25	2.6	
		Placebo	39	36 (92.3)	0.98 (0.81)	0.0	0.11	1.00	1.77	2.4	
	Week 27	Tezepelumab	54	45 (83.3)	0.95 (0.79)	0.0	0.10	1.00	1.50	3.1	
		Placebo	39	35 (89.7)	1.06 (0.88)	0.0	0.00	1.00	1.93	2.7	
	Week 28	Tezepelumab	54	48 (88.9)	0.90 (0.81)	0.0	0.04	1.00	1.61	2.8	
		Placebo	39	35 (89.7)	1.04 (0.82)	0.0	0.00	1.07	2.00	2.1	
	Week 29	Tezepelumab	54	47 (87.0)	0.88 (0.77)	0.0	0.07	1.00	1.29	2.6	
		Placebo	39	36 (92.3)	1.08 (0.83)	0.0	0.12	1.04	1.95	2.9	
	Week 30	Tezepelumab	54	47 (87.0)	0.94 (0.77)	0.0	0.21	1.00	1.50	2.4	
		Placebo	39	35 (89.7)	0.96 (0.79)	0.0	0.21	1.00	1.40	3.0	
	Week 31	Tezepelumab	54	47 (87.0)	0.82 (0.72)	0.0	0.00	1.00	1.25	2.0	
		Placebo	39	36 (92.3)	0.92 (0.77)	0.0	0.04	1.00	1.24	3.0	
	Week 32	Tezepelumab	54	48 (88.9)	0.86 (0.76)	0.0	0.04	1.00	1.45	2.3	
		Placebo	39	36 (92.3)	1.00 (0.83)	0.0	0.14	1.00	1.62	3.0	
	Week 33	Tezepelumab	54	47 (87.0)	0.88 (0.75)	0.0	0.07	1.00	1.57	2.1	
		Placebo	39	36 (92.3)	1.04 (0.80)	0.0	0.15	1.04	1.63	3.0	
	Week 34	Tezepelumab	54	49 (90.7)	0.88 (0.73)	0.0	0.00	1.00	1.43	2.0	
		Placebo	39	37 (94.9)	1.07 (0.81)	0.0	0.14	1.00	1.75	3.0	
	Week 35	Tezepelumab	54	47 (87.0)	0.92 (0.77)	0.0	0.08	1.00	1.50	2.5	
		Placebo	39	35 (89.7)	1.03 (0.79)	0.0	0.29	1.00	1.64	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMH0: Course of ASD weekly chest tightness score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	54	47 (87.0)	0.93 (0.79)	0.0	0.00	1.00	1.64	2.7	
		Placebo	39	37 (94.9)	1.10 (0.76)	0.0	0.75	1.00	1.60	3.0	
	Week 37	Tezepelumab	54	46 (85.2)	0.91 (0.77)	0.0	0.07	1.00	1.50	2.6	
		Placebo	39	36 (92.3)	1.08 (0.78)	0.0	0.54	1.00	1.42	3.0	
	Week 38	Tezepelumab	54	46 (85.2)	0.97 (0.79)	0.0	0.08	1.00	1.58	2.5	
		Placebo	39	36 (92.3)	1.04 (0.79)	0.0	0.42	1.00	1.36	3.0	
	Week 39	Tezepelumab	54	48 (88.9)	0.93 (0.81)	0.0	0.08	1.00	1.58	2.9	
		Placebo	39	36 (92.3)	1.07 (0.83)	0.0	0.36	1.00	1.57	3.0	
	Week 40	Tezepelumab	54	48 (88.9)	0.93 (0.77)	0.0	0.08	1.00	1.68	2.1	
		Placebo	39	37 (94.9)	1.11 (0.89)	0.0	0.43	1.00	1.93	3.0	
	Week 41	Tezepelumab	54	49 (90.7)	0.91 (0.77)	0.0	0.10	1.00	1.50	2.6	
		Placebo	39	35 (89.7)	1.09 (0.90)	0.0	0.21	1.00	1.93	3.0	
	Week 42	Tezepelumab	54	46 (85.2)	0.91 (0.78)	0.0	0.00	1.00	1.50	2.5	
		Placebo	39	35 (89.7)	1.11 (0.87)	0.0	0.25	1.00	2.00	3.0	
	Week 43	Tezepelumab	54	48 (88.9)	0.90 (0.82)	0.0	0.00	1.00	1.61	2.8	
		Placebo	39	36 (92.3)	1.09 (0.81)	0.0	0.36	1.04	1.85	3.0	
	Week 44	Tezepelumab	54	47 (87.0)	0.85 (0.75)	0.0	0.00	1.00	1.29	2.2	
		Placebo	39	34 (87.2)	1.10 (0.85)	0.0	0.29	1.08	1.83	3.0	
	Week 45	Tezepelumab	54	47 (87.0)	0.91 (0.79)	0.0	0.00	1.00	1.60	2.2	
		Placebo	39	35 (89.7)	0.99 (0.85)	0.0	0.21	1.00	1.43	3.0	
	Week 46	Tezepelumab	54	46 (85.2)	0.91 (0.74)	0.0	0.00	1.00	1.43	2.1	
		Placebo	39	36 (92.3)	1.01 (0.84)	0.0	0.12	1.00	1.54	3.0	
	Week 47	Tezepelumab	54	45 (83.3)	0.88 (0.75)	0.0	0.07	1.00	1.50	2.0	
		Placebo	39	36 (92.3)	0.98 (0.84)	0.0	0.13	1.00	1.69	3.0	
	Week 48	Tezepelumab	54	48 (88.9)	0.94 (0.81)	0.0	0.04	1.00	1.71	2.6	
		Placebo	39	36 (92.3)	0.96 (0.84)	0.0	0.04	1.00	1.54	3.0	
	Week 49	Tezepelumab	54	46 (85.2)	1.00 (0.81)	0.0	0.08	1.00	1.75	2.7	
		Placebo	39	35 (89.7)	1.01 (0.85)	0.0	0.08	1.00	1.93	3.0	
	Week 50	Tezepelumab	54	43 (79.6)	0.99 (0.80)	0.0	0.07	1.00	1.86	2.5	
		Placebo	39	34 (87.2)	1.01 (0.80)	0.0	0.21	1.00	1.50	3.0	
	Week 51	Tezepelumab	54	44 (81.5)	1.03 (0.78)	0.0	0.09	1.00	1.83	2.1	
		Placebo	39	32 (82.1)	0.99 (0.79)	0.0	0.33	1.00	1.55	3.0	
	Week 52	Tezepelumab	54	38 (70.4)	0.98 (0.77)	0.0	0.07	1.00	1.83	2.0	
		Placebo	39	31 (79.5)	1.04 (0.81)	0.0	0.29	1.00	1.90	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMH0: Course of ASD weekly chest tightness score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	54	53 (98.1)	-0.15 (0.50)	-2.2	-0.22	0.00	0.07	0.5	-0.10 [-0.52, 0.31]
		Placebo	39	39 (100.0)	-0.11 (0.32)	-1.0	-0.29	-0.07	0.07	0.6	
	Week 2	Tezepelumab	54	53 (98.1)	-0.23 (0.52)	-2.6	-0.29	-0.13	0.00	0.5	-0.05 [-0.46, 0.37]
		Placebo	39	38 (97.4)	-0.20 (0.66)	-2.1	-0.48	0.00	0.08	1.6	
	Week 3	Tezepelumab	54	54 (100.0)	-0.23 (0.58)	-2.6	-0.43	-0.10	0.07	0.7	0.09 [-0.33, 0.51]
		Placebo	39	37 (94.9)	-0.28 (0.72)	-2.6	-0.57	-0.07	0.07	1.4	
	Week 4	Tezepelumab	54	53 (98.1)	-0.26 (0.56)	-2.6	-0.43	-0.07	0.07	0.5	-0.06 [-0.47, 0.36]
		Placebo	39	38 (97.4)	-0.22 (0.65)	-2.5	-0.54	0.00	0.21	1.0	
	Week 5	Tezepelumab	54	52 (96.3)	-0.30 (0.62)	-2.6	-0.51	-0.13	0.00	0.9	0.08 [-0.35, 0.50]
		Placebo	39	37 (94.9)	-0.36 (0.82)	-2.9	-0.79	-0.20	0.07	2.1	
	Week 6	Tezepelumab	54	51 (94.4)	-0.32 (0.61)	-2.6	-0.58	-0.14	0.00	0.7	-0.17 [-0.58, 0.25]
		Placebo	39	39 (100.0)	-0.21 (0.72)	-2.6	-0.64	-0.07	0.21	1.4	
	Week 7	Tezepelumab	54	50 (92.6)	-0.30 (0.56)	-2.6	-0.50	-0.16	0.00	0.6	-0.06 [-0.48, 0.36]
		Placebo	39	39 (100.0)	-0.26 (0.66)	-2.7	-0.70	-0.07	0.08	1.0	
	Week 8	Tezepelumab	54	50 (92.6)	-0.36 (0.59)	-2.6	-0.79	-0.21	0.00	0.6	-0.08 [-0.51, 0.34]
		Placebo	39	38 (97.4)	-0.30 (0.75)	-2.6	-0.79	-0.17	0.07	1.5	
	Week 9	Tezepelumab	54	52 (96.3)	-0.39 (0.61)	-2.6	-0.86	-0.23	0.00	0.9	-0.09 [-0.50, 0.33]
		Placebo	39	39 (100.0)	-0.33 (0.76)	-2.6	-0.70	-0.07	0.00	1.6	
	Week 10	Tezepelumab	54	52 (96.3)	-0.41 (0.64)	-2.6	-0.86	-0.21	0.00	0.8	-0.07 [-0.49, 0.34]
		Placebo	39	39 (100.0)	-0.36 (0.73)	-2.6	-0.79	-0.21	0.02	0.9	
	Week 11	Tezepelumab	54	50 (92.6)	-0.37 (0.63)	-2.6	-0.86	-0.20	0.00	0.8	0.07 [-0.35, 0.49]
		Placebo	39	39 (100.0)	-0.42 (0.72)	-2.4	-0.80	-0.29	0.00	0.9	
	Week 12	Tezepelumab	54	51 (94.4)	-0.41 (0.63)	-2.6	-0.80	-0.25	0.00	0.5	0.04 [-0.38, 0.47]
		Placebo	39	37 (94.9)	-0.44 (0.78)	-2.5	-0.80	-0.21	0.00	1.5	
	Week 13	Tezepelumab	54	48 (88.9)	-0.40 (0.68)	-2.6	-0.86	-0.18	0.00	0.9	0.15 [-0.28, 0.58]
		Placebo	39	37 (94.9)	-0.51 (0.76)	-2.6	-0.85	-0.50	-0.04	1.8	
	Week 14	Tezepelumab	54	51 (94.4)	-0.44 (0.69)	-2.6	-0.93	-0.21	0.00	0.6	0.13 [-0.30, 0.56]
		Placebo	39	36 (92.3)	-0.53 (0.81)	-2.7	-0.99	-0.36	0.00	0.8	
	Week 15	Tezepelumab	54	50 (92.6)	-0.43 (0.64)	-2.6	-0.86	-0.22	0.00	0.6	0.10 [-0.32, 0.53]
		Placebo	39	38 (97.4)	-0.50 (0.83)	-2.4	-1.00	-0.42	0.00	1.8	
	Week 16	Tezepelumab	54	50 (92.6)	-0.47 (0.65)	-2.6	-0.86	-0.23	0.00	0.7	0.11 [-0.31, 0.54]
		Placebo	39	37 (94.9)	-0.55 (0.77)	-2.6	-1.00	-0.29	0.00	1.0	
	Week 17	Tezepelumab	54	51 (94.4)	-0.49 (0.66)	-2.6	-1.00	-0.29	0.00	0.4	-0.04 [-0.46, 0.39]
		Placebo	39	37 (94.9)	-0.47 (0.72)	-2.6	-0.70	-0.29	0.00	0.9	
	Week 18	Tezepelumab	54	51 (94.4)	-0.49 (0.66)	-2.6	-1.00	-0.29	-0.06	0.5	-0.04 [-0.46, 0.39]
		Placebo	39	37 (94.9)	-0.47 (0.74)	-2.5	-0.79	-0.25	0.00	0.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMH0: Course of ASD weekly chest tightness score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	54	48 (88.9)	-0.48 (0.67)	-2.6	-0.93	-0.27	0.00	0.4	0.00 [-0.42, 0.43]
		Placebo	39	38 (97.4)	-0.48 (0.76)	-2.9	-0.91	-0.25	0.00	0.9	
	Week 20	Tezepelumab	54	50 (92.6)	-0.50 (0.65)	-2.6	-0.88	-0.32	0.00	0.6	0.02 [-0.41, 0.45]
		Placebo	39	36 (92.3)	-0.51 (0.71)	-2.1	-0.89	-0.25	-0.03	0.9	
	Week 21	Tezepelumab	54	45 (83.3)	-0.45 (0.64)	-2.6	-0.93	-0.25	0.00	0.5	0.09 [-0.35, 0.52]
		Placebo	39	37 (94.9)	-0.51 (0.81)	-2.5	-1.00	-0.36	0.00	1.4	
	Week 22	Tezepelumab	54	46 (85.2)	-0.40 (0.64)	-2.6	-0.79	-0.21	0.00	0.4	0.14 [-0.30, 0.57]
		Placebo	39	37 (94.9)	-0.50 (0.76)	-2.5	-0.91	-0.29	0.00	1.1	
	Week 23	Tezepelumab	54	48 (88.9)	-0.49 (0.67)	-2.6	-0.99	-0.29	0.00	0.6	0.10 [-0.34, 0.53]
		Placebo	39	35 (89.7)	-0.56 (0.72)	-2.4	-1.00	-0.30	0.00	0.9	
	Week 24	Tezepelumab	54	50 (92.6)	-0.51 (0.67)	-2.6	-1.00	-0.29	0.00	0.6	0.21 [-0.22, 0.65]
		Placebo	39	35 (89.7)	-0.66 (0.75)	-2.9	-1.03	-0.47	-0.07	0.9	
	Week 25	Tezepelumab	54	48 (88.9)	-0.48 (0.61)	-2.6	-0.88	-0.36	0.00	0.4	0.19 [-0.25, 0.62]
		Placebo	39	35 (89.7)	-0.61 (0.79)	-2.9	-1.07	-0.50	0.00	0.9	
	Week 26	Tezepelumab	54	49 (90.7)	-0.51 (0.65)	-2.6	-0.86	-0.29	0.00	0.5	0.15 [-0.28, 0.58]
		Placebo	39	36 (92.3)	-0.62 (0.89)	-2.9	-1.15	-0.48	0.00	1.7	
	Week 27	Tezepelumab	54	45 (83.3)	-0.38 (0.67)	-2.6	-0.65	-0.14	0.00	0.7	0.21 [-0.23, 0.65]
		Placebo	39	35 (89.7)	-0.55 (0.96)	-2.9	-1.00	-0.43	0.00	2.6	
	Week 28	Tezepelumab	54	48 (88.9)	-0.41 (0.65)	-2.5	-0.86	-0.23	0.00	0.6	0.18 [-0.26, 0.62]
		Placebo	39	35 (89.7)	-0.54 (0.85)	-2.9	-0.86	-0.29	0.00	1.4	
	Week 29	Tezepelumab	54	47 (87.0)	-0.49 (0.66)	-2.6	-1.00	-0.21	0.00	0.6	0.03 [-0.41, 0.46]
		Placebo	39	36 (92.3)	-0.51 (0.88)	-2.9	-0.93	-0.32	0.00	1.3	
	Week 30	Tezepelumab	54	47 (87.0)	-0.49 (0.66)	-2.6	-0.94	-0.27	0.00	0.5	0.22 [-0.21, 0.66]
		Placebo	39	35 (89.7)	-0.65 (0.82)	-2.9	-1.06	-0.70	-0.07	1.1	
	Week 31	Tezepelumab	54	47 (87.0)	-0.53 (0.71)	-2.6	-0.98	-0.40	0.00	0.8	0.20 [-0.24, 0.63]
		Placebo	39	36 (92.3)	-0.67 (0.79)	-2.9	-1.09	-0.79	-0.14	0.9	
	Week 32	Tezepelumab	54	48 (88.9)	-0.50 (0.67)	-2.6	-0.96	-0.29	0.00	0.6	0.13 [-0.31, 0.56]
		Placebo	39	36 (92.3)	-0.59 (0.83)	-2.9	-1.00	-0.64	-0.04	1.2	
	Week 33	Tezepelumab	54	47 (87.0)	-0.50 (0.71)	-2.6	-1.00	-0.30	0.00	0.9	0.06 [-0.38, 0.49]
		Placebo	39	36 (92.3)	-0.54 (0.81)	-2.9	-0.90	-0.40	0.00	0.9	
	Week 34	Tezepelumab	54	49 (90.7)	-0.53 (0.70)	-2.6	-1.00	-0.43	0.00	0.9	0.01 [-0.42, 0.44]
		Placebo	39	37 (94.9)	-0.54 (0.80)	-2.9	-0.86	-0.49	0.00	0.9	
	Week 35	Tezepelumab	54	47 (87.0)	-0.43 (0.72)	-2.6	-0.90	-0.29	0.00	1.2	0.21 [-0.23, 0.65]
		Placebo	39	35 (89.7)	-0.58 (0.74)	-2.9	-0.93	-0.43	0.00	0.5	
	Week 36	Tezepelumab	54	47 (87.0)	-0.47 (0.72)	-2.6	-1.00	-0.29	0.00	0.9	0.05 [-0.38, 0.48]
		Placebo	39	37 (94.9)	-0.51 (0.78)	-2.9	-0.92	-0.25	0.00	0.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMH0: Course of ASD weekly chest tightness score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	54	46 (85.2)	-0.44 (0.68)	-2.6	-1.00	-0.27	0.00	0.8	0.10 [-0.33, 0.54]
		Placebo	39	36 (92.3)	-0.51 (0.72)	-2.3	-0.89	-0.29	0.00	0.9	
	Week 38	Tezepelumab	54	46 (85.2)	-0.38 (0.75)	-2.6	-0.95	-0.27	0.07	1.0	0.24 [-0.20, 0.67]
		Placebo	39	36 (92.3)	-0.55 (0.72)	-2.0	-1.06	-0.39	0.00	0.9	
	Week 39	Tezepelumab	54	48 (88.9)	-0.43 (0.75)	-2.6	-0.96	-0.27	0.00	1.3	0.13 [-0.30, 0.57]
		Placebo	39	36 (92.3)	-0.53 (0.75)	-2.0	-1.00	-0.39	0.00	1.1	
	Week 40	Tezepelumab	54	48 (88.9)	-0.47 (0.72)	-2.6	-1.00	-0.29	0.00	1.3	0.03 [-0.40, 0.46]
		Placebo	39	37 (94.9)	-0.50 (0.84)	-2.4	-1.00	-0.43	0.00	1.5	
	Week 41	Tezepelumab	54	49 (90.7)	-0.48 (0.74)	-2.5	-1.07	-0.29	0.00	1.5	0.02 [-0.41, 0.46]
		Placebo	39	35 (89.7)	-0.50 (0.92)	-2.6	-1.08	-0.36	0.00	2.2	
	Week 42	Tezepelumab	54	46 (85.2)	-0.47 (0.75)	-2.6	-1.00	-0.27	0.00	0.7	-0.00 [-0.44, 0.44]
		Placebo	39	35 (89.7)	-0.47 (0.73)	-2.0	-0.93	-0.29	0.00	1.1	
	Week 43	Tezepelumab	54	48 (88.9)	-0.48 (0.72)	-2.6	-1.07	-0.29	0.04	0.6	0.03 [-0.40, 0.46]
		Placebo	39	36 (92.3)	-0.50 (0.70)	-2.0	-0.92	-0.29	-0.05	0.9	
	Week 44	Tezepelumab	54	47 (87.0)	-0.54 (0.70)	-2.6	-1.00	-0.36	-0.06	0.6	-0.03 [-0.47, 0.41]
		Placebo	39	34 (87.2)	-0.52 (0.72)	-2.0	-0.81	-0.47	0.00	0.9	
	Week 45	Tezepelumab	54	47 (87.0)	-0.47 (0.76)	-2.6	-1.00	-0.29	0.00	1.1	0.20 [-0.23, 0.64]
		Placebo	39	35 (89.7)	-0.62 (0.79)	-2.6	-1.00	-0.57	-0.07	0.9	
	Week 46	Tezepelumab	54	46 (85.2)	-0.42 (0.76)	-2.6	-1.00	-0.32	0.00	0.9	0.21 [-0.23, 0.65]
		Placebo	39	36 (92.3)	-0.59 (0.80)	-2.9	-1.01	-0.51	0.00	0.9	
	Week 47	Tezepelumab	54	45 (83.3)	-0.46 (0.78)	-2.6	-1.00	-0.29	0.00	1.3	0.19 [-0.25, 0.63]
		Placebo	39	36 (92.3)	-0.61 (0.80)	-2.9	-1.00	-0.39	-0.04	0.9	
	Week 48	Tezepelumab	54	48 (88.9)	-0.38 (0.77)	-2.6	-0.88	-0.14	0.07	1.1	0.33 [-0.11, 0.76]
		Placebo	39	36 (92.3)	-0.63 (0.76)	-2.9	-1.01	-0.46	-0.07	0.9	
	Week 49	Tezepelumab	54	46 (85.2)	-0.38 (0.73)	-2.6	-0.79	-0.15	0.00	1.1	0.26 [-0.18, 0.70]
		Placebo	39	35 (89.7)	-0.58 (0.77)	-2.9	-1.00	-0.57	0.00	0.9	
	Week 50	Tezepelumab	54	43 (79.6)	-0.41 (0.68)	-2.6	-0.86	-0.25	0.00	0.6	0.20 [-0.25, 0.65]
		Placebo	39	34 (87.2)	-0.55 (0.74)	-2.9	-1.00	-0.39	-0.05	0.9	
	Week 51	Tezepelumab	54	44 (81.5)	-0.33 (0.73)	-2.6	-0.71	-0.14	0.03	1.6	0.39 [-0.06, 0.85]
		Placebo	39	32 (82.1)	-0.63 (0.77)	-2.9	-1.08	-0.51	-0.02	0.9	
	Week 52	Tezepelumab	54	38 (70.4)	-0.36 (0.72)	-2.6	-0.93	-0.14	0.00	1.4	0.37 [-0.10, 0.85]
		Placebo	39	31 (79.5)	-0.64 (0.77)	-2.9	-0.94	-0.54	-0.07	0.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	54	53 (98.1)	-0.19 (0.09)	(-0.36, -0.02)	-0.13 (0.13)	(-0.40, 0.13)	0.318
	Placebo	39	39 (100.0)	-0.05 (0.10)	(-0.25, 0.15)			
Week 2	Tezepelumab	54	53 (98.1)	-0.26 (0.09)	(-0.43, -0.09)	-0.13 (0.13)	(-0.39, 0.13)	0.339
	Placebo	39	38 (97.4)	-0.13 (0.10)	(-0.33, 0.07)			
Week 3	Tezepelumab	54	54 (100.0)	-0.26 (0.09)	(-0.43, -0.10)	-0.06 (0.13)	(-0.32, 0.21)	0.679
	Placebo	39	37 (94.9)	-0.21 (0.10)	(-0.41, -0.01)			
Week 4	Tezepelumab	54	53 (98.1)	-0.32 (0.09)	(-0.49, -0.15)	-0.16 (0.13)	(-0.42, 0.10)	0.235
	Placebo	39	38 (97.4)	-0.16 (0.10)	(-0.36, 0.04)			
Week 5	Tezepelumab	54	52 (96.3)	-0.34 (0.09)	(-0.51, -0.17)	-0.07 (0.13)	(-0.33, 0.20)	0.625
	Placebo	39	37 (94.9)	-0.28 (0.10)	(-0.48, -0.08)			
Week 6	Tezepelumab	54	51 (94.4)	-0.35 (0.09)	(-0.52, -0.18)	-0.19 (0.13)	(-0.45, 0.07)	0.153
	Placebo	39	39 (100.0)	-0.16 (0.10)	(-0.36, 0.04)			
Week 7	Tezepelumab	54	50 (92.6)	-0.36 (0.09)	(-0.53, -0.19)	-0.15 (0.13)	(-0.41, 0.11)	0.264
	Placebo	39	39 (100.0)	-0.21 (0.10)	(-0.41, -0.01)			
Week 8	Tezepelumab	54	50 (92.6)	-0.39 (0.09)	(-0.56, -0.22)	-0.17 (0.13)	(-0.43, 0.10)	0.211
	Placebo	39	38 (97.4)	-0.22 (0.10)	(-0.42, -0.02)			
Week 9	Tezepelumab	54	52 (96.3)	-0.43 (0.09)	(-0.60, -0.26)	-0.15 (0.13)	(-0.41, 0.11)	0.257
	Placebo	39	39 (100.0)	-0.28 (0.10)	(-0.47, -0.08)			
Week 10	Tezepelumab	54	52 (96.3)	-0.45 (0.09)	(-0.62, -0.28)	-0.14 (0.13)	(-0.40, 0.12)	0.287
	Placebo	39	39 (100.0)	-0.31 (0.10)	(-0.51, -0.11)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	54	50 (92.6)	-0.44 (0.09)	(-0.61, -0.27)	-0.07 (0.13)	(-0.34, 0.19)	0.585	
	Placebo	39	39 (100.0)	-0.37 (0.10)	(-0.57, -0.17)				
Week 12	Tezepelumab	54	51 (94.4)	-0.46 (0.09)	(-0.63, -0.29)	-0.10 (0.13)	(-0.37, 0.16)	0.434	
	Placebo	39	37 (94.9)	-0.35 (0.10)	(-0.55, -0.15)				
Week 13	Tezepelumab	54	48 (88.9)	-0.47 (0.09)	(-0.64, -0.30)	-0.05 (0.13)	(-0.32, 0.21)	0.690	
	Placebo	39	37 (94.9)	-0.42 (0.10)	(-0.62, -0.22)				
Week 14	Tezepelumab	54	51 (94.4)	-0.44 (0.09)	(-0.61, -0.27)	-0.01 (0.13)	(-0.28, 0.25)	0.915	
	Placebo	39	36 (92.3)	-0.43 (0.10)	(-0.63, -0.23)				
Week 15	Tezepelumab	54	50 (92.6)	-0.46 (0.09)	(-0.63, -0.29)	-0.01 (0.13)	(-0.28, 0.25)	0.919	
	Placebo	39	38 (97.4)	-0.45 (0.10)	(-0.65, -0.25)				
Week 16	Tezepelumab	54	50 (92.6)	-0.51 (0.09)	(-0.68, -0.33)	-0.03 (0.13)	(-0.29, 0.23)	0.820	
	Placebo	39	37 (94.9)	-0.47 (0.10)	(-0.68, -0.27)				
Week 17	Tezepelumab	54	51 (94.4)	-0.51 (0.09)	(-0.68, -0.34)	-0.11 (0.13)	(-0.37, 0.15)	0.411	
	Placebo	39	37 (94.9)	-0.40 (0.10)	(-0.60, -0.20)				
Week 18	Tezepelumab	54	51 (94.4)	-0.51 (0.09)	(-0.68, -0.34)	-0.11 (0.13)	(-0.38, 0.15)	0.407	
	Placebo	39	37 (94.9)	-0.40 (0.10)	(-0.60, -0.20)				
Week 19	Tezepelumab	54	48 (88.9)	-0.52 (0.09)	(-0.69, -0.35)	-0.11 (0.13)	(-0.37, 0.16)	0.432	
	Placebo	39	38 (97.4)	-0.41 (0.10)	(-0.61, -0.21)				
Week 20	Tezepelumab	54	50 (92.6)	-0.53 (0.09)	(-0.70, -0.36)	-0.06 (0.13)	(-0.33, 0.20)	0.632	
	Placebo	39	36 (92.3)	-0.46 (0.10)	(-0.67, -0.26)				

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	54	45 (83.3)	-0.51 (0.09)	(-0.68, -0.34)	-0.07 (0.14)	(-0.34, 0.19)	0.593	
	Placebo	39	37 (94.9)	-0.44 (0.10)	(-0.64, -0.24)				
Week 22	Tezepelumab	54	46 (85.2)	-0.47 (0.09)	(-0.64, -0.30)	-0.05 (0.14)	(-0.31, 0.22)	0.725	
	Placebo	39	37 (94.9)	-0.42 (0.10)	(-0.62, -0.22)				
Week 23	Tezepelumab	54	48 (88.9)	-0.51 (0.09)	(-0.68, -0.34)	-0.09 (0.14)	(-0.35, 0.18)	0.524	
	Placebo	39	35 (89.7)	-0.43 (0.10)	(-0.63, -0.22)				
Week 24	Tezepelumab	54	50 (92.6)	-0.53 (0.09)	(-0.70, -0.35)	0.01 (0.14)	(-0.26, 0.27)	0.968	
	Placebo	39	35 (89.7)	-0.53 (0.10)	(-0.73, -0.33)				
Week 25	Tezepelumab	54	48 (88.9)	-0.53 (0.09)	(-0.71, -0.36)	-0.04 (0.14)	(-0.30, 0.23)	0.790	
	Placebo	39	35 (89.7)	-0.50 (0.10)	(-0.70, -0.29)				
Week 26	Tezepelumab	54	49 (90.7)	-0.57 (0.09)	(-0.74, -0.40)	-0.06 (0.14)	(-0.32, 0.21)	0.683	
	Placebo	39	36 (92.3)	-0.51 (0.10)	(-0.72, -0.31)				
Week 27	Tezepelumab	54	45 (83.3)	-0.45 (0.09)	(-0.63, -0.28)	-0.00 (0.14)	(-0.27, 0.26)	0.977	
	Placebo	39	35 (89.7)	-0.45 (0.10)	(-0.65, -0.25)				
Week 28	Tezepelumab	54	48 (88.9)	-0.52 (0.09)	(-0.69, -0.34)	-0.10 (0.14)	(-0.37, 0.17)	0.459	
	Placebo	39	35 (89.7)	-0.42 (0.10)	(-0.62, -0.21)				
Week 29	Tezepelumab	54	47 (87.0)	-0.55 (0.09)	(-0.72, -0.38)	-0.13 (0.14)	(-0.40, 0.14)	0.339	
	Placebo	39	36 (92.3)	-0.42 (0.10)	(-0.62, -0.21)				
Week 30	Tezepelumab	54	47 (87.0)	-0.54 (0.09)	(-0.71, -0.37)	-0.00 (0.14)	(-0.27, 0.26)	0.986	
	Placebo	39	35 (89.7)	-0.54 (0.10)	(-0.74, -0.34)				

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
DITTB - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	54	47 (87.0)	-0.56 (0.09)	(-0.73, -0.39)	0.02 (0.14)	(-0.25, 0.29)	0.877
	Placebo	39	36 (92.3)	-0.58 (0.10)	(-0.78, -0.38)			
Week 32	Tezepelumab	54	48 (88.9)	-0.56 (0.09)	(-0.73, -0.38)	-0.05 (0.14)	(-0.32, 0.21)	0.692
	Placebo	39	36 (92.3)	-0.50 (0.10)	(-0.71, -0.30)			
Week 33	Tezepelumab	54	47 (87.0)	-0.56 (0.09)	(-0.73, -0.39)	-0.08 (0.14)	(-0.35, 0.18)	0.543
	Placebo	39	36 (92.3)	-0.48 (0.10)	(-0.68, -0.27)			
Week 34	Tezepelumab	54	49 (90.7)	-0.57 (0.09)	(-0.75, -0.40)	-0.11 (0.14)	(-0.38, 0.16)	0.411
	Placebo	39	37 (94.9)	-0.46 (0.10)	(-0.67, -0.26)			
Week 35	Tezepelumab	54	47 (87.0)	-0.50 (0.09)	(-0.68, -0.33)	-0.02 (0.14)	(-0.29, 0.25)	0.869
	Placebo	39	35 (89.7)	-0.48 (0.10)	(-0.69, -0.28)			
Week 36	Tezepelumab	54	47 (87.0)	-0.48 (0.09)	(-0.65, -0.30)	-0.04 (0.14)	(-0.31, 0.23)	0.757
	Placebo	39	37 (94.9)	-0.43 (0.10)	(-0.64, -0.23)			
Week 37	Tezepelumab	54	46 (85.2)	-0.53 (0.09)	(-0.71, -0.36)	-0.10 (0.14)	(-0.37, 0.17)	0.481
	Placebo	39	36 (92.3)	-0.44 (0.10)	(-0.64, -0.23)			
Week 38	Tezepelumab	54	46 (85.2)	-0.47 (0.09)	(-0.65, -0.30)	-0.00 (0.14)	(-0.27, 0.27)	0.983
	Placebo	39	36 (92.3)	-0.47 (0.10)	(-0.68, -0.27)			
Week 39	Tezepelumab	54	48 (88.9)	-0.51 (0.09)	(-0.68, -0.33)	-0.06 (0.14)	(-0.33, 0.21)	0.666
	Placebo	39	36 (92.3)	-0.45 (0.10)	(-0.65, -0.24)			
Week 40	Tezepelumab	54	48 (88.9)	-0.51 (0.09)	(-0.69, -0.34)	-0.08 (0.14)	(-0.35, 0.18)	0.535
	Placebo	39	37 (94.9)	-0.43 (0.10)	(-0.63, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	54	49 (90.7)	-0.51 (0.09)	(-0.68, -0.33)	-0.08 (0.14)	(-0.35, 0.19)	0.572
	Placebo	39	35 (89.7)	-0.43 (0.10)	(-0.63, -0.22)			
Week 42	Tezepelumab	54	46 (85.2)	-0.49 (0.09)	(-0.67, -0.32)	-0.06 (0.14)	(-0.33, 0.21)	0.675
	Placebo	39	35 (89.7)	-0.44 (0.10)	(-0.64, -0.23)			
Week 43	Tezepelumab	54	48 (88.9)	-0.52 (0.09)	(-0.70, -0.35)	-0.10 (0.14)	(-0.37, 0.17)	0.485
	Placebo	39	36 (92.3)	-0.43 (0.10)	(-0.63, -0.22)			
Week 44	Tezepelumab	54	47 (87.0)	-0.56 (0.09)	(-0.74, -0.39)	-0.11 (0.14)	(-0.38, 0.16)	0.414
	Placebo	39	34 (87.2)	-0.45 (0.11)	(-0.66, -0.25)			
Week 45	Tezepelumab	54	47 (87.0)	-0.53 (0.09)	(-0.71, -0.36)	0.01 (0.14)	(-0.26, 0.28)	0.957
	Placebo	39	35 (89.7)	-0.54 (0.11)	(-0.74, -0.33)			
Week 46	Tezepelumab	54	46 (85.2)	-0.51 (0.09)	(-0.69, -0.34)	0.01 (0.14)	(-0.26, 0.28)	0.952
	Placebo	39	36 (92.3)	-0.52 (0.11)	(-0.73, -0.31)			
Week 47	Tezepelumab	54	45 (83.3)	-0.51 (0.09)	(-0.68, -0.34)	0.03 (0.14)	(-0.24, 0.30)	0.812
	Placebo	39	36 (92.3)	-0.54 (0.11)	(-0.75, -0.34)			
Week 48	Tezepelumab	54	48 (88.9)	-0.44 (0.09)	(-0.61, -0.26)	0.13 (0.14)	(-0.14, 0.40)	0.357
	Placebo	39	36 (92.3)	-0.56 (0.11)	(-0.77, -0.36)			
Week 49	Tezepelumab	54	46 (85.2)	-0.47 (0.09)	(-0.64, -0.29)	0.04 (0.14)	(-0.23, 0.31)	0.759
	Placebo	39	35 (89.7)	-0.51 (0.11)	(-0.72, -0.30)			
Week 50	Tezepelumab	54	43 (79.6)	-0.48 (0.09)	(-0.66, -0.30)	0.02 (0.14)	(-0.26, 0.29)	0.904
	Placebo	39	34 (87.2)	-0.50 (0.11)	(-0.70, -0.29)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC_ABMC0: Change from baseline in ASD weekly chest tightness score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	44 (81.5)	-0.44 (0.09)	(-0.62, -0.26)	0.09 (0.14)	(-0.18, 0.37)	0.507
	Placebo	39	32 (82.1)	-0.53 (0.11)	(-0.74, -0.32)			
Week 52	Tezepelumab	54	38 (70.4)	-0.45 (0.09)	(-0.64, -0.27)	0.06 (0.14)	(-0.22, 0.34)	0.688
	Placebo	39	31 (79.5)	-0.51 (0.11)	(-0.72, -0.30)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMH0: Course of ASD weekly waking score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	54	54 (100.0)	0.96 (0.75)	0.0	0.57	0.93	1.00	3.3	
		Placebo	39	39 (100.0)	0.89 (0.62)	0.0	0.43	1.00	1.29	3.0	
	Week 1	Tezepelumab	54	53 (98.1)	0.70 (0.73)	0.0	0.14	0.57	1.00	3.3	
		Placebo	39	39 (100.0)	0.82 (0.67)	0.0	0.29	0.86	1.14	3.0	
	Week 2	Tezepelumab	54	53 (98.1)	0.68 (0.70)	0.0	0.00	0.57	1.00	3.0	
		Placebo	39	38 (97.4)	0.74 (0.62)	0.0	0.29	0.86	1.00	3.0	
	Week 3	Tezepelumab	54	54 (100.0)	0.64 (0.64)	0.0	0.00	0.64	1.00	2.9	
		Placebo	39	37 (94.9)	0.71 (0.63)	0.0	0.14	0.86	1.00	3.0	
	Week 4	Tezepelumab	54	54 (100.0)	0.61 (0.63)	0.0	0.00	0.71	1.00	3.0	
		Placebo	39	38 (97.4)	0.70 (0.66)	0.0	0.14	0.79	1.00	2.7	
	Week 5	Tezepelumab	54	53 (98.1)	0.51 (0.60)	0.0	0.00	0.29	0.86	3.0	
		Placebo	39	38 (97.4)	0.65 (0.66)	0.0	0.00	0.57	1.00	2.7	
	Week 6	Tezepelumab	54	52 (96.3)	0.60 (0.68)	0.0	0.00	0.46	1.00	2.9	
		Placebo	39	39 (100.0)	0.74 (0.71)	0.0	0.00	0.71	1.00	2.7	
	Week 7	Tezepelumab	54	52 (96.3)	0.56 (0.68)	0.0	0.00	0.29	1.00	3.4	
		Placebo	39	39 (100.0)	0.70 (0.76)	0.0	0.00	0.60	1.00	2.7	
	Week 8	Tezepelumab	54	52 (96.3)	0.50 (0.66)	0.0	0.00	0.29	0.93	3.3	
		Placebo	39	38 (97.4)	0.69 (0.72)	0.0	0.00	0.77	1.00	2.6	
	Week 9	Tezepelumab	54	54 (100.0)	0.42 (0.55)	0.0	0.00	0.14	0.86	2.0	
		Placebo	39	39 (100.0)	0.71 (0.73)	0.0	0.00	0.80	1.00	2.7	
	Week 10	Tezepelumab	54	53 (98.1)	0.45 (0.62)	0.0	0.00	0.14	0.71	3.1	
		Placebo	39	39 (100.0)	0.64 (0.67)	0.0	0.00	0.57	1.00	2.6	
	Week 11	Tezepelumab	54	53 (98.1)	0.45 (0.65)	0.0	0.00	0.14	0.71	3.3	
		Placebo	39	39 (100.0)	0.60 (0.68)	0.0	0.00	0.43	1.00	2.4	
	Week 12	Tezepelumab	54	52 (96.3)	0.45 (0.57)	0.0	0.00	0.15	0.79	2.3	
		Placebo	39	37 (94.9)	0.58 (0.71)	0.0	0.00	0.14	1.00	3.0	
	Week 13	Tezepelumab	54	50 (92.6)	0.47 (0.56)	0.0	0.00	0.29	1.00	2.6	
		Placebo	39	38 (97.4)	0.55 (0.67)	0.0	0.00	0.29	1.00	2.3	
	Week 14	Tezepelumab	54	51 (94.4)	0.48 (0.61)	0.0	0.00	0.14	1.00	2.9	
		Placebo	39	37 (94.9)	0.55 (0.67)	0.0	0.00	0.14	1.00	2.1	
	Week 15	Tezepelumab	54	51 (94.4)	0.40 (0.50)	0.0	0.00	0.17	0.86	2.2	
		Placebo	39	38 (97.4)	0.60 (0.80)	0.0	0.00	0.23	1.00	3.2	
	Week 16	Tezepelumab	54	52 (96.3)	0.44 (0.54)	0.0	0.00	0.15	0.93	2.4	
		Placebo	39	37 (94.9)	0.52 (0.66)	0.0	0.00	0.17	1.00	2.6	
Week 17	Tezepelumab	54	52 (96.3)	0.44 (0.58)	0.0	0.00	0.23	0.76	2.9		
	Placebo	39	37 (94.9)	0.57 (0.67)	0.0	0.00	0.29	1.00	2.2		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMH0: Course of ASD weekly waking score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	54	52 (96.3)	0.49 (0.66)	0.0	0.00	0.14	0.93	3.0	
		Placebo	39	39 (100.0)	0.60 (0.74)	0.0	0.00	0.29	1.00	2.5	
	Week 19	Tezepelumab	54	52 (96.3)	0.44 (0.64)	0.0	0.00	0.14	0.86	3.3	
		Placebo	39	39 (100.0)	0.57 (0.65)	0.0	0.00	0.29	1.00	2.0	
	Week 20	Tezepelumab	54	51 (94.4)	0.42 (0.63)	0.0	0.00	0.00	0.83	3.1	
		Placebo	39	38 (97.4)	0.57 (0.65)	0.0	0.00	0.37	1.00	2.0	
	Week 21	Tezepelumab	54	49 (90.7)	0.42 (0.64)	0.0	0.00	0.00	0.86	3.0	
		Placebo	39	38 (97.4)	0.52 (0.64)	0.0	0.00	0.14	1.00	2.3	
	Week 22	Tezepelumab	54	51 (94.4)	0.43 (0.63)	0.0	0.00	0.14	1.00	3.3	
		Placebo	39	38 (97.4)	0.56 (0.69)	0.0	0.00	0.21	1.00	2.3	
	Week 23	Tezepelumab	54	51 (94.4)	0.46 (0.70)	0.0	0.00	0.00	0.86	3.3	
		Placebo	39	36 (92.3)	0.52 (0.67)	0.0	0.00	0.14	1.00	2.5	
	Week 24	Tezepelumab	54	52 (96.3)	0.41 (0.64)	0.0	0.00	0.14	0.64	3.3	
		Placebo	39	36 (92.3)	0.50 (0.55)	0.0	0.00	0.29	1.00	2.0	
	Week 25	Tezepelumab	54	49 (90.7)	0.38 (0.55)	0.0	0.00	0.00	0.71	2.6	
		Placebo	39	37 (94.9)	0.50 (0.65)	0.0	0.00	0.00	1.00	2.3	
	Week 26	Tezepelumab	54	52 (96.3)	0.49 (0.70)	0.0	0.00	0.15	0.93	3.1	
		Placebo	39	36 (92.3)	0.48 (0.55)	0.0	0.00	0.29	1.00	2.1	
	Week 27	Tezepelumab	54	52 (96.3)	0.48 (0.70)	0.0	0.00	0.14	0.85	3.4	
		Placebo	39	35 (89.7)	0.48 (0.56)	0.0	0.00	0.29	1.00	2.0	
	Week 28	Tezepelumab	54	52 (96.3)	0.50 (0.64)	0.0	0.00	0.07	1.00	3.0	
		Placebo	39	36 (92.3)	0.50 (0.54)	0.0	0.00	0.36	1.00	1.8	
	Week 29	Tezepelumab	54	51 (94.4)	0.38 (0.60)	0.0	0.00	0.00	0.71	2.9	
		Placebo	39	36 (92.3)	0.49 (0.57)	0.0	0.00	0.21	1.00	2.3	
	Week 30	Tezepelumab	54	51 (94.4)	0.41 (0.63)	0.0	0.00	0.00	1.00	2.7	
		Placebo	39	36 (92.3)	0.54 (0.66)	0.0	0.00	0.15	1.00	2.7	
	Week 31	Tezepelumab	54	53 (98.1)	0.38 (0.52)	0.0	0.00	0.14	0.71	2.6	
		Placebo	39	37 (94.9)	0.57 (0.74)	0.0	0.00	0.00	1.00	3.0	
	Week 32	Tezepelumab	54	52 (96.3)	0.41 (0.59)	0.0	0.00	0.00	0.79	2.1	
		Placebo	39	37 (94.9)	0.53 (0.68)	0.0	0.00	0.14	1.00	3.0	
	Week 33	Tezepelumab	54	52 (96.3)	0.48 (0.60)	0.0	0.00	0.18	0.83	2.7	
		Placebo	39	37 (94.9)	0.56 (0.71)	0.0	0.00	0.17	1.00	3.0	
	Week 34	Tezepelumab	54	53 (98.1)	0.43 (0.61)	0.0	0.00	0.00	0.86	3.0	
		Placebo	39	37 (94.9)	0.57 (0.71)	0.0	0.00	0.20	1.00	3.0	
	Week 35	Tezepelumab	54	52 (96.3)	0.43 (0.64)	0.0	0.00	0.07	0.93	3.1	
		Placebo	39	35 (89.7)	0.49 (0.67)	0.0	0.00	0.00	1.00	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMH0: Course of ASD weekly waking score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	54	51 (94.4)	0.44 (0.63)	0.0	0.00	0.14	1.00	3.0	
		Placebo	39	37 (94.9)	0.59 (0.68)	0.0	0.00	0.33	1.00	2.9	
	Week 37	Tezepelumab	54	51 (94.4)	0.45 (0.61)	0.0	0.00	0.14	0.86	2.6	
		Placebo	39	37 (94.9)	0.56 (0.71)	0.0	0.00	0.20	1.00	3.0	
	Week 38	Tezepelumab	54	49 (90.7)	0.47 (0.63)	0.0	0.00	0.17	0.86	2.9	
		Placebo	39	37 (94.9)	0.53 (0.69)	0.0	0.00	0.14	1.00	3.0	
	Week 39	Tezepelumab	54	51 (94.4)	0.44 (0.65)	0.0	0.00	0.00	0.86	3.1	
		Placebo	39	37 (94.9)	0.54 (0.70)	0.0	0.00	0.14	1.00	3.0	
	Week 40	Tezepelumab	54	52 (96.3)	0.45 (0.64)	0.0	0.00	0.00	0.86	3.0	
		Placebo	39	37 (94.9)	0.57 (0.78)	0.0	0.00	0.17	1.00	3.0	
	Week 41	Tezepelumab	54	52 (96.3)	0.45 (0.62)	0.0	0.00	0.14	1.00	2.6	
		Placebo	39	36 (92.3)	0.58 (0.77)	0.0	0.00	0.29	1.00	3.0	
	Week 42	Tezepelumab	54	49 (90.7)	0.50 (0.76)	0.0	0.00	0.00	1.00	3.0	
		Placebo	39	37 (94.9)	0.56 (0.72)	0.0	0.00	0.14	1.00	3.0	
	Week 43	Tezepelumab	54	50 (92.6)	0.44 (0.66)	0.0	0.00	0.00	1.00	3.3	
		Placebo	39	36 (92.3)	0.51 (0.67)	0.0	0.00	0.29	1.00	3.0	
	Week 44	Tezepelumab	54	50 (92.6)	0.41 (0.60)	0.0	0.00	0.00	1.00	2.9	
		Placebo	39	35 (89.7)	0.52 (0.67)	0.0	0.00	0.29	1.00	3.0	
	Week 45	Tezepelumab	54	50 (92.6)	0.40 (0.62)	0.0	0.00	0.00	0.86	2.9	
		Placebo	39	36 (92.3)	0.48 (0.66)	0.0	0.00	0.07	1.00	3.0	
	Week 46	Tezepelumab	54	51 (94.4)	0.44 (0.63)	0.0	0.00	0.14	1.00	3.0	
		Placebo	39	36 (92.3)	0.46 (0.64)	0.0	0.00	0.14	1.00	3.0	
	Week 47	Tezepelumab	54	49 (90.7)	0.41 (0.62)	0.0	0.00	0.00	0.83	2.9	
		Placebo	39	36 (92.3)	0.51 (0.66)	0.0	0.00	0.29	1.00	3.0	
	Week 48	Tezepelumab	54	51 (94.4)	0.44 (0.62)	0.0	0.00	0.14	0.86	3.0	
		Placebo	39	37 (94.9)	0.53 (0.71)	0.0	0.00	0.14	1.00	3.0	
	Week 49	Tezepelumab	54	51 (94.4)	0.46 (0.63)	0.0	0.00	0.00	1.00	3.0	
		Placebo	39	37 (94.9)	0.49 (0.72)	0.0	0.00	0.00	1.00	3.0	
	Week 50	Tezepelumab	54	50 (92.6)	0.41 (0.57)	0.0	0.00	0.07	1.00	2.3	
		Placebo	39	35 (89.7)	0.43 (0.70)	0.0	0.00	0.00	1.00	3.0	
	Week 51	Tezepelumab	54	46 (85.2)	0.43 (0.62)	0.0	0.00	0.07	0.80	2.7	
		Placebo	39	34 (87.2)	0.43 (0.67)	0.0	0.00	0.00	1.00	3.0	
	Week 52	Tezepelumab	54	42 (77.8)	0.37 (0.56)	0.0	0.00	0.00	0.83	2.4	
		Placebo	39	32 (82.1)	0.41 (0.66)	0.0	0.00	0.07	0.86	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMH0: Course of ASD weekly waking score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	54	53 (98.1)	-0.26 (0.53)	-2.6	-0.43	-0.14	0.00	0.6	-0.38 [-0.80, 0.04]
		Placebo	39	39 (100.0)	-0.07 (0.44)	-1.0	-0.26	0.00	0.00	1.5	
	Week 2	Tezepelumab	54	53 (98.1)	-0.28 (0.54)	-2.6	-0.57	-0.14	0.00	0.7	-0.29 [-0.71, 0.13]
		Placebo	39	38 (97.4)	-0.14 (0.38)	-1.3	-0.14	0.00	0.00	0.6	
	Week 3	Tezepelumab	54	54 (100.0)	-0.32 (0.52)	-2.6	-0.57	-0.14	0.00	0.6	-0.35 [-0.77, 0.08]
		Placebo	39	37 (94.9)	-0.15 (0.43)	-1.3	-0.14	0.00	0.00	0.9	
	Week 4	Tezepelumab	54	54 (100.0)	-0.35 (0.56)	-2.6	-0.71	-0.23	0.00	0.8	-0.34 [-0.76, 0.08]
		Placebo	39	38 (97.4)	-0.17 (0.45)	-1.4	-0.43	0.00	0.02	0.8	
	Week 5	Tezepelumab	54	53 (98.1)	-0.45 (0.57)	-2.6	-0.86	-0.29	0.00	0.5	-0.44 [-0.86, -0.02]
		Placebo	39	38 (97.4)	-0.22 (0.46)	-1.4	-0.43	-0.14	0.00	0.6	
	Week 6	Tezepelumab	54	52 (96.3)	-0.36 (0.52)	-2.6	-0.57	-0.20	0.00	0.4	-0.40 [-0.82, 0.02]
		Placebo	39	39 (100.0)	-0.15 (0.53)	-1.4	-0.43	0.00	0.14	0.9	
	Week 7	Tezepelumab	54	52 (96.3)	-0.37 (0.58)	-2.6	-0.70	-0.29	0.00	1.5	-0.33 [-0.75, 0.09]
		Placebo	39	39 (100.0)	-0.19 (0.50)	-1.4	-0.50	-0.14	0.00	1.3	
	Week 8	Tezepelumab	54	52 (96.3)	-0.47 (0.54)	-2.6	-0.75	-0.43	-0.11	0.9	-0.51 [-0.94, -0.09]
		Placebo	39	38 (97.4)	-0.18 (0.61)	-1.4	-0.50	-0.14	0.00	2.0	
	Week 9	Tezepelumab	54	54 (100.0)	-0.54 (0.54)	-2.6	-0.86	-0.43	-0.14	0.7	-0.62 [-1.04, -0.20]
		Placebo	39	39 (100.0)	-0.18 (0.63)	-1.4	-0.43	-0.14	0.00	1.7	
	Week 10	Tezepelumab	54	53 (98.1)	-0.52 (0.54)	-2.6	-0.86	-0.45	-0.14	0.6	-0.52 [-0.94, -0.10]
		Placebo	39	39 (100.0)	-0.25 (0.48)	-1.4	-0.50	-0.26	0.00	1.1	
	Week 11	Tezepelumab	54	53 (98.1)	-0.51 (0.57)	-2.6	-0.86	-0.43	0.00	0.6	-0.42 [-0.84, 0.00]
		Placebo	39	39 (100.0)	-0.29 (0.48)	-1.3	-0.57	-0.29	0.00	1.0	
	Week 12	Tezepelumab	54	52 (96.3)	-0.51 (0.58)	-2.6	-0.93	-0.43	-0.07	0.9	-0.41 [-0.83, 0.02]
		Placebo	39	37 (94.9)	-0.27 (0.57)	-1.3	-0.57	-0.17	0.00	2.0	
	Week 13	Tezepelumab	54	50 (92.6)	-0.48 (0.63)	-2.6	-1.00	-0.36	0.00	0.9	-0.26 [-0.68, 0.17]
		Placebo	39	38 (97.4)	-0.33 (0.49)	-1.3	-0.57	-0.29	0.00	1.3	
	Week 14	Tezepelumab	54	51 (94.4)	-0.51 (0.58)	-2.6	-1.00	-0.43	0.00	1.0	-0.37 [-0.80, 0.05]
		Placebo	39	37 (94.9)	-0.30 (0.55)	-1.4	-0.57	-0.29	0.00	1.1	
	Week 15	Tezepelumab	54	51 (94.4)	-0.51 (0.62)	-2.6	-1.00	-0.43	0.00	0.9	-0.36 [-0.79, 0.06]
		Placebo	39	38 (97.4)	-0.28 (0.63)	-1.4	-0.57	-0.29	0.00	2.2	
	Week 16	Tezepelumab	54	52 (96.3)	-0.49 (0.65)	-2.6	-1.00	-0.42	0.00	0.9	-0.26 [-0.68, 0.16]
		Placebo	39	37 (94.9)	-0.34 (0.49)	-1.4	-0.57	-0.29	0.00	1.1	
	Week 17	Tezepelumab	54	52 (96.3)	-0.49 (0.64)	-2.6	-0.93	-0.43	0.00	0.9	-0.33 [-0.75, 0.09]
		Placebo	39	37 (94.9)	-0.29 (0.52)	-1.4	-0.57	-0.14	0.00	1.0	
Week 18	Tezepelumab	54	52 (96.3)	-0.47 (0.65)	-2.6	-0.93	-0.43	0.00	1.1	-0.30 [-0.72, 0.12]	
	Placebo	39	39 (100.0)	-0.29 (0.55)	-1.4	-0.57	-0.14	0.00	1.1		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMH0: Course of ASD weekly waking score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	54	52 (96.3)	-0.52 (0.60)	-2.6	-0.93	-0.48	0.00	0.7	-0.35 [-0.76, 0.07]
		Placebo	39	39 (100.0)	-0.32 (0.50)	-1.4	-0.57	-0.29	0.00	0.7	
	Week 20	Tezepelumab	54	51 (94.4)	-0.51 (0.61)	-2.6	-1.00	-0.43	-0.05	1.0	-0.28 [-0.70, 0.14]
		Placebo	39	38 (97.4)	-0.34 (0.54)	-1.6	-0.57	-0.21	0.00	0.7	
	Week 21	Tezepelumab	54	49 (90.7)	-0.51 (0.58)	-2.6	-0.86	-0.43	-0.14	0.7	-0.28 [-0.71, 0.14]
		Placebo	39	38 (97.4)	-0.35 (0.49)	-1.4	-0.57	-0.27	0.00	0.7	
	Week 22	Tezepelumab	54	51 (94.4)	-0.50 (0.61)	-2.6	-1.00	-0.43	0.00	0.9	-0.32 [-0.75, 0.10]
		Placebo	39	38 (97.4)	-0.32 (0.52)	-1.6	-0.57	-0.21	0.00	1.2	
	Week 23	Tezepelumab	54	51 (94.4)	-0.48 (0.60)	-2.6	-0.86	-0.43	0.00	1.4	-0.27 [-0.70, 0.16]
		Placebo	39	36 (92.3)	-0.33 (0.50)	-1.6	-0.54	-0.21	0.00	0.7	
	Week 24	Tezepelumab	54	52 (96.3)	-0.52 (0.62)	-2.6	-0.90	-0.46	-0.07	1.4	-0.37 [-0.80, 0.06]
		Placebo	39	36 (92.3)	-0.31 (0.50)	-1.6	-0.54	-0.14	0.00	0.6	
	Week 25	Tezepelumab	54	49 (90.7)	-0.58 (0.60)	-2.6	-1.00	-0.57	-0.14	0.7	-0.37 [-0.80, 0.06]
		Placebo	39	37 (94.9)	-0.37 (0.50)	-1.6	-0.57	-0.43	0.00	0.6	
	Week 26	Tezepelumab	54	52 (96.3)	-0.45 (0.67)	-2.6	-0.86	-0.36	0.00	1.2	-0.19 [-0.62, 0.24]
		Placebo	39	36 (92.3)	-0.33 (0.53)	-1.6	-0.60	-0.24	0.00	0.7	
	Week 27	Tezepelumab	54	52 (96.3)	-0.45 (0.66)	-2.6	-0.93	-0.43	0.00	1.0	-0.19 [-0.62, 0.24]
		Placebo	39	35 (89.7)	-0.34 (0.51)	-1.6	-0.57	-0.17	0.00	0.6	
	Week 28	Tezepelumab	54	52 (96.3)	-0.43 (0.64)	-2.6	-0.86	-0.43	0.00	1.3	-0.22 [-0.65, 0.21]
		Placebo	39	36 (92.3)	-0.30 (0.55)	-1.6	-0.57	-0.21	0.00	0.8	
	Week 29	Tezepelumab	54	51 (94.4)	-0.56 (0.56)	-2.6	-1.00	-0.45	-0.14	0.4	-0.45 [-0.88, -0.02]
		Placebo	39	36 (92.3)	-0.30 (0.57)	-1.4	-0.57	-0.21	0.00	0.9	
	Week 30	Tezepelumab	54	51 (94.4)	-0.56 (0.56)	-2.6	-1.00	-0.57	-0.14	0.6	-0.52 [-0.96, -0.09]
		Placebo	39	36 (92.3)	-0.26 (0.60)	-1.6	-0.50	-0.20	0.00	1.2	
	Week 31	Tezepelumab	54	53 (98.1)	-0.58 (0.63)	-2.6	-1.00	-0.43	-0.14	0.9	-0.48 [-0.90, -0.05]
		Placebo	39	37 (94.9)	-0.28 (0.63)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 32	Tezepelumab	54	52 (96.3)	-0.54 (0.61)	-2.6	-1.00	-0.57	0.00	0.4	-0.36 [-0.78, 0.07]
		Placebo	39	37 (94.9)	-0.32 (0.62)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 33	Tezepelumab	54	52 (96.3)	-0.51 (0.61)	-2.6	-1.00	-0.46	0.00	0.9	-0.36 [-0.78, 0.07]
		Placebo	39	37 (94.9)	-0.29 (0.60)	-1.4	-0.57	-0.29	0.00	1.6	
	Week 34	Tezepelumab	54	53 (98.1)	-0.53 (0.60)	-2.6	-0.86	-0.57	-0.14	1.0	-0.43 [-0.85, -0.00]
		Placebo	39	37 (94.9)	-0.28 (0.61)	-1.6	-0.57	-0.21	0.00	1.6	
	Week 35	Tezepelumab	54	52 (96.3)	-0.52 (0.62)	-2.6	-1.00	-0.50	-0.14	1.3	-0.31 [-0.75, 0.12]
		Placebo	39	35 (89.7)	-0.32 (0.62)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 36	Tezepelumab	54	51 (94.4)	-0.50 (0.58)	-2.6	-0.86	-0.43	-0.14	0.9	-0.41 [-0.84, 0.01]
		Placebo	39	37 (94.9)	-0.27 (0.57)	-1.4	-0.57	-0.14	0.00	1.4	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMH0: Course of ASD weekly waking score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	54	51 (94.4)	-0.50 (0.59)	-2.6	-0.86	-0.43	0.00	0.9	-0.35 [-0.77, 0.08]
		Placebo	39	37 (94.9)	-0.29 (0.58)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 38	Tezepelumab	54	49 (90.7)	-0.49 (0.64)	-2.6	-0.86	-0.43	-0.14	1.3	-0.27 [-0.70, 0.16]
		Placebo	39	37 (94.9)	-0.33 (0.58)	-1.6	-0.57	-0.17	0.00	1.6	
	Week 39	Tezepelumab	54	51 (94.4)	-0.55 (0.58)	-2.6	-1.00	-0.50	-0.14	0.7	-0.41 [-0.84, 0.02]
		Placebo	39	37 (94.9)	-0.31 (0.61)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 40	Tezepelumab	54	52 (96.3)	-0.53 (0.61)	-2.6	-1.00	-0.52	-0.11	0.7	-0.40 [-0.83, 0.03]
		Placebo	39	37 (94.9)	-0.28 (0.65)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 41	Tezepelumab	54	52 (96.3)	-0.53 (0.59)	-2.6	-0.93	-0.57	-0.07	0.7	-0.43 [-0.86, 0.00]
		Placebo	39	36 (92.3)	-0.27 (0.64)	-1.4	-0.57	-0.15	0.00	1.6	
	Week 42	Tezepelumab	54	49 (90.7)	-0.43 (0.59)	-2.6	-0.86	-0.31	0.00	1.1	-0.22 [-0.65, 0.20]
		Placebo	39	37 (94.9)	-0.30 (0.58)	-1.5	-0.57	-0.14	0.00	1.6	
	Week 43	Tezepelumab	54	50 (92.6)	-0.51 (0.56)	-2.6	-0.88	-0.50	-0.14	0.9	-0.40 [-0.84, 0.03]
		Placebo	39	36 (92.3)	-0.29 (0.54)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 44	Tezepelumab	54	50 (92.6)	-0.55 (0.60)	-2.6	-1.00	-0.57	-0.14	1.0	-0.46 [-0.89, -0.02]
		Placebo	39	35 (89.7)	-0.28 (0.58)	-1.4	-0.57	-0.14	0.00	1.6	
	Week 45	Tezepelumab	54	50 (92.6)	-0.56 (0.57)	-2.6	-1.00	-0.55	-0.14	0.9	-0.43 [-0.87, 0.00]
		Placebo	39	36 (92.3)	-0.32 (0.59)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 46	Tezepelumab	54	51 (94.4)	-0.51 (0.62)	-2.6	-1.00	-0.50	-0.14	0.9	-0.29 [-0.72, 0.14]
		Placebo	39	36 (92.3)	-0.34 (0.58)	-1.6	-0.62	-0.18	0.00	1.6	
	Week 47	Tezepelumab	54	49 (90.7)	-0.55 (0.60)	-2.6	-1.00	-0.57	-0.14	1.0	-0.45 [-0.88, -0.01]
		Placebo	39	36 (92.3)	-0.28 (0.58)	-1.6	-0.57	-0.14	0.00	1.6	
	Week 48	Tezepelumab	54	51 (94.4)	-0.52 (0.63)	-2.6	-1.00	-0.43	0.00	0.7	-0.32 [-0.75, 0.10]
		Placebo	39	37 (94.9)	-0.32 (0.58)	-1.6	-0.57	-0.26	0.00	1.6	
	Week 49	Tezepelumab	54	51 (94.4)	-0.50 (0.61)	-2.6	-1.00	-0.47	0.00	0.9	-0.23 [-0.66, 0.19]
		Placebo	39	37 (94.9)	-0.36 (0.58)	-1.6	-0.69	-0.29	0.00	1.6	
	Week 50	Tezepelumab	54	50 (92.6)	-0.56 (0.60)	-2.6	-1.00	-0.43	-0.14	0.9	-0.34 [-0.78, 0.09]
		Placebo	39	35 (89.7)	-0.35 (0.59)	-1.6	-0.57	-0.29	0.00	1.6	
	Week 51	Tezepelumab	54	46 (85.2)	-0.51 (0.58)	-2.6	-1.00	-0.43	-0.14	0.7	-0.22 [-0.67, 0.22]
		Placebo	39	34 (87.2)	-0.38 (0.59)	-1.6	-0.57	-0.36	0.00	1.6	
	Week 52	Tezepelumab	54	42 (77.8)	-0.53 (0.59)	-2.6	-1.00	-0.57	-0.14	0.6	-0.25 [-0.72, 0.21]
		Placebo	39	32 (82.1)	-0.38 (0.59)	-1.6	-0.64	-0.42	0.00	1.6	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	54	53 (98.1)	-0.23 (0.07)	(-0.37, -0.10)	-0.16 (0.11)	(-0.37, 0.05)	0.140
	Placebo	39	39 (100.0)	-0.07 (0.08)	(-0.23, 0.09)			
Week 2	Tezepelumab	54	53 (98.1)	-0.25 (0.07)	(-0.39, -0.12)	-0.13 (0.11)	(-0.34, 0.08)	0.241
	Placebo	39	38 (97.4)	-0.13 (0.08)	(-0.29, 0.03)			
Week 3	Tezepelumab	54	54 (100.0)	-0.30 (0.07)	(-0.43, -0.16)	-0.17 (0.11)	(-0.38, 0.04)	0.119
	Placebo	39	37 (94.9)	-0.13 (0.08)	(-0.29, 0.03)			
Week 4	Tezepelumab	54	54 (100.0)	-0.33 (0.07)	(-0.46, -0.19)	-0.15 (0.11)	(-0.36, 0.06)	0.152
	Placebo	39	38 (97.4)	-0.18 (0.08)	(-0.34, -0.01)			
Week 5	Tezepelumab	54	53 (98.1)	-0.42 (0.07)	(-0.56, -0.29)	-0.20 (0.11)	(-0.41, 0.01)	0.059
	Placebo	39	38 (97.4)	-0.22 (0.08)	(-0.38, -0.06)			
Week 6	Tezepelumab	54	52 (96.3)	-0.34 (0.07)	(-0.47, -0.20)	-0.18 (0.11)	(-0.39, 0.03)	0.085
	Placebo	39	39 (100.0)	-0.15 (0.08)	(-0.31, 0.01)			
Week 7	Tezepelumab	54	52 (96.3)	-0.34 (0.07)	(-0.48, -0.21)	-0.15 (0.11)	(-0.36, 0.06)	0.170
	Placebo	39	39 (100.0)	-0.20 (0.08)	(-0.36, -0.04)			
Week 8	Tezepelumab	54	52 (96.3)	-0.44 (0.07)	(-0.57, -0.30)	-0.28 (0.11)	(-0.49, -0.07)	0.009 *
	Placebo	39	38 (97.4)	-0.16 (0.08)	(-0.32, 0.00)			
Week 9	Tezepelumab	54	54 (100.0)	-0.52 (0.07)	(-0.65, -0.38)	-0.33 (0.11)	(-0.54, -0.12)	0.002 *
	Placebo	39	39 (100.0)	-0.18 (0.08)	(-0.34, -0.03)			
Week 10	Tezepelumab	54	53 (98.1)	-0.49 (0.07)	(-0.63, -0.36)	-0.24 (0.11)	(-0.45, -0.03)	0.027 *
	Placebo	39	39 (100.0)	-0.26 (0.08)	(-0.42, -0.10)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	54	53 (98.1)	-0.49 (0.07)	(-0.62, -0.35)	-0.19 (0.11)	(-0.40, 0.01)	0.068
	Placebo	39	39 (100.0)	-0.29 (0.08)	(-0.45, -0.13)			
Week 12	Tezepelumab	54	52 (96.3)	-0.50 (0.07)	(-0.63, -0.36)	-0.23 (0.11)	(-0.44, -0.01)	0.036 *
	Placebo	39	37 (94.9)	-0.27 (0.08)	(-0.43, -0.11)			
Week 13	Tezepelumab	54	50 (92.6)	-0.46 (0.07)	(-0.60, -0.33)	-0.14 (0.11)	(-0.36, 0.07)	0.179
	Placebo	39	38 (97.4)	-0.32 (0.08)	(-0.48, -0.16)			
Week 14	Tezepelumab	54	51 (94.4)	-0.47 (0.07)	(-0.61, -0.33)	-0.19 (0.11)	(-0.40, 0.02)	0.079
	Placebo	39	37 (94.9)	-0.28 (0.08)	(-0.44, -0.12)			
Week 15	Tezepelumab	54	51 (94.4)	-0.50 (0.07)	(-0.63, -0.36)	-0.23 (0.11)	(-0.44, -0.02)	0.031 *
	Placebo	39	38 (97.4)	-0.27 (0.08)	(-0.43, -0.11)			
Week 16	Tezepelumab	54	52 (96.3)	-0.47 (0.07)	(-0.60, -0.33)	-0.16 (0.11)	(-0.37, 0.05)	0.133
	Placebo	39	37 (94.9)	-0.30 (0.08)	(-0.46, -0.14)			
Week 17	Tezepelumab	54	52 (96.3)	-0.46 (0.07)	(-0.59, -0.32)	-0.20 (0.11)	(-0.41, 0.01)	0.068
	Placebo	39	37 (94.9)	-0.26 (0.08)	(-0.42, -0.10)			
Week 18	Tezepelumab	54	52 (96.3)	-0.45 (0.07)	(-0.59, -0.31)	-0.16 (0.11)	(-0.37, 0.05)	0.142
	Placebo	39	39 (100.0)	-0.29 (0.08)	(-0.45, -0.13)			
Week 19	Tezepelumab	54	52 (96.3)	-0.50 (0.07)	(-0.63, -0.36)	-0.17 (0.11)	(-0.38, 0.04)	0.114
	Placebo	39	39 (100.0)	-0.33 (0.08)	(-0.49, -0.17)			
Week 20	Tezepelumab	54	51 (94.4)	-0.49 (0.07)	(-0.63, -0.35)	-0.14 (0.11)	(-0.35, 0.07)	0.182
	Placebo	39	38 (97.4)	-0.35 (0.08)	(-0.51, -0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	54	49 (90.7)	-0.49 (0.07)	(-0.63, -0.35)	-0.13 (0.11)	(-0.35, 0.08)	0.211
	Placebo	39	38 (97.4)	-0.36 (0.08)	(-0.52, -0.20)			
Week 22	Tezepelumab	54	51 (94.4)	-0.48 (0.07)	(-0.62, -0.34)	-0.16 (0.11)	(-0.37, 0.05)	0.136
	Placebo	39	38 (97.4)	-0.32 (0.08)	(-0.48, -0.16)			
Week 23	Tezepelumab	54	51 (94.4)	-0.45 (0.07)	(-0.58, -0.31)	-0.14 (0.11)	(-0.36, 0.07)	0.182
	Placebo	39	36 (92.3)	-0.30 (0.08)	(-0.46, -0.14)			
Week 24	Tezepelumab	54	52 (96.3)	-0.48 (0.07)	(-0.62, -0.34)	-0.19 (0.11)	(-0.40, 0.02)	0.078
	Placebo	39	36 (92.3)	-0.29 (0.08)	(-0.45, -0.13)			
Week 25	Tezepelumab	54	49 (90.7)	-0.53 (0.07)	(-0.66, -0.39)	-0.18 (0.11)	(-0.39, 0.03)	0.099
	Placebo	39	37 (94.9)	-0.35 (0.08)	(-0.51, -0.18)			
Week 26	Tezepelumab	54	52 (96.3)	-0.44 (0.07)	(-0.57, -0.30)	-0.12 (0.11)	(-0.33, 0.09)	0.270
	Placebo	39	36 (92.3)	-0.32 (0.08)	(-0.48, -0.15)			
Week 27	Tezepelumab	54	52 (96.3)	-0.43 (0.07)	(-0.57, -0.30)	-0.09 (0.11)	(-0.31, 0.12)	0.385
	Placebo	39	35 (89.7)	-0.34 (0.08)	(-0.50, -0.17)			
Week 28	Tezepelumab	54	52 (96.3)	-0.43 (0.07)	(-0.56, -0.29)	-0.13 (0.11)	(-0.34, 0.08)	0.231
	Placebo	39	36 (92.3)	-0.30 (0.08)	(-0.46, -0.13)			
Week 29	Tezepelumab	54	51 (94.4)	-0.53 (0.07)	(-0.67, -0.39)	-0.19 (0.11)	(-0.40, 0.02)	0.077
	Placebo	39	36 (92.3)	-0.34 (0.08)	(-0.50, -0.18)			
Week 30	Tezepelumab	54	51 (94.4)	-0.52 (0.07)	(-0.66, -0.38)	-0.23 (0.11)	(-0.44, -0.02)	0.035 *
	Placebo	39	36 (92.3)	-0.29 (0.08)	(-0.46, -0.13)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	54	53 (98.1)	-0.55 (0.07)	(-0.69, -0.42)	-0.25 (0.11)	(-0.46, -0.04)	0.021 *
	Placebo	39	37 (94.9)	-0.30 (0.08)	(-0.47, -0.14)			
Week 32	Tezepelumab	54	52 (96.3)	-0.52 (0.07)	(-0.66, -0.39)	-0.18 (0.11)	(-0.39, 0.03)	0.094
	Placebo	39	37 (94.9)	-0.34 (0.08)	(-0.51, -0.18)			
Week 33	Tezepelumab	54	52 (96.3)	-0.48 (0.07)	(-0.61, -0.34)	-0.16 (0.11)	(-0.38, 0.05)	0.128
	Placebo	39	37 (94.9)	-0.31 (0.08)	(-0.47, -0.15)			
Week 34	Tezepelumab	54	53 (98.1)	-0.52 (0.07)	(-0.65, -0.38)	-0.22 (0.11)	(-0.43, -0.00)	0.045 *
	Placebo	39	37 (94.9)	-0.30 (0.08)	(-0.46, -0.14)			
Week 35	Tezepelumab	54	52 (96.3)	-0.50 (0.07)	(-0.64, -0.37)	-0.16 (0.11)	(-0.37, 0.05)	0.143
	Placebo	39	35 (89.7)	-0.34 (0.08)	(-0.51, -0.18)			
Week 36	Tezepelumab	54	51 (94.4)	-0.48 (0.07)	(-0.62, -0.35)	-0.20 (0.11)	(-0.41, 0.02)	0.069
	Placebo	39	37 (94.9)	-0.29 (0.08)	(-0.45, -0.12)			
Week 37	Tezepelumab	54	51 (94.4)	-0.47 (0.07)	(-0.61, -0.34)	-0.16 (0.11)	(-0.37, 0.06)	0.147
	Placebo	39	37 (94.9)	-0.32 (0.08)	(-0.48, -0.15)			
Week 38	Tezepelumab	54	49 (90.7)	-0.47 (0.07)	(-0.61, -0.33)	-0.12 (0.11)	(-0.34, 0.09)	0.260
	Placebo	39	37 (94.9)	-0.35 (0.08)	(-0.51, -0.18)			
Week 39	Tezepelumab	54	51 (94.4)	-0.52 (0.07)	(-0.66, -0.38)	-0.19 (0.11)	(-0.40, 0.02)	0.080
	Placebo	39	37 (94.9)	-0.33 (0.08)	(-0.49, -0.17)			
Week 40	Tezepelumab	54	52 (96.3)	-0.50 (0.07)	(-0.64, -0.37)	-0.20 (0.11)	(-0.42, 0.01)	0.063
	Placebo	39	37 (94.9)	-0.30 (0.08)	(-0.46, -0.14)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	54	52 (96.3)	-0.50 (0.07)	(-0.64, -0.37)	-0.22 (0.11)	(-0.44, -0.01)	0.040 *
	Placebo	39	36 (92.3)	-0.28 (0.08)	(-0.44, -0.12)			
Week 42	Tezepelumab	54	49 (90.7)	-0.42 (0.07)	(-0.56, -0.28)	-0.10 (0.11)	(-0.32, 0.11)	0.353
	Placebo	39	37 (94.9)	-0.32 (0.08)	(-0.48, -0.15)			
Week 43	Tezepelumab	54	50 (92.6)	-0.49 (0.07)	(-0.63, -0.35)	-0.15 (0.11)	(-0.36, 0.07)	0.172
	Placebo	39	36 (92.3)	-0.34 (0.08)	(-0.50, -0.17)			
Week 44	Tezepelumab	54	50 (92.6)	-0.52 (0.07)	(-0.66, -0.38)	-0.19 (0.11)	(-0.40, 0.03)	0.085
	Placebo	39	35 (89.7)	-0.33 (0.08)	(-0.50, -0.17)			
Week 45	Tezepelumab	54	50 (92.6)	-0.54 (0.07)	(-0.68, -0.40)	-0.17 (0.11)	(-0.39, 0.04)	0.111
	Placebo	39	36 (92.3)	-0.36 (0.08)	(-0.53, -0.20)			
Week 46	Tezepelumab	54	51 (94.4)	-0.49 (0.07)	(-0.63, -0.35)	-0.11 (0.11)	(-0.32, 0.11)	0.332
	Placebo	39	36 (92.3)	-0.38 (0.08)	(-0.55, -0.22)			
Week 47	Tezepelumab	54	49 (90.7)	-0.52 (0.07)	(-0.66, -0.38)	-0.20 (0.11)	(-0.41, 0.02)	0.074
	Placebo	39	36 (92.3)	-0.32 (0.08)	(-0.49, -0.16)			
Week 48	Tezepelumab	54	51 (94.4)	-0.51 (0.07)	(-0.65, -0.37)	-0.16 (0.11)	(-0.38, 0.05)	0.132
	Placebo	39	37 (94.9)	-0.34 (0.08)	(-0.51, -0.18)			
Week 49	Tezepelumab	54	51 (94.4)	-0.49 (0.07)	(-0.63, -0.36)	-0.11 (0.11)	(-0.33, 0.10)	0.293
	Placebo	39	37 (94.9)	-0.38 (0.08)	(-0.54, -0.22)			
Week 50	Tezepelumab	54	50 (92.6)	-0.55 (0.07)	(-0.69, -0.41)	-0.16 (0.11)	(-0.38, 0.05)	0.144
	Placebo	39	35 (89.7)	-0.39 (0.08)	(-0.55, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC_ABMC0: Change from baseline in ASD weekly waking score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	46 (85.2)	-0.52 (0.07)	(-0.67, -0.38)	-0.12 (0.11)	(-0.34, 0.10)	0.286
	Placebo	39	34 (87.2)	-0.41 (0.08)	(-0.57, -0.24)			
Week 52	Tezepelumab	54	42 (77.8)	-0.52 (0.07)	(-0.67, -0.38)	-0.14 (0.11)	(-0.36, 0.08)	0.223
	Placebo	39	32 (82.1)	-0.39 (0.09)	(-0.56, -0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMH0: Course of ASD weekly limiting activity score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	54	54 (100.0)	1.61 (0.70)	0.0	1.00	1.70	2.00	3.4	
		Placebo	39	39 (100.0)	1.82 (0.73)	0.1	1.29	1.86	2.20	3.9	
	Week 1	Tezepelumab	54	53 (98.1)	1.49 (0.68)	0.0	1.00	1.43	2.00	3.0	
		Placebo	39	39 (100.0)	1.59 (0.60)	0.0	1.17	1.67	2.00	2.9	
	Week 2	Tezepelumab	54	53 (98.1)	1.38 (0.75)	0.0	1.00	1.29	2.00	3.0	
		Placebo	39	38 (97.4)	1.51 (0.68)	0.0	1.00	1.29	2.00	3.3	
	Week 3	Tezepelumab	54	54 (100.0)	1.36 (0.75)	0.0	1.00	1.17	1.86	3.0	
		Placebo	39	37 (94.9)	1.52 (0.82)	0.0	1.00	1.29	2.00	3.0	
	Week 4	Tezepelumab	54	54 (100.0)	1.29 (0.74)	0.0	1.00	1.14	1.71	3.0	
		Placebo	39	38 (97.4)	1.50 (0.67)	0.0	1.00	1.36	2.00	2.8	
	Week 5	Tezepelumab	54	53 (98.1)	1.31 (0.75)	0.0	1.00	1.14	1.86	3.0	
		Placebo	39	38 (97.4)	1.39 (0.73)	0.0	1.00	1.23	2.00	3.0	
	Week 6	Tezepelumab	54	52 (96.3)	1.38 (0.80)	0.0	1.00	1.29	1.93	3.0	
		Placebo	39	39 (100.0)	1.47 (0.69)	0.0	1.00	1.43	2.00	3.3	
	Week 7	Tezepelumab	54	51 (94.4)	1.36 (0.87)	0.0	1.00	1.17	2.00	3.4	
		Placebo	39	39 (100.0)	1.43 (0.74)	0.0	1.00	1.43	2.00	4.0	
	Week 8	Tezepelumab	54	53 (98.1)	1.29 (0.80)	0.0	1.00	1.20	2.00	3.0	
		Placebo	39	39 (100.0)	1.50 (0.73)	0.0	1.00	1.33	2.00	3.9	
	Week 9	Tezepelumab	54	54 (100.0)	1.21 (0.74)	0.0	0.83	1.00	2.00	3.0	
		Placebo	39	39 (100.0)	1.41 (0.69)	0.0	1.00	1.33	2.00	2.9	
	Week 10	Tezepelumab	54	53 (98.1)	1.24 (0.78)	0.0	0.71	1.00	2.00	3.0	
		Placebo	39	39 (100.0)	1.45 (0.63)	0.0	1.00	1.43	1.86	2.6	
	Week 11	Tezepelumab	54	53 (98.1)	1.22 (0.82)	0.0	0.83	1.00	1.86	3.0	
		Placebo	39	39 (100.0)	1.34 (0.67)	0.0	1.00	1.29	2.00	2.9	
	Week 12	Tezepelumab	54	53 (98.1)	1.23 (0.80)	0.0	0.71	1.00	2.00	2.9	
		Placebo	39	37 (94.9)	1.35 (0.79)	0.0	1.00	1.14	2.00	3.5	
	Week 13	Tezepelumab	54	51 (94.4)	1.16 (0.84)	0.0	0.43	1.00	1.86	3.1	
		Placebo	39	38 (97.4)	1.34 (0.75)	0.0	1.00	1.29	1.86	3.6	
	Week 14	Tezepelumab	54	52 (96.3)	1.22 (0.82)	0.0	0.77	1.14	1.71	3.0	
		Placebo	39	37 (94.9)	1.40 (0.73)	0.0	1.00	1.17	2.00	2.9	
	Week 15	Tezepelumab	54	52 (96.3)	1.18 (0.77)	0.0	0.79	1.00	1.92	3.0	
		Placebo	39	39 (100.0)	1.31 (0.77)	0.0	0.86	1.14	2.00	3.5	
	Week 16	Tezepelumab	54	53 (98.1)	1.15 (0.79)	0.0	0.57	1.00	2.00	3.0	
		Placebo	39	38 (97.4)	1.36 (0.82)	0.0	1.00	1.15	2.00	3.1	
Week 17	Tezepelumab	54	53 (98.1)	1.12 (0.80)	0.0	0.43	1.00	1.75	3.0		
	Placebo	39	38 (97.4)	1.38 (0.76)	0.0	1.00	1.30	2.00	3.0		

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMH0: Course of ASD weekly limiting activity score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	54	52 (96.3)	1.13 (0.81)	0.0	0.27	1.07	1.93	3.0	
		Placebo	39	38 (97.4)	1.36 (0.78)	0.0	1.00	1.14	2.00	3.7	
	Week 19	Tezepelumab	54	50 (92.6)	1.13 (0.83)	0.0	0.17	1.07	2.00	2.6	
		Placebo	39	38 (97.4)	1.36 (0.73)	0.0	1.00	1.24	2.00	2.9	
	Week 20	Tezepelumab	54	50 (92.6)	1.08 (0.83)	0.0	0.14	1.00	2.00	3.0	
		Placebo	39	38 (97.4)	1.30 (0.74)	0.0	1.00	1.14	2.00	2.6	
	Week 21	Tezepelumab	54	49 (90.7)	1.10 (0.82)	0.0	0.29	1.00	2.00	3.0	
		Placebo	39	37 (94.9)	1.26 (0.82)	0.0	0.86	1.00	2.00	3.0	
	Week 22	Tezepelumab	54	48 (88.9)	1.15 (0.73)	0.0	1.00	1.00	1.85	3.0	
		Placebo	39	38 (97.4)	1.33 (0.80)	0.0	1.00	1.15	2.00	3.0	
	Week 23	Tezepelumab	54	51 (94.4)	1.08 (0.78)	0.0	0.57	1.00	1.71	3.1	
		Placebo	39	36 (92.3)	1.30 (0.73)	0.0	1.00	1.24	2.00	2.9	
	Week 24	Tezepelumab	54	52 (96.3)	1.09 (0.82)	0.0	0.50	1.00	1.93	3.4	
		Placebo	39	37 (94.9)	1.33 (0.76)	0.0	0.83	1.14	2.00	2.9	
	Week 25	Tezepelumab	54	51 (94.4)	1.11 (0.79)	0.0	0.60	1.00	1.86	2.7	
		Placebo	39	36 (92.3)	1.32 (0.79)	0.0	1.00	1.00	2.00	3.0	
	Week 26	Tezepelumab	54	52 (96.3)	1.08 (0.79)	0.0	0.34	1.00	1.64	2.7	
		Placebo	39	37 (94.9)	1.38 (0.90)	0.0	1.00	1.33	2.00	3.4	
	Week 27	Tezepelumab	54	49 (90.7)	1.15 (0.81)	0.0	0.75	1.00	1.86	3.0	
		Placebo	39	35 (89.7)	1.34 (0.93)	0.0	0.83	1.14	2.00	4.0	
	Week 28	Tezepelumab	54	51 (94.4)	1.15 (0.88)	0.0	0.43	1.00	2.00	3.3	
		Placebo	39	37 (94.9)	1.39 (0.88)	0.0	1.00	1.00	2.00	3.1	
	Week 29	Tezepelumab	54	50 (92.6)	1.03 (0.74)	0.0	0.43	1.00	1.57	2.8	
		Placebo	39	36 (92.3)	1.32 (0.92)	0.0	0.85	1.00	2.00	3.3	
	Week 30	Tezepelumab	54	48 (88.9)	1.17 (0.78)	0.0	0.69	1.14	1.79	3.0	
		Placebo	39	36 (92.3)	1.27 (0.90)	0.0	0.57	1.00	2.00	3.0	
	Week 31	Tezepelumab	54	52 (96.3)	1.14 (0.79)	0.0	0.86	1.00	1.68	3.0	
		Placebo	39	36 (92.3)	1.20 (0.89)	0.0	0.50	1.00	2.00	3.3	
	Week 32	Tezepelumab	54	51 (94.4)	1.08 (0.76)	0.0	0.50	1.00	1.50	2.7	
		Placebo	39	36 (92.3)	1.20 (0.87)	0.0	0.57	1.00	1.86	3.0	
	Week 33	Tezepelumab	54	51 (94.4)	1.09 (0.78)	0.0	0.29	1.00	1.71	3.0	
		Placebo	39	37 (94.9)	1.28 (0.85)	0.0	0.57	1.00	2.00	3.0	
	Week 34	Tezepelumab	54	51 (94.4)	1.03 (0.80)	0.0	0.00	1.00	1.57	3.0	
		Placebo	39	37 (94.9)	1.23 (0.82)	0.0	0.71	1.00	1.86	3.0	
	Week 35	Tezepelumab	54	49 (90.7)	1.11 (0.80)	0.0	0.57	1.00	1.57	3.0	
		Placebo	39	36 (92.3)	1.19 (0.83)	0.0	0.64	1.00	2.00	3.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMH0: Course of ASD weekly limiting activity score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	54	50 (92.6)	1.12 (0.81)	0.0	0.57	1.00	1.71	3.0	
		Placebo	39	37 (94.9)	1.28 (0.76)	0.0	0.83	1.00	1.83	3.0	
	Week 37	Tezepelumab	54	49 (90.7)	1.19 (0.81)	0.0	0.86	1.00	2.00	3.0	
		Placebo	39	37 (94.9)	1.32 (0.79)	0.0	1.00	1.00	1.86	3.0	
	Week 38	Tezepelumab	54	50 (92.6)	1.16 (0.87)	0.0	0.50	1.00	2.00	3.0	
		Placebo	39	37 (94.9)	1.27 (0.87)	0.0	0.71	1.00	2.00	3.0	
	Week 39	Tezepelumab	54	51 (94.4)	1.10 (0.85)	0.0	0.29	1.00	2.00	3.0	
		Placebo	39	37 (94.9)	1.23 (0.90)	0.0	0.43	1.00	2.00	3.0	
	Week 40	Tezepelumab	54	51 (94.4)	1.11 (0.80)	0.0	0.57	1.00	1.71	3.0	
		Placebo	39	37 (94.9)	1.24 (0.92)	0.0	0.57	1.00	2.00	3.0	
	Week 41	Tezepelumab	54	52 (96.3)	1.13 (0.83)	0.0	0.77	1.00	1.77	3.0	
		Placebo	39	36 (92.3)	1.34 (0.96)	0.0	0.79	1.00	2.00	3.4	
	Week 42	Tezepelumab	54	50 (92.6)	1.19 (0.85)	0.0	0.40	1.00	2.00	3.0	
		Placebo	39	37 (94.9)	1.30 (0.91)	0.0	0.71	1.14	2.00	3.1	
	Week 43	Tezepelumab	54	50 (92.6)	1.12 (0.86)	0.0	0.20	1.00	2.00	3.1	
		Placebo	39	37 (94.9)	1.28 (0.90)	0.0	0.86	1.17	2.00	3.0	
	Week 44	Tezepelumab	54	49 (90.7)	1.05 (0.77)	0.0	0.14	1.00	1.71	2.7	
		Placebo	39	35 (89.7)	1.30 (0.84)	0.0	0.86	1.14	2.00	3.0	
	Week 45	Tezepelumab	54	50 (92.6)	1.10 (0.84)	0.0	0.43	1.00	2.00	3.3	
		Placebo	39	37 (94.9)	1.15 (0.84)	0.0	1.00	1.00	1.71	3.0	
	Week 46	Tezepelumab	54	51 (94.4)	1.11 (0.79)	0.0	0.40	1.00	2.00	2.9	
		Placebo	39	36 (92.3)	1.16 (0.89)	0.0	0.36	1.00	2.00	3.0	
	Week 47	Tezepelumab	54	45 (83.3)	1.11 (0.80)	0.0	0.57	1.00	1.86	3.0	
		Placebo	39	37 (94.9)	1.15 (0.87)	0.0	0.33	1.00	2.00	3.0	
	Week 48	Tezepelumab	54	50 (92.6)	1.17 (0.82)	0.0	0.83	1.07	2.00	3.0	
		Placebo	39	36 (92.3)	1.13 (0.88)	0.0	0.43	1.00	1.71	3.0	
	Week 49	Tezepelumab	54	48 (88.9)	1.26 (0.88)	0.0	0.93	1.00	2.00	2.9	
		Placebo	39	36 (92.3)	1.15 (0.88)	0.0	0.24	1.00	1.93	3.0	
	Week 50	Tezepelumab	54	48 (88.9)	1.15 (0.78)	0.0	0.88	1.00	1.93	3.0	
		Placebo	39	35 (89.7)	1.08 (0.82)	0.0	0.14	1.00	1.71	3.0	
	Week 51	Tezepelumab	54	46 (85.2)	1.19 (0.80)	0.0	1.00	1.00	2.00	3.0	
		Placebo	39	32 (82.1)	1.09 (0.88)	0.0	0.00	1.00	1.61	3.0	
	Week 52	Tezepelumab	54	42 (77.8)	1.22 (0.81)	0.0	1.00	1.14	2.00	2.9	
		Placebo	39	32 (82.1)	1.17 (0.90)	0.0	0.45	1.00	1.69	3.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMH0: Course of ASD weekly limiting activity score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	54	53 (98.1)	-0.13 (0.52)	-1.8	-0.29	0.00	0.14	0.9	0.20 [-0.22, 0.61]
		Placebo	39	39 (100.0)	-0.23 (0.46)	-1.7	-0.55	-0.14	0.00	0.5	
	Week 2	Tezepelumab	54	53 (98.1)	-0.23 (0.55)	-2.2	-0.43	-0.14	0.00	0.6	0.14 [-0.27, 0.56]
		Placebo	39	38 (97.4)	-0.32 (0.69)	-2.1	-0.71	-0.14	0.00	1.3	
	Week 3	Tezepelumab	54	54 (100.0)	-0.25 (0.66)	-2.2	-0.43	-0.14	0.00	1.0	0.09 [-0.33, 0.50]
		Placebo	39	37 (94.9)	-0.31 (0.83)	-2.9	-0.43	-0.14	0.00	1.0	
	Week 4	Tezepelumab	54	54 (100.0)	-0.32 (0.59)	-2.2	-0.57	-0.14	0.00	1.1	0.00 [-0.41, 0.42]
		Placebo	39	38 (97.4)	-0.32 (0.70)	-2.5	-0.40	-0.13	0.00	0.9	
	Week 5	Tezepelumab	54	53 (98.1)	-0.31 (0.55)	-2.2	-0.57	-0.14	0.00	0.9	0.18 [-0.23, 0.60]
		Placebo	39	38 (97.4)	-0.43 (0.79)	-2.7	-0.86	-0.14	0.00	1.0	
	Week 6	Tezepelumab	54	52 (96.3)	-0.24 (0.58)	-2.2	-0.43	-0.14	0.13	0.9	0.16 [-0.25, 0.58]
		Placebo	39	39 (100.0)	-0.34 (0.68)	-2.7	-0.57	-0.14	0.02	0.9	
	Week 7	Tezepelumab	54	51 (94.4)	-0.24 (0.69)	-2.2	-0.67	0.00	0.14	1.4	0.20 [-0.22, 0.62]
		Placebo	39	39 (100.0)	-0.38 (0.71)	-2.5	-0.86	-0.14	0.00	0.9	
	Week 8	Tezepelumab	54	53 (98.1)	-0.31 (0.68)	-2.2	-0.67	-0.14	0.00	1.2	0.01 [-0.40, 0.43]
		Placebo	39	39 (100.0)	-0.32 (0.73)	-2.7	-0.67	0.00	0.14	0.9	
	Week 9	Tezepelumab	54	54 (100.0)	-0.39 (0.74)	-2.4	-0.86	-0.17	0.00	1.0	0.02 [-0.39, 0.43]
		Placebo	39	39 (100.0)	-0.41 (0.73)	-2.7	-0.81	-0.17	0.00	0.9	
	Week 10	Tezepelumab	54	53 (98.1)	-0.36 (0.69)	-2.2	-0.86	-0.14	0.00	1.0	0.01 [-0.40, 0.42]
		Placebo	39	39 (100.0)	-0.37 (0.73)	-2.7	-0.91	-0.14	0.12	0.7	
	Week 11	Tezepelumab	54	53 (98.1)	-0.37 (0.70)	-2.2	-0.86	-0.17	0.00	1.0	0.14 [-0.27, 0.56]
		Placebo	39	39 (100.0)	-0.48 (0.78)	-2.7	-1.00	-0.29	0.14	0.9	
	Week 12	Tezepelumab	54	53 (98.1)	-0.39 (0.72)	-2.2	-0.86	-0.14	0.00	1.0	0.12 [-0.30, 0.54]
		Placebo	39	37 (94.9)	-0.49 (0.93)	-2.7	-1.00	-0.14	0.00	2.3	
	Week 13	Tezepelumab	54	51 (94.4)	-0.44 (0.78)	-2.2	-0.86	-0.29	0.00	1.3	0.06 [-0.36, 0.48]
		Placebo	39	38 (97.4)	-0.49 (0.88)	-2.7	-1.00	-0.29	0.00	2.4	
	Week 14	Tezepelumab	54	52 (96.3)	-0.39 (0.73)	-2.2	-0.79	-0.15	0.00	1.1	0.06 [-0.36, 0.48]
		Placebo	39	37 (94.9)	-0.44 (0.92)	-2.6	-1.06	-0.29	0.00	1.7	
	Week 15	Tezepelumab	54	52 (96.3)	-0.41 (0.70)	-2.2	-0.86	-0.20	0.00	0.8	0.12 [-0.30, 0.53]
		Placebo	39	39 (100.0)	-0.50 (0.94)	-2.7	-1.29	-0.29	0.00	2.3	
	Week 16	Tezepelumab	54	53 (98.1)	-0.47 (0.69)	-2.2	-0.79	-0.29	0.00	0.6	0.00 [-0.42, 0.42]
		Placebo	39	38 (97.4)	-0.47 (0.91)	-2.7	-1.00	-0.29	0.00	2.0	
	Week 17	Tezepelumab	54	53 (98.1)	-0.50 (0.72)	-2.4	-0.86	-0.43	0.00	0.6	-0.07 [-0.48, 0.35]
		Placebo	39	38 (97.4)	-0.44 (0.84)	-2.7	-1.00	-0.29	0.00	1.7	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMH0: Course of ASD weekly limiting activity score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	54	52 (96.3)	-0.50 (0.78)	-2.4	-1.00	-0.31	0.00	1.0	-0.06 [-0.48, 0.36]
		Placebo	39	38 (97.4)	-0.45 (0.82)	-2.7	-0.86	-0.29	0.00	1.7	
	Week 19	Tezepelumab	54	50 (92.6)	-0.48 (0.79)	-2.4	-0.86	-0.29	0.00	0.9	-0.04 [-0.46, 0.38]
		Placebo	39	38 (97.4)	-0.45 (0.84)	-2.7	-1.00	-0.29	0.00	1.5	
	Week 20	Tezepelumab	54	50 (92.6)	-0.53 (0.75)	-2.4	-1.00	-0.29	0.00	0.6	-0.03 [-0.45, 0.39]
		Placebo	39	38 (97.4)	-0.51 (0.84)	-2.7	-1.00	-0.21	0.00	1.2	
	Week 21	Tezepelumab	54	49 (90.7)	-0.54 (0.79)	-2.4	-1.04	-0.29	0.00	0.9	0.03 [-0.39, 0.46]
		Placebo	39	37 (94.9)	-0.57 (0.91)	-2.7	-1.00	-0.43	0.00	1.8	
	Week 22	Tezepelumab	54	48 (88.9)	-0.48 (0.76)	-2.4	-0.93	-0.29	0.00	0.9	0.02 [-0.40, 0.45]
		Placebo	39	38 (97.4)	-0.50 (0.92)	-2.7	-1.00	-0.21	0.00	1.8	
	Week 23	Tezepelumab	54	51 (94.4)	-0.54 (0.76)	-2.4	-1.03	-0.29	0.00	0.7	0.02 [-0.41, 0.44]
		Placebo	39	36 (92.3)	-0.56 (0.81)	-2.7	-1.06	-0.36	0.00	0.9	
	Week 24	Tezepelumab	54	52 (96.3)	-0.52 (0.79)	-2.4	-1.07	-0.29	0.00	0.9	-0.00 [-0.43, 0.42]
		Placebo	39	37 (94.9)	-0.52 (0.85)	-2.7	-1.00	-0.23	0.00	0.9	
	Week 25	Tezepelumab	54	51 (94.4)	-0.52 (0.74)	-2.4	-1.00	-0.29	0.00	0.9	-0.00 [-0.43, 0.42]
		Placebo	39	36 (92.3)	-0.52 (0.89)	-2.7	-1.10	-0.26	0.00	1.4	
	Week 26	Tezepelumab	54	52 (96.3)	-0.51 (0.75)	-2.2	-1.00	-0.29	0.00	0.9	-0.05 [-0.47, 0.37]
		Placebo	39	37 (94.9)	-0.47 (1.00)	-2.7	-1.11	-0.24	0.14	1.6	
	Week 27	Tezepelumab	54	49 (90.7)	-0.44 (0.75)	-2.4	-0.86	-0.17	0.00	0.7	0.09 [-0.34, 0.53]
		Placebo	39	35 (89.7)	-0.52 (1.01)	-2.7	-1.20	-0.29	0.00	2.0	
	Week 28	Tezepelumab	54	51 (94.4)	-0.43 (0.81)	-2.4	-1.00	-0.29	0.00	1.1	0.03 [-0.39, 0.45]
		Placebo	39	37 (94.9)	-0.46 (0.94)	-2.7	-1.11	-0.29	0.00	1.6	
	Week 29	Tezepelumab	54	50 (92.6)	-0.55 (0.75)	-2.4	-0.86	-0.29	0.00	0.9	-0.05 [-0.48, 0.38]
		Placebo	39	36 (92.3)	-0.51 (1.04)	-2.7	-1.23	-0.36	0.08	1.9	
	Week 30	Tezepelumab	54	48 (88.9)	-0.51 (0.67)	-2.4	-0.86	-0.31	0.00	0.4	0.13 [-0.31, 0.56]
		Placebo	39	36 (92.3)	-0.62 (0.97)	-2.7	-1.29	-0.57	0.05	1.6	
	Week 31	Tezepelumab	54	52 (96.3)	-0.49 (0.76)	-2.4	-1.00	-0.41	0.00	1.0	0.16 [-0.27, 0.58]
		Placebo	39	36 (92.3)	-0.63 (1.02)	-2.7	-1.56	-0.50	0.00	1.9	
	Week 32	Tezepelumab	54	51 (94.4)	-0.57 (0.76)	-2.4	-1.00	-0.43	0.00	1.1	0.07 [-0.35, 0.50]
		Placebo	39	36 (92.3)	-0.63 (0.99)	-2.7	-1.39	-0.64	0.00	1.6	
	Week 33	Tezepelumab	54	51 (94.4)	-0.53 (0.77)	-2.4	-1.00	-0.29	0.00	0.9	0.03 [-0.39, 0.46]
		Placebo	39	37 (94.9)	-0.56 (0.96)	-2.7	-1.12	-0.43	0.00	1.6	
	Week 34	Tezepelumab	54	51 (94.4)	-0.61 (0.69)	-2.4	-1.00	-0.54	0.00	0.4	0.00 [-0.42, 0.42]
		Placebo	39	37 (94.9)	-0.61 (0.96)	-2.7	-1.14	-0.54	0.00	1.6	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMH0: Course of ASD weekly limiting activity score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	54	49 (90.7)	-0.52 (0.76)	-2.4	-0.98	-0.29	0.00	0.9	0.21 [-0.22, 0.64]
		Placebo	39	36 (92.3)	-0.70 (0.96)	-2.7	-1.57	-0.43	-0.07	1.3	
	Week 36	Tezepelumab	54	50 (92.6)	-0.50 (0.72)	-2.3	-0.86	-0.36	0.00	0.9	0.08 [-0.35, 0.50]
		Placebo	39	37 (94.9)	-0.56 (0.87)	-2.7	-1.17	-0.31	0.00	1.1	
	Week 37	Tezepelumab	54	49 (90.7)	-0.43 (0.74)	-2.4	-0.86	-0.29	0.00	1.1	0.10 [-0.33, 0.53]
		Placebo	39	37 (94.9)	-0.51 (0.90)	-2.7	-1.00	-0.40	0.00	1.6	
	Week 38	Tezepelumab	54	50 (92.6)	-0.46 (0.82)	-2.6	-0.86	-0.32	0.00	1.4	0.13 [-0.30, 0.55]
		Placebo	39	37 (94.9)	-0.57 (0.88)	-2.6	-1.00	-0.29	0.00	1.3	
	Week 39	Tezepelumab	54	51 (94.4)	-0.50 (0.78)	-2.3	-1.00	-0.29	0.00	0.9	0.12 [-0.30, 0.55]
		Placebo	39	37 (94.9)	-0.61 (0.89)	-2.7	-1.11	-0.29	0.00	0.9	
	Week 40	Tezepelumab	54	51 (94.4)	-0.52 (0.75)	-2.4	-1.00	-0.29	0.00	0.9	0.09 [-0.33, 0.52]
		Placebo	39	37 (94.9)	-0.60 (0.92)	-2.7	-1.20	-0.29	0.00	1.1	
	Week 41	Tezepelumab	54	52 (96.3)	-0.51 (0.75)	-2.4	-0.86	-0.29	0.00	0.9	-0.03 [-0.45, 0.40]
		Placebo	39	36 (92.3)	-0.49 (1.02)	-2.7	-1.20	-0.21	0.00	2.1	
	Week 42	Tezepelumab	54	50 (92.6)	-0.46 (0.75)	-2.4	-0.86	-0.21	0.00	0.9	0.10 [-0.33, 0.52]
		Placebo	39	37 (94.9)	-0.54 (0.89)	-2.5	-1.11	-0.14	0.10	1.1	
	Week 43	Tezepelumab	54	50 (92.6)	-0.50 (0.74)	-2.4	-0.86	-0.29	0.00	0.9	0.07 [-0.36, 0.49]
		Placebo	39	37 (94.9)	-0.56 (0.89)	-2.7	-1.00	-0.31	0.00	1.2	
	Week 44	Tezepelumab	54	49 (90.7)	-0.58 (0.72)	-2.4	-1.00	-0.43	0.00	0.9	-0.02 [-0.46, 0.41]
		Placebo	39	35 (89.7)	-0.56 (0.90)	-2.7	-1.14	-0.29	0.00	1.4	
	Week 45	Tezepelumab	54	50 (92.6)	-0.53 (0.74)	-2.2	-1.00	-0.29	0.00	0.9	0.20 [-0.23, 0.62]
		Placebo	39	37 (94.9)	-0.69 (0.91)	-2.7	-1.20	-0.71	0.00	1.6	
	Week 46	Tezepelumab	54	51 (94.4)	-0.52 (0.77)	-2.4	-1.00	-0.29	0.00	0.9	0.18 [-0.25, 0.60]
		Placebo	39	36 (92.3)	-0.67 (0.95)	-2.7	-1.40	-0.66	0.00	1.3	
	Week 47	Tezepelumab	54	45 (83.3)	-0.50 (0.86)	-2.4	-1.00	-0.29	0.00	1.9	0.21 [-0.22, 0.65]
		Placebo	39	37 (94.9)	-0.69 (0.91)	-2.7	-1.29	-0.36	0.00	1.1	
	Week 48	Tezepelumab	54	50 (92.6)	-0.43 (0.85)	-2.4	-1.00	-0.14	0.00	1.4	0.31 [-0.12, 0.74]
		Placebo	39	36 (92.3)	-0.70 (0.91)	-2.7	-1.24	-0.59	-0.01	1.1	
	Week 49	Tezepelumab	54	48 (88.9)	-0.39 (0.83)	-2.4	-1.00	0.00	0.00	1.0	0.34 [-0.09, 0.78]
		Placebo	39	36 (92.3)	-0.68 (0.85)	-2.7	-1.14	-0.31	0.00	0.7	
	Week 50	Tezepelumab	54	48 (88.9)	-0.46 (0.78)	-2.4	-0.93	-0.27	0.00	1.4	0.35 [-0.09, 0.79]
		Placebo	39	35 (89.7)	-0.74 (0.85)	-2.7	-1.43	-0.45	0.00	0.3	
	Week 51	Tezepelumab	54	46 (85.2)	-0.46 (0.76)	-2.4	-0.94	-0.29	0.00	1.0	0.39 [-0.07, 0.84]
		Placebo	39	32 (82.1)	-0.77 (0.88)	-2.7	-1.43	-0.63	-0.07	0.4	
	Week 52	Tezepelumab	54	42 (77.8)	-0.42 (0.79)	-2.4	-0.86	-0.21	0.00	0.9	0.37 [-0.09, 0.84]
		Placebo	39	32 (82.1)	-0.72 (0.87)	-2.7	-1.32	-0.63	-0.14	0.7	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	54	53 (98.1)	-0.17 (0.10)	(-0.36, 0.02)	0.00 (0.15)	(-0.29, 0.30)	0.978
	Placebo	39	39 (100.0)	-0.18 (0.11)	(-0.40, 0.05)			
Week 2	Tezepelumab	54	53 (98.1)	-0.28 (0.10)	(-0.46, -0.09)	-0.02 (0.15)	(-0.31, 0.27)	0.875
	Placebo	39	38 (97.4)	-0.25 (0.11)	(-0.47, -0.03)			
Week 3	Tezepelumab	54	54 (100.0)	-0.30 (0.10)	(-0.49, -0.11)	-0.07 (0.15)	(-0.36, 0.22)	0.654
	Placebo	39	37 (94.9)	-0.23 (0.11)	(-0.45, -0.01)			
Week 4	Tezepelumab	54	54 (100.0)	-0.37 (0.10)	(-0.55, -0.18)	-0.11 (0.15)	(-0.40, 0.18)	0.466
	Placebo	39	38 (97.4)	-0.26 (0.11)	(-0.48, -0.04)			
Week 5	Tezepelumab	54	53 (98.1)	-0.35 (0.10)	(-0.54, -0.16)	0.02 (0.15)	(-0.27, 0.31)	0.876
	Placebo	39	38 (97.4)	-0.37 (0.11)	(-0.59, -0.15)			
Week 6	Tezepelumab	54	52 (96.3)	-0.26 (0.10)	(-0.45, -0.07)	0.04 (0.15)	(-0.26, 0.33)	0.813
	Placebo	39	39 (100.0)	-0.29 (0.11)	(-0.51, -0.07)			
Week 7	Tezepelumab	54	51 (94.4)	-0.28 (0.10)	(-0.47, -0.09)	0.05 (0.15)	(-0.24, 0.34)	0.725
	Placebo	39	39 (100.0)	-0.33 (0.11)	(-0.55, -0.11)			
Week 8	Tezepelumab	54	53 (98.1)	-0.35 (0.10)	(-0.54, -0.16)	-0.08 (0.15)	(-0.37, 0.21)	0.573
	Placebo	39	39 (100.0)	-0.27 (0.11)	(-0.49, -0.04)			
Week 9	Tezepelumab	54	54 (100.0)	-0.44 (0.10)	(-0.63, -0.25)	-0.08 (0.15)	(-0.37, 0.21)	0.580
	Placebo	39	39 (100.0)	-0.36 (0.11)	(-0.58, -0.14)			
Week 10	Tezepelumab	54	53 (98.1)	-0.42 (0.10)	(-0.61, -0.23)	-0.10 (0.15)	(-0.39, 0.19)	0.504
	Placebo	39	39 (100.0)	-0.32 (0.11)	(-0.54, -0.10)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	54	53 (98.1)	-0.44 (0.10)	(-0.62, -0.25)	-0.01 (0.15)	(-0.30, 0.28)	0.948
	Placebo	39	39 (100.0)	-0.43 (0.11)	(-0.65, -0.21)			
Week 12	Tezepelumab	54	53 (98.1)	-0.42 (0.10)	(-0.61, -0.23)	-0.01 (0.15)	(-0.30, 0.28)	0.964
	Placebo	39	37 (94.9)	-0.41 (0.11)	(-0.63, -0.19)			
Week 13	Tezepelumab	54	51 (94.4)	-0.46 (0.10)	(-0.65, -0.28)	-0.04 (0.15)	(-0.33, 0.26)	0.814
	Placebo	39	38 (97.4)	-0.43 (0.11)	(-0.65, -0.21)			
Week 14	Tezepelumab	54	52 (96.3)	-0.41 (0.10)	(-0.60, -0.22)	-0.05 (0.15)	(-0.34, 0.24)	0.738
	Placebo	39	37 (94.9)	-0.36 (0.11)	(-0.58, -0.14)			
Week 15	Tezepelumab	54	52 (96.3)	-0.44 (0.10)	(-0.63, -0.25)	0.02 (0.15)	(-0.27, 0.31)	0.898
	Placebo	39	39 (100.0)	-0.46 (0.11)	(-0.68, -0.23)			
Week 16	Tezepelumab	54	53 (98.1)	-0.50 (0.10)	(-0.69, -0.31)	-0.09 (0.15)	(-0.38, 0.21)	0.563
	Placebo	39	38 (97.4)	-0.41 (0.11)	(-0.63, -0.19)			
Week 17	Tezepelumab	54	53 (98.1)	-0.53 (0.10)	(-0.72, -0.34)	-0.14 (0.15)	(-0.43, 0.15)	0.357
	Placebo	39	38 (97.4)	-0.39 (0.11)	(-0.61, -0.17)			
Week 18	Tezepelumab	54	52 (96.3)	-0.52 (0.10)	(-0.71, -0.33)	-0.13 (0.15)	(-0.42, 0.16)	0.381
	Placebo	39	38 (97.4)	-0.39 (0.11)	(-0.61, -0.16)			
Week 19	Tezepelumab	54	50 (92.6)	-0.51 (0.10)	(-0.70, -0.32)	-0.13 (0.15)	(-0.42, 0.16)	0.380
	Placebo	39	38 (97.4)	-0.38 (0.11)	(-0.60, -0.16)			
Week 20	Tezepelumab	54	50 (92.6)	-0.55 (0.10)	(-0.74, -0.36)	-0.07 (0.15)	(-0.36, 0.23)	0.657
	Placebo	39	38 (97.4)	-0.48 (0.11)	(-0.71, -0.26)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
DITTB - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	54	49 (90.7)	-0.57 (0.10)	(-0.76, -0.38)	-0.08 (0.15)	(-0.37, 0.22)	0.602
	Placebo	39	37 (94.9)	-0.49 (0.11)	(-0.72, -0.27)			
Week 22	Tezepelumab	54	48 (88.9)	-0.53 (0.10)	(-0.72, -0.34)	-0.08 (0.15)	(-0.38, 0.21)	0.584
	Placebo	39	38 (97.4)	-0.45 (0.11)	(-0.67, -0.22)			
Week 23	Tezepelumab	54	51 (94.4)	-0.58 (0.10)	(-0.76, -0.39)	-0.15 (0.15)	(-0.44, 0.15)	0.323
	Placebo	39	36 (92.3)	-0.43 (0.11)	(-0.65, -0.20)			
Week 24	Tezepelumab	54	52 (96.3)	-0.54 (0.10)	(-0.73, -0.35)	-0.14 (0.15)	(-0.43, 0.16)	0.355
	Placebo	39	37 (94.9)	-0.40 (0.11)	(-0.63, -0.18)			
Week 25	Tezepelumab	54	51 (94.4)	-0.54 (0.10)	(-0.73, -0.35)	-0.15 (0.15)	(-0.44, 0.15)	0.332
	Placebo	39	36 (92.3)	-0.40 (0.11)	(-0.62, -0.17)			
Week 26	Tezepelumab	54	52 (96.3)	-0.54 (0.10)	(-0.73, -0.35)	-0.18 (0.15)	(-0.47, 0.11)	0.228
	Placebo	39	37 (94.9)	-0.36 (0.11)	(-0.59, -0.14)			
Week 27	Tezepelumab	54	49 (90.7)	-0.48 (0.10)	(-0.67, -0.29)	-0.08 (0.15)	(-0.37, 0.22)	0.597
	Placebo	39	35 (89.7)	-0.40 (0.11)	(-0.63, -0.18)			
Week 28	Tezepelumab	54	51 (94.4)	-0.49 (0.10)	(-0.68, -0.30)	-0.14 (0.15)	(-0.43, 0.16)	0.364
	Placebo	39	37 (94.9)	-0.36 (0.11)	(-0.58, -0.13)			
Week 29	Tezepelumab	54	50 (92.6)	-0.61 (0.10)	(-0.80, -0.42)	-0.18 (0.15)	(-0.48, 0.11)	0.227
	Placebo	39	36 (92.3)	-0.43 (0.11)	(-0.65, -0.20)			
Week 30	Tezepelumab	54	48 (88.9)	-0.53 (0.10)	(-0.72, -0.34)	-0.02 (0.15)	(-0.32, 0.27)	0.882
	Placebo	39	36 (92.3)	-0.51 (0.11)	(-0.74, -0.29)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	54	52 (96.3)	-0.52 (0.10)	(-0.71, -0.33)	0.03 (0.15)	(-0.26, 0.33)	0.824
	Placebo	39	36 (92.3)	-0.55 (0.11)	(-0.78, -0.33)			
Week 32	Tezepelumab	54	51 (94.4)	-0.59 (0.10)	(-0.78, -0.40)	-0.04 (0.15)	(-0.33, 0.26)	0.802
	Placebo	39	36 (92.3)	-0.55 (0.12)	(-0.78, -0.32)			
Week 33	Tezepelumab	54	51 (94.4)	-0.58 (0.10)	(-0.77, -0.40)	-0.09 (0.15)	(-0.38, 0.21)	0.557
	Placebo	39	37 (94.9)	-0.50 (0.12)	(-0.72, -0.27)			
Week 34	Tezepelumab	54	51 (94.4)	-0.62 (0.10)	(-0.81, -0.44)	-0.08 (0.15)	(-0.38, 0.21)	0.584
	Placebo	39	37 (94.9)	-0.54 (0.12)	(-0.77, -0.32)			
Week 35	Tezepelumab	54	49 (90.7)	-0.56 (0.10)	(-0.75, -0.37)	0.04 (0.15)	(-0.26, 0.33)	0.798
	Placebo	39	36 (92.3)	-0.60 (0.12)	(-0.83, -0.37)			
Week 36	Tezepelumab	54	50 (92.6)	-0.51 (0.10)	(-0.70, -0.32)	-0.01 (0.15)	(-0.31, 0.28)	0.935
	Placebo	39	37 (94.9)	-0.49 (0.12)	(-0.72, -0.27)			
Week 37	Tezepelumab	54	49 (90.7)	-0.51 (0.10)	(-0.70, -0.32)	-0.06 (0.15)	(-0.36, 0.23)	0.681
	Placebo	39	37 (94.9)	-0.45 (0.12)	(-0.68, -0.22)			
Week 38	Tezepelumab	54	50 (92.6)	-0.48 (0.10)	(-0.67, -0.30)	0.02 (0.15)	(-0.28, 0.32)	0.891
	Placebo	39	37 (94.9)	-0.51 (0.12)	(-0.73, -0.28)			
Week 39	Tezepelumab	54	51 (94.4)	-0.54 (0.10)	(-0.73, -0.35)	0.00 (0.15)	(-0.29, 0.30)	0.993
	Placebo	39	37 (94.9)	-0.54 (0.12)	(-0.77, -0.32)			
Week 40	Tezepelumab	54	51 (94.4)	-0.55 (0.10)	(-0.74, -0.36)	-0.02 (0.15)	(-0.31, 0.28)	0.910
	Placebo	39	37 (94.9)	-0.54 (0.12)	(-0.76, -0.31)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	54	52 (96.3)	-0.54 (0.10)	(-0.73, -0.35)	-0.09 (0.15)	(-0.39, 0.20)	0.537
	Placebo	39	36 (92.3)	-0.44 (0.12)	(-0.67, -0.22)			
Week 42	Tezepelumab	54	50 (92.6)	-0.48 (0.10)	(-0.67, -0.29)	-0.01 (0.15)	(-0.30, 0.29)	0.961
	Placebo	39	37 (94.9)	-0.48 (0.12)	(-0.70, -0.25)			
Week 43	Tezepelumab	54	50 (92.6)	-0.54 (0.10)	(-0.73, -0.34)	-0.04 (0.15)	(-0.34, 0.26)	0.786
	Placebo	39	37 (94.9)	-0.49 (0.12)	(-0.72, -0.27)			
Week 44	Tezepelumab	54	49 (90.7)	-0.60 (0.10)	(-0.79, -0.41)	-0.08 (0.15)	(-0.38, 0.21)	0.576
	Placebo	39	35 (89.7)	-0.51 (0.12)	(-0.74, -0.29)			
Week 45	Tezepelumab	54	50 (92.6)	-0.57 (0.10)	(-0.76, -0.38)	0.05 (0.15)	(-0.24, 0.35)	0.727
	Placebo	39	37 (94.9)	-0.63 (0.12)	(-0.85, -0.40)			
Week 46	Tezepelumab	54	51 (94.4)	-0.55 (0.10)	(-0.74, -0.36)	0.04 (0.15)	(-0.26, 0.34)	0.788
	Placebo	39	36 (92.3)	-0.59 (0.12)	(-0.82, -0.36)			
Week 47	Tezepelumab	54	45 (83.3)	-0.56 (0.10)	(-0.76, -0.37)	0.06 (0.15)	(-0.23, 0.36)	0.675
	Placebo	39	37 (94.9)	-0.63 (0.12)	(-0.85, -0.40)			
Week 48	Tezepelumab	54	50 (92.6)	-0.49 (0.10)	(-0.68, -0.30)	0.13 (0.15)	(-0.17, 0.43)	0.390
	Placebo	39	36 (92.3)	-0.62 (0.12)	(-0.85, -0.39)			
Week 49	Tezepelumab	54	48 (88.9)	-0.45 (0.10)	(-0.64, -0.25)	0.17 (0.15)	(-0.12, 0.47)	0.250
	Placebo	39	36 (92.3)	-0.62 (0.12)	(-0.85, -0.39)			
Week 50	Tezepelumab	54	48 (88.9)	-0.52 (0.10)	(-0.71, -0.32)	0.13 (0.15)	(-0.17, 0.43)	0.398
	Placebo	39	35 (89.7)	-0.65 (0.12)	(-0.88, -0.42)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC_ABMC0: Change from baseline in ASD weekly limiting activity score - MMRM results
 DITTB - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	54	46 (85.2)	-0.51 (0.10)	(-0.70, -0.31)	0.16 (0.15)	(-0.14, 0.46)	0.301
	Placebo	39	32 (82.1)	-0.67 (0.12)	(-0.90, -0.43)			
Week 52	Tezepelumab	54	42 (77.8)	-0.48 (0.10)	(-0.68, -0.28)	0.12 (0.16)	(-0.19, 0.43)	0.440
	Placebo	39	32 (82.1)	-0.60 (0.12)	(-0.83, -0.36)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table MT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	66	64 (97.0)	64.0 (16.9)	26	50.0	65.5	80.0	95	
		Placebo	48	46 (95.8)	61.2 (15.7)	37	50.0	61.0	75.0	96	
	Week 2	Tezepelumab	66	62 (93.9)	65.9 (16.1)	30	53.0	68.0	80.0	98	
		Placebo	48	44 (91.7)	65.8 (17.9)	5	54.0	67.0	76.5	98	
	Week 4	Tezepelumab	66	64 (97.0)	70.5 (14.2)	37	60.0	71.0	80.0	95	
		Placebo	48	45 (93.8)	65.1 (18.1)	19	50.0	63.0	79.0	96	
	Week 6	Tezepelumab	66	62 (93.9)	68.9 (15.8)	24	59.0	69.5	81.0	100	
		Placebo	48	44 (91.7)	65.7 (17.8)	22	51.5	69.0	80.5	95	
	Week 8	Tezepelumab	66	64 (97.0)	66.8 (18.5)	0	54.0	70.0	80.0	98	
		Placebo	48	46 (95.8)	64.3 (19.3)	14	50.0	66.0	79.0	96	
	Week 10	Tezepelumab	66	62 (93.9)	71.1 (16.5)	35	60.0	76.5	83.0	100	
		Placebo	48	43 (89.6)	65.2 (18.9)	27	50.0	66.0	80.0	97	
	Week 12	Tezepelumab	66	63 (95.5)	69.0 (16.5)	35	58.0	68.0	84.0	98	
		Placebo	48	45 (93.8)	64.8 (19.6)	31	46.0	70.0	81.0	95	
	Week 14	Tezepelumab	66	60 (90.9)	69.1 (17.9)	35	52.0	70.5	82.5	100	
		Placebo	48	44 (91.7)	66.0 (18.1)	25	54.5	70.0	78.5	96	
	Week 16	Tezepelumab	66	63 (95.5)	68.3 (17.5)	30	52.0	68.0	84.0	96	
		Placebo	48	45 (93.8)	67.9 (18.2)	29	55.0	72.0	83.0	94	
	Week 18	Tezepelumab	66	64 (97.0)	69.1 (16.6)	35	53.5	70.0	83.0	96	
		Placebo	48	43 (89.6)	65.9 (20.6)	20	50.0	71.0	80.0	97	
	Week 20	Tezepelumab	66	65 (98.5)	68.4 (17.9)	28	55.0	71.0	81.0	97	
		Placebo	48	46 (95.8)	67.4 (20.6)	22	51.0	72.5	85.0	96	
	Week 22	Tezepelumab	66	63 (95.5)	69.2 (16.6)	35	57.0	73.0	85.0	95	
		Placebo	48	41 (85.4)	68.3 (19.8)	25	59.0	75.0	83.0	96	
	Week 24	Tezepelumab	66	65 (98.5)	69.1 (18.2)	12	57.0	70.0	82.0	100	
		Placebo	48	44 (91.7)	66.8 (19.9)	20	51.5	71.5	83.0	95	
	Week 26	Tezepelumab	66	64 (97.0)	69.3 (16.9)	35	58.0	70.0	83.0	98	
		Placebo	48	40 (83.3)	67.6 (18.9)	15	56.5	70.0	81.0	95	
	Week 28	Tezepelumab	66	65 (98.5)	68.9 (17.3)	31	54.0	70.0	83.0	98	
		Placebo	48	44 (91.7)	65.8 (20.0)	15	50.5	70.0	80.5	95	
	Week 30	Tezepelumab	66	64 (97.0)	69.2 (17.3)	22	59.5	68.5	85.0	97	
		Placebo	48	42 (87.5)	64.5 (20.9)	20	50.0	65.5	81.0	96	
	Week 32	Tezepelumab	66	65 (98.5)	69.7 (16.2)	35	61.0	70.0	85.0	95	
		Placebo	48	44 (91.7)	68.6 (21.5)	19	55.0	73.0	82.5	100	
	Week 34	Tezepelumab	66	65 (98.5)	71.1 (16.9)	24	60.0	75.0	84.0	100	
		Placebo	48	41 (85.4)	67.4 (20.5)	19	54.0	72.0	82.0	100	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	66	64 (97.0)	68.5 (17.3)	31	55.0	69.0	83.0	98	
		Placebo	48	44 (91.7)	66.2 (20.5)	16	50.5	66.5	81.0	100	
	Week 38	Tezepelumab	66	64 (97.0)	71.2 (15.7)	35	58.5	72.5	85.0	97	
		Placebo	48	41 (85.4)	67.3 (20.1)	15	57.0	70.0	81.0	96	
	Week 40	Tezepelumab	66	64 (97.0)	68.8 (17.6)	30	54.0	70.5	84.0	98	
		Placebo	48	44 (91.7)	67.4 (20.9)	10	54.5	74.5	81.5	96	
	Week 42	Tezepelumab	66	65 (98.5)	67.7 (18.2)	19	54.0	70.0	85.0	96	
		Placebo	48	41 (85.4)	66.8 (20.9)	15	50.0	71.0	84.0	96	
	Week 44	Tezepelumab	66	64 (97.0)	70.2 (17.9)	30	55.5	72.5	85.5	99	
		Placebo	48	44 (91.7)	65.0 (20.6)	15	50.0	65.0	83.0	96	
	Week 46	Tezepelumab	66	65 (98.5)	66.5 (18.8)	30	51.0	69.0	81.0	98	
		Placebo	48	41 (85.4)	68.9 (21.1)	10	58.0	75.0	80.0	98	
	Week 48	Tezepelumab	66	65 (98.5)	68.2 (18.8)	30	50.0	70.0	85.0	100	
		Placebo	48	44 (91.7)	69.0 (21.0)	15	55.0	75.0	84.0	100	
	Week 50	Tezepelumab	66	63 (95.5)	69.2 (17.8)	23	56.0	72.0	85.0	99	
		Placebo	48	42 (87.5)	68.6 (20.4)	10	60.0	74.0	82.0	97	
	Week 52	Tezepelumab	66	52 (78.8)	69.2 (17.1)	35	54.5	70.0	84.0	98	
		Placebo	48	38 (79.2)	68.1 (22.4)	9	59.0	74.0	85.0	97	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	66	62 (93.9)	2.0 (15.8)	-39	-7.0	0.5	9.0	36	-0.12 [-0.51, 0.27]
		Placebo	48	44 (91.7)	3.9 (16.0)	-46	-3.5	2.0	11.5	58	
	Week 4	Tezepelumab	66	64 (97.0)	6.5 (16.6)	-40	-3.0	5.0	19.5	42	0.17 [-0.21, 0.56]
		Placebo	48	45 (93.8)	3.7 (14.3)	-35	-5.0	3.0	10.0	52	
	Week 6	Tezepelumab	66	62 (93.9)	5.0 (17.7)	-45	-4.0	1.5	14.0	46	0.04 [-0.35, 0.43]
		Placebo	48	44 (91.7)	4.3 (17.4)	-35	-4.5	2.0	12.5	51	
	Week 8	Tezepelumab	66	64 (97.0)	2.8 (20.3)	-70	-5.0	3.0	13.0	39	-0.02 [-0.40, 0.36]
		Placebo	48	46 (95.8)	3.2 (18.6)	-40	-5.0	2.5	17.0	53	
	Week 10	Tezepelumab	66	62 (93.9)	6.6 (19.0)	-41	-1.0	5.5	17.0	56	0.18 [-0.21, 0.57]
		Placebo	48	43 (89.6)	3.3 (18.0)	-34	-10.0	2.0	14.0	57	
	Week 12	Tezepelumab	66	63 (95.5)	4.9 (18.9)	-40	-4.0	2.0	20.0	45	0.08 [-0.31, 0.46]
		Placebo	48	45 (93.8)	3.4 (20.3)	-40	-7.0	-1.0	10.0	54	
	Week 14	Tezepelumab	66	60 (90.9)	4.8 (20.6)	-40	-8.0	4.5	18.5	44	0.04 [-0.35, 0.43]
		Placebo	48	44 (91.7)	4.0 (17.2)	-35	-7.0	0.5	12.0	42	
	Week 16	Tezepelumab	66	63 (95.5)	4.2 (19.0)	-46	-6.0	4.0	15.0	45	-0.12 [-0.50, 0.26]
		Placebo	48	45 (93.8)	6.5 (18.9)	-46	-4.0	4.0	18.0	54	
	Week 18	Tezepelumab	66	63 (95.5)	4.9 (19.4)	-40	-5.0	7.0	18.0	45	0.07 [-0.32, 0.46]
		Placebo	48	43 (89.6)	3.6 (17.9)	-35	-8.0	1.0	16.0	52	
	Week 20	Tezepelumab	66	64 (97.0)	4.3 (18.2)	-45	-4.5	5.0	14.0	47	-0.10 [-0.48, 0.28]
		Placebo	48	46 (95.8)	6.3 (20.3)	-35	-8.0	3.0	17.0	56	
	Week 22	Tezepelumab	66	62 (93.9)	4.9 (18.7)	-38	-8.0	5.0	19.0	47	-0.04 [-0.44, 0.35]
		Placebo	48	41 (85.4)	5.8 (19.5)	-50	-5.0	0.0	18.0	50	
	Week 24	Tezepelumab	66	64 (97.0)	5.0 (18.0)	-34	-10.0	4.5	17.0	47	-0.03 [-0.42, 0.35]
		Placebo	48	44 (91.7)	5.6 (20.5)	-50	-8.0	3.0	19.5	54	
	Week 26	Tezepelumab	66	62 (93.9)	4.7 (20.2)	-43	-7.0	2.5	19.0	60	-0.03 [-0.43, 0.36]
		Placebo	48	40 (83.3)	5.3 (18.4)	-45	-4.5	2.0	16.5	51	
	Week 28	Tezepelumab	66	63 (95.5)	4.8 (20.4)	-43	-7.0	4.0	19.0	50	0.03 [-0.35, 0.42]
		Placebo	48	44 (91.7)	4.1 (18.4)	-55	-6.0	2.0	18.0	47	
	Week 30	Tezepelumab	66	62 (93.9)	5.2 (20.5)	-43	-9.0	5.5	19.0	47	0.14 [-0.25, 0.53]
		Placebo	48	42 (87.5)	2.4 (19.8)	-54	-11.0	1.5	16.0	50	
	Week 32	Tezepelumab	66	63 (95.5)	5.5 (19.1)	-43	-10.0	4.0	16.0	47	-0.07 [-0.46, 0.31]
		Placebo	48	44 (91.7)	7.0 (21.5)	-56	-4.5	6.0	19.5	54	
	Week 34	Tezepelumab	66	63 (95.5)	7.0 (20.9)	-43	-5.0	7.0	20.0	58	0.10 [-0.30, 0.49]
		Placebo	48	41 (85.4)	4.9 (22.3)	-56	-5.0	6.0	20.0	49	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 36	Tezepelumab	66	62 (93.9)	4.1 (21.2)	-46	-9.0	3.5	18.0	45	-0.02 [-0.41, 0.37]
		Placebo	48	44 (91.7)	4.5 (19.4)	-55	-5.0	0.5	14.5	52	
	Week 38	Tezepelumab	66	62 (93.9)	6.9 (19.4)	-43	-5.0	6.0	19.0	47	0.11 [-0.29, 0.50]
		Placebo	48	41 (85.4)	4.8 (20.8)	-57	-5.0	5.0	18.0	44	
	Week 40	Tezepelumab	66	62 (93.9)	3.8 (21.7)	-43	-7.0	2.0	18.0	61	-0.09 [-0.48, 0.30]
		Placebo	48	44 (91.7)	5.8 (20.8)	-55	-7.0	4.5	21.0	50	
	Week 42	Tezepelumab	66	63 (95.5)	3.3 (20.6)	-43	-10.0	3.0	16.0	47	-0.05 [-0.44, 0.35]
		Placebo	48	41 (85.4)	4.3 (20.1)	-60	-6.0	3.0	17.0	43	
	Week 44	Tezepelumab	66	62 (93.9)	5.8 (20.1)	-43	-9.0	7.0	17.0	61	0.12 [-0.26, 0.51]
		Placebo	48	44 (91.7)	3.4 (19.3)	-56	-7.5	1.0	14.0	50	
	Week 46	Tezepelumab	66	63 (95.5)	2.7 (20.7)	-43	-11.0	3.0	20.0	47	-0.18 [-0.57, 0.22]
		Placebo	48	41 (85.4)	6.3 (20.6)	-56	-7.0	4.0	18.0	54	
	Week 48	Tezepelumab	66	63 (95.5)	3.9 (20.0)	-44	-6.0	6.0	11.0	47	-0.17 [-0.55, 0.22]
		Placebo	48	44 (91.7)	7.3 (21.6)	-60	-5.5	2.5	22.5	55	
	Week 50	Tezepelumab	66	61 (92.4)	4.6 (20.5)	-43	-8.0	6.0	16.0	45	-0.07 [-0.46, 0.32]
		Placebo	48	42 (87.5)	6.1 (21.3)	-65	-7.0	3.0	20.0	50	
	Week 52	Tezepelumab	66	50 (75.8)	5.5 (19.5)	-43	-5.0	8.0	16.0	47	-0.08 [-0.50, 0.35]
		Placebo	48	38 (79.2)	7.0 (21.2)	-60	-4.0	4.5	24.0	51	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 2	Tezepelumab	66	62 (93.9)	2.7 (1.8)	(-0.9, 6.2)	-0.1 (2.8)	(-5.6, 5.5)	0.980																																																																																																																										
	Placebo	48	44 (91.7)	2.7 (2.1)	(-1.5, 7.0)				Week 4	Tezepelumab	66	64 (97.0)	6.9 (1.7)	(3.6, 10.3)	4.6 (2.6)	(-0.6, 9.9)	0.085	Placebo	48	44 (91.7)	2.3 (2.0)	(-1.7, 6.3)	Week 6	Tezepelumab	66	62 (93.9)	5.5 (1.9)	(1.7, 9.2)	2.1 (3.0)	(-3.8, 8.0)	0.478	Placebo	48	42 (87.5)	3.4 (2.3)	(-1.1, 7.9)	Week 8	Tezepelumab	66	64 (97.0)	3.2 (2.2)	(-1.1, 7.6)	1.0 (3.4)	(-5.7, 7.7)	0.770	Placebo	48	45 (93.8)	2.2 (2.6)	(-2.9, 7.4)	Week 10	Tezepelumab	66	61 (92.4)	7.5 (2.0)	(3.4, 11.5)	5.4 (3.2)	(-0.9, 11.7)	0.094	Placebo	48	42 (87.5)	2.1 (2.4)	(-2.7, 6.9)	Week 12	Tezepelumab	66	61 (92.4)	6.0 (2.1)	(1.7, 10.2)	3.9 (3.3)	(-2.6, 10.4)	0.240	Placebo	48	44 (91.7)	2.1 (2.5)	(-2.9, 7.0)	Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)	Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo
Week 4	Tezepelumab	66	64 (97.0)	6.9 (1.7)	(3.6, 10.3)	4.6 (2.6)	(-0.6, 9.9)	0.085																																																																																																																										
	Placebo	48	44 (91.7)	2.3 (2.0)	(-1.7, 6.3)				Week 6	Tezepelumab	66	62 (93.9)	5.5 (1.9)	(1.7, 9.2)	2.1 (3.0)	(-3.8, 8.0)	0.478	Placebo	48	42 (87.5)	3.4 (2.3)	(-1.1, 7.9)	Week 8	Tezepelumab	66	64 (97.0)	3.2 (2.2)	(-1.1, 7.6)	1.0 (3.4)	(-5.7, 7.7)	0.770	Placebo	48	45 (93.8)	2.2 (2.6)	(-2.9, 7.4)	Week 10	Tezepelumab	66	61 (92.4)	7.5 (2.0)	(3.4, 11.5)	5.4 (3.2)	(-0.9, 11.7)	0.094	Placebo	48	42 (87.5)	2.1 (2.4)	(-2.7, 6.9)	Week 12	Tezepelumab	66	61 (92.4)	6.0 (2.1)	(1.7, 10.2)	3.9 (3.3)	(-2.6, 10.4)	0.240	Placebo	48	44 (91.7)	2.1 (2.5)	(-2.9, 7.0)	Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)	Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)										
Week 6	Tezepelumab	66	62 (93.9)	5.5 (1.9)	(1.7, 9.2)	2.1 (3.0)	(-3.8, 8.0)	0.478																																																																																																																										
	Placebo	48	42 (87.5)	3.4 (2.3)	(-1.1, 7.9)				Week 8	Tezepelumab	66	64 (97.0)	3.2 (2.2)	(-1.1, 7.6)	1.0 (3.4)	(-5.7, 7.7)	0.770	Placebo	48	45 (93.8)	2.2 (2.6)	(-2.9, 7.4)	Week 10	Tezepelumab	66	61 (92.4)	7.5 (2.0)	(3.4, 11.5)	5.4 (3.2)	(-0.9, 11.7)	0.094	Placebo	48	42 (87.5)	2.1 (2.4)	(-2.7, 6.9)	Week 12	Tezepelumab	66	61 (92.4)	6.0 (2.1)	(1.7, 10.2)	3.9 (3.3)	(-2.6, 10.4)	0.240	Placebo	48	44 (91.7)	2.1 (2.5)	(-2.9, 7.0)	Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)	Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																								
Week 8	Tezepelumab	66	64 (97.0)	3.2 (2.2)	(-1.1, 7.6)	1.0 (3.4)	(-5.7, 7.7)	0.770																																																																																																																										
	Placebo	48	45 (93.8)	2.2 (2.6)	(-2.9, 7.4)				Week 10	Tezepelumab	66	61 (92.4)	7.5 (2.0)	(3.4, 11.5)	5.4 (3.2)	(-0.9, 11.7)	0.094	Placebo	48	42 (87.5)	2.1 (2.4)	(-2.7, 6.9)	Week 12	Tezepelumab	66	61 (92.4)	6.0 (2.1)	(1.7, 10.2)	3.9 (3.3)	(-2.6, 10.4)	0.240	Placebo	48	44 (91.7)	2.1 (2.5)	(-2.9, 7.0)	Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)	Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																						
Week 10	Tezepelumab	66	61 (92.4)	7.5 (2.0)	(3.4, 11.5)	5.4 (3.2)	(-0.9, 11.7)	0.094																																																																																																																										
	Placebo	48	42 (87.5)	2.1 (2.4)	(-2.7, 6.9)				Week 12	Tezepelumab	66	61 (92.4)	6.0 (2.1)	(1.7, 10.2)	3.9 (3.3)	(-2.6, 10.4)	0.240	Placebo	48	44 (91.7)	2.1 (2.5)	(-2.9, 7.0)	Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)	Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																																				
Week 12	Tezepelumab	66	61 (92.4)	6.0 (2.1)	(1.7, 10.2)	3.9 (3.3)	(-2.6, 10.4)	0.240																																																																																																																										
	Placebo	48	44 (91.7)	2.1 (2.5)	(-2.9, 7.0)				Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)	Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																																																		
Week 14	Tezepelumab	66	58 (87.9)	6.0 (2.1)	(1.8, 10.1)	2.5 (3.2)	(-3.9, 8.9)	0.445																																																																																																																										
	Placebo	48	43 (89.6)	3.5 (2.5)	(-1.4, 8.4)				Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)	Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																																																																
Week 16	Tezepelumab	66	61 (92.4)	5.2 (2.1)	(1.0, 9.4)	0.1 (3.3)	(-6.3, 6.6)	0.970																																																																																																																										
	Placebo	48	44 (91.7)	5.1 (2.5)	(0.2, 10.0)				Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)	Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																																																																														
Week 18	Tezepelumab	66	61 (92.4)	5.9 (2.1)	(1.8, 10.1)	2.7 (3.2)	(-3.8, 9.1)	0.412																																																																																																																										
	Placebo	48	42 (87.5)	3.3 (2.5)	(-1.6, 8.1)				Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																																																																																												
Week 20	Tezepelumab	66	62 (93.9)	5.0 (2.2)	(0.7, 9.4)	-0.3 (3.4)	(-7.0, 6.4)	0.928																																																																																																																										
	Placebo	48	45 (93.8)	5.3 (2.6)	(0.2, 10.4)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table MT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	66	60 (90.9)	5.9 (2.1)	(1.7, 10.0)	0.5 (3.3)	(-5.9, 7.0)	0.871
	Placebo	48	40 (83.3)	5.3 (2.5)	(0.4, 10.3)			
Week 24	Tezepelumab	66	62 (93.9)	5.8 (2.2)	(1.5, 10.1)	1.8 (3.4)	(-4.8, 8.5)	0.591
	Placebo	48	43 (89.6)	4.0 (2.6)	(-1.1, 9.1)			
Week 26	Tezepelumab	66	60 (90.9)	5.8 (2.1)	(1.7, 10.0)	1.9 (3.3)	(-4.6, 8.3)	0.570
	Placebo	48	39 (81.3)	4.0 (2.5)	(-1.0, 8.9)			
Week 28	Tezepelumab	66	60 (90.9)	5.9 (2.2)	(1.6, 10.2)	3.2 (3.4)	(-3.5, 9.9)	0.342
	Placebo	48	43 (89.6)	2.7 (2.6)	(-2.4, 7.8)			
Week 30	Tezepelumab	66	59 (89.4)	6.7 (2.2)	(2.4, 11.0)	5.5 (3.4)	(-1.3, 12.2)	0.111
	Placebo	48	41 (85.4)	1.2 (2.6)	(-3.9, 6.4)			
Week 32	Tezepelumab	66	60 (90.9)	6.7 (2.2)	(2.3, 11.1)	0.9 (3.4)	(-6.0, 7.7)	0.805
	Placebo	48	43 (89.6)	5.8 (2.6)	(0.6, 11.0)			
Week 34	Tezepelumab	66	60 (90.9)	8.2 (2.3)	(3.7, 12.8)	4.8 (3.6)	(-2.3, 11.9)	0.180
	Placebo	48	41 (85.4)	3.4 (2.7)	(-2.0, 8.8)			
Week 36	Tezepelumab	66	59 (89.4)	5.2 (2.3)	(0.8, 9.7)	2.2 (3.5)	(-4.7, 9.1)	0.531
	Placebo	48	43 (89.6)	3.0 (2.6)	(-2.2, 8.3)			
Week 38	Tezepelumab	66	58 (87.9)	8.1 (2.1)	(3.8, 12.3)	3.7 (3.3)	(-2.8, 10.3)	0.260
	Placebo	48	40 (83.3)	4.3 (2.5)	(-0.7, 9.3)			
Week 40	Tezepelumab	66	58 (87.9)	5.1 (2.3)	(0.4, 9.7)	0.4 (3.6)	(-6.7, 7.6)	0.903
	Placebo	48	43 (89.6)	4.6 (2.7)	(-0.8, 10.1)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table MT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	66	59 (89.4)	4.5 (2.2)	(0.0, 8.9)	0.5 (3.5)	(-6.4, 7.5)	0.879
	Placebo	48	39 (81.3)	4.0 (2.7)	(-1.3, 9.2)			
Week 44	Tezepelumab	66	57 (86.4)	7.3 (2.2)	(2.9, 11.8)	5.2 (3.5)	(-1.6, 12.0)	0.135
	Placebo	48	44 (91.7)	2.1 (2.6)	(-3.0, 7.3)			
Week 46	Tezepelumab	66	59 (89.4)	3.7 (2.3)	(-0.9, 8.4)	-1.6 (3.6)	(-8.7, 5.6)	0.668
	Placebo	48	41 (85.4)	5.3 (2.7)	(-0.2, 10.7)			
Week 48	Tezepelumab	66	59 (89.4)	4.9 (2.4)	(0.2, 9.7)	-1.4 (3.7)	(-8.6, 5.9)	0.706
	Placebo	48	43 (89.6)	6.3 (2.8)	(0.8, 11.8)			
Week 50	Tezepelumab	66	57 (86.4)	5.8 (2.3)	(1.3, 10.3)	0.8 (3.5)	(-6.2, 7.8)	0.823
	Placebo	48	42 (87.5)	5.0 (2.7)	(-0.3, 10.3)			
Week 52	Tezepelumab	66	43 (65.2)	6.6 (2.4)	(1.9, 11.3)	-0.1 (3.6)	(-7.3, 7.1)	0.981
	Placebo	48	33 (68.8)	6.7 (2.8)	(1.2, 12.2)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table NT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	55	55 (100.0)	64.6 (17.1)	26	50.0	67.0	80.0	95	
		Placebo	40	40 (100.0)	62.0 (15.8)	37	50.0	62.0	75.0	96	
	Week 2	Tezepelumab	55	53 (96.4)	66.4 (15.2)	30	54.0	68.0	80.0	98	
		Placebo	40	38 (95.0)	66.5 (17.5)	5	55.0	69.5	75.0	98	
	Week 4	Tezepelumab	55	55 (100.0)	70.8 (13.7)	37	60.0	71.0	80.0	95	
		Placebo	40	39 (97.5)	65.5 (18.5)	19	50.0	68.0	80.0	96	
	Week 6	Tezepelumab	55	53 (96.4)	69.5 (15.2)	35	60.0	70.0	80.0	100	
		Placebo	40	38 (95.0)	66.8 (16.4)	28	51.0	70.0	80.0	95	
	Week 8	Tezepelumab	55	55 (100.0)	66.7 (18.3)	0	53.0	70.0	80.0	98	
		Placebo	40	40 (100.0)	65.7 (17.1)	27	50.0	68.5	78.5	96	
	Week 10	Tezepelumab	55	53 (96.4)	72.2 (16.1)	40	60.0	78.0	84.0	100	
		Placebo	40	37 (92.5)	66.6 (17.5)	27	53.0	70.0	80.0	97	
	Week 12	Tezepelumab	55	54 (98.2)	68.7 (16.0)	40	58.0	67.5	83.0	98	
		Placebo	40	39 (97.5)	65.6 (18.7)	31	49.0	70.0	81.0	95	
	Week 14	Tezepelumab	55	51 (92.7)	69.0 (17.6)	36	51.0	69.0	83.0	100	
		Placebo	40	38 (95.0)	66.8 (17.5)	25	58.0	72.5	78.0	96	
	Week 16	Tezepelumab	55	54 (98.2)	68.4 (16.9)	30	52.0	68.5	82.0	96	
		Placebo	40	39 (97.5)	68.7 (17.5)	29	55.0	72.0	83.0	94	
	Week 18	Tezepelumab	55	54 (98.2)	69.3 (16.1)	39	54.0	70.0	83.0	96	
		Placebo	40	37 (92.5)	67.2 (19.3)	20	59.0	71.0	80.0	97	
	Week 20	Tezepelumab	55	55 (100.0)	68.0 (17.9)	28	54.0	71.0	81.0	97	
		Placebo	40	40 (100.0)	69.2 (18.7)	30	56.0	76.0	82.5	96	
	Week 22	Tezepelumab	55	53 (96.4)	69.2 (16.5)	38	57.0	72.0	85.0	95	
		Placebo	40	35 (87.5)	69.8 (18.2)	25	60.0	75.0	83.0	96	
	Week 24	Tezepelumab	55	55 (100.0)	68.9 (18.0)	12	56.0	70.0	85.0	100	
		Placebo	40	38 (95.0)	67.9 (19.0)	20	56.0	72.0	82.0	95	
	Week 26	Tezepelumab	55	53 (96.4)	69.5 (16.4)	40	60.0	69.0	84.0	98	
		Placebo	40	34 (85.0)	68.7 (18.0)	15	60.0	70.5	80.0	95	
	Week 28	Tezepelumab	55	54 (98.2)	69.3 (17.0)	31	54.0	70.0	85.0	98	
		Placebo	40	38 (95.0)	67.8 (18.5)	15	60.0	70.0	80.0	95	
	Week 30	Tezepelumab	55	53 (96.4)	70.4 (16.8)	22	60.0	70.0	85.0	97	
		Placebo	40	36 (90.0)	66.1 (20.0)	20	50.5	69.5	80.5	96	
	Week 32	Tezepelumab	55	54 (98.2)	70.4 (15.3)	39	61.0	70.0	85.0	95	
		Placebo	40	38 (95.0)	70.8 (19.8)	19	59.0	73.0	83.0	100	
Week 34	Tezepelumab	55	54 (98.2)	71.8 (16.5)	24	62.0	75.0	84.0	100		
	Placebo	40	35 (87.5)	68.0 (19.1)	19	54.0	72.0	82.0	94		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	55	53 (96.4)	68.2 (16.6)	31	55.0	70.0	81.0	98	
		Placebo	40	38 (95.0)	66.7 (19.4)	16	57.0	69.5	80.0	95	
	Week 38	Tezepelumab	55	53 (96.4)	71.5 (14.2)	40	61.0	73.0	81.0	97	
		Placebo	40	35 (87.5)	69.0 (19.8)	15	57.0	73.0	82.0	96	
	Week 40	Tezepelumab	55	53 (96.4)	68.9 (17.4)	30	54.0	71.0	83.0	98	
		Placebo	40	38 (95.0)	68.1 (20.2)	10	57.0	74.5	81.0	96	
	Week 42	Tezepelumab	55	54 (98.2)	67.7 (18.0)	19	54.0	70.0	85.0	96	
		Placebo	40	35 (87.5)	67.4 (20.1)	15	54.0	71.0	84.0	94	
	Week 44	Tezepelumab	55	53 (96.4)	70.4 (17.4)	30	56.0	73.0	85.0	99	
		Placebo	40	38 (95.0)	66.3 (19.7)	15	50.0	68.5	83.0	96	
	Week 46	Tezepelumab	55	54 (98.2)	67.0 (19.1)	30	51.0	69.5	80.0	98	
		Placebo	40	35 (87.5)	69.9 (20.0)	10	61.0	78.0	80.0	97	
	Week 48	Tezepelumab	55	54 (98.2)	68.4 (18.6)	30	50.0	70.5	85.0	100	
		Placebo	40	38 (95.0)	70.3 (19.3)	15	59.0	75.0	84.0	97	
	Week 50	Tezepelumab	55	52 (94.5)	69.5 (17.6)	23	56.0	73.0	82.0	99	
		Placebo	40	36 (90.0)	70.6 (20.1)	10	63.5	75.0	82.0	97	
	Week 52	Tezepelumab	55	41 (74.5)	70.0 (16.3)	41	60.0	70.0	82.0	98	
		Placebo	40	32 (80.0)	70.1 (21.0)	9	61.0	75.0	84.5	96	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	55	53 (96.4)	1.8 (15.1)	-39	-4.0	2.0	9.0	36	-0.11 [-0.53, 0.30]
		Placebo	40	38 (95.0)	3.6 (16.1)	-46	-3.0	2.0	12.0	58	
	Week 4	Tezepelumab	55	55 (100.0)	6.2 (15.3)	-25	-3.0	5.0	19.0	42	0.19 [-0.22, 0.60]
		Placebo	40	39 (97.5)	3.3 (14.7)	-35	-6.0	2.0	11.0	52	
	Week 6	Tezepelumab	55	53 (96.4)	5.1 (17.0)	-45	-2.0	1.0	11.0	46	0.03 [-0.39, 0.45]
		Placebo	40	38 (95.0)	4.6 (16.9)	-35	-4.0	2.0	12.0	51	
	Week 8	Tezepelumab	55	55 (100.0)	2.1 (18.5)	-70	-5.0	3.0	12.0	39	-0.09 [-0.50, 0.32]
		Placebo	40	40 (100.0)	3.8 (17.2)	-40	-3.0	2.5	15.5	53	
	Week 10	Tezepelumab	55	53 (96.4)	7.0 (18.1)	-35	0.0	6.0	14.0	56	0.18 [-0.24, 0.60]
		Placebo	40	37 (92.5)	3.8 (17.5)	-34	-2.0	2.0	14.0	57	
	Week 12	Tezepelumab	55	54 (98.2)	3.9 (18.0)	-40	-4.0	2.0	10.0	45	0.03 [-0.38, 0.44]
		Placebo	40	39 (97.5)	3.4 (20.4)	-40	-7.0	1.0	14.0	54	
	Week 14	Tezepelumab	55	51 (92.7)	4.0 (20.6)	-40	-8.0	4.0	15.0	44	0.01 [-0.41, 0.43]
		Placebo	40	38 (95.0)	3.9 (17.2)	-35	-7.0	0.5	13.0	42	
	Week 16	Tezepelumab	55	54 (98.2)	3.6 (18.0)	-46	-5.0	4.5	10.0	45	-0.15 [-0.57, 0.26]
		Placebo	40	39 (97.5)	6.5 (19.1)	-46	-4.0	4.0	18.0	54	
	Week 18	Tezepelumab	55	54 (98.2)	4.6 (18.4)	-35	-5.0	6.5	15.0	45	0.04 [-0.38, 0.46]
		Placebo	40	37 (92.5)	3.9 (17.2)	-35	-6.0	1.0	14.0	52	
	Week 20	Tezepelumab	55	55 (100.0)	3.4 (17.8)	-45	-5.0	5.0	11.0	47	-0.21 [-0.62, 0.20]
		Placebo	40	40 (100.0)	7.3 (19.4)	-35	-4.5	4.0	18.5	56	
	Week 22	Tezepelumab	55	53 (96.4)	4.3 (18.4)	-38	-8.0	5.0	14.0	47	-0.10 [-0.53, 0.33]
		Placebo	40	35 (87.5)	6.2 (19.0)	-50	-3.0	3.0	19.0	50	
	Week 24	Tezepelumab	55	55 (100.0)	4.2 (17.2)	-34	-10.0	4.0	15.0	47	-0.09 [-0.50, 0.33]
		Placebo	40	38 (95.0)	5.8 (20.4)	-50	-7.0	4.0	20.0	54	
	Week 26	Tezepelumab	55	53 (96.4)	4.5 (18.9)	-35	-7.0	2.0	14.0	60	-0.04 [-0.47, 0.39]
		Placebo	40	34 (85.0)	5.3 (18.4)	-45	-3.0	2.5	15.0	51	
	Week 28	Tezepelumab	55	54 (98.2)	4.5 (19.3)	-40	-5.0	3.5	16.0	50	-0.04 [-0.45, 0.38]
		Placebo	40	38 (95.0)	5.2 (18.0)	-55	-4.0	2.0	19.0	47	
	Week 30	Tezepelumab	55	53 (96.4)	5.5 (20.0)	-38	-9.0	5.0	16.0	47	0.13 [-0.29, 0.55]
		Placebo	40	36 (90.0)	2.9 (19.9)	-54	-9.5	3.5	16.5	50	
	Week 32	Tezepelumab	55	54 (98.2)	5.7 (18.0)	-35	-5.0	4.0	14.0	47	-0.13 [-0.55, 0.28]
		Placebo	40	38 (95.0)	8.2 (21.2)	-56	-1.0	7.0	19.0	54	
	Week 34	Tezepelumab	55	54 (98.2)	7.0 (19.8)	-38	-4.0	7.0	16.0	58	0.13 [-0.30, 0.55]
		Placebo	40	35 (87.5)	4.4 (22.1)	-56	-5.0	8.0	20.0	49	
	Week 36	Tezepelumab	55	53 (96.4)	3.4 (19.9)	-46	-9.0	3.0	13.0	45	-0.04 [-0.46, 0.38]
		Placebo	40	38 (95.0)	4.1 (18.8)	-55	-5.0	2.0	15.0	52	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	55	53 (96.4)	6.7 (17.9)	-37	-5.0	6.0	17.0	47	0.07 [-0.36, 0.50]
		Placebo	40	35 (87.5)	5.4 (20.0)	-57	-5.0	7.0	19.0	42	
	Week 40	Tezepelumab	55	53 (96.4)	3.7 (21.2)	-39	-6.0	2.0	14.0	61	-0.09 [-0.51, 0.33]
		Placebo	40	38 (95.0)	5.6 (20.5)	-55	-4.0	6.0	21.0	50	
	Week 42	Tezepelumab	55	54 (98.2)	3.0 (19.9)	-42	-10.0	3.0	15.0	47	-0.04 [-0.47, 0.38]
		Placebo	40	35 (87.5)	3.8 (19.8)	-60	-5.0	4.0	17.0	43	
	Week 44	Tezepelumab	55	53 (96.4)	5.6 (19.0)	-35	-7.0	6.0	14.0	61	0.09 [-0.32, 0.51]
		Placebo	40	38 (95.0)	3.8 (19.4)	-56	-6.0	1.0	14.0	50	
	Week 46	Tezepelumab	55	54 (98.2)	2.2 (20.1)	-40	-11.0	2.5	14.0	47	-0.20 [-0.63, 0.22]
		Placebo	40	35 (87.5)	6.3 (20.2)	-56	-7.0	5.0	19.0	54	
	Week 48	Tezepelumab	55	54 (98.2)	3.7 (18.9)	-44	-5.0	5.5	10.0	47	-0.20 [-0.62, 0.21]
		Placebo	40	38 (95.0)	7.7 (21.2)	-60	-4.0	4.0	21.0	55	
	Week 50	Tezepelumab	55	52 (94.5)	4.6 (19.7)	-38	-7.5	5.0	13.5	45	-0.12 [-0.54, 0.31]
		Placebo	40	36 (90.0)	6.9 (20.8)	-65	-2.0	3.0	19.0	50	
	Week 52	Tezepelumab	55	41 (74.5)	5.7 (18.4)	-35	-5.0	8.0	15.0	47	-0.12 [-0.58, 0.34]
		Placebo	40	32 (80.0)	8.0 (20.9)	-60	-2.5	7.5	22.5	51	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 2	Tezepelumab	55	53 (96.4)	2.5 (1.9)	(-1.2, 6.2)	0.3 (2.9)	(-5.5, 6.0)	0.925																																																																																																																										
	Placebo	40	38 (95.0)	2.2 (2.2)	(-2.2, 6.6)				Week 4	Tezepelumab	55	55 (100.0)	6.5 (1.8)	(2.9, 10.0)	4.7 (2.8)	(-0.9, 10.2)	0.096	Placebo	40	39 (97.5)	1.8 (2.1)	(-2.4, 6.0)	Week 6	Tezepelumab	55	53 (96.4)	5.3 (1.9)	(1.5, 9.1)	1.8 (3.0)	(-4.1, 7.7)	0.543	Placebo	40	38 (95.0)	3.5 (2.3)	(-1.0, 8.0)	Week 8	Tezepelumab	55	55 (100.0)	2.4 (2.1)	(-1.8, 6.7)	-0.4 (3.3)	(-6.9, 6.2)	0.908	Placebo	40	40 (100.0)	2.8 (2.5)	(-2.2, 7.8)	Week 10	Tezepelumab	55	53 (96.4)	7.5 (2.1)	(3.4, 11.6)	5.2 (3.2)	(-1.2, 11.6)	0.110	Placebo	40	37 (92.5)	2.3 (2.5)	(-2.5, 7.2)	Week 12	Tezepelumab	55	54 (98.2)	4.5 (2.2)	(0.1, 8.9)	2.5 (3.4)	(-4.3, 9.3)	0.471	Placebo	40	39 (97.5)	2.0 (2.6)	(-3.2, 7.2)	Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo
Week 4	Tezepelumab	55	55 (100.0)	6.5 (1.8)	(2.9, 10.0)	4.7 (2.8)	(-0.9, 10.2)	0.096																																																																																																																										
	Placebo	40	39 (97.5)	1.8 (2.1)	(-2.4, 6.0)				Week 6	Tezepelumab	55	53 (96.4)	5.3 (1.9)	(1.5, 9.1)	1.8 (3.0)	(-4.1, 7.7)	0.543	Placebo	40	38 (95.0)	3.5 (2.3)	(-1.0, 8.0)	Week 8	Tezepelumab	55	55 (100.0)	2.4 (2.1)	(-1.8, 6.7)	-0.4 (3.3)	(-6.9, 6.2)	0.908	Placebo	40	40 (100.0)	2.8 (2.5)	(-2.2, 7.8)	Week 10	Tezepelumab	55	53 (96.4)	7.5 (2.1)	(3.4, 11.6)	5.2 (3.2)	(-1.2, 11.6)	0.110	Placebo	40	37 (92.5)	2.3 (2.5)	(-2.5, 7.2)	Week 12	Tezepelumab	55	54 (98.2)	4.5 (2.2)	(0.1, 8.9)	2.5 (3.4)	(-4.3, 9.3)	0.471	Placebo	40	39 (97.5)	2.0 (2.6)	(-3.2, 7.2)	Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)										
Week 6	Tezepelumab	55	53 (96.4)	5.3 (1.9)	(1.5, 9.1)	1.8 (3.0)	(-4.1, 7.7)	0.543																																																																																																																										
	Placebo	40	38 (95.0)	3.5 (2.3)	(-1.0, 8.0)				Week 8	Tezepelumab	55	55 (100.0)	2.4 (2.1)	(-1.8, 6.7)	-0.4 (3.3)	(-6.9, 6.2)	0.908	Placebo	40	40 (100.0)	2.8 (2.5)	(-2.2, 7.8)	Week 10	Tezepelumab	55	53 (96.4)	7.5 (2.1)	(3.4, 11.6)	5.2 (3.2)	(-1.2, 11.6)	0.110	Placebo	40	37 (92.5)	2.3 (2.5)	(-2.5, 7.2)	Week 12	Tezepelumab	55	54 (98.2)	4.5 (2.2)	(0.1, 8.9)	2.5 (3.4)	(-4.3, 9.3)	0.471	Placebo	40	39 (97.5)	2.0 (2.6)	(-3.2, 7.2)	Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																								
Week 8	Tezepelumab	55	55 (100.0)	2.4 (2.1)	(-1.8, 6.7)	-0.4 (3.3)	(-6.9, 6.2)	0.908																																																																																																																										
	Placebo	40	40 (100.0)	2.8 (2.5)	(-2.2, 7.8)				Week 10	Tezepelumab	55	53 (96.4)	7.5 (2.1)	(3.4, 11.6)	5.2 (3.2)	(-1.2, 11.6)	0.110	Placebo	40	37 (92.5)	2.3 (2.5)	(-2.5, 7.2)	Week 12	Tezepelumab	55	54 (98.2)	4.5 (2.2)	(0.1, 8.9)	2.5 (3.4)	(-4.3, 9.3)	0.471	Placebo	40	39 (97.5)	2.0 (2.6)	(-3.2, 7.2)	Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																						
Week 10	Tezepelumab	55	53 (96.4)	7.5 (2.1)	(3.4, 11.6)	5.2 (3.2)	(-1.2, 11.6)	0.110																																																																																																																										
	Placebo	40	37 (92.5)	2.3 (2.5)	(-2.5, 7.2)				Week 12	Tezepelumab	55	54 (98.2)	4.5 (2.2)	(0.1, 8.9)	2.5 (3.4)	(-4.3, 9.3)	0.471	Placebo	40	39 (97.5)	2.0 (2.6)	(-3.2, 7.2)	Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																																				
Week 12	Tezepelumab	55	54 (98.2)	4.5 (2.2)	(0.1, 8.9)	2.5 (3.4)	(-4.3, 9.3)	0.471																																																																																																																										
	Placebo	40	39 (97.5)	2.0 (2.6)	(-3.2, 7.2)				Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																																																		
Week 14	Tezepelumab	55	51 (92.7)	4.7 (2.2)	(0.3, 9.2)	1.1 (3.4)	(-5.7, 7.9)	0.742																																																																																																																										
	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)				Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)	Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																																																																
Week 16	Tezepelumab	55	54 (98.2)	4.1 (2.2)	(-0.2, 8.5)	-0.8 (3.4)	(-7.4, 5.9)	0.822																																																																																																																										
	Placebo	40	39 (97.5)	4.9 (2.6)	(-0.2, 10.0)				Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)	Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																																																																														
Week 18	Tezepelumab	55	54 (98.2)	5.1 (2.1)	(0.9, 9.3)	1.6 (3.2)	(-4.8, 8.1)	0.622																																																																																																																										
	Placebo	40	37 (92.5)	3.5 (2.5)	(-1.4, 8.4)				Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																																																																																												
Week 20	Tezepelumab	55	55 (100.0)	3.7 (2.2)	(-0.7, 8.1)	-2.6 (3.4)	(-9.4, 4.2)	0.448																																																																																																																										
	Placebo	40	40 (100.0)	6.3 (2.6)	(1.1, 11.5)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 22	Tezepelumab	55	53 (96.4)	4.9 (2.2)	(0.6, 9.2)	-0.9 (3.4)	(-7.6, 5.8)	0.792																																																																																																																										
	Placebo	40	35 (87.5)	5.8 (2.6)	(0.7, 10.9)				Week 24	Tezepelumab	55	55 (100.0)	4.5 (2.2)	(0.1, 9.0)	0.3 (3.5)	(-6.6, 7.2)	0.927	Placebo	40	38 (95.0)	4.2 (2.7)	(-1.0, 9.5)	Week 26	Tezepelumab	55	53 (96.4)	5.2 (2.1)	(0.9, 9.4)	1.3 (3.3)	(-5.3, 7.9)	0.699	Placebo	40	34 (85.0)	3.9 (2.6)	(-1.2, 9.0)	Week 28	Tezepelumab	55	54 (98.2)	5.1 (2.2)	(0.6, 9.5)	1.5 (3.5)	(-5.4, 8.3)	0.669	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 30	Tezepelumab	55	53 (96.4)	6.1 (2.3)	(1.5, 10.8)	4.4 (3.6)	(-2.8, 11.6)	0.229	Placebo	40	36 (90.0)	1.8 (2.8)	(-3.7, 7.2)	Week 32	Tezepelumab	55	54 (98.2)	6.2 (2.2)	(1.8, 10.7)	-0.6 (3.5)	(-7.5, 6.3)	0.871	Placebo	40	38 (95.0)	6.8 (2.7)	(1.5, 12.1)	Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)	Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo
Week 24	Tezepelumab	55	55 (100.0)	4.5 (2.2)	(0.1, 9.0)	0.3 (3.5)	(-6.6, 7.2)	0.927																																																																																																																										
	Placebo	40	38 (95.0)	4.2 (2.7)	(-1.0, 9.5)				Week 26	Tezepelumab	55	53 (96.4)	5.2 (2.1)	(0.9, 9.4)	1.3 (3.3)	(-5.3, 7.9)	0.699	Placebo	40	34 (85.0)	3.9 (2.6)	(-1.2, 9.0)	Week 28	Tezepelumab	55	54 (98.2)	5.1 (2.2)	(0.6, 9.5)	1.5 (3.5)	(-5.4, 8.3)	0.669	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 30	Tezepelumab	55	53 (96.4)	6.1 (2.3)	(1.5, 10.8)	4.4 (3.6)	(-2.8, 11.6)	0.229	Placebo	40	36 (90.0)	1.8 (2.8)	(-3.7, 7.2)	Week 32	Tezepelumab	55	54 (98.2)	6.2 (2.2)	(1.8, 10.7)	-0.6 (3.5)	(-7.5, 6.3)	0.871	Placebo	40	38 (95.0)	6.8 (2.7)	(1.5, 12.1)	Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)	Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)										
Week 26	Tezepelumab	55	53 (96.4)	5.2 (2.1)	(0.9, 9.4)	1.3 (3.3)	(-5.3, 7.9)	0.699																																																																																																																										
	Placebo	40	34 (85.0)	3.9 (2.6)	(-1.2, 9.0)				Week 28	Tezepelumab	55	54 (98.2)	5.1 (2.2)	(0.6, 9.5)	1.5 (3.5)	(-5.4, 8.3)	0.669	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)	Week 30	Tezepelumab	55	53 (96.4)	6.1 (2.3)	(1.5, 10.8)	4.4 (3.6)	(-2.8, 11.6)	0.229	Placebo	40	36 (90.0)	1.8 (2.8)	(-3.7, 7.2)	Week 32	Tezepelumab	55	54 (98.2)	6.2 (2.2)	(1.8, 10.7)	-0.6 (3.5)	(-7.5, 6.3)	0.871	Placebo	40	38 (95.0)	6.8 (2.7)	(1.5, 12.1)	Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)	Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																								
Week 28	Tezepelumab	55	54 (98.2)	5.1 (2.2)	(0.6, 9.5)	1.5 (3.5)	(-5.4, 8.3)	0.669																																																																																																																										
	Placebo	40	38 (95.0)	3.6 (2.6)	(-1.6, 8.8)				Week 30	Tezepelumab	55	53 (96.4)	6.1 (2.3)	(1.5, 10.8)	4.4 (3.6)	(-2.8, 11.6)	0.229	Placebo	40	36 (90.0)	1.8 (2.8)	(-3.7, 7.2)	Week 32	Tezepelumab	55	54 (98.2)	6.2 (2.2)	(1.8, 10.7)	-0.6 (3.5)	(-7.5, 6.3)	0.871	Placebo	40	38 (95.0)	6.8 (2.7)	(1.5, 12.1)	Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)	Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																						
Week 30	Tezepelumab	55	53 (96.4)	6.1 (2.3)	(1.5, 10.8)	4.4 (3.6)	(-2.8, 11.6)	0.229																																																																																																																										
	Placebo	40	36 (90.0)	1.8 (2.8)	(-3.7, 7.2)				Week 32	Tezepelumab	55	54 (98.2)	6.2 (2.2)	(1.8, 10.7)	-0.6 (3.5)	(-7.5, 6.3)	0.871	Placebo	40	38 (95.0)	6.8 (2.7)	(1.5, 12.1)	Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)	Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																																				
Week 32	Tezepelumab	55	54 (98.2)	6.2 (2.2)	(1.8, 10.7)	-0.6 (3.5)	(-7.5, 6.3)	0.871																																																																																																																										
	Placebo	40	38 (95.0)	6.8 (2.7)	(1.5, 12.1)				Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)	Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																																																		
Week 34	Tezepelumab	55	54 (98.2)	7.5 (2.4)	(2.8, 12.2)	4.9 (3.7)	(-2.4, 12.2)	0.186																																																																																																																										
	Placebo	40	35 (87.5)	2.6 (2.8)	(-3.0, 8.2)				Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)	Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																																																																
Week 36	Tezepelumab	55	53 (96.4)	4.0 (2.3)	(-0.6, 8.5)	1.6 (3.5)	(-5.5, 8.6)	0.661																																																																																																																										
	Placebo	40	38 (95.0)	2.4 (2.7)	(-3.0, 7.8)				Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)	Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																																																																														
Week 38	Tezepelumab	55	53 (96.4)	6.9 (2.1)	(2.7, 11.2)	3.0 (3.3)	(-3.6, 9.6)	0.371																																																																																																																										
	Placebo	40	35 (87.5)	3.9 (2.5)	(-1.1, 9.0)				Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																																																																																												
Week 40	Tezepelumab	55	53 (96.4)	4.3 (2.5)	(-0.6, 9.1)	0.1 (3.8)	(-7.4, 7.7)	0.970																																																																																																																										
	Placebo	40	38 (95.0)	4.1 (2.9)	(-1.7, 9.9)																																																																																																																													

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	55	54 (98.2)	3.5 (2.4)	(-1.2, 8.2)	-0.1 (3.7)	(-7.4, 7.2)	0.972
	Placebo	40	35 (87.5)	3.6 (2.8)	(-2.0, 9.2)			
Week 44	Tezepelumab	55	53 (96.4)	6.3 (2.3)	(1.7, 10.8)	4.1 (3.5)	(-2.9, 11.2)	0.249
	Placebo	40	38 (95.0)	2.2 (2.7)	(-3.2, 7.6)			
Week 46	Tezepelumab	55	54 (98.2)	2.7 (2.5)	(-2.1, 7.6)	-2.4 (3.8)	(-10.0, 5.1)	0.525
	Placebo	40	35 (87.5)	5.2 (2.9)	(-0.6, 11.0)			
Week 48	Tezepelumab	55	54 (98.2)	4.2 (2.4)	(-0.6, 9.0)	-2.0 (3.7)	(-9.4, 5.4)	0.593
	Placebo	40	38 (95.0)	6.2 (2.8)	(0.5, 11.8)			
Week 50	Tezepelumab	55	52 (94.5)	4.8 (2.4)	(0.1, 9.6)	-0.9 (3.7)	(-8.2, 6.5)	0.812
	Placebo	40	36 (90.0)	5.7 (2.8)	(0.1, 11.3)			
Week 52	Tezepelumab	55	41 (74.5)	5.8 (2.4)	(1.0, 10.7)	-2.1 (3.8)	(-9.6, 5.3)	0.572
	Placebo	40	32 (80.0)	8.0 (2.9)	(2.3, 13.6)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table PT3VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	12	10 (83.3)	61.4 (16.0)	38	51.0	55.5	72.0	90	
		Placebo	9	7 (77.8)	56.6 (14.4)	47	47.0	50.0	65.0	86	
	Week 1	Tezepelumab	12	10 (83.3)	67.7 (17.5)	31	56.0	77.0	80.0	83	
		Placebo	9	7 (77.8)	53.1 (25.7)	18	36.0	49.0	77.0	95	
	Week 2	Tezepelumab	12	10 (83.3)	64.0 (20.8)	31	49.0	69.5	82.0	85	
		Placebo	9	7 (77.8)	62.7 (19.7)	39	49.0	57.0	85.0	94	
	Week 3	Tezepelumab	12	10 (83.3)	70.7 (18.9)	38	53.0	75.0	86.0	90	
		Placebo	9	7 (77.8)	64.6 (21.4)	44	45.0	56.0	85.0	94	
	Week 4	Tezepelumab	12	10 (83.3)	69.8 (17.1)	50	50.0	72.0	87.0	91	
		Placebo	9	7 (77.8)	63.9 (15.6)	45	57.0	59.0	73.0	94	
	Week 5	Tezepelumab	12	10 (83.3)	72.4 (16.4)	45	58.0	77.0	85.0	92	
		Placebo	9	7 (77.8)	66.4 (16.3)	47	53.0	60.0	77.0	94	
	Week 6	Tezepelumab	12	10 (83.3)	67.5 (19.8)	24	58.0	72.5	85.0	85	
		Placebo	9	7 (77.8)	60.6 (23.7)	22	52.0	55.0	85.0	94	
	Week 7	Tezepelumab	12	10 (83.3)	67.8 (18.5)	30	54.0	70.5	84.0	91	
		Placebo	9	7 (77.8)	61.3 (26.0)	17	49.0	63.0	86.0	94	
	Week 8	Tezepelumab	12	10 (83.3)	69.2 (21.1)	31	58.0	68.0	88.0	94	
		Placebo	9	7 (77.8)	57.3 (29.1)	14	29.0	55.0	87.0	94	
	Week 9	Tezepelumab	12	10 (83.3)	69.8 (19.5)	40	58.0	73.0	86.0	93	
		Placebo	9	7 (77.8)	62.7 (23.1)	36	45.0	59.0	93.0	94	
	Week 10	Tezepelumab	12	10 (83.3)	66.9 (18.7)	35	49.0	73.0	83.0	85	
		Placebo	9	7 (77.8)	58.6 (24.5)	30	30.0	55.0	84.0	94	
	Week 11	Tezepelumab	12	10 (83.3)	69.0 (20.1)	35	52.0	75.0	87.0	90	
		Placebo	9	7 (77.8)	60.3 (21.7)	36	42.0	54.0	86.0	94	
	Week 12	Tezepelumab	12	10 (83.3)	71.4 (18.8)	35	59.0	75.0	87.0	92	
		Placebo	9	7 (77.8)	60.3 (23.9)	34	40.0	60.0	90.0	94	
	Week 13	Tezepelumab	12	10 (83.3)	70.8 (19.9)	35	59.0	74.0	88.0	92	
		Placebo	9	7 (77.8)	60.6 (20.8)	44	45.0	50.0	86.0	94	
	Week 14	Tezepelumab	12	10 (83.3)	71.1 (20.2)	35	55.0	77.5	85.0	94	
		Placebo	9	7 (77.8)	62.1 (20.9)	38	45.0	58.0	87.0	94	
	Week 15	Tezepelumab	12	10 (83.3)	69.8 (23.5)	35	42.0	75.0	90.0	95	
		Placebo	9	7 (77.8)	57.9 (26.9)	12	43.0	60.0	79.0	94	
	Week 16	Tezepelumab	12	10 (83.3)	69.4 (21.1)	35	58.0	74.5	88.0	92	
		Placebo	9	7 (77.8)	63.0 (21.2)	31	48.0	58.0	81.0	94	
Week 17	Tezepelumab	12	10 (83.3)	67.2 (21.3)	35	52.0	71.0	87.0	91		
	Placebo	9	7 (77.8)	58.7 (30.4)	7	37.0	66.0	81.0	94		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 18	Tezepelumab	12	11 (91.7)	69.6 (20.2)	35	50.0	73.0	89.0	93	
		Placebo	9	7 (77.8)	58.9 (25.8)	23	34.0	55.0	82.0	94	
	Week 19	Tezepelumab	12	11 (91.7)	67.6 (19.9)	35	48.0	67.0	87.0	90	
		Placebo	9	7 (77.8)	59.1 (27.5)	22	30.0	59.0	82.0	94	
	Week 20	Tezepelumab	12	11 (91.7)	71.7 (17.9)	35	62.0	70.0	86.0	97	
		Placebo	9	7 (77.8)	59.1 (29.0)	22	30.0	55.0	85.0	94	
	Week 21	Tezepelumab	12	11 (91.7)	71.9 (18.8)	35	63.0	75.0	88.0	93	
		Placebo	9	7 (77.8)	60.4 (29.4)	16	41.0	57.0	89.0	94	
	Week 22	Tezepelumab	12	11 (91.7)	71.2 (18.1)	35	60.0	75.0	85.0	92	
		Placebo	9	7 (77.8)	62.6 (26.6)	26	38.0	58.0	90.0	94	
	Week 23	Tezepelumab	12	11 (91.7)	70.5 (18.1)	35	58.0	75.0	85.0	92	
		Placebo	9	7 (77.8)	60.0 (26.4)	24	34.0	60.0	89.0	94	
	Week 24	Tezepelumab	12	11 (91.7)	72.0 (19.5)	35	60.0	75.0	90.0	93	
		Placebo	9	7 (77.8)	63.1 (24.8)	26	49.0	55.0	91.0	94	
	Week 25	Tezepelumab	12	11 (91.7)	69.5 (19.8)	35	53.0	75.0	87.0	93	
		Placebo	9	7 (77.8)	62.7 (26.8)	22	45.0	57.0	91.0	94	
	Week 26	Tezepelumab	12	12 (100.0)	69.6 (19.8)	35	51.0	76.0	84.5	95	
		Placebo	9	7 (77.8)	62.9 (22.5)	31	45.0	58.0	82.0	94	
	Week 27	Tezepelumab	12	12 (100.0)	68.3 (19.2)	35	53.5	72.0	82.0	92	
		Placebo	9	7 (77.8)	61.0 (24.5)	22	47.0	59.0	81.0	94	
	Week 28	Tezepelumab	12	12 (100.0)	69.0 (19.3)	35	53.0	70.0	85.5	93	
		Placebo	9	7 (77.8)	55.7 (24.5)	30	32.0	49.0	84.0	94	
	Week 29	Tezepelumab	12	12 (100.0)	69.1 (19.6)	35	51.5	72.5	88.0	92	
		Placebo	9	7 (77.8)	53.1 (25.9)	19	37.0	45.0	80.0	94	
	Week 30	Tezepelumab	12	12 (100.0)	66.1 (20.1)	35	47.5	62.0	85.0	94	
		Placebo	9	7 (77.8)	57.3 (24.4)	25	35.0	57.0	82.0	94	
	Week 31	Tezepelumab	12	12 (100.0)	67.6 (21.0)	35	47.0	72.0	85.5	92	
		Placebo	9	7 (77.8)	60.0 (23.1)	27	38.0	59.0	81.0	94	
	Week 32	Tezepelumab	12	12 (100.0)	68.1 (20.5)	35	52.0	70.5	87.0	92	
		Placebo	9	7 (77.8)	57.1 (26.6)	20	38.0	55.0	80.0	94	
	Week 33	Tezepelumab	12	12 (100.0)	70.0 (20.5)	35	53.0	72.0	89.5	94	
		Placebo	9	7 (77.8)	60.9 (23.4)	30	43.0	60.0	80.0	94	
	Week 34	Tezepelumab	12	12 (100.0)	69.7 (19.6)	35	53.0	74.5	85.5	93	
		Placebo	9	7 (77.8)	64.9 (27.0)	23	48.0	56.0	90.0	100	
	Week 35	Tezepelumab	12	12 (100.0)	69.6 (20.5)	35	54.0	70.5	88.5	94	
Placebo		9	7 (77.8)	64.0 (25.7)	33	44.0	57.0	89.0	100		

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	12	12 (100.0)	71.1 (20.8)	35	52.5	74.5	90.0	94	
		Placebo	9	7 (77.8)	65.0 (26.4)	31	44.0	58.0	92.0	100	
	Week 37	Tezepelumab	12	12 (100.0)	70.2 (21.2)	35	51.5	74.0	91.0	93	
		Placebo	9	7 (77.8)	58.7 (22.8)	26	44.0	56.0	85.0	91	
	Week 38	Tezepelumab	12	12 (100.0)	70.2 (21.3)	35	51.5	72.0	89.5	96	
		Placebo	9	7 (77.8)	60.6 (20.5)	34	46.0	60.0	80.0	94	
	Week 39	Tezepelumab	12	12 (100.0)	71.1 (20.6)	35	54.0	74.5	89.5	95	
		Placebo	9	7 (77.8)	61.6 (27.1)	31	32.0	60.0	90.0	94	
	Week 40	Tezepelumab	12	12 (100.0)	70.4 (20.1)	35	52.5	71.0	90.5	93	
		Placebo	9	7 (77.8)	64.0 (24.3)	37	43.0	58.0	90.0	95	
	Week 41	Tezepelumab	12	12 (100.0)	68.6 (20.3)	35	52.0	66.5	89.0	94	
		Placebo	9	7 (77.8)	62.7 (26.3)	27	40.0	58.0	87.0	96	
	Week 42	Tezepelumab	12	12 (100.0)	69.7 (20.1)	35	54.0	69.0	90.0	94	
		Placebo	9	7 (77.8)	64.0 (24.5)	34	44.0	56.0	87.0	96	
	Week 43	Tezepelumab	12	12 (100.0)	69.1 (20.2)	35	51.0	73.0	87.0	93	
		Placebo	9	7 (77.8)	59.6 (25.5)	18	45.0	60.0	83.0	96	
	Week 44	Tezepelumab	12	12 (100.0)	69.7 (20.0)	35	53.5	73.5	87.5	93	
		Placebo	9	7 (77.8)	58.9 (24.6)	23	42.0	55.0	84.0	96	
	Week 45	Tezepelumab	12	12 (100.0)	69.6 (20.1)	35	52.0	76.5	86.0	93	
		Placebo	9	7 (77.8)	63.7 (27.1)	25	45.0	57.0	91.0	95	
	Week 46	Tezepelumab	12	12 (100.0)	66.7 (19.1)	35	49.0	68.0	82.5	93	
		Placebo	9	7 (77.8)	64.9 (26.2)	34	42.0	58.0	94.0	98	
	Week 47	Tezepelumab	12	12 (100.0)	67.1 (18.7)	35	51.0	70.5	82.5	93	
		Placebo	9	7 (77.8)	61.7 (26.2)	33	34.0	62.0	89.0	91	
	Week 48	Tezepelumab	12	12 (100.0)	68.9 (20.5)	35	49.5	70.5	89.0	93	
		Placebo	9	7 (77.8)	63.0 (28.5)	29	31.0	62.0	89.0	100	
	Week 49	Tezepelumab	12	12 (100.0)	68.1 (20.1)	35	51.5	68.5	88.0	93	
		Placebo	9	7 (77.8)	62.9 (23.9)	38	43.0	54.0	85.0	97	
	Week 50	Tezepelumab	12	12 (100.0)	69.2 (19.1)	35	53.5	69.5	87.5	93	
		Placebo	9	7 (77.8)	60.1 (19.8)	31	43.0	62.0	80.0	88	
	Week 51	Tezepelumab	12	12 (100.0)	67.4 (20.1)	35	53.0	61.0	88.0	93	
		Placebo	9	7 (77.8)	62.6 (26.5)	21	43.0	59.0	85.0	97	
	Week 52	Tezepelumab	12	12 (100.0)	67.8 (20.2)	35	51.0	64.5	88.0	93	
		Placebo	9	7 (77.8)	60.7 (27.8)	21	38.0	59.0	85.0	97	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 1	Tezepelumab	12	10 (83.3)	6.3 (16.2)	-20	-7.0	7.5	19.0	30	0.53 [-0.45, 1.51]
		Placebo	9	7 (77.8)	-3.4 (21.1)	-32	-29.0	2.0	9.0	27	
	Week 2	Tezepelumab	12	10 (83.3)	2.6 (19.6)	-23	-11.0	-3.5	23.0	33	-0.20 [-1.17, 0.77]
		Placebo	9	7 (77.8)	6.1 (15.1)	-11	-6.0	8.0	10.0	35	
	Week 3	Tezepelumab	12	10 (83.3)	9.3 (20.0)	-21	-5.0	11.0	31.0	34	0.07 [-0.90, 1.03]
		Placebo	9	7 (77.8)	8.0 (18.9)	-9	-5.0	-3.0	31.0	38	
	Week 4	Tezepelumab	12	10 (83.3)	8.4 (23.0)	-40	-2.0	17.0	28.0	30	0.06 [-0.91, 1.02]
		Placebo	9	7 (77.8)	7.3 (10.7)	-6	-5.0	9.0	10.0	26	
	Week 5	Tezepelumab	12	10 (83.3)	11.0 (17.3)	-15	-2.0	12.5	20.0	38	0.07 [-0.89, 1.04]
		Placebo	9	7 (77.8)	9.9 (13.3)	-5	-4.0	8.0	27.0	28	
	Week 6	Tezepelumab	12	10 (83.3)	6.1 (21.5)	-28	-10.0	7.0	26.0	33	0.10 [-0.87, 1.07]
		Placebo	9	7 (77.8)	4.0 (20.6)	-29	-10.0	6.0	13.0	38	
	Week 7	Tezepelumab	12	10 (83.3)	6.4 (22.9)	-39	-4.0	13.5	25.0	34	0.07 [-0.89, 1.04]
		Placebo	9	7 (77.8)	4.7 (22.3)	-33	-2.0	2.0	21.0	39	
	Week 8	Tezepelumab	12	10 (83.3)	7.8 (29.1)	-59	-6.0	11.5	35.0	38	0.25 [-0.72, 1.22]
		Placebo	9	7 (77.8)	0.7 (25.9)	-36	-22.0	8.0	19.0	40	
	Week 9	Tezepelumab	12	10 (83.3)	8.4 (21.3)	-25	-12.0	14.5	22.0	36	0.11 [-0.86, 1.08]
		Placebo	9	7 (77.8)	6.1 (20.1)	-15	-6.0	0.0	15.0	46	
	Week 10	Tezepelumab	12	10 (83.3)	5.5 (23.5)	-41	-8.0	8.0	24.0	33	0.16 [-0.81, 1.12]
		Placebo	9	7 (77.8)	2.0 (20.8)	-21	-20.0	8.0	13.0	37	
	Week 11	Tezepelumab	12	10 (83.3)	7.6 (23.5)	-38	-10.0	13.5	26.0	35	0.18 [-0.79, 1.15]
		Placebo	9	7 (77.8)	3.7 (18.2)	-15	-11.0	6.0	8.0	39	
	Week 12	Tezepelumab	12	10 (83.3)	10.0 (22.6)	-31	-2.0	13.5	30.0	38	0.29 [-0.68, 1.26]
		Placebo	9	7 (77.8)	3.7 (19.7)	-17	-10.0	-4.0	10.0	43	
	Week 13	Tezepelumab	12	10 (83.3)	9.4 (23.2)	-31	-7.0	13.5	28.0	40	0.26 [-0.71, 1.23]
		Placebo	9	7 (77.8)	4.0 (16.2)	-7	-6.0	-3.0	8.0	39	
	Week 14	Tezepelumab	12	10 (83.3)	9.7 (20.1)	-16	-8.0	11.0	22.0	42	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	5.6 (17.0)	-9	-7.0	2.0	11.0	40	
	Week 15	Tezepelumab	12	10 (83.3)	8.4 (28.5)	-51	-10.0	16.0	29.0	43	0.27 [-0.70, 1.24]
		Placebo	9	7 (77.8)	1.3 (21.6)	-35	-8.0	-3.0	20.0	32	
	Week 16	Tezepelumab	12	10 (83.3)	8.0 (23.3)	-30	-14.0	12.0	22.0	38	0.07 [-0.89, 1.04]
		Placebo	9	7 (77.8)	6.4 (17.7)	-16	-9.0	8.0	23.0	34	
	Week 17	Tezepelumab	12	10 (83.3)	5.8 (23.5)	-36	-12.0	10.5	22.0	39	0.15 [-0.82, 1.12]
		Placebo	9	7 (77.8)	2.1 (25.5)	-40	-14.0	1.0	30.0	34	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 18	Tezepelumab	12	10 (83.3)	7.9 (24.7)	-40	-7.0	15.0	22.0	40	0.24 [-0.73, 1.21]
		Placebo	9	7 (77.8)	2.3 (21.5)	-27	-13.0	-1.0	27.0	32	
	Week 19	Tezepelumab	12	10 (83.3)	8.2 (21.2)	-23	-9.0	13.0	22.0	35	0.26 [-0.72, 1.23]
		Placebo	9	7 (77.8)	2.6 (23.3)	-28	-17.0	-4.0	30.0	35	
	Week 20	Tezepelumab	12	10 (83.3)	10.0 (19.7)	-20	-4.0	13.0	24.0	41	0.34 [-0.64, 1.31]
		Placebo	9	7 (77.8)	2.6 (25.4)	-25	-20.0	-8.0	35.0	38	
	Week 21	Tezepelumab	12	10 (83.3)	10.2 (21.5)	-23	-7.0	14.5	25.0	40	0.27 [-0.70, 1.24]
		Placebo	9	7 (77.8)	3.9 (25.9)	-31	-9.0	-8.0	37.0	39	
	Week 22	Tezepelumab	12	10 (83.3)	9.4 (20.2)	-16	-10.0	13.5	28.0	33	0.16 [-0.81, 1.13]
		Placebo	9	7 (77.8)	6.0 (23.4)	-21	-12.0	-1.0	35.0	40	
	Week 23	Tezepelumab	12	10 (83.3)	8.6 (20.2)	-18	-12.0	13.5	27.0	33	0.25 [-0.72, 1.22]
		Placebo	9	7 (77.8)	3.4 (21.8)	-23	-16.0	-2.0	23.0	39	
	Week 24	Tezepelumab	12	10 (83.3)	10.3 (22.0)	-19	-10.0	17.0	32.0	38	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	6.6 (21.7)	-21	-10.0	0.0	29.0	41	
	Week 25	Tezepelumab	12	10 (83.3)	7.5 (24.6)	-37	-11.0	14.0	25.0	39	0.06 [-0.91, 1.02]
		Placebo	9	7 (77.8)	6.1 (23.7)	-25	-8.0	-1.0	34.0	41	
	Week 26	Tezepelumab	12	10 (83.3)	6.4 (26.2)	-43	-15.0	13.0	27.0	43	0.00 [-0.96, 0.97]
		Placebo	9	7 (77.8)	6.3 (18.8)	-16	-7.0	2.0	31.0	32	
	Week 27	Tezepelumab	12	10 (83.3)	6.1 (25.7)	-43	-10.0	11.5	25.0	40	0.07 [-0.90, 1.04]
		Placebo	9	7 (77.8)	4.4 (20.2)	-25	-6.0	-2.0	26.0	34	
	Week 28	Tezepelumab	12	10 (83.3)	7.4 (26.1)	-43	-11.0	14.5	28.0	39	0.35 [-0.63, 1.32]
		Placebo	9	7 (77.8)	-0.9 (19.7)	-20	-16.0	-3.0	8.0	37	
	Week 29	Tezepelumab	12	10 (83.3)	5.2 (24.5)	-43	-15.0	13.0	22.0	38	0.38 [-0.59, 1.36]
		Placebo	9	7 (77.8)	-3.4 (19.3)	-28	-14.0	-9.0	8.0	33	
	Week 30	Tezepelumab	12	10 (83.3)	5.1 (23.8)	-43	-12.0	12.5	22.0	37	0.20 [-0.77, 1.17]
		Placebo	9	7 (77.8)	0.7 (19.0)	-22	-16.0	-1.0	9.0	35	
	Week 31	Tezepelumab	12	10 (83.3)	6.3 (24.9)	-43	-12.0	13.0	25.0	33	0.13 [-0.84, 1.09]
		Placebo	9	7 (77.8)	3.4 (18.2)	-20	-13.0	7.0	14.0	34	
	Week 32	Tezepelumab	12	10 (83.3)	5.6 (24.8)	-43	-12.0	15.5	25.0	34	0.21 [-0.76, 1.18]
		Placebo	9	7 (77.8)	0.6 (22.2)	-30	-13.0	-8.0	24.0	33	
	Week 33	Tezepelumab	12	10 (83.3)	7.2 (25.4)	-43	-12.0	16.0	27.0	39	0.13 [-0.84, 1.09]
		Placebo	9	7 (77.8)	4.3 (18.7)	-17	-8.0	-5.0	29.0	30	
	Week 34	Tezepelumab	12	10 (83.3)	7.7 (26.7)	-43	-16.0	13.0	30.0	43	-0.02 [-0.99, 0.94]
		Placebo	9	7 (77.8)	8.3 (23.3)	-24	-10.0	6.0	35.0	40	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 35	Tezepelumab	12	10 (83.3)	7.5 (25.1)	-43	-10.0	13.0	22.0	39	0.00 [-0.96, 0.97]
		Placebo	9	7 (77.8)	7.4 (21.4)	-14	-8.0	-6.0	33.0	39	
	Week 36	Tezepelumab	12	10 (83.3)	8.9 (26.7)	-43	-6.0	13.0	30.0	42	0.02 [-0.95, 0.98]
		Placebo	9	7 (77.8)	8.4 (22.5)	-16	-7.0	-3.0	35.0	42	
	Week 37	Tezepelumab	12	10 (83.3)	7.9 (27.1)	-43	-11.0	12.5	29.0	40	0.21 [-0.76, 1.18]
		Placebo	9	7 (77.8)	2.1 (26.9)	-26	-21.0	-7.0	38.0	41	
	Week 38	Tezepelumab	12	10 (83.3)	8.1 (26.7)	-43	-11.0	13.0	25.0	44	0.16 [-0.81, 1.12]
		Placebo	9	7 (77.8)	4.0 (25.2)	-26	-13.0	-5.0	33.0	44	
	Week 39	Tezepelumab	12	10 (83.3)	8.5 (26.9)	-43	-12.0	13.5	30.0	43	0.13 [-0.83, 1.10]
		Placebo	9	7 (77.8)	5.0 (24.5)	-18	-16.0	-5.0	34.0	44	
	Week 40	Tezepelumab	12	10 (83.3)	6.4 (24.9)	-43	-14.0	14.5	22.0	38	-0.04 [-1.01, 0.92]
		Placebo	9	7 (77.8)	7.4 (22.6)	-10	-7.0	-7.0	34.0	45	
	Week 41	Tezepelumab	12	10 (83.3)	5.7 (25.3)	-43	-15.0	9.5	22.0	40	-0.02 [-0.98, 0.95]
		Placebo	9	7 (77.8)	6.1 (22.6)	-20	-11.0	-2.0	36.0	37	
	Week 42	Tezepelumab	12	10 (83.3)	6.8 (24.9)	-43	-11.0	15.0	22.0	40	-0.03 [-0.99, 0.94]
		Placebo	9	7 (77.8)	7.4 (21.4)	-13	-9.0	-4.0	37.0	37	
	Week 43	Tezepelumab	12	10 (83.3)	7.0 (25.3)	-43	-12.0	14.0	27.0	37	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	3.0 (20.1)	-29	-6.0	1.0	14.0	36	
	Week 44	Tezepelumab	12	10 (83.3)	7.3 (25.1)	-43	-12.0	15.5	28.0	35	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	2.3 (19.1)	-24	-9.0	4.0	10.0	37	
	Week 45	Tezepelumab	12	10 (83.3)	7.3 (26.0)	-43	-14.0	14.0	33.0	34	0.01 [-0.96, 0.97]
		Placebo	9	7 (77.8)	7.1 (24.2)	-22	-8.0	-3.0	39.0	41	
	Week 46	Tezepelumab	12	10 (83.3)	6.9 (24.4)	-43	-10.0	14.0	26.0	33	-0.06 [-1.02, 0.91]
		Placebo	9	7 (77.8)	8.3 (22.8)	-13	-8.0	-5.0	35.0	44	
	Week 47	Tezepelumab	12	10 (83.3)	5.9 (25.2)	-43	-13.0	10.5	25.0	34	0.03 [-0.94, 1.00]
		Placebo	9	7 (77.8)	5.1 (23.3)	-17	-13.0	-3.0	36.0	39	
	Week 48	Tezepelumab	12	10 (83.3)	6.0 (25.5)	-43	-16.0	16.5	23.0	36	-0.02 [-0.98, 0.95]
		Placebo	9	7 (77.8)	6.4 (23.9)	-19	-18.0	-3.0	36.0	39	
	Week 49	Tezepelumab	12	10 (83.3)	6.3 (24.8)	-43	-16.0	14.5	22.0	38	0.00 [-0.97, 0.97]
		Placebo	9	7 (77.8)	6.3 (20.3)	-11	-9.0	-7.0	33.0	35	
	Week 50	Tezepelumab	12	10 (83.3)	5.6 (24.2)	-43	-14.0	11.0	22.0	34	0.08 [-0.88, 1.05]
		Placebo	9	7 (77.8)	3.6 (24.4)	-23	-16.0	-8.0	33.0	38	
	Week 51	Tezepelumab	12	10 (83.3)	4.8 (23.2)	-43	-14.0	11.5	21.0	34	-0.05 [-1.02, 0.91]
		Placebo	9	7 (77.8)	6.0 (22.4)	-26	-8.0	3.0	30.0	38	
	Week 52	Tezepelumab	12	10 (83.3)	5.2 (23.9)	-43	-13.0	11.5	22.0	34	0.04 [-0.92, 1.01]
		Placebo	9	7 (77.8)	4.1 (23.3)	-26	-13.0	-5.0	30.0	38	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 2	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 3	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 5	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 6	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	5 (55.6)						
Week 7	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 9	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 10	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 12	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 13	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 14	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 15	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 16	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 17	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 18	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 19	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 22	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 23	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 25	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	5 (55.6)						
Week 26	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 27	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 29	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 30	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 33	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 34	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 35	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 36	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 37	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 38	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 39	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 42	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	5 (55.6)						
Week 43	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 44	Tezepelumab	12	5 (41.7)	NE		NE			
	Placebo	9	7 (77.8)						
Week 45	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 46	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 47	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 48	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 49	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 50	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	7 (77.8)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table ST1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	12	12 (100.0)	61.8 (17.9)	24	51.0	58.5	80.0	85	
		Placebo	11	11 (100.0)	55.8 (20.8)	24	40.0	60.0	75.0	90	
	Week 2	Tezepelumab	12	12 (100.0)	62.4 (17.2)	26	52.0	60.5	76.0	86	
		Placebo	11	11 (100.0)	52.2 (21.2)	22	30.0	57.0	60.0	87	
	Week 4	Tezepelumab	12	12 (100.0)	62.3 (20.6)	13	51.5	69.5	74.0	86	
		Placebo	11	11 (100.0)	58.5 (10.5)	35	56.0	58.0	65.0	75	
	Week 6	Tezepelumab	12	11 (91.7)	64.4 (16.2)	34	60.0	65.0	70.0	89	
		Placebo	11	11 (100.0)	58.1 (13.7)	36	50.0	59.0	66.0	90	
	Week 8	Tezepelumab	12	12 (100.0)	65.2 (15.5)	42	55.5	62.0	76.5	90	
		Placebo	11	11 (100.0)	57.1 (16.1)	30	41.0	63.0	69.0	76	
	Week 10	Tezepelumab	12	12 (100.0)	62.9 (14.8)	40	53.5	64.5	71.5	88	
		Placebo	11	11 (100.0)	51.1 (15.7)	30	38.0	51.0	60.0	83	
	Week 12	Tezepelumab	12	11 (91.7)	62.9 (16.2)	35	54.0	66.0	74.0	87	
		Placebo	11	11 (100.0)	54.7 (15.2)	35	40.0	51.0	69.0	80	
	Week 14	Tezepelumab	12	11 (91.7)	58.1 (16.9)	37	42.0	60.0	70.0	86	
		Placebo	11	11 (100.0)	53.7 (15.4)	40	42.0	50.0	62.0	91	
	Week 16	Tezepelumab	12	11 (91.7)	62.1 (16.2)	37	52.0	60.0	73.0	88	
		Placebo	11	11 (100.0)	52.5 (14.5)	35	44.0	50.0	55.0	84	
	Week 18	Tezepelumab	12	11 (91.7)	63.1 (20.9)	28	43.0	67.0	82.0	90	
		Placebo	11	11 (100.0)	56.0 (15.7)	37	42.0	52.0	60.0	87	
	Week 20	Tezepelumab	12	11 (91.7)	67.1 (15.8)	40	51.0	69.0	80.0	90	
		Placebo	11	11 (100.0)	54.5 (14.4)	35	42.0	52.0	67.0	83	
	Week 22	Tezepelumab	12	11 (91.7)	65.4 (14.2)	45	57.0	62.0	79.0	88	
		Placebo	11	11 (100.0)	58.0 (14.7)	30	52.0	55.0	70.0	85	
	Week 24	Tezepelumab	12	11 (91.7)	63.5 (15.9)	37	51.0	61.0	77.0	89	
		Placebo	11	11 (100.0)	54.5 (18.5)	30	37.0	54.0	70.0	85	
	Week 26	Tezepelumab	12	11 (91.7)	59.2 (21.7)	20	47.0	61.0	73.0	87	
		Placebo	11	11 (100.0)	55.8 (17.9)	30	43.0	55.0	60.0	91	
	Week 28	Tezepelumab	12	10 (83.3)	61.0 (16.8)	35	51.0	59.0	72.0	87	
		Placebo	11	11 (100.0)	49.5 (14.5)	35	38.0	48.0	51.0	85	
	Week 30	Tezepelumab	12	10 (83.3)	60.7 (15.4)	40	49.0	57.5	66.0	87	
		Placebo	11	11 (100.0)	50.9 (13.6)	36	40.0	51.0	60.0	84	
	Week 32	Tezepelumab	12	10 (83.3)	61.0 (14.6)	39	55.0	60.0	64.0	86	
		Placebo	11	11 (100.0)	53.9 (18.0)	30	41.0	51.0	60.0	92	
	Week 34	Tezepelumab	12	10 (83.3)	63.6 (13.8)	48	53.0	59.5	71.0	87	
		Placebo	11	11 (100.0)	55.6 (17.0)	25	48.0	50.0	74.0	81	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	12	10 (83.3)	61.5 (17.8)	32	51.0	60.0	79.0	87	
		Placebo	11	11 (100.0)	56.6 (17.8)	35	44.0	53.0	65.0	94	
	Week 38	Tezepelumab	12	9 (75.0)	61.4 (17.1)	33	55.0	60.0	62.0	88	
		Placebo	11	11 (100.0)	54.0 (18.1)	30	36.0	53.0	60.0	90	
	Week 40	Tezepelumab	12	10 (83.3)	61.8 (18.9)	28	54.0	62.5	77.0	85	
		Placebo	11	11 (100.0)	53.5 (20.0)	25	36.0	52.0	60.0	90	
	Week 42	Tezepelumab	12	8 (66.7)	66.5 (13.9)	50	57.0	64.0	75.0	90	
		Placebo	11	11 (100.0)	54.3 (18.4)	35	41.0	50.0	60.0	94	
	Week 44	Tezepelumab	12	9 (75.0)	67.9 (16.6)	41	60.0	67.0	77.0	93	
		Placebo	11	11 (100.0)	54.3 (18.6)	35	40.0	51.0	60.0	98	
	Week 46	Tezepelumab	12	8 (66.7)	63.0 (15.3)	49	50.0	60.0	73.0	89	
		Placebo	11	11 (100.0)	53.0 (19.8)	31	37.0	52.0	60.0	99	
	Week 48	Tezepelumab	12	9 (75.0)	67.0 (13.2)	50	60.0	61.0	76.0	88	
		Placebo	11	10 (90.9)	56.8 (18.7)	32	44.0	55.0	60.0	94	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	12	12 (100.0)	0.7 (8.3)	-13	-5.5	1.5	6.5	13	0.29 [-0.53, 1.11]
		Placebo	11	11 (100.0)	-3.6 (19.8)	-51	-13.0	0.0	9.0	22	
	Week 4	Tezepelumab	12	12 (100.0)	0.5 (13.5)	-20	-10.5	-1.5	11.5	20	-0.14 [-0.96, 0.68]
		Placebo	11	11 (100.0)	2.6 (17.6)	-31	-8.0	0.0	18.0	25	
	Week 6	Tezepelumab	12	11 (91.7)	1.6 (11.5)	-15	-10.0	4.0	10.0	20	-0.04 [-0.88, 0.79]
		Placebo	11	11 (100.0)	2.3 (18.5)	-31	-6.0	6.0	12.0	31	
	Week 8	Tezepelumab	12	12 (100.0)	3.4 (17.1)	-20	-9.5	1.5	11.0	39	0.12 [-0.70, 0.94]
		Placebo	11	11 (100.0)	1.3 (18.9)	-34	-7.0	0.0	11.0	35	
	Week 10	Tezepelumab	12	12 (100.0)	1.2 (17.2)	-40	-5.5	2.0	15.5	23	0.29 [-0.53, 1.11]
		Placebo	11	11 (100.0)	-4.7 (23.4)	-57	-12.0	0.0	6.0	22	
	Week 12	Tezepelumab	12	11 (91.7)	2.8 (18.6)	-45	0.0	3.0	16.0	23	0.17 [-0.66, 1.01]
		Placebo	11	11 (100.0)	-1.1 (26.0)	-50	-15.0	3.0	21.0	35	
	Week 14	Tezepelumab	12	11 (91.7)	-2.0 (16.3)	-39	-8.0	0.0	13.0	18	0.00 [-0.83, 0.84]
		Placebo	11	11 (100.0)	-2.1 (24.0)	-42	-15.0	-9.0	21.0	30	
	Week 16	Tezepelumab	12	11 (91.7)	2.0 (14.2)	-27	-11.0	3.0	13.0	22	0.27 [-0.57, 1.11]
		Placebo	11	11 (100.0)	-3.4 (24.1)	-46	-15.0	1.0	9.0	32	
	Week 18	Tezepelumab	12	11 (91.7)	3.0 (15.8)	-22	-9.0	4.0	15.0	31	0.13 [-0.71, 0.96]
		Placebo	11	11 (100.0)	0.2 (27.3)	-53	-14.0	1.0	19.0	47	
	Week 20	Tezepelumab	12	11 (91.7)	7.0 (10.8)	-10	-2.0	8.0	11.0	30	0.49 [-0.36, 1.33]
		Placebo	11	11 (100.0)	-1.3 (21.6)	-38	-14.0	5.0	18.0	27	
	Week 22	Tezepelumab	12	11 (91.7)	5.3 (14.6)	-34	3.0	6.0	15.0	21	0.17 [-0.67, 1.00]
		Placebo	11	11 (100.0)	2.2 (21.7)	-38	-12.0	1.0	17.0	31	
	Week 24	Tezepelumab	12	11 (91.7)	3.4 (12.9)	-28	0.0	4.0	9.0	26	0.21 [-0.63, 1.05]
		Placebo	11	11 (100.0)	-1.3 (28.9)	-57	-11.0	0.0	29.0	39	
	Week 26	Tezepelumab	12	11 (91.7)	-0.9 (20.9)	-60	-3.0	2.0	8.0	21	-0.04 [-0.87, 0.80]
		Placebo	11	11 (100.0)	0.0 (26.5)	-51	-14.0	0.0	13.0	44	
	Week 28	Tezepelumab	12	10 (83.3)	-2.7 (17.1)	-39	-4.0	2.0	4.0	21	0.20 [-0.66, 1.06]
		Placebo	11	11 (100.0)	-6.3 (18.3)	-39	-17.0	5.0	7.0	11	
	Week 30	Tezepelumab	12	10 (83.3)	-3.0 (13.6)	-31	-11.0	1.5	5.0	12	0.10 [-0.76, 0.96]
		Placebo	11	11 (100.0)	-4.9 (23.1)	-51	-19.0	0.0	7.0	27	
	Week 32	Tezepelumab	12	10 (83.3)	-2.7 (10.2)	-18	-11.0	0.0	3.0	13	-0.04 [-0.90, 0.82]
		Placebo	11	11 (100.0)	-1.9 (24.8)	-48	-14.0	0.0	14.0	39	
	Week 34	Tezepelumab	12	10 (83.3)	-0.1 (12.7)	-24	-2.0	3.0	6.0	20	0.00 [-0.85, 0.86]
		Placebo	11	11 (100.0)	-0.2 (21.3)	-35	-15.0	-1.0	7.0	41	
	Week 36	Tezepelumab	12	10 (83.3)	-2.2 (13.5)	-27	-11.0	1.0	6.0	19	-0.14 [-1.00, 0.72]
		Placebo	11	11 (100.0)	0.8 (26.3)	-39	-21.0	2.0	8.0	54	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC_IBMH0: Course of EQ-5D-VAS
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	12	9 (75.0)	-3.7 (10.9)	-18	-16.0	-1.0	5.0	8	-0.08 [-0.96, 0.80]
		Placebo	11	11 (100.0)	-1.8 (29.6)	-56	-15.0	0.0	9.0	50	
	Week 40	Tezepelumab	12	10 (83.3)	-1.9 (14.7)	-22	-16.0	-0.5	7.0	26	0.02 [-0.84, 0.88]
		Placebo	11	11 (100.0)	-2.4 (26.9)	-42	-16.0	-4.0	6.0	50	
	Week 42	Tezepelumab	12	8 (66.7)	-0.4 (8.3)	-15	-5.5	-0.5	7.0	10	0.05 [-0.86, 0.97]
		Placebo	11	11 (100.0)	-1.5 (27.3)	-40	-15.0	0.0	5.0	54	
	Week 44	Tezepelumab	12	9 (75.0)	2.8 (10.5)	-19	0.0	6.0	8.0	16	0.19 [-0.69, 1.08]
		Placebo	11	11 (100.0)	-1.5 (28.4)	-44	-18.0	-1.0	5.0	58	
	Week 46	Tezepelumab	12	8 (66.7)	-3.9 (11.8)	-22	-14.5	1.0	5.0	8	-0.04 [-0.96, 0.87]
		Placebo	11	11 (100.0)	-2.8 (29.1)	-47	-16.0	-5.0	1.0	59	
	Week 48	Tezepelumab	12	9 (75.0)	1.9 (11.6)	-20	0.0	4.0	9.0	16	0.10 [-0.80, 1.01]
		Placebo	11	10 (90.9)	-0.5 (29.6)	-46	-10.0	0.0	2.0	54	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 2	Tezepelumab	12	12 (100.0)	NE		NE		
	Placebo	11	11 (100.0)					
Week 4	Tezepelumab	12	12 (100.0)	NE		NE		
	Placebo	11	11 (100.0)					
Week 6	Tezepelumab	12	11 (91.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 8	Tezepelumab	12	12 (100.0)	NE		NE		
	Placebo	11	11 (100.0)					
Week 10	Tezepelumab	12	12 (100.0)	NE		NE		
	Placebo	11	11 (100.0)					
Week 12	Tezepelumab	12	11 (91.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 14	Tezepelumab	12	11 (91.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 16	Tezepelumab	12	11 (91.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 18	Tezepelumab	12	11 (91.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 20	Tezepelumab	12	11 (91.7)	NE		NE		
	Placebo	11	11 (100.0)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 22	Tezepelumab	12	11 (91.7)	NE		NE			
	Placebo	11	11 (100.0)						
Week 24	Tezepelumab	12	11 (91.7)	NE		NE			
	Placebo	11	11 (100.0)						
Week 26	Tezepelumab	12	11 (91.7)	NE		NE			
	Placebo	11	11 (100.0)						
Week 28	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	11	11 (100.0)						
Week 30	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	11	11 (100.0)						
Week 32	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	11	11 (100.0)						
Week 34	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	11	11 (100.0)						
Week 36	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	11	11 (100.0)						
Week 38	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	11	11 (100.0)						
Week 40	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	11	11 (100.0)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 42	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 44	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	11	11 (100.0)					
Week 46	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	11	11 (100.0)					
Week 48	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	11	10 (90.9)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table NT1VSC_ABMH0: Course of EQ-5D-VAS
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	54	54 (100.0)	64.5 (17.2)	26	50.0	66.5	80.0	95	
		Placebo	39	39 (100.0)	62.0 (16.0)	37	50.0	63.0	75.0	96	
	Week 2	Tezepelumab	54	52 (96.3)	66.3 (15.3)	30	54.0	68.0	80.0	98	
		Placebo	39	37 (94.9)	66.4 (17.7)	5	55.0	69.0	75.0	98	
	Week 4	Tezepelumab	54	54 (100.0)	70.6 (13.8)	37	60.0	71.0	80.0	95	
		Placebo	39	38 (97.4)	65.4 (18.8)	19	50.0	67.0	80.0	96	
	Week 6	Tezepelumab	54	52 (96.3)	69.1 (15.2)	35	59.5	69.5	80.0	100	
		Placebo	39	37 (94.9)	66.7 (16.6)	28	51.0	70.0	80.0	95	
	Week 8	Tezepelumab	54	54 (100.0)	66.3 (18.2)	0	53.0	70.0	80.0	98	
		Placebo	39	39 (100.0)	65.6 (17.3)	27	50.0	67.0	79.0	96	
	Week 10	Tezepelumab	54	52 (96.3)	71.9 (16.1)	40	60.0	76.5	83.5	100	
		Placebo	39	36 (92.3)	66.5 (17.7)	27	51.5	69.5	80.0	97	
	Week 12	Tezepelumab	54	53 (98.1)	68.5 (16.1)	40	58.0	67.0	83.0	98	
		Placebo	39	38 (97.4)	65.7 (19.0)	31	49.0	70.0	81.0	95	
	Week 14	Tezepelumab	54	50 (92.6)	68.7 (17.6)	36	51.0	67.0	82.0	100	
		Placebo	39	37 (94.9)	66.7 (17.7)	25	58.0	74.0	78.0	96	
	Week 16	Tezepelumab	54	53 (98.1)	68.2 (17.0)	30	52.0	68.0	82.0	96	
		Placebo	39	38 (97.4)	68.8 (17.7)	29	55.0	73.5	83.0	94	
	Week 18	Tezepelumab	54	53 (98.1)	69.0 (16.0)	39	54.0	70.0	83.0	96	
		Placebo	39	36 (92.3)	67.2 (19.5)	20	54.5	71.5	80.0	97	
	Week 20	Tezepelumab	54	54 (100.0)	67.8 (18.0)	28	54.0	71.0	80.0	97	
		Placebo	39	39 (100.0)	68.9 (18.9)	30	53.0	75.0	85.0	96	
	Week 22	Tezepelumab	54	52 (96.3)	68.8 (16.4)	38	54.5	72.0	82.5	95	
		Placebo	39	34 (87.2)	69.4 (18.4)	25	60.0	75.0	83.0	96	
	Week 24	Tezepelumab	54	54 (100.0)	68.5 (18.0)	12	56.0	70.0	81.0	100	
		Placebo	39	37 (94.9)	67.5 (19.2)	20	56.0	72.0	82.0	95	
	Week 26	Tezepelumab	54	52 (96.3)	69.2 (16.4)	40	59.0	68.0	82.5	98	
		Placebo	39	33 (84.6)	68.6 (18.3)	15	60.0	70.0	80.0	95	
	Week 28	Tezepelumab	54	53 (98.1)	68.9 (17.0)	31	54.0	70.0	83.0	98	
		Placebo	39	37 (94.9)	67.7 (18.8)	15	60.0	70.0	80.0	95	
	Week 30	Tezepelumab	54	52 (96.3)	70.0 (16.7)	22	60.0	70.0	85.0	97	
		Placebo	39	35 (89.7)	66.0 (20.3)	20	50.0	69.0	81.0	96	
	Week 32	Tezepelumab	54	53 (98.1)	70.1 (15.3)	39	61.0	70.0	85.0	95	
		Placebo	39	37 (94.9)	70.8 (20.1)	19	59.0	73.0	83.0	100	
	Week 34	Tezepelumab	54	53 (98.1)	71.5 (16.5)	24	62.0	75.0	82.0	100	
		Placebo	39	34 (87.2)	67.9 (19.4)	19	54.0	73.0	82.0	94	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
 Source Data: avas, created on: 20FEB2022

Table NT1VSC_ABMH0: Course of EQ-5D-VAS
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	54	52 (96.3)	67.9 (16.6)	31	55.0	69.0	81.0	98	
		Placebo	39	37 (94.9)	66.4 (19.6)	16	57.0	68.0	80.0	95	
	Week 38	Tezepelumab	54	52 (96.3)	71.4 (14.3)	40	60.5	72.5	82.5	97	
		Placebo	39	34 (87.2)	68.7 (20.0)	15	57.0	71.5	82.0	96	
	Week 40	Tezepelumab	54	52 (96.3)	68.4 (17.2)	30	54.0	70.5	81.5	98	
		Placebo	39	37 (94.9)	68.1 (20.5)	10	57.0	75.0	81.0	96	
	Week 42	Tezepelumab	54	53 (98.1)	67.3 (17.9)	19	54.0	70.0	81.0	96	
		Placebo	39	34 (87.2)	67.4 (20.4)	15	54.0	71.0	84.0	94	
	Week 44	Tezepelumab	54	52 (96.3)	70.3 (17.6)	30	55.5	72.5	85.5	99	
		Placebo	39	37 (94.9)	66.2 (19.9)	15	50.0	67.0	83.0	96	
	Week 46	Tezepelumab	54	53 (98.1)	66.5 (19.0)	30	51.0	69.0	80.0	98	
		Placebo	39	34 (87.2)	69.7 (20.2)	10	61.0	76.5	80.0	97	
	Week 48	Tezepelumab	54	53 (98.1)	68.1 (18.6)	30	50.0	70.0	84.0	100	
		Placebo	39	37 (94.9)	70.1 (19.6)	15	59.0	75.0	84.0	97	
	Week 50	Tezepelumab	54	51 (94.4)	69.2 (17.7)	23	56.0	73.0	82.0	99	
		Placebo	39	35 (89.7)	70.3 (20.3)	10	62.0	75.0	82.0	97	
	Week 52	Tezepelumab	54	40 (74.1)	69.7 (16.4)	41	57.5	70.0	81.0	98	
		Placebo	39	31 (79.5)	69.8 (21.2)	9	60.0	75.0	86.0	96	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
 Source Data: avas, created on: 20FEB2022

Table NT1VSC_ABMH0: Course of EQ-5D-VAS
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	54	52 (96.3)	1.8 (15.2)	-39	-4.0	1.5	9.0	36	-0.10 [-0.52, 0.32]
		Placebo	39	37 (94.9)	3.4 (16.3)	-46	-3.0	2.0	12.0	58	
	Week 4	Tezepelumab	54	54 (100.0)	6.1 (15.4)	-25	-3.0	4.5	19.0	42	0.20 [-0.22, 0.61]
		Placebo	39	38 (97.4)	3.1 (14.9)	-35	-6.0	2.0	11.0	52	
	Week 6	Tezepelumab	54	52 (96.3)	4.8 (17.1)	-45	-3.0	1.0	10.5	46	0.03 [-0.40, 0.45]
		Placebo	39	37 (94.9)	4.4 (17.1)	-35	-4.0	2.0	12.0	51	
	Week 8	Tezepelumab	54	54 (100.0)	1.8 (18.5)	-70	-5.0	3.0	12.0	39	-0.10 [-0.51, 0.31]
		Placebo	39	39 (100.0)	3.6 (17.4)	-40	-4.0	2.0	17.0	53	
	Week 10	Tezepelumab	54	52 (96.3)	6.8 (18.2)	-35	0.0	5.5	14.5	56	0.18 [-0.25, 0.61]
		Placebo	39	36 (92.3)	3.6 (17.7)	-34	-3.5	2.0	14.5	57	
	Week 12	Tezepelumab	54	53 (98.1)	3.9 (18.2)	-40	-4.0	2.0	10.0	45	0.03 [-0.39, 0.45]
		Placebo	39	38 (97.4)	3.3 (20.7)	-40	-7.0	0.0	14.0	54	
	Week 14	Tezepelumab	54	50 (92.6)	3.8 (20.8)	-40	-8.0	4.0	15.0	44	0.01 [-0.42, 0.43]
		Placebo	39	37 (94.9)	3.7 (17.4)	-35	-7.0	0.0	13.0	42	
	Week 16	Tezepelumab	54	53 (98.1)	3.5 (18.2)	-46	-5.0	3.0	10.0	45	-0.16 [-0.58, 0.26]
		Placebo	39	38 (97.4)	6.5 (19.4)	-46	-4.0	3.5	18.0	54	
	Week 18	Tezepelumab	54	53 (98.1)	4.3 (18.5)	-35	-5.0	6.0	13.0	45	0.03 [-0.40, 0.45]
		Placebo	39	36 (92.3)	3.8 (17.5)	-35	-7.0	1.0	15.0	52	
	Week 20	Tezepelumab	54	54 (100.0)	3.3 (17.9)	-45	-5.0	4.5	11.0	47	-0.20 [-0.61, 0.22]
		Placebo	39	39 (100.0)	6.9 (19.6)	-35	-5.0	3.0	17.0	56	
	Week 22	Tezepelumab	54	52 (96.3)	4.1 (18.5)	-38	-8.0	4.5	14.0	47	-0.09 [-0.52, 0.35]
		Placebo	39	34 (87.2)	5.7 (19.0)	-50	-3.0	1.5	18.0	50	
	Week 24	Tezepelumab	54	54 (100.0)	4.0 (17.2)	-34	-10.0	4.0	15.0	47	-0.08 [-0.50, 0.34]
		Placebo	39	37 (94.9)	5.4 (20.6)	-50	-7.0	3.0	19.0	54	
	Week 26	Tezepelumab	54	52 (96.3)	4.3 (19.1)	-35	-7.0	2.0	13.5	60	-0.04 [-0.48, 0.40]
		Placebo	39	33 (84.6)	5.1 (18.6)	-45	-3.0	2.0	15.0	51	
	Week 28	Tezepelumab	54	53 (98.1)	4.3 (19.4)	-40	-5.0	3.0	14.0	50	-0.04 [-0.46, 0.38]
		Placebo	39	37 (94.9)	5.1 (18.2)	-55	-4.0	2.0	19.0	47	
	Week 30	Tezepelumab	54	52 (96.3)	5.2 (20.1)	-38	-9.0	5.0	15.5	47	0.13 [-0.30, 0.55]
		Placebo	39	35 (89.7)	2.7 (20.2)	-54	-11.0	3.0	17.0	50	
	Week 32	Tezepelumab	54	53 (98.1)	5.5 (18.1)	-35	-5.0	4.0	13.0	47	-0.14 [-0.56, 0.28]
		Placebo	39	37 (94.9)	8.2 (21.5)	-56	-1.0	7.0	19.0	54	
	Week 34	Tezepelumab	54	53 (98.1)	6.8 (19.9)	-38	-4.0	7.0	15.0	58	0.13 [-0.31, 0.56]
		Placebo	39	34 (87.2)	4.2 (22.4)	-56	-5.0	6.5	20.0	49	
	Week 36	Tezepelumab	54	52 (96.3)	3.2 (20.1)	-46	-9.0	2.0	14.0	45	-0.03 [-0.45, 0.39]
		Placebo	39	37 (94.9)	3.8 (19.0)	-55	-5.0	1.0	14.0	52	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
 Source Data: avas, created on: 20FEB2022

Table NT1VSC_ABMH0: Course of EQ-5D-VAS
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	54	52 (96.3)	6.7 (18.1)	-37	-5.0	5.5	17.5	47	0.09 [-0.34, 0.52]
		Placebo	39	34 (87.2)	5.0 (20.2)	-57	-5.0	6.5	18.0	42	
	Week 40	Tezepelumab	54	52 (96.3)	3.3 (21.2)	-39	-6.5	1.5	14.0	61	-0.10 [-0.52, 0.32]
		Placebo	39	37 (94.9)	5.5 (20.8)	-55	-4.0	5.0	21.0	50	
	Week 42	Tezepelumab	54	53 (98.1)	2.7 (19.9)	-42	-10.0	3.0	13.0	47	-0.05 [-0.48, 0.38]
		Placebo	39	34 (87.2)	3.6 (20.0)	-60	-5.0	3.5	17.0	43	
	Week 44	Tezepelumab	54	52 (96.3)	5.5 (19.2)	-35	-8.0	6.0	14.5	61	0.10 [-0.32, 0.52]
		Placebo	39	37 (94.9)	3.6 (19.6)	-56	-6.0	1.0	14.0	50	
	Week 46	Tezepelumab	54	53 (98.1)	1.9 (20.1)	-40	-11.0	2.0	13.0	47	-0.20 [-0.63, 0.23]
		Placebo	39	34 (87.2)	5.9 (20.4)	-56	-7.0	4.5	18.0	54	
	Week 48	Tezepelumab	54	53 (98.1)	3.5 (19.0)	-44	-5.0	5.0	10.0	47	-0.20 [-0.62, 0.22]
		Placebo	39	37 (94.9)	7.5 (21.5)	-60	-4.0	3.0	21.0	55	
	Week 50	Tezepelumab	54	51 (94.4)	4.5 (19.9)	-38	-8.0	4.0	14.0	45	-0.10 [-0.53, 0.33]
		Placebo	39	35 (89.7)	6.6 (21.0)	-65	-3.0	3.0	20.0	50	
	Week 52	Tezepelumab	54	40 (74.1)	5.5 (18.6)	-35	-5.0	6.5	15.5	47	-0.11 [-0.58, 0.36]
		Placebo	39	31 (79.5)	7.6 (21.1)	-60	-3.0	6.0	24.0	51	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_ABMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB - adult

Change from baseline in EQ-5D-VAS				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 2	Tezepelumab	54	52 (96.3)	2.4 (1.9)	(-1.4, 6.2)	0.4 (3.0)	(-5.5, 6.2)	0.906																																																																																																																										
	Placebo	39	37 (94.9)	2.1 (2.3)	(-2.4, 6.6)				Week 4	Tezepelumab	54	54 (100.0)	6.4 (1.8)	(2.7, 10.0)	4.7 (2.8)	(-0.9, 10.4)	0.101	Placebo	39	38 (97.4)	1.7 (2.2)	(-2.7, 6.0)	Week 6	Tezepelumab	54	52 (96.3)	5.1 (1.9)	(1.2, 8.9)	1.6 (3.0)	(-4.4, 7.6)	0.593	Placebo	39	37 (94.9)	3.4 (2.3)	(-1.1, 8.0)	Week 8	Tezepelumab	54	54 (100.0)	2.1 (2.2)	(-2.2, 6.4)	-0.6 (3.3)	(-7.3, 6.1)	0.858	Placebo	39	39 (100.0)	2.7 (2.6)	(-2.4, 7.8)	Week 10	Tezepelumab	54	52 (96.3)	7.4 (2.1)	(3.2, 11.6)	5.1 (3.3)	(-1.4, 11.7)	0.121	Placebo	39	36 (92.3)	2.2 (2.5)	(-2.8, 7.2)	Week 12	Tezepelumab	54	53 (98.1)	4.4 (2.3)	(-0.1, 8.9)	2.4 (3.5)	(-4.5, 9.4)	0.489	Placebo	39	38 (97.4)	2.0 (2.7)	(-3.3, 7.3)	Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)	Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo
Week 4	Tezepelumab	54	54 (100.0)	6.4 (1.8)	(2.7, 10.0)	4.7 (2.8)	(-0.9, 10.4)	0.101																																																																																																																										
	Placebo	39	38 (97.4)	1.7 (2.2)	(-2.7, 6.0)				Week 6	Tezepelumab	54	52 (96.3)	5.1 (1.9)	(1.2, 8.9)	1.6 (3.0)	(-4.4, 7.6)	0.593	Placebo	39	37 (94.9)	3.4 (2.3)	(-1.1, 8.0)	Week 8	Tezepelumab	54	54 (100.0)	2.1 (2.2)	(-2.2, 6.4)	-0.6 (3.3)	(-7.3, 6.1)	0.858	Placebo	39	39 (100.0)	2.7 (2.6)	(-2.4, 7.8)	Week 10	Tezepelumab	54	52 (96.3)	7.4 (2.1)	(3.2, 11.6)	5.1 (3.3)	(-1.4, 11.7)	0.121	Placebo	39	36 (92.3)	2.2 (2.5)	(-2.8, 7.2)	Week 12	Tezepelumab	54	53 (98.1)	4.4 (2.3)	(-0.1, 8.9)	2.4 (3.5)	(-4.5, 9.4)	0.489	Placebo	39	38 (97.4)	2.0 (2.7)	(-3.3, 7.3)	Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)	Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)										
Week 6	Tezepelumab	54	52 (96.3)	5.1 (1.9)	(1.2, 8.9)	1.6 (3.0)	(-4.4, 7.6)	0.593																																																																																																																										
	Placebo	39	37 (94.9)	3.4 (2.3)	(-1.1, 8.0)				Week 8	Tezepelumab	54	54 (100.0)	2.1 (2.2)	(-2.2, 6.4)	-0.6 (3.3)	(-7.3, 6.1)	0.858	Placebo	39	39 (100.0)	2.7 (2.6)	(-2.4, 7.8)	Week 10	Tezepelumab	54	52 (96.3)	7.4 (2.1)	(3.2, 11.6)	5.1 (3.3)	(-1.4, 11.7)	0.121	Placebo	39	36 (92.3)	2.2 (2.5)	(-2.8, 7.2)	Week 12	Tezepelumab	54	53 (98.1)	4.4 (2.3)	(-0.1, 8.9)	2.4 (3.5)	(-4.5, 9.4)	0.489	Placebo	39	38 (97.4)	2.0 (2.7)	(-3.3, 7.3)	Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)	Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																								
Week 8	Tezepelumab	54	54 (100.0)	2.1 (2.2)	(-2.2, 6.4)	-0.6 (3.3)	(-7.3, 6.1)	0.858																																																																																																																										
	Placebo	39	39 (100.0)	2.7 (2.6)	(-2.4, 7.8)				Week 10	Tezepelumab	54	52 (96.3)	7.4 (2.1)	(3.2, 11.6)	5.1 (3.3)	(-1.4, 11.7)	0.121	Placebo	39	36 (92.3)	2.2 (2.5)	(-2.8, 7.2)	Week 12	Tezepelumab	54	53 (98.1)	4.4 (2.3)	(-0.1, 8.9)	2.4 (3.5)	(-4.5, 9.4)	0.489	Placebo	39	38 (97.4)	2.0 (2.7)	(-3.3, 7.3)	Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)	Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																						
Week 10	Tezepelumab	54	52 (96.3)	7.4 (2.1)	(3.2, 11.6)	5.1 (3.3)	(-1.4, 11.7)	0.121																																																																																																																										
	Placebo	39	36 (92.3)	2.2 (2.5)	(-2.8, 7.2)				Week 12	Tezepelumab	54	53 (98.1)	4.4 (2.3)	(-0.1, 8.9)	2.4 (3.5)	(-4.5, 9.4)	0.489	Placebo	39	38 (97.4)	2.0 (2.7)	(-3.3, 7.3)	Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)	Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																																				
Week 12	Tezepelumab	54	53 (98.1)	4.4 (2.3)	(-0.1, 8.9)	2.4 (3.5)	(-4.5, 9.4)	0.489																																																																																																																										
	Placebo	39	38 (97.4)	2.0 (2.7)	(-3.3, 7.3)				Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)	Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																																																		
Week 14	Tezepelumab	54	50 (92.6)	4.6 (2.3)	(0.1, 9.1)	1.0 (3.5)	(-5.9, 8.0)	0.770																																																																																																																										
	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.7, 8.8)				Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)	Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																																																																
Week 16	Tezepelumab	54	53 (98.1)	4.0 (2.2)	(-0.4, 8.4)	-1.0 (3.4)	(-7.8, 5.9)	0.780																																																																																																																										
	Placebo	39	38 (97.4)	5.0 (2.6)	(-0.2, 10.2)				Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)	Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																																																																														
Week 18	Tezepelumab	54	53 (98.1)	4.8 (2.1)	(0.6, 9.1)	1.3 (3.3)	(-5.2, 7.9)	0.685																																																																																																																										
	Placebo	39	36 (92.3)	3.5 (2.5)	(-1.5, 8.5)				Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																																																																																												
Week 20	Tezepelumab	54	54 (100.0)	3.5 (2.3)	(-0.9, 8.0)	-2.5 (3.5)	(-9.4, 4.4)	0.477																																																																																																																										
	Placebo	39	39 (100.0)	6.0 (2.7)	(0.8, 11.3)																																																																																																																													

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_ABMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB - adult

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	54	52 (96.3)	4.6 (2.2)	(0.3, 9.0)	-0.8 (3.4)	(-7.5, 6.0)	0.823
	Placebo	39	34 (87.2)	5.4 (2.6)	(0.2, 10.6)			
Week 24	Tezepelumab	54	54 (100.0)	4.3 (2.3)	(-0.2, 8.7)	0.3 (3.5)	(-6.7, 7.3)	0.926
	Placebo	39	37 (94.9)	3.9 (2.7)	(-1.4, 9.3)			
Week 26	Tezepelumab	54	52 (96.3)	5.0 (2.2)	(0.7, 9.3)	1.2 (3.4)	(-5.6, 8.0)	0.724
	Placebo	39	33 (84.6)	3.8 (2.6)	(-1.4, 9.0)			
Week 28	Tezepelumab	54	53 (98.1)	4.8 (2.3)	(0.3, 9.3)	1.3 (3.5)	(-5.7, 8.2)	0.718
	Placebo	39	37 (94.9)	3.5 (2.7)	(-1.8, 8.8)			
Week 30	Tezepelumab	54	52 (96.3)	5.8 (2.4)	(1.1, 10.5)	4.2 (3.7)	(-3.1, 11.5)	0.254
	Placebo	39	35 (89.7)	1.6 (2.8)	(-4.0, 7.2)			
Week 32	Tezepelumab	54	53 (98.1)	6.0 (2.3)	(1.4, 10.5)	-0.8 (3.5)	(-7.9, 6.2)	0.820
	Placebo	39	37 (94.9)	6.8 (2.7)	(1.4, 12.2)			
Week 34	Tezepelumab	54	53 (98.1)	7.3 (2.4)	(2.5, 12.1)	4.8 (3.8)	(-2.7, 12.3)	0.204
	Placebo	39	34 (87.2)	2.5 (2.9)	(-3.2, 8.2)			
Week 36	Tezepelumab	54	52 (96.3)	3.8 (2.3)	(-0.9, 8.4)	1.7 (3.6)	(-5.5, 8.8)	0.648
	Placebo	39	37 (94.9)	2.1 (2.8)	(-3.4, 7.6)			
Week 38	Tezepelumab	54	52 (96.3)	6.9 (2.2)	(2.6, 11.2)	3.3 (3.4)	(-3.4, 10.0)	0.332
	Placebo	39	34 (87.2)	3.6 (2.6)	(-1.6, 8.7)			
Week 40	Tezepelumab	54	52 (96.3)	3.9 (2.5)	(-1.0, 8.9)	-0.1 (3.9)	(-7.8, 7.6)	0.976
	Placebo	39	37 (94.9)	4.0 (3.0)	(-1.9, 9.9)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC_ABMC0: Change from baseline in EQ-5D-VAS - MMRM results
 DITTB - adult

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	54	53 (98.1)	3.1 (2.4)	(-1.6, 7.9)	-0.4 (3.7)	(-7.8, 7.1)	0.922
	Placebo	39	34 (87.2)	3.5 (2.9)	(-2.2, 9.2)			
Week 44	Tezepelumab	54	52 (96.3)	6.2 (2.3)	(1.6, 10.9)	4.2 (3.6)	(-3.0, 11.4)	0.254
	Placebo	39	37 (94.9)	2.1 (2.8)	(-3.4, 7.6)			
Week 46	Tezepelumab	54	53 (98.1)	2.4 (2.5)	(-2.6, 7.3)	-2.5 (3.9)	(-10.2, 5.2)	0.520
	Placebo	39	34 (87.2)	4.8 (3.0)	(-1.0, 10.7)			
Week 48	Tezepelumab	54	53 (98.1)	3.9 (2.4)	(-0.9, 8.8)	-2.1 (3.8)	(-9.6, 5.5)	0.586
	Placebo	39	37 (94.9)	6.0 (2.9)	(0.2, 11.8)			
Week 50	Tezepelumab	54	51 (94.4)	4.6 (2.4)	(-0.2, 9.5)	-0.8 (3.8)	(-8.4, 6.7)	0.825
	Placebo	39	35 (89.7)	5.5 (2.9)	(-0.3, 11.2)			
Week 52	Tezepelumab	54	40 (74.1)	5.6 (2.5)	(0.7, 10.6)	-2.1 (3.8)	(-9.7, 5.6)	0.592
	Placebo	39	31 (79.5)	7.7 (2.9)	(1.9, 13.5)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table MT1QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	66	64 (97.0)	3.99 (0.93)	2.0	3.39	4.00	4.58	6.2	
		Placebo	48	46 (95.8)	3.61 (0.93)	1.2	3.03	3.66	4.22	5.3	
	Week 4	Tezepelumab	66	64 (97.0)	4.75 (1.13)	2.6	4.02	4.48	5.58	7.0	
		Placebo	48	45 (93.8)	4.35 (1.11)	1.0	3.63	4.38	5.25	6.7	
	Week 12	Tezepelumab	66	62 (93.9)	4.92 (1.19)	2.3	4.06	4.94	5.88	7.0	
		Placebo	48	43 (89.6)	4.50 (1.08)	1.0	3.91	4.41	5.03	6.5	
	Week 24	Tezepelumab	66	63 (95.5)	5.00 (1.28)	1.0	4.06	4.97	6.09	7.0	
		Placebo	48	41 (85.4)	4.44 (1.36)	1.0	3.44	4.53	5.53	6.7	
	Week 36	Tezepelumab	66	63 (95.5)	4.96 (1.20)	2.7	3.91	4.94	6.06	7.0	
		Placebo	48	43 (89.6)	4.54 (1.16)	2.3	3.41	4.34	5.53	6.6	
	Week 52	Tezepelumab	66	60 (90.9)	5.00 (1.20)	2.8	4.05	4.95	5.98	7.0	
		Placebo	48	41 (85.4)	4.73 (1.05)	3.0	4.06	4.66	5.22	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	66	64 (97.0)	0.76 (0.95)	-0.8	-0.02	0.70	1.42	3.3	0.04 [-0.34, 0.42]
		Placebo	48	45 (93.8)	0.73 (0.83)	-1.0	0.28	0.53	1.16	4.0	
	Week 12	Tezepelumab	66	62 (93.9)	0.96 (1.10)	-1.7	0.25	0.83	1.75	4.0	0.10 [-0.29, 0.49]
		Placebo	48	43 (89.6)	0.85 (1.01)	-0.8	0.13	0.63	1.47	3.6	
	Week 24	Tezepelumab	66	62 (93.9)	1.03 (1.32)	-4.7	0.28	0.92	1.84	3.6	0.19 [-0.21, 0.58]
		Placebo	48	41 (85.4)	0.80 (1.09)	-1.3	0.13	0.72	1.44	4.3	
	Week 36	Tezepelumab	66	61 (92.4)	0.99 (1.08)	-1.1	0.16	0.78	1.66	3.4	0.13 [-0.26, 0.52]
		Placebo	48	43 (89.6)	0.85 (1.14)	-2.0	0.22	0.75	1.44	3.4	
	Week 52	Tezepelumab	66	58 (87.9)	1.07 (1.04)	-0.8	0.28	0.92	1.81	3.4	0.03 [-0.37, 0.43]
		Placebo	48	41 (85.4)	1.04 (1.04)	-0.8	0.41	0.97	1.38	4.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
 DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.80 (0.11)	(0.58, 1.02)	0.12 (0.17)	(-0.22, 0.47)	0.477
	Placebo	48	45 (93.8)	0.68 (0.13)	(0.41, 0.94)			
Week 12	Tezepelumab	66	61 (92.4)	1.03 (0.13)	(0.77, 1.29)	0.21 (0.20)	(-0.19, 0.61)	0.305
	Placebo	48	43 (89.6)	0.82 (0.15)	(0.51, 1.13)			
Week 24	Tezepelumab	66	60 (90.9)	1.06 (0.15)	(0.76, 1.37)	0.29 (0.24)	(-0.19, 0.77)	0.234
	Placebo	48	40 (83.3)	0.77 (0.18)	(0.41, 1.14)			
Week 36	Tezepelumab	66	58 (87.9)	1.01 (0.14)	(0.74, 1.29)	0.25 (0.22)	(-0.18, 0.67)	0.258
	Placebo	48	42 (87.5)	0.77 (0.16)	(0.44, 1.09)			
Week 52	Tezepelumab	66	51 (77.3)	1.05 (0.13)	(0.79, 1.30)	0.05 (0.20)	(-0.35, 0.45)	0.793
	Placebo	48	36 (75.0)	1.00 (0.15)	(0.69, 1.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	55	55 (100.0)	3.98 (0.93)	2.0	3.34	3.94	4.47	6.2	
		Placebo	40	40 (100.0)	3.57 (0.98)	1.2	2.80	3.61	4.16	5.3	
	Week 4	Tezepelumab	55	55 (100.0)	4.72 (1.16)	2.6	3.84	4.41	5.63	7.0	
		Placebo	40	39 (97.5)	4.33 (1.16)	1.0	3.44	4.44	5.31	6.7	
	Week 12	Tezepelumab	55	53 (96.4)	4.86 (1.22)	2.3	4.03	4.91	5.84	7.0	
		Placebo	40	37 (92.5)	4.47 (1.08)	1.0	3.91	4.59	5.03	6.1	
	Week 24	Tezepelumab	55	53 (96.4)	4.96 (1.34)	1.0	4.00	4.94	6.09	7.0	
		Placebo	40	35 (87.5)	4.41 (1.35)	1.0	3.44	4.56	5.47	6.7	
	Week 36	Tezepelumab	55	52 (94.5)	4.91 (1.22)	2.7	3.86	4.95	5.95	7.0	
		Placebo	40	37 (92.5)	4.47 (1.11)	2.3	3.41	4.34	5.38	6.5	
	Week 52	Tezepelumab	55	49 (89.1)	4.95 (1.24)	2.8	3.97	4.81	5.97	7.0	
		Placebo	40	35 (87.5)	4.71 (0.99)	3.0	4.06	4.69	5.22	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	55	55 (100.0)	0.74 (0.91)	-0.8	-0.03	0.69	1.25	3.3	-0.00 [-0.41, 0.41]
		Placebo	40	39 (97.5)	0.74 (0.84)	-1.0	0.28	0.59	1.22	4.0	
	Week 12	Tezepelumab	55	53 (96.4)	0.91 (1.09)	-1.7	0.25	0.81	1.66	3.5	0.06 [-0.36, 0.48]
		Placebo	40	37 (92.5)	0.85 (0.98)	-0.4	0.13	0.66	1.47	3.6	
	Week 24	Tezepelumab	55	53 (96.4)	1.00 (1.37)	-4.7	0.22	0.88	1.66	3.6	0.15 [-0.28, 0.58]
		Placebo	40	35 (87.5)	0.81 (1.05)	-1.1	0.13	0.72	1.44	4.3	
	Week 36	Tezepelumab	55	52 (94.5)	0.96 (1.07)	-1.1	0.14	0.75	1.59	3.3	0.14 [-0.28, 0.56]
		Placebo	40	37 (92.5)	0.80 (1.13)	-2.0	0.22	0.75	1.34	3.4	
	Week 52	Tezepelumab	55	49 (89.1)	1.04 (1.05)	-0.8	0.25	0.91	1.81	3.3	-0.00 [-0.44, 0.43]
		Placebo	40	35 (87.5)	1.05 (0.99)	-0.8	0.47	0.97	1.38	4.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
 DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	55	55 (100.0)	0.78 (0.12)	(0.54, 1.01)	0.08 (0.18)	(-0.29, 0.45)	0.670
	Placebo	40	39 (97.5)	0.70 (0.14)	(0.42, 0.98)			
Week 12	Tezepelumab	55	53 (96.4)	0.98 (0.14)	(0.71, 1.26)	0.15 (0.22)	(-0.28, 0.58)	0.479
	Placebo	40	37 (92.5)	0.83 (0.16)	(0.50, 1.16)			
Week 24	Tezepelumab	55	53 (96.4)	1.01 (0.17)	(0.68, 1.34)	0.21 (0.26)	(-0.31, 0.73)	0.422
	Placebo	40	35 (87.5)	0.80 (0.20)	(0.41, 1.20)			
Week 36	Tezepelumab	55	52 (94.5)	0.98 (0.15)	(0.69, 1.27)	0.23 (0.23)	(-0.22, 0.68)	0.317
	Placebo	40	37 (92.5)	0.75 (0.17)	(0.41, 1.09)			
Week 52	Tezepelumab	55	49 (89.1)	1.02 (0.14)	(0.75, 1.29)	0.01 (0.21)	(-0.41, 0.43)	0.963
	Placebo	40	35 (87.5)	1.01 (0.16)	(0.69, 1.33)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	12	10 (83.3)	4.06 (0.94)	2.2	3.59	4.48	4.69	5.0	
		Placebo	9	7 (77.8)	3.85 (0.37)	3.4	3.63	3.72	4.22	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	5.06 (1.07)	3.6	4.13	5.06	5.81	6.6	
		Placebo	9	7 (77.8)	4.50 (0.74)	3.8	3.97	4.38	4.72	6.0	
	Week 8	Tezepelumab	12	10 (83.3)	5.15 (1.17)	3.4	4.09	5.22	5.97	6.7	
		Placebo	9	7 (77.8)	4.74 (1.05)	3.3	3.94	4.63	5.72	6.3	
	Week 12	Tezepelumab	12	10 (83.3)	5.41 (1.05)	4.1	4.34	5.59	6.22	6.9	
		Placebo	9	7 (77.8)	4.74 (1.06)	3.7	4.00	4.22	5.91	6.5	
	Week 16	Tezepelumab	12	10 (83.3)	5.36 (0.87)	4.1	4.84	5.47	5.78	6.8	
		Placebo	9	7 (77.8)	4.84 (1.14)	3.3	4.06	4.56	5.91	6.5	
	Week 20	Tezepelumab	12	11 (91.7)	5.38 (0.96)	4.1	4.47	5.38	6.19	6.9	
		Placebo	9	7 (77.8)	4.79 (1.37)	2.4	4.00	4.72	5.97	6.3	
	Week 24	Tezepelumab	12	11 (91.7)	5.39 (0.98)	4.1	4.69	5.28	6.13	7.0	
		Placebo	9	7 (77.8)	4.63 (1.44)	2.4	3.59	4.53	5.91	6.4	
	Week 28	Tezepelumab	12	12 (100.0)	5.27 (1.10)	3.8	4.42	4.97	6.23	7.0	
		Placebo	9	7 (77.8)	4.62 (1.31)	2.2	3.94	4.75	5.91	6.1	
	Week 32	Tezepelumab	12	12 (100.0)	5.19 (1.14)	3.9	4.06	5.02	5.97	7.0	
		Placebo	9	7 (77.8)	4.69 (1.31)	2.7	3.84	4.41	5.91	6.4	
	Week 36	Tezepelumab	12	12 (100.0)	5.33 (1.18)	3.9	4.30	5.16	6.34	7.0	
		Placebo	9	7 (77.8)	4.92 (1.34)	3.0	3.84	4.69	6.16	6.6	
	Week 40	Tezepelumab	12	12 (100.0)	5.21 (1.05)	3.7	4.41	5.14	5.73	7.0	
		Placebo	9	7 (77.8)	5.01 (1.49)	2.5	3.88	5.63	6.34	6.5	
	Week 44	Tezepelumab	12	12 (100.0)	5.23 (1.13)	3.8	4.08	5.25	5.98	7.0	
		Placebo	9	7 (77.8)	4.68 (1.31)	3.2	3.78	4.19	6.28	6.6	
	Week 48	Tezepelumab	12	12 (100.0)	5.26 (1.09)	3.6	4.30	5.33	6.08	7.0	
		Placebo	9	7 (77.8)	4.74 (1.42)	3.2	3.81	4.19	6.44	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.31 (1.07)	3.6	4.39	5.41	6.08	7.0	
		Placebo	9	7 (77.8)	4.87 (1.30)	3.8	3.88	4.19	6.44	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	12	10 (83.3)	1.01 (1.19)	-0.5	0.00	1.20	1.56	3.3	0.34 [-0.63, 1.31]
		Placebo	9	7 (77.8)	0.65 (0.78)	0.0	0.16	0.38	0.88	2.3	
	Week 8	Tezepelumab	12	10 (83.3)	1.10 (1.36)	-1.0	0.00	1.20	1.88	3.8	0.17 [-0.79, 1.14]
		Placebo	9	7 (77.8)	0.88 (1.00)	-0.4	0.16	0.78	1.50	2.6	
	Week 12	Tezepelumab	12	10 (83.3)	1.35 (1.19)	-0.1	0.47	1.34	1.91	4.0	0.40 [-0.58, 1.38]
		Placebo	9	7 (77.8)	0.88 (1.15)	-0.8	0.16	0.53	1.69	2.8	
	Week 16	Tezepelumab	12	10 (83.3)	1.30 (0.91)	0.3	0.59	1.31	1.69	3.4	0.33 [-0.64, 1.30]
		Placebo	9	7 (77.8)	0.99 (1.02)	-0.4	0.22	0.94	1.69	2.8	
	Week 20	Tezepelumab	12	10 (83.3)	1.33 (1.01)	0.1	0.50	1.48	1.69	3.4	0.36 [-0.61, 1.33]
		Placebo	9	7 (77.8)	0.93 (1.21)	-1.3	0.16	1.09	1.69	2.5	
	Week 24	Tezepelumab	12	10 (83.3)	1.34 (1.05)	0.1	0.38	1.48	1.97	3.4	0.49 [-0.49, 1.48]
		Placebo	9	7 (77.8)	0.77 (1.29)	-1.3	-0.25	0.91	1.69	2.7	
	Week 28	Tezepelumab	12	10 (83.3)	1.42 (1.04)	0.1	0.56	1.56	2.16	3.4	0.57 [-0.41, 1.56]
		Placebo	9	7 (77.8)	0.76 (1.26)	-1.5	0.09	0.97	1.69	2.4	
	Week 32	Tezepelumab	12	10 (83.3)	1.15 (1.22)	-0.6	0.28	1.09	2.03	3.4	0.26 [-0.71, 1.23]
		Placebo	9	7 (77.8)	0.83 (1.17)	-1.0	0.00	0.78	1.69	2.7	
	Week 36	Tezepelumab	12	10 (83.3)	1.31 (1.18)	-0.1	0.28	1.52	2.19	3.4	0.21 [-0.76, 1.18]
		Placebo	9	7 (77.8)	1.06 (1.16)	-0.7	0.31	1.06	1.69	2.9	
	Week 40	Tezepelumab	12	10 (83.3)	1.29 (1.06)	0.1	0.44	1.08	2.03	3.4	0.11 [-0.85, 1.08]
		Placebo	9	7 (77.8)	1.16 (1.36)	-1.2	0.03	1.69	2.00	2.8	
	Week 44	Tezepelumab	12	10 (83.3)	1.24 (1.17)	-0.6	0.47	1.08	2.03	3.4	0.34 [-0.63, 1.31]
		Placebo	9	7 (77.8)	0.83 (1.28)	-0.5	-0.28	0.56	2.06	2.9	
	Week 48	Tezepelumab	12	10 (83.3)	1.28 (1.09)	-0.2	0.44	1.30	2.06	3.4	0.33 [-0.64, 1.30]
		Placebo	9	7 (77.8)	0.88 (1.39)	-0.5	-0.28	0.41	2.22	3.3	
	Week 52	Tezepelumab	12	10 (83.3)	1.35 (1.01)	0.3	0.47	1.30	2.06	3.4	0.30 [-0.67, 1.27]
		Placebo	9	7 (77.8)	1.01 (1.28)	-0.3	0.03	0.41	2.22	3.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
 DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 36	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
 DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	12	12 (100.0)	4.48 (1.06)	2.7	3.89	4.52	5.05	6.8	
		Placebo	11	11 (100.0)	3.83 (1.14)	1.8	2.72	4.00	4.56	5.8	
	Week 4	Tezepelumab	12	11 (91.7)	4.27 (1.25)	2.4	3.53	3.84	5.28	6.4	
		Placebo	11	11 (100.0)	4.35 (0.94)	3.0	3.94	4.22	5.06	6.3	
	Week 40	Tezepelumab	12	10 (83.3)	4.66 (1.05)	3.0	3.97	4.78	5.22	6.4	
		Placebo	11	11 (100.0)	4.47 (1.24)	2.3	3.56	4.66	5.09	6.8	
	Week 44	Tezepelumab	12	9 (75.0)	4.91 (1.22)	2.3	4.66	4.78	5.53	6.7	
		Placebo	11	10 (90.9)	4.70 (1.03)	3.3	3.88	4.63	5.44	6.9	
	Week 48	Tezepelumab	12	9 (75.0)	4.69 (1.42)	2.8	3.41	4.66	5.78	6.8	
		Placebo	11	10 (90.9)	4.62 (1.21)	2.7	3.72	4.83	5.09	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QTC_IBMH0: Course of AQLQ+12 total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	12	11 (91.7)	-0.17 (1.33)	-3.2	-0.34	-0.16	0.84	1.8	-0.68 [-1.54, 0.19]
		Placebo	11	11 (100.0)	0.52 (0.57)	-0.4	0.09	0.50	1.03	1.6	
	Week 40	Tezepelumab	12	10 (83.3)	0.16 (1.12)	-1.5	-0.47	0.09	0.97	1.8	-0.45 [-1.32, 0.41]
		Placebo	11	11 (100.0)	0.64 (0.98)	-1.0	0.25	0.41	0.97	2.3	
	Week 44	Tezepelumab	12	9 (75.0)	0.41 (1.60)	-2.3	0.34	0.59	1.75	2.1	-0.22 [-1.12, 0.69]
		Placebo	11	10 (90.9)	0.67 (0.73)	-0.8	0.22	0.77	1.13	1.8	
	Week 48	Tezepelumab	12	9 (75.0)	0.18 (1.18)	-1.8	-0.53	0.31	0.66	2.2	-0.69 [-1.62, 0.24]
		Placebo	11	10 (90.9)	0.80 (0.51)	0.0	0.53	0.89	1.09	1.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
 DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	11 (91.7)	-0.09 (0.28)	(-0.68, 0.51)	-0.50 (0.41)	(-1.35, 0.36)	0.241
	Placebo	11	11 (100.0)	0.41 (0.29)	(-0.19, 1.01)			
Week 40	Tezepelumab	12	10 (83.3)	0.26 (0.30)	(-0.37, 0.90)	-0.27 (0.43)	(-1.17, 0.63)	0.543
	Placebo	11	11 (100.0)	0.53 (0.29)	(-0.09, 1.15)			
Week 44	Tezepelumab	12	9 (75.0)	0.49 (0.35)	(-0.24, 1.21)	-0.08 (0.49)	(-1.09, 0.94)	0.878
	Placebo	11	10 (90.9)	0.56 (0.33)	(-0.14, 1.26)			
Week 48	Tezepelumab	12	9 (75.0)	0.28 (0.29)	(-0.32, 0.88)	-0.36 (0.41)	(-1.21, 0.49)	0.388
	Placebo	11	10 (90.9)	0.64 (0.28)	(0.05, 1.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	66	64 (97.0)	4.08 (0.98)	2.2	3.55	4.09	4.59	6.6	
		Placebo	48	46 (95.8)	3.69 (0.92)	1.2	3.18	3.59	4.45	5.3	
	Week 4	Tezepelumab	66	64 (97.0)	4.79 (1.21)	2.5	3.73	4.45	5.86	7.0	
		Placebo	48	45 (93.8)	4.34 (1.28)	1.0	3.45	4.18	5.27	6.7	
	Week 12	Tezepelumab	66	62 (93.9)	5.00 (1.21)	2.1	4.09	5.09	5.91	7.0	
		Placebo	48	43 (89.6)	4.45 (1.21)	1.1	3.55	4.36	5.45	6.5	
	Week 24	Tezepelumab	66	63 (95.5)	5.08 (1.29)	1.0	4.18	5.18	6.09	7.0	
		Placebo	48	41 (85.4)	4.43 (1.47)	1.0	3.55	4.64	5.55	6.8	
	Week 36	Tezepelumab	66	63 (95.5)	5.04 (1.19)	2.5	4.09	5.00	6.09	7.0	
		Placebo	48	43 (89.6)	4.56 (1.25)	1.5	3.82	4.27	5.55	6.8	
	Week 52	Tezepelumab	66	60 (90.9)	5.01 (1.19)	2.3	4.00	4.82	5.95	7.0	
		Placebo	48	41 (85.4)	4.79 (1.04)	3.2	3.91	4.73	5.27	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	66	64 (97.0)	0.71 (0.95)	-1.1	0.00	0.64	1.45	3.1	0.07 [-0.31, 0.45]
		Placebo	48	45 (93.8)	0.64 (0.93)	-1.0	0.18	0.45	1.09	4.0	
	Week 12	Tezepelumab	66	62 (93.9)	0.95 (1.08)	-1.1	0.27	0.91	1.64	4.2	0.21 [-0.18, 0.60]
		Placebo	48	43 (89.6)	0.73 (1.01)	-0.8	0.00	0.45	1.45	3.7	
	Week 24	Tezepelumab	66	62 (93.9)	1.01 (1.32)	-5.1	0.27	0.91	1.73	3.5	0.22 [-0.18, 0.61]
		Placebo	48	41 (85.4)	0.73 (1.19)	-1.8	0.09	0.55	1.45	4.1	
	Week 36	Tezepelumab	66	61 (92.4)	0.98 (1.07)	-1.1	0.18	0.82	1.64	3.5	0.18 [-0.21, 0.57]
		Placebo	48	43 (89.6)	0.78 (1.11)	-1.6	0.00	0.64	1.64	3.9	
	Week 52	Tezepelumab	66	58 (87.9)	0.99 (1.04)	-1.5	0.27	0.91	1.55	3.5	0.01 [-0.39, 0.41]
		Placebo	48	41 (85.4)	0.99 (0.95)	-0.2	0.36	0.73	1.36	4.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
 DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.74 (0.12)	(0.51, 0.97)	0.16 (0.18)	(-0.21, 0.52)	0.398
	Placebo	48	45 (93.8)	0.58 (0.14)	(0.30, 0.86)			
Week 12	Tezepelumab	66	61 (92.4)	1.00 (0.13)	(0.75, 1.26)	0.32 (0.20)	(-0.08, 0.73)	0.118
	Placebo	48	43 (89.6)	0.68 (0.16)	(0.37, 0.99)			
Week 24	Tezepelumab	66	60 (90.9)	1.02 (0.16)	(0.70, 1.34)	0.30 (0.25)	(-0.20, 0.80)	0.234
	Placebo	48	40 (83.3)	0.72 (0.19)	(0.34, 1.10)			
Week 36	Tezepelumab	66	58 (87.9)	0.99 (0.14)	(0.72, 1.27)	0.26 (0.21)	(-0.16, 0.69)	0.225
	Placebo	48	42 (87.5)	0.73 (0.16)	(0.41, 1.05)			
Week 52	Tezepelumab	66	51 (77.3)	0.94 (0.12)	(0.69, 1.19)	0.04 (0.19)	(-0.34, 0.43)	0.819
	Placebo	48	36 (75.0)	0.90 (0.15)	(0.60, 1.19)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	55	55 (100.0)	4.10 (0.98)	2.2	3.55	4.09	4.55	6.6	
		Placebo	40	40 (100.0)	3.65 (0.97)	1.2	3.00	3.55	4.50	5.3	
	Week 4	Tezepelumab	55	55 (100.0)	4.76 (1.24)	2.5	3.73	4.55	5.91	7.0	
		Placebo	40	39 (97.5)	4.36 (1.32)	1.0	3.45	4.36	5.27	6.7	
	Week 12	Tezepelumab	55	53 (96.4)	4.94 (1.22)	2.1	4.09	5.09	5.91	7.0	
		Placebo	40	37 (92.5)	4.45 (1.20)	1.1	3.55	4.45	5.27	6.5	
	Week 24	Tezepelumab	55	53 (96.4)	5.05 (1.34)	1.0	4.09	5.18	6.00	7.0	
		Placebo	40	35 (87.5)	4.40 (1.45)	1.0	3.55	4.36	5.55	6.8	
	Week 36	Tezepelumab	55	52 (94.5)	5.01 (1.21)	2.5	4.09	5.05	6.00	7.0	
		Placebo	40	37 (92.5)	4.49 (1.18)	1.5	3.82	4.27	5.36	6.6	
	Week 52	Tezepelumab	55	49 (89.1)	4.96 (1.23)	2.3	3.91	4.73	5.91	7.0	
		Placebo	40	35 (87.5)	4.75 (0.98)	3.2	3.91	4.73	5.27	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	55	55 (100.0)	0.66 (0.93)	-1.1	0.00	0.64	1.09	2.9	-0.05 [-0.46, 0.36]
		Placebo	40	39 (97.5)	0.71 (0.95)	-1.0	0.18	0.55	1.09	4.0	
	Week 12	Tezepelumab	55	53 (96.4)	0.87 (1.03)	-1.1	0.09	0.91	1.55	3.2	0.11 [-0.31, 0.53]
		Placebo	40	37 (92.5)	0.76 (1.00)	-0.8	0.00	0.64	1.27	3.7	
	Week 24	Tezepelumab	55	53 (96.4)	0.97 (1.35)	-5.1	0.27	0.91	1.73	3.4	0.18 [-0.25, 0.61]
		Placebo	40	35 (87.5)	0.74 (1.18)	-1.8	0.09	0.55	1.45	4.1	
	Week 36	Tezepelumab	55	52 (94.5)	0.94 (1.04)	-1.1	0.18	0.82	1.68	3.3	0.18 [-0.24, 0.60]
		Placebo	40	37 (92.5)	0.74 (1.09)	-1.6	0.00	0.64	1.27	3.9	
	Week 52	Tezepelumab	55	49 (89.1)	0.91 (1.02)	-1.5	0.18	0.91	1.36	3.0	-0.06 [-0.49, 0.38]
		Placebo	40	35 (87.5)	0.97 (0.93)	-0.2	0.27	0.82	1.36	4.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
 DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	55	55 (100.0)	0.70 (0.13)	(0.44, 0.95)	0.05 (0.20)	(-0.35, 0.45)	0.800
	Placebo	40	39 (97.5)	0.65 (0.15)	(0.35, 0.95)			
Week 12	Tezepelumab	55	53 (96.4)	0.94 (0.14)	(0.67, 1.21)	0.23 (0.21)	(-0.20, 0.65)	0.289
	Placebo	40	37 (92.5)	0.71 (0.16)	(0.39, 1.04)			
Week 24	Tezepelumab	55	53 (96.4)	0.98 (0.17)	(0.63, 1.32)	0.24 (0.27)	(-0.30, 0.77)	0.376
	Placebo	40	35 (87.5)	0.74 (0.21)	(0.33, 1.14)			
Week 36	Tezepelumab	55	52 (94.5)	0.95 (0.14)	(0.67, 1.24)	0.26 (0.22)	(-0.19, 0.70)	0.252
	Placebo	40	37 (92.5)	0.69 (0.17)	(0.36, 1.03)			
Week 52	Tezepelumab	55	49 (89.1)	0.89 (0.13)	(0.63, 1.15)	-0.01 (0.21)	(-0.42, 0.40)	0.966
	Placebo	40	35 (87.5)	0.90 (0.16)	(0.59, 1.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	12	10 (83.3)	3.96 (0.99)	2.2	3.36	4.27	4.64	5.2	
		Placebo	9	7 (77.8)	3.87 (0.42)	3.4	3.45	3.91	4.18	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	5.10 (1.12)	3.6	4.27	4.82	6.00	6.9	
		Placebo	9	7 (77.8)	4.19 (0.92)	3.3	3.36	4.09	4.64	5.9	
	Week 8	Tezepelumab	12	10 (83.3)	5.10 (1.19)	3.4	4.27	5.09	6.09	6.5	
		Placebo	9	7 (77.8)	4.49 (1.20)	2.8	3.91	4.09	5.64	6.5	
	Week 12	Tezepelumab	12	10 (83.3)	5.45 (1.14)	3.9	4.27	5.64	6.36	7.0	
		Placebo	9	7 (77.8)	4.51 (1.27)	3.4	3.36	4.18	6.00	6.5	
	Week 16	Tezepelumab	12	10 (83.3)	5.34 (0.88)	4.2	4.55	5.32	5.91	6.7	
		Placebo	9	7 (77.8)	4.88 (1.32)	2.9	3.91	5.27	6.00	6.6	
	Week 20	Tezepelumab	12	11 (91.7)	5.41 (0.99)	4.0	4.27	5.55	6.27	7.0	
		Placebo	9	7 (77.8)	4.68 (1.55)	2.1	4.09	4.09	5.91	6.6	
	Week 24	Tezepelumab	12	11 (91.7)	5.38 (1.07)	3.9	4.27	5.55	6.27	7.0	
		Placebo	9	7 (77.8)	4.58 (1.57)	2.0	3.45	5.00	5.82	6.6	
	Week 28	Tezepelumab	12	12 (100.0)	5.32 (1.10)	4.2	4.36	4.95	6.32	7.0	
		Placebo	9	7 (77.8)	4.70 (1.51)	2.0	3.91	5.09	5.82	6.7	
	Week 32	Tezepelumab	12	12 (100.0)	5.26 (1.17)	3.9	4.32	5.05	6.18	7.0	
		Placebo	9	7 (77.8)	4.64 (1.57)	1.7	4.00	4.55	5.82	6.5	
	Week 36	Tezepelumab	12	12 (100.0)	5.32 (1.20)	3.8	4.27	5.09	6.45	7.0	
		Placebo	9	7 (77.8)	4.88 (1.55)	2.5	3.82	5.09	6.27	6.8	
	Week 40	Tezepelumab	12	12 (100.0)	5.24 (1.05)	4.0	4.36	5.05	5.95	7.0	
		Placebo	9	7 (77.8)	5.05 (1.72)	2.0	4.09	5.64	6.73	6.8	
	Week 44	Tezepelumab	12	12 (100.0)	5.33 (1.09)	4.0	4.36	5.45	6.09	7.0	
		Placebo	9	7 (77.8)	4.74 (1.55)	2.5	3.82	4.55	6.36	6.9	
	Week 48	Tezepelumab	12	12 (100.0)	5.28 (1.11)	3.8	4.27	5.27	6.32	7.0	
		Placebo	9	7 (77.8)	4.75 (1.62)	2.3	3.82	4.55	6.45	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.39 (1.05)	3.8	4.36	5.55	6.32	7.0	
		Placebo	9	7 (77.8)	5.00 (1.28)	3.7	4.00	4.55	6.45	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	12	10 (83.3)	1.14 (1.12)	-0.3	0.00	1.50	1.91	3.1	0.83 [-0.18, 1.84]
		Placebo	9	7 (77.8)	0.32 (0.71)	-0.4	-0.27	0.18	0.55	1.7	
	Week 8	Tezepelumab	12	10 (83.3)	1.14 (1.45)	-1.3	0.00	1.41	1.64	3.7	0.40 [-0.58, 1.38]
		Placebo	9	7 (77.8)	0.62 (0.98)	-0.7	0.09	0.55	1.45	2.3	
	Week 12	Tezepelumab	12	10 (83.3)	1.49 (1.34)	-0.5	0.45	1.55	1.91	4.2	0.68 [-0.31, 1.68]
		Placebo	9	7 (77.8)	0.64 (1.11)	-0.7	-0.18	0.45	1.82	2.4	
	Week 16	Tezepelumab	12	10 (83.3)	1.37 (1.06)	0.3	0.55	1.18	2.00	3.5	0.35 [-0.63, 1.32]
		Placebo	9	7 (77.8)	1.01 (1.00)	-0.6	0.45	1.00	1.82	2.5	
	Week 20	Tezepelumab	12	10 (83.3)	1.44 (1.15)	-0.4	0.55	1.32	2.55	3.5	0.53 [-0.46, 1.51]
		Placebo	9	7 (77.8)	0.81 (1.25)	-1.5	0.18	0.73	1.64	2.5	
	Week 24	Tezepelumab	12	10 (83.3)	1.40 (1.24)	-0.2	0.27	1.36	2.27	3.5	0.55 [-0.44, 1.54]
		Placebo	9	7 (77.8)	0.71 (1.26)	-1.5	0.09	0.82	1.64	2.5	
	Week 28	Tezepelumab	12	10 (83.3)	1.53 (1.17)	-0.2	0.73	1.55	2.55	3.5	0.58 [-0.41, 1.57]
		Placebo	9	7 (77.8)	0.83 (1.26)	-1.5	0.55	0.82	1.64	2.5	
	Week 32	Tezepelumab	12	10 (83.3)	1.29 (1.36)	-0.4	0.09	1.23	2.55	3.5	0.39 [-0.58, 1.37]
		Placebo	9	7 (77.8)	0.77 (1.30)	-1.8	0.64	0.82	1.64	2.4	
	Week 36	Tezepelumab	12	10 (83.3)	1.41 (1.33)	-0.2	0.18	1.50	2.55	3.5	0.31 [-0.66, 1.28]
		Placebo	9	7 (77.8)	1.01 (1.19)	-1.0	0.36	1.18	1.82	2.6	
	Week 40	Tezepelumab	12	10 (83.3)	1.38 (1.28)	-0.2	0.36	1.18	2.55	3.5	0.15 [-0.82, 1.12]
		Placebo	9	7 (77.8)	1.18 (1.39)	-1.5	0.73	1.64	2.27	2.6	
	Week 44	Tezepelumab	12	10 (83.3)	1.38 (1.29)	-0.3	0.36	1.41	2.55	3.5	0.39 [-0.58, 1.37]
		Placebo	9	7 (77.8)	0.87 (1.30)	-1.1	0.09	0.55	2.18	2.7	
	Week 48	Tezepelumab	12	10 (83.3)	1.42 (1.25)	-0.2	0.45	1.32	2.55	3.5	0.41 [-0.57, 1.39]
		Placebo	9	7 (77.8)	0.88 (1.38)	-1.3	0.09	0.55	2.27	2.8	
	Week 52	Tezepelumab	12	10 (83.3)	1.55 (1.15)	-0.2	0.64	1.32	2.55	3.5	0.38 [-0.60, 1.35]
		Placebo	9	7 (77.8)	1.13 (1.04)	0.1	0.36	0.55	2.27	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
 DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 36	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
 DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	12	12 (100.0)	4.26 (1.08)	2.6	3.59	4.05	4.73	6.8	
		Placebo	11	11 (100.0)	3.84 (1.08)	2.4	2.64	3.91	4.45	6.1	
	Week 4	Tezepelumab	12	11 (91.7)	4.28 (1.16)	2.8	3.36	3.82	5.18	6.4	
		Placebo	11	11 (100.0)	4.26 (0.92)	3.0	3.55	4.09	4.91	6.3	
	Week 40	Tezepelumab	12	10 (83.3)	4.61 (1.24)	3.0	3.27	4.73	5.91	6.4	
		Placebo	11	11 (100.0)	4.32 (1.47)	1.7	3.18	4.27	5.18	6.9	
	Week 44	Tezepelumab	12	9 (75.0)	4.95 (1.31)	2.0	4.82	5.27	5.45	6.5	
		Placebo	11	10 (90.9)	4.62 (1.24)	3.2	3.27	4.64	5.09	7.0	
	Week 48	Tezepelumab	12	9 (75.0)	4.70 (1.46)	2.4	3.55	4.82	6.00	6.6	
		Placebo	11	10 (90.9)	4.54 (1.37)	2.0	3.55	4.77	5.18	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QAC_IBMH0: Course of AQLQ+12 activity limitations score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	12	11 (91.7)	0.09 (1.31)	-3.0	-0.36	-0.09	1.09	1.8	-0.32 [-1.16, 0.52]
		Placebo	11	11 (100.0)	0.42 (0.63)	-0.9	0.09	0.27	1.09	1.2	
	Week 40	Tezepelumab	12	10 (83.3)	0.35 (1.23)	-1.2	-0.82	0.32	1.09	2.4	-0.11 [-0.97, 0.75]
		Placebo	11	11 (100.0)	0.48 (1.08)	-1.4	-0.55	0.55	1.45	2.3	
	Week 44	Tezepelumab	12	9 (75.0)	0.72 (1.62)	-1.9	-0.18	1.09	1.91	2.6	0.07 [-0.83, 0.97]
		Placebo	11	10 (90.9)	0.63 (0.89)	-1.3	0.36	0.59	1.27	2.0	
	Week 48	Tezepelumab	12	9 (75.0)	0.46 (1.23)	-1.5	-0.09	0.73	1.09	2.6	-0.24 [-1.15, 0.66]
		Placebo	11	10 (90.9)	0.70 (0.65)	-0.4	0.27	0.91	1.00	1.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
 DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	12	11 (91.7)	0.14 (0.28)	(-0.45, 0.72)	-0.22 (0.40)	(-1.05, 0.62)	0.591
	Placebo	11	11 (100.0)	0.36 (0.28)	(-0.23, 0.94)			
Week 40	Tezepelumab	12	10 (83.3)	0.39 (0.35)	(-0.34, 1.13)	-0.02 (0.49)	(-1.05, 1.01)	0.970
	Placebo	11	11 (100.0)	0.41 (0.34)	(-0.30, 1.13)			
Week 44	Tezepelumab	12	9 (75.0)	0.63 (0.39)	(-0.19, 1.45)	0.16 (0.55)	(-0.99, 1.31)	0.773
	Placebo	11	10 (90.9)	0.47 (0.38)	(-0.32, 1.26)			
Week 48	Tezepelumab	12	9 (75.0)	0.40 (0.32)	(-0.28, 1.07)	-0.18 (0.45)	(-1.12, 0.77)	0.698
	Placebo	11	10 (90.9)	0.57 (0.31)	(-0.08, 1.22)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	66	64 (97.0)	3.90 (1.25)	1.0	3.00	4.00	4.88	6.5	
	Placebo	48	46 (95.8)	3.52 (1.27)	1.3	2.75	3.50	4.50	6.0	
Week 4	Tezepelumab	66	64 (97.0)	4.71 (1.31)	1.8	3.75	4.75	5.88	7.0	
	Placebo	48	45 (93.8)	4.24 (1.49)	1.0	3.50	4.50	5.50	6.5	
Week 12	Tezepelumab	66	62 (93.9)	4.92 (1.41)	1.8	4.00	5.00	6.00	7.0	
	Placebo	48	43 (89.6)	4.26 (1.32)	1.0	3.50	4.25	5.25	6.8	
Week 24	Tezepelumab	66	63 (95.5)	5.04 (1.43)	1.0	4.00	5.00	6.25	7.0	
	Placebo	48	41 (85.4)	4.16 (1.74)	1.0	2.75	4.25	5.75	7.0	
Week 36	Tezepelumab	66	63 (95.5)	5.02 (1.31)	2.0	4.00	5.00	6.25	7.0	
	Placebo	48	43 (89.6)	4.33 (1.54)	1.0	3.00	4.75	5.50	7.0	
Week 52	Tezepelumab	66	60 (90.9)	4.92 (1.40)	1.8	4.00	5.00	6.00	7.0	
	Placebo	48	41 (85.4)	4.60 (1.30)	1.5	3.75	4.75	5.50	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	66	64 (97.0)	0.80 (1.04)	-1.5	0.25	0.75	1.25	4.0	0.09 [-0.29, 0.47]
		Placebo	48	45 (93.8)	0.71 (1.13)	-1.5	0.00	0.50	1.00	4.3	
	Week 12	Tezepelumab	66	62 (93.9)	1.03 (1.31)	-2.5	0.00	0.75	1.75	4.8	0.31 [-0.08, 0.70]
		Placebo	48	43 (89.6)	0.64 (1.17)	-1.5	-0.25	0.50	1.00	3.0	
	Week 24	Tezepelumab	66	62 (93.9)	1.15 (1.46)	-4.3	0.25	1.00	2.25	5.3	0.40 [0.00, 0.80]
		Placebo	48	41 (85.4)	0.58 (1.32)	-1.8	-0.25	0.50	1.00	4.8	
	Week 36	Tezepelumab	66	61 (92.4)	1.13 (1.30)	-1.5	0.25	1.00	1.75	5.5	0.34 [-0.05, 0.74]
		Placebo	48	43 (89.6)	0.67 (1.40)	-2.3	-0.25	0.50	1.50	4.0	
	Week 52	Tezepelumab	66	58 (87.9)	1.07 (1.35)	-1.3	0.25	1.00	2.00	5.0	0.04 [-0.36, 0.44]
		Placebo	48	41 (85.4)	1.02 (1.27)	-1.0	0.00	0.75	1.75	4.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
 DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.85 (0.13)	(0.59, 1.10)	0.20 (0.20)	(-0.21, 0.60)	0.339
	Placebo	48	45 (93.8)	0.65 (0.16)	(0.34, 0.96)			
Week 12	Tezepelumab	66	61 (92.4)	1.11 (0.15)	(0.80, 1.41)	0.40 (0.24)	(-0.07, 0.87)	0.096
	Placebo	48	43 (89.6)	0.71 (0.18)	(0.35, 1.07)			
Week 24	Tezepelumab	66	60 (90.9)	1.20 (0.18)	(0.85, 1.55)	0.54 (0.28)	(-0.01, 1.09)	0.054
	Placebo	48	40 (83.3)	0.66 (0.21)	(0.24, 1.08)			
Week 36	Tezepelumab	66	58 (87.9)	1.17 (0.17)	(0.84, 1.50)	0.51 (0.26)	(-0.00, 1.02)	0.051
	Placebo	48	42 (87.5)	0.66 (0.20)	(0.27, 1.05)			
Week 52	Tezepelumab	66	51 (77.3)	1.07 (0.16)	(0.75, 1.39)	0.00 (0.25)	(-0.50, 0.50)	0.993
	Placebo	48	36 (75.0)	1.06 (0.19)	(0.68, 1.45)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	55	55 (100.0)	3.90 (1.28)	1.0	3.00	4.00	5.00	6.5	
	Placebo	40	40 (100.0)	3.54 (1.31)	1.3	2.75	3.50	4.50	6.0	
Week 4	Tezepelumab	55	55 (100.0)	4.68 (1.35)	1.8	3.75	4.75	6.00	7.0	
	Placebo	40	39 (97.5)	4.24 (1.50)	1.0	3.50	4.50	5.50	6.5	
Week 12	Tezepelumab	55	53 (96.4)	4.85 (1.45)	1.8	4.00	5.00	6.00	7.0	
	Placebo	40	37 (92.5)	4.27 (1.33)	1.0	3.50	4.50	5.00	6.8	
Week 24	Tezepelumab	55	53 (96.4)	4.99 (1.50)	1.0	4.00	5.00	6.25	7.0	
	Placebo	40	35 (87.5)	4.21 (1.74)	1.0	2.75	4.50	5.75	7.0	
Week 36	Tezepelumab	55	52 (94.5)	4.99 (1.36)	2.0	4.00	5.13	6.25	7.0	
	Placebo	40	37 (92.5)	4.35 (1.52)	1.0	3.50	4.75	5.50	7.0	
Week 52	Tezepelumab	55	49 (89.1)	4.86 (1.49)	1.8	4.00	5.00	6.25	7.0	
	Placebo	40	35 (87.5)	4.60 (1.29)	1.5	3.75	4.75	5.50	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	55	55 (100.0)	0.78 (0.99)	-1.5	0.25	0.75	1.25	3.8	0.09 [-0.32, 0.50]
		Placebo	40	39 (97.5)	0.69 (1.14)	-1.5	0.00	0.50	1.00	4.3	
	Week 12	Tezepelumab	55	53 (96.4)	0.97 (1.29)	-2.5	0.00	0.75	2.00	4.5	0.29 [-0.13, 0.72]
		Placebo	40	37 (92.5)	0.61 (1.16)	-1.5	-0.25	0.50	1.00	3.0	
	Week 24	Tezepelumab	55	53 (96.4)	1.10 (1.51)	-4.3	0.25	1.00	2.25	5.3	0.35 [-0.08, 0.78]
		Placebo	40	35 (87.5)	0.59 (1.33)	-1.8	0.00	0.50	1.25	4.8	
	Week 36	Tezepelumab	55	52 (94.5)	1.11 (1.31)	-1.5	0.25	1.00	1.75	5.5	0.34 [-0.08, 0.76]
		Placebo	40	37 (92.5)	0.64 (1.44)	-2.3	-0.25	0.50	1.50	4.0	
	Week 52	Tezepelumab	55	49 (89.1)	1.02 (1.40)	-1.3	0.00	1.00	2.00	5.0	0.02 [-0.41, 0.46]
		Placebo	40	35 (87.5)	0.99 (1.20)	-0.8	0.00	0.75	1.75	4.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
 DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	55	55 (100.0)	0.82 (0.14)	(0.54, 1.09)	0.16 (0.22)	(-0.26, 0.59)	0.450
	Placebo	40	39 (97.5)	0.65 (0.16)	(0.33, 0.98)			
Week 12	Tezepelumab	55	53 (96.4)	1.05 (0.16)	(0.72, 1.38)	0.33 (0.26)	(-0.18, 0.84)	0.203
	Placebo	40	37 (92.5)	0.72 (0.19)	(0.33, 1.11)			
Week 24	Tezepelumab	55	53 (96.4)	1.13 (0.19)	(0.75, 1.51)	0.40 (0.30)	(-0.20, 0.99)	0.190
	Placebo	40	35 (87.5)	0.73 (0.23)	(0.28, 1.19)			
Week 36	Tezepelumab	55	52 (94.5)	1.14 (0.18)	(0.79, 1.49)	0.46 (0.28)	(-0.09, 1.01)	0.100
	Placebo	40	37 (92.5)	0.68 (0.21)	(0.26, 1.10)			
Week 52	Tezepelumab	55	49 (89.1)	1.01 (0.17)	(0.67, 1.36)	-0.04 (0.27)	(-0.57, 0.50)	0.895
	Placebo	40	35 (87.5)	1.05 (0.20)	(0.65, 1.45)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	12	10 (83.3)	3.95 (1.08)	1.8	3.00	4.25	4.75	5.0	
	Placebo	9	7 (77.8)	3.36 (0.97)	1.5	3.25	3.25	4.25	4.5	
Week 4	Tezepelumab	12	10 (83.3)	5.00 (1.14)	3.5	4.00	5.00	5.75	7.0	
	Placebo	9	7 (77.8)	4.14 (1.38)	2.3	2.50	4.25	5.50	5.5	
Week 8	Tezepelumab	12	10 (83.3)	5.30 (0.90)	4.0	4.50	5.50	6.00	6.8	
	Placebo	9	7 (77.8)	4.82 (1.78)	1.5	4.00	5.75	6.25	6.5	
Week 12	Tezepelumab	12	10 (83.3)	5.40 (1.07)	4.0	4.50	5.25	6.50	7.0	
	Placebo	9	7 (77.8)	4.18 (1.30)	2.3	3.25	4.00	5.25	6.3	
Week 16	Tezepelumab	12	10 (83.3)	5.10 (0.68)	4.0	4.75	5.00	5.50	6.3	
	Placebo	9	7 (77.8)	4.32 (1.48)	1.5	4.00	4.25	5.25	6.3	
Week 20	Tezepelumab	12	11 (91.7)	5.20 (0.85)	4.0	4.50	5.00	5.75	7.0	
	Placebo	9	7 (77.8)	4.25 (1.41)	1.5	3.50	5.00	5.25	5.5	
Week 24	Tezepelumab	12	11 (91.7)	5.45 (1.05)	4.0	4.50	5.00	6.50	7.0	
	Placebo	9	7 (77.8)	3.89 (1.73)	1.0	2.50	4.25	5.25	6.3	
Week 28	Tezepelumab	12	12 (100.0)	5.23 (1.03)	4.0	4.50	5.00	5.88	7.0	
	Placebo	9	7 (77.8)	4.54 (1.38)	2.0	3.75	5.25	5.50	6.0	
Week 32	Tezepelumab	12	12 (100.0)	5.25 (1.09)	4.0	4.25	5.00	6.00	7.0	
	Placebo	9	7 (77.8)	4.14 (1.59)	1.3	3.25	4.25	5.25	6.0	
Week 36	Tezepelumab	12	12 (100.0)	5.33 (1.08)	4.0	4.38	5.00	6.38	7.0	
	Placebo	9	7 (77.8)	4.11 (1.71)	1.0	3.00	4.25	5.25	6.3	
Week 40	Tezepelumab	12	12 (100.0)	5.27 (1.16)	3.8	4.50	5.00	6.38	7.0	
	Placebo	9	7 (77.8)	4.46 (1.88)	1.0	3.25	5.25	5.75	6.5	
Week 44	Tezepelumab	12	12 (100.0)	5.31 (1.17)	4.0	4.25	5.00	6.50	7.0	
	Placebo	9	7 (77.8)	4.00 (1.73)	1.3	3.25	3.50	5.75	6.5	
Week 48	Tezepelumab	12	12 (100.0)	5.21 (1.04)	4.0	4.25	5.00	6.00	7.0	
	Placebo	9	7 (77.8)	4.50 (1.39)	3.0	3.50	4.00	5.75	7.0	
Week 52	Tezepelumab	12	12 (100.0)	5.29 (0.97)	4.0	4.75	5.00	6.00	7.0	
	Placebo	9	7 (77.8)	4.50 (1.39)	3.0	3.50	4.00	5.75	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	12	10 (83.3)	1.05 (1.30)	-0.5	0.00	1.13	1.25	4.0	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	0.79 (1.06)	-0.8	0.00	0.75	2.00	2.3	
	Week 8	Tezepelumab	12	10 (83.3)	1.35 (1.42)	-0.8	0.25	1.38	1.75	4.3	-0.09 [-1.05, 0.88]
		Placebo	9	7 (77.8)	1.46 (1.15)	0.0	0.75	1.25	3.00	3.0	
	Week 12	Tezepelumab	12	10 (83.3)	1.45 (1.37)	0.0	0.25	1.38	1.75	4.8	0.48 [-0.50, 1.46]
		Placebo	9	7 (77.8)	0.82 (1.24)	-1.3	0.50	0.75	1.00	3.0	
	Week 16	Tezepelumab	12	10 (83.3)	1.15 (0.99)	-0.3	0.25	1.38	1.50	3.0	0.19 [-0.78, 1.16]
		Placebo	9	7 (77.8)	0.96 (0.95)	0.0	0.50	0.75	1.00	3.0	
	Week 20	Tezepelumab	12	10 (83.3)	1.20 (1.09)	-0.3	0.25	1.38	1.75	3.3	0.31 [-0.66, 1.28]
		Placebo	9	7 (77.8)	0.89 (0.83)	0.0	0.25	0.50	1.75	2.3	
	Week 24	Tezepelumab	12	10 (83.3)	1.48 (1.15)	-0.5	0.25	1.75	2.25	3.3	0.78 [-0.23, 1.79]
		Placebo	9	7 (77.8)	0.54 (1.29)	-0.8	-0.50	0.25	1.00	3.0	
	Week 28	Tezepelumab	12	10 (83.3)	1.43 (1.09)	-0.5	0.50	1.50	2.00	3.3	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	1.18 (1.19)	-0.5	0.25	1.00	2.25	2.8	
	Week 32	Tezepelumab	12	10 (83.3)	1.35 (1.21)	-0.5	0.25	1.63	2.25	3.3	0.50 [-0.48, 1.48]
		Placebo	9	7 (77.8)	0.79 (0.99)	-0.3	0.00	0.75	1.00	2.8	
	Week 36	Tezepelumab	12	10 (83.3)	1.38 (1.25)	-0.8	0.25	1.63	2.25	3.3	0.52 [-0.47, 1.50]
		Placebo	9	7 (77.8)	0.75 (1.15)	-0.5	-0.25	0.50	1.00	3.0	
	Week 40	Tezepelumab	12	10 (83.3)	1.55 (1.06)	0.0	0.25	1.88	2.25	3.3	0.38 [-0.59, 1.36]
		Placebo	9	7 (77.8)	1.11 (1.30)	-0.5	0.00	1.00	2.25	3.3	
	Week 44	Tezepelumab	12	10 (83.3)	1.50 (1.24)	-1.0	0.50	2.00	2.25	3.3	0.65 [-0.34, 1.65]
		Placebo	9	7 (77.8)	0.64 (1.41)	-1.0	-0.25	0.00	1.50	3.3	
	Week 48	Tezepelumab	12	10 (83.3)	1.38 (1.20)	-1.0	0.50	1.63	2.00	3.3	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	1.14 (1.62)	-1.0	-0.25	1.00	2.50	3.8	
	Week 52	Tezepelumab	12	10 (83.3)	1.48 (1.00)	0.0	0.50	1.63	2.00	3.3	0.26 [-0.71, 1.23]
		Placebo	9	7 (77.8)	1.14 (1.62)	-1.0	-0.25	1.00	2.50	3.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
 Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
 DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 36	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
 DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	12	12 (100.0)	4.40 (1.47)	2.3	3.00	5.13	5.50	6.5	
	Placebo	11	11 (100.0)	4.09 (1.34)	1.3	3.50	4.00	5.25	6.3	
Week 4	Tezepelumab	12	11 (91.7)	3.91 (1.91)	2.0	2.00	3.25	6.00	6.8	
	Placebo	11	11 (100.0)	4.43 (1.62)	2.3	2.75	4.25	6.00	6.5	
Week 40	Tezepelumab	12	10 (83.3)	4.18 (1.50)	1.8	3.25	4.00	5.50	6.5	
	Placebo	11	11 (100.0)	4.55 (1.69)	1.0	3.75	5.25	5.75	6.8	
Week 44	Tezepelumab	12	9 (75.0)	4.17 (1.88)	1.0	3.50	4.25	5.50	7.0	
	Placebo	11	10 (90.9)	4.68 (1.64)	1.5	3.25	5.00	5.75	7.0	
Week 48	Tezepelumab	12	9 (75.0)	4.28 (1.78)	1.5	3.25	4.50	5.25	6.8	
	Placebo	11	10 (90.9)	4.55 (1.35)	2.5	3.75	4.50	5.25	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	12	11 (91.7)	-0.41 (1.25)	-3.3	-1.00	-0.50	0.50	1.5	-0.69 [-1.55, 0.17]
		Placebo	11	11 (100.0)	0.34 (0.90)	-0.8	-0.75	0.25	1.00	2.0	
	Week 40	Tezepelumab	12	10 (83.3)	-0.05 (0.97)	-1.3	-1.25	0.00	0.50	1.3	-0.44 [-1.31, 0.43]
		Placebo	11	11 (100.0)	0.45 (1.28)	-2.5	0.00	0.50	1.25	2.5	
	Week 44	Tezepelumab	12	9 (75.0)	0.11 (1.55)	-2.3	-1.00	0.75	1.25	1.8	-0.13 [-1.04, 0.77]
		Placebo	11	10 (90.9)	0.30 (1.26)	-2.0	-0.50	0.50	1.00	2.5	
	Week 48	Tezepelumab	12	9 (75.0)	0.22 (1.03)	-1.5	-0.50	0.25	1.25	1.5	-0.17 [-1.07, 0.73]
		Placebo	11	10 (90.9)	0.40 (1.03)	-1.0	-0.50	0.50	1.25	1.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
 DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	12	11 (91.7)	-0.39 (0.34)	(-1.10, 0.31)	-0.73 (0.47)	(-1.72, 0.26)	0.141
	Placebo	11	11 (100.0)	0.33 (0.33)	(-0.37, 1.03)			
Week 40	Tezepelumab	12	10 (83.3)	-0.01 (0.35)	(-0.75, 0.72)	-0.46 (0.49)	(-1.48, 0.56)	0.359
	Placebo	11	11 (100.0)	0.45 (0.34)	(-0.26, 1.16)			
Week 44	Tezepelumab	12	9 (75.0)	0.17 (0.43)	(-0.72, 1.06)	-0.23 (0.60)	(-1.47, 1.02)	0.707
	Placebo	11	10 (90.9)	0.40 (0.41)	(-0.47, 1.26)			
Week 48	Tezepelumab	12	9 (75.0)	0.22 (0.33)	(-0.47, 0.90)	-0.17 (0.45)	(-1.12, 0.77)	0.704
	Placebo	11	10 (90.9)	0.39 (0.31)	(-0.26, 1.04)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QGC_IBMH0: Course of AQLQ+12 emotional function score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	66	64 (97.0)	4.18 (1.40)	1.2	3.30	4.20	5.20	6.8	
		Placebo	48	46 (95.8)	3.87 (1.50)	1.0	3.00	3.80	4.80	7.0	
	Week 4	Tezepelumab	66	64 (97.0)	4.86 (1.48)	1.0	3.60	5.20	6.00	7.0	
		Placebo	48	45 (93.8)	4.62 (1.60)	1.0	3.60	4.60	5.80	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.02 (1.49)	1.4	4.20	5.20	6.20	7.0	
		Placebo	48	43 (89.6)	4.81 (1.50)	1.0	4.20	5.20	6.00	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.14 (1.55)	1.0	4.20	5.20	6.40	7.0	
		Placebo	48	41 (85.4)	4.64 (1.81)	1.0	3.20	5.00	6.20	7.0	
	Week 36	Tezepelumab	66	63 (95.5)	5.18 (1.58)	1.0	4.00	5.40	6.80	7.0	
		Placebo	48	43 (89.6)	4.75 (1.56)	1.2	3.60	4.80	6.00	7.0	
	Week 52	Tezepelumab	66	60 (90.9)	5.07 (1.51)	1.0	4.00	5.40	6.40	7.0	
		Placebo	48	41 (85.4)	4.84 (1.51)	1.4	3.80	5.00	6.00	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	66	64 (97.0)	0.69 (1.25)	-1.8	-0.20	0.80	1.50	4.6	-0.04 [-0.42, 0.34]
		Placebo	48	45 (93.8)	0.74 (1.09)	-1.6	0.00	0.60	1.40	4.6	
	Week 12	Tezepelumab	66	62 (93.9)	0.85 (1.38)	-2.6	0.00	0.80	2.00	4.6	-0.03 [-0.42, 0.36]
		Placebo	48	43 (89.6)	0.90 (1.30)	-1.8	0.00	0.80	1.40	4.0	
	Week 24	Tezepelumab	66	62 (93.9)	0.97 (1.59)	-5.2	0.00	0.80	1.80	4.6	0.18 [-0.21, 0.58]
		Placebo	48	41 (85.4)	0.70 (1.35)	-2.0	-0.20	0.60	1.60	4.6	
	Week 36	Tezepelumab	66	61 (92.4)	1.01 (1.43)	-2.2	0.00	1.00	1.80	5.0	0.16 [-0.23, 0.55]
		Placebo	48	43 (89.6)	0.79 (1.46)	-5.0	0.00	0.80	1.80	3.6	
	Week 52	Tezepelumab	66	58 (87.9)	0.96 (1.34)	-1.4	0.00	0.90	2.00	4.6	0.02 [-0.38, 0.42]
		Placebo	48	41 (85.4)	0.93 (1.51)	-2.6	0.00	1.00	1.80	5.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.73 (0.14)	(0.45, 1.01)	0.03 (0.22)	(-0.41, 0.46)	0.909
	Placebo	48	45 (93.8)	0.70 (0.17)	(0.37, 1.03)			
Week 12	Tezepelumab	66	61 (92.4)	0.93 (0.16)	(0.62, 1.24)	0.04 (0.24)	(-0.44, 0.53)	0.855
	Placebo	48	43 (89.6)	0.89 (0.19)	(0.52, 1.26)			
Week 24	Tezepelumab	66	60 (90.9)	0.98 (0.18)	(0.63, 1.33)	0.29 (0.28)	(-0.26, 0.84)	0.293
	Placebo	48	40 (83.3)	0.69 (0.21)	(0.27, 1.11)			
Week 36	Tezepelumab	66	58 (87.9)	1.02 (0.17)	(0.68, 1.35)	0.32 (0.26)	(-0.21, 0.84)	0.232
	Placebo	48	42 (87.5)	0.70 (0.20)	(0.30, 1.10)			
Week 52	Tezepelumab	66	51 (77.3)	0.94 (0.16)	(0.61, 1.26)	0.03 (0.26)	(-0.47, 0.54)	0.893
	Placebo	48	36 (75.0)	0.90 (0.20)	(0.51, 1.29)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	55	55 (100.0)	4.09 (1.39)	1.2	3.20	4.00	5.00	6.8	
		Placebo	40	40 (100.0)	3.79 (1.54)	1.0	3.00	3.80	4.80	7.0	
	Week 4	Tezepelumab	55	55 (100.0)	4.81 (1.54)	1.0	3.60	5.20	6.00	7.0	
		Placebo	40	39 (97.5)	4.57 (1.62)	1.0	3.60	4.60	5.60	7.0	
	Week 12	Tezepelumab	55	53 (96.4)	4.89 (1.52)	1.4	4.00	4.80	6.20	7.0	
		Placebo	40	37 (92.5)	4.74 (1.52)	1.0	4.20	5.20	5.80	7.0	
	Week 24	Tezepelumab	55	53 (96.4)	5.02 (1.62)	1.0	4.00	5.00	6.40	7.0	
		Placebo	40	35 (87.5)	4.63 (1.90)	1.0	3.00	5.00	6.20	7.0	
	Week 36	Tezepelumab	55	52 (94.5)	5.06 (1.63)	1.0	3.90	5.20	6.60	7.0	
		Placebo	40	37 (92.5)	4.70 (1.55)	1.2	3.60	4.60	5.80	7.0	
	Week 52	Tezepelumab	55	49 (89.1)	4.96 (1.57)	1.0	4.00	5.40	6.20	7.0	
		Placebo	40	35 (87.5)	4.93 (1.48)	1.4	4.20	5.00	6.00	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	55	55 (100.0)	0.72 (1.21)	-1.6	-0.20	0.80	1.40	4.6	-0.04 [-0.45, 0.37]
		Placebo	40	39 (97.5)	0.76 (1.13)	-1.6	0.00	0.60	1.40	4.6	
	Week 12	Tezepelumab	55	53 (96.4)	0.81 (1.40)	-2.6	0.00	0.80	2.00	4.6	-0.06 [-0.48, 0.36]
		Placebo	40	37 (92.5)	0.90 (1.35)	-1.8	0.00	0.80	1.40	4.0	
	Week 24	Tezepelumab	55	53 (96.4)	0.95 (1.63)	-5.2	0.00	0.80	1.80	4.6	0.13 [-0.30, 0.55]
		Placebo	40	35 (87.5)	0.76 (1.41)	-2.0	-0.20	0.60	1.80	4.6	
	Week 36	Tezepelumab	55	52 (94.5)	1.00 (1.42)	-2.2	0.00	0.90	1.80	5.0	0.14 [-0.29, 0.56]
		Placebo	40	37 (92.5)	0.80 (1.54)	-5.0	0.00	1.00	1.80	3.6	
	Week 52	Tezepelumab	55	49 (89.1)	0.97 (1.35)	-1.4	0.00	0.80	2.00	3.8	-0.09 [-0.53, 0.34]
		Placebo	40	35 (87.5)	1.10 (1.43)	-2.4	0.20	1.20	1.80	5.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
 DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis																																																								
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																						
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																				
Week 4	Tezepelumab	55	55 (100.0)	0.76 (0.15)	(0.45, 1.06)	0.02 (0.24)	(-0.46, 0.49)	0.939																																																				
	Placebo	40	39 (97.5)	0.74 (0.18)	(0.38, 1.10)				Week 12	Tezepelumab	55	53 (96.4)	0.90 (0.17)	(0.55, 1.25)	-0.01 (0.27)	(-0.55, 0.53)	0.979	Placebo	40	37 (92.5)	0.91 (0.21)	(0.49, 1.32)	Week 24	Tezepelumab	55	53 (96.4)	0.98 (0.20)	(0.58, 1.37)	0.19 (0.31)	(-0.43, 0.80)	0.544	Placebo	40	35 (87.5)	0.79 (0.24)	(0.32, 1.26)	Week 36	Tezepelumab	55	52 (94.5)	1.02 (0.19)	(0.65, 1.39)	0.27 (0.29)	(-0.30, 0.85)	0.347	Placebo	40	37 (92.5)	0.75 (0.22)	(0.31, 1.19)	Week 52	Tezepelumab	55	49 (89.1)	0.97 (0.17)	(0.63, 1.32)	-0.08 (0.27)	(-0.61, 0.45)	0.758	Placebo
Week 12	Tezepelumab	55	53 (96.4)	0.90 (0.17)	(0.55, 1.25)	-0.01 (0.27)	(-0.55, 0.53)	0.979																																																				
	Placebo	40	37 (92.5)	0.91 (0.21)	(0.49, 1.32)				Week 24	Tezepelumab	55	53 (96.4)	0.98 (0.20)	(0.58, 1.37)	0.19 (0.31)	(-0.43, 0.80)	0.544	Placebo	40	35 (87.5)	0.79 (0.24)	(0.32, 1.26)	Week 36	Tezepelumab	55	52 (94.5)	1.02 (0.19)	(0.65, 1.39)	0.27 (0.29)	(-0.30, 0.85)	0.347	Placebo	40	37 (92.5)	0.75 (0.22)	(0.31, 1.19)	Week 52	Tezepelumab	55	49 (89.1)	0.97 (0.17)	(0.63, 1.32)	-0.08 (0.27)	(-0.61, 0.45)	0.758	Placebo	40	35 (87.5)	1.06 (0.20)	(0.65, 1.46)										
Week 24	Tezepelumab	55	53 (96.4)	0.98 (0.20)	(0.58, 1.37)	0.19 (0.31)	(-0.43, 0.80)	0.544																																																				
	Placebo	40	35 (87.5)	0.79 (0.24)	(0.32, 1.26)				Week 36	Tezepelumab	55	52 (94.5)	1.02 (0.19)	(0.65, 1.39)	0.27 (0.29)	(-0.30, 0.85)	0.347	Placebo	40	37 (92.5)	0.75 (0.22)	(0.31, 1.19)	Week 52	Tezepelumab	55	49 (89.1)	0.97 (0.17)	(0.63, 1.32)	-0.08 (0.27)	(-0.61, 0.45)	0.758	Placebo	40	35 (87.5)	1.06 (0.20)	(0.65, 1.46)																								
Week 36	Tezepelumab	55	52 (94.5)	1.02 (0.19)	(0.65, 1.39)	0.27 (0.29)	(-0.30, 0.85)	0.347																																																				
	Placebo	40	37 (92.5)	0.75 (0.22)	(0.31, 1.19)				Week 52	Tezepelumab	55	49 (89.1)	0.97 (0.17)	(0.63, 1.32)	-0.08 (0.27)	(-0.61, 0.45)	0.758	Placebo	40	35 (87.5)	1.06 (0.20)	(0.65, 1.46)																																						
Week 52	Tezepelumab	55	49 (89.1)	0.97 (0.17)	(0.63, 1.32)	-0.08 (0.27)	(-0.61, 0.45)	0.758																																																				
	Placebo	40	35 (87.5)	1.06 (0.20)	(0.65, 1.46)																																																							

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	12	10 (83.3)	4.54 (1.43)	1.8	3.80	5.10	5.60	6.2	
		Placebo	9	7 (77.8)	4.40 (1.11)	2.8	3.80	4.20	5.40	6.2	
	Week 4	Tezepelumab	12	10 (83.3)	5.30 (1.06)	3.8	4.40	5.40	6.00	7.0	
		Placebo	9	7 (77.8)	4.94 (1.45)	3.2	3.60	4.40	6.60	6.8	
	Week 8	Tezepelumab	12	10 (83.3)	5.64 (1.05)	4.0	4.80	5.70	6.40	7.0	
		Placebo	9	7 (77.8)	5.17 (1.09)	3.8	4.20	5.60	6.00	6.6	
	Week 12	Tezepelumab	12	10 (83.3)	5.86 (1.00)	4.2	4.80	6.30	6.60	7.0	
		Placebo	9	7 (77.8)	5.29 (1.26)	3.8	4.00	5.20	6.60	6.8	
	Week 16	Tezepelumab	12	10 (83.3)	5.66 (0.97)	4.0	5.00	5.90	6.40	7.0	
		Placebo	9	7 (77.8)	4.94 (1.19)	3.6	4.00	4.60	6.20	6.8	
	Week 20	Tezepelumab	12	11 (91.7)	5.96 (1.00)	4.2	5.00	6.20	7.00	7.0	
		Placebo	9	7 (77.8)	5.06 (1.16)	3.8	4.00	5.00	6.20	6.6	
	Week 24	Tezepelumab	12	11 (91.7)	5.82 (0.90)	4.2	5.20	5.80	6.60	7.0	
		Placebo	9	7 (77.8)	4.86 (1.26)	2.8	3.80	5.20	6.20	6.2	
	Week 28	Tezepelumab	12	12 (100.0)	5.75 (1.15)	4.0	4.80	5.90	6.90	7.0	
		Placebo	9	7 (77.8)	4.86 (1.01)	4.0	4.00	4.40	6.20	6.2	
	Week 32	Tezepelumab	12	12 (100.0)	5.60 (1.17)	3.8	4.60	5.80	6.60	7.0	
		Placebo	9	7 (77.8)	4.86 (1.38)	2.6	3.80	5.20	6.20	6.6	
	Week 36	Tezepelumab	12	12 (100.0)	5.80 (1.16)	3.8	4.60	6.20	6.90	7.0	
		Placebo	9	7 (77.8)	5.14 (1.57)	2.2	4.40	5.20	6.40	6.8	
	Week 40	Tezepelumab	12	12 (100.0)	5.65 (1.03)	4.0	4.90	5.60	6.50	7.0	
		Placebo	9	7 (77.8)	5.20 (1.15)	3.6	4.00	5.40	6.20	6.8	
	Week 44	Tezepelumab	12	12 (100.0)	5.62 (1.18)	4.0	4.50	5.80	6.70	7.0	
		Placebo	9	7 (77.8)	5.00 (1.48)	3.4	3.60	4.60	6.60	6.6	
	Week 48	Tezepelumab	12	12 (100.0)	5.70 (1.16)	3.8	4.90	5.80	6.80	7.0	
		Placebo	9	7 (77.8)	5.03 (1.72)	2.8	3.80	4.20	6.80	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.68 (1.15)	4.0	4.80	5.80	6.80	7.0	
		Placebo	9	7 (77.8)	4.54 (1.66)	2.8	3.60	3.80	6.80	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	12	10 (83.3)	0.76 (1.68)	-1.8	-0.40	0.60	1.80	3.8	0.16 [-0.81, 1.12]
		Placebo	9	7 (77.8)	0.54 (0.73)	-0.2	0.00	0.40	1.20	1.8	
	Week 8	Tezepelumab	12	10 (83.3)	1.10 (1.76)	-1.2	-0.20	0.90	2.00	4.4	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	0.77 (0.86)	-0.2	-0.20	1.20	1.60	1.6	
	Week 12	Tezepelumab	12	10 (83.3)	1.32 (1.41)	-0.8	0.00	1.40	2.00	3.8	0.35 [-0.62, 1.33]
		Placebo	9	7 (77.8)	0.89 (0.89)	-0.6	0.20	1.20	1.60	2.0	
	Week 16	Tezepelumab	12	10 (83.3)	1.12 (1.55)	-1.2	-0.20	1.00	2.00	4.0	0.43 [-0.55, 1.41]
		Placebo	9	7 (77.8)	0.54 (0.98)	-1.0	0.00	0.40	1.40	2.0	
	Week 20	Tezepelumab	12	10 (83.3)	1.46 (1.58)	-0.6	0.00	1.40	2.00	4.6	0.53 [-0.45, 1.52]
		Placebo	9	7 (77.8)	0.66 (1.39)	-2.2	0.00	1.20	1.40	2.0	
	Week 24	Tezepelumab	12	10 (83.3)	1.30 (1.45)	-0.4	0.00	1.30	2.00	4.6	0.66 [-0.33, 1.65]
		Placebo	9	7 (77.8)	0.46 (0.96)	-1.0	-0.20	0.60	1.00	2.0	
	Week 28	Tezepelumab	12	10 (83.3)	1.42 (1.60)	-0.6	0.00	1.50	2.00	4.6	0.63 [-0.36, 1.63]
		Placebo	9	7 (77.8)	0.46 (1.38)	-2.2	0.00	0.80	1.40	2.0	
	Week 32	Tezepelumab	12	10 (83.3)	1.06 (1.66)	-1.6	0.00	1.30	1.60	4.6	0.42 [-0.56, 1.40]
		Placebo	9	7 (77.8)	0.46 (1.00)	-1.0	-0.20	0.60	1.20	2.0	
	Week 36	Tezepelumab	12	10 (83.3)	1.30 (1.61)	-1.0	0.00	1.50	2.00	4.6	0.41 [-0.57, 1.39]
		Placebo	9	7 (77.8)	0.74 (0.85)	-0.6	0.20	0.80	1.40	2.0	
	Week 40	Tezepelumab	12	10 (83.3)	1.24 (1.46)	-0.4	0.00	1.40	1.60	4.6	0.32 [-0.65, 1.29]
		Placebo	9	7 (77.8)	0.80 (1.24)	-1.4	-0.40	1.20	1.80	2.0	
	Week 44	Tezepelumab	12	10 (83.3)	1.12 (1.58)	-0.6	-0.20	1.40	1.60	4.6	0.38 [-0.60, 1.35]
		Placebo	9	7 (77.8)	0.60 (1.02)	-0.6	-0.40	0.60	1.20	2.4	
	Week 48	Tezepelumab	12	10 (83.3)	1.22 (1.50)	-0.4	0.00	1.50	1.60	4.6	0.44 [-0.54, 1.42]
		Placebo	9	7 (77.8)	0.63 (1.10)	-0.6	0.00	0.40	1.60	2.6	
	Week 52	Tezepelumab	12	10 (83.3)	1.20 (1.52)	-0.6	0.00	1.50	1.60	4.6	0.67 [-0.33, 1.66]
		Placebo	9	7 (77.8)	0.14 (1.66)	-2.6	-0.60	0.00	1.60	2.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
 Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
 DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 36	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
 DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	12	12 (100.0)	4.92 (1.38)	2.4	4.30	5.20	5.70	7.0	
		Placebo	11	11 (100.0)	3.93 (1.39)	1.0	3.60	4.40	4.60	5.8	
	Week 4	Tezepelumab	12	11 (91.7)	4.49 (1.77)	1.8	2.80	4.60	6.20	6.8	
		Placebo	11	11 (100.0)	4.64 (1.18)	2.8	3.80	4.40	5.40	6.6	
	Week 40	Tezepelumab	12	10 (83.3)	5.16 (1.46)	2.0	4.40	5.60	6.00	7.0	
		Placebo	11	11 (100.0)	5.05 (1.31)	2.4	4.00	5.60	6.20	6.8	
	Week 44	Tezepelumab	12	9 (75.0)	5.22 (1.39)	3.8	4.00	5.00	6.80	7.0	
		Placebo	11	10 (90.9)	5.06 (1.11)	3.6	4.40	4.90	6.00	7.0	
	Week 48	Tezepelumab	12	9 (75.0)	4.80 (1.89)	1.8	3.40	4.60	6.20	7.0	
		Placebo	11	10 (90.9)	4.86 (1.32)	3.0	3.60	4.70	5.60	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QGC_IBMH0: Course of AQLQ+12 emotional function score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	12	11 (91.7)	-0.44 (1.35)	-3.2	-1.00	-0.60	0.40	1.6	-0.95 [-1.83, -0.06]
		Placebo	11	11 (100.0)	0.71 (1.05)	-0.6	-0.20	0.20	1.80	2.2	
	Week 40	Tezepelumab	12	10 (83.3)	0.28 (0.97)	-1.0	-0.60	0.10	1.20	1.8	-0.67 [-1.55, 0.21]
		Placebo	11	11 (100.0)	1.13 (1.48)	-1.0	0.00	1.00	2.00	4.4	
	Week 44	Tezepelumab	12	9 (75.0)	0.38 (1.17)	-2.0	-0.20	0.40	1.40	1.8	-0.43 [-1.35, 0.48]
		Placebo	11	10 (90.9)	0.84 (0.97)	-0.6	0.00	0.80	1.60	2.4	
	Week 48	Tezepelumab	12	9 (75.0)	-0.04 (1.09)	-1.8	-0.80	0.00	0.60	1.8	-0.92 [-1.88, 0.03]
		Placebo	11	10 (90.9)	0.96 (1.09)	-1.4	0.40	1.10	1.80	2.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
 DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	11 (91.7)	-0.23 (0.36)	(-0.98, 0.52)	-0.74 (0.52)	(-1.82, 0.35)	0.174
	Placebo	11	11 (100.0)	0.51 (0.36)	(-0.24, 1.26)			
Week 40	Tezepelumab	12	10 (83.3)	0.51 (0.36)	(-0.23, 1.26)	-0.41 (0.51)	(-1.48, 0.65)	0.429
	Placebo	11	11 (100.0)	0.93 (0.35)	(0.20, 1.65)			
Week 44	Tezepelumab	12	9 (75.0)	0.65 (0.32)	(-0.01, 1.31)	-0.11 (0.44)	(-1.04, 0.82)	0.804
	Placebo	11	10 (90.9)	0.76 (0.30)	(0.14, 1.39)			
Week 48	Tezepelumab	12	9 (75.0)	0.22 (0.38)	(-0.58, 1.02)	-0.38 (0.53)	(-1.50, 0.75)	0.492
	Placebo	11	10 (90.9)	0.60 (0.36)	(-0.17, 1.36)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	66	64 (97.0)	3.85 (0.85)	1.3	3.29	3.88	4.42	5.6	
		Placebo	48	46 (95.8)	3.45 (0.96)	1.3	2.75	3.54	4.33	5.3	
	Week 4	Tezepelumab	66	64 (97.0)	4.67 (1.15)	2.3	3.83	4.50	5.71	7.0	
		Placebo	48	45 (93.8)	4.27 (1.14)	1.0	3.83	4.42	5.17	6.6	
	Week 12	Tezepelumab	66	62 (93.9)	4.81 (1.26)	1.2	4.00	4.75	5.92	7.0	
		Placebo	48	43 (89.6)	4.49 (1.16)	1.0	3.83	4.58	5.08	6.6	
	Week 24	Tezepelumab	66	63 (95.5)	4.87 (1.34)	1.1	4.00	4.75	5.92	7.0	
		Placebo	48	41 (85.4)	4.45 (1.37)	1.0	3.42	4.17	5.42	6.7	
	Week 36	Tezepelumab	66	63 (95.5)	4.77 (1.30)	1.7	3.83	4.58	5.92	7.0	
		Placebo	48	43 (89.6)	4.50 (1.20)	2.2	3.58	4.42	5.42	6.8	
	Week 52	Tezepelumab	66	60 (90.9)	4.97 (1.28)	2.8	4.00	5.08	5.92	7.0	
		Placebo	48	41 (85.4)	4.68 (1.17)	2.1	3.92	4.58	5.50	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	66	64 (97.0)	0.82 (1.01)	-1.0	0.04	0.79	1.50	3.3	0.02 [-0.37, 0.40]
		Placebo	48	45 (93.8)	0.81 (0.97)	-1.4	0.25	0.75	1.08	3.9	
	Week 12	Tezepelumab	66	62 (93.9)	0.98 (1.18)	-1.8	0.17	0.88	1.83	3.7	-0.03 [-0.42, 0.36]
		Placebo	48	43 (89.6)	1.01 (1.15)	-1.0	0.33	0.83	1.67	3.8	
	Week 24	Tezepelumab	66	62 (93.9)	1.04 (1.36)	-4.3	0.25	0.88	1.83	3.9	0.05 [-0.35, 0.44]
		Placebo	48	41 (85.4)	0.98 (1.23)	-1.3	0.17	0.83	1.67	4.1	
	Week 36	Tezepelumab	66	61 (92.4)	0.94 (1.21)	-2.4	0.08	0.75	2.00	3.4	-0.03 [-0.42, 0.36]
		Placebo	48	43 (89.6)	0.99 (1.27)	-2.4	0.17	0.83	1.75	3.8	
	Week 52	Tezepelumab	66	58 (87.9)	1.19 (1.09)	-0.8	0.17	1.13	2.08	3.5	0.04 [-0.36, 0.44]
		Placebo	48	41 (85.4)	1.14 (1.14)	-0.8	0.42	1.08	1.75	4.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
 Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
 DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.87 (0.12)	(0.63, 1.11)	0.13 (0.19)	(-0.25, 0.51)	0.501
	Placebo	48	45 (93.8)	0.74 (0.15)	(0.46, 1.03)			
Week 12	Tezepelumab	66	61 (92.4)	1.07 (0.14)	(0.79, 1.36)	0.12 (0.23)	(-0.32, 0.57)	0.583
	Placebo	48	43 (89.6)	0.95 (0.17)	(0.61, 1.29)			
Week 24	Tezepelumab	66	60 (90.9)	1.09 (0.17)	(0.76, 1.42)	0.21 (0.26)	(-0.31, 0.72)	0.422
	Placebo	48	40 (83.3)	0.88 (0.20)	(0.49, 1.27)			
Week 36	Tezepelumab	66	58 (87.9)	0.98 (0.16)	(0.67, 1.29)	0.11 (0.24)	(-0.37, 0.60)	0.637
	Placebo	48	42 (87.5)	0.87 (0.18)	(0.50, 1.23)			
Week 52	Tezepelumab	66	51 (77.3)	1.19 (0.15)	(0.90, 1.48)	0.10 (0.23)	(-0.36, 0.55)	0.672
	Placebo	48	36 (75.0)	1.09 (0.17)	(0.75, 1.44)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	55	55 (100.0)	3.85 (0.86)	1.3	3.33	3.83	4.42	5.6	
		Placebo	40	40 (100.0)	3.41 (1.00)	1.3	2.67	3.50	4.29	5.3	
	Week 4	Tezepelumab	55	55 (100.0)	4.65 (1.18)	2.3	3.75	4.42	5.83	7.0	
		Placebo	40	39 (97.5)	4.22 (1.18)	1.0	3.67	4.25	5.17	6.6	
	Week 12	Tezepelumab	55	53 (96.4)	4.78 (1.30)	1.2	4.00	4.75	5.92	7.0	
		Placebo	40	37 (92.5)	4.43 (1.17)	1.0	3.83	4.58	5.00	6.4	
	Week 24	Tezepelumab	55	53 (96.4)	4.83 (1.40)	1.1	4.00	4.50	5.92	7.0	
		Placebo	40	35 (87.5)	4.40 (1.31)	1.0	3.42	4.08	5.42	6.6	
	Week 36	Tezepelumab	55	52 (94.5)	4.72 (1.32)	1.7	3.75	4.50	5.83	7.0	
		Placebo	40	37 (92.5)	4.40 (1.13)	2.2	3.58	4.33	5.17	6.4	
	Week 52	Tezepelumab	55	49 (89.1)	4.98 (1.31)	2.8	4.00	5.17	5.92	6.9	
		Placebo	40	35 (87.5)	4.63 (1.15)	2.1	3.83	4.67	5.50	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	55	55 (100.0)	0.80 (1.00)	-1.0	0.00	0.83	1.42	3.3	0.02 [-0.39, 0.43]
		Placebo	40	39 (97.5)	0.78 (0.94)	-1.4	0.25	0.75	1.17	3.9	
	Week 12	Tezepelumab	55	53 (96.4)	0.95 (1.18)	-1.8	0.17	0.83	1.83	3.4	-0.03 [-0.45, 0.39]
		Placebo	40	37 (92.5)	0.99 (1.09)	-1.0	0.42	0.83	1.58	3.6	
	Week 24	Tezepelumab	55	53 (96.4)	1.01 (1.42)	-4.3	0.25	0.83	1.75	3.9	0.03 [-0.39, 0.46]
		Placebo	40	35 (87.5)	0.96 (1.12)	-0.9	0.17	0.83	1.67	4.1	
	Week 36	Tezepelumab	55	52 (94.5)	0.91 (1.23)	-2.4	0.04	0.75	1.88	3.4	-0.01 [-0.43, 0.42]
		Placebo	40	37 (92.5)	0.92 (1.22)	-2.4	0.17	0.75	1.50	3.8	
	Week 52	Tezepelumab	55	49 (89.1)	1.21 (1.12)	-0.8	0.17	1.17	2.08	3.5	0.08 [-0.35, 0.52]
		Placebo	40	35 (87.5)	1.12 (1.05)	-0.8	0.42	1.08	1.75	4.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis																																																								
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																						
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																				
Week 4	Tezepelumab	55	55 (100.0)	0.85 (0.13)	(0.60, 1.11)	0.12 (0.20)	(-0.28, 0.53)	0.545																																																				
	Placebo	40	39 (97.5)	0.73 (0.15)	(0.42, 1.04)				Week 12	Tezepelumab	55	53 (96.4)	1.04 (0.15)	(0.73, 1.35)	0.11 (0.24)	(-0.37, 0.59)	0.657	Placebo	40	37 (92.5)	0.93 (0.18)	(0.57, 1.30)	Week 24	Tezepelumab	55	53 (96.4)	1.04 (0.18)	(0.69, 1.39)	0.15 (0.28)	(-0.40, 0.70)	0.583	Placebo	40	35 (87.5)	0.88 (0.21)	(0.46, 1.30)	Week 36	Tezepelumab	55	52 (94.5)	0.94 (0.16)	(0.61, 1.26)	0.11 (0.25)	(-0.39, 0.62)	0.654	Placebo	40	37 (92.5)	0.82 (0.19)	(0.44, 1.21)	Week 52	Tezepelumab	55	49 (89.1)	1.17 (0.15)	(0.86, 1.47)	0.09 (0.24)	(-0.38, 0.57)	0.692	Placebo
Week 12	Tezepelumab	55	53 (96.4)	1.04 (0.15)	(0.73, 1.35)	0.11 (0.24)	(-0.37, 0.59)	0.657																																																				
	Placebo	40	37 (92.5)	0.93 (0.18)	(0.57, 1.30)				Week 24	Tezepelumab	55	53 (96.4)	1.04 (0.18)	(0.69, 1.39)	0.15 (0.28)	(-0.40, 0.70)	0.583	Placebo	40	35 (87.5)	0.88 (0.21)	(0.46, 1.30)	Week 36	Tezepelumab	55	52 (94.5)	0.94 (0.16)	(0.61, 1.26)	0.11 (0.25)	(-0.39, 0.62)	0.654	Placebo	40	37 (92.5)	0.82 (0.19)	(0.44, 1.21)	Week 52	Tezepelumab	55	49 (89.1)	1.17 (0.15)	(0.86, 1.47)	0.09 (0.24)	(-0.38, 0.57)	0.692	Placebo	40	35 (87.5)	1.07 (0.18)	(0.71, 1.43)										
Week 24	Tezepelumab	55	53 (96.4)	1.04 (0.18)	(0.69, 1.39)	0.15 (0.28)	(-0.40, 0.70)	0.583																																																				
	Placebo	40	35 (87.5)	0.88 (0.21)	(0.46, 1.30)				Week 36	Tezepelumab	55	52 (94.5)	0.94 (0.16)	(0.61, 1.26)	0.11 (0.25)	(-0.39, 0.62)	0.654	Placebo	40	37 (92.5)	0.82 (0.19)	(0.44, 1.21)	Week 52	Tezepelumab	55	49 (89.1)	1.17 (0.15)	(0.86, 1.47)	0.09 (0.24)	(-0.38, 0.57)	0.692	Placebo	40	35 (87.5)	1.07 (0.18)	(0.71, 1.43)																								
Week 36	Tezepelumab	55	52 (94.5)	0.94 (0.16)	(0.61, 1.26)	0.11 (0.25)	(-0.39, 0.62)	0.654																																																				
	Placebo	40	37 (92.5)	0.82 (0.19)	(0.44, 1.21)				Week 52	Tezepelumab	55	49 (89.1)	1.17 (0.15)	(0.86, 1.47)	0.09 (0.24)	(-0.38, 0.57)	0.692	Placebo	40	35 (87.5)	1.07 (0.18)	(0.71, 1.43)																																						
Week 52	Tezepelumab	55	49 (89.1)	1.17 (0.15)	(0.86, 1.47)	0.09 (0.24)	(-0.38, 0.57)	0.692																																																				
	Placebo	40	35 (87.5)	1.07 (0.18)	(0.71, 1.43)																																																							

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	12	10 (83.3)	3.98 (0.85)	2.6	3.25	4.25	4.67	4.8	
		Placebo	9	7 (77.8)	3.77 (0.62)	2.8	3.42	3.67	4.33	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	4.95 (1.08)	3.5	3.92	5.13	5.67	6.4	
		Placebo	9	7 (77.8)	4.73 (0.75)	3.8	4.25	4.58	5.25	6.1	
	Week 8	Tezepelumab	12	10 (83.3)	4.95 (1.49)	2.0	3.75	5.21	5.92	6.7	
		Placebo	9	7 (77.8)	4.75 (1.06)	3.2	3.92	4.50	5.75	6.1	
	Week 12	Tezepelumab	12	10 (83.3)	5.18 (1.13)	3.6	4.17	5.29	6.25	6.8	
		Placebo	9	7 (77.8)	4.90 (1.05)	3.8	4.08	4.58	5.92	6.6	
	Week 16	Tezepelumab	12	10 (83.3)	5.33 (0.99)	3.6	4.92	5.42	6.08	6.8	
		Placebo	9	7 (77.8)	4.93 (1.09)	3.5	4.08	4.58	5.92	6.3	
	Week 20	Tezepelumab	12	11 (91.7)	5.15 (1.11)	3.6	4.17	4.83	6.25	6.8	
		Placebo	9	7 (77.8)	4.95 (1.42)	2.4	3.92	5.08	6.08	6.4	
	Week 24	Tezepelumab	12	11 (91.7)	5.19 (1.05)	3.6	4.17	4.92	6.17	7.0	
		Placebo	9	7 (77.8)	4.81 (1.65)	2.2	3.58	4.58	6.33	6.7	
	Week 28	Tezepelumab	12	12 (100.0)	5.04 (1.22)	3.3	4.13	5.04	5.88	7.0	
		Placebo	9	7 (77.8)	4.46 (1.39)	1.8	4.00	4.83	5.50	6.1	
	Week 32	Tezepelumab	12	12 (100.0)	4.94 (1.23)	3.5	4.00	4.75	5.83	7.0	
		Placebo	9	7 (77.8)	4.85 (1.25)	2.9	3.75	4.92	6.08	6.3	
	Week 36	Tezepelumab	12	12 (100.0)	5.15 (1.29)	3.3	4.08	5.04	6.25	7.0	
		Placebo	9	7 (77.8)	5.12 (1.44)	2.8	4.42	4.83	6.50	6.8	
	Week 40	Tezepelumab	12	12 (100.0)	4.97 (1.21)	2.9	4.25	4.96	5.46	7.0	
		Placebo	9	7 (77.8)	5.08 (1.49)	2.5	3.75	5.67	6.17	6.6	
	Week 44	Tezepelumab	12	12 (100.0)	4.96 (1.28)	3.0	4.08	4.83	5.79	7.0	
		Placebo	9	7 (77.8)	4.71 (1.22)	3.1	3.83	4.58	6.25	6.4	
	Week 48	Tezepelumab	12	12 (100.0)	5.06 (1.22)	3.1	4.13	5.08	5.96	7.0	
		Placebo	9	7 (77.8)	4.68 (1.56)	2.4	3.75	4.33	6.50	6.9	
	Week 52	Tezepelumab	12	12 (100.0)	5.09 (1.22)	3.1	4.08	5.08	5.96	7.0	
		Placebo	9	7 (77.8)	5.00 (1.18)	4.1	4.25	4.33	6.50	6.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	12	10 (83.3)	0.97 (1.10)	-0.4	0.08	0.96	1.75	3.1	0.02 [-0.95, 0.99]
		Placebo	9	7 (77.8)	0.95 (1.12)	0.0	0.17	0.92	1.00	3.3	
	Week 8	Tezepelumab	12	10 (83.3)	0.97 (1.44)	-1.9	0.25	0.92	2.00	3.3	-0.00 [-0.97, 0.97]
		Placebo	9	7 (77.8)	0.98 (1.21)	-0.3	0.00	0.67	1.50	3.3	
	Week 12	Tezepelumab	12	10 (83.3)	1.21 (1.14)	-0.2	0.25	0.96	1.92	3.7	0.06 [-0.91, 1.03]
		Placebo	9	7 (77.8)	1.13 (1.48)	-0.7	-0.25	1.08	1.67	3.8	
	Week 16	Tezepelumab	12	10 (83.3)	1.36 (0.83)	0.4	0.83	1.17	1.75	3.2	0.20 [-0.77, 1.17]
		Placebo	9	7 (77.8)	1.15 (1.27)	-0.3	0.00	0.92	1.67	3.6	
	Week 20	Tezepelumab	12	10 (83.3)	1.22 (0.97)	0.1	0.42	0.92	2.00	2.9	0.03 [-0.93, 1.00]
		Placebo	9	7 (77.8)	1.18 (1.48)	-1.1	-0.42	1.67	1.92	3.3	
	Week 24	Tezepelumab	12	10 (83.3)	1.26 (0.93)	0.1	0.42	1.08	1.83	2.9	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	1.04 (1.70)	-1.3	-0.75	0.92	2.17	3.6	
	Week 28	Tezepelumab	12	10 (83.3)	1.31 (0.94)	0.1	0.75	0.96	2.17	2.9	0.52 [-0.46, 1.50]
		Placebo	9	7 (77.8)	0.69 (1.48)	-1.8	-0.33	0.58	1.83	2.8	
	Week 32	Tezepelumab	12	10 (83.3)	0.99 (1.12)	-0.5	0.25	0.75	2.17	2.9	-0.06 [-1.03, 0.90]
		Placebo	9	7 (77.8)	1.07 (1.42)	-0.6	-0.58	1.17	1.83	3.5	
	Week 36	Tezepelumab	12	10 (83.3)	1.21 (1.05)	-0.3	0.25	1.25	2.17	2.9	-0.11 [-1.08, 0.86]
		Placebo	9	7 (77.8)	1.35 (1.48)	-0.8	0.08	1.17	2.33	3.8	
	Week 40	Tezepelumab	12	10 (83.3)	1.15 (0.99)	0.0	0.25	0.96	2.17	2.9	-0.13 [-1.09, 0.84]
		Placebo	9	7 (77.8)	1.31 (1.59)	-1.0	-0.58	1.83	2.25	3.4	
	Week 44	Tezepelumab	12	10 (83.3)	1.07 (1.13)	-0.8	0.25	0.92	2.17	2.9	0.10 [-0.87, 1.06]
		Placebo	9	7 (77.8)	0.94 (1.52)	-0.5	-0.42	0.92	2.00	3.7	
	Week 48	Tezepelumab	12	10 (83.3)	1.16 (0.96)	-0.3	0.58	0.88	2.00	2.9	0.18 [-0.78, 1.15]
		Placebo	9	7 (77.8)	0.90 (1.83)	-1.1	-0.58	0.67	2.25	4.2	
	Week 52	Tezepelumab	12	10 (83.3)	1.19 (0.91)	0.2	0.58	0.83	2.00	2.9	-0.03 [-0.99, 0.94]
		Placebo	9	7 (77.8)	1.23 (1.56)	-0.3	-0.25	0.83	2.25	4.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
 DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 8	Tezepelumab	12	10 (83.3)	NE		NE			
	Placebo	9	7 (77.8)						
Week 12	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 16	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	6 (66.7)						
Week 20	Tezepelumab	12	9 (75.0)	NE		NE			
	Placebo	9	7 (77.8)						
Week 24	Tezepelumab	12	8 (66.7)	NE		NE			
	Placebo	9	6 (66.7)						
Week 28	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 32	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 36	Tezepelumab	12	7 (58.3)	NE		NE			
	Placebo	9	6 (66.7)						
Week 40	Tezepelumab	12	6 (50.0)	NE		NE			
	Placebo	9	6 (66.7)						

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
 DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	12	12 (100.0)	4.53 (1.10)	3.0	3.71	4.63	5.33	6.7	
		Placebo	11	11 (100.0)	3.69 (1.28)	1.8	2.08	4.00	4.42	5.5	
	Week 4	Tezepelumab	12	11 (91.7)	4.28 (1.27)	2.3	3.25	4.42	5.08	6.8	
		Placebo	11	11 (100.0)	4.28 (1.20)	2.8	3.25	3.83	5.33	6.3	
	Week 40	Tezepelumab	12	10 (83.3)	4.67 (1.05)	3.3	3.83	4.63	5.42	6.2	
		Placebo	11	11 (100.0)	4.33 (1.22)	2.6	3.42	4.50	4.75	6.8	
	Week 44	Tezepelumab	12	9 (75.0)	5.00 (1.25)	2.5	4.92	5.25	5.67	6.6	
		Placebo	11	10 (90.9)	4.63 (1.16)	2.8	4.08	4.67	5.25	6.7	
	Week 48	Tezepelumab	12	9 (75.0)	4.78 (1.19)	3.2	3.83	4.58	5.50	6.9	
		Placebo	11	10 (90.9)	4.61 (1.46)	2.8	3.00	4.96	5.58	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QMC_IBMH0: Course of AQLQ+12 symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	12	11 (91.7)	-0.23 (1.53)	-3.4	-0.42	-0.25	0.92	2.1	-0.69 [-1.56, 0.17]
		Placebo	11	11 (100.0)	0.59 (0.66)	-0.4	0.00	0.75	1.08	1.5	
	Week 40	Tezepelumab	12	10 (83.3)	0.01 (1.44)	-2.5	-0.42	0.08	1.25	2.0	-0.53 [-1.40, 0.35]
		Placebo	11	11 (100.0)	0.64 (0.96)	-0.8	0.08	0.50	1.25	2.3	
	Week 44	Tezepelumab	12	9 (75.0)	0.23 (1.95)	-3.2	-0.08	0.67	1.92	1.9	-0.38 [-1.29, 0.53]
		Placebo	11	10 (90.9)	0.77 (0.68)	-0.4	0.25	0.88	1.17	1.7	
	Week 48	Tezepelumab	12	9 (75.0)	0.01 (1.33)	-2.1	-0.75	-0.08	0.58	2.3	-0.88 [-1.83, 0.06]
		Placebo	11	10 (90.9)	0.95 (0.75)	-0.7	0.50	1.04	1.50	2.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
 DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	11 (91.7)	-0.09 (0.33)	(-0.77, 0.59)	-0.47 (0.48)	(-1.47, 0.52)	0.332
	Placebo	11	11 (100.0)	0.39 (0.33)	(-0.31, 1.08)			
Week 40	Tezepelumab	12	10 (83.3)	0.18 (0.34)	(-0.52, 0.89)	-0.25 (0.48)	(-1.26, 0.75)	0.605
	Placebo	11	11 (100.0)	0.44 (0.33)	(-0.24, 1.12)			
Week 44	Tezepelumab	12	9 (75.0)	0.45 (0.39)	(-0.36, 1.27)	-0.12 (0.56)	(-1.28, 1.05)	0.837
	Placebo	11	10 (90.9)	0.57 (0.38)	(-0.23, 1.36)			
Week 48	Tezepelumab	12	9 (75.0)	0.24 (0.33)	(-0.45, 0.94)	-0.48 (0.48)	(-1.48, 0.52)	0.334
	Placebo	11	10 (90.9)	0.72 (0.32)	(0.04, 1.40)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table NT1QTC_ABMH0: Course of AQLQ+12 total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	54	54 (100.0)	3.97 (0.93)	2.0	3.34	3.91	4.47	6.2	
		Placebo	39	39 (100.0)	3.56 (1.00)	1.2	2.78	3.59	4.22	5.3	
	Week 4	Tezepelumab	54	54 (100.0)	4.69 (1.15)	2.6	3.84	4.41	5.53	7.0	
		Placebo	39	38 (97.4)	4.32 (1.18)	1.0	3.44	4.39	5.31	6.7	
	Week 12	Tezepelumab	54	52 (96.3)	4.83 (1.20)	2.3	4.00	4.89	5.73	7.0	
		Placebo	39	36 (92.3)	4.45 (1.09)	1.0	3.81	4.50	5.03	6.1	
	Week 24	Tezepelumab	54	52 (96.3)	4.92 (1.33)	1.0	3.98	4.94	6.05	7.0	
		Placebo	39	34 (87.2)	4.40 (1.37)	1.0	3.44	4.48	5.47	6.7	
	Week 36	Tezepelumab	54	51 (94.4)	4.87 (1.21)	2.7	3.84	4.94	5.94	7.0	
		Placebo	39	36 (92.3)	4.46 (1.13)	2.3	3.33	4.33	5.39	6.5	
	Week 52	Tezepelumab	54	48 (88.9)	4.92 (1.22)	2.8	3.94	4.80	5.97	7.0	
		Placebo	39	34 (87.2)	4.71 (1.01)	3.0	4.06	4.67	5.22	7.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC_ABMH0: Course of AQLQ+12 total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	54	54 (100.0)	0.71 (0.90)	-0.8	-0.03	0.67	1.19	3.3	-0.03 [-0.44, 0.39]
		Placebo	39	38 (97.4)	0.74 (0.85)	-1.0	0.28	0.58	1.22	4.0	
	Week 12	Tezepelumab	54	52 (96.3)	0.88 (1.08)	-1.7	0.19	0.78	1.58	3.5	0.03 [-0.39, 0.46]
		Placebo	39	36 (92.3)	0.84 (1.00)	-0.4	0.13	0.64	1.47	3.6	
	Week 24	Tezepelumab	54	52 (96.3)	0.97 (1.37)	-4.7	0.20	0.88	1.64	3.6	0.13 [-0.30, 0.57]
		Placebo	39	34 (87.2)	0.80 (1.06)	-1.1	0.13	0.58	1.44	4.3	
	Week 36	Tezepelumab	54	51 (94.4)	0.93 (1.06)	-1.1	0.13	0.72	1.53	3.3	0.11 [-0.31, 0.54]
		Placebo	39	36 (92.3)	0.80 (1.15)	-2.0	0.17	0.75	1.36	3.4	
	Week 52	Tezepelumab	54	48 (88.9)	1.02 (1.04)	-0.8	0.16	0.88	1.75	3.3	-0.03 [-0.47, 0.41]
		Placebo	39	34 (87.2)	1.05 (1.00)	-0.8	0.47	0.97	1.38	4.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC_ABMC0: Change from baseline in AQLQ+12 total score - MMRM results
 DITTB - adult

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	54	54 (100.0)	0.76 (0.12)	(0.52, 0.99)	0.06 (0.19)	(-0.31, 0.43)	0.747
	Placebo	39	38 (97.4)	0.70 (0.14)	(0.41, 0.98)			
Week 12	Tezepelumab	54	52 (96.3)	0.96 (0.14)	(0.68, 1.24)	0.14 (0.22)	(-0.30, 0.57)	0.538
	Placebo	39	36 (92.3)	0.83 (0.17)	(0.49, 1.16)			
Week 24	Tezepelumab	54	52 (96.3)	0.99 (0.17)	(0.66, 1.32)	0.19 (0.26)	(-0.34, 0.72)	0.475
	Placebo	39	34 (87.2)	0.80 (0.20)	(0.40, 1.20)			
Week 36	Tezepelumab	54	51 (94.4)	0.95 (0.15)	(0.66, 1.24)	0.20 (0.23)	(-0.25, 0.66)	0.376
	Placebo	39	36 (92.3)	0.75 (0.17)	(0.40, 1.09)			
Week 52	Tezepelumab	54	48 (88.9)	0.99 (0.14)	(0.72, 1.27)	-0.02 (0.22)	(-0.44, 0.41)	0.943
	Placebo	39	34 (87.2)	1.01 (0.16)	(0.68, 1.33)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC_ABMH0: Course of AQLQ+12 activity limitations score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	54	54 (100.0)	4.10 (0.99)	2.2	3.55	4.09	4.55	6.6	
		Placebo	39	39 (100.0)	3.65 (0.98)	1.2	2.91	3.55	4.55	5.3	
	Week 4	Tezepelumab	54	54 (100.0)	4.73 (1.23)	2.5	3.73	4.45	5.82	7.0	
		Placebo	39	38 (97.4)	4.36 (1.34)	1.0	3.45	4.32	5.27	6.7	
	Week 12	Tezepelumab	54	52 (96.3)	4.91 (1.21)	2.1	4.05	5.05	5.86	7.0	
		Placebo	39	36 (92.3)	4.44 (1.22)	1.1	3.55	4.41	5.36	6.5	
	Week 24	Tezepelumab	54	52 (96.3)	5.01 (1.33)	1.0	4.09	5.18	6.00	7.0	
		Placebo	39	34 (87.2)	4.40 (1.47)	1.0	3.55	4.45	5.55	6.8	
	Week 36	Tezepelumab	54	51 (94.4)	4.97 (1.19)	2.5	4.09	5.00	6.00	7.0	
		Placebo	39	36 (92.3)	4.50 (1.20)	1.5	3.82	4.27	5.41	6.6	
	Week 52	Tezepelumab	54	48 (88.9)	4.92 (1.22)	2.3	3.91	4.73	5.91	7.0	
		Placebo	39	34 (87.2)	4.75 (1.00)	3.2	3.91	4.73	5.27	7.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC_ABMH0: Course of AQLQ+12 activity limitations score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	54	54 (100.0)	0.63 (0.90)	-1.1	0.00	0.59	1.00	2.9	-0.08 [-0.49, 0.34]
		Placebo	39	38 (97.4)	0.70 (0.96)	-1.0	0.18	0.55	1.09	4.0	
	Week 12	Tezepelumab	54	52 (96.3)	0.84 (1.01)	-1.1	0.05	0.86	1.50	3.2	0.09 [-0.33, 0.52]
		Placebo	39	36 (92.3)	0.75 (1.01)	-0.8	0.00	0.55	1.36	3.7	
	Week 24	Tezepelumab	54	52 (96.3)	0.93 (1.34)	-5.1	0.23	0.91	1.64	3.4	0.15 [-0.28, 0.59]
		Placebo	39	34 (87.2)	0.73 (1.19)	-1.8	0.09	0.50	1.45	4.1	
	Week 36	Tezepelumab	54	51 (94.4)	0.90 (1.01)	-1.1	0.09	0.82	1.64	3.3	0.15 [-0.28, 0.58]
		Placebo	39	36 (92.3)	0.74 (1.11)	-1.6	0.00	0.59	1.36	3.9	
	Week 52	Tezepelumab	54	48 (88.9)	0.88 (1.00)	-1.5	0.14	0.91	1.32	3.0	-0.08 [-0.52, 0.36]
		Placebo	39	34 (87.2)	0.96 (0.94)	-0.2	0.27	0.77	1.36	4.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC_ABMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
 DITTB - adult

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	54	54 (100.0)	0.67 (0.13)	(0.41, 0.92)	0.02 (0.20)	(-0.37, 0.42)	0.906
	Placebo	39	38 (97.4)	0.64 (0.15)	(0.34, 0.94)			
Week 12	Tezepelumab	54	52 (96.3)	0.91 (0.14)	(0.64, 1.18)	0.21 (0.21)	(-0.22, 0.64)	0.334
	Placebo	39	36 (92.3)	0.70 (0.16)	(0.38, 1.03)			
Week 24	Tezepelumab	54	52 (96.3)	0.94 (0.17)	(0.60, 1.28)	0.20 (0.27)	(-0.34, 0.75)	0.454
	Placebo	39	34 (87.2)	0.73 (0.21)	(0.32, 1.15)			
Week 36	Tezepelumab	54	51 (94.4)	0.91 (0.14)	(0.63, 1.20)	0.22 (0.22)	(-0.22, 0.66)	0.328
	Placebo	39	36 (92.3)	0.69 (0.17)	(0.36, 1.03)			
Week 52	Tezepelumab	54	48 (88.9)	0.86 (0.13)	(0.59, 1.12)	-0.03 (0.21)	(-0.44, 0.38)	0.877
	Placebo	39	34 (87.2)	0.89 (0.16)	(0.58, 1.20)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC_ABMH0: Course of AQLQ+12 environmental stimuli score
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	54	54 (100.0)	3.89 (1.29)	1.0	3.00	4.00	5.00	6.5	
	Placebo	39	39 (100.0)	3.55 (1.33)	1.3	2.75	3.50	4.50	6.0	
Week 4	Tezepelumab	54	54 (100.0)	4.65 (1.35)	1.8	3.75	4.75	6.00	7.0	
	Placebo	39	38 (97.4)	4.26 (1.52)	1.0	3.50	4.50	5.50	6.5	
Week 12	Tezepelumab	54	52 (96.3)	4.82 (1.45)	1.8	4.00	5.00	6.00	7.0	
	Placebo	39	36 (92.3)	4.28 (1.34)	1.0	3.50	4.50	5.13	6.8	
Week 24	Tezepelumab	54	52 (96.3)	4.96 (1.49)	1.0	4.00	5.00	6.25	7.0	
	Placebo	39	34 (87.2)	4.22 (1.77)	1.0	2.75	4.50	5.75	7.0	
Week 36	Tezepelumab	54	51 (94.4)	4.95 (1.35)	2.0	4.00	5.00	6.25	7.0	
	Placebo	39	36 (92.3)	4.38 (1.53)	1.0	3.25	4.75	5.50	7.0	
Week 52	Tezepelumab	54	48 (88.9)	4.82 (1.48)	1.8	4.00	4.88	6.13	7.0	
	Placebo	39	34 (87.2)	4.62 (1.31)	1.5	3.75	4.75	5.50	7.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC_ABMH0: Course of AQLQ+12 environmental stimuli score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	54	54 (100.0)	0.76 (0.99)	-1.5	0.25	0.75	1.25	3.8	0.06 [-0.35, 0.48]
		Placebo	39	38 (97.4)	0.69 (1.16)	-1.5	0.00	0.50	1.00	4.3	
	Week 12	Tezepelumab	54	52 (96.3)	0.95 (1.29)	-2.5	0.00	0.75	1.75	4.5	0.28 [-0.15, 0.71]
		Placebo	39	36 (92.3)	0.60 (1.17)	-1.5	-0.25	0.50	1.38	3.0	
	Week 24	Tezepelumab	54	52 (96.3)	1.08 (1.51)	-4.3	0.25	0.88	2.13	5.3	0.34 [-0.10, 0.78]
		Placebo	39	34 (87.2)	0.59 (1.35)	-1.8	0.00	0.50	1.25	4.8	
	Week 36	Tezepelumab	54	51 (94.4)	1.08 (1.31)	-1.5	0.25	1.00	1.75	5.5	0.31 [-0.12, 0.74]
		Placebo	39	36 (92.3)	0.65 (1.46)	-2.3	-0.25	0.63	1.50	4.0	
	Week 52	Tezepelumab	54	48 (88.9)	0.99 (1.40)	-1.3	0.00	0.88	2.00	5.0	-0.00 [-0.44, 0.44]
		Placebo	39	34 (87.2)	0.99 (1.22)	-0.8	0.00	0.63	1.75	4.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC_ABMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
 DITTB - adult

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	54	54 (100.0)	0.80 (0.14)	(0.52, 1.07)	0.14 (0.22)	(-0.30, 0.57)	0.534
	Placebo	39	38 (97.4)	0.66 (0.17)	(0.33, 0.99)			
Week 12	Tezepelumab	54	52 (96.3)	1.03 (0.17)	(0.70, 1.36)	0.31 (0.26)	(-0.21, 0.82)	0.242
	Placebo	39	36 (92.3)	0.72 (0.20)	(0.33, 1.12)			
Week 24	Tezepelumab	54	52 (96.3)	1.11 (0.19)	(0.72, 1.49)	0.37 (0.30)	(-0.23, 0.97)	0.227
	Placebo	39	34 (87.2)	0.74 (0.23)	(0.27, 1.20)			
Week 36	Tezepelumab	54	51 (94.4)	1.11 (0.18)	(0.76, 1.47)	0.42 (0.28)	(-0.14, 0.98)	0.137
	Placebo	39	36 (92.3)	0.70 (0.21)	(0.27, 1.12)			
Week 52	Tezepelumab	54	48 (88.9)	0.99 (0.17)	(0.64, 1.33)	-0.07 (0.27)	(-0.61, 0.47)	0.790
	Placebo	39	34 (87.2)	1.06 (0.21)	(0.65, 1.47)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC_ABMH0: Course of AQLQ+12 emotional function score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	54	54 (100.0)	4.11 (1.40)	1.2	3.20	4.00	5.00	6.8	
		Placebo	39	39 (100.0)	3.77 (1.55)	1.0	3.00	3.80	4.80	7.0	
	Week 4	Tezepelumab	54	54 (100.0)	4.78 (1.54)	1.0	3.60	5.10	6.00	7.0	
		Placebo	39	38 (97.4)	4.56 (1.64)	1.0	3.60	4.60	5.60	7.0	
	Week 12	Tezepelumab	54	52 (96.3)	4.86 (1.52)	1.4	4.00	4.80	6.10	7.0	
		Placebo	39	36 (92.3)	4.72 (1.54)	1.0	4.20	5.10	5.80	7.0	
	Week 24	Tezepelumab	54	52 (96.3)	4.99 (1.63)	1.0	4.00	5.00	6.30	7.0	
		Placebo	39	34 (87.2)	4.60 (1.92)	1.0	3.00	5.00	6.20	7.0	
	Week 36	Tezepelumab	54	51 (94.4)	5.03 (1.63)	1.0	3.80	5.20	6.60	7.0	
		Placebo	39	36 (92.3)	4.67 (1.57)	1.2	3.50	4.60	5.80	7.0	
	Week 52	Tezepelumab	54	48 (88.9)	4.91 (1.56)	1.0	3.90	5.40	6.10	7.0	
		Placebo	39	34 (87.2)	4.91 (1.49)	1.4	4.20	5.00	6.00	7.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC_ABMH0: Course of AQLQ+12 emotional function score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	54	54 (100.0)	0.67 (1.17)	-1.6	-0.20	0.80	1.20	4.6	-0.09 [-0.50, 0.33]
		Placebo	39	38 (97.4)	0.77 (1.15)	-1.6	0.00	0.60	1.40	4.6	
	Week 12	Tezepelumab	54	52 (96.3)	0.77 (1.37)	-2.6	-0.10	0.70	1.80	4.6	-0.10 [-0.52, 0.33]
		Placebo	39	36 (92.3)	0.90 (1.37)	-1.8	0.00	0.70	1.40	4.0	
	Week 24	Tezepelumab	54	52 (96.3)	0.91 (1.62)	-5.2	0.00	0.80	1.80	4.6	0.10 [-0.33, 0.54]
		Placebo	39	34 (87.2)	0.75 (1.43)	-2.0	-0.20	0.60	1.80	4.6	
	Week 36	Tezepelumab	54	51 (94.4)	0.96 (1.40)	-2.2	0.00	0.80	1.60	5.0	0.11 [-0.32, 0.54]
		Placebo	39	36 (92.3)	0.79 (1.56)	-5.0	-0.10	0.90	1.90	3.6	
	Week 52	Tezepelumab	54	48 (88.9)	0.91 (1.31)	-1.4	0.00	0.80	2.00	3.8	-0.13 [-0.57, 0.31]
		Placebo	39	34 (87.2)	1.09 (1.45)	-2.4	0.20	1.20	1.80	5.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC_ABMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
 DITTB - adult

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis																																																								
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																						
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																				
Week 4	Tezepelumab	54	54 (100.0)	0.72 (0.15)	(0.41, 1.02)	-0.03 (0.24)	(-0.50, 0.44)	0.900																																																				
	Placebo	39	38 (97.4)	0.75 (0.18)	(0.38, 1.11)				Week 12	Tezepelumab	54	52 (96.3)	0.86 (0.18)	(0.51, 1.21)	-0.05 (0.27)	(-0.59, 0.50)	0.863	Placebo	39	36 (92.3)	0.90 (0.21)	(0.49, 1.32)	Week 24	Tezepelumab	54	52 (96.3)	0.94 (0.20)	(0.54, 1.33)	0.16 (0.31)	(-0.47, 0.78)	0.616	Placebo	39	34 (87.2)	0.78 (0.24)	(0.30, 1.26)	Week 36	Tezepelumab	54	51 (94.4)	0.98 (0.19)	(0.61, 1.36)	0.25 (0.29)	(-0.34, 0.83)	0.404	Placebo	39	36 (92.3)	0.74 (0.22)	(0.29, 1.18)	Week 52	Tezepelumab	54	48 (88.9)	0.92 (0.17)	(0.58, 1.27)	-0.12 (0.27)	(-0.66, 0.41)	0.646	Placebo
Week 12	Tezepelumab	54	52 (96.3)	0.86 (0.18)	(0.51, 1.21)	-0.05 (0.27)	(-0.59, 0.50)	0.863																																																				
	Placebo	39	36 (92.3)	0.90 (0.21)	(0.49, 1.32)				Week 24	Tezepelumab	54	52 (96.3)	0.94 (0.20)	(0.54, 1.33)	0.16 (0.31)	(-0.47, 0.78)	0.616	Placebo	39	34 (87.2)	0.78 (0.24)	(0.30, 1.26)	Week 36	Tezepelumab	54	51 (94.4)	0.98 (0.19)	(0.61, 1.36)	0.25 (0.29)	(-0.34, 0.83)	0.404	Placebo	39	36 (92.3)	0.74 (0.22)	(0.29, 1.18)	Week 52	Tezepelumab	54	48 (88.9)	0.92 (0.17)	(0.58, 1.27)	-0.12 (0.27)	(-0.66, 0.41)	0.646	Placebo	39	34 (87.2)	1.05 (0.20)	(0.64, 1.46)										
Week 24	Tezepelumab	54	52 (96.3)	0.94 (0.20)	(0.54, 1.33)	0.16 (0.31)	(-0.47, 0.78)	0.616																																																				
	Placebo	39	34 (87.2)	0.78 (0.24)	(0.30, 1.26)				Week 36	Tezepelumab	54	51 (94.4)	0.98 (0.19)	(0.61, 1.36)	0.25 (0.29)	(-0.34, 0.83)	0.404	Placebo	39	36 (92.3)	0.74 (0.22)	(0.29, 1.18)	Week 52	Tezepelumab	54	48 (88.9)	0.92 (0.17)	(0.58, 1.27)	-0.12 (0.27)	(-0.66, 0.41)	0.646	Placebo	39	34 (87.2)	1.05 (0.20)	(0.64, 1.46)																								
Week 36	Tezepelumab	54	51 (94.4)	0.98 (0.19)	(0.61, 1.36)	0.25 (0.29)	(-0.34, 0.83)	0.404																																																				
	Placebo	39	36 (92.3)	0.74 (0.22)	(0.29, 1.18)				Week 52	Tezepelumab	54	48 (88.9)	0.92 (0.17)	(0.58, 1.27)	-0.12 (0.27)	(-0.66, 0.41)	0.646	Placebo	39	34 (87.2)	1.05 (0.20)	(0.64, 1.46)																																						
Week 52	Tezepelumab	54	48 (88.9)	0.92 (0.17)	(0.58, 1.27)	-0.12 (0.27)	(-0.66, 0.41)	0.646																																																				
	Placebo	39	34 (87.2)	1.05 (0.20)	(0.64, 1.46)																																																							

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC_ABMH0: Course of AQLQ+12 symptom score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	54	54 (100.0)	3.83 (0.85)	1.3	3.33	3.83	4.25	5.6	
		Placebo	39	39 (100.0)	3.39 (1.01)	1.3	2.67	3.42	4.33	5.3	
	Week 4	Tezepelumab	54	54 (100.0)	4.62 (1.17)	2.3	3.75	4.42	5.75	7.0	
		Placebo	39	38 (97.4)	4.19 (1.19)	1.0	3.67	4.25	5.17	6.6	
	Week 12	Tezepelumab	54	52 (96.3)	4.74 (1.29)	1.2	4.00	4.71	5.83	7.0	
		Placebo	39	36 (92.3)	4.41 (1.18)	1.0	3.79	4.46	4.96	6.4	
	Week 24	Tezepelumab	54	52 (96.3)	4.80 (1.40)	1.1	3.96	4.46	5.88	7.0	
		Placebo	39	34 (87.2)	4.38 (1.32)	1.0	3.42	4.08	5.42	6.6	
	Week 36	Tezepelumab	54	51 (94.4)	4.68 (1.31)	1.7	3.67	4.42	5.75	7.0	
		Placebo	39	36 (92.3)	4.38 (1.13)	2.2	3.50	4.29	5.29	6.4	
	Week 52	Tezepelumab	54	48 (88.9)	4.95 (1.30)	2.8	3.96	5.08	5.92	6.9	
		Placebo	39	34 (87.2)	4.62 (1.17)	2.1	3.83	4.63	5.50	7.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC_ABMH0: Course of AQLQ+12 symptom score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	54	54 (100.0)	0.79 (1.01)	-1.0	0.00	0.67	1.42	3.3	0.01 [-0.40, 0.43]
		Placebo	39	38 (97.4)	0.78 (0.95)	-1.4	0.25	0.75	1.17	3.9	
	Week 12	Tezepelumab	54	52 (96.3)	0.94 (1.19)	-1.8	0.17	0.79	1.83	3.4	-0.05 [-0.47, 0.38]
		Placebo	39	36 (92.3)	0.99 (1.11)	-1.0	0.38	0.83	1.63	3.6	
	Week 24	Tezepelumab	54	52 (96.3)	1.00 (1.44)	-4.3	0.21	0.83	1.88	3.9	0.03 [-0.41, 0.46]
		Placebo	39	34 (87.2)	0.96 (1.14)	-0.9	0.17	0.79	1.67	4.1	
	Week 36	Tezepelumab	54	51 (94.4)	0.89 (1.24)	-2.4	0.00	0.75	2.00	3.4	-0.02 [-0.45, 0.41]
		Placebo	39	36 (92.3)	0.92 (1.23)	-2.4	0.17	0.67	1.54	3.8	
	Week 52	Tezepelumab	54	48 (88.9)	1.19 (1.13)	-0.8	0.17	1.17	2.08	3.5	0.06 [-0.38, 0.50]
		Placebo	39	34 (87.2)	1.13 (1.06)	-0.8	0.42	1.08	1.75	4.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC_ABMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
 DITTB - adult

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis																																																								
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																						
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																				
Week 4	Tezepelumab	54	54 (100.0)	0.85 (0.13)	(0.59, 1.11)	0.13 (0.21)	(-0.29, 0.54)	0.544																																																				
	Placebo	39	38 (97.4)	0.72 (0.16)	(0.41, 1.04)				Week 12	Tezepelumab	54	52 (96.3)	1.03 (0.16)	(0.72, 1.34)	0.10 (0.25)	(-0.39, 0.59)	0.688	Placebo	39	36 (92.3)	0.93 (0.19)	(0.56, 1.30)	Week 24	Tezepelumab	54	52 (96.3)	1.03 (0.18)	(0.67, 1.38)	0.15 (0.28)	(-0.41, 0.71)	0.596	Placebo	39	34 (87.2)	0.88 (0.22)	(0.45, 1.31)	Week 36	Tezepelumab	54	51 (94.4)	0.92 (0.17)	(0.59, 1.25)	0.11 (0.26)	(-0.41, 0.62)	0.683	Placebo	39	36 (92.3)	0.82 (0.20)	(0.43, 1.21)	Week 52	Tezepelumab	54	48 (88.9)	1.16 (0.16)	(0.85, 1.46)	0.08 (0.24)	(-0.41, 0.56)	0.753	Placebo
Week 12	Tezepelumab	54	52 (96.3)	1.03 (0.16)	(0.72, 1.34)	0.10 (0.25)	(-0.39, 0.59)	0.688																																																				
	Placebo	39	36 (92.3)	0.93 (0.19)	(0.56, 1.30)				Week 24	Tezepelumab	54	52 (96.3)	1.03 (0.18)	(0.67, 1.38)	0.15 (0.28)	(-0.41, 0.71)	0.596	Placebo	39	34 (87.2)	0.88 (0.22)	(0.45, 1.31)	Week 36	Tezepelumab	54	51 (94.4)	0.92 (0.17)	(0.59, 1.25)	0.11 (0.26)	(-0.41, 0.62)	0.683	Placebo	39	36 (92.3)	0.82 (0.20)	(0.43, 1.21)	Week 52	Tezepelumab	54	48 (88.9)	1.16 (0.16)	(0.85, 1.46)	0.08 (0.24)	(-0.41, 0.56)	0.753	Placebo	39	34 (87.2)	1.08 (0.18)	(0.71, 1.45)										
Week 24	Tezepelumab	54	52 (96.3)	1.03 (0.18)	(0.67, 1.38)	0.15 (0.28)	(-0.41, 0.71)	0.596																																																				
	Placebo	39	34 (87.2)	0.88 (0.22)	(0.45, 1.31)				Week 36	Tezepelumab	54	51 (94.4)	0.92 (0.17)	(0.59, 1.25)	0.11 (0.26)	(-0.41, 0.62)	0.683	Placebo	39	36 (92.3)	0.82 (0.20)	(0.43, 1.21)	Week 52	Tezepelumab	54	48 (88.9)	1.16 (0.16)	(0.85, 1.46)	0.08 (0.24)	(-0.41, 0.56)	0.753	Placebo	39	34 (87.2)	1.08 (0.18)	(0.71, 1.45)																								
Week 36	Tezepelumab	54	51 (94.4)	0.92 (0.17)	(0.59, 1.25)	0.11 (0.26)	(-0.41, 0.62)	0.683																																																				
	Placebo	39	36 (92.3)	0.82 (0.20)	(0.43, 1.21)				Week 52	Tezepelumab	54	48 (88.9)	1.16 (0.16)	(0.85, 1.46)	0.08 (0.24)	(-0.41, 0.56)	0.753	Placebo	39	34 (87.2)	1.08 (0.18)	(0.71, 1.45)																																						
Week 52	Tezepelumab	54	48 (88.9)	1.16 (0.16)	(0.85, 1.46)	0.08 (0.24)	(-0.41, 0.56)	0.753																																																				
	Placebo	39	34 (87.2)	1.08 (0.18)	(0.71, 1.45)																																																							

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1GTC_IBMH0: Course of SGRQ total score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	55	47 (85.5)	54.54 (17.12)	13.3	40.34	57.49	69.87	81.3
		Placebo	40	33 (82.5)	56.29 (17.86)	18.5	46.84	56.15	64.88	91.0
	Week 24	Tezepelumab	55	52 (94.5)	38.69 (22.95)	0.0	20.98	39.56	58.22	87.0
		Placebo	40	35 (87.5)	48.55 (19.57)	7.5	38.05	48.86	61.51	79.9
	Week 52	Tezepelumab	55	48 (87.3)	41.05 (24.30)	0.0	20.35	39.47	61.40	80.0
		Placebo	40	35 (87.5)	46.53 (19.49)	2.3	38.21	49.06	59.91	84.8

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC_IBMH0: Course of SGRQ total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Tezepelumab	55	45 (81.8)	-15.82 (18.39)	-58.7	-28.99	-12.76	-3.51	22.0	-0.40 [-0.88, 0.07]
		Placebo	40	28 (70.0)	-8.94 (14.67)	-47.0	-16.78	-7.64	4.93	16.0	
	Week 52	Tezepelumab	55	41 (74.5)	-14.66 (17.19)	-50.9	-26.39	-11.62	-5.68	17.2	-0.27 [-0.74, 0.20]
		Placebo	40	30 (75.0)	-10.33 (14.39)	-40.8	-18.24	-8.45	-1.47	16.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC_IBMC0: Change from baseline in SGRQ total score - MMRM results
 DITTB

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	55	45 (81.8)	-15.86 (2.54)	(-20.92, -10.81)	-6.33 (3.98)	(-14.26, 1.60)	0.116	
	Placebo	40	28 (70.0)	-9.53 (3.07)	(-15.64, -3.43)				
Week 52	Tezepelumab	55	41 (74.5)	-14.37 (2.53)	(-19.42, -9.33)	-4.01 (3.92)	(-11.83, 3.80)	0.309	
	Placebo	40	30 (75.0)	-10.36 (2.99)	(-16.33, -4.40)				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GTC_IBMH0: Course of SGRQ total score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	12	12 (100.0)	58.66 (16.11)	33.8	50.44	61.35	64.84	86.7	
		Placebo	11	11 (100.0)	63.59 (23.52)	9.5	53.19	69.38	79.81	94.6	
	Week 48	Tezepelumab	12	9 (75.0)	47.76 (24.13)	23.5	27.41	38.71	60.49	87.1	
		Placebo	11	10 (90.9)	60.29 (25.32)	0.0	42.51	73.10	75.59	78.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GTC_IBMH0: Course of SGRQ total score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 total score	Tezepelumab	12	9 (75.0)	-9.53 (19.34)	-36.9	-26.24	-9.50	-3.82	25.6	-0.47 [-1.38, 0.44]
	Placebo	11	10 (90.9)	-2.11 (11.79)	-15.8	-9.48	-4.96	3.06	19.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GTC_IBMC0: Change from baseline in SGRQ total score - MMRM results
 DITTB

Change from baseline in SGRQ total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 48	Tezepelumab	12	9 (75.0)	-9.85 (5.37)	(-21.24, 1.54)	-8.04 (7.43)	(-23.80, 7.72)	0.296
	Placebo	11	10 (90.9)	-1.82 (5.10)	(-12.62, 8.99)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GTC_BBMH0: Course of SGRQ total score
 DITTNB - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Teze+Teze	45	38 (84.4)	53.35 (17.86)	13.3	39.62	56.86	69.16	81.3
		Pbo+Pbo	19	15 (78.9)	54.58 (19.70)	18.5	41.92	54.44	66.27	91.0
	Week 24	Teze+Teze	45	44 (97.8)	37.05 (23.74)	0.0	17.27	33.46	58.22	87.0
		Pbo+Pbo	19	19 (100.0)	45.45 (20.23)	7.5	30.96	43.73	60.06	79.9
	Week 52	Teze+Teze	45	44 (97.8)	39.89 (24.36)	0.0	20.35	37.40	59.47	80.0
		Pbo+Pbo	19	18 (94.7)	45.46 (21.43)	2.3	35.78	47.79	57.55	84.8
	Week 76	Teze+Teze	45	44 (97.8)	34.65 (21.83)	0.0	12.33	35.68	53.39	86.0
		Pbo+Pbo	19	19 (100.0)	38.24 (17.67)	6.0	29.66	41.54	50.75	65.6
	Week 104	Teze+Teze	45	41 (91.1)	33.57 (22.60)	0.0	13.79	33.07	52.82	79.7
		Pbo+Pbo	19	19 (100.0)	39.83 (18.15)	2.2	24.74	42.87	50.84	75.5

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC_BBMH0: Course of SGRQ total score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Teze+Teze	45	38 (84.4)	-16.63 (18.87)	-58.7	-28.99	-16.42	-5.80	22.0	-0.30 [-0.90, 0.30]
		Pbo+Pbo	19	15 (78.9)	-11.00 (17.57)	-47.0	-23.07	-7.83	4.22	16.0	
	Week 52	Teze+Teze	45	37 (82.2)	-14.59 (17.21)	-50.9	-24.69	-12.53	-5.68	24.5	-0.20 [-0.80, 0.40]
		Pbo+Pbo	19	15 (78.9)	-11.30 (15.25)	-39.7	-28.49	-6.94	0.98	10.1	
	Week 76	Teze+Teze	45	37 (82.2)	-19.16 (18.07)	-62.1	-28.97	-18.12	-8.60	20.1	-0.04 [-0.64, 0.56]
		Pbo+Pbo	19	15 (78.9)	-18.51 (18.94)	-48.5	-35.08	-18.88	-4.84	22.1	
	Week 104	Teze+Teze	45	34 (75.6)	-20.06 (17.00)	-61.8	-28.86	-18.18	-10.13	24.1	-0.25 [-0.86, 0.36]
		Pbo+Pbo	19	15 (78.9)	-15.90 (14.98)	-52.3	-23.40	-13.82	-8.24	8.6	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC_BBMC0: Change from baseline in SGRQ total score - MMRM results
 DITTNB - LTE

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	45	38 (84.4)	-16.66 (2.97)	(-22.63, -10.70)	-5.89 (5.59)	(-17.11, 5.33)	0.297	
	Pbo+Pbo	19	15 (78.9)	-10.77 (4.73)	(-20.27, -1.27)				
Week 52	Teze+Teze	45	37 (82.2)	-15.67 (2.87)	(-21.43, -9.90)	-4.59 (5.38)	(-15.42, 6.24)	0.398	
	Pbo+Pbo	19	15 (78.9)	-11.07 (4.56)	(-20.24, -1.91)				
Week 76	Teze+Teze	45	37 (82.2)	-18.42 (2.90)	(-24.26, -12.58)	-0.14 (5.43)	(-11.07, 10.80)	0.980	
	Pbo+Pbo	19	15 (78.9)	-18.29 (4.59)	(-27.53, -9.04)				
Week 104	Teze+Teze	45	34 (75.6)	-19.07 (2.71)	(-24.52, -13.62)	-3.40 (5.05)	(-13.55, 6.75)	0.504	
	Pbo+Pbo	19	15 (78.9)	-15.67 (4.26)	(-24.23, -7.11)				

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table NT1GMC_IBMH0: Course of SGRQ symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	55	47 (85.5)	69.13 (17.90)	29.6	56.03	71.97	83.12	95.5	
		Placebo	40	33 (82.5)	66.28 (18.08)	26.1	54.57	65.93	79.03	95.0	
	Week 24	Tezepelumab	55	52 (94.5)	45.19 (26.98)	0.0	25.36	47.66	65.65	92.8	
		Placebo	40	35 (87.5)	54.04 (24.50)	6.8	32.62	58.29	76.85	92.7	
	Week 52	Tezepelumab	55	48 (87.3)	46.87 (26.55)	0.0	30.23	47.70	69.28	84.3	
		Placebo	40	35 (87.5)	50.39 (22.61)	0.0	36.44	54.19	68.27	95.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC_IBMH0: Course of SGRQ symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Tezepelumab	55	45 (81.8)	-24.26 (23.93)	-90.3	-36.33	-19.20	-9.43	7.6	-0.43 [-0.90, 0.05]
		Placebo	40	28 (70.0)	-14.14 (23.47)	-58.2	-33.52	-12.21	4.13	38.7	
	Week 52	Tezepelumab	55	41 (74.5)	-23.19 (22.37)	-90.3	-38.00	-16.98	-7.44	16.3	-0.20 [-0.67, 0.28]
		Placebo	40	30 (75.0)	-18.72 (23.20)	-65.0	-33.00	-11.13	-3.28	16.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC_IBMC0: Change from baseline in SGRQ symptom score - MMRM results
 DITTB

Change from baseline in SGRQ symptom score				Repeated measures analysis					
				Change from Baseline			Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	55	45 (81.8)	-23.90 (3.53)	(-30.94, -16.87)	-8.76 (5.57)	(-19.86, 2.35)	0.120	
	Placebo	40	28 (70.0)	-15.14 (4.31)	(-23.72, -6.56)				
Week 52	Tezepelumab	55	41 (74.5)	-23.15 (3.45)	(-30.02, -16.28)	-3.97 (5.33)	(-14.60, 6.65)	0.458	
	Placebo	40	30 (75.0)	-19.18 (4.06)	(-27.27, -11.08)				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GMC_IBMH0: Course of SGRQ symptom score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	12	12 (100.0)	68.26 (16.90)	35.3	57.61	69.30	79.10	97.4	
		Placebo	11	11 (100.0)	69.28 (18.73)	45.9	48.92	73.45	85.83	100.0	
	Week 48	Tezepelumab	12	9 (75.0)	60.37 (22.41)	27.5	38.58	61.37	72.02	92.8	
		Placebo	11	10 (90.9)	62.34 (25.18)	0.0	57.28	67.33	78.88	88.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GMC_IBMH0: Course of SGRQ symptom score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 symptom score	Tezepelumab	12	9 (75.0)	-7.80 (28.97)	-49.8	-24.73	-12.38	-4.18	40.0	-0.16 [-1.07, 0.74]
	Placebo	11	10 (90.9)	-3.88 (18.60)	-45.9	-16.16	1.21	5.47	18.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GMC_IBMC0: Change from baseline in SGRQ symptom score - MMRM results
 DITTB

Change from baseline in SGRQ symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 48	Tezepelumab	12	9 (75.0)	-7.27 (7.67)	(-23.53, 8.98)	-2.92 (10.58)	(-25.34, 19.50)	0.786
	Placebo	11	10 (90.9)	-4.35 (7.27)	(-19.77, 11.07)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GMC_BBMH0: Course of SGRQ symptom score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Teze+Teze	45	38 (84.4)	67.59 (18.93)	29.6	54.05	71.22	82.97	95.5	
		Pbo+Pbo	19	15 (78.9)	65.63 (20.31)	26.1	50.26	69.18	82.91	92.8	
	Week 24	Teze+Teze	45	44 (97.8)	42.72 (28.23)	0.0	18.46	44.51	65.65	92.8	
		Pbo+Pbo	19	19 (100.0)	50.05 (21.68)	6.8	32.62	49.06	67.82	83.6	
	Week 52	Teze+Teze	45	44 (97.8)	44.25 (27.73)	0.0	28.18	43.82	64.13	84.3	
		Pbo+Pbo	19	18 (94.7)	46.68 (23.87)	0.0	30.63	50.65	64.02	77.7	
	Week 76	Teze+Teze	45	44 (97.8)	38.70 (26.52)	0.0	13.39	35.10	55.57	90.8	
		Pbo+Pbo	19	19 (100.0)	43.12 (18.14)	8.9	25.78	38.85	61.01	74.0	
	Week 104	Teze+Teze	45	41 (91.1)	37.53 (26.44)	0.0	13.78	34.40	55.46	100.0	
		Pbo+Pbo	19	19 (100.0)	52.98 (19.03)	13.0	35.79	56.75	68.57	87.6	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC_BBMH0: Course of SGRQ symptom score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Teze+Teze	45	38 (84.4)	-25.38 (24.88)	-90.3	-37.42	-18.85	-9.43	7.6	-0.25 [-0.85, 0.35]
		Pbo+Pbo	19	15 (78.9)	-19.27 (22.79)	-58.2	-37.01	-21.54	-1.36	16.6	
	Week 52	Teze+Teze	45	37 (82.2)	-25.42 (21.79)	-90.3	-40.15	-23.29	-7.56	8.8	-0.16 [-0.76, 0.44]
		Pbo+Pbo	19	15 (78.9)	-21.94 (22.54)	-65.0	-36.27	-14.99	-4.66	16.4	
	Week 76	Teze+Teze	45	37 (82.2)	-29.04 (23.27)	-80.7	-45.45	-28.72	-16.98	33.6	-0.13 [-0.73, 0.47]
		Pbo+Pbo	19	15 (78.9)	-26.05 (20.00)	-67.7	-32.59	-28.44	-12.18	5.3	
	Week 104	Teze+Teze	45	34 (75.6)	-29.91 (21.26)	-80.7	-40.06	-27.74	-14.76	18.3	-0.64 [-1.26, -0.02]
		Pbo+Pbo	19	15 (78.9)	-16.24 (21.18)	-52.0	-33.66	-16.86	-2.82	36.9	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC_BBMC0: Change from baseline in SGRQ symptom score - MMRM results
 DITTNB - LTE

Change from baseline in SGRQ symptom score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	45	38 (84.4)	-25.10 (3.85)	(-32.82, -17.37)	-5.59 (7.23)	(-20.11, 8.92)	0.443	
	Pbo+Pbo	19	15 (78.9)	-19.50 (6.12)	(-31.79, -7.22)				
Week 52	Teze+Teze	45	37 (82.2)	-26.01 (3.67)	(-33.39, -18.62)	-3.83 (6.88)	(-17.66, 9.99)	0.580	
	Pbo+Pbo	19	15 (78.9)	-22.17 (5.81)	(-33.85, -10.49)				
Week 76	Teze+Teze	45	37 (82.2)	-28.73 (3.52)	(-35.81, -21.66)	-2.45 (6.58)	(-15.67, 10.77)	0.711	
	Pbo+Pbo	19	15 (78.9)	-26.28 (5.56)	(-37.44, -15.12)				
Week 104	Teze+Teze	45	34 (75.6)	-29.90 (3.46)	(-36.85, -22.94)	-13.42 (6.36)	(-26.21, -0.64)	0.040 *	
	Pbo+Pbo	19	15 (78.9)	-16.47 (5.33)	(-27.20, -5.74)				

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table NT1GAC_IBMH0: Course of SGRQ activities score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	55	47 (85.5)	64.39 (18.55)	17.1	53.53	66.19	80.32	92.5	
		Placebo	40	33 (82.5)	68.44 (21.39)	23.3	54.36	66.95	87.16	100.0	
	Week 24	Tezepelumab	55	52 (94.5)	51.99 (27.90)	0.0	35.73	53.62	73.25	100.0	
		Placebo	40	35 (87.5)	61.17 (25.21)	0.0	47.70	61.02	79.52	100.0	
	Week 52	Tezepelumab	55	48 (87.3)	52.93 (29.61)	0.0	28.15	60.26	75.93	100.0	
		Placebo	40	35 (87.5)	62.53 (24.24)	0.0	47.37	66.31	80.32	100.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC_IBMH0: Course of SGRQ activities score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Tezepelumab	55	45 (81.8)	-13.38 (24.49)	-75.4	-24.36	-12.57	0.00	45.6	-0.24 [-0.72, 0.23]
		Placebo	40	28 (70.0)	-7.89 (19.28)	-66.9	-19.92	-6.28	5.70	25.8	
	Week 52	Tezepelumab	55	41 (74.5)	-14.81 (23.64)	-75.4	-19.71	-9.71	0.00	20.0	-0.37 [-0.84, 0.11]
		Placebo	40	30 (75.0)	-7.02 (17.35)	-47.2	-19.09	-7.49	5.93	32.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC_IBMC0: Change from baseline in SGRQ activities score - MMRM results
 DITTB

Change from baseline in SGRQ activities score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 24	Tezepelumab	55	45 (81.8)	-13.54 (3.31)	(-20.14, -6.94)	-5.24 (5.22)	(-15.65, 5.16)	0.319
	Placebo	40	28 (70.0)	-8.30 (4.03)	(-16.32, -0.27)			
Week 52	Tezepelumab	55	41 (74.5)	-13.49 (3.31)	(-20.09, -6.90)	-6.58 (5.12)	(-16.80, 3.64)	0.203
	Placebo	40	30 (75.0)	-6.91 (3.91)	(-14.71, 0.88)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GAC_IBMH0: Course of SGRQ activities score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	12	12 (100.0)	72.56 (20.15)	41.3	56.94	76.41	87.27	100.0	
		Placebo	11	11 (100.0)	74.38 (28.19)	0.0	66.95	85.87	86.67	100.0	
	Week 48	Tezepelumab	12	9 (75.0)	57.91 (21.86)	25.1	47.66	48.04	66.19	100.0	
		Placebo	11	10 (90.9)	75.81 (30.08)	0.0	66.31	86.79	92.51	100.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GAC_IBMH0: Course of SGRQ activities score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 activities score	Tezepelumab	12	9 (75.0)	-11.49 (22.74)	-39.5	-25.98	-17.29	0.00	33.8	-0.76 [-1.70, 0.18]
	Placebo	11	10 (90.9)	1.23 (8.30)	-12.8	-0.64	-0.04	5.88	14.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GAC_IBMC0: Change from baseline in SGRQ activities score - MMRM results
 DITTB

Change from baseline in SGRQ activities score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 48	Tezepelumab	12	9 (75.0)	-12.04 (5.47)	(-23.62, -0.45)	-13.75 (7.55)	(-29.76, 2.26)	0.087
	Placebo	11	10 (90.9)	1.72 (5.18)	(-9.27, 12.71)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GAC_BBMH0: Course of SGRQ activities score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Teze+Teze	45	38 (84.4)	62.35 (18.93)	17.1	53.49	60.66	75.39	92.5	
		Pbo+Pbo	19	15 (78.9)	67.16 (21.96)	23.3	47.24	66.95	92.51	93.9	
	Week 24	Teze+Teze	45	44 (97.8)	50.06 (28.28)	0.0	29.45	53.58	69.97	100.0	
		Pbo+Pbo	19	19 (100.0)	59.40 (27.01)	0.0	47.24	59.46	73.04	100.0	
	Week 52	Teze+Teze	45	44 (97.8)	52.83 (28.79)	0.0	28.15	59.81	75.93	100.0	
		Pbo+Pbo	19	18 (94.7)	63.26 (26.45)	0.0	47.69	66.76	85.81	100.0	
	Week 76	Teze+Teze	45	44 (97.8)	48.38 (27.51)	0.0	23.37	53.62	66.57	100.0	
		Pbo+Pbo	19	19 (100.0)	53.10 (23.68)	0.0	47.24	59.46	66.19	92.5	
	Week 104	Teze+Teze	45	41 (91.1)	45.62 (27.34)	0.0	23.72	47.70	66.19	92.5	
		Pbo+Pbo	19	19 (100.0)	56.41 (25.64)	0.0	41.73	60.47	72.82	92.5	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC_BBMH0: Course of SGRQ activities score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Teze+Teze	45	38 (84.4)	-13.52 (24.09)	-75.4	-24.36	-12.61	0.00	45.6	-0.19 [-0.79, 0.41]
		Pbo+Pbo	19	15 (78.9)	-8.98 (22.63)	-66.9	-11.44	-6.63	6.14	24.4	
	Week 52	Teze+Teze	45	37 (82.2)	-11.63 (22.41)	-75.4	-19.62	-7.50	0.00	38.0	-0.18 [-0.78, 0.42]
		Pbo+Pbo	19	15 (78.9)	-7.65 (21.78)	-47.2	-25.16	-12.47	6.14	32.5	
	Week 76	Teze+Teze	45	37 (82.2)	-14.40 (23.92)	-75.4	-26.70	-11.16	-0.03	50.6	0.11 [-0.49, 0.71]
		Pbo+Pbo	19	15 (78.9)	-17.01 (25.20)	-66.9	-34.40	-15.04	0.00	30.3	
	Week 104	Teze+Teze	45	34 (75.6)	-17.42 (20.73)	-75.4	-25.52	-12.90	-5.84	12.7	-0.26 [-0.87, 0.35]
		Pbo+Pbo	19	15 (78.9)	-11.75 (23.63)	-66.9	-25.22	-6.70	0.06	25.7	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC_BBMC0: Change from baseline in SGRQ activities score - MMRM results
 DITTNB - LTE

Change from baseline in SGRQ activities score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 24	Teze+Teze	45	38 (84.4)	-13.74 (3.83)	(-21.43, -6.04)	-5.37 (7.23)	(-19.89, 9.15)	0.461
	Pbo+Pbo	19	15 (78.9)	-8.37 (6.11)	(-20.65, 3.91)			
Week 52	Teze+Teze	45	37 (82.2)	-12.55 (3.65)	(-19.87, -5.23)	-5.52 (6.87)	(-19.31, 8.28)	0.426
	Pbo+Pbo	19	15 (78.9)	-7.03 (5.80)	(-18.69, 4.62)			
Week 76	Teze+Teze	45	37 (82.2)	-13.26 (3.99)	(-21.31, -5.22)	3.13 (7.51)	(-12.00, 18.25)	0.679
	Pbo+Pbo	19	15 (78.9)	-16.39 (6.34)	(-29.17, -3.62)			
Week 104	Teze+Teze	45	34 (75.6)	-15.74 (3.64)	(-23.06, -8.42)	-4.61 (6.81)	(-18.30, 9.08)	0.502
	Pbo+Pbo	19	15 (78.9)	-11.13 (5.73)	(-22.66, 0.40)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table NT1GRC_IBMH0: Course of SGRQ impact score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Tezepelumab	55	47 (85.5)	44.29 (20.88)	3.6	26.04	47.56	60.61	80.9	
		Placebo	40	33 (82.5)	46.14 (21.38)	3.6	32.42	48.96	57.97	90.8	
	Week 24	Tezepelumab	55	52 (94.5)	29.00 (22.96)	0.0	8.35	25.43	47.47	84.3	
		Placebo	40	35 (87.5)	39.54 (19.66)	5.6	26.08	39.37	55.33	73.5	
	Week 52	Tezepelumab	55	48 (87.3)	32.37 (24.75)	0.0	9.32	25.22	51.92	85.0	
		Placebo	40	35 (87.5)	36.13 (20.68)	1.7	20.57	37.73	49.49	87.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GRC_IBMH0: Course of SGRQ impact score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Tezepelumab	55	45 (81.8)	-14.60 (19.96)	-63.4	-24.45	-10.25	-4.53	29.8	-0.37 [-0.85, 0.11]
		Placebo	40	28 (70.0)	-7.88 (14.86)	-36.0	-17.85	-7.42	4.68	25.1	
	Week 52	Tezepelumab	55	41 (74.5)	-11.95 (18.60)	-62.8	-26.17	-9.57	0.33	22.2	-0.14 [-0.61, 0.34]
		Placebo	40	30 (75.0)	-9.57 (15.84)	-42.7	-18.44	-9.50	0.54	18.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GRC_IBMC0: Change from baseline in SGRQ impact score - MMRM results
 DITTB

Change from baseline in SGRQ impact score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 24	Tezepelumab	55	45 (81.8)	-14.73 (2.54)	(-19.80, -9.66)	-6.71 (4.01)	(-14.70, 1.28)	0.098
	Placebo	40	28 (70.0)	-8.02 (3.10)	(-14.19, -1.85)			
Week 52	Tezepelumab	55	41 (74.5)	-12.26 (2.67)	(-17.57, -6.94)	-2.99 (4.13)	(-11.22, 5.24)	0.471
	Placebo	40	30 (75.0)	-9.27 (3.15)	(-15.55, -2.99)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GRC_IBMH0: Course of SGRQ impact score
 DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Tezepelumab	12	12 (100.0)	47.58 (19.32)	17.7	32.75	51.05	60.96	75.8	
		Placebo	11	11 (100.0)	55.64 (27.72)	3.5	39.41	61.07	73.98	94.4	
	Week 48	Tezepelumab	12	9 (75.0)	37.85 (27.72)	7.8	13.51	26.75	57.64	78.0	
		Placebo	11	10 (90.9)	50.73 (25.10)	0.0	33.28	60.15	67.92	77.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GRC_IBMH0: Course of SGRQ impact score
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 impact score	Tezepelumab	12	9 (75.0)	-8.95 (19.11)	-48.8	-16.67	-4.15	2.35	16.5	-0.30 [-1.21, 0.60]
	Placebo	11	10 (90.9)	-3.50 (16.79)	-27.8	-17.29	-5.60	10.80	22.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table ST1GRC_IBMC0: Change from baseline in SGRQ impact score - MMRM results
 DITTB

Change from baseline in SGRQ impact score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 48	Tezepelumab	12	9 (75.0)	-9.83 (5.86)	(-22.25, 2.59)	-7.12 (8.12)	(-24.33, 10.10)	0.394
	Placebo	11	10 (90.9)	-2.71 (5.56)	(-14.49, 9.07)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GRC_BBMH0: Course of SGRQ impact score
 DITTNB - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Teze+Teze	45	38 (84.4)	43.70 (21.89)	3.6	25.11	46.60	60.61	80.9
		Pbo+Pbo	19	15 (78.9)	43.86 (22.39)	3.8	25.01	44.04	51.45	90.8
	Week 24	Teze+Teze	45	44 (97.8)	27.78 (23.76)	0.0	7.80	20.83	47.47	84.3
		Pbo+Pbo	19	19 (100.0)	36.01 (20.79)	8.0	21.69	29.07	56.86	73.5
	Week 52	Teze+Teze	45	44 (97.8)	31.05 (24.92)	0.0	8.27	25.01	50.78	85.0
		Pbo+Pbo	19	18 (94.7)	34.89 (22.69)	4.0	13.70	33.18	44.77	87.9
	Week 76	Teze+Teze	45	44 (97.8)	25.55 (21.21)	0.0	5.21	22.56	41.75	81.7
		Pbo+Pbo	19	19 (100.0)	28.23 (18.39)	0.0	15.10	32.83	42.04	57.7
	Week 104	Teze+Teze	45	41 (91.1)	25.49 (22.14)	0.0	4.14	21.44	38.45	81.7
		Pbo+Pbo	19	19 (100.0)	26.22 (19.30)	0.0	7.62	28.19	41.45	65.1

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC_BBMH0: Course of SGRQ impact score
 DITTNB - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Teze+Teze	45	38 (84.4)	-15.69 (21.02)	-63.4	-30.02	-14.85	-6.99	29.8	-0.31 [-0.91, 0.29]
		Pbo+Pbo	19	15 (78.9)	-9.53 (17.66)	-36.0	-27.08	-7.78	4.06	25.1	
	Week 52	Teze+Teze	45	37 (82.2)	-12.93 (19.74)	-62.8	-26.30	-9.89	0.33	26.9	-0.16 [-0.76, 0.44]
		Pbo+Pbo	19	15 (78.9)	-10.01 (15.73)	-40.1	-18.44	-8.26	5.38	12.6	
	Week 76	Teze+Teze	45	37 (82.2)	-18.74 (19.84)	-69.4	-30.95	-17.38	-4.78	24.9	-0.09 [-0.69, 0.51]
		Pbo+Pbo	19	15 (78.9)	-16.95 (19.26)	-44.0	-31.54	-16.30	-7.12	29.9	
	Week 104	Teze+Teze	45	34 (75.6)	-18.40 (19.70)	-69.4	-31.18	-19.92	-5.28	32.3	-0.02 [-0.62, 0.59]
		Pbo+Pbo	19	15 (78.9)	-18.12 (14.41)	-49.3	-22.37	-15.84	-10.09	4.1	

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC_BBMC0: Change from baseline in SGRQ impact score - MMRM results
 DITTNB - LTE

Change from baseline in SGRQ impact score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 24	Teze+Teze	45	38 (84.4)	-15.64 (3.04)	(-21.75, -9.52)	-6.22 (5.72)	(-17.71, 5.27)	0.282
	Pbo+Pbo	19	15 (78.9)	-9.41 (4.84)	(-19.14, 0.32)			
Week 52	Teze+Teze	45	37 (82.2)	-14.11 (3.13)	(-20.42, -7.81)	-4.22 (5.88)	(-16.04, 7.61)	0.477
	Pbo+Pbo	19	15 (78.9)	-9.90 (4.97)	(-19.90, 0.11)			
Week 76	Teze+Teze	45	37 (82.2)	-17.88 (2.82)	(-23.54, -12.21)	-1.05 (5.26)	(-11.64, 9.54)	0.843
	Pbo+Pbo	19	15 (78.9)	-16.83 (4.45)	(-25.78, -7.88)			
Week 104	Teze+Teze	45	34 (75.6)	-17.53 (2.79)	(-23.13, -11.93)	0.48 (5.18)	(-9.93, 10.89)	0.927
	Pbo+Pbo	19	15 (78.9)	-18.01 (4.36)	(-26.79, -9.23)			

Note: DITTNB - LTE = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC_HBMH0: Course of SGRQ total score
 DITTNB - LTE - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Teze+Teze	44	37 (84.1)	53.83 (17.85)	13.3	40.34	57.49	69.16	81.3
		Pbo+Pbo	19	15 (78.9)	54.58 (19.70)	18.5	41.92	54.44	66.27	91.0
	Week 24	Teze+Teze	44	43 (97.7)	37.77 (23.53)	0.0	17.54	34.37	58.67	87.0
		Pbo+Pbo	19	19 (100.0)	45.45 (20.23)	7.5	30.96	43.73	60.06	79.9
	Week 52	Teze+Teze	44	43 (97.7)	40.65 (24.12)	0.0	20.41	38.79	59.93	80.0
		Pbo+Pbo	19	18 (94.7)	45.46 (21.43)	2.3	35.78	47.79	57.55	84.8
	Week 76	Teze+Teze	44	43 (97.7)	35.27 (21.69)	0.0	13.23	36.25	54.34	86.0
		Pbo+Pbo	19	19 (100.0)	38.24 (17.67)	6.0	29.66	41.54	50.75	65.6
	Week 104	Teze+Teze	44	40 (90.9)	34.24 (22.48)	0.0	14.24	33.22	52.84	79.7
		Pbo+Pbo	19	19 (100.0)	39.83 (18.15)	2.2	24.74	42.87	50.84	75.5

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC_HBMH0: Course of SGRQ total score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Teze+Teze	44	37 (84.1)	-16.29 (19.01)	-58.7	-26.66	-16.33	-5.80	22.0	-0.28 [-0.89, 0.32]
		Pbo+Pbo	19	15 (78.9)	-11.00 (17.57)	-47.0	-23.07	-7.83	4.22	16.0	
	Week 52	Teze+Teze	44	36 (81.8)	-14.20 (17.29)	-50.9	-24.51	-12.23	-5.62	24.5	-0.17 [-0.78, 0.43]
		Pbo+Pbo	19	15 (78.9)	-11.30 (15.25)	-39.7	-28.49	-6.94	0.98	10.1	
	Week 76	Teze+Teze	44	36 (81.8)	-18.93 (18.27)	-62.1	-29.70	-18.05	-7.95	20.1	-0.02 [-0.62, 0.58]
		Pbo+Pbo	19	15 (78.9)	-18.51 (18.94)	-48.5	-35.08	-18.88	-4.84	22.1	
	Week 104	Teze+Teze	44	33 (75.0)	-19.80 (17.20)	-61.8	-28.86	-17.79	-10.13	24.1	-0.24 [-0.85, 0.38]
		Pbo+Pbo	19	15 (78.9)	-15.90 (14.98)	-52.3	-23.40	-13.82	-8.24	8.6	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC_HBMC0: Change from baseline in SGRQ total score - MMRM results
 DITTNE - LTE - adult

Change from baseline in SGRQ total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	44	37 (84.1)	-16.29 (3.02)	(-22.35, -10.23)	-5.46 (5.62)	(-16.74, 5.82)	0.336	
	Pbo+Pbo	19	15 (78.9)	-10.83 (4.74)	(-20.35, -1.31)				
Week 52	Teze+Teze	44	36 (81.8)	-15.29 (2.92)	(-21.16, -9.43)	-4.16 (5.42)	(-15.06, 6.75)	0.447	
	Pbo+Pbo	19	15 (78.9)	-11.14 (4.57)	(-20.33, -1.94)				
Week 76	Teze+Teze	44	36 (81.8)	-18.15 (2.95)	(-24.09, -12.22)	0.19 (5.46)	(-10.80, 11.19)	0.972	
	Pbo+Pbo	19	15 (78.9)	-18.35 (4.60)	(-27.61, -9.09)				
Week 104	Teze+Teze	44	33 (75.0)	-18.79 (2.76)	(-24.34, -13.23)	-3.05 (5.09)	(-13.29, 7.18)	0.551	
	Pbo+Pbo	19	15 (78.9)	-15.73 (4.27)	(-24.33, -7.13)				

Note: DITTNE - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC_HBMH0: Course of SGRQ symptom score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Teze+Teze	44	37 (84.1)	68.62 (18.09)	34.7	54.85	71.97	82.97	95.5	
		Pbo+Pbo	19	15 (78.9)	65.63 (20.31)	26.1	50.26	69.18	82.91	92.8	
	Week 24	Teze+Teze	44	43 (97.7)	43.72 (27.77)	0.0	20.23	47.46	67.37	92.8	
		Pbo+Pbo	19	19 (100.0)	50.05 (21.68)	6.8	32.62	49.06	67.82	83.6	
	Week 52	Teze+Teze	44	43 (97.7)	45.28 (27.19)	0.0	28.77	44.02	65.58	84.3	
		Pbo+Pbo	19	18 (94.7)	46.68 (23.87)	0.0	30.63	50.65	64.02	77.7	
	Week 76	Teze+Teze	44	43 (97.7)	39.39 (26.43)	0.0	13.78	35.41	56.14	90.8	
		Pbo+Pbo	19	19 (100.0)	43.12 (18.14)	8.9	25.78	38.85	61.01	74.0	
	Week 104	Teze+Teze	44	40 (90.9)	38.41 (26.16)	0.0	17.85	34.70	57.44	100.0	
		Pbo+Pbo	19	19 (100.0)	52.98 (19.03)	13.0	35.79	56.75	68.57	87.6	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC_HBMH0: Course of SGRQ symptom score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Teze+Teze	44	37 (84.1)	-25.27 (25.22)	-90.3	-37.42	-18.50	-9.43	7.6	-0.24 [-0.85, 0.36]
		Pbo+Pbo	19	15 (78.9)	-19.27 (22.79)	-58.2	-37.01	-21.54	-1.36	16.6	
	Week 52	Teze+Teze	44	36 (81.8)	-25.30 (22.09)	-90.3	-41.07	-22.02	-7.54	8.8	-0.15 [-0.75, 0.45]
		Pbo+Pbo	19	15 (78.9)	-21.94 (22.54)	-65.0	-36.27	-14.99	-4.66	16.4	
	Week 76	Teze+Teze	44	36 (81.8)	-29.27 (23.56)	-80.7	-46.31	-28.76	-15.62	33.6	-0.14 [-0.75, 0.46]
		Pbo+Pbo	19	15 (78.9)	-26.05 (20.00)	-67.7	-32.59	-28.44	-12.18	5.3	
	Week 104	Teze+Teze	44	33 (75.0)	-29.99 (21.58)	-80.7	-40.06	-28.20	-14.76	18.3	-0.64 [-1.26, -0.02]
		Pbo+Pbo	19	15 (78.9)	-16.24 (21.18)	-52.0	-33.66	-16.86	-2.82	36.9	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC_HBMC0: Change from baseline in SGRQ symptom score - MMRM results
 DITTNE - LTE - adult

Change from baseline in SGRQ symptom score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	44	37 (84.1)	-24.88 (3.92)	(-32.76, -17.00)	-5.16 (7.31)	(-19.84, 9.51)	0.483	
	Pbo+Pbo	19	15 (78.9)	-19.72 (6.16)	(-32.09, -7.35)				
Week 52	Teze+Teze	44	36 (81.8)	-25.82 (3.75)	(-33.37, -18.26)	-3.43 (6.96)	(-17.43, 10.58)	0.625	
	Pbo+Pbo	19	15 (78.9)	-22.39 (5.86)	(-34.17, -10.61)				
Week 76	Teze+Teze	44	36 (81.8)	-28.87 (3.60)	(-36.11, -21.62)	-2.37 (6.67)	(-15.78, 11.04)	0.724	
	Pbo+Pbo	19	15 (78.9)	-26.50 (5.61)	(-37.77, -15.22)				
Week 104	Teze+Teze	44	33 (75.0)	-29.89 (3.54)	(-37.01, -22.76)	-13.20 (6.45)	(-26.17, -0.22)	0.046 *	
	Pbo+Pbo	19	15 (78.9)	-16.69 (5.38)	(-27.53, -5.85)				

Note: DITTNE - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC_HBMH0: Course of SGRQ activities score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Teze+Teze	44	37 (84.1)	63.57 (17.60)	17.1	53.53	61.05	75.39	92.5	
		Pbo+Pbo	19	15 (78.9)	67.16 (21.96)	23.3	47.24	66.95	92.51	93.9	
	Week 24	Teze+Teze	44	43 (97.7)	51.09 (27.78)	0.0	29.63	53.62	72.82	100.0	
		Pbo+Pbo	19	19 (100.0)	59.40 (27.01)	0.0	47.24	59.46	73.04	100.0	
	Week 52	Teze+Teze	44	43 (97.7)	53.92 (28.20)	0.0	29.45	60.16	79.03	100.0	
		Pbo+Pbo	19	18 (94.7)	63.26 (26.45)	0.0	47.69	66.76	85.81	100.0	
	Week 76	Teze+Teze	44	43 (97.7)	49.36 (27.03)	0.0	23.41	53.62	66.95	100.0	
		Pbo+Pbo	19	19 (100.0)	53.10 (23.68)	0.0	47.24	59.46	66.19	92.5	
	Week 104	Teze+Teze	44	40 (90.9)	46.61 (26.93)	0.0	26.68	50.62	66.19	92.5	
		Pbo+Pbo	19	19 (100.0)	56.41 (25.64)	0.0	41.73	60.47	72.82	92.5	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC_HBMH0: Course of SGRQ activities score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Teze+Teze	44	37 (84.1)	-13.58 (24.42)	-75.4	-24.36	-12.65	0.00	45.6	-0.19 [-0.79, 0.41]
		Pbo+Pbo	19	15 (78.9)	-8.98 (22.63)	-66.9	-11.44	-6.63	6.14	24.4	
	Week 52	Teze+Teze	44	36 (81.8)	-11.65 (22.72)	-75.4	-19.67	-7.12	2.97	38.0	-0.18 [-0.78, 0.43]
		Pbo+Pbo	19	15 (78.9)	-7.65 (21.78)	-47.2	-25.16	-12.47	6.14	32.5	
	Week 76	Teze+Teze	44	36 (81.8)	-14.50 (24.25)	-75.4	-27.20	-9.82	-0.02	50.6	0.10 [-0.50, 0.71]
		Pbo+Pbo	19	15 (78.9)	-17.01 (25.20)	-66.9	-34.40	-15.04	0.00	30.3	
	Week 104	Teze+Teze	44	33 (75.0)	-17.61 (21.02)	-75.4	-25.52	-13.23	-5.84	12.7	-0.27 [-0.88, 0.34]
		Pbo+Pbo	19	15 (78.9)	-11.75 (23.63)	-66.9	-25.22	-6.70	0.06	25.7	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC_HBMC0: Change from baseline in SGRQ activities score - MMRM results
 DITTNB - LTE - adult

Change from baseline in SGRQ activities score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 24	Teze+Teze	44	37 (84.1)	-13.76 (3.92)	(-21.63, -5.90)	-5.28 (7.31)	(-19.97, 9.41)	0.474
	Pbo+Pbo	19	15 (78.9)	-8.48 (6.16)	(-20.86, 3.90)			
Week 52	Teze+Teze	44	36 (81.8)	-12.54 (3.73)	(-20.03, -5.05)	-5.39 (6.94)	(-19.35, 8.56)	0.441
	Pbo+Pbo	19	15 (78.9)	-7.15 (5.85)	(-18.90, 4.60)			
Week 76	Teze+Teze	44	36 (81.8)	-13.28 (4.07)	(-21.49, -5.07)	3.23 (7.57)	(-12.04, 18.49)	0.672
	Pbo+Pbo	19	15 (78.9)	-16.51 (6.37)	(-29.36, -3.66)			
Week 104	Teze+Teze	44	33 (75.0)	-15.83 (3.73)	(-23.33, -8.33)	-4.58 (6.89)	(-18.45, 9.28)	0.509
	Pbo+Pbo	19	15 (78.9)	-11.25 (5.78)	(-22.88, 0.39)			

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC_HBMH0: Course of SGRQ impact score
 DITTNB - LTE - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Teze+Teze	44	37 (84.1)	43.57 (22.18)	3.6	25.11	45.37	60.61	80.9
		Pbo+Pbo	19	15 (78.9)	43.86 (22.39)	3.8	25.01	44.04	51.45	90.8
	Week 24	Teze+Teze	44	43 (97.7)	28.23 (23.85)	0.0	7.56	23.39	49.00	84.3
		Pbo+Pbo	19	19 (100.0)	36.01 (20.79)	8.0	21.69	29.07	56.86	73.5
	Week 52	Teze+Teze	44	43 (97.7)	31.53 (25.01)	0.0	8.22	25.69	52.36	85.0
		Pbo+Pbo	19	18 (94.7)	34.89 (22.69)	4.0	13.70	33.18	44.77	87.9
	Week 76	Teze+Teze	44	43 (97.7)	25.93 (21.31)	0.0	3.06	23.26	42.02	81.7
		Pbo+Pbo	19	19 (100.0)	28.23 (18.39)	0.0	15.10	32.83	42.04	57.7
	Week 104	Teze+Teze	44	40 (90.9)	25.90 (22.27)	0.0	3.88	22.90	39.47	81.7
		Pbo+Pbo	19	19 (100.0)	26.22 (19.30)	0.0	7.62	28.19	41.45	65.1

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC_HBMH0: Course of SGRQ impact score
 DITTNB - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Teze+Teze	44	37 (84.1)	-15.02 (20.90)	-63.4	-24.45	-14.40	-6.99	29.8	-0.27 [-0.88, 0.33]
		Pbo+Pbo	19	15 (78.9)	-9.53 (17.66)	-36.0	-27.08	-7.78	4.06	25.1	
	Week 52	Teze+Teze	44	36 (81.8)	-12.22 (19.54)	-62.8	-26.24	-9.87	0.97	26.9	-0.12 [-0.72, 0.48]
		Pbo+Pbo	19	15 (78.9)	-10.01 (15.73)	-40.1	-18.44	-8.26	5.38	12.6	
	Week 76	Teze+Teze	44	36 (81.8)	-18.17 (19.81)	-69.4	-30.55	-16.28	-4.63	24.9	-0.06 [-0.66, 0.54]
		Pbo+Pbo	19	15 (78.9)	-16.95 (19.26)	-44.0	-31.54	-16.30	-7.12	29.9	
	Week 104	Teze+Teze	44	33 (75.0)	-17.76 (19.65)	-69.4	-30.87	-18.35	-5.28	32.3	0.02 [-0.59, 0.63]
		Pbo+Pbo	19	15 (78.9)	-18.12 (14.41)	-49.3	-22.37	-15.84	-10.09	4.1	

Note: DITTNB - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC_HBMC0: Change from baseline in SGRQ impact score - MMRM results
 DITTNE - LTE - adult

Change from baseline in SGRQ impact score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 24	Teze+Teze	44	37 (84.1)	-14.99 (3.07)	(-21.15, -8.82)	-5.61 (5.71)	(-17.09, 5.87)	0.331
	Pbo+Pbo	19	15 (78.9)	-9.37 (4.82)	(-19.06, 0.31)			
Week 52	Teze+Teze	44	36 (81.8)	-13.47 (3.16)	(-19.83, -7.10)	-3.61 (5.87)	(-15.43, 8.21)	0.542
	Pbo+Pbo	19	15 (78.9)	-9.86 (4.95)	(-19.82, 0.10)			
Week 76	Teze+Teze	44	36 (81.8)	-17.31 (2.85)	(-23.05, -11.58)	-0.52 (5.27)	(-11.13, 10.09)	0.922
	Pbo+Pbo	19	15 (78.9)	-16.79 (4.44)	(-25.72, -7.87)			
Week 104	Teze+Teze	44	33 (75.0)	-16.96 (2.81)	(-22.61, -11.30)	1.02 (5.18)	(-9.40, 11.43)	0.845
	Pbo+Pbo	19	15 (78.9)	-17.97 (4.34)	(-26.72, -9.23)			

Note: DITTNE - LTE - adult = Dossier Biomarker Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20JUL2022

Table NT1GTC_ABMH0: Course of SGRQ total score
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	54	46 (85.2)	54.95 (17.07)	13.3	41.08	57.97	69.87	81.3
		Placebo	39	32 (82.1)	56.95 (17.74)	18.5	47.13	56.77	65.57	91.0
	Week 24	Tezepelumab	54	51 (94.4)	39.33 (22.71)	0.0	23.54	40.45	58.67	87.0
		Placebo	39	34 (87.2)	49.51 (19.01)	7.5	39.61	48.98	61.51	79.9
	Week 52	Tezepelumab	54	47 (87.0)	41.77 (24.04)	0.0	20.41	40.15	62.59	80.0
		Placebo	39	34 (87.2)	47.39 (19.10)	2.3	39.21	49.53	59.91	84.8

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC_ABMH0: Course of SGRQ total score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Tezepelumab	54	44 (81.5)	-15.52 (18.48)	-58.7	-27.83	-12.06	-3.18	22.0	-0.41 [-0.89, 0.08]
		Placebo	39	27 (69.2)	-8.55 (14.81)	-47.0	-14.95	-7.44	5.12	16.0	
	Week 52	Tezepelumab	54	40 (74.1)	-14.32 (17.27)	-50.9	-25.36	-10.65	-5.62	17.2	-0.26 [-0.74, 0.22]
		Placebo	39	29 (74.4)	-10.06 (14.57)	-40.8	-16.28	-8.10	-1.47	16.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC_ABMC0: Change from baseline in SGRQ total score - MMRM results
 DITTB - adult

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	54	44 (81.5)	-15.58 (2.57)	(-20.71, -10.46)	-6.45 (4.05)	(-14.52, 1.62)	0.116	
	Placebo	39	27 (69.2)	-9.13 (3.13)	(-15.36, -2.90)				
Week 52	Tezepelumab	54	40 (74.1)	-14.08 (2.57)	(-19.21, -8.95)	-4.02 (4.00)	(-11.99, 3.95)	0.318	
	Placebo	39	29 (74.4)	-10.06 (3.06)	(-16.15, -3.96)				

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GMC_ABMH0: Course of SGRQ symptom score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	54	46 (85.2)	69.99 (17.09)	34.7	59.89	72.58	83.12	95.5	
		Placebo	39	32 (82.1)	66.37 (18.37)	26.1	52.42	66.64	79.59	95.0	
	Week 24	Tezepelumab	54	51 (94.4)	46.07 (26.48)	0.0	25.36	47.86	67.37	92.8	
		Placebo	39	34 (87.2)	55.28 (23.72)	6.8	33.77	58.69	76.85	92.7	
	Week 52	Tezepelumab	54	47 (87.0)	47.87 (25.91)	0.0	30.93	51.38	72.98	84.3	
		Placebo	39	34 (87.2)	51.59 (21.78)	0.0	36.75	54.66	68.27	95.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC_ABMH0: Course of SGRQ symptom score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Tezepelumab	54	44 (81.5)	-24.13 (24.20)	-90.3	-36.88	-18.85	-7.14	7.6	-0.48 [-0.97, 0.00]
		Placebo	39	27 (69.2)	-12.75 (22.71)	-58.2	-31.59	-10.69	5.61	38.7	
	Week 52	Tezepelumab	54	40 (74.1)	-23.03 (22.63)	-90.3	-38.97	-16.78	-7.10	16.3	-0.24 [-0.72, 0.24]
		Placebo	39	29 (74.4)	-17.50 (22.61)	-65.0	-29.55	-11.03	-3.28	16.4	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC_ABMC0: Change from baseline in SGRQ symptom score - MMRM results
 DITTB - adult

Change from baseline in SGRQ symptom score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Tezepelumab	54	44 (81.5)	-23.64 (3.53)	(-30.69, -16.59)	-9.55 (5.61)	(-20.74, 1.64)	0.093	
	Placebo	39	27 (69.2)	-14.09 (4.35)	(-22.75, -5.43)				
Week 52	Tezepelumab	54	40 (74.1)	-22.87 (3.46)	(-29.78, -15.96)	-4.65 (5.37)	(-15.37, 6.07)	0.390	
	Placebo	39	29 (74.4)	-18.21 (4.10)	(-26.39, -10.04)				

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GAC_ABMH0: Course of SGRQ activities score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	54	46 (85.2)	65.42 (17.35)	17.1	53.62	66.19	80.32	92.5	
		Placebo	39	32 (82.1)	68.72 (21.67)	23.3	53.99	69.89	89.84	100.0	
	Week 24	Tezepelumab	54	51 (94.4)	52.89 (27.40)	0.0	35.86	53.62	73.68	100.0	
		Placebo	39	34 (87.2)	61.92 (25.19)	0.0	47.70	63.56	79.52	100.0	
	Week 52	Tezepelumab	54	47 (87.0)	53.93 (29.10)	0.0	29.45	60.35	79.03	100.0	
		Placebo	39	34 (87.2)	62.98 (24.46)	0.0	47.69	66.65	80.32	100.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC_ABMH0: Course of SGRQ activities score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Tezepelumab	54	44 (81.5)	-13.43 (24.78)	-75.4	-24.88	-12.61	0.00	45.6	-0.27 [-0.75, 0.21]
		Placebo	39	27 (69.2)	-7.29 (19.39)	-66.9	-19.68	-5.92	6.14	25.8	
	Week 52	Tezepelumab	54	40 (74.1)	-14.90 (23.93)	-75.4	-21.27	-8.61	0.00	20.0	-0.37 [-0.86, 0.11]
		Placebo	39	29 (74.4)	-6.84 (17.63)	-47.2	-19.09	-7.49	5.93	32.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC_ABMC0: Change from baseline in SGRQ activities score - MMRM results
 DITTB - adult

Change from baseline in SGRQ activities score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 24	Tezepelumab	54	44 (81.5)	-13.55 (3.38)	(-20.28, -6.82)	-5.75 (5.34)	(-16.39, 4.89)	0.285
	Placebo	39	27 (69.2)	-7.80 (4.13)	(-16.03, 0.43)			
Week 52	Tezepelumab	54	40 (74.1)	-13.49 (3.39)	(-20.25, -6.73)	-6.65 (5.26)	(-17.15, 3.85)	0.210
	Placebo	39	29 (74.4)	-6.83 (4.02)	(-14.86, 1.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GRC_ABMH0: Course of SGRQ impact score
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Tezepelumab	54	46 (85.2)	44.20 (21.10)	3.6	26.04	46.47	60.61	80.9
		Placebo	39	32 (82.1)	47.21 (20.80)	3.6	33.74	49.05	60.90	90.8
	Week 24	Tezepelumab	54	51 (94.4)	29.40 (23.00)	0.0	8.29	26.51	49.00	84.3
		Placebo	39	34 (87.2)	40.54 (19.04)	5.8	28.19	39.39	55.33	73.5
	Week 52	Tezepelumab	54	47 (87.0)	32.84 (24.80)	0.0	8.31	26.12	52.36	85.0
		Placebo	39	34 (87.2)	37.14 (20.09)	4.0	27.12	38.11	49.49	87.9

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GRC_ABMH0: Course of SGRQ impact score
 DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Tezepelumab	54	44 (81.5)	-14.02 (19.80)	-63.4	-22.73	-10.22	-4.05	29.8	-0.33 [-0.82, 0.15]
		Placebo	39	27 (69.2)	-7.94 (15.14)	-36.0	-18.33	-7.78	5.29	25.1	
	Week 52	Tezepelumab	54	40 (74.1)	-11.29 (18.35)	-62.8	-25.90	-8.88	0.97	22.2	-0.10 [-0.58, 0.38]
		Placebo	39	29 (74.4)	-9.55 (16.12)	-42.7	-18.44	-9.22	0.54	18.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.
 Source Data: asgrq, created on: 20FEB2022

Table NT1GRC_ABMC0: Change from baseline in SGRQ impact score - MMRM results
 DITTB - adult

Change from baseline in SGRQ impact score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 24	Tezepelumab	54	44 (81.5)	-14.30 (2.57)	(-19.42, -9.18)	-6.43 (4.07)	(-14.54, 1.68)	0.118
	Placebo	39	27 (69.2)	-7.87 (3.15)	(-14.14, -1.59)			
Week 52	Tezepelumab	54	40 (74.1)	-11.80 (2.69)	(-17.17, -6.44)	-2.77 (4.18)	(-11.12, 5.57)	0.510
	Placebo	39	29 (74.4)	-9.03 (3.19)	(-15.41, -2.66)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1PSC_IBMH0: Course of PGI-S
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
PGI-S	Baseline	Tezepelumab	55	55 (100.0)	2.7 (1.0)	0	2.0	3.0	3.0	4	
		Placebo	40	40 (100.0)	2.9 (0.7)	1	2.5	3.0	3.0	5	
	Week 2	Tezepelumab	55	53 (96.4)	2.0 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	40	38 (95.0)	2.5 (1.0)	1	2.0	3.0	3.0	5	
	Week 4	Tezepelumab	55	55 (100.0)	1.9 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	40	40 (100.0)	2.4 (0.9)	0	2.0	2.0	3.0	4	
	Week 8	Tezepelumab	55	55 (100.0)	2.1 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	40	40 (100.0)	2.4 (1.0)	0	2.0	3.0	3.0	4	
	Week 12	Tezepelumab	55	54 (98.2)	1.8 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	40	39 (97.5)	2.2 (1.1)	0	1.0	2.0	3.0	5	
	Week 52	Tezepelumab	55	49 (89.1)	2.0 (1.2)	0	1.0	2.0	3.0	4	
		Placebo	40	35 (87.5)	2.3 (1.0)	0	2.0	3.0	3.0	4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC_IBMH0: Course of PGI-S
 DITTB

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in PGI-S Week 2	Tezepelumab	55	53 (96.4)	-0.7 (1.1)	-3	-1.0	-1.0	0.0	2	-0.27 [-0.69, 0.15]
	Placebo	40	38 (95.0)	-0.4 (1.0)	-3	-1.0	0.0	0.0	2	
Week 4	Tezepelumab	55	55 (100.0)	-0.8 (1.2)	-3	-2.0	-1.0	0.0	1	-0.30 [-0.70, 0.11]
	Placebo	40	40 (100.0)	-0.5 (0.9)	-3	-1.0	0.0	0.0	1	
Week 8	Tezepelumab	55	55 (100.0)	-0.6 (1.1)	-3	-1.0	0.0	0.0	1	-0.15 [-0.55, 0.26]
	Placebo	40	40 (100.0)	-0.5 (1.0)	-3	-1.0	0.0	0.0	2	
Week 12	Tezepelumab	55	54 (98.2)	-0.9 (1.2)	-3	-2.0	-1.0	0.0	2	-0.17 [-0.59, 0.24]
	Placebo	40	39 (97.5)	-0.7 (1.2)	-5	-2.0	0.0	0.0	2	
Week 52	Tezepelumab	55	49 (89.1)	-0.8 (1.2)	-3	-2.0	-1.0	0.0	1	-0.24 [-0.67, 0.20]
	Placebo	40	35 (87.5)	-0.5 (0.9)	-3	-1.0	0.0	0.0	1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC_IBMC0: Change from baseline in PGI-S - MMRM results
 DITTB

Change from baseline in PGI-S				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	55	53 (96.4)	-0.7 (0.1)	(-1.0, -0.5)	-0.4 (0.2)	(-0.8, -0.0)	0.040 *
	Placebo	40	38 (95.0)	-0.3 (0.2)	(-0.6, 0.0)			
Week 4	Tezepelumab	55	55 (100.0)	-0.9 (0.1)	(-1.1, -0.6)	-0.4 (0.2)	(-0.8, -0.0)	0.047 *
	Placebo	40	40 (100.0)	-0.5 (0.1)	(-0.8, -0.2)			
Week 8	Tezepelumab	55	55 (100.0)	-0.6 (0.1)	(-0.9, -0.4)	-0.2 (0.2)	(-0.6, 0.2)	0.242
	Placebo	40	40 (100.0)	-0.4 (0.2)	(-0.7, -0.1)			
Week 12	Tezepelumab	55	54 (98.2)	-1.0 (0.1)	(-1.3, -0.7)	-0.3 (0.2)	(-0.8, 0.1)	0.144
	Placebo	40	39 (97.5)	-0.7 (0.2)	(-1.0, -0.3)			
Week 52	Tezepelumab	55	49 (89.1)	-0.8 (0.1)	(-1.1, -0.5)	-0.3 (0.2)	(-0.8, 0.1)	0.125
	Placebo	40	35 (87.5)	-0.5 (0.2)	(-0.8, -0.1)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

PGI-S = Patient global impression of severity.

Source Data: apgi, created on: 23FEB2022

Table NT1PSC_ABMH0: Course of PGI-S
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
PGI-S	Baseline	Tezepelumab	54	54 (100.0)	2.7 (1.0)	0	2.0	3.0	3.0	4	
		Placebo	39	39 (100.0)	2.9 (0.7)	1	2.0	3.0	3.0	5	
	Week 2	Tezepelumab	54	52 (96.3)	2.1 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	39	37 (94.9)	2.5 (1.0)	1	2.0	3.0	3.0	5	
	Week 4	Tezepelumab	54	54 (100.0)	1.9 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	39	39 (100.0)	2.4 (0.9)	0	2.0	2.0	3.0	4	
	Week 8	Tezepelumab	54	54 (100.0)	2.1 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	39	39 (100.0)	2.4 (1.0)	0	2.0	3.0	3.0	4	
	Week 12	Tezepelumab	54	53 (98.1)	1.8 (1.1)	0	1.0	2.0	3.0	4	
		Placebo	39	38 (97.4)	2.1 (1.1)	0	1.0	2.0	3.0	5	
	Week 52	Tezepelumab	54	48 (88.9)	2.0 (1.2)	0	1.0	2.0	3.0	4	
		Placebo	39	34 (87.2)	2.3 (1.0)	0	2.0	3.0	3.0	4	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC_ABMH0: Course of PGI-S
 DITTB - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in PGI-S Week 2	Tezepelumab	54	52 (96.3)	-0.7 (1.1)	-3	-1.0	-1.0	0.0	2	-0.26 [-0.69, 0.16]
	Placebo	39	37 (94.9)	-0.4 (1.0)	-3	-1.0	0.0	0.0	2	
Week 4	Tezepelumab	54	54 (100.0)	-0.9 (1.2)	-3	-2.0	-1.0	0.0	1	-0.35 [-0.76, 0.07]
	Placebo	39	39 (100.0)	-0.5 (0.9)	-3	-1.0	0.0	0.0	1	
Week 8	Tezepelumab	54	54 (100.0)	-0.6 (1.1)	-3	-1.0	0.0	0.0	1	-0.13 [-0.54, 0.29]
	Placebo	39	39 (100.0)	-0.5 (1.0)	-3	-1.0	0.0	0.0	2	
Week 12	Tezepelumab	54	53 (98.1)	-0.9 (1.2)	-3	-2.0	-1.0	0.0	2	-0.16 [-0.57, 0.26]
	Placebo	39	38 (97.4)	-0.7 (1.2)	-5	-2.0	0.0	0.0	2	
Week 52	Tezepelumab	54	48 (88.9)	-0.8 (1.2)	-3	-1.5	-0.5	0.0	1	-0.23 [-0.67, 0.21]
	Placebo	39	34 (87.2)	-0.5 (0.9)	-3	-1.0	0.0	0.0	1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC_ABMC0: Change from baseline in PGI-S - MMRM results
 DITTB - adult

Change from baseline in PGI-S				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	54	52 (96.3)	-0.7 (0.1)	(-1.0, -0.4)	-0.4 (0.2)	(-0.8, -0.0)	0.045 *
	Placebo	39	37 (94.9)	-0.3 (0.2)	(-0.6, 0.0)			
Week 4	Tezepelumab	54	54 (100.0)	-0.9 (0.1)	(-1.1, -0.6)	-0.4 (0.2)	(-0.8, -0.1)	0.025 *
	Placebo	39	39 (100.0)	-0.4 (0.1)	(-0.7, -0.1)			
Week 8	Tezepelumab	54	54 (100.0)	-0.6 (0.1)	(-0.9, -0.4)	-0.2 (0.2)	(-0.6, 0.2)	0.290
	Placebo	39	39 (100.0)	-0.4 (0.2)	(-0.7, -0.1)			
Week 12	Tezepelumab	54	53 (98.1)	-1.0 (0.1)	(-1.3, -0.7)	-0.3 (0.2)	(-0.8, 0.1)	0.176
	Placebo	39	38 (97.4)	-0.7 (0.2)	(-1.0, -0.3)			
Week 52	Tezepelumab	54	48 (88.9)	-0.8 (0.1)	(-1.1, -0.5)	-0.3 (0.2)	(-0.8, 0.1)	0.151
	Placebo	39	34 (87.2)	-0.5 (0.2)	(-0.8, -0.1)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
 PGI-S = Patient global impression of severity.
 Source Data: apgi, created on: 23FEB2022